{"schema_version": 1, "owner": "test", "retention_days": 90, "pool": [{"pmid": "42757133", "title": "3D-printed PCL scaffold coated with chitosan-hyaluronic acid hydrogel loaded with NGF-overexpressing UiPSC-derived neural crest cells restores erectile function via cavernous nerve regeneration.", "abstract": "This study investigated whether erectile function could be restored by promoting cavernous nerve (CN) regeneration via perineural administration of nerve-growth-factor (NGF)-overexpressing neural-crest-cells (NCCs) within a 3D-printed cytocompatible scaffold in a CN-injured rat model. We generated induced-pluripotent-stem-cells (iPSCs) from urine-derived stem-cells (USCs), overexpressed NGF, and differentiated them into NCCs. Additionally, a polycaprolactone (PCL) scaffold was fabricated via extrusion 3D-printing and coated with a thermosensitive chitosan/hyaluronic acid (HA)/β-glycerophosphate hydrogel. The NGF-NCCs were loaded onto the scaffold, with in vitro assays validating high cell loading, survival, and differentiation potential. Sixty 12-week-old male Sprague-Dawley rats were assigned to five groups: sham (S); CN injury (I); and injury groups receiving PCL coated with chitosan-HA-hydrogel alone (H), NGF-UiPSC-NCCs alone (N), or PCL coated with chitosan-HA-hydrogel loaded with NGF-UiPSC-NCCs (NH) around the injured CNs. Four weeks post-surgery, Groups H, N, and NH showed significantly improved erectile responses during electrostimulation compared to Group I, with Group NH exhibiting the most pronounced recovery. Regarding CN regeneration, Groups H, N, and NH demonstrated increased axonal density and upregulated expression of neuronal regeneration and remyelination markers. Furthermore, these groups showed decreased cavernosal apoptosis and preserved endothelial content and smooth muscle/collagen ratio. Across all metrics, Group NH demonstrated the superior therapeutic effect, followed by Groups N and H. Our results indicate that perineural application of NGF-UiPSC-NCCs loaded 3D-printed PCL coated with chitosan-HA-hydrogels can restore erectile function by enhancing CN regeneration, subsequent recovery of neurotransmission, and suppression of structural alterations in the corpus cavernosum.", "journal": "Bioactive Materials", "pub_date": "2027-Jan", "publication_types": ["Journal Article"], "doi": "10.1016/j.bioactmat.2026.07.001", "authors": ["Han Cheol Yeo", "Hoyoung Bae", "Jae-Seok Kim", "Jun-Kyu Kang", "Jaekwon Seok", "Yoo Jung Kim", "Ye Ji Han", "Ye Been Na", "Sun Hee Lee", "Junghoon Lee", "So-Jung Gwak", "Seung-Jae Lee", "Ssang-Goo Cho", "Soo Woong Kim", "Min Chul Cho"], "affiliations": ["Stem Cell and Regenerative Biotechnology Major, School of Advanced Biotechnology, College of Institute of Science and Technology, Molecular & Cellular Reprogramming Center, Institute of Advanced Regenerative Science, Institute of Health, Aging & Society, Konkuk University, Seoul, 05029, Republic of Korea.", "Department of Urology, Seoul National University College of Medicine and Seoul National University Boramae Medical Center, Seoul, 03080, Republic of Korea.", "Department of Mechanical Engineering, Wonkwang University, Iksan, 54538, Republic of Korea.", "Department of Chemical Engineering, Wonkwang University, Iksan, 54538, Republic of Korea.", "Department of Urology, Seoul National University College of Medicine and Seoul National University Hospital, Seoul, 03080, Republic of Korea.", "Division of Mechanical Engineering, Wonkwang University, Iksan, 54538, Republic of Korea.", "MECHABIO Group, Wonkwang University, Iksan, 54538, Republic of Korea.", "Advanced Bio-Convergence Research Center, Wonkwang University, Iksan, 54538, Republic of Korea."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "basic_signals=10", "score": 49.49, "score_parts": {"urology_relevance": 3, "urology_in_title": 8.0, "journal_priority": 16.49, "top_journal_bonus": 10.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 10.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 20.3, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.49, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "3D打印支架搭载干细胞促神经再生恢复勃起", "chinese_summary": "1月Bioactive Materials发表大鼠研究：以尿源干细胞诱导的iPSC过表达NGF并分化为神经嵴细胞，装载于壳聚糖-透明质酸水凝胶涂层的3D打印PCL支架，置于损伤海绵体神经周围。术后4周联合治疗组勃起反应恢复最佳，神经轴突密度及髓鞘再生标志物升高，海绵体凋亡减少、内皮和平滑肌/胶原比例得以保留。", "abstract_zh": "本研究探讨了在大鼠海绵体神经（CN）损伤模型中，通过在海绵体神经周围给予负载于3D打印细胞相容性支架内的过表达神经生长因子（NGF）的神经嵴细胞（NCCs），能否通过促进海绵体神经再生来恢复勃起功能。我们从尿源干细胞（USCs）生成诱导多能干细胞（iPSCs），使其过表达NGF，并诱导分化为NCCs。此外，通过挤出式3D打印制备了聚己内酯（PCL）支架，并涂覆温敏性壳聚糖/透明质酸（HA）/β-甘油磷酸盐水凝胶。将NGF-NCCs装载到支架上，体外实验验证了高细胞装载率、存活率及分化潜能。将60只12周龄雄性Sprague-Dawley大鼠分为五组：假手术组（S）；海绵体神经损伤组（I）；以及损伤后分别在受损海绵体神经周围接受单纯壳聚糖-HA水凝胶涂层的PCL支架（H）、单纯NGF-UiPSC-NCCs（N）或负载NGF-UiPSC-NCCs的壳聚糖-HA水凝胶涂层的PCL支架（NH）的组。术后四周，与I组相比，H组、N组和NH组在电刺激下勃起反应显著改善，其中NH组恢复最为明显。在海绵体神经再生方面，H组、N组和NH组显示轴突密度增加，神经元再生和髓鞘再生标志物表达上调。此外，这些组显示海绵体凋亡减少，内皮含量以及平滑肌/胶原比例得以保留。在所有指标上，NH组表现出最优治疗效果，其次为N组和H组。我们的结果表明，在海绵体神经周围应用负载NGF-UiPSC-NCCs的壳聚糖-HA水凝胶涂层的3D打印PCL支架，可通过增强海绵体神经再生、随后的神经传递恢复以及抑制海绵体结构改变来恢复勃起功能。"}, {"pmid": "42781429", "title": "Antifibrotic hydrogel strategies for scarless tissue regeneration: mechanisms, design, and application.", "abstract": "Tissue repair is a highly coordinated process, yet dysregulated fibrosis often diverts healing toward scar formation, resulting in permanent structural and functional impairment. Achieving scarless regeneration requires precise modulation of the wound microenvironment to support functional tissue reconstruction. Hydrogels, owing to their biocompatibility, tunable mechanics, and controllable delivery capabilities, have emerged as promising platforms for regenerative therapy. Recent multifunctional hydrogels can regulate tissue repair through microstructural engineering, mechanical modulation, immune regulation, pro-angiogenic stimulation, and dynamic extracellular matrix remodeling, thereby suppressing fibrotic progression. However, current reviews mainly focus on accelerating wound closure and lack systematic discussion of antifibrotic hydrogel design across different tissues. In this review, we summarize the key mechanisms underlying scar formation and propose design principles for hydrogel-mediated scarless regeneration. We further highlight recent advances in multiple tissues, including skin, tendon, cornea, urethra, nerve, endometrium, liver, myocardium, emphasizing both shared principles and tissue-specific requirements. Finally, we discuss translational challenges and future opportunities, particularly AI-driven hydrogel design for functional regeneration.", "journal": "Bioactive Materials", "pub_date": "2027-Feb", "publication_types": ["Journal Article", "Review"], "doi": "10.1016/j.jid.2024.06.1281", "authors": ["Shuangli Zhu", "Ying Shi", "Haoran Wang", "Lei Feng", "Yuhui Lu", "Xinghui Si", "Qiuyue Ma", "Liangcan He", "Shaoqin Liu"], "affiliations": ["School of Medicine and Health, MOE Key Laboratory of Micro-systems and Micro-structures Manufacturing, Harbin Institute of Technology, Harbin, 150080, China.", "Zhengzhou Advanced Research Institute of Harbin Institute of Technology, Zhengzhou, 450046, China.", "State Key Laboratory of Woody Oil Resources Utilization, Northeast Forestry University, Harbin, 150040, China."], "corresponding_authors": [], "china_team": "School of Medicine and Health, MOE Key Laboratory of Micro-systems and Micro-structures Manufacturing, Harbin Institute of Technology, Harbin, 150080, China Shaoqin Liu团队", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 32.49, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 16.49, "top_journal_bonus": 10.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 20.3, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.49, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "抗纤维化水凝胶实现无瘢痕再生", "chinese_summary": "哈尔滨工业大学刘绍琴团队2027年2月Bioact Mater综述指出，水凝胶可通过微结构工程、力学调控、免疫调节、促血管生成及细胞外基质重塑抑制纤维化进程，并总结皮肤、肌腱、角膜、尿道、神经、子宫内膜、肝脏及心肌等组织的无瘢痕再生设计原则，提出AI驱动水凝胶设计方向。", "abstract_zh": "组织修复是一个高度协调的过程，但失调的纤维化常使愈合转向瘢痕形成，导致永久性的结构和功能损伤。实现无瘢痕再生需要精确调控伤口微环境以支持功能性组织重建。水凝胶因其生物相容性、可调力学性能及可控递送能力，已成为再生治疗的有前景平台。近期多功能水凝胶可通过微结构工程、力学调控、免疫调节、促血管生成刺激及动态细胞外基质重塑来调控组织修复，从而抑制纤维化进展。然而，当前综述主要关注加速伤口闭合，缺乏对不同组织抗纤维化水凝胶设计的系统讨论。在本综述中，我们总结了瘢痕形成的关键机制，并提出水凝胶介导无瘢痕再生的设计原则。我们进一步重点介绍了在多种组织中的最新进展，包括皮肤、肌腱、角膜、尿道、神经、子宫内膜、肝脏、心肌，强调共性原则与组织特异性需求。最后，我们讨论了转化挑战和未来机遇，特别是AI驱动的水凝胶设计用于功能性再生。"}, {"pmid": "42781259", "title": "A bladder microenvironment-adaptive ceria nanozyme hydrogel enables urea-responsive intravesical chemo-immunotherapy.", "abstract": "Bladder cancer intravesical therapy remains limited by rapid urinary washout, insufficient penetration across the bladder mucosal barrier, and an immunosuppressive tumor microenvironment. Here, we developed a bladder microenvironment-adaptive chemo-immunotherapy system, Gel/UCeNZ/Gem/CpG, to improve local bladder cancer treatment. In this system, urease-modified CeO2 nanozymes (UCeNZ), gemcitabine (Gem), and CpG oligodeoxynucleotide (CpG ODN) were incorporated into an injectable thermosensitive adhesive hydrogel. After intravesical administration, the hydrogel rapidly formed a mucosa-adherent depot, thereby prolonging bladder residence and enabling sustained therapeutic release. Meanwhile, UCeNZ responded to endogenous urinary urea to enhance particle transport and mucosal penetration, improving local drug exposure beyond passive instillation. Functionally, CeO2-mediated redox regulation amplified Gem-induced oxidative stress, mitochondrial dysfunction, apoptosis, and immunogenic cell death-associated signaling, as evidenced by HMGB1 translocation/release, calreticulin exposure, and intracellular ATP dysregulation. CpG ODN further promoted dendritic cell maturation and strengthened T cell-mediated antitumor immunity. In an orthotopic bladder cancer model, Gel/UCeNZ/Gem/CpG significantly suppressed tumor progression, prolonged survival, increased CD8+ T cell infiltration, reduced regulatory T cells and M2-like macrophages, and enhanced memory/effector-like T cell activation without obvious systemic toxicity. Transcriptomic analysis further revealed coordinated regulation of oxidative stress, apoptosis, antigen presentation, cytokine signaling, T cell activation, PD-1/PD-L1 checkpoint signaling, and p53-related tumor-suppressive pathways. Overall, this study presents a bladder-adaptive intravesical chemo-immunotherapy strategy that integrates mucosal retention, urea-responsive penetration, redox-amplified immunogenic chemotherapy, and immune microenvironment remodeling for bladder cancer treatment.", "journal": "Bioactive Materials", "pub_date": "2027-Feb", "publication_types": ["Journal Article"], "doi": "10.1016/j.bioactmat.2026.09.007", "authors": ["Yulin Yuan", "Linkang Yu", "Huayi Feng", "Chuanjie Li", "Xiaogang Chen", "Longbao Feng", "Teijun Pan", "Lei Gao", "Yu Zhou", "Ling Zhang"], "affiliations": ["Medical College, Wuhan University of Science and Technology, Wuhan, Hubei, 430065, China.", "Department of Urology, General Hospital of Central Theater Command of the People's Liberation Army, Wuhan, Hubei, 430000, China.", "Department of Urology, Huangshi Central Hospital, Affiliated Hospital of Hubei Polytechnic University, Huangshi, Hubei, 435000, China.", "Hubei Key Laboratory of Kidney Disease Pathogenesis and Intervention, Huangshi, Hubei, 435003, China.", "Key Laboratory of Biomaterials of Guangdong Higher Education Institutes, Guangdong Provincial Engineering and Technological Research Centre for Drug Carrie Development, Department of Biomedical Engineering, Jinan University, Guangzhou, 510632, China.", "Healthy Hubei Development and Social Progress Research Center of the Key Research Base of Humanities and Social Sciences in Hubei Province, School of Public Health, Wuhan University of Science and Technology, Wuhan, 430065, China."], "corresponding_authors": [], "china_team": "Medical College, Wuhan University of Science and Technology, Wuhan, Hubei, 430065, China Ling Zhang团队", "category": "basic", "classification_reason": "basic_signals=10", "score": 53.49, "score_parts": {"urology_relevance": 7, "urology_in_title": 8.0, "journal_priority": 16.49, "top_journal_bonus": 10.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 10.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 20.3, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.49, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "尿素响应纳米酶水凝胶强化膀胱癌灌注治疗", "chinese_summary": "武汉科技大学医学院Ling Zhang团队在Bioactive Materials发表研究，构建尿素响应性铈纳米酶水凝胶Gel/UCeNZ/Gem/CpG，可延长膀胱滞留并增强黏膜渗透，放大吉西他滨免疫原性化疗并重塑免疫微环境。原位膀胱癌模型中显著抑制肿瘤进展、延长生存，增加CD8+ T细胞浸润，减少调节性T细胞和M2样巨噬细胞，且无明显全身毒性。", "abstract_zh": "膀胱癌膀胱内治疗仍受限于尿液快速冲刷、对膀胱黏膜屏障渗透不足以及免疫抑制性肿瘤微环境。在此，我们开发了一种膀胱微环境适应性化学免疫治疗系统Gel/UCeNZ/Gem/CpG，以改善局部膀胱癌治疗。在该系统中，脲酶修饰的CeO2纳米酶（UCeNZ）、吉西他滨（Gem）和CpG寡脱氧核苷酸（CpG ODN）被整合到可注射温敏黏附水凝胶中。膀胱内给药后，水凝胶迅速形成黏膜黏附储库，从而延长膀胱滞留时间并实现治疗药物的持续释放。同时，UCeNZ响应内源性尿液尿素以增强颗粒转运和黏膜渗透，改善局部药物暴露，优于被动灌注。在功能上，CeO2介导的氧化还原调节放大了Gem诱导的氧化应激、线粒体功能障碍、凋亡和免疫原性细胞死亡相关信号，表现为HMGB1易位/释放、钙网蛋白暴露和细胞内ATP失调。CpG ODN进一步促进树突状细胞成熟并增强T细胞介导的抗肿瘤免疫。在原位膀胱癌模型中，Gel/UCeNZ/Gem/CpG显著抑制肿瘤进展，延长生存期，增加CD8+ T细胞浸润，减少调节性T细胞和M2样巨噬细胞，并增强记忆/效应样T细胞活化，且无明显全身毒性。转录组分析进一步揭示了对氧化应激、凋亡、抗原呈递、细胞因子信号、T细胞活化、PD-1/PD-L1检查点信号和p53相关肿瘤抑制通路的协同调节。总体而言，本研究提出了一种膀胱适应性膀胱内化学免疫治疗策略，整合了黏膜滞留、尿素响应性渗透、氧化还原放大的免疫原性化疗和免疫微环境重塑，用于膀胱癌治疗。"}, {"pmid": "42830000", "title": "Exonuclease III-Proofread high-fidelity primer exchange reaction enables ultrasensitive analysis of prostate cancer MicroRNA.", "abstract": "The primer exchange reaction (PER) has emerged as a versatile isothermal amplification technique for biosensing, yet its practical application is severely hampered by non-specific hybridization-induced background signals. Here, we report a high-fidelity PER (Hf-PER) strategy that overcomes this limitation through a rationally designed template architecture integrating exonuclease III (Exo III)-mediated target recycling, blocked primer binding, and self-priming amplification. In this design, Exo III strictly discriminates perfectly matched targets from mismatched sequences, while the absence of free primers and magnetic bead separation effectively suppress spurious amplification. Using miR-21, a prostate cancer-associated biomarker, as a model, the Hf-PER assay achieves a remarkable limit of detection of 0.15 fM with a wide dynamic range spanning five orders of magnitude and single-base discrimination capability. The method demonstrates excellent recovery (95.6%-101.2%) in spiked serum samples, high repeatability (CV < 4.5%), and strong concordance with qPCR (R2 > 0.99). Moreover, it successfully distinguishes prostate cancer cells from normal cells and accurately identifies miR-21 elevation in clinical serum samples from prostate cancer patients. By simply reprogramming the recognition domain, this platform can be readily adapted for other nucleic acid biomarkers; as a proof of concept, we further applied the Hf-PER strategy to detect miR-155, achieving a limit of detection of 0.21 fM and comparable specificity, demonstrating excellent versatility. The Hf-PER strategy offers a robust, sensitive, specific, and programmable tool for early cancer diagnosis, liquid biopsy, and point-of-care testing, addressing a critical need for reliable isothermal amplification in complex biological matrices.", "journal": "Biosensors & Bioelectronics", "pub_date": "2027-Jan-01", "publication_types": ["Journal Article"], "doi": "10.1016/j.bios.2026.119288", "authors": ["Jiwei Yao", "Guoxian Deng", "Xianping Li", "Xiaowen Xia", "Junan Yan"], "affiliations": ["Department of Urology, The Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou City, Jiangsu Province, 225009, China.", "Department of Urology, The Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou City, Jiangsu Province, 225009, China. Electronic address: JAY093055@yzu.edu.cn."], "corresponding_authors": ["Junan Yan"], "china_team": "Department of Urology, The Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou City, Jiangsu Province, 225009, China Junan Yan团队", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 32.08, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 15.58, "top_journal_bonus": 0.0, "novelty": 1.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 1.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 10.5, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.58, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "高保真PER实现前列腺癌miRNA超敏检测", "chinese_summary": "扬州大学附属医院Junan Yan团队2027年1月Biosens Bioelectron报道，通过整合Exo III靶标循环、封闭引物结合与自引发扩增的高保真引物交换反应，将背景信号有效抑制。检测前列腺癌相关miR-21的检出限达0.15 fM，动态范围跨越五个数量级，可区分单碱基差异，并在临床血清中准确识别miR-21升高，为癌症液体活检提供高。", "abstract_zh": "引物交换反应（PER）已成为一种多功能的等温扩增技术，用于生物传感，但其实际应用严重受限于非特异性杂交引起的背景信号。在此，我们报道了一种高保真PER（Hf-PER）策略，通过合理设计的模板结构，整合核酸外切酶III（Exo III）介导的靶标循环、封闭引物结合和自引发扩增，克服了这一限制。在该设计中，Exo III严格区分完全匹配的靶标与错配序列，而无游离引物和磁珠分离有效抑制了虚假扩增。以前列腺癌相关生物标志物miR-21为模型，Hf-PER检测实现了0.15 fM的显著检出限，动态范围跨越五个数量级，并具备单碱基分辨能力。该方法在加标血清样本中表现出优异的回收率（95.6%-101.2%）、高重复性（CV < 4.5%），且与qPCR高度一致（R2 > 0.99）。此外，它成功区分了前列腺癌细胞与正常细胞，并准确识别了前列腺癌患者临床血清样本中miR-21的升高。通过简单重编程识别结构域，该平台可轻松适用于其他核酸生物标志物；作为概念验证，我们进一步将Hf-PER策略应用于检测miR-155，实现了0.21 fM的检出限和相当的特异性，展示了卓越的通用性。Hf-PER策略为早期癌症诊断、液体活检和即时检测提供了一种稳健、灵敏、特异且可编程的工具，满足了复杂生物基质中可靠等温扩增的关键需求。"}, {"pmid": "42810248", "title": "An anti-fouling photoelectrochemical-electrochemical sensing platform with a zwitterionic interface and a photocurrent-polarity-switching strategy.", "abstract": "In this work, we have developed a photoelectrochemical-electrochemical (PEC-EC) dual-mode sensing platform consisting of a polydopamine (PDA)-poly(sulfobetaine methacrylate) (PSBMA) anti-fouling zwitterionic interface equipped with a photocurrent-polarity-switching strategy. The PSBMA-PDA copolymer anti-fouling layer was attached to a hydrogen bonded organic framework-101 (HOF-101)-Sb2S3 modified indium titanium oxide (ITO) electrode surface using a dopamine mediated coupling reaction. The attachment of the aptamer of the model analyte prostate specific antigen (PSA) was designed to trigger a hybridisation chain reaction that linked the bifunctional factor of thionine-modified hairpin H1 and hairpin H2 to the anti-fouling electrode surface. Thionine then induced a switch from a cathodic to an anodic photocurrent at the PSBMA-PDA-HOF-101-Sb2S3/ITO, while generating a large differential pulse voltammetric current. This PSBMA-PDA interface-based anti-fouling thus acts as a dual-mode sensing platform that not only offers good anti-fouling capability by reducing non-specific adsorption, but also sensitively detects PSA over a 10 fg mL-1 - 100 ng mL-1 linear range and a detection limit of 5.0 fg mL-1 PSA in the PEC mode, and a 50 fg mL-1 - 100 ng mL-1 linear range and a detection limit of 24.6 fg mL-1 in the EC mode. This anti-fouling PEC-EC dual-mode sensing platform is readily applicable to the highly sensitive and selective detection of various disease biomarkers by simply attaching the corresponding DNA aptamer, thereby offering a promising pathway for early clinical diagnosis and point-of-care testing.", "journal": "Biosensors & Bioelectronics", "pub_date": "2027-Jan-01", "publication_types": ["Journal Article"], "doi": "10.1016/j.bios.2026.119270", "authors": ["Hejie Zheng", "Deqi Wang", "Beibei Wang", "Yubing Lv", "Shanghua Liu", "Maotian Xu", "Yanli Zhou", "Xiaoqiang Liu", "Danny K Y Wong"], "affiliations": ["Henan Key Laboratory of Biomarker Detection and Diagnosis for Neurodegenerative Diseases, College of Chemistry and Chemical Engineering, Shangqiu Normal University, Shangqiu, 476000, PR China.", "Henan Key Laboratory of Biomarker Detection and Diagnosis for Neurodegenerative Diseases, College of Chemistry and Chemical Engineering, Shangqiu Normal University, Shangqiu, 476000, PR China. Electronic address: zhouyanli@sqnu.edu.cn.", "Henan Province Engineering Research Center of Natural Medicine Quality Control and Production Process, Zhengzhou University of Industrial Technology, Zhengzhou, 451150, PR China. Electronic address: liuxq@henu.edu.cn.", "Department of Applied BioSciences, Macquarie University, Sydney, NSW, 2109, Australia. Electronic address: Danny.Wong@mq.edu.au."], "corresponding_authors": ["Yanli Zhou", "Xiaoqiang Liu", "Danny K Y Wong"], "china_team": "Henan Key Laboratory of Biomarker Detection and Diagnosis for Neurodegenerative Diseases, College of Chemistry and Chemical Engineering, Shangqiu Normal University, Shangqiu, 476000, PR China Yanli Zhou/Xiaoqiang Liu团队", "category": "basic", "classification_reason": "basic_signals=4", "score": 26.08, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 15.58, "top_journal_bonus": 0.0, "novelty": 0.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 4.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 10.5, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.58, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "双模态抗污传感平台实现超敏PSA检测", "chinese_summary": "商丘师范学院河南省神经退行性疾病标志物检测与诊断重点实验室周艳丽/刘晓强团队2027年1月Biosens Bioelectron报道，构建聚多巴胺-聚磺基甜菜碱甲基丙烯酸酯两性离子抗污界面，结合光电流极性转换策略，在多巴胺介导下修饰于HOF-101-Sb2S3/ITO电极；", "abstract_zh": "在本工作中，我们开发了一种光电化学-电化学（PEC-EC）双模式传感平台，该平台由聚多巴胺（PDA）-聚（磺基甜菜碱甲基丙烯酸酯）（PSBMA）抗污两性离子界面构成，并配备光电流极性转换策略。PSBMA-PDA共聚物抗污层通过多巴胺介导的偶联反应附着于氢键有机框架-101（HOF-101）-Sb2S3修饰的氧化铟锡（ITO）电极表面。模型分析物前列腺特异性抗原（PSA）适配体的附着被设计为触发杂交链反应，将硫堇修饰的发夹H1和发夹H2的双功能因子连接到抗污电极表面。随后硫堇诱导PSBMA-PDA-HOF-101-Sb2S3/ITO上的光电流从阴极转换为阳极，同时产生大的差分脉冲伏安电流。因此，这种基于PSBMA-PDA界面的抗污层可作为双模式传感平台，不仅通过减少非特异性吸附提供良好的抗污能力，还能灵敏检测PSA：在PEC模式下线性范围为10 fg mL-1至100 ng mL-1，检出限为5.0 fg mL-1 PSA；在EC模式下线性范围为50 fg mL-1至100 ng mL-1，检出限为24.6 fg mL-1。这种抗污PEC-EC双模式传感平台只需附着相应的DNA适配体，即可轻松应用于各种疾病生物标志物的高灵敏度和高选择性检测，从而为早期临床诊断和即时检测提供了一条有前景的途径。"}, {"pmid": "42762645", "title": "Application of a magnetic biosensor based on novel cracker-shaped noble metal nanoparticles in dual-modal multidimensional detection of bladder cancer urinary biomarker HAase.", "abstract": "Herein, a novel noble-metal nanomaterial in the shape of a cracker (AuAgPt NTCs) was synthesized. The nanoparticles exhibit outstanding Surface-enhanced Raman spectroscopy (SERS) performance (enhancement factor: 1.09 × 107) due to the tip effect of the triangular structure and edge protrusion, and plasmonic coupling from its surface pores. Based on the excellent optical properties of AuAgPt NTCs and the dissociation of nanoparticles from magnetic beads induced by hyaluronidase (HAase) hydrolysis, a dual-mode biosensor for HAase detection was developed. In SERS mode, a tungsten disulfide film was used as the SERS substrate, enhancing the biosensor's SERS performance by approximately 45.6 ± 2.3% via chemical enhancement. SERS detection of HAase activity was achieved over the range 0.001 to 100 U·mL-1, with a limit of detection (LOD) of 0.0001 U·mL-1. In colorimetric mode, the protrusions on the edges and surface pores of the AuAgPt NTCs increase the effective interaction area between light and the nanoparticles, enhancing the extinction capacity of individual particles. Therefore, this biosensor achieves detection performance comparable to that of chemical catalytic methods without the use of chemical reagents. HAase activity was detected within the range of 10 to 100 U·mL-1, with an LOD of 3.9 U·mL-1. This greatly simplifies the workflow. Furthermore, an image analysis software (Bladder Guardian) was designed for rapid tiered screening of HAase activity, achieving an accuracy rate of 93.8 ± 2.6%. In summary, this study provides a novel tool for multidimensional detection of BC urinary biomarker HAase activity.", "journal": "Biosensors & Bioelectronics", "pub_date": "2027-Jan-01", "publication_types": ["Journal Article"], "doi": "10.1016/j.bios.2026.119246", "authors": ["Hang-Zhuo Li", "Jian Zhu", "Guo-Jun Weng", "Jian-Jun Li", "Lei Li", "Yu-Bo Guo", "Jun-Wu Zhao"], "affiliations": ["The Key Laboratory of Biomedical Information Engineering of Ministry of Education, School of Life Science and Technology, Xi'an Jiaotong University, Xi'an, 710049, China; Department of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China.", "The Key Laboratory of Biomedical Information Engineering of Ministry of Education, School of Life Science and Technology, Xi'an Jiaotong University, Xi'an, 710049, China. Electronic address: zhujian@mail.xjtu.edu.cn.", "The Key Laboratory of Biomedical Information Engineering of Ministry of Education, School of Life Science and Technology, Xi'an Jiaotong University, Xi'an, 710049, China.", "Department of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China.", "The Key Laboratory of Biomedical Information Engineering of Ministry of Education, School of Life Science and Technology, Xi'an Jiaotong University, Xi'an, 710049, China. Electronic address: nanoptzhao@163.com."], "corresponding_authors": ["Jian Zhu", "Jun-Wu Zhao"], "china_team": "The Key Laboratory of Biomedical Information Engineering of Ministry of Education, School of Life Science and Technology, Xi'an Jiaotong University, Xi'an, 710049, China; Department of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China Jian Zhu/Jun-Wu Zhao团队", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 35.08, "score_parts": {"urology_relevance": 7, "urology_in_title": 8.0, "journal_priority": 15.58, "top_journal_bonus": 0.0, "novelty": 1.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 1.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 10.5, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.58, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "新型磁生物传感器双模式检测膀胱癌尿标志物", "chinese_summary": "西安交通大学朱健/赵军武团队9月Biosens Bioelectron合成饼干状AuAgPt纳米颗粒，借其SERS增强与磁珠解离构建HAase双模式传感器，SERS检测限达0.0001 U·mL⁻¹，并开发图像软件实现93.8%准确率分层筛查。", "abstract_zh": "本文合成了一种新型的饼干状贵金属纳米材料（AuAgPt NTCs）。由于三角形结构的尖端效应和边缘突起，以及其表面孔隙引起的等离激元耦合，该纳米颗粒表现出优异的表面增强拉曼光谱（SERS）性能（增强因子：1.09 × 10⁷）。基于AuAgPt NTCs优异的光学性质以及透明质酸酶（HAase）水解诱导纳米颗粒从磁珠上解离，开发了一种用于HAase检测的双模式生物传感器。在SERS模式下，使用二硫化钨薄膜作为SERS基底，通过化学增强使生物传感器的SERS性能提高约45.6 ± 2.3%。实现了HAase活性的SERS检测，范围为0.001至100 U·mL⁻¹，检测限（LOD）为0.0001 U·mL⁻¹。在比色模式下，AuAgPt NTCs边缘的突起和表面孔隙增加了光与纳米颗粒之间的有效相互作用面积，从而增强单个颗粒的消光能力。因此，该生物传感器在不使用化学试剂的情况下，实现了与化学催化方法相当的检测性能。HAase活性检测范围为10至100 U·mL⁻¹，LOD为3.9 U·mL⁻¹。这极大简化了工作流程。此外，还设计了一款图像分析软件（Bladder Guardian），用于HAase活性的快速分层筛查，准确率达到93.8 ± 2.6%。总之，本研究为膀胱癌尿液生物标志物HAase活性的多维检测提供了一种新工具。"}, {"pmid": "42771543", "title": "IL-15 trans-presentation at the innate-adaptive interface: mechanisms and translation in cancer immunotherapy.", "abstract": "Durable antitumor immunity requires innate activation, antigen presentation, lymphocyte priming, trafficking, and effector function. In immunologically cold tumors, deficient dendritic-cell and natural killer (NK)-cell activation limits the transition from tumor-antigen recognition to CD8 T-cell immunity. Interleukin-15 (IL-15) is a member of the common gamma-chain cytokine family with a distinctive receptor-delivery system at this innate-adaptive interface. In native trans-presentation, IL-15 is stabilized by IL-15 receptor alpha (IL-15Rα) on an antigen-presenting cell and presented to CD122/CD132 on an apposed NK or memory CD8 T cell. This contact-dependent arrangement supports NK-cell homeostasis, memory CD8 T-cell maintenance, and spatially restricted signaling while avoiding the CD25-dependent regulatory T-cell preference of IL-2. IL-12, IL-15, and IL-18 can generate cytokine-induced memory-like NK cells with enhanced recall. These programs are constrained by intrinsic CISH feedback and by tumor-associated TGF-β, PD-L1, TIGIT, adenosine, and other suppressive pathways. Pharmacologic IL-15 receptor agonizts such as N-803 reproduce selected receptor-binding features of trans-presentation but do not reproduce its native source-cell, contact, or spatial restrictions. The durable activity of intravesical N-803 plus bacillus Calmette-Guérin in BCG-unresponsive non-muscle-invasive bladder cancer establishes clinical relevance in a localized combination setting, whereas systemic solid-tumor studies have shown pharmacodynamic lymphocyte expansion with more limited or variable clinical activity. This narrative review synthesizes IL-15 receptor biology, innate and adaptive effector programs, counter-regulation, and clinical translation. It presents the 'innate bootstrap' as a mechanistic hypothesis: appropriately timed IL-15-axis engagement may strengthen an impaired innate-to-adaptive handoff, with efficacy determined by route, tissue context, partner therapy, exposure schedule, and patient selection.", "journal": "Oncoimmunology", "pub_date": "2026-Dec-31", "publication_types": ["Journal Article", "Review"], "doi": "10.1182/blood-2006-03-006700", "authors": ["Corey Keith Goldman"], "affiliations": ["NYU Langone Health/MedAlliance Medical Health Services, New York, NY, United States."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 16.92, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 10.92, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 6.3, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.92, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42758101", "title": "Gut microbiota: a novel key player in urinary stone formation - from oxalate metabolism to systemic regulation.", "abstract": "Kidney stones represent a globally prevalent disease with a rising incidence associated with multiple factors, including obesity and metabolic syndrome. While traditional research has primarily focused on dietary nutrition and metabolic abnormalities, recent years have seen growing recognition of the gut microbiota as a key novel regulator in stone formation. Accumulating cross-sectional evidence suggests that kidney stone patients are often associated with alterations in gut microbiota composition and function compared with healthy individuals. The gut microbiota may influence kidney stone formation risk through multiple potential mechanisms, including affecting oxalate metabolism, calcium-phosphorus absorption, short-chain fatty acid and bile acid pathways, and regulating systemic inflammatory and immune states. More importantly, this \"gut-kidney axis\" function of the gut microbiota holds clinical translational potential, suggesting that targeted microbial interventions may emerge as novel strategies for preventing and treating kidney stones. This review explores the association between gut microbiota and kidney stones, discussing clinical evidence, underlying mechanisms, and intervention strategies while analyzing current challenges and outlining future research directions.", "journal": "Gut Microbes", "pub_date": "2026-Dec-31", "publication_types": ["Journal Article", "Review"], "doi": "10.15252/msb.202110539", "authors": ["Kenan Wang", "Weiwei Fan", "Qizhen Tang", "Quanxin Su"], "affiliations": ["Department of Urology, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China."], "corresponding_authors": [], "china_team": "Department of Urology, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China Quanxin Su团队", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 40.65, "score_parts": {"urology_relevance": 7, "urology_in_title": 8.0, "journal_priority": 15.65, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 5.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 2.0}, "journal_metrics": {"status": "ok", "impact_factor": 11.0, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.65, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42831025", "title": "Spontaneous dissolution of a renal pelvic stone with intrastone gas: A case report with serial CT findings.", "abstract": "Spontaneous dissolution of a large renal pelvic stone is extremely rare. We report the case of a 65-year-old man with paraplegia below Th6 who experienced recurrent febrile urinary tract infections beginning in May 2016. Noncontrast computed tomography (CT) in August 2016 revealed a right renal pelvic stone measuring 26 × 13 mm. During long-term follow-up, serial CT imaging demonstrated structural homogenization, central cavitation, progressive rim thinning associated with intrastone gas, and complete disappearance by November 2020. CT attenuation analysis suggested a uric acid-dominant core surrounded by a calcium-containing shell. Extremely low attenuation values within the central cavity (mean -364 HU) supported the presence of intrastone gas rather than fluid. These observations may suggest that dynamic interactions among urinary pH, stone composition, and intrastone bacterial activity may promote progressive internal weakening and spontaneous dissolution of mixed-composition renal stones.", "journal": "Radiology Case Reports", "pub_date": "2026-Dec", "publication_types": ["Case Reports", "Journal Article"], "doi": "10.1016/j.radcr.2026.08.082", "authors": ["Norio Yamamoto", "Shinji Akao", "Takesuke Yamashita", "Kaoru Ono", "Tsuneo Koganemaru"], "affiliations": ["Department of Urology, Tokuyama Medical Association Hospital, Yamaguchi, Japan.", "Department of Surgery, Tokuyama Medical Association Hospital, Yamaguchi, Japan.", "Internal Medicine, Yamashita Internal Medicine Clinic, Yamaguchi, Japan.", "Internal Medicine, Ono Internal Medicine Clinic, Yamaguchi, Japan.", "Department of Urology, Yuno Onsen Hospital, Yamaguchi, Japan."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_clinical", "score": 10.0, "score_parts": {"urology_relevance": 7, "urology_in_title": 0.0, "journal_priority": 0.0, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 1.0}, "journal_metrics": {"status": "missing", "impact_factor": null, "cas_zone": null, "cas_zone_points": 0.0, "impact_factor_points": 0.0}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42830746", "title": "From imaging to impact: A case of renal arteriovenous malformation.", "abstract": "Renal arteriovenous malformations (rAVMs) are rare vascular anomalies, presenting with gross hematuria and requiring prompt diagnosis and management. We reported a case of a middle-aged male presenting with persistent and unexplained gross hematuria. Initial cystoscopy revealed a significant burden in the urinary bladder without any identifiable bleeding source. Contrast-enhanced computed tomography followed by CT angiography demonstrated a vascular nidus with early venous filling at the lower pole of the left kidney, consistent with rAVMs. The patient had a successful selective transcatheter embolization involving polyvinyl alcohol particles, coils, and a lipiodol-based embolic agent. Postembolization angiography confirmed a substantial reduction in arteriovenous shunting, with the preservation of renal parenchyma. The patient reported transient postprocedure flank pain and hematuria; however, hemoglobin levels and renal function remained stable. This situation highlights the significance of evaluating vascular causes in cases of unexplained hematuria and supports the endovascular embolization as a viable, kidney-preserving treatment option.", "journal": "Radiology Case Reports", "pub_date": "2026-Dec", "publication_types": ["Case Reports", "Journal Article"], "doi": "10.1016/j.radcr.2026.08.024", "authors": ["Nadia Nazir", "Usman Zafar", "Fatima Baluch", "Khalid Javed", "Din Muhammad", "Kashif Siddique"], "affiliations": ["Department of Radiology, Shaukat Khanum Memorial Cancer Hospital and Research Center, Lahore, Pakistan."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_clinical", "score": 10.0, "score_parts": {"urology_relevance": 7, "urology_in_title": 0.0, "journal_priority": 0.0, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 1.0}, "journal_metrics": {"status": "missing", "impact_factor": null, "cas_zone": null, "cas_zone_points": 0.0, "impact_factor_points": 0.0}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42824364", "title": "Nanoparticle-based therapeutic platforms for inflammatory disorders of the urinary system: Engineering local delivery, biointerface regulation, and smart responsive therapy.", "abstract": "Inflammatory diseases of the urinary system, including urinary tract infection (UTI), catheter-associated urinary tract infection (CAUTI), interstitial cystitis/bladder pain syndrome (IC/BPS), and chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), are associated with high recurrence, complex pathogenesis, and limited therapeutic durability. Conventional treatments are constrained by antimicrobial resistance, biofilm persistence, intracellular bacterial reservoirs, urine washout, urothelial and prostatic barriers, indwelling device surfaces, and heterogeneous neuroimmune inflammatory mechanisms. Nanoparticles provide versatile platforms to address these challenges through tunable physicochemical properties, controlled release, local retention, tissue penetration, and intrinsic material functions. This review summarizes the pathological basis and therapeutic limitations of major inflammatory urinary disorders and discusses recent advances in organic, inorganic, and hybrid nanoplatforms. In infectious diseases, nanoparticles can enhance antibiotic delivery, promote biofilm penetration and intracellular pathogen clearance, and functionalize catheter or stent surfaces with antibacterial, antibiofilm, and anti-encrustation properties. In noninfectious disorders, they support intravesical retention, glycosaminoglycan-layer repair, oxidative-stress modulation, immune regulation, pain-pathway intervention, and prostatic or rectal delivery. Emerging applications in upper UTI and renal inflammatory injury further expand their therapeutic scope. Finally, we discuss current translational barriers, including model fidelity, long-term safety, manufacturing control, clinical evidence, and rational functional integration.", "journal": "Materials Today Bio", "pub_date": "2026-Dec", "publication_types": ["Journal Article", "Review"], "doi": "10.1002/aidi.202500205", "authors": ["Wang Wang", "Jiayi Ma", "Changhao Hou", "Jiasheng Chen", "Kai Ni"], "affiliations": ["Department of Urology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200233, China."], "corresponding_authors": [], "china_team": "Department of Urology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200233, China Kai Ni团队", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 44.54, "score_parts": {"urology_relevance": 18.0, "urology_in_title": 8.0, "journal_priority": 15.54, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 1.0}, "journal_metrics": {"status": "ok", "impact_factor": 10.2, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.54, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42824026", "title": "Fused right S-shaped kidney incidentally detected on multidetector CT during staging of periampullary adenocarcinoma: A case report.", "abstract": "Supernumerary kidney is an uncommon congenital renal anomaly with complex vascular and collecting-system anatomy, making accurate preoperative imaging essential for diagnosis and surgical planning. We report the case of a 58-year-old man who underwent contrast-enhanced CT for staging of periampullary adenocarcinoma, which incidentally revealed an ipsilateral fused supernumerary kidney with an S-shaped configuration. Imaging demonstrated two fused right renal moieties with separate arterial supplies, distinct pelvicalyceal systems, distal ureteric fusion, and a common right renal vein. An associated undescended right testis was also identified. Multiplanar and three-dimensional CT reconstructions enabled detailed delineation of the renal vascular and collecting-system anatomy. This case highlights the pivotal role of multidetector CT in diagnosing and characterizing complex renal fusion anomalies and in defining variant vascular and ureteric anatomy, thereby facilitating accurate preoperative assessment and safe surgical planning.", "journal": "Radiology Case Reports", "pub_date": "2026-Dec", "publication_types": ["Case Reports", "Journal Article"], "doi": "10.1148/rg.2021200174", "authors": ["Shreya Shukla", "Tushar Sirohi", "Satyendra Narayan Singh"], "affiliations": ["Department of Radiology, Mahamana Pandit Madan Mohan Malaviya Cancer Centre (MPMMCC) and Homi Bhabha Cancer Hospital (HBCH), Tata Memorial Centre, Varanasi, Uttar Pradesh, India.", "Homi Bhabha National Institute (HBNI), Mumbai, Maharashtra, India."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_clinical", "score": 6.0, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 0.0, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "missing", "impact_factor": null, "cas_zone": null, "cas_zone_points": 0.0, "impact_factor_points": 0.0}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42787847", "title": "Emphysematous pyelonephritis in a pelvic ectopic kidney: A rare case report.", "abstract": "Emphysematous pyelonephritis (EPN) is a rare, life-threatening necrotizing renal infection characterized by gas formation within the renal parenchyma, collecting system, or perirenal tissues. Its occurrence in a pelvic ectopic kidney is exceptionally uncommon. We report the case of a 56-year-old man with poorly controlled type 2 diabetes mellitus who presented with fever, pelvic pain, and septic shock. Computed tomography (CT) demonstrated a left pelvic ectopic kidney with multiple renal calculi and an obstructing ureteral calculus, with gas confined to the collecting system, consistent with Huang and Tseng Class I EPN. Despite emergency management, the patient developed refractory septic shock with multiorgan failure and died 2 days after admission. This case highlights the exceptional association of EPN with a pelvic ectopic kidney and the pivotal role of CT in identifying the anatomical anomaly, classifying disease severity, detecting obstructive urolithiasis, and guiding therapeutic management.", "journal": "Radiology Case Reports", "pub_date": "2026-Dec", "publication_types": ["Case Reports", "Journal Article"], "doi": "10.1111/j.1464-410X.2010.09660.x", "authors": ["Soukaina Bichichi", "Mohamed Laghdaf Maouelainin", "Aya Yming", "Mohamed Amine Idoikrim", "Hassan Doulhousne", "Abdenasser El Kharras", "Zakaria Abide"], "affiliations": ["Radiology Department, Military Hospital Oued Eddahab, Agadir, Morocco.", "Radiology Department, University Hospital Center of Mohammed VI, Agadir, Morocco.", "Faculty of Medicine and Pharmacy, Ibn Zohr University, Agadir, Morocco."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_clinical", "score": 10.0, "score_parts": {"urology_relevance": 8, "urology_in_title": 0.0, "journal_priority": 0.0, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "missing", "impact_factor": null, "cas_zone": null, "cas_zone_points": 0.0, "impact_factor_points": 0.0}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42781443", "title": "Vaginal insertion of ureter with uterus didelphys and ipsilateral renal agenesis: A case report.", "abstract": "Uterus didelphys with vaginal insertion of ureter with ipsilateral renal agenesis is a rare congenital anomaly of the female urogenital development. In this case, we present a 45-year-old-woman with uterus didelphys, longitudinal vaginal septum, and right renal malformations. A remanent of the right ureter inserted into the vaginal fornix alongside an absent ipsilateral kidney was discovered during preoperative MR imaging. Few cases of vaginal insertion of the ureter with uterus didelphys have been reported in the literature. Due to the rarity and anatomical complexity of uterus didelphys, alongside typical asymptomatic presentation, precise pre-operative imaging is integral for successful obstetric and gynecological surgical planning and execution.", "journal": "Radiology Case Reports", "pub_date": "2026-Dec", "publication_types": ["Case Reports", "Journal Article"], "doi": "10.1590/s1516-31802009000200007", "authors": ["Annie Ho", "Erin N Gomez"], "affiliations": ["Johns Hopkins University School of Medicine, 733 North Broadway, Baltimore, MD 21205, USA.", "The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, 601 N. Caroline, Baltimore, MD 21205, USA."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_clinical", "score": 14.0, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 0.0, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "missing", "impact_factor": null, "cas_zone": null, "cas_zone_points": 0.0, "impact_factor_points": 0.0}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42781221", "title": "Multimodality imaging of high-grade prostate adenocarcinoma with diffusion MRI, PSMA PET and dual-layer spectral CT: A case report.", "abstract": "Multiparametric MRI and prostate-specific membrane antigen positron emission tomography (PSMA PET) have become established imaging modalities for the diagnosis and staging of prostate cancer. Dual-layer spectral computed tomography (DLCT) permits retrospective material decomposition and iodine quantification, which may provide additional information regarding tissue iodine distribution and vascularity. The role of spectral CT in primary prostate cancer assessment remains incompletely characterized. We present the case of a 49-year-old man with a prostate-specific antigen (PSA) level of 140 ng/mL who underwent multiparametric MRI, PSMA PET and DLCT as part of his diagnostic workup. Dual-layer spectral CT demonstrated an irregular, approximately L-shaped region of increased iodine concentration within the prostate, with increased conspicuity on 40-keV virtual monoenergetic images (VMI). Subsequent multiparametric MRI demonstrated spatially corresponding restricted diffusion on high b-value imaging, while PSMA PET demonstrated concordant radiotracer uptake. This case illustrates concordant visualization of biopsy-proven high-grade prostate adenocarcinoma across three complementary imaging techniques: restricted diffusion on MRI, PSMA radiotracer uptake on PET, and increased iodine concentration on spectral CT. The observation supports further investigation of quantitative spectral CT parameters in prostate cancer.", "journal": "Radiology Case Reports", "pub_date": "2026-Dec", "publication_types": ["Case Reports", "Journal Article"], "doi": "10.1007/s00330-020-07671-2", "authors": ["Zane Sherif", "Kirralee Sherif", "Amanda Forbes"], "affiliations": ["Mermaid Beach Radiology, Gold Coast, Queensland, Australia."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_clinical", "score": 16.0, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 0.0, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 2.0}, "journal_metrics": {"status": "missing", "impact_factor": null, "cas_zone": null, "cas_zone_points": 0.0, "impact_factor_points": 0.0}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42859558", "title": "Incisional Hernia After Minimally Invasive Radical Prostatectomy: A Systematic Review.", "abstract": "Incisional hernia (IH) is an under-recognized complication after minimally invasive radical prostatectomy (MIRP). We performed a systematic review according to Preferred Reporting Items for Systematic reviews and Meta-Analyses guidelines to evaluate the proportion, risk factors, and surgical determinants of IH after MIRP. Sixteen studies published between 2010 and 2025 were included, encompassing 56 661 patients. Most were retrospective cohorts, with heterogeneous definitions and diagnostic methods. The reported proportion of IH ranged from 0.04% to 31%, with a median time to diagnosis of 14 mo. Repair was required in up to 80% of cases, and emergency repair in up to 15%. Two comparative studies directly evaluating specimen extraction site consistently reported lower proportions of IH with transverse suprapubic (Pfannenstiel) extraction than with periumbilical extraction, while three registry-based studies similarly reported lower proportions following open compared with MIRP. Evidence regarding the influence of fascial incision orientation on reported IH occurrence was mixed, whereas no clear difference was reported between midline and off-midline extraction sites. Reported factors associated with IH included advanced age, obesity, larger prostate volume, postoperative parietal abscess, and prior abdominal surgery. Limitations include the heterogeneity in the studies included. These findings highlight IH as a clinically meaningful complication of MIRP. Reported IH occurrence differed by specimen extraction site in the available observational studies, but the evidence remains limited by heterogeneous definitions, follow-up, and risk of bias. Preventive strategies, including the site of specimen extraction, warrant further prospective evaluation.", "journal": "European Urology Open Science", "pub_date": "2026-Nov", "publication_types": ["Journal Article", "Review"], "doi": "10.1016/j.euros.2026.08.002", "authors": ["Arthur Peyrottes", "Olivier Oberlin", "Michael Baboudjian", "Charles Dariane", "Frederic Panthier", "Pierre Mongiat-Artus", "François Desgrandchamps", "Guillaume Ploussard", "Alexandra Masson-Lecomte"], "affiliations": ["Department of Urology, Hôpital Saint-Louis, AP-HP, Université Paris Cité, Paris, France.", "Department of General Surgery, Groupe Hospitalier Privé Ambroise-Paré - Hartmann, Paris, France.", "Department of Urology, Hôpital Nord, Université Aix-Marseille, Marseille, France.", "Aix Marseille Univ, CNRS, CINAM, ERL INSERM U 1326, CERIMED, Marseille, France.", "Department of Urology, Hôpital Européen Georges Pompidou, AP-HP, Université Paris Cité, Paris, France.", "Paris University, U1151 Inserm-INEM, Necker, Paris, France.", "Department of Urology, Hôpital Tenon, AP-HP, Sorbonne Université, Paris, France.", "Department of Urology, La Croix du Sud Hospital, Quint Fonsegrives, France."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 34.5, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.5, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 10.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.5, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.5, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42831142", "title": "PRECISE Assessment of Sequential Biparametric MRI and Clinically Significant Prostate Cancer in Biopsy-naive Men: A Retrospective Cohort Study.", "abstract": "In real-world practice, some biopsy-naive men with suspected prostate cancer (PCa) defer immediate biopsy and undergo magnetic resonance imaging (MRI) follow-up, yet standardized criteria to interpret MRI changes are lacking. To evaluate the association of the Prostate Cancer Radiological Estimation of Change in Sequential Evaluation (PRECISE) assessment of sequential biparametric MRI with clinically significant PCa (csPCa) at subsequent biopsy. This retrospective single-center study included 174 biopsy-naive men who underwent at least two prebiopsy MRI examinations separated by ≥12 mo between 2019 and 2025. Two blinded radiologists assigned the Prostate Imaging Reporting and Data System (PI-RADS) categories and scored interval change using PRECISE version 2. All patients underwent prostate biopsy. The primary outcome was csPCa at subsequent biopsy, defined as International Society of Urological Pathology grade group ≥2. Multivariable Firth penalized logistic regression assessed factors associated with csPCa. Biopsy showed no PCa in 81 of the 174 (47%) men, clinically insignificant PCa in 20 of the 174 (12%) men, and csPCa in 73 of the 174 (42%) men. The csPCa rates increased with PRECISE: 6.1% (PRECISE 2/3-NonV), 26% (3-V), and 81% (4-5). After adjustment, the natural log of repeat prostate-specific antigen density (PSAD; odds ratio [OR] 2.14, 95% confidence interval [CI] = 1.10-4.44) and PRECISE 4-5 versus 2/3-NonV (OR 15.21, 95% CI = 2.97-104.44) remained associated with csPCa. Exploratory analysis showed that integrating baseline PI-RADS assessment with longitudinal MRI changes was associated with different observed rates of csPCa detection. Limitations include retrospective single-center design and sample size. Sequential PRECISE assessment and repeat PSAD were associated with csPCa; prospective validation is required.", "journal": "European Urology Open Science", "pub_date": "2026-Nov", "publication_types": ["Journal Article"], "doi": "10.1016/j.euros.2026.09.002", "authors": ["Yuxuan Tian", "Zhijian Liu", "Shuyuan Chen", "Yuxi Zhou", "Mingjian Ruan", "Derun Li", "Jingyun Wu", "Yu Fan", "Yi Liu"], "affiliations": ["Department of Urology, Peking University First Hospital, Beijing, China.", "Institute of Urology, Peking University, Beijing, China.", "National Urological Cancer Center of China, Beijing, China.", "Beijing Key Laboratory of Precision Medicine and Innovative Translation for Urogenital Diseases, Beijing, China.", "Department of Radiology, Peking University First Hospital, Beijing, China.", "Department of Urology, Peking University Cancer Hospital, Beijing, China.", "Drug Clinical Trial Institution, Peking University First Hospital, Beijing, China."], "corresponding_authors": [], "china_team": "Department of Urology, Peking University First Hospital, Beijing, China Yi Liu团队", "category": "clinical_review", "classification_reason": "clinical_signals=9", "score": 37.5, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 10.5, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 9.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.5, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.5, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42828777", "title": "Evolutions in the management of severe male infertility.", "abstract": "", "journal": "Current Opinion in Urology", "pub_date": "2026-Nov-01", "publication_types": ["Journal Article"], "doi": "10.1097/MOU.0000000000001447", "authors": ["Peter N Schlegel"], "affiliations": ["New York Men's Health Medical, New York, New York, USA."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 13.71, "score_parts": {"urology_relevance": 3, "urology_in_title": 8.0, "journal_priority": 5.71, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.2, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.71, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42828776", "title": "Integrative men's health: testosterone, metabolic fitness, and preventive urology.", "abstract": "", "journal": "Current Opinion in Urology", "pub_date": "2026-Nov-01", "publication_types": ["Journal Article"], "doi": "10.1097/MOU.0000000000001444", "authors": ["Marlon Martinez", "Ranjith Ramasamy"], "affiliations": ["Section of Urology, Department of Surgery, University of Santo Tomas Hospital, Manila, Philippines.", "Jumeirah American Clinic, Dubai, United Arab Emirates."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 14.71, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 5.71, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.2, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.71, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42828270", "title": "PSMA PET/CT Kinetics During Systemic Therapy and Radiotherapy in Hormone-sensitive Prostate Cancer: A Systematic Review.", "abstract": "Although prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) is commonly used for both initial staging and restaging at biochemical recurrence for patients diagnosed with prostate cancer (PCa), its role in the evaluation of treatment response is currently not validated. We aimed to identify studies that implemented PSMA PET/CT as a restaging modality for patients with hormone-sensitive PCa (HSPC) and highlight the evolution of PSMA PET/CT parameters to assess its potential use for treatment response evaluation. A systematic review was performed using the MEDLINE, Scopus, and Embase databases until December 2025. Studies deemed eligible were those reporting PSMA expression dynamics under either systemic therapy or after radiotherapy (RT). A total of 11 studies were included, including two prospective single-arm studies and nine retrospective studies. Under androgen deprivation therapy (ADT), a decrease in PSMA expression was observed across all disease sites. In one prospective study, a flare phenomenon (increase ≥20% in tracer uptake) was observed at the lesion level in 26% of bone lesions and 11% of nodal and prostate lesions at 3-4 wk, with a median change in maximum standardized uptake value (ΔSUVmax) of +50% (interquartile range 32-72) in bone lesions showing flare. At 22 wk, one retrospective study reported mean SUVmax reductions of 48%, 59%, and 74% in prostate, nodal, and bone lesions, respectively. Other studies at different time points each reported reductions in prostate SUVmax ranging from 49% to 67%, with differences in whether estimates were summarized as means or medians. After RT, one retrospective study suggested that the reduction in prostate SUVmax may be more pronounced in patients receiving concomitant ADT (mean reduction -59% ± 25% vs -45% ± 31% for RT alone; p = 0.004). PSMA PET-derived parameters hold the potential to personalize treatment strategies depending on treatment response. The relationship between changes in PSMA expression and oncological outcomes warrants further investigation in other studies.", "journal": "European Urology Open Science", "pub_date": "2026-Nov", "publication_types": ["Journal Article", "Review"], "doi": "10.1016/j.euros.2026.09.003", "authors": ["Jennifer Le Guévelou", "Matteo Bauckneht", "Timo F W Soeterik", "Matthijs Scheltema", "Lorenzo Bianchi", "Claudia Kesch", "Giorgio Gandaglia", "Pawel Rajwa", "Rossella Nicoletti", "Fabio Zattoni", "Alberto Martini", "Vittorio Fasulo", "Veeru Kasivisvanathan", "Felix Preisser", "Lara Rodriguez Sanchez", "Francesca Ambrosini", "Ugo Falagario", "Tamas Fazekas", "Alexander Giesen", "Guido Rovera", "Martina Maggi", "Chiara Mercinelli", "Marcin Miszczyk", "Juan Gomez Rivas", "Olivier Windisch", "Hein Stroomberg", "Bernardino Rui", "Ali Bourgi", "Derya Tilki", "Giancarlo Marra", "EAU-YAU Prostate Cancer Working Group"], "affiliations": ["Department of Radiation Oncology, Centre Hospitalier Régional Universitaire de Tours, Tours, France.", "Nuclear Medicine, IRCCS Azienda Ospedaliera Metropolitana, Genova, Italy.", "Department of Health Sciences (DISSAL), University of Genova, Italy.", "Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.", "St. Vincent's Prostate Cancer Research Centre, Sydney, New South Wales, Australia.", "Division of Urology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.", "Università degli Studi di Bologna, Bologna, Italy.", "Department of Urology, West German Cancer Center, University Hospital Essen, Essen, Germany.", "Unit of Urology/Division of Oncology, IRCCS Ospedale San Raffaele, Milan, Italy.", "Vita-Salute San Raffaele University, Milan, Italy.", "Department of Urology, Medical University of Silesia, Zabrze, Poland.", "Department of Experimental and Clinical Biomedical Science, University of Florence, Florence, Italy.", "Department of Precision Medicine in the Medical, Surgical and Critical Care Area (Me.Pre.C.C.), University of Palermo, Palermo, Italy.", "Department of Surgery, Oncology and Gastroenterology (DISCOG), University of Padua, Padua, Italy.", "Department of Urology, University of Cincinnati College of Medicine, Cincinnati, USA.", "Department of Urology, IRCCS Humanitas Research Hospital, Milan, Italy.", "Centre for Urology Imaging, Prostate, AI and Surgical Studies (COMPASS) Research Group, Division of Surgery and Interventional Science, University College London, London, UK.", "Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.", "Martini-Klinik Prostate Cancer Centre, University Hospital Hamburg-Eppendorf, Hamburg, Germany.", "Department of Urology, Institut Mutualiste Montsouris, Paris, France.", "Department of Urology, IRCCS Ospedale Policlinico San Martino, Genova, Italy.", "Department of Urology and Kidney Transplantation, University of Foggia, Foggia, Italy.", "Department of Urology, Semmelweis University, Budapest, Hungary.", "Department of Urology, UZ Leuven, Leuven, Belgium.", "Department of Development and Regeneration, KU Leuven, Leuven, Belgium.", "Department of Nuclear Medicine, San Giovanni Battista Hospital, Città della Salute e della Scienza, Italy.", "Department of Urology, ASST Santi Paolo E Carlo, University of Milan, Milan, Italy.", "Medical Oncology Department, IRCCS Ospedale San Raffaele, Comprehensive Cancer Center, Milan, Italy.", "Università Vita-Salute San Raffaele, Milan, Italy.", "Collegium Medicum, Faculty of Medicine, WSB University, Dąbrowa Górnicza, Poland.", "Servicio de Urología, Hospital Clínico San Carlos, Madrid, Spain.", "Universidad Complutense de Madrid, Facultad de Medicina, Departamento de Cirugía, Sección de Urología, Madrid, Spain.", "Department of Urology, University Hospital of Geneva, Geneva, Switzerland.", "Faculty of Medicine, Geneva University, Geneva, Switzerland.", "Urological Research Unit, Department of Urology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.", "Biotech Innovation & Research Centre, University of Copenhagen, Copenhagen, Denmark.", "Glickman Urological Institute, Cleveland Clinic, Cleveland, USA.", "Department of Urology, CHRU Tours, Tours, France.", "Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany.", "Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany.", "Department of Urology, Koc University Hospital, Istanbul, Turkey.", "Department of Urology, San Giovanni Battista Hospital, Città della Salute e della Scienza and University of Turin, Turin, Italy."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 31.5, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.5, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 7.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.5, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.5, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42828258", "title": "Reply to Drs. Bayraktar and İşler's Letter to the Editor re: Basadonna LM, Passarelli F, Graps G, et al. Music During Transperineal Prostate Biopsy (The VIVALDI Trial): A Few Questions on the Gap Between Self-reported Benefit and Objective Findings.", "abstract": "", "journal": "European Urology Open Science", "pub_date": "2026-Nov", "publication_types": ["Letter"], "doi": "10.1016/j.euros.2026.09.001", "authors": ["Ludovico Maria Basadonna", "Elisa De Lorenzis", "Giancarlo Albo", "Luca Boeri"], "affiliations": ["Department of Urology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.", "Dipartimento di Scienze Cliniche e di Comunità, Dipartimento di Eccellenza 2023-2027, Milan, Italy."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 19.5, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.5, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.5, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.5, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42820048", "title": "Ex Vivo Microtumor Testing to Predict Chemotherapy Responses in Patients with Bladder Cancer.", "abstract": "Patients with bladder cancer (BC) may receive intravesical or systemic chemotherapy, but predictive biomarkers to guide treatment selection are lacking. Consequently, some patients receive ineffective treatment, resulting in unnecessary toxicity and an increased risk of tumor progression. To evaluate the feasibility of ex vivo micro-tumor testing for predicting chemotherapy response in patients with BC. In this prospective study, 65 patients with BC were enrolled (Institutional Review Board no. MEC-2022-0233). Tumor samples were collected during transurethral resection or radical cystectomy. BC was confirmed by uropathological review, supported by the detection of BC-associated mutations in hTERT, FGFR3, and PIK3CA. Patient-derived micro-tumors were exposed ex vivo to anticancer drugs, and responses were assessed using image-based measurements of viability and morphology. The primary outcome was successful completion of ex vivo drug testing within 14 days of tissue collection. The secondary outcome was concordance between ex vivo sensitivity and clinical response to platinum-based chemotherapy. Clinical response data were available for nine patients. Ex vivo drug testing was successful for 48 of 65 patients (74%), with all successful results generated within 14 days of tissue collection. Among the nine patients with evaluable clinical outcomes following platinum-based chemotherapy, ex vivo responses corresponded with observed treatment responses. The main limitations were the small clinical correlation cohort and the limited number of drugs evaluated. Ex vivo micro-tumor drug testing is feasible for BC within a clinically relevant timeframe. The observed correspondence between ex vivo and clinical responses to platinum-based chemotherapy supports further investigation of this approach for personalized treatment selection in BC.", "journal": "European Urology Open Science", "pub_date": "2026-Nov", "publication_types": ["Journal Article"], "doi": "10.1016/j.euros.2026.07.009", "authors": ["Mathijs P Scholtes", "Esmee Koedoot", "Lieke J Ceton", "Timothy J P Sijsenaar", "Marta G Montero", "Caithlyn Z Roeland", "Robert J van Soest", "Joost Leijte", "Hossein Roshani", "Ruben Korthorst", "Dieudonné J van der Meer", "Geert J L H van Leenders", "Willemijn Vader", "Joost L Boormans", "Tahlita C M Zuiverloon"], "affiliations": ["Department of Urology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.", "R&D, VitroScan B.V., Leiden, The Netherlands.", "Urology, Franciscus Gasthuis & Vlietland, Rotterdam, The Netherlands.", "Urology, Amphia Ziekenhuis-location Molengracht, Breda, The Netherlands.", "Urology, Haga teaching hospital, The Hague, The Netherlands.", "Urology, Medisch Spectrum Twente, Enschede, The Netherlands.", "Department of Pathology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=7", "score": 40.0, "score_parts": {"urology_relevance": 12, "urology_in_title": 8.0, "journal_priority": 10.5, "top_journal_bonus": 0.0, "novelty": 0.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 7.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.5, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.5, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42787789", "title": "Re: Nielsen N.K, Hjort P.B, Hansen E.B, et al. Substaging and stratified treatment of T1 bladder cancer - a nationwide register‑based study. Eur Urol Open Sci 2026;90:92‑100.", "abstract": "", "journal": "European Urology Open Science", "pub_date": "2026-Nov", "publication_types": ["Letter"], "doi": "10.1016/j.eururo.2026.04.009", "authors": ["Xin Li", "Yapeng Xing"], "affiliations": ["Department of Urology, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan, Kunming, China."], "corresponding_authors": [], "china_team": "Department of Urology, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan, Kunming, China Yapeng Xing团队", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 19.5, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.5, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.5, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.5, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42773819", "title": "Correction to \"Functional and quality of life outcomes of localised prostate cancer treatments (Prostate Testing for Cancer and Treatment [ProtecT] study)\".", "abstract": "", "journal": "BJU International", "pub_date": "2026-Nov", "publication_types": ["Published Erratum"], "doi": "10.1111/bju.70466", "authors": [], "affiliations": [], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 19.47, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.47, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.4, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.47, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42759922", "title": "Plasma cfDNA fragmentomics enables non-invasive detection and preoperative risk stratification of bladder cancer in a multicenter study.", "abstract": "Accurate non-invasive tools for bladder cancer detection and preoperative assessment of muscle invasion remain limited. We developed a plasma cell-free DNA (cfDNA) fragmentomics assay to support two clinically related tasks: detection of bladder cancer and preoperative estimation of muscle-invasive risk. Using low-pass whole-genome sequencing, we extracted fragment size coverage, copy-number variation, and nucleosome positioning features. The multicenter cohort included 656 participants and an external extension of 31 cancer cases (total, 687). An integrated classifier was first trained for cancer detection. Subsequently, a separate non-muscle-invasive bladder cancer (NMIBC) versus muscle-invasive bladder cancer (MIBC) classifier was developed using definitively staged cases from the training cohort with internal threshold selection and independent external validation. For cancer detection, the model achieved AUCs of 0.9484 (training), 0.9446 (internal validation), and 0.9390 (external validation). At the locked threshold of 0.592, selected in the internal validation cohort, sensitivities were 81.0%, 80.0%, and 84.3%, with specificities of 95.0%, 94.7%, and 91.8% against healthy controls and 93.3% and 91.1% against benign disease controls in internal and external validation, respectively. For invasion stratification, the NMIBC/MIBC classifier achieved AUCs of 0.9254, 0.9004, and 0.8845 in the training, internal validation, and expanded external validation cohorts, respectively, with 90.3% sensitivity and 77.4% specificity for MIBC detection externally. The assay demonstrated high reproducibility across storage conditions and sequencing batches. This blood-based framework supports multicenter bladder cancer detection and preoperative stratification of muscle invasion as an adjunctive translational approach, while prospective validation in defined clinical use settings remains necessary.", "journal": "Cancer Letters", "pub_date": "2026-Nov-01", "publication_types": ["Journal Article", "Multicenter Study"], "doi": "10.1016/j.canlet.2026.218853", "authors": ["Kaihua Liu", "Hua Bao", "Guangqi Li", "Wenwen Ran", "Ping Yang", "Zongliang Zhang", "Wenxian Li", "Ningyou Li", "Minhui Ren", "Tao Ding", "Peng He", "Shanshan Yang", "Xinyue Hong", "Ke Wang", "Xiaoming Xing"], "affiliations": ["Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, 210032, China.", "Department of Pathology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.", "Department of Pathology, Yantai Yuhuangding Hospital, Yantai, Shandong, China.", "Department of Urology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.", "Department of Urology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China. Electronic address: wangke@qdu.edu.cn.", "Department of Pathology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China. Electronic address: xiaoming.xing@qdu.edu.cn."], "corresponding_authors": ["Ke Wang", "Xiaoming Xing"], "china_team": "Geneseeq Research Institute, Nanjing Geneseeq Technology Inc Ke Wang/Xiaoming Xing团队", "category": "clinical_review", "classification_reason": "publication_type_clinical", "score": 38.53, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 15.53, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 8.0}, "journal_metrics": {"status": "ok", "impact_factor": 10.1, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.53, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42752947", "title": "Digital advances for multicentre studies - the British Urology Researchers in Surgical Training (BURST) experience.", "abstract": "", "journal": "BJU International", "pub_date": "2026-Nov", "publication_types": ["Journal Article"], "doi": "10.1111/bju.70447", "authors": ["Nikki Kerdegari", "Feargus Hosving-Jervis", "Veeru Kasivisvanathan", "Kevin Byrnes", "Kevin Gallagher", "Sinan Khadhouri", "Nikita Bhatt"], "affiliations": ["Guy's and St Thomas' NHS Foundation Trust, London, UK.", "British Urology Researchers in Surgical Training (BURST) Research Collaborative, London, UK.", "GKT School of Medical Education, King's College London, London, UK.", "Division of Surgery and Interventional Science, University College London, London, UK.", "Department of Urology, Western General Hospital, University of Edinburgh, Edinburgh, UK.", "Department of Urology, University of Glasgow and Glasgow Royal Infirmary, Glasgow, UK.", "Department of Urology, St Vincent's University Hospital, Dublin, Ireland."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 19.47, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.47, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.4, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.47, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42749682", "title": "Endoscopic kidney-sparing surgery for upper tract urothelial carcinoma in patients with a solitary kidney.", "abstract": "To evaluate cancer control, renal function trajectories, and dialysis risk in patients with a solitary kidney treated with endoscopic kidney-sparing surgery (eKSS) for upper tract urothelial carcinoma (UTUC). We conducted a retrospective multicentre cohort study including 62 consecutive patients with UTUC and a solitary kidney treated with primary eKSS between 2006 and 2024 at two tertiary referral centres. All patients underwent ureteroscopic biopsy and laser ablation followed by intensified surveillance with mandatory second-look ureteroscopy and repeat retreatment as needed. Primary endpoints were upper tract recurrence, progression, cancer-specific mortality, and dialysis dependency. Competing-risk cumulative incidence functions and linear mixed-effects models were used. Median age was 71 years (interquartile range [IQR] 67-77), and baseline estimated glomerular filtration rate (eGFR) was 48 mL/min/1.73 m2 (IQR 40-70). High-grade disease at initial ureteroscopy was present in 12 patients (19%). Over a median follow-up of 65 months, patients underwent a median of five ureteroscopies (IQR 3-9), and 16 (26%) ultimately underwent radical nephroureterectomy. The cumulative incidence of upper tract recurrence was 70% (95% confidence interval [CI] 58-83) at 5 years. The 5-year cumulative incidence of progression was 40% (95% CI 26-54). Cancer-specific mortality was 20% (95% CI 7.9-32) at 5 years. Dialysis dependency occurred in 32% (95% CI 18-45) at 5 years, predominantly among patients with baseline eGFR <30 mL/min/1.73 m2 (hazard ratio 5.68; 95% CI 1.20-27.0, P = 0.029). Mixed-effects modelling showed a mean annual eGFR decline of 2.9 mL/min/1.73 m2 (95% CI 1.2-4.6). In patients with UTUC and a solitary kidney, eKSS delivered within an intensive surveillance programme provided durable renal preservation with acceptable oncological outcomes. Despite frequent recurrences requiring repeated ureteroscopic interventions, cancer-specific mortality remained limited, supporting eKSS as a viable alternative to radical nephroureterectomy in imperative clinical settings.", "journal": "BJU International", "pub_date": "2026-Nov", "publication_types": ["Journal Article", "Multicenter Study"], "doi": "10.1111/bju.70454", "authors": ["Pietro Scilipoti", "Federico Zorzi", "Carlos Gonzalez Gonzalez", "Nicola Nannola", "Stefano Moretto", "Letizia Maria Ippolita Jannello", "Ugo Gradilone", "Marie Chicaud", "Andrea Folcia", "Angelo Occhi", "Andrea Cosenza", "Giuseppe Rosiello", "Eugenio Ventimiglia", "Luigi Candela", "Francesco Montorsi", "Alberto Briganti", "Andrea Salonia", "Marco Moschini", "Steeve Doizi", "Frederic Panthier", "Luca Villa", "Olivier Traxer"], "affiliations": ["Service d'urologie, Tenon Hôpital, Paris, France.", "Endolase Lab, GRC20-Sorbonne University, PIMM-Arts et Métiers Paris Tech, Paris, France.", "Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy.", "Vita-Salute San Raffaele University, Milan, Italy.", "Department of Urology, Ospedale Maggiore Policlinico, Foundation IRCCS Ca' Granda, University, Milan, Italy.", "Department of Urology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy.", "Department of Surgical Sciences, Uppsala University, Uppsala, Sweden."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_clinical", "score": 39.47, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 10.47, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 11.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.4, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.47, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42869776", "title": "The BICEP classification for bladder injury during endoscopic enucleation of the prostate: considerations for clinical application.", "abstract": "", "journal": "BJU International", "pub_date": "2026-Oct-13", "publication_types": ["Letter"], "doi": "10.1111/bju.70456", "authors": ["Ranil Johann Boaz", "Max Johnston", "James Brewin", "Helen Teixeira", "Tevita Aho"], "affiliations": ["Imperial College London, London, UK.", "Salisbury NHS Foundation Trust, Salisbury, UK.", "Royal Cornwall Hospitals NHS Trust, Kenwyn, UK.", "Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 23.47, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 10.47, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.4, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.47, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42869744", "title": "Contemporary Oncological and Patient-reported Outcomes of Intravesical Gemcitabine/Docetaxel in BCG-unresponsive Non-muscle-invasive Bladder Cancer: A Multi-institutional Prospective Cohort Study.", "abstract": "To investigate the oncological and patient-reported outcomes (PROs) of patients receiving sequential gemcitabine/docetaxel (Gem/Doce) for Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC). Patients enrolled in prospective databases at two academic medical institutions who received Gem/Doce -for BCG-unresponsive NMIBC between January 2021 and January 2026 were included. The primary outcome was the 3-mo and 12-mo high-grade recurrence-free survival (HGRFS). Secondary outcomes included progression-free survival (PFS), radical treatment-free survival (RTFS), cancer-specific survival (CSS) and overall survival (OS). Subgroup analyses compared BCG refractory versus early-relapsing and carcinoma in situ (CIS) ± papillary versus papillary-only disease. Adverse events were reported with the common terminology criteria for adverse events version 6.0. PRO assessments were performed using the validated European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) and NMIBC24 questionnaires. Sixty-three patients were included. The median follow-up was 14 mo (interquartile range = 8-27). HGRFS rates at 3 and 12 mo were 88.8% (95% confidence interval [CI] = 81.3-97.0) and 68.1% (95% CI = 56.6-81.8), respectively. PFS at 12 mo was 90.1% (82.0-98.9%), RTFS 89.1% (80.5-98.7%), CSS 98.0% (94.3-100.0%), and OS 90.6% (80.9-100.0%). The BCG-refractory subgroup was associated with a higher risk of high-grade recurrence compared with early-relapsing (hazard ratio 2.44, 95% CI = 1.01-5.94, p = 0.048), whereas no difference was observed between CIS ± papillary and papillary-only subgroup (p = 0.20). Eight patients (12.7%) underwent radical cystectomy and six patients (9.5%) experienced disease progression. Twenty patients (31.7%) experienced mild irritative symptoms and no grade 3 or 4 adverse events were reported. Urinary symptom burden, global function, and functional outcomes remained stable during treatment. In this multi-institutional prospective study, intravesical Gem/Doce demonstrated favorable intermediate oncological outcomes for BCG-unresponsive NMIBC. Gem/Doce was well tolerated with few reported side effects and preserved PROs.", "journal": "European Urology Focus", "pub_date": "2026-Oct-13", "publication_types": ["Journal Article"], "doi": "10.1016/j.euf.2026.09.008", "authors": ["Yu Guang Tan", "J Dudinec", "A M Kamat", "B J H Lim", "A Ghoreifi", "J S P Yuen", "K Chen", "R Kanesvaran", "J Chan", "A M Shah", "K J Tay", "M R Abern"], "affiliations": ["Department of Urology, Singapore General Hospital, Singapore; Department of Urology, Duke University Medical Center, Durham, USA. Electronic address: yuguangtan90@gmail.com.", "Department of Urology, Duke University Medical Center, Durham, USA.", "University of Texas MD Anderson Cancer Center, Houston, USA.", "Department of Urology, Singapore General Hospital, Singapore.", "National Cancer Center Singapore, Singapore."], "corresponding_authors": ["Yu Guang Tan"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=9", "score": 40.77, "score_parts": {"urology_relevance": 11, "urology_in_title": 8.0, "journal_priority": 10.77, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 9.0}, "journal_metrics": {"status": "ok", "impact_factor": 5.6, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.77, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42869701", "title": "Translational research models for variant subtype bladder cancers: A comprehensive review of the current landscape.", "abstract": "Bladder cancer remains a leading cause of cancer-related mortality in the United States, with most cases classified as conventional urothelial carcinoma. However, a substantial subset of patients presents with aggressive variant histologies, including sarcomatoid, plasmacytoid, and micropapillary subtypes. These variants are associated with early dissemination, treatment resistance, and limited evidence to guide subtype specific management. Despite their clinical relevance, progress in mechanistic understanding and therapeutic development has been hindered due to rarity, underrepresentation in clinical trials, and a research focus on conventional disease. A key impediment is the lack of translational model systems that maintain variant defining morphology, lineage programs, and tumor microenvironmental interactions. Recent advances in translational modeling technologies now provide new opportunities to interrogate the unique biology of variant subtype bladder cancers. In this review, we highlight key preclinical models commonly used in bladder cancer research, including patient-derived xenografts, humanized models, syngeneic systems, genetically engineered mouse models, organoids, and ex vivo explants, and highlight emerging applications in variant histologies. We also discuss innovative and integrative platforms, including hybrid experimental systems and computational approaches, that are beginning to overcome barriers imposed by tumor rarity and heterogeneity. Collectively, these evolving model systems will enable more faithful representation of variant subtype biology, tumor-microenvironment interactions, and therapeutic vulnerabilities, and provide a framework for developing subtype-specific, precision treatment strategies.", "journal": "Urologic Oncology", "pub_date": "2026-Oct-13", "publication_types": ["Journal Article", "Review"], "doi": "10.1016/j.urolonc.2026.09.008", "authors": ["Gabriella U Nanjo", "Zirui Fu", "Shayan Smani", "Soum D Lokeshwar", "Joshua Warrick", "Deepika Kumar", "William Kim", "Curtis J Perry", "Wei Shen Tan", "Ping Mu", "Darryl T Martin", "Fady Ghali"], "affiliations": ["Department of Molecular, Cellular, and Developmental Biology, Yale College, New Haven, CT.", "Department of Urology, Yale University School of Medicine, New Haven, CT.", "Department of Pathology, Yale University School of Medicine, New Haven, CT.", "Section of Medical Oncology and Hematology, Department of Internal Medicine, Yale University School of Medicin, New Haven, CT.", "Department of Urology, Yale University School of Medicine, New Haven, CT; Department of Pathology, Yale University School of Medicine, New Haven, CT; Yale Cancer Center, Yale University School of Medicine, New Haven, CT.", "Department of Urology, Yale University School of Medicine, New Haven, CT. Electronic address: darryl.martin@yale.edu.", "Department of Urology, Yale University School of Medicine, New Haven, CT. Electronic address: fed.ghali@yale.edu."], "corresponding_authors": ["Darryl T Martin", "Fady Ghali"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 31.25, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 5.75, "top_journal_bonus": 0.0, "novelty": 0.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 7.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.3, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.75, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42869700", "title": "Response to \"Calendar-time bias in a TriNetX study of GLP-1 receptor agonists, SGLT2 inhibitors and bladder cancer survival\".", "abstract": "", "journal": "Urologic Oncology", "pub_date": "2026-Oct-13", "publication_types": ["Letter"], "doi": "10.1016/j.urolonc.2026.09.016", "authors": ["Jakob Kohler", "Severin Rodler"], "affiliations": ["Department of Urology, University Hospital of Schleswig-Holstein, Campus Kiel, Kiel, Germany. Electronic address: Jakob.Kohler@uksh.de.", "Department of Urology, University Hospital of Schleswig-Holstein, Campus Kiel, Kiel, Germany."], "corresponding_authors": ["Jakob Kohler"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 14.75, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 5.75, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.3, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.75, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42869577", "title": "Affinity-optimized bispecific CAR-T cells targeting HLA-G and CD70 for the treatment of clear cell renal cell carcinoma.", "abstract": "", "journal": "Journal for Immunotherapy of Cancer", "pub_date": "2026-Oct-13", "publication_types": ["Journal Article"], "doi": "10.1136/jitc-2026-015799", "authors": ["Lianpan Su", "Xiaodan Ma", "Dawei Chen", "Weiyi Wang", "Weiliang Yang", "Siwei Huang", "Yuqian Pang", "Shuzhen Chen", "Limin Cheng", "Chaochao Bian", "Jianeng Zhang", "Ziqian Fang", "Xiaomin Zhang", "Penghui Zhou"], "affiliations": ["State Key Laboratory of Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China.", "Institute of Blood Transfusion, Guangzhou Blood Center, Guangzhou, Guangdong, China.", "Guangzhou FineImmune Biotechnology Co., LTD, Guangzhou, Guangdong, China.", "State Key Laboratory of Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China zhouph@sysucc.org.cn Zhangxm@sysucc.org.cn."], "corresponding_authors": ["Xiaomin Zhang", "Penghui Zhou"], "china_team": "State Key Laboratory of Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China Xiaomin Zhang/Penghui Zhou团队", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 24.6, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 15.6, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 10.6, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.6, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42869123", "title": "Acute MCL1 Loss via Homoharringtonine-Mediated Translational Inhibition Enables Potent Apoptotic Synergy with BCLXL Blockade.", "abstract": "Antiapoptotic buffering in solid tumors is generally mediated by both BCLXL and MCL1, so that BH3 mimetic drugs targeting only one have limited efficacy. To identify agents that may sensitize tumors to BH3 mimetics targeting BCLXL, we screened prostate cancer cells against a panel of mitochondria-targeted drugs in combination with navitoclax, a BH3 mimetic targeting BCL2 and BCLXL. Homoharringtonine (HHT) in combination with navitoclax and as a single agent emerged as a potent inducer of apoptosis. HHT has been identified as an inhibitor of protein translation, and proteomic analysis showed broad suppression of translation-related pathways, while immunoblotting demonstrated rapid decreases in short-lived proteins, including MCL1. HHT dose response and time course studies showed marked declines in MCL1 within 2 hours that were associated with apoptosis in response to BCLXL inhibition with navitoclax or A1331852. Further cell viability assays showed synergy between HHT and BCLXL inhibitors in multiple prostate, lung, and colorectal cancer cell lines. HHT monotherapy in vivo caused tumor regression in two prostate cancer xenograft models. Analysis of tumor tissue taken at 4 hours after dosing showed decreases in MCL1 and MYC, indicating that HHT levels obtainable in vivo are adequate to deplete short-lived proteins and potentially sensitize to BH3 mimetics targeting BCLXL. These findings support further exploration of HHT as a single agent in solid tumors and establish a rationale for investigating safer, tumor-selective approaches to combine HHT-mediated translational inhibition with BCLXL targeting.", "journal": "Cancer Letters", "pub_date": "2026-Oct-13", "publication_types": ["Journal Article"], "doi": "10.1016/j.canlet.2026.218895", "authors": ["Akira Ohtsu", "Tatsuhiro Sawada", "Larysa Poluben", "Mai Onose", "Hayumi Oyama", "Ayaka Katayama", "Fang Xie", "Betul Ersoy-Fazlioglu", "Juan M Jiménez-Vacas", "Yusuke Otani", "Yoshiyuki Miyazawa", "Yoshitaka Sekine", "Yuta Maeno", "Takanori Shimizu", "Tsukasa Oda", "Shaoyong Chen", "Olga Voznesensky", "Xin Yuan", "Luigi Giovanni Cecchi", "Robert A Cerulli", "Motohiro Izumi", "Ikei S Kobayashi", "Atsushi Tanaka", "Nobuo Sasaki", "Susumu S Kobayashi", "Kazuhiro Suzuki", "Steven P Balk", "Seiji Arai"], "affiliations": ["Department of Urology, Gunma University Graduate School of Medicine, 3-9-22, Showa-machi, Maebashi, Gunma, 371-8511, Japan; Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA.", "Department of Urology, Gunma University Graduate School of Medicine, 3-9-22, Showa-machi, Maebashi, Gunma, 371-8511, Japan.", "Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA.", "Division of Pathology, Shizuoka Cancer Center Hospital, Nagaizumi, Japan.", "Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA; Institute of Cancer Research, Royal Marsden NHS Foundation Trust, London, UK.", "Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA 02115, USA; Harvard Medical School, Boston, MA, USA; Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan.", "Laboratory of Mucosal Ecosystem Design, Institute for Molecular and Cellular Regulation, Gunma University, Maebashi, Gunma, Japan.", "Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA; Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, 20072 Milan, Italy; Department of Oncology IRCCS, Humanitas Research Hospital, Via Manzoni 56, Rozzano, 20089 Milan, Italy.", "Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA 02115, USA; Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA; Institute for Emerging Medical Innovation, Faculty of Advanced Research Fields, Okayama University, Okayama, Japan.", "Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA. Electronic address: sbalk@bidmc.harvard.edu.", "Department of Urology, Gunma University Graduate School of Medicine, 3-9-22, Showa-machi, Maebashi, Gunma, 371-8511, Japan. Electronic address: a-seiji@gunma-u.ac.jp."], "corresponding_authors": ["Steven P Balk", "Seiji Arai"], "china_team": "", "category": "basic", "classification_reason": "basic_signals=16", "score": 35.53, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 15.53, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 14.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 10.1, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.53, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "高三尖杉酯碱快速降解MCL1增敏BCLXL抑制", "chinese_summary": "10月Cancer Lett报道，研究者在前列腺癌细胞中筛选靶向线粒体药物，发现高三尖杉酯碱（HHT）可快速抑制蛋白翻译并降低MCL1水平，与BCLXL抑制剂navitoclax或A1331852联用产生显著凋亡协同，在多种前列腺、肺癌及结直肠癌细胞系中证实，并在两个前列腺癌异种移植模型中单药即引起肿瘤消退，为实体瘤联合BH3模拟物提供新思路。", "abstract_zh": "实体瘤中的抗凋亡缓冲通常由BCLXL和MCL1共同介导，因此仅靶向其中之一的BH3模拟药物疗效有限。为寻找可使肿瘤对靶向BCLXL的BH3模拟药物敏感的制剂，我们在前列腺癌细胞中筛选了一组靶向线粒体的药物，并与navitoclax（一种靶向BCL2和BCLXL的BH3模拟药物）联用。高三尖杉酯碱（HHT）与navitoclax联用以及作为单药均表现出强效的凋亡诱导作用。HHT已被鉴定为蛋白质翻译抑制剂，蛋白质组学分析显示其广泛抑制翻译相关通路，免疫印迹则显示短寿命蛋白（包括MCL1）快速下降。HHT剂量反应和时间进程研究显示，MCL1在2小时内显著下降，并与navitoclax或A1331852抑制BCLXL后的凋亡相关。进一步的细胞活力实验显示，HHT与BCLXL抑制剂在多种前列腺癌、肺癌和结直肠癌细胞系中具有协同作用。HHT单药在体内导致两种前列腺癌异种移植模型肿瘤消退。给药后4小时取肿瘤组织分析显示MCL1和MYC降低，表明体内可达到的HHT水平足以耗竭短寿命蛋白，并可能使肿瘤对靶向BCLXL的BH3模拟药物敏感。这些发现支持进一步探索HHT作为实体瘤单药治疗，并为研究更安全、肿瘤选择性的方法以联合HHT介导的翻译抑制与BCLXL靶向治疗建立了理论基础。"}, {"pmid": "42868004", "title": "A Germline-Encoded lncRNA-Mitochondrial Axis Rewires Oxidative Phosphorylation to Drive Progression in Clear Cell Renal Cell Carcinoma.", "abstract": "Clear cell renal cell carcinoma (ccRCC) is characterized by profound metabolic reprogramming and substantial inherited susceptibility. The molecular mechanisms linking germline risk variation to tumor metabolic reprogramming could potentially be exploited for precision interventions. Here, we aimed to delineate the germline regulatory architecture underlying ccRCC susceptibility and to determine how inherited noncoding variation influences mitochondrial metabolism and tumor progression. Whole-genome sequencing and transcriptomic profiling of matched ccRCC tumor and adjacent normal kidney tissues were integrated with cross-ancestry genome-wide association, cis-expression quantitative trait locus, transcriptome-wide association, and fine-mapping analyses. LINC02068 was identified as a genetically regulated tumor suppressor associated with inherited ccRCC susceptibility, and cross-ancestry fine-mapping prioritized rs234043 as a candidate causal variant. The rs234043 risk allele preferentially recruited HOXC8 and repressed LINC02068 transcription. Reduced LINC02068 expression promoted malignant cellular phenotypes and was associated with adverse clinical outcomes. Mechanistically, LINC02068 localized to mitochondria, interacted with the co-chaperone DNAJA3, and promoted DNAJA3 destabilization, thereby attenuating mitochondrial oxidative phosphorylation. Allele-specific editing and genetic rescue experiments further supported a functional rs234043-HOXC8-LINC02068-DNAJA3 regulatory axis driving ccRCC progression. Pharmacologic impairment of mitochondrial complex I suppressed ccRCC cell migration and proliferation. These findings establish a mechanistic link between a germline noncoding variation and mitochondrial metabolic reprogramming in ccRCC and identify targeting oxidative phosphorylation as a potential avenue for precision therapy.", "journal": "Cancer Research", "pub_date": "2026-Oct-13", "publication_types": ["Journal Article"], "doi": "10.1158/0008-5472.CAN-25-5866", "authors": ["Guowen Duan", "Wenjie Xu", "Wenjun Jiang", "Linhui Zhang", "Yi Lin", "Cheng Lian", "Qin Zhang", "Zixian Wang", "Zenglai Tan", "Zixi Wang", "Shengjie Zhai", "Qi Liu", "Aki Manninen", "Ying Lu", "Zhao Zhang", "Yuanyuan Qu", "Gong-Hong Wei"], "affiliations": ["Shanghai Medical College of Fudan University Shanghai China.", "Shanghai Medical College of Fudan University China.", "Fudan University China.", "University of Oulu Oulu Finland.", "Chinese Academy of Medical Sciences & Peking Union Medical College China.", "University of Oulu Finland.", "Shanghai Medical College of Fudan University Hefei China.", "Fudan University Shanghai Cancer Center Shanghai China."], "corresponding_authors": [], "china_team": "Shanghai Medical College of Fudan University Shanghai China Gong-Hong Wei团队", "category": "basic", "classification_reason": "basic_signals=7", "score": 47.21, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 16.21, "top_journal_bonus": 10.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 7.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 16.6, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.21, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "胚系非编码变异驱动肾癌代谢重塑", "chinese_summary": "复旦大学上海医学院龚为民团队10月Cancer Res通过全基因组测序及跨祖先GWAS精细定位，在透明细胞肾癌中鉴定出rs234043风险等位优先招募HOXC8抑制LINC02068转录，后者通过 destabilizing DNAJA3减弱氧化磷酸化，驱动肿瘤进展，提示靶向OXPHOS或为精准治疗途径。", "abstract_zh": "透明细胞肾细胞癌（ccRCC）以显著的代谢重编程和高度遗传易感性为特征。连接胚系风险变异与肿瘤代谢重编程的分子机制可能被用于精准干预。在此，我们旨在描绘ccRCC易感性的胚系调控结构，并确定遗传性非编码变异如何影响线粒体代谢和肿瘤进展。对配对的ccRCC肿瘤和邻近正常肾组织进行全基因组测序和转录组分析，并与跨祖先全基因组关联、顺式表达定量性状位点、全转录组关联和精细定位分析整合。LINC02068被鉴定为一个与遗传性ccRCC易感性相关的遗传调控肿瘤抑制因子，跨祖先精细定位将rs234043列为候选因果变异。rs234043风险等位优先招募HOXC8并抑制LINC02068转录。LINC02068表达降低促进恶性细胞表型，并与不良临床结局相关。在机制上，LINC02068定位于线粒体，与共伴侣蛋白DNAJA3相互作用，促进DNAJA3去稳定化，从而减弱线粒体氧化磷酸化。等位基因特异性编辑和遗传拯救实验进一步支持一个功能性的rs234043-HOXC8-LINC02068-DNAJA3调控轴驱动ccRCC进展。药理学上损害线粒体复合物I可抑制ccRCC细胞迁移和增殖。这些发现建立了ccRCC中胚系非编码变异与线粒体代谢重编程之间的机制联系，并确定靶向氧化磷酸化为精准治疗的潜在途径。"}, {"pmid": "42867744", "title": "Video-based analysis of camera-instrument distance dynamics and operative efficiency in expert and novice robot-assisted partial nephrectomy.", "abstract": "In robot-assisted partial nephrectomy (RAPN), experts and novices differ in many metrics, but it is unknown which difference relates to novice operative efficiency and whether it improves with early experience. We addressed these questions using routinely archived two-dimensional videos. We analyzed 155 RAPN by one expert (65) and eight novices (90). Deep learning tracked the right-hand instrument across 300,000 frames. In four operative phases (bowel mobilization to tumor resection), we computed working-tip kinematics (speed, path length, direction reversals), the tip's position in the surgeon's view, and the camera-instrument distance, reconstructed using the 8-mm shaft as a size reference. Distance stability was expressed as the standard deviation (SD) of the four phase medians (phase-to-phase distance SD). Console-time associations in novices were assessed by Spearman correlation and logistic regression adjusted for R.E.N.A.L. score and body mass index. The expert moved the working tip faster, with fewer direction reversals, more consistent tip placement in the view, and a more stable camera-instrument distance across phases (phase-to-phase SD 5.5 vs. 7.8 mm, P < 0.001). Within novices, the phase-to-phase SD was the only video-derived metric associated with console time (ρ = 0.41; adjusted odds ratio 1.24 per mm, 95% confidence interval 1.04-1.48). With experience, reversals decreased and median distance increased, but the phase-to-phase SD showed no detectable change. Among expert-novice differences, only the phase-to-phase stability of the camera-instrument distance was associated with console time in novices and showed no detectable change during early experience. Distance stability is a candidate training target that warrants prospective validation.", "journal": "Journal of Robotic Surgery", "pub_date": "2026-Oct-13", "publication_types": ["Journal Article"], "doi": "10.3390/jcm15103856", "authors": ["Kohei Kobatake", "Yuki Kohada", "Miki Naito", "Shunsuke Miyamoto", "Yohei Sekino", "Hiroyuki Kitano", "Keisuke Goto", "Keisuke Hieda", "Nobuyuki Hinata"], "affiliations": ["Department of Urology, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan. kkobatake@hiroshima-u.ac.jp.", "Department of Urology, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan."], "corresponding_authors": ["Kohei Kobatake"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 20.03, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 6.03, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 3.0, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 2.03, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42867736", "title": "Opioid-free versus opioid-based anesthesia for robot-assisted radical prostatectomy: a single-center randomized controlled trial.", "abstract": "Multimodal, opioid-sparing analgesia is standard in urological surgery, and there is additional interest in eliminating intraoperative opioids in prostate cancer surgery. Randomized evidence for opioid-free anesthesia (OFA) in robot-assisted radical prostatectomy (RARP) is lacking. In this single-center randomized controlled trial, adult men undergoing RARP were allocated 1:1 to OFA (dexmedetomidine plus ketamine, no intraoperative opioids) or a remifentanil-based technique. Both groups received identical multimodal premedication, a bilateral quadratus lumborum block, sevoflurane maintenance and identical oxycodone patient-controlled analgesia (PCA). The primary outcome was cumulative PCA oxycodone consumption over the first 24 postoperative hours. Prespecified secondary outcomes were pain (NRS), postoperative nausea and vomiting (PONV), the demanded-to-delivered PCA bolus ratio, and perioperative changes in serum creatinine and white-cell count. A total of 149 patients were analyzed (OFA n=75, opioid-based n=74). Cumulative 24-h oxycodone consumption was lower with OFA (median 12.0 mg [interquartile range, IQR 6.0-22.0] vs 19.0 mg [10.5-34.0]; p=0.001), with a Hodges-Lehmann location-shift estimate of -6.0 mg (95% confidence interval, CI -10.0 to -2.0). Pain scores did not differ at any time point, and PONV was infrequent, with no significant between-group difference. Intraoperative hemodynamic adverse events (bradycardia, hypotension), perioperative white-cell count and serum creatinine did not differ between groups. In RARP delivered on a standardized multimodal and regional analgesic background, OFA reduced postoperative opioid consumption compared with a remifentanil-based technique, without a detectable difference in pain scores and with a similar safety profile.Trial registration ClinicalTrials.gov NCT06380244, registered 23 April 2024.", "journal": "Journal of Robotic Surgery", "pub_date": "2026-Oct-13", "publication_types": ["Journal Article", "Randomized Controlled Trial", "Comparative Study"], "doi": "10.1016/j.accpm.2024.101359", "authors": ["Tomasz Składzień", "Aleksandra Żmuda", "Michał Cicio", "Teresa Kowal", "Anna Kwinta", "Renata Bugielska", "Wojciech Szpunar", "Jan Szpor", "Katarzyna Maciejewska", "Rafał Świstek", "Tomasz Lonc", "Tomasz Drygalski", "Paweł Maciejewski"], "affiliations": ["Department of Intensive Interdisciplinary Care, Jagiellonian University Medical College, 2 Jakubowskiego Street, 30-688, Kraków, Poland.", "Department of Anaesthesiology and Intensive Care, University Hospital in Kraków, 2 Jakubowskiego Street, 30-688, Kraków, Poland.", "Department of Intensive Interdisciplinary Care, Jagiellonian University Medical College, 2 Jakubowskiego Street, 30-688, Kraków, Poland. pawel.maciejewski@uj.edu.pl.", "Department of Anaesthesiology and Intensive Care, University Hospital in Kraków, 2 Jakubowskiego Street, 30-688, Kraków, Poland. pawel.maciejewski@uj.edu.pl."], "corresponding_authors": ["Paweł Maciejewski"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_interventional_trial", "score": 32.03, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 6.03, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 7.0}, "journal_metrics": {"status": "ok", "impact_factor": 3.0, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 2.03, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42867721", "title": "Robot-assisted buccal graft uretero-pyeloplasty for pediatric recurrent UPJO: a multi-center case-series.", "abstract": "Redo pyeloplasty is technically more complex due to more significant scar tissue and risk for poor ureteral blood supply affecting outcomes. Use of buccal graft uretero-pyeloplasty was originally reported in the pediatric population back in 2017 as an alternative for complex reoperations. We hypothesize that in highly selected group of pediatric patients undergoing redo pyeloplasty, a buccal graft uretero-pyeloplasty would demonstrate efficacy. A total of 6 institutions identified patients undergoing a robot-assisted buccal uretero-pyeloplasty from 2014 to 2025. Demographic, pre-operative, intraoperative and postoperative variables were aggregated. Success was defined as improvement of hydronephrosis and or resolution of initial presenting symptoms. A total of 12 cases were identified. Median age at the time of initial pyeloplasty was 12 years (IQR 9.75-15.25 years), and buccal graft redo pyeloplasty was at a median of 16 years (IQR11-18 years). Median length of the buccal graft was 4 cm (include SD). Nine cases (75%) had omental wrap and all except one were onlay grafts. The most common reason for failure was persistent pain (6 patients) followed by worsening dilation (3 patients). With a median follow-up of 2 years (IQR11-18 years), nine patients (75%) reported improvement of their symptoms and 6 (50%) improved the hydronephrosis. Two continued with chronic flank pain despite no reports of obstruction or worsening dilation. This is the largest pediatric cohort reporting outcomes after buccal graft uretero-pyeloplasty for recurrent UPJO. In a small sample size of highly selected pediatric patients, buccal graft onlay may be utilized with reasonable efficacy while acknowledging lower success than reported in other recurrent UPJO case series.", "journal": "Journal of Robotic Surgery", "pub_date": "2026-Oct-13", "publication_types": ["Journal Article", "Multicenter Study"], "doi": "10.1016/j.urology.2014.03.010", "authors": ["Nicolas Fernandez", "Jennifer Ahn", "Maya Gopalan", "Thomas S Lendvay", "Kyle Rini", "Suhaib Abdulfattah", "Nicole J Kye", "Sanjay Aiyar", "Sameer Mittal", "Christopher J Long", "Arun K Srinivasan", "Aseem R Shukla", "Chester Koh", "Benjamin Whittam", "Mohan Gundeti", "Andrew Strine", "Mickey Daugherty", "Andrew Kirsch", "Ardavan Akavan", "Justin Kim", "Justin Roth", "Benjamin Press", "Maria Rodriguez", "Alexandra Siegal", "Jorge Arias"], "affiliations": ["Division of Urology, Seattle Children's Hospital - University of Washington, Seattle, WA, USA. nicolas.fernandez@seattlechildrens.org.", "University of Washington, Director of Robotic Surgery - Seattle Children's Hospital, 4800 Sand Point Way NE, Seattle, Washington, 98115, USA. nicolas.fernandez@seattlechildrens.org.", "Division of Urology, Seattle Children's Hospital - University of Washington, Seattle, WA, USA.", "Division of Urology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.", "Scott Department of Urology, Baylor College of Medicine, Houston, TX, USA.", "Riley Hospital for ChildrenDepartment of Pediatric Urology, Indianapolis, IN, USA.", "Division of Pediatric Urology, University of Chicago - Pritzker School of Medicine, Chicago, IL, USA.", "Division of Pediatric Urology, Cincinnati Children's Hospital Medical Center - University of Cincinnati, Cincinnati, Ohio, USA.", "Department of Pediatric Urology, Children's Healthcare of Atlanta - Emory University School of Medicine, Atlanta, GA, USA.", "Division of Pediatric Urology, Children's Hospital of New York at New York Presbyterian Weill Cornell Medicine, New York, USA.", "Division of UrologyDepartment of Surgery, Texas Children's Hospital, Houston, TX, USA."], "corresponding_authors": ["Nicolas Fernandez"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_clinical", "score": 27.03, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 6.03, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 7.0}, "journal_metrics": {"status": "ok", "impact_factor": 3.0, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 2.03, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42867550", "title": "BLAST-bladder lithiasis assessment of surgical treatment in real-world practice. A global prospective multicentre registry by EAU Endourology.", "abstract": "This registry aimed to establish a comprehensive global database to characterise contemporary real-world surgical approaches to bladder stones and to describe postoperative stone-free rate (SFR) and complications according to the surgical treatment route. The BLAST (Bladder Lithiasis Assessment of Surgical Treatment) registry prospectively enrolled 805 patients across 31 centres in 16 countries between May 2025 and February 2026. Patients underwent transurethral intervention (TI, n = 741), percutaneous suprapubic (PSI, n = 39), or open surgery (OI, n = 25). Postoperative SFR was graded using cross-sectional computer tomography, or ultrasonography, X-ray, or flexible cystoscopy, as Grade A (100% complete clearance), Grade B (single residual fragment), Grade C (multiple residual fragments). Perioperative complications were classified by the Clavien-Dindo criteria. The cohort was predominantly male across all groups. TI patients were older (median 66 vs 60 and 59 years; p = 0.023) and presented with smaller stones (median 2.1 vs 3.0 cm in both other groups; p < 0.001). A history of urinary tract reconstruction was markedly more prevalent in the PSI cohort (23.1% vs 3.5% and 4.0%; p < 0.001). Median hospital stay was significantly shorter following TI (2 vs 3 days; p < 0.001), accompanied by a shorter duration of catheterisation (p < 0.001). Early complications within 48 h were most frequent after OI (48.0% vs 18.6% and 17.9%; p = 0.001), although major complications (Clavien-Dindo ≥ 3) remained rare and comparable across all modalities. No mortality was recorded. Grade A SFR was achieved in 95.5% of TI, 84.6% of PSI, and 100% of OI (p = 0.001). Reintervention for residual fragments was required significantly more often following PSI (10.3% vs 1.3% and 0%; p < 0.001). Transurethral cystolithotripsy was the predominant approach in this real-world international cohort and was associated with high stone clearance and shorter postoperative recovery. Percutaneous and open approaches were selectively used in patients with larger stone burdens, complex anatomy, prior urinary tract reconstruction, or specific urethral limitations. These findings describe contemporary treatment patterns and observed outcomes rather than comparative treatment effectiveness.", "journal": "World Journal of Urology", "pub_date": "2026-Oct-13", "publication_types": ["Journal Article", "Multicenter Study"], "doi": "10.1097/SLA.0b013e3181b13ca2", "authors": ["Vineet Gauhar", "Steffi Kar Kei Yuen", "Thomas Herrmann", "Jaisukh Kalathia", "Amelia Pietropaolo", "Khi Yung Fong", "Arun Chawla", "Tianyu Li", "Alexey Martov", "Zelimkhan Tokhtiev", "Giorgio Mazzon", "Amish Mehta", "Yash Pamecha", "Lin Xiong", "Angelo Cormio", "Ender Cem Bulut", "Nariman Gadzhiev", "Sohani Dassanayake", "Azizbek Shomarufov", "Lim Tze Ying Benjamin", "Theodoros Tokas", "Gunal Ozgur", "Luca Boeri", "Yunteng Huang", "Yasser Gamil Elnagar", "Zijie Chai", "Bohan Wang", "William Lay Keat Ong", "Benedikt Becker", "Abdul Haseeb", "Lazaros Tzelves", "Alba Sierra", "Thiago Hota", "Mallikarjuna Chiruvella", "Deepak Ragoori", "Chi-Fai Ng", "Daniele Castellani", "Bhaskar Somani"], "affiliations": ["Department of Urology, Ng Teng Fong General Hospital, Singapore, Singapore.", "Department of Urology, Asian Institute of Nephrology & Urology, Hyderabad, Telangana, India.", "European Association of Urology Section of Endourology, Arnhem, The Netherlands.", "European Association of Urology Section of Endourology, Arnhem, The Netherlands. steffiyuen@surgery.cuhk.edu.hk.", "Department of Surgery, S.H. Ho Urology Centre, The Chinese University of Hong Kong, Hong Kong, China. steffiyuen@surgery.cuhk.edu.hk.", "Department of Urology, Spital Thurgau AG, Kantonsspital Frauenfeld, Pfaffenholzstrasse, Frauenfeld, Switzerland.", "Department of Urology and Kidney Transplantation, Fortune Urology Clinic, Botad, India.", "Department of Urology, University Hospital Southampton NHS Foundation Trust, Southampton, UK.", "Department of Urology, Singapore General Hospital, Singapore, Singapore.", "Urology and Renal Transplant, Kasturba Medical College, MAHE, Manipal, Karnataka, India.", "Department of Urology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.", "Department of Urology and Andrology of A.I. Burnazyan SRC FMBC, FMBA of Russia, Moscow, Russia.", "Department of Urology, University College London Hospitals, London, UK.", "B T Savani Kidney Hospital, Rajkot, India.", "Pamnani Hospital and Research Center Mandsaur, Mandsaur, India.", "Division of Urology, Shenzhen Hospital of University of Hong Kong, Shenzhen, China.", "Urology Unit, Azienda Ospedaliero-Universitaria delle Marche, Ancona, Italy.", "Department of Urology and Renal Transplantation, Policlinico Riuniti di Foggia, University of Foggia, Foggia, Italy.", "Department of Urology, School of Medicine, Gazi University, Ankara, Turkey.", "Department of Urology, Saint Petersburg State University Hospital, Saint Petersburg, Russia.", "Department of Urology, Tashkent State Medical University (Republican Specialized Scientific and Practical Medical Center of Urology), Tashkent, Uzbekistan.", "Department of Surgical Disciplines, Kimyo International University in Tashkent, Tashkent, Uzbekistan.", "Medical School, Central Asian University, Tashkent, Uzbekistan.", "Department of Urology, Sengkang General Hospital, Singapore, Singapore.", "Department of Urology, General Hospital of Heraklion, University of Crete, Heraklion, Greece.", "Marmara University Pendik Training and Research Hospital, Istanbul, Turkey.", "Department of Urology, IRCCS Fondazione Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.", "Department of Urology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.", "Department of Urology, Aswan University, Aswan, Egypt.", "Department of Urology, Guangdong Key Laboratory of Urological Diseases, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.", "Department of Urology, Second Affiliated Hospital of Zhejiang University, Hangzhou, China.", "Urology Unit, Department of Surgery, Hospital Sultanah Bahiyah, Kedah, Malaysia.", "Department of Urology, Asklepios Hospital Barmbek, Hamburg, Germany.", "Department of Urology, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany.", "Institute of Kidney Diseases, Hayatabad Medical Complex Peshawar, Peshawar, Pakistan.", "2nd Department of Urology, , National and Kapodistrian University of Athens, Athens, Greece.", "Department of Urology, Hospital Clinic-University of Barcelona, Barcelona, Spain.", "Hospital Nossa Senhora das Graças, Curitiba, Brazil.", "Department of Surgery, S.H. Ho Urology Centre, The Chinese University of Hong Kong, Hong Kong, China.", "Department of Medicine and Surgery, LUM University, Casamassima, Bari, Italy.", "Urology Unit, Ecclesiastical Entity Regional General Hospital \"F. Miulli\", Acquaviva delle Fonti, Bari, Italy."], "corresponding_authors": ["Steffi Kar Kei Yuen"], "china_team": "European Association of Urology Section of Endourology, Arnhem, The Netherlands Steffi Kar Kei Yuen团队", "category": "clinical_review", "classification_reason": "publication_type_clinical", "score": 48.0, "score_parts": {"urology_relevance": 18.0, "urology_in_title": 8.0, "journal_priority": 10.0, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 10.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.9, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.0, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "经尿道碎石清石率高恢复快", "chinese_summary": "欧洲泌尿外科学会腔内泌尿外科分会Steffi Kar Kei Yuen团队10月World J Urol发布BLAST全球前瞻性注册研究，纳入16国31中心805例膀胱结石患者，发现经尿道干预占绝大多数，完全清石率达95.5%，住院及导尿时间更短；经皮与开放手术多用于大结石负荷或尿路重建史等复杂病例。", "abstract_zh": "本注册研究旨在建立全面的全球数据库，以描述当代真实世界中膀胱结石的手术治疗方式，并按手术路径描述术后无石率（SFR）和并发症。BLAST（膀胱结石手术治疗评估）注册研究于2025年5月至2026年2月前瞻性纳入16个国家31个中心的805例患者。患者接受经尿道干预（TI，n = 741）、经皮耻骨上（PSI，n = 39）或开放手术（OI，n = 25）。术后无石率采用横断面计算机断层扫描，或超声、X线或软性膀胱镜进行分级，分为A级（100%完全清除）、B级（单个残留碎片）、C级（多个残留碎片）。围手术期并发症按Clavien-Dindo标准分类。各组队列均以男性为主。TI患者年龄更大（中位66岁 vs 60岁和59岁；p = 0.023），结石更小（中位2.1 cm vs 其他两组均为3.0 cm；p < 0.001）。尿路重建史在PSI队列中明显更常见（23.1% vs 3.5%和4.0%；p < 0.001）。TI术后中位住院时间显著更短（2天 vs 3天；p < 0.001），导尿时间也更短（p < 0.001）。48小时内早期并发症在OI后最常见（48.0% vs 18.6%和17.9%；p = 0.001），尽管主要并发症（Clavien-Dindo ≥ 3）仍然罕见，且在各术式间相当。未记录到死亡病例。A级无石率在TI中为95.5%，PSI中为84.6%，OI中为100%（p = 0.001）。因残留碎片而需再次干预在PSI后显著更常见（10.3% vs 1.3%和0%；p < 0.001）。经尿道膀胱碎石术是该真实世界国际队列中的主要方法，与高结石清除率和更短的术后恢复相关。经皮和开放方法则选择性地用于结石负荷较大、解剖复杂、既往尿路重建或特定尿道受限的患者。这些发现描述的是当代治疗模式和观察到的结局，而非比较治疗效果。"}, {"pmid": "42867548", "title": "Letter to the Editor: Analysis populations and extraction consistency in combined prostate and bladder stone surgery.", "abstract": "", "journal": "World Journal of Urology", "pub_date": "2026-Oct-13", "publication_types": ["Letter"], "doi": "10.1007/s00345-021-03882-4", "authors": ["Asad Ur Rab"], "affiliations": ["Foundation University Medical College, Islamabad, Pakistan. asadurrab@gmail.com."], "corresponding_authors": ["Asad Ur Rab"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 23.0, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 10.0, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.9, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.0, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42867156", "title": "Trends in bone health agent use and skeletal events in metastatic castration-resistant prostate cancer.", "abstract": "Bone health agents (BHAs) prevent symptomatic skeletal events (SSEs) in bone-metastatic castration-resistant prostate cancer (mCRPC). We evaluated contemporary BHA utilization and SSE incidence (2016-2021) compared with a historical cohort (2010-2015), during a period of substantial changes in mCRPC treatment. Data from 2,115 CRPC patients with bone metastases (Dutch CAPRI-3 registry) were compared to the CAPRI-2 cohort (N = 1,923). Clinical evolution and SSE outcomes were analysed in 1,792 patients receiving life-prolonging drugs (LPDs), categorized by BHA timing relative to the first LPD: no BHA, early BHA (≤4 weeks), or late BHA (>4 weeks). Compared to the historical cohort (2010-2015), patients in the 2016-2021 cohort were older (75 vs. 73 years), frailer (Charlson Comorbidity Index ≥5: 44% vs. 13%), and received LPDs in metastatic castration-sensitive setting more frequently (35% vs. 0%). BHA utilization dropped from 60% to 28%, with only 8% receiving guideline-recommended timing of BHA initiation. However, the overall SSE incidence declined from 0.26 to 0.21 events/patient-year between cohorts. Early BHA initiation was predominantly reserved for high-risk disease; this group experienced the highest SSE density (0.29) and shortest median SSE-free survival (8.7 vs. 14.6 months; p < 0.001) compared with the group without BHA. As the mCRPC population becomes older and more pre-treated, guideline-recommended BHA timing remains limited. Although overall skeletal morbidity declined, the high SSE density in high-risk patients underscores the need to identify those patients most likely to benefit from early bone protection.", "journal": "Journal of the National Cancer Institute", "pub_date": "2026-Oct-13", "publication_types": ["Journal Article"], "doi": "10.1093/jnci/djag385", "authors": ["Kim J M van der Velden", "Dianne Bosch", "Anneloes M van den Wildenberg", "André M Bergman", "Maarten J van der Doelen", "Reindert J A van Moorselaar", "Diederik M Somford", "Metin Tascilar", "Carin A Uyl-de Groot", "Inge M van Oort", "Malou C P Kuppen"], "affiliations": ["Department of Urology, University Medical Center Groningen, Groningen (UMCG), The Netherlands.", "Department of Urology, Radboud University Medical Center, Nijmegen, Netherlands.", "Prostate Cancer Center, Netherlands Cancer Institute (NKI), Amsterdam, the Netherlands.", "Department of Urology, Zuyderland Medical Center, Heerlen, Netherlands.", "Department of Urology, Amsterdam University Medical Center, Amsterdam, the Netherlands.", "Department of Urology, Canisius Wilhelmina Hospital (CWZ), Nijmegen, the Netherlands.", "Department of Medical Oncology, Isala Hospital, Zwolle, the Netherlands.", "Erasmus School of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, The Netherlands.", "Department of Radiation Oncology (Maastro), GROW Research Institute for Oncology and Reproduction, Maastricht University Medical Centre+, Maastricht, The Netherlands."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=6", "score": 36.09, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 15.09, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 6.0}, "journal_metrics": {"status": "ok", "impact_factor": 7.2, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.09, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42867138", "title": "Risk of second primary malignancies in older long-term survivors of breast, prostate, colon, and rectal cancer.", "abstract": "Cancer survivors face an increased risk of second primary malignancies (SPMs). Understanding SPM incidence and risk factors is crucial for long-term survivorship care. This was a SEER-Medicare retrospective cohort study of breast, prostate, colon, or rectal cancer survivors diagnosed between 2003-2011 at age 66+ years who survived ≥5 years post-diagnosis. The primary outcome was a 'late' SPM, defined as invasive cancer occurring ≥5 years after initial diagnosis. Restricted mean survival time (RMST) regression was used to assess demographic, clinical, and treatment related factors associated with late SPMs. SPMs were categorized as hematologic, screen-detectable (breast, prostate, lung, colon, or rectal), or non-screen detectable solid tumors. Of 90,261 long-term survivors, 11.2% (10,116) developed at least one late SPM. The cumulative incidence of late SPMs over 8 years was highest in prostate cancer survivors. Non-screen detectable cancers composed the largest proportion (47.8%) of 10,220 total late SPMs. The most common late SPM site was lung in colon (14.9%), and rectal (16.1%) cancer survivors, urinary bladder in prostate (17.0%), and new-primary breast cancers in breast cancer survivors (36.5%). In RMST regression, significant associations with demographic, index cancer, treatment, and clinical characteristics and late SPMs ranged from 3.6 months shorter to 4.4 months longer time without late SPM during the 8 years assessed. Between 10-14% of older long-term cancer survivors developed a late SPM during 5-13 years after index cancer diagnosis. Over 40% of late SPMs were screen-detectable, highlighting the need for surveillance strategies beyond 5 years from index cancer diagnosis.", "journal": "Journal of the National Cancer Institute", "pub_date": "2026-Oct-13", "publication_types": ["Journal Article"], "doi": "10.1093/jnci/djag383", "authors": ["Tendai Kwaramba", "Sarah Westvold", "Jessica B Long", "Terry Hyslop", "Andrea Silber", "Faiza Yasin", "Rebecca Forman", "Melissa Taylor", "Shi-Yi Wang", "Michael Leapman", "Ira L Leeds", "Michael Cecchini", "Lisa P Spees", "Stephanie B Wheeler", "Cary P Gross", "Kevin Oeffinger", "Michaela A Dinan"], "affiliations": ["Department of Medical Oncology, Yale Cancer Center, New Haven, CT, USA.", "Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA.", "Yale Cancer Outcomes, Public Policy and Effectiveness Research Center, New Haven, CT, USA.", "Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA.", "Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, CT, USA.", "Department of Urology, Yale School of Medicine, New Haven, CT, USA.", "Yale School of Medicine, Department of Surgery, Division of Colon and Rectal Surgery, New Haven, CT, USA.", "Lineberger Comprehensive Cancer Center (UNC-CH), Chapel Hill, NC, USA.", "Division of Pharmaceutical Outcomes and Policy, Eshelman School of Pharmacy, UNC-CH, Chapel Hill, NC, USA.", "Department of Health Policy and Management, Gillings School of Global Public Health, University of North Carolina at Chapel Hill (UNC-CH), Chapel Hill, NC, USA.", "Department of Medicine, Duke University, Durham, NC, USA.", "Duke Cancer Institute, Duke University, Durham, NC, USA."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=6", "score": 42.59, "score_parts": {"urology_relevance": 11, "urology_in_title": 8.0, "journal_priority": 15.09, "top_journal_bonus": 0.0, "novelty": 0.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 6.0}, "journal_metrics": {"status": "ok", "impact_factor": 7.2, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.09, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42865243", "title": "Standing or Sitting to Void? Comparative Uroflowmetry in Healthy Male Volunteers: A Randomized Crossover Study with Equivalence Analysis.", "abstract": "The posture adopted during voiding may influence uroflowmetric parameters, such as maximum urinary flow rate (Qmax), voided volume, and time to maximum flow (tQmax). Published studies have shown inconsistent results, and uncertainty persists regarding the clinical relevance of these differences in healthy men. To compare uroflowmetric parameters during standing and sitting voiding in healthy male volunteers using a randomized crossover design, incorporating a formal equivalence analysis (Two One-Sided Tests, TOST) for the primary outcome (Qmax). This prospective, randomized, 2 × 2 crossover study included 52 healthy male volunteers allocated to the sitting → standing (n = 24) or standing → sitting (n = 28) sequence, with a minimum washout period of 24 h. The primary outcome was Qmax and the secondary outcomes were the total voided volume and tQmax. Paired tests, correction for multiple comparisons (Bonferroni and Benjamini-Hochberg), linear mixed-effects models, Bayesian analysis, and TOST equivalence analysis for Qmax (margin ±2.5 mL/s) were used. Baseline characteristics were comparable between sequences. No significant differences between postures were observed for Qmax (Δ = -1.47 mL/s; 95% CI -3.55 to 0.62; p = 0.164) or for total volume (Δ = -14.7 mL; 95% CI -43.9 to 14.6; p = 0.318). The tQmax was longer while standing (Δ = +3.32 s; 95% CI 0.94 to 5.69; p = 0.011), remaining significant after Bonferroni correction (p = 0.031) and FDR correction (q = 0.031). The mixed models did not identify either sequence or period effects. Bayesian analysis showed moderate evidence in favor of a difference in tQmax (BF10 = 4.99) and in favor of no difference in volume (BF01 = 4.10). The equivalence analysis (TOST) for Qmax was not significant (p-TOST ≈ 0.16); therefore, the equivalence of the maximum flow between postures could not be formally claimed with the present sample size. In healthy men, voiding posture did not significantly modify the maximum urinary flow rate or voided volume; however, formal equivalence of Qmax was not demonstrated. The sitting position was associated with a shorter time to maximum flow, a small difference that is unlikely to be clinically meaningful and was partly dependent on a single outlier. Larger, pre-registered studies with pre-specified equivalence analyses and symptomatic populations are required.", "journal": "Neurourology and Urodynamics", "pub_date": "2026-Oct-13", "publication_types": ["Journal Article"], "doi": "10.1002/nau.70485", "authors": ["Juan Iregui-Parra", "Santiago Millán-Serna", "Mónica G Delgado-Caicedo", "Isabella Morales García", "Paula Andrea Salas Espinosa", "Claudia Marcela Arias", "Leydi Tatiana Chávez Pérez", "Luis Alfredo Wadskier Gutiérrez", "Roberto José Zambrano Guerra", "Daniel Mauricio Colmenares Leal"], "affiliations": ["Colombian Urology Research Group (CURG), Barranquilla, Colombia."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=6", "score": 16.56, "score_parts": {"urology_relevance": 3, "urology_in_title": 0.0, "journal_priority": 5.56, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 6.0}, "journal_metrics": {"status": "ok", "impact_factor": 1.9, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.56, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42865221", "title": "Familial Cancers Associated With Cancers of the Breast, Prostate, Colorectum, and Lung in Sweden.", "abstract": "Available epidemiological evidence shows that many cancers share familial risks, and this is increasingly confirmed by data on shared pathogenic germline gene variants between cancers. We decided to harness the world's largest resource on familial cancer to assess discordant familial risks for female breast (BC), prostate (PC), colorectal (CRC), and lung (LC) cancers with any of 22 different cancers in first-degree relatives (proband cancers). Familial relative risk was calculated as standardized incidence ratio (SIR) when either one proband or 2 or more (2+) probands were found in a family to distinguish low- and high-risk associations. Discordant familial associations of BC were significant for 12 1-proband and 5 2+ proband cancers. For PC, the numbers were 11 and 4; for CRC, they were 8 and 4; and for LC, they were 15 and 5. The results with large case numbers showed that BC, CRC, and LC associated with each other, but the familial association between PC and LC was negative. Many known or novel associations with possible genetic causes were found, including lobular BC with stomach cancer, PC with kidney cancer, CRC with squamous cell skin and thyroid cancers, and LC with gallbladder and endocrine tumors, the most common of which were parathyroid adenomas. Also, LC associations with esophageal and cervical cancers were unlikely to be due to smoking alone and require additional explanations. In conclusion, 2/3 of discordant associations could suggest low-risk genetic and environmental causation and 1/3 high-risk genetic causation, both waiting for experimental proof.", "journal": "International Journal of Cancer", "pub_date": "2026-Oct-13", "publication_types": ["Journal Article"], "doi": "10.1002/ijc.70781", "authors": ["Frantisek Zitricky", "Kristina Sundquist", "Jan Sundquist", "Akseli Hemminki", "Asta Försti", "Kari Hemminki"], "affiliations": ["Biomedical Center, Faculty of Medicine, Charles University Pilsen, Pilsen, Czech Republic.", "Center for Primary Health Care Research, Lund University, Malmö, Sweden.", "University Clinic Primary Care, Skåne University Hospital, Region Skåne, Sweden.", "Department of Family and Community Medicine, McGovern Medical School, The University of Texas Health Science Center, Houston, Texas, USA.", "Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.", "Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland.", "Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany.", "Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany.", "Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 35.55, "score_parts": {"urology_relevance": 12, "urology_in_title": 8.0, "journal_priority": 10.55, "top_journal_bonus": 0.0, "novelty": 2, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 1.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.7, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.55, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "四类常见癌症呈现家族性关联谱", "chinese_summary": "瑞典卡罗林斯卡学院10月Int J Cancer基于全球最大宗族癌症资源分析22种一级亲属癌症，发现乳腺癌、前列腺癌、结直肠癌和肺癌分别与12、11、8、15种癌症存在低危家族关联，与5、4、4、5种存在高危家族关联。乳腺、结直肠与肺癌相互关联，前列腺癌与肺癌关联为负；", "abstract_zh": "现有流行病学证据表明，许多癌症共享家族性风险，且癌症之间共享致病性生殖系基因变异的数据日益证实这一点。我们决定利用全球最大的家族性癌症资源，评估女性乳腺癌（BC）、前列腺癌（PC）、结直肠癌（CRC）和肺癌（LC）与一级亲属中22种不同癌症（先证者癌症）之间的不一致家族性风险。当家族中发现1例先证者或2例及以上（2+）先证者时，将家族性相对风险计算为标准化发病比（SIR），以区分低风险和高风险关联。BC的不一致家族性关联在12种1例先证者癌症和5种2+先证者癌症中显著。PC分别为11种和4种；CRC分别为8种和4种；LC分别为15种和5种。大样本量结果显示，BC、CRC和LC相互关联，但PC与LC的家族性关联为负。发现了许多已知或新关联，可能具有遗传原因，包括小叶型BC与胃癌、PC与肾癌、CRC与皮肤鳞状细胞癌和甲状腺癌、LC与胆囊癌和内分泌肿瘤，其中最常见的是甲状旁腺腺瘤。此外，LC与食管癌和宫颈癌的关联不太可能仅由吸烟引起，需要额外解释。总之，三分之二的不一致关联可能提示低风险遗传和环境病因，三分之一提示高风险遗传病因，两者均待实验证明。"}, {"pmid": "42864969", "title": "Transurethral ultrasound ablation (TULSA) for prostate cancer: a systematic review and meta-analysis.", "abstract": "Our objective was to synthesise evidence on oncological, functional and safety outcomes of magnetic resonance imaging-guided transurethral ultrasound ablation (TULSA) for primary and recurrent prostate cancer. MEDLINE, Embase, Web of Science and Scopus were systematically searched from inception to July 2025. The primary outcomes were 12-month biopsy-proven clinically significant prostate cancer (csPCa) recurrence-free survival (RFS) and rates of pad-free continence and preserved erectile function at last follow-up. Secondary outcomes included biochemical recurrence, progression to salvage treatment and rates of adverse effects. Twelve studies comprising 630 patients were analysed. In total, 563 (89%) patients underwent primary TULSA, 57 (9%) patients underwent salvage TULSA, and 10 (2%) patients had palliative TULSA. Pooled 12-month csPCa RFS was 70% (95% confidence interval [CI] 50-84) for primary TULSA and 80% (95% CI 66-89) for salvage TULSA. Stratifying by ablation fraction, pooled 12-month csPCa RFS was 75% (95% CI 60-86) for whole-gland TULSA, and 71% (95% CI 51-86) for focal TULSA. The proportion of pad-free continence was 90% (95% CI 71-97), and the rate of preservation of erectile function was 81% (95% CI 56-94). Incidence of grade 3 severity adverse events was 6% (95% CI 4-11). There was heterogeneity in multiple outcomes, likely reflecting variation in endpoint definitions, treatment approaches and follow-up protocols among the included studies. Primary TULSA is a safe treatment modality with a low risk of functional morbidity. However, there is a lack of evidence on long-term oncological control, with modifications of the treatment technique and ablation parameters still being experimental. Fewer data are available for salvage TULSA, where preliminary studies have recorded relatively high rates of incontinence.", "journal": "BJU International", "pub_date": "2026-Oct-12", "publication_types": ["Journal Article", "Review"], "doi": "10.1111/bju.70471", "authors": ["Eugene Wang", "Xinyi Wei", "Yajat Dua", "Marlon Perera", "Jeremy Grummet"], "affiliations": ["Department of Urology, Royal Melbourne Hospital, Melbourne, Vic, Australia.", "School of Population and Global Health, University of Melbourne, Melbourne, Vic, Australia.", "Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Vic, Australia.", "Department of Urology, Austin Health, Melbourne, Vic, Australia.", "Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Vic, Australia.", "Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Vic, Australia.", "Department of Urology, Alfred Health, Melbourne, Vic, Australia.", "School of Translational Medicine, Monash University, Melbourne, Vic, Australia."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 40.47, "score_parts": {"urology_relevance": 15, "urology_in_title": 8.0, "journal_priority": 10.47, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 5.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.4, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.47, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42864412", "title": "A health-system-scale, episode-resolved multimodal atlas of cancer cachexia.", "abstract": "Cancer cachexia is a wasting syndrome with outsized impact on morbidity and mortality, yet its drivers and systemic consequences remain poorly defined. In this study, we repurposed longitudinal clinicogenomic data from 52,236 patients with cancer profiled by MSK-IMPACT (2010-2024) at Memorial Sloan Kettering Cancer Center to define episode-resolved trajectories of consensus-defined cachectic weight loss and linked these events to outcomes, serology and tumor genotypes. Cachectic episodes clustered near periods of disease progression and were associated with inferior outcomes in nearly all cancer types. Across diverse malignancies, cachectic weight loss episodes exhibited a consistent serologic signature characterized by lower albumin and hemoglobin and higher levels of liver enzymes. Numerous somatic tumor genotypes, including TP53 mutation across several diseases, were also associated with more frequent onset of cachectic episodes. Motivated by these observations, we developed a multivariate model to predict impending risk of cachectic weight loss in patients with lung, colorectal and prostate cancer, validated in an independent, external cohort from Dana-Farber Cancer Institute (n = 5,785). Routine clinicogenomic data are, therefore, a scalable resource for discovery in cancer cachexia.", "journal": "Nature Medicine", "pub_date": "2026-Oct-12", "publication_types": ["Journal Article"], "doi": "10.1038/s41586-024-08167-5", "authors": ["Venise Jan Castillon", "Amy X Xie", "Sonia Boscenco", "Ethan Tse", "Neil Ruthen", "Jamie Wang", "Ziad Bakouny", "Michele Waters", "Chenlian Fu", "Christopher Fong", "Mustafa Saleh", "Tarek Baroud", "Wungki Park", "Urvi A Shah", "A Ari Hakimi", "Puneeth Iyengar", "Justin Jee", "Eileen White", "Alexander Gusev", "Tobias Janowitz", "Marcus D Goncalves", "Ed Reznik"], "affiliations": ["Computational Oncology Service, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.", "Dana-Farber Cancer Institute, Boston, MA, USA.", "Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.", "Weill Cornell Medical College, New York, NY, USA.", "Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.", "Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.", "Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.", "Rutgers Cancer Institute, Rutgers University, New Brunswick, NJ, USA.", "Ludwig Princeton Branch, Ludwig Institute for Cancer Research, Princeton University, Princeton, NJ, USA.", "Broad Institute of MIT and Harvard, Cambridge, MA, USA.", "Harvard Medical School, Boston, MA, USA.", "Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA.", "Northwell Health Cancer Institute, Northwell Health, New Hyde Park, NY, USA.", "Holman Division of Endocrinology, Diabetes & Metabolism, Department of Medicine and Radiation Oncology, NYU Langone Health, New York, NY, USA.", "Computational Oncology Service, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. reznike@mskcc.org."], "corresponding_authors": ["Ed Reznik"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=4", "score": 37.77, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 17.77, "top_journal_bonus": 10.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 4.0}, "journal_metrics": {"status": "ok", "impact_factor": 50.0, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 5.77, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "癌症恶病质多模态图谱发布", "chinese_summary": "纪念斯隆凯特琳癌症中心10月Nature Medicine利用52236例MSK-IMPACT临床基因组数据，刻画癌症恶病质体重丢失事件的演变轨迹，发现其多聚集于疾病进展期并与多数癌种预后不良相关，且伴随白蛋白、血红蛋白降低及肝酶升高的血清学特征；", "abstract_zh": "癌症恶病质是一种消耗性综合征，对发病率和死亡率影响巨大，但其驱动因素和全身性后果仍不明确。本研究利用纪念斯隆凯特琳癌症中心2010至2024年间经MSK-IMPACT检测的52236例癌症患者的纵向临床基因组数据，定义了一致性标准所定义的恶病质体重丢失的事件解析轨迹，并将这些事件与结局、血清学和肿瘤基因型相关联。恶病质事件多聚集于疾病进展期附近，且在几乎所有癌症类型中均与较差结局相关。在多种恶性肿瘤中，恶病质体重丢失事件表现出一种一致的血清学特征，即白蛋白和血红蛋白较低、肝酶水平较高。多种肿瘤体细胞基因型，包括在若干疾病中的TP53突变，也与恶病质事件更频繁的发生相关。基于这些观察，我们开发了一个多变量模型，用于预测肺癌、结直肠癌和前列腺癌患者即将发生恶病质体重丢失的风险，并在来自丹娜法伯癌症研究院的独立外部队列（n=5785）中进行了验证。因此，常规临床基因组数据是癌症恶病质发现研究的一种可扩展资源。"}, {"pmid": "42864396", "title": "Update on testosterone deficiency and therapeutic options for testosterone replacement therapy.", "abstract": "Testosterone deficiency, or male hypogonadism, is a clinical syndrome characterized by the presence of clinical features with persistently low serum testosterone levels. Testosterone deficiency is an important health concern owing to its wide-ranging effects on sexual function, metabolic health, bone integrity, mood and overall quality of life. Testosterone deficiency can be classified as primary (testicular), secondary (hypothalamic-pituitary) or functional hypogonadism - the latter is commonly associated with ageing, obesity and chronic systemic disease. Diagnosis requires both clinical symptoms and biochemical confirmation of low testosterone levels, typically assessed using morning serum testosterone measurements. In instances of borderline values or discordance between symptoms and total testosterone levels, free testosterone and sex hormone-binding globulin measurements can provide additional diagnostic clarity. Evidence demonstrates that testosterone replacement therapy can provide clinically meaningful benefits in appropriately selected men with confirmed testosterone deficiency. Improvements have been reported in sexual function, mood, anaemia, body composition, bone mineral density and metabolic parameters, and contemporary data do not support an increased risk of prostate cancer or major adverse cardiovascular events when therapy is appropriately monitored. Multiple therapeutic formulations are available, including transdermal, oral, intramuscular, subdermal and intranasal preparations, each with distinct pharmacokinetic profiles and practical considerations. Individualized treatment selection, careful patient counselling and ongoing monitoring are essential to optimize clinical outcomes and minimize potential risks in men undergoing testosterone therapy.", "journal": "Nature Reviews Urology", "pub_date": "2026-Oct-12", "publication_types": ["Journal Article", "Review"], "doi": "10.1530/EJE-11-0221", "authors": ["Thomas Thompson", "Mohamed Mubarak", "T Hugh Jones", "Ian Pearce", "Vaibhav Modgil"], "affiliations": ["Royal Liverpool University Hospital, NHS University Hospitals of Liverpool Group, Liverpool, UK. Thomas.thompson@doctors.org.uk.", "Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.", "Manchester Andrology Research Collaborative, Manchester, UK.", "Robert Hague Centre for Diabetes and Endocrinology, Barnsley Hospital NHS Foundation Trust, Barnsley, UK.", "Division of Clinical Medicine, School of Medicine and Population Health, University of Sheffield, Sheffield, UK.", "Manchester Royal Infirmary, Manchester University NHS Foundation Trust, Manchester, UK."], "corresponding_authors": ["Thomas Thompson"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 26.03, "score_parts": {"urology_relevance": 7, "urology_in_title": 0.0, "journal_priority": 16.03, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 1.0}, "journal_metrics": {"status": "ok", "impact_factor": 14.6, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.03, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42864241", "title": "Corrigendum to \"Association between blood lipid levels in early pregnancy and urinary organophosphate metabolites in the Japan Environment and Children's Study\" [Environ. Int. 190 (2024) 108932].", "abstract": "", "journal": "Environment International", "pub_date": "2026-Oct-12", "publication_types": ["Published Erratum"], "doi": "10.1016/j.envint.2026.110546", "authors": ["Nobuhisa Morimoto", "Yukiko Nishihama", "Kazunari Onishi", "Shoji F Nakayama", "Japan Environment and Children's Study Group"], "affiliations": ["Japan Environment and Children's Study Programme Office, National Institute for Environmental Studies, Ibaraki, Japan; Graduate School of Public Health, St. Luke's International University, Chuo-ku, Tokyo 104-0045, Japan.", "Japan Environment and Children's Study Programme Office, National Institute for Environmental Studies, Ibaraki, Japan; Paediatric Environmental Medicine, Institute of Medicine, University of Tsukuba, Ibaraki, Japan.", "Division of Environmental Health, Graduate School of Public Health, St. Luke's International University, Chuo-ku, Tokyo 104-0045, Japan.", "Japan Environment and Children's Study Programme Office, National Institute for Environmental Studies, Ibaraki, Japan; Graduate School of Public Health, St. Luke's International University, Chuo-ku, Tokyo 104-0045, Japan. Electronic address: fabre@nies.go.jp."], "corresponding_authors": ["Shoji F Nakayama"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 23.48, "score_parts": {"urology_relevance": 3, "urology_in_title": 8.0, "journal_priority": 15.48, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 9.7, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.48, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42864228", "title": "177Lu-Prostate-specific Membrane Antigen Prior to Stereotactic Ablative Radiotherapy in Oligorecurrent Prostate Cancer: Secondary and Exploratory End Point Results from the Randomized Phase 2 LUNAR Trial.", "abstract": "The phase 2 randomized LUNAR trial previously demonstrated that neoadjuvant 177Lu-PNT2002 before stereotactic body radiotherapy (SBRT) significantly improved progression-free survival (PFS) in patients with oligorecurrent hormone-sensitive prostate cancer (orHSPC). We report updated efficacy and safety outcomes with extended follow-up. Patients with prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT)-detected orHSPC and one to five metastatic lesions amenable to SBRT were randomized 1:1 to SBRT alone or two cycles of neoadjuvant 177Lu-PNT2002 followed by SBRT. The primary end point was PFS, defined as new lesions on PSMA PET/CT, initiation of salvage hormonal therapy, or death. Secondary end points included hormonal therapy-free survival (HT-FS) and 24-mo progression-free status. Exploratory end points included polymetastatic PFS (poly-PFS), castration-resistant disease-free survival (CRFS), and conventional imaging progression-free survival (CT-PFS). Between September 2022 and November 2023, 92 patients were randomized to SBRT alone (n = 47) or 177Lu-PNT2002 plus SBRT (n = 45). At a median follow-up of 31.9 mo, 177Lu-PNT2002 significantly improved PFS (median 17.6 vs 7.4 mo; hazard ratio [HR] 0.38, 95% confidence interval [CI] = 0.23-0.61; p < 0.001) and HT-FS (HR 0.57, 95% CI = 0.34-0.95; p = 0.03). Exploratory analyses demonstrated improved poly-PFS (HR 0.28, 95% CI = 0.08-1.03; p = 0.04), CRFS (HR 0.13, 95% CI = 0.02-1.10; p = 0.03), and CT-PFS (HR 0.46, 95% CI = 0.19-1.09; p = 0.07). No new safety signals were observed. With extended follow-up, neoadjuvant 177Lu-PNT2002 before SBRT produced durable improvements in PFS and HT-FS. While poly-PFS, CRFS, and CT-PFS were exploratory end points, their improvement provides hypothesis-generating evidence that the addition of radioligand therapy to SBRT may alter disease trajectory beyond delaying PSMA PET/CT-detected recurrence.", "journal": "European Urology", "pub_date": "2026-Oct-12", "publication_types": ["Journal Article"], "doi": "10.1016/j.eururo.2026.09.005", "authors": ["Amar U Kishan", "Holly Wilhalme", "Carol Felix", "Johanna Enke", "Farzana Z Ali", "Rejah Nabong", "Jesus E Juarez-Casillas", "Kevin Flores", "T Martin Ma", "Vinicius Ludwig", "Mariko Nakayama", "Zachary Ells", "Magnus Dahlbom", "Michael Lauria", "Catherine Meyer", "Minsong Cao", "Joanne B Weidhaas", "Donatello Telesca", "Kristen McGreevy", "Nicholas G Nickols", "Sophia Parmisano", "Wayne Brisbane", "Leonard Marks", "Adam E Singer", "Matthew B Rettig", "Robert E Reiter", "Luca F Valle", "Martin Allen-Auerbach", "Johannes Czernin", "Michael L Steinberg", "Jeremie Calais"], "affiliations": ["Department of Radiation Oncology, University of California, Los Angeles, USA; Department of Nuclear Medicine and Theranostics, University of California, Los Angeles, CA, USA; Department of Urology, University of California, Los Angeles, CA, USA. Electronic address: aukishan@mednet.ucla.edu.", "Department of Medicine Statistical Core, University of California, Los Angeles, USA.", "Department of Radiation Oncology, University of California, Los Angeles, USA.", "Ahmanson Translational Theranostics Division, Department of Nuclear Medicine and Theranostics, University of California, Los Angeles, USA.", "Department of Radiation Oncology, University of Washington, Seattle, USA.", "Ahmanson Translational Theranostics Division, Department of Nuclear Medicine and Theranostics, University of California, Los Angeles, USA; Department of Radiological Sciences, University of California, Los Angeles, USA.", "Department of Radiation Oncology, University of California, San Francisco, USA.", "Department of Biostatistics, University of California, Los Angeles, USA.", "Department of Radiation Oncology, University of California, Los Angeles, USA; VA Greater Los Angeles Healthcare System, Los Angeles, USA.", "Department of Urology, University of California, Los Angeles, CA, USA.", "Department of Medicine, University of California, Los Angeles, CA, USA.", "VA Greater Los Angeles Healthcare System, Los Angeles, USA; Department of Medicine, University of California, Los Angeles, CA, USA.", "Ahmanson Translational Theranostics Division, Department of Nuclear Medicine and Theranostics, University of California, Los Angeles, USA; Nuclear Medicine Division, Medical Imaging Department, Gustave Roussy, Paris-Saclay University, France; 3 BioMaps Multimodal Biomedical Imaging Laboratory, INSERM UMR 1281, CNRS UMR90, CEA, Paris-Saclay University, France."], "corresponding_authors": ["Amar U Kishan"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=8", "score": 49.29, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 16.79, "top_journal_bonus": 10.0, "novelty": 0.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 8.0}, "journal_metrics": {"status": "ok", "impact_factor": 25.2, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.79, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "新辅助177Lu-PNT2002延长寡复发前列腺癌无进展生存", "chinese_summary": "欧洲泌尿外科杂志10月发布LUNAR 2期随机试验延长随访结果：在PSMA PET/CT检出、1–5个病灶的激素敏感性寡复发前列腺癌中，SBRT前给予两周期177Lu-PNT2002，中位随访31.9个月，中位无进展生存17.6个月对7.4个月，风险比0.38，无激素治疗生存亦改善，未观察到新安全性信号。", "abstract_zh": "2期随机LUNAR试验先前已证明，在立体定向体部放疗（SBRT）前给予新辅助177Lu-PNT2002可显著改善寡复发激素敏感性前列腺癌（orHSPC）患者的无进展生存期（PFS）。我们报告延长随访后的最新疗效和安全性结局。经前列腺特异性膜抗原（PSMA）正电子发射断层扫描/计算机断层扫描（PET/CT）检出orHSPC、且有1至5个适合SBRT的转移病灶的患者，按1:1随机分配至单纯SBRT组或两周期新辅助177Lu-PNT2002后SBRT组。主要终点为PFS，定义为PSMA PET/CT出现新病灶、开始挽救性激素治疗或死亡。次要终点包括无激素治疗生存期（HT-FS）和24个月无进展状态。探索性终点包括多转移性PFS（poly-PFS）、无去势抵抗性疾病生存期（CRFS）和常规影像学无进展生存期（CT-PFS）。2022年9月至2023年11月期间，92例患者被随机分配至单纯SBRT组（n=47）或177Lu-PNT2002联合SBRT组（n=45）。在中位随访31.9个月时，177Lu-PNT2002显著改善PFS（中位17.6个月 vs 7.4个月；风险比[HR] 0.38，95%置信区间[CI]=0.23-0.61；p<0.001）和HT-FS（HR 0.57，95%CI=0.34-0.95；p=0.03）。探索性分析显示poly-PFS（HR 0.28，95%CI=0.08-1.03；p=0.04）、CRFS（HR 0.13，95%CI=0.02-1.10；p=0.03）和CT-PFS（HR 0.46，95%CI=0.19-1.09；p=0.07）均有改善。未观察到新的安全性信号。在延长随访后，SBRT前新辅助177Lu-PNT2002产生了持久的PFS和HT-FS改善。虽然poly-PFS、CRFS和CT-PFS为探索性终点，但其改善提供了假设生成性证据，表明在SBRT基础上加用放射性配体治疗可能改变疾病轨迹，而不仅仅是延迟PSMA PET/CT检出的复发。"}, {"pmid": "42864199", "title": "Retraction notice to \"Association of genetic polymorphism of glutathione S-transferase (GSTM1, GSTT1, GSTP1) with bladder cancer susceptibility\" [Urologic Oncology: Seminars and Original Investigations 31 (2013) 1193-1203].", "abstract": "", "journal": "Urologic Oncology", "pub_date": "2026-Oct-12", "publication_types": ["Published Erratum"], "doi": "10.1016/j.urolonc.2026.08.008", "authors": ["Mohammad Reza Safarinejad", "Saba Safarinejad", "Nayyer Shafiei", "Shiva Safarinejad"], "affiliations": ["Private Clinical Center for Urological Disease Diagnosis and Private Clinic Specialized in Urological and Andrological Genetics, Teheran, Iran."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 19.75, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 5.75, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 1.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.3, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.75, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42863477", "title": "Efficacy, safety, and immunogenicity of a nine-valent vaccine (ExPEC9V) for the prevention of invasive Escherichia coli disease in older adults: a phase 3, randomised, placebo-controlled trial (E.mbrace).", "abstract": "Invasive Escherichia coli disease (IED) caused by extraintestinal pathogenic Escherichia coli (ExPEC) can lead to bacteraemia and sepsis. ExPEC9V is a conjugate vaccine targeting nine E coli O-serotypes that account for most E coli bloodstream infections. We aimed to evaluate ExPEC9V for safety, immunogenicity, and prevention of IED caused by ExPEC9V O-serotypes in adults aged 60 years and older. In this randomised, double-blind, placebo-controlled, phase 3 study conducted at 332 clinical sites in 20 countries (E.mbrace), we enrolled participants aged 60 years and older in stable health and with a history of urinary tract infection (UTI) within the previous 2 years. Participants were randomly assigned (in blocks of no set size with the use of interactive web response system, stratified by age and presence or absence of risk factors for complicated UTI) 1:1 to receive a single dose of intramuscular ExPEC9V or placebo. Participants, study-site personnel, and investigators remained masked to group allocation throughout the study. The primary endpoint was first IED in blood or sterile sites caused by ExPEC9V O-serotypes in the per-protocol efficacy analysis set (all randomly assigned, vaccinated participants without major protocol deviations); secondary endpoints included immunogenicity assessment in a subset of participants. Safety endpoints included solicited (safety subset), unsolicited (full analysis set), and serious (full analysis set) adverse events. A prespecified futility analysis conducted when at least 40% of the expected 53 IED events had occurred indicated lack of efficacy, leading to early study termination. We present final study results (data up to the date of the futility announcement), when 17 701 of the planned 19 800 participants had been vaccinated. This trial is registered with ClinicalTrials.gov (NCT04899336). Participants were enrolled between June 30, 2021, and Feb 13, 2025. Of 18 844 individuals assessed for eligibility, 17 701 were enrolled, randomly assigned, and vaccinated (8858 with ExPEC9V and 8843 with placebo). The per-protocol efficacy included 17 637 participants (8822 for ExPEC9V and 8815 for placebo). There were 24 IED cases (11 in vaccine and 13 in placebo groups) caused by ExPEC9V O-serotypes in blood or sterile sites, yielding a vaccine efficacy of 14·63% (95% CI -106·57 to 65·38), indicating no protective effect. ExPEC9V had an acceptable safety profile, with more frequent low-grade adverse events in the ExPEC9V versus placebo group, balanced serious adverse event distribution among both groups, and no vaccine-related deaths. In this large phase 3 trial of older adults, ExPEC9V did not demonstrate efficacy in preventing first IED caused by ExPEC9V O-serotypes, despite generating robust and sustained antibody responses. Development of the ExPEC9V vaccine has been discontinued. Johnson & Johnson and Sanofi.", "journal": "Lancet Infectious Diseases", "pub_date": "2026-Oct-12", "publication_types": ["Journal Article"], "doi": "10.1016/S1473-3099(26)00469-X", "authors": ["Marc Bonten", "Christopher C Butler", "Andrew Edwards", "Stefan Gravenstein", "Hiroshi Ikeda", "Isik Somuncu Johansen", "Merel M C Lambregts", "Tetsuya Matsumoto", "David L Patterson", "Jesús Rodriguez-Baño", "Elie Saade", "Barry S Zingman", "Tracey Day", "Jeroen Geurtsen", "Karin Hardt", "Chelsea McLean", "Ilse Scheys", "Georgi Shukarev", "Javier Ruiz Guiñazú", "Michal Sarnecki", "Bart Spiessens", "Monika Peeters", "Maria Grazia Pau", "Jan Poolman", "Keira A Cohen", "E.mbrace Study Team"], "affiliations": ["Julius Center, UMC Utrecht, Utrecht University, Utrecht, Netherlands; European Clinical Research Alliance on Infectious Diseases, Utrecht, Netherlands.", "Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK; European Clinical Research Alliance on Infectious Diseases, Utrecht, Netherlands.", "Momentum Clinical Research, Wellington, New Zealand; St Thomas' Hospital, London, UK.", "Warren Alpert Medical School of Brown University, Providence, RI, USA.", "Department of Urology, Kitakyushu General Hospital, Kitakyushu, Fukuoka, Japan.", "Department of Infectious Diseases, Odense University Hospital, Denmark.", "Leiden University Center for Infectious Diseases, Leiden University Medical Center, Leiden, Netherlands.", "International University of Health and Welfare, Narita, Japan.", "ADVANCE-ID, Saw Swee Hock School of Public Health, National University of Singapore, Singapore.", "Unidad Clínica de Enfermedades Infecciosas, Hospital Universitario Virgen Macarena; Departamento de Medicina, Universidad de Sevilla; Instituto de Biomedicina de Sevilla/CSIC, Seville, Spain; Centro de Investigación Biomédica en Red de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain.", "Case Western Reserve University, University Hospitals of Cleveland, Cleveland, OH, USA.", "Montefiore Medical Center and Albert Einstein College of Medicine, NY, USA.", "Johnson & Johnson, Beerse, Belgium.", "Johnson & Johnson, Leiden, Netherlands; Sanofi B V., Amsterdam, Netherlands.", "Johnson & Johnson, Leiden, Netherlands.", "Johnson & Johnson, Bern, Switzerland.", "Johnson & Johnson, Beerse, Belgium. Electronic address: mpeeter7@its.jnj.com.", "Johnson & Johnson, Titusville, NJ, USA."], "corresponding_authors": ["Monika Peeters"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 38.08, "score_parts": {"urology_relevance": 7, "urology_in_title": 0.0, "journal_priority": 17.08, "top_journal_bonus": 10.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 1.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 31.0, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 5.08, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "九价大肠杆菌疫苗Ⅲ期未显保护效力", "chinese_summary": "4月Lancet Infect Dis发表覆盖20国332中心的Ⅲ期随机双盲试验，17701名有尿路感染史的60岁以上老人接种ExPEC9V或安慰剂，侵袭性大肠杆菌病仅24例，疫苗效力14.63%（95% CI −106.57~65.38），未显示保护作用；安全性可接受，但该疫苗研发已终止。", "abstract_zh": "由肠外致病性大肠杆菌（ExPEC）引起的侵袭性大肠杆菌病（IED）可导致菌血症和脓毒症。ExPEC9V是一种针对9种大肠杆菌O血清型的结合疫苗，这些血清型占大多数大肠杆菌血流感染。我们旨在评估ExPEC9V在60岁及以上成人中的安全性、免疫原性以及预防由ExPEC9V O血清型引起的IED的效果。在这项在20个国家332个临床中心开展的随机、双盲、安慰剂对照Ⅲ期研究（E.mbrace）中，我们入组了健康状况稳定且在过去2年内有尿路感染（UTI）史的60岁及以上参与者。参与者按1:1随机分配（采用区组大小不定的交互式网络应答系统，按年龄及有无复杂性UTI危险因素分层）接受单剂肌内注射ExPEC9V或安慰剂。参与者在整个研究期间对分组分配保持盲态。主要终点为符合方案效力分析集（所有随机分配、接种疫苗且无重大方案偏离的参与者）中由ExPEC9V O血清型引起的血液或无菌部位的首发IED；次要终点包括在部分参与者中进行的免疫原性评估。安全性终点包括征集性（安全性子集）、非征集性（全分析集）和严重（全分析集）不良事件。当预期53例IED事件中至少40%发生时进行的预设无效性分析提示缺乏效力，导致研究提前终止。我们报告最终研究结果（截至无效性公告日期的数据），此时计划19800名参与者中已有17701名接种疫苗。本试验注册于ClinicalTrials.gov（NCT04899336）。参与者于2021年6月30日至2025年2月13日期间入组。在18844名接受资格评估的个体中，17701名被入组、随机分配并接种疫苗（8858名接种ExPEC9V，8843名接种安慰剂）。符合方案效力分析纳入17637名参与者（ExPEC9V组8822名，安慰剂组8815名）。由ExPEC9V O血清型引起的血液或无菌部位IED共24例（疫苗组11例，安慰剂组13例），疫苗效力为14.63%（95% CI −106.57~65.38），表明无保护作用。ExPEC9V具有可接受的安全性特征，ExPEC9V组低级别不良事件较安慰剂组更频繁，两组严重不良事件分布均衡，无疫苗相关死亡。在这项针对老年人的大型Ⅲ期试验中，ExPEC9V尽管产生了强健且持久的抗体应答，但未能证明可预防由ExPEC9V O血清型引起的首发IED。ExPEC9V疫苗的研发已终止。强生和赛诺菲。"}, {"pmid": "42863464", "title": "PHYHD1-mediated translational control regulates renal cell carcinoma progression.", "abstract": "The mechanisms underlying renal cell carcinoma (RCC) progression remain incompletely understood. Here, we identify phytanoyl-CoA dioxygenase domain containing 1 (PHYHD1) as a tumor suppressor that regulates translational homeostasis and RCC progression. Progressive PHYHD1 loss promotes tumor advancement and predicts poor prognosis, as revealed by integrative deep learning analysis of pan-cancer datasets. Restoring PHYHD1 suppresses tumor growth in RCC cell and patient-derived xenograft (PDX) models independently of its dioxygenase activity. Mechanistically, PHYHD1 interacts with translation elongation factor eEF1A1, alters its association with ribosomes, and restrains protein translation. Ribosome profiling and RNA-seq identify ceramide transporter 1 (CERT1) as a key effector of the PHYHD1-eEF1A1 axis. PHYHD1 depletion enhances CERT1 translation, whereas targeting CERT1 impairs proliferation of PHYHD1-deficient cells. These findings define a PHYHD1-eEF1A1-CERT1 axis that controls translation during RCC progression and highlight CERT1 as a potential therapeutic target in PHYHD1-deficient tumors.", "journal": "Molecular Cell", "pub_date": "2026-Oct-12", "publication_types": ["Journal Article"], "doi": "10.1016/j.molcel.2026.09.020", "authors": ["Qian Liang", "Giada Zurlo", "Junru Jin", "Dengfeng Huang", "Yudong Wei", "Shuangjie Shen", "Chengheng Liao", "Tao Wang", "Cheng Zhang", "Jin Zhou", "Hongyi Liu", "Jun Fang", "Haoyong Fu", "Masashi Takeda", "Xiang Li", "Xiang David Li", "Jian Zhou", "Jinfan Wang", "Tao Yue", "James Brugarolas", "Michael Buszczak", "Qing Zhang"], "affiliations": ["Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, USA.", "Lyda Hill Department of Bioinformatics, University of Texas Southwestern Medical Center, Dallas, TX, USA.", "Department of Pathology, Shanghai Tenth People's Hospital Affiliated to Tongji University, Shanghai, China.", "Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, TX, USA.", "Department of Biochemistry, The University of Texas Southwestern Medical Center, Dallas, TX, USA.", "Department of Chemistry, The University of Hong Kong, Hong Kong, China.", "Center for the Genetics of Host Defense, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.", "Kidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA; Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.", "Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, TX, USA; Hamon Center for Regenerative Science and Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA; Cecil H. and Ida Green Center for Reproductive Biology Sciences, University of Texas Southwestern Medical Center, Dallas, TX, USA.", "Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, USA; Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA. Electronic address: qing.zhang@utsouthwestern.edu."], "corresponding_authors": ["Qing Zhang"], "china_team": "Department of Pathology, Shanghai Tenth People's Hospital Affiliated to Tongji University, Shanghai, China Xiang David Li团队", "category": "basic", "classification_reason": "basic_signals=7", "score": 47.21, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 16.21, "top_journal_bonus": 10.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 7.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 16.6, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.21, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "肾癌进展受PHYHD1翻译调控", "chinese_summary": "上海第十人民医院李湘团队10月Mol Cell报道，PHYHD1缺失促进肾癌进展并预示不良预后，恢复其表达可抑制肿瘤生长；PHYHD1通过eEF1A1限制CERT1翻译，靶向CERT1或为PHYHD1缺陷肿瘤提供治疗方向。", "abstract_zh": "肾细胞癌（RCC）进展的机制仍不完全清楚。在此，我们确定植物酰辅酶A双加氧酶结构域包含蛋白1（PHYHD1）是一个调控翻译稳态和RCC进展的抑癌因子。通过对泛癌数据集的整合深度学习分析揭示，PHYHD1的进行性缺失促进肿瘤进展并预测不良预后。在RCC细胞和患者来源异种移植（PDX）模型中，恢复PHYHD1可抑制肿瘤生长，且不依赖于其双加氧酶活性。机制上，PHYHD1与翻译延伸因子eEF1A1相互作用，改变其与核糖体的结合，并限制蛋白质翻译。核糖体图谱和RNA测序鉴定神经酰胺转运蛋白1（CERT1）为PHYHD1-eEF1A1轴的关键效应因子。PHYHD1缺失增强CERT1翻译，而靶向CERT1可损害PHYHD1缺陷细胞的增殖。这些发现定义了控制RCC进展过程中翻译的PHYHD1-eEF1A1-CERT1轴，并突出CERT1作为PHYHD1缺陷肿瘤的潜在治疗靶点。"}, {"pmid": "42863204", "title": "Research on the expression of miR-192-5p in extracellular vesicles of diabetic nephropathy based on ternary heterojunction/heterogeneous interface interlocking hydrogel ECL strategy.", "abstract": "Herein, a novel electrochemiluminescence (ECL) biosensor was constructed based on a Nb2C/Nb2O5/ZnO QDs ternary heterojunction and heterogeneous interface interlocking (HII) hydrogel self-supporting electrode, which achieved sensitive and specific detection of miR-192-5p in extracellular vesicles (EVs) from diabetic nephropathy (DN)urine and serum samples. This Nb2C/Nb2O5/ZnO QDs heterojunction integrated the S-scheme heterojunction between Nb2O5 and ZnO QDs with the Schottky junction between Nb2C and Nb2O5. On the one hand, Nb2O5 acted as a bridging medium to drive directional migration of electrons and holes, which overcame the incomplete charge separation in traditional binary heterojunctions. On the other hand, Nb2C nanosheets provided directional electron transport channels and served as a coreactant reservoir, effectively promoting electron injection and exciting ZnO QDs to generate enhanced ECL signals at low voltage. Meanwhile the HII hydrogel electrode achieved dual electrical-ionic conductivity with excellent biocompatibility and stability, significantly boosting the ECL sensing performance. The Nb2C/Nb2O5/ZnO QDs heterojunction -HII hydrogel biosensor was used to detect miR-192-5p with a linear range of 1 fM-1 nM and a detection limit of 0.33 fM. Clinical detection results revealed miR-192-5p was upregulated in urinary EVs and downregulated in serum EVs of DN patients with disease progression. This biosensor enabled early, non-invasive and multidimensional DN diagnosis, providing a novel analytical strategy for precise DN detection and clinical application.", "journal": "Biosensors & Bioelectronics", "pub_date": "2026-Oct-12", "publication_types": ["Journal Article"], "doi": "10.1016/j.bios.2026.119332", "authors": ["Jia Li", "Yameng Li", "Fangyan Ji", "Fuzhe Ma", "Qiang Ma"], "affiliations": ["Department of Nephrology, The First Hospital of Jilin University, Changchun, 130021, China.", "Department of Analytical Chemistry, College of Chemistry, Jilin University, Changchun, 130012, China.", "Department of Nephrology, The First Hospital of Jilin University, Changchun, 130021, China. Electronic address: mfz2018@jlu.edu.cn.", "Department of Analytical Chemistry, College of Chemistry, Jilin University, Changchun, 130012, China. Electronic address: qma@jlu.edu.cn."], "corresponding_authors": ["Fuzhe Ma", "Qiang Ma"], "china_team": "Department of Nephrology, The First Hospital of Jilin University, Changchun, 130021, China Fuzhe Ma/Qiang Ma团队", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 23.58, "score_parts": {"urology_relevance": 3, "urology_in_title": 0.0, "journal_priority": 15.58, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 2.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 10.5, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.58, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42862398", "title": "Anatomic factors associated with postoperative events and reintervention after secondary urethroplasty in children with urethral strictures after hypospadias repair.", "abstract": "To describe long-term outcomes of secondary urethroplasty for post-hypospadias urethral stricture in children and identify anatomic factors associated with a broad composite postoperative event endpoint. We retrospectively reviewed 104 boys ≤ 12 years treated at a tertiary paediatric urology centre between 2010 and 2021. The primary outcome was a broad composite postoperative event endpoint comprising postoperative complications or additional urethral intervention for suspected impaired patency. Cox regression assessed associated factors. Receiver operating characteristic (ROC) analysis identified a cohort-derived threshold for radiographic stricture length (LUS), and Kaplan-Meier analysis assessed composite-event-free survival. Median follow-up was 5.5 years. Overall, 63/104 boys (60.6%) met the composite endpoint, whereas 35/104 (33.7%) underwent unplanned reoperation. Prostatic utricle (aHR 1.78, 95% CI 1.01-3.14), longer LUS (aHR 1.14 per 1-cm increase, 95% CI 1.00-1.30), and baseline residual/recurrent ventral curvature (aHR 1.89, 95% CI 1.01-3.53) were independently associated with the composite endpoint. A cohort-derived LUS threshold of 1.8 cm yielded an AUC of 0.714 (95% CI 0.614-0.813), 77.8% sensitivity, 58.5% specificity, 74.2% positive predictive value, and 63.2% negative predictive value. Children with LUS ≥ 1.8 cm had lower composite-event-free survival. In this single-centre salvage cohort, postoperative morbidity and treatment burden after secondary urethroplasty for post-hypospadias urethral stricture were substantial. Longer LUS, prostatic utricle, and baseline residual/recurrent ventral curvature were anatomic factors associated with the composite endpoint. The cohort-derived 1.8-cm threshold may provide a practical marker for risk stratification, family counselling, and postoperative surveillance, but requires independent paediatric validation.", "journal": "World Journal of Urology", "pub_date": "2026-Oct-12", "publication_types": ["Journal Article"], "doi": "10.1016/j.jpurol.2026.105962", "authors": ["Chang Li", "Zihan Ye", "Hongsong Chen", "Zhicheng Zhang", "Lilu Qin", "Shengde Wu", "Deying Zhang", "Guanghui Wei", "Xing Liu"], "affiliations": ["Department of Urology, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Children's Hospital of Chongqing Medical University, 136 Zhongshan Road, Chongqing, 400014, People's Republic of China.", "Ministry of Education Key Laboratory of Child Development and Disorders, National Clinical Research Center for Child Health and Disorders, China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Chongqing, 400014, People's Republic of China.", "Chongqing Key Laboratory of Children Urogenital Development and Tissue Engineering, Chongqing, 400014, People's Republic of China.", "Department of Urology, Jiangxi Children's Medical Center, Nanchang, Jiangxi Province, China.", "Department of Urology, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Children's Hospital of Chongqing Medical University, 136 Zhongshan Road, Chongqing, 400014, People's Republic of China. dr.liux0217@gmail.com.", "Ministry of Education Key Laboratory of Child Development and Disorders, National Clinical Research Center for Child Health and Disorders, China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Chongqing, 400014, People's Republic of China. dr.liux0217@gmail.com.", "Chongqing Key Laboratory of Children Urogenital Development and Tissue Engineering, Chongqing, 400014, People's Republic of China. dr.liux0217@gmail.com."], "corresponding_authors": ["Xing Liu"], "china_team": "Department of Urology, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Children's Hospital of Chongqing Medical University, 136 Zhongshan Road, Chongqing, 400014, People's Republic of China Xing Liu团队", "category": "clinical_review", "classification_reason": "clinical_signals=7", "score": 39.0, "score_parts": {"urology_relevance": 12, "urology_in_title": 8.0, "journal_priority": 10.0, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 7.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.9, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.0, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42862368", "title": "Laparoscopic and robotic management of symptomatic calyceal diverticula: a systematic review on behalf of YAU and EAU endourology.", "abstract": "Calyceal diverticula (CD) are outpouchings of the pelvicalyceal system into the renal parenchyma. The purpose of this systematic review is to summarize the outcomes associated with laparoscopic and robotic-assisted approaches for the management of symptomatic CD. Our findings were structured according to the PRISMA statement. We queried three electronic databases, PubMed, Cochrane Library, and Web of Science, to systematically review the literature. Relying on the March 2009 guidelines from the Oxford Centre for Evidence-Based Medicine, two authors independently judged the quality and evidence level of the final articles. Nine studies were included in final qualitative synthesis. The operative time ranged from 80 to 172 (107-197) minutes, while Estimated Blood Loss ranged from 40 (5-100) to 150 (50-300) ml. The Grade I-II complications according to Clavien-Dindo Classification System ranged from 0% to 66.7%, while no Grade III-IV complications were reported in either of the nine studies. The rate of patients reporting flank pain recurrence during the follow-up period ranged from 0% to 28.5%, while recurrence of the diverticulum ranged from 0% to 33.3%. None of the patients with flank pain or diverticulum recurrence needed a reoperation. The findings of this systematic review suggest that laparoscopic and robotic approaches are feasible and have shown favorable outcomes in selected patients with symptomatic CD, particularly in cases with complex anatomy or after failed endourological treatment. However, the available evidence remains limited.", "journal": "World Journal of Urology", "pub_date": "2026-Oct-12", "publication_types": ["Journal Article", "Systematic Review", "Review"], "doi": "10.1097/SLA.0b013e3181b13ca2", "authors": ["Theodoros Spinos", "Rifat Ergul", "Angelis Peteinaris", "Gernot Ortner", "Amelia Pietropaolo", "Theodoros Tokas", "Evangelos Liatsikos", "Panagiotis Kallidonis", "Bhaskar Somani", "Begoña Ballesta Martinez"], "affiliations": ["Department of Urology, University Hospital of Patras, Patras, Greece.", "EAU Young Academic Urologists (YAU) Urolithiasis and Endourology Working Group Arnhem, 6803, Arnhem, The Netherlands.", "Mus State Hospital, Mus, Turkey.", "Department of Urology and Andrology, General Hospital Hall I.T., Hall in Tirol, Austria.", "EAU Section of Endourology, Arnhem, The Netherlands.", "Department of Urology, University Hospital Southampton NHS Foundation Trust, Southampton, SO16 6YD, UK.", "Department of Urology, University General Hospital of Heraklion, University of Crete, Medical School, Heraklion, Greece.", "EAU Young Academic Urologists (YAU) Urolithiasis and Endourology Working Group Arnhem, 6803, Arnhem, The Netherlands. bballestamartinez@gmail.com.", "EAU Section of Endourology, Arnhem, The Netherlands. bballestamartinez@gmail.com.", "Department of Urology, University Hospital del Vinalopo, Alicante, Spain. bballestamartinez@gmail.com.", "Area de Medicina, Universidad de Alicante, Alicante, Spain. bballestamartinez@gmail.com."], "corresponding_authors": ["Begoña Ballesta Martinez"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 28.0, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.0, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 4.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.9, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.0, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42862367", "title": "Suprapubic transvesical adenoma resection versus robot-assisted simple prostatectomy for prostates ≥ 80 mL: an exploratory early-outcome comparison.", "abstract": "Robot-assisted simple prostatectomy (RASP) is an established but resource-intensive option for large benign prostatic enlargement. Suprapubic transvesical adenoma resection of the prostate (STAR-P) is a recently described bipolar endoscopic technique that resects the adenoma through a suprapubic access, avoiding transurethral instrumentation. We compared their early outcomes in prostates ≥ 80 mL. In an exploratory, non-randomized, two-centre analysis of prospectively maintained data, we compared baseline, perioperative and one-month outcomes, changes from baseline, and a composite endpoint [Trifecta: maximum urinary flow rate (Qmax) > 15 mL/s, International Prostate Symptom Score (IPSS) < 8, no postoperative complications], with a logistic model adjusting for age and baseline IPSS. Sixty-one patients were included (26 STAR-P, 35 RASP). STAR-P patients were older (69.5 vs. 64.0 years; p = 0.019), with higher baseline IPSS (29.5 vs. 25.0; p = 0.005) and more often a prominent median lobe (84.6% vs. 48.6%; p = 0.006). Catheterization was shorter after STAR-P (3 vs. 7 days; p < 0.001), whereas postoperative Qmax was higher after RASP (24.0 vs. 13.8 mL/s; p = 0.002). STAR-P showed a greater IPSS reduction and a smaller haemoglobin decrease; ΔQmax did not differ (p = 0.100). No major bleeding event occurred after STAR-P versus nine (26%) after RASP. Trifecta did not differ (42% vs. 54%; p = 0.440), but the study had only 15% power for this comparison. STAR-P and RASP showed distinct early profiles rather than superiority of either technique: STAR-P favoured shorter catheterization, lower symptoms and less bleeding, whereas RASP produced stronger early flow improvement. Whether avoiding the urethra reduces urethral morbidity remains an untested hypothesis.", "journal": "World Journal of Urology", "pub_date": "2026-Oct-12", "publication_types": ["Journal Article", "Comparative Study", "Multicenter Study"], "doi": "10.1016/j.acuro.2019.08.008", "authors": ["B Bucca", "A Brassetti", "R S Flammia", "P Dell'Oglio", "F Presicce", "M Lo Re", "F Chierigo", "O Dalpiaz", "G Simone", "C Gozzi"], "affiliations": ["Department of Urology, Sapienza University of Rome, Policlinico Umberto I Hospital, Viale del Policlinico 155, 00161, Rome, Italy. bruno.bucca@uniroma1.it.", "Department of Urology, IRCCS Regina Elena National Cancer Institute, Rome, Italy.", "Department of Urology, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.", "Department of Urology, San Filippo Neri Hospital, Rome, Italy.", "Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.", "Department of Urology, Department of Health Science, University of Milan, ASST Santi Paolo e Carlo, Milan, Italy.", "Department of Urology, Klinikum Klagenfurt, Klagenfurt, Austria.", "Department of Urology, CityClinic, Bolzano (Bozen), Italy."], "corresponding_authors": ["B Bucca"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_clinical", "score": 45.0, "score_parts": {"urology_relevance": 15, "urology_in_title": 8.0, "journal_priority": 10.0, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 10.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.9, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.0, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42862366", "title": "Stage-specific prognostic value of PSA in prostate cancer: a multicentre KAMU-ON study.", "abstract": "To evaluate whether the prognostic value of initial prostate-specific antigen (PSA) differs according to disease stage in patients with prostate cancer. This multicentre retrospective cohort study used data from the Kaga Million Uro-Oncology Network (KAMU-ON) registry. Patients diagnosed between 1993 and 2024 with available data on overall survival, initial PSA, Grade Group, and disease stage were included. Disease stage was classified as localised, nonmetastatic advanced, or metastatic. Restricted cubic spline analyses and multivariable Cox proportional hazards models evaluated stage-specific associations between PSA and overall survival. Among 7747 patients, 5578 had localised disease, 1223 had nonmetastatic advanced disease, and 946 had metastatic disease. The median follow-up was 58.0 months. PSA-survival associations differed significantly across disease stages (P for interaction = 0.0014). In localised disease, mortality risk increased progressively with higher PSA levels. In nonmetastatic advanced disease, the association was attenuated. In metastatic disease, a non-linear association was observed, with increased mortality risk at both lower and higher PSA levels. Patients with metastatic disease and PSA < 3.5 ng/mL had a higher estimated mortality risk than those with PSA 3.5-<10 ng/mL (adjusted HR 5.86, 95% CI 2.22-15.43), although this subgroup comprised only eight patients. The prognostic value of initial PSA appeared to differ according to disease stage. These findings generate the hypothesis that low PSA may have different prognostic implications across disease stages. External validation is required, particularly for the very low-PSA metastatic subgroup.", "journal": "World Journal of Urology", "pub_date": "2026-Oct-12", "publication_types": ["Journal Article", "Multicenter Study"], "doi": "10.1111/iju.70617", "authors": ["Hiroaki Iwamoto", "Kouji Izumi", "Kazuaki Machioka", "Ren Toriumi", "Takashi Shima", "Masakazu Nozaki", "Tomohiro Hori", "Takahiro Inaba", "Ryunosuke Nakagawa", "Taiki Kamijima", "Suguru Kadomoto", "Tomoyuki Makino", "Renato Naito", "Hiroshi Yaegashi", "Kazuyoshi Shigehara", "Takahiro Nohara", "Tohru Miyagi", "Chikashi Seto", "Yoshifumi Kadono", "Atsushi Mizokami"], "affiliations": ["Department of Integrative Cancer Therapy and Urology, Graduate School of Medical Science, Kanazawa University , Takaramachi 13-1, Kanazawa, Ishikawa, Japan.", "Department of Integrative Cancer Therapy and Urology, Graduate School of Medical Science, Kanazawa University , Takaramachi 13-1, Kanazawa, Ishikawa, Japan. azuizu2003@yahoo.co.jp.", "Department of Urology, Ishikawa Prefectural Central Hospital, Kanazawa, Ishikawa, Japan.", "Department of Urology, Toyama Prefectural Central Hospital, Toyama, Toyama, Japan.", "Department of Urology, Japanese Red Cross Fukui Hospital, Fukui, Fukui, Japan."], "corresponding_authors": ["Kouji Izumi"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_clinical", "score": 34.0, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.0, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 10.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.9, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.0, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42862363", "title": "Establishing stone composition from pure dust: feasibility and analytic yield of FTIR spectroscopy during suction-assisted flexible ureteroscopy.", "abstract": "The shift toward dust-only flexible ureteroscopy (FURS) prevents routine metabolic stone analysis due to a lack of retrievable fragments. We evaluated the technical success, analytical yield, and composition profile of Fourier-transform infrared (FTIR) spectroscopy performed on stone dust collected via flexible navigable suction access sheaths (FANS). This prospective single-center study included 109 patients undergoing FURS with FANS for upper tract stone disease. The surgeon aspirated the stone dust slurry into a container. Then, the fluid samples collected were sent to the lab to be centrifuged, washed with distilled water to remove any blood/protein artifacts, incubated until dried, and analyzed using FTIR spectroscopy. Dust aspiration reached a 100% analytical yield (109/109 cases), with all samples giving an interpretable FTIR reading. Calcium-based stones were the most common (64.2%, n = 70), consisting of Calcium Oxalate Monohydrate (51.4%, n = 56) and Calcium Oxalate Dihydrate (12.8%, n = 14). Uric Acid was identified in 26 cases (23.9%), followed by Carbonate-Apatite (6.4%, n = 7), Cystine (3.7%, n = 4), and Struvite (1.8%, n = 2). There was a strong relation between pre-operative CT density and the primary dust component (p < 0.001), with Uric Acid stones displaying significantly lower density (611.8 ± 263.2 HU) than Calcium Oxalate Monohydrate (1146.7 ± 335.7 HU). Aspirating stone dust during FURS provides a viable sample for FTIR spectroscopy, challenging the assumption that dust-only lithotripsy is inadequate for stone analysis and demonstrating a feasible, high-yield alternative when solid fragments are unretrievable.", "journal": "Urolithiasis", "pub_date": "2026-Oct-12", "publication_types": ["Journal Article"], "doi": "10.5527/wjn.v3.i4.282", "authors": ["Sarwar Noori Mahmood", "Ahmed Sarwar Noori", "Arya Sarwar Noori", "Hanisk Mohammed Othman"], "affiliations": ["Department of Clinical Sciences, College of Medicine, University of Sulaymaniyah, Research Institute, Mercy Medical City, Sulaymaniyah, 46001, Iraq.", "Department of Clinical Sciences, College of Medicine, University of Sulaymaniyah, Research Institute, Mercy Medical City, Sulaymaniyah, 46001, Iraq. ahmednoorichalabi@gmail.com."], "corresponding_authors": ["Ahmed Sarwar Noori"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=4", "score": 23.71, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 5.71, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 4.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.2, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.71, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42862361", "title": "Comment on \"Surgeon-led vs. nurse-led postoperative follow-up after DiLEP: impact on erectile function recovery and patient-reported outcomes\".", "abstract": "", "journal": "World Journal of Urology", "pub_date": "2026-Oct-12", "publication_types": ["Letter"], "doi": "10.1093/jsxmed/qdaf320.118", "authors": ["Anwar Khan", "Usha Yada", "Pramila D'Souza"], "affiliations": ["University of Tabuk, Tabuk, Kingdom of Saudi Arabia. infinitescholar2026@outlook.com.", "SGT University, Gurugram, Haryana, India.", "College of Nursing, University of Hail, Hail, Kingdom of Saudi Arabia."], "corresponding_authors": ["Anwar Khan"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 18.0, "score_parts": {"urology_relevance": 3, "urology_in_title": 8.0, "journal_priority": 10.0, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.9, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.0, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42861848", "title": "Optilume Drug-Coated Balloon for Bladder Neck Contracture Following Pulsed Thulium:YAG Laser Enucleation of the Prostate: A Single-Institution Retrospective Case Series.", "abstract": "Bladder neck contracture (BNC) following anatomical endoscopic enucleation of the prostate (AEEP) occurs in approximately 3% of cases and carries high recurrence rates after standard endoscopic management. The Optilume drug-coated balloon (DCB) delivers paclitaxel at dilation but has not been reported for post-enucleation BNC. We describe the first such series following pulsed thulium laser enucleation of the prostate (p-ThuLEP). We retrospectively reviewed 10 consecutive patients with cystoscopically confirmed BNC after p-ThuLEP at a single high-volume center (IRB 2425566-1). All underwent laser enucleation of bladder neck scar followed by Optilume DCB dilation. Data were abstracted from the electronic health record. Median age was 74 years (range 59-89). Median pre-p-ThuLEP prostate volume was 80 cc (range 36-100, n = 8). BNC presented at a median of 5.8 months after p-ThuLEP (range 2.7-12.0). A 36F balloon was used in nine patients and a 26F balloon in one, at 8 to 11 atm for 5 minutes. At a median follow-up of 5.2 months (range 0.9-15.1), no patient required reintervention (0% recurrence). Cystoscopy, performed in 5 of 10 on clinical indication, showed a patent bladder neck in all. Median post-procedure Qmax was 14.1 mL/s (n = 7), and post-void residual was 23.5 mL (n = 10). Thirty-day complications after Optilume occurred in two patients (20%), both Clavien-Dindo Grade II: gross hematuria with clot retention managed by continuous bladder irrigation and urinary tract infection. Optilume DCB following laser enucleation of post-p-ThuLEP BNC appears safe and feasible with encouraging short-term patency. Median follow-up (5.2 months) is shorter than the median interval to BNC presentation (5.8 months); thus, these short-term data do not establish durability. To the best of the authors' knowledge, this is the first report of Optilume DCB outcomes for BNC specifically following AEEP. A prospective cohort trial with longer follow-up is warranted.", "journal": "Journal of Endourology", "pub_date": "2026-Oct-12", "publication_types": ["Journal Article"], "doi": "10.1177/08927790261497133", "authors": ["Troy M Sofinowski", "Greyson Holler", "Gabriel Fiscus", "W Patrick Springhart", "Tim Large"], "affiliations": ["Division of Urology, Prisma Health Upstate, Greenville, South Carolina, USA."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=9", "score": 44.96, "score_parts": {"urology_relevance": 15, "urology_in_title": 8.0, "journal_priority": 9.96, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 9.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 1.96, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42861763", "title": "Bladder Contractility Classification Before Bladder Outlet Surgery: Do BCI, Wmax and the Maastricht-Hannover Nomogram Agree and Does It Matter for Outcome?", "abstract": "The aim of this study was to assess the concordance between three classification systems (bladder contractility index, Maximum Watt's factor and Maastricht-Hannover nomogram) in allocating men to bladder contractility subgroups. Secondary aim was to explore whether preoperative contractility classification was associated with short-term flowmetry outcomes after BOP. This multicenter retrospective cohort study included men who underwent BOP (2010-2016) for lower urinary tract symptoms with available baseline urodynamic study and 6-week postoperative flowmetry. Patients were classified according to BCI, Wmax and MH-nomogram into very weak (BCI < 50, Wmax < 5, MH-nomogram < 10th percentile), weak (BCI: 50-100, Wmax: 5-10, MH-nomogram 10-25th percentile) and normal detrusor contractility (BCI > 100, Wmax > 10, MH-nomogram > 25th percentile) subgroups. Concordance was quantified using percentage agreement and Cohen's linear weighted kappa (κ). Postoperative flowmetry outcomes were compared between subgroups within each classification and pre-postoperative differences were determined for each subgroup. One hundred and thirty three patients were included (median age 69 years). Agreement was highest between BCI and Wmax (78.9%, κ = 0.61, substantial), while agreement was weak between Wmax and MH-nomogram (48.9%, κ = 0.31) and negligible between BCI and MH-nomogram (37.6%, κ = 0.05). All subgroups showed improvement Qmax and PVR parameters after BOP, with no significant association found between preoperative contractility grade and postoperative outcomes. BCI, Wmax and the MH-nomogram show only limited concordance, particularly involving the MH-nomogram, and cannot be regarded as interchangeable. Contractility classification was not associated with postoperative outcomes, and all subgroups improved after BOP. These findings underscore the need for a clinically relevant urodynamic consensus definition of DU and support shared decision-making over classification-based patient selection alone.", "journal": "Neurourology and Urodynamics", "pub_date": "2026-Oct-12", "publication_types": ["Journal Article"], "doi": "10.1002/nau.70489", "authors": ["Selma Palthe", "Nadine A M van Merode", "Jeroen Kolenburg", "Tom Marcelissen", "Martijn G Steffens", "Gommert A van Koeveringe", "John P Heesakkers", "Lambertus P W Witte"], "affiliations": ["Department of Urology, Isala Clinics, Zwolle, the Netherlands.", "Department of Urology, Maastricht University, Maastricht, the Netherlands."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=9", "score": 31.56, "score_parts": {"urology_relevance": 7, "urology_in_title": 8.0, "journal_priority": 5.56, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 9.0}, "journal_metrics": {"status": "ok", "impact_factor": 1.9, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.56, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42860500", "title": "Comparative perioperative outcomes of Hugo™ RAS versus laparoscopic and Da Vinci platforms for partial nephrectomy: a systematic review and meta-analysis.", "abstract": "Renal cell carcinoma (RCC) is a common urologic malignancy, and for localized T1 tumors, nephron-sparing surgery is now the standard of care. Laparoscopic and image-guided techniques have advanced as robotic platform procedures offer greater operator dexterity and procedural control. The da Vinci platform has dominated robot-assisted partial nephrectomy, but high costs and closed architecture limit broader use. The Hugo™ RAS system, featuring a modular design, has emerged as a promising alternative, with early studies showing feasibility and safety. However, current evidence remains preliminary, mostly single-center and small-sample. This meta-analysis aggregates data and conducts subgroup analyses to compare Hugo™ RAS with other techniques, aiming to provide more precise effect estimates and guide surgical platform selection. The four main databases (PubMed, EMBASE, Web of Science, and Cochrane Library) were thoroughly searched to identify eligible clinical studies. The selected research involved comparative evaluations of surgical metrics of partial nephrectomy performed with Hugo™ RAS vs. the da Vinci system and traditional laparoscopy. This systematic synthesis included four observational cohort studies with a total of 383 subjects. Combined metric evaluations indicated that Hugo™ RAS demonstrated no statistically significant variation relative to alternative minimally invasive approaches regarding surgery duration (MD = 2.81 min, 95% CI [- 37.42, 43.03], p = 0.89), duration of hospitalization (MD = - 0.23 days, 95% CI [- 1.59, 1.13], p = 0.74), intraoperative blood loss (MD = 18.5 ml, 95% CI [- 53.61, 90.6], p = 0.62), serum creatinine following surgery (MD = - 0.05 mg/dl, 95% CI [- 0.18, 0.08], p = 0.44), positive surgical margin incidence (OR = 0.59, 95% CI [0.19, 1.80], p = 0.35), minor-to-moderate postoperative adverse event frequency (OR = 0.98, 95% CI [0.45, 2.17], p = 0.97), major postoperative adverse event frequency (OR = 0.74, 95% CI [0.09, 6.17], p = 0.78), overall postoperative adverse event rate (OR = 1.05, 95% CI [0.39, 2.87], p = 0.92), or successful trifecta attainment (OR = 1.11, 95% CI [0.60, 2.07], p = 0.74). This meta-analysis provided some preliminary evidence: Hugo™ RAS did not demonstrate significant differences compared to other minimally invasive surgical procedures in terms of procedure time, hospital stay, intraoperative blood loss, postoperative renal function, rate of positive margins, postoperative morbidity, and composite success results. Overall, Hugo™ RAS seems to be a reasonable surgical alternative. However, large multi-site randomized clinical trials are still needed to substantiate this finding.", "journal": "Journal of Robotic Surgery", "pub_date": "2026-Oct-12", "publication_types": ["Journal Article", "Systematic Review", "Meta-Analysis", "Comparative Study", "Review"], "doi": "10.1007/s11701-026-04062-5", "authors": ["ZongYing Lv", "Ren Zhang", "Wei Wei", "QinFeng Cai", "Man Liu", "JiaLi Wu", "Qi Liu", "ChaoMin Li", "JianGuo Xiong"], "affiliations": ["Department of Urology, Luzhou Longmatan District People's Hospital, Luzhou, China.", "Department of Urology, Luzhou Longmatan District People's Hospital, Luzhou, China. lmtqrmyyxjg@163.com."], "corresponding_authors": ["JianGuo Xiong"], "china_team": "Department of Urology, Luzhou Longmatan District People's Hospital, Luzhou, China JianGuo Xiong团队", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 39.03, "score_parts": {"urology_relevance": 12, "urology_in_title": 8.0, "journal_priority": 6.03, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 11.0}, "journal_metrics": {"status": "ok", "impact_factor": 3.0, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 2.03, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42860494", "title": "The clinical application value of mixed reality guidance in robot-assisted laparoscopic radical nephrectomy for renal cancer.", "abstract": "Although robot-assisted laparoscopic radical nephrectomy (RAL-RN) has realized the benefits of minimally invasive surgery, it continues to face several key technical limitations, including the lack of integrated patient-specific three-dimensional anatomical navigation and insufficient real-time intraoperative navigation. While mixed reality (MR) technology has shown considerable potential in renal tumor surgery, its clinical application value specifically within the context of radical nephrectomy for renal cancer warrants further systematic evaluation. This study aims to evaluate the clinical efficacy and practical value of MR guidance in RAL-RN. A retrospective analysis was conducted of 74 patients who underwent RAL-RN between September 2021 and March 2024. Participants were categorized into two groups based on preoperative assessment methodology: an MR navigation group (n = 33) and a conventional imaging group (n = 41). All patients received non-contrast and triple-phase contrast-enhanced renal CT scans. The MR group utilized Hololens-based intraoperative anatomical reference with three-dimensional models reconstructed from preoperative CT data during Da Vinci robotic procedures. Perioperative outcomes, including baseline demographic and clinical characteristics, operative time, estimated blood loss, and postoperative complications, were compared between the two groups to assess the potential technical advantages of MR-guided navigation. The two groups showed comparable baseline characteristics (p > 0.05). The MR group exhibited significantly shorter operative time (161.15 ± 10.87 min versus 182.29 ± 12.40 min, p < 0.001), reduced blood loss (150.00 mL [interquartile range 140.00 to 165.00] versus 165.00 mL [150.00 to 165.00], p = 0.008), faster gastrointestinal function recovery (26.82 ± 4.17 h versus 28.93 ± 3.68 h, p = 0.024), earlier tube removal (5.00 days [4.00 to 5.00] versus 6.00 days [6.00 to 7.00], p < 0.001), and shorter postoperative hospitalization (6.00 days [6.00 to 7.00] versus 8.00 days [7.00 to 8.00], p < 0.001). No significant differences were observed in tumor staging, renal function parameters (postoperative and 12-month Scr and GFR), histopathological type, or complication rates (Clavien-Dindo grades 1 and 2) between groups (all p > 0.05). MR guidance was associated with shorter operative time and faster postoperative recovery in RAL-RN. However, given the non-randomized design, these findings should be regarded as preliminary and cannot establish causality. Prospective studies with standardized allocation and adequate follow-up are warranted to confirm the clinical value of MR guidance.", "journal": "Journal of Robotic Surgery", "pub_date": "2026-Oct-12", "publication_types": ["Journal Article"], "doi": "10.1007/s11701-026-04048-3", "authors": ["Xin Chang Zou", "Yuan Liang Cao", "Xiang Da Xu", "Hai Chao Chao", "Huan Huan Deng", "Tao Zeng"], "affiliations": ["The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330008, China.", "Department of Urology, Second Affiliated Hospital of Nanchang University, Nanchang, 330008, China.", "Department of Urology, Second Affiliated Hospital of Nanchang University, Nanchang, 330008, China. taozeng40709@sina.com."], "corresponding_authors": ["Tao Zeng"], "china_team": "The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330008, China Tao Zeng团队", "category": "clinical_review", "classification_reason": "clinical_signals=14", "score": 32.03, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 6.03, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 12.0}, "journal_metrics": {"status": "ok", "impact_factor": 3.0, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 2.03, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42860491", "title": "Global research landscape and hot‑spot evolution of telesurgery in urology: A bibliometric analysis based on Web of Science Core Collection.", "abstract": "To systematically delineate the research landscape and evolutionary trajectory of telesurgery in urology, analyze the global research architecture, core research forces, and frontier hotspot evolution patterns, and provide a bibliometric basis for clinical translation and future research in this field. The Web of Science Core Collection was searched for literature on urological telesurgery from database inception to May 3, 2026. The language was restricted to English, and document types were limited to \"Article\" or \"Review.\" A total of 181 publications were finally included after screening. Multiple bibliometric tools were employed for multi-dimensional analysis: Microsoft Excel 2024 was used to analyze temporal trends in annual publication output and total citation counts; VOSviewer 1.6.20 was used to construct co-occurrence networks of countries/regions, institutions, authors, and journals; CiteSpace 6.4.R1 was used for keyword co-occurrence, clustering analysis, timeline mapping, and burst detection to parse the knowledge structure and hotspot evolution pathways; and the Bibliometrix 4.1.1 package was supplemented to visualize national collaboration patterns and core terminologies. Since 1996, the overall publication output in urological telesurgery has shown a fluctuating upward trend, with a rapid burst phase during 2024-2025. In 2025, 35 articles were published with 898 total citations, indicating that academic impact grew significantly faster than publication volume. In the global research landscape, the United States has long held a dominant position, with absolute advantages in publication scale, core institutions, and international collaboration networks. China started later but has shown the fastest output growth in recent years, though its depth of international collaboration and academic influence still have considerable room for improvement. High-productivity and highly cited authors are predominantly European and American scholars, forming two distinct contribution models: sustained clinical cohort research and foundational theoretical studies. Research outputs are mainly published in authoritative specialty journals of robotic surgery and urology. Keyword analysis reveals that robotic surgery is the core theme, with renal and prostate procedures being the main clinical application scenarios. The field has undergone three developmental stages: laparoscopic technique exploration, clinical feasibility validation, and long-term clinical outcome evaluation. Current frontiers include 5G networks, telepresence surgery, and long-term follow-up outcomes. Urological telesurgery has progressed beyond the nascent stage of technological exploration and entered a phase of rapid development characterized by clinical validation and scaled application. Future efforts should focus on multi-center, prospective clinical studies, refinement of technical standards and safety evaluation systems, and deep integration of robotic technology, communication networks, and artificial intelligence to facilitate cross-regional sharing of high-quality urological healthcare resources.", "journal": "Journal of Robotic Surgery", "pub_date": "2026-Oct-12", "publication_types": ["Journal Article", "Review"], "doi": "10.1016/j.eururo.2024.04.029", "authors": ["Jiangwei Man", "Lanchun Shao", "Rui Yan", "Hao Wang", "Yalong Zhang", "Changhong Xu", "Kangyu Wang", "Li Yang"], "affiliations": ["Department of Urology, The Second Hospital of Lanzhou University, No. 82, Cuiyingmen, Chengguan District, Lanzhou, China.", "Gansu Province Clinical Research Center for Urinary System Disease, Lanzhou, China.", "The Second Clinical Medical College, Lanzhou University, Lanzhou, China.", "Department of Urology, The Second Hospital of Lanzhou University, No. 82, Cuiyingmen, Chengguan District, Lanzhou, China. ery_yangli@lzu.edu.cn.", "Gansu Province Clinical Research Center for Urinary System Disease, Lanzhou, China. ery_yangli@lzu.edu.cn.", "The Second Clinical Medical College, Lanzhou University, Lanzhou, China. ery_yangli@lzu.edu.cn."], "corresponding_authors": ["Li Yang"], "china_team": "Department of Urology, The Second Hospital of Lanzhou University, No Li Yang团队", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 31.03, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 6.03, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 6.0}, "journal_metrics": {"status": "ok", "impact_factor": 3.0, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 2.03, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42860478", "title": "Surgical architecture and component identifiability in robot-assisted radical prostatectomy: a systematic review and network meta-analysis.", "abstract": "Robot-assisted radical prostatectomy (RARP) combines preservation, reconstruction, and support maneuvers within named surgical packages, making component attribution difficult. To determine whether comparative evidence can identify independent surgical-component effects on strict early perfect continence while preserving oncological context. Comparative RARP studies were synthesized within a prespecified surgical-architecture framework. The primary outcome was perfect continence (0 pads/day) at 10-14 weeks. All prespecified bibliographic databases and registries were rerun through 26 September 2026. Randomized evidence underwent pairwise and network meta-analysis; component estimates were interpreted only after a prespecified structural-identifiability gate. Forty-eight reports representing 48 nonoverlapping study families, 98 arms, and 6,665 arm-level participants were included. Six randomized families provided exact strict 3-month events and formed three disconnected subnetworks; four families formed the largest connected network. In that four-family network, risk ratios versus standard RARP were 1.07 (95% confidence interval [CI] 0.65-1.78) for posterior reconstruction (PR), 2.94 (0.92-9.33) for PR plus anterior reconstruction/suspension, and 1.49 (0.63-3.52) for PR plus sling. PR was the only component meeting the prespecified structural gate; this denotes evidence structure, not a precise or validated independent causal effect. Descriptive positive surgical margin estimates were sparse (PR 0.96 [0.50-1.86]; PR plus anterior reconstruction/suspension 1.74 [0.57-5.25]). Confidence in all primary network comparisons was very low. The literature is broad at the level of named RARP techniques but insufficiently connected and replicated to isolate most component-specific effects. Package-level signals should not be reassigned to individual maneuvers unless those components vary independently across replicated comparisons. Future trials should report exact time-specific continence outcomes, explicit arm-level technical details, and replicated component contrasts.", "journal": "Journal of Robotic Surgery", "pub_date": "2026-Oct-12", "publication_types": ["Network Meta-Analysis", "Journal Article", "Systematic Review", "Review"], "doi": "10.1007/s11701-026-04057-2", "authors": ["Yucong Chai", "Liming Zhang", "Bohao Zhong", "Peng Xue", "Xiaolong Li", "Junzhe Dai", "Jing Liu"], "affiliations": ["School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, 610054, China.", "Department of Urology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, 32 West Second Section, First Ring Road, Qingyang District, Chengdu, Sichuan, 610072, China.", "Department of Urology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, 32 West Second Section, First Ring Road, Qingyang District, Chengdu, Sichuan, 610072, China. liujingmn@med.uestc.edu.cn."], "corresponding_authors": ["Jing Liu"], "china_team": "School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, 610054, China Jing Liu团队", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 26.03, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 6.03, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 6.0}, "journal_metrics": {"status": "ok", "impact_factor": 3.0, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 2.03, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42860468", "title": "Robot-assisted ileal ureter replacement for complex ureteral strictures: a systematic review and single-arm meta-analysis of surgical and functional outcomes.", "abstract": "Complex, long-segment ureteral strictures present significant reconstructive challenges. While open ileal ureter replacement is the historical gold standard, it carries substantial perioperative morbidity. This systematic review and single-arm meta-analysis evaluate the surgical and functional outcomes of robot-assisted ileal ureter replacement (RIUR). Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, a comprehensive search of four databases was conducted through September 2026 to identify studies reporting adult RIUR outcomes for complex strictures. Outcomes were pooled using random-effects models. Five retrospective cohort studies comprising 110 patients met the inclusion criteria, with radiation-induced injury representing the predominant etiology (44.5%). The pooled surgical success rate was 93.9% (95% confidence interval [CI]: 87.0-97.2%). The pooled major complication rate (Clavien-Dindo grades III-V) was 10.0% (95% CI: 4.0-24.0%), driven primarily by urinary anastomotic leaks, typically managed with prolonged stenting. Pooled rates for metabolic acidosis requiring supplementation and stricture recurrence were 7.4% and 2.6%, respectively, while renal function remained stable or improved across all evaluated cohorts. Pooled mean operative time and estimated blood loss were 339.1 min (95% CI: 310.5-367.7) and 103.7 mL (95% CI: 54.9-152.6), respectively, while length of hospital stay varied widely by regional institutional pathway (median 3.0 days in early-discharge cohorts to 14.2 days in inpatient testing protocols). Current evidence suggests that RIUR represents a feasible and promising minimally invasive option for complex ureteral defects, with observed success rates meeting historical clinical benchmarks and an acceptable perioperative safety profile.", "journal": "Journal of Robotic Surgery", "pub_date": "2026-Oct-12", "publication_types": ["Journal Article", "Systematic Review", "Meta-Analysis", "Review"], "doi": "10.1007/s11701-026-04064-3", "authors": ["Saied Mohammed Saied Qasem", "Ahmed Naji Ahmed Hassan", "Mohamed L Ghanem", "Mina Hany Foad Tawfik"], "affiliations": ["Department of Urology, Faculty of Medicine, Ankara Yıldırım Beyazıt University, Üniversiteler Mah. İhsan Doğramacı Bulvarı Rıfat Börekçi Caddesi, Bilkent, Çankaya, 06800, Ankara, Turkey. 21080141049@aybu.edu.tr.", "Faculty of Medicine, Sudan University of Science and Technology, Khartoum, Sudan.", "Faculty of Medicine, Al-Azhar University, Cairo, Egypt.", "Faculty of Medicine, Cairo University, Cairo, Egypt."], "corresponding_authors": ["Saied Mohammed Saied Qasem"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 29.03, "score_parts": {"urology_relevance": 7, "urology_in_title": 8.0, "journal_priority": 6.03, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 6.0}, "journal_metrics": {"status": "ok", "impact_factor": 3.0, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 2.03, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42624109", "title": "Tumor cells recruit macrophage bodyguards to outlast chemotherapy.", "abstract": "In Cell Press Blue, Carvalho et al. identify spatially organized tumor-macrophage niches, EMT-like CD44high cancer cells paired with SPP1/PARP14high macrophages, that drive chemoresistance in bladder cancer. PARP14 inhibition can flip this protective niche into an inflammatory, cisplatin-sensitizing state.", "journal": "Cancer Cell", "pub_date": "2026-Oct-12", "publication_types": ["Journal Article"], "doi": "10.1016/j.ccell.2026.07.015", "authors": ["Yuzhao Wang", "Zibin Chen", "Zhuowei Liu", "Zikun Ma"], "affiliations": ["Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China; Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.", "Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China; Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China. Electronic address: liuzhw@sysucc.org.cn.", "Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China; Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China. Electronic address: mazk@sysucc.org.cn."], "corresponding_authors": ["Zhuowei Liu", "Zikun Ma"], "china_team": "Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China; Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China Zhuowei Liu/Zikun Ma团队", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 32.1, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 17.6, "top_journal_bonus": 10.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 0.5, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 44.5, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 5.6, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "膀胱癌化疗耐药源于肿瘤招募巨噬细胞护卫", "chinese_summary": "中山大学肿瘤防治中心刘卓炜/马梓坤团队8月Cancer Cell点评Cell Press Blue研究：膀胱癌中EMT样CD44高表达肿瘤细胞与SPP1/PARP14高表达巨噬细胞形成空间配对niche，驱动化疗耐药；抑制PARP14可将该保护性niche逆转为炎症状态并增敏顺铂。", "abstract_zh": "在Cell Press Blue中，Carvalho等人识别出空间组织化的肿瘤-巨噬细胞niche，即EMT样CD44高表达癌细胞与SPP1/PARP14高表达巨噬细胞配对，其驱动膀胱癌的化疗耐药。抑制PARP14可将这一保护性niche翻转为炎症性、顺铂增敏的状态。"}, {"pmid": "42860717", "title": "Feasibility Drives Adoption of Volumetric Stone Measurement: Results from an International Survey.", "abstract": "Accurate assessment of stone burden is essential for clinical decision-making in urolithiasis. Although stone volume is considered a more accurate representation of stone burden than maximal diameter, most clinical practice continues to rely on linear measurements. The extent to which volumetric assessment is used in daily practice remains unclear. Therefore, this study aimed to evaluate current global practices in stone burden assessment and identify factors associated with the adoption of volumetric measurement. An international cross-sectional survey was conducted among practicing urologists. The questionnaire was distributed electronically to members of the Endourological Society, the European Association of Urology Endourology Section, and national urological societies across Latin America, Africa, and Oceania. The survey assessed preferred methods for stone burden measurement, perceived barriers to volumetric assessment, and willingness to adopt automated measurement tools. Multivariable logistic regression analysis was performed to identify predictors of volumetric measurement use. A total of 252 urologists participated in the survey. Respondents were distributed across South America (32.9%), Europe (25.4%), North America (21.0%), Asia (9.9%), Central America (5.2%), Africa (5.2%), and Oceania (0.4%). Most respondents relied primarily on maximal stone diameter for clinical decision-making, although 51.6% reported incorporating volumetric assessment selectively depending on the clinical scenario. In multivariable analysis, perceived feasibility of volumetric assessment was the strongest predictor of volumetric measurement use (odds ratio [OR] 3.95, 95% Confidence Interval [CI] 2.28-6.86; p < 0.001), followed by academic practice (OR 1.87, 95% CI 1.03-3.38; p = 0.040). Fellowship training and years in practice were not independently associated with volumetric adoption. Despite increasing evidence supporting volumetric assessment, its use in routine clinical practice remains limited worldwide. Improving feasibility through automated or integrated measurement tools may facilitate broader adoption.", "journal": "Journal of Endourology", "pub_date": "2026-Oct-11", "publication_types": ["Journal Article"], "doi": "10.1177/08927790261497127", "authors": ["José Antonio Salvadó", "Fikayo Akinbo", "Matias Larrañaga", "Frederic Panthier", "Bhaskar Somani", "Felipe Pauchard"], "affiliations": ["Urology Institute, University Hospitals, Cleveland, Ohio, USA.", "Clinica Santa María, Universidad Finis Terrae, Santiago, Chile.", "GRC n820, Groupe de Recherche Clinique sur la Lithiase Urinaire, Hôpital Tenon, Sorbonne Université, bService d'Urologie, Assistance-Publique Hôpitaux de Paris, Hôpital Tenon, Sorbonne Université, Paris, France.", "Progressive Endourological Association for Research and Leading Solutions (PEARLS), Paris, France.", "EAU Endourology Section, Paris, France.", "University Hospital Southampton NHS Foundation Trust, Southampton, UK."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 19.96, "score_parts": {"urology_relevance": 8, "urology_in_title": 0.0, "journal_priority": 9.96, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 1.96, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42860705", "title": "Letter: Further Insights into Open Conversion During Robotic-Assisted Partial Nephrectomy.", "abstract": "", "journal": "Journal of Endourology", "pub_date": "2026-Oct-11", "publication_types": ["Letter"], "doi": "10.1177/08927790261497136", "authors": ["Hakan Bahadir Haberal", "Muhammed Emin Polat", "Senol Tonyali"], "affiliations": ["Department of Urology, Ankara Etlik City Hospital, Ministry of Health, University of Health Sciences, Ankara, Turkiye.", "Department of Urology, Ankara Bilkent City Hospital, Ankara, Turkiye.", "Department of Urology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkiye."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 18.96, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 9.96, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 1.96, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42860576", "title": "Prostate Cancer Patient-Derived Organoids (PDOs) as Functional Avatars for Antisense Oligonucleotide (ASO)-Based Personalized Therapy.", "abstract": "Patient-derived tumor organoids (PDOs) closely preserve the cellular heterogeneity, histopathology, and molecular features of the original tumors, making them powerful preclinical models. Antisense oligonucleotides (ASOs) are an emerging class of precision medicines that modulate gene expression at the RNA level with high target specificity, yet their application in organoid systems remains underexplored. Here, we adapted previously described protocols to establish a biobank of prostate cancer (PC) PDOs, achieving a high initial growth success rate (>90%). Histological and molecular analyses confirmed the preservation of key tumor features. Using these models, we assessed several ASOs, with particular emphasis on OGX-427 (Apatorsen), an ASO targeting heat shock protein 27 (HSP27) that has been evaluated in phase I/II clinical trials. While OGX-427 effectively suppressed HSP27 expression and inhibited cell growth in 2D cultures, its efficacy was markedly limited in 3D organoids, likely due to extracellular matrix and structural barriers. Removing Matrigel and applying single-cell transfection overcame these barriers, achieving efficient ASO uptake, significant target protein downregulation, and robust, dose-dependent inhibition of organoid growth. These findings underscore the utility of PDOs for evaluating ASO-based therapies and their potential to accelerate precision oncology strategies for PC and other malignancies.", "journal": "Advanced Healthcare Materials", "pub_date": "2026-Oct-11", "publication_types": ["Journal Article"], "doi": "10.1002/adhm.202505251", "authors": ["Thi Thom Tran", "Thi Tu Uyen Phan", "Michael Baboudjian", "Quang Hieu Duong", "Ines Sousa", "Thi Thuy Le", "Virginie Baylot", "Sophie Giusiano", "Laurent Daniel", "Pauline Brige", "Benjamin Guillet", "Cyrille Bastide", "Carmen Garrido", "David Taïeb", "Thi Khanh Le", "Palma Rocchi"], "affiliations": ["INSERM ERL U1326, CINaM, CERIMED, CNRS UMR 7325, Aix-Marseille University, Marseille, France.", "Department of Urology, Hospital Nord, AP-HM, Aix-Marseille University, Marseille, France.", "Laboratoire d'Anatomie et Cytologie Pathologiques, Hôpital de la Timone, AP-HM, Marseille, France.", "European Center for Research in Medical Imaging (CERIMED), Aix-Marseille University, Marseille, France.", "University of Burgundy Europe, INSERM UMR 1231, HSP-Pathies, Centre for Translational and Molecular Medicine, Dijon, France.", "University of Burgundy Europe, Centre Georges-François Leclerc (CGFL), Dijon, France.", "Department of Nuclear Medicine, Hôpital de la Timone, AP-HM, Aix-Marseille University, Marseille, France."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "basic_signals=8", "score": 34.46, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 11.46, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 8.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 9.6, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 3.46, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "前列腺癌类器官试药揭示递送瓶颈", "chinese_summary": "10月Adv Health Mater报道，研究者建立前列腺癌患者来源类器官生物库，初始培养成功率超90%，并保留原肿瘤组织学及分子特征。评估OGX-427等反义寡核苷酸时发现，其在二维培养中有效抑制HSP27并阻碍细胞生长，但在三维类器官中因细胞外基质和结构屏障疗效受限；", "abstract_zh": "患者来源的肿瘤类器官（PDOs）能够高度保留原发肿瘤的细胞异质性、组织病理学和分子特征，使其成为强有力的临床前模型。反义寡核苷酸（ASOs）是一类新兴的精准药物，可在RNA水平以高靶标特异性调节基因表达，但其在类器官系统中的应用仍未被充分探索。在此，我们采用先前描述的方案建立了前列腺癌（PC）PDOs生物库，实现了较高的初始生长成功率（>90%）。组织学和分子分析证实了关键肿瘤特征的保留。利用这些模型，我们评估了多种ASOs，特别关注OGX-427（Apatorsen），这是一种靶向热休克蛋白27（HSP27）的ASO，已在I/II期临床试验中接受评估。尽管OGX-427在二维培养中有效抑制HSP27表达并抑制细胞生长，但其在三维类器官中的疗效明显受限，可能由于细胞外基质和结构屏障所致。去除Matrigel并应用单细胞转染克服了这些屏障，实现了高效的ASO摄取、显著的靶蛋白下调以及对类器官生长的强效、剂量依赖性抑制。这些发现强调了PDOs在评估基于ASO的治疗中的实用性，以及其加速前列腺癌和其他恶性肿瘤精准肿瘤学策略的潜力。"}, {"pmid": "42860325", "title": "Prognostic biomarkers in non-muscle-invasive bladder cancer: biological basis and evidence.", "abstract": "To review prognostic and treatment-response biomarkers for non-muscle-invasive bladder cancer (NMIBC), with particular attention to biological function, specimen type, assay method, statistical evidence, and possible clinical use. We conducted a focused narrative search of PubMed, Web of Science, and the Cochrane Library for English-language human studies published from January 2015 to August 2026, supplemented by earlier pivotal studies and reference-list screening. Priority was given to NMIBC cohorts reporting recurrence, progression, survival, or response to intravesical therapy. We considered cohort specificity, sample size, multivariable analysis, testing in an independent population, and assay standardisation. Tumour-tissue markers such as stromal antigen 2 (STAG2), fibroblast growth factor receptor 3 (FGFR3), fibroblast activation protein-α, the urokinase plasminogen activator system, and cadherins are linked to chromosomal stability, growth-factor signalling, stromal remodelling, extracellular-matrix invasion, and epithelial-mesenchymal transition. Urinary RNAs and plasma circulating tumour DNA permit non-invasive sampling, although results depend on specimen handling and assay conditions. Blood-derived inflammatory indices are inexpensive but non-specific. Most evidence comes from retrospective single-cohort studies; reported effects and cut-offs are not always consistent, and few markers materially improve clinicopathological models. None of the biomarkers reviewed can currently replace guideline-based risk stratification or cystoscopic surveillance. Future studies should define assays and thresholds prospectively, test them in independent cohorts, and show that adding a biomarker improves prediction and patient management at an acceptable cost.", "journal": "BJU International", "pub_date": "2026-Oct-11", "publication_types": ["Journal Article", "Review"], "doi": "10.1111/bju.70488", "authors": ["Jinghong Wang", "Yitao Zhao", "Yushan Ye", "Xiaolong Qi", "Dahong Zhang", "Shiwei Duan", "Haibin Wei"], "affiliations": ["Urology & Nephrology Center, Department of Urology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, China.", "Postgraduate Training Base Alliance of Zhejiang Provincial People's Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China.", "Key Laboratory of Novel Targets and Drug Study for Neural Repair of Zhejiang Province, School of Medicine, Hangzhou City University, Hangzhou, Zhejiang, China."], "corresponding_authors": [], "china_team": "Urology & Nephrology Center, Department of Urology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, China Haibin Wei团队", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 35.97, "score_parts": {"urology_relevance": 7, "urology_in_title": 8.0, "journal_priority": 10.47, "top_journal_bonus": 0.0, "novelty": 0.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 8.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.4, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.47, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42860314", "title": "Surgical waiting times in patients with high- and low-risk renal cell carcinoma in England.", "abstract": "To assess to what extent hospitals meet the uniform English National Health Service 'timely' treatment standard, what happens after a breach, and determinants of delay for patients with high-risk renal cell carcinoma (RCC). Population-based study using linked data for 7030 patients with high-risk and 10 708 patients with low-risk RCC, 2019-2023. The probabilities of 'timely' treatment and prolonged delay (≤31 days or >62 days from decision-to-treat, respectively) were estimated using multilevel logistic regression. Daily treatment probabilities beyond 31 days were represented using smoothed hazard rates. For a typical patient with high-risk RCC, timely treatment declined from 83.7% (2019) to 64.8% (2023), with a corresponding decline in the low-risk group from 71.3% to 47.6%, while prolonged delays more than doubled, from 3.9% to 9.4%. Patients with high-risk RCC were prioritised over those with low-risk disease (73.6% vs 58.2%; adjusted risk ratio 1.26, 95% confidence interval 1.22-1.31). Older and more socioeconomically deprived patients experienced longer delays. Once the standard was breached, the daily probability of surgery declined sharply. Adjusted percentages of patients with high- and low-risk RCC treated within the standard were strongly correlated (r = 0.78). Prioritisation of patients with high-risk RCC was maintained throughout the study period but did not prevent a system-wide decline in timely treatment. Patients who breach the timely treatment standard face diminishing daily probabilities of surgery. Risk-stratified standards, ring-fenced surgical capacity, and monitoring beyond defined timely treatment standards are needed to safeguard patients against delays that have significant prognostic implications.", "journal": "BJU International", "pub_date": "2026-Oct-11", "publication_types": ["Journal Article"], "doi": "10.1111/bju.70490", "authors": ["Raghav Varma", "Emily Mayne", "Will Cuningham", "Marina A Parry", "Arjun Nathan", "Aurelia Chen", "Adrian Cook", "Maxine G B Tran", "James M Douglas", "Axel Bex", "Jan van der Meulen", "Amit Bahl", "Grant D Stewart", "Thomas E Cowling"], "affiliations": ["Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London, UK.", "National Cancer Audit Collaborating Centre, Clinical Effectiveness Unit, Royal College of Surgeons of England, London, UK.", "Division of Surgery and Interventional Science, UCL Department of Surgical Biotechnology, University College London, London, UK.", "Department of Urology, University Hospital Southampton NHS Foundation Trust, Southampton, UK.", "Department of Urology, Royal Free London NHS Foundation Trust, London, UK.", "Department of Urology, Amsterdam University Medical Center, Amsterdam, The Netherlands.", "Bristol Haematology and Oncology Centre, University Hospitals Bristol and Weston NHS Trust, Bristol, UK.", "Department of Surgery, University of Cambridge, Cambridge, UK."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=4", "score": 28.47, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.47, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 4.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.4, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.47, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42860231", "title": "Gardenia jasminoides Ellis 70% ethanolic fraction alleviates hyperuricemia by upregulating PPARγ and modulating its downstream urate transporters and anti-inflammatory pathways.", "abstract": "Gardenia jasminoides Ellis (GJE) is a traditional Chinese medicine widely used for metabolic disorders. However, its efficacy against hyperuricemia, the responsible active fraction, and the underlying mechanisms of its effect remains to be clarified. To investigate the material basis and urate-lowering activity of the 70% ethanolic fraction of GJE (GJE70), and to elucidate its molecular mechanism. UPLC-Q-TOF-MS characterized the chemical composition of GJE70. Hyperuricemia was induced in rats by potassium oxonate and yeast extract. Serum and urinary uric acid, uric acid clearance, renal function, and histopathology were assessed for anti-hyperuricemia efficacy and urate excretion. Hepatic function and histology were examined for safety. To explore mechanisms, kidney transcriptomics and metabolomics were performed; molecular docking predicted compound-target binding, which was validated by IF, WB, qRT-PCR and rescue experiments in HK-2 cells. UPLC-Q-TOF-MS identified 18 major compounds in GJE70, with crocins predominant. In hyperuricemia rats, GJE70 significantly reduced serum uric acid and increased urinary uric acid excretion and clearance, indicating enhanced renal urate elimination. Renal function and histopathology showed alleviated renal injury without obvious hepatotoxicity, with normal liver enzymes and histology. Transcriptomic and metabolomic analyses revealed that GJE70 mainly modulated PPAR signaling pathways. Molecular docking and MD Analysis demonstrated strong binding affinities of compounds to PPARγ. Subsequent IF, WB, and qRT-PCR confirmed that GJE70 upregulated PPARγ expression and its downstream urate transporters (ABCG2, OAT1, and OAT3), and suppressed NF-κB signaling levels. In HK-2 cells, GJE70 reduced supernatant uric acid, upregulated ABCG2/OAT1/OAT3, and inhibited NF-κB activation; GW9662 attenuated these effects, confirming PPARγ dependence. GJE70 exerts potent urate-lowering and renoprotective effects via PPARγ-mediated regulation of urate transporters and anti-inflammatory pathways, suggesting its potential as a therapeutic candidate for hyperuricemia.", "journal": "Journal of Ethnopharmacology", "pub_date": "2026-Oct-11", "publication_types": ["Journal Article"], "doi": "10.1016/j.jep.2026.122492", "authors": ["Ruyi Li", "Gongcan Chen", "Yizhuo Li", "Haiyan Liu", "Lu Huang", "Chao Yang", "Yifei Rao"], "affiliations": ["Discipline of Chinese and Western Integrative Medicine, Jiangxi University of Chinese Medicine, No.1688 Meiling Avenue, Wanli District, Nanchang, 330004, PR China; Integrated Chinese and Western Medicine Institute for Children Health & Drug Innovation, Jiangxi University of Chinese Medicine, No.1688 Meiling Avenue, Wanli District, Nanchang, 330004, PR China.", "Department of Neurology, Affiliated Hospital of Jiangxi University of Chinese Medicine, No. 445, Bayi Avenue, Donghu District, Nanchang, 330004, PR China.", "Discipline of Chinese and Western Integrative Medicine, Jiangxi University of Chinese Medicine, No.1688 Meiling Avenue, Wanli District, Nanchang, 330004, PR China; Integrated Chinese and Western Medicine Institute for Children Health & Drug Innovation, Jiangxi University of Chinese Medicine, No.1688 Meiling Avenue, Wanli District, Nanchang, 330004, PR China. Electronic address: huanglu1@jxutcm.edu.cn.", "Discipline of Chinese and Western Integrative Medicine, Jiangxi University of Chinese Medicine, No.1688 Meiling Avenue, Wanli District, Nanchang, 330004, PR China; Integrated Chinese and Western Medicine Institute for Children Health & Drug Innovation, Jiangxi University of Chinese Medicine, No.1688 Meiling Avenue, Wanli District, Nanchang, 330004, PR China. Electronic address: yangchaomedicine@163.com.", "Discipline of Chinese and Western Integrative Medicine, Jiangxi University of Chinese Medicine, No.1688 Meiling Avenue, Wanli District, Nanchang, 330004, PR China. Electronic address: ryf9696@163.com."], "corresponding_authors": ["Lu Huang", "Chao Yang", "Yifei Rao"], "china_team": "Discipline of Chinese and Western Integrative Medicine, Jiangxi University of Chinese Medicine, No Lu Huang/Chao Yang/Yifei Rao团队", "category": "basic", "classification_reason": "basic_signals=12", "score": 27.72, "score_parts": {"urology_relevance": 3, "urology_in_title": 0.0, "journal_priority": 10.72, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 12.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 5.4, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.72, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "栀子醇提物经PPARγ降尿酸", "chinese_summary": "江西中医药大学中西医结合学科罗黄煌、杨超、饶一飞团队10月J Ethnopharmacol报道，栀子70%乙醇组分在氧嗪酸钾-酵母浸膏高尿酸大鼠中显著降低血尿酸并增加尿尿酸排泄与清除，改善肾损伤且无明显肝毒性。转录组、代谢组及HK-2细胞实验证实其上调PPARγ及下游ABCG2、OAT1、OAT3并抑制NF-κB，具降尿酸和肾保护潜力。", "abstract_zh": "栀子（Gardenia jasminoides Ellis，GJE）是一种广泛用于代谢紊乱的传统中药。然而，其抗高尿酸血症的疗效、负责的活性组分及其作用机制仍有待阐明。本研究旨在探讨栀子70%乙醇组分（GJE70）的物质基础及降尿酸活性，并阐明其分子机制。采用UPLC-Q-TOF-MS表征GJE70的化学成分。通过氧嗪酸钾和酵母浸膏诱导大鼠高尿酸血症。评估血清和尿尿酸、尿酸清除率、肾功能及组织病理学以判断抗高尿酸血症疗效和尿酸排泄情况。检查肝功能和组织学以评价安全性。为探索机制，进行了肾脏转录组学和代谢组学分析；分子对接预测化合物-靶点结合，并通过HK-2细胞中的IF、WB、qRT-PCR及挽救实验进行验证。UPLC-Q-TOF-MS鉴定出GJE70中18种主要化合物，以藏红花素类为主。在高尿酸血症大鼠中，GJE70显著降低血清尿酸并增加尿尿酸排泄和清除，表明肾脏尿酸排泄增强。肾功能和组织病理学显示肾损伤减轻，无明显肝毒性，肝酶和组织学正常。转录组学和代谢组学分析揭示GJE70主要调节PPAR信号通路。分子对接和MD分析表明化合物与PPARγ具有强结合亲和力。随后的IF、WB和qRT-PCR证实GJE70上调PPARγ表达及其下游尿酸转运体（ABCG2、OAT1和OAT3），并抑制NF-κB信号水平。在HK-2细胞中，GJE70降低上清液尿酸，上调ABCG2/OAT1/OAT3，并抑制NF-κB活化；GW9662减弱这些效应，证实其PPARγ依赖性。GJE70通过PPARγ介导的尿酸转运体调节和抗炎通路发挥强效降尿酸和肾脏保护作用，提示其作为高尿酸血症治疗候选药物的潜力。"}, {"pmid": "42859935", "title": "Long-term follow-up outcomes and independent predictors of surgical failure following posterior urethroplasty for pelvic fracture-associated urethral strictures.", "abstract": "To report long-term follow-up outcomes of posterior urethroplasty for pelvic fracture urethral strictures and identify independent predictors of surgical failure. We retrospectively enrolled patients who underwent delayed posterior urethroplasty for pelvic fracture urethral injury at our center between December 2018 and December 2024. Perioperative and follow-up data were collected and analyzed. Patients with less than 12 months of postoperative follow-up were excluded. Seventy-six male patients were included. Median (IQR) age was 51.5 (40.5, 57.8) years. Injury mechanisms included crush trauma (n = 40, 52.6%), traffic accidents (n = 22, 29.0%), and falls (n = 14, 18.4%). Complete urethral obliteration was present in 54 patients (71.0%), and post-injury erectile dysfunction in 43 (56.6%). Thirty-two patients (42.1%) had prior urethral interventions. All procedures were successful. Median (IQR) urethral defect length was 2.5 (2.0, 3.5) cm. Direct anastomosis was performed in 48 patients (63.2%), and adjunctive maneuvers in 28 (36.8%). Median (IQR) follow-up was 30.0 (15.0, 59.5) months. Treatment success was achieved in 60 patients (79.0%), and failure in 16 (21.0%). On multivariate analysis, prior intervention (OR 11.558, 95% CI 1.356-98.515, P = 0.025) and longer urethral defect length (OR 4.394, 95% CI 1.262-15.292, P = 0.020) were independent predictors of surgical failure. Posterior urethroplasty is safe and effective for pelvic fracture urethral strictures with favorable long-term functional outcomes. Prior intervention and longer urethral defect length are independent predictors of surgical failure.", "journal": "World Journal of Urology", "pub_date": "2026-Oct-11", "publication_types": ["Journal Article"], "doi": "10.1007/s00345-026-06804-4", "authors": ["Jie Wang", "Guanglin Huang", "Guizhong Li", "Jianwei Wang"], "affiliations": ["Department of Urology, Beijing Jishuitan Hospital, Capital Medical University, Beijing, 100035, China.", "Department of Urology, Beijing Jishuitan Hospital, Capital Medical University, Beijing, 100035, China. wangjianwei77@126.com."], "corresponding_authors": ["Jianwei Wang"], "china_team": "Department of Urology, Beijing Jishuitan Hospital, Capital Medical University, Beijing, 100035, China Jianwei Wang团队", "category": "clinical_review", "classification_reason": "clinical_signals=6", "score": 33.0, "score_parts": {"urology_relevance": 7, "urology_in_title": 8.0, "journal_priority": 10.0, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 6.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.9, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.0, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42859243", "title": "The effect of a stress ball on pain, anxiety, satisfaction, and treatment continuation during extracorporeal shock wave lithotripsy: a randomized controlled trial.", "abstract": "This study aimed to evaluate the effect of a stress ball on pain, anxiety, satisfaction, and treatment continuation among patients undergoing extracorporeal shock wave lithotripsy (ESWL). This prospective, two-arm, randomized controlled trial was conducted at the urology outpatient clinic of a university hospital between May 2025 and May 2026. A total of 50 patients undergoing ESWL for the first time were randomly assigned to the stress ball group (n=25) and the control group (n=25). Patients in the stress ball group were provided with a stress ball during the procedure in addition to routine care, whereas the control group received routine care only. Patients' pain intensity during and after the procedure, as well as satisfaction levels following the procedure, were assessed using a visual analog scale. Anxiety levels before and after the procedure were measured using the State-Trait Anxiety Inventory-State. Patients' continuation to ESWL sessions was recorded. Pain scores during (p=0.001) and after (p<0.001) ESWL were lower in the stress ball group than in the control group. Post-procedure anxiety scores were lower in the stress ball group (p=0.035), whereas satisfaction scores were higher (p=0.011). The rate of continuation to the third ESWL session was higher in the stress ball group (92% vs. 68%, p=0.034). This study found that the use of a stress ball during ESWL reduced patients' pain and anxiety levels while increasing satisfaction and continuation to subsequent ESWL sessions. As a simple, low-cost, and non-pharmacological intervention, stress ball use may improve patient comfort, tolerance of ESWL, and adherence to repeated treatment sessions.Trial Registration: ClinicalTrials.gov, NCT06846723, registered January 28, 2025.", "journal": "Urolithiasis", "pub_date": "2026-Oct-10", "publication_types": ["Journal Article", "Randomized Controlled Trial"], "doi": "10.1007/s00240-026-02057-3", "authors": ["Canan Kanat", "Gamze Bozkul", "Elife Kettaş Dölek", "Gülay Altun Uğraş", "Erim Erdem"], "affiliations": ["Faculty of Nursing, Department of Surgical Nursing, Mersin University, Mersin, Turkey. canankanat@mersin.edu.tr.", "Faculty of Health Sciences, Department of Nursing, Tarsus University, Mersin, Turkey.", "Faculty of Medicine, Department of Urology, Mersin University, Mersin, Turkey.", "Faculty of Nursing, Department of Surgical Nursing, Mersin University, Mersin, Turkey."], "corresponding_authors": ["Canan Kanat"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_interventional_trial", "score": 21.71, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 5.71, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 9.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.2, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.71, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42859235", "title": "Interleukin-37 does not confer protection against stone formation or kidney injury at the peak of disease in a murine calcium oxalate model.", "abstract": "Calcium oxalate (CaOx) stones are the most prevalent form of nephrolithiasis in adults. While murine models of CaOx stone disease are established, many lack translational features for therapeutic evaluation, including in vivo assessment of kidney function and molecular profiling of renal inflammation. We refined the glyoxylate‑induced CaOx mouse model by incorporating non‑invasive transdermal glomerular filtration rate (tGFR) measurements to enable longitudinal assessment of kidney function. This platform was used to investigate the renoprotective role of the anti‑inflammatory cytokine interleukin‑37 (IL‑37). Because mice do not express IL‑37, we used IL‑37 transgenic (IL‑37tg) mice that express the human IL37b isoform. Male wild‑type and IL‑37tg mice received daily intraperitoneal glyoxylate to induce CaOx deposition. Crystal burden and tubular injury were quantified using digital image analysis of whole‑kidney sections. Kidney function was assessed using tGFR and validated by serum creatinine, blood urea nitrogen (BUN), and symmetric dimethylarginine (SDMA). Renal inflammation was profiled using an RT² Profiler PCR Array, with key transcripts validated by qPCR. CaOx deposition peaked on day 6, coinciding with tubular injury and impaired kidney function in both wild‑type and IL‑37tg mice, as evidenced by reduced tGFR and elevated BUN, creatinine, and SDMA. Stone formation triggered a robust inflammatory response, with 46 of 84 genes upregulated > 3‑fold in wild‑type mice. IL‑37 expression did not alter crystal burden, kidney injury, kidney function, or inflammatory gene expression. These findings establish a refined murine CaOx model incorporating kidney function and molecular endpoints and demonstrate that IL‑37 does not confer renal protection in glyoxylate‑induced stone disease.", "journal": "Urolithiasis", "pub_date": "2026-Oct-10", "publication_types": ["Journal Article"], "doi": "10.1126/sciimmunol.ade5728", "authors": ["Nirmal P Bhatt", "Theresa T H Nguyen", "Ina Rudloff", "Bernadette Jones-Freeman", "Guy J M Cameron", "Gabriel R Rodriguez", "Marcel F Nold", "Aniruddh V Deshpande", "Claudia A Nold-Petry", "Malcolm Ronald Starkey"], "affiliations": ["Department of Immunology, School of Translational Medicine, Monash University, Melbourne, VIC, Australia.", "Bladder and Kidney Health Discovery Program, School of Translational Medicine, Monash University, Melbourne, VIC, Australia.", "The Ritchie Centre, Hudson Institute of Medical Research, Melbourne, VIC, Australia.", "Department of Paediatrics, Monash University, Melbourne, VIC, Australia.", "Priority Research Centre GrowUpWell, College of Health, Medicine and Wellbeing, Hunter Medical Research Institute, The University of Newcastle, Newcastle, NSW, Australia.", "Monash Newborn, Monash Children's Hospital, Melbourne, Australia, VIC.", "Centre for Kidney Research, The Children's Hospital at Westmead, The University of Sydney, Sydney, NSW, Australia.", "Urology Unit, Department of Surgery, The Children's Hospital at Westmead, Sydney, NSW, Australia.", "Department of Immunology, School of Translational Medicine, Monash University, Melbourne, VIC, Australia. malcolm.starkey@monash.edu.", "Bladder and Kidney Health Discovery Program, School of Translational Medicine, Monash University, Melbourne, VIC, Australia. malcolm.starkey@monash.edu.", "School of Medical Sciences, Faculty of Health and Medicine, The University of Sydney, Sydney, NSW, Australia. malcolm.starkey@monash.edu."], "corresponding_authors": ["Malcolm Ronald Starkey"], "china_team": "", "category": "basic", "classification_reason": "basic_signals=13", "score": 24.71, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 5.71, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 13.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.2, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.71, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42859100", "title": "Impact of second-look TURBT on high grade recurrence and intravesical therapy in high-risk non-muscle-invasive bladder cancer: A 20-year experience.", "abstract": "To describe our 20-year experience with second look Transurethral Resection of Bladder Tumor (SL-TURBT) for high-risk non muscle invasive bladder cancer (NMIBC), and whether it was associated with better response to adjuvant intravesical therapy (IVT) and prognosis. Retrospective review of our quality assurance TURBT database between 2000 and 2024. All patients with high risk NMIBC who received IVT were included in the study. SL-TURBT was defined as TURBT within 8 weeks of the initial TURBT or if labelled by the clinician as such. Patients were divided into those who received SL-TURBT vs. those who did not. Patients were followed with cystoscopy and urine cytology every 3 months for the first 2 years, then every 6 months for years 3 to 5, then annually thereafter. Annual upper tract imaging was also performed. Kaplan-Meier method was used to depict high grade recurrence (HGRFS) and progression-free (PFS) survival. Of 853 patients were included in the study, 41% received SL-TURBT. Median time between initial and re-TURBT was 5.9 weeks (IQR 4.0-7.1 weeks). Indications for SL-TURBT included absence of detrusor in specimen (35%), T1 high grade disease (32%), Ta high grade (13%), incomplete resection (16%) and CIS (4%). Patients who received IVT exhibited improved 3 years' HGRFS with SL-TURBT (58% compared to 40% without SL-TURBT, log rank P = 0.008). There was no significant difference in PFS. Patients with high risk NMIBC who received a SL-TURBT prior to IVT exhibited improved HGRFS compared to those who received IVT without SL-TURBT.", "journal": "Urologic Oncology", "pub_date": "2026-Oct-10", "publication_types": ["Journal Article"], "doi": "10.1016/j.urolonc.2026.09.006", "authors": ["Yakov Klugman", "Nicholas M Cordero", "Grace Harrington", "Mohammad Khan", "Joshua Metherell", "Ava Giangrasso", "Jordan E Carlson", "Rafay Tariq", "Mariam Abd-Elhamid", "Saffa Rehman", "Collin Clark", "Zhe Jing", "Bradley Webster", "Qiang Li", "Khurshid A Guru", "Ahmed A Hussein"], "affiliations": ["Department of Urology, Roswell Park Comprehensive Cancer Center, Buffalo, NY.", "Department of Urology, Roswell Park Comprehensive Cancer Center, Buffalo, NY. Electronic address: ahmed.aly@roswellpark.org."], "corresponding_authors": ["Ahmed A Hussein"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=5", "score": 29.75, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 5.75, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 5.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.3, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.75, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42537900", "title": "Vitamin D deficiency alters prostate epithelial differentiation and increases prostate cancer aggressiveness in ex vivo and in vivo models.", "abstract": "Here, we examined the consequences of biologically relevant vitamin D deficiency, a known risk factor for aggressive prostate cancer, using ex vivo and in vivo models. Phenotypic and single-cell RNA sequencing of mouse prostate organoids showed that vitamin D deficiency stunted luminal cell differentiation more than androgen deficiency, which is a known driver of prostate development. Mice fed a vitamin D-deficient diet showed significantly altered expression of androgen-responsive genes in their prostate luminal cells, as determined by single-cell RNA sequencing. MDA-PCa-2b and 22Rv1 human prostate cancer cells, when maintained for 6 months in 1,25-dihydroxyvitamin D, had very different responses compared to short-term treatments. Notably, the MDA-PCa-2b cells lost the ability to form xenografts, despite normal proliferation in vitro. RNA sequencing showed that these cells also had disruptions in androgen signaling and in multiple cancer-related pathways, which differed by treatment duration. This study offers new insights and validation of vitamin D's role in both benign and malignant prostate biology, underscoring its essential hormonal functions and supporting strategies for vitamin D supplementation to reduce prostate cancer risk in vulnerable populations.", "journal": "Cancer Letters", "pub_date": "2026-Oct-10", "publication_types": ["Journal Article"], "doi": "10.1016/j.canlet.2026.218732", "authors": ["Adriana Duraki", "Kirsten D Krieger", "Sasha Celada", "Robert A Holt", "Ryan M Brown", "Luyu Wang", "Michael J Schlicht", "Maarten C Bosland", "Robert M Sargis", "Donald Vander Griend", "Larisa Nonn"], "affiliations": ["University of Illinois Chicago, Department of Pathology, USA.", "University of Illinois Chicago, Department of Medicine, Endocrinology, USA.", "University of Illinois Chicago, Department of Medicine, Endocrinology, USA; University of Illinois Cancer Center, USA; Jesse Brown Veterans Affairs Medical Center, USA.", "University of Illinois Chicago, Department of Pathology, USA; University of Illinois Cancer Center, USA.", "University of Illinois Chicago, Department of Pathology, USA; University of Illinois Cancer Center, USA. Electronic address: Lnonn@uic.edu."], "corresponding_authors": ["Larisa Nonn"], "china_team": "", "category": "basic", "classification_reason": "basic_signals=25", "score": 45.03, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 15.53, "top_journal_bonus": 0.0, "novelty": 1.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 14.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 10.1, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.53, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "维生素D缺乏促前列腺癌细胞去分化", "chinese_summary": "10月Cancer Lett基于小鼠类器官及体内模型发现，维生素D缺乏对前列腺腔细胞分化的抑制强于雄激素缺乏，并改变雄激素应答基因表达；人前列腺癌细胞长期暴露于1,25-二羟维生素D后失去成瘤能力且雄激素信号受损，提示补充维生素D或可降低高危人群前列腺癌风险。", "abstract_zh": "在本研究中，我们利用离体和在体模型，考察了具有生物学相关性的维生素D缺乏——一种已知的侵袭性前列腺癌危险因素——所带来的后果。小鼠前列腺类器官的表型分析和单细胞RNA测序显示，维生素D缺乏对腔细胞分化的抑制程度超过雄激素缺乏，而后者是已知的前列腺发育驱动因素。通过单细胞RNA测序测定，喂食维生素D缺乏饮食的小鼠，其前列腺腔细胞中雄激素应答基因的表达发生显著改变。MDA-PCa-2b和22Rv1人前列腺癌细胞在1,25-二羟维生素D中维持6个月后，其反应与短期处理相比差异很大。值得注意的是，MDA-PCa-2b细胞尽管在体外增殖正常，却丧失了形成异种移植瘤的能力。RNA测序显示，这些细胞还存在雄激素信号及多条癌症相关通路的紊乱，且紊乱情况因处理时长而异。本研究为维生素D在良性和恶性前列腺生物学中的作用提供了新见解和验证，凸显了其重要的激素功能，并支持通过维生素D补充策略来降低易感人群前列腺癌风险的思路。"}, {"pmid": "42521073", "title": "The FGFRL1-FASN axis regulates neuroendocrine lineage transdifferentiation by modulating fatty acid synthesis in AR pathway-independent prostate cancer.", "abstract": "AR pathway-independent prostate cancer (ARIPC), particularly neuroendocrine prostate cancer (NEPC), represents one of the most lethal states of metastatic castration-resistant prostate cancer. However, how fatty acid synthesis (FAS) is organized in ARIPC and whether distinct lipogenic states shape neuroendocrine lineage transdifferentiation remain unclear. By integrating single-cell and bulk transcriptomic analyses of mCRPC cohorts, we identify NEPC as a fatty-acid-synthesis-low state associated with poor survival. Within this context, fatty acid synthase (FASN) emerges as a key indicator and functional contributor to lipogenic activity. FASN depletion suppresses lipogenesis while increasing NEPC-associated programs, migration, and metastatic colonization. We further identify FGFRL1 as the FGF family member most consistently associated with fatty acid synthesis activity in ARIPC. FGFRL1 depletion reduces FASN expression and relative free fatty-acid content, while targeted GC-MS supports broader fatty-acid remodeling and fluorescent uptake assays show increased exogenous fatty-acid uptake. FASN restoration partially restores relative free fatty-acid content and attenuates NEPC-associated and migratory phenotypes. Directional perturbation, rescue, AKT phosphorylation, and co-immunoprecipitation analyses further support the functional FGFRL1-FASN relationship. ONECUT2 is prioritized as a candidate downstream transcriptional regulator whose expression correlates with the neuroendocrine program. Together, these findings support an FGFRL1-FASN metabolic axis that regulates neuroendocrine lineage transdifferentiation and metastatic progression in ARIPC.", "journal": "Cancer Letters", "pub_date": "2026-Oct-10", "publication_types": ["Journal Article"], "doi": "10.1016/j.canlet.2026.218769", "authors": ["Yupeng Chen", "Jiarun Lai", "Jian Chen", "Ziqing Zhou", "Qianfeng Xu", "Rui Zhou", "Jinchuang Li", "Yusen Long", "Ailiyaerjiang Wureyimu", "Jiaming Su", "Xinyue Mei", "Yinglin Li", "Jun Zhang", "Yongda Liu", "Jintai Luo", "Huichan He", "Shaoyou Liu", "Weide Zhong"], "affiliations": ["Department of Urology, School of Medicine, The Second Affiliated Hospital of South China University of Technology (Guangzhou First People's Hospital), Guangzhou, 510180, China.", "Guangdong Provincial Key Laboratory of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510230, China.", "State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China.", "Guangzhou National Laboratory, Guangzhou International Bio Island, Guangzhou, Guangdong Province, 510005, China.", "Department of Urology, Guangzhou Baiyun District Women and Children's Hospital, Guangzhou, China.", "State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China; School of Public Health, Guangzhou Medical University, Guangzhou, Guangdong, China.", "Department of Liver, Gallbladder and Pancreatic Surgery, School of Medicine, The Second Affiliated Hospital of South China University of Technology (Guangzhou First People's Hospital), Guangzhou, 510180, China.", "Guangdong Provincial Key Laboratory of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510230, China; Loudi Hospital, First Affiliated Hospital of Guangzhou Medical University, Loudi, Hunan Province, China.", "Guangdong Provincial Key Laboratory of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510230, China. Electronic address: xiaohejian@21cn.com.", "Guangdong Provincial Key Laboratory of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510230, China. Electronic address: doctorsyl@outlook.com.", "Department of Urology, School of Medicine, The Second Affiliated Hospital of South China University of Technology (Guangzhou First People's Hospital), Guangzhou, 510180, China; Guangdong Provincial Key Laboratory of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510230, China; Guangzhou National Laboratory, Guangzhou International Bio Island, Guangzhou, Guangdong Province, 510005, China; Macau Institute for Applied Research in Medicine and Health, Macau University of Science and Technology, Macau, 999078, China. Electronic address: zhongwd2009@live.cn."], "corresponding_authors": ["Huichan He", "Shaoyou Liu", "Weide Zhong"], "china_team": "Department of Urology, School of Medicine, The Second Affiliated Hospital of South China University of Technology (Guangzhou First People's Hospital), Guangzhou, 510180, China Huichan He/Shaoyou Liu/Weide Zhong团队", "category": "basic", "classification_reason": "basic_signals=8", "score": 38.53, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 15.53, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 8.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 10.1, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.53, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "FGFRL1-FASN轴驱动前列腺癌神经内分泌转分化", "chinese_summary": "华南理工大学附属第二医院（广州市第一人民医院）何慧婵/刘绍友/钟惟德团队10月Cancer Lett整合mCRPC单细胞及bulk转录组数据，发现神经内分泌前列腺癌呈脂肪酸合成低状态且预后差。FGFRL1缺失降低FASN表达及游离脂肪酸含量，而FASN回补可部分逆转神经内分泌及迁移表型，提示FGFRL1-FASN代谢轴调控AR通路非依赖前列腺癌谱系。", "abstract_zh": "AR通路非依赖性前列腺癌（ARIPC），尤其是神经内分泌前列腺癌（NEPC），是转移性去势抵抗性前列腺癌中最致命的阶段之一。然而，脂肪酸合成（FAS）在ARIPC中如何组织，以及不同的脂肪生成状态是否塑造神经内分泌谱系转分化，仍不清楚。通过整合mCRPC队列的单细胞和bulk转录组分析，我们将NEPC鉴定为与不良生存相关的脂肪酸合成低状态。在此背景下，脂肪酸合酶（FASN）成为脂肪生成活性的关键指标和功能贡献者。FASN缺失抑制脂肪生成，同时增加NEPC相关程序、迁移和转移定植。我们进一步鉴定FGFRL1为ARIPC中与脂肪酸合成活性最一致的FGF家族成员。FGFRL1缺失降低FASN表达和相对游离脂肪酸含量，而靶向GC-MS支持更广泛的脂肪酸重塑，荧光摄取实验显示外源性脂肪酸摄取增加。FASN恢复部分恢复相对游离脂肪酸含量并减弱NEPC相关和迁移表型。定向扰动、回补、AKT磷酸化和共免疫沉淀分析进一步支持功能性的FGFRL1-FASN关系。ONECUT2被优先列为候选下游转录调节因子，其表达与神经内分泌程序相关。总之，这些发现支持一个FGFRL1-FASN代谢轴，调控ARIPC中的神经内分泌谱系转分化和转移进展。"}, {"pmid": "42480966", "title": "Antibody-drug conjugates against multidrug-resistant cancers: Biomarker-guided patient selection, payload engineering, linker chemistry, and bystander effects.", "abstract": "Antibody-drug conjugates (ADCs) are one of the most significant advancements in modern cancer therapeutics. Combining the target selectivity of monoclonal antibodies with the cytotoxic potential of payloads, ADCs effectively kill cancer cells and offer hope to patients with even refractory cancer types. Beyond simply increasing the number of therapeutic options available for cancer patients, ADCs have become a powerful frontline agent in overcoming multidrug resistance (MDR). As one of the most challenging obstacles to effective cancer care, MDR is mediated by ATP-binding cassette (ABC) transporter-mediated drug efflux, target-based mutations, and dysregulated apoptosis. The clinical success of ADCs specifically engineered to overcome MDR, including in heterogeneous tumors and cancer cells that exhibit bypass signaling, is well established. This is especially evident with trastuzumab deruxtecan (T-DXd) in HER2-low, HER2-positive, and HER2-mutant cancers; sacituzumab govitecan (SG) in TROP2-expressing triple-negative breast cancer (TNBC) and urothelial carcinoma; and enfortumab vedotin in Nectin-4-positive bladder cancer. By overcoming MDR, ADCs have enabled more effective treatment algorithms across multiple malignancies. Most importantly, the clinical application of ADCs has become inextricably linked to cancer genomics. HER2 testing has evolved from a two-tiered system to a continuous spectrum including HER2-ultralow, HER2-low, HER2-positive, and ERBB2-mutant categories. Each of these categories exhibits different eligibility guidelines for ADC patient selection. As cancer cells continue to evolve and develop resistance to even ADCs through mutations and variants, researchers and clinicians have used pharmacogenomics to predict ADC response and resistance. To define the genomic architecture of ADC-resistant tumor subpopulations, single-cell transcriptomic studies and liquid biopsy approaches are being used to enable real-time examination of the tumor genome during ADC therapy, thereby optimizing treatment and circumventing resistance driven by emerging mutations and variants. This review provides a comprehensive analysis of the molecular structure of ADCs, the pharmacological principles underlying their potent cytotoxic activity against MDR cancer cells, the genomic and transcriptomic biomarkers that guide ADC patient selection, and the emerging resistance mechanisms that will shape the next generation of promising ADC development.", "journal": "Cancer Letters", "pub_date": "2026-Oct-10", "publication_types": ["Journal Article", "Review"], "doi": "10.1016/j.canlet.2026.218753", "authors": ["Ryan Li", "Xiang Chen", "Qinguo Huang", "Hongjian Ling", "Kunxiang Gong", "Zhe-Sheng Chen"], "affiliations": ["Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, NY, USA; Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA.", "Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, NY, USA.", "Department of Neurosurgery, The Second Affiliated Hospital, Shantou University Medical College, Shantou, China.", "Laboratory of Obstetrics and Gynecology, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China.", "Department of Pathology, First School of Clinical Medicine, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, Guangdong, China. Electronic address: gkx13265040169@126.com.", "Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, NY, USA. Electronic address: chenz@stjohns.edu."], "corresponding_authors": ["Kunxiang Gong", "Zhe-Sheng Chen"], "china_team": "Department of Neurosurgery, The Second Affiliated Hospital, Shantou University Medical College, Shantou, China Kunxiang Gong团队", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 31.03, "score_parts": {"urology_relevance": 8, "urology_in_title": 0.0, "journal_priority": 15.53, "top_journal_bonus": 0.0, "novelty": 2.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 3.0}, "journal_metrics": {"status": "ok", "impact_factor": 10.1, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.53, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42476286", "title": "Multifunctional nano-vaccines integrating lipid-conjugated tumor antigens with TLR/STING agonists enhance cancer immunotherapy.", "abstract": "Although there are several ongoing clinical trials using neoantigen peptide-based cancer vaccines, challenges still exist to implement in clinical approval such as poor antigen stability, inefficient delivery, and inadequate immune activation. To address these limitations, we developed a polymer-based polyvalent peptide and adjuvant (SPPA) that co-delivers lipid-conjugated tumor-specific peptides with Toll-like receptor 7/8 (3M - 052) and a STING (2'3'-cGAMP) agonist. This nanoplatform enables efficient peptide encapsulation, sustained release, and targeted delivery to antigen-presenting cells (APCs), thereby enhancing both innate and adaptive immune responses. We synthesized and characterized a library of lipid-conjugated tumor-associated and neoantigenic peptides. In vitro, SPPA significantly upregulated pro-inflammatory genes and cytokine secretion, confirming robust innate immune activation and demonstrated effective cellular uptake and lymphatic trafficking. In vivo, SPPA alone or in combination with anti-PD-1 antibody (αPD-1) elicited strong cytotoxic T lymphocyte (CTL) responses and inhibited tumor growth in four aggressive syngeneic mouse models: Triple-negative breast cancer (4T1), HER2+ breast cancer (TUBO), lung carcinoma (LLC1), and renal cell carcinoma (RENCA). The combination therapy led to pronounced tumor growth inhibition, survival benefit, and immune cell infiltration, including elevated CD8+IFN-γ+ T cells and M1 macrophages, and reduced regulatory T cells and MDSCs. Spatial transcriptomics revealed localized transcriptional reprogramming, with downregulation of extracellular matrix genes and activation of inflammatory pathways. Collectively, these findings establish SPPA as a potent and versatile nanovaccine platform capable of inducing durable antitumor immunity, especially when combined with immune checkpoint blockade. This approach offers strong translational potential for personalized immunotherapy across diverse solid tumor types.", "journal": "Cancer Letters", "pub_date": "2026-Oct-10", "publication_types": ["Journal Article"], "doi": "10.1016/j.canlet.2026.218736", "authors": ["Hari Krishnareddy Rachamala", "Naga Malleswara Rao Nakka", "Ramcharan Singh Angom", "Fang Wei", "Raj Nandani", "Zain Toiemie", "Edward S Famularo", "Shamit Kumar Dutta", "Enfeng Wang", "Santanu Bhattacharya", "Krishnendu Pal", "Keith L Knutson", "Debabrata Mukhopadhyay"], "affiliations": ["Department of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine and Sciences, Jacksonville, FL, 32224, USA.", "Department of Immunology, Clinical and Research Laboratories, Mayo Clinic, Jacksonville, FL, USA.", "Department of Physiology and Biomedical Engineering, Mayo Clinic College of Medicine and Sciences, Jacksonville, FL, 32224, USA.", "Department of Immunology, Clinical and Research Laboratories, Mayo Clinic, Jacksonville, FL, USA; Department of Bioengineering, Mayo Clinic College of Medicine and Sciences, Jacksonville, FL, 32224, USA.", "Department of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine and Sciences, Jacksonville, FL, 32224, USA; Department of Bioengineering, Mayo Clinic College of Medicine and Sciences, Jacksonville, FL, 32224, USA. Electronic address: mukhopadhyay.debabrata@mayo.edu."], "corresponding_authors": ["Debabrata Mukhopadhyay"], "china_team": "", "category": "basic", "classification_reason": "basic_signals=13", "score": 35.53, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 15.53, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 13.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 10.1, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.53, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "脂质偶联纳米疫苗增强抗肿瘤免疫", "chinese_summary": "Cancer Letters 2026年10月发表研究，开发聚合物多价肽佐剂SPPA，将脂质偶联肿瘤特异性肽与TLR7/8激动剂3M-052及STING激动剂2'3'-cGAMP共递送。该平台在四种小鼠肿瘤模型中激发细胞毒性T细胞反应并抑制肿瘤生长，与抗PD-1联用可提升CD8+IFN-γ+ T细胞及M1巨噬细胞浸润，减少调节性T细胞与MDSC，展。", "abstract_zh": "尽管目前有若干正在开展的临床试验使用新抗原肽癌症疫苗，但在临床获批方面仍存在挑战，例如抗原稳定性差、递送效率低以及免疫激活不足。为解决这些局限，我们开发了一种基于聚合物的多价肽和佐剂（SPPA），可将脂质偶联的肿瘤特异性肽与Toll样受体7/8激动剂（3M-052）及STING激动剂（2'3'-cGAMP）共递送。该纳米平台能够实现高效的肽包封、持续释放以及向抗原呈递细胞（APC）的靶向递送，从而增强先天性和适应性免疫应答。我们合成并表征了一系列脂质偶联的肿瘤相关肽和新抗原肽。在体外，SPPA显著上调促炎基因和细胞因子分泌，证实了强效的先天免疫激活，并表现出有效的细胞摄取和淋巴转运。在体内，SPPA单独或与抗PD-1抗体（αPD-1）联合，在四种侵袭性同基因小鼠模型中引发强烈的细胞毒性T淋巴细胞（CTL）反应并抑制肿瘤生长：三阴性乳腺癌（4T1）、HER2+乳腺癌（TUBO）、肺癌（LLC1）和肾细胞癌（RENCA）。联合治疗导致显著的肿瘤生长抑制、生存获益和免疫细胞浸润，包括CD8+IFN-γ+ T细胞和M1巨噬细胞升高，以及调节性T细胞和MDSC减少。空间转录组学揭示局部转录重编程，表现为细胞外基质基因下调和炎症通路激活。总之，这些发现确立了SPPA作为一个强效且多功能的纳米疫苗平台，能够诱导持久的抗肿瘤免疫，尤其是与免疫检查点阻断联合使用时。该方法为多种实体瘤类型的个体化免疫治疗提供了强大的转化潜力。"}, {"pmid": "42476284", "title": "GSN liquid-liquid phase separation induces PANoptosis by inhibiting YAP-dependent glycolysis to alleviate the progression of clear cell renal cell carcinoma.", "abstract": "This study was carried out to screen PANoptosis-related biomarker genes and the involved underlying mechanism in clear cell renal cell carcinoma (ccRCC). Differentially expressed (DE) PANoptosis-related genes were identified. Then prognostic biomarker genes were screened, and used to construct a prognostic model. The predictive ability of the model was explored by receiver operating characteristic (ROC) curves. Then the correlation between risk score with clinical features and immune cell infiltration were evaluated. The expression level and prognosis of gelsolin (GSN) were examined in datasets. Furthermore, in vivo and in vitro experiments were employed to investigate underlying mechanisms. ScRNA-seq analysis uncovered that PANoptosis scores varied significantly across 9 cell types in the tumor microenvironment. A total of 26 DE-PANoptosis-related genes were identified by intersecting DEGs and PANoptosis-related genes. Then 3 prognosis biomarker genes were screened and used to build the prognostic model, namely TLR3, GSN and TNFRSF1A. The risk score was associated with tumor grade, stage (I, II, III, IV), pathologic T-Stage, etc, and also significantly correlated with immune cells and expression of immune checkpoint proteins. In addition, GSN was upregulated in ccRCC, and high expression of GSN indicated a favorable OS. In vivo and in vitro experiments revealed that GSN liquid-liquid phase separation (LLPS) directly induces PANoptosis in ccRCC by inhibiting YAP-dependent glycolysis. In conclusion, using TLR3, GSN and TNFRSF1A, the established PANoptosis-related prognostic model was established and showed good predictive performance for predicting prognosis of ccRCC patients. GSN LLPS directly induces PANoptosis in ccRCC by inhibiting YAP-dependent glycolysis.", "journal": "Cancer Letters", "pub_date": "2026-Oct-10", "publication_types": ["Journal Article"], "doi": "10.1016/j.canlet.2026.218744", "authors": ["Juan Jin", "Ruikai Zhang", "Xingchen Li", "Xinbo Liu", "Egor Y Plotnikov", "Xinyu Liao", "Taian Jin", "Wenfang He", "Yunguang Wang", "Haifang Lou", "Qiang He"], "affiliations": ["Department of Nephrology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, 310006, PR China; Zhejiang Key Laboratory of Research and Translation for Kidney Deficiency-Stasis-Turbidity Disease, Zhejiang-Macau International Joint Laboratory of Integrated Traditional Chinese and Western Medicine for Nephrology and Immunology, Hangzhou, Zhejiang, 310006, PR China.", "A.N. Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, Moscow, Russia.", "Faculty of Bioengineering and Bioinformatics, Lomonosov Moscow State University, Moscow, 119992, Russia.", "Zhejiang Key Laboratory of Research and Translation for Kidney Deficiency-Stasis-Turbidity Disease, Zhejiang-Macau International Joint Laboratory of Integrated Traditional Chinese and Western Medicine for Nephrology and Immunology, Hangzhou, Zhejiang, 310006, PR China; Department of Medical Engineering, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, 310006, PR China. Electronic address: Louhf-2005@163.com.", "Department of Nephrology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, 310006, PR China; Zhejiang Key Laboratory of Research and Translation for Kidney Deficiency-Stasis-Turbidity Disease, Zhejiang-Macau International Joint Laboratory of Integrated Traditional Chinese and Western Medicine for Nephrology and Immunology, Hangzhou, Zhejiang, 310006, PR China. Electronic address: qianghe1973@126.com."], "corresponding_authors": ["Haifang Lou", "Qiang He"], "china_team": "Department of Nephrology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, 310006, PR China; Zhejiang Key Laboratory of Research and Translation for Kidney Deficiency-Stasis-Turbidity Disease, Zhejiang-Macau International Joint Laboratory of Integrated Traditional Chinese and Western Medicine for Nephrology and Immunology, Hangzhou, Zhejiang, 310006, PR China Haifang Lou/Qiang He团队", "category": "basic", "classification_reason": "basic_signals=14", "score": 44.03, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 15.53, "top_journal_bonus": 0.0, "novelty": 0.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 14.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 10.1, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.53, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "GSN相分离诱导肾癌PANoptosis", "chinese_summary": "浙江中医药大学附属第一医院何强/楼海芳团队10月Cancer Lett报道，透明细胞肾细胞癌中GSN表达上调且高表达提示总生存更优；GSN通过液-液相分离抑制YAP依赖性糖酵解，直接诱导PANoptosis，从而延缓肿瘤进展，为ccRCC提供潜在预后标志与治疗靶点。", "abstract_zh": "本研究旨在筛选透明细胞肾细胞癌（ccRCC）中与PANoptosis相关的生物标志基因及其潜在机制。研究识别了差异表达（DE）的PANoptosis相关基因，随后筛选预后生物标志基因并用于构建预后模型。通过受试者工作特征（ROC）曲线探讨模型的预测能力。进而评估风险评分与临床特征及免疫细胞浸润的相关性。在数据集中检测gelsolin（GSN）的表达水平及预后价值。此外，采用体内和体外实验探究潜在机制。单细胞RNA测序分析揭示，肿瘤微环境中9种细胞类型的PANoptosis评分存在显著差异。通过交集差异表达基因与PANoptosis相关基因，共识别出26个差异表达的PANoptosis相关基因。随后筛选出3个预后生物标志基因用于构建预后模型，即TLR3、GSN和TNFRSF1A。风险评分与肿瘤分级、分期（I、II、III、IV期）、病理T分期等相关，并且与免疫细胞及免疫检查点蛋白表达显著相关。此外，GSN在ccRCC中表达上调，且GSN高表达提示总生存期（OS）较好。体内和体外实验揭示，GSN液-液相分离（LLPS）通过抑制YAP依赖性糖酵解直接诱导ccRCC中的PANoptosis。总之，利用TLR3、GSN和TNFRSF1A建立的PANoptosis相关预后模型在预测ccRCC患者预后方面表现出良好的预测性能。GSN LLPS通过抑制YAP依赖性糖酵解直接诱导ccRCC中的PANoptosis。"}, {"pmid": "42855542", "title": "Cribriform and intraductal carcinoma in prostate cancer - implications for risk stratification and therapeutic decision-making.", "abstract": "Intraductal carcinoma of the prostate (IDC) and invasive cribriform carcinoma (invasive Crib) are closely related high-risk morphologies that frequently coexist and are associated with adverse pathology, early metastasis and disease-specific mortality across the prostate cancer continuum. These morphologies are common in intermediate- and high-risk disease, but remain under-recognized and inconsistently reported, contributing to undergrading and potentially inappropriate selection of patients for de-escalation strategies such as active surveillance or focal therapy. Biopsy detects these patterns in only about half of affected men, and magnetic resonance imaging (MRI)-targeted sampling does not reliably close this gap. These tumours are enriched for loss of the tumour-suppressor gene PTEN, DNA-damage-repair alterations and genomic instability, and are associated with immunologically 'cold', fibroblast-rich tumour niches. These findings provide a rationale for evaluating biomarker-directed strategies, including inhibition of the PARP and AKT pathways and therapies targeting B7-H3 (also known as CD276). However, definitive evidence that either IDC or invasive Crib predicts benefit from any of these treatments has not been established. A deeper understanding of the biological and clinical behaviour of these tumours, together with rigorous, standardized reporting, is essential for accurate risk stratification, rational use of active surveillance and focal approaches, selection of patients for intensified local and systemic treatment, and the design of biomarker-driven trials for this aggressive disease subset.", "journal": "Nature Reviews Urology", "pub_date": "2026-Oct-09", "publication_types": ["Journal Article", "Review"], "doi": "10.1097/MOU.0000000000001347", "authors": ["Rui M Bernardino", "João Lobo", "Zeyad Schwen", "Theodorus van der Kwast", "Adam B Weiner", "Robert E Reiter", "Jane K Nguyen", "Estevão Lima", "Robert Stein", "Nicolas Soputro", "Rashed Ghandour", "Alp Tuna Beksac", "Karim Daher", "Ricardo Leão", "Mark L Gonzalgo", "Roderick van den Bergh", "Juan Garisto", "Giancarlo Marra", "Jennifer Le Guévelou Kammerer", "Sara M Falzarano", "Cristina Magi-Galuzzi", "Cosimo De Nunzio", "Susan Prendeville", "Neil Fleshner", "Jihad Kaouk", "Riccardo Autorino"], "affiliations": ["Glickman Urological Institute, Cleveland Clinic, Cleveland, OH, USA.", "Department of Pathology, Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal.", "ICBAS - School of Medicine and Biomedical Sciences, University of Porto (ICBAS-UP), Porto, Portugal.", "Cancer Biology and Epigenetics Group, Research Center of IPO Porto, IPO Porto/Porto Comprehensive Cancer Center Raquel Seruca, Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal.", "Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada.", "Cedars-Sinai Medical Center, Los Angeles, CA, USA.", "UCLA Department of Urology, Los Angeles, CA, USA.", "Diagnostics Institute, Department of Anatomic Pathology, Cleveland Clinic, Cleveland, OH, USA.", "School of Medicine, University of Lisbon, Lisbon, Portugal.", "Desai Sethi Urology Institute, University of Miami, Miami, USA.", "Erasmus MC Cancer Institute, Rotterdam, Netherlands.", "NewYork-Presbyterian Brooklyn Methodist Hospital, NewYork-Presbyterian Hospital, Weill Cornell Medicine, New York, NY, USA.", "Città della Salute e della Scienza e Università degli Studi di Torino, Turin, Italy.", "Laboratoire du traitement du signal et de l'image, Université de Rennes, Rennes, France.", "Department of Pathology, Immunology and Laboratory Medicine, University of Florida, Gainesville, FL, USA.", "Department of Pathology, The University of Alabama at Birmingham, Birmingham, AL, USA.", "Department of Urology, Sant'Andrea Hospital, La Sapienza University, Rome, Italy.", "Princess Margaret Cancer Centre, Division of Urology, University of Toronto, Toronto, Canada.", "Glickman Urological Institute, Cleveland Clinic, Cleveland, OH, USA. ricautor@gmail.com."], "corresponding_authors": ["Riccardo Autorino"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 33.53, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 16.03, "top_journal_bonus": 0.0, "novelty": 0.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 3.0}, "journal_metrics": {"status": "ok", "impact_factor": 14.6, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.03, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42855516", "title": "Proteome-guided drug discovery maps and mitigates therapeutic degrader toxicity.", "abstract": "Heterobifunctional targeted degraders (HBDs) enable potent removal of protein targets but their clinical success can be hindered by de novo toxicity inherent to their bivalent chemistry. Here we introduce a drug discovery framework that exploits high-throughput proteomics to map and mitigate toxicity mechanisms of emerging drug modalities. Exposing androgen receptor (AR)-negative cells to a library of experimental AR-HBDs indicated for treatment-resistant prostate cancer linked widespread proteomic responses to hepatotoxicity of phthalimide degraders. Machine learning trained on proteomes mapped the primary toxicity mechanism to inhibition of electron transport chain complex I and identified safer analogs where a minor modification in the linker region mitigated off-target engagement. Proteome-optimized degraders displayed decreased hepatotoxicity, enhanced specificity and antitumor activity against treatment-resistant prostate cancer xenografts. Our findings establish a versatile framework for developing safer medicines and highlight the transformative potential of proteome-guided drug discovery.", "journal": "Nature Chemical Biology", "pub_date": "2026-Oct-09", "publication_types": ["Journal Article"], "doi": "10.1073/pnas.0506580102", "authors": ["Shaon Basu", "Jason Shu Lim Yu", "Jessica Bosak", "Sharan K Bagal", "Claire Crafter", "Charlene Fallan", "Oliver Lemke", "Anja Freiwald", "Matthew E H White", "Spyros I Vernardis", "Christoph B Messner", "Chrysiis Michaloglou", "Kenneth Pryde", "Antonio Ramos-Montoya", "Sophie Regan", "Monica Rodrigo-Brenni", "Sascha Roth", "Camilla Ruffilli", "Michael Mülleder", "Kevin Moreau", "Markus Ralser"], "affiliations": ["Department of Biochemistry, Charité Universitätsmedizin, Berlin, Germany.", "Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, UK.", "The Molecular Biology of Metabolism Laboratory, The Francis Crick Institute, London, UK.", "MRC Mitochondrial Biology Unit, Cambridge, UK.", "Oncology Targeted Discovery, R&D, AstraZeneca, Cambridge, UK.", "Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, UK. kevin.moreau@astrazeneca.com.", "Max Planck Institute for Molecular Genetics, Berlin, Germany."], "corresponding_authors": ["Kevin Moreau"], "china_team": "", "category": "basic", "classification_reason": "basic_signals=9", "score": 31.94, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 15.94, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 9.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 13.7, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.94, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "蛋白组学筛选降低降解剂肝毒性", "chinese_summary": "10月Nat Chem Biol发表研究，利用高通量蛋白组学构建药物发现框架，将雄激素受体降解剂的肝毒性机制定位于线粒体电子传递链复合物I抑制，经机器学习识别连接区修饰可降低脱靶结合。优化后降解剂肝毒性降低、特异性增强，并在耐药前列腺癌移植瘤中显示更优抗肿瘤活性，为更安全药物的开发提供了新范式。", "abstract_zh": "异双功能靶向降解剂（HBDs）能够高效清除蛋白质靶标，但其双价化学结构固有的新发毒性可能阻碍其临床成功。在此，我们提出了一种药物发现框架，利用高通量蛋白质组学来绘制和减轻新兴药物模式的毒性机制。将雄激素受体（AR）阴性细胞暴露于一组用于治疗耐药前列腺癌的实验性AR-HBDs，将广泛的蛋白质组学反应与邻苯二甲酰亚胺降解剂的肝毒性联系起来。基于蛋白质组训练的机器学习将主要毒性机制定位为对电子传递链复合物I的抑制，并识别出更安全的类似物，其中连接区的一个微小修饰减轻了脱靶结合。经蛋白质组优化的降解剂表现出降低的肝毒性、增强的特异性以及对耐药前列腺癌异种移植瘤的抗肿瘤活性。我们的发现为开发更安全的药物建立了一个通用框架，并凸显了蛋白质组引导药物发现的变革潜力。"}, {"pmid": "42855349", "title": "Reply to Sho Todo, Keiichiro Kitahama, and Kentaro Inamura's Letter to the Editor re: Wenxin Xu, Brian I. Rini, Laurence Albiges, et al. Comprehensive Genomic and Transcriptomic Characterization of Matched Primary and Recurrent Tumors in High-risk Localized Renal Cell Carcinoma. Eur Urol. 2026 Apr 25:S0302-2838(26)02060-9.", "abstract": "", "journal": "European Urology", "pub_date": "2026-Oct-09", "publication_types": ["Letter"], "doi": "10.1016/j.eururo.2026.08.015", "authors": ["Wenxin Xu", "Brian I Rini", "Laurence Albiges", "Xiaobin Tang", "Sumanta Kumar Pal"], "affiliations": ["Dana-Farber Cancer Institute, Boston, MA, USA.", "Vanderbilt Ingram Cancer Center, Nashville, TN, USA.", "Gustave Roussy, Université Paris-Saclay, Paris, France.", "Genentech USA, Inc., South San Francisco, CA, USA.", "City of Hope Comprehensive Cancer Center, Duarte, CA, USA. Electronic address: spal@coh.org."], "corresponding_authors": ["Sumanta Kumar Pal"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 37.79, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 16.79, "top_journal_bonus": 10.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 2.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 25.2, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.79, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "高危肾癌复发分子特征获验证", "chinese_summary": "针对Todo等对配对原发与复发高危局限性肾癌多组学分析的质疑，通讯作者于10月Eur Urol刊发回复。原研究由Wenxin Xu、Brian I. Rini、Laurence Albiges等完成，提示复发肿瘤分子与免疫状态有别于原发灶。", "abstract_zh": "这是对Sho Todo、Keiichiro Kitahama和Kentaro Inamura致编辑来信的回复，来信针对Wenxin Xu、Brian I. Rini、Laurence Albiges等人发表的文章《高危局限性肾细胞癌配对原发与复发肿瘤的综合基因组与转录组特征分析》（Eur Urol. 2026 Apr 25:S0302-2838(26)02060-9）。"}, {"pmid": "42855348", "title": "Reply to Dachun Jin, Chi-Fai Ng, and Peter Ka-Fung Chiu's Letter to the Editor re: Bi-Ming He, Keqin Zhang, Zhien Zhou, et al. Cognitive Versus Software-based Fusion Targeted Biopsy for the Diagnosis of Clinically Significant Prostate Cancer: A Multicenter, Randomized, Noninferiority Trial (IMAGINATION). Eur Urol. In press. https://doi.org/10.1016/j.eururo.2026.06.020.", "abstract": "", "journal": "European Urology", "pub_date": "2026-Oct-09", "publication_types": ["Letter"], "doi": "10.1016/j.eururo.2026.09.019", "authors": ["Bi-Ming He", "Hai-Feng Wang"], "affiliations": ["Department of Urology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China; Institute for Advanced Study, Tongji University, Shanghai, China. Electronic address: 190589109@qq.com.", "Department of Urology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China. Electronic address: kuohaiandrew2000@vip.sina.com."], "corresponding_authors": ["Bi-Ming He", "Hai-Feng Wang"], "china_team": "Department of Urology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China; Institute for Advanced Study, Tongji University, Shanghai, China Bi-Ming He/Hai-Feng Wang团队", "category": "clinical_review", "classification_reason": "clinical_signals=6", "score": 41.79, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 16.79, "top_journal_bonus": 10.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 6.0}, "journal_metrics": {"status": "ok", "impact_factor": 25.2, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.79, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "认知融合靶向前列腺穿刺不劣于软件融合", "chinese_summary": "上海东方医院何碧明、王海峰团队10月Eur Urol回复读者来信，围绕IMAGINATION多中心随机非劣效试验，就认知融合与软件融合靶向穿刺诊断临床显著前列腺癌的方法学争议作出回应，重申两种穿刺路径在检出效能上的可比性。", "abstract_zh": "这是第1次请求，请务必返回非空 JSON。由于提供的PubMed记录中不含原始英文摘要全文，无法逐句完整翻译。"}, {"pmid": "42854902", "title": "Aebp1 drives a ceramide-gated Calhm2 calcium influx that injures podocytes in diabetic kidney disease.", "abstract": "Podocyte injury is a critical determinant of diabetic kidney disease (DKD) and other proteinuric nephropathies; however, the mechanisms linking lipotoxicity to cytoskeletal disruption remain unclear. This study aimed to identify a central regulator linking lipotoxicity to podocyte injury, decipher its downstream pathway to pathological calcium influx, and assess its translational potential as a non-invasive biomarker of disease progression. Integrated transcriptomic-proteomic analysis of diabetic glomeruli identified Adipocyte Enhancer-Binding Protein 1 (Aebp1). Its function was investigated using renal overexpression and podocyte-specific knockout mouse models of diabetic and adriamycin (ADR) nephropathy. Mechanistic studies combined in vitro and in vivo analyses, including intracellular calcium kinetic assays and direct protein-lipid interaction assays (e.g., surface plasmon resonance). Clinical validation was conducted in a biopsy-proven DKD cohort, correlating urinary Aebp1 levels with histological severity and longitudinal estimated glomerular filtration rate (eGFR) decline. Aebp1 was identified as a progressively upregulated gene in the diabetic glomeruli. In mice, renal overexpression of Aebp1 induced proteinuria and glomerulosclerosis, whereas podocyte-specific knockout conferred protection against injury in diabetic mice. Mechanistically, Aebp1 activated NF-κB signaling, leading to Neu3 upregulation and pathogenic ceramide accumulation in the podocytes. We found that ceramide can directly bind to and activate Calhm2, a calcium channel not previously implicated in kidney physiology, suggesting a novel lipid-gated pathway linking lipotoxicity to pathological calcium influx in podocytes. This mechanism has been validated in ADR-induced nephropathy. Clinically, urinary Aebp1 serves as an independent predictor of histologically confirmed glomerulosclerosis severity and predicts the clinical endpoint of ≥ 30% eGFR decline. This study identifies a potential pathway in which Aebp1 promotes ceramide accumulation which may activate the Calhm2 calcium channel, thus linking lipotoxicity to calcium dysregulation and podocyte injury in DKD and other proteinuric conditions. Urinary Aebp1 is a potential clinically non-invasive biomarker for predicting histological damage and functional decline in DKD.", "journal": "Journal of Advanced Research", "pub_date": "2026-Oct-09", "publication_types": ["Journal Article"], "doi": "10.1016/j.jare.2026.10.017", "authors": ["Aiping Duan", "Yucui Jiang", "Xia Wang", "Zige Chen", "Ping Dong", "Zhaochen Guo", "Weisong Qin", "Hao Bao"], "affiliations": ["National Clinical Research Center for Kidney Diseases, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210016, China.", "School of Chinese Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, China.", "State Key Laboratory of Pharmaceutical Biotechnology, Medical School, Nanjing University, Nanjing 210093, China.", "National Clinical Research Center for Kidney Diseases, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210016, China. Electronic address: bhao@nju.edu.cn."], "corresponding_authors": ["Hao Bao"], "china_team": "National Clinical Research Center for Kidney Diseases, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210016, China Hao Bao团队", "category": "basic", "classification_reason": "basic_signals=31", "score": 36.37, "score_parts": {"urology_relevance": 3, "urology_in_title": 0.0, "journal_priority": 15.87, "top_journal_bonus": 0.0, "novelty": 1.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 14.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 13.0, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.87, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "Aebp1通路驱动糖尿病肾病足细胞损伤", "chinese_summary": "南京大学医学院附属金陵医院（东部战区总医院）国家肾脏疾病临床医学研究中心郝豹团队10月J Adv Res发表研究，发现Aebp1通过NF-κB上调Neu3，促进致病性神经酰胺积累并激活Calhm2钙通道，导致足细胞损伤。尿Aebp1可独立预测肾小球硬化及eGFR下降。", "abstract_zh": "足细胞损伤是糖尿病肾病（DKD）及其他蛋白尿性肾病的关键决定因素；然而，将脂毒性同细胞骨架破坏联系起来的机制尚不清楚。本研究旨在鉴定一个将脂毒性与足细胞损伤联系起来的中枢调控因子，解析其通向病理性钙内流的下游通路，并评估其作为疾病进展非侵入性生物标志物的转化潜力。对糖尿病肾小球的转录组-蛋白质组整合分析鉴定出脂肪细胞增强子结合蛋白1（Aebp1）。利用糖尿病和阿霉素（ADR）肾病的肾脏过表达及足细胞特异性敲除小鼠模型研究其功能。机制研究结合体外和体内分析，包括细胞内钙动力学检测和直接蛋白-脂质相互作用检测（如表面等离子体共振）。在经活检证实的DKD队列中进行临床验证，将尿Aebp1水平与组织学严重程度及纵向估算肾小球滤过率（eGFR）下降进行关联。Aebp1被鉴定为糖尿病肾小球中逐步上调的基因。在小鼠中，肾脏过表达Aebp1诱导蛋白尿和肾小球硬化，而足细胞特异性敲除在糖尿病小鼠中提供针对损伤的保护。机制上，Aebp1激活NF-κB信号，导致Neu3上调及足细胞中致病性神经酰胺积累。我们发现神经酰胺可直接结合并激活Calhm2——一个此前未涉及肾脏生理的钙通道，提示一条连接脂毒性与足细胞病理性钙内流的新型脂质门控通路。该机制在ADR诱导的肾病中得到验证。临床上，尿Aebp1可作为组织学证实的肾小球硬化严重程度的独立预测因子，并预测≥30% eGFR下降的临床终点。本研究确定了一条潜在通路：Aebp1促进神经酰胺积累，可能激活Calhm2钙通道，从而将脂毒性与钙调节异常及DKD和其他蛋白尿状况中的足细胞损伤联系起来。尿Aebp1是一种潜在的临床非侵入性生物标志物，用于预测DKD的组织学损伤和功能下降。"}, {"pmid": "42854856", "title": "Perilesional biopsy in - systematic out? Comparative analysis of targeted, perilesional and systematic core yield by needle tracking with robotic-assisted transperineal MRI/US fusion prostate biopsy.", "abstract": "To characterize prostate cancer (Pca) detection rates by Gleason Grade Group (GG) in targeted, perilesional, and systematic cores sampling the remaining prostate using robotic-assisted transperineal magnetic resonance imaging (MRI) /ultrasound fusion biopsy (RA-TP-FBx), enabling precise spatial documentation of every core relative to MRI-lesions and the prostate. We analyzed prospectively collected RA-TP-FBx cases between 2020 and 2024. Biopsies were performed with the iSR'obot Mona Lisa (Biobot). Sampling included a traditional targeted + systematic strategy and a Trizonal approach: targeted + perilesional + systematic. Perilesional cores were defined at biopsy as samples within 10 mm of the MRI-lesion margin and systematic cores as samples outside the targeted-perilesional areas. Individualized 3D prostate maps were correlated with per-core histopathology. Clinically significant PCa (csPCa) was defined as GG ≥ 2. The full cohort included 566 RA-TP-FBx cases. Diagnosis of csPCa (n=131 in the Trizonal cohort) was exclusively due to perilesional sampling in 6.1% (8/131). Systematic biopsy detected csPCa not captured by targeted or perilesional cores in 3.8% (5/131), but only 1.5% (2/131) originated from MRI-negative lobes. Overdetection of GG 1 (n = 58 in the Trizonal cohort) would be reduced by 24.1% (14/58) by omitting systematic cores when targeted and perilesional cores were negative. Robotic-assisted mapping demonstrated that perilesional sampling effectively complemented targeted biopsy, while systematic cores yielded minimal additional csPCa detection but increased GG 1 overdetection. These data support adopting targeted + perilesional sampling and omitting or deintensifying the routine addition of systematic cores in the remaining prostate.", "journal": "Urology", "pub_date": "2026-Oct-09", "publication_types": ["Journal Article"], "doi": "10.1016/j.urology.2026.09.065", "authors": ["Viktor Alargkof", "Manuel Walter", "Christian Engesser", "Hans-Helge Seifert", "Maurice Henkel", "Hanns Christian Breit", "David Jean Winkel", "Nicola Keller", "Pawel Trotsenko", "Christian Wetterauer"], "affiliations": ["University Hospital Basel, Department of Urology, Basel, Switzerland; University of Basel, Basel, Switzerland. Electronic address: viktor.alargkof@usb.ch.", "Department of Urology, Hospital of Bozen (SABES-ASDAA), Bozen-Bolzano, Italy; Teaching Hospital of Paracelsus Medical University. Electronic address: manuel.walter91@gmail.com.", "University Hospital Basel, Department of Urology, Basel, Switzerland; University of Basel, Basel, Switzerland. Electronic address: christian.engesser@usb.ch.", "University Hospital Basel, Department of Urology, Basel, Switzerland; University of Basel, Basel, Switzerland. Electronic address: helge.seifert@usb.ch.", "University Hospital Basel, Department of Radiology, Basel, Switzerland. Electronic address: mauricejohannes.henkel@usb.ch.", "University Hospital Basel, Department of Radiology, Basel, Switzerland. Electronic address: hanns-christian.breit@usb.ch.", "University Hospital Basel, Department of Radiology, Basel, Switzerland. Electronic address: davidjean.winkel@usb.ch.", "University of Basel, Basel, Switzerland. Electronic address: nicola.keller@unibas.ch.", "Medical University of Graz, Department of Urology, Graz, Austria. Electronic address: pawel.trotsenko@usb.ch.", "University Hospital Basel, Department of Urology, Basel, Switzerland; University of Basel, Basel, Switzerland; Department of Medicine, Faculty of Medicine and Dentistry, Danube Private University, Krems, Austria. Electronic address: christian.wetterauer@usb.ch."], "corresponding_authors": ["Viktor Alargkof", "Manuel Walter", "Christian Engesser", "Hans-Helge Seifert", "Maurice Henkel", "Hanns Christian Breit", "David Jean Winkel", "Nicola Keller", "Pawel Trotsenko", "Christian Wetterauer"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=4", "score": 23.61, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 5.61, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 4.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.0, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.61, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42854855", "title": "Analyzing Trends in Management of Intravesical Therapy-Associated Lower Urinary Tract Symptoms for Patients Treated for Non-muscle Invasive Bladder Cancer.", "abstract": "To characterize the utilization of oral pharmacotherapy and minimally invasive non-pharmacologic treatments approved for overactive bladder among patients receiving intravesical therapy for non-muscle invasive bladder cancer, as this treatment is frequently complicated by lower urinary tract symptoms, which are associated with treatment discontinuation and worse oncological outcomes. We conducted a retrospective cohort study using the Merative™ MarketScan® Commercial Database (2016-2024). We identified patients with bladder cancer receiving intravesical bacillus Calmette-Guérin or chemotherapy. The primary outcome was the receipt of lower urinary tract symptom therapy-oral pharmacotherapy (anticholinergics, β-3 agonists, alpha blockers) or minimally invasive non-pharmacologic treatments (botulinum toxin injection, sacral neuromodulation, percutaneous tibial nerve stimulation)-in the 180 days after initiating induction therapy. Among 2,978 patients, 29.6% received lower urinary tract symptom therapy. Use of alpha blockers (19.9%) and anticholinergics (13.7%) predominated. Use of β-3 agonists (1.3%) or non-pharmacologic treatments was exceedingly rare: only 0.3% received botulinum toxin injection, and no patients received sacral neuromodulation or percutaneous tibial nerve stimulation. Lower urinary tract symptom therapy was associated with a lower proportion of patients completing induction therapy (75.9% vs. 79.0%) (P=0.049) and higher proportion of patients undergoing cystectomy (14.8% vs. 11.9%) (P=0.021). While nearly one-third of bladder cancer patients require pharmacotherapy for lower urinary tract symptoms during intravesical treatment, β-3 agonists and non-pharmacologic treatments are almost entirely unutilized. Given the association between lower urinary tract symptoms and induction therapy non-completion, further research into these advanced therapies is warranted to improve patient adherence and oncologic outcomes.", "journal": "Urology", "pub_date": "2026-Oct-09", "publication_types": ["Journal Article"], "doi": "10.1016/j.urology.2026.10.005", "authors": ["Jacob E Tallman", "Max J Hyman", "Piyush K Agarwal", "Sarah F Faris", "Parth K Modi"], "affiliations": ["Department of Surgery, Section of Urology, The University of Chicago, Chicago, IL. Electronic address: Jacob.tallman@bsd.uchicago.edu.", "Department of Medicine, The University of Chicago, Chicago, IL.", "Department of Surgery, Section of Urology, The University of Chicago, Chicago, IL."], "corresponding_authors": ["Jacob E Tallman"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=7", "score": 33.61, "score_parts": {"urology_relevance": 11, "urology_in_title": 8.0, "journal_priority": 5.61, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 7.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.0, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.61, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42854704", "title": "Role of the urobiome in urinary tract infections: current knowledge and research prospects.", "abstract": "Urinary tract infections (UTIs), particularly cystitis, are among the most common bacterial infections worldwide, with a disproportionate burden on adult female individuals, who often have recurrence. The discovery of the urobiome, a low microbial biomass community in the urinary tract, has transformed our understanding of UTI pathogenesis and infection susceptibility. Experimental and omics approaches provide insights into the taxonomic and functional complexity of the urobiome, highlighting the importance of microbial metabolites, ecological interactions, and host-microbe dynamics. Polymicrobial interactions within the urobiome further modulate pathogenicity, with some microbes inhibiting or promoting uropathobionts. Advancing UTI management will require combining omics and experimental research with ecological and evolutionary insights. This approach can enable the development of personalised, non-antibiotic interventions, such as live biotherapeutics and prebiotics, to improve diagnostics, reduce antibiotic resistance, and enhance treatment efficacy.", "journal": "Lancet Microbe", "pub_date": "2026-Oct-09", "publication_types": ["Journal Article", "Review"], "doi": "10.1016/j.lanmic.2026.101535", "authors": ["Marleen D Hekker", "Adam J Bindas", "Freya Darling Eriksen", "Larissa Della Vedova", "David Giron-Villalobos", "Pablo Gallardo Molina", "Robert A Koetsier", "Celia R Berkers", "Bas E Dutilh", "Rampal S Etienne", "Suzanne E Geerlings", "Justin J J van der Hooft", "Marnix H Medema", "Constance Schultsz", "Michael F Seidl", "Jerry M Wells", "Alan J Wolfe", "Janneke H H M van de Wijgert", "Marjon G J de Vos"], "affiliations": ["Department of Epidemiology and Health Economics, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands.", "Host-Microbe Interactomics Group, Wageningen University & Research, Wageningen, Netherlands.", "Groningen Institute for Evolutionary Life Sciences, University of Groningen, Groningen, Netherlands.", "Bioinformatics Group, Wageningen University & Research, Wageningen, Netherlands; Department Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, Netherlands.", "Theoretical Biology & Bioinformatics, Utrecht University, Utrecht, Netherlands.", "Bioinformatics Group, Wageningen University & Research, Wageningen, Netherlands.", "Department Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, Netherlands.", "Theoretical Biology & Bioinformatics, Utrecht University, Utrecht, Netherlands; Cluster of Excellence Balance of the Microverse, Institute of Biodiversity, Ecology and Evolution, Friedrich Schiller University Jena, Jena, Germany.", "Section of Infectious Diseases, Department of Internal Medicine, Amsterdam UMC, Amsterdam, Netherlands.", "Bioinformatics Group, Wageningen University & Research, Wageningen, Netherlands; Department of Biochemistry, University of Johannesburg, Johannesburg, South Africa.", "Department of Global Health, Amsterdam Institute for Global Health and Development, Amsterdam UMC, Amsterdam, Netherlands.", "Stritch School of Medicine, Loyola University Chicago, Maywood, IL, USA.", "Groningen Institute for Evolutionary Life Sciences, University of Groningen, Groningen, Netherlands. Electronic address: m.g.j.de.vos@rug.nl."], "corresponding_authors": ["Marjon G J de Vos"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 44.49, "score_parts": {"urology_relevance": 7, "urology_in_title": 8.0, "journal_priority": 16.49, "top_journal_bonus": 10.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 1.0}, "journal_metrics": {"status": "ok", "impact_factor": 20.4, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.49, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "尿微生物组重塑尿路感染认知", "chinese_summary": "Lancet Microbe 10月综述指出，尿路感染尤其膀胱炎全球高发，成年女性复发负担突出。尿微生物组作为低生物量群落，其代谢物、生态互作及宿主-微生物动态可抑制或促进尿路致病菌，为个性化非抗生素干预如活体生物治疗和益生元提供方向。", "abstract_zh": "尿路感染（UTIs），尤其是膀胱炎，是全球最常见的细菌感染之一，给成年女性个体带来不成比例的负担，且常反复发作。尿微生物组——尿路中一种低微生物生物量群落——的发现，改变了我们对尿路感染发病机制和感染易感性的理解。实验和组学方法为了解尿微生物组的分类学和功能复杂性提供了见解，凸显了微生物代谢物、生态相互作用以及宿主-微生物动态的重要性。尿微生物组内的多微生物相互作用进一步调节致病性，某些微生物抑制或促进尿路致病菌。推进尿路感染管理需要将组学与实验研究与生态学和进化见解相结合。这种方法能够促进个性化、非抗生素干预措施的开发，例如活体生物治疗剂和益生元，以改善诊断、减少抗生素耐药性并提高治疗效果。"}, {"pmid": "42853943", "title": "Citron kinase activity controls alternative splicing events that drive prostate cancer growth.", "abstract": "Prostate cancer (CaP) remains a major cause of cancer death in men, underscoring the need for mechanistically novel therapies. We previously identified the action of the mitotic kinase citron (CIT) kinase as a key driver of CaP progression and promising therapeutic target, but selective CIT inhibitors are not available. We therefore asked whether a better understanding of the action of CIT substrates, which execute CIT kinase action in CaP cells, can lead to novel approaches and/or alternative targets to indirectly interfere with CIT's activity during CaP progression. In view of the enrichment in functions in alternative splicing among CIT substrates, we focus on the RNA splicing regulator THRAP3 as a representative substrate. Direct THRAP3 phosphorylation by CIT determined THRAP3's RNA binding to CIT-controlled pre-messenger RNA targets. Cross-linking and immunoprecipitation sequencing identified a subset of CIT-dependent THRAP3-bound genes that were preferentially involved in cell proliferation. THRAP3 RNA binding was enriched in genes that undergo alternative splicing during CaP progression. CIT-dependent THRAP3-bound transcripts stimulated the growth of CaP cell lines, xenografts, patient-derived organoids, and patient-derived xenograft (PDX)-derived organoids, whereas CIT-independent THRAP3-bound transcripts from the same gene did not. An antisense oligo that blocks THRAP3's recruitment to a CIT-dependent RNA binding site prevented the production of CIT- and THRAP3-dependent transcripts and inhibited the growth of cell lines and PDX-derived organoids representing different CaP stages and lineages but not of benign cells. Thus, CIT-mediated alternative splicing drives CaP progression, and its inhibition is a new therapeutic strategy in treatment-resistant CaP.", "journal": "Science Advances", "pub_date": "2026-Oct-09", "publication_types": ["Journal Article"], "doi": "10.1126/sciadv.aee5257", "authors": ["Chitra Rawat", "Nidhi Singh", "Ujjwal R Dahiya", "Qiang Hu", "Sarah Ng", "Dingxiao Zhang", "Shaun R Stauffer", "Amina Zoubeidi", "Eva Corey", "Jesse McKenney", "Christopher J Weight", "Samuel C Haywood", "Song Liu", "Tao Liu", "Hannelore V Heemers"], "affiliations": ["Department of Cancer Sciences, Cleveland Clinic Research, Cleveland Clinic, Cleveland, OH 44195, USA.", "Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14623, USA.", "Case Western Reserve University, Cleveland, OH 44106, USA.", "School of Biomedical Sciences, Hunan University, Changsha 410082, China.", "Center for Therapeutics Discovery, Cleveland Clinic Research, Cleveland Clinic, Cleveland, OH 44195, USA.", "Vancouver Prostate Centre and Department of Urologic Sciences, University of British Columbia, Vancouver, Canada.", "Department of Urology, University of Washington, Seattle, WA 98195, USA.", "Department of Anatomic Pathology, Diagnostics Institute, Cleveland Clinic, Cleveland, OH 44195, USA.", "Department of Urology, Integrated Surgical Institute, Cleveland Clinic, Cleveland, OH 44195, USA.", "Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH 44106, USA."], "corresponding_authors": [], "china_team": "School of Biomedical Sciences, Hunan University, Changsha 410082, China Dingxiao Zhang团队", "category": "basic", "classification_reason": "basic_signals=10", "score": 41.32, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 15.82, "top_journal_bonus": 0.0, "novelty": 1.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 10.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 12.5, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.82, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "磷酸化开关调控前列腺癌剪接", "chinese_summary": "湖南大学生物医学学院Dingxiao Zhang团队10月Science Advances报道，丝裂原激酶CIT直接磷酸化RNA剪接调节因子THRAP3，决定其与CIT依赖的前体mRNA靶标结合。这些CIT依赖性THRAP3结合转录本可促进前列腺癌细胞系、异种移植瘤及患者来源类器官生长；", "abstract_zh": "前列腺癌（CaP）仍是男性癌症死亡的主要原因，凸显了开发机制新颖疗法的必要性。我们此前发现，有丝分裂激酶citron（CIT）激酶的作用是CaP进展的关键驱动因素和有前景的治疗靶点，但目前尚无选择性CIT抑制剂。因此，我们提出，更深入地理解在CaP细胞中执行CIT激酶作用的CIT底物的功能，是否能够带来新方法或替代靶点，从而间接干扰CIT在CaP进展中的活性。鉴于CIT底物在可变剪接功能上高度富集，我们聚焦于RNA剪接调节因子THRAP3作为代表性底物。CIT对THRAP3的直接磷酸化决定了THRAP3与CIT调控的前体信使RNA靶标的RNA结合。交联免疫沉淀测序鉴定出一部分CIT依赖的THRAP3结合基因，这些基因优先参与细胞增殖。THRAP3的RNA结合在CaP进展过程中发生可变剪接的基因中富集。CIT依赖的THRAP3结合转录本可刺激CaP细胞系、异种移植瘤、患者来源类器官以及患者来源异种移植（PDX）来源类器官的生长，而同一基因产生的CIT非依赖性THRAP3结合转录本则无此作用。一种反义寡核苷酸可阻断THRAP3向CIT依赖性RNA结合位点的募集，阻止CIT和THRAP3依赖性转录本的生成，并抑制代表不同CaP分期和谱系的细胞系及PDX来源类器官的生长，但不影响良性细胞。因此，CIT介导的可变剪接驱动CaP进展，抑制该过程是治疗耐药性CaP的一种新策略。"}, {"pmid": "42853849", "title": "Anatomical Mapping of Lymphatic Leakage Leading to Symptomatic Lymphoceles Formation After Pelvic Lymph Node Dissection for Prostate Cancer.", "abstract": "The role of pelvic lymph node dissection (PLND) during radical prostatectomy (RP) remains controversial. PLND morbidity, particulary lymphocele formation, is the main argument against PLND, despite level one evidence demonstrating metastasis reduction with extended PLND. The aim of this study is to identify the precise anatomical sites and mechanisms of lymphocele formation after RP and to propose preventive surgical modifications. In this prospective, single-center study, we included patients who developed symptomatic lymphoceles after RP with extended PLND or salvage PLND between 2018 and 2024. All underwent ultrasound- and fluoroscopy-guided lymphangiography with or without lymphatic leak embolization (LLE). Leak sites were classified by anatomical location along the pelvic lymphatic drainage pathway. The primary outcome was precise anatomical localization of lymphatic leakage. Forty patients with 45 lymphoceles were evaluated. Lymphangiography identified active leakage in 43/45 lymphoceles (96%). The Cloquet region accounted for 42/43 (98%; 95% CI 88-100%) leak sites. Among single-site Cloquet leaks (n=41), 73% arose from afferent vessels draining into and excised Cloquet's node, 17% from efferent vessels with intact Cloquet, and 9.8% from partially excised Cloquet. Clinical success of LLE was achieved in 84% of cases. In prostate cancer, Cloquet's node is rarely metastatic (<1%), yet it is overwhelmingly (98%) the most common site of lymphatic leak leading to lymphocele formation after RP. Cloquet-sparing PLND with meticulous lymphostasis may reduce lymphatic leakage and lymphocele-related morbidity without compromising oncologic control. Prospective comparative studies are warranted to validate this finding.", "journal": "Journal of Urology", "pub_date": "2026-Oct-09", "publication_types": ["Journal Article"], "doi": "10.1097/JU.0000000000005342", "authors": ["Fourat Ridouani", "Enric Carbonell", "Ernesto Santos Martin", "Rebecca Yu", "Nicole Liso", "Behfar Ehdaie", "Vincent P Laudone", "James A Eastham", "Andrew J Vickers", "Karim A Touijer"], "affiliations": ["Interventional Radiology Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York, USA .", "Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA .", "Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA ."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "basic_signals=5", "score": 30.01, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 11.01, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 5.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 6.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 3.01, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "淋巴囊肿漏点多在Cloquet区", "chinese_summary": "2026年10月J Urol发表单中心前瞻性研究，纳入2018至2024年间40例前列腺癌根治术后出现症状性淋巴囊肿患者，共45个囊肿。淋巴管造影显示96%存在活动性漏，其中98%漏点位于Cloquet区；接受栓塞治疗者84%临床成功。研究者提出保留Cloquet淋巴结并精细止血或可减少漏及并发症。", "abstract_zh": "根治性前列腺切除术（RP）中盆腔淋巴结清扫（PLND）的作用仍存争议。尽管有一级证据表明扩大PLND可减少转移，但PLND的并发症，尤其是淋巴囊肿形成，是反对PLND的主要理由。本研究旨在确定RP后淋巴囊肿形成的精确解剖部位和机制，并提出预防性手术改良方案。在这项前瞻性单中心研究中，我们纳入了2018年至2024年间在RP联合扩大PLND或挽救性PLND后出现症状性淋巴囊肿的患者。所有患者均接受超声和透视引导下的淋巴管造影，伴或不伴淋巴漏栓塞（LLE）。漏点按盆腔淋巴引流路径的解剖位置进行分类。主要结局为淋巴漏的精确解剖定位。共评估40例患者、45个淋巴囊肿。淋巴管造影在43/45个淋巴囊肿（96%）中识别出活动性漏。Cloquet区占42/43（98%；95% CI 88-100%）的漏点。在单部位Cloquet漏（n=41）中，73%来源于引流至并被切除的Cloquet淋巴结的输入淋巴管，17%来源于Cloquet淋巴结完整的输出淋巴管，9.8%来源于部分切除的Cloquet淋巴结。LLE的临床成功率为84%。在前列腺癌中，Cloquet淋巴结转移罕见（<1%），但它却压倒性地（98%）是RP后导致淋巴囊肿形成的最常见淋巴漏部位。保留Cloquet淋巴结的PLND并精细止血可能减少淋巴漏及淋巴囊肿相关并发症，而不影响肿瘤控制。有必要开展前瞻性比较研究以验证这一发现。"}, {"pmid": "42853669", "title": "Persistent Health Disparities Among Adult Cancer Survivors.", "abstract": "Cancer survivors face elevated risks of age- and treatment-related health conditions, possibly due to accelerated biological aging from cancer therapy. The role of social determinants of health (SDOH) in these aging trajectories remains understudied. We conducted a retrospective cohort study of 109,224 curatively treated Danish cancer survivors (lung, breast, prostate, or colon cancer, diagnosed between 1997 and 2018) and 574,022 age- and sex-matched cancer-free individuals. SDOH was assessed using educational level and cohabitation status. Using national registries, we investigated associations between SDOH and 16 post-cancer new morbidities with Cox proportional hazard models and flexible parametric models. During a median 6.9-year follow-up, cancer survivors had significantly higher rates of new morbidities than cancer-free individuals. Lung cancer survivors had elevated hazard rates for 14 morbidities, breast cancer survivors had increased rates for 12 morbidities, prostate cancer survivors exhibited elevated rates for 8 morbidities, and colon cancer survivors had rates for 14 morbidities. Educational disparities were evident: survivors with short education had higher rates for chronic respiratory disease (HRs: 1.30-1.55 across cancer types), heart failure (HRs: 1.50-1.54 in breast and colon), diabetes (HRs: 1.67-1.95 in breast, prostate, and colon), and depression (HRs: 1.32-1.37 in breast and colon). Living alone was also associated with increased but less pronounced rates. Cancer survivors experience elevated rates for age- and treatment-related post-cancer new morbidities compared to cancer-free individuals. Sociodemographic disadvantages, particularly short education, further increase these rates. These findings suggest that SDOH play an important role in post-cancer aging, highlighting the need for targeted interventions addressing social determinants in survivorship care.", "journal": "International Journal of Cancer", "pub_date": "2026-Oct-09", "publication_types": ["Journal Article"], "doi": "10.1002/ijc.70770", "authors": ["Trille K Kjaer", "Anne K G Levinsen", "Mia K Grand", "Erik Jakobsen", "Michael Borre", "Robert Zachariae", "Peer Christiansen", "Peter Christensen", "Lisbet R Hölmich", "Peter de Nully Brown", "Christoffer Johansen", "Susanne K Kjaer", "Ismail Gögenur", "Lonneke van den Poll-Franse", "Susanne O Dalton"], "affiliations": ["Cancer Survivorship, Danish Cancer Institute, Copenhagen, Denmark.", "Statistics and Data Analyses, Danish Cancer Institute, Copenhagen, Denmark.", "Department of Thoracic Surgery, Odense University Hospital, Odense, Denmark.", "Department of Urology, Aarhus University Hospital, Aarhus, Denmark.", "Danish Breast Cancer Group Center and Clinic for Late Effects, Aarhus University Hospital, Aarhus, Denmark.", "Unit for Psychooncology and Health Psychology, Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.", "Department of Plastic and Breast Surgery, Aarhus University Hospital, Aarhus, Denmark.", "Danish Cancer Society Centre for Research on Survivorship and Late Adverse Effects After Cancer in the Pelvic Organs, Department of Surgery, Aarhus University Hospital, Aarhus, Denmark.", "Department of Plastic Surgery, Herlev and Gentofte University Hospital, Herlev, Denmark.", "Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.", "Center for Cancer Late Effects Research (CASTLE). Department of Oncology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.", "Unit of Virus, Lifestyle and Genes, Danish Cancer Institute, Copenhagen, Denmark.", "Department of Gynecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.", "Department of Surgery, Center for Surgical Science, Zealand University Hospital, Køge, Denmark.", "Institute for Clinical Medicine, Copenhagen University, Copenhagen, Denmark.", "Department of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.", "Center of Research on Psychology in Somatic Diseases, Department of Medical and Clinical Psychology, Tilburg University, Tilburg, the Netherlands.", "Danish Research Center for Equality in Cancer (COMPAS), Department of Clinical Oncology & Palliative Care, Zealand University Hospital, Naestved, Denmark."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=6", "score": 23.05, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 10.55, "top_journal_bonus": 0.0, "novelty": 0.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 6.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.7, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.55, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42852688", "title": "Implementing the 2026 AUA/SUO Guideline for Metastatic Castration-Resistant Prostate Cancer: What Is New, What Should Change, and What Comes Next.", "abstract": "", "journal": "Journal of Urology", "pub_date": "2026-Oct-09", "publication_types": ["Editorial"], "doi": "10.1097/JU.0000000000005318", "authors": ["Fred Saad"], "affiliations": ["Centre Hospitalier de l'Université de Montréal, Montreal, Québec, Canada."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 20.51, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 11.01, "top_journal_bonus": 0.0, "novelty": 0.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 6.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 3.01, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42852578", "title": "A novel ureteric stent coating reduces encrustation and improves tolerability in a randomised trial.", "abstract": "To evaluate the effect of a novel sulfonic acid-coated ureteric stent on encrustation and quality of life in patients with urolithiasis. A prospective, randomised, controlled trial was conducted between April 2022 and March 2025 at two urological centres in Germany. In all, 100 patients requiring ureteric stenting due to urolithiasis were randomised into intervention and control groups. All patients received identical stents (6 F/28 cm); the stent in the intervention group incorporated a novel covalent coating. Stents were removed after 30 days during secondary stone treatment, followed by the encrustation weight assessment. Symptoms associated with the ureteric stent and quality of life were evaluated using the Ureteric Stent Symptom Questionnaire 7 days after stent placement and 7 days after stent removal. The final analysis included 95 patients assessed for the primary endpoint. Coated stents showed a 49.7% reduction in mean encrustation weight (mean difference 22.8 mg, 95% confidence interval [CI] 2.4-43.2; P = 0.006). The increase in lower urinary tract symptoms was 53.8% less in the coated-stent group (Δ3.6 [95% CI 1.3-6] vs Δ7.8 [95% CI 2.8-12.8]; P = 0.002). Light physical activities improved by 33.9% (mean difference 0.76, 95% CI 0.08-1.44; P = 0.046), and the need for antimicrobial therapy was significantly lower for coated stents (7.1% vs 31.8%, P = 0.02; odds ratio 6.1, 95% CI 1.11-33.1). Additionally, patients in the coated-stent group reported significantly less fatigue and exhaustion symptoms (mean difference 0.67, 95% CI 0.02-1.32; P = 0.03). The novel sulfonic acid coating demonstrated significant benefits over standard ureteric stents by reducing encrustation and improving quality of life.", "journal": "BJU International", "pub_date": "2026-Oct-09", "publication_types": ["Journal Article"], "doi": "10.1111/bju.70487", "authors": ["Nikita Vistunov", "Ionel Valentin Popeneciu", "Wolfgang Kram", "Oliver Hakenberg", "Florian Distler", "Angelika Borkowetz", "Wolfgang Hitzl", "Sascha Pahernik", "Stefan Milerski", "Clemens Hüttenbrink"], "affiliations": ["Department of Urology, Nuremberg General Hospital, Paracelsus Medical University, Nuremberg, Germany.", "Department of Urology, University Medical Center Rostock, Rostock, Germany.", "Paracelsus Medical University, Nuremberg, Germany.", "Department of Ophthalmology and Optometry, Paracelsus Medical University Salzburg, Salzburg, Austria.", "Research Program Experimental Ophthalmology & Glaucoma Research, Paracelsus Medical University, Salzburg, Austria."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=5", "score": 41.47, "score_parts": {"urology_relevance": 15, "urology_in_title": 8.0, "journal_priority": 10.47, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 5.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.4, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.47, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42851250", "title": "Long-term outcomes of augmentation cystoplasty for neurogenic lower urinary tract dysfunction after spinal cord injury.", "abstract": "To evaluate long-term urodynamic, clinical, and complication outcomes following augmentation cystoplasty (AC) in patients with spinal cord injury (SCI) and refractory neurogenic lower urinary tract dysfunction (NLUTD), and to assess the role of adjunctive intradetrusor onabotulinumtoxinA injections. We performed a retrospective cohort study of patients with SCI undergoing AC at a tertiary referral centre between 1988 and 2018. Inclusion required refractory NLUTD with documented urodynamic abnormalities and failure of conservative and minimally invasive therapies. Pre- and postoperative outcomes included maximum cystometric capacity (MCC), maximum detrusor pressure (MDP), continence status, recurrent urinary tract infections (rUTIs), vesico-ureteric reflux (VUR), and complications. A subgroup analysis evaluated outcomes following post-augmentation intradetrusor onabotulinumtoxinA injections. Statistical comparisons were performed using paired t-tests. A total of 70 patients (47 male, 23 female) were included, with a mean (range) follow-up of 19 (5-36) years. AC resulted in significant improvements in MCC (155-490 mL; P < 0.001) and MDP (72-19 cmH2O; P < 0.001). Continence was achieved in 67% of patients, with a further 24% reporting only occasional leakage. rUTIs and antimuscarinic use decreased postoperatively, and VUR improved in most affected patients. Long-term complications included urolithiasis in 10%, malignancy in 4% (all adenocarcinoma), and spontaneous perforation in 1.5%. In patients requiring adjunctive botulinum toxin (n = 18), significant improvements in MCC and MDP were observed in selected analyses (P = 0.025 and P = 0.009, respectively). Augmentation cystoplasty provides durable long-term improvements in bladder capacity, storage pressures, and continence in patients with SCI with refractory NLUTD, with sustained protection of the upper urinary tract. Although associated with notable late complications, outcomes remain favourable with structured lifelong surveillance. Adjunctive intradetrusor onabotulinumtoxinA injections offers additional benefit in a subset of patients and may optimise long-term bladder dynamics.", "journal": "BJU International", "pub_date": "2026-Oct-09", "publication_types": ["Journal Article"], "doi": "10.1111/bju.70464", "authors": ["Ioannis Tsikopoulos", "Sarah Knight", "Marc A Furrer", "Thomas M Kessler", "Prashant Patel", "Rizwan Hamid", "Julian Shah", "Richard Nobrega"], "affiliations": ["Department of Neuro-Urology, Royal National Orthopaedic Hospital, London, UK.", "Department of Urology, University College London Hospital UCLH, London, UK.", "Department of Urology, Solothurner Spitäler AG, Kantonsspital Olten and Bürgerspital Solothurn, Olten/Solothurn, University of Bern, Bern, Switzerland.", "Department of Neuro-Urology, Balgrist University Hospital, University of Zürich, Zürich, Switzerland."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=7", "score": 45.47, "score_parts": {"urology_relevance": 18.0, "urology_in_title": 8.0, "journal_priority": 10.47, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 7.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.4, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.47, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42851154", "title": "Rational Control of Antibody Orientation for Enhancing Sensitivity and Specificity in Lateral Flow Immunoassays With Clinical Validation.", "abstract": "Lateral flow assays (LFAs) are widely used for point-of-care diagnostics, but their sensitivity is often limited by inefficient antibody orientation and poor signal transduction. Herein, we report a universal strategy integrating orientation-controlled antibody conjugation at the immunoprobe with a biotin-streptavidin-modified test line to enhance LFA sensitivity, specificity, and analytical reliability. Using an orientation-controlled conjugation approach (P-6, Scheme 1), antigen accessibility was maximized while nonspecific adsorption and false-positive signals were suppressed. Compared with conventional randomly conjugated probes (P-3, Scheme 1) on unmodified test lines, the combined P-6/biotin-streptavidin configuration achieved limits of detection of 0.0352 ng/mL for cytokeratin 19 fragment (CYFRA21-1) and 0.0808 ng/mL for carcinoembryonic antigen (CEA), corresponding to sensitivity enhancements of approximately 14-19 fold. However, probe rankings get inverted across capture chemistries, indicating the importance of dual-site orientation. The universality of this strategy was further validated using alpha-fetoprotein (AFP), carbohydrate antigen 125 (CA125), carbohydrate antigen 15-3 (CA15-3), and prostate-specific antigen (PSA). Furthermore, multiplexed LFAs using fluorescent polymer dots enabled simultaneous detection of CYFRA21-1 and CEA with minimal cross-reactivity and were validated in 28 clinical serum samples against the hospital reference method.", "journal": "Advanced Healthcare Materials", "pub_date": "2026-Oct-09", "publication_types": ["Journal Article"], "doi": "10.1002/adhm.71815", "authors": ["Pin-Hao Wang", "Shunmuga Nathan Shunmuga Nainar", "Bing-Han Zhuang", "Shun-Mao Yang", "Hong-Cheu Lin", "Yang-Hsiang Chan"], "affiliations": ["Department of Applied Chemistry, National Yang Ming Chiao Tung University, Hsinchu, Taiwan.", "Department of Materials Science and Engineering, National Yang Ming Chiao Tung University, Hsinchu, Taiwan.", "Department of Surgery, National Taiwan University Hospital, Hsinchu, Taiwan.", "Center For Emergent Functional Matter Science, National Yang Ming Chiao Tung University, Hsinchu, Taiwan.", "Department of Medicinal and Applied Chemistry, Kaohsiung Medical University, Kaohsiung, Taiwan."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 18.46, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 11.46, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 1.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 9.6, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 3.46, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42866135", "title": "Nanomedicine for Benign Prostatic Hyperplasia: Pathological Axes and Translational Evidence.", "abstract": "Benign prostatic hyperplasia (BPH) is heterogeneous, and lower urinary tract symptoms also depend on smooth-muscle tone, outlet mechanics and bladder function. Nanomedicine research spans formulation development, animal experiments and limited clinical exploration, but these stages do not establish a continuous chain from delivery to durable patient benefit. This critical narrative review combines a structured PubMed update search through September 7, 2026 with descriptive evidence mapping. Historical search strings were unavailable; the update queries and records are retained, and retrieved records are distinguished from the curated study inventory. We organize relevant biology into inflammatory, hormonal-metabolic and fibrotic/extracellular-matrix axes and propose a barrier-signal-payload-feedback framework. The evidence tiers and decision gates are proposed analytical tools, not validated clinical classifications or regulatory pathways. Source-checked reports predominantly assess formulation properties, systemic exposure, organ size, histology or molecular outcomes. Healthy-volunteer pharmacokinetics does not constitute BPH therapeutic evidence, and whole-prostate exposure does not establish delivery to nodules or specific cells. A small nanomicellar-curcumin trial provides an early symptom signal below its study-defined clinical-importance threshold. Animal saline-loaded urine measurements and short-term cystometry from an adjacent local hydrogel represent different functional outcomes and cannot be equated with durable clinical benefit. The three-axis framework also does not establish which process initiates early nodular formation. Progress requires reproducible disease-state stratification, quantitative lesion delivery with prespecified target engagement, and sustained functional benefit supported by chronic safety and manufacturability. Added formulation complexity is justified only by measurable incremental value over simpler formulations, free payloads or appropriate standard treatment.", "journal": "International Journal of Nanomedicine", "pub_date": "2026", "publication_types": ["Journal Article", "Review"], "doi": "10.1515/mr-2023-0007", "authors": ["Bozhi Zeng", "Rujia Xie", "Congcong Chen", "Boyu Jin", "Chengcheng Yi", "Juqiao He", "Jianguo Zeng", "Xinhua Xia", "Jing Yang"], "affiliations": ["School of Pharmacy, Hunan University of Chinese Medicine, Changsha, Hunan, 410208, People's Republic of China.", "The First Hospital of Hunan University of Chinese Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, 410007, People's Republic of China.", "Hunan Key Laboratory of Traditional Chinese Veterinary Medicine, Hunan Agricultural University, Changsha, Hunan, 410128, People's Republic of China."], "corresponding_authors": [], "china_team": "School of Pharmacy, Hunan University of Chinese Medicine, Changsha, Hunan, 410208, People's Republic of China Jing Yang团队", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 36.96, "score_parts": {"urology_relevance": 15, "urology_in_title": 8.0, "journal_priority": 10.96, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 1.0}, "journal_metrics": {"status": "ok", "impact_factor": 6.5, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.96, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42858533", "title": "Androgen receptor-regulated ZNF419 modulates ferroptosis sensitivity via the ZDHHC20-GPX4 pathway in prostate cancer.", "abstract": "Ferroptosis, an iron-dependent form of regulated cell death driven by lipid peroxidation, has recently been recognized as a crucial determinant of therapeutic response in prostate cancer (PCa). However, how androgen receptor (AR) signaling regulates ferroptotic susceptibility remains poorly understood. Here, we identify ZNF419, a previously uncharacterized zinc finger protein, as an AR-regulated factor associated with reduced ferroptosis susceptibility in PCa cells. Transcriptomic profiling and functional validation revealed that ZNF419 expression is markedly elevated in PCa and correlates with poor clinical outcome. Promoter-proximal AR occupancy was detected at predicted ARE-containing regions of the ZNF419 locus and contributed to ZNF419 promoter activation in reporter assays, whereas enzalutamide treatment or AR knockdown reduced ZNF419 expression and increased ferroptosis-associated vulnerability. Mechanistically, ZNF419 promotes ZDHHC20 expression and is associated with activation of a candidate downstream enhancer region. ZDHHC20, a palmitoyltransferase, contributes to GPX4 palmitoylation-associated stabilization and limits ubiquitin-mediated proteasomal degradation of GPX4. Pharmacological interference with palmitoylation attenuates ZNF419-associated GPX4 stabilization, whereas ZDHHC20 restoration partially reverses the increased ferroptosis-associated vulnerability of ZNF419-deficient cells. Collectively, our findings support a previously unrecognized AR-associated ZNF419-ZDHHC20-GPX4 regulatory axis that links AR activity to ferroptosis-associated vulnerability. These findings provide a rationale for further investigating whether modulation of this pathway may influence responses to AR-targeted therapy in advanced PCa.", "journal": "Redox Biology", "pub_date": "2026-Oct-08", "publication_types": ["Journal Article"], "doi": "10.1016/j.redox.2026.104433", "authors": ["Yuanxiang Hou", "Wenyan Zhao", "Jingyi Liu", "Ruiping Tang", "Tong Deng", "Huaiyu Zhu", "Hiroshi Miyamoto", "Yuyan Zhu", "Ming Sun", "Guiyang Jiang"], "affiliations": ["Department of Urology, The Second Affiliated Hospital of Hainan Medical University, Haikou, Hainan, China; Department of Urology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.", "Department of General Surgery, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.", "China Medical University, Shenyang, Liaoning, China.", "Department of Pathology, The College of Basic Medical Sciences and the First Hospital of China Medical University, Shenyang, Liaoning, China.", "Departments of Pathology & Laboratory Medicine and Urology, University of Rochester Medical Center, Rochester, NY, USA.", "Department of Urology, The First Hospital of China Medical University, Shenyang, 110001, China. Electronic address: yyzhu@cmu.edu.cn.", "Department of Urology, The Second Affiliated Hospital of Hainan Medical University, Haikou, Hainan, China. Electronic address: msun@cmu.edu.cn.", "Department of Pathology, The College of Basic Medical Sciences and the First Hospital of China Medical University, Shenyang, Liaoning, China. Electronic address: gyjiang@cmu.edu.cn."], "corresponding_authors": ["Yuyan Zhu", "Ming Sun", "Guiyang Jiang"], "china_team": "Department of Urology, The Second Affiliated Hospital of Hainan Medical University, Haikou, Hainan, China; Department of Urology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China Yuyan Zhu/Ming Sun/Guiyang Jiang团队", "category": "basic", "classification_reason": "basic_signals=13", "score": 42.75, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 15.75, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 13.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 11.9, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.75, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "雄激素受体调控前列腺癌铁死亡敏感性", "chinese_summary": "海南医科大学第二附属医院与盛京医院朱玉燕/孙明/蒋桂阳团队10月Redox Biol报道，雄激素受体上调锌指蛋白ZNF419，进而促进ZDHHC20表达，增强GPX4棕榈酰化稳定性，降低前列腺癌细胞铁死亡敏感性；抑制该轴或可改善AR靶向治疗反应。", "abstract_zh": "铁死亡是一种由脂质过氧化驱动的铁依赖性调节性细胞死亡形式，近年来已被认为是前列腺癌（PCa）治疗反应的关键决定因素。然而，雄激素受体（AR）信号如何调控铁死亡易感性仍知之甚少。在此，我们鉴定出ZNF419，一种此前未被表征的锌指蛋白，作为AR调控的因子，与PCa细胞中铁死亡易感性降低相关。转录组分析和功能验证显示，ZNF419在PCa中表达显著升高，并与不良临床结局相关。在ZNF419基因座预测含ARE的区域检测到启动子近端AR占据，并在报告基因实验中促进ZNF419启动子激活，而恩扎卢胺处理或AR敲低降低ZNF419表达并增加铁死亡相关易感性。机制上，ZNF419促进ZDHHC20表达，并与候选下游增强子区域的激活相关。ZDHHC20是一种棕榈酰转移酶，有助于GPX4棕榈酰化相关的稳定化，并限制GPX4的泛素介导的蛋白酶体降解。药理学干扰棕榈酰化可减弱ZNF419相关的GPX4稳定化，而ZDHHC20恢复可部分逆转ZNF419缺陷细胞增加的铁死亡相关易感性。总之，我们的发现支持一个此前未被认识的AR相关ZNF419-ZDHHC20-GPX4调控轴，将AR活性与铁死亡相关易感性联系起来。这些发现为进一步研究调节该通路是否可能影响晚期PCa对AR靶向治疗的反应提供了依据。"}, {"pmid": "42852159", "title": "Spontaneous Pregnancy After Laparoscopic Treatment of Ovarian Endometrioma: A Retrospective Cohort Study Comparing Stripping and Ethanol Sclerotherapy.", "abstract": "Ovarian endometrioma is associated with infertility, whereas its treatment may compromise ovarian reserve. This retrospective cohort evaluated factors associated with spontaneous pregnancy after laparoscopic treatment of ovarian endometrioma, with particular attention to the Endometriosis Fertility Index (EFI) and reproductive outcomes after cystectomy using the stripping technique vs ethanol sclerotherapy. Forty-eight infertile women with histologically confirmed ovarian endometrioma and revised American Society for Reproductive Medicine stage III-IV endometriosis underwent laparoscopic treatment between 2022 and 2024 in Kinshasa, Democratic Republic of the Congo, with follow-up through June 2026; 33 underwent cystectomy, and 15 underwent ethanol sclerotherapy. Overall, 29/48 women (60.4%) had primary infertility, 30/48 (62.5%) had bilateral endometriomas, and 29/48 (60.4%) had stage IV disease. Spontaneous pregnancy occurred in 17/48 women (35.4%), and 11/48 (22.9%) achieved a live birth. Pregnancy occurred in 9/15 women (60.0%) after sclerotherapy vs 8/33 (24.2%) after cystectomy (p = 0.024). Among women with EFI ≥7, 15/26 (57.7%) conceived, compared with 2/22 (9.1%) with EFI <7 (p < 0.001). In the adjusted Cox model, EFI ≥7 (adjusted hazard ratio (aHR) 7.96, 95% confidence interval (CI) 1.78-35.57; p = 0.007) and ethanol sclerotherapy (aHR 3.11, 95% CI 1.17-8.29; p = 0.023) were associated with a higher rate of spontaneous pregnancy. Both ovarian-reserve markers improved in 15/15 women (100.0%) after sclerotherapy vs 9/33 (27.3%) after cystectomy (p < 0.001). These findings suggest that a favorable EFI identifies women with a higher likelihood of spontaneous pregnancy and that ethanol sclerotherapy may offer reproductive advantages over cystectomy; however, the retrospective design, small sample, and nonrandomized treatment allocation limit causal inference.", "journal": "Cureus", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.7759/cureus.117643", "authors": ["Guy Lambert M Monzango Sibo", "Gracia K Ntanga"], "affiliations": ["Gynecology, University of Kinshasa, Kinshasa, COD.", "Gynecology, Cliniques Universitaires de Kinshasa, Kinshasa, COD."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=10", "score": 18.22, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 2.22, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 10.0}, "journal_metrics": {"status": "ok", "impact_factor": 1.3, "cas_zone": 4, "cas_zone_points": 1.0, "impact_factor_points": 1.22, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42850759", "title": "Active surveillance for prostate cancer: evidence interpretation and research priorities.", "abstract": "", "journal": "BJU International", "pub_date": "2026-Oct-08", "publication_types": ["Letter"], "doi": "10.1111/bju.70486", "authors": ["Takeshi Takahashi"], "affiliations": ["Health and Welfare Bureau, Kitakyushu City Office, Kitakyushu, Japan."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 19.47, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.47, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.4, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.47, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42850571", "title": "RE: Comprehensive clinical and genomic analysis of early onset cancer of the bladder and upper urinary tract.", "abstract": "", "journal": "Journal of the National Cancer Institute", "pub_date": "2026-Oct-08", "publication_types": ["Journal Article"], "doi": "10.1093/jnci/djag368", "authors": ["Yang Liu", "Dan Zhao"], "affiliations": ["Sixth Ward of Thoracic Surgery, Dalian University of Technology Affiliated Cancer Hospital, Liaoning Provincial Cancer Hospital, Shenyang, Liaoning, China.", "Urology Ward 3, Dalian University of Technology Affiliated Cancer Hospital, Liaoning Provincial Cancer Hospital, Shenyang, Liaoning, China."], "corresponding_authors": [], "china_team": "Sixth Ward of Thoracic Surgery, Dalian University of Technology Affiliated Cancer Hospital, Liaoning Provincial Cancer Hospital, Shenyang, Liaoning, China Dan Zhao团队", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 27.09, "score_parts": {"urology_relevance": 7, "urology_in_title": 8.0, "journal_priority": 15.09, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 7.2, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.09, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "早发膀胱癌与上尿路癌临床基因组特征获验证", "chinese_summary": "大连理工大学附属肿瘤医院辽宁省肿瘤医院胸外科六病区Dan Zhao团队10月J Natl Cancer Inst发表通讯，针对早发膀胱癌及上尿路癌的综合临床与基因组分析研究提出评议，强调该病种在年轻患者中的分子特征与临床管理需进一步区分。", "abstract_zh": "本文是对《早发膀胱癌与上尿路癌的综合临床与基因组分析》一文的通讯评论。"}, {"pmid": "42850272", "title": "Artificial intelligence in prostate cancer care from performance to clinical integration.", "abstract": "", "journal": "Prostate Cancer and Prostatic Diseases", "pub_date": "2026-Oct-08", "publication_types": ["Editorial"], "doi": "10.1038/s41391-025-00990-9", "authors": ["Riccardo Lombardo", "Daniele Amparore"], "affiliations": ["Department of Urology, Ospedale Sant'Andrea, Sapienza University of Rome, Rome, Italy. rlombardo@me.com.", "Division of Urology, Department of Oncology, University of Turin, San Luigi Gonzaga Hospital, Turin, Italy."], "corresponding_authors": ["Riccardo Lombardo"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 20.81, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.81, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 5.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.81, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42850079", "title": "Nonmuscle-invasive bladder cancer after solid organ transplantation: Clinical outcomes and recurrence patterns.", "abstract": "Solid organ transplant recipients face an increased risk of bladder cancer and require lifelong immunosuppression, which may alter the natural history and treatment response of nonmuscle-invasive bladder cancer (NMIBC). Balancing cancer control with allograft preservation complicates clinical decision-making, yet outcome data in this population remain scarce. A retrospective study of transplant recipients diagnosed with NMIBC post-transplant was conducted. The index date was NMIBC diagnosis. NMIBC recurrence was the primary endpoint, with death before recurrence as a competing event. Recurrence-free survival was estimated using Kaplan-Meier methods, and cumulative incidence of recurrence and competing mortality using the Aalen-Johansen estimator. Cox models evaluated predictors of recurrence. Fifty-nine transplant recipients met inclusion criteria (median age 68 years; 89.8% male), with high-risk disease present in 40/59 (67.8%). High-grade disease was present in 38/59 patients (64.4%), with T1 stage in 20/59 (33.9%) and concomitant carcinoma in situ in 13/59 (22.0%). Over a median follow-up of 37.4 months, 11/59 patients (18.6%) experienced recurrence at a median of 15.1 months, all among those receiving Bacillus Calmette-Guérin (BCG) induction. The 5-year cumulative incidence for recurrence was 20.4%, compared with 40.5% for competing mortality. Progression to advanced disease (≥pT2 and/or nodal involvement) occurred in 3/59 (5.1%) overall, predominantly within the high-grade subcohort. All-cause mortality was 36/59 (61.0%), with a bladder cancer-specific mortality of 5/59 (8.5%). In univariable models, tumor size >3 cm (HR 19.53, P = 0.005) and increasing age (HR 1.10, P = 0.066) were associated with recurrence. Granular information on specific non-BCG intravesical regimens was limited, precluding analysis of comparative efficacy among alternative agents in this population. In this single-institution transplant cohort, competing mortality exceeded recurrence risk. Traditional prognostic factors like tumor size predicted recurrence, yet survival was driven by transplant-related comorbidities. These findings support the use of competing-risk methodologies for accurate outcome estimation and highlight the need for individualized, multidisciplinary management in this complex population.", "journal": "Urologic Oncology", "pub_date": "2026-Oct-08", "publication_types": ["Journal Article"], "doi": "10.1016/j.urolonc.2026.08.020", "authors": ["Taeris Guzman", "Sean McSweeney", "Can Aydogdu", "Gabriela Diaz", "Mikayla Baer", "Christopher Weight", "Nima Almassi", "Venkakesh Krishnamurthi", "Mohamed Eltemamy", "Rebecca Campbell", "Mohit Sindhani", "Laura Bukavina"], "affiliations": ["Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH.", "Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH. Electronic address: bukavil2@ccf.org."], "corresponding_authors": ["Laura Bukavina"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=9", "score": 28.75, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 5.75, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 9.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.3, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.75, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42849919", "title": "Stereotactic body radiation therapy enriches mediators of humoral immune activity in metastatic renal cell carcinoma.", "abstract": "Stereotactic body radiation therapy (SBRT) has recently been shown to be effective against renal cell carcinoma (RCC); ongoing clinical trials seek to assess the impact of SBRT on immune checkpoint blockade (ICB) efficacy in patients with RCC. Previous analysis of SBRT-treated RCC tumors has elucidated a phenotypic maturation of tumor-infiltrating T cells and increased tumor-associated antigen expression compared with non-irradiated tumors. However, the impacts of SBRT on humoral immunity, which has consistently been linked to ICB responsiveness in RCC, remain unknown. Analysis of bulk RNA sequencing of SBRT-treated tumors obtained from a prospective clinical trial (NCT01892930) compared with non-irradiated tumors was performed. A subset of samples was further profiled with single-cell RNA sequencing (scRNA-seq) to investigate the impacts of SBRT on B cell populations. Full spectrum flow cytometry was also employed to phenotype B cell subsets. The impact of findings on ICB response in RCC patients was validated in two clinical cohorts—IMmotion151 and HCRN-GU16-260—using immune deconvolution of tumor transcriptomic data. Bulk transcriptomic analysis of SBRT-treated RCC tumor samples revealed a significant increase in the predicted abundance of B cells and class-switched memory B cells relative to controls, along with consistent upregulation of B cell-, tertiary lymphoid structure-, and phagocytosis-associated gene sets. SBRT was associated with a transition to mature, effector plasma cells by scRNA-seq, with significantly increased expression of immunoglobulin-encoding genes. This was validated by flow cytometry, with heightened IgG and CD38 expression in SBRT-enriched clusters compared with overexpression of non-class switched immunoglobulins (IgD/IgM) in control-enriched clusters. Antibody-secreting B cells were significantly increased in SBRT while control tumors demonstrated a significant increase in naïve B cells. In IMmotion151 and HCRN-GU16-260, mature B cell populations (memory and class switched memory) were significantly enriched in ICB responders compared with non-responders, whereas naïve B cell scores were heightened in ICB non-responders. SBRT is associated with maturation of the humoral immune compartment within the RCC microenvironment, which ultimately correlates with ICB response among RCC patients. Together, these findings support ongoing investigations into the impact of SBRT as an immune adjuvant to improve ICB sensitivity.", "journal": "Journal for Immunotherapy of Cancer", "pub_date": "2026-Oct-08", "publication_types": ["Journal Article"], "doi": "10.5281/zenodo.21420034", "authors": ["Nicholas J Salgia", "Adil Khan", "Yu Fujiwara", "Mark Long", "Gavin C Twoey", "Kyle Leatt", "Jacky Chow", "Scott I Abrams", "Thomas Schwaab", "Anurag K Singh", "Jason B Muhitch"], "affiliations": ["Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA nicholas.salgia@roswellpark.org jason.muhitch@roswellpark.org.", "Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York, USA.", "Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.", "Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.", "Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.", "Department of Microbiology and Immunology, University at Buffalo, Buffalo, New York, USA.", "Department of Chemical and Biological Engineering, University at Buffalo, Buffalo, New York, USA.", "Helen F Graham Cancer Center and Research Institute, Newark, Delaware, USA.", "Department of Radiation Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA."], "corresponding_authors": ["Nicholas J Salgia", "Jason B Muhitch"], "china_team": "", "category": "basic", "classification_reason": "basic_signals=10", "score": 40.6, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 15.6, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 10.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 10.6, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.6, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "立体定向放疗增强肾癌体液免疫", "chinese_summary": "一项前瞻性临床试验（NCT01892930）的肿瘤转录组分析显示，立体定向体部放疗（SBRT）后转移性肾细胞癌中B细胞及类别转换记忆B细胞预测丰度显著增加，B细胞、三级淋巴结构和吞噬相关基因集上调；单细胞测序與流式细胞术证实SBRT促进成熟效应浆细胞及IgG、CD38表达。", "abstract_zh": "立体定向体部放疗（SBRT）近期已被证明对肾细胞癌（RCC）有效；正在进行的临床试验试图评估SBRT对RCC患者免疫检查点阻断（ICB）疗效的影响。先前对接受SBRT治疗的RCC肿瘤的分析已阐明，与非照射肿瘤相比，肿瘤浸润T细胞出现表型成熟且肿瘤相关抗原表达增加。然而，SBRT对体液免疫的影响仍属未知，而体液免疫一直与RCC的ICB反应性相关。本研究对来自一项前瞻性临床试验（NCT01892930）的SBRT治疗肿瘤与非照射肿瘤进行了批量RNA测序分析比较。部分样本进一步通过单细胞RNA测序（scRNA-seq）分析，以探究SBRT对B细胞群体的影响。同时采用全光谱流式细胞术对B细胞亚群进行表型分析。研究结果对RCC患者ICB反应的影响在两个临床队列——IMmotion151和HCRN-GU16-260——中通过肿瘤转录组数据的免疫解卷积得到验证。对SBRT治疗的RCC肿瘤样本的批量转录组分析显示，相对于对照组，B细胞和类别转换记忆B细胞的预测丰度显著增加，同时B细胞、三级淋巴结构和吞噬作用相关基因集持续上调。scRNA-seq显示SBRT与向成熟效应浆细胞的转变相关，免疫球蛋白编码基因表达显著增加。流式细胞术验证了这一点，与对照富集簇中非类别转换免疫球蛋白（IgD/IgM）过表达相比，SBRT富集簇中IgG和CD38表达增高。SBRT中抗体分泌B细胞显著增加，而对照肿瘤中初始B细胞显著增加。在IMmotion151和HCRN-GU16-260中，成熟B细胞群体（记忆和类别转换记忆）在ICB应答者中较无应答者显著富集，而初始B细胞评分在ICB无应答者中升高。SBRT与RCC微环境中体液免疫区室的成熟相关，最终与RCC患者的ICB反应相关。总之，这些发现支持正在进行的关于SBRT作为免疫佐剂以提高ICB敏感性影响的研究。"}, {"pmid": "42849820", "title": "Understanding the Impact of Rurality: Outcomes for Women with Urinary Incontinence.", "abstract": "To evaluate the burden of social drivers of health in rural women with urinary incontinence (UI) across quality of life, financial, and psychosocial domains compared to their non-rural counterparts. Adult women with any type and severity of UI were recruited from outpatient urology clinics and electronically via ResearchMatch from the surrounding community between December 2022 and May 2023. Participants were asked to complete anonymous questionnaires in REDCap assessing sociodemographics (including zip code to determine rurality), urinary symptoms, unmet social needs, and disease burden. Rural and non-rural participants were compared, and multivariable logistic regression was used to assess associations between individual unmet social needs and rurality. Of the 1,006 women with UI in our cohort, 15.9% lived in a rural area. Rural women differed significantly in sociodemographics from non-rural women (Table 1). Despite similar UI severity between groups, rural women reported a greater burden of unmet social needs, worse LUTS-specific QOL, and greater financial toxicity and psychosocial burden as compared to non-rural women. In this cohort of women with UI, rural women face a compounding set of psycho-socio-financial burdens of their urinary symptoms, despite similar UI severity as compared to non-rural women. Effective care for this population requires a multi-disciplinary approach beyond the clinic by integrating telehealth, social work, financial counseling, and community-based resources into management of UI.", "journal": "Urology", "pub_date": "2026-Oct-08", "publication_types": ["Journal Article"], "doi": "10.1016/j.urology.2026.09.062", "authors": ["Lan Anh S Galloway", "Janavi Sethurathnam", "William Furuyama", "Karla Rebullar", "Melissa R Kaufman", "Roger R Dmochowski", "Elisabeth M Sebesta"], "affiliations": ["Department of Urology, Vanderbilt University Medical Center, Nashville, TN.", "Vanderbilt University School of Medicine, Nashville, TN.", "Divison of Urology, Mackenzie Health, Richmond Hill, Ontario, Canada.", "Department of Urology, Vanderbilt University Medical Center, Nashville, TN. Electronic address: elisabeth.sebesta@vumc.org."], "corresponding_authors": ["Elisabeth M Sebesta"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=4", "score": 30.61, "score_parts": {"urology_relevance": 11, "urology_in_title": 8.0, "journal_priority": 5.61, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 4.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.0, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.61, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42849819", "title": "Who you see last matters: The recency effect in treatment decision-making for localized prostate cancer.", "abstract": "To evaluate the impact of the sequence of specialist physician consultations (e.g., urology, radiation oncology) on definitive treatment choices in newly diagnosed prostate cancer patients. Using electronic medical records from two US healthcare systems, we examined the number and order of specialty appointments and final treatment decisions for patients newly diagnosed with localized prostate cancer. We analyzed data using Fisher's exact and ANOVA tests. Patients (N=254) had a mean age of 64±6.86 years and PSA 6.86±3.81 ng/mL. All patients (100%, n=254) consulted with a urologist for their first treatment consultation. Most patients (72.0%, n=183) subsequently consulted with a radiation oncologist. Final treatment decisions included surgery (33.5%; n=85), radiation therapy (48.8%; n=124), and active surveillance (17.7%;(n=45). Among patients who consulted with more than one physician (n=183), the specialty of the last physician was significantly associated with the final treatment chosen (p<.001). Most patients who consulted with a radiation oncologist last opted for radiation (75.0%, 96/128). When urology was the final specialty visited (either exclusively or after a radiation oncologist consultation), 60.0% (33/55) selected surgery or active surveillance. A recency effect was observed, as patients' treatment choices strongly aligned with the specialty of the last physician consulted. To ensure patients receive care concordant with their personal preferences while promoting optimal cancer control, multidisciplinary consulting models are recommended, which may provide balanced treatment recommendations and enhance patient satisfaction.", "journal": "Urology", "pub_date": "2026-Oct-08", "publication_types": ["Journal Article"], "doi": "10.1016/j.urology.2026.09.063", "authors": ["Karen Huang", "Simon J Hall", "Manish Vira", "Alexander Kutikov", "Suzanne M Miller", "Michael A Diefenbach"], "affiliations": ["Northwell Urology, Department of Urology, Zucker School of Medicine, Northwell Health, New Hyde Park, USA.", "Fox Chase Cancer Center, Philadelphia, USA.", "Northwell Urology, Department of Urology, Zucker School of Medicine, Northwell Health, New Hyde Park, USA; Institute of Health System Science, Feinstein Institutes for Medical Research, Northwell Health, New Hyde Park, USA. Electronic address: Mdiefenbach@northwell.edu."], "corresponding_authors": ["Michael A Diefenbach"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=4", "score": 29.11, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 5.61, "top_journal_bonus": 0.0, "novelty": 1.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 4.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.0, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.61, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42849355", "title": "A randomised, open-label, phase II study of tobemstomig combinations in patients with previously untreated advanced clear-cell renal cell carcinoma.", "abstract": "Immune checkpoint inhibitors combined with vascular endothelial growth factor (VEGF)-targeted tyrosine kinase inhibitors (TKIs) have improved advanced renal cell carcinoma (RCC) outcomes, yet median progression-free survival (PFS) remains <2 years. This randomised (1 : 1 : 1), open-label, phase II study (NCT05805501) evaluated tobemstomig [bispecific anti-programmed cell death protein 1 (PD-1)/lymphocyte-activation gene 3] plus axitinib (VEGF-TKI) and tobemstomig plus tiragolumab (anti-T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibition motif domains) plus axitinib versus pembrolizumab (anti-PD-1) plus axitinib (control) in patients with untreated, locally advanced unresectable/metastatic clear-cell RCC with intermediate/poor International Metastatic Renal Cell Carcinoma Database Consortium risk. Following a protocol-specified interim futility analysis that led to study termination, the primary endpoint was amended from PFS and incidence/severity of adverse events (AEs) to the latter only. Efficacy was evaluated descriptively. In the safety population (198 patients: tobemstomig-axitinib, n = 66; tobemstomig-tiragolumab-axitinib, n = 65; control, n = 67), grade 3-4 AEs occurred in 62.1%, 67.7% and 56.7% of patients in the respective arms and treatment-related serious AEs occurred in 22.7%, 29.2% and 13.4%. Confirmed overall response rates were 51.5%, 53.8% and 51.5%; median PFS was 12.4 [95% confidence interval (CI) 8.4-16.3], 12.5 (95% CI 7.3-17.2) and 12.5 months (95% CI 9.5 to not estimable). Tobemstomig-containing regimens were associated with increased toxicity and did not demonstrate meaningful efficacy improvement relative to control.", "journal": "Esmo Open", "pub_date": "2026-Oct-08", "publication_types": ["Journal Article"], "doi": "10.1016/j.esmoop.2026.108587", "authors": ["B I Rini", "T Powles", "P Tomczak", "S J Shin", "J Guo", "J Molina-Cerrillo", "X Ren", "J L Lee", "P J Wysocki", "J Puente", "A Basu", "N Mar", "S Bernhard", "O Khan", "J Ha", "L Colley", "H Prizant", "L Albiges"], "affiliations": ["Department of Medicine, Vanderbilt-Ingram Cancer Center, Nashville, USA. Electronic address: brian.rini@vumc.org.", "Barts Cancer Centre, Barts Health NHS Trust, Queen Mary University of London, London, UK.", "Department of Medical Oncology, Poznań University of Medical Sciences, Poznań, Poland.", "Yonsei Cancer Center, Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.", "Department of Neurology and Melanoma, Peking University Cancer Hospital and Institute, Beijung, China.", "Medical Oncology Department, Ramón y Cajal Health Research Institute (IRYCIS), CIBERONC, Alcalá University, University Hospital Ramon y Cajal, Madrid, Spain.", "Department of Biotherapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.", "Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.", "Department of Oncology, Jagiellonian University Medical College, Cracow, Poland.", "Medical Oncology Department, Hospital Clínico San Carlos, Madrid, Spain.", "Division of Hematology and Oncology, University of Alabama at Birmingham, Birmingham, USA.", "Division of Hematology and Oncology, University of California at Irvine, Irvine, USA.", "Roche Products Limited, Welwyn Garden City, UK.", "Hoffmann-La Roche, Mississauga, Canada.", "Genentech, Inc. South San Francisco, San Francisco, USA.", "Department of Cancer Medicine, Institut Gustave Roussy, Villejuif, France."], "corresponding_authors": ["B I Rini"], "china_team": "Department of Neurology and Melanoma, Peking University Cancer Hospital and Institute, Beijung, China X Ren团队", "category": "clinical_review", "classification_reason": "clinical_signals=7", "score": 36.27, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 15.27, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 7.0}, "journal_metrics": {"status": "ok", "impact_factor": 8.3, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.27, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42849089", "title": "The cost of intensification in high-risk non-muscle-invasive bladder cancer.", "abstract": "", "journal": "Esmo Open", "pub_date": "2026-Oct-08", "publication_types": ["Editorial"], "doi": "10.1016/j.esmoop.2026.108598", "authors": ["M Zugman", "I Kirche Duarte", "W Baccaglini"], "affiliations": ["Centro de Oncologia e Hematologia Einstein Família Dayan-Daycoval, Hospital Israelita Albert Einstein, São Paulo, Brazil. Electronic address: miguel.zugman@einstein.br.", "Division of Urology, Hospital Israelita Albert Einstein, São Paulo, Brazil.", "Division of Urology, Hospital Israelita Albert Einstein, São Paulo, Brazil; Discipline of Urology, Faculdade de Medicina do ABC, Centro Universitário FMABC, Santo André, Brazil."], "corresponding_authors": ["M Zugman"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 24.27, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 15.27, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 8.3, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.27, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42849062", "title": "Advanced Practice Provider-Attributed Outpatient Visits and Procedures for Urologic Oncology Care in the United States.", "abstract": "Integration of advanced practice providers (APPs) into the clinic setting holds potential to streamline care in urologic oncology. The impact of APP-attributed care in genitourinary oncology has not been well described. We sought to characterize national trends and the financial impact of APP-attributed outpatient visits and procedures within a privately insured urologic oncology population. We identified bladder, kidney, prostate, and testis cancer claims within the Merative MarketScan database from 2010 to 2023. Annual proportions of first-visit, overall, and select procedural APP-attributed claims were assessed descriptively. Comparisons by geographic status, urbanicity, insurance plan, and metastatic status were evaluated using chi-squared testing and multivariable modeling. Overall and out-of-pocket twelve-month health expenditures were assessed by whether first oncologic visit was APP-attributed. There were 507,053 APP-attributed claims, increasing from 0.88% in 2010 to 3.38% in 2023. In adjusted analysis, later calendar year (OR: 1.1; p<0.001) had significantly higher odds of APP involvement, while residence within the Northeast (OR: 0.68; p<0.001) had significantly lower odds. APP-attributed first visits were associated with lower 12-month insurer-paid (SR: 0.81; p<0.001) and out-of-pocket (SR: 0.90; p<0.001) spending. Rates of APP-attributed cystoscopy and prostate biopsy remained modest. APP-attributed office and procedural outpatient visits are increasing, with variations in uptake present by practice region and patient characteristics. APP-attributed first visits were associated with lower 12-month insurer-paid spending without increased patient out-of-pocket spending.", "journal": "Urology Practice", "pub_date": "2026-Oct-08", "publication_types": ["Journal Article"], "doi": "10.1097/UPJ.0000000000001104", "authors": ["Aidan S Weitzner", "Achyutha Kodavatikanti", "Laura Alvim", "Soum D Lokeshwar", "Craig Cronin", "Philipp Korn", "Nirmish Singla"], "affiliations": ["Department of Urology, The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.", "Georgetown University School of Medicine, Washington, DC, USA.", "Department of Urology, Rechts der Isar Medical Center, TUM School of Medicine and Health, Munich, Germany."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 28.46, "score_parts": {"urology_relevance": 15, "urology_in_title": 8.0, "journal_priority": 2.46, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 1.7, "cas_zone": 4, "cas_zone_points": 1.0, "impact_factor_points": 1.46, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "泌尿肿瘤门诊高级实践护士参与度上升", "chinese_summary": "美国Merative MarketScan数据库2010–2023年507,053条泌尿肿瘤索赔分析显示，高级实践提供者（APP）参与的索赔比例从0.88%升至2023年3.38%，东北部参与几率较低；APP首诊与12个月保险公司支付及自付支出降低相关，但膀胱镜和前列腺穿刺参与率仍不高。", "abstract_zh": "将高级实践提供者（APP）整合到临床环境中，有望优化泌尿肿瘤诊疗流程。APP参与照护在泌尿生殖系统肿瘤中的影响尚未得到充分描述。我们旨在描述私人保险泌尿肿瘤人群中APP参与的门诊就诊和操作的全国趋势及其财务影响。我们识别了Merative MarketScan数据库中2010年至2023年膀胱癌、肾癌、前列腺癌和睾丸癌的索赔记录。对首诊、总体及特定操作的APP参与索赔的年度比例进行了描述性评估。采用卡方检验和多变量模型评估了按地理区域、城乡属性、保险计划和转移状态进行的比较。根据首次肿瘤就诊是否由APP参与，评估了总体和自付的12个月医疗支出。共有507,053条APP参与的索赔，从2010年的0.88%上升至2023年的3.38%。在调整分析中，较晚的日历年份（OR：1.1；p<0.001）与APP参与几率显著较高相关，而居住在东北部（OR：0.68；p<0.001）与APP参与几率显著较低相关。APP参与的首诊与较低的12个月保险公司支付（SR：0.81；p<0.001）和自付（SR：0.90；p<0.001）支出相关。APP参与的膀胱镜检查和前列腺活检比例仍然不高。APP参与的办公室和操作性门诊就诊正在增加，其采用率因执业区域和患者特征而存在差异。APP参与的首诊与较低的12个月保险公司支付支出相关，且未增加患者自付支出。"}, {"pmid": "42849042", "title": "Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography / Magnetic Resonance Imaging in Selected Men with Equivocal Prostate Imaging Reporting and Data System Category 3 Lesion (PANDORA): A Prospective Paired Diagnostic Study.", "abstract": "Equivocal Prostate Imaging Reporting and Data System (PI-RADS) category 3 lesions carry an intermediate risk of clinically significant prostate cancer (csPCa). We evaluated the diagnostic value of prostate-specific membrane antigen positron emission tomography/magnetic resonance imaging (PSMA PET/MRI) with [18F]JK-PSMA-7, performed after diagnostic MRI, in biopsy-eligible men with an equivocal PI-RADS category 3 lesion. We hypothesized that PSMA PET-targeted biopsy would detect more csPCa than MRI-targeted biopsy. We conducted a single-center prospective paired diagnostic study from November 2023 to February 2026. Biopsy-eligible men with an equivocal PI-RADS category 3 lesion on diagnostic MRI and ≥1 high-risk feature underwent pre-biopsy PSMA PET/MRI, with positivity defined as a PRIMARY score ≥3, followed by transperineal MRI-targeted, PSMA PET-targeted when positive, and systematic biopsy. The primary outcome was the per-patient csPCa detection rate (International Society of Urological Pathology grade group ≥2 with ≥10% Gleason pattern 4) of PSMA PET-targeted vs MRI-targeted biopsy, assessed with the exact McNemar test. Of 83 men assessed, 66 completed PSMA PET/MRI and biopsy. PSMA PET was positive in 21 of 66 (32%). PSMA PET-targeted biopsy detected csPCa in 10 of 66 (15%) vs 4 of 66 (6%) for MRI-targeted biopsy (difference 9%; 95% CI 2%-18%; P = .03). Sensitivity, specificity, and negative predictive value of PSMA PET were 100%, 82%, and 100%. Biopsy would have been avoided in 45 of 66 men (68%) with a negative result, none of whom had csPCa. In biopsy-eligible men with an equivocal PI-RADS category 3 lesion, PSMA PET-targeted biopsy detected more csPCa than MRI-targeted biopsy. The high negative predictive value suggests that deferral of biopsy after a negative result merits evaluation in larger multicentre studies.", "journal": "Journal of Urology", "pub_date": "2026-Oct-08", "publication_types": ["Journal Article"], "doi": "10.1097/JU.0000000000005343", "authors": ["Romain Diamand", "Carlos Artigas", "Alexandre Peltier", "Marie Van Eycken", "Mutaz Kassas", "Marc-André Léger", "Yolène Lefebvre", "Maxime Deforche", "Marc Lemort", "Lorenzo Tosco", "Françoise Rothé", "Thierry Roumeguère", "Patrick Flamen"], "affiliations": ["Department of Urology, Jules Bordet Institute-Erasme Hospital, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium.", "GU-CaRe Unit, Bordet Cancer Research Laboratories, Jules Bordet Institute, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium.", "Department of Nuclear Medicine, Jules Bordet Institute-Erasme Hospital, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium.", "Department of Pathology, Jules Bordet Institute-Erasme Hospital, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium.", "Department of Radiology, Jules Bordet Institute-Erasme Hospital, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 29.01, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 11.01, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 6.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 3.01, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "PSMA PET靶向活检提升可疑前列腺癌检出", "chinese_summary": "2023年11月至2026年2月单中心前瞻性配对诊断研究纳入66例MRI示PI-RADS 3类且伴高危特征男性，活检前加做[18F]JK-PSMA-7 PET/MRI。PSMA PET靶向活检检出15%临床显著前列腺癌，MRI靶向活检仅6%，阴性者中68%可免于活检。", "abstract_zh": "意义不明确的前列腺影像报告和数据系统（PI-RADS）3类病灶具有中等临床显著前列腺癌（csPCa）风险。我们评估了在诊断性MRI之后、对活检适应人群且PI-RADS 3类意义不明确病灶行[18F]JK-PSMA-7前列腺特异性膜抗原正电子发射断层扫描/磁共振成像（PSMA PET/MRI）的诊断价值。我们假设PSMA PET靶向活检较MRI靶向活检可检出更多csPCa。我们于2023年11月至2026年2月开展了一项单中心前瞻性配对诊断研究。诊断性MRI示PI-RADS 3类意义不明确病灶且≥1项高危特征的活检适应男性接受活检前PSMA PET/MRI，阳性定义为PRIMARY评分≥3，随后行经会阴MRI靶向活检、PSMA PET阳性时行PSMA PET靶向活检以及系统活检。主要结局为PSMA PET靶向活检与MRI靶向活检的每患者csPCa检出率（国际泌尿病理学会分级组≥2且Gleason模式4≥10%），采用精确McNemar检验评估。在83例评估男性中，66例完成PSMA PET/MRI及活检。66例中21例（32%）PSMA PET阳性。PSMA PET靶向活检在66例中检出10例（15%）csPCa，而MRI靶向活检为4例（6%）（差异9%；95% CI 2%-18%；P = .03）。PSMA PET的敏感性、特异性和阴性预测值分别为100%、82%和100%。66例中45例（68%）结果为阴性者可避免活检，其中无一例csPCa。在PI-RADS 3类意义不明确病灶的活检适应男性中，PSMA PET靶向活检较MRI靶向活检检出更多csPCa。高阴性预测值提示阴性后推迟活检值得在更大规模多中心研究中评估。"}, {"pmid": "42848391", "title": "Disitamab Vedotin Plus Tislelizumab in Transurethrally Unresectable, ERBB2-Positive, Non-Muscle-Invasive Bladder Cancer: A Nonrandomized Clinical Trial.", "abstract": "Very high-risk non-muscle-invasive bladder cancer (VHR NMIBC) includes extensive high-grade T1 (T1HG) disease, T1HG with carcinoma in situ, variant histology, lymphovascular invasion, or bacille Calmette-Guérin (BCG)-unresponsive disease. Transurethrally unresectable disease warrants radical cystectomy, but patients ineligible for or declining cystectomy lack established nonsurgical therapy. To evaluate the efficacy and safety of disitamab vedotin (DV, an anti-ERBB2 [formerly HER2] antibody-drug conjugate) plus tislelizumab (an anti-programmed cell death 1 protein immune checkpoint inhibitor) in transurethrally unresectable ERBB2-positive VHR NMIBC. This was an open-label, single-arm, phase 2, nonrandomized clinical trial with a Simon 2-stage design, conducted in an academic hospital from August 2022 to May 2024 with a median follow-up of 29.4 months. The analysis included adults with transurethrally unresectable ERBB2-positive NMIBC who met the 2019 European Association of Urology VHR criteria and who were ineligible for or declined cystectomy. Patients received an intravenous injection of DV (120 mg, day 1) plus tislelizumab (200 mg, day 2) every 3 weeks for 3 cycles; patients who responded received up to 8 DV cycles and 17 tislelizumab cycles. The primary outcome was complete response (CR) of high-risk disease, defined as no high-grade tumor, T1 disease, carcinoma in situ, or progression. Secondary outcomes were response duration, progression-free survival, overall survival, and safety. Among 137 screened patients, 28 participants (median [IQR] age, 72 [67-74] years; 25 male [89%]) were included. Two preassessment withdrawals were counted as nonresponders in the all-treated analysis, which left 26 efficacy-evaluable patients. CR of high-risk disease was achieved in 19 of 26 (73.1%; 95% CI, 54.8%-91.3%), meeting the prespecified 70% alternative-rate goal. Among all 28, 19 responded (67.9%; 95% CI, 49.4%-86.3%), exceeding the 17-response exact binomial threshold. Both analyses met the primary criterion. Among responders, the 24-month sustained response was 83.5% (95% CI, 68.0%-100.0%), and no muscle invasive or metastatic progression occurred. Treatment-related adverse events occurred in 25 patients (89.3%), most commonly paresthesia (12 [42.9%]), alopecia (11 [39.3%]), and pruritus (10 [35.7%]); 4 (14.3%) had grade 3 to 4 events; 2 (7.1%) discontinued treatment; and none had grade 5 events. Findings of this nonrandomized clinical trial suggest that DV plus tislelizumab may show a high CR rate and durable disease control in patients with transurethrally unresectable ERBB2-positive VHR NMIBC, supporting randomized clinical trials. ClinicalTrials.gov Identifier: NCT05495724.", "journal": "JAMA Oncology", "pub_date": "2026-Oct-08", "publication_types": ["Journal Article"], "doi": "10.1007/s11136-020-02637-9", "authors": ["Yunkai Qie", "Kaipeng Jia", "Shiwang Huang", "Jiazeng Zhao", "Zihan Xue", "Shizheng Guo", "Tianxiao Zhang", "Zhouliang Wu", "Chong Shen", "Hailong Hu"], "affiliations": ["Department of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China.", "Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China.", "Department of Urology Surgery, Shanxi Provincial People's Hospital Affiliated to Shanxi Medical University, Taiyuan, Shanxi, China.", "Department of Urology, The Third Medical Center, Chinese People's Liberation Army General Hospital, Beijing, China.", "Department of Urology, Chu Hsien-I Memorial Hospital, Tianjin Medical University, Tianjin, China."], "corresponding_authors": [], "china_team": "Department of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China Hailong Hu团队", "category": "clinical_review", "classification_reason": "clinical_signals=15", "score": 64.47, "score_parts": {"urology_relevance": 16, "urology_in_title": 8.0, "journal_priority": 16.47, "top_journal_bonus": 10.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 12.0}, "journal_metrics": {"status": "ok", "impact_factor": 20.1, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.47, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "维迪西妥单抗联合替雷利珠单抗治疗高危膀胱癌获高缓解率", "chinese_summary": "天津医科大学第二医院胡海龙团队2026年10月JAMA Oncol发表单臂2期试验，纳入28例经尿道无法切除的ERBB2阳性极高危非肌层浸润性膀胱癌患者，维迪西妥单抗联合替雷利珠单抗治疗高危病变完全缓解率达73.1%，24个月持续缓解率83.5%，未出现肌层浸润或转移进展，3-4级不良事件发生率14.3%。", "abstract_zh": "极高危非肌层浸润性膀胱癌（VHR NMIBC）包括广泛的高级别T1（T1HG）病变、伴原位癌的T1HG、变异组织学、淋巴血管侵犯或卡介苗（BCG）无应答性疾病。经尿道无法切除的病变需行根治性膀胱切除术，但无法耐受或拒绝膀胱切除术的患者缺乏已确立的非手术治疗方案。评估维迪西妥单抗（DV，一种抗ERBB2[原称HER2]抗体药物偶联物）联合替雷利珠单抗（一种抗程序性细胞死亡蛋白1免疫检查点抑制剂）在经尿道无法切除的ERBB2阳性VHR NMIBC中的疗效和安全性。这是一项开放标签、单臂、2期、非随机临床试验，采用Simon两阶段设计，于2022年8月至2024年5月在一家学术医院开展，中位随访29.4个月。分析纳入符合2019年欧洲泌尿外科学会VHR标准且无法耐受或拒绝膀胱切除术的经尿道无法切除的ERBB2阳性NMIBC成人患者。患者接受静脉注射DV（120 mg，第1天）联合替雷利珠单抗（200 mg，第2天），每3周1次，共3个周期；有应答的患者接受最多8个DV周期和17个替雷利珠单抗周期。主要结局为高危病变的完全缓解（CR），定义为无高级别肿瘤、T1病变、原位癌或进展。次要结局为缓解持续时间、无进展生存期、总生存期和安全性。在137例筛选患者中，纳入28例参与者（中位[IQR]年龄72[67-74]岁；25例男性[89%]）。2例在评估前退出被计为全治疗分析中的无应答者，最终26例可评估疗效。26例中19例（73.1%；95% CI，54.8%-91.3%）达到高危病变CR，达到预设的70%替代率目标。在全部28例中，19例有应答（67.9%；95% CI，49.4%-86.3%），超过17例应答的精确二项阈值。两项分析均达到主要标准。在有应答者中，24个月持续缓解率为83.5%（95% CI，68.0%-100.0%），未发生肌层浸润或转移进展。25例患者（89.3%）发生治疗相关不良事件，最常见为感觉异常（12例[42.9%]）、脱发（11例[39.3%]）和瘙痒（10例[35.7%]）；4例（14.3%）发生3至4级事件；2例（7.1%）终止治疗；无5级事件。这项非随机临床试验的结果提示，DV联合替雷利珠单抗在经尿道无法切除的ERBB2阳性VHR NMIBC患者中可能显示高CR率和持久疾病控制，支持开展随机临床试验。ClinicalTrials.gov标识符：NCT05495724。"}, {"pmid": "42848268", "title": "Global research trends and hotspots of robot-assisted urological telesurgery: a bibliometric analysis.", "abstract": "With the integration of telecommunication and intelligent robotic technology, robot-assisted urological telesurgery has progressively evolved from early technical exploration toward broader clinical applications and procedural optimization, yet the global knowledge architecture, collaborative patterns and thematic evolution of this field remain unsystematically characterized. This study adopted bibliometric methodologies to systematically map the global research landscape, thematic evolutionary trends, and collaborative patterns of robot-assisted urological telesurgery over the period 2005-2025. The results demonstrated an overall increase in cumulative publication output from 2005 to 2025, accompanied by fluctuating annual productivity. China surpassed the United States in publication output in 2023, whereas the United States retained the highest citation impact and a central position in international collaboration. Qingdao University was the most productive affiliation, and author productivity was led by Patel V, followed by Moschovas MC, Niu HT and Yang XC. Journal of Robotic Surgery was the most productive source, whereas Surgical Endoscopy and European Urology occupied prominent positions in the local citation structure. Keyword co-occurrence, clustering, burst detection and timeline analyses revealed a progressive transition from early system development and feasibility exploration toward broader minimally invasive and robot-assisted urological applications. \"Minimally invasive surgical procedures\" remained an active burst term from 2023 to 2025, while current thematic clusters prominently involved minimally invasive surgery, robotic surgical procedures, robot-assisted surgery and remote surgery. Despite increasing research activity, international and inter-institutional collaboration remained geographically clustered. This bibliometric research summarizes the global knowledge framework and hotspot transitions within this discipline, and underscores the requirements for extensive international collaboration, standardized training programmes, high-end communication infrastructure and accessible remotesurgical care services.", "journal": "Journal of Robotic Surgery", "pub_date": "2026-Oct-08", "publication_types": ["Journal Article"], "doi": "10.1007/s11701-026-04043-8", "authors": ["Biao Zhang", "Xuan Li", "Shujun Yang", "Cheng Wang", "Can Li", "Hong Chang", "Panfeng Shang", "Su Zhang"], "affiliations": ["Department of Urology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China.", "Institute of Urology, Gansu Province Clinical Research Center for Urinary System Diseases, Lanzhou, Gansu, China.", "Department of Urology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China. shangpf@lzu.edu.cn.", "Institute of Urology, Gansu Province Clinical Research Center for Urinary System Diseases, Lanzhou, Gansu, China. shangpf@lzu.edu.cn.", "Department of Urology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China. zhangsu1215@163.com.", "Institute of Urology, Gansu Province Clinical Research Center for Urinary System Diseases, Lanzhou, Gansu, China. zhangsu1215@163.com."], "corresponding_authors": ["Panfeng Shang", "Su Zhang"], "china_team": "Department of Urology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China Panfeng Shang/Su Zhang团队", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 20.03, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 6.03, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 3.0, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 2.03, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42848085", "title": "Retroperitoneal lymph node dissection for isolated node recurrence of renal cell carcinoma after nephrectomy: a systematic review.", "abstract": "Isolated retroperitoneal lymph node recurrence after nephrectomy for renal cell carcinoma (RCC) occurrs in approximately 1-3% of patients. The optimal management of this condition remains undefined. This systematic review aims to evaluate perioperative and oncologic outcomes following retroperitoneal lymph node dissection (RPLND) for isolated nodal recurrence of RCC after nephrectomy. A systematic literature search was performed in MEDLINE/PubMed and Embase (January 2000-August 2025) according to PRISMA 2020 guidelines (PROSPERO ID: CRD420251167754). Data extracted included patient demographics, perioperative parameters, and oncologic outcomes. The risk of bias was assessed using the ROBINS-I tool. Seven retrospective studies published between 2008 and 2022 met inclusion criteria, encompassing 144 patients. Median age ranged from 57 to 65 years, with a predominance of clear-cell histology (60-100%). The median interval between nephrectomy and recurrence was 9.6-25 months. Median operative time ranged from 155 to 271 min, with estimated blood loss between 200 and 575 mL and hospital stay of 2-6 days. Overall complication rates were 26-47%, with major (Clavien ≥ III) complications in approximately 10%. Median recurrence-free or progression-free survival ranged from 9 to 19.5 months, and 5-year cancer-specific survival from 61% to 74%. Adverse prognostic factors included a disease-free interval ≤ 12 months, high-grade tumors, pN1 status, and nodal metastasis > 3 cm. RPLND is an option for isolated retroperitoneal nodal recurrence of RCC after nephrectomy. Prospective multicentre studies are warranted to define optimal patient selection, the role of minimally invasive techniques, and integration with contemporary systemic immunotherapy.", "journal": "World Journal of Urology", "pub_date": "2026-Oct-08", "publication_types": ["Journal Article", "Systematic Review"], "doi": "10.1007/s00345-026-06853-9", "authors": ["Alberto Costa Silva", "Noel Clarke", "Aziz Gulamhusein"], "affiliations": ["The Christie NHS Foundation Trust, Manchester, UK. albertocsilva8@gmail.com.", "University Hospital Centre of São João, Faculty of Medicine of University of Porto, RISE - Health Research Network, Alameda Professor Hernâni Monteiro , 4200-319, Porto, Portugal. albertocsilva8@gmail.com.", "The Christie NHS Foundation Trust, Manchester, UK.", "Salford Royal, NHS Foundation Trust, Manchester, UK."], "corresponding_authors": ["Alberto Costa Silva"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 35.0, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 10.0, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 7.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.9, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.0, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42848042", "title": "UroVision: a new artificial intelligence software for functional magnetic resonance urography evaluation in children with congenital anomalies of the kidney and urinary tract.", "abstract": "This study compared UroVision, a novel AI-based tool for automated three-dimensional (3D) segmentation and magnetic resonance urography (MRU) functional analysis, with the validated ImageJ MRU software, focusing on split renal function (SRF) and drainage curve classification in children with congenital anomalies of the kidney and urinary tract (CAKUT). MRU examinations in children with CAKUT were retrospectively analysed using UroVision and ImageJ MRU. UroVision functional assessment was limited to the two-dimensional slice showing the largest amount of renal parenchyma, matching the ImageJ MRU workflow. Two paediatric radiologists independently performed the evaluations. Agreement was assessed using Pearson correlation, linear regression, Bland-Altman analysis, and intraclass correlation coefficients (ICC). Drainage curve morphology was evaluated by an expert pediatric radiologist, with inter-method agreement assessed using weighted Cohen's κ. The full 3D UroVision analysis was reviewed to aid the interpretation of borderline and discordant cases. Fifty patients (28 males, 22 females; mean age 2.4 years, range 0-18 years) were included, yielding 100 kidneys for validation. UroVision showed excellent agreement with ImageJ MRU: renal volume correlation was high (r = 0.99), while functional parameters showed moderate correlation (glomerular slope r = 0.63; Patlak coefficient r = 0.57). Bland-Altman analysis showed minimal bias. Inter-reader and intra-reader reproducibility were excellent (ICCs: 0.87-1.00 and 0.89-0.99, respectively). Agreement for drainage curves was similarly high (weighted κ = 0.86). Full 3D analysis enabled reclassification of borderline curves in 16 out of 23 kidneys. UroVision provides results comparable to ImageJ MRU, while offering automated analyses and improved reproducibility. Question Can UroVision provide reliable quantitative and qualitative renal and urinary tract functional assessment in children with CAKUT compared with ImageJ MRU? Findings UroVision showed excellent agreement with ImageJ MRU for renal function parameters and drainage curve classification, with high inter- and intra-reader reproducibility. Clinical relevance UroVision uses AI-based automated MRU analysis to deliver reproducible and standardised functional assessment in children with CAKUT, reducing operator dependence and improving workflow efficiency while providing reproducible and standardised functional assessment in clinical practice.", "journal": "European Radiology", "pub_date": "2026-Oct-08", "publication_types": ["Journal Article"], "doi": "10.1007/s00247-009-1538-5", "authors": ["Giulia Gnocchi", "Edoardo Minetti", "Nicole Martinelli", "Elena Vincenzi", "Luca Basso", "Curzio Basso", "Maria Beatrice Damasio"], "affiliations": ["Department of Radiology, IRCCS Istituto Giannina Gaslini, Genoa, Italy. giulia.gnocchi@hotmail.it.", "School of Medicine and Surgery, University of Genoa, Genoa, Italy.", "Camelot Biomedical System, Genoa, Italy.", "Department of Radiology, IRCCS Istituto Giannina Gaslini, Genoa, Italy."], "corresponding_authors": ["Giulia Gnocchi"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=4", "score": 30.05, "score_parts": {"urology_relevance": 3, "urology_in_title": 8.0, "journal_priority": 10.55, "top_journal_bonus": 0.0, "novelty": 2.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 4.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.7, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.55, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42848034", "title": "Pressure-flow behavior during RIRS irrigation: a controlled ex vivo porcine kidney study of flow-dependent apparent outflow resistance.", "abstract": "To measure actual irrigation flow and intrarenal pressure (IRP) under different irrigation modes during retrograde intrarenal surgery (RIRS), and to develop a controlled ex vivo empirical pressure-flow model for the tested endoscope-sheath configurations. A controlled ex vivo porcine kidney-ureter model was used, with all measurements taken using a 200 μm holmium laser fiber in the working channel of a 7.5Fr or 6.3Fr flexible ureteroscope and 10/12Fr or 12/14Fr suction access sheaths. Manual syringe, gravity, and automatic pump irrigation were tested across three porcine kidney-ureter units. Each condition was measured in triplicate (technical repeats); condition-level means were used for model fitting and internal assessment. Actual flow rose with driving pressure and fell with scope deflection. For the ZSR pump, flow increased from 32.0 to 99.8 mL/min (7.5Fr) and from 9.3 to 49.7 mL/min (6.3Fr) across the tested pressures. Pooling pump and syringe data, apparent outflow resistance increased at higher flow, so the non-suction relation was described by [Formula: see text]. Across 20 condition-level means, the complete model gave an RMSE of 1.04 mmHg and R² of 0.994. In a single-operator full-speed syringe test, back-calculated driving pressure was approximately 600 to 770 mmHg. In this controlled ex vivo model, apparent outflow resistance was flow-dependent, and the empirical model described the tested pressure-flow behavior. Forceful syringe flushing should not be routine when controlled pump, water-injection, or adequate gravity irrigation is available. Clinical safety claims require in vivo and clinical validation.", "journal": "World Journal of Urology", "pub_date": "2026-Oct-08", "publication_types": ["Journal Article"], "doi": "10.1007/s00345-026-06817-z", "authors": ["Baorong Feng", "Yan Yang", "Shoule Wang", "Xiaoming Li", "Ziteng Shen", "Haoyuan Liu", "Wen Zhong"], "affiliations": ["Department of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510230, China.", "Department of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510230, China. gzgyzhongwen@163.com."], "corresponding_authors": ["Wen Zhong"], "china_team": "Department of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510230, China Wen Zhong团队", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 18.0, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 10.0, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 2.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.9, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.0, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42847673", "title": "Nivolumab and Cabozantinib in People with HIV and Advanced Solid Tumors: A Pilot Trial and Systematic Review.", "abstract": "People living with HIV (PWH) are underrepresented in immune checkpoint inhibitor (ICI) and targeted therapy trials, despite a growing burden of malignancies. Cabozantinib may remodel the tumor microenvironment by reducing immunosuppressive myeloid populations and enhancing cytotoxic T-cell infiltration, thereby augmenting antitumor immunity and providing a biologic rationale for combination with PD-1 blockade. However, prospective data on combined ICI and antiangiogenic strategies in PWH are limited. We conducted a multicenter pilot trial of cabozantinib plus nivolumab in PWH with advanced solid tumors receiving stable antiretroviral therapy. The primary endpoints were safety and feasibility. Secondary endpoints included disease control and longitudinal HIV parameters. To place the trial findings in context, we also conducted a focused systematic review of prospective studies evaluating ICIs and relevant targeted therapies in PWH with cancer. Between November 2021 and January 2024, 8 participants were enrolled and 7 initiated treatment (Kaposi sarcoma, n = 5; chondrosarcoma, n = 1; prostate cancer, n = 1). No dose-limiting toxicities occurred. Grade 3 treatment-related adverse events were infrequent; no grade 4 or 5 treatment-related adverse events occurred. Among 6 response-evaluable participants, best overall response was stable disease in 5, including disease stabilization lasting >12 months in 3 heavily pretreated participants. HIV viral load and CD4 counts remained stable during treatment. The literature review supported the feasibility of immune checkpoint inhibition in selected PWH receiving antiretroviral therapy, with the strongest prospective activity signal in Kaposi sarcoma. Nivolumab plus cabozantinib had a manageable safety profile without an apparent loss of HIV virologic control in available measurements. Durable disease stabilization occurred in some participants, but antitumor efficacy cannot be determined from this small, heterogeneous cohort. These findings support larger dedicated studies in PWH, particularly in Kaposi sarcoma. ClinicalTrials.gov identifier NCT04514484.", "journal": "Oncologist", "pub_date": "2026-Oct-08", "publication_types": ["Journal Article"], "doi": "10.1093/oncolo/oyag390", "authors": ["Haiying Cheng", "Ece Cali", "Mumtu Lalla", "Shuai Wang", "Hong Wang", "Xiaonan Xue", "Benjamin A Gartrell", "Joseph Sparano", "Lakshmi Rajdev", "Melissa A Burgess", "Seth Michaels Pollack", "Liza C Villaruz", "Missak Haigentz", "Chaoyuan Kuang", "Balazs Halmos"], "affiliations": ["Department of Oncology, Montefiore Einstein Comprehensive Cancer Center, Albert Einstein College of Medicine, Montefiore Medical Center, 1695 Eastchester Rd, Bronx, NY, 10467, USA.", "Division of Oncology, Washington University School of Medicine, 660 S Euclid Ave, St. Louis, MO, 63110, USA.", "Department of Oncology, Vanderbilt-Ingram Cancer Center, 2220 Pierce Avenue. Nashville, TN, 37232, USA.", "Department of Medicine and Immunology, Hillman Cancer Center/University of Pittsburgh, 5115 Centre Ave, Pittsburgh, PA, 15232, USA.", "Department of Epidemiology & Population Health, Albert Einstein College of Medicine, New York, New York, 10461, USA.", "Department of Medical Oncology, Icahn School of Medicine at Mount Sinai, 425 West 59th Street, New York, NY, 10019, USA.", "Department of Oncology, Hillman Cancer Center/University of Pittsburgh, 5110 Centre Ave, Pittsburgh, PA, 15232, USA.", "Department of Oncology, Northwestern University Feinberg School of Medicine, 303 E. Superior St, Chicago, IL, 60611, USA.", "Department of Oncology, Rutgers Cancer Institute of New Jersey, 195 Little Albany St, New Brunswick, NJ, 08903, USA."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 25.42, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 10.42, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 9.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.2, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.42, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42847568", "title": "Fracture risk and initiation of bone-specific drug therapy following radical cystectomy with urinary diversion.", "abstract": "To assess the risk of fractures among patients with bladder cancer who underwent radical cystectomy (RC) with urinary diversion (UD), compared with matched referents from the general population. We identified 2908 patients who underwent RC between 2011 and 2019, and 13 669 matched referents in a nationwide, register-based Swedish cohort study. Outcomes were femoral fracture, any fracture, and initiation of bone-specific drug therapy (BDT). Cumulative incidence was estimated using competing-risk analyses, and hazard ratios (HRs) were derived from multivariable Cox models stratified by sex. Additional analyses were conducted among patients with muscle-invasive bladder cancer treated with curative radiotherapy (n = 328). Compared to referents, RC with UD was associated with a higher cumulative incidence of fractures. Women had an increased risk of femoral fracture (HR 1.97, 95% confidence interval [CI] 1.25-3.10) and any fracture (HR 2.06, 95% CI 1.54-2.76), while men had an increased risk of any fracture (HR 1.51, 95% CI 1.22-1.88). No association was observed for initiation of BDT in either sex. In the additional cohort, men treated with radiotherapy had an increased risk of any fracture (HR 2.14, 95% CI 1.26-3.62), whereas estimates for women were imprecise. Patients undergoing RC with UD experienced increased fracture risks, particularly women. Additional analyses suggest that fracture risk may be influenced by factors related to both bladder cancer and its treatment, although the strongest and most consistent associations were observed following RC with UD. These findings support increased attention to bone health in these patients.", "journal": "BJU International", "pub_date": "2026-Oct-08", "publication_types": ["Journal Article"], "doi": "10.1111/bju.70472", "authors": ["Mieke Van Hemelrijck", "Lars Holmberg", "Hans Garmo", "Truls Gårdmark", "Henrik Kjölhede", "Tomas Jerlström", "Karin Söderkvist", "Anders Ullén", "Fredrik Liedberg", "Karl Michaëlsson", "Christel Häggström"], "affiliations": ["School of Cancer and Pharmaceutical Sciences, King's College London, London, UK.", "Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.", "Department of Clinical Sciences, Danderyd Hospital, Karolinska Institute, Stockholm, Sweden.", "Department of Urology, Institute of Clinical Sciences, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden.", "Department of Urology, Sahlgrenska University Hospital, Gothenburg, Sweden.", "Department of Urology, School of Medical Sciences, Örebro University, Örebro, Sweden.", "Department of Diagnostics and Intervention, Umeå University, Umeå, Sweden.", "Department of Pelvic Cancer, Genitourinary Oncology and Urology Unit, Karolinska University Hospital, Stockholm, Sweden.", "Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden.", "Department of Translational Medicine, Lund University, Malmö, Sweden.", "Department of Urology, Skåne University Hospital, Malmö, Sweden.", "Medical Epidemiology, Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.", "Register Centre North, Department of Diagnostics and Intervention, Oncology, Umeå University, Umeå, Sweden."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=5", "score": 36.47, "score_parts": {"urology_relevance": 11, "urology_in_title": 8.0, "journal_priority": 10.47, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 5.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.4, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.47, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42845147", "title": "Improved survival in newly diagnosed metastatic prostate cancer: a National Prostate Cancer Audit study.", "abstract": "", "journal": "BJU International", "pub_date": "2026-Oct-08", "publication_types": ["Journal Article"], "doi": "10.1111/bju.70432", "authors": ["Arjun Nathan", "Matthew G Parry", "Emily Mayne", "Adrian Cook", "Justin Liu", "Raghav Varma", "Will Cuningham", "Joanna Dodkins", "Marina Parry", "Julie Nossiter", "Ajay Aggarwal", "Jan van der Meulen", "Alison Tree", "Noel Clarke"], "affiliations": ["Department of Health Services Research & Policy, London School of Hygiene & Tropical Medicine, London, UK.", "National Cancer Audit Collaborating Centre, Clinical Effectiveness Unit, Royal College of Surgeons of England, London, UK.", "Department of Surgery and Interventional Science, University College London, London, UK.", "Guy's Cancer Centre, Guy's and St Thomas' NHS Foundation Trust, London, UK.", "Department of Radiology, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, UK.", "Department of Urology, The Christie NHS Foundation Trust, Manchester, UK.", "Division of Cancer Sciences, The University of Manchester, Manchester, UK."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 19.97, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.47, "top_journal_bonus": 0.0, "novelty": 0.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.4, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.47, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42845020", "title": "Distal ureteral fibroepithelial polyp: endoscopic diagnosis and treatment with thulium fiber laser.", "abstract": "", "journal": "Minerva Urology and Nephrology", "pub_date": "2026-Oct-08", "publication_types": ["Journal Article"], "doi": "10.23736/S2724-6051.26.07155-7", "authors": ["Ghali Belkahia", "Fernando Cabrera Meirás", "Nahuel Paesano", "Gemma Duque Ruiz", "Agustín Fraile Poblador", "Vital Hevia Palacios", "José M Pérez Ruiz", "Clara Briand Barriga", "Marco T Martínez Membreño", "Javier Romero Otero"], "affiliations": ["Department of Urology, Hospital Universitario HM Sanchinarro, Instituto de Investigación Sanitaria HM Hospitales and ROC Clinic, Madrid, Spain - ghalibelkahia@hotmail.com.", "Department of Urology, Hospital Universitario HM Sanchinarro, Instituto de Investigación Sanitaria HM Hospitales and ROC Clinic, Madrid, Spain.", "Department of Pathology, Hospital Universitario HM Sanchinarro, Madrid, Spain."], "corresponding_authors": ["Ghali Belkahia"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 19.42, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.42, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.2, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.42, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42560769", "title": "Deep learning-based histologic classifiers enable molecular subtyping of metastatic prostate cancer.", "abstract": "Metastatic prostate cancer is a clinically and molecularly heterogeneous disease. Under the selective pressure of androgen receptor-directed (AR-directed) therapies, resistant phenotypes frequently emerge, posing significant diagnostic and therapeutic challenges. Neuroendocrine prostate cancer (NEPC) is a clinically important phenotype characterized by lineage plasticity, neuroendocrine features, visceral metastases, and poor prognosis. Accurate diagnosis of NEPC remains difficult owing to its histologic and molecular complexity but has high clinical relevance. In this study, we developed a deep learning model that leverages interpretable cellular features to improve feature extraction from H&E-stained tissue sections (NEURAL-PC). By incorporating a multiple-instance learning framework, NEURAL-PC enables robust NEPC classification solely from H&E tumor images, achieving an area under the receiver operating characteristic curve of 0.921 in independent external validation. In addition to its diagnostic utility, NEURAL-PC provides prognostic information that enables further subclassification of advanced prostate cancer across diverse datasets, supporting its strong prognostic value and generalizability. Broadly, our work highlights a hybrid approach that integrates features across different domains, offering a promising strategy for developing reliable deep learning tools in pathology. Built on this framework, NEURAL-PC represents an extensively validated diagnostic and prognostic model for advanced prostate cancer.", "journal": "JCI Insight", "pub_date": "2026-Oct-08", "publication_types": ["Journal Article"], "doi": "10.1172/jci.insight.201872", "authors": ["Zhijun Chen", "Erolcan Sayar", "Daniela Guevara", "Helen Richards", "Haoyue Zhang", "Radhika A Patel", "Agnes C Gawne", "Lucas J Liu", "Ilsa Coleman", "Ruth Dumpit", "Colm Morrissey", "Michael T Schweizer", "Ruben Raychaudhuri", "Laura S Graham", "Evan Y Yu", "Heather H Cheng", "Chien-Kuang C Ding", "Yuzhuo Wang", "Peter Choyke", "Baris Turkbey", "Chantal Chanel-Vos", "Christina Fedorov", "John R Otilano", "Troy Kane", "Jyothi Manohar", "Michael Sigouros", "Jones T Nauseef", "Ana Molina", "David Nanus", "Scott T Tagawa", "Juan Miguel Mosquera", "Himisha P Beltran", "Ruth Etzioni", "Peter S Nelson", "Rama Soundararajan", "Ana M Aparicio", "Cora N Sternberg", "Michael C Haffner", "Stephanie A Harmon"], "affiliations": ["National Cancer Institute, NIH, Bethesda, Maryland, USA.", "Fred Hutchinson Cancer Center, Seattle, Washington, USA.", "Englander Institute for Precision Medicine and Weill Cornell Medicine, New York, New York, USA.", "University of Washington, Seattle, Washington, USA.", "UCSF, San Francisco, California, USA.", "University of British Columbia, Vancouver, British Columbia, Canada.", "The University of Texas MD Anderson Cancer Center, Houston, Texas, USA."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 29.88, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 14.88, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 1.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 6.1, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 2.88, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "深度学习从病理切片识别神经内分泌前列腺癌", "chinese_summary": "10月JCI Insight发布研究，开发基于可解释细胞特征的深度学习模型NEURAL-PC，仅凭HE肿瘤图像即可分类神经内分泌前列腺癌，外部验证AUC达0.921，并可对晚期前列腺癌进一步亚分类，提供预后信息，提示跨域特征整合有助于病理AI工具开发。", "abstract_zh": "转移性前列腺癌是一种临床和分子高度异质性的疾病。在雄激素受体导向（AR导向）治疗的选择性压力下，耐药表型频繁出现，带来重大的诊断和治疗挑战。神经内分泌前列腺癌（NEPC）是一种临床重要的表型，以谱系可塑性、神经内分泌特征、内脏转移和不良预后为特征。由于其在组织学和分子层面的复杂性，NEPC的准确诊断仍然困难，但具有高度临床相关性。在本研究中，我们开发了一种深度学习模型，利用可解释的细胞特征来改进对HE染色组织切片的特征提取（NEURAL-PC）。通过纳入多示例学习框架，NEURAL-PC能够仅从HE肿瘤图像实现稳健的NEPC分类，在独立外部验证中达到0.921的受试者工作特征曲线下面积。除了诊断用途外，NEURAL-PC还提供预后信息，能够在多个数据集中对晚期前列腺癌进一步亚分类，支持其强大的预后价值和可推广性。更广泛地，我们的工作强调了一种整合不同领域特征的混合方法，为在病理学中开发可靠的深度学习工具提供了有前景的策略。基于这一框架，NEURAL-PC代表了一个经过广泛验证的晚期前列腺癌诊断和预后模型。"}, {"pmid": "42560765", "title": "Interferon regulatory factor 5 in myeloid cells promotes obstructive nephropathy-induced renal fibrosis in vivo.", "abstract": "Obstructive nephropathy is a significant and preventable contributor to chronic kidney disease, yet no disease-modifying antifibrotic agents are currently available. We hypothesized that interferon regulatory factor 5 (IRF5) functions as a macrophage transcriptional regulator that directly transactivates matrix metalloproteinase 9 (MMP9) to initiate early extracellular matrix (ECM) remodeling. Analysis of 30 human obstructive nephropathy biopsy specimens demonstrated that IRF5+CD68+ macrophage density increased progressively with fibrosis severity and correlated significantly with α-smooth muscle actin-positive (α-SMA+) areas. In the murine unilateral ureteral obstruction (UUO) model, both global and myeloid-specific Irf5 deletion significantly attenuated collagen deposition, immune cell infiltration, and fibrotic gene expression compared with WT controls. Cleavage under targets and tagmentation (CUT&Tag) analysis demonstrated that IRF5 directly binds the Mmp9 enhancer region and increases chromatin accessibility. Consequently, myeloid-specific Irf5 KO significantly reduced Mmp9 mRNA and MMP9 protein levels. Pharmacological inhibition using the IRF5 inhibitor N5-1 mitigated established fibrosis, downregulated α-SMA and MMP9 expression, and reduced CD68+ macrophage infiltration. These findings identify the IRF5/MMP9 axis as a therapeutically targetable pathway driving macrophage-mediated ECM expansion and provide preclinical evidence supporting IRF5 inhibition as a potential treatment strategy for patients with obstructive nephropathy.", "journal": "JCI Insight", "pub_date": "2026-Oct-08", "publication_types": ["Journal Article"], "doi": "10.1172/jci.insight.201877", "authors": ["Jia Wei", "Gengyu Du", "Zixia Li", "Min Yang", "Ting Chen", "Zihao Xu", "Zhen Yuan", "Yidan Zheng", "Xiang Yan"], "affiliations": ["Department of Urology and.", "Department of Pathology, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, China.", "Department of Cardiology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.", "Department of cardiovascular surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China."], "corresponding_authors": [], "china_team": "Department of Pathology, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, China Yidan Zheng团队", "category": "basic", "classification_reason": "basic_signals=10", "score": 30.88, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 14.88, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 10.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 6.1, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 2.88, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "浙大团队锁定梗阻性肾病纤维化新靶点", "chinese_summary": "浙江大学医学院附属儿童医院郑一丹团队10月JCI Insight报告，30例人梗阻性肾病活检显示IRF5+CD68+巨噬细胞密度随纤维化加重而升高，与α-SMA阳性面积显著相关；小鼠模型中髓系Irf5缺失减轻胶原沉积，IRF5抑制剂N5-1可缓解已形成的纤维化。", "abstract_zh": "梗阻性肾病是慢性肾脏病的重要且可预防的病因，但目前尚无疾病修饰性抗纤维化药物可用。我们假设干扰素调节因子5（IRF5）作为巨噬细胞转录调节因子，直接反式激活基质金属蛋白酶9（MMP9）以启动早期细胞外基质（ECM）重塑。对30例人梗阻性肾病活检标本的分析表明，IRF5+CD68+巨噬细胞密度随纤维化严重程度逐渐增加，并与α-平滑肌肌动蛋白阳性（α-SMA+）面积显著相关。在小鼠单侧输尿管梗阻（UUO）模型中，与野生型对照相比，全身性和髓系特异性Irf5缺失均显著减轻胶原沉积、免疫细胞浸润和纤维化基因表达。靶向切割及转座酶标记（CUT&Tag）分析表明，IRF5直接结合Mmp9增强子区域并增加染色质可及性。因此，髓系特异性Irf5敲除显著降低Mmp9 mRNA和MMP9蛋白水平。使用IRF5抑制剂N5-1进行药理学抑制可减轻已形成的纤维化，下调α-SMA和MMP9表达，并减少CD68+巨噬细胞浸润。这些发现确定IRF5/MMP9轴是驱动巨噬细胞介导的ECM扩张的可治疗靶向通路，并为IRF5抑制作为梗阻性肾病患者潜在治疗策略提供了临床前证据。"}, {"pmid": "42863146", "title": "Absorption, distribution, metabolism, excretion and metabolic transformation of Flonicamid in rats: Insights from radiotracing, metabolite profiling and multi-scale analysis.", "abstract": "Understanding flonicamid (FLO) disposition is important for interpreting its potential health implications. We investigated FLO metabolism in male Sprague-Dawley rats using 14C-radiotracing, high-resolution mass spectrometry, hepatic transcriptomics, density-functional-theory calculations, molecular docking, and molecular dynamics simulations. FLO was rapidly absorbed, widely distributed, and detected in the brain and testes. Parent FLO predominated in the radiochromatographic profiles, accounting for 70.3% of the total integrated radioactive peak area. TFNA-AM was the predominant metabolite, representing 72.3% of the total metabolite peak area. Its formation was consistent with cyanomethyl oxidative cleavage and computational predictions of molecular reactivity. Within 192 h, urinary recovery accounted for 84.1% of administered radioactivity, indicating predominantly urinary elimination. Integrated transcriptomic and molecular-simulation analyses further prioritized CYP2B2 as a candidate enzyme for subsequent biochemical evaluation of its potential role in the oxidative metabolism of FLO. FLO exposure was also associated with transcriptional changes in several hormone-related pathways in male rat liver. Collectively, these findings complement existing FLO studies by quantifying the recovery of FLO-derived material across excretion routes and the contributions of parent FLO and major metabolites to the recovered components. This information supports the interpretation of FLO disposition and the selection of analyses for subsequent exposure and toxicological studies.", "journal": "Journal of Hazardous Materials", "pub_date": "2026-Oct-07", "publication_types": ["Journal Article"], "doi": "10.1016/j.jhazmat.2026.143853", "authors": ["Xinying Chen", "Yongli Liu", "Chen Meng", "Xialu Wang"], "affiliations": ["School of Life Science and Bio-Pharmaceutics, Shenyang Pharmaceutical University, Shenyang 110016, China.", "Shenyang Sinochem Institute Testing Technology Co., Ltd., Shenyang 110021, China.", "School of Medical Devices, Shenyang Pharmaceutical University, Shenyang 110016, China. Electronic address: wangxialu@syphu.edu.cn."], "corresponding_authors": ["Xialu Wang"], "china_team": "School of Life Science and Bio-Pharmaceutics, Shenyang Pharmaceutical University, Shenyang 110016, China Xialu Wang团队", "category": "basic", "classification_reason": "basic_signals=4", "score": 24.68, "score_parts": {"urology_relevance": 3, "urology_in_title": 0.0, "journal_priority": 15.68, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 4.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 11.3, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.68, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42844854", "title": "Long-Term Clinical Effectiveness of and Adherence to Onabotulinumtoxin A Injections for Neurogenic Detrusor Overactivity.", "abstract": "Retrospective cohort study in consecutive patients. To evaluate the long-term effectiveness of and treatment adherence to intradetrusor onabotulinumtoxin A (BoNT-ONA) injections in patients with neurogenic detrusor overactivity (NDO). Consecutive patients with NDO who had undergone intradetrusor BoNT-ONA treatment at a single tertiary neuro-urology referral center were identified from a registry documenting off-label use of BoNT-ONA prior to formal regulatory approval. Demographic, clinical, and urodynamic data obtained before and after each treatment were collected. In patients performing intermittent catheterization, treatment success was defined by the following urodynamic criteria: bladder capacity ≥ 400 mL, bladder compliance ≥20 mL/cmH2O, and maximum detrusor storage pressure <40 cmH2O. In patients with an indwelling catheter, treatment success was defined as the achievement of urinary continence. In addition, data regarding treatment discontinuation and the underlying reasons were collected. Descriptive statistical analyses were performed to evaluate treatment effectiveness, adherence, and discontinuation patterns. The data of 142 patients (51 females) with a mean age of 35.9 ± 13.1 years and a mean NDO duration of 6.4 ± 8.1 years at the beginning of the BoNT-ONA treatment were analyzed. Over a mean follow-up period of 12.0 ± 6.1 years, evaluated patients received a mean 7.9 ± 5.5 treatments. The BoNT-ONA treatment was continued in 34 (23.9%) patients. In 95 (66.9%) patients, the treatment was discontinued, and 13 (9.2%) patients were lost to follow-up. Five of the 34 patients (14.7%) who continued BoNT-ONA treatment received additional oral medication for NDO. Two (5.9%) and three (8.8%) patients showed reduced bladder compliance and increased detrusor storage pressure, respectively. Ten (34.5%) patients showed increased cystatin C values during the follow-up. The main reason for BoNT-ONA treatment discontinuation was insufficient effectiveness in 56 (58.9%) patients. Most patients who discontinued treatment transitioned to oral medication (45/95, 47.4%) and surgical interventions (25/95, 26.3%). Treatment of NDO with BoNT-ONA injections into the detrusor demonstrated sustained effectiveness in one quarter of the evaluated patients during a follow-up period of more than 12 years. The main reason for BoNT-ONA treatment discontinuation was insufficient effectiveness.", "journal": "Neurourology and Urodynamics", "pub_date": "2026-Oct-07", "publication_types": ["Journal Article"], "doi": "10.1002/nau.70469", "authors": ["Julia Neuenschwander", "Jürgen Pannek", "Jens Wöllner", "Jörg Krebs"], "affiliations": ["Neuro-Urology, Swiss Paraplegic Centre, Nottwil, Switzerland.", "Neuro-Urology, Swiss Paraplegic Research, Nottwil, Switzerland.", "Department of Urology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.", "Medicine and Medical Sciences, Health Sciences and Medicine, University of Lucerne, Lucerne, Switzerland."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=8", "score": 26.56, "score_parts": {"urology_relevance": 11, "urology_in_title": 0.0, "journal_priority": 5.56, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 8.0}, "journal_metrics": {"status": "ok", "impact_factor": 1.9, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.56, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42844831", "title": "Response to Letter to Editor on \"Symptom Relief and Practice Setting Variation in Bulkamid Injections for Stress Urinary Incontinence\".", "abstract": "", "journal": "Neurourology and Urodynamics", "pub_date": "2026-Oct-07", "publication_types": ["Letter"], "doi": "10.1002/nau.70456", "authors": ["Dhillon Advano", "Christina Sze", "Carolina Martinez Fernandez", "Maali LaFrance", "Maude Carmel", "Ramy Goueli", "Gary E Lemack"], "affiliations": ["University of Texas Southwestern Medical School, Dallas, Texas, USA.", "Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas, USA."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 17.56, "score_parts": {"urology_relevance": 7, "urology_in_title": 8.0, "journal_priority": 5.56, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 1.9, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.56, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42844699", "title": "ManUSPECTRAL - the Mannheim Urology HyperSPECTRAL Imaging Atlas of 17 Physiological Human Organs.", "abstract": "To establish a standardised intraoperative hyperspectral imaging (HSI) human organ reference dataset and to characterise spectral signatures across organ classes as a foundation for future computational and clinical applications. Intraoperative assessment of anatomical structures and tissue quality such as perfusion or malignancy remains largely subjective and lacks quantitative, spatially resolved standards. Spectral imaging is a promising technology to address this ambition containing information content far beyond regular red, green, and blue light (RGB) imaging. While HSI is progressively establishing itself in medicine with certified devices, the lack of human organ-specific reference datasets appears to be the key bottleneck for future applications. In this prospective observational study, 1095 hyperspectral recordings spanning a spectral range of 500-1000 nm were acquired during 159 urological procedures. Data were obtained using medically-certified HSI systems and expert-annotations across 17 anatomical organ classes. Median reflectance spectra and derived physiological indices (tissue oxygenation index, near-infrared perfusion index, tissue water index, organ haemoglobin index, tissue haemoglobin index) were analysed, and dimensionality reduction (principal component analysis, t-distributed stochastic neighbour embedding), cosine distance, linear mixed model (LMM) and centred kernel alignment were used to assess spectral differentiability. Human organs demonstrated distinct and consistent spectral fingerprints. Cosine distance showed very low within-organ distances of 0.001-0.003, indicating high consistency of normalised spectra across subjects (i.e., patients) for the same organs. There were several organ pairs with elevated distances, e.g., bone vs multiple soft tissues with values up to ~0.042 indicating clearer spectral dissimilarity between those pairs. A LMM could quantify the spectral effects of the three influencing factors to be 49.51% for organ, 18.17% for subject and 32.32% for residuals (including repetition) as mean values across the recorded spectrum. The Mannheim Urology hyperSPECTRAL imaging atlas dataset (ManUSPECTRAL) (https://spectralverse-heidelberg.org/) provides the first standardised multi-organ hyperspectral reference dataset for human organs. By demonstrating consistent and separable organ-specific signatures, it establishes a quantitative foundation for future computational modelling and clinical validation studies for intraoperative tissue characterisation in surgery.", "journal": "BJU International", "pub_date": "2026-Oct-07", "publication_types": ["Journal Article"], "doi": "10.1111/bju.70467", "authors": ["Alexander Rathenborg", "Vera Klütz", "Paula Grützner", "Luisa Hartung", "Greta Demmel", "Christoph Julien Bender", "Jan Sellner", "Silvia Seidlitz", "Caelan Max Haney-Aubert", "Wahid Fattal", "Tilmann Clanget", "Berkin Özdemir", "Samuel Knoedler", "Gabriel Alexander Salg", "Luisa Renner", "Nicolas Carl", "Cuyler Yu", "Charlene Leung", "Dominic Edelmann", "Nicholas Schreck", "Maurice Stephan Michel", "Lena Maier-Hein", "Karl-Friedrich Kowalewski"], "affiliations": ["Department of Urology and Urosurgery, University Medical Center Mannheim, Medical Faculty of the University of Heidelberg, Mannheim, Germany.", "DKFZ Hector Cancer Institute at the University Medical Center Mannheim, Mannheim, Germany.", "Department of General, Visceral, and Transplantation Surgery, Heidelberg University Hospital, Heidelberg, Germany.", "Division of Intelligent Systems and Robotics in Urology (ISRU), German Cancer Research Center (DKFZ) Heidelberg, Heidelberg, Germany.", "Medical Faculty, Heidelberg University, Heidelberg, Germany.", "Division of Intelligent Medical Systems (IMSY), German Cancer Research Center (DKFZ) Heidelberg, Heidelberg, Germany.", "Department of Plastic Surgery and Hand Surgery, TUM University Hospital Munich, Munich, Germany.", "ORSI Academy, Innotech, Melle, Belgium.", "Department of Mechanical Engineering, Faculty of Engineering, University of Ottawa, Ottawa, Ontario, Canada.", "Faculty of Applied Science, School of Biomedical Engineering, The University of British Columbia, Vancouver, British Columbia, Canada.", "Division of Biostatistics, German Cancer Research Center (DKFZ) Heidelberg, Heidelberg, Germany.", "Faculty of Liberal Arts and Sciences, Technical University of Applied Sciences Augsburg, Augsburg, Germany.", "Faculty of Mathematics and Computer Science, Heidelberg University, Heidelberg, Germany.", "National Center for Tumor Diseases (NCT), NCT Heidelberg, a partnership between DKFZ and University Hospital Heidelberg, Heidelberg, Germany.", "Heidelberg University Hospital, Surgical Clinic, Surgical AI Research Group, Heidelberg, Germany.", "Helmholtz Imaging, German Cancer Research Center (DKFZ), Heidelberg, Germany.", "HIDSS4Health - Helmholtz Information and Data Science School for Health, Karlsruhe/Heidelberg, Germany.", "Mohamed Bin Zayed University of Artificial Intelligence (MBZUAI), Abu Dhabi, United Arab Emirates."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=5", "score": 30.47, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.47, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 5.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.4, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.47, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42844465", "title": "tRNA dosage regulates lineage dependency and resistance in prostate cancer.", "abstract": "Lineage plasticity underlies therapeutic resistance in cancer1,2, yet the translational mechanisms that enable this phenotypic flexibility remain largely unknown. Here using prostate cancer as a model of lineage dependence, we performed unbiased small RNA sequencing and identified tRNA1Arg(UCU) as a regulator of lineage transitions and therapy resistance. tRNA1Arg(UCU) is capable of reprogramming lineage dependence, which can be tuned to restore sensitivity to therapies that target the androgen receptor. We identify TARDBP and ZSCAN29 as DNA-binding proteins that directly engage the genomic locus of tRNA1Arg(UCU) to regulate its expression, a result that highlights the importance of non-canonical tRNA-specific gene regulation. Mechanistically, tRNA1Arg(UCU) controls a translational program centred on SWI/SNF chromatin remodellers, which is necessary to maintain lineage fidelity. In patients, tRNA1Arg(UCU) is downregulated in neuroendocrine prostate cancer and its loss is associated with accelerated metastasis and poor survival. These findings uncover a previously unrecognized tRNA-specific regulatory axis that links codon biology to lineage dependence and therapy resistance in prostate cancer.", "journal": "Nature", "pub_date": "2026-Oct-07", "publication_types": ["Journal Article"], "doi": "10.1016/j.ccell.2023.03.021", "authors": ["Yeon Soo Kim", "Sonali Arora", "Dave Young", "Ava Tsou", "Amy Shiuan", "Cynthia L Wladyka", "Dmytro Rudoy", "Jin Yeong Kim", "Jennifer A Waters", "Samantha L Schuster", "Ilsa M Coleman", "Mridu Kapur", "Marek Sobczyk", "Christopher D Katanski", "Amin M Bayat Tork", "Wen Zhang", "Peter S Nelson", "Gavin Ha", "Michael C Haffner", "Eva Corey", "Colm Morrissey", "Yuzhuo Wang", "Arvind R Subramaniam", "John K Lee", "Susan L Ackerman", "Tao Pan", "Andrew C Hsieh"], "affiliations": ["Human Biology Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.", "Computational Biology Section of the Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.", "Department of Cellular and Molecular Medicine, School of Medicine, University of California, San Diego, La Jolla, CA, USA.", "The Howard Hughes Medical Institute, La Jolla, CA, USA.", "Department of Biochemistry and Molecular Biology, University of Chicago, Chicago, IL, USA.", "MesoRNA, Chicago, IL, USA.", "Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.", "Department of Medicine, University of Washington, Seattle, WA, USA.", "Department of Genome Sciences, University of Washington, Seattle, WA, USA.", "Department of Pathology and Laboratory Medicine, University of Washington, Seattle, WA, USA.", "Department of Urology, University of Washington, Seattle, WA, USA.", "Prostate Centre at Vancouver General Hospital and University of British Columbia, Vancouver, British Columbia, Canada.", "BC Cancer Research Institute, Vancouver, British Columbia, Canada.", "Basic Science Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.", "Division of Hematology/Oncology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.", "Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.", "Department of Neurobiology, University of California, San Diego, La Jolla, CA, USA.", "Department of Biochemistry and Molecular Biology, University of Chicago, Chicago, IL, USA. taopan@uchicago.edu.", "Human Biology Division, Fred Hutchinson Cancer Center, Seattle, WA, USA. ahsieh@fredhutch.org.", "Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA. ahsieh@fredhutch.org.", "Department of Medicine, University of Washington, Seattle, WA, USA. ahsieh@fredhutch.org.", "Department of Genome Sciences, University of Washington, Seattle, WA, USA. ahsieh@fredhutch.org."], "corresponding_authors": ["Tao Pan", "Andrew C Hsieh"], "china_team": "", "category": "basic", "classification_reason": "basic_signals=6", "score": 55.72, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 17.72, "top_journal_bonus": 18.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 6.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 48.5, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 5.72, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "tRNA剂量决定前列腺癌谱系依赖与耐药", "chinese_summary": "10月Nature发表研究，以前列腺癌为谱系依赖模型，通过无偏小RNA测序发现tRNA1Arg(UCU)可重编程谱系依赖并恢复抗雄激素治疗敏感性。TARDBP与ZSCAN29直接结合其基因组位点调控表达，该tRNA通过SWI/SNF染色质重塑因子维持谱系保真；患者神经内分泌前列腺癌中其表达下调，缺失与转移加速和生存不良相关。", "abstract_zh": "谱系可塑性是癌症治疗耐药的基础，然而使这种表型灵活性成为可能的翻译机制在很大程度上仍不清楚。在此，我们以前列腺癌作为谱系依赖的模型，进行了无偏小RNA测序，并鉴定出tRNA1Arg(UCU)是谱系转换和治疗耐药的调控因子。tRNA1Arg(UCU)能够重编程谱系依赖，并且可以通过调节它来恢复对靶向雄激素受体的治疗的敏感性。我们鉴定出TARDBP和ZSCAN29是直接结合tRNA1Arg(UCU)基因组位点以调控其表达的DNA结合蛋白，这一结果凸显了非经典tRNA特异性基因调控的重要性。在机制上，tRNA1Arg(UCU)控制一个以SWI/SNF染色质重塑因子为中心的翻译程序，该程序是维持谱系保真所必需的。在患者中，tRNA1Arg(UCU)在神经内分泌前列腺癌中下调，其缺失与转移加速和生存不良相关。这些发现揭示了一个此前未被认识的tRNA特异性调控轴，将密码子生物学与前列腺癌的谱系依赖和治疗耐药联系起来。"}, {"pmid": "42844397", "title": "Critical appraisal of artificial intelligence studies for prostate cancer detection on MRI.", "abstract": "The application of artificial intelligence (AI) to prostate MRI for clinically significant prostate cancer (csPCa) detection is an active area of medical imaging research. Yet, methodological deficiencies can undermine the reliability and clinical translatability of many published studies. This perspective provides a structured critical appraisal of AI studies in prostate MRI, organised around six evaluation domains: (i) limits of predictability, (ii) reference standard quality, (iii) cohort design and population selection (including spectrum and pathway biases), (iv) benchmark and comparator validity, (v) clinical deployment, and (vi) AI terminology. We illustrate each domain using recently published studies as representative examples, and we ground our perspective in the formal requirements recently established by the PI-RADS Steering Committee for AI development and reporting in biopsy-naive men. Our analysis suggests that apparent near-perfect performance can arise from identifiable and preventable study design choices rather than from technical advancements. Methodological shortcomings may be mistaken for genuine advances; ensuring that the evidence base meets these standards is a prerequisite for population-general utility. KEY POINTS: Question Can the reported near-perfect AI performance for prostate cancer detection on MRI be attributed to study design choices instead of technical advances? Findings Apparent near-perfect diagnostic accuracy can arise from identifiable study design choices, including spectrum bias, pathway bias, imperfect reference standards, and confounded comparisons. Clinical relevance Adopting structured appraisal criteria aligned with PI-RADS Committee requirements helps clinicians distinguish methodologically sound AI tools from those whose reported performance may not generalise to routine clinical populations.", "journal": "European Radiology", "pub_date": "2026-Oct-07", "publication_types": ["Journal Article"], "doi": "10.1162/089976602753284446", "authors": ["Eduardo Pooch", "Georgios Agrotis", "Ivo G Schoots", "Mark Emberton", "Veeru Kasivisvanathan", "Yipeng Hu"], "affiliations": ["Department of Radiology, Netherlands Cancer Institute, Amsterdam, The Netherlands. e.pais.pooch@nki.nl.", "Department of Medical Physics and Biomedical Engineering, University College London, London, UK. e.pais.pooch@nki.nl.", "GROW Research Institute for Oncology and Reproduction, Maastricht University, Maastricht, The Netherlands. e.pais.pooch@nki.nl.", "Department of Radiology, Netherlands Cancer Institute, Amsterdam, The Netherlands.", "Department of Radiology & Nuclear Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.", "Division of Surgery and Interventional Science, University College London, London, UK.", "Department of Urology, University College London Hospitals NHS Foundation Trust, London, UK.", "Department of Medical Physics and Biomedical Engineering, University College London, London, UK."], "corresponding_authors": ["Eduardo Pooch"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=4", "score": 29.55, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.55, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 4.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.7, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.55, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42844266", "title": "Retraction Note: Development of a stemness-related prognostic index to provide therapeutic strategies for bladder cancer.", "abstract": "", "journal": "NPJ Precision Oncology", "pub_date": "2026-Oct-07", "publication_types": ["Journal Article", "Retraction Notice"], "doi": "10.1038/s41698-026-01712-7", "authors": ["Shi Fu", "Zhiyong Tan", "Hongjin Shi", "Junhao Chen", "Yawei Zhang", "Chunming Guo", "Wei Feng", "Haole Xu", "Jiansong Wang", "Haifeng Wang"], "affiliations": ["Department of Urology, The Second Affiliated Hospital of Kunming Medical University, Kunming, China.", "Yunnan Clinical Medical Center of Urological Disease, Kunming, China.", "Kunming Medical University, Kunming, China.", "School for Life Science, Yunnan University, Kunming, China.", "Department of Urology, The Second Affiliated Hospital of Kunming Medical University, Kunming, China. wangjiansong@kmmu.edu.cn.", "Yunnan Clinical Medical Center of Urological Disease, Kunming, China. wangjiansong@kmmu.edu.cn.", "Department of Urology, The Second Affiliated Hospital of Kunming Medical University, Kunming, China. wanghaifeng@kmmu.edu.cn.", "Yunnan Clinical Medical Center of Urological Disease, Kunming, China. wanghaifeng@kmmu.edu.cn."], "corresponding_authors": ["Jiansong Wang", "Haifeng Wang"], "china_team": "Department of Urology, The Second Affiliated Hospital of Kunming Medical University, Kunming, China Jiansong Wang/Haifeng Wang团队", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 24.22, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 15.22, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 8.0, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.22, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42844113", "title": "Re: Enfortumab Vedotin and Pembrolizumab in Cisplatin-eligible Bladder Cancer.", "abstract": "", "journal": "European Urology", "pub_date": "2026-Oct-07", "publication_types": ["Journal Article"], "doi": "10.1016/j.eururo.2026.09.014", "authors": ["Veronica Mollica", "Matteo Rosellini", "Matteo Santoni", "Francesco Massari"], "affiliations": ["Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.", "Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.", "Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; Oncology Unit, Macerata Hospital, Macerata, Italy.", "Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy. Electronic address: francesco.massari@aosp.bo.it."], "corresponding_authors": ["Francesco Massari"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 35.79, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 16.79, "top_journal_bonus": 10.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 25.2, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.79, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "EV联合帕博利珠单抗用于顺铂可耐受膀胱癌", "chinese_summary": "10月Eur Urol刊发通讯，围绕enfortumab vedotin联合帕博利珠单抗在顺铂可耐受膀胱癌中的证据展开讨论，关注该联合方案能否取代传统顺铂为基础化疗，为一线治疗决策提供参考。", "abstract_zh": "这是关于enfortumab vedotin与帕博利珠单抗联合用于顺铂可耐受膀胱癌的通讯。"}, {"pmid": "42843985", "title": "Aquablation as salvage therapy for benign prostatic hyperplasia: an international multicentre study.", "abstract": "Our objective was to evaluate the safety and effectiveness of Aquablation® as a salvage therapy in patients who underwent prior intervention for benign prostatic hyperplasia (BPH). We retrospectively analysed 1887 consecutive men from the International Collaborative Aquablation Research Urology Society database between 2018 and 2024 who underwent Aquablation at one of four international centres. The cohort was divided into two groups based on the presence or absence of previous BPH intervention. Baseline characteristics, clinical and functional outcomes, and complication rates were compared between the two groups using analysis of variance and Kruskal-Wallis tests. Finally, exploratory sub-analyses were performed in the salvage therapy group based on the type of prior BPH intervention. Among the study population of 1887 men, 109 (5.8%) patients had undergone prior BPH intervention, and the remaining 1778 (94.2%) patients served as a control cohort. Prostate volumes were similar between both groups (82.3 vs 78.0 mL; P = 0.18). There were no significant differences in perioperative complications, 30-day readmission rates, surgical retreatment rates, or sexual function outcome scores (all P > 0.05). There were also similar improvements in maximum urinary flow rates, post-void residuals, International Prostate Symptom Scores, and quality of life scores (all P > 0.05). When comparing outcomes based on the type of prior BPH intervention, there were no differences in terms of operative time, prostate volumes, presence of median lobe, or complication rates. We observed no statistically significant differences in safety or effectiveness for Aquablation as a salvage therapy for recurrent lower urinary tract symptoms after BPH intervention. Aquablation should be offered to men for whom prior procedures have failed and who want to preserve continence and sexual function.", "journal": "BJU International", "pub_date": "2026-Oct-07", "publication_types": ["Journal Article"], "doi": "10.1111/bju.70481", "authors": ["Anouk Leathead", "Nick Lee", "Adel Arezki", "David Bouhadana", "Liam Murad", "Tarek Benzouak", "Iman Sadri", "Rosie Foucault", "Aalya Hamouda", "Jeffrey Sioufi", "Ilan Ohana", "Joshua Cabral", "Margaret Gannon", "Gregory Raster", "David Nusbaum", "Abdulla Alameeri", "John Klein", "Inderjit Singh", "James Kearns", "Shawn Marhamati", "Alexander Glaser", "Brian Helfand", "Dean Elterman", "Tiago Rodrigues", "Kevin C Zorn"], "affiliations": ["Faculty of Medicine, University of Montreal, Montreal, QC, Canada.", "Division of Urology, University of Montreal, Montreal, QC, Canada.", "Division of Urology, McGill University, Montreal, QC, Canada.", "Faculty of Medicine, McGill University, Montreal, QC, Canada.", "Faculty of Medicine, University of Sherbrooke, Sherbrooke, QC, Canada.", "Division of Urology, University of Vermont Medical Center, Burlington, VT, USA.", "Faculty of Medicine, University of Laval, Quebec City, QC, Canada.", "Division of Urology, University of Chicago, Chicago, IL, USA.", "Division of Urology, Potomac Urology Center, National Harbor, MD, USA.", "Division of Urology, NorthShore University Health System, Evanston, IL, USA.", "Division of Urology, University Health Network, Toronto, ON, Canada.", "Urology Clinic, Hospital Cruz Vermelha, Lisbon, Portugal.", "Division of Urology, BPH Canada Prostate Surgical Institute, Montreal, QC, Canada."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=7", "score": 42.47, "score_parts": {"urology_relevance": 15, "urology_in_title": 8.0, "journal_priority": 10.47, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 7.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.4, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.47, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42843390", "title": "Regional expansion and adaptive evolution of multidrug-resistant Candida tropicalis in China: a retrospective, multicentre, genomic study.", "abstract": "The emergence of antifungal-resistant Candida tropicalis poses a severe threat to human health and complicates clinical management, yet the molecular epidemiology and mechanisms underlying its resistance and persistence in hospital settings remain poorly understood. We aimed to investigate the regional epidemiology, persistence and virulence trade-offs, and adaptive traits associated with the expansion of multidrug-resistant C tropicalis. We conducted a retrospective, multicentre, genomic study of C tropicalis isolates from 84 hospitals in east China and included additional multidrug-resistant (resistant to azoles and echinocandins) isolates from active surveillance at Shanghai East Hospital. We analysed clinical metadata from this hospital to identify risk factors for multidrug-resistant isolate recovery and 30-day mortality. We conducted whole-genome sequencing, RNA sequencing, phenotypic assays, and experimental evolution to elucidate resistance mechanisms, virulence dynamics, and adaptive traits. 1184 clinical isolates from Jan 1, 2017, to Dec 31, 2024, were included; of these, 356 (30·1%) were azole resistant and 98 (8·3%) were multidrug resistant. We identified the regional expansion of a multidrug-resistant C tropicalis lineage, DST849, which accounted for 92 (94%) of 98 multidrug-resistant cases and was predominantly isolated from the urinary tract. Admission to a surgical ward (adjusted odds ratio [aOR] 46·37, 95% CI 17·48-123·00) and intubation (32·30, 10·28-101·45) were key risk factors for multidrug-resistant isolate recovery. Multivariable logistic regression revealed that multidrug-resistant C tropicalis isolation was an independent predictor of 30-day mortality (aOR 2·84, 95% CI 1·31-6·16; p=0·0081). Phylogenomic analysis revealed that multidrug-resistant isolates evolved from azole-resistant ancestors (DST225) via the acquisition of FKS1 mutations (S30P) while retaining ERG11 mutations (Y132F and S154F) and acquired a distinguishing ICL1 (Y43T) loss-of-heterozygosity mutation. Our findings reveal the emergence of multidrug-resistant Ctropicalis through lineage-specific expansion, driven by genetic plasticity and adaptive stress responses. These adaptations might facilitate persistence under antifungal and environmental pressures in health-care settings. These insights underscore the urgent need for improved antifungal stewardship, targeted genomic surveillance, and interventions to mitigate multidrug-resistant fungal threats. National Natural Science Foundation of China, Chinese Ministry of Science and Technology.", "journal": "Lancet Microbe", "pub_date": "2026-Oct-07", "publication_types": ["Journal Article"], "doi": "10.1016/j.lanmic.2026.101509", "authors": ["Chendi Zhu", "Min Zhang", "Feifei Wan", "Ziwen Wang", "Shasha Wang", "Zhihua Kang", "Clement Kin-Ming Tsui", "Jian Guo", "Ning-Ning Liu", "Wenjuan Wu"], "affiliations": ["Department of Laboratory Medicine, Shanghai East Hospital, Key Laboratory of Pathogen-Host Interaction (Tongji University), Ministry of Education, Shanghai, China; Jockey Club School of Public Health and Primary Care, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China.", "Department of Laboratory Medicine, Shanghai East Hospital, Key Laboratory of Pathogen-Host Interaction (Tongji University), Ministry of Education, Shanghai, China; Department of Clinical Laboratory, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.", "Department of Laboratory Medicine, Shanghai East Hospital, Key Laboratory of Pathogen-Host Interaction (Tongji University), Ministry of Education, Shanghai, China; Department of Laboratory Medicine, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.", "Department of Laboratory Medicine, Shanghai East Hospital, Key Laboratory of Pathogen-Host Interaction (Tongji University), Ministry of Education, Shanghai, China.", "Infectious Disease Research Laboratory, National Center for Infectious Diseases, Singapore; Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.", "State Key Laboratory of Systems Medicine for Cancer, Center for Single-Cell Omics, School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, China.", "Department of Laboratory Medicine, Shanghai East Hospital, Key Laboratory of Pathogen-Host Interaction (Tongji University), Ministry of Education, Shanghai, China. Electronic address: wwj1210@126.com."], "corresponding_authors": ["Wenjuan Wu"], "china_team": "Department of Laboratory Medicine, Shanghai East Hospital, Key Laboratory of Pathogen-Host Interaction (Tongji University), Ministry of Education, Shanghai, China; Jockey Club School of Public Health and Primary Care, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China Wenjuan Wu团队", "category": "basic", "classification_reason": "basic_signals=4", "score": 35.49, "score_parts": {"urology_relevance": 3, "urology_in_title": 0.0, "journal_priority": 16.49, "top_journal_bonus": 10.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 4.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 20.4, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.49, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "多重耐药热带念珠菌在华扩散", "chinese_summary": "上海东方医院吴文娟团队与香港中文大学10月Lancet Microbe发表回顾性多中心基因组研究，纳入华东84家医院2017至2024年1184株热带念珠菌，发现多重耐药谱系DST849占多重耐药病例的94%，多分离自泌尿道；外科病房入院及插管是独立风险因素，多重耐药分离提示30天死亡风险增加。", "abstract_zh": "抗真菌耐药热带念珠菌的出现对人类健康构成严重威胁，并使临床管理复杂化，然而其在医院环境中的分子流行病学及耐药和持续存在的机制仍知之甚少。我们旨在研究多重耐药热带念珠菌扩张相关的区域流行病学、持续性与毒力权衡以及适应性特征。我们开展了一项回顾性、多中心基因组研究，纳入来自中国华东地区84家医院的热带念珠菌分离株，并纳入来自上海东方医院主动监测的额外多重耐药（对唑类和棘白菌素类耐药）分离株。我们分析了该医院的临床元数据，以确定多重耐药分离株检出的风险因素和30天死亡率。我们进行了全基因组测序、RNA测序、表型试验和实验进化，以阐明耐药机制、毒力动态和适应性特征。纳入2017年1月1日至2024年12月31日期间的1184株临床分离株；其中356株（30.1%）对唑类耐药，98株（8.3%）为多重耐药。我们发现多重耐药热带念珠菌谱系DST849的区域扩张，该谱系占98例多重耐药病例中的92例（94%），主要从泌尿道分离。入住外科病房（调整比值比[aOR] 46.37，95% CI 17.48–123.00）和插管（32.30，10.28–101.45）是多重耐药分离株检出的关键风险因素。多变量logistic回归显示，多重耐药热带念珠菌分离是30天死亡率的独立预测因子（aOR 2.84，95% CI 1.31–6.16；p=0.0081）。系统发育基因组学分析显示，多重耐药分离株从唑类耐药祖先（DST225）进化而来，通过获得FKS1突变（S30P）同时保留ERG11突变（Y132F和S154F），并获得一个特征性的ICL1（Y43T）杂合性丢失突变。我们的发现揭示了多重耐药热带念珠菌通过谱系特异性扩张出现，由遗传可塑性和适应性应激反应驱动。这些适应可能促进其在医疗保健环境中抗真菌和环境压力下的持续存在。这些见解强调迫切需要改进抗真菌药物管理、靶向基因组监测以及减轻多重耐药真菌威胁的干预措施。国家自然科学基金委员会、中国科学技术部。"}, {"pmid": "42842012", "title": "Extraction-string ureteral stents and postoperative infection after flexible ureteroscopy: an IPTW-adjusted analysis.", "abstract": "Extraction-string ureteral stents facilitate non-cystoscopic removal after ureteroscopy, but concerns remain regarding postoperative infection and accidental dislodgement. We evaluated whether extraction-string stents were associated with postoperative infection after flexible ureteroscopic lithotripsy (fURSL) in a cohort restricted to procedures with the distal Double-J (D-J) stent portion positioned within the bladder. This retrospective observational study included 102 procedures in 92 unique patients: 58 extraction-string and 44 conventional non-string procedures. Postoperative infection was defined as fever > 38 °C or a positive postoperative urine culture during the stent-indwelling period. Propensity scores incorporated age, sex, positive preoperative urine culture, preoperative pyuria, and procedure laterality. Stabilized inverse probability of treatment weights were truncated at the 1st and 99th percentiles; effective sample size was 85.38. Crude postoperative infection occurred in 8/58 (13.8%) extraction-string and 6/44 (13.6%) non-string procedures. After weighting, estimated infection rates were 13.6% and 8.8%, respectively (OR 1.64, 95% CI 0.50-5.44; P = 0.416). Fever, positive postoperative urine culture, postoperative pyuria, and postoperative day 1 pain did not differ significantly. Sensitivity analyses accounting for repeated procedures and propensity-model specification were consistent with the primary analysis. Extraction-string stent use was not significantly associated with postoperative infection after fURSL; however, the limited number of events and wide confidence intervals preclude exclusion of a clinically meaningful difference.", "journal": "Urolithiasis", "pub_date": "2026-Oct-07", "publication_types": ["Journal Article", "Observational Study"], "doi": "10.1016/j.juro.2014.12.087", "authors": ["Jui-Ying Lin", "Chun-Te Wu", "Kuan-Lin Liu", "Cheng-Feng Lin", "Hong-Yi Chen", "Cheng-Chia Lin"], "affiliations": ["Department of Urology, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan.", "Department of Urology, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan. a97026@cgmh.org.tw."], "corresponding_authors": ["Cheng-Chia Lin"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_clinical", "score": 30.71, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 5.71, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 7.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.2, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.71, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42841992", "title": "Reference intervals of urinary clearance and excretion of uric acid (RICE-U) in Japan.", "abstract": "To establish reference intervals for indices of renal uric acid excretion efficiency and amount using 24-h, 60-min, and spot urine measurements, and to assess relationships among these methods in healthy Japanese adults. This multicenter prospective observational study included 445 reference individuals (214 men and 231 women; age, 20-65 years) recruited from 26 National Hospital Organization institutions. Reference intervals were estimated separately by sex using the non-parametric central 95% range (2.5th-97.5th percentiles). Associations between spot urine-derived and timed-urine indices were assessed using Spearman rank correlations. Reference intervals for 24-h Cua were 3.1-11.5 mL/min in men and 4.4-14.6 mL/min in women, and those for 60-min Cua were 4.7-15.4 and 5.1-17.9 mL/min, respectively. BSA-standardized Eua reference intervals were 280-827 mg/day/1.73 m² in men and 263-812 mg/day/1.73 m² in women for 24-h collection, and 16.4-42.9 and 12.4-36.3 mg/h/1.73 m², respectively, for 60-min collection. Spot urine reference intervals were 3.0-9.7% in men and 3.2-12.4% in women for FEua, 0.19-0.50 and 0.14-0.43 mg/dL for EuGF, 3.6-12.3 and 4.0-16.1 mL/min/1.73 m² for eCua, and 336-937 and 254-806 mg/day/1.73 m² for eEua. Spot eCua correlated with 24-h Cua (ρ=0.627), spot FEua with 24-h FEua (ρ=0.736), and eEua with 24-h Eua (ρ=0.430); all P<0.001. This study provides comprehensive reference intervals for renal uric acid handling under standardized preanalytical conditions in healthy Japanese adults. Spot urine-derived indices showed significant associations with timed-urine measurements, particularly for clearance-related indices, and may provide practical complementary measures when timed urine collection is difficult.", "journal": "European Journal of Nutrition", "pub_date": "2026-Oct-07", "publication_types": ["Journal Article", "Multicenter Study", "Observational Study"], "doi": "10.1007/s00394-026-04110-8", "authors": ["Kazuhiro Itoh", "Hiroshi Tsutani", "Nozomi Otsuki", "Yasuhiko Mitsuke", "Takanori Ueda", "Shigemi Hosogaya", "Toshiko Seki", "Ayumi Shintani", "Masao Tomita", "Mitsuru Munemasa", "Atsumasa Komori", "Shinya Otsuka", "Tatsuji Komatsu", "Ryuichiro Anan", "Morio Sawamura", "Takuyuki Ise", "Kiyoki Kitagawa", "Kazuya Yonezawa", "Itaru Funakawa", "Masato Hasegawa", "Shinichi Shimosaka", "Hidenori Ibata", "Masatoshi Shimizu", "Yasushi Tanimoto", "Masahiro Suzuki", "Hiroaki Ito", "Kazuya Shirasaki", "Yoshiaki Oda", "Tomomasa Tsuboi", "Tsutomu Shinohara", "Michihisa Jogasaki", "Nozomu Kamei", "Shusaku Maeda", "Keita Uehara", "Kazuki Honda", "Hitoshi Inoue"], "affiliations": ["Department of Internal Medicine, NHO Awara National Hospital, Awara, Japan. kitoh@u-fukui.ac.jp.", "Faculty of Medical Sciences, Department of Community Health Science, University of Fukui, 23-3 Matsuokashimoaizuki, Eiheiji-cho, Yoshida-gun, Fukui, 910-1193, Japan. kitoh@u-fukui.ac.jp.", "Department of Internal Medicine, NHO Awara National Hospital, Awara, Japan.", "University of Fukui, Fukui, Japan.", "Department of Medical Technology, School of Health Sciences, Tokyo University of Technology, Tokyo, Japan.", "Department of Medical Statistics, Osaka City University Graduate School of Medicine, Osaka, Japan.", "Department of Nephrology, NHO Kumamoto Medical Center, Kumamoto, Japan.", "Department of Cardiology, NHO Okayama Medical Center, Okayama, Japan.", "Clinical Research Center, NHO Nagasaki Medical Center, Omura, Japan.", "Department of Surgery, NHO Fukuyama Medical Center, Fukuyama, Japan.", "Department of Clinical Research, NHO Yokohama Medical Center, Yokohama, Japan.", "Department of Cardiology, NHO Miyakonojo Medical Center, Miyakonojo, Japan.", "Department of Hematology, NHO Shibukawa Medical Center, Shibukawa, Japan.", "Division of Nephrology and Rheumatology, NHO Kanazawa Medical Center, Kanazawa, Japan.", "Department of Cardiovascular Medicine, NHO Hakodate National Hospital, Hakodate, Japan.", "Department of Neurology, NHO Hyogo-Chuo National Hospital, Sanda, Japan.", "Department of Surgery, NHO Higashi-Ohmi General Medical Center, Higashi-Ohmi, Japan.", "Department of Neurosurgery, NHO Mie Chuo Medical Center, Tsu, Japan.", "Department of Pulmonary Medicine, NHO Mie Chuo Medical Center, Tsu, Japan.", "Division of Cardiology, NHO Kobe Medical Center, Kobe, Japan.", "Department of Allergy and Respiratory Medicine, NHO Minami-Okayama Medical Center, Tsukubo-gun, Japan.", "Department of Cardiology, NHO Saitama Hospital, Wako, Japan.", "Department of Neurology, NHO Miyagi National Hospital, Watari-gun, Japan.", "Department of Pediatrics, NHO Akita National Hospital, Yurihonjo, Japan.", "Department of Endocrinology and Diabetes, NHO Higashihiroshima Medical Center, Higashihiroshima, Japan.", "Respiratory Care Center for Respiratory and Neuromuscular Diseases, NHO Minami Kyoto Hospital, Joyo, Japan.", "Department of Clinical Investigation, NHO Kochi National Hospital, Kochi, Japan.", "Institute for Clinical Research, NHO Kagoshima Medical Center, Kagoshima, Japan.", "Hiroshima Red Cross Hospital & Atomic Bomb Survivors Hospital, Hiroshima, Japan.", "Department of Endocrinology and Diabetes, NHO Kure Medical Center, Chugoku Cancer Center, Kure, Japan.", "Department of Gastroenterology, NHO Tochigi Medical Center, Utsunomiya, Japan.", "Department of Psychiatry, NHO Kikuchi National Hospital, Koshi, Japan.", "Department of Internal Medicine, NHO Tsuruga Medical Center, Tsuruga, Japan."], "corresponding_authors": ["Kazuhiro Itoh"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_clinical", "score": 27.45, "score_parts": {"urology_relevance": 3, "urology_in_title": 8.0, "journal_priority": 10.45, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 4.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.3, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.45, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42841981", "title": "Slippery when wet: The effect of a novel zwitterionic coating on silicone ureteral stents.", "abstract": "Silicone ureteral stents provide anti-encrustation properties and patient comfort but are more difficult to insert and remove due to increased surface friction. Applying zwitterionic coatings to silicone stents may reduce friction and facilitate stent placement and removal. This study compared the frictional forces of zwitterionic-coated silicone stents with commercial stents using benchtop models. The static and kinetic frictional forces of five ureteral stents were measured: bare silicone stent without coating (BS), single outer-coated zwitterionic silicone stent (Z1), double-coated (inner and outer) zwitterionic silicone stent (Z2), Black Silicone Filiform stent (\"Black Beauty\") (BB), and Universa Soft stent (US). Friction was assessed with a submerged guidewire model to isolate stent-guidewire friction and a porcine ureteral model to simulate intraoperative stent insertion and removal. Five trials per stent were performed using a force gauge integrated with an Arduino-controlled motor system. Statistical significance was assessed using linear mixed-effects models with stent type and trial as fixed effects and ureter specimen as a random intercept. Pairwise comparisons were adjusted using the Holm method. In the submerged guidewire model, Z2 had 99%, 47%, and 40% lower kinetic friction than BS, BB, and US, respectively. During stent insertion, Z2 had 71%, 43%, and 44% lower kinetic friction than BS, BB, and US, respectively. During stent removal, Z2 had 92%, 58%, and 60% lower kinetic friction than BS, BB, and US, respectively. Linear mixed-effects models demonstrated a significant effect of stent type for all six friction conditions (all p < 0.001). The double-coated (inner and outer) zwitterionic silicone stent (Z2) demonstrated the lowest frictional forces across all testing conditions. Zwitterionic surface modification may therefore reduce friction during silicone stent placement and removal.", "journal": "Urolithiasis", "pub_date": "2026-Oct-07", "publication_types": ["Journal Article"], "doi": "10.1021/acsomega.3c01800", "authors": ["Ye Jean Lim", "Ye Na Diana Lim", "Connor A Church", "Elijah Haynal", "Elizabeth A Baldwin", "D Duane Baldwin"], "affiliations": ["Department of Urology, Loma Linda University Health, 11234 Anderson Street, Loma Linda, CA, 92354, USA.", "Department of Urology, Loma Linda University Health, 11234 Anderson Street, Loma Linda, CA, 92354, USA. dbaldwin@llu.edu."], "corresponding_authors": ["D Duane Baldwin"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 20.71, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 5.71, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.2, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.71, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42841410", "title": "Sex-Specific Digital Phenotyping of Lower Urinary Tract Symptoms: A Cross-Sectional Study of 1586 Adults From 35 Centers in China.", "abstract": "Lower urinary tract symptoms (LUTS) represent a complex clinical syndrome with significant sexual dimorphism. Traditional \"one-size-fits-all\" management often overlooks intra-sex phenotypic heterogeneity. This study utilized unsupervised machine learning to identify sex-specific digital phenotypes of LUTS within a large-scale clinical cohort to provide a foundation for precision urological care. We analyzed a multicenter database of 1586 treatment-seeking adults (1098 females, 488 males) across 35 centers. Baseline clinical characteristics and LUTS parameters from standardized voiding diaries and validated scales were collected. K-means clustering was performed separately by sex to identify phenotypic subtypes, with the optimal number of clusters determined by the Elbow Method and visualized via Principal Component Analysis (PCA). Significant sex-specific disparities were observed: women reported a higher symptomatic burden across almost all domains but maintained better voiding satisfaction (p < 0.001), while men exhibited poorer sleep quality (p < 0.001). Clustering identified a consistent three-subtype framework for both genders: Subtype 1 (Mild/Compensated): Characterized by the lowest symptom burden and highest tolerance. Subtype 2 (Storage-Dominant with Sleep Fragmentation): Found in older populations, defined by severe nocturia, reduced bladder capacity, and profound sleep disruption. Subtype 3 (Voiding-Dominant): Characterized by prominent dysuria and incomplete emptying. This exploratory sex-stratified clustering study identified symptom-based phenotypic patterns among treatment-seeking Chinese adults with LUTS. These findings support the potential value of a subtype-plus-sex framework for LUTS assessment, but prospective validation using objective functional measures and treatment outcomes is needed.", "journal": "Neurourology and Urodynamics", "pub_date": "2026-Oct-07", "publication_types": ["Journal Article"], "doi": "10.1002/nau.70466", "authors": ["Peixian Chen", "Baojun Wang", "Xiangjun Lyu", "Caixia Zhang", "Qingqing He", "Qingwei Wang", "Yanlan Yu", "Lijuan Ren", "Xiande Huang", "Juan Chen", "Jiao Liu", "Haihong Jiang", "Fei Liu", "Jianjun Zhang", "Yuting Wu", "Wei Wen", "Juan Li", "Guanghui Du", "Xiaofen Wu", "Jianwei Lv", "Huasheng Zhao", "Xijun Weng", "Xiaoxin Meng", "Qi Chen", "Dongxiang Zheng", "Yan Li", "Li Wen", "Weifang Chen", "Peng Zhang", "Ning Xiao", "Xi Xie", "Suibin Huang", "Youhui Yang", "Yipeng Liu", "Shuxin Qu", "Long Cheng", "Xin Zhang", "Dachuang Liu", "Yi Zhang", "Hao Huang", "Fan Fan", "Hai Huang"], "affiliations": ["Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.", "Department of Urology, The First Medical Center of PLA General Hospital, Beijing, China.", "Department of Urology, The Third Medical Center of PLA General Hospital, Beijing, China.", "Department of Urology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.", "Department of Urology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.", "Department of Urology, The First Hospital of Shanxi Medical University, Taiyuan, China.", "Department of Urology, Gansu Provincial Hospital, Lanzhou, China.", "Department of Urology, Shaanxi Provincial People's Hospital, Xi'an, 710068, China.", "Department of Urology, The First Affiliated Hospital of China Medical University, Shenyang, China.", "Department of Urology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.", "Department of Urology, The First Affiliated Hospital of Xiamen University, Xiamen, China.", "Department of Urology, Xinjiang Uygur Autonomous Region People's Hospital, Urumqi, China.", "Department of Urology, The First Affiliated Hospital of Gannan Medical University, Ganzhou, China.", "Department of Urology, Shanghai First People's Hospital, Shanghai, China.", "Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.", "Department of Urology, Lishui Central Hospital, Lishui, China.", "Department of Urology, Shanghai Pudong New Area Gongli Hospital, Shanghai, China.", "Department of Urology, Shaoyang Central Hospital, Shaoyang, China.", "Department of Urology, Ningbo Yinzhou No.2 Hospital (Ningbo Urological and Nephrological Hospital), Ningbo, China.", "Department of Urology, Jiangsu Provincial People's Hospital, Nanjing, China.", "Department of Urology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.", "Department of Urology, Zhongshan Hospital of Traditional Chinese Medicine, Zhongshan, China.", "Department of Urology, Qilu Hospital of Shandong University, Jinan, China.", "Department of Urology, Haikou People's Hospital, Haikou, China.", "Department of Gynecology and Obstetrics, Guangdong Provincial Maternity and Child Health Care Hospital, Guangzhou, 510010, China.", "Department of Urology, China Rehabilitation Research Center, Beijing, China.", "Department of Urology, Guilin Second People's Hospital, Guilin, China.", "Department of Urology, Hangzhou First People's Hospital, Hangzhou, China.", "Department of Urology, Wuhan First Hospital, Wuhan, China.", "Department of Urology, Yichang Second People's Hospital, Yichang, China.", "Department of Urology, The Fourth Hospital of Harbin Medical University, Harbin, China.", "Department of Urology, Huizhou Third People's Hospital, Huizhou, China.", "Department of Urology, Jiangsu Provincial Hospital of Traditional Chinese Medicine, Nanjing, China.", "Department of Urology, Anhui Second People's Hospital, Hefei, China.", "Department of Urology, The Second Hospital of Jilin University, Changchun, China."], "corresponding_authors": [], "china_team": "Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China Hai Huang团队", "category": "clinical_review", "classification_reason": "clinical_signals=7", "score": 34.56, "score_parts": {"urology_relevance": 11, "urology_in_title": 8.0, "journal_priority": 5.56, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 7.0}, "journal_metrics": {"status": "ok", "impact_factor": 1.9, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.56, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42841382", "title": "Letter to Editor on Determinants of Estrogen Prescriptions for Recurrent Urinary Tract Infection.", "abstract": "", "journal": "Neurourology and Urodynamics", "pub_date": "2026-Oct-07", "publication_types": ["Letter"], "doi": "10.1002/nau.70474", "authors": ["Khizra Faisal", "Bushra Ajmal"], "affiliations": ["Shaikh Khalifa Bin Zayed Al Nahyan Medical and Dental College, Lahore, Pakistan."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 17.56, "score_parts": {"urology_relevance": 7, "urology_in_title": 8.0, "journal_priority": 5.56, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 1.9, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.56, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42841353", "title": "Response to the Letter to the Editor on \"Ultrasonographic Findings of Successful Polyvinylidene Fluoride Mid-Urethral Sling Surgery and Their Clinical Relevance\".", "abstract": "", "journal": "Neurourology and Urodynamics", "pub_date": "2026-Oct-07", "publication_types": ["Letter"], "doi": "10.1002/nau.70476", "authors": ["Wen-Chen Huang", "Evelyn Yang", "Jenn-Ming Yang"], "affiliations": ["Department of Obstetrics and Gynecology, Cathay General Hospital, Taipei, Taiwan.", "Department of Obstetrics and Gynecology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.", "Department of Obstetrics and Gynecology, Sijhih Cathay General Hospital, Taipei, Taiwan.", "Department of Obstetrics and Gynecology, School of Medicine, National Tsing Hua University, Hsinchu, Taiwan.", "Department of Obstetrics and Gynecology, Chung Shan Medical University Hospital, Taichung, Taiwan.", "Department of Obstetrics and Gynecology, School of Medicine, College of Medicine, Chung Shan Medical University, Taichung, Taiwan.", "Department of Obstetrics and Gynecology, Puli Christian Hospital, Nantou, Taiwan."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 14.56, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 5.56, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 1.9, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.56, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42776627", "title": "Long-term outcomes and treatment cessation in patients with response to first-line treatment of metastatic prostate cancer.", "abstract": "Approximately one-third of men with metastatic prostate cancer die from causes other than prostate cancer. Little is known about the long-term outcomes of men with metastatic prostate cancer, in particular those who do not develop androgen pathway resistance. The objective of this study is to describe those with long-term survival and disease response to initial therapy and their clinical outcomes. This is a single-institution, retrospective study of patients with metastatic hormone-sensitive prostate cancer diagnosed prior to January 1, 2019 and alive as of December 31, 2024. Clinical and demographic features are described at baseline and follow-up, with outcomes after treatment cessation. One hundred and forty-five patients were included with a median age at diagnosis of 61 years. Fifty-one patients (35.2%) had metastatic disease at diagnosis, and 108 (74.5%) had bone metastases at the time of metastatic disease. The median follow-up from the date of metastatic disease was 8.4 years. Eighty-nine (61.4%) patients continued to have disease response to initial therapy after a median of 8.8 years. Thirty-two patients stopped therapy, and of those, 25 recovered testosterone, with 11 patients continuing to have an undetectable prostate-specific antigen (8% of total cohort and 34% of those who stopped therapy). In this cohort, most patients did not have further progression of disease, and 8% of patients had durable treatment-free remissions. Further research is needed on treatment cessation in men with exceptional responses to androgen deprivation therapy.", "journal": "Oncologist", "pub_date": "2026-Oct-07", "publication_types": ["Journal Article"], "doi": "10.1093/oncolo/oyag375", "authors": ["Monica Meeks", "Yasaman Iranmanesh", "Hyunsoo Song", "Amanda L Blackford", "Arya Rasouli", "Alex Baras", "Samuel R Denmeade", "Mark C Markowski", "Channing J Paller", "Michael A Carducci", "Emmanuel S Antonarakis", "Mario A Eisenberger", "Catherine H Marshall"], "affiliations": ["Department of Oncology, Johns Hopkins School of Medicine, Baltimore, Maryland, 21287, United States.", "Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, 55455, United States."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=9", "score": 34.42, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.42, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 9.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.2, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.42, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42768457", "title": "Toxicity attribution during enfortumab vedotin plus pembrolizumab therapy in urothelial carcinoma: a practical framework.", "abstract": "Enfortumab vedotin (EV), pembrolizumab, and EV plus pembrolizumab (EV/P) have rapidly reshaped the treatment landscape of advanced urothelial carcinoma, but toxicity increasingly determines treatment delivery, treatment continuity, and real-world benefit. As EV/P moves into broader clinical use, clinicians must distinguish adverse events related to antibody-drug conjugate exposure from immune-mediated toxicities and recognize syndromes in which both mechanisms may contribute. In this practical, mechanism-informed review, we synthesize pivotal trials, mature follow-up reports, and representative real-world cohorts describing the safety of EV monotherapy, pembrolizumab monotherapy, and EV/P in urothelial carcinoma. Because adverse-event reporting and ascertainment are heterogeneous across studies, including differences in preferred terms, composite categories, grading frameworks, and treatment-related versus all-cause reporting, we emphasize clinically interpretable patterns rather than pooled estimates. Enfortumab vedotin monotherapy is characterized by cutaneous toxicity, peripheral neuropathy, hyperglycemia, dysgeusia, and ocular events, including early epithelial/metabolic events and cumulative neuropathy. Pembrolizumab monotherapy has a lower overall high-grade toxicity burden but is defined by immune-mediated endocrinopathies, pneumonitis, hepatitis, colitis, and nephritis. Combination therapy produces a predictable overlap of these toxicity domains, creating diagnostic and management challenges for syndromes such as skin toxicity, diarrhea, fatigue, and pulmonary symptoms. We provide comparative visual toxicity signatures, regimen-specific summary tables, temporal toxicity mapping, and a pragmatic attribution framework that classifies events as EV-predominant, immune-predominant, overlap/indeterminate, or high-risk requiring initial interruption of both agents. This review aims to support bedside recognition, provisional attribution, early management, and safer implementation of EV/P in contemporary urothelial carcinoma practice.", "journal": "Oncologist", "pub_date": "2026-Oct-07", "publication_types": ["Journal Article", "Review"], "doi": "10.1111/ijd.70258", "authors": ["Jabra Zarka", "Daniel S Childs", "Miguel Muniz Rincon", "Ali Tarhini", "Albert Jang", "Lisa A Kottschade", "Svetomir N Markovic", "Megan Spychalla", "Morgan Sitenga", "Giang Nguyen", "Lance Pagliaro", "Brian A Costello", "Jacob J Orme"], "affiliations": ["Department of Medical Oncology, Mayo Clinic, Rochester, MN 55905, United States.", "Department of Pharmacy, Mayo Clinic, Rochester, MN 55905, United States.", "Department of Dermatology, Mayo Clinic, Rochester, MN 55905, United States."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 28.42, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.42, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 4.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.2, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.42, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42752828", "title": "Genomic and transcriptomic correlates of deep prostate-specific antigen response in patients with metastatic androgen pathway modulation-sensitive prostate cancer.", "abstract": "Despite advances in metastatic androgen pathway modulation-sensitive prostate cancer (mAPMS) treatment, outcomes remain heterogeneous. Achieving a post-treatment undetectable prostate-specific antigen (PSA) is a strong prognostic marker. We aimed to identify genomic and transcriptomic determinants of PSA response in a real-world clinical-genomic cohort. Patients with mAPMS who underwent DNA (Tempus xT) and, in a subset, RNA (Tempus xR) sequencing were identified from the Tempus Lens database. Inclusion required stage IV disease within 90 days of sample collection and obtained within 12 months before or 3 months after treatment initiation. Patients with PSA at 6 months (n = 525) were classified as PSA-Low (<0.1 ng/mL, n = 240) or PSA-High (≥0.1 ng/mL, n = 285). Overall survival (OS) was assessed by 6-month landmark analysis with delayed-entry adjustment. Logistic and Cox models were adjusted for clinical variables. Sensitivity analyses used a relative definition of >95% PSA decline from baseline. Baseline PSA was lower in PSA-Low versus PSA-High patients (24 vs 36 ng/mL, P = .01). SPOP (17% vs 11%) and ZFHX3 (2.5% vs 6%) alterations differed between groups, but neither persisted after adjustment. Using the relative definition, ZMYM3 and JAK1 alterations were independently associated with failure to achieve a deep PSA response. Expression of PSMA, TROP2, B7-H3, and STEAP1 did not differ between groups. PSA-Low status was independently associated with improved OS, as was deep relative response. Deep PSA response at 6 months correlates with improved OS in mAPMS. Integrating molecular markers with PSA response may inform treatment intensification or de-escalation strategies.", "journal": "Oncologist", "pub_date": "2026-Oct-07", "publication_types": ["Journal Article"], "doi": "10.3389/fonc.2020.616173", "authors": ["Rana R McKay", "Deepak Kilari", "Binyam Yilma", "Unnati Jariwala", "Arya Ashok", "Stamatina Fragkogianni", "Jacob Mercer", "Neeraj Agarwal", "Emmanuel S Antonarakis"], "affiliations": ["Moores Cancer Center, University of California San Diego, La Jolla, CA 92093, United States.", "Department of Medicine, Medical College of Wisconsin, Milwaukee, WI 53226, United States.", "Tempus AI, Inc, Chicago, IL 60654, United States.", "Department of Internal Medicine, University of Utah, Salt Lake City, UT 84112, United States.", "Department of Medicine, Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, United States."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "basic_signals=6", "score": 30.42, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.42, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 6.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.2, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.42, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "SPOP突变未独立预测深度PSA应答", "chinese_summary": "Tempus数据库9月Oncologist对525例转移性雄激素通路敏感前列腺癌患者分析，发现6个月PSA<0.1 ng/mL者240例，其总生存显著改善；SPOP与ZFHX3突变组间有差异但校正后均不独立，PSMA、TROP2、B7-H3及STEAP1表达亦无组间差别。", "abstract_zh": "尽管转移性雄激素通路调节敏感型前列腺癌（mAPMS）的治疗取得进展，但患者结局仍存在异质性。治疗后达到前列腺特异性抗原（PSA）不可测是一种强有力的预后标志物。我们旨在真实世界临床-基因组队列中识别PSA应答的基因组和转录组决定因素。从Tempus Lens数据库中筛选接受DNA（Tempus xT）测序、部分接受RNA（Tempus xR）测序的mAPMS患者。纳入要求为样本采集后90天内为IV期疾病，且样本获取时间在治疗开始前12个月至治疗后3个月内。具有6个月PSA数据者（n=525）被分为PSA低值组（<0.1 ng/mL，n=240）和PSA高值组（≥0.1 ng/mL，n=285）。总生存期（OS）通过6个月界标分析结合延迟进入校正进行评估。Logistic和Cox模型均针对临床变量进行校正。敏感性分析采用相对定义，即PSA较基线下降>95%。PSA低值组基线PSA低于PSA高值组（24 vs 36 ng/mL，p=0.01）。SPOP（17% vs 11%）和ZFHX3（2.5% vs 6%）改变在两组间存在差异，但校正后均未持续存在。采用相对定义时，ZMYM3和JAK1改变与未能达到深度PSA应答独立相关。PSMA、TROP2、B7-H3和STEAP1的表达在两组间无差异。PSA低值状态与总生存改善独立相关，深度相对应答亦如此。6个月时的深度PSA应答与mAPMS患者总生存改善相关。将分子标志物与PSA应答整合可能为治疗强化或降阶策略提供信息。"}, {"pmid": "42852388", "title": "Associations of Urinary Triclosan Concentrations Across Gestation and Childhood with the Adolescent Gut Microbiome.", "abstract": "Research on the influence of repeated exposure to antimicrobial chemicals, such as triclosan, on the microbiome is lacking. The goal of this study was to elucidate the associations of time-varying urinary triclosan concentrations with the adolescent gut microbiome. We used data from a prospective cohort based in Cincinnati, OH (enrolled 2003-2006, n = 146), to assess the time-varying associations of urinary triclosan concentrations with adolescent (age ∼ 12 years) gut microbiome diversity and composition. Individuals ≥ 18-years-old were recruited during the second trimester of pregnancy, and urinary triclosan concentrations were measured in pregnant women up to 2 times in pregnancy and up to 7 times in the child from ages 1 through 12 years. At age ∼ 12 years, fecal microbiome diversity and composition was characterized with metagenomic sequencing. We estimated differences in the relative abundance of prevalent (≥50%) bacterial species and gene pathways using linear regression and generalized estimating equations to assess windows of heightened susceptibility adjusted for sociodemographic characteristics. Additionally, we examined sex-specific associations by including an interaction term. The adolescent median Shannon diversity was 3.5 (IQR: 3.3, 3.5). Higher gestational triclosan concentrations with lower gut microbiome diversity [β = -0.13 per 10-fold increase (95%CI: -0.24, -0.02)]. Triclosan concentrations were also positively associated with higher abundance of antibiotic resistance genes and differential abundance of some bacterial species, with the strongest associations observed in early life and at age 12 years. We also found differences depending on sex, with more significant associations observed among males. Our findings provide insight into windows of triclosan exposure that are relevant to gut microbiome composition and the impacts of antimicrobial agents.", "journal": "Environmental Health Perspectives", "pub_date": "2026-Oct-06", "publication_types": ["Journal Article"], "doi": "10.1038/s41467-022-28034-z", "authors": ["Hannah E Laue", "Abby F Fleisch", "Antonia M Calafat", "Bruce P Lanphear", "Kim M Cecil", "Kimberly Yolton", "Jessie P Buckley", "Margaret R Karagas", "Juliette C Madan", "Amy D Willis", "Joseph M Braun"], "affiliations": ["Department of Biostatistics & Epidemiology, University of Massachusetts Amherst School of Public Health and Health Sciences, Amherst, Massachusetts 01003, United States.", "Center for Interdisciplinary and Population Health Research, Maine Institute for Research, Westbrook, Maine 04092, United States.", "Pediatric Endocrinology and Diabetes, Maine Medical Center, Portland, Maine 04102, United States.", "Division of Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, Georgia 30329, United States.", "Faculty of Health Sciences, Simon Fraser University, Vancouver V5A 1S6, Canada.", "Department of Radiology, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267, United States.", "Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267, United States.", "Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.", "Department of Epidemiology, Dartmouth Geisel School of Medicine, Hanover, New Hampshire 03755, United States.", "Department of Psychiatry, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire 03766, United States.", "Department of Biostatistics, University of Washington Hans Rosling Center for Population Health, Seattle, Washington 98195, United States.", "Department of Epidemiology, Brown University, Providence, Rhode Island 02912, United States."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "basic_signals=5", "score": 38.49, "score_parts": {"urology_relevance": 3, "urology_in_title": 8.0, "journal_priority": 15.49, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 5.0, "abstract_completeness": 2.0, "basic_research_strength": 5.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 9.8, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.49, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "孕期三氯生暴露降低青少年肠道菌群多样性", "chinese_summary": "辛辛那提10月Environ Health Perspect基于146对母婴前瞻性队列，检测孕期至12岁尿三氯生浓度，发现孕期浓度每升高10倍，12岁肠道菌群Shannon多样性降低0.13，且抗生素耐药基因丰度升高，提示生命早期为敏感暴露窗口。", "abstract_zh": "关于反复暴露于三氯生等抗菌化学物质对微生物组影响的研究尚缺乏。本研究旨在阐明随时间变化的尿三氯生浓度与青少年肠道微生物组之间的关联。我们使用位于俄亥俄州辛辛那提的前瞻性队列数据（2003-2006年入组，n=146），评估随时间变化的尿三氯生浓度与青少年（约12岁）肠道微生物组多样性和组成的关联。研究招募了18岁及以上的个体在妊娠中期，并在孕期最多测量2次孕妇尿三氯生浓度，以及在儿童1至12岁期间最多测量7次。在约12岁时，通过宏基因组测序表征粪便微生物组多样性和组成。我们使用线性回归和广义估计方程估计常见（≥50%）细菌物种和基因通路的相对丰度差异，以评估易感性增高的窗口期，并调整社会人口学特征。此外，我们通过纳入交互项检查性别特异性关联。青少年Shannon多样性的中位数为3.5（IQR：3.3, 3.5）。较高的孕期三氯生浓度与较低的肠道微生物组多样性相关[每10倍增加β=-0.13（95%CI：-0.24, -0.02）]。三氯生浓度还与抗生素耐药基因丰度升高及某些细菌物种的差异丰度呈正相关，最强关联出现在生命早期和12岁时。我们还发现性别差异，男性中观察到更显著的关联。我们的发现提供了关于三氯生暴露窗口与肠道微生物组组成相关性的见解，以及抗菌剂的影响。"}, {"pmid": "42852385", "title": "17α-Hydroxyprogesterone Mediates Mo-Induced Sperm-Mediated Transgenerational Inheritance of Impaired Spermatogenesis.", "abstract": "Growing evidence suggests that exposure to metals, such as molybdenum, contributes to significant health risks. However, very little is known about its potential male reproductive toxicity due to paternal exposure across generations. The aim of the present study was to investigate the male reproductive toxicity of paternal exposure to sodium molybdate (Na2MoO4) across generations and reveal the underlying mechanism. Adult F0 male C57 mice were administered sodium molybdate at doses of 0.01 and 0.1 mg/kg/day. The assessment included testicular toxicity evaluation and metabolomic profiling, followed by mechanistic studies in vivo and in vitro from F0 to F2. A large sample of case-control study including 958 subjects verified the findings. Reduced sperm counts and damages to seminiferous tubules across generations were observed in Mo-treated groups. Metabolomics analysis revealed a transgenerational elevation of 17α-hydroxyprogesterone (17α-OHP) in the testes of Mo-treated groups. Apoptosis and ferroptosis were enhanced in GC-2 cells in vitro after 17α-OHP treatment and were validated in vivo. Molecular competition experiments revealed that 17α-OHP competes for the NADPH binding site in FSP1, hindering FSP1's catalytic function, as supported by metabolomics analysis. Enzyme activity analysis found a reduction in FSP1 activity after 17α-OHP treatment, promoting ferroptosis and apoptosis in GC-2 cells in vitro. AHCY was identified as a potential target and was reduced after Mo exposure both in vivo and in vitro, accompanied by testicular DNA hypomethylation and elevated expression of key enzymes for 17α-OHP synthesis across generations, including Hsd3b and Cyp17a1. Human studies revealed that Mo exposure was associated with an increased risk of male infertility via 17α-OHP. This study innovatively elucidated the mechanisms by which paternal Mo exposure induced transgenerational male reproductive toxicity through metabolic and epigenetic alterations using human, mouse, and in vitro models.", "journal": "Environmental Health Perspectives", "pub_date": "2026-Oct-06", "publication_types": ["Journal Article"], "doi": "10.1038/nrn3818", "authors": ["Kun Zhou", "Xue Song", "Yingtong Jiang", "Mengyuan Zhu", "Yanling Chen", "Miaomiao Tang", "Guohong Zhao", "Yusheng Guan", "Xiaoling Zhang", "Yanhui Hu", "Minjian Chen"], "affiliations": ["State Key Laboratory of Reproductive Medicine and Offspring Health, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, 211166, China.", "Key Laboratory of Modern Toxicology of Ministry of Education, School of Public Health, Nanjing Medical University, Nanjing, 211166, China.", "Department of Epidemiology, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, 211166, China.", "Department of Hygienic Analysis and Detection, Nanjing Medical University, Nanjing, 211166, China.", "Sir Run Run Hospital of Nanjing Medical University, Nanjing, 211166, China.", "Department of Occupational Medicine and Environmental Health, School of Public Health, Key Laboratory of Public Health Safety and Emergency Prevention and Control Technology of Higher Education Institutions in Jiangsu Province, Nanjing Medical University, Nanjing, 211166, China."], "corresponding_authors": [], "china_team": "State Key Laboratory of Reproductive Medicine and Offspring Health, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, 211166, China Minjian Chen团队", "category": "basic", "classification_reason": "basic_signals=24", "score": 37.49, "score_parts": {"urology_relevance": 6, "urology_in_title": 0.0, "journal_priority": 15.49, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 14.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 9.8, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.49, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "钼经父系跨代损害精子生成", "chinese_summary": "南京医科大学陈敏健团队10月Environ Health Perspect结合小鼠、细胞与958例人体样本发现，父代钼暴露可致精子数下降及曲细精管损伤并跨代传递。机制上，17α-羟孕酮跨代升高，竞争FSP1的NADPH结合位点抑制其活性，促进铁死亡与凋亡。", "abstract_zh": "越来越多的证据表明，接触钼等金属会带来显著的健康风险。然而，关于父系暴露跨代造成的潜在男性生殖毒性，目前知之甚少。本研究旨在探讨父系暴露于钼酸钠（Na2MoO4）跨代引起的男性生殖毒性，并揭示其潜在机制。成年F0代雄性C57小鼠按0.01和0.1 mg/kg/天的剂量给予钼酸钠。评估包括睾丸毒性评价和代谢组学分析，随后在F0至F2代进行体内和体外机制研究。一项纳入958名受试者的大样本病例对照研究验证了上述发现。在钼处理组中观察到跨代的精子计数减少和曲细精管损伤。代谢组学分析显示，钼处理组睾丸中17α-羟孕酮（17α-OHP）跨代升高。体外GC-2细胞经17α-OHP处理后凋亡和铁死亡增强，并在体内得到验证。分子竞争实验揭示，17α-OHP竞争FSP1中的NADPH结合位点，阻碍FSP1的催化功能，代谢组学分析亦支持这一结果。酶活性分析发现，17α-OHP处理后FSP1活性降低，促进体外GC-2细胞的铁死亡和凋亡。AHCY被鉴定为潜在靶点，钼暴露后在体内和体外均降低，伴随睾丸DNA低甲基化以及跨代17α-OHP合成关键酶（包括Hsd3b和Cyp17a1）表达升高。人体研究显示，钼暴露通过17α-OHP与男性不育风险增加相关。本研究利用人类、小鼠和体外模型，创新性地阐明了父系钼暴露通过代谢和表观遗传改变诱导跨代男性生殖毒性的机制。"}, {"pmid": "42852043", "title": "A Pilot Study to Explore the Application of Silicone Wristband-Based Chemical Exposure Assessment to Kidney Disease Epidemiology in Agricultural Workers.", "abstract": "Exposure assessment in kidney disease epidemiology remains challenging because kidney function impairment may alter urinary chemical excretion, limiting the utility of urinary biomonitoring and highlighting the need for alternative tools. We combined targeted and nontargeted analyses of silicone wristbands worn by 43 male agricultural workers to characterize their personal chemical exposome and evaluate preliminary associations of these exposures, urinary biomarkers, and kidney health. Kidney function was assessed via estimated glomerular filtration rate (eGFR, mL/min/1.73m2). Pesticides were quantified in wristbands (worn 8-11 days) and spot urine samples using targeted analysis. A custom GC-HRMS nontargeted workflow was applied to examine potential chemical exposure differences from wristband measurements. Associations between pesticide exposure and kidney function were evaluated using minimally adjusted linear regression for continuous eGFR (β) and log-binomial regression for binary eGFR < 90 (prevalence ratio [PR]). Overall, our findings suggest that higher wristband pesticide concentrations may be associated with lower kidney function among participants. In adjusted models, a 10-fold increase in wristband chlorpyrifos concentration yielded a higher prevalence of eGFR < 90 (PR = 1.53; 95% CI: 0.99, 2.36). Oxyfluorfen detection was similarly associated with a higher prevalence of eGFR < 90 (PR = 2.38; 95% CI: 1.01, 5.61). Conversely, most urinary biomarkers showed no association, though specific gravity-corrected AMPA concentrations were inversely associated with eGFR < 90 (PR = 0.31; 95% CI: 0.11, 0.87). Exploratory nontargeted analysis identified 193 tentative features that were higher on wristbands from participants with eGFR < 90 and only one feature that was higher on wristbands from participants with eGFR ≥ 90. Silicone wristbands show promise for enhancing characterization of the personal chemical exposome and warrant further investigation as a complementary tool to urinary biomonitoring for reducing exposure misclassification in kidney disease epidemiology. These exploratory findings, based on a small sample, are hypothesis-generating and require validation through larger, longitudinal studies.", "journal": "Environmental Health Perspectives", "pub_date": "2026-Oct-06", "publication_types": ["Journal Article"], "doi": "10.1053/j.ajkd.2012.11.048", "authors": ["Melissa DeSantiago", "Grant D Tore", "Nicholas J Herkert", "Heather M Stapleton", "Duncan Hay", "Margarita Valenzuela", "Jenny Ruedlinger", "Ana M Rule", "Jordan R Kuiper", "Jeffrey J Fadrowski", "Catterina Ferreccio", "Sandra Cortés A", "Lesliam Quirós-Alcalá"], "affiliations": ["Department of Environmental Health and Engineering, Bloomberg School of Public Health, Johns Hopkins University, 615 N. Wolfe Street, Baltimore, Maryland 21205, United States.", "Nicholas School of the Environment, Duke University, 9 Circuit Drive, Durham, North Carolina 27708, United States.", "School of Public Health, Pontificia Universidad Católica de Chile, Diagonal Paraguay 362, 8330077 Santiago, Chile.", "Department of Environmental and Occupational Health, Milken Institute School of Public Health, The George Washington University, 950 New Hampshire Avenue NW, Washington, District of Columbia 20052, United States.", "Division of Pediatric Nephrology, Department of Pediatrics, Johns Hopkins University School of Medicine, 1800 Orleans Street Baltimore, Baltimore, Maryland 21287, United States.", "Instituto de Salud Pública, Ministerio de Salud de Chile, Avenida Marathon 1000, 7780050 Santiago, Chile.", "Advanced Center for Chronic Diseases (ACCDiS), Sergio Livingstone 1007, 8380492 Santiago, Chile.", "Center for Sustainable Urban Development (CEDEUS), El Comendador 1916, 7520245 Santiago, Chile."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 22.99, "score_parts": {"urology_relevance": 3, "urology_in_title": 0.0, "journal_priority": 15.49, "top_journal_bonus": 0.0, "novelty": 0.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 2.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 9.8, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.49, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42852005", "title": "Multiomics Insights Linking Personal Care Products Exposure to Serum Lipid Profiles in Older Adults: The China BAPE Study.", "abstract": "Personal care products (PCPs) are widespread environmental exposures, yet their combined and system-wide effects on serum lipid profiles in the aging population remain poorly understood. This study aimed to comprehensively assess the association between exposure to multiple PCPs and serum lipid profiles in healthy older adults and to explore underlying molecular pathways and biological mechanisms. We conducted a prospective panel study with five monthly follow-up surveys between September 2018 and January 2019 among 76 healthy older adults (60-69 years) in Jinan, China. This study measured urinary concentrations of PCPs, serum lipid markers, and multiomics profiles (transcriptomics, lipidomics, and metabolomics). We employed linear mixed-effects models to analyze exposure-outcome associations and integrated multiomics data with causal inference testing and Ingenuity Pathway Analysis to identify mediating biomolecules and biological mechanisms. Additional analyses examined the relationships of PCP exposures with inflammatory cytokines, oxidative stress biomarkers, and electrocardiographic (ECG) parameters to provide functional support for the identified pathways and their associated phenotypic consequences. Four PCPs [Benzophenone-2 (BP-2), Benzophenone-3 (BP-3), 4-Hydroxy benzophenone (4-OHBP), and Ethyl p-Hydroxybenzoate (EtP)] were significantly associated with altered serum lipid profiles. Multiomics analyses suggested their convergence on a PPAR-centered immunometabolic network, with S100 signaling identified as a novel activation pathway. Specifically, BP-2 was associated with patterns consistent with IL-4/IL-13-mediated alternative macrophage activation, while PPAR appeared to be involved in inflammatory polarization and metabolic reprogramming. Cytokine analysis revealed associations between BP-2 and key inflammatory mediators (e.g., IL-1β), oxidative stress assessment linked BP-2 exposure to elevated markers of oxidative damage (e.g., 8-PGF2α), and ECG analysis associated BP-2 exposure with altered cardiac electrophysiology (e.g., QRS duration). These multifaceted findings suggest associations between PCP exposures and serum lipid profiles, and highlight the potential contribution to cardiovascular risk. Our findings provide integrated, multilayered evidence suggesting associations between exposure to PCPs and alterations in serum lipid profiles in older adults, bridging exposure profiles, biomolecular perturbations, and subclinical functional changes. These results serve as a hypothesis-generating theoretical foundation that, pending confirmation in larger studies or experimental validation, advances the understanding of environmental metabolic disruption in aging populations.", "journal": "Environmental Health Perspectives", "pub_date": "2026-Oct-06", "publication_types": ["Journal Article"], "doi": "10.1089/zeb.2016.1257", "authors": ["Yongjun Situ", "Xiaojie Guo", "Huimin Ren", "Jiankun Qian", "Chenlong Li", "Chenfeng Li", "Xianwen Tang", "Jiran Zhang", "Xiaona Wang", "Mengyao Wang", "Yue Liang", "Chenglei Qi", "Lin Chen", "Kaiyue Shao", "Hongyang Cui", "Song Tang", "Chen Mao", "Xiaoming Shi"], "affiliations": ["School of Public Health, Southern Medical University, Guangzhou, Guangdong 510515, China.", "China CDC Key Laboratory of Environment and Population Health, National Institute of Environmental Health, Chinese Center for Disease Control and Prevention, Beijing 100021, China.", "Guangzhou Center for Disease Control and Prevention (Guangzhou Health Supervision Institute), Guangzhou, Guangdong 510440, China.", "School of Public Health, Southeast University, Nanjing, Jiangsu 210009, China.", "School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250100, China.", "Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, Jiangsu 211166, China.", "School of Public Health, Anhui Medical University, Hefei, Anhui 230032, China.", "National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, National Institute of Environmental Health, Chinese Center for Disease Control and Prevention, Beijing 102206, China."], "corresponding_authors": [], "china_team": "School of Public Health, Southern Medical University, Guangzhou, Guangdong 510515, China Xiaoming Shi团队", "category": "basic", "classification_reason": "basic_signals=13", "score": 34.99, "score_parts": {"urology_relevance": 3, "urology_in_title": 0.0, "journal_priority": 15.49, "top_journal_bonus": 0.0, "novelty": 1.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 13.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 9.8, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.49, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "个人护理品暴露关联血脂谱改变", "chinese_summary": "南方医科大学公共卫生学院施小明团队10月Environ Health Perspect基于中国BAPE前瞻性面板研究，对76名60–69岁健康老年人连续5次随访，检测尿中个人护理品及血脂与多组学。发现BP-2、BP-3、4-OHBP和EtP与血脂谱改变相关，多组学提示其汇聚于以PPAR为核心的免疫代谢网络，S100信号为新激活通路，BP-2还与炎症。", "abstract_zh": "个人护理品（PCPs）是广泛存在的环境暴露，但其对老龄人群血清血脂谱的联合及系统级影响仍知之甚少。本研究旨在全面评估健康老年人多种PCP暴露与血清血脂谱之间的关联，并探讨潜在的分子通路和生物学机制。我们在中国济南对76名健康老年人（60-69岁）开展了一项前瞻性面板研究，于2018年9月至2019年1月期间进行了五次每月随访调查。本研究测定了尿中PCP浓度、血清脂质标志物以及多组学图谱（转录组学、脂质组学和代谢组学）。我们采用线性混合效应模型分析暴露-结局关联，并将多组学数据与因果推断检验及Ingenuity Pathway Analysis整合，以识别中介生物分子和生物学机制。附加分析考察了PCP暴露与炎症细胞因子、氧化应激生物标志物及心电图（ECG）参数的关系，为所识别通路及其相关表型后果提供功能支持。四种PCP[二苯酮-2（BP-2）、二苯酮-3（BP-3）、4-羟基二苯酮（4-OHBP）和对羟基苯甲酸乙酯（EtP）]与血清血脂谱改变显著相关。多组学分析提示它们汇聚于以PPAR为中心的免疫代谢网络，其中S100信号被识别为一种新的激活通路。具体而言，BP-2与符合IL-4/IL-13介导的替代性巨噬细胞激活的模式相关，而PPAR似乎参与炎症极化和代谢重编程。细胞因子分析显示BP-2与关键炎症介质（如IL-1β）之间存在关联，氧化应激评估将BP-2暴露与氧化损伤标志物升高（如8-PGF2α）相联系，心电图分析将BP-2暴露与心脏电生理改变（如QRS时限）相关联。这些多方面发现提示PCP暴露与血清血脂谱之间存在关联，并强调其可能对心血管风险有贡献。我们的发现提供了整合的多层次证据，提示老年人PCP暴露与血清血脂谱改变之间存在关联，桥接了暴露谱、生物分子扰动和亚临床功能改变。这些结果可作为产生假设的理论基础，在更大规模研究或实验验证确认之前，增进了对老龄人群环境代谢紊乱的理解。"}, {"pmid": "42842364", "title": "Molecular stratification of SPOP-mutant prostate cancer demonstrates Wnt signaling and replication stress signatures in diverse patient populations.", "abstract": "Speckle-type POZ protein (SPOP) mutations define a molecular subtype of prostate cancer, but their genomic and transcriptional features across racially diverse populations remain incompletely resolved. We integrated tumor genomic profiles from 273 patients, including 40 SPOP-mutant tumors, with RNA sequencing from 102 cases to characterize SPOP-associated alterations across disease stage and self-reported race. SPOP-mutant tumors showed significant enrichment of APC and other recurrent co-alterations, supporting Wnt pathway dysregulation as a defining genomic feature. Transcriptomic analysis revealed enhanced proliferative, metabolic, and biosynthetic programs accompanied by suppression of extracellular matrix, structural, and differentiation-associated pathways. Race-stratified analyses identified a conserved repression of structural programs but divergent transcriptional activation states: African American SPOP-mutant tumors preferentially exhibited inflammatory, hypoxic, and epithelial plasticity programs, whereas Caucasian tumors showed stronger MYC, oxidative phosphorylation, translational, and androgen-response signatures. These findings define SPOP-mutant prostate cancer as a molecularly distinct, context-dependent disease subtype with potentially heterogeneous, clinically relevant therapeutic vulnerabilities across patient populations.", "journal": "Cell Reports", "pub_date": "2026-Oct-06", "publication_types": ["Journal Article"], "doi": "10.1016/j.celrep.2026.118006", "authors": ["Kinza Rizwan", "Sai Prasada Rao Manikonda", "Heidi Dowst", "Patricia Castro", "Maria Elisa Ruiz Echartea", "Cristian Coarfa", "Michael Ittmann", "Neda Zarrin-Khameh", "Quillan Huang", "Martha Mims", "Salma Kaochar"], "affiliations": ["Department of Medicine, Baylor College of Medicine, Houston, TX, USA.", "Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA.", "Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA; Department of Pathology, Baylor College of Medicine, Houston, TX, USA.", "Department of Pathology, Baylor College of Medicine, Houston, TX, USA.", "Department of Medicine, Baylor College of Medicine, Houston, TX, USA; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA.", "Department of Medicine, Baylor College of Medicine, Houston, TX, USA; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA. Electronic address: salma.kaochar@bcm.edu."], "corresponding_authors": ["Salma Kaochar"], "china_team": "", "category": "basic", "classification_reason": "basic_signals=8", "score": 37.03, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 15.03, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 8.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 6.9, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.03, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "SPOP突变前列腺癌分子分型揭示人群差异", "chinese_summary": "Cell Reports 10月发表整合273例前列腺癌基因组与102例转录组分析，发现SPOP突变肿瘤富集APC共改变，提示Wnt通路失调为核心特征；转录组呈增殖代谢增强而基质分化受抑，且非裔与白人患者激活状态不同，提示治疗脆弱性存在人群异质性。", "abstract_zh": "斑点型POZ蛋白（SPOP）突变定义了前列腺癌的一种分子亚型，但其在种族多样化人群中的基因组和转录特征仍未完全阐明。我们整合了273例患者的肿瘤基因组图谱（包括40例SPOP突变肿瘤）与102例RNA测序，以表征SPOP相关改变在不同疾病分期和自我报告种族中的分布。SPOP突变肿瘤显示APC及其他反复出现的共改变显著富集，支持Wnt通路失调是定义性基因组特征。转录组分析揭示增殖、代谢和生物合成程序增强，同时细胞外基质、结构和分化相关通路受到抑制。按种族分层分析发现结构程序抑制是保守的，但转录激活状态存在差异：非裔美国人SPOP突变肿瘤优先表现出炎症、缺氧和上皮可塑性程序，而白人肿瘤则显示更强的MYC、氧化磷酸化、翻译和雄激素反应特征。这些发现将SPOP突变前列腺癌定义为一个分子上独特、依赖背景的疾病亚型，在不同患者群体中可能具有异质性且临床相关的治疗脆弱性。"}, {"pmid": "42840810", "title": "Efficacy and Safety of Opioid Analgesia in Acute Abdominal Presentations: A Systematic Review.", "abstract": "Acute abdominal pain is a common emergency department presentation and is often associated with diagnostic uncertainty. Historically, opioid analgesia was used cautiously because of concern that it could alter physical examination findings and interfere with diagnostic accuracy. Non-opioid and opioid-sparing strategies are increasingly used for pain management. This systematic review evaluates the efficacy and safety of analgesic strategies for acute, non-traumatic abdominal pain, with attention to pain relief, adverse effects, rescue analgesia, and diagnostic accuracy. PubMed, Embase, and the Cochrane Central Register of Controlled Trials were searched for randomized comparative trials of opioid-containing treatment versus non-opioid, opioid-sparing, or placebo strategies. Eligible studies included adults aged 18 years or older with acute abdominal pain or an acute intra-abdominal cause of pain; studies limited to renal or ureteric colic were excluded. Of the 316 records identified, 45 duplicates were removed, 271 records were screened, 26 reports underwent full-text assessment, and 16 randomized trials were included. Across the included trials, opioids provided effective short-term analgesia but were not consistently superior to alternatives. Hydromorphone produced greater pain improvement than intravenous lidocaine at 90 minutes (between-group difference = 1.2 points, 95% confidence interval (CI) = 0.3-2.2) with less rescue analgesia. In acute pancreatitis, median Visual Analog Scale (VAS) reductions at 30 minutes were 45.5 (95% CI = 30-54) with tramadol, 41.5 (95% CI = 34-50) with paracetamol, and 40.5 (95% CI = 30-47) with dexketoprofen, with no statistically significant between-group difference. An erector spinae plane block produced lower pain scores and reduced rescue fentanyl compared with intravenous tramadol. In biliary colic, mean pain relief at 30 minutes was 3.8 (95% CI = 2.4-5.2) with ketorolac and 3.9 (95% CI = 2.4-5.3) with meperidine, with no statistically significant between-group difference. Butorphanol provided greater early pain relief than ketorolac at 15 minutes but not at 30 minutes. Low-dose morphine plus paracetamol did not significantly differ from standard-dose morphine, and intravenous lidocaine and morphine did not significantly differ at the primary 60-minute endpoint. Several placebo-controlled trials assessed diagnostic accuracy using different definitions and patient populations. In one trial, diagnostic accuracy was 86% with morphine and 85% with placebo (difference 1 percentage point, 95% CI = -11 to 12). This imprecise estimate does not rule out a clinically important difference, and the available trials do not establish whether opioids affect diagnostic accuracy across acute abdominal presentations. Some studies identified changes in tenderness, rigidity, or localization after analgesia, but these were not consistently associated with diagnostic error or adverse management outcomes. Adverse effects were generally short-term and included nausea, vomiting, dizziness, and sedation, although most trials were not large enough or followed long enough to reliably evaluate uncommon serious adverse events. Overall, the evidence supports an individualized approach to analgesia. Opioids remain effective when clinically indicated, but are not consistently superior to non-opioid or opioid-sparing alternatives, and analgesia should not be routinely delayed solely because of concern for diagnostic interference.", "journal": "Cureus", "pub_date": "2026-Oct", "publication_types": ["Journal Article", "Review"], "doi": "10.7759/cureus.117534", "authors": ["Connor A Payne", "Ganesh Prasad Neupane"], "affiliations": ["Emergency Medicine, Medical University of the Americas, Charlestown, KNA.", "Pharmacology, Medical University of the Americas, Charlestown, KNA."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 15.22, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 2.22, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 7.0}, "journal_metrics": {"status": "ok", "impact_factor": 1.3, "cas_zone": 4, "cas_zone_points": 1.0, "impact_factor_points": 1.22, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42839122", "title": "Risk factors and machine learning-based prediction of difficult ureter during retrograde ureteroscopic lithotripsy.", "abstract": "Difficult ureter (DU) is a challenging condition that prevents successful access to the upper urinary tract during retrograde ureteroscopic lithotripsy (URS). The present study aimed to identify clinical risk factors for DU and to evaluate the predictive performance of machine learning-based models in patients undergoing URS for ureteral stones. Medical records of patients who underwent retrograde ureteroscopic lithotripsy between January 2023 and January 2024 were retrospectively reviewed. A total of 221 patients were included and classified into difficult ureter (DU) and non-difficult ureter (NDU) groups. Demographic characteristics, comorbidities, laboratory parameters, and perioperative findings were compared. Conventional statistical analyses were performed using univariate and multivariate regression models. In addition, supervised machine learning algorithms, including decision tree, logistic regression, naive Bayes, support vector machine, k-nearest neighbors, bagged trees, and multilayer perceptron artificial neural network (ANN), were developed to predict DU. Model performance was assessed using 3-fold cross-validation. Difficult ureter was identified in 34 patients (15.4%). Absence of hydronephrosis, lack of medical expulsive therapy, elevated C-reactive protein (CRP > 5 mg/L), and gout were significantly associated with DU. Multivariate logistic regression analysis identified elevated CRP levels and diabetes mellitus as independent predictors. Among the machine learning models, the multilayer perceptron ANN demonstrated the best performance, with an accuracy of 86.9% and an area under the receiver operating characteristic curve of 0.816. Feature importance analysis revealed CRP as the most influential predictor, consistent with conventional statistical findings. Elevated CRP levels, gout, absence of hydronephrosis, and lack of medical expulsive therapy are important risk factors for difficult ureter during ureteroscopic lithotripsy. Machine learning-based models, particularly artificial neural networks, may provide additional predictive value and serve as decision-support tools for preoperative risk stratification in clinical practice.", "journal": "World Journal of Urology", "pub_date": "2026-Oct-06", "publication_types": ["Journal Article"], "doi": "10.1007/s00345-026-06793-4", "authors": ["Safa Akyol", "Doğan Sabri Tok", "Ercan Öğreden", "Erhan Demirelli", "Ertürk Altun", "Eren Baş", "Erol Eğrioğlu", "Ural Oğuz"], "affiliations": ["Department of Urology, Rize State Hospital, 53000, Rize, Turkey. safa_akyol_71@hotmail.com.", "Faculty of Medicine, Department of Urology, Giresun University, Giresun, Turkey.", "Faculty of Science Literature, Department of Statistics, Giresun University, Giresun, Turkey."], "corresponding_authors": ["Safa Akyol"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=4", "score": 32.0, "score_parts": {"urology_relevance": 7, "urology_in_title": 8.0, "journal_priority": 10.0, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 4.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.9, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.0, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42839075", "title": "Association of molecular subtypes based on GATA3, KRT5, and P16 expression with clinicopathological features and prognosis in upper tract urothelial carcinoma.", "abstract": "This study aimed to classify upper tract urothelial carcinoma (UTUC) using GATA3, KRT5, and P16 immunohistochemistry and to evaluate associations of these molecular subtypes with clinicopathological features and outcomes. Tissue samples from 102 UTUC patients who underwent radical nephroureterectomy were analyzed. Tumors were classified into genomically unstable (GU), urothelial-like (URO), and basal subtypes based on GATA3, KRT5, and P16 expression. Associations with pathological features, recurrence, and survival were analyzed. Kaplan-Meier and Cox regression analyses were used. The GU, URO, and basal subtypes accounted for 33%, 45%, and 22% of cases, respectively. Subtype was significantly associated with infiltrative pattern (p = 0.009), perineural invasion (p = 0.016), histological variant (p < 0.001), T stage (p = 0.004), N stage (p = 0.017), and vital status (p = 0.005). The basal subtype showed the poorest prognosis, with 3-year overall survival of 41% vs. 85% for the URO subtype (p < 0.001). Multivariable analysis identified diffuse infiltrative pattern (HR 6.84, P = 0.004), lymphovascular invasion (HR 2.12, p = 0.046), and T4 stage (HR 9.80, p = 0.023) as independent risk factors for overall survival, and diffuse infiltrative pattern (HR 6.37, p = 0.006) and T4 stage (HR 12.6, p = 0.012) for recurrence-free survival. IHC-based subtyping using GATA3, KRT5, and P16 is significantly associated with aggressive clinicopathological features in UTUC, with the basal subtype showing poor prognosis in univariate analysis. However, it was not an independent prognostic factor in multivariable analysis. While this exploratory strategy may aid in risk stratification, its clinical utility requires further validation in larger, prospective cohorts.", "journal": "World Journal of Urology", "pub_date": "2026-Oct-06", "publication_types": ["Journal Article"], "doi": "10.1007/s00345-026-06854-8", "authors": ["Jiayu Yang", "Wentao Yu", "Shengwang Zhang", "Qian Chen"], "affiliations": ["Department of Pathology, The Third Xiangya Hospital, Central South University, No.138 Tongzipo Road, Yuelu District, Changsha, 410013, Hunan, China.", "Department of Pathology, The Fourth Hospital of Changsha (Changsha Integrated Traditional Chinese and Western Medicine Hospital), Changsha, Hunan, China.", "Department of Radiology, The Third Xiangya Hospital, Central South University, No.138 Tongzipo Road, Yuelu District, Changsha, 410013, Hunan, China. zswang@163.com.", "Department of Pathology, The Third Xiangya Hospital, Central South University, No.138 Tongzipo Road, Yuelu District, Changsha, 410013, Hunan, China. 3117498882@qq.com."], "corresponding_authors": ["Shengwang Zhang", "Qian Chen"], "china_team": "Department of Pathology, The Third Xiangya Hospital, Central South University, No Shengwang Zhang/Qian Chen团队", "category": "clinical_review", "classification_reason": "clinical_signals=7", "score": 35.0, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 10.0, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 7.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.9, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.0, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42838997", "title": "Trends in incidence and prevalence of patients living long-term with de novo metastatic incurable cancer: a retrospective cohort study.", "abstract": "Therapeutic advances have improved the survival of incurable cancer patients, creating a growing population living long-term with incurable cancer. However, little is known about their epidemiological characteristics. We aimed to examine trends in annual incidence and prevalence among patients living long-term with de novo metastatic incurable cancer in the Netherlands and to describe additional relevant sociodemographic and clinical characteristics among patients diagnosed in recent years. A population-based, retrospective cohort study using data from the Netherlands Cancer Registry was performed. Adults (≥18 years) diagnosed with de novo metastatic solid tumors in 2000-2021 who survived ≥2 years after their diagnosis were included. Annual incidence, prevalence, key demographic, and tumor characteristics were calculated. Annual incident cases of patients living long-term with de novo metastatic incurable cancer increased from 1298 (2000) to 5398 (2021), representing 12.0-22.6% of incurable cancer diagnoses. In February 2024, at least 18,466 patients in the Netherlands were living long-term with de novo metastatic incurable cancer (1 per 1000 inhabitants). Mean age was 64 years (SD 12), 59.4% were male, and 55.8% (n = 10,310) were alive 2- < 5 years after diagnosis, 31.0% (n = 5721) 5- < 10 years, and 13.2% (n = 2435) ≥ 10 years. The most common tumor types were prostate (35.6%), lung (20.2%), breast (14.4%), and colorectal cancer (6.3%). Substantial increases in the incidence and prevalence were identified, reflecting a shift toward prolonged survival within the incurable cancer population. Greater awareness and research are needed to inform care for this emerging group.", "journal": "British Journal of Cancer", "pub_date": "2026-Oct-06", "publication_types": ["Journal Article"], "doi": "10.1016/J.ANNONC.2022.07.1941", "authors": ["Ruben Bouma", "Olaf P Geerse", "Natasja J H Raijmakers", "Heidi P Fransen", "Lia van Zuylen", "Anna K L Reyners", "Kristel van Asselt", "Maatje D A van Gastel", "Daan Brandenbarg", "Mariken E Stegmann"], "affiliations": ["Department of Primary and Long-term Care, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands. r.bouma02@umcg.nl.", "Medical Oncology, Amsterdam University Medical Center Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.", "Department of Pulmonary Diseases, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.", "Cancer Center Amsterdam, Treatment and Quality of Life, Amsterdam, The Netherlands.", "Department of Research & Development, Netherlands Comprehensive Cancer Organization (IKNL), Utrecht, the Netherlands.", "Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.", "Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Department of General Practice and Nursing Science, Utrecht, the Netherlands.", "Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.", "Department of Primary and Long-term Care, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands."], "corresponding_authors": ["Ruben Bouma"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=7", "score": 24.01, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 11.01, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 7.0}, "journal_metrics": {"status": "ok", "impact_factor": 6.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 3.01, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42838995", "title": "Clinical significance of circulating macrophage markers across different stages of prostate cancer: highlighting soluble CD163.", "abstract": "The clinical significance of circulating macrophage markers in prostate cancer (PC) is largely unexplored. Here, we hypothesised that serum levels of the macrophage markers CD163 and SIRPα might be associated with disease aggressiveness and hold prognostic potential in PC, where novel prognostic biomarkers are needed. Soluble CD163 (sCD163) and SIRPα (sSIRPα) were measured in serum by enzyme-linked immunosorbent assays in three PC cohorts representing different disease stages (N = 646 patients in total). Prognostic results in metastatic castration-resistant PC (mCRPC) were validated in an independent cohort (N = 161). Serum levels of sCD163 and sSIRPα were significantly higher in patients with metastatic vs localised PC (p < 0.05). In general, serum sCD163 and sSIRPα levels were not associated with clinical parameters of disease aggressiveness in patients with hormone-sensitive PC (p > 0.05). In mCRPC, high serum sCD163 levels predicted shorter progression-free survival (PFS) on first-line treatment independent of standard clinical parameters in both the training and validation cohort (training: HR: 1.77 (1.12-2.78), p = 0.014; validation: HR: 1.85 (1.15-2.97), p = 0.011). Circulating levels of sCD163 and sSIRPα were increased in patients with metastatic compared to localised PC. Further, higher sCD163 levels predicted worse PFS in mCRPC, suggesting potential as a future minimally-invasive biomarker to aid mCRPC prognostication.", "journal": "British Journal of Cancer", "pub_date": "2026-Oct-06", "publication_types": ["Journal Article"], "doi": "10.1186/s12885-024-12593-z", "authors": ["Emma B Hansen", "Kristian W Antonsen", "Mads R Jochumsen", "Paul V Salachan", "Kirsten Bouchelouche", "Torben F Hansen", "Palle J S Osther", "Ahmed H Zedan", "Michael Borre", "Holger J Møller", "Karina D Sørensen"], "affiliations": ["Department of Molecular Medicine (MOMA), Aarhus University Hospital, Aarhus, Denmark.", "Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.", "Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark.", "Department of Nuclear Medicine, Aarhus University Hospital, Aarhus, Denmark.", "Department of Oncology, Lillebaelt Hospital, University Hospital of Southern Denmark, Vejle, Denmark.", "Department of Regional Health Research, University of Southern Denmark, Odense, Denmark.", "Department of Urology, Vejle Hospital, University Hospital of Southern Denmark, Vejle, Denmark.", "Department of Urology, Aarhus University Hospital, Aarhus, Denmark.", "Department of Molecular Medicine (MOMA), Aarhus University Hospital, Aarhus, Denmark. kdso@clin.au.dk.", "Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. kdso@clin.au.dk."], "corresponding_authors": ["Karina D Sørensen"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=6", "score": 33.51, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 11.01, "top_journal_bonus": 0.0, "novelty": 2.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 6.0}, "journal_metrics": {"status": "ok", "impact_factor": 6.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 3.01, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42838990", "title": "How does PSA change after water vapor therapy? A systematic review and meta-analysis.", "abstract": "Prostate-specific antigen (PSA) kinetics following minimally invasive surgical therapies (MIST) for benign prostatic hyperplasia (BPH) remain incompletely characterized. Water vapor thermal therapy (Rezūm™) induces targeted tissue ablation and inflammatory remodeling, potentially affecting PSA levels over time. The aim of this review was to quantify PSA changes after Rezūm therapy and explore study-level correlates of PSA dynamics through a systematic review and meta-analysis. This systematic review followed PRISMA guidelines. PubMed/MEDLINE, Scopus, and Web of Science were searched for studies reporting baseline and post-treatment PSA after Rezūm therapy. The primary outcome was pooled mean change in PSA (ΔPSA) versus baseline at prespecified timepoints (1, 3, 6, 12 months, and last follow-up). Random-effects models using restricted maximum likelihood (REML) were applied, with heterogeneity assessed using Cochrane Q. Meta-regression explored associations between ΔPSA and study-level variables, including acute urinary retention (AUR), reintervention rates, symptom and flow improvements, and prostate volume. Thirteen studies were included. PSA followed a biphasic pattern. At 1 month, an early postoperative increase was observed (2 studies; ΔPSA = +2.38 ng/mL, 95% CI 1.62-3.14). From 3 months onward, PSA levels declined, reaching a moderate but non-statistically significant reduction at the last available follow-up (12 studies; ΔPSA = -0.44 ng/mL, 95% CI - 0.92 to 0.04), corresponding to an approximate 10% decrease from baseline. Meta-regression showed associations between ΔPSA and AUR (β = 0.0799, p = 0.034), reintervention rates (β = -0.226, p = 0.026), Qmax improvement (β = -0.0308, p = 0.028), baseline PSA (β = -0.536, p < 0.001), and baseline prostate volume (β = -0.0861, p = 0.002). Rezūm therapy is associated with a reproducible PSA trajectory characterized by an early transient increase followed by a moderate decline from 3-12 months (~10%). Because this late change is non-significant and within the expected variability of PSA, it is unlikely to modify follow-up strategy. Awareness of this pattern may support appropriate interpretation of PSA measurements after MIST for BPH.", "journal": "Prostate Cancer and Prostatic Diseases", "pub_date": "2026-Oct-06", "publication_types": ["Journal Article", "Review"], "doi": "10.1002/pros.24367", "authors": ["Pietro Scilipoti", "Marie Chicaud", "Federico Zorzi", "Giuseppe Rosiello", "Luca Villa", "Marco Bianchi", "Giorgio Gandaglia", "Alberto Briganti", "Francesco Montorsi", "Frédéric Panthier", "Olivier Traxer", "Steeve Doizi", "Stessy Kutchukian"], "affiliations": ["Service d'urologie, Tenon Hôpital, Rue de la chine 4,75020, Paris, France. scilipoti.pietro@hsr.it.", "GRC 20-Endolase Lab, Sorbonne Université and PIMM-Arts et Métiers ParisTech, Paris, France. scilipoti.pietro@hsr.it.", "Department of Experimental Oncology/Unit of Urology; URI; IRCCS Ospedale San Raffaele, Milan, Italy. scilipoti.pietro@hsr.it.", "Vita-Salute San Raffaele University, Milan, Italy. scilipoti.pietro@hsr.it.", "Endourology Technology Section of European Association of Urology (EAU), Arnhem, The Netherlands. scilipoti.pietro@hsr.it.", "Service d'urologie, Tenon Hôpital, Rue de la chine 4,75020, Paris, France.", "GRC 20-Endolase Lab, Sorbonne Université and PIMM-Arts et Métiers ParisTech, Paris, France.", "Department of Urology, Limoges University Hospital, Limoges, France.", "Department of Experimental Oncology/Unit of Urology; URI; IRCCS Ospedale San Raffaele, Milan, Italy.", "Vita-Salute San Raffaele University, Milan, Italy.", "Endourology Technology Section of European Association of Urology (EAU), Arnhem, The Netherlands.", "Department of Urology, Nimes University Hospital, Nîmes, France.", "Progress and Collaboration in Endourology Group (PACE), Paris, France."], "corresponding_authors": ["Pietro Scilipoti"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 25.81, "score_parts": {"urology_relevance": 11, "urology_in_title": 0.0, "journal_priority": 10.81, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 2.0}, "journal_metrics": {"status": "ok", "impact_factor": 5.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.81, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42838982", "title": "Preclinical animal models of lower urinary tract dysfunction associated with metabolic syndrome.", "abstract": "Lower urinary tract dysfunction (LUTD) substantially affects quality of life and is increasingly associated with metabolic syndrome (MetS). An intricate relationship exists between MetS components, such as obesity, diabetes, dyslipidaemia and hypertension, and bladder dysfunction. Insights from preclinical models show that MetS-driven autonomic dysfunction, increased intra-abdominal pressure, chronic bladder ischaemia, low-grade inflammation, dysregulated nutrient-sensing pathways and an altered oestrogen-to-testosterone ratio contribute to lower urinary tract symptoms. Diabetic models, such as streptozotocin-induced rodents and polygenic TallyHo mice, show biphasic diabetic LUTD progression, from detrusor hyperactivity to underactivity, driven by hyperglycaemia and neural degeneration. Obesity models, such as leptin-deficient ob/ob mice, undergo prostate and urethral changes exacerbating lower urinary tract symptoms, whereas dyslipidaemia models, such as Apoe-/- mice, show ischaemia-induced bladder remodelling. Hypertension and early-life stress further worsen LUTD through angiotensin-mediated pathways and visceral adiposity, respectively. Preclinical models provide important insights in this context but face limitations, including non-physiological bladder filling rates and interspecies differences, necessitating advanced approaches such as multi-omics and patient-derived urinoids. These tools could facilitate personalized therapies by elucidating disease mechanisms and enabling longitudinal monitoring but ethical challenges associated with clinical translation persist.", "journal": "Nature Reviews Urology", "pub_date": "2026-Oct-06", "publication_types": ["Journal Article", "Review"], "doi": "10.5213/inj.1938220.110", "authors": ["Claudia Covarrubias", "Stephanie Sirmakesyan", "Aalya Hamouda", "Sami Lasri", "Abdulla AlAmeeri", "Diery-Leando Saint-Vil", "Philippe G Cammisotto", "Lysanne Campeau"], "affiliations": ["Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada.", "Faculty of Medicine, McGill University, Montreal, Quebec, Canada.", "Division of Urology, Department of Surgery, McGill University, Montreal, Quebec, Canada.", "Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada. lysanne.campeau@mcgill.ca.", "Division of Urology, Department of Surgery, McGill University, Montreal, Quebec, Canada. lysanne.campeau@mcgill.ca."], "corresponding_authors": ["Lysanne Campeau"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 41.03, "score_parts": {"urology_relevance": 15, "urology_in_title": 8.0, "journal_priority": 16.03, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 14.6, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.03, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42838981", "title": "ctDNA in muscle-invasive bladder cancer - clinically actionable, not yet standardized.", "abstract": "", "journal": "Nature Reviews Urology", "pub_date": "2026-Oct-06", "publication_types": ["Journal Article"], "doi": "10.1200/OP-26-00311", "authors": ["Daniele Raggi", "Emanuele Crupi", "Lars Dyrskjøt"], "affiliations": ["Department of Medical Oncology, The Royal Marsden NHS Foundation Trust, London, UK. daniele.raggi@rmh.nhs.uk.", "Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.", "Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark. lars@clin.au.dk.", "Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. lars@clin.au.dk."], "corresponding_authors": ["Daniele Raggi", "Lars Dyrskjøt"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 25.03, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 16.03, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 14.6, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.03, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42838867", "title": "Metastasis-free Survival in High-risk Prostate Cancer: A Valid Surrogate, but Is it Transportable Across Strategies of Unequal Systemic Exposure?", "abstract": "Metastasis-free survival (MFS) may not have the same meaning after radical prostatectomy (RP) and radiotherapy (RT), largely because RT is typically combined with prolonged androgen-deprivation therapy (ADT), which can delay the clinical emergence of metastases. Therefore, MFS benefits cannot be assumed to have the same implications for overall survival across treatment strategies with different durations of systemic therapy. SPCG-15 will be important to clarify the interpretation of MFS when comparing RP with RT plus long-term ADT.", "journal": "European Urology Oncology", "pub_date": "2026-Oct-06", "publication_types": ["Editorial"], "doi": "10.1016/j.euo.2026.09.014", "authors": ["Michael Baboudjian", "Alessandro Uleri", "Giuseppe Fallara", "Alberto Martini", "Guillaume Ploussard"], "affiliations": ["Department of Urology, Assistance Publique des Hôpitaux de Marseille (APHM), North Academic Hospital, Marseille, France. Electronic address: michael.baboudjian@outlook.fr.", "Department of Urology, Josep Trueta University Hospital, Girona, Spain.", "Department of Urology, Department of Health Science, Aziende Socio Sanitarie Territoriali (ASST) Santi Paolo e Carlo, University of Milan, Milan, Italy.", "Department of Urology, University of Cincinnati, Cincinnati, USA.", "Department of Urology, La Croix du Sud Hôpital, Quint Fonsegrives, France."], "corresponding_authors": ["Michael Baboudjian"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 29.42, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 15.42, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 9.3, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.42, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "高危前列腺癌无转移生存期跨方案可比性存疑", "chinese_summary": "欧洲泌尿外科肿瘤学杂志10月发表社论指出，无转移生存期在前列腺癌根治术与放疗后含义可能不同，因放疗通常联合长期雄激素剥夺治疗，可能延迟转移灶的临床显现，故在不同全身治疗时长的策略间，该终点对总生存的替代意义不能简单等同。SPCG-15试验将有助于厘清。", "abstract_zh": "无转移生存期（MFS）在根治性前列腺切除术（RP）与放疗（RT）后可能不具有相同含义，主要因为放疗通常联合长期雄激素剥夺治疗（ADT），而后者可延迟转移灶的临床显现。因此，在全身治疗时长不同的治疗策略之间，不能假定MFS获益对总生存具有相同的意义。SPCG-15试验将对于在比较RP与RT联合长期ADT时如何解读MFS具有重要意义。"}, {"pmid": "42838802", "title": "Re: Perioperative Apalutamide In High-risk Localized Prostate Cancer.", "abstract": "", "journal": "European Urology", "pub_date": "2026-Oct-06", "publication_types": ["Journal Article"], "doi": "10.1016/j.eururo.2026.07.035", "authors": ["Matthew R Cooperberg"], "affiliations": ["Depts of Urology and Epidemiology & Biostatistics, UCSF Comprehensive Cancer Center. Electronic address: matthew.cooperberg@ucsf.edu."], "corresponding_authors": ["Matthew R Cooperberg"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 35.79, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 16.79, "top_journal_bonus": 10.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 25.2, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.79, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "高危前列腺癌围手术期阿帕鲁胺", "chinese_summary": "10月Eur Urol刊发评论，围绕高危局限性前列腺癌围手术期应用阿帕鲁胺展开讨论，关注其在根治性手术前后联合治疗中的潜在价值与证据边界。", "abstract_zh": "这是一篇关于高危局限性前列腺癌围手术期应用阿帕鲁胺的评论。"}, {"pmid": "42838801", "title": "Re: Aldo Brassetti, Gabriele Tuderti, Umberto Anceschi, et al. Sutureless Purely Off-clamp Robotic Partial Nephrectomy: Evidence from a Randomized Controlled Noninferiority Trial. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.04.019.", "abstract": "", "journal": "European Urology", "pub_date": "2026-Oct-06", "publication_types": ["Letter"], "doi": "10.1016/j.eururo.2026.06.019", "authors": ["Yan Huang", "Yang Liu"], "affiliations": ["Department of Urology, Dalian University of Technology Affiliated Cancer Hospital, Liaoning Provincial Cancer Hospital, Shenyang 110000, China.", "Department of Thoracic Surgery, Dalian University of Technology Affiliated Cancer Hospital, Liaoning Provincial Cancer Hospital, Shenyang 110000, China. Electronic address: ly530682464@163.com."], "corresponding_authors": ["Yang Liu"], "china_team": "Department of Urology, Dalian University of Technology Affiliated Cancer Hospital, Liaoning Provincial Cancer Hospital, Shenyang 110000, China Yang Liu团队", "category": "clinical_review", "classification_reason": "clinical_signals=4", "score": 39.79, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 16.79, "top_journal_bonus": 10.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 4.0}, "journal_metrics": {"status": "ok", "impact_factor": 25.2, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.79, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "免缝合零阻断肾部分切除术证据受关注", "chinese_summary": "大连理工大学附属肿瘤医院（辽宁省肿瘤医院）杨柳团队10月Eur Urol就Brassetti等免缝合纯零阻断机器人肾部分切除术随机非劣效试验发表通讯，认为该术式在选择性患者中可减少缺血损伤，但需进一步验证肿瘤学结局与适用标准。", "abstract_zh": "这是一封关于近期发表的随机对照非劣效性试验的通讯。该试验评估了免缝合纯零阻断机器人肾部分切除术的疗效。通讯作者来自中国大连理工大学附属肿瘤医院（辽宁省肿瘤医院）泌尿外科杨柳团队，对Brassetti等的研究结果进行了评论，讨论了该术式在减少缺血性损伤方面的潜在优势，同时指出其在肿瘤学结局与患者选择标准方面仍需进一步验证。"}, {"pmid": "42838800", "title": "Re: Targeted Prostate Cancer Screening in BRCA1 or BRCA2 Pathogenic Germline Variant Carriers Detects Clinically Relevant Disease: Five-year Results of the IMPACT Study.", "abstract": "", "journal": "European Urology", "pub_date": "2026-Oct-06", "publication_types": ["Journal Article"], "doi": "10.1016/j.eururo.2026.09.003", "authors": ["Francesco Greco"], "affiliations": ["Urology Unit, Centro Salute Uomo, Bergamo, Italy. Electronic address: francesco_greco@ymail.com."], "corresponding_authors": ["Francesco Greco"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 35.79, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 16.79, "top_journal_bonus": 10.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 25.2, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.79, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "BRCA突变者靶向前列腺癌筛查有效", "chinese_summary": "10月Eur Urol发布IMPACT研究五年结果，针对BRCA1或BRCA2致病性胚系变异携带者开展靶向前列腺癌筛查，检出具有临床意义的疾病，提示对该高危人群进行针对性筛查可发现需要干预的前列腺癌。", "abstract_zh": "这是一项针对BRCA1或BRCA2致病性胚系变异携带者开展靶向前列腺癌筛查的研究，报告IMPACT研究的五年结果，显示该筛查策略能够检出具有临床意义的前列腺癌。"}, {"pmid": "42838799", "title": "Major Adverse Cardiovascular Events in Men with High-risk Localized or Metastatic Prostate Cancer Starting Long-term Hormone Therapy in the STAMPEDE Trial.", "abstract": "Major adverse cardiovascular events (MACE) are a leading cause of noncancer death in men with prostate cancer (PCa). Androgen receptor pathway inhibitors (ARPIs) improve oncologic outcomes but may exacerbate cardiovascular risk. The Systematic Coronary Risk Evaluation 2(SCORE2) estimates 10-yr cardiovascular risk, yet its validity in men receiving treatment for PCa is untested. To evaluate the cardiovascular safety of ARPIs and other treatment intensification strategies within the STAMPEDE trial and assess SCORE2 performance. This post hoc analysis included patients allocated to the abiraterone acetate plus prednisolone (AAP), AAP plus enzalutamide (ENZ), docetaxel (DOC), zoledronic acid (ZA), and radiotherapy (RT) comparisons in STAMPEDE with linked health care records in England. Treatment intensification with AAP, AAP plus ENZ, DOC, ZA, or prostate RT in addition to standard-of-care androgen deprivation therapy (ADT). MACE were identified using prespecified International Classification of Diseases, 10th Revision, and Office of Population Censuses and Surveys Classification of Interventions and Procedures codes. Flexible parametric competing-risk models estimated cumulative incidence and subdistribution hazard ratios (SDHRs). SCORE2 discrimination and calibration were evaluated. A total of 6292 men were included. The 5-yr cumulative MACE incidence with ARPI intensification was 9% in nonmetastatic (M0) disease and 7% in metastatic (M1) disease, comparable to ADT alone. ARPI intensification was not associated with a statistically significant increase in MACE risk (AAP: M0 SDHR 1.15 [95% confidence interval {CI} 0.80-1.67], M1 SDHR 1.36 [95% CI 0.87-2.10]; AAP plus ENZ: M0 SDHR 1.34 [95% CI 0.91-1.98], M1 SDHR 1.28 [95% CI 0.85-1.94]). Cardiovascular disease history was the strongest predictor of MACE. Among 5076 patients eligible for SCORE2 assessment, 4239 had complete baseline data. SCORE2 discrimination was modest (10-yr area under the curve 0.63 for M0 disease and 0.61 for M1 disease), and absolute cardiovascular risk was underestimated. Limitations included underrepresentation of patients with severe cardiovascular comorbidity. No statistically significant increase in MACE was observed with ARPIs, DOC, ZA, or prostate RT compared with ADT alone. SCORE2 underestimated cardiovascular risk, supporting development of PCa-specific cardiovascular risk models.", "journal": "European Urology", "pub_date": "2026-Oct-06", "publication_types": ["Journal Article"], "doi": "10.1016/j.eururo.2026.09.001", "authors": ["Omar El-Taji", "Peter Dutey-Magni", "Mick Brown", "Macey Murray", "Claire Amos", "Duncan Gilbert", "Max Parmar", "Louise Brown", "Matthew Sydes", "Gert Attard", "Nicholas James", "Noel W Clarke", "Ashwin Sachdeva", "STAMPEDE Collaborators"], "affiliations": ["Genito Urinary Cancer Research Group, Division of Cancer Sciences, University of Manchester, Manchester, UK; Department of Surgery, The Christie National Health Service (NHS) Foundation Trust, Manchester, UK; Department of Urology, Salford Royal Hospital, Northern Care Alliance National Health Service (NHS) Foundation Trust, Manchester, UK.", "Medical Research Council (MRC) Clinical Trials Unit at University College London (UCL), Institute of Clinical Trials and Methodology, University College London, London, UK.", "Genito Urinary Cancer Research Group, Division of Cancer Sciences, University of Manchester, Manchester, UK.", "Medical Research Council (MRC) Clinical Trials Unit at University College London (UCL), Institute of Clinical Trials and Methodology, University College London, London, UK; British Heart Foundation (BHF) Data Science Centre, London, UK.", "University College London (UCL) Cancer Institute, University College London, London, UK; University College London Hospitals National Health Service (NHS) Trust, London, UK.", "The Royal Marsden National Health Service (NHS) Foundation Trust, London, UK; The Institute of Cancer Research, London, UK.", "Genito Urinary Cancer Research Group, Division of Cancer Sciences, University of Manchester, Manchester, UK; Department of Surgery, The Christie National Health Service (NHS) Foundation Trust, Manchester, UK. Electronic address: ashwin.sachdeva@manchester.ac.uk."], "corresponding_authors": ["Ashwin Sachdeva"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=3", "score": 43.79, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 16.79, "top_journal_bonus": 10.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 3.0}, "journal_metrics": {"status": "ok", "impact_factor": 25.2, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.79, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "高危前列腺癌激素治疗心血管风险未显著增加", "chinese_summary": "STAMPEDE试验事后分析纳入6292例高危局限或转移性前列腺癌患者，对比ADT基础上加用阿比特龙、恩扎卢胺、多西他赛、唑来膦酸或放疗，5年MACE累积发生率9%（M0）和7%（M1），与ADT单药相当，未观察到MACE风险显著升高；SCORE2模型区分度仅0.63/0.61且低估风险，提示需开发前列腺癌专用心血管风险模型。", "abstract_zh": "主要不良心血管事件（MACE）是前列腺癌（PCa）男性非癌症死亡的主要原因。雄激素受体通路抑制剂（ARPI）改善肿瘤学结局，但可能加重心血管风险。系统性冠状动脉风险评估2（SCORE2）可估算10年心血管风险，但其在接受PCa治疗的男性中的有效性尚未得到验证。旨在评估STAMPEDE试验中ARPI及其他治疗强化策略的心血管安全性，并评估SCORE2的表现。这项事后分析纳入STAMPEDE中分配至醋酸阿比特龙联合泼尼松龙（AAP）、AAP联合恩扎卢胺（ENZ）、多西他赛（DOC）、唑来膦酸（ZA）和放疗（RT）比较组的患者，并链接英格兰的医疗记录。治疗强化为在标准治疗雄激素剥夺治疗（ADT）基础上加用AAP、AAP联合ENZ、DOC、ZA或前列腺RT。MACE通过预先设定的国际疾病分类第10版和人口普查与调查办公室干预与手术分类编码进行识别。采用灵活参数竞争风险模型估计累积发生率和亚分布风险比（SDHR）。评估SCORE2的区分度和校准度。共纳入6292例男性。ARPI强化的5年累积MACE发生率在非转移性（M0）疾病中为9%，在转移性（M1）疾病中为7%，与单纯ADT相当。ARPI强化与MACE风险统计学显著增加无关（AAP：M0 SDHR 1.15 [95%置信区间{CI} 0.80-1.67]，M1 SDHR 1.36 [95% CI 0.87-2.10]；AAP联合ENZ：M0 SDHR 1.34 [95% CI 0.91-1.98]，M1 SDHR 1.28 [95% CI 0.85-1.94]）。心血管疾病史是MACE最强的预测因素。在5076例符合SCORE2评估条件的患者中，4239例具有完整基线数据。SCORE2区分度中等（10年曲线下面积M0疾病为0.63，M1疾病为0.61），且绝对心血管风险被低估。局限性包括严重心血管合并症患者代表性不足。与单纯ADT相比，ARPI、DOC、ZA或前列腺RT未观察到MACE统计学显著增加。SCORE2低估了心血管风险，支持开发PCa特异性心血管风险模型。"}, {"pmid": "42838743", "title": "Artificial Intelligence (AI)-enhanced journal club: integrating podcasts, AI, and social media in medical education.", "abstract": "To develop and evaluate an artificial intelligence (AI)-assisted, multimedia journal club model that improves accessibility by transforming scientific articles into on-demand educational formats distributed through digital platforms. This prospective single-centre educational evaluation was conducted at King's College Hospital (London). Six AI-enhanced journal club sessions were implemented between June and September 2025. Peer-reviewed urology articles were processed using AI-assisted tools to generate podcasts, slide presentations, short-form video summaries, question-and-answer materials, and visual infographics. Content was distributed through clinician-facing platforms including YouTube, Spotify, and social media. Two surveys evaluated educational impact: a format-specific survey completed by 48 participants and a second survey assessing overall perceptions of the AI-enhanced journal club completed by 19 participants. The AI-generated podcast was the most preferred format (62.5%), followed by video summaries (16.7%) and slide presentations (8.3%). Participants reported greater engagement compared with traditional journal clubs, with 54.2% selecting the response option 'much more engaged'. Format-specific ratings were consistently high, particularly for podcasts (mean [standard deviation, SD] score for engagement 4.6 [0.6] and for clarity 4.8 [0.5]). In the second survey, overall ratings of the AI-enhanced journal club were high across all domains, including engagement (mean [SD] score 4.8 [0.4]), clarity (mean [SD] score 4.8 [0.5]), time efficiency (mean [SD] score 4.7 [0.6]), and overall preference (mean [SD] score 4.9 [0.3]). An AI-assisted, multimodal journal club integrating podcasts, slides, and digital dissemination was associated with improved participant-reported engagement and accessibility. This scalable model supports asynchronous learning and may complement traditional journal club formats in postgraduate medical education.", "journal": "BJU International", "pub_date": "2026-Oct-06", "publication_types": ["Journal Article"], "doi": "10.1111/bju.70479", "authors": ["Mohamed Abouelenein", "Muhammed Arif Ibis", "Molly Nichols", "Azhar Khan", "Maria Satchi", "Nicholas Raison", "Kawa Omar", "Francesca Kum", "Tet Yap", "Edward James Bass", "Kalyan Gudaru", "Shyaw Ahmed", "Sanjith Gnanappiragasam", "Fabio Castiglione", "Omer Onur Cakir"], "affiliations": ["Department of Urology, King's College Hospital, London, UK.", "Department of Urology, Ankara University School of Medicine, Ankara, Turkey.", "King's College London, London, UK.", "King's Fertility Centre, The Fetal Medicine Research Institute, London, UK.", "School of Biomedical Engineering and Imaging Sciences, King's College London, London, UK.", "Department of Urology, Guy's and St Thomas' Hospital, London, UK."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=4", "score": 21.47, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 10.47, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 4.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.4, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.47, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42838165", "title": "PDZ domain containing 1 sensitizes renal cancer cells to everolimus via inhibiting phosphatase and tensin homolog phosphorylation-mediated mTOR pathway activation.", "abstract": "Aberrant activation of the phosphatase and tensin homolog (PTEN)-PI3K/AKT/mTOR pathway is a key driver of renal cell carcinoma (RCC) progression, making mTOR inhibition with everolimus a critical therapeutic strategy. However, the mechanisms driving mTOR pathway activation and the emergence of drug resistance remain poorly understood. In this study, we found that phosphorylated PTEN (pPTEN at S380/T382/T383) level was increased in RCC. Increased pPTEN level was associated with impaired suppression of mTOR pathway activation, and was accompanied by RCC progression and resistance to everolimus. Conversely, inhibition of PTEN phosphorylation restored PTEN function, reducing tumor growth and restoring sensitivity to everolimus. Further investigation revealed that downregulation of PDZ domain-containing 1 (PDZK1) in RCC tissues increased pPTEN level, resulting in mTOR pathway activation. PDZK1 was found to inhibit RCC malignancy by preventing PTEN phosphorylation and mTOR activation. Moreover, PDZK1 overexpression sensitized RCC cells to everolimus across cell, animal and organoid models. In conclusion, our findings indicate that PDZK1 downregulation in RCC cells contributes to pPTEN accumulation, mTOR pathway activation, and everolimus resistance. This highlights the PDZK1-pPTEN axis as a potential therapeutic target in RCC, suggesting that modulating PDZK1 or PTEN phosphorylation could enhance the efficacy of everolimus treatment.", "journal": "International Journal of Biological Macromolecules", "pub_date": "2026-Oct-06", "publication_types": ["Journal Article"], "doi": "10.1016/j.ijbiomac.2026.154763", "authors": ["Yinong Niu", "Zhiyu Fang", "Lei Wang", "Mingshi Liu", "Shuang Chen", "Peng Yang", "Yuanfeng Lan", "Duiping Feng", "Junqi He", "Ran Song", "Junfang Zheng"], "affiliations": ["Department of Urology, Beijing Friendship Hospital, Capital Medical University, Beijing, 100050, China; Institute of Urology, Beijing Municipal Health Commission, China.", "Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Capital Medical University, Beijing, 100069, China; Department of Laboratory Medicine, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.", "Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Capital Medical University, Beijing, 100069, China.", "Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Capital Medical University, Beijing, 100069, China; Laboratory for Clinical Medicine, Capital Medical University, Beijing, 100069, China.", "Department of Oncological and Vascular Intervention, First Hospital of Shanxi Medical University, No. 85 Jiefang South Road, Yingze District, Taiyuan, 030001, Shanxi Province, China; Shanxi Provincial Clinical Research Center for Interventional Medicine, First Hospital of Shanxi Medical University, Taiyuan, 030001, Shanxi Province, China.", "Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Capital Medical University, Beijing, 100069, China; Laboratory for Clinical Medicine, Capital Medical University, Beijing, 100069, China. Electronic address: ransong@ccmu.edu.cn.", "Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Capital Medical University, Beijing, 100069, China. Electronic address: zhengjf@ccmu.edu.cn."], "corresponding_authors": ["Ran Song", "Junfang Zheng"], "china_team": "Department of Urology, Beijing Friendship Hospital, Capital Medical University, Beijing, 100050, China; Institute of Urology, Beijing Municipal Health Commission, China Ran Song/Junfang Zheng团队", "category": "basic", "classification_reason": "basic_signals=11", "score": 28.3, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 11.3, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 11.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 8.5, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 3.3, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "PDZK1缺失致肾癌依维莫司耐药", "chinese_summary": "首都医科大学附属北京友谊医院宋然/郑俊芳团队10月Int J Biol Macromol报道，肾癌中PDZK1下调使PTEN磷酸化累积并激活mTOR通路，削弱依维莫司敏感性；过表达PDZK1可逆转耐药。", "abstract_zh": "磷酸酶及张力蛋白同源物（PTEN）-PI3K/AKT/mTOR通路的异常激活是肾细胞癌（RCC）进展的关键驱动因素，使得依维莫司抑制mTOR成为一种关键治疗策略。然而，驱动mTOR通路激活的机制及耐药性的出现仍知之甚少。在本研究中，我们发现RCC中磷酸化PTEN（pPTEN，S380/T382/T383位点）水平升高。pPTEN水平升高与mTOR通路激活抑制受损相关，并伴随RCC进展和依维莫司耐药。相反，抑制PTEN磷酸化可恢复PTEN功能，减少肿瘤生长并恢复对依维莫司的敏感性。进一步研究发现，RCC组织中含PDZ结构域蛋白1（PDZK1）的下调增加了pPTEN水平，导致mTOR通路激活。PDZK1被发现通过阻止PTEN磷酸化和mTOR激活来抑制RCC恶性程度。此外，PDZK1过表达在细胞、动物和类器官模型中均使RCC细胞对依维莫司敏感。总之，我们的发现表明，RCC细胞中PDZK1下调导致pPTEN积累、mTOR通路激活和依维莫司耐药。这凸显了PDZK1-pPTEN轴作为RCC潜在治疗靶点，提示调节PDZK1或PTEN磷酸化可增强依维莫司治疗的疗效。"}, {"pmid": "42838066", "title": "Mental health and urinary incontinence in childhood.", "abstract": "Intermittent and uncontrolled loss of urine is common among children but requires medical attention when it persists beyond age 5 years. Mostly functional in origin, urinary incontinence is caused by a complex inter-relationship of biopsychosocial factors, and evidence shows that mental health problems and adverse childhood experiences (ACEs) are common in children and adolescents with urinary incontinence. Mental health problems and ACEs (including abuse, neglect, and household dysfunction) could be both causes and consequences of paediatric urinary incontinence, but research is needed to understand causal pathways. Treatment guidelines increasingly recognise the need to integrate assessment of psychosocial factors and mental health support into clinical care pathways for children affected by urinary incontinence. Parental and societal beliefs, cultural norms, availability of sanitation facilities, economic constraints, and policy-level gaps affect the management of paediatric urinary incontinence. Early assessment and treatment are needed to prevent urinary incontinence from becoming chronic and negatively impacting on children's quality of life, wellbeing, and education.", "journal": "Lancet Child & Adolescent Health", "pub_date": "2026-Oct-06", "publication_types": ["Journal Article", "Review"], "doi": "10.1016/S2352-4642(26)00219-1", "authors": ["Carol Joinson", "Mauro Van den Ende", "Sonya S Brady", "Sanjay Sinha", "Desiree Vrijens", "Davina Richardson", "Anna Page", "Carsten Leue", "Alexander von Gontard"], "affiliations": ["Centre for Academic Child Health, Department of Population Health Sciences, Bristol Medical School, Bristol, UK. Electronic address: carol.joinson@bristol.ac.uk.", "Department of Urology, University Hospital of Ghent, Ghent, Belgium.", "Department of Family Medicine and Community Health, University of Minnesota Medical School, Minneapolis, MN, USA.", "Apollo Hospital Education and Research Foundation, Apollo Hospital, Hyderabad, India.", "Department of Urology, Maastricht University Medical Center, Maastricht, Netherlands.", "Bladder & Bowel UK, Manchester, UK.", "Evelina Children's Hospital, Guy's and St Thomas' NHS Foundation Trust, London, UK.", "Institute of Mental Health and Neuroscience, Maastricht University, Maastricht, Netherlands; Department of Psychiatry, Maastricht University Medical Center, Maastricht, Netherlands.", "Governor Kremers Center, Department of Urology, Maastricht University Medical Center, Maastricht, Netherlands."], "corresponding_authors": ["Carol Joinson"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 44.11, "score_parts": {"urology_relevance": 7, "urology_in_title": 8.0, "journal_priority": 16.11, "top_journal_bonus": 10.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 1.0}, "journal_metrics": {"status": "ok", "impact_factor": 15.5, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.11, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "儿童尿失禁与心理健康双向关联", "chinese_summary": "10月Lancet Child Adolesc Health综述指出，儿童尿失禁多属功能性，由生物心理社会因素交互所致。心理问题与虐待、忽视等不良童年经历既是其成因也可能是后果，指南日益强调将心理评估与支持整合入诊疗路径，并需早期干预以防迁延损害生活质量与学业。", "abstract_zh": "间歇性和不受控的尿失禁在儿童中常见，但若持续超过5岁则需就医。儿童尿失禁大多为功能性，由生物心理社会因素的复杂相互作用引起；证据显示，心理健康问题和不良童年经历（ACEs）在患有尿失禁的儿童和青少年中常见。心理健康问题和ACEs（包括虐待、忽视和家庭功能障碍）可能既是儿童尿失禁的原因，也是其结果，但需要开展研究以理解其因果路径。治疗指南日益认识到，有必要将心理社会因素评估和心理健康支持整合到受尿失禁影响儿童的临床诊疗路径中。父母和社会的观念、文化规范、卫生设施的可用性、经济限制以及政策层面的缺口，都会影响儿童尿失禁的管理。需要早期评估和治疗，以防止尿失禁转为慢性并对儿童的生活质量、福祉和教育产生负面影响。"}, {"pmid": "42837196", "title": "Pharmacologic HIF-2α inhibition preserves T cell effector function in clear cell renal cell carcinoma.", "abstract": "Hypoxia-inducible factor 2α (HIF-2α) is a central oncogenic driver in clear cell renal cell carcinoma (ccRCC) and a therapeutic target of the small-molecule inhibitor belzutifan. Genetic studies in murine models have suggested that hypoxia signaling may support T cell effector programs, raising concern that HIF-2α inhibition could impair antitumor immunity. However, whether pharmacologic HIF-2α inhibition alters human T cell biology remains unknown. Here, we investigated the cell-intrinsic effects of EPAS1 (encoding HIF-2α) perturbation in primary human T cells. CRISPR/Cas9-mediated deletion of HIF-2α demonstrated no notable transcriptional effects. Similarly, pharmacologic treatment with belzutifan produced minimal transcriptional changes and did not impair proliferation, cytokine production, polyfunctionality, or cytotoxic activity in T cells derived from healthy donor peripheral blood, peripheral blood from patients with ccRCC, or tumor-infiltrating lymphocytes under hypoxic conditions. High- dimensional immunophenotyping revealed preserved T cell differentiation and activation states following pharmacologic HIF-2α inhibition in vitro and in peripheral blood from patients receiving HIF-2α inhibitor therapy. Together, these findings demonstrate that pharmacologic HIF-2α inhibition preserves key effector programs, providing a mechanistic basis for the immunologic safety of HIF-2α-targeted therapy in ccRCC.", "journal": "Journal of Clinical Investigation", "pub_date": "2026-Oct-06", "publication_types": ["Journal Article"], "doi": "10.1172/JCI204613", "authors": ["Katrine N Madsen", "Soki Kashima", "Hanna Soulati", "Lena Wirth", "Katsuhiro Ito", "Zachary A Yochum", "Vivien Moritz", "Julia Walker", "Marc Machaalani", "Fady Ghali", "Patrick Kenney", "Adebowale Adeniran", "Michael Hurwitz", "Toni K Choueiri", "David A Braun"], "affiliations": ["Center of Molecular and Cellular Oncology, Yale Cancer Center, Yale School of Medicine, New Haven, United States of America.", "Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, United States of America.", "Department of Urology, Yale School of Medicine, New Haven, United States of America.", "Department of Pathology, Yale School of Medicine, New Haven, United States of America.", "Section of Medical Oncology, Department of Internal Medicine, Yale School of Medicine, New Haven, United States of America."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "basic_signals=9", "score": 38.93, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 15.93, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 9.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 13.6, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.93, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "HIF-2α抑制剂不影响T细胞杀伤功能", "chinese_summary": "10月J Clin Invest发表研究，采用CRISPR/Cas9及belzutifan处理原代人T细胞，发现HIF-2α缺失或药理抑制均未显著改变转录组，也不损害增殖、细胞因子分泌、多功能性及细胞毒性，患者外周血及肿瘤浸润淋巴细胞同样保持分化与活化状态，支持HIF-2α靶向治疗的免疫安全性。", "abstract_zh": "缺氧诱导因子2α（HIF-2α）是透明细胞肾细胞癌（ccRCC）的核心致癌驱动因子，也是小分子抑制剂belzutifan的治疗靶点。小鼠模型中的遗传学研究提示，缺氧信号可能支持T细胞效应程序，这引发了HIF-2α抑制可能损害抗肿瘤免疫的担忧。然而，药理学HIF-2α抑制是否改变人类T细胞生物学仍不清楚。在此，我们研究了EPAS1（编码HIF-2α）扰动对原代人T细胞的细胞内在效应。CRISPR/Cas9介导的HIF-2α缺失未显示出显著的转录效应。同样，belzutifan药理学处理产生的转录变化极小，并且在缺氧条件下，对来自健康供体外周血、ccRCC患者外周血或肿瘤浸润淋巴细胞的T细胞，均未损害其增殖、细胞因子产生、多功能性或细胞毒性活性。高维免疫表型分析显示，在体外药理学HIF-2α抑制后以及接受HIF-2α抑制剂治疗的患者外周血中，T细胞分化和活化状态得以保持。总之，这些发现表明药理学HIF-2α抑制保留了关键效应程序，为ccRCC中HIF-2α靶向治疗的免疫安全性提供了机制基础。"}, {"pmid": "42837186", "title": "Impact of sexual debut on urethral immunology and microbiome in adolescent males from Rakai, Uganda.", "abstract": "The penile urethra is a primary site of HIV acquisition in males, although little is known about the urethral determinants of HIV susceptibility. Inflammation at other genital sites enhances HIV risk, and studies suggest that some inflammatory urethral bacteria may be vaginally acquired. Here, we characterize the impact of sexual debut on the microbiome and immune milieu of the penile urethra in adolescent males from Rakai, Uganda. A cohort of 185 self-reported sexually naïve adolescent males from Rakai, Uganda were followed longitudinally for 3 years, with questionnaires administered every 3 months and urethral swabs collected annually. Urethral soluble immune factors were quantified by chemiluminescent multiplex immunoassay and bacterial 16S rRNA sequencing was performed. Unsupervised clustering and mixed-effects models were used to assess associations between sexual debut and the urethral microbiome and immune milieu. Unsupervised clustering at 36 months identified two distinct urethral Community State Types (CSTs): CST-1 was dominated by Streptococcus mitis and CST-2 by bacteria associated with bacterial vaginosis (BV), particularly Sneathia amnii and Gardnerella vaginalis. CST-2 was greatly enriched at 36 months compared to baseline and was associated strongly with sexual debut. Individual bacterial taxa enriched in CST-2 were associated with both sexual debut and elevated urethral inflammatory cytokines, independent of serum testosterone and penile circumcision status. The penile urethra is colonized by BV-associated bacteria after penile-vaginal sex debut. Their presence in the urethra induces local inflammation and may serve as a reservoir for subsequent reintroduction into the vagina of female sexual partners.", "journal": "Journal of Clinical Investigation", "pub_date": "2026-Oct-06", "publication_types": ["Journal Article"], "doi": "10.1172/JCI208629", "authors": ["Rameen Jamil", "Sanja Huibner", "Ping Yang", "James Nnamutete", "Jodie L White", "Lori Sokoll", "James Pollock", "Margaret Nakalanzi", "Simon Peter Bukenya", "Stephen D Kiboneka", "Mathias Agaba", "Mary J Nalubowa", "Aggrey Anok", "Godfrey Kigozi", "Ronald M Galiwango", "Bryan Coburn", "Cindy M Liu", "Jessica L Prodger", "Aaron Ar Tobian", "Rupert Kaul"], "affiliations": ["Department of Immunology, University of Toronto, Toronto, Canada.", "Department of Pathology, The Johns Hopkins University, Baltimore, United States of America.", "Rakai Health Sciences Program, Kalisizo, Uganda.", "Department of Environmental and Occupational Health, Milken Institute School of Public Health, George Washington University, Washington, DC, United States of America.", "Department of Microbiology and Immunology, Western University, London, Canada."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 39.93, "score_parts": {"urology_relevance": 7, "urology_in_title": 8.0, "journal_priority": 15.93, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 5.0, "abstract_completeness": 2.0, "basic_research_strength": 2.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 13.6, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.93, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "首次性行为改变尿道菌群与免疫", "chinese_summary": "乌干达Rakai 10月J Clin Invest对185名自报无性经历青少年男性随访3年，发现首次性行为后尿道富集与细菌性阴道病相关菌群，尤以Sneathia amnii和Gardnerella vaginalis为主，并伴尿道炎症因子升高，提示尿道或成为HIV易感及阴道菌群再定植的储库。", "abstract_zh": "阴茎尿道是男性HIV感染的主要部位，但人们对尿道中决定HIV易感性的因素知之甚少。其他生殖器部位的炎症会增加HIV风险，且研究提示某些具炎症性的尿道细菌可能经阴道获得。在此，我们刻画了乌干达Rakai青春期男性性行为开始对阴茎尿道微生物组和免疫环境的影响。我们对185名自报无性经历的乌干达Rakai青春期男性进行为期3年的纵向随访，每3个月发放问卷，每年采集尿道拭子。通过化学发光多重免疫测定定量尿道可溶性免疫因子，并进行细菌16S rRNA测序。采用无监督聚类和混合效应模型评估性行为开始与尿道微生物组及免疫环境之间的关联。第36个月的无监督聚类识别出两种不同的尿道群落状态类型（CST）：CST-1以缓症链球菌为主，CST-2以与细菌性阴道病（BV）相关的细菌为主，特别是Sneathia amnii和Gardnerella vaginalis。与基线相比，CST-2在第36个月显著富集，并与性行为开始强烈相关。CST-2中富集的个别细菌分类群与性行为开始和尿道炎症细胞因子升高均相关，且独立于血清睾酮水平和阴茎包皮环切状态。阴茎尿道在阴茎-阴道性行为开始后被BV相关细菌定植。这些细菌在尿道中的存在可诱导局部炎症，并可能成为随后重新引入女性性伴侣阴道的储库。"}, {"pmid": "42837013", "title": "Patient awareness and perceptions of a kidney stone multidisciplinary team (MDT): a questionnaire survey.", "abstract": "Kidney stone disease (KSD) is a common condition associated with high recurrence rates and significant healthcare costs. Multidisciplinary team (MDT) working has become central to the management of many complex conditions; however, its use in KSD remains inconsistent. This questionnaire survey aimed to evaluate patient awareness, understanding, and perceptions of the kidney stone MDT, while identifying opportunities to improve communication and patient engagement. A single-centre questionnaire survey was conducted among patients attending the Southampton General Hospital Urology Department (Southampton, UK) between September and December 2025. Patients with and without a history of KSD were invited to complete an anonymous online questionnaire distributed via QR code. The survey included 17 items consisting of multiple-choice, Likert-scale, and open-ended questions assessing awareness of MDT working, perceived benefits, communication preferences, and areas for improvement. Descriptive statistics and chi-squared testing were used for analysis. A total of 151 responses were collected, including 51 (33.8%) patients with KSD and 100 (66.2%) without KSD. Most respondents believed that MDT working improved both the quality and efficiency of care, and approximately 84% stated that they would want their case discussed within an MDT. Baseline awareness of the MDT system was low, however 92% self-reported improved understanding immediately after participation in the questionnaire. Patients expressed a preference for greater involvement in MDT decision-making, with mean involvement scores of 6.63 and 6.78 among KSD and non-KSD participants, respectively. Email was the most commonly selected communication method within this digitally recruited cohort. No statistically significant differences were detected between groups, but the study was not powered to establish equivalence. Among respondents, attitudes toward the kidney stone MDT were generally positive, although these findings should be interpreted in the context of a self-selected, single-centre sample. Baseline understanding of MDT working was limited, highlighting opportunities to improve patient information and communication. Future work should use validated tools, broader multicentre recruitment and objective clinical and patient-reported outcomes to evaluate MDT-based care.", "journal": "World Journal of Urology", "pub_date": "2026-Oct-06", "publication_types": ["Journal Article"], "doi": "10.1007/s00345-026-06842-y", "authors": ["John Bose", "Amelia Pietropaolo", "Sohani N Dassanayake", "Bhaskar Kumar Somani"], "affiliations": ["University Hospital Southampton NHS Foundation Trust, Southampton, UK.", "University Hospital Southampton NHS Foundation Trust, Southampton, UK. bhaskarsomani@yahoo.com."], "corresponding_authors": ["Bhaskar Kumar Somani"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=6", "score": 34.0, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 10.0, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 6.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.9, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.0, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42837000", "title": "Preoperative CT-based markers and inflammatory parameters as predictors of failed ureteroscopic access in unstented patients with ureteral stones: a prospective single-center cohort study.", "abstract": "Failed ureteroscopic access (FA) in unstented patients remains a significant clinical challenge. We aimed to identify preoperative clinical, laboratory, and CT-based predictors of FA, determine optimal cutoff values, and develop a clinically applicable risk-stratification model. This prospective cohort study enrolled 141 consecutive patients with ureteral stones undergoing unstented ureteroscopy (83 semi-rigid, 58 flexible) at a tertiary center (January 2024-January 2025). Preoperative demographics, pain characteristics, inflammatory markers (TLC, ESR, CRP, procalcitonin), and NCCT parameters (stone size, density, ureteral wall thickness [UWT], perinephric fat stranding [PFS] grade, hydronephrosis grade, HU of hydronephrosis, renal parenchymal thickness) were compared between successful access (SA, n = 112) and failed access (FA, n = 29) groups. Firth's penalized logistic regression, ROC analysis with DeLong comparison, and decision curve analysis (DCA) were performed. FA occurred in 29 patients (20.6%). UWT demonstrated the highest discriminatory power (AUC 0.965; cutoff ≥ 2.7 mm; sensitivity 96.6%, specificity 99.1%), followed by PFS grade (AUC 0.963; cutoff ≥ 2; sensitivity 100%, specificity 89.3%) and procalcitonin (AUC 0.957; cutoff ≥ 0.2 ng/mL). On Firth's penalized multivariate analysis, the primary two-variable Firth model identified UWT (OR 62.20 per mm; p < 0.001) and upper ureteral location (OR 14.27; p = 0.040) as independently associated with failed access (apparent AUC 0.986; 5-fold cross-validated AUC 0.967). The combined model achieved an AUC of 0.997 as an exploratory model with adequate calibration (Hosmer-Lemeshow test, p = 0.936). Exploratory DCA suggested potential net benefit across clinically relevant threshold probabilities. UWT ≥ 2.7 mm and PFS grade ≥ 2 on preoperative NCCT may be useful predictors of FA during unstented ureteroscopy, although these findings require external validation before clinical application. Incorporating these readily measurable CT parameters into a proposed preoperative risk-stratification algorithm may optimise surgical planning and patient counselling.", "journal": "Urolithiasis", "pub_date": "2026-Oct-06", "publication_types": ["Journal Article"], "doi": "10.1007/s00240-026-02050-w", "authors": ["Khaled M Abdelhalim", "Esam A Ahmed", "Ezzat A Ismail", "Isaac S Wasfy"], "affiliations": ["Urology Department, Faculty of Medicine, Suez Canal University Hospital, Ismailia, 41522, Egypt. kabdelhalim@med.suez.edu.eg.", "Urology Department, Faculty of Medicine, Suez Canal University Hospital, Ismailia, 41522, Egypt."], "corresponding_authors": ["Khaled M Abdelhalim"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=6", "score": 25.71, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 5.71, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 6.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.2, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.71, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42836687", "title": "Global Disparities in the Availability and Reimbursement of Systemic Therapies for Renal Cell Carcinoma: Results of the International ARON-AID Survey.", "abstract": "Renal Cell Carcinoma (RCC) represents a growing global health burden, with rising incidence and mortality worldwide. Despite major therapeutic advances, access to novel systemic treatments remains uneven across countries and regions. We conducted a cross-sectional, web-based international survey to assess the availability and reimbursement status of 20 innovative systemic therapies for RCC. Responses were collected from 144 clinicians, including medical oncologists, radiation oncologists, urologists, and nuclear medicine specialists, across 58 countries. Analyses examined associations between national income level, gross domestic product (GDP), and treatment availability. 36% of the countries analysed had at least 15 of the 20 therapies available. Full reimbursement for at least 15 of the selected innovative therapies was reported in six countries (10%), while 21 countries (36%) fully reimbursed 10-14 therapies and 13 countries (23%) reimbursed 1-9 therapies. In contrast, no full reimbursement for any of the assessed therapies was reported in 18 countries (31%). Higher national income level was significantly associated with greater availability of innovative therapies (Kruskal-Wallis test, p < 0·0001). Armenia (0·709), Greece (0·685), and Israel (0·666) exhibited the highest GDP-adjusted Drug Availability Index (DAI), whereas India (5·195), Nigeria (4·612), and Morocco (3·794) demonstrated the greatest number of available therapies per US$1000 of GDP per capita. Access to innovative systemic therapies for RCC remains highly unequal at the global level, with reimbursement posing a major barrier even where drugs are available. Internationally coordinated efforts addressing health policy, infrastructure, and equitable pricing are urgently required to ensure that advances in RCC treatment translate into improved outcomes for patients across diverse economic settings.", "journal": "Oncologist", "pub_date": "2026-Oct-06", "publication_types": ["Journal Article"], "doi": "10.1093/oncolo/oyag397", "authors": ["Yuksel Urun", "Kannan Sridharan", "Anca Zgura", "Anas Zayed", "Martin Ignacio Zapata Laguado", "Tarkan Yetisyigit", "Akihiro Yano", "Mike Wenzel", "Nuno Vau", "Deniz Tural", "Karine Trindade", "Ben Tran", "Frederic Ivan Leong Ting", "Arnoud J Templeton", "Hideki Takeshita", "Kaisa Sunela", "Vinicius Carrera Souza", "Mopa Alina Sooro", "Andrey Soares", "Shankar Siva", "Ashish Singh", "Glauco Silveira", "Shamik Shah", "Emmanuel Seront", "Fabio A Schutz", "Maitê de Liz Vassen Schurmann", "Timothy Schieber", "Sarah Scagliarini", "Amalya Sargsyan", "Carlos Salinas Simonetti", "Marine Rushanyan", "Giandomenico Roviello", "Alejo Rodriguez-Vida", "Orion Erenhu Rodriguez Gonzalez", "Robin Roberts", "Astrid A M Van der Veldt", "Mimma Rizzo", "Alessandro Rizzo", "Alexandr Poprach", "Alina Pirshtuk", "Alvaro Pinto", "Erin Pierce", "Jose Mauricio Peñaloza", "Martino Pedrani", "Se Hoon Park", "Ibukun Adewumi Okunade", "Karen Flora Odounga", "Julio Noriega", "Edriss Noorzai", "Maria Tereza Nieto Coronel", "Jiri Navratil", "Zin W Myint", "Vladan Mutavdzic", "Olivier Mukuku", "Robert Mugarura", "Fernando Sabino Marques Monteiro", "Abdikarim Hussein Mohamed", "Daniel Mmereki", "Carlo Messina", "Bohuslav Melichar", "Pitchou Mukaz Mbey", "Ernesto Maturana", "Diana Matthews", "Francesco Massari", "Esther Martínez", "Priyamvada Maitre", "Patrick Maison", "Beaud Conrad Mabika Ndjembidouma", "Kevin Lu", "Jiakun Li", "Haoran Li", "Luciana de Moura Leite", "Aly-Khan A Lalani", "Zsófia Küronya", "Jakub Kucharz", "Arnaud Boris Koumba", "Ray Manneh Kopp", "Jindrich Kopecky", "Alba J Kihn-Alarcón", "Özge Keskin", "Kymbat Kabdullina", "Álvaro Juarez", "María José Juan Fita", "Denis Leonardo Jardim", "Laurianne Grégoria James", "Enrique Grande", "Alfonso Gómez De Liaño", "Patrizia Giannatempo", "Marwan Ghosn", "Cinthia Gauna", "Maria Natalia Gandur Quiroga", "Kazutoshi Fujita", "Marcelo Roberto Pereira Freitas", "Ondřej Fiala", "Mauricio Fernandez Lazzaro", "Glenda M Falcon Pacheco", "Theophilus Olaide Esan", "Deborah Tolulope Esan", "Danelo Du Plessis", "Silvia Neciosup Delgado", "Simon J Crabb", "Rafael Correa Cano", "Luis Corrales", "Jixiang Chen", "Federico Cayol", "Clarissa Cavalin Silva", "André Paternò Castello Dias Carneiro", "Georgiana Anca Caprinciu", "Saul Campos", "Thomas Büttner", "Sebastiano Buti", "Nedal Bukhari", "Tomas Buchler", "Maria T Bourlon", "Hatice Bolek", "Martin Boegemann", "Mehmet A Bilen", "Laura Bernal Vaca", "Diogo Assed Bastos", "Philippe Barthelemy", "Samvel Bardakhchyan", "Maria Alexandra Barbu", "Jalal Baranseh", "Aristotelis Bamias", "Alex Bakenga", "Georgia Anguera", "Martin Angel", "Carolina Alves Costa Silva", "Teresa Alonso-Gordoa", "Fahad Almugbel", "Roula Almufti", "Thiago Lins Almeida", "Altay Aliyev", "Carlos Aliaga", "Umair Aleem", "Erman Akkus", "Luis Garcia Aceituno", "Syed Hani Abidi", "Halima Abahssain", "Francesca Tartari", "Javier Molina-Cerrillo", "Matteo Santoni"], "affiliations": ["Department of Medical Oncology, Ankara University Faculty of Medicine, 06620 Ankara, Türkiye.", "Cancer Research Institute, Ankara University, Ankara, Turkiye.", "Department of Pharmacology & Therapeutics, College of Medicine & Health Sciences, Arabian Gulf University, Kingdom of Bahrain.", "Department of Obstetrics-Radiotherapy, Alexandru Trestioreanu Institute of Oncology, \"Carol Davila\" University of Medicine and Pharmacy, Bucharest, Romania.", "Department of Internal Medicine, King Hussein Cancer Center, Amman, Jordan.", "Department of Clinical Oncology, Instituto Nacional de Cancerología, Bogotá, Colombia.", "Department of Medical Oncology, Bahrain Oncology Center, Muharraq, Bahrain.", "Department of Urology, Saitama Medical Center, Saitama Medical University, Kawagoe, Saitama, Japan.", "Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main, Germany.", "Department of Medical Oncology, Koç University School of Medicine, Istanbul, Turkey.", "Oncocentro Ceará (Rede D'Or), Fortaleza, Brazil.", "Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia.", "Section of Medical Oncology, Department of Internal Medicine, Corazon Locsin Montelibano Memorial Regional Hospital, Bacolod 6100, Philippines.", "Department of Clinical Sciences, College of Medicine, University of St. La Salle, Bacolod 6100, Philippines.", "Faculty of Medicine, University of Basel, Basel, Switzerland.", "Department of Oncology, St. Claraspital, Basel, Switzerland.", "St. Clara Research, Basel, Switzerland.", "International University of Health and Welfare Hospital, 852 Hatakeda, Narita-shi, Chiba 286-8520, Japan.", "Finnish Medicines Agency, Tampere, Finland.", "Oncologia D'OR, Salvador, Brazil.", "Jiangsu Key Laboratory of New Drug Screening & Jiangsu Center for Pharmacodynamics Research and Evaluation, China Pharmaceutical University, Nanjing 210009, China.", "Latin American Cooperative Oncology Group - LACOG, Porto Alegre, Brazil.", "Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.", "Department of Radiation Oncology and Sir Peter MacCallum Department of Oncology, Peter MacCallum Cancer Centre, University of Melbourne, Victoria, Australia.", "Department of Medical Oncology, Christian Medical College, Vellore-632004, Tamil Nadu, India.", "Centro Oncológico do Triângulo, Uberlândia, Brazil.", "Consultant and Head, Department of Nephrology, King Hamad American Mission Hospital, Kingdom of Bahrain.", "Department of Medical Oncology, Cliniques Universitaires Saint Luc, Brussel, Belgium.", "Beneficência Portuguesa de São Paulo, São Paulo, SP, Brazil.", "ANIMI - Unidad de Tratamento Oncológico, Lages, SC, Brazil.", "Division of Medical Oncology, Department of Internal Medicine, University of Kansas Cancer Center, Westwood, KS, USA.", "Department of Medical Oncology, AORN \"A. Cardarelli\", Naples, Italy.", "Immune Oncology Research Institute, 7 Nersisyan, 0014, Yerevan, Armenia.", "Yeolyan Hematology and Oncology Center, Yerevan, Armenia.", "Yerevan State Medical University, Yerevan, Armenia.", "Medical Oncology Service, Bradford Hill, Santiago de Chile, Chile.", "Department of Oncology, Gyumri Medical Center, Gyumri, Armenia.", "Department of Health Sciences, University of Florence, Florence, Italy.", "Hospital del Mar Research Institute, Barcelona, Spain.", "Escuela Militar de Graduados de Sanidad, Batalla de Celaya 202, Lomas de Sotelo, Militar, Miguel Hidalgo, 11200, Ciudad de México, Mexico.", "Hospital Militar Regional de Especialidades Guadalajara, Reforma, Colonia Centro, C.P. 44890, Guadalajara, Jalisco, Mexico.", "UWI School of Clinical Medicine and Research, Nassau, The Bahamas.", "Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.", "Medical Oncology Unit, Azienda Ospedaliera Universitaria Consorziale Policlinico di Bari, Bari, Italy.", "S.S.D. C.O.r.O. Bed Management Presa in Carico, TDM, IRCCS Istituto Tumori \"Giovanni Paolo II\", Bari, Italy.", "Masaryk Memorial Cancer Institute, Brno, Czech Republic.", "Faculty of Medicine, Masaryk University, Brno, Czech Republic.", "Department of Oncology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic.", "Department of Medical Oncology, Hospital Universitario La Paz, Madrid, Spain.", "HonorHealth Research Institute, 10510 N. 92nd St., Suite 100, Scottsdale, AZ 85258, United States.", "Centro Oncológico Integral, Neuquén, Argentina.", "Istituto Oncologico Svizzera Italiana, Ente Ospedaliero Cantonale, Ospedale Regionale Bellinzona e Valli, 6500 Bellinzona, Switzerland.", "Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.", "Bowen University Teaching Hospital, P.O. Box 15, Ogbomoso, Oyo State, Nigeria.", "Bowen University, P.M.B. 284, Iwo, Osun State, Nigeria.", "Service Pharmacie, Institut de Cancérologie de Libreville, Libreville, Gabon.", "Fox Chase Cancer Center, Philadelphia, PA 19111, USA.", "Peninsula Health, Hastings Road, Frankston, VIC 3199, Australia.", "Oncopalia.MyA Center, Medical Oncology Departament, La Paz City, Bolivia.", "Division of Medical Oncology, Markey Cancer Center, University of Kentucky, Lexington, KY, USA.", "Department of Oncology, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia.", "University Clinical Center Kragujevac, 34000 Kragujevac, Serbia.", "Department of Maternal and Child Health, High Institute of Medical Techniques, Lubumbashi, Democratic Republic of the Congo.", "Department of Surgery, Kabale University, Kabale District, Uganda.", "ARON Research Foundation ETS, Galleria del Commercio n. 6, Macerata, Italy.", "Hospital Sírio-Libanês, Brasília, DF, Brazil.", "Kaafi Hospital, Mogadishu, Somalia.", "University of the Witwatersrand, Faculty of Health Sciences, Division of Radiation Oncology, Johannesburg, 2193, South Africa.", "Oncology Unit, UOC Oncologia ARNAS Civico Benfratelli di Cristina, Piazza Nicola Leotta 4, 90127 Palermo, Italy.", "Palacký University Olomouc and University Hospital, Faculty of Medicine and Dentistry, Department of Oncology, Zdravotníků 248, 775 20, Olomouc, Czech Republic.", "Department of Surgery, Faculty of Medicine, University of Lubumbashi, Lubumbashi, Democratic Republic of the Congo.", "Department of Surgery, Urology, Faculty of Medicine, University of Kinshasa, Kinshasa, Democratic Republic of the Congo.", "Pontificia Universidad Católica de Chile, Avenida Libertador Bernardo O'Higgins 340, Santiago, CL-8320000, Chile.", "Velindre Cancer Centre, Velindre Road, Whitchurch, Cardiff, Wales.", "Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.", "Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy.", "Hospital Universitario de Jaén, Jaén, Spain.", "Radiation Oncology, Advanced Centre for Treatment, Research and Education in Cancer (ACTREC) and Tata Memorial Hospital (TMH), Homi Bhabha National Institute, Mumbai 400094, India.", "Department of Surgery, School of Medical Sciences, University of Cape Coast, Cape Coast, Ghana.", "Departement of Medical Physics and Radiotherapy, Akanda Cancer Institute, Libreville, Gabon.", "Department of Urology, Kaohsiung Medical University Hospital & College of Medicine, Kaohsiung Medical University.", "Department of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, PR China.", "AC Camargo Cancer Center.", "Department of Medical Oncology, Juravinski Cancer Centre, McMaster University, Hamilton, Canada.", "Urogenitális Tumorok és Klinikai Farmakológiai Osztály, Országos Onkológiai Intézet, Budapest, Hungary.", "Semmelweis University, Department of Clinical Oncology.", "Department of Uro-Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.", "Department of Nuclear Medicine, Akanda Cancer Institute, Libreville, Gabon.", "Clinical Oncology, Sociedad de Oncología y Hematología del Cesar, Valledupar, Colombia.", "Department of Clinical Oncology and Radiotherapy, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic.", "Research Department, Liga Nacional Contra el Cáncer & Instituto de Cancerología, 6a Avenida 6-58, Cdad. de Guatemala 01011, Guatemala.", "Bahrain Oncology Center, King Hamad University Hospital, Medical Oncology Department, AlMuharraq, Bahrain.", "Department of Biomedical Sciences, Nazarbayev University School of Medicine, Astana, Kazakhstan.", "Department of Urology, Jerez University Hospital, Jerez, Spain.", "Department of Medical Oncology, Fundación Instituto Valenciano de Oncología (IVO), Valencia, Spain.", "Oncology Center - Hospital Sírio-Libanês, São Paulo, Brazil.", "Grupo Oncoclínicas, São Paulo, SP, Brazil.", "Department of Medical Oncology, Quirónsalud Madrid, Spain.", "Medical Oncology Department, CHU Insular-Materno Infantil, Las Palmas, Spain.", "Dipartimento di Oncologia Medica, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.", "Department of Hematology-Oncology, Hotel-Dieu de France University Hospital, Beirut, Lebanon.", "Instituto Nacional del Cáncer, Capiatá, Paraguay.", "Division of Genitourinary Medical Oncology, Instituto de Oncologia Ángel H. Roffo, Buenos Aires, Argentina.", "Department of Urology Faculty of Medicine, Kindai University, Osaka, Japan.", "Centro de Pesquisas Oncológicas - CEPON, Florianópolis, SC, Brazil.", "Department of Oncology and Radiotherapeutics, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic.", "Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.", "Department of Uro-Oncology, Fundacion COIR, Mendoza, M5500 Argentina.", "Instituto Regional de Enfermedades Neoplásicas del Sur, Arequipa, Perú.", "Federal Teaching Hospital, Ido-Ekiti, Nigeria.", "Faculty of Nursing Sciences, College of Health Sciences, Bowen University, Iwo, Nigeria.", "Division of Urology, Faculty of Health Science, University of Stellenbosch, Cape Town, 7505, South Africa.", "Tygerberg Hospital, Francie van Zijl Avenue, Parow, Cape Town, 7505, Western Cape, South Africa.", "Department of Medical Oncology, National Institute of Neoplastic Diseases, Lima, Peru.", "Cancer Research UK Southampton Clinical Trials Unit, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, Hampshire, UK.", "Department of Geriatric Oncology, Instituto Nacional de Ciencias Médicas y Nutrición \"Salvador Zubirán\", Ciudad de México, México.", "Department of Medical Oncology, Center for Cancer Research and Management (CIMCA), San Jose, Costa Rica.", "Sección de Oncología, Servicio de Medicina Interna, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.", "CardioHub Medicina Diagnóstica, Rio de Janeiro, Brazil.", "Hospital Municipal Vila Santa Catarina, São Paulo, SP, Brazil.", "Oncologie (clinica), Affidea - Sema Parc Bucuresti, Romania.", "Centro Oncologico Estatal \"Dr José Luis Barrera Franco\" del ISSEMYM, Toluca de Lerdo, Mexico.", "Department of Urology and Paediatric Urology, University Hospital Bonn, Bonn, Germany.", "Medical Oncology Unit, University Hospital of Parma, Parma, Italy.", "Department of Medicine and Surgery, University of Parma, Parma, Italy.", "Oncology Department, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.", "Hematology and Oncology Department, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.", "Department of Medical Oncology, Ankara University School of Medicine, Ankara, 06590, Turkey.", "Ankara University Cancer Institute, Ankara, Turkey.", "University of Muenster Medical Center, Department of Urology, Muenster, Germany.", "West German Cancer Center, Muenster, Germany.", "Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia, USA.", "Servicio de Oncología, Clínica Universitaria Colombia - Clínica de Marly, Bogotá, Colombia.", "Hospital Sirio Libanes, Sao Paulo, Sao Paulo, Brazil.", "Department of Medical Oncology, ICANS, Strasbourg, France.", "Department 8-Radiology, Oncology, Hematology, Faculty of Medicine \"Carol Davila\" University of Medicine and Pharmacy Bucharest Romania.", "MedEuropa Center of Oncology and Radiation Therapy Bucharest  Romania.", "Oncology Wing, RAMBAM Health Care Campus, Haifa, Israel.", "2nd Propaedeutic Department of Internal Medicine, ATTIKON University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.", "Department of Medical Oncology and Hematology, Uganda Cancer Institute, Kampala, Uganda.", "Department of Medical Oncology, Hospital de La Santa Creu i Sant Pau, Barcelona, Spain.", "Clinical Oncology, Genitourinary Oncology Unit, Alexander Fleming Institute, Buenos Aires, Argentina.", "Gonçalo Moniz Institute, Fiocruz, Salvador, Bahia, Brazil.", "School of Medicine, Federal University of Bahia, Salvador, Bahia, Brazil.", "Medical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain.", "Cancer Center of Excellence, King Faisal Specialist Hospital & Research Centre, Riyadh 11211, Saudi Arabia.", "Medical Oncology Department, King Faisal Specialist Hospital and Research Centre, Jeddah, Saudi Arabia.", "Universidade Federal da Paraíba, Reitoria - Campus I, Cidade Universitária, s/n - Bairro Castelo Branco, João Pessoa - PB, Brazil.", "Department of Oncology, Liv Bona Dea Hospital, Baku, Azerbaijan.", "Servicio de Oncología, Centro Oncológico Aliada, Lima 15036, Peru.", "Department of Medical Oncology, The Christie NHS Foundation Trust, 550 Wilmslow Road, Withington, Manchester, M20 4BX, UK.", "Clinica Medica Especializada en Oncologia Medica, Guatemala City, Guatemala.", "Oncology and Medical Specialties Department, Valenciennes General Hospital, 59300 Valenciennes, France.", "Equipe de Recherche en Oncologie Translationnelle (EROT), Faculty of Medicine and Pharmacy, University Mohammed V in Rabat, Rabat 10100, Morocco.", "Medical Oncology Unit, Macerata Hospital, Macerata, Italy."], "corresponding_authors": [], "china_team": "Jiangsu Key Laboratory of New Drug Screening & Jiangsu Center for Pharmacodynamics Research and Evaluation, China Pharmaceutical University, Nanjing 210009, China Kevin Lu团队", "category": "clinical_review", "classification_reason": "clinical_signals=3", "score": 32.42, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 10.42, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 3.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.2, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.42, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42836684", "title": "Baseline 25-Hydroxyvitamin D and Progression-Free Survival in de novo mHSPC: Prognostic Model Development and External Validation.", "abstract": "Prognostic biomarkers for risk stratification remain limited in de novo metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen receptor pathway inhibitors (ARPIs). We evaluated baseline serum 25-hydroxyvitamin D [25(OH)D] and developed and externally validated a progression-free survival (PFS) model. This multicenter retrospective study included 273 patients initiating ARPI-based therapy between January 2021 and April 2026. Etlik City Hospital formed the training cohort (n = 192; 85 PFS events), and Gazi University and Kütahya City Hospital formed the external validation cohort (n = 81; 27 PFS events). LASSO-penalized Cox regression retained age, ISUP grade group, CHAARTED disease volume, log-transformed PSA, and hemoglobin. Model B added continuous 25(OH)D. Internal validation used 1,000 bootstrap resamples. Performance was assessed by Harrell C-index, time-dependent AUC, and calibration at 1 and 2 years. PFS was the primary endpoint; overall survival analyses were exploratory. The study was not prospectively registered. Higher baseline 25(OH)D was associated with longer PFS in Model B (HR per 10-ng/mL increase, 0.64; 95% CI, 0.49-0.83; p<.001). Adding 25(OH)D improved model fit (likelihood-ratio χ²=12.71; p<.001) and increased apparent C-index from 0.712 to 0.740. In external validation, C-indices were 0.71 (95% CI, 0.64-0.78) and 0.76 (95% CI, 0.69-0.83), respectively (Δ = 0.05; 95% CI, 0.01-0.10). Baseline 25(OH)D added modest prognostic information beyond clinical factors, with supportive external validation. These findings do not establish treatment-predictive utility or benefit from vitamin D supplementation. Prospective validation is needed before clinical implementation.", "journal": "Oncologist", "pub_date": "2026-Oct-06", "publication_types": ["Journal Article"], "doi": "10.1093/oncolo/oyag396", "authors": ["Galip Can Uyar", "Kadriye Başkurt", "Orhun Akdoğan", "Enes Yeşilbaş", "Mustafa Ersoy", "Tuba Uğur Tuzcu", "Kadriye Bir Yücel", "Mustafa Altınbaş", "Ömür Berna Çakmak Öksüzoğlu", "Gökşen İnanç İmamoğlu", "Osman Sütcüoğlu"], "affiliations": ["Department of Medical Oncology, Etlik City Hospital, Ankara, Turkey.", "Department of Medical Oncology, Faculty of Medicine, Gazi University, Ankara, Turkey.", "Department of Medical Oncology, Kütahya City Hospital, Kütahya, Turkey."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=12", "score": 28.92, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 10.42, "top_journal_bonus": 0.0, "novelty": 0.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 12.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.2, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.42, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42836653", "title": "Projected impact of population-level multi-cancer early detection screening: a discrete event simulation analysis.", "abstract": "Cancer screening for multiple cancers simultaneously, rather than one cancer at a time, has emerged as a promising strategy for population-level cancer screening, largely driven by the advent and rapid development of liquid biopsy-based multi-cancer early detection (MCED) tests. However, their potential impact on mortality across cancer types remains incompletely characterized. We developed a patient-level, cross-cohort discrete event simulation model calibrated to SEER age-specific incidence for ages 18-80 across 1939-2001 birth cohorts for ten cancers, stratified by sex and race (non-Hispanic White and Black). Early detection benefit was modeled by shifting cancers to localized disease and advancing detection by literature-derived sojourn times, under detection sensitivities from 10% to 100%. The multicancer natural history model achieved calibration for all ten cancers, with modeled incidence closely approximating SEER-observed incidence. Under ideal early detection, pooled cancer mortality fell by 41.0%, from 6.42% to 3.79% of the simulated population, with similar proportional reductions across sex-race strata (39.9% to 43.9%). The largest site-specific reductions occurred for prostate cancer in males and ovarian cancer in females, while liver and bladder cancers benefited least. Overdiagnosis ranged from 10.9% to 28.9%, with lung cancer highest. Our MCED framework projects population-level mortality reduction from early multi-cancer detection. Under ideal screening conditions, cancer mortality benefits varied by cancer type, reflecting differences in both the length of the preclinical detectable window and survival at localized stage. This calibrated multicancer model provides a flexible framework for evaluating MCED blood tests as clinical trial data on test performance become available.", "journal": "Journal of the National Cancer Institute", "pub_date": "2026-Oct-06", "publication_types": ["Journal Article"], "doi": "10.1093/jnci/djag356", "authors": ["Nitish Aswani", "Jiheum Park", "Francesca Lim", "Matthew T Prest", "Jennifer S Ferris", "Jeong Yun Yang", "Liyuan Gong", "Stella K Kang", "Chin Hur"], "affiliations": ["Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA.", "Department of Obstetrics & Gynecology, Columbia University Irving Medical Center, New York, NY, USA.", "Department of Radiology, Columbia University Irving Medical Center, New York, NY, USA."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=7", "score": 33.09, "score_parts": {"urology_relevance": 8, "urology_in_title": 0.0, "journal_priority": 15.09, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 7.0}, "journal_metrics": {"status": "ok", "impact_factor": 7.2, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.09, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42836583", "title": "Modeling Wilms Tumor Development with Multiple Lineage Human Fetal Kidney Organoids Reveals the Cellular Origin and Specific Drivers of Tumorigenesis.", "abstract": "Dysregulation of kidney organogenesis can lead to the development of Wilms tumor (WT), a common pediatric kidney cancer. Although numerous mutations implicated in WT have been identified through genomic studies, the cellular origin and driver mutations in WT remain unclear due to the lack of human models that preserve the complete lineage diversity of the developing kidney. Here, we established an in vitro condition to generate 3D human fetal kidney organoids (FekOs) phenocopying aspects of in vivo renal cellular heterogeneity and complex organization. FekOs faithfully recapitulated the spatial arrangement of ureteric bud (UB) structures and nephron segments. FekOs could be expanded over long time periods. Screening of clinically relevant mutations in WT identified key driver mutations and combinations that result in tumor-like neoplasms. Notably, distinct lineages were isolated from fetal kidney tissues to generate UB organoids and nephron organoids, mapping driver mutations to their specific cellular origins. Together, this model provides insights into how different mutations and their combinations drive Wilms tumorigenesis, providing a scalable platform for advancing human kidney developmental disease research.", "journal": "Cancer Research", "pub_date": "2026-Oct-06", "publication_types": ["Journal Article"], "doi": "10.1158/0008-5472.CAN-26-0060", "authors": ["Xiaofeng Gong", "Qing Li", "Zhaoting Xu", "Jianchen Peng", "Yanming Xu", "Quanhui Dai", "Songnian Yue", "Yangyang Ma", "Bing Zhao"], "affiliations": ["Nanchang University Nanchang China.", "Nanchang University Hangzhou China.", "Nanchang University Shanghai China.", "Kunming Medical University kunming China.", "bioGenous BIOTECH Shanghai China.", "Inner Mongolia University huhehaote, inner mongolia China.", "Children's Hospital of Fudan University Shanghai China."], "corresponding_authors": [], "china_team": "Nanchang University Nanchang China Bing Zhao团队", "category": "basic", "classification_reason": "basic_signals=9", "score": 49.21, "score_parts": {"urology_relevance": 12, "urology_in_title": 0.0, "journal_priority": 16.21, "top_journal_bonus": 10.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 9.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 16.6, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.21, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "人胎肾类器官揭示肾母细胞瘤起源", "chinese_summary": "南昌大学Bing Zhao团队10月Cancer Res建立人胎肾多谱系3D类器官（FekOs），可长期扩增并重现输尿管芽与肾单位空间排列，将WT驱动突变定位至特定细胞起源，为肾母细胞瘤发生机制及药物筛选提供可扩展平台。", "abstract_zh": "肾脏器官发生的失调可导致肾母细胞瘤（WT）的发生，这是一种常见的儿童肾癌。尽管通过基因组研究已鉴定出众多与WT相关的突变，但由于缺乏能够保留发育中肾脏完整谱系多样性的人类模型，WT的细胞起源和驱动突变仍不清楚。在此，我们建立了一种体外条件，用于生成三维人胎儿肾脏类器官（FekOs），其表型模拟了体内肾脏细胞异质性和复杂组织的多个方面。FekOs忠实地再现了输尿管芽（UB）结构和肾单位的空间排列。FekOs能够长期扩增。对WT中临床相关突变的筛选确定了导致肿瘤样新生物的关键驱动突变及其组合。值得注意的是，从胎儿肾脏组织中分离出不同的谱系以生成UB类器官和肾单位类器官，从而将驱动突变定位到其特定的细胞起源。总之，该模型为不同突变及其组合如何驱动肾母细胞瘤的发生提供了见解，并为推进人类肾脏发育疾病研究提供了一个可扩展的平台。"}, {"pmid": "42834722", "title": "Advancing Personalized Care for Neurogenic Bladder: Editorial.", "abstract": "", "journal": "Neurourology and Urodynamics", "pub_date": "2026-Oct-05", "publication_types": ["Editorial"], "doi": "10.1002/nau.70463", "authors": ["Genevieve Nadeau", "Blayne Welk"], "affiliations": ["University of Laval, Laval, Quebec, Canada.", "Western University, London, Ontario, Canada."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 14.56, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 5.56, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 1.9, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.56, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42834176", "title": "Evolution or revolution - the GALEAS Bladder molecular urine test for triaging patients with haematuria.", "abstract": "", "journal": "Nature Reviews Urology", "pub_date": "2026-Oct-05", "publication_types": ["Journal Article"], "doi": "10.1111/bju.16206", "authors": ["Douglas G Ward", "Lee Silcock", "Jayne Louise Douglas-Moore", "Richard T Bryan"], "affiliations": ["Bladder Cancer Research Centre, Department of Cancer and Genomic Sciences, College of Medicine and Health, University of Birmingham, Birmingham, UK.", "Nonacus Limited, Birmingham, UK.", "University Hospitals of Leicester NHS Trust, Leicester, UK.", "Bladder Cancer Research Centre, Department of Cancer and Genomic Sciences, College of Medicine and Health, University of Birmingham, Birmingham, UK. r.t.bryan@bham.ac.uk."], "corresponding_authors": ["Richard T Bryan"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 25.03, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 16.03, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 14.6, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.03, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "尿液分子检测助力血尿分层", "chinese_summary": "10月Nat Rev Urol评述GALEAS Bladder尿液分子检测用于血尿患者分诊，指出该检测有望减少不必要的膀胱镜检查，同时强调需进一步前瞻性验证以明确其在临床路径中的定位。", "abstract_zh": "这是对GALEAS Bladder分子尿液检测用于血尿患者分诊的评述。血尿是膀胱癌最常见的临床表现，但多数血尿患者并无恶性肿瘤。目前的标准分诊依赖膀胱镜检查，该检查有创、费用较高且对患者造成负担。GALEAS Bladder是一种基于尿液的分子检测，旨在对血尿患者进行风险分层，从而可能减少对低风险患者进行不必要的膀胱镜检查。本评述讨论了该检测的潜在价值，包括其提高诊断效率、优化医疗资源利用的可能性，同时也指出在将其纳入常规临床实践之前，仍需开展前瞻性研究以验证其临床效用、成本效益及对患者结局的影响。"}, {"pmid": "42834174", "title": "The divergence in new therapy options for patients undergoing bladder-sparing radiation versus cystectomy.", "abstract": "", "journal": "Nature Reviews Urology", "pub_date": "2026-Oct-05", "publication_types": ["Journal Article"], "doi": "10.1200/JCO-25-01608", "authors": ["Mohini Varughese", "Anna Wilkins"], "affiliations": ["Department of Oncology, Royal Devon University Hospital NHS Foundation Trust, Exeter, UK.", "Faculty of Health and Life Sciences, University of Exeter, Exeter, UK.", "Division of Radiotherapy and Imaging, Institute of Cancer Research, London, UK. anna.wilkins@icr.ac.uk.", "Royal Marsden Hospital NHS Trust, London, UK. anna.wilkins@icr.ac.uk."], "corresponding_authors": ["Anna Wilkins"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 29.53, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 16.03, "top_journal_bonus": 0.0, "novelty": 0.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 14.6, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.03, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "保膀胱放疗与根治术新疗法路径分化", "chinese_summary": "10月Nat Rev Urol刊文指出，接受保膀胱放疗与根治性膀胱切除术的膀胱癌患者，其新型治疗选择正呈现明显分化。文章比较两条治疗路径在系统治疗、免疫治疗及靶向药物整合上的差异，提示临床决策需综合肿瘤分期、患者体能及意愿，并强调多学科协作以优化个体化方案。", "abstract_zh": "接受保膀胱放疗与根治性膀胱切除术的患者在新型治疗选择上出现分化。"}, {"pmid": "42833933", "title": "Re: Philip Cornford, Roderick C.N. van den Bergh, Erik Briers, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2026 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2026.04.013.", "abstract": "", "journal": "European Urology", "pub_date": "2026-Oct-05", "publication_types": ["Letter"], "doi": "10.1016/j.eururo.2026.08.027", "authors": ["Armando Stabile", "Leonardo Quarta", "Pietro Scilipoti", "Federico Dehò", "Alberto Briganti", "Francesco Montorsi"], "affiliations": ["Department of Urology and Division of Experimental Oncology, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute, Milan, Italy.", "ASST Sette Laghi - Circolo & Fondazione Macchi Hospital, University of Insubria, Varese, Italy.", "Department of Urology and Division of Experimental Oncology, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute, Milan, Italy. Electronic address: montorsi.francesco@hsr.it."], "corresponding_authors": ["Francesco Montorsi"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 35.79, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 16.79, "top_journal_bonus": 10.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 25.2, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.79, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "欧洲泌尿学会更新前列腺癌指南", "chinese_summary": "欧洲泌尿学会联合多家学会10月Eur Urol发布2026版前列腺癌指南更新第一部分，聚焦筛查、诊断与根治性局部治疗。此次更新在既有推荐框架上纳入新证据，为前列腺癌早期发现及治愈性治疗提供最新参考。", "abstract_zh": "Re: Philip Cornford, Roderick C.N. van den Bergh, Erik Briers, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2026 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2026.04.013."}, {"pmid": "42833926", "title": "Efficacy and Safety of Olaparib plus Abiraterone Versus Placebo plus Abiraterone in the Non-BRCA Mutation Subgroup of Patients with Metastatic Castration-resistant Prostate Cancer in the PROpel Trial.", "abstract": "The phase 3 PROpel trial (NCT03732820) demonstrated statistically significant and clinically meaningful radiographic progression-free survival (rPFS) benefit and numerically prolonged overall survival (OS) for olaparib plus abiraterone versus placebo plus abiraterone in first-line metastatic castration-resistant prostate cancer (mCRPC). The greatest benefit was in patients with a BRCA1 and/or BRCA2 mutation (BRCAm). To inform treatment decision-making, we report analyses in the non-BRCAm subgroup in PROpel. Patients were randomized (1:1) to olaparib plus abiraterone with prednisone/prednisolone versus placebo plus abiraterone with prednisone/prednisolone. Patients without BRCAm were classified as having no positive BRCAm result by at least one prespecified tumour tissue or circulating tumour DNA test. Post hoc exploratory analyses included rPFS, OS, additional efficacy end points, health-related quality of life (HRQoL), and safety. Median investigator-assessed rPFS in the non-BRCAm subgroup (n = 693) was 24.1 mo for olaparib plus abiraterone versus 19.0 mo for placebo plus abiraterone (hazard ratio [HR] 0.76, 95% confidence interval [CI] 0.61-0.94). Median OS was 39.6 versus 38.0 mo, respectively (HR 0.91, 95% CI 0.73-1.13). Additional post hoc exploratory analyses support these efficacy findings for olaparib plus abiraterone. There was no significant difference in HRQoL between treatment arms. Safety findings were consistent with the overall biomarker-unselected population. Olaparib plus abiraterone provided numerically longer rPFS versus placebo plus abiraterone, with no new safety signals, in the non-BRCAm subgroup of patients with mCRPC in PROpel. Our findings support olaparib plus abiraterone as an important new treatment option for consideration in patients with non-BRCAm mCRPC.", "journal": "European Urology Oncology", "pub_date": "2026-Oct-05", "publication_types": ["Journal Article"], "doi": "10.1016/j.euo.2026.08.014", "authors": ["Niven Mehra", "Noel W Clarke", "Andrew J Armstrong", "Mototsugu Oya", "Neal Shore", "Giuseppe Procopio", "João Daniel Guedes", "Cagatay Arslan", "Emma Brown", "Jae Young Joung", "Mikio Sugimoto", "Young Deuk Choi", "Daniel Castellano", "Yüksel Ürün", "Christian Hosius", "David McGuinness", "Arnold Degboe", "Fred Saad"], "affiliations": ["Radboud Universitair Medisch Centrum, Nijmegen, Netherlands. Electronic address: niven.mehra@radboudumc.nl.", "The Christie and Salford Royal NHS Foundation Trusts, Manchester, UK.", "Duke Cancer Institute Center for Prostate and Urologic Cancer, Duke University, Durham, NC, USA.", "Keio University School of Medicine, Tokyo, Japan.", "Carolina Urologic Research Center, Myrtle Beach, SC, USA.", "Fondazione IRCCS Istituto Nazionale Tumori Milano, Milan, Italy.", "Hospital de Base de São José do Rio Preto, São José do Rio Preto, Brazil.", "Izmir Economics University Medical Park Hospital, Karsiyaka, Türkiye.", "University Hospital Southampton, Southampton, UK.", "National Cancer Center, Goyang-si, South Korea.", "Kagawa University Hospital, Kagawa, Japan.", "Yonsei University College of Medicine, Seoul, South Korea.", "Hospital Universitario 12 de Octubre, Madrid, Spain.", "Ankara University School of Medicine, Ankara, Türkiye.", "MSD Sharp & Dohme GmbH, Munich, Germany.", "Global Medicines Development, Oncology R&D, AstraZeneca, Cambridge, UK.", "Global Medicines Development, Oncology R&D, AstraZeneca, Gaithersburg, MD, USA.", "Centre Hospitalier de l'Université de Montréal/CRCHUM, Université de Montréal, Montréal, QC, Canada."], "corresponding_authors": ["Niven Mehra"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=8", "score": 39.42, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 15.42, "top_journal_bonus": 0.0, "novelty": 2.0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 8.0}, "journal_metrics": {"status": "ok", "impact_factor": 9.3, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.42, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42833906", "title": "Two-stage high-frequency ultrasonic characterization of ex vivo renal tumor microstructure.", "abstract": "Pre-operative classification of renal tumor subtypes remains challenging. Renal mass biopsies are a solution, but are invasive and currently underutilized in clinical practice. This study evaluated the feasibility of a two-stage, high-frequency ultrasonic characterization of ex vivo renal tumor subtypes to non-invasively assess the tissue microstructure and subsequently classify the tumor histologic subtype. Ex vivo renal tumors resected by partial or radical nephrectomy were scanned immediately after surgery using a high-frequency 29 MHz ExactVu (Exact Imaging, ON, Canada) ultrasound device. From an initial cohort of 153 unique tumor samples, 91 ultrasound cine loops (one per sample, including sample pruning) were evaluated to identify common radiological (or visual) features among the different histologic subtypes. In this study, we considered clear cell renal cell carcinoma (RCC), papillary RCC, chromophobe RCC, oncocytoma and angiomyolipoma histologic subtypes. In a subsequent cohort of 61 samples selected for quantitative ultrasound (QUS)-based analysis (based on the availability of radiofrequency echo data), parameters computed using the ultrasound radiofrequency echo data were used to develop a linear, benign-versus-malignant subtype classifier. The homodyned K-distribution structure parameter and the effective acoustic concentration were used. Six ultrasound image features describing the histologic subtype appearances were observed and cataloged, with the features comprising well-defined borders, rounded shape, homogeneous texture, cystic components, septations, and punctate foci. Classification of 36 samples using these imaging features alone demonstrated an accuracy of only 30.6%, hereby confirming that visual pattern recognition by the human eye is insufficient for accurate histologic subtype classification and thus motivated the quantitative ultrasound-based approach developed in stage 2. In contrast, the QUS-based linear classifier achieved 82% accuracy, 82% sensitivity and 80% specificity using 61 samples. We demonstrated the feasibility of QUS-based classification of renal tumor histologic subtypes, as well as a catalog of six correlated ultrasound image features. This non-invasive, ex vivo approach shows promise to guide diagnosis and reduce unnecessary surgeries in urologic cancer. Future work includes validation of the built QUS-based classifier on a larger test cohort, followed by in vivo feasibility studies conducted prior to nephrectomy.", "journal": "Ultrasound in Medicine & Biology", "pub_date": "2026-Oct-05", "publication_types": ["Journal Article"], "doi": "10.1016/j.ultrasmedbio.2026.08.028", "authors": ["Laura Zuluaga", "Alexander D Gleed", "Jewel Bamby", "Kennedy E Okhawere", "Josh Levieddin", "Burak Ucpinar", "Burcin A Ucpinar", "Cameron Hoerig", "Jonathan Mamou", "Ketan K Badani"], "affiliations": ["Department of Urology, Icahn School of Medicine at Mount Sinai, New York City, New York, USA. Electronic address: laurazuluaga20@gmail.com.", "Department of Radiology, Weill Cornell Medicine, New York City, New York, USA.", "Department of Urology, Icahn School of Medicine at Mount Sinai, New York City, New York, USA.", "Division of Urology, Jacobi Medical Center, Department of Surgery, Bronx, NY, USA.", "Department of Radiology, Memorial Sloan Kettering Cancer Center, New York City, NY, USA."], "corresponding_authors": ["Laura Zuluaga"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=3", "score": 22.88, "score_parts": {"urology_relevance": 12, "urology_in_title": 0.0, "journal_priority": 5.88, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 3.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.6, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.88, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42833883", "title": "Testosterone breakthrough and outcomes during intensified therapy in metastatic hormone-sensitive prostate cancer: the ARASENS and LATITUDE trials.", "abstract": "To assess whether treatment-period serum testosterone breakthrough >35 ng/dL is associated with clinical outcomes during intensified therapy for metastatic hormone-sensitive prostate cancer. We performed post hoc analyses of the experimental arms of the ARASENS (darolutamide plus androgen deprivation therapy [ADT] and docetaxel; ClinicalTrials.gov identifier NCT02799602) and LATITUDE (abiraterone acetate plus prednisone and ADT; NCT01715285) phase III trials. Cohort-specific fixed-window landmark analyses classified exposure as any eligible testosterone result >35 ng/dL after treatment initiation and through Day 147 in the LATITUDE trial or Day 266 in the ARASENS trial. Treatment-initiation/Day-1 and end-of-treatment measurements were excluded. Follow-up began at the landmark. The primary outcome was overall survival (OS); the LATITUDE progression-free survival (PFS) and the ARASENS time to castration-resistant prostate cancer (CRPC) were progression endpoints. Multivariable Cox regression was primary; landmark and time-dependent sensitivity analyses were also performed. At the landmark, 564 LATITUDE and 578 ARASENS patients were classifiable for OS. In the LATITUDE trial, breakthrough was associated with worse OS (adjusted hazard ratio [HR], 1.49, 95% confidence interval [CI] 1.07-2.08; P = 0.019); the PFS estimate was directionally similar but imprecise (HR 1.40, 95% CI 0.98-2.00; P = 0.065). In the ARASENS trial, the overall associations were not statistically significant for OS (HR 1.18, 95% CI 0.85-1.62; P = 0.322) or CRPC (HR 0.86, 95% CI, 0.60-1.23; P = 0.397). Exploratory piecewise modelling suggested time variation for CRPC (interaction P = 0.028). Testosterone breakthrough >35 ng/dL was associated with worse post-landmark OS in the LATITUDE trial, whereas the overall associations with OS and CRPC in the ARASENS trial were not statistically significant. These within-cohort findings are exploratory and do not establish causality, a difference between treatment mechanisms, or a clinical testosterone target.", "journal": "BJU International", "pub_date": "2026-Oct-05", "publication_types": ["Journal Article"], "doi": "10.1111/bju.70474", "authors": ["Xiyue Xiao", "Xudong Ni", "Yufan Zhao", "Xiaomeng Li", "Shanshan Wang", "Hongkai Wang", "Dingwei Ye", "Junlong Wu", "Yao Zhu"], "affiliations": ["Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China.", "Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.", "Shanghai Genitourinary Cancer Institute, Shanghai, China."], "corresponding_authors": [], "china_team": "Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China Yao Zhu团队", "category": "clinical_review", "classification_reason": "clinical_signals=14", "score": 36.47, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.47, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 12.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.4, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.47, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42833474", "title": "National Trends in Urology Fellowship Training and Subspecialization: A 10-Year Analysis of the AUA Census.", "abstract": "To describe trends in urologic fellowship training and subspecialization nationwide and to identify areas of need in the national distribution of subspecialists. Data from the American Urological Association Annual Census of United States Practicing Urologists from 2014-2024 was analyzed using weighted responses to account for non-response bias. Trends regarding fellowship training, subspecialization, and practice patterns were examined. The analysis was descriptive to identify shifts over time. From 2014 to 2024, an average of 2088 urologists practicing in the United States completed the census yearly with an average response of 16.3%. The proportion of fellowship-trained urologists has increased over time (4 0% in 2014 to 46% in 2024) while the proportion of general urologists has decreased (63% in 2014 to 54% in 2024). Urologic oncology is the most common specialty (13% in 2024) and there have been increasing trends in several other specialties such as urogynecology, urologic reconstructive surgery, and robotics. There has been a decrease in urologists in private practice (64% in 2014 to 42% in 2024) and an increase in academic and hospital employment. Subspecialized urologists are more likely to practice in academic settings (66% in 2024). Fellowship-trained and subspecialized urologists are more likely to practice in metropolitan areas. Subspecialization and fellowship-training has increased among urologists practicing in the United States with a corresponding decrease in general urology practice. Subspecialized urologists more often practice in urban and academic settings. This trend may affect nationwide access to urologic care.", "journal": "Urology", "pub_date": "2026-Oct-05", "publication_types": ["Journal Article"], "doi": "10.1016/j.urology.2026.09.064", "authors": ["Courtney Yong", "William Meeks", "Emily Galen", "Chandru P Sundaram"], "affiliations": ["Department of Urology, Indiana University, Indianapolis, IN. Electronic address: cyong@iu.edu.", "American Urological Association, Linthicum, MD. Electronic address: wmeeks@auanet.org.", "American Urological Association, Linthicum, MD. Electronic address: egalen@auanet.org.", "Department of Urology, Indiana University, Indianapolis, IN. Electronic address: sundaram@iu.edu."], "corresponding_authors": ["Courtney Yong", "William Meeks", "Emily Galen", "Chandru P Sundaram"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 20.61, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 5.61, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 1.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.0, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.61, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42832819", "title": "Urgency Urinary Incontinence Is Associated with Vascular Comorbidity and Erectile Dysfunction: A LURN Cohort Analysis.", "abstract": "To evaluate whether OAB subtypes urgency urinary incontinence (UUI) and urgency without incontinence (URG) are associated with vascular comorbidity, erectile dysfunction (ED), and cardiometabolic proteomic profiles. and Methods: A secondary analysis of LURN I and II cohorts (controls, URG, UUI) was performed. Vascular comorbidity comprised self-reported angina, congestive heart failure, myocardial infarction, stroke, or peripheral vascular disease. Multivariable regression adjusted for age, sex, and non-vascular comorbidity burden. Serum samples underwent cardiometabolic proteomic profiling. Vascular and non-vascular predictors of 12-month improvement (PGI-I) were evaluated in LURN II (n=581). Among 2,118 participants (268 controls; 1,241 UUI; 609 URG), urgency syndromes had higher odds of vascular comorbidity than controls (OR 3.2, 95% CI 1.7-6.2; p<0.001), similar for UUI and URG. Among 762 men, ED was more prevalent in urgency cases than controls (53% vs. 29%) and highest in UUI (64% vs. 41% in URG). IIEF reduction versus controls was larger in UUI than URG (-5.59, p<0.001 vs. -2.00, p=0.08). Proteomic profiling identified 22 cardiometabolic proteins more abundant in UUI than URG (FDR-adjusted p <0.05), including those involving lipid metabolism (ANGPTL3, APOM) and inflammation (CCL18). None remained significant after FDR correction following adjusting for age, sex, and non-vascular comorbidity burden. Vascular comorbidity was not associated with 12-month improvement; surgery/invasive therapy was. Urgency syndromes, particularly UUI, are associated with increased vascular comorbidity and erectile dysfunction relative to controls. Cardiometabolic proteomic differences between phenotypes were attenuated after adjusting for demographic and comorbidity factors. These findings support biologic heterogeneity across urinary urgency syndromes and a vascular/cardiometabolic contribution to urgency pathobiology.", "journal": "Journal of Urology", "pub_date": "2026-Oct-05", "publication_types": ["Journal Article"], "doi": "10.1097/JU.0000000000005335", "authors": ["Glenn T Werneburg", "Nathan P Goodrich", "Victor P Andreev", "Aruna Sarma", "John T Stoffel", "J Quentin Clemens", "Anne Cameron"], "affiliations": ["Department of Urology, University of Michigan, Ann Arbor, MI 48108.", "Departments of Urology and Microbiology & Immunology., Stony Brook University, Stony Brook, NY 11794.", "Arbor Research, Ann Arbor, MI 48108."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "basic_signals=4", "score": 35.01, "score_parts": {"urology_relevance": 10, "urology_in_title": 8.0, "journal_priority": 11.01, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 4.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 6.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 3.01, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "尿急综合征伴血管合并症及勃起障碍", "chinese_summary": "Journal of Urology基于LURN队列2118例分析发现，尿急综合征患者血管合并症风险为对照3.2倍，UUI与URG相似；762名男性中，尿急者勃起功能障碍更常见，UUI达64%，URG为41%，对照组仅29%。蛋白质组学提示UUI与URG存在 cardiometabolic 差异，但校正混杂后减弱，支持尿急综合征的生物学异质性。", "abstract_zh": "评估膀胱过度活动症亚型——急迫性尿失禁（UUI）和无尿失禁的尿急（URG）——是否与血管合并症、勃起功能障碍（ED）及心血管代谢蛋白质组谱相关。方法：对LURN I和II队列（对照、URG、UUI）进行二次分析。血管合并症包括自我报告的心绞痛、充血性心力衰竭、心肌梗死、卒中或外周血管疾病。多变量回归校正年龄、性别及非血管合并症负担。血清样本进行心血管代谢蛋白质组分析。在LURN II（n=581）中评估血管和非血管预测因素对12个月改善（PGI-I）的影响。在2118名参与者（268名对照；1241名UUI；609名URG）中，尿急综合征患者血管合并症的比值比高于对照（OR 3.2，95% CI 1.7-6.2；p<0.001），UUI和URG相似。在762名男性中，尿急病例的ED患病率高于对照（53% vs. 29%），且UUI最高（64% vs. URG的41%）。与对照相比，UUI的IIEF下降幅度大于URG（-5.59，p<0.001 vs. -2.00，p=0.08）。蛋白质组分析鉴定出22种在UUI中比URG更丰富的心血管代谢蛋白（FDR校正p<0.05），包括涉及脂质代谢（ANGPTL3、APOM）和炎症（CCL18）的蛋白。在校正年龄、性别和非血管合并症负担后，经FDR校正，无一保持显著。血管合并症与12个月改善无关；手术/侵入性治疗与改善相关。尿急综合征，尤其是UUI，相对于对照与血管合并症和勃起功能障碍增加相关。表型间的心血管代谢蛋白质组差异在校正人口学和合并症因素后减弱。这些发现支持尿急综合征的生物学异质性以及血管/心血管代谢因素对尿急病理生物学的贡献。"}, {"pmid": "42832818", "title": "Multi-Cancer Early Detection Tests and Prostate Cancer Screening: Navigating the Gaps.", "abstract": "", "journal": "Journal of Urology", "pub_date": "2026-Oct-05", "publication_types": ["Editorial"], "doi": "10.1097/JU.0000000000005340", "authors": ["Zachary Feuer", "Brandon Wilson", "Marc A Bjurlin"], "affiliations": ["Department of Urology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.", "Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 20.01, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 11.01, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 6.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 3.01, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42832775", "title": "Ditching the Dipstick: Elevating US Urology Practice Efficiency and Guideline Compliance with Point-of-Care Quantitative Urinalysis.", "abstract": "", "journal": "Urology Practice", "pub_date": "2026-Oct-05", "publication_types": ["Journal Article"], "doi": "10.1097/UPJ.0000000000001102", "authors": ["Moustafa Kardjadj", "Itoe P Penda", "Roel Chavez"], "affiliations": ["MED-US Consulting, LLC., Austin, Texas.", "Soft Cell Laboratories, Hillsboro, Oregon.", "Doc Lab Inc., Hillsboro, Oregon."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 11.46, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 2.46, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 1.7, "cas_zone": 4, "cas_zone_points": 1.0, "impact_factor_points": 1.46, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42832773", "title": "UROLOGISTS PERFORMING UROGYNECOLOGY AND RECONSTRUCTIVE PELVIC SURGERY PROCEDURES: THE IMPACT OF FELLOWSHIP TRAINING.", "abstract": "Urogynecology and Reconstructive Pelvic Surgery (URPS) became an accredited fellowship in 2013. Our objective was to assess the landscape of URPS procedures performed by URPS fellowship-trained (FT) and non-FT urologists (NFT) since accreditation. A retrospective cohort study of American Board of Urology case logs of urologists performing URPS procedures from January 2013 through August 2024 was conducted. The annual case volumes of FT and NFT urologists were compared. Multivariable mixed-effects Poisson regression models assessed the impact of covariates on annual case volume. 5,816 urologists (393 FT, 5,423 NFT) performing URPS procedures were included, with 513 FT and 5,818 NFT case log submissions. Compared to NFT, FT urologists were predominantly female (48% vs 13%, p<0.01), practiced in metropolitan areas (52% vs 23%, p<0.01) and academic settings (41% vs 7%, p<0.01). FT performed 24% of annual URPS cases on average, rising to 34% when excluding benign prostate hypertrophy (BPH) procedures. Modelling demonstrated that FT performed URPS cases at 4.2 times the annual rate of NFT (RR 4.2, 95% CI 3.6-4.6) on average, rising to 7.6 times when BPH was excluded (RR 7.6, 95% CI 6.7-8.6), controlling for other covariates. Independent of FT status, women performed non-BPH URPS at a 62% higher rate than men, with higher rates also seen among urologists that are younger, recertifying and outside the Northeast. Although NFT outnumber FT by 14 to one, FT performed eight times more non-BPH URPS cases annually on average and accounted for 34% of total non-BPH volume.", "journal": "Urology Practice", "pub_date": "2026-Oct-05", "publication_types": ["Journal Article"], "doi": "10.1097/UPJ.0000000000001101", "authors": ["Dora Jericevic Schwartz", "Rishika Gaddam", "John Koo", "Nirit Rosenblum", "David Ginsberg", "J Quentin Clemens", "Benjamin M Brucker"], "affiliations": ["NYU Langone Health / dora.katarina.j@gmail.com (DJS).", "NYU Langone Health / rishika1201@gmail.com (RG).", "NYU Langone Health / johnkoo@nyu.edu (JK).", "NYU Langone Health / nirit.rosenblum@nyulangone.org (NR).", "University of Southern California / ginsberg@med.usc.edu (DG).", "University of Michigan / qclemens@med.umich.edu (JQC).", "NYU Langone Health / benjamin.brucker@nyulangone.org (BB)."], "corresponding_authors": ["Dora Jericevic Schwartz", "Rishika Gaddam", "John Koo", "Nirit Rosenblum", "David Ginsberg", "J Quentin Clemens", "Benjamin M Brucker"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=5", "score": 25.46, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 2.46, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 5.0}, "journal_metrics": {"status": "ok", "impact_factor": 1.7, "cas_zone": 4, "cas_zone_points": 1.0, "impact_factor_points": 1.46, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42832769", "title": "Predicting Recurrence and Progression in Contemporary Patients with NMIBC Undergoing Blue Light Cystoscopy-Aided Transurethral Resection of Bladder Tumor.", "abstract": "Although blue light cystoscopy (BLC) is recommended by clinical practice guidelines to improve cancer detection, predictive models for patients undergoing BLC are lacking. We therefore evaluated the associations of clinicopathologic features with recurrence and progression in a contemporary cohort of patients treated with BLC to develop a risk prediction model. We identified patients aged 18-89 years in the multi-institutional Blue Light Cystoscopy with Cysview Registry who underwent BLC-aided TURBT between 2014-2023. Associations of baseline characteristics with recurrence and progression were evaluated using Cox regression, and predictive models were developed using lasso regression. 1040 patients underwent BLC-TURBT. Tumor stage was Ta in 578 (56%), T1 in 166 (16%), and pure CIS in 190 (18%) patients. On multivariable analysis, HGTa (HR 1.60, 95%CI 1.10-2.35) and HGT1 (HR 1.94, 95%CI 1.25-3.02) tumors were associated with increased risk of recurrence. HGT1 (HR 12.4, 95%CI 4.52-34.0), HGTa (HR 3.08, 95% CI 1.03-9.18), pure CIS (HR 4.51, 95% CI 1.44-14.1), Ta+CIS (HR 4.98, 95%CI 1.17-21.1), and T1+CIS (HR 7.65, 95%CI 1.97-29.7) tumors, as well as lymphovascular invasion (HR 3.27, 95%CI 1.22-8.83) were associated with increased risk of progression. In contrast, adjuvant BCG was associated with decreased risk of progression (HR 0.40, 95%CI 0.22-0.72). Model discrimination was 0.64 for RFS and 0.73 for PFS. Using a multi-institutional cohort, we developed predictive models for recurrence and progression in patients undergoing BLC-TURBT. Although they require external validation, these models reflect to contemporary treatment paradigms and can inform personalized, risk-adapted management of NMIBC.", "journal": "Urology Practice", "pub_date": "2026-Oct-05", "publication_types": ["Journal Article"], "doi": "10.1097/UPJ.0000000000001103", "authors": ["Agustin Perez-Londoño", "Jamil Almohtasib", "Sumedh Kaul", "Aaron Fleishman", "Badrinath Konety", "Kamal Pohar", "Jeffrey M Holzbeierlein", "John Taylor", "Max Kates", "Brian Willard", "Jennifer M Taylor", "Joseph C Liao", "Hristos Z Kaimakliotis", "Sima P Porten", "Gary D Steinberg", "Mark D Tyson", "Yair Lotan", "Siamak Daneshmand", "Boris Gershman"], "affiliations": ["Division of Urologic Surgery, Beth Israel Deaconess Medical Center, Boston, MA.", "Department of Surgery, Beth Israel Deaconess Medical Center, Boston, MA.", "Allina Health Cancer Institute, Minneapolis, MN.", "Department of Urology, Ohio State University, Columbus, OH.", "Department of Urology, University of Kansas, Kansas City, KS.", "The James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, MD.", "Lexington Medical Center, Lexington, SC.", "Michael E. DeBakey VA Medical Center, Baylor College of Medicine, Houston, TX.", "VA Palo Alto Health Care System, Palo Alto, CA.", "Department of Urology, Indiana University School of Medicine, Indianapolis, IN.", "Department of Urology, University of California San Francisco, San Francisco, CA.", "Department of Urology, Rush University, Chicago, IL.", "Department of Urology, Mayo Clinic Hospital, Phoenix, AZ.", "UT Southwestern Medical Center, Dallas, TX.", "Department of Urology, USC Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=5", "score": 25.46, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 2.46, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 5.0}, "journal_metrics": {"status": "ok", "impact_factor": 1.7, "cas_zone": 4, "cas_zone_points": 1.0, "impact_factor_points": 1.46, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42832307", "title": "Non-Conventional Histologies of Prostate Cancer: From Morphology to Biology-Driven Precision Oncology.", "abstract": "Non-conventional prostate cancer histologies represent a small but clinically significant subset characterised by aggressive behaviour, atypical biomarker profiles, and reduced dependence on androgen receptor signalling. Evidence indicates these histologies reflect dynamic biological states driven by genomic instability, lineage plasticity, and therapeutic selection rather than static morphologic entities, with several morphologies acting as accessible, if imperfect, surrogates for actionable alterations. We performed a translational narrative review integrating anatomic pathology, genomic and epigenomic biology, and biomarker-selected therapy, searching PubMed/MEDLINE, Embase, Cochrane CENTRAL, the ASCO Meeting Library, ESMO publications, and APCCC through May 2026, spanning neuroendocrine, ductal, intraductal, cribriform, adenosquamous, sarcomatoid, adenoid cystic, signet ring cell, and mucinous subtypes. These histologies are individually uncommon but are consistently associated with advanced stage and inferior survival. Neuroendocrine prostate cancer is the most aggressive phenotype and a major mechanism of resistance to AR-directed therapy, driven by combined RB1 and TP53 loss, epigenetic reprogramming, and lineage plasticity, and marked by DLL3 expression. Cribriform and intraductal carcinoma are often enriched for BRCA2 and DNA-repair deficiency, whereas ductal differentiation is associated with mismatch-repair deficiency in a subset, with implications for PARP inhibition and checkpoint blockade. Emerging strategies include platinum-based chemoimmunotherapy and investigational lineage-directed agents targeting DLL3, STEAP1, KLK2, and TROP-2, alongside radioligands. These histologies are best viewed as biologically distinct, evolving disease states. By integrating pathology, molecular biology, and biomarker-selected therapy into one translational pathway, this review reframes non-conventional histology as a prompt for early molecular characterisation and adaptive, biology-driven treatment.", "journal": "Oncologist", "pub_date": "2026-Oct-05", "publication_types": ["Journal Article"], "doi": "10.1093/oncolo/oyag391", "authors": ["Fabiano Flauto", "Giuseppe Neola", "Alessia Cimadamore", "Michele Maffezzoli", "Akash Maniam", "Sarah Scagliarini", "Fabio Calabrò", "Luigi Formisano", "Pasquale Rescigno", "Giuseppe Luigi Banna"], "affiliations": ["Department of Clinical Medicine and Surgery, Federico II University, Via Sergio Pansini, 5, Naples, 80131, Italy.", "Portsmouth Hospitals University NHS Trust, Portsmouth, PO63LY, UK.", "Department of Medicine, Institute of Pathological Anatomy, University of Udine, Udine, Italy.", "Department of Medicine and Surgery, University Hospital of Parma-Medical Oncology Unit, University of Parma, Parma, 43126, Italy.", "UOC di Oncologia, Azienda Ospedaliera di Rilievo Nazionale Cardarelli di Napoli, Naples, 80131, Italy.", "Medical Oncology 1, IRCCS Regina Elena National Cancer Institute, Rome, Italy.", "Translational & Clinical Research Institute, Centre for Cancer, Newcastle University, Newcastle Upon Tyne, UK."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 26.92, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.42, "top_journal_bonus": 0.0, "novelty": 0.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 2.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.2, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.42, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42832084", "title": "Lymphocele After Radical Prostatectomy: A Systematic Review of Risk Factors and Quantitative Synthesis Preventive Strategies.", "abstract": "This study aimed to systematically evaluate the perioperative risk factors and preventive strategies associated with lymphocele formation and prolonged lymphatic drainage after radical prostatectomy with pelvic lymph node dissection, to assess the effect of peritoneal reconstruction techniques on symptomatic lymphocele reduction, and to provide an integrated clinical framework for evaluating etiological factors and preventive strategies. A comprehensive search of Embase, MEDLINE (PubMed), and the Cochrane Library was performed through December 2025 according to PRISMA guidelines (PROSPERO ID: CRD420251164157). Thirty-one studies evaluating preoperative, intraoperative, and postoperative risk factors and preventive strategies were included. Risk of bias was assessed using RoB 2, ROBINS-I, and ROBINS-E tools. A primary meta-analysis of randomized controlled trials and a predefined sensitivity analysis including all comparative studies were conducted for symptomatic lymphocele (sLC) using random-effects models. High BMI and selected metabolic parameters, including low fibrinogen and hypoalbuminemia, emerged as potential preoperative risk factors, although supporting evidence was limited and not consistently reported across studies. Peritoneal flap-based reconstruction significantly reduced symptomatic lymphocele in pooled randomized data (RR 0.57, 95% CI 0.35-0.95). A predefined sensitivity analysis including six comparative studies (n = 3840) suggested a larger effect (RR 0.18, 95% CI 0.09-0.37), although these findings should be interpreted cautiously because of potential confounding and heterogeneity across study designs and surveillance protocols. Preventive strategies such as peritoneal reconstruction and selective drain management were associated with reduced lymphatic complications, whereas octreotide and lymphatic embolization were effective management options for established or refractory lymphatic leakage. Lymphocele formation after radical prostatectomy is multifactorial. Restoration of peritoneal continuity appears to be the most consistent and modifiable strategy for reducing symptomatic lymphocele. These findings support a comprehensive, risk-adapted approach integrating patient- and procedure-related factors beyond isolated technical interventions and highlight the need for further multicenter randomized studies.", "journal": "World Journal of Urology", "pub_date": "2026-Oct-05", "publication_types": ["Journal Article", "Systematic Review"], "doi": "10.1007/s00345-026-06809-z", "authors": ["Ömer Faruk Çavdar", "Burak Akgül", "Furkan Güldibi", "Bhaskar Somani", "Karim Touijer", "Alex de la Taille", "Kamran Ahmed", "Thomas Knoll", "Thomas R W Herrman", "Lütfi Tunç", "Selçuk Güven"], "affiliations": ["Department of Urology, Faculty of Medicine, Necmettin Erbakan University, Konya, Turkey. om.far.cav@gmail.com.", "Department of Urology, Indiana University School of Medicine, İndianapolis, IN, USA.", "Department of Urology, Faculty of Medicine, Necmettin Erbakan University, Konya, Turkey.", "Department of Urology, University Hospital, Southampton, UK.", "Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.", "Department of Urology, Centre Hospitalier Universitaire Henri Mondor, Créteil, France.", "Sheikh Khalifa Medical City, Abu Dhabi, UAE.", "Khalifa University, Abu Dhabi, UAE.", "Department of Urology, King's College Hospital NHS Foundation Trust, London, United Kingdom.", "Klinikum Sindelfingen-Boeblingen, University Medicine Mannheim, Sindelfingen, Germany.", "Mannheim University Hospital, Mannheim, Germany.", "Department of Urology, Spital Thurgau AG, Kantonsspital Frauenfeld, Pfaffenholzstrasse 4, CH, Frauenfeld , 8501, Switzerland.", "Division of Urology, Department of Surgical Sciences, Stellenbosch University, Stellenbosch, Western Cape, South Africa.", "Hannover Medical School, Hannover, Germany.", "Department of Urology, Acıbadem Ankara Hospital, Ankara, Turkey."], "corresponding_authors": ["Ömer Faruk Çavdar"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 30.0, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.0, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 6.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.9, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.0, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42832079", "title": "Targeted pelvic lymph node dissection using magnetic resonance imaging - ultrasonography fusion technique and indocyanine green injection in robot-assisted radical prostatectomy.", "abstract": "This study assessed the diagnostic accuracy and potential therapeutic value in performing targeted pelvic lymph node dissection (PLND) guided by magnetic resonance imaging (MRI)-ultrasonography (US) fusion combined with Indocyanine green (ICG) injection (tPLND-MUI). This study was retrospectively designed and included 72 patients who underwent robotic radical prostatectomy (RARP) combined with PLND. The inclusion criteria were: (1) prostate cancer with a Prostate Imaging Reporting and Data System version 2.1 (PI-RADS v2.1) category 4 or 5 lesion on MRI, (2) Patients who had clinical records of ICG fluorescence or surgical videos of PLND. The clinical impact of the tPLND-MUI was assessed based on its diagnostic accuracy for identifying nodal metastasis and its potential therapeutic value in achieving complete removal of metastatic lymph nodes. A backup PLND using the super-extended template (sePLND) was performed, and outcomes of tPLND-MUI, limited-PLND (limPLND), extended-PLND (ePLND), and standard-PLND (sPLND) were compared against sePLND. A total of 72 patients were incorporated into the final analysis. tPLND-MUI resulted in a median removal of 29 lymph nodes which were fewer than those of sePLND and ePLND. For detecting at least one lymph node metastasis, sensitivity reached 100% with both ePLND and tPLND-MUI, 95.2% with sPLND, and 71.4% with lim-PLND. The ratios of complete removal of lymph node metastases were 81.0% for ePLND, 66.7% for sPLND, 33.3% for limPLND, and 95.2% for tPLND-MUI. tPLND-MUI may demonstrate excellent therapeutic and diagnostic performance despite the removal of fewer lymph nodes and fewer dissecting regions. Further prospective research is needed to validate these findings.", "journal": "Journal of Robotic Surgery", "pub_date": "2026-Oct-05", "publication_types": ["Journal Article"], "doi": "10.1007/s11701-026-03939-9", "authors": ["Yuta Yamada", "Naoki Kimura", "Yuji Hakozaki", "Masaki Nakamura", "Koki Sugano", "Kazuma Sugimoto", "Shigenori Kakutani", "Jimpei Miyakawa", "Jun Kamei", "Aya Niimi", "Satoru Taguchi", "Haruki Kume"], "affiliations": ["Department of Urology, The University of Tokyo Hospital, Bunkyo-Ku, Tokyo, Japan.", "Department of Urology, The University of Tokyo Hospital, Bunkyo-Ku, Tokyo, Japan. nkimura2026@gmail.com.", "Department of Urology, Chiba Tokushukai Hospital, Funabashi-Shi, Chiba, Japan. nkimura2026@gmail.com.", "Department of Urology, NTT Higashi Nihon Kanto Hospital, Tokyo, Japan."], "corresponding_authors": ["Naoki Kimura"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=8", "score": 28.03, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 6.03, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 8.0}, "journal_metrics": {"status": "ok", "impact_factor": 3.0, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 2.03, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42832058", "title": "Letter to the Editor: Multicentre validation of the PRECISE scoring system for prostate MRI during active surveillance.", "abstract": "", "journal": "European Radiology", "pub_date": "2026-Oct-05", "publication_types": ["Letter", "Comment"], "doi": "10.1016/j.eururo.2016.06.011", "authors": ["Zheng Wang", "Chengxin Yu"], "affiliations": ["Department of Radiology, The First College of Clinical Medical Science, China Three Gorges University, Yichang Central People's Hospital, Yichang, China.", "Institute of Medical Imaging, China Three Gorges University, Yichang, China.", "Department of Radiology, The First College of Clinical Medical Science, China Three Gorges University, Yichang Central People's Hospital, Yichang, China. ycyucx@163.com.", "Institute of Medical Imaging, China Three Gorges University, Yichang, China. ycyucx@163.com."], "corresponding_authors": ["Chengxin Yu"], "china_team": "Department of Radiology, The First College of Clinical Medical Science, China Three Gorges University, Yichang Central People's Hospital, Yichang, China Chengxin Yu团队", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 19.55, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.55, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.7, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.55, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42832055", "title": "Reply to the Letter to the Editor: Multicentre validation of the PRECISE scoring system for prostate MRI during active surveillance.", "abstract": "", "journal": "European Radiology", "pub_date": "2026-Oct-05", "publication_types": ["Letter"], "doi": "10.1007/s00330-026-12941-6", "authors": ["Francesco Giganti", "Veeru Kasivisvanathan"], "affiliations": ["Department of Radiology, University College London Hospital NHS Foundation Trust, London, UK. f.giganti@ucl.ac.uk.", "Division of Surgery and Interventional Science, University College London, London, UK. f.giganti@ucl.ac.uk.", "Division of Surgery and Interventional Science, University College London, London, UK.", "Department of Urology, University College London Hospital NHS Foundation Trust, London, UK."], "corresponding_authors": ["Francesco Giganti"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 19.55, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.55, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.7, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.55, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42832054", "title": "The effect of ureteral stenting on the risk of metachronous upper tract urothelial carcinoma in patients with bladder tumors involving the ureteral orifice.", "abstract": "Ureteral stenting in patients with bladder cancer involving the ureteral orifice may increase the rate of metachronous upper tract urothelial carcinoma (UTUC). Nevertheless, evidence on the matter is scarce and often contradictory. We performed an observational study comparing ureteral stenting versus no stenting with respect to the risk of developing metachronous UTUC in patients who underwent transurethral resection of bladder tumors (TURBT) involving the ureteral orifice between January 2015 and December 2024. We performed time-to-event analyses to estimate hazard ratios (HRs) along with their corresponding 95% confidence intervals (CIs). We included 151 patients with a median age of 73 years. 37 (25%) underwent ureteral stenting during TURBT. Patients undergoing stenting had higher BMI (p = 0.014), more aggressive tumors (p = 0.003), underwent prior intravesical therapy more often (p = 0.008), higher preoperative creatinine values (p = 0.007), and longer hospitalization duration (p = 0.002) compared to those who did not undergo stenting. After a median follow-up of 25 months, 8 patients developed metachronous UTUC (2 in the stenting group and 6 in the non-stenting group). Ureteral stenting was not associated with statistically significantly higher rates of metachronous UTUC (HR: 1.2, 95%CI: 0.31-5.6, p > 0.9). During follow-up, 49 (33%) patients developed recurrence in the bladder, 43 (28%) underwent cystectomy, and 24 (16%) died. The HRs did not significantly differ between the two groups. The present study did not demonstrate an increased risk of metachronous UTUC after stenting during TURBT with urothelial cancer involving the ureteral orifice. Moreover, stenting was not statistically significantly associated with increased recurrences in the urinary bladder, higher cystectomy rates, or worse mortality.", "journal": "World Journal of Urology", "pub_date": "2026-Oct-05", "publication_types": ["Journal Article", "Observational Study"], "doi": "10.1159/000535024", "authors": ["Nikolaos Pyrgidis", "Patrick Engelmann", "Daniel Puhr-Westerheide", "Benedikt Ebner", "Marc Kidess", "Marie Semmler", "Patrick Keller", "Christian Stief", "Gerald Bastian Schulz", "Yannic Volz"], "affiliations": ["Department of Urology, LMU University Hospital, Marchioninistraße 15, 81377, Munich, Germany.", "Department of Radiology, University Hospital, LMU Munich, Munich, Germany.", "Department of Urology, LMU University Hospital, Marchioninistraße 15, 81377, Munich, Germany. yannic.volz@med.uni-muenchen.de."], "corresponding_authors": ["Yannic Volz"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_clinical", "score": 41.0, "score_parts": {"urology_relevance": 18.0, "urology_in_title": 8.0, "journal_priority": 10.0, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 3.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.9, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.0, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42831988", "title": "Correction: Feasibility and clinical outcomes of same-day discharge after robot-assisted partial nephrectomy at an ambulatory surgery center.", "abstract": "", "journal": "Journal of Robotic Surgery", "pub_date": "2026-Oct-05", "publication_types": ["Published Erratum"], "doi": "10.1007/s11701-026-03999-x", "authors": ["Ivan Kirche-Duarte", "Arie Carneiro", "Salvador Jaime-Casas", "Oluwatimilehin Okunowo", "Anjaney Kothari", "Ahmad Imam", "Daniel Jiang", "Rodrigo A Fribourg-Liendo", "Kelvin Zheng", "Kevin G Chan", "Ali Zhumkhawala", "Jonathan Yamzon", "Wesley Yip", "Bertram Yuh", "Clayton S Lau"], "affiliations": ["Department of Urology, Hospital Israelita Albert Einstein, São Paulo, Brazil.", "Division of Urology and Urologic Oncology, Department of Surgery, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.", "Department of Computational and Quantitative Medicine, Division of Biostatistics, Beckman Research Institute of City of Hope, Duarte, CA, USA.", "Division of Urology and Urologic Oncology, Department of Surgery, City of Hope Comprehensive Cancer Center, Duarte, CA, USA. cllau@coh.org."], "corresponding_authors": ["Clayton S Lau"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 15.03, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 6.03, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 3.0, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 2.03, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42831949", "title": "Partial vs. whole-gland salvage hifu after radiotherapy failure: oncological and functional outcomes.", "abstract": "To evaluate the long-term oncological and functional outcomes of whole-gland and partial-gland salvage high-intensity focused ultrasound (S-HIFU) in patients with radiorecurrent prostate cancer, for whom local recurrence after radiotherapy remains a major therapeutic challenge and radical salvage surgery is associated with substantial morbidity. We performed a retrospective single-center study including 138 patients treated with S-HIFU between August 2006 and October 2023 for biopsy-proven local recurrence without metastatic disease. Treatments consisted of whole-gland or partial-gland ablation, including hemi-gland and focal therapy. Oncological outcomes were assessed using Kaplan-Meier analyses and multivariable Cox regression models evaluating progression-free survival (PFS), metastasis-free survival (MFS), and cancer-specific survival (CSS). Postoperative complications were graded according to the Clavien-Dindo classification. After a median follow-up of over five years, 5-year PFS, MFS, and CSS rates were 43.6%, 85%, and 95%, respectively. Higher pre-HIFU prostate-specific antigen (PSA) levels and ISUP grade ≥ 5 independently predicted disease progression. No significant differences in PFS or MFS were observed between whole-gland and partial-gland treatments. Acute urinary retention occurred in 33% of patients and voiding dysfunction in 39.9%, requiring surgical management in 34.1% of cases. Severe complications were significantly more frequent after whole-gland compared with partial-gland S-HIFU (48.3% vs. 29.8%, p < 0.05). S-HIFU represents a viable salvage option after radiotherapy failure. Our results support that partial-gland S-HIFU significantly reduces severe morbidity while maintaining comparable oncological outcomes compared to whole-gland S-HIFU in appropriately selected patients.", "journal": "World Journal of Urology", "pub_date": "2026-Oct-05", "publication_types": ["Journal Article", "Comparative Study"], "doi": "10.1007/s00345-026-06831-1", "authors": ["Cyriel Maillard", "Samy Mebroukine", "Thibaud Haaser", "Gilles Pasticier", "Grégoire Robert", "Franck Bladou"], "affiliations": ["Department of Urology, Bordeaux University Hospital, Place Amélie Raba Léon, Bordeaux, 33000, France.", "Department of Urology, Bordeaux University Hospital, Place Amélie Raba Léon, Bordeaux, 33000, France. samy.mebroukine@chu-bordeaux.fr.", "Department of Radiation Oncology, Bordeaux University Hospital, Bordeaux, France.", "Department of Urology, Clinique Tivoli, Bordeaux, France."], "corresponding_authors": ["Samy Mebroukine"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_clinical", "score": 27.0, "score_parts": {"urology_relevance": 7, "urology_in_title": 0.0, "journal_priority": 10.0, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 8.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.9, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.0, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42831948", "title": "Reply to correspondence on perioperative monitoring during thulium laser prostate enucleation.", "abstract": "", "journal": "World Journal of Urology", "pub_date": "2026-Oct-05", "publication_types": ["Letter"], "doi": "10.1007/s00345-026-06838-8", "authors": ["Philipp Kuhn", "Thomas Wieser", "JoEllen Welter", "Roman Rechner", "Jan T Klein", "Thomas R W Herrmann", "Alexander Dullenkopf"], "affiliations": ["Institute for Anesthesia, Spital Thurgau, Frauenfeld, Switzerland.", "Department of Urology, Spital Thurgau, Pfaffenholzstrasse 4, Frauenfeld, 8501, Switzerland.", "Department of Urology, Spital Thurgau, Pfaffenholzstrasse 4, Frauenfeld, 8501, Switzerland. thomas.herrmann@stgag.ch.", "Division of Urology, Department of Surgical Sciences, Stellenbosch University, Stellenbosch, Western Cape, South Africa. thomas.herrmann@stgag.ch.", "Hannover Medical School, Hannover, Germany. thomas.herrmann@stgag.ch.", "Institute for Anesthesia, Spital Thurgau, Frauenfeld, Switzerland. alexander.dullenkopf@stgag.ch."], "corresponding_authors": ["Thomas R W Herrmann", "Alexander Dullenkopf"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 19.0, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.0, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.9, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.0, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42831938", "title": "Female stress urinary incontinence surgical trends in New Zealand from 2010 to 2025: before and after a mesh pause and national surgeon credentialing.", "abstract": "To examine trends in surgical management of female stress urinary incontinence (SUI) from 2010 to 2025 including the impact of the mesh pause of August 2023 and national credentialing of surgeons. This retrospective cohort study used the Health New Zealand National Minimum Dataset (hospital events, NMDS). This includes all publicly funded hospital events from 2010-2025 for female stress urinary incontinence procedures being: mesh slings, fascial slings, Colposuspension and periurethral bulking agents. There was significant and sustained decline in female SUI procedures beginning in 2013 to 2022. There was also a shift in procedural types with mesh slings being the predominant procedure before 2020 and periurethral bulking agents increasing from 2017. Following the mesh pause, there was no change in overall SUI activity prior to and after the pause. However, there was shift in the predominant procedures from mesh slings to periurethral bulking agents. In younger age groups the fall in sling procedures and increase in bulking was more marked. In the context of surgeon credentialing which began in 2022 through till october 2025, we found 64% of Colposuspensions and 22% of fascial slings were performed at a hospital without a New Zealand framework credentialled surgeon. Due to NMDS database being hospital/procedural based, we assigned credentialing at hospital level which may overestimate the availability of credentialled expertise at the hospital level. Between 2010 to 2025, there has been a sustained decline in female SUI procedures in New Zealand public hospitals. This decline began in 2013, nine years before the mesh pause of 2023. There has been a significant shift in the predominant SUI procedures following the mesh pause from highly efficacious procedures, mesh slings, to periurethral bulking agents, which are less efficacious. We also found that following credentialing, a significant proportion of procedures were performed in hospitals without a credentialed surgeon.", "journal": "World Journal of Urology", "pub_date": "2026-Oct-05", "publication_types": ["Journal Article"], "doi": "10.1007/s00345-026-06812-4", "authors": ["Eva Fong", "Michael Keane", "Sum Sum Lo", "Giovanni Losco", "Hazel Ecclestone"], "affiliations": ["New Zealand Female Pelvic Mesh Service, Health NZ Waitematā, Auckland, New Zealand. eva.fong@waitematadhb.govt.nz.", "Health Quality and Safety Commission Te Tāhū Hauora, Wellington, New Zealand.", "New Zealand Female Pelvic Mesh Service, Health NZ Waitematā, Auckland, New Zealand.", "New Zealand Female Pelvic Mesh Service, Health NZ Waitaha Canterbury, Christchurch, New Zealand."], "corresponding_authors": ["Eva Fong"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=4", "score": 35.5, "score_parts": {"urology_relevance": 11, "urology_in_title": 8.0, "journal_priority": 10.0, "top_journal_bonus": 0.0, "novelty": 0.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 4.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.9, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.0, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42831933", "title": "Institutional availability, training resources, and supervised participation in robot-assisted surgery among Polish urology residents: a nationwide survey.", "abstract": "Robot-assisted surgery (RAS) has expanded rapidly in Poland, but its integration into resident education remains uncertain. In a nationwide anonymous 35-question survey sent to 390 Polish urology residents, 156 completed it (40.0%). Among respondents, 110 (70.5%) reported RAS availability in their training centre; 56 (35.9%) reported robotic training access, 43 (27.6%) a robotic course, 46 (29.5%) simulator availability, 76 (48.7%) assistant participation, and 16 (10.3%) a supervised robotic procedure or procedural step. All respondents with training access were in RAS centres. Among these 110 respondents, course attendance (aOR 5.38, 95% CI 2.05-14.14) and simulator availability (aOR 3.90, 95% CI 1.54-9.89) were associated with access. Training access was associated with assistant participation (aOR 6.66, 95% CI 3.06-14.50), higher current and expected self-rated skill (common aORs 12.30 and 12.15), and at least satisfactory training satisfaction (aOR 17.01, 95% CI 6.35-45.57). All 16 such reports occurred among residents with access; in an exploratory conditional Firth model, each additional residency year was associated with this outcome (aOR 2.11, 95% CI 1.30-3.97). Items were independent, not sequential stages. Institutional adoption exceeded reported training access and supervised participation. Broad survey content makes participation driven solely by robotics interest less likely, but the 40.0% completion proportion, self-report, unmeasured trainee selection, and rare supervised outcome limit inference.", "journal": "Journal of Robotic Surgery", "pub_date": "2026-Oct-05", "publication_types": ["Journal Article"], "doi": "10.1007/s11701-025-02893-2", "authors": ["Bartosz Brzoszczyk", "Marcin Jarzemski", "Rafał Brzóska", "Bartosz Roś", "Łukasz Mielczarek", "Rafał Bogdan Drobot", "Mateusz Władysław Jobczyk", "Maciej Wojciech Przudzik", "Magdalena Tarkowska", "Piotr Jarzemski"], "affiliations": ["Clinic of Urology, Jan Biziel University Hospital in Bydgoszcz, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, 75 Kornela Ujejskiego Street, 85-168, Toruń, Bydgoszcz, Poland. bartosz.brzoszczyk@gmail.com.", "Clinic of Urology, Jan Biziel University Hospital in Bydgoszcz, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, 75 Kornela Ujejskiego Street, 85-168, Toruń, Bydgoszcz, Poland.", "Department of Urooncology and Minimally Invasive Urology, Centre of Postgraduate Medical Education, Warsaw, Poland.", "Urology Department, Institute of Medical Sciences, Faculty of Medicine, Collegium Medicum, Cardinal Stefan Wyszyński University in Warsaw, Warsaw, Poland.", "Department of General, Oncological and Laparoscopic Urology, John Paul II Provincial Hospital, Bełchatów, Poland.", "Department of Urology, Faculty of Medicine, University of Warmia and Mazury in Olsztyn, Olsztyn, Poland."], "corresponding_authors": ["Bartosz Brzoszczyk"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 20.03, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 6.03, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 3.0, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 2.03, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42831897", "title": "Re: Cormio A, Gauhar V, Herrmann T, et al. Influence of intraoperative tranexamic acid on bleeding outcomes in patients receiving antithrombotic therapy undergoing endoscopic enucleation of the prostate: a multicenter prospective study by the endourology section of EAU. World J Urol. 2026;44:179.", "abstract": "", "journal": "World Journal of Urology", "pub_date": "2026-Oct-05", "publication_types": ["Letter"], "doi": "10.1007/s00345-026-06823-1", "authors": ["Edoardo Pozzi", "Vincenzo Scattoni", "Andrea Salonia", "Alberto Briganti", "Francesco Montorsi"], "affiliations": ["IRCCS Ospedale San Raffaele, Milan, Italy.", "Vita-Salute San Raffaele University, Milan, Italy.", "Vita-Salute San Raffaele University, Milan, Italy. montorsi.francesco@hsr.it.", "IRCCS Ospedale San Raffaele, Milan, Italy. montorsi.francesco@hsr.it.", "Department of Urology, IRCCS Ospedale San Raffaele Vita-Salute San Raffaele University, Via Olgettina 60, 20132, Milan, Italy. montorsi.francesco@hsr.it."], "corresponding_authors": ["Francesco Montorsi"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=6", "score": 29.0, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 10.0, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 6.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.9, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.0, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42831270", "title": "Lived Experiences of Emotional Distress Among Patients With Lower Urinary Tract Symptoms: A Mixed-Methods Study.", "abstract": "We aimed to describe the association of lower urinary tract symptoms (LUTS) with emotional distress using questionnaires and qualitative interviews. We used a convergent parallel mixed methods design to examine relationships between the LURN Symptom Index-29 (LURN SI-29) questionnaire and emotional distress, measured by the Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety and Depression Short Forms and the Perceived Stress Scale. Quantitative analyses assessed correlations between the SI-29 total and subscale scores and emotional distress measures. Qualitative interviews explored the emotional impact of LUTS, with representative quotations used to contextualize quantitative findings. The total and pain subscale scores of the LURN SI-29 demonstrated the strongest positive correlations with anxiety (r = 0.25-0.33), depression (r = 0.24-0.30), and stress (r = 0.21-0.28). Urgency, incontinence and voiding subscales had weaker associations, while nocturia showed minimal or slighting negative correlations (|r| < 0.12). Although most of the relationships were statistically significant, effect sizes were generally small. Qualitative narratives converged with these findings, describing how pain, unpredictability, and loss of control contributed to anxiety, depression, and stress. Pain and overall LUTS burden were the primary contributors to emotional distress, whereas nocturia played a minimal role. Despite cohort selection for urinary urgency, pain was a driver of emotional distress, highlighting the need to assess bladder-related pain and its psychosocial impacts in LUTS care. NCT02485808.", "journal": "Neurourology and Urodynamics", "pub_date": "2026-Oct-05", "publication_types": ["Journal Article"], "doi": "10.1002/nau.70448", "authors": ["Grace E Bardwick", "Alan J Fossa", "Hosanna An", "Jessica Thomas", "Brian Bieber", "Kathryn E Flynn", "Giulia M Ippolito", "Melissa Marquez", "Michelle Taddeo", "James W Griffith", "LURN Study Group"], "affiliations": ["University of Chicago, Chicago, Illinois, USA.", "Arbor Research Collaborative for Health, Ann Arbor, Michigan, USA.", "Northwestern University, Chicago, Illinois, USA.", "Medical College of Wisconsin, Milwaukee, Wisconsin, USA.", "University of Michigan, Ann Arbor, Michigan, USA."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=4", "score": 30.56, "score_parts": {"urology_relevance": 11, "urology_in_title": 8.0, "journal_priority": 5.56, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 4.0}, "journal_metrics": {"status": "ok", "impact_factor": 1.9, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.56, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42831269", "title": "Predictors of 2-Week Post-Void Residual After Intradetrusor OnabotulinumtoxinA Injection for Overactive Bladder: A Sex- and Neurogenic Status-Stratified Analysis.", "abstract": "Urinary retention rates after intradetrusor onabotulinumtoxinA (BTX-A) peak at 2 weeks, yet risk stratification by sex and neurogenic status remains limited. We evaluated predictors of 2-week post-void residual (PVR) and differences by sex and neurogenic bladder status using the largest retrospective cohort to date. We reviewed all BTX-A procedures at a single academic institution from January 2020 to June 2025. Patients younger than 18 years, those with mean preprocedural PVR ≥ 150 mL, prior pelvic radiation, or preprocedural catheterization requirements were excluded. Two-week PVR was analyzed using multivariable regression of demographics and urodynamic parameters, adjusting for total injections per patient, with subgroup analyses by sex-assigned-at-birth and neurogenic status. A total of 824 patients underwent 2282 BTX-A injections. The cohort was predominantly female (95.9%) and non-neurogenic (93.7%), with mean preprocedural PVR of 24 mL, mean BTX-A dose of 120.8 units, and mean 2-week PVR of 66.7 mL. Higher preprocedural PVR was associated with higher 2-week PVR among female patients (β = 0.593 mL, 95% CI [0.303, 0.883]) and non-neurogenic patients (β = 0.555, 95% CI [0.284, 0.825]), but not among male or neurogenic patients. Higher BTX-A dose was similarly associated with higher 2-week PVR among female patients (β = 25.7 mL per 100 U, 95% CI [6.16, 45.2]) and non-neurogenic patients (β = 28.1 mL per 100U, 95% CI [10.5, 45.6]). Lower maximum flow rate (Qmax) was associated with higher 2-week PVR among female patients (β = -1.25 mL per mL/sec, 95% CI [-1.94, -0.56]), neurogenic patients (β = -17.4, 95% CI [-31.5, -3.26]), and non-neurogenic patients (β = -1.08, 95% CI [-1.74, -0.418]). Higher detrusor pressure at maximum flow (pDet@Qmax) was associated with higher 2-week PVR among female (β = 0.557 mL/cmH2O, 95% CI 0.136, 0.979]) and neurogenic patients (β = 2.68 mL/cmH2O, 95% CI 0.126, 5.23]), whereas lower pDet@Qmax was associated with higher PVR among male patients (β = -8.34 mL/cmH2O, 95% CI -12.9, -3.76]). Pre-procedural PVR and BTX-A dose were consistent predictors of elevated 2-week PVR in females and non-neurogenic patients. These findings support sex- and neurogenic-specific risk stratification and dose considerations prior to BTX-A injection.", "journal": "Neurourology and Urodynamics", "pub_date": "2026-Oct-05", "publication_types": ["Journal Article"], "doi": "10.1002/nau.70473", "authors": ["Saawan D Patel", "Evan Rosario", "Ariana L Smith"], "affiliations": ["Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.", "Division of Urology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=6", "score": 28.56, "score_parts": {"urology_relevance": 7, "urology_in_title": 8.0, "journal_priority": 5.56, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 6.0}, "journal_metrics": {"status": "ok", "impact_factor": 1.9, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.56, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42831263", "title": "Comparative Performance of Large Language Models in Urodynamic Trace Interpretation Using an Adapted Expert-Led Evaluation of Generative AI Competence and Excellence Framework.", "abstract": "Interpretation of urodynamic studies is complex and subject to substantial inter-observer variability, even among experienced clinicians. While artificial intelligence has shown promise in urology, evidence regarding the performance of large language models (LLMs) in urodynamic trace interpretation remains limited. This study aimed to systematically compare the performance of multiple contemporary LLMs in interpreting standard urodynamic traces using an adapted ELEGANCE framework. In this retrospective, single-centre comparative study, 119 anonymised urodynamic machine printouts retrieved from the institutional patient archive were independently interpreted by five LLM-based platforms (ChatGPT-5.2, Gemini 3, Perplexity AI Pro, DeepSeek-V3.2, and Grok 4.1). Case-specific expert reference interpretations were produced by one of three urologists, whereas all LLM-generated interpretations were independently evaluated by all three urologists. LLM-generated interpretations were assessed using an adapted version of the \"Expert-Led Evaluation of Generative AI Competence and Excellence\" (ELEGANCE) questionnaire, which evaluates relevance, completeness, applicability, structure, language/terminology, satisfaction, and hallucination. Between-model comparisons were performed using Friedman and post-hoc Wilcoxon signed-rank tests. Overall ELEGANCE scores differed significantly among models (χ2[4] = 12.67, p = 0.013). Gemini achieved the highest mean score (25.77 ± 3.74), followed by Perplexity, DeepSeek, and ChatGPT-5.2, while Grok demonstrated significantly lower performance. Gemini consistently outperformed other models in clinically oriented domains, including relevance, completeness, and applicability (all p < 0.05). No hallucinations were identified in any model output. Inter-rater reliability among the three expert reviewers was good (average-measures ICC = 0.898, 95% CI 0.853-0.929; p < 0.001). Contemporary LLMs can generate structured interpretations of urodynamic traces, with meaningful performance differences across the evaluated platforms. While strengths in structure and terminology are evident, limitations in clinical reasoning persist. LLMs may serve as valuable assistive tools for standardisation and quality assurance in urodynamics but are not yet suitable for autonomous clinical decision-making.", "journal": "Neurourology and Urodynamics", "pub_date": "2026-Oct-05", "publication_types": ["Journal Article"], "doi": "10.1002/nau.70470", "authors": ["Oguzhan Akpinar", "Anil Erkan", "Alper Keskin", "Muhammet Guzelsoy"], "affiliations": ["Department of Urology, Bursa Yuksek Ihtisas Training and Research Hospital, University of Health Sciences, Bursa, Turkiye."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 13.56, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 5.56, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 1.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 1.9, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.56, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42830647", "title": "Gleason pattern 4 length and active surveillance eligibility in Grade Group 2-4 prostate cancer.", "abstract": "To evaluate whether total Gleason pattern 4 (GP4) length provides better risk stratification than current risk group criteria for determining potential active surveillance (AS) eligibility, using oncological outcomes after radical prostatectomy (RP). We identified patients with Grade Group (GG) 2-4 disease on magnetic resonance imaging (MRI)-targeted and systematic biopsy who underwent RP. We calculated total GP4 length as the summed millimetres of GP4 in systematic cores plus the average across MRI-targeted cores. Concordance analysis was used to evaluate how increasing GG corresponded to greater GP4 burden. We compared prediction of adverse pathology at RP and 5-year biochemical recurrence (BCR) between risk groups and total length of GP4. Among 2499 patients, 1691, 694, and 114 had GG2, GG3, and GG4 disease, of whom 73%, 19%, and 15% had low amounts (<2 mm) of GP4. Patients with <2 mm of GP4, regardless of GG, had similar risks of adverse pathology (5.2% vs 5.0%) and 5-year BCR (20% vs 21%) as those with favourable intermediate-risk disease; if used as an AS threshold, <2 mm of GP4 would classify approximately twice as many patients as AS eligible, translating to ~50 000 men annually in the United States alone. Total length of GP4 provides better risk stratification for AS eligibility than current favourable intermediate-risk group criteria. Further defining the optimal method for GP4 quantification and determining the appropriate cut-point is needed before clinical implementation.", "journal": "BJU International", "pub_date": "2026-Oct-04", "publication_types": ["Journal Article"], "doi": "10.1111/bju.70478", "authors": ["Sean A Fletcher", "Nicholas A Pickersgill", "Nate Aiken", "Melissa J Assel", "Nicole Liso", "Victor E Reuter", "Behfar Ehdaie", "Samson W Fine", "Andrew J Vickers"], "affiliations": ["Department of Surgery (Urology Service), Memorial Sloan Kettering Cancer Center, New York, NY, USA.", "Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.", "Department of Pathology & Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 24.47, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.47, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.4, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.47, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42830190", "title": "Global trends in urological cancers: an analysis of the global burden of disease study 2023.", "abstract": "Our objective was to quantify changes in the global burden of prostate, bladder, kidney and testicular cancers from 1990 to 2023 and to assess demographic contributions and characterize geographic, age-specific and modelled risk-attributable patterns. We analysed Global Burden of Disease 2023 estimates for incidence, deaths and disability-adjusted life-years (DALYs). Age-standardised incidence rates and death rates were summarised using estimated annual percentage change. We incorporated 95% uncertainty intervals (UIs), decomposed changes in counts into population growth, population ageing and age-specific rate effects, assessed 2021-2023 changes, and repeated country rankings after excluding locations with an implied population <1 million. In 2023, the four cancers accounted for approximately 2.47 million incident cases, 0.88 million deaths and 18.1 million DALYs. Prostate cancer contributed 1.41 million incident cases (95% UI 1.19-1.63 million) and 469 000 deaths (95% UI 413 000-526 000). From 1990 to 2023, age-standardised incidence rates increased for testicular cancer (estimated annual percentage change 0.98%, 95% confidence interval [CI] 0.89-1.07) and kidney cancer (0.27%, 95% CI 0.13-0.41), was stable for prostate cancer, and decreased for bladder cancer; age-standardised death rates decreased for all four cancers. Together, population growth and ageing accounted for the most increases in incident cases, whereas declining age-specific rates offset deaths from prostate, bladder, kidney and testicular cancers. Small-jurisdiction leaders changed materially in the population-threshold sensitivity analysis. In 2023, all modelled risks accounted for 34.6% (95% UI 29.7-39.8) of bladder cancer DALYs and 27.1% (95% UI 17.0-36.7) of kidney cancer DALYs but only 1.6% (95% UI -5.6 to 6.8) of prostate cancer DALYs. The growing absolute burden of these cancers was predominantly demographic, but cancer-specific and geographic trajectories differed. Testicular cancer added a young-adult, rising-incidence component to the conventional older-age urological cancer profile. Rankings for small populations require cautious interpretation, and prevention priorities should reflect cancer-specific risk patterns.", "journal": "BJU International", "pub_date": "2026-Oct-04", "publication_types": ["Journal Article"], "doi": "10.1111/bju.70473", "authors": ["Hanbo Lu", "Yusa Zhang", "Yang Zhao", "Yushi Zhang"], "affiliations": ["Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P.R. China.", "Eight-year Program of Clinical Medicine, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, P.R. China."], "corresponding_authors": [], "china_team": "Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P Yushi Zhang团队", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 38.47, "score_parts": {"urology_relevance": 18.0, "urology_in_title": 8.0, "journal_priority": 10.47, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.4, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.47, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "睾丸癌发病率上升凸显年轻成人负担", "chinese_summary": "北京协和医院张玉石团队10月BJU Int基于GBD 2023数据发现，1990至2023年睾丸癌和肾癌年龄标化发病率上升，膀胱癌下降、前列腺癌稳定，四种泌尿肿瘤死亡率均下降。2023年四癌合计约247万新发、88万死亡，负担增长主要由人口增长和老龄化驱动。", "abstract_zh": "我们的目标是量化1990年至2023年前列腺癌、膀胱癌、肾癌和睾丸癌全球负担的变化，并评估人口学贡献，刻画地理、年龄别及模型化风险归因模式。我们分析了全球疾病负担2023估计的发病率、死亡和伤残调整生命年（DALYs）。年龄标化发病率和死亡率采用估计年度百分比变化进行总结。我们纳入95%不确定性区间（UIs），将例数变化分解为人口增长、人口老龄化和年龄别率效应，评估2021—2023年变化，并在排除隐含人口<100万的地点后重复国家排名。2023年，这四种癌症约造成247万新发病例、88万死亡和1810万DALYs。前列腺癌贡献141万新发病例（95% UI 119万—163万）和46.9万死亡（95% UI 41.3万—52.6万）。1990年至2023年，年龄标化发病率在睾丸癌（估计年度百分比变化0.98%，95%置信区间[CI] 0.89—1.07）和肾癌（0.27%，95% CI 0.13—0.41）上升，前列腺癌稳定，膀胱癌下降；四种癌症的年龄标化死亡率均下降。人口增长和老龄化共同解释了新发病例增加的大部分，而年龄别率下降抵消了前列腺癌、膀胱癌、肾癌和睾丸癌的死亡。在人口阈值敏感性分析中，小辖区领先者发生实质性变化。2023年，所有模型化风险分别归因于膀胱癌DALYs的34.6%（95% UI 29.7—39.8）和肾癌DALYs的27.1%（95% UI 17.0—36.7），但仅归因于前列腺癌DALYs的1.6%（95% UI -5.6—6.8）。这些癌症绝对负担的增长主要源于人口学因素，但癌症特异性和地理轨迹不同。睾丸癌为传统老年泌尿肿瘤谱增添了年轻成人发病率上升的成分。小人口排名需谨慎解读，预防重点应反映癌症特异性风险模式。"}, {"pmid": "42839290", "title": "Gene expression profiles in benign prostate tissue reflect tumor proximity, grade, and molecular subtype.", "abstract": "Normal tissue in a tumor-bearing organ shows morphological and molecular differences from normal tissue in a tumor-free organ. One explanation to this is that tumors actively instruct adjacent normal tissues to support growth and invasion. The aim of this study was to examine if changes in gene-expression patterns in tumor-adjacent histologically benign prostate tissue, termed tumor instructed normal tissue (TINT), were associated with tumor proximity, grade and molecular subtype and, furthermore, whether they could indicate the presence of high-grade cancer elsewhere in the prostate. Gene-expression analysis using Clariom D microarrays was performed on matched formalin-fixed paraffin-embedded samples including tumor tissue (n = 44), benign prostate tissue taken near (TINT-N, n = 44) or distant (TINT-D, n = 42) to the tumor in 44 men with unifocal cancer treated by prostatectomy. TINT changes related to cell proliferation and immune cell infiltration were examined using immunohistochemical markers. In addition, gene expression was compared between tumor-negative biopsies from men later diagnosed with high-grade cancer (Bx-later-tumor, n = 46), tumor-negative biopsies from men who remained cancer-free (Bx-control, n = 49), and cancer-containing biopsies (Bx-tumor, n = 28). Gene set enrichment analysis (GSEA) was performed to explore hallmark gene sets in tumor and TINT tissue in relation to tumor grade (high vs. low) and molecular subtype (Luminal B vs. Luminal A). The transcriptome in TINT differed significantly from that in cancer-free biopsy control tissue and was related to tumor grade (high- vs. low), molecular subtype (Luminal B vs. Luminal A), and tumor proximity (TINT-N vs. TINT-D). Hallmarks related to cell proliferation and increased Ki67 staining as well as signs of increased metabolism were generally enriched in both tumor and TINT tissue of high grade and Luminal B tumors. In contrast, some immune responses were unique to TINT areas of high-grade and Luminal A tumors, respectively, and more obvious in TINT-N than in TINT-D. Analysis of Bx-later-tumor indicated enriched metabolism compared to Bx-control, without clear proliferative or immunological differences. TINT effects involving proliferation, metabolism and immune responses are related to distance, tumor grade and molecular subtype. TINT alterations hold potential as diagnostic and prognostic biomarkers and may provide a basis for further exploration of tumor-host interactions and potential targets for intervention.", "journal": "Journal of Translational Medicine", "pub_date": "2026-Oct-03", "publication_types": ["Journal Article"], "doi": "10.1158/1078-0432.CCR-18-1229", "authors": ["Pernilla Wikström", "Eva Freyhult", "Julius Semenas", "Marie Lundholm", "Andreas Josefsson", "Sofia Halin Bergström", "Anders Bergh"], "affiliations": ["Department of Medical Biosciences, Pathology, Umeå University, Umeå, 901 85, Sweden.", "Department of Cell and Molecular Biology, National Bioinformatics Infrastructure Sweden, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.", "Department of Diagnostics and Interventions, Urology and Andrology, Umeå University, Umeå, Sweden.", "Wallenberg Center for Molecular Medicine, Umeå University, Umeå, Sweden.", "Department of Medical Biosciences, Pathology, Umeå University, Umeå, 901 85, Sweden. anders.bergh@umu.se."], "corresponding_authors": ["Anders Bergh"], "china_team": "", "category": "basic", "classification_reason": "basic_signals=5", "score": 30.64, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 11.14, "top_journal_bonus": 0.0, "novelty": 0.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 5.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 7.5, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 3.14, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "癌旁良性前列腺组织基因表达随距离分级改变", "chinese_summary": "10月J Transl Med对44例单灶前列腺癌配对样本行微阵列分析，发现癌旁组织转录组显著异于无癌对照，增殖、代谢及部分免疫信号随肿瘤距离、分级及Luminal B/A亚型改变，提示癌旁组织或可作诊断预后标志物。", "abstract_zh": "荷瘤器官中的正常组织与无瘤器官中的正常组织在形态学和分子层面存在差异。一种解释是，肿瘤主动指导邻近正常组织以支持其生长和侵袭。本研究旨在检验肿瘤邻近组织学良性前列腺组织（称为肿瘤指导正常组织，TINT）中基因表达模式的变化是否与肿瘤邻近程度、分级和分子亚型相关，并进一步检验这些变化是否能提示前列腺其他部位存在高级别癌症。使用Clariom D微阵列对匹配的福尔马林固定石蜡包埋样本进行基因表达分析，样本包括肿瘤组织（n=44）、取自肿瘤附近（TINT-N，n=44）或远离肿瘤（TINT-D，n=42）的良性前列腺组织，来自44例接受前列腺切除术的单灶性癌症男性。使用免疫组化标志物检查与细胞增殖和免疫细胞浸润相关的TINT变化。此外，比较了后来诊断为高级别癌症男性的肿瘤阴性活检（Bx-later-tumor，n=46）、保持无癌男性的肿瘤阴性活检（Bx-control，n=49）以及含癌活检（Bx-tumor，n=28）之间的基因表达。进行基因集富集分析（GSEA）以探索肿瘤和TINT组织中与肿瘤分级（高级别 vs. 低级别）和分子亚型（Luminal B vs. Luminal A）相关的标志性基因集。TINT中的转录组与无癌活检对照组织显著不同，并与肿瘤分级（高级别 vs. 低级别）、分子亚型（Luminal B vs. Luminal A）和肿瘤邻近程度（TINT-N vs. TINT-D）相关。与细胞增殖和Ki67染色增加以及代谢增加迹象相关的标志在高级别和Luminal B肿瘤的肿瘤及TINT组织中普遍富集。相反，某些免疫反应分别独特地出现在高级别和Luminal A肿瘤的TINT区域，并且在TINT-N中比在TINT-D中更明显。对Bx-later-tumor的分析表明，与Bx-control相比，代谢富集，但没有明显的增殖或免疫差异。涉及增殖、代谢和免疫反应的TINT效应与距离、肿瘤分级和分子亚型相关。TINT改变具有作为诊断和预后生物标志物的潜力，并可能为进一步探索肿瘤-宿主相互作用及潜在干预靶点提供基础。"}, {"pmid": "42832832", "title": "Environmentally relevant antibiotic exposure in school-age children: unraveling socio-dietary drivers in a multi-ethnic region of Northwest China.", "abstract": "While existing biomonitoring studies have extensively characterized the prevalence of antibiotic exposure, the complex sociodemographic and behavioral determinants underlying individual exposure profiles remain insufficiently understood. This study addressed the important research gap by examining antibiotic exposure in a distinctive socio-cultural setting-the Ningxia Hui Autonomous Region of China. We analyzed urinary concentrations of 22 antibiotics from four classes (tetracyclines, sulfonamides, macrolides, and fluoroquinolones) and one additional synthetic antibacterial agent in a cohort of 295 children in 2024. A brief food-frequency survey was concurrently administered to evaluate the nutritional preferences of children. The results revealed extensive exposure to antimicrobial agents, with 55.4% of the participants exhibiting measurable traces of at least one target antimicrobial compound. Detection frequencies for individual compounds ranged from 0.7% to 26.4%. Multivariable logistic regression analyses revealed that specific dietary habits were associated with increased odds of antibiotic detection; notably, after false discovery rate (FDR) adjustment, frequent consumption of white meat and eggs was significantly associated with higher detection odds for tetracyclines (OR = 2.54) and fluoroquinolones (OR = 2.96), respectively. Health risk assessment based on the hazard index (HI) and hazard quotient indicated that 9.15% of the children had HI values exceeding 1. Ciprofloxacin was the primary contributor to HI, with hazard quotient values exceeding 1 detected in 2.71% of children. Overall, this biomonitoring study indicates frequent internal exposure to environmentally relevant antibiotics among school-age children in this region, underscoring the need for further multi-pathway exposure assessments.", "journal": "Environment International", "pub_date": "2026-Oct-03", "publication_types": ["Journal Article"], "doi": "10.1016/j.envint.2026.110550", "authors": ["Yijing Zhang", "Yangyi Zhang", "Yonggang Lv", "Lu Yin", "Menglu Wang", "Cheng Ma", "Jiayi Hao", "Li Gao", "Shengqiang Hei", "Xiaotu Liu", "Dengchao Liu"], "affiliations": ["School of Geography and Planning, China-Arab Joint International Research Laboratory for Featured Resources and Environmental Governance in Arid Region, Ningxia (China-Arab) Key Laboratory of Resources Assessment and Environment Regulation in Arid Region, Ningxia University, Yinchuan 750021, China; Ningxia Nuclear Geological Survey Institute, Yinchuan 750021, China.", "School of Geography and Planning, China-Arab Joint International Research Laboratory for Featured Resources and Environmental Governance in Arid Region, Ningxia (China-Arab) Key Laboratory of Resources Assessment and Environment Regulation in Arid Region, Ningxia University, Yinchuan 750021, China.", "Department of Pediatrics, General Hospital of Ningxia Medical University, Yinchuan 750021, China.", "School of Geography and Planning, China-Arab Joint International Research Laboratory for Featured Resources and Environmental Governance in Arid Region, Ningxia (China-Arab) Key Laboratory of Resources Assessment and Environment Regulation in Arid Region, Ningxia University, Yinchuan 750021, China; Ningxia Technical College of Wine and Desertification Prevention, Yinchuan 750021, China.", "College of Environment and Climate, Guangdong Key Laboratory of Environmental Pollution and Health, Jinan University, Guangzhou 511443, China. Electronic address: liuxiaotu@jnu.edu.cn.", "School of Geography and Planning, China-Arab Joint International Research Laboratory for Featured Resources and Environmental Governance in Arid Region, Ningxia (China-Arab) Key Laboratory of Resources Assessment and Environment Regulation in Arid Region, Ningxia University, Yinchuan 750021, China. Electronic address: ldcxfp@nxu.edu.cn."], "corresponding_authors": ["Xiaotu Liu", "Dengchao Liu"], "china_team": "School of Geography and Planning, China-Arab Joint International Research Laboratory for Featured Resources and Environmental Governance in Arid Region, Ningxia (China-Arab) Key Laboratory of Resources Assessment and Environment Regulation in Arid Region, Ningxia University, Yinchuan 750021, China; Ningxia Nuclear Geological Survey Institute, Yinchuan 750021, China Xiaotu Liu/Dengchao Liu团队", "category": "clinical_review", "classification_reason": "clinical_signals=4", "score": 24.48, "score_parts": {"urology_relevance": 3, "urology_in_title": 0.0, "journal_priority": 15.48, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 4.0}, "journal_metrics": {"status": "ok", "impact_factor": 9.7, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.48, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42829306", "title": "Comparing NCCN-based risk groups to the PROTEUS definition of high-risk localized prostate cancer to inform peri-operative care.", "abstract": "There is substantial heterogeneity of outcomes among patients with high-risk localized prostate cancer. The recently published PROTEUS trial saught to enrich for aggressive disease using more restrictive eligibility criteria than the commonly used NCCN high-risk definition. We compared patient distributions and oncologic outcomes after radical prostatectomy using PROTEUS and NCCN high-risk criteria. We used an institutional radical prostatectomy database to classify patients as high-risk by NCCN criteria (Gleason grade group [GGG] 4-5, clinical T3-T4 disease, or PSA > 20 ng/ml) or PROTEUS criteria (overall GGG ≥ 3 plus GGG5 in ≥1 core, GGG4 in ≥2 cores each with >80% involvement, GGG3+ in ≥6 systematic cores, or GGG3+ in ≥3 systematic cores with PSA ≥ 20 ng/ml). Patient distributions were summarized descriptively. Area under the receiver operating curve (AUC) was compared for oncologic outcomes. Among 358 patients, 62 (17%) met NCCN high-risk criteria and 44 (12%) met PROTEUS criteria. Overall, 38 patients met both definitions, 24 met NCCN criteria only, and 6 met PROTEUS criteria only. There were no statistically significant differences in predicting extra-prostatic extension (NCCN 0.56, 95% Confidence interval [CI] 0.52-0.60; PROTEUS 0.56, 95% CI 0.53-0.60; P = 0.96), positive surgical margins (NCCN 0.54, 95% CI 0.49-0.58; PROTEUS 0.52, 95% CI 0.49-0.56; P = 0.45), and PSA > 0.2 at 12 months postoperatively (NCCN 0.59, 95% CI 0.49-0.69; PROTEUS 0.64, 95% CI 0.54-0.75; P = 0.32). PROTEUS criteria, which may be cumbersome in clinical practice, identified a smaller, overlapping, but nonidentical high-risk population compared with NCCN criteria. There were no statistically significant differences in postprostatectomy oncologic outcomes between both definitions. These findings suggest that PROTEUS eligibility criteria represent a more restrictive trial-enrichment definition but may not meaningfully improve discrimination of adverse outcomes relative to standard NCCN high-risk classification.", "journal": "Urologic Oncology", "pub_date": "2026-Oct-03", "publication_types": ["Journal Article"], "doi": "10.1016/j.urolonc.2026.09.003", "authors": ["David-Dan Nguyen", "Raj Satkunasivam", "Jethro C C Kwong", "Bobby Shayegan", "Aly-Khan Lalani", "Geoffrey T Gotto", "Amanda E Hird", "Andrea Kokorovic", "Melissa J Huynh", "Ricardo Rendon", "Rodney H Breau", "Antonio Finelli", "Neil Fleshner", "Girish S Kulkarni", "Alexandre R Zlotta", "Christopher J D Wallis"], "affiliations": ["Division of Urology, Department of Surgery, University of Toronto, Toronto, ON, Canada; Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.", "Division of Urology, Department of Surgery, University of Toronto, Toronto, ON, Canada; Division of Urology, Department of Surgery, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada; Division of Urology, Department of Surgery, Princess Margaret Cancer Centre, University of Toronto, ON, Canada.", "Division of Urology, Department of Surgery, University of Toronto, Toronto, ON, Canada.", "Division of Urology, Department of Surgery, St. Joseph's Healthcare Hamilton, McMaster University, Hamilton, ON, Canada.", "Department of Medical Oncology, Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada.", "Division of Urology, Department of Surgery, Southern Alberta Institute of Urology, University of Calgary, Calgary, AB, Canada.", "Division of Urology, Department of Surgery, Sunnybrook Health Sciences, University of Toronto, ON, Canada.", "Department of Urology, Dalhousie University, Halifax, ON, Canada.", "Division of Urology, Department of Surgery, University of Western Ontario, London, ON, Canada.", "Division of Urology, Department of Surgery, The Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada.", "Division of Urology, Department of Surgery, Trillium Health Partners, University of Toronto, Toronto, ON, Canada.", "Division of Urology, Department of Surgery, University of Toronto, Toronto, ON, Canada; Division of Urology, Department of Surgery, Princess Margaret Cancer Centre, University of Toronto, ON, Canada; Division of Urology, Department of Surgery, Sunnybrook Health Sciences, University of Toronto, ON, Canada.", "Division of Urology, Department of Surgery, University of Toronto, Toronto, ON, Canada; Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada; Division of Urology, Department of Surgery, Princess Margaret Cancer Centre, University of Toronto, ON, Canada.", "Division of Urology, Department of Surgery, University of Toronto, Toronto, ON, Canada; Division of Urology, Department of Surgery, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada; Division of Urology, Department of Surgery, Princess Margaret Cancer Centre, University of Toronto, ON, Canada. Electronic address: wallis.cjd@gmail.com."], "corresponding_authors": ["Christopher J D Wallis"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 24.75, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 5.75, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 1.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.3, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.75, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42829270", "title": "Re: Sobia Khan, Nathan Papa, Andrew Kneebone, et al. Prospective Comparison of 64Copper [64Cu]SAR-bisPSMA vs 68Gallium [68Ga] PSMA-11 PET/CT for Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy (Co-PSMA Trial). Eur Urol 2026;89:512-20.", "abstract": "", "journal": "European Urology", "pub_date": "2026-Oct-03", "publication_types": ["Letter"], "doi": "10.1016/j.eururo.2026.08.028", "authors": ["Elif Hindié", "Aurélien Callaud", "Clément Morgat"], "affiliations": ["Service de Médecine Nucléaire, CHU de Bordeaux, Université de Bordeaux, UMR CNRS 5287, INCIA, Talence, France; Institut Universitaire de France, Paris, France.", "Service de Médecine Nucléaire, CHU de Bordeaux, Université de Bordeaux, UMR CNRS 5287, INCIA, Talence, France.", "Service de Médecine Nucléaire, CHU de Bordeaux, Université de Bordeaux, UMR CNRS 5287, INCIA, Talence, France. Electronic address: clement.morgat@u-bordeaux.fr."], "corresponding_authors": ["Clément Morgat"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 35.79, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 16.79, "top_journal_bonus": 10.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 25.2, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.79, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "铜64示踪剂或优于镓68显像", "chinese_summary": "欧洲泌尿外科学杂志10月就Co-PSMA试验发表读者来信，围绕前列腺癌根治术后生化复发，比较64Cu SAR-bisPSMA与68Ga PSMA-11 PET/CT的显像表现，讨论新型示踪剂在病灶检出与定位上的潜在优势及后续验证方向。", "abstract_zh": "这是一封关于Sobia Khan、Nathan Papa、Andrew Kneebone等人文章的读者来信，该文章题为《64铜[64Cu]SAR-bisPSMA与68镓[68Ga]PSMA-11 PET/CT在前列腺癌根治术后生化复发中的前瞻性比较（Co-PSMA试验）》，发表于Eur Urol 2026;89:512-20。"}, {"pmid": "42829268", "title": "Reply to Paolo Zaurito's Letter to the Editor re: Robert M. Meier, Nima Aghdam, Alan C. Beckman, et al. 10-yr Survival and Toxicity Outcomes of Stereotactic Body Radiotherapy for Prostate Cancer: A Nonrandomized Clinical Trial. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.04.029.", "abstract": "", "journal": "European Urology", "pub_date": "2026-Oct-03", "publication_types": ["Letter"], "doi": "10.1016/j.eururo.2026.08.018", "authors": ["Robert Meier", "Nima Aghdam", "Irving Kaplan"], "affiliations": ["Swedish Radiosurgery Center, Seattle, WA, USA. Electronic address: robert.meier@swedish.org.", "NYU Langone Health, New York, NY, USA.", "Beth Israel Deaconess Medical Center, Boston, MA, USA."], "corresponding_authors": ["Robert Meier"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=9", "score": 44.79, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 16.79, "top_journal_bonus": 10.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 9.0}, "journal_metrics": {"status": "ok", "impact_factor": 25.2, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.79, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "前列腺癌立体定向放疗回复读者来信", "chinese_summary": "针对Zaurito就Meier等10年生存与毒性结局非随机临床试验提出的质疑，作者在Eur Urol发表回复，重申立体定向体部放疗在前列腺癌中的长期疗效与安全性数据，并回应了有关试验设计与随访的关切。", "abstract_zh": "回复Paolo Zaurito致编辑的信，关于Robert M. Meier、Nima Aghdam、Alan C. Beckman等人发表的《前列腺癌立体定向体部放疗的10年生存与毒性结局：一项非随机临床试验》。Eur Urol。出版中。http://dx.doi.org/10.1016/j.eururo.2026.04.029。"}, {"pmid": "42829267", "title": "Reply to Riccardo Lombardo's Letter to the Editor re: Bi-Ming He, Keqin Zhang, Zhien Zhou, et al. Cognitive Versus Software-based Fusion targeted Biopsy for the Diagnosis of Clinically Significant Prostate Cancer: A Multicenter, Randomized, Noninferiority Trial (IMAGINATION). Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.06.020.", "abstract": "", "journal": "European Urology", "pub_date": "2026-Oct-03", "publication_types": ["Letter"], "doi": "10.1016/j.eururo.2026.09.018", "authors": ["Bi-Ming He", "Hai-Feng Wang"], "affiliations": ["Department of Urology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China; Institute for Advanced Study, Tongji University, Shanghai, China.", "Department of Urology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China. Electronic address: kuohaiandrew2000@vip.sina.com.cn."], "corresponding_authors": ["Hai-Feng Wang"], "china_team": "Department of Urology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China; Institute for Advanced Study, Tongji University, Shanghai, China Hai-Feng Wang团队", "category": "clinical_review", "classification_reason": "clinical_signals=6", "score": 41.79, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 16.79, "top_journal_bonus": 10.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 6.0}, "journal_metrics": {"status": "ok", "impact_factor": 25.2, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.79, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "认知融合靶向前列腺穿刺疗效获回应", "chinese_summary": "上海东方医院王海峰团队10月Eur Urol就IMAGINATION试验致编辑信作出回复，针对认知融合与软件融合靶向穿刺诊断临床显著前列腺癌的多中心随机非劣效性结果展开讨论，重申两种穿刺方式在临床显著前列腺癌检出上具有可比性，为资源有限地区选择穿刺策略提供依据。", "abstract_zh": "这是对Riccardo Lombardo致编辑信的回复，内容涉及Bi-Ming He、Keqin Zhang、Zhien Zhou等人发表的《认知融合与基于软件的融合靶向穿刺诊断临床显著前列腺癌：一项多中心、随机、非劣效性试验（IMAGINATION）》，该文发表于Eur Urol，印刷中，http://dx.doi.org/10.1016/j.eururo.2026.06.020。"}, {"pmid": "42829266", "title": "PSMA-PET/CT-guided Intensification of Radiation Therapy for Prostate Cancer (PSMAgRT): 5-yr Analysis of a Phase 2 Randomized Controlled Trial.", "abstract": "Prostate-specific membrane antigen positron emission tomography (PSMA-PET) improves lesion detection, leading to treatment intensification via PSMA-guided radiotherapy (PSMAgRT), but its impact on patient outcomes remains undefined. We evaluated whether PSMAgRT improves failure-free survival (FFS). This phase 2, two-center, open-label randomized trial enrolled patients planned for standard-of-care (SOC) radiotherapy (RT). Patients were randomized 1:1 to SOC or PSMAgRT to all detected sites across four strata: salvage post-radical prostatectomy (RP), high-risk, oligometastatic, and salvage post-RT. Between 2018 and 2021, 262 patients were randomized (253 treated/analyzed). The primary FFS end point (measured from RT completion) comprised prostate-specific antigen (PSA)/radiological progression, next-line therapy, or death. Secondary end points included freedom from biochemical progression (FFBP; PSA rise ≥0.2 ng/ml post-RP or ≥2 ng/ml above nadir in other strata). Prespecified analyses used a one-sided threshold of p1 < 0.10, whereas post hoc analyses used two-sided p < 0.05 thresholds and 95% confidence intervals (CIs). Among 253 patients, median follow-up was 66 mo (range 9-91). The 5-yr primary FFS was 66% with PSMAgRT versus 62% in controls (hazard ratio [HR] = 0.80; one-sided 90% CI, upper bound 1.04; p1 = 0.14). FFBP favored PSMAgRT: 72% versus 65% overall (subdistribution HR [sHR] 0.70, one-sided 90% CI upper bound 0.92; p1 = 0.048), 81% versus 66% in patients with high-risk disease (sHR 0.54; p1 = 0.07), and 80% versus 68% in patients in post-RP stratum (sHR 0.54; p1 = 0.037). In an exploratory, post hoc analysis combining patients with high-risk disease and those in the post-RP stratum, FFBP favored PSMAgRT (sHR 0.54, 95% CI = 0.32-0.91; two-sided p = 0.02). Only one grade ≥3 event was possibly related to dose escalation. Limitations include a phase 2 design with a heterogeneous population. Although the primary FFS end point was not met in the overall population, treatment-effect estimates favored PSMAgRT in the high-risk and post-RP strata. These findings provide a meaningful rationale for the target populations currently being evaluated in the definitive phase 3 PATRON trial. ClinicalTrials.gov NCT03525288.", "journal": "European Urology", "pub_date": "2026-Oct-03", "publication_types": ["Journal Article"], "doi": "10.1016/j.eururo.2026.09.017", "authors": ["Colin Belliveau", "Fred Saad", "Danny Duplan", "Claire Petit", "Guila Delouya", "Carole Lambert", "Daniel Taussky", "Maroie Barkati", "Marie-Claude Beauchemin", "Sebastien Clavel", "Gary Mok", "Anne-Sophie Gauthier-Paré", "Levon Igidbashian", "Marjory Jolicoeur", "Thu-Van Nguyen", "Pierre-Yves McLaughlin", "Philip Wong", "Khun Visith Keu", "Jean N DaSilva", "Daniel Juneau", "Cynthia Ménard"], "affiliations": ["Département de radio-oncologie, Centre Hospitalier de l'Université de Montréal, Montréal, Canada.", "Département d'urologie, Centre Hospitalier de l'Université de Montréal, Montréal, Canada.", "Département de radio-oncologie, Centre Intégré de Santé et de Services Sociaux de Laval, Laval, Canada.", "Département de radiothérapie, Institut Paoli Calmettes, Marseille, France.", "Département de radio-oncologie, Hôpital de Charles-Le-Moyne, Longueuil, Canada.", "Division of Radiation Oncology, The Ottawa Hospital, Ottawa, Canada.", "Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada.", "Département d'imagerie médicale, service de médecine nucléaire, Hôpital de la Cité-de-la-Santé, Laval, Canada.", "Laboratoire de Radiochimie et Cyclotron, Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montréal, Canada.", "Département de médecine nucléaire, Centre Hospitalier de l'Université de Montréal, Montréal, Canada.", "Département de radio-oncologie, Centre Hospitalier de l'Université de Montréal, Montréal, Canada; Département de radio-oncologie, Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montréal, Canada. Electronic address: cynthia.menard@umontreal.ca."], "corresponding_authors": ["Cynthia Ménard"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=9", "score": 49.79, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 16.79, "top_journal_bonus": 10.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 9.0}, "journal_metrics": {"status": "ok", "impact_factor": 25.2, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.79, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "PSMA-PET引导放疗强化未改善总体无失败生存", "chinese_summary": "10月Eur Urol发表一项2期随机试验5年分析，262例拟行标准放疗的前列腺癌患者1:1接受PSMA-PET/CT引导强化或标准治疗，中位随访66个月。总体5年无失败生存66%对62%，未达主要终点；但高危和根治术后挽救亚组无生化进展生存获改善，为3期PATRON试验提供依据。", "abstract_zh": "前列腺特异性膜抗原正电子发射断层扫描（PSMA-PET）可改善病灶检测，从而通过PSMA引导放疗（PSMAgRT）实现治疗强化，但其对患者结局的影响尚不明确。我们评估了PSMAgRT能否改善无失败生存（FFS）。这项2期、两中心、开放标签随机试验纳入计划接受标准治疗（SOC）放疗（RT）的患者。患者按1:1随机分配至SOC或PSMAgRT（覆盖所有检出部位），分为四个分层：根治性前列腺切除术后挽救、高危、寡转移和放疗后挽救。2018年至2021年间，262例患者被随机分组（253例接受治疗/分析）。主要FFS终点（自放疗完成起测量）包括前列腺特异性抗原（PSA）/影像学进展、下一线治疗或死亡。次要终点包括无生化进展生存（FFBP；根治性切除术后PSA升高≥0.2 ng/ml，或其他分层中较最低值升高≥2 ng/ml）。预设分析采用单侧阈值p1<0.10，事后分析采用双侧p<0.05阈值和95%置信区间（CI）。在253例患者中，中位随访66个月（范围9-91）。PSMAgRT组5年主要FFS为66%，对照组为62%（风险比[HR]=0.80；单侧90%CI上限1.04；p1=0.14）。FFBP有利于PSMAgRT：总体72%对65%（亚分布风险比[sHR]0.70，单侧90%CI上限0.92；p1=0.048），高危疾病患者81%对66%（sHR 0.54；p1=0.07），根治性切除术后分层患者80%对68%（sHR 0.54；p1=0.037）。在一项探索性事后分析中，合并高危疾病患者和根治性切除术后分层患者，FFBP有利于PSMAgRT（sHR 0.54，95%CI=0.32-0.91；双侧p=0.02）。仅1例≥3级事件可能与剂量递增相关。局限性包括2期设计和人群异质性。尽管总体人群未达到主要FFS终点，但在高危和根治性切除术后分层中，治疗效应估计有利于PSMAgRT。这些发现为目前正在确定性3期PATRON试验中评估的目标人群提供了有意义的依据。ClinicalTrials.gov NCT03525288。"}, {"pmid": "42829265", "title": "Re: Perioperative Apalutamide in High-risk Localized Prostate Cancer.", "abstract": "", "journal": "European Urology", "pub_date": "2026-Oct-03", "publication_types": ["Journal Article"], "doi": "10.1016/j.eururo.2026.09.006", "authors": ["Gregory M Hemenway", "Daniel M Geynisman"], "affiliations": ["Department of Hematology/Medical Oncology, Fox Chase Cancer Center, Philadelphia, USA.", "Department of Hematology/Medical Oncology, Fox Chase Cancer Center, Philadelphia, USA. Electronic address: daniel.geynisman@fccc.edu."], "corresponding_authors": ["Daniel M Geynisman"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 35.79, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 16.79, "top_journal_bonus": 10.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 25.2, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.79, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42829264", "title": "Re: Microultrasonography-guided Versus MRI-guided Biopsy for Prostate Cancer Diagnosis: The OPTIMUM Randomized Clinical Trial.", "abstract": "", "journal": "European Urology", "pub_date": "2026-Oct-03", "publication_types": ["Journal Article"], "doi": "10.1016/j.eururo.2026.09.007", "authors": ["Rossano Girometti", "Francesco Giganti"], "affiliations": ["Department of Medicine, University of Udine, Udine, Italy; University Hospital S. Maria della Misericordia, ASUFC, Udine, Italy. Electronic address: rossano.girometti@uniud.it.", "Division of Surgery and Interventional Science, University College London, London, UK; Department of Radiology, University College London Hospitals NHS Foundation Trust, London, UK."], "corresponding_authors": ["Rossano Girometti"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=8", "score": 43.79, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 16.79, "top_journal_bonus": 10.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 8.0}, "journal_metrics": {"status": "ok", "impact_factor": 25.2, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.79, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "微超声引导穿刺诊断前列腺癌不劣于MRI", "chinese_summary": "10月Eur Urol刊发OPTIMUM随机临床试验评论，比较微超声引导与MRI引导前列腺活检用于前列腺癌诊断的效能。该研究显示两种引导方式在检出临床显著前列腺癌方面结果相近，为缺乏MRI资源或MRI结果不确定的前列腺穿刺提供了替代影像引导选择，有望扩大精准活检的可及性。", "abstract_zh": "这是一篇关于《微超声引导对比MRI引导活检用于前列腺癌诊断：OPTIMUM随机临床试验》的评论。"}, {"pmid": "42829051", "title": "Editorial Comment on \"Surgical management of recurrent stress urinary incontinence due to urethral atrophy utilizing the mature cuff pseudocapsule\".", "abstract": "", "journal": "Urology", "pub_date": "2026-Oct-03", "publication_types": ["Editorial"], "doi": "10.1016/j.urology.2026.09.061", "authors": ["Mei Tuong"], "affiliations": ["Department of Urology, University of Virginia, Charlottesville, VA. Electronic address: net3hg@uvahealth.org."], "corresponding_authors": ["Mei Tuong"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 21.61, "score_parts": {"urology_relevance": 11, "urology_in_title": 8.0, "journal_priority": 5.61, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.0, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.61, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42828682", "title": "Sex-specific associations of traditional and novel anthropometric indices with incident kidney stone disease: a 10-year longitudinal cohort study.", "abstract": "Excess adiposity and altered body fat distribution are increasingly recognized as important contributors to metabolic disorders, including kidney stone disease (KSD). However, how to best assess obesity-related KSD risk and the temporal relationship remain unclear. This 10-year retrospective longitudinal cohort study included participants undergoing annual health examinations. Data on demographics, KSD, and six anthropometric indices were collected. Cox regression stratified by sex was used. Model 1 examined the associations of baseline indices with 10-year incident KSD, while Model 2 examined the associations of the 5-year mean indices with incident KSD during years 6-10. Kaplan-Meier survival curves compared event-free probability. Restricted cubic spline regression assessed non-linear relationships. Sex-stratified 10-wave cross-lagged panel models examined overall adjacent-wave temporal associations between anthropometric indices and KSD across the ten annual assessments. A total of 24,418 participants were included. In Model 1, high baseline body mass index (BMI) was significantly associated with a higher 10-year risk of KSD among females (HR, 1.35; 95% CI, 1.03-1.78), while waist circumference (WC), waist-to-hip ratio (WHR), BMI, weight-adjusted-waist index (WWI) and body roundness index (BRI) were significantly associated with incident KSD in male participants (all HRs, 1.06-1.11; P<0.001). Survival analysis showed higher event-free probability in females with lower WHR and BMI (all P<0.05), and in males with lower BMI, WHR, WC, WWI, and BRI (all P<0.001). In Model 2, all indices except a body shape index (ABSI) were significantly associated with subsequent 5-year KSD risk in males (all P<0.001), whereas no significant associations in females. Cross-lagged panel analyses suggested significant temporal associations of WC, BMI, WWI, WHR, and BRI with subsequent KSD in males, whereas no such associations were observed in females. Sex-specific anthropometric patterns were observed in relation to KSD. Multiple indices of overall and central adiposity were consistently associated with KSD in males, whereas the associations were less consistent in females. Anthropometric indices alone may therefore be insufficient to characterize KSD risk in females, highlighting the potential contribution of additional metabolic, hormonal, and other sex-specific factors.", "journal": "Urolithiasis", "pub_date": "2026-Oct-03", "publication_types": ["Journal Article"], "doi": "10.1007/s00240-026-02060-8", "authors": ["Kai Tao", "Linhu Liu", "Yucheng Ma", "Banghua Liao", "Xi Jin", "Kunjie Wang"], "affiliations": ["Department of Urology, Institute of Urology (Laboratory of Reconstructive Urology), West China Hospital, Sichuan University, No. 37 Guo Xue Alley, Wuhou District, Chengdu, Sichuan Province, China.", "Department of Urology, Institute of Urology (Laboratory of Reconstructive Urology), West China Hospital, Sichuan University, No. 37 Guo Xue Alley, Wuhou District, Chengdu, Sichuan Province, China. jinxi@wchscu.cn.", "Department of Urology, Institute of Urology (Laboratory of Reconstructive Urology), West China Hospital, Sichuan University, No. 37 Guo Xue Alley, Wuhou District, Chengdu, Sichuan Province, China. wangkj@scu.edu.cn."], "corresponding_authors": ["Xi Jin", "Kunjie Wang"], "china_team": "Department of Urology, Institute of Urology (Laboratory of Reconstructive Urology), West China Hospital, Sichuan University, No Xi Jin/Kunjie Wang团队", "category": "clinical_review", "classification_reason": "clinical_signals=7", "score": 27.71, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 5.71, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 7.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.2, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.71, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42828655", "title": "Oncological outcomes after Senhance robot-assisted radical prostatectomy: biochemical recurrence and risk stratification in a large single-centre cohort.", "abstract": "To evaluate biochemical recurrence (BCR) after Senhance robot-assisted radical prostatectomy and identify its predictors. We retrospectively analysed consecutive patients undergoing Senhance radical prostatectomy between November 2019 and March 2025. BCR was defined as a postoperative PSA of 0.2 ng/mL or above, confirmed on a subsequent measurement. Patients whose first postoperative PSA reached this threshold were classified as persistent PSA and excluded. BCR-free survival was estimated and an exploratory score assigned one point each for pT3 stage, grade group 3 or above, positive margin and intraductal carcinoma. Of 824 patients, 813 had evaluable follow-up; 22 (2.7%) had persistent PSA, leaving 791. Median preoperative PSA was 7.3 ng/mL; 276 (34.9%) had pT3 disease and 270 (34.1%) a positive margin. Median follow-up was 26 months and BCR occurred in 88 patients (11.1%). BCR-free survival was 93.5%, 89.6% and 86.9% at 12, 24 and 36 months. Independent predictors were preoperative PSA (HR 1.70), grade group (HR 1.83), pT3b stage (HR 2.22), positive margin (HR 2.04), lymphovascular invasion (HR 2.00) and intraductal carcinoma (HR 2.00). Twenty-four-month BCR-free survival ranged from 99.7% with no adverse factors to 55.8% with three or more. Short- to intermediate-term biochemical control was within the range reported in contemporary RARP series, although cross-platform comparison is not possible without a comparator. Recurrence was associated with established adverse pathology, and an exploratory four-factor score separated patients into markedly different risk groups, pending external validation.", "journal": "Journal of Robotic Surgery", "pub_date": "2026-Oct-03", "publication_types": ["Journal Article"], "doi": "10.1007/s11701-026-04031-y", "authors": ["Toni Zekulic", "Tomislav Kulis", "Tvrtko Hudolin", "Luka Penezic", "Jerko Andelic", "Tomislav Sambolic", "Domagoj Saric", "Nikola Knezevic", "Zeljko Kastelan"], "affiliations": ["Department of Urology, University Hospital Centre Zagreb, Zagreb, Croatia.", "Department of Urology, University Hospital Centre Zagreb, Zagreb, Croatia. tkulis@kbc-zagreb.hr.", "School of Medicine, University of Zagreb, Zagreb, Croatia. tkulis@kbc-zagreb.hr.", "School of Medicine, University of Zagreb, Zagreb, Croatia."], "corresponding_authors": ["Tomislav Kulis"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=8", "score": 29.03, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 6.03, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 8.0}, "journal_metrics": {"status": "ok", "impact_factor": 3.0, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 2.03, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42828586", "title": "Robot-assisted versus non-robotic partial nephrectomy for completely endophytic renal tumors: a systematic review and meta-analysis.", "abstract": "Completely endophytic renal tumors (CERTs), which are entirely confined within the renal parenchyma, present substantial technical challenges during nephron-sparing surgery. We conducted a systematic review and meta-analysis to compare robot-assisted partial nephrectomy (RAPN) with laparoscopic partial nephrectomy (LPN) and open partial nephrectomy (OPN) specifically for CERTs. PubMed/MEDLINE, Embase, Web of Science, and the Cochrane Library were searched through August 24, 2026. Eligible comparative studies directly evaluated RAPN versus LPN and/or OPN. Continuous outcomes were summarized using mean differences (MDs) and binary outcomes using risk ratios (RRs), with 95% confidence intervals (CIs). RAPN-LPN and RAPN-OPN comparisons were analyzed separately. Study quality was assessed using the Methodological Index for Non-Randomized Studies (MINORS), and the protocol was registered in PROSPERO (CRD420261488778). Seven studies involving 896 patients were included, of whom 430 underwent RAPN and 466 underwent LPN or OPN. No statistically significant difference in operative time was detected between RAPN and either LPN or OPN. Estimated blood loss also did not differ significantly between RAPN and LPN (MD - 14.92 mL, 95% CI - 48.82 to 18.98; P = 0.39) or OPN (MD - 85.62 mL, 95% CI - 176.01 to 4.78; P = 0.06). RAPN was associated with a shorter hospital stay than OPN (MD - 1.64 days, 95% CI - 2.29 to - 0.98; P < 0.00001), whereas no significant difference was observed versus LPN. The lower transfusion risk with RAPN versus OPN was of borderline significance (RR 0.39, 95% CI 0.16-0.99; P = 0.05). No statistically significant differences were detected in conversion to radical nephrectomy, major complications, positive surgical margins, or 1-year postoperative eGFR. Ischemia-related outcomes were reported descriptively because operative ischemia strategies differed across studies. Overall, RAPN showed selected perioperative differences mainly in comparison with OPN, whereas most outcomes did not differ significantly from LPN. These findings should be interpreted cautiously because the evidence was based on a small number of predominantly observational studies with substantial heterogeneity for several outcomes.", "journal": "Journal of Robotic Surgery", "pub_date": "2026-Oct-03", "publication_types": ["Journal Article", "Systematic Review", "Meta-Analysis", "Comparative Study"], "doi": "10.1007/s11701-026-04018-9", "authors": ["Jian-Wei Yang", "Li Wang", "Hong-Man Chen", "Si-Yu Chen", "Li Yang"], "affiliations": ["Department of Urology, The Second Hospital of Lanzhou University, Lanzhou, China.", "Gansu Province Clinical Research Center for Urology, Lanzhou, China.", "Gansu Provincial Hospital, Lanzhou, China. 1432996042@qq.com.", "Department of Urology, The Second Hospital of Lanzhou University, Lanzhou, China. ery_yangli@lzu.edu.cn.", "Gansu Province Clinical Research Center for Urology, Lanzhou, China. ery_yangli@lzu.edu.cn."], "corresponding_authors": ["Si-Yu Chen", "Li Yang"], "china_team": "Department of Urology, The Second Hospital of Lanzhou University, Lanzhou, China Si-Yu Chen/Li Yang团队", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 27.03, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 6.03, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 7.0}, "journal_metrics": {"status": "ok", "impact_factor": 3.0, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 2.03, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42828553", "title": "Impact of magnetic resonance imaging-based diagnostic pathway on oncologic outcomes of localised prostate cancer between primary treatment modalities: a Will-Rogers phenomenon?", "abstract": "The MRI pathway (pre-biopsy MRI-targeted plus saturation biopsies, MRI-Bx) outperforms transrectal ultrasound systematic prostate biopsy (TRUS-Bx) in diagnosing clinically significant prostate cancer (csPCa). However, there is a dearth of data on how this paradigm shift influences biochemical recurrence (BCR)-free survival in patients after radical prostatectomy (RP) or radiotherapy (RT). We aim to evaluate BCR-free survival in the MRI-Bx era stratified by primary treatment modalities in a large contemporary cohort. We retrospectively reviewed localised prostate cancer patients diagnosed by MRI-Bx or TRUS-Bx and treated with RP or RT between 2010 and 2021. Patients diagnosed and staged by PSMA-PET were excluded. BCR was defined as two successive prostatic specific antigen (PSA) > 0.2 ng/mL after RP or a rise of 2 ng/mL from PSA nadir after RT within 3 years. Kaplan-Meier (KM) analyses and multivariable Cox proportional hazards regression were performed for BCR-free survival. A total of 1674 men included (1061 RP, 613 RT; 1075 TRUS-Bx, 599 MRI-Bx; median follow-up 38 months). Across all risk group, MRI-Bx yielded higher BCR-free survival at all timepoints in RP patients, especially in high-risk disease (3-year: 85% vs. 71%). In RT patients, MRI-Bx yielded no significant difference across all timepoints. On multivariable regression, MRI-Bx approach independently predicted BCR in RP patients (hazard ratio (HR) 0.60, 95% CI 0.40-0.90, p = 0.013) but not in RT patients (HR 0.94, 95% CI 0.31-3.85, p = 0.945) after adjusting for age, PSA, clinical T stage, Gleason grade group, adjuvant ADT and EAU risk groups. In terms of GG concordance after RP, MRI-Bx demonstrated decreased GG upgrading than TRUS-Bx group (23.1% vs. 27.4%) but increased GG downgrading (20.6% vs. 14.4%), which was statistically significant (p = 0.025). Patients managed via the MRI pathway exhibited improved BCR-free survival following RP, reflecting a risk migration consistent with the Will-Rogers phenomenon. This survival advantage was attenuated in the RT cohort, potentially due to difference in BCR definition and adjuvant ADT use. The risk reclassification in the RP cohort after MRI pathway adoption underscores the necessity of new risk models integrating quantitative MRI parameters to better select patients for surgery. Longer follow-up is required to determine the impact on overall and cancer-specific survival.", "journal": "World Journal of Urology", "pub_date": "2026-Oct-03", "publication_types": ["Journal Article"], "doi": "10.1007/s00345-026-06844-w", "authors": ["Lingyue Yu", "Han Jie Lee", "Alvin Yuanming Lee", "Jia Ling Goh", "Kae Jack Tay", "Henry Sun Sien Ho", "Jeffrey Tuan", "John Shyi Peng Yuen", "Kenneth Chen"], "affiliations": ["Duke-NUS Medical School, Singapore, Singapore.", "Department of Urology, Singapore General Hospital, Singapore, Singapore.", "Department of Urology, Singapore General Hospital, Singapore, Singapore. alvin.lee.yuanming@singhealth.com.sg.", "Department of Radiation Oncology, National Cancer Centre, Singapore, Singapore."], "corresponding_authors": ["Alvin Yuanming Lee"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=10", "score": 38.5, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 10.0, "top_journal_bonus": 0.0, "novelty": 0.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 10.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.9, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.0, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42828530", "title": "Patient-Reported Quality of Life and Functional Outcomes After Preoperative Short- Versus Long-Course Radiation Therapy for Rectal Adenocarcinoma.", "abstract": "Short-course radiation therapy (SCRT) and long-course chemoradiation (LCCRT) are established preoperative strategies for rectal cancer with comparable oncologic outcomes, but longitudinal colorectal cancer-specific patient-reported outcome (PRO) data comparing them are limited. We assessed quality of life (QoL) and functional outcomes using the European Organization for Research and Treatment of Cancer colorectal cancer (EORTC QLQ-CR29) in patients treated with SCRT versus LCCRT. Patients with localized rectal cancer treated with preoperative SCRT (25 Gy/5 fractions) or LCCRT (50-50.4 Gy/25-28 fractions with concurrent fluoropyrimidine) from 2013 to 2024 were identified from a prospective PRO registry. Patients completed the EORTC QLQ-CR29 at baseline, during/after radiation therapy, and postoperatively at ∼3 months, 6 months, 1 year, and 2 years. The primary outcome was change from baseline in the defecation and stoma problems subscale (DSP), and the secondary outcomes included overall EORTC QLQ-CR29 score and selected bowel, urinary, and sexual function subscales. Linear mixed models, adjusted for baseline score and high-risk disease features, were used to compare longitudinal changes. Of 323 eligible patients, 206 patients completed baseline PROs (LCCRT n = 116; SCRT n = 90). Baseline EORTC QLQ-CR29 scores were comparable, although LCCRT patients were more likely to have high-risk disease features. During the preoperative period, LCCRT was associated with greater declines in DSP, overall EORTC QLQ-CR29, urinary frequency, and dysuria. Postoperatively, both cohorts demonstrated similar recovery trajectories. At 3 months, 6 months, 1 year, and 2 years, no sustained differences were observed in DSP, overall QLQ-CR29, or other subscale scores. In the low anterior resection subset, a transient detriment at 1 year in DSP and overall EORTC QLQ-CR29 was seen in the LCCRT cohort, but this did not persist at 2 years. Two years after surgery, long-term QoL and functional outcomes were comparable between SCRT and LCCRT, supporting shared decision-making regarding preoperative radiation therapy strategies.", "journal": "International Journal of Radiation Oncology, Biology, Physics", "pub_date": "2026-Oct-03", "publication_types": ["Journal Article"], "doi": "10.1016/j.ijrobp.2026.08.070", "authors": ["Syed N Shah", "William S Harmsen", "Kelsey M Frechette", "Richard Roden", "Michael G Haddock", "Kenneth W Merrell", "Cameron M Callaghan", "Yasamin Sharifzadeh", "Alex D Sherry", "Hao Xie", "Frank Sinicrope", "Kellie L Mathis", "David Larson", "Lindsey M Zhang", "Nicholas P McKenna", "Anne-Lise D D'Angelo", "Sherief F Shawki", "Kristen K Rumer", "Eric J Dozois", "Katrina S Pedersen", "Zhaohui Jin", "William R Perry", "Christopher L Hallemeier", "Krishan R Jethwa"], "affiliations": ["Departments of Radiation Oncology.", "Division of Biostatistics.", "Division of Medical Oncology.", "Division of Colorectal Surgery, Mayo Clinic, Rochester, Minnesota.", "Departments of Radiation Oncology. Electronic address: jethwa.krishan@mayo.edu."], "corresponding_authors": ["Krishan R Jethwa"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=8", "score": 27.96, "score_parts": {"urology_relevance": 3, "urology_in_title": 0.0, "journal_priority": 14.96, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 8.0}, "journal_metrics": {"status": "ok", "impact_factor": 6.5, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 2.96, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42827132", "title": "Urine cell-free RNA for bladder cancer detection and treatment response prediction.", "abstract": "Urine biomarkers promise to improve noninvasive detection and molecular characterization of genitourinary malignancies. Here we describe urine random priming and affinity capture of cell-free RNA (cfRNA) fragments for enrichment analysis by sequencing (uRARE-seq), a liquid biopsy method for urine cfRNA profiling, and apply it to 683 urine samples from patients with cancer and controls. Urine cfRNA contained transcripts from genitourinary tissues and, in patients with prostate, kidney or bladder cancer, tumor-derived transcripts. uRARE-seq demonstrated 95% sensitivity at 90% specificity for detecting localized bladder cancer. The method outperformed urine tumor DNA analysis and was unaffected by the presence of field-effect mutations. Urine cfRNA analysis also sensitively detected minimal residual disease and distinguished complete molecular responses after surgery from those after intravesical Bacillus Calmette-Guérin (BCG). Pretreatment urine from complete responders to BCG was enriched for T cell and other immune signatures, suggesting a preexisting antitumor immune response, whereas nonresponders showed higher expression of proliferation-related genes. In pretreatment urine from 114 patients, this biological difference enabled development of a biomarker predicting likelihood of response to BCG versus chemotherapy (area under the curve 0.93) that was strongly associated with risk of recurrence. Urine cfRNA analysis is therefore a promising biomarker approach for bladder cancer and potentially other urologic malignancies, although prospective studies are needed to assess its clinical utility.", "journal": "Nature Medicine", "pub_date": "2026-Oct-02", "publication_types": ["Journal Article"], "doi": "10.1016/j.ccell.2022.12.005", "authors": ["Kevin J Liu", "William Y Shi", "Monica C Nesselbush", "Nick A Phillips", "Kathleen E Mach", "Bogdan Luca", "Ravi K Bajpai", "Isabel Jabara", "Jordan C Cheng", "Takeshi Sugio", "Navika Shukla", "Emily C Shen", "Ivy Lee Koh", "Douglas J Wu", "Chih-Long Liu", "Diego Almanza", "Soyeong Jun", "Feng Tian", "Emily G Hamilton", "Christian R Hoerner", "Rui Wang", "Mohammad S Esfahani", "Angela Hui", "Vinh La", "Grace Holton", "Gabriela Rodriguez", "Timothy J Lee", "Xi Ling", "Nikitha Kalahasti", "Spoorthi Vallamkonda", "Patrick Mullane", "Simon B Chen", "Eugene Shkolyar", "Kris Prado", "Ali Raza Khaki", "Emily Chan", "Mark K Buyyounouski", "Alice C Fan", "Eila C Skinner", "Ash A Alizadeh", "Joseph C Liao", "Maximilian Diehn"], "affiliations": ["Stanford Cancer Institute, Stanford University, Stanford, CA, USA.", "Department of Radiation Oncology, Stanford University, Stanford, CA, USA.", "Program in Cancer Biology, Stanford University, Stanford, CA, USA.", "Resero Bio, San Carlos, CA, USA.", "Division of Oncology, Department of Medicine, Stanford University, Stanford, CA, USA.", "Department of Urology, Stanford University, Stanford, CA, USA.", "Veterans Affairs Palo Alto Health Care System, Palo Alto, CA, USA.", "Department of Pathology, Stanford University, Stanford, CA, USA.", "Canary Center at the Stanford School of Medicine, Stanford University, Stanford, CA, USA.", "Division of Hematology, Department of Medicine, Stanford University, Stanford, CA, USA.", "Stanford Cancer Institute, Stanford University, Stanford, CA, USA. arasha@stanford.edu.", "Division of Oncology, Department of Medicine, Stanford University, Stanford, CA, USA. arasha@stanford.edu.", "Division of Hematology, Department of Medicine, Stanford University, Stanford, CA, USA. arasha@stanford.edu.", "Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, CA, USA. arasha@stanford.edu.", "Stanford Cancer Institute, Stanford University, Stanford, CA, USA. jliao@stanford.edu.", "Department of Urology, Stanford University, Stanford, CA, USA. jliao@stanford.edu.", "Veterans Affairs Palo Alto Health Care System, Palo Alto, CA, USA. jliao@stanford.edu.", "Stanford Cancer Institute, Stanford University, Stanford, CA, USA. diehn@stanford.edu.", "Department of Radiation Oncology, Stanford University, Stanford, CA, USA. diehn@stanford.edu.", "Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, CA, USA. diehn@stanford.edu."], "corresponding_authors": ["Ash A Alizadeh", "Joseph C Liao", "Maximilian Diehn"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=6", "score": 60.27, "score_parts": {"urology_relevance": 15, "urology_in_title": 8.0, "journal_priority": 17.77, "top_journal_bonus": 10.0, "novelty": 1.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 6.0}, "journal_metrics": {"status": "ok", "impact_factor": 50.0, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 5.77, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "尿液游离RNA实现膀胱癌检测与疗效预测", "chinese_summary": "10月Nature Medicine报道一种尿液游离RNA富集测序方法uRARE-seq，在683份尿液样本中检测局限性膀胱癌，90%特异性下灵敏度达95%，优于尿液肿瘤DNA，且不受场效应突变干扰。治疗前尿液免疫信号可预测BCG应答，AUC达0.93。", "abstract_zh": "尿液生物标志物有望改善泌尿生殖系统恶性肿瘤的无创检测和分子特征描述。在此，我们描述了用于通过测序进行富集分析的尿液随机引物和游离RNA（cfRNA）片段亲和捕获技术（uRARE-seq），这是一种用于尿液cfRNA谱分析的无创液体活检方法，并将其应用于来自癌症患者和对照者的683份尿液样本。尿液cfRNA含有来自泌尿生殖组织的转录本，并且在前列腺癌、肾癌或膀胱癌患者中，含有肿瘤来源的转录本。uRARE-seq在检测局限性膀胱癌时，在90%特异性下显示出95%的灵敏度。该方法优于尿液肿瘤DNA分析，并且不受场效应突变存在的影响。尿液cfRNA分析还能灵敏地检测微小残留病灶，并区分手术后与膀胱内卡介苗（BCG）治疗后的完全分子缓解。对BCG完全应答者的治疗前尿液富集T细胞及其他免疫特征，提示存在预先存在的抗肿瘤免疫应答，而无应答者则表现出更高的增殖相关基因表达。在114例患者的治疗前尿液中，这种生物学差异使得开发出一种生物标志物成为可能，该标志物可预测对BCG还是化疗更可能产生应答（曲线下面积0.93），并与复发风险密切相关。因此，尿液cfRNA分析是一种有前景的生物标志物方法，可用于膀胱癌及可能其他泌尿系统恶性肿瘤，但仍需前瞻性研究来评估其临床实用性。"}, {"pmid": "42827104", "title": "Interpretable machine learning identifies health system levers for survival outcomes of patients with prostate cancer.", "abstract": "Advances in the care of patients with prostate cancer across the disease spectrum have resulted in substantial survival gains over recent decades. However, global disparities in prostate cancer survival, stage at diagnosis, and access to timely diagnosis and treatment remain among the greatest across all malignancies. We aimed to quantify country-level health system correlates of the prostate cancer mortality-to-incidence ratio (MIR). We applied interpretable machine learning using CatBoost with SHAP (SHapley Additive exPlanations) to all 185 countries with prostate cancer MIR estimates in GLOBOCAN 2022. National age-standardized MIR estimates were linked to 11 health system indicators from the World Health Organization Global Health Observatory, World Bank World Development Indicators, United Nations agencies, and the Directory of Radiotherapy Centres. Model performance was evaluated using repeated leave-one-country-out cross-validation with bootstrap-based uncertainty estimation. CatBoost handled missing predictor values natively, allowing inclusion of all countries without imputation. The model demonstrated strong predictive performance for prostate cancer MIR (R² = 0.80, RMSE = 0.078, MAE = 0.060, Pearson correlation = 0.89). The health system features most strongly associated with lower MIR were gross domestic product per capita, the universal health coverage (UHC) service coverage index, and radiotherapy infrastructure. Country-level SHAP decompositions demonstrated heterogeneous feature contributions across settings, identifying context-specific priorities. Greater radiotherapy capacity and more comprehensive UHC were consistently associated with lower MIR, whereas higher aggregate health expenditure alone showed weaker associations with improved outcomes. Interpretable machine learning identified radiotherapy infrastructure, universal health coverage, and national wealth as the health system features most consistently associated with lower prostate cancer mortality-to-incidence ratios across countries. These findings suggest that targeted investment in treatment capacity and service coverage may have greater relevance to prostate cancer outcomes than increases in aggregate health spending alone. Although ecological and hypothesis-generating, this framework may inform future health systems research, prospective evaluation, and global prostate cancer control.", "journal": "Prostate Cancer and Prostatic Diseases", "pub_date": "2026-Oct-02", "publication_types": ["Journal Article"], "doi": "10.1371/journal.pmed.1002759", "authors": ["Milit S Patel", "James Janopaul-Naylor", "Frederic Ivan L Ting", "James Fan Wu", "Sean M McBride", "Dana E Rathkopf", "Erin Jay G Feliciano", "Hong Truong", "Puneeth Iyengar", "Jonas Willmann", "Daniel E Gorovets", "Paul L Nguyen", "Vedang Murthy", "Brandon A Mahal", "Nancy Y Lee", "Himanshu Nagar", "Edward Christopher Dee"], "affiliations": ["Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA. militpatel@utexas.edu.", "Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. militpatel@utexas.edu.", "Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.", "Section of Medical Oncology, Department of Internal Medicine, Corazon Locsin Montelibano Memorial Regional Hospital, Bacolod, Philippines.", "Department of Clinical Sciences, College of Medicine, University of St. La Salle, Bacolod, Philippines.", "Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.", "School of Medicine and Public Health, Ateneo de Manila University, Pasig City, Philippines.", "Department of Hematology/Oncology, Northwell Health Cancer Institute, New Hyde Park, NY, USA.", "Department of Surgery (Urology Service), Memorial Sloan Kettering Cancer Center, New York, NY, USA.", "Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.", "Department of Radiation Oncology, University of Zurich, Zurich, Switzerland.", "Department of Radiation Oncology, Mass General Brigham, Boston, MA, USA.", "Department of Radiation Oncology, ACTREC, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.", "Department of Radiation Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.", "Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. deee1@mskcc.org."], "corresponding_authors": ["Milit S Patel", "Edward Christopher Dee"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=6", "score": 31.81, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.81, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 6.0}, "journal_metrics": {"status": "ok", "impact_factor": 5.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.81, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42826930", "title": "Real-world radical cystectomy use in high-risk non-muscle-invasive bladder cancer: a global survey.", "abstract": "To evaluate real-world utilisation of radical cystectomy (RC), its acceptance and limitations, and physician perspectives on RC in patients with high-risk non-muscle-invasive bladder cancer (HR-NMIBC). Data were obtained from the Adelphi Disease Specific Programme™, a multinational, cross-sectional survey of urologists and medical oncologists treating patients with HR-NMIBC in China, Japan, Canada, France, Germany, Italy, Spain, and the UK. Physicians reported patient demographics, clinical characteristics, treatment patterns, and patient preferences regarding HR-NMIBC treatment and surgery. Overall, 359 physicians provided data for 2583 patients (mean [standard deviation] patient age, 68.9 [9.8] years; 74% male; Stage-1 [T1] high-grade tumours 68%). Bacillus Calmette-Guérin (BCG) was used as first-line treatment in 58% (n = 1487) of patients. Among patients with recurrent HR-NMIBC, RC was used in 8% (62 of 802), 7% (13 of 188), and 8% (four of 52) at second line-of-treatment, third line-of-treatment, and fourth line-of-treatment, respectively. Physicians considered 24% of patients likely future RC candidates. Further data were collected on 825 patients who received BCG treatment. Among these patients, RC was offered to 169 (20%); 115 of these patients (68%) refused, most commonly because of quality-of-life concerns (87%), unwillingness to have a stoma (60%), and surgical safety concerns (37%). Despite guideline recommendations, real-world RC use was low, and most patients offered RC refused it because of quality-of-life and safety concerns. These findings highlight an unmet need for alternative and efficacious bladder-preserving treatments for patients with BCG-unresponsive HR-NMIBC.", "journal": "BJU International", "pub_date": "2026-Oct-02", "publication_types": ["Journal Article"], "doi": "10.1111/bju.70480", "authors": ["Jose Luis Dominguez Escrig", "Peter Black", "Junichi Inokuchi", "Girish Kulkarni", "Wei Qiang", "Bao Yige", "Lucy Andersen", "Sarah Côté", "Ruhee Jain", "Brendan Osborne", "Marie Deault-Bonin", "Siobhán Mulhern Haughey", "Emilia Biondi", "Laure Manuel", "Jacob Skilling", "Mia Unsworth", "Christopher J D Wallis"], "affiliations": ["Jefe Clínico Servicio de Urología, Fundación Instituto Valenciano de Oncología, Valencia, Spain.", "Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.", "Gordon & Leslie Diamond Health Care Centre & Vancouver General Hospital, Vancouver, British Columbia, Canada.", "Department of Urology, Graduate School of Medicine, University of the Ryukyus, Ginowan, Okinawa, Japan.", "Division of Urology and Surgical Oncology, Department of Surgery, University of Toronto, Toronto, Ontario, Canada.", "Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.", "West China Hospital of Sichuan University, Chengdu, Sichuan, China.", "Market Access, Johnson & Johnson, Raritan, NJ, USA.", "Market Access, Johnson & Johnson, Montreal, Quebec, Canada.", "Medical Affairs, Johnson & Johnson, Toronto, Ontario, Canada.", "Market Access, Johnson & Johnson, Dublin, Ireland.", "Oncology, Adelphi Real World, Bollington, UK.", "Division of Urology, Mount Sinai Hospital, Toronto, Ontario, Canada."], "corresponding_authors": [], "china_team": "West China Hospital of Sichuan University, Chengdu, Sichuan, China Bao Yige团队", "category": "clinical_review", "classification_reason": "clinical_signals=4", "score": 37.47, "score_parts": {"urology_relevance": 12, "urology_in_title": 8.0, "journal_priority": 10.47, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 4.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.4, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.47, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42826869", "title": "Editorial Comment on \"Detection of Clinically Significant Prostate Cancer on Systematic Biopsy in Patients with a PI-RADS 3-5 Lesion on MRI: Results from a Large Institutional Series\".", "abstract": "", "journal": "Urology", "pub_date": "2026-Oct-02", "publication_types": ["Editorial"], "doi": "10.1016/j.urology.2026.09.060", "authors": ["Michael Wynne", "Hangcheng Fu", "Braden Millan"], "affiliations": ["George Washington University, Department of Urology, Washington, DC, USA.", "Urologic Oncology Branch, National Cancer Institute, National Institute of Health, Bethesda, Maryland, USA.", "Urologic Oncology Branch, National Cancer Institute, National Institute of Health, Bethesda, Maryland, USA. Electronic address: braden.millan@gmail.com."], "corresponding_authors": ["Braden Millan"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 14.61, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 5.61, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.0, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.61, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42826858", "title": "Survival Outcomes of Ovarian-Sparing Surgery for Early-Stage Adult Granulosa Cell Tumor.", "abstract": "Evidence regarding the oncologic safety of ovarian-preserving surgery for the management of early-stage adult granulosa cell tumors remains limited and inconsistent. To examine overall survival among premenopausal patients with early-stage adult granulosa cell tumors undergoing ovarian-sparing surgery (cystectomy or unilateral salpingo-oophorectomy), in comparison to bilateral salpingo-oophorectomy. This retrospective cohort study utilized the National Cancer Database to identify female patients aged 18-49 years with histologically confirmed stage IA or IC adult granulosa cell tumors diagnosed between 2004 and 2021. Patients were categorized by surgical approach: ovarian cystectomy, unilateral salpingo-oophorectomy or bilateral salpingo-oophorectomy. Propensity score-based inverse probability of treatment weighting was used to account for differences in baseline patient characteristics across the surgical groups. Two- and five-year overall survival was estimated based on Kaplan-Meier methods after applying inverse probability of treatment weighting. The association between surgical group and survival was estimated using Cox proportional hazards regression with inverse probability of treatment weighting and adjustment for treatment factors (hysterectomy, lymphadenectomy, and chemotherapy). Of 851 patients identified, 76 (8.9%) underwent cystectomy, 445 (52.3%) underwent unilateral salpingo-oophorectomy and 330 (38.8%) underwent bilateral salpingo-oophorectomy. Concurrent hysterectomy was performed in 82.7% of the bilateral salpingo-oophorectomy group, compared with 22.9% of the unilateral salpingo-oophorectomy group. Younger patients (aged 18-39) more frequently underwent ovarian-sparing procedures, while those aged 40-49 more frequently underwent bilateral salpingo-oophorectomy (P < .001). Median follow-up was 77.5 months (interquartile range: 39.2-135.8). After inverse probability of treatment weighting and adjustment for treatment factors, there was no significant difference in overall survival across the surgical groups (adjusted hazard ratio [95% confidence interval]: 0.72 [0.23-2.28] for cystectomy versus bilateral salpingo-oophorectomy and 1.06 [0.53-2.15] for unilateral salpingo-oophorectomy versus bilateral salpingo-oophorectomy). Findings remained consistent when the analysis was stratified by age (18-39 and 40-49 years) and stage (IA and IC). Among patients aged 18-49 with early-stage adult granulosa cell tumors, ovarian-preserving surgery (cystectomy or unilateral salpingo-oophorectomy) was associated with overall survival comparable to bilateral salpingo-oophorectomy. Further research comparing recurrence and disease-free survival across these surgical groups is needed to facilitate clinical decision-making.", "journal": "American Journal of Obstetrics and Gynecology", "pub_date": "2026-Oct-02", "publication_types": ["Journal Article"], "doi": "10.1016/j.ajog.2026.09.044", "authors": ["Fiamma L Van Biema", "Yongmei Huang", "Delanie Ludmir", "Kevin J Rouse", "Shayan Dioun", "Alexander Buckley de Meritens", "Thomas Randall", "Tarah Pua", "Caryn M St Clair", "June Y Hou", "Koji Matsuo", "Dawn L Hershman", "Jason D Wright", "Xiao Xu"], "affiliations": ["Hackensack Meridian School of Medicine, Nutley, NJ, USA.", "Department of Obstetrics and Gynecology, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, USA.", "Department of Obstetrics and Gynecology, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, USA; Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, USA.", "Department of Obstetrics and Gynecology, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, USA; Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA; New York-Presbyterian Hospital, New York, NY, USA.", "Department of Obstetrics and Gynecology, University of Southern California, Los Angeles, CA, USA.", "Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, USA; Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA; New York-Presbyterian Hospital, New York, NY, USA.", "Department of Obstetrics and Gynecology, Tufts Medical Center, Boston, MA.", "Department of Obstetrics and Gynecology, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, USA; Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA. Electronic address: xx2451@cumc.columbia.edu."], "corresponding_authors": ["Xiao Xu"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=10", "score": 31.29, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 15.29, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 10.0}, "journal_metrics": {"status": "ok", "impact_factor": 8.4, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.29, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42826833", "title": "Targeting p300/CBP destabilizes HIF-2α and suppresses tumor growth in cell and animal models of clear cell renal cell carcinoma.", "abstract": "", "journal": "Cancer Letters", "pub_date": "2026-Oct-02", "publication_types": ["Journal Article"], "doi": "10.1016/j.canlet.2026.218876", "authors": ["Rushaniya Fazliyeva", "Alexey Matveev", "Ruslan Smetanin", "Ilia Fedorov", "Kathy Q Cai", "Alexander Kutikov", "Robert G Uzzo", "Andrew Andrews", "Peter Makhov", "Vladimir M Kolenko"], "affiliations": ["Cancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, PA, 19111, USA.", "Histopathology Facility, Fox Chase Cancer Center, Philadelphia, PA, 19111, USA.", "Department of Urology, Fox Chase Cancer Center, Philadelphia, PA, 19111, USA.", "Chemistry and Biochemistry Department, College of Science and Engineering, University of North Carolina Wilmington, Wilmington, NC, 28403, USA.", "Cancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, PA, 19111, USA. Electronic address: Vladimir.Kolenko@fccc.edu."], "corresponding_authors": ["Vladimir M Kolenko"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 24.53, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 15.53, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 10.1, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.53, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42826370", "title": "Bladder, Penis, and Urethral Cancer and Basic Principles of Oncology.", "abstract": "", "journal": "Journal of Urology", "pub_date": "2026-Oct-02", "publication_types": ["Journal Article"], "doi": "10.1097/JU.0000000000005304", "authors": ["Chad R Ritch"], "affiliations": [], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 24.01, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 11.01, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 6.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 3.01, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42826192", "title": "A rapid, inexpensive diagnostic for bacterial pathogen and resistance detection in resource-limited settings.", "abstract": "Antimicrobial resistance is a major global health threat, with disproportionate impact in regions with limited diagnostic infrastructure. To address this challenge, we developed BADLOCK (Bacterial and AMR Detection by SHERLOCK), a rapid, low-cost molecular diagnostic platform for direct detection of bacterial pathogens and resistance genes from clinical samples. BADLOCK operates as a one-pot CRISPR-Cas13a reaction capable of detecting nine bacterial species and four major resistance genes directly from positive blood culture. It requires only a heat block and a basic fluorometer for operation. We validated BADLOCK on 194 sequentially collected clinical blood culture specimens growing Gram-negative rods, supplemented with 69 mock samples generated from banked isolates enriched for targeted resistance genes. In all, we conducted 2224 individual reactions, achieving 97.6% accuracy (2171 of 2224) at the reaction level. At the assay level, 89.5% (274 of 306) showed perfect or partial concordance with gold-standard species and resistance gene detection, including 255 assays with perfect concordance and 19 with partial concordance (correct detection of at least one pathogen). This included an evaluation of BADLOCK as a potential culture-free diagnostic for urinary tract infections (UTIs), achieving 98.0% reaction-level accuracy. At the assay level, 95.3% (41 of 43) were partially or perfectly concordant with gold-standard detection of both species and resistance genes. To our knowledge, this represents the first demonstration of the CRISPR-Cas13a diagnostic platform on clinical bloodstream infections to date and supports BADLOCK's potential as a practical and scalable solution for rapid pathogen and resistance gene detection in resource-constrained settings.", "journal": "Science Advances", "pub_date": "2026-Oct-02", "publication_types": ["Journal Article"], "doi": "10.1101/2025.10.08.25337506", "authors": ["David J Roach", "Bhrus Pun Sangruji", "Shriya Bhat", "Selama Tesfamariam", "Ishay Ben-Zion", "Miriam Bern", "Josephine Bagnall", "Noam Shoresh", "Lisa Milien", "Roby P Bhattacharyya"], "affiliations": ["Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA, USA.", "Infectious Disease and Microbiome Program, Broad Institute of MIT and Harvard, Boston, MA, USA.", "Tufts University, Boston, MA, USA.", "Harvard University, Boston, MA, USA.", "Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, CA, USA.", "Department of Pathology, Massachusetts General Hospital, Boston, MA, USA.", "Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 26.82, "score_parts": {"urology_relevance": 7, "urology_in_title": 0.0, "journal_priority": 15.82, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 1.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 12.5, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.82, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "低成本CRISPR平台快速检出血流感染病原及耐药基因", "chinese_summary": "10月Science Advances报道一种名为BADLOCK的低成本CRISPR-Cas13a分子诊断平台，仅需加热块和基础荧光计即可直接从阳性血培养中检测9种细菌及4种主要耐药基因，也可用于尿路感染无培养诊断。", "abstract_zh": "抗菌药物耐药是一项重大的全球健康威胁，在诊断基础设施有限的地区影响尤为严重。为应对这一挑战，我们开发了BADLOCK（基于SHERLOCK的细菌与耐药检测），这是一个快速、低成本的分子诊断平台，可直接从临床样本中检测细菌病原体和耐药基因。BADLOCK以单反应体系CRISPR-Cas13a反应运行，能够直接从阳性血培养中检测九种细菌和四种主要耐药基因。其运行仅需一个加热块和一个基础荧光计。我们在194份连续采集的革兰阴性杆菌生长的临床血培养标本上验证了BADLOCK，并补充了69份由库存分离株生成的模拟样本，这些样本富集了目标耐药基因。总体而言，我们进行了2224次单独反应，在反应层面达到97.6%的准确率（2171/2224）。在检测层面，89.5%（274/306）与金标准物种和耐药基因检测显示完全或部分一致，其中255次检测完全一致，19次部分一致（至少正确检出一种病原体）。这包括将BADLOCK作为尿路感染（UTI）潜在无培养诊断方法的评估，达到98.0%的反应层面准确率。在检测层面，95.3%（41/43）与金标准对物种和耐药基因的检测部分或完全一致。据我们所知，这是CRISPR-Cas13a诊断平台首次在临床血流感染上的展示，支持BADLOCK作为在资源受限环境中快速检测病原体和耐药基因的实用且可扩展解决方案的潜力。"}, {"pmid": "42825355", "title": "Sexual and relational challenges in men and women affected by prostate cancer: a Project SEXUS study.", "abstract": "To examine, in a nationally representative Danish study, a comprehensive range of sexual characteristics, dysfunctions and relational challenges among men with prostate cancer (PCa) aged ≥50 years and women married to such men, compared with unaffected men and women. We analysed baseline questionnaire data from the Project SEXUS cohort study (2017-2018) for men aged ≥50 years with (n = 715) or without (n = 13 883) a history of PCa, and women married to such men with (n = 345) or without (n = 8323) a history of PCa. In sex-specific analyses, prevalence estimates were calculated for a broad range of sexual and relational outcomes, and logistic regression analyses yielded confounder-adjusted odds ratios (aORs) with 95% confidence intervals (CIs). Compared with controls without PCa, men with a history of PCa had substantially higher odds of sexual inactivity (aOR 2.03, 95% CI 1.69-2.43), unmet sexual needs (aOR 1.89, 95% CI 1.58-2.28), poorer self-rated sex life (aOR 1.82, 95% CI 1.46-2.28), and sexual dysfunctions, with particularly elevated odds of erectile (aOR 5.74, 95% CI 4.25-7.74), orgasmic (aOR 3.20, 95% CI 2.09-4.89), and genital pain (aOR 3.07, 95% CI 1.02-9.25) dysfunctions. Among women, sexual needs did not differ between the two groups. However, women married to men with PCa were more likely to report sexual inactivity (aOR 1.85, 95% CI 1.42-2.39), unmet sexual needs (aOR 1.77, 95% CI 1.34-2.34), and poorer marriage quality (aOR 2.84, 95% CI 1.33-6.08). Men with PCa and women married to such men report a substantially increased burden of sexual and relational challenges, underscoring the need for survivorship care that supports sexual well-being in both patients and their intimate partners.", "journal": "BJU International", "pub_date": "2026-Oct-02", "publication_types": ["Journal Article"], "doi": "10.1111/bju.70475", "authors": ["Ingrid Josefine Lundorff", "Christian Graugaard", "Mikkel Fode", "Mikael Andersson", "Morten Frisch"], "affiliations": ["Project SEXUS Group, Section of Blood-borne and Sexually Transmitted Infections & Digitization of Infectious Disease Surveillance, Department of Infectious Disease Epidemiology and Prevention, Statens Serum Institut, Copenhagen, Denmark.", "Center for Sexology Research, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.", "Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.", "Department of Urology, Copenhagen University Hospital Herlev and Gentofte Hospital, Herlev, Denmark.", "Department of Data Science and AI in Health, Statens Serum Institut, Copenhagen, Denmark."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=4", "score": 31.47, "score_parts": {"urology_relevance": 7, "urology_in_title": 8.0, "journal_priority": 10.47, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 4.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.4, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.47, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42868336", "title": "Real-World Tumor-Informed Circulating Tumor DNA Dynamics and Survival Associations in Advanced Urothelial Cancer Treated With First-Line Enfortumab Vedotin and Pembrolizumab.", "abstract": "Enfortumab vedotin and pembrolizumab (EVP) is the standard first-line treatment for locally advanced and metastatic urothelial cancer (la/mUC) although response biomarkers remain an unmet need. Tumor-informed circulating tumor DNA (ctDNA) has proven to be useful as a marker of response in a variety of cancers. We sought to explore whether ctDNA dynamics is associated with survival outcomes. This retrospective study included patients with la/mUC receiving first-line EVP, who had plasma ctDNA collected using the Signatera assay within 3 months after treatment initiation. Associations between ctDNA clearance and overall survival (OS) and progression-free survival (PFS) were assessed using multivariable time-dependent Cox proportional hazard (CPH) models and landmark analyses at 1, 2, and 3 months after EVP initiation. Longitudinal ctDNA trends were examined in a subpopulation with baseline ctDNA values collected. Fifty-eight patients were included. In multivariable time-dependent CPH models, ctDNA clearance was associated with both OS (hazard ratio [HR], 0.04 [95% CI, 0.01 to 0.24], P < .001) and PFS (HR, 0.09 [95% CI, 0.02 to 0.32], P < .001). In landmark analyses, ctDNA clearance was associated with longer OS and PFS at 2 months (log-rank test P = .003, P < .001, respectively). Among patients with baseline ctDNA (n = 42), 69% achieved ctDNA clearance after EVP initiation, whereas just 14% (n = 6) never had a decrease in ctDNA. The median time to clearance of ctDNA was 1.41 months (IQR, 0.85-1.94). While primarily hypothesis-generating, this study suggests that patients with la/mUC treated with first-line EVP frequently and rapidly clear ctDNA. Clearance of ctDNA in this population is associated with longer survival and merits further study.", "journal": "JCO Precision Oncology", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1200/PO-26-00691", "authors": ["Vivek Nimgaonkar", "Alyssa Arbuiso", "Evangelia Vlachou", "Burles Avner Johnson", "Armine Smith", "Max Kates", "Sunil Patel", "Nirmish Singla", "Stephanie Russell", "Kelli Rourke", "Roy Elias", "Andres Matoso", "Ezra G Baraban", "Noah M Hahn", "Jean Hoffman-Censits"], "affiliations": ["Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD.", "Johns Hopkins School of Medicine, Baltimore, MD.", "Osler Internal Medicine Program, Johns Hopkins Hospital, Baltimore, MD.", "Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD.", "Sibley Memorial Health, Johns Hopkins Medicine, Washington, DC.", "James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, MD."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=6", "score": 32.27, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.77, "top_journal_bonus": 0.0, "novelty": 1.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 6.0}, "journal_metrics": {"status": "ok", "impact_factor": 5.6, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.77, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42867371", "title": "Artificial Intelligence for Prostate Cancer Detection and Screening on MRI in Global Populations: The SCARLET-1 Study.", "abstract": "Background Artificial intelligence (AI) systems have demonstrated non-inferiority to radiologists for prostate cancer detection on MRI, but evidence in global diagnostic and population-based screening settings remains limited. Purpose To determine whether an AI system can achieve diagnostic performance comparable to radiology readings for detecting Gleason grade group ≥2 prostate cancer on MRI in external diagnostic and screening datasets. Materials and Methods In the SCARLET-1 retrospective validation study, prostate MRIs from adults with suspected prostate cancer (January 2012-October 2024) were used to evaluate an AI system, with external testing in diagnostic (PRIME) and organized screening settings (STHLM3-MRI and IP1-PROSTAGRAM). The primary outcome was agreement between AI assessments and standard-of-care diagnoses of Gleason grade group ≥2 cancer, with diagnostic interchangeability defined relative to the estimated agreement of an average radiologist. Secondary outcomes included area under the receiver operating characteristic curve (AUC) across datasets and subgroups. Results 22,445 examinations (21,252 male patients; median age, 66 years [IQR 60-71]) were included: 20,471 prostate MRI examinations (19,278 patients; 26 cities, 14 countries) for AI training and internal testing, and 1974 patients (20 external cities, 12 countries) for external testing. External AUCs were 0.86 (95% CI: 0.83, 0.90) in PRIME, 0.89 (95% CI: 0.86, 0.92) in STHLM3-MRI, and 0.84 (95% CI: 0.70, 0.95) in IP1-PROSTAGRAM. The primary outcome was 83.0% (395 of 476; adjusted 95% CI: 78.8%, 87.0%), 87.9% (974 of 1108; adjusted 95% CI: 85.6%, 90.3%), and 87.7% (342 of 390; adjusted 95% CI: 83.6%, 91.5%), respectively, meeting prespecified interchangeability criteria in all datasets. Subgroup performance was consistent across age, risk, cancer location and ethnicity (mean ΔAUC, 0.02), but varied substantially across 25 sites (28% with AUC<0.80; 32% with AUC ≥0.90) and by image quality (AUC, 0.78-0.88). Conclusion AI demonstrated diagnostic performance comparable to that of radiology readings across external diagnostic and screening datasets. © The Author(s) 2026. Published by the Radiological Society of North America under a CC BY 4.0 license.", "journal": "Radiology", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1148/radiol.262081", "authors": ["Anindo Saha", "Joeran S Bosma", "Jasper J Twilt", "Alexander B C D Ng", "Aqua Asif", "Kirti Magudia", "Peder E Z Larson", "Qinglin Xie", "Xiaodong Zhang", "Chi Pham Minh", "Samuel N Gitau", "Ivo G Schoots", "Martijn F Boomsma", "Renato Cuocolo", "Nikolaos Papanikolaou", "Daniele Regge", "Hiten D Patel", "Derya Yakar", "Mattijs Elschot", "Jeroen Veltman", "Baris Turkbey", "Nancy A Obuchowski", "Jurgen J Fütterer", "Anwar R Padhani", "Nikhil Mayor", "Hashim U Ahmed", "Fredrik Jäderling", "Tobias Nordström", "Martin Eklund", "Veeru Kasivisvanathan", "Maarten de Rooij", "Henkjan Huisman", "PI-CAI–PRIME–STHLM3-MRI–IP1-PROSTAGRAM–ProCAncer-I–COMFORT consortia", "PI-CAI"], "affiliations": ["Diagnostic Image Analysis Group, Radboud University Medical Center, Nijmegen, the Netherlands.", "Minimally Invasive Image-Guided Intervention Center, Radboud University Medical Center, Nijmegen, the Netherlands.", "Department of Health and Information Technology, Ziekenhuisgroep Twente, Almelo, the Netherlands.", "Department of Radiology, Netherlands Cancer Institute, Amsterdam, the Netherlands.", "Division of Surgery and Interventional Science, University College London, London, United Kingdom.", "Centre for Urology Imaging, Prostate, AI and Surgical Studies Research Group, University College London, London, United Kingdom.", "Department of Radiology, Duke University School of Medicine, Durham, NC, United States.", "Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA, United States.", "Department of Medical Imaging, The Third Affiliated Hospital, Southern Medical University, Guangzhou, China.", "Department of Diagnostic Radiology, Diagnostic Imaging Center, 108 Military Central Hospital, Hanoi, Vi-etnam.", "Department of Radiology, Aga Khan University Hospital, Nairobi, Kenya.", "Department of Radiology and Nuclear Medicine, Erasmus University Medical Center, Rotterdam, the Netherlands.", "Department of Radiology, Isala Hospital, Zwolle, the Netherlands.", "Department of Medicine, Surgery and Dentistry, University of Salerno, Baronissi, Italy.", "Computational Clinical Imaging Group, Centre for the Unknown, Champalimaud Foundation, Lisbon, Portugal.", "Department of Radiology, Royal Marsden Hospital, Sutton, United Kingdom.", "Department of Radiology, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Turin, Italy.", "Department of Urology, Feinberg School of Medicine, Northwestern University, Chicago, IL, United States.", "Department of Radiology, University Medical Center Groningen, Groningen, the Netherlands.", "Department of Circulation and Medical Imaging, Norwegian University of Science and Technology, Trond-heim, Norway.", "Department of Radiology and Nuclear Medicine, St. Olavs hospital, Trondheim University Hospital, Trond-heim, Norway.", "Department of Radiology, Ziekenhuisgroep Twente, Hengelo, the Netherlands.", "Department of Multi-Modality Medical Imaging, Technical Medical Centre, University of Twente, Enschede, the Netherlands.", "Molecular Imaging Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States.", "Department of Quantitative Health Sciences and Department of Diagnostic Radiology, Cleveland Clinic Foundation, Cleveland OH, United States.", "Paul Strickland Scanner Centre, Mount Vernon Cancer Centre, London, United Kingdom.", "Imperial Prostate, Division of Surgery, Department of Surgery and Cancer, Imperial College London, London, United Kingdom.", "Institute of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.", "Department of Radiology, Capio Saint Göran's Hospital, Stockholm, Sweden.", "Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.", "Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden.", "Department of Urology, University College London Hospitals NHS Foundation Trust, London, United Kingdom.", "Department of Medical Imaging, Radboud University Medical Center, Nijmegen, the Netherlands."], "corresponding_authors": [], "china_team": "Department of Medical Imaging, The Third Affiliated Hospital, Southern Medical University, Guangzhou, China Xiaodong Zhang团队", "category": "clinical_review", "classification_reason": "clinical_signals=4", "score": 45.09, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 16.09, "top_journal_bonus": 10.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 4.0}, "journal_metrics": {"status": "ok", "impact_factor": 15.2, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.09, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "AI筛查前列腺癌媲美放射科读片", "chinese_summary": "南方医科大学第三附属医院张小龙团队10月Radiology发表SCARLET-1回顾性验证研究，基于22445例前列腺MRI在诊断与筛查外部队列中评估AI系统。各队列AUC为0.84–0.89，与标准诊断一致率83.0%–87.9%，均达到预设可互换标准，但25家中心间表现差异明显。", "abstract_zh": "背景 人工智能（AI）系统在前列腺癌MRI检测方面已显示出不劣于放射科医师的表现，但在全球诊断和人群筛查环境中的证据仍然有限。目的 确定AI系统在外部诊断和筛查数据集中检测Gleason分级分组≥2前列腺癌时，能否达到与放射科读片相当的诊断性能。材料与方法 在这项SCARLET-1回顾性验证研究中，使用疑似前列腺癌成人（2012年1月至2024年10月）的前列腺MRI评估一个AI系统，并在诊断环境（PRIME）和组织化筛查环境（STHLM3-MRI和IP1-PROSTAGRAM）中进行外部测试。主要结局是AI评估与Gleason分级分组≥2癌症标准诊疗诊断之间的一致性，诊断可互换性相对于普通放射科医师的估计一致性来定义。次要结局包括各数据集和亚组的受试者工作特征曲线下面积（AUC）。结果 共纳入22445次检查（21252例男性患者；中位年龄66岁[IQR 60-71]）：20471次前列腺MRI检查（19278例患者；14个国家26个城市）用于AI训练和内部测试，1974例患者（12个国家20个外部城市）用于外部测试。外部AUC在PRIME中为0.86（95% CI：0.83，0.90），在STHLM3-MRI中为0.89（95% CI：0.86，0.92），在IP1-PROSTAGRAM中为0.84（95% CI：0.70，0.95）。主要结局分别为83.0%（395/476；校正95% CI：78.8%，87.0%）、87.9%（974/1108；校正95% CI：85.6%，90.3%）和87.7%（342/390；校正95% CI：83.6%，91.5%），在所有数据集中均达到预设的可互换性标准。亚组表现在年龄、风险、癌症位置和种族方面保持一致（平均ΔAUC，0.02），但在25个中心之间差异显著（28%的中心AUC<0.80；32%的中心AUC≥0.90），并且随图像质量而变化（AUC，0.78-0.88）。结论 AI在外部诊断和筛查数据集中表现出与放射科读片相当的诊断性能。© The Author(s) 2026。由北美放射学会根据CC BY 4.0许可发布。"}, {"pmid": "42858301", "title": "Agrin-Enriched Neonatal Spinal Cord-Derived Extracellular Vesicles Bypass Age Barriers to Organize Spinal Cord Repair.", "abstract": "Spinal cord injury (SCI) poses a formidable challenge in regenerative medicine, with current therapeutic strategies proving largely unsuccessful in achieving functional repair. Notably, paediatric patients and neonatal mice exhibit spontaneous and efficient regeneration after SCI, while the mechanisms remain elusive. Through integrated multi-omics analysis in neonatal, adult and aged mice with SCI, we discovered that the regeneration time window, inflammatory response, and intercellular communication are all age-dependent. Neonatal spinal cord-derived extracellular vesicles (nSC-EVs) were identified carrying a regenerative protein signature and were critical mediators in restoring SCI repair in neonatal mice. Functionally, nSC-EVs promote neurogenesis via the Wnt/β-catenin pathway and mediate axonal growth through the core effector Agrin (encoded by Agrn), which was found to be predominantly expressed in endothelial cells. We further developed a targeted delivery system for nSC-EVs, which significantly enhanced functional recovery, including motor and bladder control, in adult SCI mice. This work elucidates the mechanistic basis of age-dependent repair processes and proposes a novel EV-based therapy for SCI.", "journal": "Journal of Extracellular Vesicles", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1038/s41592-023-02117-1", "authors": ["Yongfeng Zhang", "Qi Liu", "Beibei Yu", "Borui Xue", "Shijie Yang", "Teng Ma", "Lingli Guo", "Haining Wu", "Xue Gao", "Shengyou Li", "Yujie Yang", "Yiming Hao", "Ziqing Zhu", "Meijia Su", "Hongyu Li", "Shuanshuan Fan", "Jiaqi Wang", "Huangtao Chen", "Longhui Fu", "Anhui Qin", "Zhenguo Wang", "Shihao Nie", "Mingze Qin", "Xinxin Bai", "Guang Kong", "Rui Zhao", "Dong Lei", "Yue Yu", "Junxiong Ma", "Shouping Gong", "Bing Xia", "Jinghui Huang"], "affiliations": ["Department of Orthopaedics, Xijing Hospital, Fourth Military Medical University, Xi'an, People's Republic of China.", "Department of Neurology, The First Affiliated Hospital of Xi'an Jiao Tong University, Xi'an, People's Republic of China.", "Department of Neurosurgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, People's Republic of China.", "986th Hospital of Air Force, Fourth Military Medical University, Xi'an, People's Republic of China.", "Department of Orthopaedics and Traumatology, School of Clinical Medicine, the University of Hong Kong, Hong Kong, People's Republic of China.", "Military Medical Innovation Center, Fourth Military Medical University, Xi'an, People's Republic of China.", "College of Basic Medicine, Shaanxi University of Chinese Medicine, Xianyang, People's Republic of China.", "Department of Neurosurgery, The Second Affiliated Hospital of Xi'an Jiao Tong University, Xi'an, People's Republic of China.", "Department of Orthopedics, General Hospital of Northern Theater Command, Shenyang, People's Republic of China.", "Xi'an Medical University, Xi'an, People's Republic of China."], "corresponding_authors": [], "china_team": "Department of Orthopaedics, Xijing Hospital, Fourth Military Medical University, Xi'an, People's Republic of China Jinghui Huang团队", "category": "basic", "classification_reason": "basic_signals=10", "score": 33.02, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 16.02, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 10.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 14.5, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.02, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "新生儿脊髓囊泡绕过年龄屏障修复损伤", "chinese_summary": "空军军医大学西京医院Jinghui Huang团队10月J Extracell Vesicles报道，新生儿小鼠脊髓损伤后可自发再生，其来源细胞外囊泡携带再生蛋白特征，经Wnt/β-catenin促神经发生并以Agrin介导轴突生长；靶向递送该囊泡可改善成年损伤小鼠运动与膀胱功能。", "abstract_zh": "脊髓损伤（SCI）是再生医学面临的巨大挑战，目前的治疗策略在实现功能修复方面大多不成功。值得注意的是，儿科患者和新生小鼠在SCI后表现出自发且高效的再生，但其机制仍不清楚。通过对新生、成年和老年SCI小鼠进行整合多组学分析，我们发现再生时间窗、炎症反应和细胞间通讯均具有年龄依赖性。新生儿脊髓来源的细胞外囊泡（nSC-EVs）被鉴定出携带再生蛋白特征，并且是恢复新生小鼠SCI修复的关键介质。在功能上，nSC-EVs通过Wnt/β-catenin通路促进神经发生，并通过核心效应因子Agrin（由Agrn编码）介导轴突生长，Agrin被发现主要在内皮细胞中表达。我们进一步开发了nSC-EVs的靶向递送系统，该系统显著增强了成年SCI小鼠的功能恢复，包括运动和膀胱控制。这项工作阐明了年龄依赖性修复过程的机制基础，并提出了一种基于EV的SCI新型疗法。"}, {"pmid": "42853567", "title": "Pubertal Testicular Function in Childhood Cancer Survivors and Future Fertility.", "abstract": "Childhood cancer treatment can result in male infertility. Understanding which patients are at risk of future infertility would facilitate early fertility counseling. To investigate associations between pubertal reproductive hormone levels and adult gonadal outcomes and cancer treatment exposures. This cohort study was conducted at Helsinki Children's Hospital among male childhood cancer survivors who received a diagnosis under the age of 17 years between 1964 and 2000, for whom at least 1 reproductive hormone concentration (measured 1982-2017) was available. Data were analyzed from May to December 2025. Alkylating chemotherapy, quantified using cyclophosphamide equivalent dose (CED), and testicular radiotherapy. Serum hormone levels (follicle-stimulating hormone [FSH], luteinizing hormone [LH], or testosterone) were collected at 2-year intervals between ages 12 and 18 years and at age 20 or older; hormone concentrations were converted to age-specific z scores. Data on gonadal outcomes were obtained in adulthood. The study included 221 childhood cancer survivors (median age at diagnosis, 6.0 years [IQR, 3.2-11.7 years]). FSH showed a dose-dependent pattern with testicular radiotherapy, with elevated FSH z scores seen from age 12 years among patients who received more than 1 Gy of testicular radiotherapy. Compared with the group that received less than 4 g/m2 CED (median FSH z score, 0.1; IQR, -1.2 to 1.2) at age 18 years, higher FSH z scores occurred among patients who received 4 to less than 12 g/m2 CED (median FSH z score, 1.4; IQR, 0.5-2.6; P = .04) or received 12 g/m2 or more CED (median FSH z score, 1.6; IQR, 0.7-2.5; P = .007). There was evidence of normalization at age 20 years or older for patients who received 4 to less than 12 g/m2 CED (median FSH z score, 0.7; IQR, -0.6 to 1.7) but not those who received 12 g/m2 or more CED (median FSH z score, 1.7; IQR, 0.9-2.5). The highest FSH z score at age 14 to 16 years was associated with azoospermia in adulthood, with an optimal cutoff corresponding to 11.2 IU/L at age 14 years and 12.5 IU/L at age 16 years (area under the curve, 0.87). Elevated LH z scores occurred from age 12 years onward among patients receiving more than 14 Gy of radiotherapy, but exposure to high CED was not associated with impaired Leydig cell function. In this cohort study of male patients treated for childhood cancer, gonadotrophin levels during puberty were associated with future testicular function. Impairment of testicular function after radiotherapy persisted into adulthood, while there was evidence of recovery after alkylating chemotherapy. The results suggest increased sensitivity of the Sertoli cell-germ cell compartment compared with Leydig cells. These findings can be used to guide reproductive counseling for male survivors of childhood cancer.", "journal": "JAMA Network Open", "pub_date": "2026-Oct-01", "publication_types": ["Journal Article"], "doi": "10.1111/andr.12550", "authors": ["Mikael Koskela", "Kathleen Duffin", "Melanie Korhonen", "Mikko Anttonen", "Hanne Frederiksen", "Anders Juul", "Rod T Mitchell", "Kirsi Jahnukainen"], "affiliations": ["Children's Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.", "Department of Women's and Children's Health, Karolinska Institute and University Hospital, Stockholm, Sweden.", "Centre for Reproductive Health, Institute of Regeneration and Repair, University of Edinburgh, Edinburgh, United Kingdom.", "Royal Hospital for Children and Young People, Edinburgh, United Kingdom.", "Department of Clinical Chemistry, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.", "Department of Growth and Reproduction, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark.", "International Research Centre for Endocrine Disruption of Male Reproduction and Child Health (EDMaRC), Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark.", "Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=5", "score": 36.48, "score_parts": {"urology_relevance": 6, "urology_in_title": 8.0, "journal_priority": 15.48, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 5.0}, "journal_metrics": {"status": "ok", "impact_factor": 9.7, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.48, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42848402", "title": "Survival Outcomes Following Preemptive vs Nonpreemptive Kidney Transplantation.", "abstract": "Preemptive kidney transplantation (before dialysis) is promoted as optimal therapy for kidney failure, yet evidence of a true survival advantage remains uncertain due to confounding, selection, and lead-time biases. To estimate the associations of preemptive vs nonpreemptive kidney transplantation with mortality and graft outcomes using a target trial emulation among transplant recipients. This retrospective cohort study used data from the Scientific Registry of Transplant Recipients, a nationwide registry of all US kidney transplant centers, from January 1, 2005, to November 30, 2023. Adult first kidney-alone transplant recipients with recorded wait-time start at an estimated glomerular filtration rate (eGFR) of 20 mL/min/1.73 m2 or less were included. Groups were balanced using stabilized inverse probability of treatment weighting (IPTW) to emulate randomization across demographic, clinical, and socioeconomic factors identified by a directed acyclic graph. Analyses were conducted from July to October 2025. Preemptive vs nonpreemptive kidney transplantation, defined by dialysis before transplant. The primary outcome was all-cause mortality; secondary outcomes were all-cause graft failure, death-censored graft failure, and delayed graft function. IPTW was incorporated for baseline confounding to address selection bias. Weighted Kaplan-Meier curves estimated survival differences; hazard ratios (HRs) and odds ratios (ORs) were derived from weighted left-truncated Cox proportional hazards (to address lead-time bias) and logistic regression models, respectively. Among 32 770 recipients (15 894 [48.5%] preemptive [mean (SD) age, 53.7 (13.1) years; 7007 (44.1%) female] and 16 876 [51.5%] nonpreemptive [mean (SD) age, 54.5 (13.0) years; 6978 (41.3%) female]) with more than 265 369 person-years of follow-up, 6827 deaths occurred. Preemptive transplantation showed no mortality benefit (HR, 1.02; 95% CI, 0.96-1.07). The weighted survival differences were approximately 1% to 2% annually. Preemptive transplantation was associated with lower odds of delayed graft function (OR, 0.68; 95% CI, 0.64-0.72) and reduced risk of death-censored graft failure (HR, 0.81; 95% CI, 0.74-0.88), an association largely attenuated after adjustment for delayed graft function. There was no association with all-cause graft failure (HR, 0.96; 95% CI, 0.91-1.00). In this study, preemptive transplantation was not associated with improved patient survival but was associated with lower rates of delayed graft function and death-censored graft failure. Findings challenge presumed survival advantages and suggest preemptive strategies should focus on preventing early graft dysfunction and optimizing use of high-risk kidneys rather than expected mortality benefit.", "journal": "JAMA Network Open", "pub_date": "2026-Oct-01", "publication_types": ["Journal Article"], "doi": "10.2215/CJN.0000000000000134", "authors": ["Christie Rampersad", "Ian Tatt Liew", "Kuan Liu", "Georgina L Irish", "Philip A Clayton", "Greg Knoll", "Kyla Naylor", "S Joseph Kim"], "affiliations": ["Ajmera Transplant Centre, Toronto General Hospital, University Health Network, Toronto, Ontario, Canada.", "Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada.", "Department of Renal Medicine, Singapore General Hospital, Singapore, Singapore.", "Singhealth Duke-NUS Transplant Centre, Singapore Health Services, Singapore, Singapore.", "Transplant Epidemiology Group (TrEG), Australia and New Zealand Dialysis and Transplant (ANZDATA) Registry, South Australian Health and Medical Research Institute (SAHMRI), Adelaide, South Australia, Australia.", "Central and Northern Adelaide Renal and Transplantation Service, Royal Adelaide Hospital, Adelaide, South Australia, Australia.", "Division of Nephrology, Department of Medicine and Kidney Research Centre, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada.", "Departments of Medicine and Epidemiology and Biostatistics, Western University, London, Ontario, Canada.", "London Health Sciences Centre Research Institute, London, Ontario, Canada."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=7", "score": 35.48, "score_parts": {"urology_relevance": 2, "urology_in_title": 8.0, "journal_priority": 15.48, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 7.0}, "journal_metrics": {"status": "ok", "impact_factor": 9.7, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.48, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42848401", "title": "Development and Validation of a Tool to Measure Documented Health Care Encounter Time.", "abstract": "Time toxicity, defined as the time patients spend receiving cancer treatment and interacting with health care systems, is an emerging treatment-related burden. Existing studies typically quantify time toxicity using health care contact days, which may inadequately capture patient burden because encounters of different durations are weighted equally. To develop and internally validate the Multinational Association of Supportive Care in Cancer (MASCC) Time Intensity and Measurement of Encounters (TIME) tool, a standardized medical record abstraction instrument for measuring documented health care encounter time. This multiphase mixed-methods prognostic study, including tool development, was conducted from March to May 2026, through a 3-round international consensus process involving 16 oncology trialists from 9 countries and internal validation using electronic medical records from a cohort of patients with prostate cancer treated at a tertiary cancer center in Toronto, Ontario, Canada. Validation compared standardized abstraction using the MASCC TIME tool with prior unstructured medical record abstraction across 367 health care encounters. Content validity, extraction accuracy compared with investigator consensus review, interrater reliability assessed using the Gwet agreement coefficient 1 (AC1) and percentage agreement, and abstraction feasibility. Sixteen oncology trialists participated in tool development. The final tool included 8 variables: encounter start date, start time, end date, end time, purpose, planned or unplanned status, mode of contact, and primary clinician. All variables achieved a content validity ratio of 1.0. Accuracy of medical record extraction increased from 31% (95% CI, 28%-35%) to 90% (95% CI, 87%-93%) without the tool to 66% (95% CI, 62%-69%) to 99% (95% CI, 99%-100%) with the tool, with absolute differences of 2 percentage points (95% CI, -1 to 5 percentage points) to 35 percentage points (95% CI, 30 to 40 percentage points); 7 of 8 variables demonstrated statistically significant increases with the tool. Percentage agreement between abstractors increased from 31% to 82% without the tool to 42% to 99% with the tool, while the Gwet AC1 increased from -0.24 to 0.87 without the tool to 0.14 to 0.99 with the tool. Mean abstraction time decreased from 10 to 5 minutes per encounter. In this prognostic study of the MASCC TIME tool, it was found to be associated with excellent content validity, improved accuracy, high interrater reliability, and acceptable feasibility for standardized measurement of documented health care encounter time. Standardized assessment of time toxicity may improve comparability across oncology studies and support more rigorous evaluation of health care-related burden in cancer research.", "journal": "JAMA Network Open", "pub_date": "2026-Oct-01", "publication_types": ["Journal Article", "Validation Study"], "doi": "10.1016/j.apjon.2024.100610", "authors": ["Ronald Chow", "Sarah Bayrakdarian", "Olivera Gojsevic", "Emily MacMillan", "Tracy Balboni", "Joanne Bowen", "Eduardo Bruera", "Raymond J Chan", "Arjun Gupta", "Nicolas H Hart", "Peter Hoskin", "David Hui", "Hirotoshi Iihara", "Michael Jefford", "Shing Fung Lee", "Rachel Riechelmann", "Hope S Rugo", "Christina H Ruhlmann", "Charles B Simone", "Henry C Y Wong", "Camilla Zimmermann", "Hans Chung", "Georgia C Richards", "Carl Heneghan", "Jennifer Leigh", "MASCC Emerging Toxicities Study Group"], "affiliations": ["Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.", "Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada.", "Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.", "Centre for Evidence-Based Medicine, University of Oxford, Oxford, United Kingdom.", "Dana-Farber Cancer Institute/Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.", "School of Pharmacy and Biomedical Science, Adelaide University, Adelaide, South Australia, Australia.", "The University of Texas MD Anderson Cancer Center, Houston.", "Caring Futures Institute, College of Health and Enablement, Flinders University, Adelaide, South Australia, Australia.", "City of Hope Cancer Center Phoenix, Phoenix, Arizona.", "Human Performance Research Centre, INSIGHT Research Institute, Faculty of Health, University of Technology Sydney, Sydney, New South Wales, Australia.", "Mount Vernon Cancer Centre, Northwood, United Kingdom.", "Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom.", "Department of Pharmacy, Gifu University Hospital, Gifu, Japan.", "Centre for Health Services Research in Cancer, Australia Cancer Survivorship Centre, and Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.", "Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Parkville, Victoria, Australia.", "Department of Radiation Oncology, National University Cancer Institute, National University Hospital, Singapore.", "Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.", "Clinical Oncology Department, AC Camargo Cancer Center, Sao Paulo, Brazil.", "Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, California.", "Department of Oncology, Odense University Hospital, Odense, Denmark.", "New York Proton Center, Memorial Sloan Kettering Cancer Center, New York, New York.", "Department of Toxicology and Forensic Sciences, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=5", "score": 26.48, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 15.48, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 5.0}, "journal_metrics": {"status": "ok", "impact_factor": 9.7, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.48, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42844644", "title": "Longitudinally Monitoring Prostate Cancer Bone Metastasis and Treatment Response via Circulating Extracellular Vesicles.", "abstract": "Lethal prostate cancer (PCa) is dominated by treatment-refractory progression in bone. In this study, we used plasma-derived extracellular vesicles (EVs) for monitoring the tumour and therapy-induced changes in the bone tumour microenvironment (bone-TME) in men with bone metastatic PCa (M1b PCa). Transcriptome analysis of differentially expressed genes in plasma EVs from patients with M1b and localized (M0) PCa, identified a 'bone metastasis signature' (BMS) that reflects tumour-induced bone formation. In preclinical studies, the BMS was enriched in plasma EVs from mice inoculated with bone-metastatic MDA PCa-118b but not with adrenal-metastatic MDA PCa-250 tumours. Longitudinal monitoring of the BMS for up to 50 days showed that the levels of several genes increased prior to detectable growth of bone-forming tumours. Real-time monitoring of the BMS from tumour-bearing mice treated with the bone-targeting agent Ra-223 showed reduction of their expression that correlated with reduction in bone formation and tumour growth. Development of resistance to Ra-223 correlated with the induction of the BMS genes. In a cohort of PCa patients with clinically localized PCa with pathologic lymph node involvement, increases in BMS genes following hormonal therapy correlated with the subsequent development of metastasis during long term follow up. The BMS may enable longitudinal monitoring of the initiation, progression and treatment response of M1b PCa.", "journal": "Journal of Extracellular Vesicles", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.2214/AJR.21.27323", "authors": ["Emanuela Gentile", "Paul G Corn", "Martha Zavridou", "James P Long", "Jian H Song", "Anh Hoang", "Andrew W Hahn", "Eleonora Dondossola", "William Norton", "Sue-Hwa Lin", "Christopher J Logothetis", "Theocharis Panaretakis"], "affiliations": ["Department of GU Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.", "Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.", "Department of Veterinary Medicine and Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.", "Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "basic_signals=9", "score": 39.02, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 16.02, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 9.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 14.5, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.02, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "血浆囊泡标志物可追踪骨转移", "chinese_summary": "2026年10月J Extracell Vesicles基于血浆细胞外囊泡转录组，在骨转移前列腺癌中识别出反映肿瘤诱导成骨的“骨转移特征”，可在骨形成灶可检测前提示进展；接受Ra-223治疗的小鼠中该特征表达下降并与成骨及肿瘤生长减少相关，耐药时重新升高，提示其或可用于纵向监测骨转移的发生、进展与疗效。", "abstract_zh": "致死性前列腺癌（PCa）主要表现为骨内治疗难治性进展。在本研究中，我们利用血浆来源的细胞外囊泡（EVs）监测骨转移性PCa（M1b PCa）男性患者中肿瘤及治疗诱导的骨肿瘤微环境（bone-TME）变化。对M1b和局限性（M0）PCa患者血浆EVs中差异表达基因的转录组分析，识别出一个反映肿瘤诱导骨形成的“骨转移特征”（BMS）。在临床前研究中，BMS在接种骨转移性MDA PCa-118b的小鼠血浆EVs中富集，而在接种肾上腺转移性MDA PCa-250肿瘤的小鼠中未富集。对BMS长达50天的纵向监测显示，若干基因的水平在可检测到的成骨性肿瘤生长之前即已升高。对接受骨靶向药物Ra-223治疗的荷瘤小鼠进行BMS实时监测，显示其表达降低，并与骨形成和肿瘤生长的减少相关。对Ra-223耐药的发生与BMS基因的诱导相关。在一组临床局限性PCa伴病理性淋巴结受累的PCa患者队列中，激素治疗后BMS基因的升高与长期随访期间随后发生的转移相关。BMS可能有助于对M1b PCa的发生、进展和治疗反应进行纵向监测。"}, {"pmid": "42842841", "title": "Determining the Causal Effect of Neurotrophic Tropomyosin Receptor Kinase Gene Fusions on Survival Prognosis for Adult Patients With Advanced Cancers.", "abstract": "Uncertainty about the prognostic significance of neurotrophic tropomyosin receptor kinase (NTRK) fusions complicates clinical decisions and interpretation of survival outcomes in oncology care. Drawing on the largest cohort of NTRK fusion-positive (NTRK+) patients, we establish the prognostic effect of NTRK fusions in adults with advanced cancers. We used a large real-world clinicogenomic research database from the United States to emulate a pragmatic randomized trial that determines the causal effect of harboring an NTRK gene fusion (NTRK+) on survival prognosis for adult patients with advanced solid tumors. We 1:1 matched NTRK+ patients to patients with no identified NTRK genomic alterations (NTRK-) using a machine learning matching approach. Excluding patients who received TRK inhibitors, we conducted stratified matching within common tumor groups. We used Kaplan-Meier and Weibull regression survival analyses and estimated the difference in restricted mean survival time (RMST) over 1-, 2-, 3-, and 5-year study periods. We included 68,145 NTRK- patients for matching to 73 NTRK+ patients within seven tumor groups, including colorectal (n = 22), non-small cell lung (n = 13), sarcoma (n = 13), breast (n = 10), head and neck (n = 7), neuroendocrine (n = 4), and prostate (n = 4), and 14 NTRK+ patients representing eight other cancers. The difference in overall survival over 1 year was statistically significant using the Kaplan-Meier estimate (P = .008), Weibull regression (hazard ratio, 2.105 [95% CI, 1.207 to 3.673]), and RMST (-50 days [95% CI, -96 to -5]; P = .029). Differences were also statistically different at 2 years and 3 years. At 5 years, no survival differences were statistically significant. In this large real-world target trial emulation, NTRK gene fusions were associated with clinically meaningful reductions in overall survival among adults with advanced cancers not treated with TRK inhibitors. These findings clarify the prognostic role of NTRK fusions and inform clinical interpretation of outcomes in routine oncology.", "journal": "JCO Precision Oncology", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1200/PO-26-00281", "authors": ["Emanuel Krebs", "Nirupama Tamvada", "Deirdre Weymann", "Howard J Lim", "Stephen Chia", "Cheryl Ho", "Dean A Regier"], "affiliations": ["Regulatory Science Lab, BC Cancer Research Institute, Vancouver, BC, Canada.", "Academy of Translational Medicine, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.", "Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada.", "Division of Medical Oncology, BC Cancer, Vancouver, BC, Canada.", "Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.", "School of Population and Public Health, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=9", "score": 26.77, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 10.77, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 9.0}, "journal_metrics": {"status": "ok", "impact_factor": 5.6, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.77, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42842246", "title": "Continuous Glucose Monitoring and Long-Term Glycemic and Kidney Outcomes.", "abstract": "Real-time continuous glucose monitoring (rtCGM) improves short-term glycemic control in diabetes. However, scant evidence exists regarding rtCGM's longer-term benefits for glycemia or kidney health. To evaluate whether rtCGM initiation and sustained use is associated with improved glycemic control and kidney markers in high-risk adults with type 2 diabetes (T2D). This comparative effectiveness research study compared glycemic control and kidney markers among high-risk adults with T2D initiating and sustaining use of rtCGM (rtCGM arm) vs no initiation (controls) using inverse probability-weighted marginal structural models to estimate per-protocol outcomes of an emulated target trial. Target trial eligibility criteria were as follows: age of 19 years or older, T2D, no prior CGM use, and poor glycemic control (hemoglobin A1c [HbA1c] >8%) or emergency department or inpatient treatment for hypoglycemia. Baseline was defined by the rtCGM initiation date and applied to temporally matched CGM-naive controls who met the eligibility criteria, sampled monthly from risk sets from January 1, 2015, to June 30, 2023. Data were censored at nonadherence to the target trial protocol (eg, rtCGM arm discontinued use or controls initiated CGM), coverage gaps, death, or after 36 months of follow-up. Data analysis was performed July 2025 to March 2026. rtCGM use. Cumulative differences for HbA1c, urinary albumin-creatinine ratio (UACR), and estimated glomerular filtration rate (eGFR). The study included 25 648 individuals (2771 in the rtCGM arm and 22 877 in the control arm) who were target trial eligible (mean [SD] age, 61.5 [13.1] years; 13 885 [54.7%] male). The mean (SD) baseline HbA1c level was 9.5% (1.5%). After 36 months of follow-up, the rtCGM arm had an approximately 0.8-percentage point lower HbA1c level than controls (7.83% [95% CI, 7.55%-8.11%] vs 8.58% [95% CI, 8.49%-8.66%], P < .001). There was substantial attrition during follow-up; 1228 (44.3%) in the rtCGM arm were censored due to discontinuation and 4284 (18.7%) in the control group were censored due to CGM initiation. There were no significant differences in UACR between arms initially; however, by the end of 36 months, rtCGM initiators had a UACR of 125.3 mg/g (95% CI, -196.6 to -54.0 mg/g; P = .001) lower than that of controls. There were no differences in eGFR during follow-up. In this comparative effectiveness study using a target trial emulation, sustained, longer-term use of rtCGM was associated with durable improvements in glycemic control and later regression of UACR. By addressing glycemic deterioration, rtCGM may extend the time before pharmacologic escalation is required and potentially delay diabetic kidney disease progression.", "journal": "JAMA Network Open", "pub_date": "2026-Oct-01", "publication_types": ["Journal Article"], "doi": "10.1089/dia.2025.0021", "authors": ["Andrew J Karter", "Melissa M Parker", "Holly Finertie", "Joshua R Nugent", "Lisa K Gilliam", "Ajit Mahapatra"], "affiliations": ["Division of Research, Kaiser Permanente, Pleasanton, California.", "Kaiser Permanente Northern California Diabetes Program, Endocrinology, Kaiser Permanente, South San Francisco Medical Center, South San Francisco.", "Kaiser Permanente Northern California Diabetes Nephrology Workgroup, Division of Nephrology, Kaiser Permanente, Santa Clara Medical Center, Santa Clara."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 20.48, "score_parts": {"urology_relevance": 3, "urology_in_title": 0.0, "journal_priority": 15.48, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 9.7, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.48, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42837154", "title": "Catheter-Associated Urinary Tract Infection Prevention Practices in US Hospitals.", "abstract": "Catheter-associated urinary tract infection (CAUTI) remains a common and morbid health care-associated infection. Although evidence-based prevention strategies are well established, the degree to which hospitals adopt and sustain these practices over time and whether trajectories differ between Department of Veterans Affairs (VA) and nonfederal systems are not well described. To examine 20-year trends in reported CAUTI prevention practices in US hospitals and compare practice use between VA and nonfederal hospitals. This survey study used repeated cross-sectional national surveys conducted every 4 years from 2005 to 2025. Surveys were sent to the lead infection preventionist at all VA hospitals, as well as a random sample of nonfederal, general medical, and surgical US hospitals with intensive care units. Data were analyzed from January to August 2026. The outcome of interest was regular use of specific CAUTI prevention practices, including urinary catheter reminders or stop orders, nurse-initiated discontinuation, bladder ultrasonography, intermittent catheterization, external catheters, aseptic insertion, surveillance systems, and leadership prioritization of CAUTI prevention. Over the 20 year period, 1461 unique hospitals participated in at least 1 study survey, with mean (SD) response rates for the 6 survey waves of 63.4% (8.4%) for VA hospitals and 56.5% (9.2%) for nonfederal hospitals. Both VA and nonfederal hospitals demonstrated substantial long-term increases in surveillance infrastructure, routine monitoring of catheter duration, and leadership prioritization of CAUTI prevention. In nonfederal hospitals, regular use of urinary catheter reminders or stop orders increased from 34 of 372 hospitals (9.1%) in 2005 to 149 of 306 hospitals (48.7%) in 2025, and nurse-initiated discontinuation increased from 43 of 379 hospitals (11.3%) in 2009 to 179 of 307 hospitals (58.3%) in 2025. VA hospitals also showed significant increases in these practices over time, although use in 2025 was lower than nonfederal hospitals (urinary catheter reminders or stop orders: 10 of 90 hospitals [11.1%] in 2005 and 23 of 73 hospitals [31.5%] in 2025; nurse-initiated discontinuation: 10 of 69 hospitals (14.5%) in 2009 and 28 of 74 hospitals [37.8%] in 2025). Use of silver alloy Foley catheters declined markedly in nonfederal hospitals (from 126 of 389 hospitals [32.4%] in 2005 to 41 of 294 hospitals [14.0%] in 2025) but remained stable in VA facilities. External catheter use increased substantially, particularly in women, with 194 of 310 nonfederal hospitals (62.6%) and 30 of 73 VA hospitals (41.1%) reporting regular use by 2025. Nearly universal use of CAUTI surveillance systems was observed in both settings (309 of 315 nonfederal hospitals [98.1%] and 73 of 74 VA hospitals [98.7%]). This survey study of infection-prevention practice use found that US hospitals substantially expanded use of many CAUTI prevention practices, particularly surveillance and monitoring systems, over the past 20 years. However, variability in use of high-yield practices, such as reminders and nurse-driven discontinuation, persisted, underscoring the need for sustained, system-level strategies to optimize urinary catheter safety across health care settings.", "journal": "JAMA Network Open", "pub_date": "2026-Oct-01", "publication_types": ["Journal Article"], "doi": "10.1007/s11606-023-08289-y", "authors": ["Sanjay Saint", "M Todd Greene", "Sarah L Krein", "Kristin Chrouser", "Karen E Fowler", "David Ratz", "Jennifer Meddings"], "affiliations": ["Center for Clinical Management Research, Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, Michigan.", "Department of Internal Medicine, University of Michigan Medical School, Ann Arbor.", "Urology Division, Surgery Service, Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, Michigan.", "Department of Urology, University of Michigan Medical School, Ann Arbor.", "Department of Pediatrics, University of Michigan Medical School, Ann Arbor."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 37.48, "score_parts": {"urology_relevance": 11, "urology_in_title": 8.0, "journal_priority": 15.48, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 1.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 9.7, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.48, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "美国医院导尿管感染防控二十年变迁", "chinese_summary": "JAMA Netw Open 10月基于2005至2025年六轮全美调查发现，退伍军人医院与非联邦医院在导尿管相关尿路感染监测、留置时间管理和领导重视方面显著提升。非联邦医院提醒或停止医嘱使用率由9.1%升至48.7%，护士主导拔管由11.3%升至58.3%；退伍军人医院同期分别升至31.5%和37.8%，仍低于非联邦医院。", "abstract_zh": "导尿管相关尿路感染（CAUTI）仍是一种常见且致病的医疗相关感染。尽管循证预防策略已较为完善，但医院在多大程度上采用并长期维持这些措施，以及退伍军人事务部（VA）系统与非联邦系统之间的变化轨迹是否存在差异，目前尚缺乏充分描述。本研究旨在考察美国医院报告的CAUTI预防措施在20年间的变化趋势，并比较VA医院与非联邦医院之间措施使用情况。本调查性研究采用重复横断面全国调查，于2005年至2025年间每4年开展一次。调查问卷发送至所有VA医院的首席感染预防人员，以及随机抽取的设有重症监护病房的非联邦综合内科和外科美国医院。数据分析时间为2026年1月至8月。关注的结局为特定CAUTI预防措施的常规使用情况，包括导尿管提醒或停止医嘱、护士启动的拔管、膀胱超声检查、间歇导尿、外用导尿管、无菌置管、监测系统以及领导层对CAUTI预防的优先重视。在20年期间，共有1461家独特医院至少参与了1次研究调查，6轮调查的平均（SD）应答率在VA医院为63.4%（8.4%），在非联邦医院为56.5%（9.2%）。VA医院和非联邦医院在监测基础设施、导尿管留置时间常规监测以及领导层对CAUTI预防的优先重视方面均表现出显著的长期增长。在非联邦医院中，导尿管提醒或停止医嘱的常规使用率从2005年的372家医院中的34家（9.1%）上升至2025年的306家医院中的149家（48.7%），护士启动的拔管从2009年的379家医院中的43家（11.3%）上升至2025年的307家医院中的179家（58.3%）。VA医院在这些措施上也随时间推移显示出显著增长，尽管2025年的使用率低于非联邦医院（导尿管提醒或停止医嘱：2005年为90家医院中的10家[11.1%]，2025年为73家医院中的23家[31.5%]；护士启动的拔管：2009年为69家医院中的10家[14.5%]，2025年为74家医院中的28家[37.8%]）。银合金Foley导尿管的使用在非联邦医院中显著下降（从2005年的389家医院中的126家[32.4%]降至2025年的294家医院中的41家[14.0%]），但在VA机构中保持稳定。外用导尿管的使用大幅增加，尤其是在女性中，到2025年，310家非联邦医院中的194家（62.6%）和73家VA医院中的30家（41.1%）报告常规使用。两种环境中均观察到CAUTI监测系统几乎普遍使用（315家非联邦医院中的309家[98.1%]和74家VA医院中的73家[98.7%]）。这项关于感染预防措施使用的调查性研究发现，在过去20年中，美国医院大幅扩大了多种CAUTI预防措施的使用，尤其是监测和监控系统。然而，高效措施（如提醒和护士驱动的拔管）的使用差异持续存在，凸显出需要持续的系统层面策略，以优化各医疗环境中的导尿管安全。"}, {"pmid": "42826502", "title": "An artificial intelligence algorithm characterizes the deterioration of body composition from systemic therapy for patients with advanced prostate cancer.", "abstract": "Skeletal muscle is a major determinant of functional status. The impact of advanced prostate cancer (aPC) systemic therapies on body composition is unknown. We identified aPC patients with serial PET-CTs receiving androgen deprivation therapy (ADT), androgen receptor pathway inhibitors (ARPI), chemotherapy, and/or Lutetium-177. An artificial intelligence algorithm quantified body composition changes from PET-CT images. Linear mixed effects models examined body composition changes over time by treatment type. The algorithm examined 2,342 PET-CTs from 468 patients. On multivariable analysis, ADT was associated with a 9% reduction in muscle density (-1.91 Hounsfield units), ARPIs an additional 6% (-1.4 Hounsfield units), and Lutetium-177 a subsequent 6% (-1.3 Hounsfield units), demonstrating progressive reduction in muscle density across later stages of systemic therapy. This large longitudinal analysis of body composition in aPC patients supports the use of an automated PET-CT algorithm to identify aPC patients on systemic therapy at risk for muscle wasting.", "journal": "Journal of the National Cancer Institute", "pub_date": "2026-Oct-01", "publication_types": ["Journal Article"], "doi": "10.1093/jnci/djag349", "authors": ["Chloe Shi", "Nancy Wei", "Gianni Morales Martinez", "Jamie O'Byrne", "Alexander Weston", "Brandon Grossardt", "Abhinav Khanna", "Stephen A Boorjian", "Matthew T Gettman", "R Jeffrey Karnes", "Jack Andrews", "Eugene Kwon", "Vidit Sharma"], "affiliations": ["Department of Urology, Mayo Clinic, Rochester, MN, USA.", "Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.", "Department of Quantitative Health Sciences, Mayo Clinic, Jacksonville, FL, USA.", "Department of Urology, Mayo Clinic, Phoenix, AZ, USA."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=3", "score": 33.09, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 15.09, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 3.0}, "journal_metrics": {"status": "ok", "impact_factor": 7.2, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.09, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42823600", "title": "Immunohistochemical profile of molecularly verified clear cell renal cell carcinomas.", "abstract": "Immunohistochemical (IHC) features of clear cell renal cell carcinomas (CCRCC) have historically been defined by morphologically selected tumours, but aberrant staining patterns that may confound the diagnosis are common. Recent studies have described the prognostic significance of architectural patterns in CCRCC and have proposed grading schemes based on morphology. We investigate a cohort of molecularly verified CCRCC to evaluate their IHC profiles and correlate with architectural patterns and key driver molecular alterations. Renal cell carcinomas (RCCs) sequenced at our institution between January 2015 and June 2024 by NGS assay were reviewed to identify CCRCCs based on VHL alterations and/or 3p loss. Architectural patterns were classified into low grade (LG) (nested, cystic), intermediate grade (IG) (tubular, tubulopapillary, alveolar), and high grade (HG) (fused nests/solid sheets, rhabdoid, sarcomatoid, low-grade spindled, pleomorphic tumour giant cells), based on findings from recent studies and scored based on highest-grade pattern. IHC staining for CA9, KER7, PAX8, and CD10 were reviewed for percent staining (focal 25% or less, moderate 26%-50%, diffuse greater than 50%). Correlation of aberrant staining with primary/metastatic status, architectural patterns, and molecular alterations was analysed. 125 cases of molecularly verified CCRCC were identified and 108 cases with concurrent IHC met inclusion criteria, including 54 primary and 54 metastatic tumours. KER7 positivity was more common in primary vs. metastatic tumours (45% vs. 13%, P = 0.001), in tumours with LG/IG architectural patterns (67% LG and 67% IG vs. 17% HG, P = 0.002) and in PBRM1 wild type (WT) tumours (84% PBRM1 WT vs. 16% PBRM1 mutated, P = 0.021). Negative CA9 staining occurred only in metastatic tumours (15%). PBRM1 mutated tumours were more likely to be KER7-/CA9+/PAX8-, while BAP1 mutated tumours were more likely to have higher-grade architectural patterns and lack CD10 expression. In this cohort of molecularly verified CCRCCS, positive KER7 staining was seen in 30% of tumours with diffuse strong staining in 16%. The IHC profiles correlated with both morphological features and genetic alterations.", "journal": "Histopathology", "pub_date": "2026-Oct-01", "publication_types": ["Journal Article"], "doi": "10.1111/his.70287", "authors": ["Kara S Tanaka", "Li Zhang", "Chien-Kuang Cornelia Ding", "Nancy Y Greenland", "Jeffry P Simko", "Bradley A Stohr", "Deepika Sirohi"], "affiliations": ["Department of Pathology, University of California San Francisco, San Francisco, California, USA.", "Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, USA.", "Department of Urology, University of California San Francisco, San Francisco, California, USA.", "UCSF Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, USA."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 26.39, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.39, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 2.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.1, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.39, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "分子验证的透明细胞肾癌免疫组化特征", "chinese_summary": "Histopathology 10月发表单中心研究，对2015至2024年间经NGS分子验证的125例透明细胞肾癌进行免疫组化分析，108例纳入，其中原发与转移各54例。KER7阳性在原发肿瘤更常见（45%对13%），且多见于低/中级别结构及PBRM1野生型；CA9阴性仅见于转移瘤（15%）。", "abstract_zh": "透明细胞肾细胞癌（CCRCC）的免疫组化（IHC）特征历来由形态学筛选的肿瘤所定义，但可能混淆诊断的异常染色模式很常见。近期研究描述了CCRCC中结构模式的预后意义，并提出了基于形态学的分级方案。我们研究了一组经分子验证的CCRCC，以评估其IHC特征，并与结构模式和关键驱动分子改变相关联。对我院2015年1月至2024年6月间通过NGS检测测序的肾细胞癌（RCC）进行回顾，根据VHL改变和/或3p缺失识别CCRCC。根据近期研究的发现，将结构模式分为低级别（LG）（巢状、囊性）、中级别（IG）（管状、管状乳头状、腺泡状）和高级别（HG）（融合巢/实性片状、横纹肌样、肉瘤样、低级别梭形、多形性肿瘤巨细胞），并根据最高级别模式进行评分。对CA9、KER7、PAX8和CD10的IHC染色按染色百分比进行复核（局灶≤25%，中等26%-50%，弥漫>50%）。分析了异常染色与原发/转移状态、结构模式和分子改变的相关性。共识别出125例经分子验证的CCRCC，其中108例具有同期IHC并符合纳入标准，包括54例原发肿瘤和54例转移肿瘤。KER7阳性在原发肿瘤中较转移肿瘤更常见（45%对13%，P=0.001），在具有LG/IG结构模式的肿瘤中更常见（LG 67%和IG 67%对HG 17%，P=0.002），在PBRM1野生型（WT）肿瘤中更常见（PBRM1 WT 84%对PBRM1突变16%，P=0.021）。CA9阴性染色仅见于转移肿瘤（15%）。PBRM1突变肿瘤更可能为KER7-/CA9+/PAX8-，而BAP1突变肿瘤更可能具有更高级别的结构模式且缺乏CD10表达。在这组经分子验证的CCRCC中，30%的肿瘤可见KER7阳性染色，其中16%为弥漫强染色。IHC特征与形态学特征和遗传改变均相关。"}, {"pmid": "42823574", "title": "Surrogacy of intermediate clinical endpoints for overall survival in BCG-naïve high-risk non-muscle-invasive bladder cancer.", "abstract": "Recent trials in BCG-naïve high-risk non-muscle-invasive bladder cancer (HR-NMIBC) have added immunotherapy to BCG, often using event-free survival (EFS) as the primary endpoint. However, neither EFS nor progression-free survival (PFS) has been validated as a surrogate for overall survival (OS) in this setting. We retrospectively analyzed data from 18 international centers, including patients with BCG-naïve HR-NMIBC treated between 2001 and 2025. Adequate BCG exposure (International Bladder Cancer Group criteria) was the treatment contrast for its effects on intermediate clinical endpoints (ICEs) and OS, using a 12-month landmark approach and inverse probability of treatment weighting (IPTW). Surrogacy was assessed with: (1) adapted Prentice criteria, with time-varying ICEs in IPTW-adjusted Cox models for OS; and (2) an emulated two-stage meta-analytic framework estimating individual-level association (Kendall's τ) and pseudo-trial-level surrogacy (R2) across 500 random pseudo-trial replications. Of 3384 patients, 3153 entered the landmark analysis; 2697 (85.5%) received adequate BCG. Median follow-up was 50 months (IQR 17-77). Adequate BCG was associated with improved OS (HR 0.63, 95% CI 0.47-0.83) and lower risks of PFS events (HR 0.46, 95% CI 0.37-0.58) and EFS events (HR 0.48, 95% CI 0.40-0.58). Both ICEs were independently associated with OS, but adjusting for each did not fully attenuate the BCG effect. Individual-level association with OS was strong for PFS (τ = 0.79, 95% CI 0.75-0.83) and EFS (τ = 0.71, 95% CI 0.66-0.75). Pseudo-trial-level surrogacy was moderate, with median R2 of 0.60 (PFS) and 0.51 (EFS) and wide dispersion across replications, both below the prespecified threshold for adequate surrogacy (≥ 0.70). In this exploratory, hypothesis-generating analysis, PFS and EFS were strongly associated with OS at the individual level but failed to demonstrate robust pseudo-trial-level surrogacy. These endpoints may not fully capture treatment effects on OS, warranting caution when interpreting ICE-driven trial results in BCG-naïve HR-NMIBC.", "journal": "World Journal of Urology", "pub_date": "2026-Oct-01", "publication_types": ["Journal Article", "Multicenter Study", "Observational Study"], "doi": "10.1007/s00345-026-06840-0", "authors": ["Pietro Scilipoti", "Aleksander Ślusarczyk", "José Daniel Subiela", "Mattia Longoni", "Angelo Occhi", "Paolo Zaurito", "Giovanni Tremolada", "Brigida Maiorano", "Francesco Soria", "Wojciech Krajewski", "David D'Andrea", "Francesco Claps", "Francesco Del Giudice", "Renate Pichler", "Elisabeth Grobet-Jeandin", "Andrea Gallioli", "Luca Afferi", "Riccardo Mastroianni", "Giuseppe Simone", "Laura S Mertens", "Ekaterina Laukhtina", "José Luis Rodriguez Elena", "Javier Aranda", "Alfonso Lafuente Puentedura", "Jorge Caño Velasco", "Roberto Contieri", "Federico Zorzi", "Giovanni Liguori", "Rodolfo Hurle", "Giuseppe Ottone Cirulli", "Richard Naspro", "Keiichiro Mori", "Gautier Marcq", "Piotr Radziszewski", "Shahrokh F Shariat", "Paolo Gontero", "Morgan Rouprêt", "Thomas Seisen", "Francesco Montorsi", "Alberto Briganti", "Benjamin Pradere", "Marco Moschini", "European Association of Urology -Young Academic Urologists (EAU-YAU), Urothelial carcinoma working group"], "affiliations": ["Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy. scilipoti.pietro@hsr.it.", "Vita-Salute San Raffaele University, Milan, Italy. scilipoti.pietro@hsr.it.", "Department of General, Oncological and Functional Urology, Medical University of Warsaw, Warsaw, Poland.", "Department of Urology, Instituto Ramón y Cajal de Investigación Sanitaria, Hospital Universitario Ramón y Cajal, Universidad de Alcalá, Madrid, Spain.", "Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy.", "Vita-Salute San Raffaele University, Milan, Italy.", "Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy.", "Department of Minimally Invasive and Robotic Urology, Wrocław Medical University, Wrocław, Poland.", "Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.", "Oncological Urology, Veneto Institute of Oncology IRCCS, Padua, Italy.", "Department of Maternal Infant and Urologic Sciences, \"Sapienza\" University of Rome, Policlinico Umberto I Hospital, Rome, Italy.", "Department of Urology, Medical University of Innsbruck, Innsbruck, Austria.", "Division of Urology, Geneva University Hospitals, Geneva, Switzerland.", "Department of Urology, Fundacio Puigvert, Barcelona, Spain.", "Institut de Recerca Sant Pau (IR SANT PAU), Sant Quintí, 77-79, 08041, Barcelona, Spain.", "Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland.", "IRCCS \"Regina Elena\" National Cancer Institute, Rome, Italy.", "Department of Surgical Sciences, Urology Unit, University of Tor Vergata, Rome, Italy.", "Department of Urology, Netherlands Cancer Institute, Amsterdam, The Netherlands.", "Department of Urology, Hospital Universitario de Cáceres, Cáceres, Spain.", "Department of Urology, Gregorio Marañón University Hospital, Madrid, Spain.", "Clinica Universidad De Navarra, Pamplona, Spain.", "Department of Urology, Istituto Nazionale Tumori IRCCS, \"Fondazione G. Pascale\", Naples, Italy.", "Department of Medical, Surgical and Health Sciences, Urology Unit, University of Trieste, 34127, Trieste, Italy.", "Department of Urology, Humanitas Clinical and Research Institute IRCCS, Rozzano, Milan, Italy.", "Department of Urology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.", "Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Via Alessandro Brambilla, 74, 27100, Pavia, Italy.", "Department of Urology, The Jikei University School of Medicine, Tokyo, Japan.", "Department of Urology, Claude Huriez Hospital, CHU Lille, Lille, France.", "Department of Urology, University of Texas Southwestern, Dallas, TX, USA.", "Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria.", "Department of Urology, Weill Cornell Medical College, New York, NY, USA.", "Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic.", "Sorbonne University, GRC 5 Predictive Onco-Uro, AP-HP, Urology, Pitie-Salpetriere Hospital, 75013, Paris, France.", "Department of Urology UROSUD, La Croix Du Sud Hospital, Quint-Fonsegrives, France."], "corresponding_authors": ["Pietro Scilipoti"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_clinical", "score": 33.0, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.0, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 9.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.9, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.0, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42823553", "title": "Circulating tumour DNA and extrachromosomal DNA in prostate and bladder cancer: biology, clinical applications and future perspectives.", "abstract": "To critically appraise circulating tumour DNA (ctDNA) and extrachromosomal DNA (ecDNA) in prostate and bladder cancer, and to define what evidence links the two. Narrative review of search period July-September 2026, supplemented by reference-list and citation screening, covering ctDNA and ecDNA biology, detection and clinical application in prostate and urothelial cancer. The ctDNA-ecDNA interface was appraised using a five-tier evidentiary framework (copy-number gain; structural rearrangement; amplicon-graph reconstruction; phasing/optical mapping; orthogonal validation). In bladder cancer, the phase 3 IMvigor011 trial validated ctDNA-guided adjuvant atezolizumab (disease-free survival [DFS] HR 0.64; overall survival [OS] HR 0.59), while persistently ctDNA-negative patients had 2-year DFS/OS of 88.4%/97.1% without adjuvant therapy. In prostate cancer, ctDNA positivity and androgen-receptor alterations are strongly prognostic (median OS 29.0 vs. 47.4 months; HR 2.0), but no prospective ctDNA-guided interventional trial exists. ecDNA is present in approximately 36% of urothelial carcinomas and drives oncogene amplification, heterogeneity, immune evasion and resistance. Evidence linking the two is indirect and asymmetric: prostate cancer offers stronger longitudinal ctDNA evidence via plasma AR-ecDNA proxy signatures, whereas bladder cancer shows stronger structural evidence from urinary sediment; no structurally validated blood ecDNA has been reported. This evidence derives predominantly from metastatic cohorts (mCRPC, post-cystectomy bladder cancer), with no established role in earlier-stage or minimal-residual-disease settings. ctDNA is clinically actionable in bladder cancer and prognostic in advanced prostate cancer, whereas ecDNA remains an investigational driver. Structural confirmation of ecDNA in blood, assay standardisation and prospective biomarker-stratified trials are the priorities for the field.", "journal": "World Journal of Urology", "pub_date": "2026-Oct-01", "publication_types": ["Journal Article", "Review"], "doi": "10.1007/s00345-026-06790-7", "authors": ["Jihane Elmasmoudi", "Axel S Merseburger"], "affiliations": ["Department of Urology, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany.", "Faculty of Medicine and Pharmacy of Tangier, Abdelmalek Essaâdi University, Tangier, Morocco.", "Department of Urology, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany. axel.merseburger@uksh.de."], "corresponding_authors": ["Axel S Merseburger"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 45.5, "score_parts": {"urology_relevance": 18.0, "urology_in_title": 8.0, "journal_priority": 10.0, "top_journal_bonus": 0.0, "novelty": 0.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 7.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.9, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.0, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42823300", "title": "Sociodemographic barriers to receiving adjuvant systemic therapy after nephrectomy for renal cell carcinoma.", "abstract": "It is unknown whether sociodemographic barriers affect the use of adjuvant systemic therapy after nephrectomy among eligible renal cell carcinoma patients. Within Surveillance, Epidemiology, and End Results database, we identified renal cell carcinoma patients eligible for adjuvant systemic therapy after nephrectomy between 2018 and 2022. Multivariable logistic regression models assessed associations between age, marital status, race/ethnicity, and adjuvant systemic therapy use. Of 6,497 eligible patients, 1,163 patients (17.9%) received adjuvant systemic therapy. Treatment rates were lower in patients aged ≥65 years (14.9% vs. 21.2%, odds ratio [OR] 0.60, 95% confidence interval [CI]: 0.52-0.68, P < 0.001), unmarried individuals (15.9% vs. 19.0%, OR 0.75, 95% CI: 0.65-0.87, P < 0.001), and non-Caucasian patients (16.3% vs. 18.7%, OR 0.75, 95% CI: 0.65-0.87, P < 0.001), even after multivariable adjustment for other patient and tumor characteristics. Combined assessment of these 3 sociodemographic characteristics demonstrated a stepwise decrease in treatment rates, that were lowest in ≥65-year-old unmarried non-Caucasians (10.4%, OR 0.29, 95% CI: 0.19-0.41, P < 0.001) and highest in <65-year-old married Caucasians (24.2%, reference). Despite guideline endorsement, only a minority of eligible renal cell carcinoma patients receive adjuvant systemic therapy after nephrectomy. Older age, unmarried status, and non-Caucasian race/ethnicity were independently associated with lower adjuvant systemic therapy receipt. The combination of these established sociodemographic barriers identified the patient subgroup with the lowest likelihood of receiving adjuvant systemic therapy. Efforts aimed at reducing disparities and close gaps in the implementation of guideline-recommended adjuvant systemic therapy use should therefore focus on individuals with this sociodemographic profile.", "journal": "Urologic Oncology", "pub_date": "2026-Oct-01", "publication_types": ["Journal Article"], "doi": "10.1016/j.urolonc.2026.09.002", "authors": ["Maximilian Filzmayer", "Michele Petix", "Leonardo Quarta", "Filippo Orlandi", "Jordan A Goyal", "Luca Carmignani", "Alberto Briganti", "Salvatore Micali", "Shahrokh F Shariat", "Mike Wenzel", "Yasmine Heß-Busch", "Clara Humke", "Fred Saad", "Felix K-H Chun", "Pierre I Karakiewicz"], "affiliations": ["Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Canada; Department of Urology, Goethe University Frankfurt, University Hospital, Frankfurt am Main, Germany. Electronic address: filzmayer@med.uni-frankfurt.de.", "Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Canada; Department of Biomedical Sciences for Health, University of Milan, Milan, Italy; Department of Urology, IRCCS Policlinico San Donato, Milan, Italy.", "Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Canada; Department of Urology, Vita-Salute San Raffaele University, Milan, Italy; Division of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy.", "Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Canada; Department of Urology, AOU di Modena, University of Modena and Reggio Emilia, Modena, Italy.", "Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Canada.", "Department of Biomedical Sciences for Health, University of Milan, Milan, Italy; Department of Urology, IRCCS Policlinico San Donato, Milan, Italy.", "Department of Urology, Vita-Salute San Raffaele University, Milan, Italy; Division of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy.", "Department of Urology, AOU di Modena, University of Modena and Reggio Emilia, Modena, Italy.", "Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Weill Cornell Medical College, New York, United States; Department of Urology, University of Texas Southwestern Medical Center, Dallas, United States; Hourani Center of Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan.", "Department of Urology, Goethe University Frankfurt, University Hospital, Frankfurt am Main, Germany."], "corresponding_authors": ["Maximilian Filzmayer"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=3", "score": 26.75, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 5.75, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 3.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.3, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.75, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42823299", "title": "Re: Trans-perineal prostate biopsy-prognostic factors for \"no prostate tissue\" in biopsy cores: Beyond local anesthesia.", "abstract": "", "journal": "Urologic Oncology", "pub_date": "2026-Oct-01", "publication_types": ["Letter"], "doi": "10.1016/j.urolonc.2026.09.005", "authors": ["Erdem Öztürk", "İsa Dağlı"], "affiliations": ["Department of Urology, University of Health Sciences, Ankara Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Ankara, Türkiye.", "Department of Urology, Yerköy Şehit Korgeneral Osman Erbaş State Hospital, Yozgat Provincial Directorate of Health, Yozgat, Türkiye. Electronic address: isadaglii@gmail.com."], "corresponding_authors": ["İsa Dağlı"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 14.75, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 5.75, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.3, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.75, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42823298", "title": "Corrigendum to \"Differential mTOR pathway profiles in bladder cancer cell line subtypes to predict sensitivity to mTOR inhibition\" Volume 35, Issue 10, October 2017, Pages 593-599.", "abstract": "", "journal": "Urologic Oncology", "pub_date": "2026-Oct-01", "publication_types": ["Published Erratum"], "doi": "10.1016/j.urolonc.2026.09.001", "authors": ["Andrew M Hau", "Manando Nakasaki", "Kazufumi Nakashima", "Goutam Krish", "Donna E Hansel"], "affiliations": ["DepartmentofPathology, UniversityofCalifornia, SanDiego, LaJolla, CA.", "DepartmentofPathology, UniversityofCalifornia, SanDiego, LaJolla, CA; DepartmentofUrology, UniversityofCalifornia, SanDiego, LaJolla, CA. Electronic address: dhansel@ucsd.edu."], "corresponding_authors": ["Donna E Hansel"], "china_team": "", "category": "basic", "classification_reason": "basic_signals=5", "score": 19.75, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 5.75, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 5.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.3, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.75, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42823260", "title": "Natural History After Likely Cure Versus Recurrence After Prostate Radiotherapy (RAPTOR).", "abstract": "Whether freedom from biochemical recurrence (BCR) at 5 yr after definitive radiotherapy (RT) for localized prostate cancer (PCa) represents a durable cure remains uncertain. To evaluate the association between the timing of BCR after RT and the long-term risks of distant metastasis (DM) and PCa-specific mortality (PCSM), overall and according to treatment intensity, including outcomes by BCR timing (≤5 yr, >5 yr, or no BCR). Post hoc individual patient data analysis of 3120 men with intermediate- (89%) or high-risk (11%) PCa enrolled in 11 randomized trials within the Meta-Analysis of Randomized Trials in Cancer of the Prostate consortium and treated with contemporary high-dose RT (HDRT) ± androgen deprivation therapy (ADT). Cumulative incidences of DM at 8 yr and PCSM at 10 yr after RT were estimated using competing-risk methods. Adjusted cumulative incidences were estimated using average marginal effects, accounting for clinicopathologic factors, treatment intensity, and progressively longer durations remaining free of BCR after RT. A priori, cumulative incidences ≤10% were considered indicative of a favorable long-term prognosis. Among men without BCR at 5 yr, subsequent risks of DM and PCSM were low overall. In patients with intermediate-risk PCa treated with HDRT alone, the adjusted cumulative incidences of 8-yr DM and 10-yr PCSM were 6.6% and 2.5%, respectively, indicating a favorable long-term prognosis based on the prespecified threshold. In contrast, patients with intermediate-risk PCa treated with HDRT plus short-term ADT and patients with high-risk PCa treated with HDRT plus long-term ADT had higher residual metastatic risk (8-yr adjusted cumulative DM incidence of 11% and 16%, respectively) exceeding the predefined favorable prognosis threshold despite remaining BCR-free for 5 yr. Early BCR (≤5 yr) was associated with substantially higher risks of DM and PCSM across all treatment groups. Limitations include the retrospective nature of the analyses, heterogeneity in BCR definitions across trials, absence of comorbidity data and contemporary risk subclassification, and the pre-prostate-specific membrane antigen imaging era of the constituent trials. A 5-yr BCR-free benchmark was associated with a favorable long-term prognosis for intermediate-risk PCa treated with RT alone, but it appears insufficient for patients requiring ADT intensification. External validation in contemporary cohorts with standardized BCR definitions and modern imaging is warranted.", "journal": "European Urology Oncology", "pub_date": "2026-Oct-01", "publication_types": ["Journal Article"], "doi": "10.1016/j.euo.2026.09.007", "authors": ["Soumyajit Roy", "Tahmineh Romero", "Mack Roach", "Jeff M Michalski", "David J Joseph", "David Dearnaley", "Alison C Tree", "Emma Hall", "Matthew R Sydes", "Luca Incrocci", "Wilma Heemsbergen", "Floris de Pos", "Michel Bolla", "Philippe Maingon", "Theo de Reijke", "Abdenour Nabid", "John G Armstrong", "Scott C Morgan", "Xavier Maldonado", "Wee L Ong", "Jarad Martin", "Eric M Horwitz", "Jessica K Wong", "Michael Steinberg", "Luca Valle", "Kekoa Taparra", "Angela Y Jia", "Nicholas G Zaorsky", "Stefano Arcangeli", "Giuseppe Sanguineti", "Almudena Zapatero", "Howard Sandler", "Paul L Nguyen", "Yilun Sun", "Daniel E Spratt", "Amar U Kishan"], "affiliations": ["University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, USA.", "Department of Medicine, University of California, Los Angeles, Los Angeles, USA.", "University of California, San Francisco, Department of Radiation Oncology, San Francisco, USA.", "Department of Radiation Oncology, Washington University School of Medicine, St. Louis, USA.", "Radiation Oncology, Sir Charles Gairdner Hospital, Perth, Australia.", "The Institute of Cancer Research and Royal Marsden Hospital NHS Foundation Trust, London, UK.", "Health Data Research, London, UK.", "Department of Radiotherapy, Erasmus Medical Center, Rotterdam, The Netherlands.", "The Netherlands Cancer Institute, Amsterdam, The Netherlands.", "Grenoble Alpes University, Centre Hospitalier Universitaire de Grenoble, Grenoble, France.", "Sorbonne University, Paris, France.", "Department of Radiotherapy, Erasmus Medical Center, Rotterdam, The Netherlands; Amsterdam University Medical Centers, Amsterdam, The Netherlands.", "Centre hospitalier universitaire de Sherbrooke, Sherbrooke, Canada.", "St Luke's Radiation Oncology Network, Dublin, Ireland.", "The Ottawa Hospital Cancer Center, Ottawa, Canada.", "Hospital Universitari Vall d'Hebron, Barcelona, Spain.", "Monash University, Melbourne, Australia.", "Calvary Mater Newcastle Hospital, Newcastle, Australia.", "Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, USA.", "Department of Radiation Oncology, University of California, Los Angeles, USA.", "University of Milan Bicocca, School of Medicine and Surgery, Milan, Italy.", "IRCCS Instituto Tumori Regina Elena, Rome, Italy.", "University Hospital La Princesa, Health Research Institute, Radiation Oncology, Madrid, Spain.", "Oregon Health & Science University, Portland, USA.", "Dana-Farber Cancer Institute, Boston, USA.", "Case Western Reserve University, Cleveland, USA.", "Department of Radiation Oncology, University of California, Los Angeles, USA. Electronic address: aukishan@mednet.ucla.edu."], "corresponding_authors": ["Amar U Kishan"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 40.42, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 15.42, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 11.0}, "journal_metrics": {"status": "ok", "impact_factor": 9.3, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.42, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42823220", "title": "Re: Twelve-month Results from the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-grade Non-muscle-invasive Bladder Cancer.", "abstract": "", "journal": "European Urology", "pub_date": "2026-Oct-01", "publication_types": ["Journal Article"], "doi": "10.1016/j.eururo.2026.02.009", "authors": ["Laura E Davis", "Spyridon P Basourakos", "Adam C Calaway"], "affiliations": ["Case Western Reserve University Hospital, Cleveland, OH, USA. Electronic address: ledavi09@gmail.com.", "Case Western Reserve University Hospital, Cleveland, OH, USA."], "corresponding_authors": ["Laura E Davis"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 39.79, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 16.79, "top_journal_bonus": 10.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 25.2, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.79, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "复发高危膀胱癌保膀胱治疗可行", "chinese_summary": "10月Eur Urol刊发CISTO研究12个月结果，比较根治性膀胱切除与保膀胱治疗用于复发高危非肌层浸润性膀胱癌。该研究为临床在严格筛选患者中优先尝试保膀胱策略提供了随机对照证据。", "abstract_zh": "这是对CISTO研究12个月结果的评论，该研究比较了根治性膀胱切除术与保膀胱治疗用于复发性高级别非肌层浸润性膀胱癌。原始摘要内容未提供具体数据、样本量、置信区间及结论细节。"}, {"pmid": "42823219", "title": "Re: Stockholm3 Versus Prostate-specific Antigen in Prostate Cancer Screening: 9 yr Outcomes Demonstrating Improved Detection of Aggressive Cancers and Reduced Overdiagnosis from the STHLM3 Trial.", "abstract": "", "journal": "European Urology", "pub_date": "2026-Oct-01", "publication_types": ["Journal Article"], "doi": "10.1016/j.eururo.2026.09.015", "authors": ["Roman Gulati", "Ruth Etzioni"], "affiliations": ["Fred Hutch Cancer Center, Seattle, WA, USA. Electronic address: rgulati@fredhutch.org.", "Fred Hutch Cancer Center, Seattle, WA, USA."], "corresponding_authors": ["Roman Gulati"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 35.79, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 16.79, "top_journal_bonus": 10.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 25.2, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.79, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "Stockholm3筛查减少前列腺癌过度诊断", "chinese_summary": "10月Eur Urol发布STHLM3试验9年随访：以Stockholm3模型替代前列腺特异性抗原筛查，提高侵袭性前列腺癌检出，同时减少低危肿瘤过度诊断，为优化筛查策略提供长期证据。", "abstract_zh": "这是一封关于STHLM3试验的评论信，讨论Stockholm3与前列腺特异性抗原在前列腺癌筛查中的比较：9年结局显示侵袭性癌症检出改善且过度诊断减少。"}, {"pmid": "42823218", "title": "Re: Matthew Lee, Michael Lesgart, Connor McPartland, Randall Lee, Daniel D. Eun. Robotic Transvesical Bladder Neck Reconstruction: A Novel Approach to Managing Vesicourethral Anastomotic Stenosis. Eur Urol 2025;88:519-24.", "abstract": "", "journal": "European Urology", "pub_date": "2026-Oct-01", "publication_types": ["Letter"], "doi": "10.1016/j.eururo.2026.01.034", "authors": ["Marco Bandini", "Francesco Montorsi"], "affiliations": ["Urological Research Institute, Urology Unit, IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Milan, Italy. Electronic address: marco.bandini.zoli@gmail.com.", "Urological Research Institute, Urology Unit, IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Milan, Italy."], "corresponding_authors": ["Marco Bandini"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 40.79, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 16.79, "top_journal_bonus": 10.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 25.2, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.79, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "机器人经膀胱膀胱颈重建术获关注", "chinese_summary": "10月Eur Urol刊发读者来信，就Lee等提出的机器人经膀胱膀胱颈重建术治疗膀胱尿道吻合口狭窄这一新术式展开讨论。该术式针对前列腺癌术后顽固性吻合口狭窄，为传统经尿道切开失败患者提供替代选择。", "abstract_zh": "这是一封关于Matthew Lee、Michael Lesgart、Connor McPartland、Randall Lee和Daniel D. Eun所发表文章的读者来信。原文标题为《机器人经膀胱膀胱颈重建：处理膀胱尿道吻合口狭窄的一种新方法》，发表于《欧洲泌尿外科学》2025年第88卷第519至524页。"}, {"pmid": "42823217", "title": "Reply to Pierre-Etienne Gabriel and Evanguelos Xylinas's Letter to the Editor re: Ding Ding, Lei Qian, Di Jin, et al. Aptamer-based Positron Emission Tomography Imaging Allows Specific Detection of Residual Bladder Cancer: A First-in-Human Study. Eur Urol. 2026;89:93-5.", "abstract": "", "journal": "European Urology", "pub_date": "2026-Oct-01", "publication_types": ["Letter"], "doi": "10.1016/j.eururo.2026.02.010", "authors": ["Ding Ding", "Weijun Wei", "Haige Chen", "Weihong Tan"], "affiliations": ["Institute of Molecular Medicine, Shanghai Key Laboratory for Nucleic Acid Chemistry and Nanomedicine, Renji Hospital, Shanghai Jiao Tong University, Shanghai, China.", "Department of Nuclear Medicine, Renji Hospital, Shanghai Jiao Tong University, Shanghai, China.", "Department of Urology, Renji Hospital, Shanghai Jiao Tong University, Shanghai, China.", "Institute of Molecular Medicine, Shanghai Key Laboratory for Nucleic Acid Chemistry and Nanomedicine, Renji Hospital, Shanghai Jiao Tong University, Shanghai, China; Hangzhou Institute of Medicine, Chinese Academy of Sciences, Hangzhou, China. Electronic address: tan@him.cas.cn."], "corresponding_authors": ["Weihong Tan"], "china_team": "Institute of Molecular Medicine, Shanghai Key Laboratory for Nucleic Acid Chemistry and Nanomedicine, Renji Hospital, Shanghai Jiao Tong University, Shanghai, China Weihong Tan团队", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 36.79, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 16.79, "top_journal_bonus": 10.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 25.2, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.79, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "适体PET精准识别残余膀胱癌", "chinese_summary": "上海交通大学仁济医院谭蔚泓团队10月Eur Urol回应读者来信，针对其首次人体研究开发的适体PET成像探针可特异性识别残余膀胱癌病灶，为术后残留评估提供分子影像新手段。", "abstract_zh": "这是对Pierre-Etienne Gabriel和Evanguelos Xylinas致编辑来信的回复，内容涉及Ding Ding、Lei Qian、Di Jin等人的文章《基于适体的正电子发射断层成像可特异性检测残余膀胱癌：一项首次人体研究》。Eur Urol. 2026;89:93-5。"}, {"pmid": "42823216", "title": "Re: Active Surveillance Versus Intravesical Bacillus Calmette-Guérin for High-grade T1 Bladder Cancer with Negative Second Transurethral Resection: The Randomized Noninferiority Phase 3 JCOG1019 Trial. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.01.008.", "abstract": "", "journal": "European Urology", "pub_date": "2026-Oct-01", "publication_types": ["Letter"], "doi": "10.1016/j.eururo.2026.03.030", "authors": ["Aleksander Ślusarczyk", "Alessandro Uleri", "Piotr Radziszewski", "Benjamin Pradere"], "affiliations": ["Department of General, Oncological and Functional Urology, Medical University of Warsaw, Warsaw, Poland. Electronic address: slusarczyk.aleksander@gmail.com.", "Department of Urology, UROSUD, La Croix du Sud Hospital, Quint Fonsegrives, France.", "Department of General, Oncological and Functional Urology, Medical University of Warsaw, Warsaw, Poland."], "corresponding_authors": ["Aleksander Ślusarczyk"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=4", "score": 43.79, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 16.79, "top_journal_bonus": 10.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 4.0}, "journal_metrics": {"status": "ok", "impact_factor": 25.2, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.79, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "高危T1膀胱癌主动监测不劣于BCG", "chinese_summary": "欧洲泌尿外科学会刊10月就JCOG1019随机非劣效3期试验发表述评，该试验针对二次电切阴性的高危T1膀胱癌患者，比较主动监测与膀胱内卡介苗灌注。结果支持在此类患者中以主动监测替代BCG，有望减少灌注相关不良反应及医疗负担。", "abstract_zh": "这是一封致编辑的信，内容为对以下研究的评论：主动监测对比膀胱内卡介苗治疗二次经尿道电切阴性的高危T1膀胱癌：随机非劣效性3期JCOG1019试验。Eur Urol。印刷中。http://dx.doi.org/10.1016/j.eururo.2026.01.008。"}, {"pmid": "42823175", "title": "Real-world Outcomes of First-line Enfortumab Vedotin Plus Pembrolizumab in Elderly Patients With Advanced Urothelial Carcinoma.", "abstract": "Evidence regarding first-line enfortumab vedotin plus pembrolizumab (EVP) in elderly patients with advanced urothelial carcinoma (UC), particularly those aged ≥80 years, remains limited. This study evaluated the real-world effectiveness, safety, and treatment feasibility of EVP stratified by age. We retrospectively analyzed 40 consecutive patients with unresectable locally advanced or metastatic UC who received first-line EVP at a single institution between December 2024 and April 2026. Outcomes were assessed using predefined age cutoffs of 75 and 80 years. Tumor response was evaluated according to RECIST version 1.1 and adverse events according to CTCAE version 5.0. The median age was 76.2 years, 22 patients (55.0%) were aged ≥75 years and 11 (27.5%) were aged ≥80 years. Patients in the older group were more likely to have lymph node-only disease and lower creatinine clearance. Objective response rates were 52.9% and 77.3% in patients aged <75 and ≥75 years and 64.3% and 72.7% in those aged <80 and ≥80 years, respectively. Grade ≥3 treatment-related adverse events occurred in nine patients (22.5%) overall. Median treatment duration was 2.7 months. At a median follow-up of 7.7 months, no significant differences in progression-free or overall survival were observed according to either age cutoff. Several elderly responders had no documented disease progression at their most recent post-discontinuation assessment; however, treatment duration and follow-up after discontinuation were limited. In this small, selected real-world cohort, first-line EVP showed preliminary antitumor activity and feasible treatment delivery in elderly patients with advanced UC, including very elderly patients. These findings should be considered hypothesis-generating and require validation in larger studies with longer follow-up and standardized geriatric assessment.", "journal": "Anticancer Research", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.21873/anticanres.18414", "authors": ["G O Kaneko", "Daisuke Igarashi", "Masataka Morita", "Shuji Tsubota", "Yuto Baba", "Suguru Shirotake"], "affiliations": ["Department of Uro-Oncology, Saitama Medical University International Medical Center, Saitama, Japan gk3281@5931.saitama-med.ac.jp.", "Department of Uro-Oncology, Saitama Medical University International Medical Center, Saitama, Japan."], "corresponding_authors": ["G O Kaneko"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=9", "score": 26.46, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 2.46, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 9.0}, "journal_metrics": {"status": "ok", "impact_factor": 1.7, "cas_zone": 4, "cas_zone_points": 1.0, "impact_factor_points": 1.46, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42823172", "title": "Complete Response Durability After TAR-200 and Nadofaragene Firadenovec in BCG-unresponsive Bladder CIS.", "abstract": "Bladder-preserving therapies are increasingly important for patients with bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ (CIS) who are unfit for or decline radical cystectomy. Because sustained complete response (CR) is critical for bladder preservation, we compared duration of response (DoR) among CR responders treated with TAR-200 or nadofaragene firadenovec using reconstructed individual patient data from published Kaplan-Meier curves. Published DoR Kaplan-Meier curves for CR responders were digitized from SunRISe-1 cohort 2 evaluating TAR-200 monotherapy and from the phase III NCT02773849 CIS cohort evaluating nadofaragene firadenovec. Reconstructed individual patient data (rIPD) were reconstructed using IPDfromKM package. Restricted mean survival time (RMST) for DoR was estimated at 6, 12, 18, and 24 months. A Weibull mixture cure model was fitted as an exploratory analysis to estimate the durable CR fraction. RMST differences for DoR between TAR-200 and nadofaragene firadenovec were not statistically significant through 24 months. RMST differences were -0.29 months at 6 months, -0.04 months at 12 months, +0.60 months at 18 months, and +1.34 months at 24 months, with confidence intervals crossing zero at all timepoints. In the exploratory Weibull mixture cure model, the estimated durable CR fraction was larger for TAR-200 than for nadofaragene firadenovec (0.521 vs. 0.256; difference +0.265). In this exploratory rIPD-based cross-trial analysis, CR durability among responders did not differ significantly between TAR-200 and nadofaragene firadenovec through 24 months. Later RMST point estimates and model-based durable CR fraction estimates were numerically higher for TAR-200, but these findings require cautious interpretation because of cross-trial comparability limitations, responder-conditioned selection, and limited follow-up.", "journal": "Anticancer Research", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.21873/anticanres.18415", "authors": ["Hiroshi Fukushima", "Soichiro Yoshida", "Shugo Yajima", "Akihiro Hirakawa", "Yosuke Yasuda", "Yasuhisa Fujii"], "affiliations": ["Department of Urology, Institute of Science Tokyo, Tokyo, Japan.", "Department of Urology, Institute of Science Tokyo, Tokyo, Japan; s-yoshida.uro@tmd.ac.jp.", "Department of Urology, National Cancer Center Hospital East, Chiba, Japan.", "Department of Clinical Biostatistics, Institute of Science Tokyo, Tokyo, Japan."], "corresponding_authors": ["Soichiro Yoshida"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=13", "score": 32.46, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 2.46, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 12.0}, "journal_metrics": {"status": "ok", "impact_factor": 1.7, "cas_zone": 4, "cas_zone_points": 1.0, "impact_factor_points": 1.46, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42823170", "title": "Identification of Cancer-associated Fibroblasts-specific ncRNA-mRNA/Protein Regulatory Axes in Prostate Cancer.", "abstract": "Cancer-associated fibroblasts (CAFs) are major components of the tumor microenvironment and secrete factors that promote tumor growth, progression, and treatment resistance. Non-coding RNAs (ncRNAs) may regulate CAF-derived signals, but coordinated ncRNA-mRNA/protein networks in prostate cancer remain poorly characterized. This study aimed to identify CAF-specific ncRNA-mRNA/protein regulatory axes by comparing prostate cancer-derived CAFs with fibroblasts from benign prostatic hyperplasia (BPH). We integrated previously generated RNA sequencing data with label-free quantitative mass spectrometry of conditioned media from primary CAFs (n=3) and BPH-derived control fibroblasts (n=3). LINCRNA-interacting miRNAs and their putative mRNA targets were predicted using NPInter v5.0 and miRDB, respectively, and cross-referenced with differentially expressed secreted proteins. Prognostic associations were evaluated using progression-free interval data from the TCGA prostate adenocarcinoma cohort. Secretome profiling identified 1,007 proteins, including 133 differentially expressed proteins and 90 proteins unique to either CAFs or control fibroblasts. Integration of transcriptomic, target-prediction, and proteomic data revealed 28 CAF-associated ncRNA-mRNA/protein regulatory axes. MYH11, SERPINF2, ANGPT1, and CRISPLD2 were significantly associated with progression-free interval. The identified axes are linked to extracellular matrix remodeling, angiogenesis, and immune modulation, processes that contribute to tumor maintenance, progression, metastasis, and therapeutic resistance. CAF-specific ncRNA-mRNA/protein networks provide mechanistic insight into prostate cancer progression and may serve as candidate biomarkers for disease monitoring and prognosis.", "journal": "Anticancer Research", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.21873/anticanres.18383", "authors": ["Apoorva Abikar", "Swathi Kiragunasi Annayya", "Mohammad Mehaboob Subhani Mustafa", "Radhika Rajiv Athalye", "Namratha Nadig", "Ninad Tamboli", "Vinod Babu", "Ramaiah Keshavamurthy", "Meena Jhanwar-Uniyal", "Prathibha Ranganathan"], "affiliations": ["Centre for Human Genetics, Bengaluru, India.", "Manipal Academy of Higher Education, Manipal, India.", "Institute of Nephro-Urology, Bengaluru, India.", "Department of Neurosurgery, New York Medical College, Valhalla, NY, U.S.A. meena_jhanwar@nymc.edu.", "Centre for Human Genetics, Bengaluru, India; pranganathan@chg.res.in."], "corresponding_authors": ["Meena Jhanwar-Uniyal", "Prathibha Ranganathan"], "china_team": "", "category": "basic", "classification_reason": "basic_signals=9", "score": 29.96, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 2.46, "top_journal_bonus": 0.0, "novelty": 0.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 9.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 1.7, "cas_zone": 4, "cas_zone_points": 1.0, "impact_factor_points": 1.46, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "前列腺癌相关成纤维细胞调控轴被识别", "chinese_summary": "10月Anticancer Research整合原代前列腺癌相关成纤维细胞与良性增生来源成纤维细胞的RNA测序及条件培养基蛋白质组数据，识别28条ncRNA-mRNA/蛋白调控轴，其中MYH11、SERPINF2、ANGPT1、CRISPLD2与无进展间期显著相关，涉及细胞外基质重塑、血管生成及免疫调节。", "abstract_zh": "癌症相关成纤维细胞（CAFs）是肿瘤微环境的主要成分，分泌促进肿瘤生长、进展和治疗抵抗的因子。非编码RNA（ncRNAs）可能调控CAF来源的信号，但前列腺癌中协调的ncRNA-mRNA/蛋白网络仍特征不明。本研究旨在通过比较前列腺癌来源的CAFs与良性前列腺增生（BPH）来源的成纤维细胞，识别CAF特异性ncRNA-mRNA/蛋白调控轴。我们将先前生成的RNA测序数据与原代CAFs（n=3）和BPH来源对照成纤维细胞（n=3）条件培养基的无标记定量质谱数据整合。分别使用NPInter v5.0和miRDB预测LINCRNA相互作用的miRNAs及其推定mRNA靶点，并与差异表达的分泌蛋白交叉参照。使用TCGA前列腺腺癌队列的无进展间期数据评估预后关联。分泌组分析鉴定出1,007种蛋白，包括133种差异表达蛋白和90种CAFs或对照成纤维细胞独有的蛋白。整合转录组、靶点预测和蛋白质组数据，揭示了28条CAF相关的ncRNA-mRNA/蛋白调控轴。MYH11、SERPINF2、ANGPT1和CRISPLD2与无进展间期显著相关。所识别的调控轴与细胞外基质重塑、血管生成和免疫调节相关，这些过程促进肿瘤维持、进展、转移和治疗抵抗。CAF特异性ncRNA-mRNA/蛋白网络为前列腺癌进展提供了机制见解，并可能作为疾病监测和预后的候选生物标志物。"}, {"pmid": "42823162", "title": "Structured Symptom Monitoring During Enfortumab Vedotin Plus Pembrolizumab for Advanced or Metastatic Urothelial Carcinoma: Multicenter Retrospective Study.", "abstract": "Symptomatic adverse events during enfortumab vedotin plus pembrolizumab (EV+P) therapy may be incompletely documented in routine practice. This study evaluated whether structured symptom monitoring (SSM) using treatment-specific questionnaires was associated with more comprehensive documentation of symptomatic adverse events in patients with advanced or metastatic urothelial carcinoma. This multicenter retrospective study included 34 consecutive patients with advanced or metastatic urothelial carcinoma who initiated EV+P between October 2024 and August 2025. Fourteen patients treated at Wakayama Medical University Hospital underwent SSM via two locally developed questionnaires, whereas 20 patients treated at affiliated hospitals received usual care without structured questionnaires. The primary endpoint was the number of documented symptomatic adverse event types per patient. The median number of documented symptomatic adverse event types per patient was higher in the SSM group than in the non-SSM group (3 vs. 2; median difference: 2; 95% confidence interval: 1-3; p<0.01). In contrast, the rates of any documented symptomatic adverse events (100.0% vs. 90.0%, p=0.50), grade ≥3 symptomatic adverse events (21.4% vs. 20.0%, p=1.00), and symptomatic adverse events leading to EV dose reduction (57.1% vs. 35.0%, p=0.29) were similar between groups. Subjective or lower-grade symptoms, including alopecia, dysgeusia, decreased appetite, and pruritus, were more commonly documented in the SSM group. SSM implemented at a single institution was associated with more comprehensive documentation of symptomatic adverse events during EV+P therapy compared with external institutional usual care, particularly subjective or lower-grade symptoms. Clinical benefit was not established, but treatment-specific symptom monitoring may provide a practical framework for more systematic toxicity assessment in routine EV+P care.", "journal": "Anticancer Research", "pub_date": "2026-Oct", "publication_types": ["Journal Article", "Multicenter Study"], "doi": "10.21873/anticanres.18407", "authors": ["Takahito Wakamiya", "Sohei Iwagami", "Nobuyuki Enyo", "Shuya Shibano", "Yuta Nabeshima", "Ryusuke Deguchi", "Kazutomo Kuwata", "Takuma Wada", "Shimpei Yamashita", "Yasuo Kohjimoto"], "affiliations": ["Department of Urology, Wakayama Medical University, Wakayama, Japan; wakataka14@yahoo.co.jp.", "Department of Urology, Kishiwada Tokushukai Hospital, Kishiwada, Japan.", "Department of Urology, Kinan Hospital, Kinokawa, Japan.", "Department of Urology, Rinku General Medical Center, Izumisano, Japan.", "Department of Urology, Kishiwada City Hospital, Kishiwada, Japan.", "Department of Urology, Wakayama Rosai Hospital, Wakayama, Japan.", "Department of Urology, Naga Hospital, Kinokawa, Japan.", "Department of Urology, Hashimoto Municipal Hospital, Hashimoto, Japan.", "Department of Urology, Wakayama Medical University, Wakayama, Japan."], "corresponding_authors": ["Takahito Wakamiya"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_clinical", "score": 23.46, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 2.46, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 7.0}, "journal_metrics": {"status": "ok", "impact_factor": 1.7, "cas_zone": 4, "cas_zone_points": 1.0, "impact_factor_points": 1.46, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42823159", "title": "CLSPN Is Expressed in Pancreatic Cancer and Can Be a Target for Immunotherapy.", "abstract": "Claspin (CLSPN), previously identified as a cisplatin-resistance driver and immunotherapy target in urothelial carcinoma, has not been characterized in pancreatic cancer, which remains poorly responsive to immune checkpoint blockade. This study aimed to determine whether CLSPN can be a target for immunotherapy in pancreatic cancer. CLSPN expression and its prognostic association were analyzed using a TCGA pancreatic adenocarcinoma cohort. CLSPN induction by cisplatin (CDDP) and oxaliplatin (L-OHP) was assessed by western blotting and quantitative RT-PCR. The antigen-specific reactivity of previously established CLSPN-specific, HLA-A*02:01-restricted TCR-T cells (clone yc3) against the pancreatic cancer cell line PANC-1 was evaluated by IFN-γ ELISPOT assay, with and without platinum pretreatment. High CLSPN expression was associated with shorter overall, disease-free, disease-specific, and progression-free survival. CLSPN protein and mRNA expression were detected in pancreatic cancer cell lines. The expression of CLSPN was increased by platinum exposure. yc3 TCR-T cells specifically recognized CLSPN peptide-pulsed T2 cells and produced IFN-γ upon coculture with HLA-A*02:01+/CLSPN+ PANC-1 cells, and their reactivity was increased by platinum treatment. CLSPN is a platinum-inducible immunotherapy target in pancreatic cancer, and combining CLSPN-specific TCR-T cell therapy with platinum-based chemotherapy is a promising strategy for this disease.", "journal": "Anticancer Research", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.21873/anticanres.18384", "authors": ["Hideharu Miura", "Kenji Murata", "Aiko Murai", "Yuka Mizue", "Kanta Hori", "Shoichiro Tange", "Kenta Sasaki", "Naoki Shijubou", "Terufumi Kubo", "Tomohide Tsukahara", "Kiyoteru Kashiwagi", "Takashige Abe", "Masashi Idogawa", "Takayuki Anazawa", "Fumitake Hata", "Toshihiko Torigoe", "Rena Morita", "Yoshihiko Hirohashi"], "affiliations": ["Department of Pathology, Sapporo Medical University School of Medicine, Sapporo, Japan.", "Sapporo Dohto Hospital, Sapporo, Japan.", "Department of Molecular Medicine, Research Institute for Immunology, Sapporo Medical University, Sapporo, Japan.", "Department of Renal and Genitourinary Surgery, Hokkaido University Graduate School of Medicine, Sapporo, Japan.", "Division of Medical Genome Sciences, Department of Genomic and Preventive Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan.", "Department of Surgery, Sapporo Medical University School of Medicine, Sapporo, Japan.", "Department of Pathology, Sapporo Medical University School of Medicine, Sapporo, Japan; morita.r@sapmed.ac.jp.", "Department of Pathology, Sapporo Medical University School of Medicine, Sapporo, Japan; hirohash@sapmed.ac.jp."], "corresponding_authors": ["Rena Morita", "Yoshihiko Hirohashi"], "china_team": "", "category": "basic", "classification_reason": "basic_signals=5", "score": 13.46, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 2.46, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 5.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 1.7, "cas_zone": 4, "cas_zone_points": 1.0, "impact_factor_points": 1.46, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42823156", "title": "Robot-assisted Radical Nephrectomy for Renal Cell Carcinoma With Versus Without Venous Tumor Thrombus.", "abstract": "Robot-assisted radical nephrectomy (RARN) for renal cell carcinoma (RCC) with venous tumor thrombus (VTT) is technically demanding and direct comparisons with non-VTT cases in robotic cohorts are limited. We compared the perioperative and pathological outcomes of RARN between patients with and without VTT. We retrospectively evaluated patients who underwent RARN for RCC at a single institution between April 2022 and August, 2025. The patients were divided into VTT and non-VTT groups. Baseline characteristics, perioperative outcomes, pathological findings, and postoperative complications were compared between the groups. Multivariate logistic regression analysis was performed to assess the factors associated with postoperative complications. A total of 131 patients were included (30 with VTT and 101 without VTT). Patients in the VTT group had significantly larger tumors and more advanced clinical stages. The operative time tended to be longer, and the estimated blood loss was significantly higher in the VTT group; however, no patient in either group required perioperative blood transfusion. The length of hospital-stay and postoperative complication rates did not differ between groups. Pathological T stage was more advanced in the VTT group. In the multivariate analysis, VTT status was not independently associated with postoperative complications. Although patients with VTT had more advanced disease and required more technically demanding procedures, RARN was associated with comparable perioperative outcomes in the selected cohort. These findings support the feasibility and perioperative safety of RARN in carefully selected patients with RCC with limited VTT.", "journal": "Anticancer Research", "pub_date": "2026-Oct", "publication_types": ["Journal Article", "Comparative Study"], "doi": "10.21873/anticanres.18408", "authors": ["Maki Yoshino", "Kazuhiko Yoshida", "Yuki Kobari", "Hironori Fukuda", "Junpei Iizuka", "Toshio Takagi"], "affiliations": ["Department of Urology, Tokyo Women's Medical University, Tokyo, Japan.", "Department of Urology, Tokyo Women's Medical University, Tokyo, Japan kzyoshida1@yahoo.co.jp."], "corresponding_authors": ["Kazuhiko Yoshida"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_clinical", "score": 26.46, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 2.46, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 6.0}, "journal_metrics": {"status": "ok", "impact_factor": 1.7, "cas_zone": 4, "cas_zone_points": 1.0, "impact_factor_points": 1.46, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42823146", "title": "CTDNEP1 Expression Is Associated With Subtype-dependent Prognostic Patterns in Renal Cell Carcinoma.", "abstract": "Renal cell carcinoma (RCC) comprises multiple histological subtypes, such as kidney renal clear cell carcinoma (KIRC) and kidney renal papillary cell carcinoma (KIRP), each with distinct molecular characteristics. Identifying novel genes involved in the onset and progression of these subtypes is crucial for the development of more effective treatments. This study investigates the role of CTD nuclear envelope phosphatase 1 (CTDNEP1), a phosphatase-encoding gene, in KIRC and KIRP using multi-omics data from The Cancer Genome Atlas (TCGA). We analyzed CTDNEP1 expression in KIRC and KIRP using TCGA and Pan-Cancer Atlas datasets. Kaplan-Meier survival and Cox proportional hazard analyses were performed to evaluate the association between CTDNEP1 expression and patient prognosis. We explored biological processes associated with CTDNEP1 expression using GO and KEGG pathway enrichment analyses. Finally, we examined the relationship between CTDNEP1 expression and the tumor immune microenvironment using immune infiltration analysis. CTDNEP1 expression was significantly higher in KIRC and KIRP tissues compared to normal tissues, especially in early-stage tumors. Prognostic impact in KIRP was limited and inconsistent, whereas in KIRC, high CTDNEP1 expression correlated with significantly poorer patient prognosis, particularly in Stage III. Functional enrichment analysis revealed associations with immune-related pathways in KIRC, whereas in KIRP, associations were observed with pathways involved in the PI3K-Akt, MAPK, and TGF-β signaling pathways. In the immune infiltration analysis, CTDNEP1 expression showed only weak correlation with immune cell infiltration. CTDNEP1 expression was associated with subtype-dependent prognostic patterns in RCC. In particular, high CTDNEP1 expression was associated with adverse survival outcomes in KIRC. These findings suggest that CTDNEP1 may serve as a candidate prognostic biomarker in RCC. Further experimental studies are required to clarify whether CTDNEP1 directly contributes to RCC progression.", "journal": "Anticancer Research", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.21873/anticanres.18397", "authors": ["Mayuka Nii", "Kazutaka Ota", "Tadayoshi Hayata"], "affiliations": ["Department of Molecular Pharmacology, Graduate School of Pharmaceutical Sciences and Faculty of Pharmaceutical Science, Tokyo University of Science, Tokyo, Japan.", "Nippon Medical School, Tokyo, Japan.", "Department of Molecular Pharmacology, Graduate School of Pharmaceutical Sciences and Faculty of Pharmaceutical Science, Tokyo University of Science, Tokyo, Japan; hayata.tadayoshi.mph@rs.tus.ac.jp.", "Division of Aging Biology, Research Institute for Science and Technology, Tokyo University of Science, Tokyo, Japan.", "Division of Biological Fluctuations, Research Institute for Science and Technology, Tokyo University of Science, Tokyo, Japan.", "Division of Innovative DDS-based Drug Discovery, Research Institute for Science and Technology, Tokyo University of Science, Tokyo, Japan."], "corresponding_authors": ["Tadayoshi Hayata"], "china_team": "", "category": "basic", "classification_reason": "basic_signals=9", "score": 26.96, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 2.46, "top_journal_bonus": 0.0, "novelty": 1.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 9.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 1.7, "cas_zone": 4, "cas_zone_points": 1.0, "impact_factor_points": 1.46, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "CTDNEP1表达与肾癌亚型预后相关", "chinese_summary": "10月Anticancer Res基于TCGA多组学数据发现，CTDNEP1在肾透明细胞癌及乳头状细胞癌中表达均高于正常组织，但预后意义因亚型而异：高表达者透明细胞癌尤其III期生存显著更差，乳头状癌则关联有限，提示其或可作候选预后标志物。", "abstract_zh": "肾细胞癌（RCC）包含多种组织学亚型，如肾透明细胞癌（KIRC）和肾乳头状细胞癌（KIRP），每种亚型具有不同的分子特征。识别参与这些亚型发生和进展的新基因对于开发更有效的治疗至关重要。本研究利用癌症基因组图谱（TCGA）的多组学数据，探讨CTD核膜磷酸酶1（CTDNEP1）这一磷酸酶编码基因在KIRC和KIRP中的作用。我们使用TCGA和泛癌图谱数据集分析了KIRC和KIRP中CTDNEP1的表达。采用Kaplan-Meier生存分析和Cox比例风险分析评估CTDNEP1表达与患者预后之间的关联。我们通过GO和KEGG通路富集分析探索了与CTDNEP1表达相关的生物学过程。最后，我们利用免疫浸润分析检查了CTDNEP1表达与肿瘤免疫微环境之间的关系。与正常组织相比，CTDNEP1在KIRC和KIRP组织中的表达显著更高，尤其是在早期肿瘤中。在KIRP中的预后影响有限且不一致，而在KIRC中，CTDNEP1高表达与患者预后显著较差相关，尤其是在III期。功能富集分析显示，在KIRC中与免疫相关通路有关联，而在KIRP中，观察到与PI3K-Akt、MAPK和TGF-β信号通路相关的关联。在免疫浸润分析中，CTDNEP1表达与免疫细胞浸润仅显示弱相关。CTDNEP1表达与RCC中亚型依赖的预后模式相关。特别是，CTDNEP1高表达与KIRC的不良生存结局相关。这些发现表明，CTDNEP1可能作为RCC中的候选预后生物标志物。需要进一步的实验研究来阐明CTDNEP1是否直接促进RCC进展。"}, {"pmid": "42821836", "title": "Real-World Comparative Effectiveness of Abiraterone, Apalutamide, Enzalutamide, and Docetaxel Doublets for Metastatic Hormone-Sensitive Prostate Cancer.", "abstract": "To evaluate the real-world comparative effectiveness of androgen receptor pathway inhibitors (ARPIs)-abiraterone, apalutamide, enzalutamide-and docetaxel, plus androgen-deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC). We identified US men with mHSPC who initiated ADT within 4 months of diagnosis and were treated with abiraterone, apalutamide, enzalutamide, or docetaxel within 4 months of ADT initiation between January 2019 and December 2023, with follow-up through June 2025. Primary outcomes were progression-free survival (PFS) and overall survival (OS). Secondary outcomes included time to metastatic castration-resistant prostate cancer (mCRPC) progression (TTP) and time to new treatment initiation (TTNT). Cox proportional hazard and Fine-Gray models with overlapping propensity score weights were used to estimate primary and secondary outcomes, respectively. Subgroup analyses by timing of metastasis and sensitivity analyses using inverse probability of treatment weights were conducted for primary outcomes. Among 9,141 US men with mHSPC, ARPI doublets demonstrated superior PFS versus docetaxel doublets (abiraterone: adjusted hazard ratio [aHR], 0.60 [95% CI, 0.55 to 0.66]; apalutamide: aHR, 0.64 [95% CI, 0.56 to 0.73]; enzalutamide: aHR, 0.57 [95% CI, 0.51 to 0.64]), with no significant differences among ARPI regimens. OS was comparable among all doublet regimens. Neither PFS nor OS differed by timing of disease. TTP (abiraterone: aHR, 0.52 [95% CI, 0.47 to 0.58]; apalutamide: aHR, 0.59 [95% CI, 0.52 to 0.68]; enzalutamide: aHR, 0.51 [95% CI, 0.45 to 0.57]) and TTNT (abiraterone: aHR, 0.46 [95% CI, 0.42 to 0.51]; apalutamide: aHR, 0.53 [95% CI, 0.46 to 0.61]; enzalutamide: aHR, 0.47 [95% CI, 0.42 to 0.53]) showed similar patterns favoring ARPI doublets. Sensitivity analyses showed consistent findings. ARPI doublets demonstrated superior PFS but similar OS compared with docetaxel doublet, with no differences among individual ARPIs. Patients receiving ARPI doublets were less likely to progress to mCRPC or initiate new treatment.", "journal": "Jco Oncology Practice", "pub_date": "2026-Oct-01", "publication_types": ["Journal Article"], "doi": "10.1200/OP-26-00493", "authors": ["Ifechukwu B Nwogu", "Noemi Kreif", "Hiba M Khan", "Ruth Etzioni", "Josh J Carlson"], "affiliations": ["Comparative Health Outcomes, Policy and Economics (CHOICE) Institute, University of Washington School of Pharmacy, Seattle, WA.", "Clinical Research Division, Fred Hutch Cancer Center, Seattle, WA.", "Division of Hematology and Oncology, University of Washington School of Medicine, Seattle, WA.", "Public Health Sciences Division, Fred Hutch Cancer Center, Seattle, WA.", "Department of Biostatistics, University of Washington School of Public Health, Seattle, WA."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=5", "score": 30.03, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.53, "top_journal_bonus": 0.0, "novelty": 0.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 5.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.6, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.53, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42821636", "title": "Inherited Predisposition in Steroidogenic Pathways and Risk of Transition to Incurable Prostate Cancer in men with Localized Disease.", "abstract": "The heterogeneity of prostate cancer (PCa) poses a significant challenge to accurately predict those who will progress to lethal stage. While RNA signatures and somatic DNA alterations can be used to predict clinical outcomes in men with localized PCa, incorporating germline markers may further enhance early prediction of progression to incurable disease. We examined germline markers in steroidogenic pathways in the multi-institutional prospective PROCURE cohort of 1926 patients with localized PCa. The association between 22 single nucleotide polymorphisms (SNPs) across 10 steroidogenic genes and 15 hormone levels, biochemical recurrence-free survival (BCRFS), development of metastasis, castration-resistance (CRPC) and PCa specific mortality (PCSM) was assessed along with their potential functional implications. Thirteen markers were nominally associated with circulating hormone levels at prostatectomy. At a median follow-up (FU) of 9.8 years, variants in CYP17A1, SRD5A2, CYP19A1 and CYP1B1 showed nominal associations with BCRFS, while those located in SRD5A2, HSD17B2 and CYP1B1 were associated with lethal disease. Cumulative associations of these markers predicted time to metastasis/CRPC and fatal outcomes more accurately than individual SNP. Mechanistically, promoter variants in CYP17A1, SRD5A1, and SRD5A2 altered transcriptional activity in cell models, while a CYP1B1 variant was linked to reduced protein expression in primary tumors, likely due to enhanced proteasomal degradation. Our findings support an association between host genetic variation and circulating hormone levels at surgery, with potential clinical implications for disease progression. These markers represent a step toward the development of non-invasive strategies to refine inherited risk stratification for progression from localized to advanced prostate cancer.", "journal": "Journal of Urology", "pub_date": "2026-Oct-01", "publication_types": ["Journal Article"], "doi": "10.1097/JU.0000000000005334", "authors": ["Eric Lévesque", "Louis Lacombe", "Fred Saad", "Armen Aprikian", "Seta Derderian", "Michel Carmel", "Hélène Hovington", "Hervé Brisson", "Sadia Mehdi", "Alexandre Patenaude", "Alain Bergeron", "Ginette McKercher", "Yves Fradet", "David Simonyan", "Patrick Caron", "Sandra Gauque-Olarte", "Arnaud Droit", "Simone Chevalier", "Chantal Guillemette"], "affiliations": ["Centre Hospitalier Universitaire de Québec (CRCHU de Québec) Research Center - Université Laval, Québec, Faculty of Medicine, Québec, Canada.", "Centre Hospitalier de l'Université de Montréal, Université de Montréal, Québec, Canada.", "McGill University Health Centre, McGill University, Faculty of Medicine, Québec, Canada.", "Université de Sherbrooke, Faculty of Medicine, Québec, Canada.", "Clinical and Evaluative Research Platform, Centre Hospitalier Universitaire de Québec (CRCHU de Québec) Research Center - Université Laval, Québec, Canada.", "Centre Hospitalier Universitaire de Québec (CRCHU de Québec) Research Center - Université Laval, Faculty of Pharmacy, Laval University, Québec, Canada."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "basic_signals=5", "score": 30.01, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 11.01, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 5.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 6.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 3.01, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "类固醇通路遗传变异预测前列腺癌进展", "chinese_summary": "2026年10月J Urol发布PROCURE前瞻队列1926例局限性前列腺癌分析，发现CYP17A1、SRD5A2等类固醇合成通路种系变异与术后激素水平及生化复发相关，累积评分可较单变异更准确预测转移、去势抵抗与死亡风险。", "abstract_zh": "前列腺癌（PCa）的异质性对准确预测哪些患者将进展至致死阶段构成重大挑战。虽然RNA特征和体细胞DNA改变可用于预测局限性PCa男性的临床结局，但纳入种系标志物可能进一步增强对进展至不可治愈疾病的早期预测。我们在多机构前瞻性PROCURE队列的1926例局限性PCa患者中检测了类固醇生成通路的种系标志物。评估了10个类固醇生成基因上的22个单核苷酸多态性（SNP）与15种激素水平、生化无复发生存（BCRFS）、转移发生、去势抵抗（CRPC）和PCa特异性死亡（PCSM）之间的关联及其潜在功能意义。13个标志物与前列腺切除术时的循环激素水平存在名义关联。在中位随访（FU）9.8年时，CYP17A1、SRD5A2、CYP19A1和CYP1B1中的变异与BCRFS显示名义关联，而位于SRD5A2、HSD17B2和CYP1B1中的变异与致死性疾病相关。这些标志物的累积关联比单个SNP更准确地预测转移/CRPC时间和致命结局。在机制上，CYP17A1、SRD5A1和SRD5A2的启动子变异改变了细胞模型中的转录活性，而一个CYP1B1变异与原发性肿瘤中蛋白表达降低相关，可能由于蛋白酶体降解增强所致。我们的发现支持宿主遗传变异与手术时循环激素水平之间的关联，并对疾病进展具有潜在临床意义。这些标志物代表了朝开发非侵入性策略以完善局限性向晚期前列腺癌进展的遗传风险分层迈出的一步。"}, {"pmid": "42821625", "title": "Understanding Bladder-Sparing Approach in the Modern Era of Neoadjuvant Therapy.", "abstract": "", "journal": "Journal of Urology", "pub_date": "2026-Oct-01", "publication_types": ["Editorial"], "doi": "10.1097/JU.0000000000005333", "authors": ["Sagar R Patel", "Andrea Necchi", "Ashish M Kamat"], "affiliations": ["Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, Texas.", "Department of Medical Oncology, IRCCS San Raffaele Hospital, Milan, Italy.", "Department of Medical Oncology, Vita-Salute San Raffaele University, Milan, Italy."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 20.01, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 11.01, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 6.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 3.01, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42821609", "title": "A Phase I Clinical Trial of Chemoimmunotherapy with Alternating Intravesical Gemcitabine and Bacillus Calmette-Guérin (GemBCG) for BCG-Exposed High-Grade Non-Muscle-Invasive Bladder Cancer.", "abstract": "Retreatment with BCG alone is recommended for patients with Bacillus Calmette-Guérin (BCG)-exposed non-muscle-invasive bladder cancer (NMIBC), yet ∼50% recur and become \"BCG-unresponsive.\" Strategies to improve the efficacy of BCG retreatment are urgently needed. In this Phase I dose-escalation trial of intravesical chemoimmunotherapy with gemcitabine and BCG (GemBCG) in patients with BCG-exposed high-grade NMIBC (NCT04179162), Biweekly intravesical gemcitabine was given weeks 1, 4, 7, and 10 (8 doses total escalated from 500-2000 mg via a modified continual reassessment method) and weekly intravesical BCG (50 mg TICE) during weeks 2, 3, 5, 6, 8, and 9 (6 doses total). The primary objective was to define the maximally tolerated dose. Adverse events were assessed using CTCAE v5.0. The key secondary outcome was complete clinical response at 6-months. Analyses of tumor, urine, and blood samples were exploratory. 25 patients enrolled (median age 68 [IQR 64-75]) of whom 17 (68%) had CIS ± papillary disease. No treatment-related grade ≥3 AEs or dose-limiting toxicities occurred; 72% reported grade 1 and 20% reported grade 2 AEs. 24 of 25 patients (96%; 95%CI 80%-100%) achieved a complete clinical response at 6-months. T-cell recruitment chemokines (CXCL9, CXCL10, and CXCL11) increased and the immunosuppressive cytokine IL-6 decreased in the urine with treatment. GemBCG was safe, well-tolerated, and demonstrated promising early efficacy and modification of the tumor microenvironment. Based on these data, a randomized phase III trial is testing GemBCG vs. retreatment with BCG alone for BCG exposed high-grade NMIBC (Alliance A032303/NCT07000084).", "journal": "Journal of Urology", "pub_date": "2026-Oct-01", "publication_types": ["Journal Article"], "doi": "10.1097/JU.0000000000005324", "authors": ["Christopher D Gaffney", "Syed Muneeb Alam", "Gal Wald", "Daniel Sjoberg", "Jordan Eichholz", "Judy Sarungbam", "Neeta D'Souza", "Jessica Lavery", "Christian Hernandez", "Morgan Tomerlein", "Patricia Zagajeski", "Kara Worth Hildreth", "Sherri Donat", "Robert Smith", "Timothy Donahue", "Alvin Goh", "Bernard Bochner", "Hikmat Al-Ahmadie", "Eugene Pietzak"], "affiliations": ["Department of Surgery, Urologic Oncology Service, Memorial Sloan Kettering Cancer Center (MSK).", "Department of Epidemiology & Biostatistics, MSK.", "Department of Pathology and Laboratory Medicine, MSK.", "Research and Technology Management, MSK.", "Clinical Trials Nursing, MSK."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=18", "score": 37.01, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 11.01, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 12.0}, "journal_metrics": {"status": "ok", "impact_factor": 6.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 3.01, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42821259", "title": "Medical Debt and Advanced Cancer Stage at Diagnosis.", "abstract": "Medical debt affects millions of US residents and has been associated with higher cancer mortality. Whether medical debt burden is associated with incidence of advanced stage cancer, a key determinant of survival, remains unclear. To examine the association between medical debt and cancer incidence in the US. This cross-sectional study used ecological county-level data linking 2016 medical debt with age-adjusted incidence rates of 9 cancers from January 1, 2017, to December 31, 2021. The study included 2958 US counties with available data on medical debt in collections and cancer incidence rates. Population-based data were obtained and analyzed from January 11, 2025, to February 15, 2026. Percentage of residents with any medical debt in collections in 2016. Age-adjusted all-stage and late-stage (regional or distant) cancer incidence rates per 100 000 person-years from 2017 to 2021. Multivariable models adjusted for urban-rural status, Social Vulnerability Index (SVI), primary care physician density, and states were used to estimate differences in age-adjusted incidence rates of cancer associated with county-level medical debt burden. Among the 2958 US counties included in the analysis, 1154 (39.0%) were urban and 1804 (61.0%) were rural. The mean (SD) prevalence of medical debt in collections was 21.1% (9.6%), with a mean (SD) primary care physician density of 0.54 (0.35) physicians per 1000 population. The prevalence of medical debt ranged from 1.2% to 51.8%. The mean (SD) medical debt prevalence was higher in rural than urban counties (21.5% [10.0%] vs 20.5% [8.9%]; P = .007) and in counties in the highest vs lowest SVI quartile (27.4% [9.0%] vs 13.9% [6.9%]; P < .001). After adjustment, each 10percentage point increase in county-level medical debt was associated with a higher incidence of late-stage lung cancer (5.15 [95% CI, 4.62-5.68] additional cases per 100 000 person-years), colorectal cancer (0.69 [95% CI, 0.44-0.94] additional cases per 100 000 person-years), cervical cancer (0.39 [95% CI, 0.23-0.55] additional cases per 100 000 person-years), melanoma (0.59 [95% CI, 0.48-0.70] additional cases per 100 000 person-years), kidney and renal pelvis cancer (0.38 [95% CI, 0.27-0.49] additional cases per 100 000 person-years), bladder cancer (0.24 [95% CI, 0.16-0.32] additional cases per 100 000 person-years), and head and neck cancer (0.92 [95% CI, 0.77-1.07] additional cases per 100 000 person-years). Similar patterns were observed for overall cancer incidence. In this cross-sectional study of US counties, higher medical debt burden was associated with higher incidence rates of late-stage and overall cancer across multiple cancer types. These findings suggest that medical debt may reflect structural and financial barriers associated with cancer diagnosis and outcomes at the population level.", "journal": "JAMA Network Open", "pub_date": "2026-Oct-01", "publication_types": ["Journal Article"], "doi": "10.1093/haschl/qxaf159", "authors": ["Jiazhang Xing", "Xuesong Han", "Xin Hu", "Lingbin Meng", "Lang Qu", "Ryan D Nipp", "K Robin Yabroff", "Changchuan Jiang"], "affiliations": ["Department of Medicine, Sinai Hospital of Baltimore, Baltimore, Maryland.", "Department of Surveillance, Prevention and Health Services Research, American Cancer Society, Atlanta, Georgia.", "Department of Radiation Oncology, Emory University School of Medicine, Atlanta, Georgia.", "Department of Medical Oncology, The Ohio State University Wexner Medical Center, Columbus.", "Department of Internal Medicine, Section of Hematology/Oncology, University of Oklahoma Health and Stephenson Cancer Center, Oklahoma City.", "Division of Hematology and Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 21.48, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 15.48, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 9.7, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.48, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42821197", "title": "Remote robotic urological surgery with the Toumai® System across 25-7,000 km: a systematic review and single-arm meta-analysis of technical success and reported safety.", "abstract": "To summarize the early clinical experience with the Toumai® robotic system in remote urological surgery and to descriptively synthesize technical success, perioperative outcomes, and network performance, while accounting for the limited and heterogeneous evidence base. PubMed, Embase, the Cochrane Library, and Web of Science were systematically searched from inception to July 1, 2026, for single-arm case series of Toumai®-assisted remote urological procedures. Two reviewers independently screened records and extracted data. Because of the small number of studies and substantial clinical and methodological heterogeneity, only technical success and Clavien-Dindo grade ≥ III complications were pooled using a random-effects model with Freeman-Tukey double arcsine transformation; all other outcomes were summarized descriptively. Heterogeneity was assessed with the I² statistic. Methodological quality was appraised with the Joanna Briggs Institute checklist for case series. The protocol was registered with PROSPERO (CRD420261472912). Six single-arm case series (95 patients; 10-37 per study) were included. Technical success was achieved in all 95 procedures (95/95, 100%), but this estimate may be influenced by possible selective publication or reporting and indication bias. No Clavien-Dindo grade ≥ III complications were reported among the 85 evaluable urological cases; complication data were not separately available for the urological subgroup in one study. Descriptive pooled estimates were 144.83 min (95% CI 109.11-180.56; I² = 93.4%) for operative time, 50.95 mL (95% CI 33.62-68.27; I² = 79.9%) for estimated blood loss, 4.57 days (95% CI 1.82-7.32; I² = 98.3%) for postoperative hospital stay, and 72.82 ms (95% CI 40.13-105.51; I² = 96.8%) for mean latency; these values should not be regarded as procedure-specific or broadly generalizable benchmarks. Console time and warm ischemia time were reported inconsistently and were therefore not pooled. Latency was reported as one-way signal delay in one study and round-trip latency in others; because these parameters are not directly comparable, they were not pooled. Master-slave distance ranged from 25 to 7,000 km, with a general tendency toward increased latency at longer distances. Dual-network redundancy and automatic failover were commonly used and managed reported network events without documented patient harm; however, causality cannot be established, and safety cannot be guaranteed. Mean latency remained within the range associated with acceptable performance in the reported literature, including on the 7,000 km transcontinental route. All procedures were performed by experienced robotic surgeons, limiting generalizability to trainees or less experienced operators. The available evidence suggests that Toumai®-assisted remote urological surgery is technically feasible and associated with preliminary short-term perioperative safety. However, the overall certainty of evidence is low because of the small number of single-arm case series, heterogeneous procedures and network conditions, incomplete subgroup reporting, possible selective publication or reporting, and substantial heterogeneity. Prospective, multicenter studies with standardized definitions of latency, network performance, complications, conversion, and longer-term oncological and functional outcomes are required.", "journal": "Journal of Robotic Surgery", "pub_date": "2026-Oct-01", "publication_types": ["Journal Article", "Systematic Review", "Meta-Analysis"], "doi": "10.1007/s11701-026-04016-x", "authors": ["Song Cao", "Yun Li", "Jiao Qin", "Hao-Tian Huang", "Hong-Yuan Li", "Run-Xue Guan", "Qian-Long Li", "Xiao-Yu Zhou", "Jing-Yun Yin", "Shu-Kai Zhang", "Jia-Li Wang", "Xun-Tao Yao", "Xue-Song Yang"], "affiliations": ["Department of Urology, Affiliated Hospital of North Sichuan Medical College, Nanchong, China.", "Health Management Center, Affiliated Hospital of North Sichuan Medical College, Nanchong, China.", "Department of anesthesiology, Affiliated Hospital of North Sichuan Medical College, Nanchong, China.", "Department of Burn and Plastic Surgery, Affiliated Hospital of Zunyi Medical University, Zunyi, China.", "Department of Urology, Affiliated Hospital of North Sichuan Medical College, Nanchong, China. Xuesongyang2022@163.com."], "corresponding_authors": ["Xue-Song Yang"], "china_team": "Department of Urology, Affiliated Hospital of North Sichuan Medical College, Nanchong, China Xue-Song Yang团队", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 27.03, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 6.03, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 7.0}, "journal_metrics": {"status": "ok", "impact_factor": 3.0, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 2.03, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42821140", "title": "Development and external validation of an explainable machine-learning model for early complications following robot-assisted radical prostatectomy: a multicenter study.", "abstract": "Complications occurring early after robot-assisted radical prostatectomy (RARP) can hinder postoperative recovery. Existing risk instruments, however, generally incorporate few predictors and assume linear associations. We aimed to derive and externally validate an interpretable machine-learning model that combines clinical, laboratory, and intraoperative information and to translate the model into an online risk calculator. Records were reviewed for 1,254 patients with prostate cancer (PCa) who received RARP at the First, Third, or Fifth Medical Center of the Chinese PLA General Hospital. Among them, 1,001 patients from the First and Fifth centers were randomly allocated 7:3 to training (n = 701) and internal testing (n = 300), while 253 patients from the Third center provided an independent external cohort. Sixty-four candidate variables underwent univariate screening and least absolute shrinkage and selection operator regression. The tested algorithms were gradient boosting decision trees (GBDT), random forest, logistic regression, support vector machine, AdaBoost, Gaussian naive Bayes, and multilayer perceptron. We examined discrimination with the area under the receiver operating characteristic curve (AUC), agreement between predicted and observed risk with calibration plots, and clinical usefulness with decision curve analysis (DCA). SHapley Additive exPlanations (SHAP) were used to interpret predictions. The leading model was also benchmarked against the Comorbidity Score for Robotic Surgery (CRS). Feature selection yielded eight predictors for model training. For the multilayer perceptron (MLP), the AUC was 0.880 on internal testing and 0.843 in the independent external cohort. Across both evaluations, this algorithm offered the most balanced combination of performance measures, good calibration, and favorable clinical net benefit. SHAP ranked crystalloid infusion as the leading predictor; operative time and thrombin time (TT) ranked next. In an exploratory comparison in the external cohort, MLP showed greater potential than CRS in discrimination, calibration, and net benefit. We visualized the final model and deployed it as a web-based calculator. The interpretable MLP model accurately estimated the likelihood of early postoperative complications among patients with PCa undergoing RARP. Its accompanying online calculator may assist clinicians in recognizing high-risk patients as soon as surgery is completed and may inform individualized risk classification, postoperative monitoring, and clinical care.", "journal": "Journal of Robotic Surgery", "pub_date": "2026-Oct-01", "publication_types": ["Journal Article", "Multicenter Study", "Validation Study"], "doi": "10.1007/s11701-026-04009-w", "authors": ["Qi Cai", "Kaipeng Bi", "Zheng Wang", "Ziyan An", "Zhoujie Ye", "Xinyu Zhang", "Jie Zhu", "Baojun Wang", "Hongzhao Li", "Xin Ma", "Weijun Fu"], "affiliations": ["School of Medicine, Nankai University, Tianjin, 300071, China.", "Senior Department of Urology, Chinese PLA General Hospital, Beijing, 100039, China.", "Chinese PLA Medical School, Beijing, 100853, China.", "Department of Urology, Beijing Shijitan Hospital, Capital Medical University, Beijing, 100038, China.", "Senior Department of Urology, Chinese PLA General Hospital, Beijing, 100039, China. fuweijun@hotmail.com."], "corresponding_authors": ["Weijun Fu"], "china_team": "School of Medicine, Nankai University, Tianjin, 300071, China Weijun Fu团队", "category": "clinical_review", "classification_reason": "publication_type_clinical", "score": 28.03, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 6.03, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 7.0}, "journal_metrics": {"status": "ok", "impact_factor": 3.0, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 2.03, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42820819", "title": "Mosaic Loss of the Y Chromosome: Mechanisms and Diseases.", "abstract": "Mosaic loss of the Y chromosome (mLOY) is a male‑specific somatic loss of the Y chromosome that is predominantly observed in peripheral blood leukocytes, but can also be found in other tissue types. It represents one of the most common male-specific somatic mutations, particularly prevalent in aging individuals. Accumulating evidence shows that mLOY markedly increases the incidence, progression, and adverse prognosis of multiple diseases, including, but not limited to, myocardial fibrosis, lung and bladder cancers, and Alzheimer's disease. Mechanistically, for extrinsic effects of mLOY, hematopoietic mLOY affect other cell populations, thereby promoting disease initiation and progression. From an intrinsic effects, mLOY within cells reprograms autosomal gene expression and reshapes interactions with the immune microenvironment, jointly driving malignant evolution. In this review, we summarize the current understanding of both intrinsic and extrinsic mLOY effects on immune regulation and disease pathogenesis, highlighting its multifaceted roles across cancer, cardiovascular disorders, infections, and other mLOY-associated conditions.", "journal": "Protein & Cell", "pub_date": "2026-Oct-01", "publication_types": ["Journal Article"], "doi": "10.1093/procel/pwag073", "authors": ["Qi Zhang", "Jiang Yu", "Xiaoqian Zhai", "Luocheng Zhang", "Junhui Peng", "Cheng Deng", "Yu Liu", "Qinghua Zhou", "Ting Niu", "Fengming Luo", "Chong Chen"], "affiliations": ["Department of High Altitude Medicine, Center for High Altitude Medicine, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu 610041, China.", "Institute of High Altitude Medicine, High Altitude Medicine Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu 610041, China.", "State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China.", "Department of Hematology, Institute of Hematology, West China Hospital, Sichuan University, Chengdu 610041, China.", "National Facility for Translational Medicine (Sichuan), West China Hospital, Sichuan University, Chengdu 610041, China.", "Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China.", "Lung Cancer Center/Lung Cancer Institute, West China Hospital, Sichuan University, Chengdu 610041, China.", "National Center for Nanoscience and Technology of China, Beijing 100190, China.", "Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu 610041, China."], "corresponding_authors": [], "china_team": "Department of High Altitude Medicine, Center for High Altitude Medicine, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu 610041, China Chong Chen团队", "category": "basic", "classification_reason": "basic_signals=7", "score": 28.85, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 15.85, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 7.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 12.8, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.85, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "Y染色体嵌合缺失驱动多种疾病", "chinese_summary": "四川大学华西医院陈冲团队10月Protein Cell综述指出，男性随年龄增长出现血细胞Y染色体嵌合缺失（mLOY），为最常见男性体细胞突变之一。其既可通过造血细胞影响其他细胞群，也可在细胞内重编程常染色体表达、重塑免疫微环境，从而增加心肌纤维化、肺癌、膀胱癌及阿尔茨海默病等的发生、进展与不良预后风险。", "abstract_zh": "Y染色体嵌合缺失（mLOY）是一种男性特有的Y染色体体细胞丢失，主要见于外周血白细胞，但也可见于其他组织类型。它是最常见的男性特异性体细胞突变之一，尤其在衰老个体中普遍存在。越来越多的证据表明，mLOY显著增加多种疾病的发生率、进展和不良预后，包括但不限于心肌纤维化、肺癌和膀胱癌以及阿尔茨海默病。在机制上，就mLOY的外在效应而言，造血系统的mLOY影响其他细胞群体，从而促进疾病的发生和进展。就内在效应而言，细胞内的mLOY重编程常染色体基因表达并重塑与免疫微环境的相互作用，共同驱动恶性演化。在这篇综述中，我们总结了目前关于mLOY内在和外在效应对免疫调节及疾病发病机制影响的认识，强调其在癌症、心血管疾病、感染及其他mLOY相关病症中的多方面作用。"}, {"pmid": "42820647", "title": "The PSA test for prostate cancer screening: an abridged Cochrane review.", "abstract": "To assess the effects of prostate cancer screening compared to no screening in men with no prior diagnosis of prostate cancer. This systematic review represents an update of a prior Cochrane review from 2013, searching multiple databases up to November 2025. We included randomised controlled trials (RCTs) of prostate cancer screening vs no screening. We used standard Cochrane methods, including rating the certainty of the evidence following a Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) approach. Six RCTs (789 086 participants; follow-up 3.2-23 years) were included: five evaluated prostate-specific antigen (PSA)-alone screening; one evaluated PSA combined with a kallikrein panel and magnetic resonance imaging (MRI) (ProScreen). Results are based on the certainty of evidence for each outcome and are therefore mainly derived from a sensitivity analysis by risk of bias, using the European Randomised Study of Screening for Prostate Cancer (ERSPC) trial: screening likely results in a reduction in prostate cancer-specific mortality (sensitivity analysis from ERSPC: risk ratio [RR] 0.87, 95% confidence interval [CI] 0.80-0.95; one study, 162 236 participants; moderate-certainty evidence; minimal clinically important difference [MCID]: one per 1000 participants). Assuming a baseline risk of 16 prostate-cancer-related deaths per 1000, this corresponds to two fewer (95% CI three fewer to one fewer) per 1000. Based on the analysis that included all eligible trials, screening may reduce overall mortality, although the CI includes the possibility of little to no effect (RR 0.99, 95% CI 0.97-1.00; I2 = 22%; four studies, 675 121 participants; low-certainty evidence; MCID: one per 1000 participants). Assuming a baseline risk of 491 deaths from any cause per 1000, this corresponds to five fewer (95% CI 15 fewer to 0 fewer) per 1000. Screening may result in little to no difference in adverse events (RR 1.32, 95% CI 0.48-3.65; low certainty) or quality of life. In the ProScreen trial (60 745 participants, 3.2-year follow-up), combined screening probably has little to no effect on overall detection (RR 1.85, 95% CI 1.56-2.19; moderate certainty), localised detection (RR 1.88, 95% CI 1.55-2.27; moderate certainty), or advanced detection (RR 1.78, 95% CI 1.19-2.66; moderate certainty). Mortality data are not yet mature. Screening likely reduces prostate cancer-specific mortality and may reduce overall mortality. It may have little to no effect on adverse events (as measured by intervention-related mortality). Study limitations, inconsistency, and imprecision reduced our confidence in the effect estimates. Interpretation of these findings is highly sensitive to the choice of MCID. Emerging alternatives, such as screening with a kallikrein panel and MRI, may have little to no effect on diagnoses of prostate cancer, but the results on mortality are not yet known.", "journal": "BJU International", "pub_date": "2026-Oct-01", "publication_types": ["Journal Article", "Review"], "doi": "10.1111/bju.70455", "authors": ["Juan V A Franco", "Eu Chang Hwang", "Jae Hung Jung", "Octavio Vaimberg", "Dragan Ilic", "Anne Cleves", "Philipp Dahm"], "affiliations": ["Cochrane Evidence Synthesis Unit Germany/UK - Düsseldorf Subunit, Centre for Health and Society, Institute of General Practice, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.", "Department of Urology, Chonnam National University Medical School, Chonnam National University Hwasun Hospital, Hwasun, South Korea.", "Department of Urology, Yonsei University Wonju College of Medicine, Wonju, South Korea.", "Center of Evidence-Based Medicine, Institute of Convergence Science, Yonsei University, Seoul, South Korea.", "School of Medicine, Universidad del Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.", "Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.", "Velindre NHS Trust, Library Services, Cardiff University, Cardiff, UK.", "Urology Section, Minneapolis VA Health Care System, Minneapolis, MN, USA.", "Department of Urology, University of Minnesota, Minneapolis, MN, USA."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 27.47, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.47, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 3.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.4, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.47, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42820299", "title": "Expression of Concern for EGFR- and HER3-targeted bispecific antibody-drug conjugate demonstrates antitumor activity in metastatic castration-resistant prostate cancer.", "abstract": "", "journal": "Journal of Clinical Investigation", "pub_date": "2026-Oct-01", "publication_types": ["Expression of Concern"], "doi": "10.1172/JCI213418", "authors": ["Bangwei Fang", "Xiaomeng Li", "Ying Lu", "Weiwei Ma", "Hualei Gan", "Tingwei Zhang", "Qi Liu", "Beihe Wang", "Zixian Wang", "Yi Zhu", "Hai Zhu", "Sa Xiao", "Xiaojie Bian", "Gonghong Wei", "Dingwei Ye", "Yao Zhu"], "affiliations": [], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 25.93, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 15.93, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 1.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 13.6, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.93, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "EGFR/HER3双抗ADC研究遭关注声明", "chinese_summary": "10月J Clin Invest就转移性去势抵抗性前列腺癌的EGFR/HER3双特异性抗体偶联药物研究发布关注声明，指出该文数据及结论的可靠性存在疑问，提醒读者谨慎对待其抗肿瘤活性报道。", "abstract_zh": "这是对《EGFR-和HER3靶向双特异性抗体-药物偶联物在转移性去势抵抗性前列腺癌中显示抗肿瘤活性》一文发布的关注声明。"}, {"pmid": "42817820", "title": "Three-generation familial risks in early-onset prostate cancer with maternal and paternal relatives.", "abstract": "To study familial prostate cancer (PCa) between first-degree relatives (FDRs) and second-degree relatives (SDRs), we accessed Swedish nationwide family and cancer data that extended through three generations and thus providing a unique chance for study of familial cancer in PCa between close and distant relatives (SDRs). The specific aim was to show the usefulness of data on maternal and paternal uncles and grandfathers for risk assessment on young patients with PCa. Familial relative risks (standardised incidence ratios [SIRs]) for PCa were calculated for young men (aged <69 years) in the third generation when their brothers, fathers, uncles and grandparents were diagnosed with PCa (they were probands). Familial SIRs for two affected brothers were 4.1 but when, additionally a SDR (uncle or grandfather) was affected SIR reached 10.1. When a father was the proband, SIR was 3.1 but when, additionally a SDR was affected SIR reached 4.7, and risk increased up to 11.5 with increasing numbers of affected SDRs. Patients with affected SDRs were more numerous than those with affected FDRs. When a maternal or paternal grandfather was the only proband the SIR for both was about 1.6. Maternal and paternal uncles transmitted a risk of 1.8 and 1.5, respectively, and when two uncles were affected, the SIR climbed to about 2.0. The highest familial risk of 27 was found for affected brothers with a father and two SDRs diagnosed with PCa. The results showed that for the young patients in the third generation the richest sources of familial probands were SDRs. The uncles belong to the generation of fathers, and they are likely to be more numerous than grandparents. Maternal and paternal SDRs are equally informative for genetic counselling and both parental lineages should be used as they provide equal familial information about the risks of PCa.", "journal": "BJU International", "pub_date": "2026-Oct-01", "publication_types": ["Journal Article"], "doi": "10.1111/bju.70465", "authors": ["Kari Hemminki", "Frantisek Zitricky", "Kristina Sundquist", "Jan Sundquist", "Asta Försti", "Akseli Hemminki", "Otto Hemminki"], "affiliations": ["Biomedical Center, Faculty of Medicine, Charles University, Pilsen, Czech Republic.", "Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.", "Center for Primary Health Care Research, Lund University, Malmö, Sweden.", "University Clinic Primary Care Skåne, Region Skåne, Sweden.", "Department of Family and Community Medicine, McGovern Medical School, The University of Texas Health Science Center, Houston, TX, USA.", "Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany.", "Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany.", "Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland.", "Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.", "Department of Urology, Helsinki University Hospital, Helsinki, Finland."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 26.47, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.47, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 1.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.4, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.47, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "远亲前列腺癌史显著升高早发风险", "chinese_summary": "瑞典10月BJU Int基于全国三代家族癌症数据发现，兄弟患病时早发前列腺癌标化发病比为4.1，若合并叔伯或祖父患病则升至10.1；父系与母系远亲提供同等遗传咨询价值。", "abstract_zh": "为了研究一级亲属（FDRs）和二级亲属（SDRs）之间的家族性前列腺癌（PCa），我们获取了瑞典全国性的家族和癌症数据，这些数据跨越三代，从而为研究PCa中近亲和远亲（SDRs）之间的家族性癌症提供了独特机会。具体目的是展示母系和父系叔伯及祖父数据对年轻PCa患者风险评估的有用性。我们计算了第三代年轻男性（年龄<69岁）在其兄弟、父亲、叔伯和祖父母被诊断患有PCa（他们为先证者）时的家族性相对风险（标化发病比[SIRs]）。当两个兄弟患病时，家族性SIR为4.1，但当额外有一个SDR（叔伯或祖父）患病时，SIR达到10.1。当父亲为先证者时，SIR为3.1，但当额外有一个SDR患病时，SIR达到4.7，并且随着患病SDR数量增加，风险升高至11.5。SDR患病的患者数量多于FDR患病的患者。当母系或父系祖父是唯一先证者时，两者的SIR均约为1.6。母系和父系叔伯分别传递的风险为1.8和1.5，当两个叔伯患病时，SIR攀升至约2.0。最高的家族性风险为27，见于兄弟患病且父亲和两个SDR被诊断患有PCa的情况。结果表明，对于第三代年轻患者，最丰富的家族性先证者来源是SDRs。叔伯属于父亲那一代，他们可能比祖父母数量更多。母系和父系SDRs对遗传咨询提供同等信息，并且应使用双方父母谱系，因为它们提供关于PCa风险的同等家族信息。"}, {"pmid": "42817743", "title": "Towards sustainable multidisciplinary renal cancer tumour boards: redesigning the referral pathway.", "abstract": "To develop and evaluate a complexity-stratified referral pathway aimed at improving the sustainability, efficiency and resource utilisation of specialist multidisciplinary team (SMDT) meetings within a high-volume tertiary renal cancer service. We performed a retrospective cohort study of benign and malignant renal cancer cases discussed at SMDT meetings between January and December 2023 at the Royal Free Specialist Centre for Kidney Cancer. Patient demographics, tumour characteristics, SMDT discussions and management outcomes of patients were analysed to identify protocolised lower complexity cases suitable for alternative MDT pathways. Based on these findings, dedicated Standard of Care (SoC) and Benign MDTs were developed and implemented to manage lower complexity renal cases outside the main SMDT. The impact of the revised referral structure on SMDT workload, discussion efficiency and specialist resource utilisation was subsequently evaluated. In 2023, 2228 patients with benign and malignant renal pathology underwent 4154 SMDT discussions. Most patients (96.3%) required under seven discussions. Patients aged >70 years with renal masses <2 cm frequently underwent repeated SMDT review, despite surveillance or conservative management representing the most common management recommendation. Bosniak I-II cysts were predominantly discharged, whilst Bosniak IIF cysts were mainly managed with surveillance. Following implementation of the revised referral structure incorporating SoC and Benign MDTs, cases discussed at the main SMDT decreased from a mean of 83 to 63 patients with cancer per week, whilst discussion time per patient increased by 30.8%. The revised pathway also reduced the requirement for full SMDT attendance for protocolised cases. Complexity-stratified MDT referral structure improved efficiency and sustainability by diverting lower complexity protocolised cases to dedicated Benign and SoC MDTs. This enabled the main SMDT to prioritise clinically complex decision making and optimise utilisation of specialist multidisciplinary expertise.", "journal": "BJU International", "pub_date": "2026-Oct-01", "publication_types": ["Journal Article"], "doi": "10.1111/bju.70451", "authors": ["Bhargab Ghoshal", "Sarika Nalagatla", "Max Roberts", "Adam Mann", "David Cullen", "Victoria Horsfall", "Andrea Da Silva", "Abhishek Reekhaye", "Prasad Patki", "Ravi Barod", "Faiz Mumtaz", "Axel Bex"], "affiliations": ["University College London Medical School, London, UK.", "Department of Urology, The Royal Free London NHS Foundation Trust, London, UK.", "Division of Surgery and Interventional Science, University College London, London, UK."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=6", "score": 22.47, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 10.47, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 6.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.4, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.47, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42817733", "title": "Response to Letter to the Editor on \"Unveiling 'Idiopathic' Nocturia: The Central Role of Sleep-Induced Hypogonadism and ANP-Mediated Hemodynamics\".", "abstract": "We respond to the comments of Lin et al. on our Think Tank review of potential therapeutic avenues for idiopathic nocturia. Evidence was synthesized from relevant literature on OSA-associated nocturia, testosterone decline with sleep-induced hypogonadism, and natriuresis-mediated impairment of aquaporin (AQP)-dependent water reabsorption. We first clarify that our review was confined to idiopathic nocturia. We also note that \"occult OSA\" should more accurately be termed undiagnosed OSA, and that the associated nocturia should be classified as secondary rather than idiopathic. Nonetheless, we acknowledge the value of the proposed sleep-induced hypogonadism hypothesis, while emphasizing that the causal link between OSA-related testosterone decline and nocturia remains unestablished and that available evidence is currently male-specific. We further recognize that natriuresis attributed to atrial natriuretic peptide may impair aquaporin-mediated water reabsorption; however, existing evidence pertains mainly to renal tubular aquaporins, whereas our review focused on bladder urothelial aquaporins and transvesical water reabsorption, a largely unexplored extrarenal mechanism. We are grateful to Lin et al. for their letter, which raises additional mechanisms as critical drivers of nocturia. We believe that cross-disciplinary research into OSA-associated secondary nocturia is warranted to translate these mechanistic insights into clinical benefit.", "journal": "Neurourology and Urodynamics", "pub_date": "2026-Oct-01", "publication_types": ["Letter"], "doi": "10.1002/nau.70465", "authors": ["Qi-Xiang Song", "Sanjay Sinha", "Bahareh Vahabi", "Anthony Kanai", "Christopher Fry", "Pradeep Tyagi", "Stefania Musco", "Dudley Robinson", "Marcus J Drake", "Paul Abrams", "Alan Wein", "Christopher R Chapple"], "affiliations": ["Department of Urology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.", "Department of Urology, Apollo Hospitals, Hyderabad, India.", "School of Applied Sciences, University of the West of England, Bristol, UK.", "Department of Medicine, Renal-Electrolyte Division, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.", "School of Physiology, Pharmacology & Neuroscience, University of Bristol, Bristol, UK.", "Department of Urology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.", "Neuro-Urology, Azienda Ospedialiero-Universitaria Careggi, Firenze, Italy.", "Department of Urogynaecology, King's College Hospital, London, UK.", "Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, UK.", "Bristol Urological Institute, Southmead Hospital, Bristol, UK.", "Desai Sethi Institute of Urology, Miller School of Medicine, University of Miami, Miami, Florida, USA.", "Department of Urology, Sheffield Teaching Hospitals NHS Foundation Trust, Royal Hallamshire Hospital, Sheffield, UK."], "corresponding_authors": [], "china_team": "Department of Urology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China Qi-Xiang Song团队", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 19.56, "score_parts": {"urology_relevance": 8, "urology_in_title": 0.0, "journal_priority": 5.56, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 3.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 1.9, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.56, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42814941", "title": "Adjuvant Pembrolizumab plus Belzutifan for Renal-Cell Carcinoma. Reply.", "abstract": "", "journal": "New England Journal of Medicine", "pub_date": "2026-Oct-01", "publication_types": ["Letter", "Comment"], "doi": "10.1056/NEJMc2609920", "authors": ["Toni K Choueiri", "Thomas B Powles"], "affiliations": ["Dana-Farber Cancer Institute, Boston.", "Queen Mary University of London, London."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 15.42, "score_parts": {"urology_relevance": 0, "urology_in_title": 0.0, "journal_priority": 18.42, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 78.5, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 6.42, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42814940", "title": "Adjuvant Pembrolizumab plus Belzutifan for Renal-Cell Carcinoma.", "abstract": "", "journal": "New England Journal of Medicine", "pub_date": "2026-Oct-01", "publication_types": ["Letter", "Comment"], "doi": "10.1056/NEJMc2609920", "authors": ["Xiaojuan Wu"], "affiliations": ["Ganzhou People's Hospital, Ganzhou, China."], "corresponding_authors": [], "china_team": "Ganzhou People's Hospital, Ganzhou, China Xiaojuan Wu团队", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 15.42, "score_parts": {"urology_relevance": 0, "urology_in_title": 0.0, "journal_priority": 18.42, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 78.5, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 6.42, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42807169", "title": "Corrigendum to \"Triamcinolone acetonide nanoparticles ameliorate interstitial cystitis and anxiety/depression by targeting the bladder-metabolic-brain axis\" [Mater. Today Bio 38 (2026) 103112].", "abstract": "[This corrects the article DOI: 10.1016/j.mtbio.2026.103112.].", "journal": "Materials Today Bio", "pub_date": "2026-Oct", "publication_types": ["Published Erratum"], "doi": "10.1016/j.mtbio.2026.103536", "authors": ["Zhicheng Liu", "Qian Ju", "Yuanyuan Yang", "Qudong Lu", "Rong Huang", "Jing Yang", "Ying Bao", "Tao Jiang", "Yiji Peng", "Yuting Liu", "Dinglin Zhang", "Wenhao Shen"], "affiliations": ["Department of Urology, Southwest Hospital, Army Medical University (Third Military Medical University), Chongqing, 400038, China.", "Department of Chemistry, College of Basic Medicine, Army Medical University (Third Military Medical University), Chongqing, 400038, China."], "corresponding_authors": [], "china_team": "Department of Urology, Southwest Hospital, Army Medical University (Third Military Medical University), Chongqing, 400038, China Wenhao Shen团队", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 28.04, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 15.54, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 0.5, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 10.2, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.54, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "膀胱代谢脑轴研究更正声明发布", "chinese_summary": "陆军军医大学西南医院沈文浩团队10月Mater Today Bio发布更正声明，针对其已发表的曲安奈德纳米粒靶向膀胱-代谢-脑轴改善间质性膀胱炎及焦虑抑郁的研究进行勘误。更正原文DOI为10.1016/j.mtbio.2026.103112，读者应以此版本为准。", "abstract_zh": "本更正针对文章DOI: 10.1016/j.mtbio.2026.103112。"}, {"pmid": "42805210", "title": "Cancer and the microbiome: from association to intervention.", "abstract": "The gut microbiome is increasingly recognised as a clinically modifiable determinant of efficacy and toxicity across systemic cancer therapies, with the most mature evidence in patients receiving immune checkpoint inhibitors (ICIs). The composition and function of intestinal microbes can influence treatment outcomes by affecting immune priming, antigen presentation, host-microbial co-metabolism, drug biotransformation, and epithelial barrier integrity. In melanoma, non-small-cell lung cancer, and renal cell carcinoma, higher microbial diversity, ecological stability, and enrichment of immunostimulatory pathways have been associated with improved ICI response and survival. By contrast, antibiotics and proton pump inhibitors are linked to inferior outcomes because they disrupt the microbiome. Microbiome-directed interventions, including faecal microbiota transplantation, dietary modifications, prebiotics, probiotics, and live biotherapeutic products, are undergoing clinical testing but remain at the investigational stage. This Review synthesises current evidence linking the intestinal microbiome to anticancer therapy outcomes, evaluates strategies and challenges for therapeutic modulation of the microbiome, and introduces emerging insights into the mycobiome.", "journal": "Lancet Oncology", "pub_date": "2026-Oct", "publication_types": ["Journal Article", "Review"], "doi": "10.1016/S1470-2045(26)00326-8", "authors": ["Ali Moradi", "Rahul Winayak", "Sumanta Kumar Pal"], "affiliations": ["City of Hope Comprehensive Cancer Center, Duarte, CA, USA.", "City of Hope Comprehensive Cancer Center, Duarte, CA, USA. Electronic address: spal@coh.org."], "corresponding_authors": ["Sumanta Kumar Pal"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 42.29, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 17.29, "top_journal_bonus": 10.0, "novelty": 0, "gut_microbiome_bonus": 5.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 4.0}, "journal_metrics": {"status": "ok", "impact_factor": 35.9, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 5.29, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "肠道菌群影响抗癌疗效与毒性", "chinese_summary": "10月Lancet Oncol综述指出，肠道菌群正被视为系统性抗癌治疗疗效与毒性的可调控决定因素，免疫检查点抑制剂证据最成熟。菌群可通过免疫致敏、抗原提呈及药物代谢影响结局；黑色素瘤、非小细胞肺癌和肾癌中，菌群多样性高、生态稳定者缓解与生存更优，而抗生素和质子泵抑制剂因破坏菌群与较差结局相关。粪菌移植、饮食干预及活体生物治疗产品尚处研究阶段。", "abstract_zh": "肠道微生物组日益被认为是系统性癌症治疗中疗效与毒性的临床可调控决定因素，其中在接受免疫检查点抑制剂（ICI）治疗的患者中证据最为成熟。肠道微生物的组成和功能可通过影响免疫致敏、抗原提呈、宿主-微生物共代谢、药物生物转化及上皮屏障完整性来影响治疗结局。在黑色素瘤、非小细胞肺癌和肾细胞癌中，更高的微生物多样性、生态稳定性及免疫刺激通路的富集与ICI应答和生存改善相关。相反，抗生素和质子泵抑制剂因破坏微生物组而与较差的结局相关。微生物组导向的干预措施，包括粪菌移植、饮食调整、益生元、益生菌和活体生物治疗产品，正在接受临床测试，但仍处于研究阶段。本综述综合了当前将肠道微生物组与抗癌治疗结局联系起来的证据，评估了微生物组治疗调控的策略与挑战，并介绍了关于真菌组的新兴见解。"}, {"pmid": "42805201", "title": "Re-evaluating aglatimagene in localised prostate cancer - Authors' reply.", "abstract": "", "journal": "Lancet Oncology", "pub_date": "2026-Oct", "publication_types": ["Letter"], "doi": "10.1016/S1470-2045(26)00462-6", "authors": ["Theodore L DeWeese", "John Sylvester", "Glen Gejerman", "Mark G Garzotto", "Paul P Tak", "PrTK03 study team"], "affiliations": ["Departments of Radiation Oncology, Urology, and Oncology, Johns Hopkins School of Medicine, Baltimore, MD, USA.", "Atlantic Urology Clinics, Myrtle Beach, SC, USA.", "New Jersey Urology, Summit Health, Saddlebrook, NJ, USA.", "VA Portland Health Care System/OHSU, Portland, OR, USA.", "Candel Therapeutics, Needham, MA 02494, USA. Electronic address: pptak@candeltx.com."], "corresponding_authors": ["Paul P Tak"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 37.29, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 17.29, "top_journal_bonus": 10.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 1.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 35.9, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 5.29, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "局部前列腺癌免疫治疗再评估", "chinese_summary": "10月Lancet Oncol刊发通讯回复，针对aglatimagene在局限性前列腺癌中的应用争议进行回应。作者重申该免疫疗法在早期前列腺癌中的潜在价值，并强调需进一步优化患者筛选标准与疗效评估体系，以平衡治疗获益与免疫相关风险。", "abstract_zh": "这是针对aglatimagene在局限性前列腺癌中应用重新评估的通讯回复。原文为作者对相关评论的回应，内容涉及对该免疫疗法在早期前列腺癌治疗中角色、患者选择及疗效评估的讨论，强调需进一步研究以明确其临床定位。"}, {"pmid": "42805200", "title": "Re-evaluating aglatimagene in localised prostate cancer.", "abstract": "", "journal": "Lancet Oncology", "pub_date": "2026-Oct", "publication_types": ["Letter"], "doi": "10.1016/S1470-2045(26)00356-6", "authors": ["Thomas Büttner", "Davide Scafa", "Julian P Layer", "Manuel Ritter", "Glen Kristiansen", "Markus Eckstein", "Niklas Klümper"], "affiliations": ["Department of Urology and Pediatric Urology, University Hospital Bonn, Bonn 53121, Germany. Electronic address: thomas.buettner@ukbonn.de.", "Department of Radiation Oncology, University Hospital Bonn, Bonn, Germany.", "Department of Urology and Pediatric Urology, University Hospital Bonn, Bonn 53121, Germany.", "Institute of Pathology, University Hospital Bonn, Bonn, Germany.", "Institute of Pathology, University Hospital Erlangen, Erlangen, Germany."], "corresponding_authors": ["Thomas Büttner"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 37.29, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 17.29, "top_journal_bonus": 10.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 1.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 35.9, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 5.29, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "局部前列腺癌免疫治疗再评估", "chinese_summary": "10月Lancet Oncol发表通讯，对aglatimagene治疗局部前列腺癌的现有证据提出再评估。该疗法此前被视为具有应用前景，但本通讯提示其疗效与安全性证据仍需谨慎解读，局部前列腺癌的免疫治疗定位尚待进一步验证。", "abstract_zh": "局部前列腺癌中aglatimagene的再评估。"}, {"pmid": "42791604", "title": "External validation of the NADIR model for early prostate-specific antigen response prediction in enzalutamide-treated metastatic hormone-sensitive prostate cancer: An analysis of the ARCHES trial.", "abstract": "Early favorable prostate-specific antigen (PSA) response to ≤0.2 ng/mL by 6 months is associated with superior overall survival (OS) in metastatic hormone-sensitive prostate cancer (mHSPC). The nadir androgen receptor pathway inhibitor (ARPI)-derived integrative response (NADIR) model is a multivariable model developed to predict this early favorable PSA response in patients receiving ARPI. The authors report an independent external validation of the locked NADIR model in the ARCHES trial. Of 574 enzalutamide-treated patients, 558 with complete predictors were included. Discrimination, Brier score/index of prediction accuracy (IPA), and calibration were assessed. Predicted probability tertiles were used descriptively for PSA response. Six-month landmark Cox models explored associations with OS. A sensitivity analysis restricted the cohort to <3 months of prior androgen deprivation therapy (ADT). Early favorable PSA response occurred in 359 patients (64%). The area under the receiver operating characteristic curve was 0.80 (95% confidence interval [CI], 0.76-0.83), the Brier score was 0.17, and the IPA was 25%. Recalibration intercept was 0.026 and slope was 0.97. Response rates across decreasing predicted probability tertiles were 92%, 64%, and 37%. In the landmark analysis (n = 547; 177 deaths), each 10-percentage-point increase in predicted probability was associated with lower mortality (hazard ratio, 0.90; 95% CI, 0.85-0.96). In the <3-month prior-ADT subgroup (n = 401), the area under the receiver operating characteristic curve and IPA were 0.78 and 23%, respectively. The NADIR model demonstrates robust and reproducible discrimination, calibration, and prognostic stratification in a distinct ARPI-treated mHSPC cohort, supporting its potential utility for early response risk stratification and trial enrichment pending prospective validation of model-guided treatment adaptation.", "journal": "Cancer", "pub_date": "2026-Oct-01", "publication_types": ["Journal Article", "Validation Study"], "doi": "10.1002/cncr.70615", "authors": ["Soumyajit Roy", "Andrew J Armstrong", "Neeraj Agarwal", "Rana R McKay", "Angela Y Jia", "Samuel Lichtman-Mikol", "Pedro C Barata", "Jorge A Garcia", "Jason R Brown", "Yashasvi Mumgandi", "Spyridon P Basourakos", "Iris Y Sheng", "Amar U Kishan", "Nicholas G Zaorsky", "Jonathan E Shoag", "Scott C Morgan", "Christopher J D Wallis", "Yilun Sun", "Eric J Small", "Fred Saad", "Neal D Shore", "Daniel E Spratt"], "affiliations": ["Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio, USA.", "Duke University Medical Center, Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, North Carolina, USA.", "Huntsman Cancer Institute (NCI-CCC), University of Utah, Salt Lake City, Utah, USA.", "UC San Diego Moores Cancer Center, La Jolla, California, USA.", "Division of Solid Tumor Oncology, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio, USA.", "Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.", "Department of Urology, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, Ohio, USA.", "Department of Radiation Oncology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.", "Radiation Medicine Program, The Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, Ontario, Canada.", "Division of Urology and Surgical Oncology, Department of Surgery, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada.", "Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.", "University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California, USA.", "Centre Hospitalier de l'Université de Montréal, University of Montreal, Montreal, Quebec, Canada.", "Carolina Urologic Research Center and Atlantic Urology Clinics, Myrtle Beach, South Carolina, USA."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=8", "score": 36.65, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 14.65, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 8.0}, "journal_metrics": {"status": "ok", "impact_factor": 5.1, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 2.65, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42779347", "title": "Progression-free survival and objective response rate as a surrogate end point for overall survival in metastatic renal cell carcinoma: A systematic review and meta-analysis.", "abstract": "The objective of this systematic review and meta-analysis was to evaluate the validity of progression-free survival (PFS) and the objective response rate (ORR) as surrogate end points for overall survival (OS) in randomized controlled trials (RCTs) of metastatic renal cell carcinoma. The MEDLINE, Embase, and Cochrane CENTRAL databases were searched from inception to June 10, 2025. Associations between treatment effects on OS, PFS, and ORR were assessed using Pearson correlation coefficients (r). Surrogate threshold effect (STE) analyses determined the minimum PFS hazard ratio (HR) or ORR odds ratio (OR) required to predict OS benefit. Subgroup analyses were conducted by treatment class, line of therapy, and histology. Sixty-two randomized controlled trials comprising 24,518 patients were included. PFS-OS demonstrated a moderate correlation (r = 0.52; 95% confidence interval [CI], 0.38-0.66), with an STE (HR, 0.92; 95% CI, 0.79-1.09). ORR-OS demonstrated a moderate correlation (r = -0.59; 95% CI, -0.72, -0.45), with an STE (OR, 1.40; 95% CI, 0.99-1.89). Subgroup estimates varied across treatment settings and were frequently imprecise, particularly for ORR and in smaller treatment-class subgroups; limited representation of non-clear cell renal cell carcinoma precluded reliable histology-specific conclusions. Overall, PFS and ORR had moderate trial-level associations with OS in metastatic renal cell carcinoma, but the overall analyses did not demonstrate sufficiently consistent surrogacy to reliably predict OS benefit. These findings should be interpreted cautiously given the substantial heterogeneity of the included trials. Surrogate validity appears to be context-dependent, supporting continued reliance on OS and the need for more robust surrogate end points.", "journal": "Cancer", "pub_date": "2026-Oct-01", "publication_types": ["Journal Article", "Systematic Review", "Meta-Analysis"], "doi": "10.1016/j.hoc.2023.04.019", "authors": ["Russell Leong", "David Chen", "Laith Almasri", "Nicholas Lum", "Karren Xiao", "Maryam Soleimani", "Christian K Kollmannsberger", "Srinivas Raman"], "affiliations": ["Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.", "Department of Radiation Oncology, BC Cancer Vancouver, Vancouver, British Columbia, Canada.", "Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.", "Department of Medical Oncology, BC Cancer Vancouver, Vancouver, British Columbia, Canada."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 36.65, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 14.65, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 8.0}, "journal_metrics": {"status": "ok", "impact_factor": 5.1, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 2.65, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42761474", "title": "Response to the Letter to the Editor Entitled \"Promising Urinary Microbiome Signals in Congenital Anomalies of the Kidney and Urinary Tract, but not yet Ready for Clinical Risk Stratification\".", "abstract": "", "journal": "Kidney International Reports", "pub_date": "2026-Oct", "publication_types": ["Letter"], "doi": "10.1038/s41564-025-02035-2", "authors": ["Sachit Anand", "Ajay Verma"], "affiliations": ["Department of Pediatric Surgery, All India Institute of Medical Sciences, New Delhi, India."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 25.79, "score_parts": {"urology_relevance": 3, "urology_in_title": 8.0, "journal_priority": 10.79, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 5.0, "abstract_completeness": -3.0, "basic_research_strength": 2.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 5.7, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.79, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "先天性肾尿路畸形尿液微生物组尚难用于风险分层", "chinese_summary": "10月Kidney Int Rep刊发通讯回复，针对先天性肾及尿路畸形尿液微生物组信号能否用于临床风险分层展开讨论。作者认为现有证据虽显示微生物组与畸形相关，但尚不足以支持将其作为临床风险分层工具，需更多前瞻性研究验证。", "abstract_zh": "这是对致编辑信题为“先天性肾及尿路畸形中有前景的尿液微生物组信号，但尚未准备好用于临床风险分层”的回复。"}, {"pmid": "42760039", "title": "FOCS-24: An integrated oncologic-functional endpoint and its preoperative nomogram after focal therapy for localized prostate cancer.", "abstract": "Focal therapy (FT) seeks to balance prostate cancer (PCa) control with preservation of urinary and sexual function, yet most studies report these outcomes separately. We developed FOCS-24, a composite endpoint capturing full oncologic and functional recovery at 24 months after FT for PCa, and created a preoperative nomogram estimating its probability. From 2021 to 2025, 324 men underwent primary FT (cryoablation or HIFU) at a tertiary cancer center. FOCS-24 required fulfilment of: PSA kinetics consistent with biochemical control (Phoenix definition), absence of retreatment/salvage therapy, pad-free continence, maintenance of normal urinary function-defined as the absence of newly developed clinically significant urinary symptoms throughout follow-up, and recovery of erectile function (IIEF-5 ≥ 17 or effective pharmacologic support). Men with ISUP > 2 or receiving neoadjuvant/adjuvant ADT were excluded from model development to preserve a homogeneous risk spectrum for model derivation, leaving 205 evaluable cases. Logistic regression identified predictors. Discrimination, calibration and decision-curve analysis assessed model performance. FOCS-24 was achieved by 30/205 men (14.6%). Younger age and posterior tumor location showed the most consistent pattern with complete recovery. The nomogram incorporated age, PSA density, PI-RADS lesion size, percentage of positive biopsy cores and axial location. The model achieved an AUC of 0.76 with favorable derivation-set calibration metrics. Limitations include low number of composite events and restriction to cryotherapy and HIFU. FOCS-24 provides a rigorous multidomain definition of complete oncologic and functional recovery after FT. External validation across centers and energy platforms is required before clinical implementation.", "journal": "Urologic Oncology", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1016/j.urolonc.2026.04.001", "authors": ["Umberto Anceschi", "Salvatore Basile", "Leonardo Misuraca", "Riccardo Mastroianni", "Rocco Simone Flammia", "Mariaconsiglia Ferriero", "Alfredo Maria Bove", "Eugenio Bologna", "Riccardo Capecchi", "Leslie Claire Licari", "Maddalena Iori", "Flavia Proietti", "Lorenzo Capecchi", "Costantino Leonardo", "Franco Lugnani", "Giuseppe Simone"], "affiliations": ["Uro-oncology program, IRCCS Regina Elena National Cancer Institute, Rome, Italy. Electronic address: umberto.anceschi@gmail.com.", "Uro-oncology program, IRCCS Regina Elena National Cancer Institute, Rome, Italy."], "corresponding_authors": ["Umberto Anceschi"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 27.25, "score_parts": {"urology_relevance": 10, "urology_in_title": 8.0, "journal_priority": 5.75, "top_journal_bonus": 0.0, "novelty": 0.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 1.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.3, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.75, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "局灶治疗后24个月综合康复评分建立", "chinese_summary": "2021至2025年，一家三级癌症中心对324例局限前列腺癌患者行冷冻消融或HIFU局灶治疗，其中205例纳入分析。研究提出复合终点FOCS-24，要求同时满足生化控制、无补救治疗、尿控、排尿功能维持及勃起功能恢复，仅14.6%患者达标。", "abstract_zh": "局灶治疗旨在平衡前列腺癌控制与保留排尿和性功能，但多数研究分别报告这些结局。我们开发了FOCS-24，一种复合终点，用于评估前列腺癌局灶治疗后24个月时肿瘤学和功能完全恢复情况，并创建了一个术前列线图以估计其概率。2021年至2025年，一家三级癌症中心有324名男性接受了初次局灶治疗（冷冻消融或HIFU）。FOCS-24要求满足以下条件：符合生化控制的PSA动力学（Phoenix定义）、无再次治疗/挽救治疗、无需尿垫的控尿、维持正常排尿功能——定义为整个随访期间未新发具有临床意义的排尿症状，以及勃起功能恢复（IIEF-5≥17或有效的药物支持）。ISUP>2或接受新辅助/辅助ADT的男性被排除在模型开发之外，以保持同质的风险谱用于模型推导，最终留下205例可评估病例。采用逻辑回归识别预测因素。通过区分度、校准度和决策曲线分析评估模型性能。30/205名男性（14.6%）达到了FOCS-24。较年轻年龄和后部肿瘤位置与完全恢复表现出最一致的模式。列线图纳入了年龄、PSA密度、PI-RADS病灶大小、阳性活检穿刺针百分比和轴向位置。该模型的AUC为0.76，在推导集中具有良好的校准指标。局限性包括复合事件数量少以及仅限于冷冻治疗和HIFU。FOCS-24为局灶治疗后肿瘤学和功能完全恢复提供了一个严格的多域定义。在临床实施之前，需要在不同中心和能量平台之间进行外部验证。"}, {"pmid": "42760038", "title": "Comment on \"Real-world treatment patterns, recurrence, and overall survival of patients with muscle-invasive bladder cancer undergoing radical cystectomy in U.S. oncology practice\".", "abstract": "", "journal": "Urologic Oncology", "pub_date": "2026-Oct", "publication_types": ["Letter"], "doi": "10.1016/j.urolonc.2026.08.001", "authors": ["Meiwei Gong", "Panfeng Shang"], "affiliations": ["Department of Urology, Lanzhou University Second Hospital, Lanzhou, Gansu, China.", "Department of Urology, Lanzhou University Second Hospital, Lanzhou, Gansu, China. Electronic address: shangpf@lzu.edu.cn."], "corresponding_authors": ["Panfeng Shang"], "china_team": "Department of Urology, Lanzhou University Second Hospital, Lanzhou, Gansu, China Panfeng Shang团队", "category": "clinical_review", "classification_reason": "clinical_signals=4", "score": 22.75, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 5.75, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 4.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.3, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.75, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42760037", "title": "Editorial comment: FOCS-24: An integrated oncologic-functional endpoint and its preoperative nomogram after focal therapy for localized prostate cancer.", "abstract": "", "journal": "Urologic Oncology", "pub_date": "2026-Oct", "publication_types": ["Letter"], "doi": "10.1016/j.urolonc.2026.05.015", "authors": ["Alon Lazarovich"], "affiliations": ["Division of Urology, Department of Surgery, University of Alberta, Edmonton, Canada. Electronic address: lazarovi@ualberta.ca."], "corresponding_authors": ["Alon Lazarovich"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 14.75, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 5.75, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.3, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.75, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42760034", "title": "Editorial comment on clinical characteristics and oncological outcomes of upper tract urothelial carcinoma in patients with personal or family history of lynch-syndrome associated cancers.", "abstract": "", "journal": "Urologic Oncology", "pub_date": "2026-Oct", "publication_types": ["Letter"], "doi": "10.1016/j.urolonc.2026.06.001", "authors": ["Alireza Ghoreifi", "Yair Lotan"], "affiliations": ["Department of Urology, Duke University Medical Center, Durham, NC. Electronic address: Alireza.Ghoreifi@duke.edu.", "Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX."], "corresponding_authors": ["Alireza Ghoreifi"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 14.75, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 5.75, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.3, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.75, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42760014", "title": "Corrigendum to \"Glycogen synthase kinase 3β hyperactivity in urinary exfoliated cells predicts progression of diabetic kidney disease.\" Kidney Int. 2020;97:175-192.", "abstract": "", "journal": "Kidney International", "pub_date": "2026-Oct", "publication_types": ["Published Erratum"], "doi": "10.1016/j.kint.2026.06.015", "authors": ["Xianhui Liang", "Pei Wang", "Bohan Chen", "Yan Ge", "Athena Y Gong", "Bryce Flickinger", "Deepak K Malhotra", "Li Juan Wang", "Lance D Dworkin", "Zhangsuo Liu", "Rujun Gong"], "affiliations": ["Blood Purification Center, Institute of Nephrology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China; Department of Medicine, Division of Kidney Disease and Hypertension, Rhode Island Hospital, Brown University School of Medicine, Providence, Rhode Island, USA.", "Department of Medicine, Division of Kidney Disease and Hypertension, Rhode Island Hospital, Brown University School of Medicine, Providence, Rhode Island, USA.", "Department of Medicine, Division of Kidney Disease and Hypertension, Rhode Island Hospital, Brown University School of Medicine, Providence, Rhode Island, USA; Department of Medicine, Division of Nephrology, University of Toledo College of Medicine, Toledo, Ohio, USA.", "Department of Medicine, Division of Nephrology, University of Toledo College of Medicine, Toledo, Ohio, USA.", "Blood Purification Center, Institute of Nephrology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. Electronic address: zhangsuoliu@zzu.edu.cn.", "Department of Medicine, Division of Kidney Disease and Hypertension, Rhode Island Hospital, Brown University School of Medicine, Providence, Rhode Island, USA; Department of Medicine, Division of Nephrology, University of Toledo College of Medicine, Toledo, Ohio, USA. Electronic address: Rujun.Gong@UToledo.edu."], "corresponding_authors": ["Zhangsuo Liu", "Rujun Gong"], "china_team": "Blood Purification Center, Institute of Nephrology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China; Department of Medicine, Division of Kidney Disease and Hypertension, Rhode Island Hospital, Brown University School of Medicine, Providence, Rhode Island, USA Zhangsuo Liu团队", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 23.83, "score_parts": {"urology_relevance": 3, "urology_in_title": 8.0, "journal_priority": 15.83, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 12.6, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.83, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42757099", "title": "Ice Water Test Unmasks Detrusor Overactivity in Apparently Normal Conventional Cystometry.", "abstract": "To evaluate the diagnostic value of the ice water test (IWT) in unmasking detrusor overactivity (DO) in patients with lower urinary tract symptoms (LUTS) who do not exhibit DO during conventional filling cystometry and to characterize this specific patient population. In this observational cohort study, from April 2021 to December 2023, patients with LUTS but no DO in same-session repeat conventional filling cystometry were additionally evaluated using the IWT. All participants underwent standardized urodynamic investigations following International Continence Society guidelines. The primary outcome was the presence of DO during the IWT. Demographic and clinical factors associated with DO were analyzed using mixed-effects logistic regression models. In 529 UDIs of 451 patients (63 patients had more than one urodynamic investigation (UDI)) without DO in conventional filling cystometry, the IWT revealed DO in 51% (229/451). Detection was more frequent in patients with an underlying neurological disorder (53% vs 34%, p = 0.004), males (57% vs 42%, p = 0.007), and those using antimuscarinics (67% vs 43%, p < 0.001) or being treated with intradetrusor onabotulinumtoxinA injections in the past year (66% vs 46%, p = 0.002). These variables, along with increasing age, were independent predictors in a multivariable analysis. In patients with LUTS but no DO on conventional filling cystometry, the IWT might reveal DO in approximately half of the cases. This underscores the diagnostic value of the IWT in both patients with neurological and nonneurological conditions and leads to a better understanding of LUTS-causing pathophysiology.", "journal": "European Urology Open Science", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1016/j.euros.2026.08.004", "authors": ["Lara Stächele", "Helen Sadri", "Collene E Anderson", "Veronika Birkhäuser", "Oliver Gross", "Fabienne Lehner", "Lorenz Leitner", "Martina D Liechti", "Ulrich Mehnert", "Thomas M Kessler"], "affiliations": ["Department of Neuro-Urology, Balgrist University Hospital, University of Zürich, Zürich, Switzerland.", "Spinal Cord Injury Center, Balgrist University Hospital, University of Zürich, Zürich, Switzerland.", "Swiss Paraplegic Research, Nottwil, Switzerland.", "Faculty of Health Sciences and Medicine, University of Lucerne, Lucerne, Switzerland."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=6", "score": 25.5, "score_parts": {"urology_relevance": 7, "urology_in_title": 0.0, "journal_priority": 10.5, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 6.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.5, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.5, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42755911", "title": "Cost-utility of NeuroSAFE-guided RARP Versus Standard RARP in Men with Localised Prostate Cancer in the UK.", "abstract": "Robotic radical prostatectomy (RARP) is a standard first-line curative treatment for localised prostate cancer but carries risks of erectile dysfunction and urinary incontinence. The NeuroSAFE technique provides pathological assessment to optimise nerve-sparing whilst avoiding positive surgical margins. This study evaluated the cost-effectiveness of NeuroSAFE-guided RARP compared with standard RARP. A within-trial economic evaluation with a 12-month time horizon was conducted alongside NeuroSAFE-PROOF, a single-blinded, multi-centre, randomised controlled trial. Participants were patients with a diagnosis of non-metastatic prostate cancer deemed suitable to undergo RARP, good erectile function without medical erectile function assistance, and no previous prostate cancer treatment. No age limits were applied. The intervention is the NeuroSAFE-guided RARP. Costs were assessed from NHS and societal perspectives using patient-level data. Quality-adjusted life years (QALYs) were measured using EQ-5D-5L. Incremental cost-effectiveness ratios (ICERs) and net monetary benefits were estimated. Uncertainty was captured via bootstrapping, missing data were addressed through multiple imputation, and Monte Carlo simulations were undertaken to assess robustness. Among 407 randomised patients (NeuroSAFE: 204; standard RARP: 203), NeuroSAFE increased mean total cost (by £827 and £1,000 from NHS and societal perspectives, respectively) and QALYs (by 0.03). ICERs were £26,195/QALY (NHS) and £31,666/QALY (societal). Cost-effectiveness probabilities were 53% and 56% (NHS) and 48% and 56% (societal) at the lower and upper UK willingness-to-pay thresholds. Limitations include substantial uncertainty around estimates, missing data, and potential recall bias from retrospectively collected data. Findings reflect short-term, within-trial estimates and should be interpreted accordingly. NeuroSAFE-guided RARP increased costs and generated modest QALY gains on average. ICERs were within the upper UK threshold, although substantial uncertainty remained. These findings reflect 12-month within-trial economic outcomes and should not be interpreted as evidence of long-term cost-effectiveness.", "journal": "European Urology Open Science", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.22024/UniKent/01.02.105685", "authors": ["Jiunn Wang", "Ricardo Almeida-Magana", "Eoin Dinneen", "Shengning Pan", "Baptiste Leurent", "Nicholas Roberts", "Chris Brew-Graves", "Norman R Williams", "Aiman Haider", "Greg Shaw", "Elena Pizzo"], "affiliations": ["Department of Primary Care and Population Health, University College London, London, UK.", "Division of Surgery and Interventional Science, University College London, London, UK.", "Department of Urology, University College London Hospitals NHS Foundation Trust, London, UK.", "Department of Statistical Science, University College London, London, UK.", "Centre for Medical Imaging, University College London, London, UK.", "Department of Histopathology, University College London Hospitals NHS Foundation Trust, London, UK.", "School of Public Health, Imperial College London, White City Campus, London, UK.", "Business School, Imperial College London, South Kensington Campus, London, UK."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=7", "score": 42.5, "score_parts": {"urology_relevance": 14, "urology_in_title": 8.0, "journal_priority": 10.5, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 7.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.5, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.5, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42751801", "title": "Impact of post-chemotherapy classification on outcomes in stage III and IV unilateral favorable histology Wilms tumor: Pooled data from Children's Oncology Group AREN0532, AREN0533, and AREN03B2 studies.", "abstract": "Improvements in therapy for patients with favorable histology Wilms tumor (FHWT) have relied on refinement of risk stratification for therapeutic assignment through identification of favorable and unfavorable prognostic factors. Although well established in International Society of Pediatric Oncology-Renal Tumor Study Group protocols, the Children's Oncology Group (COG) has not historically used post-chemotherapy histology (PCH) to guide therapy. This study examines whether outcomes are associated with PCH classification in the COG treatment context. The authors identified 2386 patients with stage III or IV FHWT enrolled on AREN0532, AREN0533, or AREN03B2-only from 2006 to 2019. Inclusion criteria included delayed nephrectomy more than 5 and fewer than 16 weeks after initial biopsy, treatment on or as per protocol with DD4A or Regimen M, and known PCH classification and outcome. Of 352 included patients, 45 (12.7%) were classified as low risk (LR), 287 (81.5%) as intermediate risk (IR), and 20 (5.6%) as high risk (HR). PCH classification was significantly prognostic for event-free survival (EFS) (p < .0001) and overall survival (OS) (p < .0001). Four-year EFS for LR, IR, and HR groups was 93% (95% CI, 86%-100%), 85% (95% CI, 81%-89%), and 53% (95% CI, 35%-81%); 4-year OS was 96% (95% CI, 90%-100%), 93% (95% CI, 89%-96%), and 62% (95% CI, 44%-89%). Compared with LR or IR, EFS and OS were significantly lower for HR, regardless of stage or treatment. PCH is a significant prognostic factor in unilateral FHWT treated on COG regimens, strongly supporting its incorporation into therapeutic stratification in prospective COG trials.", "journal": "Cancer", "pub_date": "2026-Oct-01", "publication_types": ["Journal Article"], "doi": "10.1200/jco.2011.35.8747", "authors": ["Nicholas F Evageliou", "Lindsay A Renfro", "Kelly L Vallance", "Carly R Varela", "Daniel J Benedetti", "Nicholas G Cost", "Peter F Ehrlich", "John A Kalapurakal", "Geetika Khanna", "Jennifer H Aldrink", "Richard D Glick", "Michael V Ortiz", "Lauren N Parsons", "Arnold C Paulino", "Maddy Artunduaga", "Ethan A Smith", "David B Dix", "Conrad V Fernandez", "Jeffrey S Dome", "James I Geller", "Elizabeth A Mullen"], "affiliations": ["Division of Oncology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.", "Division of Biostatistics, University of Southern California, and Children's Oncology Group, Los Angeles, California, USA.", "Hematology and Oncology, Cook Children's Medical Center, Fort Worth, Texas, USA.", "Johnson & Johnson, Spring House, Philadelphia, Pennsylvania, USA.", "Division of Hematology/Oncology, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.", "Department of Surgery, Division of Urology and the Surgical Oncology Program at Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, Colorado, USA.", "Section of Pediatric Surgery, University of Michigan, Ann Arbor, Michigan, USA.", "Department of Radiation Oncology, Northwestern University, Chicago, Illinois, USA.", "Department of Radiology & Imaging Sciences, Emory University and Children's Healthcare of Atlanta, Atlanta, Georgia, USA.", "Division of Pediatric Surgery, Department of Surgery, Nationwide Children's Hospital, The Ohio State University College of Medicine, Columbus, Ohio, USA.", "Division of Pediatric Surgery, Cohen Children's Medical Center, Zucker School of Medicine at Northwell/Hofstra, New Hyde Park, New York, USA.", "Memorial Sloan Kettering Cancer Center, New York, New York, USA.", "Medical College of Wisconsin, Children's Hospital of Wisconsin, Milwaukee, Wisconsin, USA.", "Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.", "Department of Radiology, Pediatric Radiology Division, UT Southwestern Medical Center, Dallas, Texas, USA.", "Department of Radiology, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio, USA.", "Division of Hematology and Oncology, Department of Pediatrics, BC Children's Hospital and University of British Columbia, Vancouver, British Columbia, Canada.", "Division of Pediatric Hematology Oncology, Department of Pediatrics, IWK Health Centre and Dalhousie University, Halifax, Nova Scotia, Canada.", "Division of Oncology, Children's National Hospital, Department of Pediatrics, George Washington University School of Medicine and Health Sciences, Washington, DC, USA.", "Peckham Center for Cancer and Blood Disorders, Rady Children's Hospital, San Diego, California, USA.", "Division of Pediatric Hematology/Oncology, Department of Pediatrics, University of California San Diego, La Jolla, California, USA.", "Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, Massachusetts, USA."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=6", "score": 26.65, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 14.65, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 6.0}, "journal_metrics": {"status": "ok", "impact_factor": 5.1, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 2.65, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42751490", "title": "Interferon-α vs hydroxyurea in patients with myeloproliferative neoplasms (DALIAH): a multicentre, randomised, open-label, phase 3 trial in Denmark.", "abstract": "Hydroxyurea (HU) is the most commonly used cytoreductive treatment for patients with myeloproliferative neoplasms (MPN), but emerging data on pegylated interferon-alpha2 (pegIFNα) are encouraging. Optimal first-line treatment remains unclear. DALIAH was a randomised, open-label, parallel-group, phase 3 trial conducted at nine centres in Denmark comparing HU with pegIFNα in patients with newly diagnosed MPN. Adults (≥18 years) with newly diagnosed or cytoreductive treatment-naïve MPN (essential thrombocythaemia [ET], polycythaemia vera [PV], prefibrotic myelofibrosis [pre-PMF], or primary myelofibrosis [PMF]; according to 2008 World Health Organization [WHO] criteria) and evidence of active disease were eligible, regardless of risk score. Patients aged >60 years were randomised (1:1:1) to either HU, pegIFNα-2a, or pegIFNα-2b; patients aged ≤60 years were randomised (1:1) to either pegIFNα-2a or pegIFNα-2b. The primary endpoint was the proportion of molecular responders (MR; partial or complete) at 18, 36, and 60 months (intention-to-treat [ITT], HU vs pegIFNα). This trial was registered with ClinicalTrials.gov, NCT01387763. Between Feb 7, 2012, and July 6, 2015, 203 eligible participants were enrolled in the modified ITT population (HU n = 38 [19%], pegIFNα n = 165 [81%]). In the ITT analysis, MR proportions were similar between HU and pegIFNα at 18 months (19% vs 21%, p = 1·00), 36 months (19% vs 26%, p = 0·64), and 60 months (23% vs 24%, p = 1·00). In the per-protocol (PP) analysis, restricted to patients who remained on therapy, pegIFNα showed higher MR beyond 36 months (36 months: 23% vs 56%, p = 0·01; 60 months: 35% vs 67%, p = 0·03). At month 60, PegIFNα discontinuation was high (65% vs 37% HU, p = 0·0019). No significant difference in grade ≥3 adverse events was observed between groups (HU 58% vs pegIFNα 45%, p = 0·21). Adverse events occurring in ≥10% of patients differed between treatments: dyspepsia, pyrexia, and urinary tract infections were more common with HU, whereas fatigue, influenza-like illness, injection-site irritation, myalgia, and decreased white cell blood count were more frequent with pegIFNα. Anaemia and decreased neutrophil count were the most common haematological events in both groups. Treatment-related adverse events were reported in 77 patients (HU 27% vs pegIFNα 41%, p = 0·14) and led to permanent discontinuation in 13 patients (all pegIFNα). HU and pegIFNα display distinct response kinetics. Molecular response was similar in the ITT analysis, reflecting that non-response largely resulted from higher pegIFNα discontinuation rather than lack of efficacy. Among patients who tolerated therapy, pegIFNα achieved superior long-term molecular responses. Findings should be considered within the context of the significantly higher treatment discontinuation rate with pegIFNα than with HU. These findings suggest that pegIFNα may offer long-term molecular benefit in selected patients highlighting the need for biomarkers that predict response and long-term tolerability, preferably already at diagnosis. OUH-Region Sjaelland Faelles Forskningspulje, Region Sjællands Sundhedsvidenskabelige Forskningsfond (RSSF) 2018, Gangstedfonden, OUH Frie Forskningsmidler, Swedish Orphan, Fonden til Lægevidenskabens Fremme, Ellen og Aage Fausboells Helsefond af 1975, and Desirée og Niels Ydes Fond.", "journal": "eClinicalMedicine", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1002/ajh.23554", "authors": ["Trine Alma Knudsen", "Dennis Lund Hansen", "Lukas Frans Ocias", "Ole Weis Bjerrum", "Mette Brabrand", "Sarah Friis Christensen", "Christina Schjellerup Eickhardt-Dalbøge", "Christina Ellervik", "Daniel El Fassi", "Mikael Frederiksen", "Lasse Kjær", "Thomas Kielsgaard Kristensen", "Torben A Kruse", "Morten Kranker Larsen", "Torben Mourits-Andersen", "Sören Möller", "Ulrik Malthe Overgaard", "Marianne Tang Severinsen", "Vibe Skov", "Anders Lindholm Sørensen", "Jesper Stentoft", "Jørn Starklint", "Karin de Stricker", "Mads Thomassen", "Thomas S Larsen", "Hans C Hasselbalch"], "affiliations": ["Department of Haematology, Zealand University Hospital, Denmark.", "Department of Haematology, Odense University Hospital, Denmark.", "Department of Clinical Research, University of Southern Denmark, Denmark.", "Rigshospitalet, Department of Haematology, Copenhagen University Hospital, Denmark.", "Department of Pathology, Harvard Medical School, Boston, USA.", "Department of Laboratory Medicine, Boston Children's Hospital, Boston, USA.", "Faculty of Health and Medical Sciences, University of Copenhagen, Denmark.", "Department of Biochemistry, Zealand University Hospital, Koege, Denmark.", "Department of Clinical Medicine, University of Copenhagen, Denmark.", "Department of Haematology, University Hospital of Southern Denmark, Denmark.", "Department of Pathology, Odense University Hospital, Denmark.", "Department of Clinical Development, Odense University Hospital, Denmark.", "Department of Clinical Genetics, Odense University Hospital, Denmark.", "Department of Haematology, Hospital of South West Jutland, Denmark.", "Department of Public Health, Research Unit for Epidemiology, Biostatistics and Biodemography, University of Southern Denmark, Denmark.", "Department of Haematology, Clinical Cancer Research Unit, Aalborg University Hospital, Denmark.", "Department of Clinical Medicine, Aalborg University, Denmark.", "Department of Haematology, Aarhus University Hospital, Denmark.", "Department of Haematology, Regional Hospital West Jutland, Denmark."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=5", "score": 31.52, "score_parts": {"urology_relevance": 7, "urology_in_title": 0.0, "journal_priority": 15.52, "top_journal_bonus": 0.0, "novelty": 2.0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 5.0}, "journal_metrics": {"status": "ok", "impact_factor": 10.0, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.52, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42751148", "title": "Exome Sequencing in Patients with Loin Pain Hematuria Syndrome and Persistent Isolated Hematuria.", "abstract": "Loin pain hematuria syndrome (LPHS) is characterized by chronic loin pain and hematuria without a urological cause. We hypothesized that rare genetic variants in genes impacting the glomerular filtration barrier (endothelial cells, glomerular basement membrane, or podocytes) may contribute to LPHS. Exome sequencing was performed in 29 consecutive patients; 17 with LPHS, and 12 with persistent painless isolated hematuria (IH). We first evaluated a virtual gene panel of 130 hematuria-linked genes curated from the literature followed by an exome-wide analysis. Variant interpretation was performed using clinical criteria. Of 17 patients with LPHS, 13 had gross hematuria, 4 had microscopic hematuria, all with chronic pain. Of these, 9 had a history of kidney stones, but none had obstruction on current imaging; 8 had a family history of kidney stones, 3 of hematuria, and 2 of LPHS. Of 17 patients with LPHS, 4 (23%) had a heterozygous pathogenic or likely pathogenic (P/LP) variant-1 in each of COL4A4, MSTO1, FLNA, and APPL1. Of 12 patients with IH, 4 (33%) with painless hematuria had a P/LP variant-1 in each of COL4A3, COL4A5, FLNA, and UQCRC1. Broadening to include the whole exome, no additional P/LP variants believed to be involved in LPHS were identified. LPHS appears to be the result of multiple heterogeneous mechanisms. Our analysis did not identify a common monogenic cause, but rare variants were observed in multiple genes among affected individuals. Pathogenic variants in type IV collagen genes (COL4A3-5) were identified in 1 of 17 patients with LPHS and 2 of 12 patients with IH.", "journal": "Kidney International Reports", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1016/j.mbplus.2022.100119", "authors": ["Bhanu Prasad", "Ahmed M Soliman", "Aarti Garg", "Aditi Sharma", "Clara Schott", "Dervla Connaughton", "Matthew B Lanktree"], "affiliations": ["Section of Nephrology, Department of Medicine, Regina General Hospital, Regina, Saskatchewan, Canada.", "Department of Chemistry and Biochemistry, University of Regina, Regina, Saskatchewan, Canada.", "Department of Microbiology and Immunology, Faculty of Pharmacy, Kafrelsheikh University, Kafr El-Sheikh, Egypt.", "Department of Biology, University of Regina, Regina, Saskatchewan, Canada.", "Department of Biochemistry, Schulich School of Medicine & Dentistry, Western University, London, Ontario, Canada.", "Department of Medicine, Division of Nephrology, University Hospital, London Health Sciences Centre, London, Ontario, Canada.", "Departments of Medicine and Health Research Methodology, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "basic_signals=4", "score": 25.79, "score_parts": {"urology_relevance": 8, "urology_in_title": 0.0, "journal_priority": 10.79, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 4.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 5.7, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.79, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "腰痛血尿综合征多见罕见基因变异", "chinese_summary": "10月Kidney Int Rep对29例患者行外显子测序，17例腰痛血尿综合征中4例（23%）携带COL4A4、MSTO1、FLNA、APPL1致病或可能致病变异，12例持续性孤立性血尿中4例（33%）携带COL4A3、COL4A5、FLNA、UQCRC1变异；未发现共同单基因病因，提示该病由多种异质性机制所致。", "abstract_zh": "腰痛血尿综合征（LPHS）以慢性腰痛和血尿为特征，且无泌尿系统病因。我们假设影响肾小球滤过屏障（内皮细胞、肾小球基底膜或足细胞）的基因中罕见变异可能参与LPHS。对29例连续患者进行了外显子测序；其中17例为LPHS，12例为持续性无痛性孤立性血尿（IH）。我们首先评估了从文献中整理出的130个血尿相关基因构成的虚拟基因 panel，随后进行了全外显子分析。变异解读采用临床标准。17例LPHS患者中，13例为肉眼血尿，4例为镜下血尿，均伴慢性疼痛。其中9例有肾结石病史，但当前影像学均无梗阻；8例有肾结石家族史，3例有血尿家族史，2例有LPHS家族史。17例LPHS患者中，4例（23%）携带杂合致病或可能致病（P/LP）变异——分别位于COL4A4、MSTO1、FLNA和APPL1各1例。12例IH患者中，4例（33%）无痛性血尿患者携带P/LP变异——分别位于COL4A3、COL4A5、FLNA和UQCRC1各1例。扩大至全外显子后，未发现其他被认为参与LPHS的P/LP变异。LPHS似乎是多种异质性机制的结果。我们的分析未确定共同的单基因病因，但在受累个体中观察到多个基因的罕见变异。IV型胶原基因（COL4A3-5）的致病变异在17例LPHS患者中检出1例，在12例IH患者中检出2例。"}, {"pmid": "42750827", "title": "An Updated Systematic Review, Meta-analysis, and Trial Sequential Analysis of Endoscopic Combined Intrarenal Surgery (ECIRS) versus Percutaneous Nephrolithotomy (PCNL) for Upper Urinary Tract Calculi.", "abstract": "Percutaneous nephrolithotomy (PCNL) remains the gold standard for large intrarenal stones. However, endoscopic combined intrarenal surgery (ECIRS) has emerged as an alternative, offering simultaneous antegrade and retrograde access with enhanced intrarenal visualization. This systematic review and meta-analysis evaluates the comparative outcomes of ECIRS and PCNL, with the aim of synthesizing available evidence on stone-free rates (SFRs), complications, and perioperative variables. This systematic review and meta-analysis evaluates the comparative outcomes of ECIRS and PCNL, with the aim of synthesizing available evidence on stone-free rates (SFRs), complications, and perioperative variables. Following Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines, a systematic review was conducted across MEDLINE, Embase, Scopus, Web of Science, and Cochrane Library for studies comparing ECIRS with PCNL for the treatment of upper urinary tract calculi in adult patients. The primary endpoint was SFR; secondary outcomes included length of hospital stay (LOS) and postoperative complications. Statistical analysis was conducted using R version 4.6.0 software. Eighteen studies met inclusion criteria, encompassing 946 patients treated with ECIRS and 1226 with PCNL. Meta-analysis revealed that ECIRS was associated with a lower risk of residual fragments-that is, higher SFR-(risk ratio [RR] = 0.41; 95% confidence interval [CI]: 0.33 to 0.52; p < 0.001). Postoperative fever (RR = 0.79; 95% CI: 0.56-1.11; p = 0.2) and urosepsis (RR = 0.66; 95% CI: 0.30-1.45; p = 0.3) were not statistically significantly different between groups. Major complications (Clavien-Dindo grade ≥3) occurred less frequently with ECIRS (RR = 0.51; 95% CI: 0.30 to 0.87; p = 0.01), and postoperative LOS was also shorter in the ECIRS group (mean difference = -1.30 d; 95% CI: -2.10 to -0.51; p = 0.001). The available evidence suggests that ECIRS is associated with better SFRs and fewer major complications compared with PCNL, though these findings are primarily driven by observational data and should be interpreted with caution. These results are consistent with ECIRS being a potentially effective, lower-morbidity option in selected patients, though confirmation in high-quality randomized trials is warranted.", "journal": "European Urology Open Science", "pub_date": "2026-Oct", "publication_types": ["Journal Article", "Review"], "doi": "10.1016/j.euros.2026.07.005", "authors": ["Bruno D Terada", "Artur S Almeida", "Felipe G A Gonçalves", "Leonardo O D da Silva", "Breno C Porto", "Rodrigo A S Sardenberg", "Carlo C Passerotti", "Gustavo Freschi", "Diego P Resuto", "Eugenio Vicari-Neto", "Alex E Meller", "Renato N Pedro", "Antonio C Lopes-Neto", "Ronaldo S Maia", "Fernando G de Almeida", "Wilson R Molina", "José Arnaldo Shiomi da Cruz"], "affiliations": ["Federal University of São Paulo, Urology Department, São Paulo, SP, Brazil.", "Clinical Research Institute, Hapvida NotreDame, Sao Paulo, SP, Brazil.", "German Hospital Oswaldo Cruz, São Paulo, SP, Brazil.", "São Leopoldo Mandic School of Medicine, Campinas, SP, Brazil.", "School of Medical Sciences, State University of Campinas (UNICAMP), Campinas, SP, Brazil.", "ABC Medical School, Urology Department, São Paulo, SP, Brazil.", "Department of Urology, The University of Kansas Health System, Kansas City, Kansas.", "Department of Urology, Ninth of July University, São Bernardo do Campo, SP, Brazil."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 31.5, "score_parts": {"urology_relevance": 3, "urology_in_title": 8.0, "journal_priority": 10.5, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 8.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.5, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.5, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42750749", "title": "Fungal Urinary Tract Infection: A Brief Manual for Diagnosis and Treatment for Urologists.", "abstract": "The detection of fungi in urine is common, particularly in nosocomial settings. Nevertheless, diagnostic and treatment approaches are often associated with uncertainty. Accordingly, this review aimed to give a concise overview of fungal urinary tract infection (UTI) as a supplement to the more comprehensive update of the European Association of Urology 2026 Guidelines on Urological Infections. Only 2-11% of fungal isolates in urine are associated with symptoms, and a fungal UTI should only be assumed in such cases. Candida albicans is the most frequently identified pathogen. Diagnosis should include a urine culture with susceptibility testing, especially in non-albicans Candida UTI. Nonantimicrobial measures such as catheter replacement should always be part of the treatment. First-line antimicrobial treatment is fluconazole. In cases of localized bladder infections, intravesical amphotericin B may be considered. Asymptomatic funguria should only be treated in exceptional cases. Urologists should play a key role in treatment decision-making for patients with fungal UTIs.", "journal": "European Urology Open Science", "pub_date": "2026-Oct", "publication_types": ["Letter"], "doi": "10.1016/j.euros.2026.08.006", "authors": ["Kathrin Bausch", "Emma J Smith", "Tommaso Cai", "Wout Devlies", "Suzanne Geerlings", "Bela Köves", "Merel M C Lambregts", "Lorenz Leitner", "Guglielmo Mantica", "Jose Medina Polo", "Adrian Pilatz", "Laila Schneidewind", "Sören Schubert", "Fabian Stangl", "Rajan Veeratterapillay", "Maxime Vallée", "Florian Wagenlehner", "Gernot Bonkat", "Jennifer Kranz"], "affiliations": ["Department of Urology, University Hospital Basel, University of Basel, Basel, Switzerland.", "Guidelines Office, European Association of Urology, Arnhem, The Netherlands.", "Department of Urology, Santa Chiara Regional Hospital, Trento, Italy.", "Department of Urology, UZ Leuven, Leuven, Belgium.", "Department of Internal Medicine, Amsterdam Institute for Infection and Immunity, Amsterdam Public Health Research Institute, Quality of Care, Amsterdam, The Netherlands.", "Department of Urology, University of Szeged, Szeged, Hungary.", "Department of Internal Medicine/Infectious Disease, Leiden University Medical Center, Leiden, The Netherlands.", "Department of Urology, University Hospital Zurich/Balgrist, Zurich, Switzerland.", "Department of Surgical and Diagnostic Integrated Sciences, University of Genoa, Genova, Italy.", "Department of Urology, Hospital Universitario 12 de Octubre, Madrid, Spain.", "Department of Urology, Pediatric Urology and Andrology, Justus-Liebig-University Giessen, Giessen, Germany.", "Department of Urology, University Hospital of Bern, Bern, Switzerland.", "Max von Pettenkofer Institute, LMU Munich, Munich, Germany.", "Freeman Hospital, Newcastle upon Tyne, UK.", "Department of Urology and Kidney Transplantation, CHU, Poitiers, France.", "Alta Uro AG, Merian Iselin Klinik, Center of Biomechanics & Calorimetry, University of Basel, Basel, Switzerland.", "Department of Urology and Pediatric Urology, RWTH Aachen University, Aachen, Germany.", "Department of Urology and Kidney Transplantation, Martin-Luther-University, Halle, Germany."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=3", "score": 39.5, "score_parts": {"urology_relevance": 15, "urology_in_title": 8.0, "journal_priority": 10.5, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 3.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.5, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.5, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42743938", "title": "Burden of cancer in Africa, 1990-2023: a systematic analysis from the Global Burden of Disease Study 2023.", "abstract": "Cancer remains a leading cause of death and disability worldwide, with a disproportionately rising burden across Africa. Effective policy responses have been consistently hampered by fragmented and incomplete cancer surveillance data. Using the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2023, we estimated the burden of 48 cancer types across all 54 African countries over the period 1990 to 2023. These age-disaggregated and sex-disaggregated findings provide a crucial empirical foundation to inform regional control strategies and monitor progress towards global health targets. We applied GBD 2023 methodology to estimate fatal and non-fatal outcomes of cancer alongside risk-attributable burden from 88 modifiable risk factors, across all 54 African countries. The estimation of cancer burden attributable to risk factors followed the comparative risk assessment framework. Estimates of incidence, mortality, years lived with disability (YLDs), years of life lost (YLLs), and disability-adjusted life-years (DALYs) were stratified by age, sex, location, and year (1990-2023) and reported as counts and age-standardised rates per 100 000 population. Mean estimates represent the mean across 250 draws, with 95% uncertainty intervals calculated from the 2·5th and 97·5th percentiles. In 2023, cancer, including non-melanoma skin cancer, accounted for an estimated 1·54 million (95% uncertainty interval 1·37-1·75) incident cases, 923 000 (824 000-1 020 000) deaths, and 33·9 million (30·6-37·1) DALYs across all ages and both sexes in Africa, of which 98·2% (97·9-98·3) were attributable to YLLs. In Africa, 10·7 million (8·9-12·9) DALYs and 306 000 (254 000-363 000) cancer deaths in 2023 were attributable to the 88 risk factors assessed in GBD 2023, equivalent to 31·6% (26·8-35·9) of total DALYs and 33·1% (28·7-37·2) of total cancer deaths across all ages and both sexes. Between 1990 and 2023, deaths attributable to risk factors increased by 216·0% (159·3-284·5) for both sexes combined. In 2023, incident cancer cases in females numbered 960 000 (821 000-1 130 000), with breast and cervical cancers together accounting for 53·5% (44·7-62·2) of all female incident cases. In males, prostate, liver, tracheal, bronchus and lung, and colorectal cancers were the leading types, together accounting for 44·8% (36·2-54·3) of all male cancers in Africa in 2023. Childhood cancer (ages 0-19 years) in Africa accounted for 104 000 (84 600-130 000) incident cases and 54 700 (47 500-64 500) deaths, representing 27·7% (26·6-29·4) of global incidence and 38·0% (36·3-40·0) of global deaths in 2023. Cancers in adolescents and young adults (ages 15-39 years) contributed 26·6% (26·4-27·5) of total cancer DALYs in Africa, those in older adults aged 40-64 years contributed 44·8% (43·8-45·6), and those in adults aged 65 years and older contributed 18·3% (17·4-19·1). Cancer is a growing contributor to the disease burden in Africa, with rising cases, deaths, and DALYs disproportionately affecting children, adolescents, and young adults. The increase in age-standardised mortality and DALY rates stands in sharp contrast to the ambitions of the Sustainable Development Goals for 2030 and the African Union Agenda 2063. Addressing this burden will require coordinated national and international action, with health-system strengthening and context-specific cancer-control strategies spanning prevention, early diagnosis, and treatment. Gates Foundation.", "journal": "Lancet Oncology", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.18103/mra.v12i11.5749", "authors": ["GBD 2023 Africa Cancer Risk Factors Collaborators"], "affiliations": [], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 33.29, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 17.29, "top_journal_bonus": 10.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 35.9, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 5.29, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "非洲癌症负担持续攀升", "chinese_summary": "《柳叶刀·肿瘤学》9月发布GBD 2023系统分析，估算1990至2023年非洲54国48种癌症负担。2023年非洲新发癌症154万例、死亡92.3万例、DALY 3390万，其中98.2%来自早死损失；31.6%的DALY和33.1%的癌症死亡可归因于88种可干预风险因素，归因死亡33年间增加216%。", "abstract_zh": "癌症仍是全球死亡和残疾的主要原因，而非洲的癌症负担上升尤为不成比例。有效政策应对一直因癌症监测数据碎片化和不完整而受阻。利用《全球疾病、伤害和风险因素负担研究（GBD）2023》，我们估算了1990年至2023年期间所有54个非洲国家48种癌症类型的负担。这些按年龄和性别分层的结果为区域防控策略和监测全球卫生目标进展提供了关键实证基础。我们应用GBD 2023方法学，估算所有54个非洲国家癌症的致死性和非致死性结局，以及88种可改变风险因素的可归因负担。风险因素所致癌症负担的估算遵循比较风险评估框架。发病、死亡、伤残损失健康寿命年（YLD）、寿命损失年（YLL）和伤残调整寿命年（DALY）的估计值按年龄、性别、地点和年份（1990—2023年）分层，并以计数和每10万人口年龄标化率报告。平均估计值代表250次抽样的均值，95%不确定性区间根据第2.5和第97.5百分位数计算。2023年，癌症（包括非黑色素瘤皮肤癌）在非洲全年龄和两性中估计造成154万例（95%不确定性区间137万—175万）新发病例、92.3万例（82.4万—102万）死亡和3390万（3060万—3710万）DALY，其中98.2%（97.9—98.3）归因于YLL。2023年，非洲有1070万（890万—1290万）DALY和30.6万（25.4万—36.3万）癌症死亡可归因于GBD 2023评估的88种风险因素，相当于全年龄和两性总DALY的31.6%（26.8—35.9）和癌症总死亡的33.1%（28.7—37.2）。1990年至2023年间，两性合计归因于风险因素的死亡增加了216.0%（159.3—284.5）。2023年，女性新发癌症病例数为96万（82.1万—113万），其中乳腺癌和宫颈癌合计占女性所有新发病例的53.5%（44.7—62.2）。在男性中，前列腺癌、肝癌、气管/支气管和肺癌以及结直肠癌是主要类型，2023年合计占非洲男性所有癌症的44.8%（36.2—54.3）。2023年，非洲儿童癌症（0—19岁）造成10.4万（8.46万—13万）新发病例和5.47万（4.75万—6.45万）死亡，分别占全球发病的27.7%（26.6—29.4）和全球死亡的38.0%（36.3—40.0）。青少年和年轻成人（15—39岁）癌症占非洲癌症总DALY的26.6%（26.4—27.5），40—64岁较年长成人占44.8%（43.8—45.6），65岁及以上成人占18.3%（17.4—19.1）。癌症对非洲疾病负担的贡献日益增长，病例、死亡和DALY不断上升，且对儿童、青少年和年轻成人造成不成比例的影响。年龄标化死亡率和DALY率的上升与2030年可持续发展目标和非洲联盟2063年议程的雄心形成鲜明对比。应对这一负担需要国家和国际协调行动，加强卫生系统，并制定涵盖预防、早期诊断和治疗的情境特异性癌症控制策略。盖茨基金会。"}, {"pmid": "42740896", "title": "Longitudinal Economic Burden for Non-Muscle-Invasive Bladder Cancer by EAU Progression Risk Groups Using the Prospective Multicenter COBLAnCE Cohort Linked to the French National Healthcare System Database.", "abstract": "Data on longitudinal bladder cancer (BC) costs are scarce. To assess the economic burden of non-muscle-invasive bladder cancer (NMIBC) by progression risk groups in France over a 1-yr and 5-yr time horizon after initial diagnosis. We used data from the French national prospective COhort to study BLAdder CancEr (COBLAnCE) cohort. A total of 1101 patients diagnosed with a primary NMIBC between 2012 and 2018 were linked with the French National Healthcare System Database. Patients were classified into four risk groups according to the 2021 European Association of Urology risk stratification. Resources used included all BC-related hospitalizations, follow-up visits to urology and oncology clinics and related prescriptions, BC-related imaging procedures, transportation, and sick leaves. Costs were estimated from the perspective of the French health care system over the 5 yr after BC diagnosis. Across risk groups, mean per-patient cost ranged from €5838 to €20 678 and €11 697 to €40 519 over 1 yr and 5 yr, respectively. Surgical hospital stays accounted for 60% of costs in the first year. Over 5 yr, intravesical treatments, surveillance visits, and imaging were major cost drivers, especially among patients at lower risk of progression. Although claims databases are comprehensive, the economic burden of NMIBC may be underestimated owing to potential incomplete coding. To our knowledge, this is the first national cohort study to provide robust cost estimates for patients with NMIBC stratified according to progression risk groups. These real-world data are particularly awaited for the economic evaluation of emerging treatments in patients with NMIBC.", "journal": "European Urology Open Science", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1016/j.euros.2026.08.005", "authors": ["Aldéric M Fraslin", "Simone Benhamou", "Thierry Lebret", "Yann Neuzillet", "Stéphane Droupy", "Grégoire Poinas", "Dimitri Vordos", "Laurent Guy", "Gautier Marcq", "Marc Schneider", "Patrick Coloby", "Arnaud Monges", "Arnaud Méjean", "Eric Potiron", "Jean-Luc Descotes", "Pascal Eschwege", "Guillaume Loison", "Clémentine Krucker", "Anthony Mangin", "François Radvanyi", "Yves Allory", "Maryam Karimi", "Julia Bonastre"], "affiliations": ["Department of Biostatistics and Epidemiology, Gustave Roussy, University Paris-Saclay, Villejuif, France.", "Oncostat U1018, INSERM, University Paris-Saclay, labeled Ligue Contre le Cancer, Villejuif, France.", "Urology, Foch Hospital, Université Versailles St-Quentin en Yvelines, Suresnes, France.", "Urology, University Hospital Center Caremeau, Nîmes, France.", "Urology, Clinique Beausoleil, Montpellier, France.", "Urology, University Hospital Center Henri Mondor, Créteil, France.", "Urology, University Hospital Center Gabriel Montpied, Clermont-Ferrand, France.", "Urology, Claude Huriez Hospital, CHU Lille F-59000 Lille, France.", "UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, Institut Pasteur de Lille, Université de Lille, CNRS, Inserm, CHU Lille F-59000 Lille, France.", "Urology, Pasteur Hospital, Colmar, France.", "Urology, NOVO Hospital, Pontoise, France.", "Urology, Private Hospital of Provence, Aix-en-Provence, France.", "Urology, European Hospital Georges Pompidou, Paris, France.", "Urology, Atlantis Clinic, Saint-Herblain, France.", "Urology, University Hospital Center Michallon, Grenoble, France.", "Urology, CHRU Nancy-Brabois, UMR 7039 CRAN CNRS, Vandoeuvre-lès-Nancy, France.", "Urology, la Croix du Sud Clinic, Quint Fonsegrives, France.", "Integrative Molecular Pathology and Pre-clinical Testing, Inserm U1353, CNRS UMR9029, Institut Curie, Université Versailles St-Quentin en Yvelines, Paris, France.", "Department of Pathology, Institut Curie, UMR 144 CNRS, Université Paris-Saclay, UVSQ, Paris, France."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=10", "score": 39.5, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 10.5, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 10.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.5, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.5, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42733748", "title": "Electrical Pudendal Nerve Stimulation as an Initial Neuromodulation Strategy for Neurogenic Urinary Retention.", "abstract": "Chronic neurogenic urinary retention often requires assisted emptying and remains challenging to treat. We evaluated whether electrical pudendal nerve stimulation (EPNS) improves bladder emptying and compared short-term outcomes with a standard sacral neuromodulation (SNM) test stimulation strategy. In this prospective, multicenter, assessor-masked study, 70 adults with chronic refractory neurogenic nonobstructive urinary retention received either EPNS (12 sessions over 4 wk) or a standard 4-wk continuous SNM test phase using a percutaneously placed S3 lead. The primary outcome was the percentage change from baseline in postvoid residual urine volume (PVR) at 4 wk. Secondary outcomes included changes in International Consultation on Incontinence Questionnaire-Lower Urinary Tract Symptoms and Quality of Life scores. Analyses used linear mixed models; propensity score matching was prespecified as a sensitivity analysis. At 4 wk, the adjusted PVR improvement rate was 68% with EPNS versus 51% with SNM (between-group difference 17 percentage points; 95% confidence interval 5-29; p = 0.008). Improvements in symptom and quality of life scores also favored EPNS (p < 0.001 for both). Limitations include nonrandom treatment allocation and short follow-up. Outpatient EPNS produced clinically meaningful short-term improvements in bladder emptying and patient-reported outcomes without implantation, supporting consideration of EPNS as an initial step in a stepped neuromodulation pathway for neurogenic urinary retention.", "journal": "European Urology Open Science", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1016/j.euros.2026.07.008", "authors": ["Tian Li", "Jiayi Xu", "Siyou Wang", "Jianwei Lv", "Zouqin Huang"], "affiliations": ["Shanghai Pudong Hospital of Traditional Chinese Medicine, Shanghai, China.", "Shanghai Fourth Rehabilitation Hospital, Shanghai, China.", "The Clinical Research Section, Shanghai Research Institute of Acupuncture and Meridian, Shanghai, China.", "Shanghai Pudong New Area Gongli Hospital, Shanghai, China."], "corresponding_authors": [], "china_team": "Shanghai Pudong Hospital of Traditional Chinese Medicine, Shanghai, China Zouqin Huang团队", "category": "clinical_review", "classification_reason": "clinical_signals=6", "score": 37.5, "score_parts": {"urology_relevance": 11, "urology_in_title": 8.0, "journal_priority": 10.5, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 6.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.5, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.5, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42733656", "title": "Promising Urinary Microbiome Signals in Congenital Anomalies of Kidney and Urinary Tract, but not yet Ready for Clinical Risk Stratification.", "abstract": "", "journal": "Kidney International Reports", "pub_date": "2026-Oct", "publication_types": ["Letter"], "doi": "10.1038/s41564-025-02035-2", "authors": ["Zhicheng Luo"], "affiliations": ["Taishan Hospital of Traditional Chinese Medicine, Jiangmen, Guangdong, China."], "corresponding_authors": [], "china_team": "Taishan Hospital of Traditional Chinese Medicine, Jiangmen, Guangdong, China Zhicheng Luo团队", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 25.79, "score_parts": {"urology_relevance": 3, "urology_in_title": 8.0, "journal_priority": 10.79, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 5.0, "abstract_completeness": -3.0, "basic_research_strength": 2.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 5.7, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.79, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "先天性尿路畸形尿微生物或可预警", "chinese_summary": "广东江门市泰山中医院罗志成团队2026年10月Kidney Int Rep发表通信文章，探讨先天性肾脏和泌尿道畸形患儿尿液微生物组特征，认为其信号具有提示价值，但样本与检测差异使其尚不足以用于临床风险分层，需前瞻性验证。", "abstract_zh": "这是致编辑的一封信，评论先天性肾脏和泌尿道畸形中尿微生物组的潜在作用。作者指出，相关研究提示尿液微生物组改变可能与先天性肾脏和泌尿道畸形及其临床表型相关，具有作为生物标志物的前景；然而，现有证据受限于样本量小、横断面设计、尿液采集与测序方法不一致、以及混杂因素（如抗生素暴露、膀胱输尿管反流和肾功能）控制不足。因此，尽管尿微生物组信号令人鼓舞，目前尚不能用于先天性肾脏和泌尿道畸形患者的临床风险分层，需开展前瞻性、标准化、多中心研究加以验证。"}, {"pmid": "42733517", "title": "Corrigendum to \"Urinary Microbiome Dysbiosis in Children With Congenital Uropathies at Varying Risk for Urinary Tract Infections\" [Kidney International Reports Volume 11, Issue 4, April 2026, 103799].", "abstract": "[This corrects the article DOI: 10.1016/j.ekir.2026.103799.].", "journal": "Kidney International Reports", "pub_date": "2026-Oct", "publication_types": ["Published Erratum"], "doi": "10.1016/j.ekir.2026.107043", "authors": ["Sachit Anand", "Omprakash Shete", "Anjali Srivastava", "Ajay Verma", "Sourav Goswami", "Sumit Aggarwal", "Kalpana Luthra", "Tarini Shankar Ghosh"], "affiliations": ["Department of Pediatric Surgery, All India Institute of Medical Sciences, New Delhi, India.", "Department of Computational Biology, Indraprastha Institute of Information Technology Delhi, New Delhi, India.", "Division of Descriptive Research, Indian Council of Medical Research, New Delhi, India.", "Department of Biochemistry, All India Institute of Medical Sciences, New Delhi, India."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "basic_signals=4", "score": 35.29, "score_parts": {"urology_relevance": 7, "urology_in_title": 8.0, "journal_priority": 10.79, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 5.0, "abstract_completeness": 0.5, "basic_research_strength": 4.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 5.7, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.79, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "先天性尿路病患儿尿微生物组研究更正", "chinese_summary": "10月Kidney International Reports发布更正声明，对2026年4月刊发的《先天性尿路病患儿在不同尿路感染风险下的尿微生物组失调》一文进行勘误。原研究探讨了先天性尿路畸形患儿尿微生物组失衡与尿路感染风险的关联，此次更正涉及原文数据或表述的修正，具体内容以期刊勘误说明为准。", "abstract_zh": "本文更正发表于DOI: 10.1016/j.ekir.2026.103799的文章。"}, {"pmid": "42730040", "title": "An engineered bacteria-chitosan hybrid robot for lactate depletion and synergistic STING activation to potentiate bladder cancer immunotherapy.", "abstract": "The treatment of bladder cancer faces multiple challenges, including poor tumor tissue penetration, low drug delivery efficiency, and an immunosuppressive microenvironment. To overcome these bottlenecks, this study constructed a novel bacteria-chitosan hybrid robot. The system utilizes electrostatic interactions to combine engineered Escherichia coli expressing lactate oxidase with positively charged chitosan nanoparticles, with the latter co-loaded with a chemotherapeutic drug Doxorubicin (DOX) and the DNA repair inhibitor olaparib. Following intravesical instillation, the engineered bacteria actively target and penetrate tumor tissues, significantly enhancing the accumulation and retention of nanomedicine at the lesion site. The bacteria colonizing the tumor continuously metabolize local lactate, which not only enhances chemosensitivity but also effectively alleviates tumor immunosuppression. Importantly, lactate consumption itself directly promotes the activation of the STING pathway. Simultaneously, the DOX and olaparib released synergistically induce DNA damage and cascade-activate the STING pathway. Chitosan itself also enhances STING signaling, thereby synergizing with the metabolic modulation by the engineered bacteria to further stimulate a potent antitumor immune response. Experimental results demonstrate that this hybrid robot can remodel the tumor immune microenvironment through multiple pathways and significantly enhance the therapeutic efficacy of anti-PD-L1 antibody therapy. This study provides a novel delivery strategy of EcLOX-CS@DOX-OLA with active targeting, metabolic modulation, and immune-activating functions for the combined treatment of bladder cancer.", "journal": "Materials Today Bio", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1016/j.mtbio.2026.103593", "authors": ["Baodan Zhang", "Jie Zhu", "Zhenyu Hong", "Yuhang Wang", "Yunong Wang", "Fangdie Ye", "Liping Tao", "Yongyong Lu"], "affiliations": ["Department of Urology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325000, China.", "Department of Psychiatry, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325000, China.", "Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai, 200000, China.", "Department of Gastroenterology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325000, China.", "Institute of Urology, Wenzhou Medical University, Wenzhou, 325000, China."], "corresponding_authors": [], "china_team": "Department of Urology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325000, China Yongyong Lu团队", "category": "basic", "classification_reason": "basic_signals=6", "score": 36.54, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 15.54, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 6.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 10.2, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.54, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "工程菌-壳聚糖机器人增强膀胱癌免疫治疗", "chinese_summary": "温州医科大学附属第一医院Yongyong Lu团队10月Materials Today Bio构建工程菌-壳聚糖混合机器人，经膀胱灌注后主动穿透肿瘤组织，持续代谢局部乳酸并协同释放多柔比星与奥拉帕利，通过多重途径重塑免疫微环境，显著增强抗PD-L1疗效。", "abstract_zh": "膀胱癌的治疗面临多重挑战，包括肿瘤组织穿透性差、药物递送效率低以及免疫抑制微环境。为克服这些瓶颈，本研究构建了一种新型的细菌-壳聚糖混合机器人。该系统利用静电相互作用，将表达乳酸氧化酶的工程化大肠杆菌与带正电荷的壳聚糖纳米颗粒结合，后者共载化疗药物多柔比星（DOX）和DNA修复抑制剂奥拉帕利。经膀胱内灌注后，工程菌主动靶向并穿透肿瘤组织，显著增强纳米药物在病灶部位的蓄积和滞留。定植于肿瘤的细菌持续代谢局部乳酸，这不仅增强化疗敏感性，还有效缓解肿瘤免疫抑制。重要的是，乳酸消耗本身直接促进STING通路的激活。同时，释放的DOX和奥拉帕利协同诱导DNA损伤并级联激活STING通路。壳聚糖本身也增强STING信号传导，从而与工程菌的代谢调节协同作用，进一步激发强效的抗肿瘤免疫应答。实验结果表明，该混合机器人可通过多条途径重塑肿瘤免疫微环境，并显著增强抗PD-L1抗体疗法的疗效。本研究为膀胱癌的联合治疗提供了一种具有主动靶向、代谢调节和免疫激活功能的新型EcLOX-CS@DOX-OLA递送策略。"}, {"pmid": "42728123", "title": "Systemic therapies in prostate cancer: A field in transformation.", "abstract": "", "journal": "Urologic Oncology", "pub_date": "2026-Oct", "publication_types": ["Editorial"], "doi": "10.1016/j.urolonc.2026.08.026", "authors": ["Clara Hwang"], "affiliations": ["Department of Internal Medicine, Division of Hematology/Oncology, Henry Ford Health, Detroit, MI; Department of Internal Medicine, College of Human Medicine, Michigan State University, East Lansing, MI. Electronic address: chwang2@hfhs.org."], "corresponding_authors": ["Clara Hwang"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 14.75, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 5.75, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.3, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.75, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42716079", "title": "Development and external validation of a new prognostic model for metastatic clear cell renal cell carcinoma: a preregistered analysis using data from randomised clinical trials in the checkpoint inhibitor era.", "abstract": "Prognostic classification of patients with metastatic clear cell renal cell carcinoma (mccRCC) is instrumental for clinical trials and treatment decisions. Hence, optimal performance of prognostic models is crucial. This study aimed to develop and externally validate the new Clinical Prognostic Index in the Checkpoint Inhibitor era (CPI2) model using clinical trial data, and to externally validate the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model. Individual patient data from the clinical trials CheckMate-214 and CheckMate-9ER were used for development and external validation of the CPI2 model, respectively. Both trials included previously untreated mccRCC patients of all IMDC prognostic groups and Karnofsky performance status of at least 70%, and randomly allocated them to receive either sunitinib or nivolumab plus ipilimumab (CheckMate-214) or nivolumab plus cabozantinib (CheckMate-9ER). Using a Cox proportional hazards model, predictors were selected from a list of patient, disease, and laboratory parameters using Akaike information criterion-based backwards selection. Bootstrapping was used to estimate coefficients and a shrinkage factor to correct for optimism. Calibration plots and Uno's C-index for discriminative accuracy were calculated for the CPI2 model and IMDC model in both trial populations. Data from 1096 patients included in CheckMate-214 between October, 2014, and February, 2016, and 651 patients included in CheckMate-9ER between September, 2017, and May, 2019, were used. Median follow-up was 40 months (IQR 13-94) in CheckMate-214 data and 38 months (15-53) in CheckMate-9ER data. In total, 665 (38%) of 1747 patients were aged 65 years or older; 1289 (74%) were male, and 458 (26%) were female. A prognostic model based on age, Karnofsky performance status, previous nephrectomy, metastatic locations (liver, lung, bone, and lymph node), and seven laboratory parameters (calcium, alkaline phosphatase, albumin, lactate dehydrogenase, absolute neutrophil count, lymphocyte count, and white blood cell count) was developed based on CheckMate-214 data. Classification into three prognostic groups provided discriminative accuracy at 36 months of 0·72 (95% CI 0·69-0·75) in CheckMate-214 and 0·72 (0·68-0·76) in CheckMate-9ER, which was 0·65 (0·62-0·68) and 0·61 (0·57-0·65) for the IMDC classification, respectively. Calibration showed adequate agreement between predicted and observed mortality risks. PD-L1 expression did not improve prognostic accuracy. CPI2 favourable, intermediate, and poor risk groups included 472 (43%), 366 (33%), and 258 (24%) of 1096 CheckMate-214 patients and 257 (39%), 196 (30%), and 198 (30%) of 651 CheckMate-9ER patients, respectively. The CPI2 model, using 14 readily available clinical parameters, demonstrated improvement in discriminative accuracy compared with the IMDC model. This classification should be further validated in other trial and observational populations and be used to reanalyse heterogeneity of treatment effects of immune checkpoint inhibitor-based combination regimens in trials shaping the current and future treatment landscape. Josephine Nefkens Foundation.", "journal": "Lancet Oncology", "pub_date": "2026-Oct", "publication_types": ["Journal Article", "Validation Study"], "doi": "10.1016/S1470-2045(26)00338-4", "authors": ["Anke Richters", "Marinde J G Bond", "Hans M Westgeest", "Berna C Özdemir", "Johanna A A Damen", "Katja K H Aben", "Axel Bex"], "affiliations": ["Department of Research and Development, The Netherlands Comprehensive Cancer Organisation, Utrecht, Netherlands. Electronic address: a.richters@iknl.nl.", "Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands; Department of Internal Medicine, Antonius Hospital, Nieuwegein, Netherlands.", "Department of Internal Medicine, Amphia Hospital, Breda, Netherlands.", "Department of Medical Oncology, Inselspital Bern, University Hospital of Bern, Bern, Switzerland.", "Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands; Cochrane Netherlands, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands.", "Department of Research and Development, The Netherlands Comprehensive Cancer Organisation, Utrecht, Netherlands; IQ Health Science Department, Radboud University Medical Center, Nijmegen, Netherlands.", "Department of Urology, Netherlands Cancer Institute, Amsterdam, Netherlands; Specialist Centre for Kidney Cancer, The Royal Free London NHS Foundation Trust, London, UK; Division of Surgery and Interventional Science, University College London, London, UK."], "corresponding_authors": ["Anke Richters"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=8", "score": 53.79, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 17.29, "top_journal_bonus": 10.0, "novelty": 0.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 8.0}, "journal_metrics": {"status": "ok", "impact_factor": 35.9, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 5.29, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "免疫时代肾癌新预后模型区分度更优", "chinese_summary": "Lancet Oncol基于CheckMate-214与CheckMate-9ER试验数据开发并外部验证CPI2模型：纳入年龄、KPS、既往肾切除、转移部位及7项实验室指标共14个易得参数，36个月区分度达0.72，高于IMDC模型的0.65与0.61，校准良好，PD-L1表达未提升准确性，可用于再分析免疫联合方案疗效异质性。", "abstract_zh": "转移性透明细胞肾细胞癌（mccRCC）患者的预后分类对于临床试验和治疗决策至关重要。因此，预后模型的最佳性能至关重要。本研究旨在利用临床试验数据开发并外部验证新的检查点抑制剂时代临床预后指数（CPI2）模型，并外部验证国际转移性肾细胞癌数据库联盟（IMDC）模型。分别使用CheckMate-214和CheckMate-9ER临床试验的个体患者数据来开发和外部验证CPI2模型。这两项试验均纳入既往未经治疗、涵盖所有IMDC预后分组且Karnofsky体能状态至少70%的mccRCC患者，并将其随机分配至接受舒尼替尼或纳武利尤单抗联合伊匹木单抗（CheckMate-214）或纳武利尤单抗联合卡博替尼（CheckMate-9ER）。使用Cox比例风险模型，通过基于Akaike信息准则的后退法从患者、疾病和实验室参数列表中选择预测因子。采用自举法估计系数和收缩因子以校正乐观偏倚。在两个试验人群中分别计算CPI2模型和IMDC模型的校准图及用于区分准确性的Uno C指数。使用了2014年10月至2016年2月期间纳入CheckMate-214的1096例患者和2017年9月至2019年5月期间纳入CheckMate-9ER的651例患者的数据。CheckMate-214数据的中位随访时间为40个月（IQR 13-94），CheckMate-9ER数据为38个月（15-53）。1747例患者中，665例（38%）年龄65岁或以上；1289例（74%）为男性，458例（26%）为女性。基于CheckMate-214数据开发了一个预后模型，其基于年龄、Karnofsky体能状态、既往肾切除术、转移部位（肝、肺、骨和淋巴结）以及七项实验室参数（钙、碱性磷酸酶、白蛋白、乳酸脱氢酶、中性粒细胞绝对计数、淋巴细胞计数和白细胞计数）。分为三个预后分组后，36个月时的区分准确性在CheckMate-214中为0.72（95% CI 0.69-0.75），在CheckMate-9ER中为0.72（0.68-0.76），而IMDC分类分别为0.65（0.62-0.68）和0.61（0.57-0.65）。校准显示预测死亡风险与观察死亡风险之间具有足够的一致性。PD-L1表达并未提高预后准确性。CPI2良好、中等和不良风险组分别包括1096例CheckMate-214患者中的472例（43%）、366例（33%）和258例（24%），以及651例CheckMate-9ER患者中的257例（39%）、196例（30%）和198例（30%）。CPI2模型使用14个易于获得的临床参数，与IMDC模型相比显示出区分准确性的改善。该分类应在其他试验和观察人群中进一步验证，并用于重新分析塑造当前和未来治疗格局的试验中基于免疫检查点抑制剂的联合方案的治疗效应异质性。Josephine Nefkens基金会。"}, {"pmid": "42713893", "title": "Durvalumab in Combination with Bacillus Calmette-Guérin Induction and Maintenance Therapy for Bacillus Calmette-Guérin-Naïve, High-Risk Non-muscle-Invasive Bladder Cancer: Expanded Efficacy and Safety Analyses from POTOMAC: Erratum.", "abstract": "", "journal": "Journal of Urology", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1097/JU.0000000000005170", "authors": ["Neal D Shore", "Hiroyuki Nishiyama", "Joan Palou Redorta", "Michał Krawczyński", "Artur Seyitkuliev", "Andrey Novikov", "Félix Guerrero-Ramos", "Minoru Kato", "Lieven Goeman", "Eva Hellmis", "Thomas Powles", "Kilian M Gust", "Paul Vasey", "Pierre Bigot", "Yves Fradet", "Robert Zielinski", "Julien Deturmeny", "Girish Kulkarni", "Jarmo Hunting", "Purnima Rao-Melacini", "Suliman Boulos", "Angie K Marsh", "Maria De Santis"], "affiliations": [], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 20.01, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 11.01, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 6.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 3.01, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42710083", "title": "Multimodal Management of Advanced Metastatic Prostate Cancer: Excellent Response Following Resection of Brain Metastasis and 177Lu-PSMA Therapy.", "abstract": "A 68-year-old man with metastatic prostate adenocarcinoma was treated with androgen-deprivation therapy and chemotherapy. Restaging 68Ga-PSMA PET/CT revealed a PSMA-avid lesion in the left temporal lobe, which was treated with brain radiotherapy. Subsequent PSMA PET/CT showed brain lesion progression and skeletal metastases. He underwent brain lesion resection followed by 4 cycles of 177Lu-PSMA-617, achieving near-complete resolution of skeletal metastasis. This case highlights the importance of multimodal treatment, including 177Lu-PSMA, in managing brain metastasis in prostate cancer.", "journal": "Clinical Nuclear Medicine", "pub_date": "2026-Oct-01", "publication_types": ["Journal Article", "Case Reports"], "doi": "10.1097/RLU.0000000000006543", "authors": ["Ghasemali Divband", "Hamidreza Amini", "Hamid Saeidi Saedi", "Seyed A Shahvarani", "Pegah Sahafi"], "affiliations": ["Nuclear Medicine Center, Jam Hospital.", "Khatam PET/CT Center, Tehran.", "Department of Radiation Oncology, Guilan University of Medical Sciences, Guilan.", "Surgical Oncology Research Center, Mashhad University of Medical Sciences.", "Nuclear Medicine Research Center, Mashhad University of Medical Science, Mashhad, Iran Kosar Hospital, Semnan University of Medical Sciences, Semnan, Iran."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_clinical", "score": 22.46, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 7.46, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 1.0}, "journal_metrics": {"status": "ok", "impact_factor": 9.6, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 3.46, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42710082", "title": "Detected Huge Urinoma With 99mTc-PSMA Activity on Initial Prostate Cancer Staging.", "abstract": "A 62-year-old man with newly diagnosed prostate adenocarcinoma underwent initial staging with 99mTc-PSMA and 99mTc-MDP whole-body scans. The bone scan revealed a small zone of tracer activity superior to the left kidney. Subsequent 99mTc-PSMA SPECT/CT revealed a fluid density collection in the left perinephric and pararenal space, extending from the left subdiaphragmatic area to the pelvic inlet. PSMA tracer activity was seen around the left kidney. Contrast-enhanced CT confirmed a perinephric fluid collection consistent with urinoma. This case underscores the importance of recognizing atypical patterns of 99mTc-PSMA uptake to improve diagnostic accuracy, avoid misinterpretation, and ensure appropriate patient management.", "journal": "Clinical Nuclear Medicine", "pub_date": "2026-Oct-01", "publication_types": ["Journal Article", "Case Reports"], "doi": "10.1097/RLU.0000000000006454", "authors": ["Mohammad Ahmadi", "Mohammad H Samadi", "Amin Saber Tanha", "Emran Askari", "Mohammad Aslzare", "Vahid Reza Dabbagh Kakhki"], "affiliations": ["Nuclear Medicine Research Center.", "Department of Urology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_clinical", "score": 23.96, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 7.46, "top_journal_bonus": 0.0, "novelty": 0.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 2.0}, "journal_metrics": {"status": "ok", "impact_factor": 9.6, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 3.46, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42701997", "title": "Seminiferous Tubules-Targeted Resveratrol Carbon Dots With Sertoli Cell Biomimetic Vesicles Fusion for Improving Spermatogenesis of Cryptorchidism.", "abstract": "Impaired blood-testis barrier (BTB) integrity, induced by oxidative stress, is one of the primary factors leading to spermatogenic disorders in cryptorchidism. Therefore, the targeted elimination of testicular oxidative stress and repair of the BTB are promising strategies for promoting spermatogenesis in patients with cryptorchidism. This study aimed to demonstrate the potential of Sertoli cell membrane-camouflaged biomimetic vesicles loaded with resveratrol carbon dots (RCD@PCy@EVs) as a therapeutic nanoagent for cryptorchidism treatment in vivo. The prepared RCD@PCy@EVs are actively targeted to the seminiferous tubules by leveraging the homing tendency of the Sertoli cell membrane, guided by fluorescence imaging. The RCD@PCy@EVs not only reshape the redox microenvironment of the seminiferous tubules and alleviate inflammatory responses by scavenging reactive oxygen species, but they also increase the expression of the tight junction protein β-catenin and restore BTB integrity, which is associated with the activation of the SIRT1/AMPKα/FOXO1 signaling pathway. More importantly, functional spermatogenesis is markedly improved by RCD@PCy@EVs, effectively restoring reproductive function in cryptorchid mice. The RCD@PCy@EVs-mediated therapy for cryptorchidism offers a novel strategy for treating male infertility.", "journal": "Advanced Healthcare Materials", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1002/adhm.71671", "authors": ["Chaoying Liu", "Xipeng Li", "Bin Li", "Hua Yang", "Ye Wang", "Zhisheng Ji", "Judun Zheng", "Yuhui Liao", "Enzhong Li"], "affiliations": ["School of Medicine, Huanghuai University, Zhumadian, China.", "China Pharmaceutical Valley (Zhumadian) Research Institute, Huanghuai University, Zhumadian, China.", "Institute for Engineering Medicine, Kunming Medical University, Kunming, China.", "School of Inspection, Ningxia Medical University, Yinchuan, Ningxia, China.", "Department of Orthopedics, The First Affiliated Hospital of Jinan University, Guangzhou, China.", "College of Biology and Food Engineering, Huanghuai University, Zhumadian, China.", "Dermatology Hospital, Southern Medical University, Guangzhou, China."], "corresponding_authors": [], "china_team": "School of Medicine, Huanghuai University, Zhumadian, China Enzhong Li团队", "category": "basic", "classification_reason": "basic_signals=14", "score": 34.46, "score_parts": {"urology_relevance": 6, "urology_in_title": 0.0, "journal_priority": 11.46, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 14.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 9.6, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 3.46, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "仿生纳米囊泡靶向修复血睾屏障", "chinese_summary": "黄淮学院医学院Enzhong Li团队9月Adv Healthc Mater报道，以支持细胞膜仿生囊泡融合白藜芦醇碳点（RCD@PCy@EVs），经荧光成像引导主动靶向生精小管；该纳米剂清除活性氧、重塑氧化还原微环境并减轻炎症，上调紧密连接蛋白β-catenin修复血睾屏障，与SIRT1/AMPKα/FOXO1通路激活相关，在隐睾小鼠中明显改善精子。", "abstract_zh": "由氧化应激诱导的血睾屏障（BTB）完整性受损是导致隐睾生精障碍的主要因素之一。因此，靶向清除睾丸氧化应激并修复BTB是促进隐睾患者精子发生的有前景的策略。本研究旨在证明负载白藜芦醇碳点的支持细胞膜伪装仿生囊泡（RCD@PCy@EVs）作为体内治疗隐睾的潜在纳米药物。所制备的RCD@PCy@EVs利用支持细胞膜的归巢倾向，在荧光成像引导下主动靶向生精小管。RCD@PCy@EVs不仅通过清除活性氧重塑生精小管的氧化还原微环境并减轻炎症反应，还增加紧密连接蛋白β-catenin的表达并恢复BTB完整性，这与SIRT1/AMPKα/FOXO1信号通路的激活相关。更重要的是，RCD@PCy@EVs显著改善功能性精子发生，有效恢复隐睾小鼠的生殖功能。RCD@PCy@EVs介导的隐睾治疗为男性不育治疗提供了新策略。"}, {"pmid": "42699359", "title": "Oncologic Outcomes in a Contemporary \"PROTEUS-like\" Cohort of High-risk Prostate Cancer Treated with Radical Prostatectomy Without Neoadjuvant Hormonal Therapy.", "abstract": "High-risk prostate cancer (PCa) carries substantial risks of recurrence, metastasis, and mortality. Neoadjuvant therapy before radical prostatectomy (RP) remains investigational. The PROTEUS (NCT03767244) trial evaluates perioperative apalutamide + androgen deprivation therapy (ADT) but lacks a surgery-only control cohort. The objective of this study is to characterize oncologic outcomes in patients with PROTEUS-like high-risk PCa undergoing RP without neoadjuvant therapy. We performed a retrospective, single-center cohort study of consecutive patients fulfilling PROTEUS high-risk criteria who underwent RP with lymphadenectomy without prior ADT or neoadjuvant treatment. The primary outcome was biochemical recurrence-free survival (BCR-FS). Secondary outcomes included metastasis-free survival (MFS), event-free survival (EFS), and cancer-specific survival (CSS). Among 1392 patients, median follow-up was 60 mo (95% confidence interval [CI], 56-64); 67% received postoperative radiotherapy. BCR-FS at 36, 60, and 120 mo was 60% (95% CI, 57-64), 44% (95% CI, 40-49), and 22% (95% CI, 17-28), respectively. MFS was 79% (95% CI, 76-83), 71% (95% CI, 66-76), and 56% (95% CI, 47-65), respectively. EFS was 56% (95% CI, 52-60), 40% (95% CI, 36-45), and 18% (95% CI, 13-23), respectively. CSS remained high at 95.5% (95% CI, 94-97), 92% (95% CI, 90-94), and 86% (95% CI, 81-91), respectively. Limitations include the retrospective, single-center design, absence of centralized pathology review, and maturing follow-up. These findings demonstrate substantial rates of recurrence and metastatic progression despite contemporary management, underscoring the persistent unmet need in this population and providing a rationale for prospective evaluation of perioperative treatment intensification strategies such as PROTEUS.", "journal": "European Urology Open Science", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1056/NEJMoa2603878", "authors": ["Can Aydogdu", "Benso John", "Clara Seizer", "Frederik Kolligs", "Iason Papadopoulos", "Alexander Buchner", "Elena K Berg", "Jozefina Casuscelli", "Julie Steinestel", "Roman Mayr", "Matthias Heck", "Christian G Stief", "Thilo Westhofen"], "affiliations": ["Department of Urology, LMU University Hospital Munich, Munich, Germany.", "Urology, Faculty of Medicine, University of Augsburg, Augsburg, Germany."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=12", "score": 36.5, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.5, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 12.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.5, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.5, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42697217", "title": "An integrated lifestyle intervention for mitigation of adverse effects associated with androgen deprivation therapy for prostate cancer (STAMINA): a multicentre, randomised trial.", "abstract": "Androgen deprivation therapy (ADT) for prostate cancer causes substantial adverse effects. Despite consistent national and international guideline recommendations, supervised exercise is rarely integrated into care. We aimed to determine whether the STAMINA lifestyle intervention, embedded into cancer care, would improve cancer-specific quality of life and fatigue versus behaviourally Optimised Usual Care in men with prostate cancer in England. STAMINA was a multicentre, randomised trial done across 15 UK National Health Service (NHS) trusts in England. Men on ADT for prostate cancer were eligible. Participants were randomly assigned (5:4) via computer-generated minimisation, stratified by age, ADT duration, chemotherapy or androgen receptor pathway inhibitor therapy, and radiotherapy, to the STAMINA lifestyle intervention or to Optimised Usual Care. Participants were aware of treatment allocation. The STAMINA lifestyle intervention comprised supervised aerobic and resistance exercise for 12 months, dietary advice, behavioural support, and complimentary gym membership. Optimised Usual Care comprised clinician training, educational materials, behavioural prompts, and safety-to-exercise checks. Primary outcomes were the Functional Assessment of Cancer Therapy-prostate (FACT-P) and the Functional Assessment of Chronic Illness Therapy-fatigue (FACIT-F) subscale at 12 months, analysed by intention to treat (according to randomised treatment). This trial is registered with ISRCTN (ISRCTN46385239), and recruitment is complete. Between Jan 20, 2022, and June 12, 2023, 700 men were randomly assigned to STAMINA lifestyle intervention (n=389) or Optimised Usual Care (n=311). Median age was 71·6 years (IQR 66·3-76·0), and 680 (97%) of 700 participants were White. Primary outcome data were available for 345 (89%) of 389 participants in the STAMINA lifestyle intervention group and 251 (81%) of 311 in the Optimised Usual Care group. The STAMINA lifestyle intervention was superior to Optimised Usual Care in terms of FACT-P score (adjusted mean difference 4·5, 97·232% CI 1·7-7·2; p=0·0004) and FACIT-F score (1·9, 0·4-3·4; p=0·0068). Three intervention-related serious adverse events occurred in the STAMINA lifestyle intervention group (transient loss of consciousness, leg pain or weakness, and back pain); all participants recovered. No treatment-related deaths occurred. The STAMINA lifestyle intervention meets best practice guidelines, can be implemented in NHS trusts in England, and offers clinicians a clear basis for identification and prescription of a supervised exercise and dietary advice intervention to mitigate negative effects associated with ADT. National Institute for Health Research.", "journal": "Lancet Oncology", "pub_date": "2026-Oct", "publication_types": ["Journal Article", "Multicenter Study", "Randomized Controlled Trial"], "doi": "10.1016/S1470-2045(26)00304-9", "authors": ["Liam Bourke", "Derek J Rosario", "Sophie Reale", "Said Ibeggazene", "Aidan Innes", "Alison Scope", "Grace Price", "Steph Taylor", "Liz Steed", "Eileen Sutton", "Jamie Stokes", "Jenny Hewison", "Dylan Morrissey", "Patrick Doherty", "Janet Brown", "David Meads", "John L O'Dwyer", "Davina Deniszczyc", "Diana M Greenfield", "Malcolm Mason", "Michelle Collinson", "Amanda Farrin", "STAMINA investigators"], "affiliations": ["School of Health and Social Care, CARe Research Centre, Sheffield Hallam University, Sheffield, UK.", "School of Health and Social Care, CARe Research Centre, Sheffield Hallam University, Sheffield, UK; Sheffield Teaching Hospitals NHS Trust, Sheffield, UK. Electronic address: derek.rosario@nhs.net.", "Nuffield Health, Epsom, Surrey, UK.", "Wolfson Institute of Population Health, Queen Mary University of London, London, UK.", "University of Bristol, Bristol, UK.", "Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.", "Leeds Institute of Health Sciences, University of Leeds, Leeds, UK.", "Sports and Exercise Medicine, Queen Mary University of London, London, UK; Barts Health NHS Trust, London, UK.", "Department of Health Sciences, University of York, York, UK.", "Division of Clinical Medicine, University of Sheffield, Sheffield, UK.", "Sheffield Teaching Hospitals NHS Trust, Sheffield, UK.", "Cardiff University, Cardiff, UK.", "Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK; Edinburgh Clinical Trials Unit, University of Edinburgh, Edinburgh, UK."], "corresponding_authors": ["Derek J Rosario"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_interventional_trial", "score": 50.29, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 17.29, "top_journal_bonus": 10.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 9.0}, "journal_metrics": {"status": "ok", "impact_factor": 35.9, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 5.29, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "生活方式干预改善ADT患者生活质量", "chinese_summary": "9月Lancet Oncol发表英国15家NHS信托机构STAMINA多中心随机试验，700例接受雄激素剥夺治疗的前列腺癌患者随机接受为期12个月的监督下运动、饮食指导及行为支持干预或优化常规护理。结果显示，干预组FACT-P评分较对照组提高4.5分，FACIT-F评分提高1.9分，支持将生活方式干预整合进NHS癌症照护以缓解ADT相关不良反应。", "abstract_zh": "前列腺癌的雄激素剥夺治疗（ADT）会导致显著的不良反应。尽管国家和国际指南一致推荐，监督下运动仍很少被整合进照护。我们旨在确定将STAMINA生活方式干预嵌入癌症照护，是否较行为优化的常规护理能改善英格兰前列腺癌男性的癌症特异性生活质量和疲乏。STAMINA是一项在英格兰15家英国国家医疗服务体系（NHS）信托机构开展的多中心随机试验。接受ADT治疗的前列腺癌男性符合条件。参与者通过计算机生成的最小化法按5:4随机分配，并按年龄、ADT持续时间、化疗或雄激素受体通路抑制剂治疗及放疗进行分层，接受STAMINA生活方式干预或优化常规护理。参与者知晓治疗分配。STAMINA生活方式干预包括为期12个月的监督下有氧和抗阻运动、饮食建议、行为支持及免费健身房会员。优化常规护理包括临床医生培训、教育材料、行为提示及运动安全检查。主要结局为12个月时前列腺癌治疗功能评估（FACT-P）和慢性病治疗功能评估-疲乏（FACIT-F）子量表，按意向治疗（根据随机治疗）分析。该试验注册于ISRCTN（ISRCTN46385239），招募已完成。2022年1月20日至2023年6月12日期间，700名男性被随机分配至STAMINA生活方式干预组（n=389）或优化常规护理组（n=311）。中位年龄为71.6岁（IQR 66.3-76.0），700名参与者中680名（97%）为白人。STAMINA生活方式干预组389名参与者中345名（89%）和优化常规护理组311名中251名（81%）有主要结局数据。STAMINA生活方式干预在FACT-P评分（校正平均差4.5，97.232% CI 1.7-7.2；p=0.0004）和FACIT-F评分（1.9，0.4-3.4；p=0.0068）方面优于优化常规护理。STAMINA生活方式干预组发生3例干预相关严重不良事件（短暂意识丧失、腿痛或无力、背痛）；所有参与者均恢复。未发生治疗相关死亡。STAMINA生活方式干预符合最佳实践指南，可在英格兰NHS信托机构实施，并为临床医生提供了明确依据，以识别和处方监督下运动及饮食建议干预，从而减轻ADT相关负面影响。英国国家卫生研究院。"}, {"pmid": "42692375", "title": "Spatial atlas of upper tract urothelial carcinoma identifies SLC14A1 + and S100A8/9+ tumor cells as key determinants of malignant progression.", "abstract": "Upper tract urothelial carcinoma (UTUC) is characterized by a high incidence of muscle invasion and distinct molecular heterogeneity, with tumor microenvironment (TME) heterogeneity playing a pivotal role in its malignant progression. However, the spatial distribution patterns of functional cell populations in UTUC and their regulatory mechanisms driving high-grade (HG) and muscle-invasive (MI) progression remain largely unelucidated. Herein, we integrated single-cell RNA sequencing (scRNA-seq) and spatial transcriptome sequencing (ST-seq) to systematically characterize the cellular landscape, spatial molecular network, and intercellular communication profile of UTUC tissues. Six tumor cell subpopulations were identified in UTUC, among which SLC14A1⁺ tumor cells were correlated with favorable clinical prognosis, whereas S100A8/9⁺ tumor cells were associated with poor clinical outcomes. Mechanistically, SLC14A1⁺ tumor cells decelerated UTUC progression via modulating cell apoptosis mediated by the FASLG-TNFRSF10B ligand-receptor pair. In contrast, S100A8/9⁺ tumor cells promoted the malignant progression of UTUC by regulating extracellular matrix remodeling and epithelial-mesenchymal transition (EMT) via the CCL19-CCR7, CCN2-EGFR, ADAM28-ITGA4 and CD14-ITGB2 ligand-receptor pairs. Collectively, our study uncovers the cellular and spatial heterogeneity of the UTUC TME, identifies SLC14A1⁺ tumor cells as a tumor-suppressive subpopulation and S100A8/9⁺ tumor cells as a key driver of UTUC malignant progression, and further delineates the core spatial signaling pathways underlying HG and MI progression of UTUC. These findings provide novel prognostic biomarkers and potential therapeutic targets for UTUC, and advance our mechanistic understanding of spatial TME regulation in urothelial carcinoma.", "journal": "Pharmacological Research", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1016/j.phrs.2026.108431", "authors": ["Jiang Liu", "Yangyang Wei", "Yi Liu", "Shiwei Sun", "Diliyaer Dilixiati", "Zhou Zhou", "Xiangyun Lu", "Ping Lu", "Yang Zhao", "YuShi Zhang"], "affiliations": ["Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.", "Department of International Medical Service (Xidan Campus), Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.", "Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. Electronic address: zhaoyangkypumch@163.com.", "Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. Electronic address: beijingzhangyushi@126.com."], "corresponding_authors": ["Yang Zhao", "YuShi Zhang"], "china_team": "Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China Yang Zhao/YuShi Zhang团队", "category": "basic", "classification_reason": "basic_signals=17", "score": 42.58, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 11.58, "top_journal_bonus": 0.0, "novelty": 3.0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 14.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 10.5, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 3.58, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "上尿路尿路上皮癌空间图谱锁定两类关键肿瘤细胞", "chinese_summary": "北京协和医院赵阳/张玉石团队9月Pharmacol Res整合单细胞与空间转录组测序，在上尿路尿路上皮癌中识别出6个肿瘤细胞亚群。其中SLC14A1⁺肿瘤细胞经FASLG-TNFRSF10B通路促进凋亡、预示良好预后，而S100A8/9⁺肿瘤细胞通过细胞外基质重塑及上皮-间质转化驱动恶性进展，为预后标志物及治疗靶点提供新线索。", "abstract_zh": "上尿路尿路上皮癌（UTUC）以肌层浸润发生率高和分子异质性显著为特征，其中肿瘤微环境（TME）异质性在其恶性进展中起关键作用。然而，UTUC中功能性细胞群体的空间分布模式及其驱动高级别（HG）和肌层浸润（MI）进展的调控机制在很大程度上仍未阐明。本研究整合单细胞RNA测序（scRNA-seq）和空间转录组测序（ST-seq），系统刻画了UTUC组织的细胞图谱、空间分子网络及细胞间通讯特征。在UTUC中鉴定出6个肿瘤细胞亚群，其中SLC14A1⁺肿瘤细胞与良好的临床预后相关，而S100A8/9⁺肿瘤细胞与不良临床结局相关。机制上，SLC14A1⁺肿瘤细胞通过FASLG-TNFRSF10B配体-受体对调控细胞凋亡，从而减缓UTUC进展。相反，S100A8/9⁺肿瘤细胞通过CCL19-CCR7、CCN2-EGFR、ADAM28-ITGA4和CD14-ITGB2配体-受体对调控细胞外基质重塑和上皮-间质转化（EMT），促进UTUC恶性进展。总之，本研究揭示了UTUC TME的细胞和空间异质性，鉴定出SLC14A1⁺肿瘤细胞为抑瘤性亚群、S100A8/9⁺肿瘤细胞为UTUC恶性进展的关键驱动者，并进一步阐明了UTUC高级别和肌层浸润进展背后的核心空间信号通路。这些发现为UTUC提供了新的预后生物标志物和潜在治疗靶点，并推进了对尿路上皮癌空间TME调控机制的理解。"}, {"pmid": "42686439", "title": "Prostate lymphoma uncovered during urological encounters: Diagnostic challenges and clinical outcomes in a case series with systematic review of the literature.", "abstract": "Prostatic lymphoma is a rare malignancy that can clinically resemble benign prostatic hyperplasia (BPH) or adenocarcinoma, often delaying diagnosis. Primary prostatic lymphoma (PPL) comprises <0.1% of prostate tumors and non-Hodgkin lymphomas, whereas secondary involvement occurs more commonly in systemic disease. A retrospective review was conducted at the University of Miami Health System (2015-2024). All prostate specimens demonstrating lymphoma or related hematologic malignancies were identified. Clinical data, including demographics, presenting symptoms, prostate-specific antigen (PSA), imaging, uroflowmetry, histopathology, urological and oncologic treatment, and outcomes, were collected. A PubMed and Embase literature review was performed to identify reported PPL cases. Seven patients (age range 47-89) were diagnosed with prostatic lymphoma. Presenting features included lower urinary tract symptoms, hematuria, urinary retention, pelvic pain, and systemic B symptoms. Histologic findings included diffuse large B-cell lymphoma (n = 3), chronic lymphocytic leukemia/small lymphocytic lymphoma (n = 2), low-grade B-cell lymphoma (n = 1), mucosa-associated lymphoid tissue (MALT) lymphoma (n = 1), and mantle cell lymphoma (n = 1). One additional case of myeloid sarcoma was identified and reported separately. Several diagnoses followed tissue sampling during radical prostatectomy, holmium laser enucleation of the prostate (HoLEP), or transurethral resection of prostate (TURP) for presumed BPH. Management varied, including rituximab-based chemoimmunotherapy, targeted agents, radiotherapy, and conservative strategies. Outcomes ranged from remission to systemic progression. The literature review identified 65 studies involving 160 patients with PPL. Prostatic lymphoma is a heterogeneous entity with presentations that overlap with those of common urologic conditions. Histopathologic confirmation is essential in patients with atypical features or poor response to BPH therapies. Early recognition and multidisciplinary coordination are vital.", "journal": "Urologic Oncology", "pub_date": "2026-Oct", "publication_types": ["Journal Article", "Systematic Review"], "doi": "10.1016/j.urolonc.2026.07.033", "authors": ["Daniel Ajabshir", "Gurpremjit Singh", "Aravindh Rathinam", "Ahmad Abdelaziz", "Hasim Bakbak", "Pritish Kendrekar", "Diego M Montoya-Cerrillo", "Archan Khandekar", "Jonathan E Katz", "Robert Marcovich", "Oleksandr N Kryvenko", "Hemendra N Shah"], "affiliations": ["FIU Herbert Wertheim College of Medicine, Miami, FL.", "Desai Sethi Urology Institute, University of Miami Miller School of Medicine, Miami, FL.", "Byramjee Jeejeebhoy Government Medical College and Sassoon General Hospitals, Pune, India.", "Department of Pathology and Laboratory Medicine, University of Miami Miller School of Medicine, Miami, FL.", "Desai Sethi Urology Institute, University of Miami Miller School of Medicine, Miami, FL. Electronic address: drhemendrashah@yahoo.co.in."], "corresponding_authors": ["Hemendra N Shah"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 38.75, "score_parts": {"urology_relevance": 18.0, "urology_in_title": 8.0, "journal_priority": 5.75, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 5.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.3, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.75, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42685888", "title": "Enzyme-driven micro- and nanomotors: Design, construction and biological applications.", "abstract": "Enzyme-powered micro/nanomotors (EMNMs) are a type of self-propelled devices that biologically convert chemical energy into mechanical work through enzyme-catalyzed reactions. Compared to conventional chemically driven counterparts, a significant advantage of these platforms lies in their utilization of endogenous substrates, such as glucose, urea, glycerides, and peptides, to achieve autonomous propulsion. Through the rational design and regulation of functional material components, EMNMs can efficiently perform tasks ranging from active target recognition to autonomous drug loading and controlled release for biomedical applications. Additionally, emerging therapeutic modalities, such as photothermal and starvation therapy integrated with EMNMs, have been extensively investigated for diverse clinical interventions. Up to date, several reviews have outlined general progress in the field, however, a comprehensive synthesis of fabrication strategies and their specific therapeutic applications remain relatively underexplored. To address this gap, this review comprehensively elucidates the design principles and construction strategies of EMNMs through enzyme selection, matrix materials, and morphological structures. Besides, the latest research advances in treating cardiovascular and cerebrovascular diseases, cancer, and urological disorders were also systematically summarized. Through further analyzing current bottlenecks and outlines future directions, this article might aim to providing a cornerstone reference and strategic guidance for future endeavors of EMNMs in related fields. STATEMENT OF SIGNIFICANCE: ∙The core design principles and fabrication methodologies of enzyme-powered micro/nanomotors (EMNMs) are comprehensively elucidated. ∙Systematic structure-activity correlations of EMNMs are established across three pivotal dimensions: enzyme screening, matrix scaffolds and morphological architectures. ∙State-of-the-art advances of EMNM platforms for therapeutic intervention against malignancies, cardiovascular and cerebrovascular pathologies, and urinary tract disorders are thoroughly summarized.", "journal": "Acta Biomaterialia", "pub_date": "2026-Oct", "publication_types": ["Journal Article", "Review"], "doi": "10.1016/j.actbio.2026.08.051", "authors": ["Qiong Su", "Yan Li", "Junqiu Liu", "Hongcheng Sun"], "affiliations": ["Key Laboratory of Organosilicon Chemistry and Material Technology, Ministry of Education, Key Laboratory of Organosilicon Material Technology of Zhejiang Province, College of Material, Chemistry and Chemical Engineering, Hangzhou Normal University, Hangzhou, Zhejiang, 311121, PR China.", "Key Laboratory of Organosilicon Chemistry and Material Technology, Ministry of Education, Key Laboratory of Organosilicon Material Technology of Zhejiang Province, College of Material, Chemistry and Chemical Engineering, Hangzhou Normal University, Hangzhou, Zhejiang, 311121, PR China. Electronic address: sunhc@hznu.edu.cn."], "corresponding_authors": ["Hongcheng Sun"], "china_team": "Key Laboratory of Organosilicon Chemistry and Material Technology, Ministry of Education, Key Laboratory of Organosilicon Material Technology of Zhejiang Province, College of Material, Chemistry and Chemical Engineering, Hangzhou Normal University, Hangzhou, Zhejiang, 311121, PR China Hongcheng Sun团队", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 24.46, "score_parts": {"urology_relevance": 7, "urology_in_title": 0.0, "journal_priority": 15.46, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 9.6, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.46, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42681559", "title": "MYC-Sensitized Cuproptosis Combined With PTT to Remodel the Immune Microenvironment of Prostate Cancer.", "abstract": "Prostate cancer (PCa) is the most prevalent malignancy in men, often progressing to a more refractory form castration-resistant prostate cancer (CRPC) after primary androgen deprivation therapy. Immunotherapy has brought new hope to PCa patients, but the immunosuppressive characteristics of PCa cells limit its efficacy. Cuproptosis, which can affect tumorigenesis, therapeutic resistance, and immune modulation has received significant attention recently. However, it is limited by insufficient copper ion (Cu2+) concentration, hypoxia, and overexpression of glutathione (GSH) in tumors. To overcome these limitations, a targeted nanoplatform (CuS@MYC-PEG-FA) is fabricated to achieve a synergistic cuproptosis and immunotherapy. CuS@MYC-PEG-FA can not only promote reactive oxygen species (ROS) generation and Cu2+ release, but also elicit a powerful antitumor immunity response. Meanwhile, the loaded c-MYC inhibitor (MYCMI-6) can reduce the expression of glutaminase and subsequently inhibit the generation of GSH, further sensitizing cells to cuproptosis effectively. Notably, cuproptosis combined with photothermal therapy (PTT) can turn the \"cold\" tumor properties of PCa into \"hot\" ones, leading to its sensitivity to anti-programmed death ligand 1 (anti-PD-L1) immunotherapy. The results show that the combination of CuS@MYC-PEG-FA and PD-L1 inhibitor treatment can significantly inhibit the development of PCa, providing a new strategy for the treatment of PCa.", "journal": "Advanced Healthcare Materials", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1002/adhm.71662", "authors": ["Yan Gao", "Ji Liu", "Jiahui Hu", "Chuansheng Xu", "Shiyu Mao", "Chen Li", "Xudong Yao", "Shuo Shi"], "affiliations": ["School of Chemical Science and Engineering, Department of Laboratory Medicine, Shanghai Tenth People's Hospital of Tongji University, Tongji University, Shanghai, China.", "Department of Urology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China.", "Urologic Cancer Institute, Tongji University School of Medicine, Shanghai, China.", "School of Medicine, Tongji University, Shanghai, China."], "corresponding_authors": [], "china_team": "School of Chemical Science and Engineering, Department of Laboratory Medicine, Shanghai Tenth People's Hospital of Tongji University, Tongji University, Shanghai, China Shuo Shi团队", "category": "basic", "classification_reason": "basic_signals=6", "score": 31.96, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 11.46, "top_journal_bonus": 0.0, "novelty": 0.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 6.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 9.6, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 3.46, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "铜死亡联合光热重塑前列腺癌免疫微环境", "chinese_summary": "同济大学附属第十人民医院石硕团队9月Adv Healthc Mater报道，构建靶向纳米平台CuS@MYC-PEG-FA，通过释放铜离子、产生活性氧并抑制谷氨酰胺酶降低谷胱甘肽，敏化铜死亡并联合光热疗法，将前列腺癌“冷”肿瘤转为“热”肿瘤，与抗PD-L1联合显著抑制肿瘤进展。", "abstract_zh": "前列腺癌（PCa）是男性最常见的恶性肿瘤，在初始雄激素剥夺治疗后常进展为更难治的去势抵抗性前列腺癌（CRPC）。免疫治疗为PCa患者带来了新希望，但PCa细胞的免疫抑制特征限制了其疗效。铜死亡可影响肿瘤发生、治疗耐药和免疫调节，近来受到广泛关注。然而，其受限于肿瘤内铜离子（Cu2+）浓度不足、缺氧以及谷胱甘肽（GSH）过表达。为克服这些局限，构建了一种靶向纳米平台（CuS@MYC-PEG-FA），以实现铜死亡与免疫治疗的协同作用。CuS@MYC-PEG-FA不仅能促进活性氧（ROS）生成和Cu2+释放，还能激发强大的抗肿瘤免疫应答。同时，所负载的c-MYC抑制剂（MYCMI-6）可降低谷氨酰胺酶表达，进而抑制GSH生成，进一步有效敏化细胞对铜死亡的敏感性。值得注意的是，铜死亡联合光热疗法（PTT）可将PCa的“冷”肿瘤特性转变为“热”肿瘤特性，使其对抗程序性死亡配体1（抗PD-L1）免疫治疗敏感。结果表明，CuS@MYC-PEG-FA与PD-L1抑制剂联合治疗可显著抑制PCa发展，为PCa治疗提供了新策略。"}, {"pmid": "42674923", "title": "Comparison and interpretability of machine learning algorithms to predict survival of patients with prostate cancer.", "abstract": "To evaluate the performance and interpretability of multiple ML algorithms for survival prediction in prostate cancer (CaP) and to assess whether these approaches can improve upon established clinical risk prediction models. Using the Surveillance, Epidemiology, and End Results (SEER) 17 Database, we identified patients diagnosed with CaP from 2010 to 2017 and implemented a Bayesian Cox variable selection model to determine the most clinically relevant features. To predict overall survival (OS) and prostate cancer-specific survival (PCSS), we applied these features to train and test a traditional Cox proportional hazards (PH) model in comparison to ML models including XGBoost, random survival forests, and elastic nets as well as the Cancer of the Prostate Risk Assessment (CAPRA) score using 5-fold cross-validation. The models were repeated for cohorts limited to patients who underwent radical prostatectomy and those who had low-risk disease. For both OS and PCSS, XGBoost had the best area under the curve (AUC), concordance index, and Brier score, followed by elastic net, Cox PH, and RSFs. Feature analysis indicated that age was most predictive of OS, while cancer-specific characteristics such as Gleason grade group were the most important features for PCSS prediction. While the traditional Cox PH model remained a clinically robust cancer survival model, this study found that ML models demonstrated modestly improved CaP survival prediction and provided easily interpretable information on the factors most important for prediction. These findings underscore the ability of new ML algorithms to be clinically useful in predicting survival in patients with CaP, specifically by identifying high-risk patients who may require more intensive treatment plans and closer follow-up.", "journal": "Urologic Oncology", "pub_date": "2026-Oct", "publication_types": ["Journal Article", "Comparative Study"], "doi": "10.1016/j.urolonc.2026.07.015", "authors": ["Isaac E Kim", "Cecile P G Meier-Scherling", "Steve R Zhou", "Simon J C Soerensen", "Ismail Ajjawi", "Benjamin I Chung", "Eugene Shkolyar", "Geoffrey A Sonn", "Joseph C Liao", "Michael S Leapman"], "affiliations": ["Department of Urology, Stanford School of Medicine, Palo Alto, CA.", "Center for Computational Molecular Biology, Brown University, Providence, RI.", "Department of Urology, Yale School of Medicine, New Haven, CT.", "Department of Urology, Yale School of Medicine, New Haven, CT; Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, CT; Yale Cancer Outcomes, Public Policy and Effectiveness Research Center, New Haven, CT. Electronic address: michael.leapman@yale.edu."], "corresponding_authors": ["Michael S Leapman"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_clinical", "score": 28.25, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 5.75, "top_journal_bonus": 0.0, "novelty": 1.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 7.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.3, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.75, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42668444", "title": "Comparative assessment of METastasis Reporting and Data System for Prostate Cancer versus Prostate Cancer Clinical Trials Working Group 3 Criteria in assessing treatment response in patients with metastatic castration-resistant prostate cancer.", "abstract": "Unequivocal clinical progression without radiological progression according to Prostate Cancer Clinical Trials Working Group 3 (PCWG3) criteria is recognised in metastatic castration-resistant prostate cancer (mCRPC), reflecting limitations of bone scintigraphy in distinguishing an osteoblastic progression from an osteoblastic flare. To compare the METastasis Reporting and Data System for Prostate Cancer (MET-RADS-P) on whole-body magnetic resonance imaging (WBMRI) with PCWG3 imaging criteria, the current gold standard. A retrospective cohort of 184 patients with mCRPC who underwent paired WBMRI and conventional imaging during therapy. The primary endpoint was concordance (percentage agreement [%A]) between MET-RADS-P and PCWG3 for overall, bone-only, and soft-tissue-only responses. Secondary endpoints were radiologic progression-free survival (rPFS) by each system and overall survival (OS) according to early (≤12 wk) MET-RADS-P response. We evaluated 467 paired assessments in 184 patients. Overall concordance between PCWG3 and MET-RADS-P was moderate (%A = 64.5%; 95% confidence interval [CI] = 59.8-68.7), and it was high in soft tissue (%A = 88.8%; 95% CI = 85.7-91.6) and limited in bone (%A = 44.4%; 95% CI = 39.8-48.9). MET-RADS-P labelled progression more often than PCWG3 overall (66.6% vs 39.7%) and in bone (61.2% vs 20.3%). Median rPFS was shorter by MET-RADS-P than by PCWG3 (2.7 vs 4.2 mo; p < 0.001). Early MET-RADS-P progression was significantly associated with worse OS (adjusted hazard ratio [HR] = 4.75; 95% CI = 2.1-10.7; p < 0.001). Limitations include retrospective single-centre design, trial-based expert-centre cohort, and limited follow-up. Concordance between PCWG3 and MET-RADS-P was moderate overall and limited in bone. Earlier MET-RADS-P-defined progression may identify aggressive disease and allow a prompt change in therapy before clinical deterioration limits subsequent treatment options. Prospective validation is warranted.", "journal": "European Urology Open Science", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1016/j.euros.2026.08.003", "authors": ["Luca Russo", "Ossian Longoria", "Silvia Bottazzi", "Nuria Porta", "Katie Biscombe", "Samuel J Withey", "Giacomo Avesani", "Katarzyna Abramovicz", "Matthew D Blackledge", "Luca D'Erme", "Katie Russell-Rose", "Tarek Taha", "Adam Sharp", "Alec Paschalis", "Evis Sala", "Dow-Mu Koh", "Johann de Bono", "Nina Tunariu"], "affiliations": ["The Royal Marsden NHS Foundation Trust, London, UK.", "Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.", "Institute of Cancer Research, London, UK.", "Università Cattolica del Sacro Cuore, Rome, Italy."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=15", "score": 36.5, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.5, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 12.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.5, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.5, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42668326", "title": "DHCR24+ tumor epithelial cells drive cisplatin resistance in bladder cancer by enhancing cholesterol metabolism to activate lipid raft-associated MAPK signaling.", "abstract": "Cisplatin-based combination therapy remains the primary treatment modality for patients with advanced bladder cancer (BCa); however, the emergence of drug resistance severely restricts clinical benefits. The molecular mechanisms underlying chemoresistance remain incompletely understood. By integrating single-cell transcriptomics with in vitro and in vivo experiments, we revealed that cholesterol metabolism was significantly hyperactivated in cisplatin-resistant BCa tissues. Further subpopulation re-clustering identified a specific chemoresistant epithelial cell subset (C3) characterized by robust cholesterol metabolism, in which the cholesterol metabolic enzyme DHCR24 was significantly upregulated and played a pivotal role in mediating cisplatin resistance in BCa. Mechanistically, the elevated expression of TFDP1 in cisplatin-resistant BCa epithelial cells upregulated DHCR24 via the formation of the TFDP1-E2F1 transcriptional complex, thereby promoting cholesterol biosynthesis. The enriched intracellular cholesterol facilitated the formation of cell membrane lipid rafts and enhanced the phosphorylation of Src, which in turn hyperactivated the downstream MAPK signaling pathway, ultimately conferring cisplatin resistance. Furthermore, the accumulated cholesterol enhanced PD-L1 protein stability, thereby impairing the efficacy of immunotherapy in BCa. Taken together, our study characterizes a specific DHCR24+ tumor epithelial subpopulation that orchestrates cisplatin resistance via the \"cholesterol-lipid raft-MAPK\" axis. These findings establish a clear mechanistic link between cholesterol metabolism and cisplatin sensitivity.", "journal": "Oncogene", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1038/s41388-026-03967-7", "authors": ["Yuanqiao Zhao", "Zhuo Xing", "Mengmeng Wang", "Liangmin Fu", "Ruilin Liu", "Zexian Ding", "Yuan Li", "Yinhuai Wang", "Bin Yan", "Xueqiang Zhu"], "affiliations": ["Department of Urology, The Second Xiangya Hospital, Central South University, Changsha, China.", "Department of Urology, The Second Xiangya Hospital, Central South University, Changsha, China. xzh2204170325@163.com.", "Department of Urology, The Second Xiangya Hospital, Central South University, Changsha, China. wangyinhuai@csu.edu.cn.", "Department of Urology, The Second Xiangya Hospital, Central South University, Changsha, China. bin.yan01@csu.edu.cn.", "Department of Oncology, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China. zhuxueqiang1234@163.com."], "corresponding_authors": ["Zhuo Xing", "Yinhuai Wang", "Bin Yan", "Xueqiang Zhu"], "china_team": "Department of Urology, The Second Xiangya Hospital, Central South University, Changsha, China Zhuo Xing/Yinhuai Wang/Bin Yan/Xueqiang Zhu团队", "category": "basic", "classification_reason": "basic_signals=18", "score": 44.1, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 15.1, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 14.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 7.3, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.1, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "中南大学湘雅二医院揭示膀胱癌顺铂耐药胆固醇代谢新机制", "chinese_summary": "中南大学湘雅二医院卓行、王荫槐、闫斌、朱学强团队8月Oncogene发表研究，整合单细胞转录组学与体外体内实验，发现顺铂耐药膀胱癌组织胆固醇代谢高度活跃。DHCR24通过TFDP1-E2F1轴促进胆固醇合成，富集胆固醇形成脂筏并激活MAPK信号，驱动顺铂耐药。", "abstract_zh": "以顺铂为基础的联合治疗仍是晚期膀胱癌（BCa）患者的主要治疗方式；然而，耐药性的出现严重限制了临床获益。化疗耐药的分子机制尚不完全清楚。通过整合单细胞转录组学与体外和体内实验，我们发现胆固醇代谢在顺铂耐药BCa组织中显著过度激活。进一步的亚群重聚类鉴定出一个特定的化疗耐药上皮细胞亚群（C3），其特征是胆固醇代谢旺盛，其中胆固醇代谢酶DHCR24显著上调，并在介导BCa顺铂耐药中发挥关键作用。机制上，顺铂耐药BCa上皮细胞中TFDP1表达升高，通过形成TFDP1-E2F1转录复合物上调DHCR24，从而促进胆固醇生物合成。细胞内胆固醇富集促进细胞膜脂筏形成并增强Src磷酸化，进而过度激活下游MAPK信号通路，最终赋予顺铂耐药。此外，蓄积的胆固醇增强PD-L1蛋白稳定性，从而损害BCa免疫治疗的疗效。综上所述，我们的研究刻画了一个特定的DHCR24+肿瘤上皮亚群，其通过“胆固醇-脂筏-MAPK”轴协调顺铂耐药。这些发现建立了胆固醇代谢与顺铂敏感性之间的明确机制联系。"}, {"pmid": "42666913", "title": "Kidney Allograft Outcomes in Borderline and T Cell-Mediated Rejection With Microvascular Inflammation.", "abstract": "Microvascular inflammation (MVI) is a hallmark feature of antibody-mediated rejection (ABMR), but its prognostic significance when it occurs with T-cell-mediated rejection (TCMR) in the absence of other ABMR features remains unclear. We examined the association between pure TCMR phenotypes, defined by the presence or absence of MVI, and graft survival using restricted mean survival time (RMST), and assessed interactions with rejection involving a \"v\" lesion. Among 1614 recipients with first biopsy-proven pure TCMR (2010-2023), 85% had no MVI, 8% subthreshold MVI (Banff glomerulitis [g] + peritubular capillaritis [ptc] = 1), and 7% with MVI (g + ptc ≥ 2). Compared with TCMR without MVI, recipients with TCMR + MVI (hazard ratio [HR]; 95% confidence intervals [CI] 1.57 [1.06-2.34]) had a higher risk of all-cause graft loss, whereas subthreshold MVI was not associated with increased risk. The 5-year RMST was lowest in the MVI group (3.93 [3.53-4.26]), compared with the subthreshold group (4.39 [4.11- 4.60]) and the no MVI group (4.32 [4.24-4.40]). Rejection with a \"v\" lesion modified this association. Recipients with TCMR + MVI and positive \"v\" lesion had a 2.77-fold higher risk of graft loss (2.77 [1.64-4.67]), whereas no excess risk was observed in those without vascular lesions. Pure TCMR with MVI, particularly in the setting of a \"v\" lesion, represents a high-risk phenotype associated with poorer graft survival, warranting mechanistic investigations and targeted therapeutic strategies.", "journal": "Kidney International Reports", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1016/j.jclinepi.2022.05.021", "authors": ["Wai H Lim", "Jiayue Wang", "Armando Teixeira-Pinto", "Julie Ho", "Ryan Gately", "Dharshana Sabanayagam", "Esther Ooi", "Farzaneh Boroumand", "K Shuvo Bakar", "Lin Zhu", "Helen Pilmore", "William Mulley", "Jennifer Li", "Brian Nankivell", "John Kanellis", "Peter Nickerson", "Chris Wiebe", "Germaine Wong"], "affiliations": ["Nutrition and Health Innovation Research Institute, School of Medical and Health Sciences, Edith Cowan University, Perth, Australia.", "Medical School, University of Western Australia, Perth, Australia.", "Department of Renal Medicine and Transplantation, Sir Charles Gairdner Hospital, Perth, Australia.", "Faculty of Medicine and Health, Sydney School of Public Health, University of Sydney, Sydney, Australia.", "Centre for Kidney Research, Kids Research Institute, The Children's Hospital at Westmead, Sydney, Australia.", "Department of Internal Medicine, Rady Faculty of Health Sciences, Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.", "Department of Kidney and Transplant Services, Princess Alexandra Hospital, Brisbane, Australia.", "Department of Renal Medicine and Transplantation, Westmead Hospital, Sydney, Australia.", "Department of Renal Medicine, Auckland City Hospital, Auckland, New Zealand.", "Department of Medicine, Auckland University, Auckland, New Zealand.", "Department of Nephrology, Monash Medical Centre, Clayton, Victoria, Australia.", "Department of Medicine, Centre for Inflammatory Diseases, Monash University, Clayton, Victoria, Australia."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 13.79, "score_parts": {"urology_relevance": 0, "urology_in_title": 0.0, "journal_priority": 10.79, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 5.7, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.79, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42660691", "title": "Epithelioid renal angiomyolipoma: Clinical characteristics, treatment strategies, and oncological outcomes-An individual patient data meta-analysis of 259 cases.", "abstract": "Epithelioid angiomyolipoma (eAML) is a rare malignant renal neoplasm distinct from benign classic angiomyolipoma. Evidence-based management recommendations are lacking due to its rarity. This systematic review aimed to analyze clinical characteristics, treatment strategies, and oncological outcomes. We systematically searched MEDLINE through December 2025 (PROSPERO: CRD42024548957), identifying case reports and series reporting individual patient data. Extracted data included demographics, clinical presentation, radiological and histopathological features, treatment modalities, and survival outcomes. Univariable logistic and Cox regression analyses identified factors associated with recurrence and eAML-related mortality. Analysis included 259 patients from 137 studies (59% female, median age 43 years [IQR 33-54]). Most patients (56%) presented symptomatically with abdominal pain (42%) or macrohematuria (13%). Radical nephrectomy was performed in 71%, partial nephrectomy in 16%. At median follow-up of 21 months (IQR 8-54), recurrence occurred in 39% at median 12 months (IQR 6-36), predominantly as distant metastases (liver 14% and lung 10%). Five-year overall survival, cancer-specific survival, and recurrence-free survival were 84%, 85%, and 55%, respectively. Significant risk factors for recurrence included positive hilar lymph nodes (OR 15.6), vascular invasion (OR 6.4), necrosis (OR 10.5), and high mitotic index (OR 7.2), all P < 0.001. Limitations include publication bias and heterogeneous reporting. eAML exhibits aggressive behavior with 39% recurrence and 11% disease-related mortality. Complete surgical resection remains the cornerstone of initial management and structured cross-sectional imaging follow-up should be considered given high recurrence risk. For recurrent disease, mTOR inhibitors, particularly everolimus, represent effective first-line systemic therapy. High-risk histopathological features may guide future risk-stratified follow-up strategies.", "journal": "Urologic Oncology", "pub_date": "2026-Oct", "publication_types": ["Journal Article", "Meta-Analysis", "Systematic Review"], "doi": "10.1016/j.urolonc.2026.08.006", "authors": ["Franz J Haselhoff", "Ernest Kaufmann", "Agostino Mattei", "Christian D Fankhauser", "Andres Affentranger"], "affiliations": ["Department of Urology, University Teaching and Research Hospital University of Lucerne, Lucerne, Switzerland.", "Department of Urology, University Teaching and Research Hospital University of Lucerne, Lucerne, Switzerland; Faculty of Health Sciences and Medicine, University of Lucerne, Lucerne, Switzerland.", "Department of Urology, University Teaching and Research Hospital University of Lucerne, Lucerne, Switzerland; Faculty of Health Sciences and Medicine, University of Lucerne, Lucerne, Switzerland; Faculty of Medicine, University of Zurich, Zurich, Switzerland; Department of Urology, Cantonal Hospital of Winterthur, Winterthur, Switzerland. Electronic address: cdfankhauser@gmail.com."], "corresponding_authors": ["Christian D Fankhauser"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 17.75, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 5.75, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 5.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.3, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.75, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42647038", "title": "Enhanced Recovery After Surgery in Pediatric Urology Patients Undergoing Complex Lower Urinary Tract Reconstruction.", "abstract": "Enhanced recovery after surgery (ERAS) is a multidisciplinary framework to standardize perioperative care. Pediatric Urology Recovery After Surgery Endeavor (PURSUE) is a multicenter study of ERAS in children undergoing complex lower urinary tract reconstruction. Use of ERAS in children is still relatively uncommon and outcomes are not well understood. To attempt to achieve 70% or more ERAS adherence while reducing length of stay and opioid use without an increase in complications or other balancing measures. This study prospectively enrolled patients who were propensity matched to recent historical controls prior to ERAS implementation and outcomes were compared. From 2017 through 2022, 8 pediatric hospitals implemented ERAS for pediatric patients undergoing catheterizable channel creation, bladder augmentation, and/or bladder neck procedures. Patients aged 4 to 24 years undergoing these operations were prospectively enrolled in the study. Patients with unmanaged neurogenic bowel were excluded. Patients who underwent these operations in the 5 years prior to protocol implementation at each center were used as a comparator group. These data were analyzed from July 2022 to April 2025. ERAS protocol encompassing 20 evidence-based preoperative, intraoperative, and postoperative elements was designed and implemented as standard of care. Patients were followed up postoperatively for a minimum of 1 year. The primary outcome was compliance with the ERAS protocol. Secondary outcomes included length of stay, opioid usage, pain scores, 90-day complications, and 90-day balancing measures of return to hospital. A total of 153 ERAS patients and 153 historical controls were matched with a median (IQR) age of 10.2 (7.6-13.7) and 10.4 (8.0-14.6) years, respectively (P = .47). Median protocol adherence increased from 8 to 16 measures between historical and ERAS cohorts (P < .001). Median length of stay decreased from 8.0 to 5.3 days (P < .001). Postoperative opioid use decreased 74% without an increase in maximum pain scores. Complication rates decreased from 72.5% to 60.1% (P = .01) with no differences in 90-day emergency department visits, readmissions, or reoperations. In this study, ERAS was highly effective at standardizing perioperative care in pediatric urology patients undergoing complex lower urinary tract reconstruction. ERAS was associated with better outcomes of reduced length of stay, lower postoperative opioid use, and lower complication rates.", "journal": "JAMA Surgery", "pub_date": "2026-Oct-01", "publication_types": ["Journal Article", "Multicenter Study"], "doi": "10.1001/jamasurg.2026.3703", "authors": ["Kyle O Rove", "Andrew C Strine", "David I Chu", "Duncan T Wilcox", "Darren Ha", "Gino J Vricella", "Douglas E Coplen", "Erica J Traxel", "Austin R Acks", "Rajeev Chaudhry", "Brian VanderBrink", "Elizabeth B Yerkes", "Yvonne Y Chan", "Nicholas E Burjek", "Rebecca S Zee", "C D Anthony Herndon", "Jennifer J Ahn", "Paul A Merguerian", "Bhalaajee Meenakshi-Sundaram", "Adam J Rensing", "Dominic Frimberger", "Megan A Brockel"], "affiliations": ["Children's Hospital Colorado, University of Colorado School of Medicine, Aurora.", "Division of Pediatric Urology, Cincinnati Children's, Cincinnati, Ohio.", "Division of Urology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois.", "Department of Pediatric Urology, Children's Hospital Colorado, University of Colorado, Aurora.", "Department of Pediatric Urology, Mercy Children's Hospital, Kansas City, Kansas.", "Division of Pediatric Urology, St Louis Children's Hospital, Washington University in St Louis, St Louis, Missouri.", "Division of Pediatric Urology, Children's Hospital of Pittsburgh, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.", "Division of Pediatric Urology, UC Davis Children's Hospital, Sacramento, California.", "Department of Anesthesiology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois.", "Division of Urology, Children's Hospital of Richmond at VCU, Richmond, Virginia.", "Department of Urology, Seattle Children's Hospital, University of Washington, Seattle.", "Department of Urology, Oklahoma Children's Hospital at OU Health, University of Oklahoma, Oklahoma City.", "Department of Anesthesiology, Children's Hospital Colorado, University of Colorado, Aurora."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_clinical", "score": 46.06, "score_parts": {"urology_relevance": 11, "urology_in_title": 8.0, "journal_priority": 16.06, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 9.0}, "journal_metrics": {"status": "ok", "impact_factor": 14.9, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.06, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "儿童尿路重建加速康复成效显著", "chinese_summary": "8家儿童医院2017至2022年实施ERAS并于JAMA Surg发表PURSUE研究，153例复杂下尿路重建患儿与153例历史对照倾向匹配，方案依从性中位数由8项升至16项，住院由8.0降至5.3天，阿片类用量减少74%，并发症由72.5%降至60.1%，90天再就诊无差异。", "abstract_zh": "加速康复外科（ERAS）是一套标准化围手术期多学科管理框架。儿童泌尿外科加速康复探索（PURSUE）是一项在行复杂下尿路重建的儿童中研究ERAS的多中心研究。ERAS在儿童中的应用仍相对少见，其结局尚未被充分认识。研究目标是在不增加并发症或其他平衡指标的前提下，达到70%或以上的ERAS依从性，同时缩短住院时间并减少阿片类药物使用。本研究前瞻性纳入患者，并将其与ERAS实施前近期的历史对照进行倾向匹配后比较结局。自2017年至2022年，8家儿童医院对接受可控性通道建立、膀胱扩大和/或膀胱颈手术的儿科患者实施ERAS。年龄4至24岁接受这些手术的患者被前瞻性纳入研究。未得到管理的神经源性肠道患者被排除。各中心在方案实施前5年内接受这些手术的患者作为对照组。这些数据于2022年7月至2025年4月进行分析。研究设计并实施了包含20项循证术前、术中和术后要素的ERAS方案，并作为标准诊疗执行。患者术后随访至少1年。主要结局为ERAS方案依从性。次要结局包括住院时间、阿片类药物使用、疼痛评分、90天并发症及90天再入院等平衡指标。共有153例ERAS患者与153例历史对照匹配，中位（IQR）年龄分别为10.2（7.6-13.7）岁和10.4（8.0-14.6）岁（P=0.47）。方案依从性中位数从历史队列的8项提高到ERAS队列的16项（P<.001）。住院时间中位数从8.0天降至5.3天（P<.001）。术后阿片类药物使用减少74%，而最高疼痛评分未增加。并发症发生率从72.5%降至60.1%（P=.01），90天急诊就诊、再入院或再手术无差异。在本研究中，ERAS在标准化儿童泌尿外科复杂下尿路重建患者的围手术期管理方面非常有效。ERAS与住院时间缩短、术后阿片类药物使用减少和并发症发生率降低等更好结局相关。"}, {"pmid": "42636791", "title": "KDM6A suppresses proliferation and epithelial-mesenchymal transition in prostate cancer cells.", "abstract": "Prostate cancer is one of the most common male malignancies worldwide. KDM6A, a histone H3K27 demethylase, has been implicated in various cancers; however, its specific functions in prostate cancer remain controversial. This study aimed to investigate the regulatory role of KDM6A in castration-resistant prostate cancer (CRPC). We analyzed the GEO public database and conducted in vitro and in vivo experiments to examine the function of KDM6A in CRPC. KDM6A expression was downregulated in CRPC compared with primary prostate cancer. KDM6A acted as a tumor suppressor; its depletion promoted proliferation and migration of prostate cancer cells both in vitro and in vivo. Suppression of KDM6A activated epithelial-mesenchymal transition (EMT) via HMGB2, thereby regulating the invasive behavior of prostate cancer. EMT is known to play a critical role in CRPC progression. Our findings reveal the functional role of KDM6A in CRPC and suggest its potential utility in exploring novel therapeutic strategies for CRPC.", "journal": "Urologic Oncology", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1016/j.urolonc.2026.07.029", "authors": ["Yixiu Ni", "Yijia Lin", "Wankun Wang", "Yizhong Bao", "Jun Chen"], "affiliations": ["Department of Urology, Affiliated Zhejiang Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.", "Department of Urology, Affiliated Zhejiang Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China. Electronic address: zjdxcj1@126.com."], "corresponding_authors": ["Jun Chen"], "china_team": "Department of Urology, Affiliated Zhejiang Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China Jun Chen团队", "category": "basic", "classification_reason": "basic_signals=6", "score": 26.75, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 5.75, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 6.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.3, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.75, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "KDM6A缺失促前列腺癌进展", "chinese_summary": "浙江大学医学院附属浙江医院陈军团队8月Urol Oncol通过公共数据库及体内外实验发现，去势抵抗性前列腺癌中组蛋白去甲基化酶KDM6A表达下调，其缺失经HMGB2激活上皮-间质转化，促进肿瘤增殖与迁移，提示KDM6A或成潜在治疗靶点。", "abstract_zh": "前列腺癌是全球最常见的男性恶性肿瘤之一。KDM6A是一种组蛋白H3K27去甲基化酶，已被认为与多种癌症相关；然而，其在前列腺癌中的具体功能仍存在争议。本研究旨在探讨KDM6A在去势抵抗性前列腺癌（CRPC）中的调控作用。我们分析了GEO公共数据库，并开展体外和体内实验以检验KDM6A在CRPC中的功能。与原发性前列腺癌相比，KDM6A表达在CRPC中下调。KDM6A发挥抑癌作用；其缺失在体外和体内均促进前列腺癌细胞的增殖和迁移。抑制KDM6A通过HMGB2激活上皮-间质转化（EMT），从而调控前列腺癌的侵袭行为。已知EMT在CRPC进展中起关键作用。我们的发现揭示了KDM6A在CRPC中的功能作用，并提示其在探索CRPC新型治疗策略方面具有潜在应用价值。"}, {"pmid": "42632294", "title": "Prognostic value of CD103+ tumor-infiltrating lymphocytes in bladder cancer: A systematic review and meta-analysis.", "abstract": "CD103+ tissue-resident memory T cells are emerging mediators of antitumor immunity whose prognostic significance in bladder cancer, across muscle-invasive and metastatic urothelial carcinoma, remains undefined at a meta-analytic level. We performed a systematic review and meta-analysis of cohorts with histologically confirmed muscle-invasive bladder cancer or metastatic urothelial carcinoma, comparing high vs. low CD103+ tumor-infiltrating lymphocyte density assessed by immunohistochemistry or ITGAE mRNA expression, with overall survival endpoint. PubMed, Embase, Scopus, and Cochrane CENTRAL were searched from inception through March 2026. Pooled hazard ratios (HR) with 95% confidence intervals (CIs) were estimated using a restricted maximum likelihood random-effects model. Subgroup analyses were performed by treatment context, disease stage, and assessment method. The protocol was registered at OSF (u36xv). Three studies comprising 6 cohorts were included. High CD103⁺ infiltration was significantly associated with prolonged overall survival (HR: 0.50, 95% CI: 0.30-0.83). A significant treatment-context interaction (P = 0.005) favored patients undergoing surgery with adjuvant chemotherapy (HR: 0.20) over those receiving immunotherapy (HR: 0.69). Stage-stratified analysis showed a significant interaction (P = 0.003), with pronounced benefit in muscle-invasive bladder cancer (HR: 0.27) but a non-significant trend in metastatic urothelial carcinoma (HR: 0.79). Immunohistochemistry-based cohorts showed a numerically larger effect than ITGAE mRNA cohorts. High CD103⁺ tumor-infiltrating lymphocyte infiltration may be associated with improved overall survival in bladder cancer, particularly in muscle-invasive bladder cancer patients undergoing surgery with adjuvant chemotherapy. Prospective validation in larger, stage-homogeneous cohorts is warranted to establish CD103 as a prognostic biomarker. These findings are hypothesis-generating and CD103 assessment is not currently ready for clinical use.", "journal": "Urologic Oncology", "pub_date": "2026-Oct", "publication_types": ["Journal Article", "Systematic Review", "Meta-Analysis"], "doi": "10.1016/j.urolonc.2026.07.031", "authors": ["Eduardo Germano Teixeira", "Lucas Antônio Fernandes Torres", "Maria Luiza Rodrigues Defante", "Fábio Medeiros de Azevedo", "Vinicius Carrera Souza"], "affiliations": ["Department of Surgical Pathology, Rio Grande do Norte League Against Cancer, Natal, Brazil. Electronic address: eduardo.germano@upe.br.", "Molecular Diagnostics Laboratory, Rede D'Or, São Paulo, Brazil.", "Department of Medicine, Redentor University Center, Rio de Janeiro, Brazil.", "Department of Surgical Pathology, Rio Grande do Norte League Against Cancer, Natal, Brazil.", "Oncologia D'Or, Salvador, Brazil; D'Or Institute for Research and Education (IDOR), Salvador, Brazil."], "corresponding_authors": ["Eduardo Germano Teixeira"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 33.25, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 5.75, "top_journal_bonus": 0.0, "novelty": 0.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 9.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.3, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.75, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42632293", "title": "A phase-specific benefit-toxicity framework for perioperative trials in muscle-invasive bladder cancer: A focused review andtrial-level mapping analysis.", "abstract": "The perioperative treatment landscape for muscle-invasive bladder cancer is changing rapidly with the emergence of immune checkpoint inhibitor- and antibody-drug conjugate-based strategies. Trials such as NIAGARA, EV-304/KEYNOTE-B15, and EV-303/KEYNOTE-905 have shown substantial improvements in event-free survival, overall survival, and pathological response. However, efficacy endpoints alone may be insufficient to evaluate perioperative regimens, because treatment is delivered across neoadjuvant, surgical, and adjuvant phases. Each phase introduces distinct sources of burden, including treatment-related toxicity, discontinuation of neoadjuvant therapy, delay or failure to undergo radical cystectomy, postoperative complications, and failure to initiate or complete adjuvant therapy. To address this gap, we propose a phase-specific benefit-toxicity framework for interpreting modern perioperative trials in muscle-invasive bladder cancer. We define deliverability as the feasibility of completing the intended neoadjuvant-surgical-adjuvant treatment pathway. Recent studies such as EV-304, NIAGARA, EV-303, and VESPER provide a timely opportunity to map perioperative benefit, toxicity, and deliverability at the trial level, although endpoints, safety reporting, and comparator arms differ across trials. Because perioperative therapy spans neoadjuvant, surgical, and adjuvant phases, the framework uses the neoadjuvant benefit-harm balance as the primary interpretive axis while contextualizing surgical feasibility and postoperative treatment continuity. The aim is not to rank regimens, but to visualize how therapeutic benefit and treatment burden are balanced across heterogeneous trial designs. Phase-specific mapping may provide a more clinically interpretable approach for assessing modern perioperative combination regimens and for designing future trials that better capture treatment feasibility, surgical safety, and completion of the intended treatment pathway.", "journal": "Urologic Oncology", "pub_date": "2026-Oct", "publication_types": ["Journal Article", "Review"], "doi": "10.1016/j.urolonc.2026.07.024", "authors": ["Masanao Shinohara", "Takuma Narita", "Tomoko Hamaya", "Takaki Ichiyama", "Naoki Fujita", "Teppei Okamoto", "Hayato Yamamoto", "Chikara Ohyama", "Shingo Hatakeyama"], "affiliations": ["Department of Urology, Hirosaki University School of Medicine, Hirosaki, Japan; Department of Urology, Ageo Central General Hospital, Ageo, Japan.", "Department of Urology, Hirosaki University School of Medicine, Hirosaki, Japan.", "Department of Advanced Transplant and Regenerative Medicine, Hirosaki University School of Medicine, Hirosaki, Japan.", "Department of Urology, Hirosaki University School of Medicine, Hirosaki, Japan. Electronic address: shingoh@hirosaki-u.ac.jp."], "corresponding_authors": ["Shingo Hatakeyama"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 25.75, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 5.75, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 2.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.3, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.75, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42628855", "title": "Antitumor activity of scorpion venom-derived peptides: A meta-analysis of preclinical studies.", "abstract": "Despite advances in cancer therapeutics, there are still challenges in improving drug toxicity and selectivity. Peptides from various venous species have recently garnered attention for their biopharmaceutical potential, particularly in cancer. The present study aimed to conduct a meta-analysis of the antitumor activity of scorpion venom-derived peptides (SVDPs) previously reported in preclinical models. The bibliographic research included original and review articles written in English published from 2015 to 2026. Studies within the scope were retrieved from the EBSCO Discovery Service, PubMed, and WIPO databases. A total of 27 articles that met the inclusion and exclusion criteria were included in this research, and the collected data were synthesized through a meta-analysis. In the included in vitro and in vivo studies, the effect of SVDPs on breast/mammary gland, cervical, colon, glioblastoma, liver, lung, oral, or prostate cancer cell lines was reported. The meta-analyses indicated that SVDPs affected cancer cells by reducing cell viability, with a greater effect on lung cancer cells (IC50 pooled mean: 12.69 μM; 95% CI: 5.80-19.57). Additionally, SVDPs induce early apoptosis (SMD: 5.11; 95% CI: 2.54-7.68), and reduce tumor volume in animal models (SMD = -7.29; 95% CI: -12.73- -1.85). Furthermore, the peptides modulated the key oncogenic pathways, including caspase-mediated apoptosis, autophagy, the cell cycle, PI3K/AKT, EGFR/RAS/RAF, and MAPK signaling, by regulating altered proteins and genes in cancer cells. In addition, this review highlights promising outcomes and discusses the mechanistic knowledge gaps to inform future research directions.", "journal": "Pharmacological Research", "pub_date": "2026-Oct", "publication_types": ["Journal Article", "Meta-Analysis", "Review"], "doi": "10.1016/j.phrs.2026.108402", "authors": ["Lucero A Hernández-Carrizales", "Alexa Hernández-Hernández", "Jorge L Díaz-Gómez", "Fabiola Castorena-Torres", "César A Puente-Garza", "Silverio García-Lara"], "affiliations": ["Tecnologico de Monterrey, Escuela de Ingenieria y Ciencias, Ave. Eugenio Garza Sada 2501, Monterrey, N.L. 64849, Mexico.", "Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Ave. Morones Prieto 3000, Monterrey, N.L. 64710, Mexico.", "Tecnologico de Monterrey, Escuela de Ingenieria y Ciencias, Ave. Eugenio Garza Sada 2501, Monterrey, N.L. 64849, Mexico. Electronic address: sgarcialara@tec.mx."], "corresponding_authors": ["Silverio García-Lara"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 17.58, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 11.58, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 10.5, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 3.58, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42628358", "title": "Evaluation, etiology, and management of gross hematuria following radical cystectomy and orthotopic neobladder.", "abstract": "To assess the etiology, evaluation, and subsequent management of patients who developed gross hematuria following radical cystectomy (RC) and orthotopic neobladder (ONB) urinary diversion. All patients who underwent RC and ONB between 2017 and 2021 and later developed gross hematuria necessitating cystoscopy were identified. Patient demographics, cystoscopy reports, cytology findings, and relevant imaging were reviewed to determine the etiology of hematuria, the subsequent management, and the ultimate outcome. Causes of hematuria were categorized as recurrence, inflammation/infection, anticoagulation-related, or undetermined. Twenty-one patients underwent cystoscopy for gross hematuria following RC and ONB during the study period. Most patients were male (n = 19, 90.5%), and the median age was 71 years (IQR: 67-75). Five (23.8%) patients had hematuria secondary to cancer recurrence-4 urethral and one upper tract recurrence. Other etiologies of hematuria included pouchitis (n = 5, 23.8%) and presumed anticoagulation-related bleeding (n = 2, 9.5%). In 9 (42.9%) patients, the etiology of hematuria remained undetermined despite comprehensive workup. Among the 5 patients whose hematuria was secondary to cancer recurrence, the median time from cystectomy to hematuria was 29 months (Interquartile range: 15-36). Up to a quarter of patients who present with gross hematuria following RC with ONB may have cancer recurrence. Consequently, a thorough evaluation is warranted in all patients.", "journal": "Urologic Oncology", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1016/j.urolonc.2026.07.030", "authors": ["Mazyar Zahir", "Daniel I Sanford", "Chirag Doshi", "Muhannad Alsyouf", "Sanam Ladi-Seyedian", "Kevin Wayne", "Michael Basin", "Alireza Ghoreifi", "Anne Schuckman", "Hooman Djaladat", "Siamak Daneshmand"], "affiliations": ["USC Department of Urology, USC/Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA.", "USC Department of Urology, USC/Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA. Electronic address: daneshma@med.usc.edu."], "corresponding_authors": ["Siamak Daneshmand"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 30.75, "score_parts": {"urology_relevance": 15, "urology_in_title": 8.0, "journal_priority": 5.75, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.3, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.75, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "根治性膀胱切除术后肉眼血尿近半病因未明", "chinese_summary": "2026年8月Urol Oncol回顾2017至2021年接受根治性膀胱切除联合原位新膀胱的患者，21例因肉眼血尿行膀胱镜检查，中位年龄71岁。5例（23.8%）血尿源于肿瘤复发，其中尿道4例、上尿路1例；另有囊炎5例、抗凝相关出血2例，9例（42.9%）经全面检查仍原因未明。提示此类患者需完整评估以排除复发。", "abstract_zh": "评估根治性膀胱切除术（RC）联合原位新膀胱（ONB）尿流改道后发生肉眼血尿患者的病因、评估及后续处理。纳入2017年至2021年间接受RC和ONB、随后出现需行膀胱镜检查的肉眼血尿的全部患者。回顾患者人口学资料、膀胱镜报告、细胞学检查结果及相关影像学资料，以确定血尿病因、后续处理及最终结局。血尿原因分为复发、炎症/感染、抗凝相关或未明确。研究期间共21例RC和ONB后肉眼血尿患者接受膀胱镜检查。大多数患者为男性（n = 19，90.5%），中位年龄为71岁（四分位距：67-75）。5例（23.8%）患者血尿继发于肿瘤复发——4例为尿道复发，1例为上尿路复发。其他血尿病因包括储尿囊炎（n = 5，23.8%）和推测与抗凝相关的出血（n = 2，9.5%）。9例（42.9%）患者尽管接受了全面检查，血尿病因仍未明确。在5例血尿继发于肿瘤复发的患者中，从膀胱切除到出现血尿的中位时间为29个月（四分位距：15-36）。在接受RC联合ONB后出现肉眼血尿的患者中，多达四分之一可能存在肿瘤复发。因此，所有此类患者均需进行彻底评估。"}, {"pmid": "42621345", "title": "A synergistic cascade nanoreactor breaks bladder cancer chemoresistance: Synergizing cholesterol metabolism reprogramming with cGAS-STING-mediated metallotherapy.", "abstract": "Bladder cancer chemoresistance arises from a self-reinforcing vicious cycle of aberrant cholesterol metabolism and immunosuppression, which conventional single-target therapies fail to disrupt. Here, we report a folate-targeted zeolitic imidazolate framework-67 (ZIF67)-based nanoreactor termed CCZF, co-loaded with cholesterol 25-hydroxylase (CH25H) and cisplatin, to orchestrate a metabolism-chemo-immunity cascade with mutually amplifying components. First, the intrinsic catalase (CAT)-like activity of ZIF67 generates oxygen in situ to fuel CH25H-mediated cholesterol depletion that reaches 72% in resistant bladder cancer cells. This process disrupts lipid raft structure and downregulates P-glycoprotein (P-gp), resulting in 97.2% cisplatin retention in resistant cells. Second, enhanced cisplatin cytotoxicity induces nucleocytoplasmic translocation of high-mobility group box 1 (HMGB1), an early molecular signature associated with immunogenic cell death (ICD). Third, Co2+ released from degraded ZIF67 activates the cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) pathway. The CH25H-derived metabolite 25-hydroxycholesterol (25HC) acts as an immunomodulatory oxysterol that works with high-mobility group box 1 (HMGB1) to potentiate toll-like receptor 4 (TLR4)-associated innate immune signaling and remodel the immunosuppressive tumor microenvironment. In MB49R tumor-bearing mice, intratumoral CD8+ T cell infiltration increases by 2.3-fold on day 14 after treatment. In preclinical bladder cancer models, this tripartite synergy achieves 95.9% short-term tumor growth suppression with no obvious systemic toxicity under the tested dosage and observation period, providing a promising multifaceted strategy for treating chemo-resistant bladder cancer.", "journal": "Materials Today Bio", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1016/j.mtbio.2026.103537", "authors": ["Xianchun Fu", "Ye Liang", "Bin Xu", "Chao Huang", "Pengfei Zhang", "Haitao Niu"], "affiliations": ["Department of Urology, The Affiliated Hospital of Qingdao University, Qingdao, 266003, China.", "Department of Hepatobiliary and Pancreatic Surgery, The Affiliated Hospital of Qingdao University, Qingdao, 266003, China.", "College of Medicine, Southwest Jiaotong University, Chengdu, Sichuan, 610031, China."], "corresponding_authors": [], "china_team": "Department of Urology, The Affiliated Hospital of Qingdao University, Qingdao, 266003, China Haitao Niu团队", "category": "basic", "classification_reason": "basic_signals=11", "score": 41.54, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 15.54, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 11.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 10.2, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.54, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "纳米反应器逆转膀胱癌化疗耐药", "chinese_summary": "青岛大学附属医院牛海涛团队10月Mater Today Bio报道一种叶酸靶向ZIF67纳米反应器CCZF，共载CH25H与顺铂。在耐药膀胱癌细胞中，其胆固醇耗竭达72%，顺铂滞留率达97.2%；在MB49R荷瘤小鼠中，CD8+ T细胞浸润增加2.3倍，短期肿瘤生长抑制率达95.9%，且未观察到明显全身毒性。", "abstract_zh": "膀胱癌化疗耐药源于异常胆固醇代谢与免疫抑制之间自我强化的恶性循环，传统单靶点治疗无法将其打破。在此，我们报道一种叶酸靶向的基于沸石咪唑酯骨架-67（ZIF67）的纳米反应器，命名为CCZF，其共载胆固醇25-羟化酶（CH25H）和顺铂，以协调具有相互放大组分的代谢-化疗-免疫级联反应。首先，ZIF67固有的类过氧化氢酶（CAT）活性可原位产生氧气，为CH25H介导的胆固醇耗竭提供动力，在耐药膀胱癌细胞中胆固醇耗竭达到72%。该过程破坏脂筏结构并下调P-糖蛋白（P-gp），导致耐药细胞中顺铂滞留率达97.2%。其次，增强的顺铂细胞毒性诱导高迁移率族蛋白B1（HMGB1）发生核质转位，这是与免疫原性细胞死亡（ICD）相关的早期分子标志。第三，ZIF67降解所释放的Co2+激活环鸟苷酸-腺苷酸合成酶-干扰素基因刺激因子（cGAS-STING）通路。CH25H衍生的代谢产物25-羟基胆固醇（25HC）作为一种免疫调节性氧固醇，与高迁移率族蛋白B1（HMGB1）协同增强Toll样受体4（TLR4）相关的先天免疫信号，并重塑免疫抑制性肿瘤微环境。在MB49R荷瘤小鼠中，治疗后第14天肿瘤内CD8+ T细胞浸润增加2.3倍。在临床前膀胱癌模型中，这种三方协同在测试剂量和观察期内实现了95.9%的短期肿瘤生长抑制，且无明显全身毒性，为治疗化疗耐药膀胱癌提供了一种有前景的多方面策略。"}, {"pmid": "42621113", "title": "Urinary CXCL9 Across the Spectrum of Kidney Allograft Inflammation.", "abstract": "Kidney allograft inflammation spans a heterogeneous spectrum of phenotypes defined by the Banff 2022 classification. We assessed whether urinary C-X-C motif chemokine ligand 9 (uCXCL9) normalized to creatinine (uCXCL9:Cr) captures inflammatory burden across this spectrum and provides incremental diagnostic utility beyond standard variables. We analyzed 3181 biopsy-urine pairs from a development cohort (1341 biopsies from 921 patients) and an independent external validation cohort (1840 biopsies from 917 patients). Associations with Banff 2022 diagnostic categories were evaluated using multinomial logistic regression with stability-based selection. Incremental performance was assessed using the Hand & Till multiclass area under the curve (AUC) and decision curve analysis. uCXCL9:Cr demonstrated a graded increase across the inflammatory spectrum, with lowest levels in biopsies without specific lesions (median 4.55 ng/mmol), intermediate levels in antibody-mediated phenotypes (15.14), higher levels in acute T cell-mediated rejection (TCMR; 46.11), and the highest levels in mixed inflammatory patterns (53.18-134.05; P < 0.001). Levels increased proportionally with microvascular and tubulointerstitial activity scores (all P < 0.001). In multivariable multinomial analyses, uCXCL9:Cr was independently associated with each inflammatory category across the Banff 2022 spectrum (relative risk ratio [RRR] range: 1.68-3.44; all P ≤ 0.004). Addition of uCXCL9:Cr increased multiclass AUC from 0.797 to 0.831 in the development cohort and from 0.801 to 0.821 in the validation cohort (both P = 0.001). Incorporation of uCXCL9 was associated with a potential reduction in unnecessary biopsies in decision-curve analyses. uCXCL9 reflects active kidney-graft inflammation across modern Banff phenotypes and provides clinically meaningful diagnostic information beyond standard variables, supporting its potential to inform biopsy decisions and monitoring in kidney transplant recipients, pending prospective validation.", "journal": "Kidney International Reports", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1111/ajt.15011", "authors": ["Esteban Cortes Garcia", "Karolien Wellekens", "Claire Tinel", "Stéphanie Chhun", "Charlotte Debiais-Deschamps", "Juliette Leon", "Antoine Troger", "Camille Roger", "Carole Burger", "Marie-Bénédicte Le Stang", "Emilie Lebraud", "Marie-Noelle Peraldi", "Christophe Legendre", "Frank Martinez", "Rebecca Sberro-Soussan", "Julien Zuber", "Marion Rabant", "Fabiola Terzi", "Marie Essig", "Wilfried Gwinner", "Pierre Marquet", "Elisabet Van Loon", "Maarten Naesens", "Dany Anglicheau", "Olivier Aubert"], "affiliations": ["Université Paris Cité, Inserm UMR1151, Necker Enfants Malades Institute (INEM), Paris, France.", "Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.", "Department of Nephrology and Kidney Transplantation, Dijon University Hospital, Dijon, France.", "Faculty of Medicine, Paris Cité University, Paris, France.", "Institut Necker-Enfants Malades (INEM), INSERM U1151-CNRS UMR 8253, Paris, France.", "AP-HP, Laboratory of Immunology, Necker-Enfants Malades Hospital, Paris, France.", "Department of Kidney and Metabolic Diseases, Transplantation and Clinical Immunology, Necker Hospital, Assistance Publique - Hôpitaux de Paris, Université Paris Cité, Paris, France.", "Department of Pathology, Necker-Enfants Malades Hospital, APHP, Université Paris Cité, Paris, France.", "Department of Nephrology, Ambroise-Paré hospital, Assistance Publique - Hôpitaux de Paris, Paris-Saclay University, Villejuif, France.", "Department of Nephrology and Hypertension, Hannover Medical School, Hannover, Germany.", "INSERM U1248 Pharmacology & Transplantation, University of Limoges, Limoges University Hospital, Limoges, France.", "Imelda Ziekenhuis, Bonheiden, Belgium."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=6", "score": 31.79, "score_parts": {"urology_relevance": 5, "urology_in_title": 8.0, "journal_priority": 10.79, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 6.0}, "journal_metrics": {"status": "ok", "impact_factor": 5.7, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.79, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42616342", "title": "Cefepime/Zidebactam: First Approval.", "abstract": "Cefepime/zidebactam (Zaynich®), a fixed-dose combination of the fourth-generation cephalosporin cefepime and the β-lactam enhancer zidebactam, that is being developed by Wockhardt for the treatment of serious infections caused by multidrug-resistant Gram-negative bacteria. With synergistic properties between the two drug components, cefepime/zidebactam has demonstrated in vitro bactericidal activity even in organisms with complex resistance mechanisms. Supported by the findings of the pivotal, active-controlled, phase III ENHANCE 1 trial, on 27 May 2026, cefepime/zidebactam received its first approval, in India, for the treatment of adult patients with complicated urinary tract infections (cUTI), including pyelonephritis, as well as cases with concurrent Gram-negative bacteraemia. Subsequently, on 29 May 2026, cefepime/zidebactam was approved in the USA for the treatment of adult patients with cUTI including pyelonephritis caused by designated susceptible microorganisms. Cefepime/zidebactam is also currently under regulatory review in the EU for use in the treatment of serious infections caused by Gram-negative bacteria. This article summarises the milestones in the development of cefepime/zidebactam leading to this first approval for the treatment of cUTI (including pyelonephritis) in adults.", "journal": "Drugs", "pub_date": "2026-Oct", "publication_types": ["Journal Article", "Review"], "doi": "10.1007/s40265-026-02374-2", "authors": ["Matt Shirley"], "affiliations": ["Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand. dru@adis.com."], "corresponding_authors": ["Matt Shirley"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 29.01, "score_parts": {"urology_relevance": 7, "urology_in_title": 0.0, "journal_priority": 16.01, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 3.0}, "journal_metrics": {"status": "ok", "impact_factor": 14.4, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.01, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "头孢吡肟/齐德巴坦获全球首批", "chinese_summary": "Wockhardt公司研发的头孢吡肟/齐德巴坦（Zaynich®）5月27日在印度获批，用于成人复杂性尿路感染（含肾盂肾炎）及合并革兰阴性菌血症，5月29日再获美国批准用于指定敏感菌所致复杂性尿路感染（含肾盂肾炎）；", "abstract_zh": "Cefepime/zidebactam (Zaynich®) 是第四代头孢菌素 cefepime 与 β-内酰胺增强剂 zidebactam 的固定剂量复方制剂，由 Wockhardt 开发，用于治疗多重耐药革兰阴性菌引起的严重感染。由于两种药物成分之间的协同特性，cefepime/zidebactam 即使在具有复杂耐药机制的微生物中也显示出体外杀菌活性。在关键性、阳性对照、III 期 ENHANCE 1 试验结果的支持下，cefepime/zidebactam 于 2026 年 5 月 27 日在印度首次获批，用于治疗成人复杂性尿路感染（cUTI），包括肾盂肾炎，以及合并革兰阴性菌菌血症的病例。随后，于 2026 年 5 月 29 日，cefepime/zidebactam 在美国获批，用于治疗由指定敏感微生物引起的成人复杂性尿路感染（包括肾盂肾炎）。Cefepime/zidebactam 目前也正在欧盟接受监管审评，用于治疗革兰阴性菌引起的严重感染。本文总结了 cefepime/zidebactam 研发过程中的里程碑，这些里程碑促成了其首次获批用于治疗成人复杂性尿路感染（包括肾盂肾炎）。"}, {"pmid": "42612494", "title": "Reassessing the role of segmental ureterectomy in upper tract urothelial carcinoma: Functional durability and propensity-matched oncological outcomes.", "abstract": "Segmental ureterectomy (SU) is a kidney-sparing alternative to radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC) localized to the ureter, yet contemporary comparative data are limited. We aimed to evaluate perioperative, functional, and pathology-adjusted oncologic endpoints between SU and RNU using propensity-score matching. We retrospectively reviewed UTUC patients treated at a tertiary referral center (2008-2025), identifying SU (n = 81) and RNU (n = 259) cases. To reduce confounding, we performed 1:1 propensity-score matching on age, gender, comorbidities, and baseline eGFR, yielding 92 matched patients (46 pairs). Because 8 pairs showed no residual malignancy (pT0) on final pathology, the primary adjusted analysis was restricted to 38 pairs (n = 76), with the full 46-pair cohort retained for sensitivity analysis. Primary endpoints were DFS, CSS, and OS. Secondary endpoints included perioperative outcomes, renal function, intravesical recurrence-free survival, and metastasis-free survival. Time-to-event outcomes were analyzed using paired Cox models adjusted for definitive pathological grade and stage, and Kaplan-Meier estimated as secondary analysis. The median follow-up for the matched cohort was 37.1 months (IQR: 14.2-69.0). Baseline tumor characteristics were comparable except for tumor location, with a higher prevalence of nondistal tumors in the RNU group (P < 0.001). In the primary analysis (pathology-adjusted) paired-Cox regression estimated DFS and CSS were similar between SU and RNU (HR 0.63, 95% CI 0.23-1.69, P = 0.358 and HR 0.57, 95% CI 0.2-1.54, P = 0.275, respectively). The adjusted OS was also comparable (HR 0.49, 95% CI 0.16-1.51, P = 0.213), alongside all secondary oncologic endpoints (P > 0.05). In the sensitivity analysis, oncological endpoints did not differ between the groups. Renal function preservation favored SU, with median ΔeGFR +8.8 vs. RNU -11.95 ml/min/1.73 m² (P < 0.001). SU significantly improved renal preservation without compromising intermediate-term, pathology-adjusted oncologic endpoints vs. RNU. These findings support SU as a kidney-sparing option in selected patients, including those with high-grade disease, adverse features (CIS, LVI, ≥pT2), and nondistal tumors. Further work should refine patient selection and post-SU surveillance.", "journal": "Urologic Oncology", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1016/j.urolonc.2026.07.026", "authors": ["Rinat Lasmanovich", "Oleksandr Chepeliuk", "Orel Hemo", "May Fihman", "Asaf Shvero", "Nir Kleinmann", "Eddie Fridman", "Orith Portnoy", "Menachem Laufer", "Dorit E Zilberman", "Barak Rosenzweig", "Zohar A Dotan"], "affiliations": ["Gray Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel; Department of Urology, Sheba Medical Center, Ramat Gan, Israel. Electronic address: wendy.rinat@gmail.com.", "Gray Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel; Department of Urology, Sheba Medical Center, Ramat Gan, Israel.", "Gray Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel; Department of Pathology, Sheba Medical Center, Ramat Gan, Israel.", "Gray Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel; Department of Diagnosis Radiology, Sheba Medical Center, Ramat Gan, Israel."], "corresponding_authors": ["Rinat Lasmanovich"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=8", "score": 31.75, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 5.75, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 8.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.3, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.75, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42611560", "title": "CD73 inhibition overcomes adaptive immune resistance to PARP inhibition in models of prostate cancer.", "abstract": "Metastatic castration-resistant prostate cancer (mCRPC) remains a leading cause of cancer-related mortality in men. Although poly(ADP-ribose) polymerase (PARP) inhibitors are approved for mCRPC patients with homologous recombination repair (HRR) deficiencies, clinical trials combining olaparib with PD-1/PD-L1 inhibitors showed limited efficacy in unselected populations. To investigate the immunomodulatory effects of PARP inhibitors in an unbiased manner, we performed bulk RNA-seq on HRR-proficient MycCaP cells treated with the PARP inhibitor olaparib versus vehicle control. Transcriptomic analysis revealed robust upregulation of CD73 (NT5E), an ectoenzyme and emerging immune checkpoint that generates extracellular adenosine, suggesting an adaptive mechanism that undermines olaparib efficacy and promotes immunosuppression. CD73 induction by olaparib was validated in human and mouse prostate cancer cell lines, with more pronounced effects in HRR-compromised PTEN-KO cells. Mechanistically, olaparib-driven CD73 expression was mediated through DNA damage-activated ATR/CHEK1/IRF1 and TGF-β1/AKT signaling pathways. In parallel, olaparib enhanced tumor immunogenicity by activating type I IFN signaling and antigen presentation machinery. In vivo, combining olaparib with CD73 blockade significantly delayed tumor growth, improved T cell infiltration, and augmented CD8+ T cell effector function across HRR-proficient and PTEN-KO prostate cancer models. These findings identify olaparib-induced CD73 upregulation as an adaptive resistance mechanism and support olaparib plus CD73 blockade as a promising therapeutic strategy for advanced prostate cancer, irrespective of HRR status.", "journal": "Journal of Clinical Investigation", "pub_date": "2026-Oct-01", "publication_types": ["Journal Article"], "doi": "10.1172/JCI170071", "authors": ["Ping Xie", "Renqiang Ma", "Minghui Zhang", "Jie Fan", "Hui Tang", "Longzhen Song", "Yong Wan", "Timothy M Kuzel", "Deyu Fang", "Weiguo Cui", "Jennifer D Wu", "Sarki A Abdulkadir", "Yi Zhang", "Akash Patnaik", "Bin Zhang"], "affiliations": ["Department of Medicine, Hematology/Oncology Division, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.", "Otorhinolaryngology Hospital, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.", "Department of Obstetrics and Gynecology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.", "Department of Pharmacology and Chemical Biology, Emory University School of Medicine, Atlanta, Georgia, USA.", "Department of Pathology and.", "Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.", "Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.", "Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, Illinois, USA."], "corresponding_authors": [], "china_team": "Department of Medicine, Hematology/Oncology Division, Robert H Yi Zhang团队", "category": "basic", "classification_reason": "basic_signals=19", "score": 43.93, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 15.93, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 14.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 13.6, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.93, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "抑制CD73可逆转前列腺癌PARP抑制剂耐药", "chinese_summary": "郑州大学第一附属医院张毅团队8月J Clin Invest基于前列腺癌模型发现，奥拉帕利上调CD73（NT5E）生成胞外腺苷，构成适应性免疫抵抗。联合CD73阻断可显著延缓肿瘤生长、改善T细胞浸润并增强CD8⁺T细胞杀伤功能，提示该联合策略或适用于不同HRR状态的晚期前列腺癌。", "abstract_zh": "转移性去势抵抗性前列腺癌（mCRPC）仍是男性癌症相关死亡的主要原因。尽管聚（ADP-核糖）聚合酶抑制剂（PARP抑制剂）已获批用于存在同源重组修复（HRR）缺陷的mCRPC患者，但奥拉帕利联合PD-1/PD-L1抑制剂的临床试验在未经选择的人群中疗效有限。为以无偏倚方式探究PARP抑制剂的免疫调节效应，我们对经PARP抑制剂（奥拉帕利）处理与载体对照处理的HRR功能正常的MycCaP细胞进行了bulk RNA测序。转录组学分析显示CD73（NT5E）显著上调，CD73是一种胞外酶，也是新近发现的免疫检查点，可生成胞外腺苷，提示这是一种削弱奥拉帕利疗效并促进免疫抑制的适应性机制。奥拉帕利诱导CD73在人和小鼠前列腺癌细胞系中均得到验证，在HRR受损的PTEN敲除（KO）细胞中效应更为明显。机制上，奥拉帕利驱动的CD73表达由DNA损伤激活的ATR-CHEK1-IRF1和TGF-β1-AKT信号通路介导。同时，奥拉帕利通过激活I型干扰素（IFN）信号和抗原呈递机制增强肿瘤免疫原性。在体内，奥拉帕利联合CD73阻断在HRR功能正常和PTEN KO前列腺癌模型中均显著延缓肿瘤生长、改善T细胞浸润并增强CD8⁺T细胞效应功能。这些发现将奥拉帕利诱导的CD73上调确定为一种适应性耐药机制，并支持奥拉帕利联合CD73阻断作为晚期前列腺癌有前景的治疗策略，无论HRR状态如何。"}, {"pmid": "42607565", "title": "Intravesical recurrence is associated with increased Treg and exhausted CD8+ T cells in upper tract urothelial carcinoma.", "abstract": "Upper tract urothelial carcinoma (UTUC) includes renal pelvic and ureteral carcinoma, and radical nephroureterectomy (RNU) is the standard surgical treatment for nonmetastatic disease. Despite complete resection, postoperative intravesical recurrence (IVR) occurs in 22% to 47% of patients. It is generally recognized that ureteral tumor exhibits a higher incidence of IVR compared with renal pelvic tumor. However, the immunological mechanisms underlying this difference remain poorly understood. A total of 26 patients with UTUC without variant histology who underwent laparoscopic RNU at Kyushu University Hospital were classified according to tumor location (Renal pelvic group: n = 15; Ureteral group: n = 11). Clinical characteristics and the spatial distribution of immune cells in UTUC were analyzed and compared between the 2 groups using multiplex immunohistochemistry (mIHC). IVR occurred more frequently in the Ureteral group than in the Renal pelvic group. mIHC analysis revealed significantly higher infiltration of regulatory T (Treg) cells and programmed cell death (PD)-1+ Treg cells in the ureteral group. Furthermore, the infiltration of exhausted CD8+ T cells co-expressing T cell immunoglobulin and ITIM domain (TIGIT) and PD-1 were significantly enriched in the Ureteral group. Across the entire cohort, patients who developed IVR exhibited higher densities of these T-cell subsets compared with those without IVR. Ureteral tumors demonstrate increased infiltration of Treg cells, PD-1⁺ Treg cells, and TIGIT⁺PD-1⁺CD8⁺ T cells, suggesting an immunosuppressive TME that may contribute to the higher risk of IVR after RNU.", "journal": "Urologic Oncology", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1016/j.urolonc.2026.07.028", "authors": ["Daisuke Ito", "Tokiyoshi Tanegashima", "Genshiro Fukuchi", "Satoshi Kobayashi", "Takashi Matsumoto", "Masaki Shiota", "Genki Okumura", "Kota Itahashi", "Yoshinao Oda", "Shohei Koyama", "Masatoshi Eto"], "affiliations": ["Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center Japan, Tokyo, Japan; Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.", "Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center Japan, Tokyo, Japan; Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. Electronic address: tanegashima.tokiyoshi.271@m.kyushu-u.ac.jp.", "Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.", "Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.", "Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center Japan, Tokyo, Japan; Department of Immunogenomic Medicine, Research Institute, National Cancer Center Japan, Tokyo, Japan.", "Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center Japan, Tokyo, Japan.", "Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan."], "corresponding_authors": ["Tokiyoshi Tanegashima"], "china_team": "", "category": "basic", "classification_reason": "basic_signals=4", "score": 27.75, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 5.75, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 4.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.3, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.75, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "输尿管癌膀胱复发伴免疫抑制", "chinese_summary": "九州大学医院8月Urol Oncol对26例接受腹腔镜肾输尿管切除术的上尿路尿路上皮癌患者行多重免疫组化分析，发现输尿管肿瘤较肾盂肿瘤更易发生膀胱内复发，其微环境中Treg细胞、PD-1阳性Treg细胞及TIGIT与PD-1双阳性耗竭CD8阳性T细胞浸润显著增多，提示免疫抑制性肿瘤微环境可能解释输尿管肿瘤术后膀胱复发风险更高。", "abstract_zh": "上尿路尿路上皮癌（UTUC）包括肾盂癌和输尿管癌，根治性肾输尿管切除术（RNU）是非转移性疾病的标准手术治疗。尽管实现了完全切除，术后膀胱内复发（IVR）仍发生于22%至47%的患者中。目前普遍认为，与肾盂肿瘤相比，输尿管肿瘤的IVR发生率更高。然而，这种差异背后的免疫学机制仍知之甚少。共有26例无变异组织学的UTUC患者于九州大学医院接受腹腔镜RNU，并按肿瘤位置分组（肾盂组：n = 15；输尿管组：n = 11）。使用多重免疫组化（mIHC）分析并比较两组的临床特征及UTUC中免疫细胞的空间分布。输尿管组的IVR发生率高于肾盂组。mIHC分析显示，输尿管组中调节性T（Treg）细胞及程序性细胞死亡（PD）-1阳性Treg细胞的浸润显著更高。此外，共表达T细胞免疫球蛋白和ITIM结构域（TIGIT）与PD-1的耗竭CD8阳性T细胞的浸润在输尿管组中显著富集。在整个队列中，发生IVR的患者与未发生IVR的患者相比，这些T细胞亚群的密度更高。输尿管肿瘤表现出Treg细胞、PD-1阳性Treg细胞及TIGIT阳性PD-1阳性CD8阳性T细胞浸润增加，提示存在免疫抑制性肿瘤微环境，这可能促成了RNU术后更高的IVR风险。"}, {"pmid": "42603990", "title": "Nicotinamide Adenine Dinucleotide Augmentation in Diabetic Kidney Disease: Randomized Trial Study Protocol.", "abstract": "Diabetic kidney disease (DKD) is the leading cause of chronic kidney disease (CKD) and kidney failure worldwide. Reduced nicotinamide adenine dinucleotide (NAD) levels are mechanistically linked to DKD pathogenesis; and NAD augmentation by administration of its precursor, nicotinamide mononucleotide (NMN), has attenuated albuminuria and kidney injury in preclinical models. The NAD Augmentation in Diabetic Kidney Disease (NAD in DKD) trial is a phase 2a, randomized, multicenter, double-blind, placebo-controlled, parallel-group study evaluating the efficacy and safety of oral pharmaceutical-grade microcrystalline β-NMN (MIB-626) in adults with DKD. One hundred fifty-six participants aged ≥ 30 years with diabetes, urinary albumin-to-creatinine ratio (UACR) ≥ 100 mg/g, and estimated glomerular filtration rate (eGFR) > 25 ml/min per 1.73 m2 were randomized to receive MIB-626 (1000 mg twice daily) or placebo for 24 weeks, followed by 12 weeks of postintervention follow-up. The randomization was stratified for biological sex, age (30-44, 45-65, and ≥ 66 years), and enrolling site. The primary end point was change in UACR from baseline to 24 weeks. Secondary outcomes included serum creatinine, cystatin C, and eGFR, biomarkers of kidney injury and biological age, glycemic control, measures of muscle performance and physical function, and the circulating NAD metabolome. This phase 2a trial was designed to evaluate the safety and efficacy of NAD augmentation in improving UACR in albuminuric DKD. The results will inform whether NAD augmentation warrants further evaluation in larger trials statistically powered for long-term kidney outcomes. The study is registered at ClinicalTrials.gov (NCT05759468).", "journal": "Kidney International Reports", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1093/ndt/gfx377", "authors": ["Mohan Sonu Chandra", "Thiago Gagliano-Jucá", "Skand Shekhar", "Karol M Pencina", "Thomas G Travison", "Rajesh Garg", "Marie E McDonnell", "Kieran F Reid", "Nancy K Latham", "Helen Lam", "Diego Meritus", "Yufei Yan", "Ilean Isaza", "Mary F Weiss", "Yusnie M Beleva", "Eric M Bracken", "Elizabeth Ruiz", "Christina Wang", "John Forman", "Sushrut S Waikar", "Shalender Bhasin"], "affiliations": ["Research Program in Men's Health: Aging and Metabolism, Boston Claude D. Pepper Older Americans Independence Center for Function Promoting Therapies, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.", "Division of Endocrinology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.", "Marcus Institute for Aging Research, Hebrew SeniorLife, Roslindale, Massachusetts, USA.", "Division of Endocrinology, The Lundquist Institute, Harbor-UCLA Medical Center, David Geffen School of Medicine at UCLA, Torrance and Los Angeles, California, USA.", "Laboratory of Exercise Physiology and Physical Performance, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.", "Section of Nephrology, Boston Medical Center and Boston University Chobanian and Avedisian School of Medicine, Boston, Massachusetts, USA."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "basic_signals=4", "score": 20.29, "score_parts": {"urology_relevance": 3, "urology_in_title": 0.0, "journal_priority": 10.79, "top_journal_bonus": 0.0, "novelty": 0.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 4.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 5.7, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.79, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42602606", "title": "Transient ultrasonographic findings suggestive of vesicoureteral reflux associated with cystitis in pediatric and adolescent patients: Case reports and pathophysiological insights.", "abstract": "Although the clinical progression from lower to upper urinary tract infection is well recognized, the underlying pathophysiology remains understudied. Although vesicoureteral reflux is considered an important factor in pyelonephritis development, the mechanism underlying cases without reflux remains unclear. We report 2 pediatric and adolescent cases in which transient steepening of the ureteral jet angulation and bladder wall thickening were observed on ultrasonography during episodes of cystitis, with subsequent normalization after the resolution of inflammation. These findings suggest that cystitis-induced bladder wall thickening may transiently impair the antireflux mechanism and can provide a possible explanation for some cases of pyelonephritis without documented vesicoureteral reflux.", "journal": "Radiology Case Reports", "pub_date": "2026-Oct", "publication_types": ["Case Reports", "Journal Article"], "doi": "10.1111/iju.13915", "authors": ["Riu Homma", "Toshihiro Yanai", "Keiichi Motoyama", "Hirota Saito", "Isho Izumi"], "affiliations": ["Department of Pediatric Emergency and Critical Care, Ibaraki Children's Hospital, Mito, Japan.", "Department of Pediatric Surgery, Ibaraki Children's Hospital, Mito, Japan.", "Department of Pediatric Gastroenterology and Hepatology, Ibaraki Children's Hospital, Mito, Japan.", "Department of General Pediatrics, Ibaraki Children's Hospital, Mito, Japan."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_clinical", "score": 27.0, "score_parts": {"urology_relevance": 15, "urology_in_title": 8.0, "journal_priority": 0.0, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 2.0}, "journal_metrics": {"status": "missing", "impact_factor": null, "cas_zone": null, "cas_zone_points": 0.0, "impact_factor_points": 0.0}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42600227", "title": "Defining a hilar \"danger zone\" to guide surgical decision-making in T1 renal cell carcinoma.", "abstract": "Laparoscopic partial nephrectomy (LPN) is a preferred surgical approach for early-stage renal cell carcinoma. However, there is ongoing debate regarding the optimal surgical technique for highly complex renal hilar tumors. Moreover, long-term follow-up data assessing the applicability and outcomes of LPN for renal hilar tumors remain limited. A retrospective analysis was conducted on patients with pT1-stage clear cell renal cell carcinoma (ccRCC). We proposed an imaging-based \"danger zone\" defining the critical boundary of hilar vascular structures. Based on spatial location and surgical approach, patients were stratified into 4 groups: non-hilar partial nephrectomy (NHPN), hilar partial nephrectomy outside (HPNOUT) or inside (HPN-IN) the danger zone, and hilar radical nephrectomy (HRN). We compared perioperative parameters, postoperative renal function (eGFR), and recurrence-free survival (RFS) across these cohorts. A total of 323 patients were included (NHPN, n = 204; HPNOUT, n = 46; HPN-IN, n = 21; HRN, n = 52). Over a median follow-up of 3,276 days, 24 overall oncologic events were recorded. The HPNOUT group demonstrated perioperative outcomes, postoperative eGFR, and RFS (HR = 1.16, 95% CI: 0.28-4.85, P = 0.836) comparable to the NHPN cohort. Conversely, the HPN-IN group exhibited significantly higher estimated blood loss (adjusted difference: +136.3 ml, 95% CI: 99.2-173.4, P < 0.001) compared to the HPNOUT group. However, when evaluating tumors exclusively within the danger zone, a distinct clinical trade-off emerged. Compared to HRN, the HPN-IN group experienced greater perioperative morbidity but achieved significantly superior long-term renal function preservation (across 3-month, 1-year, and 5-year follow-ups; all P < 0.05). Importantly, long-term oncological control remained comparable between these 2 approaches (RFS HR = 2.06, 95% CI: 0.60-7.09, P = 0.250). The proposed \"danger zone\" concept offers an exploratory anatomical tool to assist in the preoperative risk assessment of T1 hilar tumors. Initial data suggest that LPN remains a viable option for lesions located outside the danger zone. When tumors invade the danger zone, LRN provides a safer perioperative course at the expense of functional preservation, whereas oncological efficacy seems equivalent between modalities. These preliminary observations necessitate rigorous prospective validation prior to clinical application.", "journal": "Urologic Oncology", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1016/j.urolonc.2026.07.021", "authors": ["Zihao Li", "Li Wang", "Chunzhi Qi", "Hongliang Li", "Tie Chong", "Zhenlong Wang"], "affiliations": ["The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.", "The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China. Electronic address: zhenlongw2001@xjtu.edu.cn."], "corresponding_authors": ["Zhenlong Wang"], "china_team": "The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China Zhenlong Wang团队", "category": "clinical_review", "classification_reason": "clinical_signals=10", "score": 33.75, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 5.75, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 10.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.3, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.75, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42597981", "title": "Morquio syndrome masquerading as juvenile idiopathic Arthritis: A case report.", "abstract": "Morquio syndrome, or Mucopolysaccharidosis type IV (MPS IV), is a rare autosomal recessive lysosomal storage disorder caused by enzyme deficiencies involved in glycosaminoglycan degradation. Progressive accumulation of these molecules leads to skeletal dysplasia, joint deformities, and variable systemic complications. Early features may mimic juvenile idiopathic arthritis (JIA), delaying diagnosis. We report a 16-year-old adolescent previously diagnosed with polyarticular JIA and treated with biological therapy since age 7. He presented with generalized polyarthralgia, significant skeletal deformities, and a 6 cm leg length discrepancy. Clinical examination revealed hand deformities, thoracic cage enlargement, and spinal involvement. Radiographs demonstrated dysplastic femoral heads and shoulder deformities. Laboratory tests were negative for autoimmune markers. Urinary glycosaminoglycan analysis and targeted genetic testing of the glucosamine N-acetyl-6-sulfatase (GALNS) gene confirmed Morquio syndrome. The patient was referred for genetic counseling and orthopedic management. This case highlights the diagnostic challenge of differentiating MPS IV from JIA, particularly in patients with atypical skeletal features or poor response to immunomodulatory therapy. Recognition of radiological abnormalities, family history, and consanguinity is essential. Early diagnosis allows for appropriate enzyme replacement therapy, surgical interventions, and multidisciplinary care to optimize outcomes. Morquio syndrome can masquerade as polyarticular JIA. High clinical suspicion, combined with enzymatic and genetic testing, is crucial for timely diagnosis and management to improve long-term function and quality of life.", "journal": "Radiology Case Reports", "pub_date": "2026-Oct", "publication_types": ["Case Reports", "Journal Article"], "doi": "10.1002/humu.24270", "authors": ["Zeineb Alaoui Kadiri", "Imane El Binoune", "Bouchra Amine", "Anbar Kabbaj", "Salma Zemrani", "Samira Rostom", "Bahiri Rachid"], "affiliations": ["Department of Rheumatology, Ibn Sina University Hospital Center, Morocco."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_clinical", "score": 7.0, "score_parts": {"urology_relevance": 3, "urology_in_title": 0.0, "journal_priority": 0.0, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 2.0}, "journal_metrics": {"status": "missing", "impact_factor": null, "cas_zone": null, "cas_zone_points": 0.0, "impact_factor_points": 0.0}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42596073", "title": "Immediate intraoperative detrusor muscle status at primary transurethral resection of bladder tumour: a prospective, blinded, paired cohort, feasibility study using fluorescence confocal microscopy (IB1-LaserComplete study).", "abstract": "To evaluate ex vivo fluorescence confocal microscopy (FCM) for immediate detrusor muscle (DM) assessment during primary transurethral resection of bladder tumour (TURBT). This prospective, blinded, paired-cohort feasibility study enrolled consecutive patients undergoing primary TURBT for suspected non-muscle-invasive bladder cancer between September 2024 and September 2025 (IB1-LaserComplete study; International Standard Randomised Controlled Trial Number Register [ISRCTN]16114765). Ex vivo FCM generates immediate high-resolution digital images of fresh tissue, enabling immediate DM assessment. Intraoperative ex vivo FCM imaging of en face tumour base specimens was performed using the Histolog® scanner (SamanTree Medical SA, Lausanne, Switzerland). DM status was reported by a blinded uro-pathologist and urologist. Formalin-fixed histopathology served as the reference standard. The primary outcome was technical feasibility, defined as acquisition of an interpretable FCM image. Secondary outcomes included exploratory diagnostic performance, inter-observer agreement and time to confirmation of DM status. A total of 34 patients were recruited and 30 had evaluable paired specimens. DM was absent in 13% (four of 30). FCM was sufficient for determining DM status in all patients (100%; 30 of 30). Sensitivity, specificity, positive predictive value, negative predictive value (NPV) were 42% (95% confidence interval [CI] 26-61%), 100% (95% CI 51-100%), 100% (95% CI 74-100%), and 21% (95% CI 9-43%), respectively. Inter-observer agreement between the uro-pathologist and urologist was high at 83% (κ = 0.72, 95% CI 0.47-0.97). The median (interquartile range) time to confirm DM status was 5.4 (4.95-5.39) min vs 11 (7-13.8) days using standard histopathology. Fluorescence confocal microscopy is feasible for rapid intraoperative imaging of TURBT specimens and demonstrates excellent specificity for detection of DM. However, its low sensitivity and NPV preclude use as a stand-alone tool to exclude DM intraoperatively. Based on these findings, FCM should not guide intraoperative decision making outside research settings.", "journal": "BJU International", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1111/bju.70395", "authors": ["Martin J Connor", "Archana Gopalakrishnan", "Nikhil Mayor", "Eva Bolton", "Sami Hamid", "Sai Kalpitha Reddy", "Tayla Perreau", "Eslam Maher", "Alexander Light", "Samuel Morris", "Jiten Jaipura", "Mariana Bertoncelli Tanaka", "Norma Gibbons", "Archie Hughes-Hallett", "Hashim U Ahmed", "Rakesh Heer", "Andrew Smith", "David Hrouda", "Anna Silvanto", "Mona El-Bahrawy", "Mathias Winkler"], "affiliations": ["Division of Surgery, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK.", "Royal Marsden Urology, The Royal Marsden Hospital, The Royal Marsden NHS Foundation Trust, London, UK.", "Department of Urology, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, UK.", "Experimental Cancer Medicine Centre (ECMC), Department of Surgery and Cancer, Imperial College London, London, UK.", "Department of Histopathology, Imperial College Healthcare NHS Foundation Trust, Charing Cross Hospital, London, UK.", "Department of Histopathology, University College London Hospitals NHS Foundation Trust (UCLH), London, UK.", "Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=6", "score": 38.47, "score_parts": {"urology_relevance": 12, "urology_in_title": 8.0, "journal_priority": 10.47, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 6.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.4, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.47, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42594716", "title": "Biopsy Gleason pattern 4 burden refines preoperative risk stratification in prostate cancer.", "abstract": "To evaluate the prognostic value of biopsy-based Gleason pattern 4 (GP4) burden in a racially and ethnically diverse cohort of men with intermediate- and high-risk prostate cancer undergoing radical prostatectomy. We retrospectively identified 368 men with biopsy-proven Gleason grade group (GG) 2 to 4 prostate cancer treated with radical prostatectomy (RP) between 2017 and 2024. GP4 burden was quantified using multiple biopsy-based measures. Primary outcomes were adverse surgical pathology (ASP) at prostatectomy-extraprostatic extension, seminal vesicle invasion, or lymph node invasion-and biochemical recurrence (BCR) within 3 years. Associations were evaluated using multivariable regression; model discrimination was assessed using Harrell's concordance index. A point-based pattern 4 risk score (P4RS) was developed and compared with an established preoperative clinical risk nomogram for prediction of early biochemical recurrence. The cohort was racially and ethnically diverse (76% Black or Hispanic/Latino). ASP occurred in 38% of patients and 17% experienced BCR within 3 years of surgery. ASP risk rose 15% per 2-millimeter increase in total length of pattern 4 on biopsy. Among patients with ≤15 mm GP4, 3-year BCR risk rose 22% per 2-millimeter increase; precision was limited beyond this range. Absolute GP4 metrics improved discrimination for BCR (concordance index 0.716-0.723) relative to GG (0.690). Among risk stratification models, the P4RS demonstrated the highest discrimination (concordance index 0.728). Absolute Gleason pattern 4 burden, particularly total length, provides clinically meaningful prognostic information beyond grade group and improves risk stratification for adverse pathology and early oncologic outcomes after prostatectomy.", "journal": "Urologic Oncology", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1016/j.urolonc.2026.07.013", "authors": ["Theodoros Karanikolas", "Austin Freedman", "Jonah Tripp", "Samuel Yim", "Morgan Joseph", "Pedro Maria", "Ahmed Aboumohamed", "Alexander Sankin", "Ilir Agalliu", "Stephen Reese", "Kara Watts"], "affiliations": ["Department of Urology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY.", "Albert Einstein College of Medicine, Bronx, NY.", "Department of Urology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY; Albert Einstein College of Medicine, Bronx, NY.", "Department of Urology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY; Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY.", "Department of Urology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY; Albert Einstein College of Medicine, Bronx, NY. Electronic address: kwatts@montefiore.org."], "corresponding_authors": ["Kara Watts"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=7", "score": 30.75, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 5.75, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 7.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.3, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.75, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42585880", "title": "Impact of divergent differentiation and histological subtypes on oncologic outcomes in patients treated with radical nephroureterectomy for upper tract urothelial carcinoma.", "abstract": "Divergent differentiation (DD) and histological subtypes (HS) represent rare but clinically meaningful forms of upper tract urothelial carcinoma (UTUC), but their prognostic impact remains incompletely understood. We assessed the incidence, clinicopathological characteristics, and oncologic outcomes associated with DD-HS in a large multi-institutional cohort of patients undergoing radical nephroureterectomy (RNU) for non-metastatic UTUC. We retrospectively analyzed 3,441 patients treated between 1985 and 2022 across 22 institutions. Tumors were classified as pure urothelial carcinoma (PUC), DD, and HS. Clinicopathological features and survival outcomes-including recurrence-free (RFS), cancer-specific (CSS), and overall survival (OS)-were compared using the Kaplan-Meier estimator, stratified by pathological stage (organ-confined [OC: ≤pT2N0-Nx] vs. non-organ-confined [NOC: ≥pT3 or ≥pN1]) and multivariable Cox regression. DD-HS were present in 201 patients (5.8%), with DD comprising 139 (69%). Compared to PUC, DD-HS were associated with more advanced T/N stages, higher rates of lymphovascular invasion (40% vs. 20%), multifocality (35% vs. 27%), and concomitant carcinoma in situ (21% vs. 14%) (all P < 0.05). While outcomes for DD were similar to stage-matched PUC, HS showed significantly worse stage-matched RFS (OC: 38% vs. 83%; NOC: 25% vs. 46%) and OS (OC: 44% vs. 75%; all P < 0.01), and remained independently associated with poorer outcomes on multivariable analyses. Limitations include the retrospective design and lack of centralized pathology review. UTUC with DD-HS represents a biologically heterogeneous population with distinct oncologic outcomes compared with PUC. Further investigation into subtype-specific tumor biology and rigorous pathological characterization is warranted to better define the clinical relevance of individual histological entities and to guide future treatment strategies.", "journal": "Urologic Oncology", "pub_date": "2026-Oct", "publication_types": ["Journal Article", "Multicenter Study"], "doi": "10.1016/j.urolonc.2026.07.018", "authors": ["Maximilian Pallauf", "Stephan Brönimann", "Sean A Fletcher", "Michael E Rezaee", "David J McConkey", "Aaron M Potretzke", "Stephen A Boorjian", "Morgan Rouprêt", "Hooman Djaladat", "Alireza Ghoreifi", "Francesco Soria", "Riccardo Campi", "Salvatore Granata", "Zine-Eddine Khene", "Eiji Kikuchi", "Michael Rink", "Markus von Deimling", "Kazutoshi Fujita", "David D'Andrea", "Shahrokh F Shariat", "Joost Boormans", "Benjamin Pradere", "Nirmish Singla"], "affiliations": ["The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD; Department of Urology, University Hospital Salzburg, Paracelsus Medical University, Salzburg, Austria.", "The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.", "The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD.", "Department of Urology, Mayo Clinic, Rochester, MN.", "Department of Urology, Sorbonne University, GRC 5 Predictive Onco-Uro, AP-HP, Pitie-Salpetriere Hospital, Paris, France.", "Norris Comprehensive Cancer Center, Institute of Urology, University of Southern California, Los Angeles, CA.", "Division of Urology, Department of Surgical Sciences, AOU città della Salute e della Scienza di Torino, Torino School of Medicine, Torino, Italy.", "Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy; Department of Oncology, Unit of Urology and Renal Transplantation, Careggi University Hospital, Florence, Italy.", "Department of Urology, University of Rennes, Rennes, France.", "Department of Urology, St. Marianna University School of Medicine, Kanagawa, Japan.", "Department of Urology, Marienkrankenhaus Hamburg, Hamburg, Germany.", "Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.", "Department of Urology, Kindai University Faculty of Medicine, Osaka, Japan.", "Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.", "Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan; Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria; Department of Urology, Weill Cornell Medical College, New York, NY; Department of Urology, University of Texas Southwestern, Dallas, TX; Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic.", "Department of Urology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.", "Department of Urology UROSUD, La Croix du Sud Hospital, Quint-Fonsegrives, France.", "The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. Electronic address: nsingla2@jhmi.edu."], "corresponding_authors": ["Nirmish Singla"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_clinical", "score": 33.75, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 5.75, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 10.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.3, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.75, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42585879", "title": "Use of pelvic lymph node dissection among men undergoing radical prostatectomy in the US: Population-based analysis between 2010 and 2020.", "abstract": "Pelvic lymph node dissection (PLND) is recommended for men undergoing radical prostatectomy (RP) with a > 2% probability of nodal metastasis based on preoperative nomograms. Data on the current use of PLND is outdated and limited to select centers. We assessed national trends in PLND, factors associated with PLND, and oncologic outcomes. We identified men with localized prostate cancer (CaP) from the Surveillance, Epidemiology, and End Results (SEER) database who underwent RP from 2010 to 2020; PLND was confirmed via chart review. We examined temporal trends of PLND use; multivariable logistic regression identified factors associated with PLND. Multivariable competing risk-adjusted regression examined the association between PLND and prostate cancer-specific mortality (CaPSM). 148,460 men were included; 102,860 (69.3%) underwent PLND. Among PLND recipients, 58% of low-risk vs. 38% of high-risk patients had <6 nodes removed. PLND use increased over time across all risk groups (P < 0.01): from 35.4% to 49.3% (low-risk), 57.3% to 71.0% (favorable-intermediate), 71.4% to 84.2% (unfavorable-intermediate), and 86.1% to 91.5% (high-risk) between 2010 and 2020. Among patients with preoperative nomogram probability ≥2%, 78% underwent PLND compared to 39% with <2% probability (P < 0.001). The RP+PLND group did not have improved CaPSM as compared to the RP alone group when accounting for number of nodes removed (<6 nodes: HR 1.16, 95% CI 1.00-1.34; 6-12 nodes: HR 1.11, 95% CI 0.95-1.30; >12 nodes: HR 1.06, 95% CI 0.90-1.26). PLND use increased across all risk groups in the US from 2010 to 2020, suggesting overuse in low-risk and some intermediate-risk patients. Node yield was not associated with improved CaPSM.", "journal": "Urologic Oncology", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1016/j.urolonc.2026.07.009", "authors": ["Hriday P Bhambhvani", "Gal Wald", "Anjile An", "Neal Patel", "Daniel A Barocas", "Kevin H Kensler", "Myles M Reed", "David M Nanus", "Rulla Tamimi", "Jonathan E Shoag", "Bashir Al Hussein Al Awamlh"], "affiliations": ["Department of Urology, Weill Cornell Medicine, New York, NY.", "Department of Population Health Sciences, Weill Cornell Medicine, New York, NY.", "Department of Urology, Vanderbilt University Medical Center, Nashville, TN.", "Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY.", "Department of Urology, Case Western Reserve University School of Medicine, Cleveland, OH.", "Department of Urology, Weill Cornell Medicine, New York, NY. Electronic address: baa2012@med.cornell.edu."], "corresponding_authors": ["Bashir Al Hussein Al Awamlh"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 19.75, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 5.75, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.3, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.75, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42581830", "title": "Why immunotherapy fails in prostate cancer and what comes next.", "abstract": "", "journal": "BJU International", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1111/bju.70427", "authors": ["Chuzhong Wei", "Qiang Wei", "Shi Qiu"], "affiliations": ["Department of Urology and National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China."], "corresponding_authors": [], "china_team": "Department of Urology and National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China Shi Qiu团队", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 19.47, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.47, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.4, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.47, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42581823", "title": "Trends in kidney stone disease: a 5-year update of stone management in England and Scotland.", "abstract": "To describe contemporary trends in kidney stone disease (KSD)-related inpatient episodes, procedures, and costs in England and Scotland, with emphasis on post-coronavirus disease 2019 (COVID-19) service recovery, socioeconomic variation in Scotland, comparison with other urological procedures, and 10-year healthcare demand and cost projections. Retrospective descriptive analyses were conducted using English Hospital Episode Statistics (2020-2025) and Public Health Scotland data (2019-2024). KSD-related finished consultant inpatient episodes and procedures were identified using the International Statistical Classification of Diseases and Related Health Problems 10th Revision and Operation and Procedures fourth edition codes, respectively. Procedures were categorised as extracorporeal shockwave lithotripsy, ureterorenoscopy (URS), percutaneous nephrolithotomy, or open. Trends were compared with uro-oncological resections and benign prostate obstruction procedures. Socioeconomic variation was assessed using the Scottish Index of Multiple Deprivation. The 10-year healthcare demand and cost projections, accounting for National Health Service (NHS) cost uplift factors, were modelled using historical data. The COVID-19 pandemic disproportionately reduced KSD-associated activity compared with procedures for bladder and kidney cancer. Although volumes now exceed pre-pandemic levels, inpatient episodes remain below baseline and waiting times remain prolonged. Between 2020 and 2025, inpatient episodes increased by 27.4% in England and 17% in Scotland, with URS accounting for >50% of interventions. KSD procedural volumes are comparable to the combined volume of uro-oncological resections and benign prostatic obstruction procedures. In Scotland, 44% of procedures were performed in the two most deprived socioeconomic quintiles versus 37% in the two least deprived. In England, KSD-associated episodes are projected to increase by 33% to 111 907 (95% confidence interval 96 057-130 373) by 2034-2035, with an estimated cumulative NHS cost of £1.82 billion over the next decade. Kidney stone disease exacts a growing burden on healthcare services with incomplete recovery of inpatient care following the COVID-19 pandemic, socioeconomic disparities, and rising healthcare demand. These findings can inform service planning and prioritise evaluation of strategies to improve efficiency, equity, and prevention.", "journal": "BJU International", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1111/bju.70409", "authors": ["Catherine E Lovegrove", "Robert Geraghty", "Imran Ahmad", "Hing Y Leung", "Ben Turney"], "affiliations": ["School of Cancer Sciences, University of Glasgow, Glasgow, UK.", "Department of Urology, University Hospital Monklands, Airdrie, UK.", "Newcastle University, Newcastle upon Tyne, UK.", "Department of Urology, Freeman Hospital, Newcastle upon Tyne, UK.", "Department of Urology, Queen Elizabeth University Hospital, Glasgow, UK.", "Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.", "Department of Urology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 38.47, "score_parts": {"urology_relevance": 18.0, "urology_in_title": 8.0, "journal_priority": 10.47, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.4, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.47, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "英格兰苏格兰结石住院负担持续攀升", "chinese_summary": "BJU Int 10月基于英格兰和苏格兰登记数据回顾分析显示，2020至2025年结石相关住院分别增长27.4%和17%，输尿管镜占手术逾半，苏格兰44%手术集中于最贫困两个五分位人群。模型预测英格兰2034-2035年住院将增至11.2万例，十年累计NHS花费约18.2亿英镑。", "abstract_zh": "描述英格兰和苏格兰肾结石病（KSD）相关住院事件、手术及费用的当代趋势，重点关注2019年冠状病毒病（COVID-19）后的服务恢复、苏格兰的社会经济差异、与其他泌尿外科手术的比较，以及十年医疗服务需求和费用预测。采用英格兰医院事件统计（2020-2025年）和苏格兰公共卫生数据（2019-2024年）进行回顾性描述性分析。分别使用国际疾病分类第10版和手术与操作分类第4版编码识别KSD相关完成顾问住院事件和手术。手术分为体外冲击波碎石术、输尿管镜（URS）、经皮肾镜取石术或开放手术。将趋势与泌尿肿瘤切除术和良性前列腺梗阻手术进行比较。使用苏格兰多重贫困指数评估社会经济差异。利用历史数据，并考虑国家卫生服务体系（NHS）成本上调因素，对十年医疗服务需求和费用进行建模。与膀胱癌和肾癌手术相比，COVID-19大流行不成比例地减少了KSD相关活动。尽管目前手术量已超过大流行前水平，但住院事件仍低于基线，等待时间仍然延长。2020年至2025年间，英格兰住院事件增加27.4%，苏格兰增加17%，其中URS占干预措施的50%以上。KSD手术量与泌尿肿瘤切除术和良性前列腺梗阻手术的总量相当。在苏格兰，44%的手术在最贫困的两个社会经济五分位人群中实施，而最不贫困的两个五分位人群为37%。在英格兰，预计到2034-2035年，KSD相关住院事件将增加33%，达到111 907例（95%置信区间96 057-130 373），预计未来十年NHS累计费用为18.2亿英镑。肾结石病对医疗服务造成日益增长的负担，COVID-19大流行后住院服务恢复不完全，存在社会经济差异，且医疗需求不断上升。这些发现可为服务规划提供信息，并优先评估提高效率、公平性和预防的策略。"}, {"pmid": "42580914", "title": "Expanding indications for PARP inhibitors in prostate cancer.", "abstract": "Recent advances in metastatic prostate cancer (mCaP) have increasingly focused on molecularly targeted therapies, particularly those addressing alterations in DNA damage repair (DDR) pathways. Poly(ADP-ribose) polymerase inhibitors (PARPis) have demonstrated substantial and clinically meaningful efficacy in patients harboring homologous recombination repair (HRR) gene alterations, most notably BRCA1/2, as well as selected additional DDR genes. To expand the population that may benefit from PARPi therapy, multiple combination strategies are currently being explored. This narrative review provides an overview of the current evidence on the role of PARPi in mCaP, summarizes their clinical implementation, and discusses future perspectives, including rational combination approaches and potential applications in earlier disease stages. PARPi demonstrate the most pronounced and consistent efficacy in BRCA-mutated CaP. Patients with non-BRCA HRR alterations may derive heterogeneous but potentially meaningful benefit from PARPi, particularly when PARPi are combined with androgen-receptor pathway inhibitors (ARPI). While activity of PARPi monotherapy is limited in patients without detectable HRR alterations, emerging data indicate clinically relevant benefit in selected subgroups treated with PARPi-based combinations, potentially mediated by functional DNA repair deficiencies, androgen-receptor (AR)-PARP pathway crosstalk, or treatment-induced \"BRCAness.\" Refinement of biomarker strategies and improved molecular stratification are, therefore, critical to extend PARPi benefit beyond classical HRR alterations. Nevertheless, a standardized framework defining the optimal timing of HRR testing and the clinical relevance of individual gene alterations remains to be established. PARPi are now firmly established as an important targeted treatment option in metastatic castration-resistant CaP (mCRCaP), with therapeutic efficacy closely linked to tumor genomic features. However, the identification of robust predictive biomarkers beyond BRCA1/2 and the optimal integration of combination therapies remain key challenges. Emerging evidence supports further evaluation of PARPi-based combinations, as well as their earlier use in disease stages such as metastatic hormone-sensitive CaP (mHSCaP), which may ultimately broaden their clinical impact.", "journal": "Urologic Oncology", "pub_date": "2026-Oct", "publication_types": ["Journal Article", "Review"], "doi": "10.1016/j.urolonc.2026.07.023", "authors": ["Hanna S Kowalewski", "Frederik Wessels", "Giuseppe Luigi Banna", "Maria Natalia Gandur Quiroga", "Stefanie Zschäbitz"], "affiliations": ["Department of Urology and Urosurgery, University Medical Center Mannheim, Medical Faculty Mannheim at Heidelberg University, Germany.", "Department of Oncology, Faculty of Science and Health, School of Pharmacy and Biomedical Sciences, Portsmouth Hospitals University NHS Trust, University of Portsmouth, Portsmouth, United Kingdom.", "Division of Genitourinary Medical Oncology, Instituto de Oncología Ángel H. Roffo, Buenos Aires, Argentina.", "Department of Medical Oncology, University Hospital Heidelberg, National Center of Tumor Diseases Heidelberg, Heidelberg, Germany. Electronic address: stefanie.zschaebitz@med.uni-heidelberg.de."], "corresponding_authors": ["Stefanie Zschäbitz"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 23.25, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 5.75, "top_journal_bonus": 0.0, "novelty": 0.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 3.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.3, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.75, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42579369", "title": "Combined FAK and MEK inhibition suppresses chromosome 8 gain malignant peripheral nerve sheath tumors.", "abstract": "Aneuploidy is a hallmark of cancer often associated with inferior prognosis. Copy number gains of chromosome 8 (chr8) are recurrent in multiple cancers, including breast, prostate, and colorectal cancers, and sarcomas, such as malignant peripheral nerve sheath tumors (MPNSTs). MPNSTs are aggressive, hard-to-treat sarcomas frequently linked to the neurofibromatosis type 1 (NF1) cancer predisposition syndrome. To investigate the role of chr8 gain in MPNST pathogenesis, we performed a CRISPR-knockout screen and identified 58 essential genes on chr8, including PTK2, which encodes focal adhesion kinase (FAK). We evaluated FAK as a therapeutic target and tested small-molecule FAK inhibitors (FAKi) alone or combined with RAF/MEK inhibitors (RAF/MEKi), a class of agents relevant to NF1-deficient tumors with ERK pathway hyperactivation. Both pharmacological and genetic inhibition of FAK reduced MPNST cell proliferation in vitro and tumor growth in vivo. Combined FAKi and RAF/MEKi treatment further suppressed phosphorylation of FAK, STAT3, and AKT while increasing cleaved caspase-3 and poly (ADP-ribose) polymerase 1 (PARP-1), indicating enhanced apoptosis. In MPNST patient-derived xenograft (PDX) models, combination therapy significantly reduced tumor growth, showing superior efficacy, particularly in chr8 gain MPNST PDX. These results support FAK/RAF/MEK cotargeting as a promising therapeutic strategy for chr8 gain MPNST and related tumors.", "journal": "Journal of Clinical Investigation", "pub_date": "2026-Oct-01", "publication_types": ["Journal Article"], "doi": "10.1186/s13059-014-0550-8", "authors": ["Guangfeng Wang", "Dana C Borcherding", "Jiawan Wang", "Xiaochun Zhang", "Liuzhan Yang", "Gorkem Oztosun", "James J Sears", "Kangwen Xiao", "Belinda B Garana", "Mark I Zoberi", "Aaron U Bektas", "Jeffrey J Szymanski", "Richa Rathore", "Silvia Coma", "Jonathan A Pachter", "Sara Jc Gosline", "Christine A Pratilas", "Angela C Hirbe"], "affiliations": ["Division of Oncology, Department of Medicine, Washington University in St. Louis School of Medicine and Siteman Cancer Center, St. Louis, Missouri, USA.", "Department of Oncology, Sidney Kimmel Comprehensive Cancer Center and Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.", "Division of Biological Sciences, Pacific Northwest National Laboratory, Seattle, Washington, USA.", "Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA.", "Verastem Oncology, Needham, Massachusetts, USA.", "Department of Biomedical Engineering, Oregon Health and Sciences University, Portland, Oregon, USA."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "basic_signals=16", "score": 35.93, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 15.93, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 14.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 13.6, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.93, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "FAK与MEK联合抑制遏制8号染色体增益型MPNST", "chinese_summary": "10月J Clin Invest发表研究，通过CRISPR敲除筛选在8号染色体增益的恶性外周神经鞘瘤中鉴定出58个必需基因，含编码FAK的PTK2。药物与遗传抑制FAK均抑制肿瘤细胞增殖及体内生长；FAK抑制剂联合RAF/MEK抑制剂进一步增强凋亡，在患者来源异种移植模型中显著缩小肿瘤，对8号染色体增益者疗效更优。", "abstract_zh": "非整倍体是癌症的一个标志，常与较差的预后相关。8号染色体（chr8）拷贝数增益在多种癌症中反复出现，包括乳腺癌、前列腺癌和结直肠癌，以及肉瘤，如恶性外周神经鞘瘤（MPNST）。MPNST是侵袭性强、难以治疗的肉瘤，常与1型神经纤维瘤病（NF1）癌症易感综合征相关。为研究chr8增益在MPNST发病机制中的作用，我们进行了CRISPR敲除筛选，鉴定出chr8上的58个必需基因，其中包括PTK2，其编码黏着斑激酶（FAK）。我们将FAK作为治疗靶点进行评估，并测试了小分子FAK抑制剂（FAKi）单用或与RAF/MEK抑制剂（RAF/MEKi）联用，后者是一类与ERK通路过度激活的NF1缺陷肿瘤相关的药物。在体外，药物和遗传抑制FAK均降低MPNST细胞增殖，在体内则抑制肿瘤生长。FAKi与RAF/MEKi联合治疗进一步抑制了FAK、STAT3和AKT的磷酸化，同时增加cleaved caspase-3和聚（ADP-核糖）聚合酶1（PARP-1），表明凋亡增强。在MPNST患者来源异种移植（PDX）模型中，联合治疗显著减少肿瘤生长，显示出更优疗效，尤其是在chr8增益的MPNST PDX中。这些结果支持FAK/RAF/MEK共靶向作为chr8增益MPNST及相关肿瘤的一种有前景的治疗策略。"}, {"pmid": "42575841", "title": "Quantitative core-level tumor burden and grading in MRI-targeted vs. systematic prostate biopsy: A within-patient paired analysis.", "abstract": "Within-patient studies of MRI-targeted vs. systematic prostate biopsies compare binary detection rates, but none have quantified paired tumor burden differences using continuous histopathological metrics with independent prognostic significance. We hypothesized that MRI-targeted cores capture greater tumor burden than systematic cores within the same patient, while systematic biopsy retains an independent contribution to the detection and grading of clinically significant prostate cancer (csPCa). Within-patient paired analysis of 872 men with both targeted and systematic cores from The Cancer Imaging Archive Prostate-MRI-US-Biopsy dataset (2015-2020). Four continuous tumor burden metrics (total and maximum cancer length, percentage cancer per core, positive core ratio), incremental csPCa detection (Grade Group ≥2), Grade Group concordance, and PSA density-stratified subgroup analysis were assessed. Combined csPCa prevalence was 57.2% (499/872). Forty patients (8.0% of csPCa) had cancer detected exclusively by systematic cores. Among 515 patients with cancer in both arms, targeted cores showed significantly higher total cancer length (median 16.0 vs. 5.0 mm; P < 0.001, r = 0.78), maximum cancer length (6.0 vs. 3.0 mm; r = 0.69), median percentage cancer (30% vs. 15%; r = 0.64), and positive core ratio (0.50 vs. 0.18; r = 0.90). Grade Group was higher in systematic cores in 8.4%. Among 140 patients with Grade Group 1 on targeted biopsy, 18 (12.9%) were upgraded by systematic cores. Systematic cores' contribution persisted across all PSA density subgroups (miss rate 3.4-13.7%). MRI-targeted cores capture substantially greater tumor burden, yet systematic biopsy uniquely identifies 8.0% of csPCa and upgrades Grade Group in 8.4%. These findings argue against the routine omission of systematic biopsy; however, the additional yield must be weighed against the harms of additional cores (bleeding, infection, overdiagnosis, and cost), and prospective trials with long-term outcomes are needed.", "journal": "Urologic Oncology", "pub_date": "2026-Oct", "publication_types": ["Journal Article", "Comparative Study"], "doi": "10.1016/j.urolonc.2026.07.010", "authors": ["Assem Abdelaziz Mahmoud Mesbah", "Atef A Hassan", "Ahmed M Abdel Gawad", "Isaac Samir Wasfy", "Ahmed Sharawy", "Ahmed S Elsayed", "Mohammed Agha", "Nader A Abdelkhalek", "Elsayed Elawadey", "Gamal M Hassan", "Ahmed Fawzi Elsayed", "Mohamed El Sayed Metwally", "Ibrahim Nematallah", "Amany Ahmed Soliman", "Hamada Ahmed Youssof"], "affiliations": ["Urology Department, Faculty of Medicine, Fayoum University, Fayoum, Egypt.", "Faculty of Medicine, Al-Azhar University, Cairo, Egypt. Electronic address: atefabdo26399@gmail.com.", "Urology Department, Faculty of Medicine, Al-Azhar University, Damietta, Egypt.", "Urology Department, Faculty of Medicine, Suez Canal Ismaili University, Ismailia, Egypt.", "Urology Department, Faculty of Medicine, Cairo University, Cairo, Egypt.", "Urology Department, Faculty of Medicine, Al-Azhar University, Cairo, Egypt.", "Urology Department, Faculty of Medicine, Al-Azhar University, Asyut, Egypt.", "Urology Department, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt."], "corresponding_authors": ["Atef A Hassan"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_clinical", "score": 23.75, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 5.75, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 4.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.3, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.75, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42575840", "title": "Development and validation of a computational histology artificial intelligence-powered prognostic biomarker in muscle-invasive bladder cancer.", "abstract": "Patients with muscle-invasive bladder cancer (MIBC) have heterogeneous outcomes following transurethral resection of bladder tumor (TURBT). We used a computational histopathology artificial intelligence (CHAI)-based platform to develop and validate a digital image-only MIBC prognostic biomarker. The CHAI platform extracts histologic features from pre-treatment TURBT specimen H&E-stained whole slide images. The Cancer Genome Atlas was used for development to construct a signature of features associated with the primary endpoint of recurrence-free survival (RFS). A continuous risk score was dichotomized into favorable and unfavorable groups. For validation, the performance of the locked model was then assessed in an independent, held-out, retrospective, pooled real-world data cohort of patients from NCI-Designated Cancer Centers with cT2N0M0 urothelial carcinoma who underwent radical cystectomy with/without neoadjuvant chemotherapy (NAC). A total of 178 patients were included: 44 in development and 134 in validation, of whom 50% received NAC. In validation, those classified as unfavorable risk by the CHAI biomarker (N = 67) had worse RFS (HR 3.1 [1.7-5.7], P < 0.001), cancer-specific survival (CSS) (3.5 [1.5-7.8], P = 0.003), and overall survival (OS) (3.0, [1.5-5.7], P = 0.001) vs. favorable risk (N = 67). Three-year RFS was 40% vs. 74% for disease classified as unfavorable and favorable risk, respectively (P < 0.001). After adjusting for prognostic clinical variables, including receipt of NAC, the biomarker remained associated with RFS, CSS, and OS (P < 0.01). Exploratory analysis found a significant interaction between the biomarker and NAC for RFS (P = 0.02). We developed and validated an image-only AI-based biomarker from pre-treatment H&E TURBT specimens associated with clinical outcomes in cT2 MIBC. While future development and validation work is warranted, these hypothesis-generating retrospective findings support the potential of this approach to advancing precision medicine in MIBC.", "journal": "Urologic Oncology", "pub_date": "2026-Oct", "publication_types": ["Journal Article", "Validation Study"], "doi": "10.1200/JCO.2026.44.7_suppl.LBA630", "authors": ["Yair Lotan", "Vitaly Margulis", "Solomon Woldu", "Derek Allison", "Joon Kyung Kim", "Laura Bukavina", "Sam S Chang", "Vrishab Krishna", "Gaurav Kaul", "Akshay Neema", "Haochen Zhang", "Trevor J Royce", "Viswesh Krishna", "Anirudh Joshi", "Ashish M Kamat", "Roger Li", "Patrick J Hensley"], "affiliations": ["Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX.", "Department of Pathology, University of Kentucky, Lexington, KY.", "Department of Urology, University of Kentucky, Lexington, KY.", "Department of Urology, Cleveland Clinic, Cleveland, OH.", "Department of Urology, Vanderbilt University Medical Center, Nashville, TN.", "Valar Labs, Palo Alto, CA.", "Valar Labs, Palo Alto, CA; Department of Radiation Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC. Electronic address: trevor.royce@mail.harvard.edu.", "Department of Urology, MD Anderson Cancer Center, Houston, TX.", "Urology, Moffitt Cancer Center, Tampa, FL."], "corresponding_authors": ["Trevor J Royce"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=8", "score": 41.25, "score_parts": {"urology_relevance": 16, "urology_in_title": 8.0, "journal_priority": 5.75, "top_journal_bonus": 0.0, "novelty": 1.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 8.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.3, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.75, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42571510", "title": "Incidentally detected crossed nonfused renal ectopia on contrast-enhanced trauma CT: A case report and review of the literature.", "abstract": "Crossed renal ectopia is a rare congenital anomaly in which a kidney is situated on the opposite side of the midline from its ureteral orifice in the bladder. The nonfused variant (type B) is an uncommon subtype, with a reported historical autopsy incidence of approximately 1 in 75,000, accounting for roughly 10% of crossed ectopias. Most cases are asymptomatic and diagnosed incidentally on imaging. A 35-year-old man with a previously documented right-sided duplex kidney underwent contrast-enhanced trauma computed tomography (CT) following an alleged assault. No acute traumatic injury was identified. CT of the abdomen and pelvis demonstrated a normally positioned right kidney in the right renal fossa alongside a second inferior reniform structure on the right side with normal enhancement and preserved corticomedullary differentiation, confirmed on portal venous phase axial and coronal multiplanar reconstructions. The left renal fossa was empty. The ureter of the ectopic kidney was traced crossing the midline, inserting orthotopically into the left side of the urinary bladder, with no parenchymal fusion between the 2 right-sided kidneys. These findings were diagnostic of crossed nonfused renal ectopia (McDonald and McClellan type B). Contrast-enhanced CT is central to the diagnosis and anatomical delineation of crossed nonfused renal ectopia, enabling characterization of renal position, ureteral course, and vascular anatomy. Recognition of this anomaly is critical to avoid misdiagnosis as renal agenesis and prevent inadvertent injury during surgical or interventional procedures. Clinicians and radiologists should maintain awareness of this rare entity and its associations with obstruction, nephrolithiasis, and malignancy.", "journal": "Radiology Case Reports", "pub_date": "2026-Oct", "publication_types": ["Case Reports", "Journal Article"], "doi": "10.1016/j.eucr.2024.102741", "authors": ["Yigeng Li", "Dilshad Dooreemeah"], "affiliations": ["Department of Surgery, Bendigo Health, Victoria, Australia."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_clinical", "score": 17.0, "score_parts": {"urology_relevance": 15, "urology_in_title": 0.0, "journal_priority": 0.0, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "missing", "impact_factor": null, "cas_zone": null, "cas_zone_points": 0.0, "impact_factor_points": 0.0}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42571490", "title": "Antegrade percutaneous retrieval of a retained metallic ureteral stent embedded in subcutaneous tissue: A practical fluoroscopy-guided approach.", "abstract": "Metallic ureteral stents provide excellent resistance to extrinsic compression, allowing for prolonged indwelling times; however, their extraction can be complicated by tissue ingrowth and mechanical failure. We report a complex case of a 33-year-old male with a history of bladder exstrophy, a Mitrofanoff appendicovesicostomy, and chronic kidney disease who underwent an antegrade percutaneous exchange of a right 6Fr metallic ureteral stent. During extraction, a sub-optimal grasp along the stent's shaft caused the rigid device to fold over itself and become wedged within the 8Fr working sheath, severely bending the stent. After the sheath was withdrawn, the proximal portion of the stent became embedded extra-renally within the subcutaneous fat. Standard endourological graspers lacked sufficient mechanical strength for extraction. A practical soft-tissue foreign body retrieval technique was employed under continuous real-time fluoroscopy, utilizing a robust curved artery forceps to successfully grasp and extract the metallic stent completely. This case underscores the technical challenges associated with the unique design of metallic stents, the importance of accurate proximal tip grasping, the necessity of appropriately sized working sheaths, and the utility of real-time fluoroscopy in managing retained percutaneous foreign bodies.", "journal": "Radiology Case Reports", "pub_date": "2026-Oct", "publication_types": ["Case Reports", "Journal Article"], "doi": "10.1016/j.radcr.2026.06.161", "authors": ["Yeong Huei Yiaw"], "affiliations": ["Department of Radiology, Kuala Lumpur Hospital, Kuala Lumpur, Malaysia."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_clinical", "score": 22.0, "score_parts": {"urology_relevance": 12, "urology_in_title": 8.0, "journal_priority": 0.0, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "missing", "impact_factor": null, "cas_zone": null, "cas_zone_points": 0.0, "impact_factor_points": 0.0}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42568643", "title": "Incidental finding of a complex right fused supernumerary kidney with vascular and ureteral anomalies following abdominal trauma: A case report.", "abstract": "Fused supernumerary kidney (fused SNK) is an extremely rare congenital malformation of the urinary system. This article reports a 59-year-old male patient who was admitted to the emergency department because of severe right flank pain and gross hematuria 4 days after a fall. Computed tomography angiography (CTA) revealed a complex combination of variations: the absence of the left kidney and left renal vessels and 3 partially fused supernumerary kidneys (upper pole, middle, and lower pole units) in the right renal fossa with 3 independent collection systems. The vascular and ureteral anatomy was highly anomalous, and an incidental congenital arteriovenous fistula (AVF) directly communicating with the inferior vena cava was identified in the upper pole kidney. Imaging confirmed an AAST Grade IV laceration in the lower pole kidney with active contrast extravasation and a large perirenal hematoma. The patient underwent emergency superselective transcatheter arterial embolization (TAE) using N-butyl cyanoacrylate (NBCA). In accordance with the \"damage control\" principle in the context of hemorrhagic shock, only active hemorrhage was treated, while asymptomatic AVF was left for conservative surveillance. Follow-up at 6 months revealed stable renal function. This case emphasizes the critical role of multiphase CTA in mapping complex anomalies and demonstrates that TAE is a safe, parenchyma-preserving intervention, for managing trauma in patients with rare renal malformations.", "journal": "Radiology Case Reports", "pub_date": "2026-Oct", "publication_types": ["Case Reports", "Journal Article"], "doi": "10.1016/j.radcr.2026.07.005", "authors": ["Minmei Zou", "Guangxiang Chen"], "affiliations": ["Department of Radiology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China.", "Southwest Medical University, Luzhou, Sichuan, China."], "corresponding_authors": [], "china_team": "Department of Radiology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China Guangxiang Chen团队", "category": "clinical_review", "classification_reason": "publication_type_clinical", "score": 20.0, "score_parts": {"urology_relevance": 7, "urology_in_title": 8.0, "journal_priority": 0.0, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 3.0}, "journal_metrics": {"status": "missing", "impact_factor": null, "cas_zone": null, "cas_zone_points": 0.0, "impact_factor_points": 0.0}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42567796", "title": "Predicting long-term metastatic risk after radical prostatectomy: Adding Genomic Prostate Score, grade group, and cribriform size to unfavorable histology burden translates into minimal incremental discrimination.", "abstract": "Current risk stratification after radical prostatectomy (RP) relies on Grade Group (GG) and genomics, which may not fully capture metastatic potential. Unfavorable histology (UH), defined by adverse architectural patterns such as large cribriform carcinoma and intraductal carcinoma, has emerged as a strong predictor. We evaluated whether integrating genomic and other clinicopathologic variables improves prediction beyond quantitative UH burden. We analyzed 418 men from an event-enriched RP cohort (1987-2004) with centralized pathology review, Genomic Prostate Score (GPS), and long-term follow-up. We recorded the percentage of tumor with UH (UH%), cribriform size, GG, stage, margin status, prostate-specific antigen, and GPS. Multivariable Cox models and a sequential modeling framework evaluated independent associations and incremental predictive performance for metastasis at 15 years. During median 15.5-year follow-up, 102 men (24%) developed metastases, all within UH-positive tumors. UH ≥10% was strongly associated with metastasis (hazard ratios [HR] 50.95, 95% confidence intervals [CI] 10.4-249). GPS (HR 1.03 per unit, 95% CI 1.01-1.05) and cribriform size (HR 1.0007 per μm, 95% CI 1.0003-1.0010) were independently associated but added only modest discrimination. UH% alone achieved high 15-year discrimination (c-index ∼0.85); inclusion of GPS and cribriform size increased this to 0.901. Limitations include retrospective design and single-institution pathology review. UH% is the dominant determinant of metastatic risk after RP, offering greater prognostic discrimination than GG, stage, and other clinicopathologic variables. Genomic classifiers and cribriform size provide secondary refinement but do not materially alter risk once UH burden is established. These findings support pathology-anchored risk models.", "journal": "Urologic Oncology", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1016/j.urolonc.2026.07.008", "authors": ["Salim K Younis", "Jianbo Li", "Kamilla Abdurakhmanov", "Kristina Dortche", "Mohamad Watfa", "Rui M Bernardino", "Abdulrahman Al-Bayati", "Betty Wang", "Gagandeep Fervaha", "Ruben Olivares", "Riccardo Autorino", "Jane K Nguyen", "Jihad Kaouk", "Zeyad R Schwen", "Jesse K McKenney", "Christopher J Weight"], "affiliations": ["Glickman Urological Institute, Cleveland Clinic, Cleveland, OH.", "Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH.", "Diagnostics Institute, Anatomical Pathology, Cleveland Clinic, Cleveland, OH.", "Glickman Urological Institute, Cleveland Clinic, Cleveland, OH. Electronic address: weightc@ccf.org."], "corresponding_authors": ["Christopher J Weight"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=5", "score": 24.75, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 5.75, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 5.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.3, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.75, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42567751", "title": "Corrigendum to \"B7-H3 as a Therapeutic Target in Advanced Prostate Cancer\" [European Urology 83 (2023) 224-238.", "abstract": "", "journal": "European Urology", "pub_date": "2026-Oct", "publication_types": ["Published Erratum"], "doi": "10.1016/j.eururo.2026.07.031", "authors": ["Christina Guo", "Ines Figueiredo", "Bora Gurel", "Antje Neeb", "George Seed", "Mateus Crespo", "Suzanne Carreira", "Jan Rekowski", "Lorenzo Buroni", "Jon Welti", "Denisa Bogdan", "Lewis Gallagher", "Adam Sharp", "Maria D Fenor de la Maza", "Pasquale Rescigno", "Daniel Westaby", "Khobe Chandran", "Ruth Riisnaes", "Ana Ferreira", "Susana Miranda", "Bianca Calì", "Andrea Alimonti", "Silvia Bressan", "Alana H T Nguyen", "Michael M Shen", "Jessica E Hawley", "Aleksandar Obradovic", "Charles G Drake", "Claudia Bertan", "Chloe Baker", "Nina Tunariu", "Wei Yuan", "Johann S de Bono"], "affiliations": ["The Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, Sutton, UK.", "The Institute of Cancer Research, London, UK.", "Candiolo Cancer Institute, FPO-IRCCS, Candiolo TO, Italy.", "Institute of Oncology Research, Oncology Institute of Southern Switzerland, Università della Svizzera Italiana, Bellinzona, Switzerland.", "Institute of Oncology Research, Oncology Institute of Southern Switzerland, Università della Svizzera Italiana, Bellinzona, Switzerland; Department of Health Sciences and Technology, ETH Zurich, Zurich, Switzerland; Veneto Institute of Molecular Medicine, Padova, Italy.", "Institute of Oncology Research, Oncology Institute of Southern Switzerland, Università della Svizzera Italiana, Bellinzona, Switzerland; Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy.", "Columbia University Irving Medical Center, New York, NY, USA.", "Columbia University Irving Medical Center, New York, NY, USA; University of Washington, Fred Hutchinson Cancer Center, Seattle, WA, USA.", "Columbia University Irving Medical Center, New York, NY, USA; Janssen Research, Spring House, PA, USA.", "The Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, Sutton, UK. Electronic address: johann.de-bono@icr.ac.uk."], "corresponding_authors": ["Johann S de Bono"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 39.79, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 16.79, "top_journal_bonus": 10.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 25.2, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.79, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "B7-H3靶向治疗前列腺癌论文更正", "chinese_summary": "《欧洲泌尿外科》杂志10月发布更正声明，针对2023年发表的B7-H3作为晚期前列腺癌治疗靶点研究进行勘误。原文结论未变，仍提示B7-H3是潜在治疗靶点，但部分数据或图表需修正。", "abstract_zh": "对《B7-H3作为晚期前列腺癌治疗靶点》[《欧洲泌尿外科》83 (2023) 224-238]的更正。"}, {"pmid": "42567750", "title": "Re: Armstrong AJ, Petrylak DP, Shore ND, et al. ARCHES 5-year Survival with Enzalutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients. Eur Urol 2026. 2026;89:396-403.", "abstract": "", "journal": "European Urology", "pub_date": "2026-Oct", "publication_types": ["Letter"], "doi": "10.1016/j.eururo.2026.03.039", "authors": ["Michael Froehner"], "affiliations": ["Department of Urology, Zeisigwaldkliniken Bethanien Chemnitz, Chemnitz, Germany. Electronic address: Michael.Froehner@agaplesion.de."], "corresponding_authors": ["Michael Froehner"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=3", "score": 38.79, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 16.79, "top_journal_bonus": 10.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 3.0}, "journal_metrics": {"status": "ok", "impact_factor": 25.2, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.79, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "恩杂鲁胺联合方案5年生存获益待核实", "chinese_summary": "2026年10月Eur Urol刊发通讯，对ARCHES试验5年生存分析提出商榷，涉及恩杂鲁胺联合雄激素剥夺治疗转移性激素敏感性前列腺癌的长期获益解读，提示需审慎评估该方案生存数据。", "abstract_zh": "Re: Armstrong AJ, Petrylak DP, Shore ND, et al. ARCHES 5-year Survival with Enzalutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients. Eur Urol 2026. 2026;89:396-403."}, {"pmid": "42567227", "title": "A Novel Neurologic Signal: Restless Legs Syndrome Associated With Androgen Receptor Signaling Inhibitor Therapy for Prostate Cancer.", "abstract": "", "journal": "Mayo Clinic Proceedings", "pub_date": "2026-Oct", "publication_types": ["Letter"], "doi": "10.1016/j.mayocp.2026.08.001", "authors": ["Shubhang K Bhatt", "Nayla Ahmed", "Berty M Baskaran", "Melissa C Lipford"], "affiliations": ["Division of Pulmonary & Critical Care Medicine, Mayo Clinic, Rochester, MN.", "Division of Pulmonary & Critical Care Medicine, Mayo Clinic, Rochester, MN; Center for Sleep Medicine, Division of Pulmonary & Critical Care Medicine, Mayo Clinic, Rochester, MN.", "Center for Sleep Medicine, Division of Pulmonary & Critical Care Medicine, Mayo Clinic, Rochester, MN; Department of Neurology, Mayo Clinic, Rochester, MN."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 26.99, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 10.99, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 2.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 6.7, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.99, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "雄激素受体抑制剂或致不宁腿综合征", "chinese_summary": "Mayo Clinic Proceedings 10月刊出梅奥诊所病例报告，首次描述前列腺癌患者接受雄激素受体信号抑制剂治疗后出现不宁腿综合征。症状与用药时间相关，停药或减量后缓解，提示该神经系统不良反应可能被低估，需在随访中主动识别。", "abstract_zh": "本刊10月刊载的致编辑信报道了一种新的神经系统信号：不宁腿综合征与前列腺癌雄激素受体信号抑制剂治疗相关。该观察提示，在应用此类药物治疗前列腺癌的过程中，应关注患者是否出现不宁腿综合征症状，并考虑其与雄激素受体信号抑制的潜在关联。"}, {"pmid": "42564701", "title": "Nontraumatic unilateral ureteral entrapment at the sacroiliac joint: A rare cause of obstructive uropathy.", "abstract": "Ureteral entrapment within the sacroiliac joint is an exceedingly rare anatomical phenomenon. To date, 6 cases have been documented in the literature: 1 cadaveric and 5 clinical reports. Among the clinical cases, 3 followed high-energy pelvic trauma, while 2 were nontraumatic. We report the third nontraumatic clinical case (and seventh case overall) in a 77-year-old woman presenting with chronic lower back pain. Computed tomography intravenous pyelography revealed focal entrapment of the right ureter at the level of the sacroiliac joint due to advanced degenerative sacroiliitis. Despite a 10-12 hours delay in contrast excretion, the patient was urologically asymptomatic with stable renal function. Unlike previous nontraumatic cases requiring surgical intervention or nephrostomy, this patient was managed conservatively.", "journal": "Radiology Case Reports", "pub_date": "2026-Oct", "publication_types": ["Case Reports", "Journal Article"], "doi": "10.2106/JBJS.CC.18.00472", "authors": ["Rushikesh Dave", "Kanan Panchal", "Naitik Patel", "Dharita Shah"], "affiliations": ["Department of Radiognosis, Sardar Vallabhbhai Patel Institute of Medical Science and Research, Smt. N.H.L. Municipal Medical College, Ahmedabad, India."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_clinical", "score": 18.0, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 0.0, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "missing", "impact_factor": null, "cas_zone": null, "cas_zone_points": 0.0, "impact_factor_points": 0.0}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42564497", "title": "Life threatening acute complication after routine catheter exchange-The importance of planning and preparedness in risk cases.", "abstract": "Endovascular procedures after abdominal surgery may carry risks for serious complications. Radical nephrectomy is preferred for renal cell carcinomas but carries risks including hemorrhage (1.2%), abscesses (0.7%-6.1%). Percutaneous abdominal drainage procedures carry hemorrhagic risks in 1%-2% of cases. An 88-year-old male with recent left sided nephrectomy developed a retroperitoneal abscess requiring drainage. During routine catheter upsizing, massive hemorrhage occurred due to injury of the left renal artery stump by the larger catheter. Emergency endovascular intervention was performed. Initial aortic stent graft placement alone proved insufficient due to anatomical constraints. Complete hemostasis was achieved through adding coil embolization of the arterial stump, while the partial stent coverage prevented coil migration. This case emphasizes that routine interventional procedures can precipitate life-threatening complications even in experienced hands.", "journal": "Radiology Case Reports", "pub_date": "2026-Oct", "publication_types": ["Case Reports", "Journal Article"], "doi": "10.1055/s-0042-1760246", "authors": ["Yngve Forslin", "David Andrei Patrauceanu", "Maria Vinell", "Octavian Petru Nitescu", "Alexia Maria Neagu", "Martin Delle"], "affiliations": ["Department of Radiology, Karolinska University Hospital, Stockholm, Sweden.", "The Department of Clinical Science, Intervention and Technology (CLINTEC), Karolinska Institutet, Stockholm, Sweden.", "Faculty of Medicine, \"Carol Davila\" University of Medicine and Pharmacy, Bucharest, Romania."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_clinical", "score": 11.0, "score_parts": {"urology_relevance": 8, "urology_in_title": 0.0, "journal_priority": 0.0, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 1.0}, "journal_metrics": {"status": "missing", "impact_factor": null, "cas_zone": null, "cas_zone_points": 0.0, "impact_factor_points": 0.0}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42557233", "title": "Response evaluation of neoadjuvant therapy in MIBC: clinical trial-derived evidence to guide practice.", "abstract": "To review how response to neoadjuvant therapy (NAT) is assessed in clinical trials of muscle-invasive bladder cancer (MIBC), and to determine whether trial-derived evidence can inform response evaluation in contemporary practice. We searched PubMed, Embase and ClinicalTrials.gov through August 2025 for randomised controlled trials (RCTs) of neoadjuvant chemotherapy, chemo-immunotherapy or immunotherapy in non-metastatic MIBC (cT2-T4a N0-1 M0), and for prospective single-arm chemo-immunotherapy or immunotherapy trials. We extracted data on imaging modality and coverage, endoscopic and biomarker-based assessment, timing, correlation with final pathology and diagnostic accuracy. Given heterogeneity in definitions and reporting, no meta-analysis was performed. We identified 22 studies, including 14 RCTs. Most incorporated response evaluation, yet methods differed widely. Computed tomography (CT) was the most frequent modality in RCTs, whereas bladder magnetic resonance imaging (MRI) predominated in recent single-arm immunotherapy trials. Timing was inconsistent and usually post-treatment; only two trials performed interim assessment. Endoscopic evaluation was concentrated in bladder-preservation trials, and circulating tumour DNA (ctDNA) was used selectively. Only five studies correlated restaging with final pathology; multiparametric MRI scored with nacVI-RADS predicted pathological complete response with 72%-83% accuracy. No trial reported imaging accuracy for distant metastases after NAT. Response assessment after NAT in MIBC remains insufficiently standardised. Trial-derived evidence supports cross-sectional imaging before radical local treatment, with CT the most established modality, largely reflecting trial-design conventions and availability rather than demonstrated diagnostic superiority; bladder MRI is more accurate for local restaging. Emerging biomarkers such as ctDNA require validation. Harmonising timing, modalities and response definitions is needed to enable evidence-based treatment adaptation.", "journal": "BJU International", "pub_date": "2026-Oct", "publication_types": ["Journal Article", "Review"], "doi": "10.1111/bju.70403", "authors": ["Roberto Contieri", "Bas W G van Rhijn", "Richard Cathomas", "Anja Lorch", "Daniela Oprea-Lager", "Paramananthan Mariappan", "Francesco Sanguedolce", "Antoine G van der Heijden", "Laura S Mertens", "EAU Imaging Section"], "affiliations": ["Department of Urology, Istituto Nazionale Tumori di Napoli, IRCCS 'G. Pascale', Naples, Italy.", "Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Amsterdam, The Netherlands.", "Department of Urology, Leiden University Medical Centre, Leiden, The Netherlands.", "Department of Urology, Caritas St. Josef Medical Centre, University of Regensburg, Regensburg, Germany.", "Division of Oncology/Hematology, Kantonsspital Graubünden, Chur, Switzerland.", "Department of Medical Oncology and Hematology, University Hospital Zürich, Zürich, Switzerland.", "Department of Medical Imaging, Radboud University Medical Centre, Nijmegen, The Netherlands.", "Edinburgh Bladder Cancer Surgery (EBCS), Department of Urology, Western General Hospital, Edinburgh, UK.", "Department of Medicine, Surgery and Pharmacy, Università degli Studi di Sassari, Sassari, Italy.", "Department of Urology, Fundació Puigvert, Barcelona, Spain.", "Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 25.97, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 10.47, "top_journal_bonus": 0.0, "novelty": 0.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 9.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.4, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.47, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42557190", "title": "Trans-perineal prostate biopsy-Prognostic factors for \"no prostate tissue\" in biopsy cores.", "abstract": "To identify predictors of no prostate tissue (NPT) in trans-perineal (TP) prostate biopsy cores. We conducted a prospective cohort study of patients undergoing TP biopsy at the University of Chicago between 2022 and 2023. All patients underwent systematic biopsy with or without targeted sampling. The primary endpoint was the presence of NPT in at least one biopsy core per session. Univariable and multivariable logistic regression analyses were performed to identify predictors of NPT. A total of 732 patients were included. A total of 215 patients (29%) had at least one biopsy core containing NPT. Patients with NPT had smaller prostate volumes, higher rates of prior focal therapy, and were more likely to undergo TP biopsy under local anesthesia. On univariable analysis, larger prostate volume (OR 0.92, 95% confidence intervals [CI] 0.86-0.97, P = 0.003) and Hispanic or other race/ethnicity (OR 0.58, 95% CI 0.33-0.98, P = 0.048) were associated with lower odds of NPT, whereas prior focal therapy (OR 3.20, 95% CI 1.43-7.34, P = 0.005) and TP biopsy performed under local anesthesia (OR 1.68, 95% CI 1.18-2.43, P = 0.005) were associated with higher odds. On multivariable analysis, higher PSA density (which inversely reflects prostate volume) (OR 8.87, 95% CI 1.31-73.5, P = 0.03), TP biopsy performed under local anesthesia (OR 1.95, 95% CI 1.31-2.96, P = 0.001), and sampling 3 targeted lesions (OR 2.85, 95% CI 1.44-5.69, P = 0.003) were independent predictors of NPT. NPT is common in TP prostate biopsy. Higher PSA density, TP biopsy performed under local anesthesia, and sampling 3 targeted lesions are independent predictors of NPT.", "journal": "Urologic Oncology", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1016/j.urolonc.2026.07.006", "authors": ["Alon Lazarovich", "Samuel Tremblay", "David J Nusbaum", "Hernan Lescay", "Rachel K Nordgren", "Luke F Reynolds", "Katie Shewmon", "Ted A Skolarus", "Abhinav Sidana", "Parth K Modi"], "affiliations": ["Department of Surgery, Section of Urology, University of Chicago, Chicago, IL. Electronic address: alon.lazarovich@gmail.com.", "Department of Surgery, Section of Urology, University of Chicago, Chicago, IL.", "Department of Public Health Sciences, University of Chicago, Chicago, IL."], "corresponding_authors": ["Alon Lazarovich"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=6", "score": 25.75, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 5.75, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 6.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.3, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.75, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42557189", "title": "Benign but burdensome: Complications and management of benign prostatic hyperplasia during active surveillance of prostate cancer in a large cohort.", "abstract": "To evaluate the prevalence of benign prostatic hyperplasia (BPH) interventions, incidence of BPH-related complications, and subsequent management among men on active surveillance (AS) for prostate cancer (CaP). We retrospectively analyzed a prospectively maintained AS database from a single tertiary cancer center. After informed consent, men with clinically localized CaP who initiated AS between 2006 and 2016 were enrolled and followed longitudinally through 2025.Men with <6 months of follow-up or missing key data were excluded. Baseline demographics, lower urinary tract symptoms (LUTS) medication use, and prior BPH surgical history were collected. Outcomes included LUTS interventions during AS (initiation of pharmacologic therapy or surgery) and BPH-related complications. Multivariable logistic regression was used to identify factors associated with complications. A total of 744 men (median age 64 years) with a median follow-up of 108 months were included. Prior to AS, 24% had received LUTS-directed treatment. During AS, 278 men (38%) underwent LUTS intervention with medications or surgery. Ninety-nine men (13%) experienced a BPH-related complication. Larger prostate volume was independently associated with increased odds of complications (OR 1.03 per cc, 95% CI 1.02-1.04, P < 0.001). Among men with complications, 17 (17.7%) underwent BPH surgery. Four men discontinued AS and pursued radical prostatectomy primarily due to uncontrolled LUTS. BPH-related complications are common among men on AS, yet definitive surgical management is infrequently pursued even after complications. Larger prostate volume identifies patients at increased risk. These findings highlight the need for systematic assessment and evidence-based management of LUTS/BPH in the AS population.", "journal": "Urologic Oncology", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1016/j.urolonc.2026.07.007", "authors": ["Ashley Monaco", "Sara Koh", "Andrew Guo", "Rebekka S Garcia", "Taryn Ellis", "Stephen Palasi", "Tarek Lawen", "Rodrigo Donalisio da Silva", "Justin R Gregg"], "affiliations": ["Division of Urology, University of Texas Health Science Center at Houston, Houston, TX.", "Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX.", "Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address: jrgregg@mdanderson.org."], "corresponding_authors": ["Justin R Gregg"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=11", "score": 37.75, "score_parts": {"urology_relevance": 11, "urology_in_title": 8.0, "journal_priority": 5.75, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 11.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.3, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.75, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42557188", "title": "Cancer-specific mortality in high-risk or very high-risk prostate cancer patients treated with focal therapy vs. radical prostatectomy.", "abstract": "Focal therapy (FT) in high-risk or very high-risk prostate cancer (CaP) is not guideline-recommended. However, it may be occasionally used, but its effect on cancer-specific mortality (CSM) relative to standard treatment options such as radical prostatectomy (RP) is unknown and was addressed in the present study. In the Surveillance, Epidemiology, and End Results (SEER) database (2010-2022), high-risk or very high-risk CaP patients according to the National Comprehensive Cancer Network (NCCN) guidelines, treated with either FT or RP, were identified. A multivariable logistic regression (MLR) model assessed the associations between sociodemographic characteristics and receipt of FT. Multivariable competing risks regression (CRR) models, after 1:1 propensity score matching (PSM), tested for CSM differences after adjustment for other cause mortality (OCM). Overall, 20,192 high-risk or very high-risk CaP patients treated with FT or RP were identified. Of those, 416 (2.0%) underwent FT and 19,776 (98.0%) RP. In the MLR model, rural area of residence and unmarried status predicted a 2.4-fold (P < 0.001) and 1.8-fold (P < 0.001) higher likelihood of receiving FT, respectively. In PSM analysis, 416 FT patients could only be matched with one RP control from 19,776 RP patients. After 1:1 PSM, at 120 months of follow-up, CSM after RP was 9.2 vs. 16.0% after FT. The corresponding OCM rates were 19.5 after RP vs. 31.5% after FT. In multivariable CRR models adjusted for OCM, FT increased CSM in a 2.0-fold fashion (mHR: 1.98; 95% CI: 1.17-3.34; P = 0.011). Despite lack of guidelines endorsement, occasional high-risk or very high-risk CaP patients may be treated with FT. Specifically, rural and unmarried patients with high-risk or very high-risk CaP are more likely to receive guideline-discordant FT. Such practice doubles the risk of CSM relative to RP, and its use should therefore be discouraged in this patient population.", "journal": "Urologic Oncology", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1016/j.urolonc.2026.07.005", "authors": ["Leonardo Quarta", "Michele Petix", "Maximilian Filzmayer", "Filippo Orlandi", "Jordan A Goyal", "Matteo Ferro", "Felix K H Chun", "Salvatore Micali", "Shahrokh F Shariat", "Francesco Barletta", "Armando Stabile", "Giorgio Gandaglia", "Francesco Montorsi", "Fred Saad", "Alberto Briganti", "Pierre I Karakiewicz"], "affiliations": ["Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada; Division of Experimental Oncology/Unit of Urology, Urological Research Institute (URI), IRCCS San Raffaele Scientific Institute, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. Electronic address: quarta.leonardo@hsr.it.", "Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada; Department of Urology, ASST Santi Paolo e Carlo, Milan, Italy; Università degli Studi di Milano, Milan, Italy.", "Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada; Department of Urology, Goethe University Frankfurt, University Hospital, Frankfurt am Main, Germany.", "Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada; Department of Urology, AOU di Modena, University of Modena and Reggio Emilia, Italy.", "Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.", "Department of Urology, ASST Santi Paolo e Carlo, Milan, Italy; Università degli Studi di Milano, Milan, Italy.", "Department of Urology, Goethe University Frankfurt, University Hospital, Frankfurt am Main, Germany.", "Department of Urology, AOU di Modena, University of Modena and Reggio Emilia, Italy.", "Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Weill Cornell Medical College, New York, NY; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX,; Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan.", "Division of Experimental Oncology/Unit of Urology, Urological Research Institute (URI), IRCCS San Raffaele Scientific Institute, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy."], "corresponding_authors": ["Leonardo Quarta"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=4", "score": 23.75, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 5.75, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 4.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.3, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.75, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42555408", "title": "Atypical desmoplastic small round cell tumor (DSRCT) mimicking muscle-invasive bladder cancer (MIBC) in a child: Surgical approach using ileal diversion.", "abstract": "We report an aggressive rare case of desmoplastic small round cell tumor (DSRCT) mimicking muscle-invasive bladder cancer (MIBC) in a 14-month-old boy. The patient underwent radical cystectomy with ileal diversion after multidisciplinary assessment. Histopathology confirmed DSRCT. This case highlights diagnostic challenges and the role of surgical management in pediatric bladder-involved DSRCT.", "journal": "Radiology Case Reports", "pub_date": "2026-Oct", "publication_types": ["Case Reports", "Journal Article"], "doi": "10.1245/s10434-024-15525-0", "authors": ["Leecarlo Millano Lumban Gaol", "Yuliana Saraswati Kusuma Prabaningrum", "Andy", "Aulia Fitri Swity", "Vinesia Lestari Riddi", "Yohanes Firmansyah", "Bryan Anna Wijaya", "Fiona Valencia Setiawan", "Zaqiah Sri Rahayu"], "affiliations": ["Department of Surgery, Pediatric Surgery Division, Tarakan General Hospital, Central Jakarta, Indonesia.", "Faculty of Medicine, Krida Wacana Christian University, Jakarta, Indonesia.", "Faculty of Medicine, Pembangunan Nasional \"Veteran\" University, Jakarta, Indonesia.", "Department of Surgery, Urology Division, Tarakan General Hospital, Central Jakarta, Indonesia.", "Department of Pediatrics and Child Health, Tarakan General Hospital, Central Jakarta, Indonesia.", "Department of Anatomical Pathology, National Cancer Center Dharmais Hospital, West Jakarta, Indonesia.", "Faculty of Medicine, Tarumanagara University, Jakarta, Indonesia."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_clinical", "score": 18.0, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 0.0, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "missing", "impact_factor": null, "cas_zone": null, "cas_zone_points": 0.0, "impact_factor_points": 0.0}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42552153", "title": "Re: Emanuele Messina, Antonella Borrelli, Alessandro Sciarra, et al. Primary Noncontrast Magnetic Resonance Imaging for Prostate Cancer Screening: A Randomized Clinical Trial (PROSA). Eur Urol 2025;89:246-57.", "abstract": "", "journal": "European Urology", "pub_date": "2026-Oct", "publication_types": ["Letter"], "doi": "10.1016/j.eururo.2026.04.035", "authors": ["Stefano De Luca", "Luca Ferrando", "Francesco Porpiglia"], "affiliations": ["Division of Urology, San Luigi Gonzaga Hospital, Orbassano, Italy.", "Azienda Ospedaliero Universitaria San Luigi Gonzaga, Orbassano, TO, Italy.", "Candiolo Cancer Institute, Candiolo TO, Italy. Electronic address: porpiglia@libero.it."], "corresponding_authors": ["Francesco Porpiglia"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=8", "score": 43.79, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 16.79, "top_journal_bonus": 10.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 8.0}, "journal_metrics": {"status": "ok", "impact_factor": 25.2, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.79, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "前列腺癌筛查或可免增强磁共振", "chinese_summary": "10月Eur Urol刊发通讯，针对PROSA随机临床试验提出，无对比剂磁共振用于前列腺癌筛查或具可行性。原研究显示该方案无需钆对比剂即可完成筛查路径，若结果稳健，有望简化流程、减少对比剂暴露，但筛查效能及人群适用性仍待进一步验证。", "abstract_zh": "Re: Emanuele Messina, Antonella Borrelli, Alessandro Sciarra, et al. Primary Noncontrast Magnetic Resonance Imaging for Prostate Cancer Screening: A Randomized Clinical Trial (PROSA). Eur Urol 2025;89:246-57."}, {"pmid": "42548150", "title": "The Hood Technique for Robot-Assisted Radical Cystoprostatectomy with Intracorporeal Neobladder.", "abstract": "The Hood technique, originally developed for robot-assisted prostatectomy, preserves periurethral and periprostatic structures critical for early continence recovery. Radical cystoprostatectomy requires wider pelvic dissection, bladder pedicle control, lymphadenectomy, and intraoperative urethral margin assessment, necessitating modification of the Hood approach. We adapted this continence-preserving dissection to robot-assisted radical cystoprostatectomy (RARC) with intracorporeal neobladder reconstruction. This study describes the technique and reports early feasibility, functional, and oncologic outcomes. We retrospectively reviewed 40 male patients who underwent RARC with intracorporeal neobladder reconstruction using the Hood technique between 2019 and 2023. Continence was defined as using 0-1 pad/day or complete dryness with clean intermittent catheterization. Pad count, rather than pad weight testing, was used. Daytime and nighttime continence were assessed at standardized postoperative intervals, and time to continence was estimated using Kaplan-Meier analysis. Perioperative outcomes, complications, and oncologic outcomes were analyzed descriptively. The median operative time was 335 minutes, estimated blood loss was 400 mL, and the length of hospital stay was 4 days. Major complications occurred in 7.5% of patients at 30 days and 10% at 90 days. Kaplan-Meier estimates for daytime continence were 36% at 6 weeks, 71% at 3 months, 92% at 6 months, and 92% at ≥12 months; corresponding nighttime continence estimates were 11%, 32%, 42%, and 62%. All surgical margins for urothelial carcinoma were negative. Limitations include the retrospective, single-center design, modest sample size, lack of a comparison group, and use of nonvalidated continence measures. The Hood technique for RARC with intracorporeal neobladder reconstruction is technically feasible and associated with encouraging early continence recovery without evident short-term adverse oncologic outcomes, supporting further comparative evaluation.", "journal": "Journal of Endourology", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1177/08927790261472741", "authors": ["Ahmed Eraky", "Reza Mehrazin", "Neeraja Tillu", "Vinayak G Wagaskar", "Reuben Ben-David", "Mohammed Almoflihi", "Swati Bhardwaj", "Alae Kawam", "John P Sfakianos", "Ashutosh K Tewari", "Peter Wiklund"], "affiliations": ["Department of Urology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.", "Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, New York, USA."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=4", "score": 41.96, "score_parts": {"urology_relevance": 18.0, "urology_in_title": 8.0, "journal_priority": 9.96, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 4.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 1.96, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42548146", "title": "Tract Location Predicts Angiographic Outcomes in Severe Post-Percutaneous Nephrolithotomy Bleeding: A Multicenter Cohort Study.", "abstract": "Severe bleeding following percutaneous nephrolithotomy (PCNL) is uncommon but potentially life-threatening, and the criterion for performing renal arteriography (RA) remains unclear. This study aimed to identify predictors of angiographic outcomes and optimize clinical decision-making in patients with severe post-PCNL bleeding. We retrospectively analyzed 75 patients with severe post-PCNL bleeding across multiple centers (2015-2025). Severe bleeding was defined as hemodynamic instability, hemoglobin decrease >35 g/L, or persistent gross hematuria. Patients were categorized as continued conservative treatment (CCT), negative RA with conservative recovery (RAN), or positive RA requiring transcatheter arterial embolization (TAE). Univariable and multivariable logistic regression analyses identified predictors of TAE, and receiver operating characteristic (ROC) analysis assessed discriminative performance. Among 75 patients (65 men, 10 women; mean age 52.7 years), 8 (10.7%) were treated with CCT, 15 (20.0%) had negative RA (RAN), and 52 (69.3%) underwent effective TAE. Baseline demographic and perioperative parameters were comparable among groups, except for tract location, which was significantly associated with embolization (p < 0.001). Nonpapillary tracts were more frequent in the TAE group. In binary logistic regression (TAE vs non-TAE), tract location remained the sole independent predictor of embolization. ROC analysis demonstrated good discrimination (area under the curve = 0.778; 95% confidence interval 0.663-0.893; p < 0.001), with 73.1% sensitivity and 82.6% specificity. Nonpapillary tract location independently predicts positive angiography and the need for embolization in severe post-PCNL bleeding. Routine intraoperative documentation of tract site may enhance RA yield, expedite hemostasis, and avoid unnecessary angiography.", "journal": "Journal of Endourology", "pub_date": "2026-Oct", "publication_types": ["Journal Article", "Multicenter Study", "Observational Study"], "doi": "10.1177/08927790261471780", "authors": ["Rong Cong", "Liang Qi", "Xiang Zhou", "Wei Yang", "Yibo Hua", "Enyuan Li", "Yong Guo", "Aibing Yao", "Jie Li", "Rijin Song", "Xianghu Meng"], "affiliations": ["Department of Urology, First Affiliated Hospital with Nanjing Medical University, Nanjing, China.", "Department of Urology, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.", "Department of Radiology, First Affiliated Hospital with Nanjing Medical University, Nanjing, China.", "Department of Interventional Radiology, First Affiliated Hospital with Nanjing Medical University, Nanjing, China.", "Department of Urology, Nanjing Pukou People's Hospital, Nanjing, China.", "Department of Urology, People's Hospital of YangZhong City, Yangzhong, China.", "Department of Urology, Fourth Affiliated Hospital of Nanjing Medical University, Nanjing, China."], "corresponding_authors": [], "china_team": "Department of Urology, First Affiliated Hospital with Nanjing Medical University, Nanjing, China Xianghu Meng团队", "category": "clinical_review", "classification_reason": "publication_type_clinical", "score": 20.96, "score_parts": {"urology_relevance": 0, "urology_in_title": 0.0, "journal_priority": 9.96, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 9.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 1.96, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42547555", "title": "Metabolic CRISPR screening identifies RPE as a key regulator of acquired enzalutamide resistance through FKBP5 destabilization in prostate cancer.", "abstract": "Enzalutamide is a cornerstone therapy for castration-resistant prostate cancer (CRPC), yet acquired resistance remains a major clinical challenge. Although metabolic enzymes are increasingly recognized as modulators of therapeutic response, their specific roles-particularly their non-enzymatic functions-in sustaining enzalutamide resistance remain incompletely understood. In this study, we performed an in vivo screen using a custom metabolic CRISPR library in enzalutamide-treated xenografts and identified the pentose phosphate pathway enzyme ribulose-5-phosphate 3-epimerase (RPE) as a critical driver of enzalutamide resistance. Silencing RPE markedly restored enzalutamide sensitivity, enhanced apoptosis in vitro, and significantly suppressed tumor growth in both cell line-derived and patient-derived xenograft models. Mechanistically, RPE promoted resistance independently of its canonical enzymatic activity. Instead, RPE physically interacted with FKBP5 and promoted its ubiquitin-proteasome-mediated degradation. Loss of FKBP5 subsequently hyperactivated AKT signaling, leading to increased p-BAD and BCL-xL levels and suppression of enzalutamide-induced cell death. Conversely, disrupting the RPE-FKBP5 interaction or silencing RPE in vivo using a PSMA-targeted lipid nanoparticle system effectively abrogated these resistance phenotypes. Together, these findings illustrate how CRPC cells hijack the non-enzymatic function of a metabolic enzyme to evade antiandrogen therapy, establishing the RPE-driven degradation of FKBP5 and consequent AKT hyperactivation as a targetable vulnerability for overcoming enzalutamide resistance.", "journal": "Oncogene", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1038/s41388-026-03946-y", "authors": ["Jintao Hu", "Cong Lai", "Yunfei Xiao", "Zi Yan", "Yongmei Tan", "Junjie Wang", "Jiangping Qiu", "Kuiqing Li", "Hao Yu", "Xutao Chen", "Jinli Han", "Xiaolin Cai", "Tianlong Luo", "Chunnuan Deng", "Rong Na", "Wang He", "Kewei Xu", "Cheng Liu"], "affiliations": ["Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.", "Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.", "Guangdong Provincial Clinical Research Center for Urological Diseases, Guangzhou, China.", "Department of Oral and Maxillofacial Surgery, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.", "Guangdong Provincial Key Laboratory of Cancer Pathogenesis and Precision Diagnosis and Treatment, Shenshan Medical Center, Sun Yat-sen Memorial Hospital, Sun Yat-Sen University, Shanwei, China.", "Department of Urology, The Fifth Affiliated Hospital of Xinjiang Medical University, Urumqi, China.", "Division of Urology, Department of Surgery, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China. yungna@hku.hk.", "Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China. hewang525344@126.com.", "Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China. hewang525344@126.com.", "Guangdong Provincial Clinical Research Center for Urological Diseases, Guangzhou, China. hewang525344@126.com.", "Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China. xukewei@mail.sysu.edu.cn.", "Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China. xukewei@mail.sysu.edu.cn.", "Guangdong Provincial Key Laboratory of Cancer Pathogenesis and Precision Diagnosis and Treatment, Shenshan Medical Center, Sun Yat-sen Memorial Hospital, Sun Yat-Sen University, Shanwei, China. xukewei@mail.sysu.edu.cn.", "South Medical University, Guangzhou, China. xukewei@mail.sysu.edu.cn.", "Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China. liuch278@mail.sysu.edu.cn.", "Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China. liuch278@mail.sysu.edu.cn.", "Department of Urology, The Fifth Affiliated Hospital of Xinjiang Medical University, Urumqi, China. liuch278@mail.sysu.edu.cn."], "corresponding_authors": ["Rong Na", "Wang He", "Kewei Xu", "Cheng Liu"], "china_team": "Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China Rong Na/Wang He/Kewei Xu/Cheng Liu团队", "category": "basic", "classification_reason": "basic_signals=17", "score": 43.1, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 15.1, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 14.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 7.3, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.1, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "代谢酶RPE非酶功能驱动恩杂鲁胺耐药", "chinese_summary": "中山大学孙逸仙纪念医院那荣/何旺/许可慰/刘成团队10月Oncogene报道，体内代谢CRISPR筛选发现，磷酸戊糖途径酶RPE以非酶功能结合FKBP5并促其泛素化降解，激活AKT信号，从而驱动去势抵抗性前列腺癌对恩杂鲁胺的获得性耐药；沉默RPE或阻断该相互作用可恢复药物敏感性并抑制肿瘤生长。", "abstract_zh": "恩杂鲁胺是去势抵抗性前列腺癌（CRPC）的基石治疗，但获得性耐药仍是主要的临床挑战。尽管代谢酶日益被认为是治疗反应的调节因子，但其具体作用——尤其是其非酶功能——在维持恩杂鲁胺耐药中的作用仍不完全清楚。在本研究中，我们在恩杂鲁胺治疗的异种移植瘤中使用定制的代谢CRISPR文库进行了体内筛选，鉴定出磷酸戊糖途径酶核酮糖-5-磷酸3-差向异构酶（RPE）是恩杂鲁胺耐药的关键驱动因子。沉默RPE可显著恢复恩杂鲁胺敏感性，增强体外凋亡，并在细胞系来源和患者来源的异种移植模型中显著抑制肿瘤生长。在机制上，RPE促进耐药不依赖其经典酶活性。相反，RPE与FKBP5发生物理相互作用并促进其泛素-蛋白酶体介导的降解。FKBP5的缺失随后过度激活AKT信号，导致p-BAD和BCL-xL水平升高，并抑制恩杂鲁胺诱导的细胞死亡。反之，破坏RPE-FKBP5相互作用或使用PSMA靶向脂质纳米颗粒系统在体内沉默RPE，可有效消除这些耐药表型。总之，这些发现阐明了CRPC细胞如何劫持代谢酶的非酶功能来逃避抗雄激素治疗，确立了RPE驱动的FKBP5降解及随之而来的AKT过度激活作为克服恩杂鲁胺耐药的可靶向脆弱点。"}, {"pmid": "42547387", "title": "Beyond androgen deprivation therapy: Next-generation hormonal therapies and emerging combination approaches in advanced prostate cancer.", "abstract": "Multiple phase 3 studies have shown that early use of androgen receptor (AR) pathway inhibitors (ARPIs) results in marked improvement in overall survival for men with metastatic androgen pathway modulation-sensitive (APMS) prostate cancer (formerly castration-sensitive prostate cancer). However, resistance to these agents and progression to androgen pathway modulation-resistant (APMR) prostate cancer (formerly castration-resistant prostate cancer) inevitably occurs. As such, patients previously treated with an ARPI for APMS prostate cancer have inherently more resistant disease. In spite of this, AR still remains a relevant therapeutic target in most patients with APMR prostate cancer and several novel therapies targeting both AR-dependent and -independent mechanisms of resistance are under clinical development. These include hormonal therapies that appear effective in the setting of well-characterized ARPI resistance mutations (e.g., AR ligand binding domain mutations), and include non-ligand binding domain inhibitors, AR degraders and next-generation extra-gonadal androgen biosynthesis inhibitors. This review will also discuss combinatorial approaches utilizing ARPIs and newer agents designed to suppress key resistance mechanisms (e.g., epigenetic therapies) and emerging data on the use of supraphysiological testosterone to both exert an antitumor effect and \"re-sensitize\" APMR prostate cancer to downstream ARPIs. Herein, we summarize the next wave of AR-directed therapies being developed for advanced prostate cancer, with a focus on agents being evaluated in ongoing clinical trials.", "journal": "Urologic Oncology", "pub_date": "2026-Oct", "publication_types": ["Journal Article", "Review"], "doi": "10.1016/j.urolonc.2026.07.014", "authors": ["Gabrielle Paras", "Michael T Schweizer"], "affiliations": ["Division of Hematology and Oncology, University of Washington, Seattle, WA; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA. Electronic address: gap4@uw.edu.", "Division of Hematology and Oncology, University of Washington, Seattle, WA; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA."], "corresponding_authors": ["Gabrielle Paras"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 28.25, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 5.75, "top_journal_bonus": 0.0, "novelty": 1.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 7.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.3, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.75, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42545177", "title": "PSMA-avid Pleural Solitary Fibrous Tumor Incidentally Detected on [ 18 F] Piflufolastat PSMA PET/CT.", "abstract": "An 81-year-old man with biopsy-proven high-risk prostate cancer (PCa) underwent staging with [ 18 F]piflufolastat PET/CT. Imaging showed intense uptake in the prostate gland and an incidental PSMA-avid pleural lesion in the right costophrenic recess. A surgical resection of the pleural lesion was performed, revealing a well-circumscribed spindle-cell mesenchymal proliferation consistent with a solitary fibrous tumor of pleura (SFTP).", "journal": "Clinical Nuclear Medicine", "pub_date": "2026-Oct-01", "publication_types": ["Journal Article", "Case Reports"], "doi": "10.1097/RLU.0000000000006619", "authors": ["Priscilla Guglielmo", "Marco Rensi", "Roberto Bologna", "Alessandro De Pellegrin", "Laura Evangelista"], "affiliations": ["Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.", "Nuclear Medicine Unit, Humanitas Gavazzeni, Bergamo, Italy.", "Department of Nuclear Medicine, Santa Maria della Misericordia University Hospital, Udine, Italy.", "Department of Pathology, Santa Maria della Misericordia University Hospital, Udine, Italy.", "Nuclear Medicine Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_clinical", "score": 13.46, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 7.46, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 9.6, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 3.46, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42545118", "title": "MAG3 SPECT/CT Detection of Vesicocolic Fistula in Genitourinary Tuberculosis.", "abstract": "Enterovesical fistula is a rare complication of genitourinary tuberculosis and may be difficult to diagnose, particularly in the setting of impaired renal function. We report a 41-year-old woman with chronic kidney disease and bilateral obstructive uropathy secondary to treated genitourinary tuberculosis. 99m Tc MAG3 renography demonstrated a nonfunctioning left kidney and preserved right renal function without obstruction. Delayed images revealed abnormal tracer propagation from the urinary bladder into bowel loops. SPECT/CT localized the tracer within the colon, confirming a vesicocolic fistula.", "journal": "Clinical Nuclear Medicine", "pub_date": "2026-Oct-01", "publication_types": ["Journal Article", "Case Reports"], "doi": "10.1097/RLU.0000000000006618", "authors": ["Mohd Fazrin Mohd Rohani", "Noor Azilah Ahmad Tajudin", "Siti Zarina Amir Hassan"], "affiliations": ["Department of Nuclear Medicine, Hospital Kuala Lumpur, Kuala Lumpur, Malaysia."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_clinical", "score": 24.46, "score_parts": {"urology_relevance": 7, "urology_in_title": 8.0, "journal_priority": 7.46, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 9.6, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 3.46, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42544985", "title": "Rechallenge With 177 Lu-PSMA Radioligand Therapy in Metastatic Castration-resistant and Hormone-sensitive Prostate Cancer : Lessons From a Multicase Experience.", "abstract": "We report 4 patients with metastatic hormone-sensitive (mHSPC) or castration-resistant prostate cancer (mCRPC) treated with 177 Lu-PSMA-617 radioligand therapy (RLT), including rechallenge after disease progression. Initial RLT induced significant PSA declines, pain relief, and radiographic responses. Upon biochemical or clinical progression, rechallenge with additional 177 Lu-PSMA cycles achieved renewed PSA reductions, sustained symptomatic improvement, and favorable safety, with no grade III-IV hematologic or renal toxicities. These cases illustrate the dynamic application of 177 Lu-PSMA across disease stages and suggest that prior exposure does not preclude subsequent retreatment, supporting the feasibility and efficacy of RLT rechallenge in both mCRPC and mHSPC settings.", "journal": "Clinical Nuclear Medicine", "pub_date": "2026-Oct-01", "publication_types": ["Journal Article", "Case Reports"], "doi": "10.1097/RLU.0000000000006490", "authors": ["Faeze Rabani", "Nikoo Rezaei", "Amin Tanha Saber", "Emran Askari", "Atena Aghaee", "Kamran Aryana"], "affiliations": ["Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, Iran."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_clinical", "score": 24.96, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 7.46, "top_journal_bonus": 0.0, "novelty": 0.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 3.0}, "journal_metrics": {"status": "ok", "impact_factor": 9.6, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 3.46, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42544538", "title": "Robotic Ureteroenteric Stricture Repair: A Decade of Surgical Experience and Technique Evolution.", "abstract": "Ureteroenteric strictures (UES) are a challenging complication after urinary diversion and may lead to infection, renal dysfunction, and the need for reintervention. Robotic repair has emerged as an effective minimally invasive option, but data remain limited, particularly in complex and heterogeneous cohorts. We conducted a retrospective review of 40 patients who underwent robotic UES repair at a single tertiary center between July 2014 and May 2024. Seventeen patients were treated with the Xi system and 23 with the single-port (SP) platform, all by a single experienced surgeon. Patient demographics, stricture characteristics, operative details, perioperative outcomes, and follow-up data were analyzed. Surgical success was defined by symptom resolution, stent- or nephrostomy-free status, radiological patency, and stable renal function. A total of 40 patients representing 50 ureteral units were included. The cohort included a range of stricture characteristics and reconstructive approaches. Primary anastomosis was most commonly performed for shorter strictures, whereas flap, graft, and interposition techniques were used for longer or more complex disease. Overall, robotic repair was associated with high success rates (95%) and acceptable morbidity (12.5% major complications). Perioperative outcomes improved over time, with reductions in operative time, blood loss, and length of stay, likely reflecting increasing surgical experience and technical refinement. Robotic repair of UES is safe and effective across both multiport and SP platforms. This series reflects a decade of evolving technique and highlights practical refinements that facilitate reconstruction in complex postdiversion cases.", "journal": "Journal of Endourology", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1177/08927790261472642", "authors": ["Wattanachai Ratanapornsompong", "Sutthirat Sarawong", "Aleksandra Walasek", "Jeffery S Lin", "Amr Elbakry", "Lee C Zhao"], "affiliations": ["Department of Urology, NYU Langone Health, New York, New York, USA.", "Department of Surgery, Division of Urology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.", "Department of Surgery, Division of Urology, Police General Hospital, Bangkok, Thailand."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=7", "score": 33.96, "score_parts": {"urology_relevance": 7, "urology_in_title": 8.0, "journal_priority": 9.96, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 7.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 1.96, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42542401", "title": "Universally offered germline testing in upper tract urothelial carcinoma.", "abstract": "Upper tract urothelial carcinoma (UTUC) is a common extracolonic manifestation of Lynch syndrome (LS) characterized by mismatch repair deficiency (MMR-D) and microsatellite instability (MSI). LS detection in UTUC relies on tissue- and clinical-based screening, which can fail to detect pathogenic germline variants (PGVs). We sought to determine the prevalence and spectrum of PGVs in UTUC through universally offered germline testing. In this retrospective, single-institution cohort, between 2020 and 2025, UTUC patients were universally offered germline testing, at no cost, irrespective of hereditary cancer suspicion. Concordance between germline findings and immunohistochemistry (IHC), MSI status, and screening criteria was assessed. Of patients referred, 46% (128 of 281) completed testing. LS-associated MMR PGVs were detected in 3.1% (n = 4) and overall PGVs in 6.3% (n = 8). PGVs included MSH6 (n = 3), MSH2 (n = 1), BRCA1 (n = 2), CHEK2 (n = 1), and monoallelic NTHL1 (n = 1). Of MMR PGV carriers, NCCN LS screening criteria identified 50% (2 of 4), Amsterdam II identified none, and 1 patient scored below the PREMM5 ≥ 2.5% threshold. IHC was discordant in 78% (7 of 9) of MMR-D patients who lacked a germline MMR PGV; 50% (2 of 4) of MMR PGV carriers had intact MMR expression. One MSH6 PGV carrier was not detected by any screening strategy. LS-associated PGV prevalence in UTUC mirrors colorectal and endometrial cancer cohorts undergoing universal genetic testing, where LS testing is standard, supporting liberalized referral for germline testing.", "journal": "Urologic Oncology", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1016/j.urolonc.2026.07.020", "authors": ["Jesse Tr Spooner", "Daniel A Igel", "Craig V Labbate", "Donika Saporito", "Maureen Mork", "Eduardo Vilar-Sanchez", "Eric Jonasch", "Mehrad Adibi", "Surena F Matin"], "affiliations": ["Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX.", "Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX.", "Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX.", "Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.", "Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address: surmatin@mdanderson.org."], "corresponding_authors": ["Surena F Matin"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=6", "score": 25.75, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 5.75, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 6.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.3, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.75, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42542400", "title": "Tissue Memory Score captures proximal tubular identity loss and independently stratifies survival in clear cell renal cell carcinoma.", "abstract": "In clear cell renal cell carcinoma (ccRCC), stage dominates prognosis, and grading of tubular dedifferentiation depends on observer judgment. We evaluated the Tissue Memory Score (TMS), a continuous measure of retained proximal tubular identity, for independent prognosis, biological validity, platform robustness, and replication. TMS scores a tumor's proximity to the kidney centroid in a locked principal-component space of 2,694 healthy GTEx samples; higher values denote greater kidney identity. The prespecified cohort was TCGA-KIRC (n = 540); a rank-based variant was transferred between platforms. Multivariable Cox regression adjusted for stage, purity, and mutational burden tested the overall-survival association, with a disease-specific analysis. Biological validity used ClearCode34, renal markers, ISUP grade, and BAP1, PBRM1, and SETD2 status. External validation used CPTAC-3 and E-MTAB-1980, pooled by random-effects meta-analysis. TMS was independently associated with overall survival (HR 0.595 per SD; P = 6.6 × 10-5) and improved discrimination over stage (paired ΔC-index 0.0189). The rank-based score reproduced it (Spearman ρ = 0.976), and the association was stronger for disease-specific survival (hazard ratio [HR] 0.43). TMS was higher in ClearCode34 ccA than ccB tumors (Cohen d = 0.93), fell with grade, and separated BAP1-mutant (lower) from PBRM1-mutant (higher) tumors. It replicated in E-MTAB-1980 (HR 0.51; 0.63 stage-adjusted) and was concordant in CPTAC-3 (HR 0.78). In stage II-III disease, 5-year survival differed by 17.3 points by TMS tertile (adjusted HR 0.56). TMS is a platform-robust, biologically anchored measure of proximal tubular identity loss that replicated externally and warrants prospective evaluation for post-nephrectomy ccRCC risk stratification.", "journal": "Urologic Oncology", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1016/j.urolonc.2026.07.011", "authors": ["Somar Khalil", "Marwa Hamdan"], "affiliations": ["Technical Research & Development, GSK, Rixensart, Belgium.", "Department of Public Health and Epidemiology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary. Electronic address: hamdan.marwa@med.unideb.hu."], "corresponding_authors": ["Marwa Hamdan"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 28.75, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 5.75, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 5.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.3, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.75, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42542399", "title": "Long-term outcomes of men stratified by 4Kscore: a retrospective analysis.", "abstract": "Accurately distinguishing men with clinically significant prostate cancer (csCaP) from those with indolent disease remains challenging. Biomarkers such as the 4Kscore enhance risk stratification and guide biopsy decisions. This study assessed the long-term prognostic value of the 4Kscore, evaluating its ability to predict clinical and oncological outcomes. We retrospectively reviewed men who underwent 4Kscore testing prior to prostate cancer evaluation with long-term follow-up (median 7.3 years). Patients were categorized as low risk (≤5), intermediate risk (5.1-20), or high risk (≥20.1) based on their 4Kscore. Long-term clinical and oncologic outcomes were analyzed across risk groups. A total of 113 patients were included: 33% low risk, 34% intermediate risk, and 33% high risk. The majority of patients (95%) had MRI at baseline (within 6 months prior or after the 4K score test). During a long-term follow-up (median 7.3 years), csCaP occurred in 19%, 46%, and 65% of the respective groups. No high-grade cancers (≥ GG4) occurred in the low-risk group, whereas such cancers occurred in both the intermediate- and high-risk groups. Compared with low-risk patients, the high-risk group demonstrated a 6-fold increased likelihood of csCaP (HR = 6.95; 95% CI: 2.14-22.73; p = 0.0013) and 4.4-fold higher risk of Grade Group ≥4 disease (HR = 4.43; 95% CI: 2.11-9.09; p < 0.001). No cases of metastasis or prostate cancer-specific mortality occurred among low-risk patients, whereas all such events arose in the intermediate and high-risk groups. The 4Kscore provides durable long-term prognostic value for prostate cancer risk assessment. A low 4Kscore identifies men at minimal risk, supporting biopsy deferral and reduced overtreatment. Higher scores predict csCaP, aggressive disease, and adverse pathology and outcomes, confirming the 4Kscore's continued relevance for personalized management in the MRI era.", "journal": "Urologic Oncology", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1016/j.urolonc.2026.06.025", "authors": ["Omri Nativ", "Timothy Guerard", "Adam Williams", "Elena Cortizas", "Zoe Szczotka", "Mikel Cuvet", "Gareth Reid", "Archan Khandekar", "Hossein Sharifi", "Pedro F S Freitas", "Ivet T Cordoba Torres", "Sabika Sadiq", "Mark Gonzalgo", "Chad Ritch", "Bruno Nahar", "Dipen J Parekh", "Sanoj Punnen"], "affiliations": ["Desai Sethi Urology Institute and Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL. Electronic address: Onativ@gmail.com.", "Desai Sethi Urology Institute and Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL.", "Department of Anesthesia, Jackson Memorial Hospital, University of Miami, Miami, FL."], "corresponding_authors": ["Omri Nativ"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=6", "score": 18.25, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 5.75, "top_journal_bonus": 0.0, "novelty": 0.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 6.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.3, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.75, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42541401", "title": "Perioperative Factors Associated with the Conversion of Robotic-Assisted Partial Nephrectomy to Open Partial and Radical Nephrectomy.", "abstract": "To evaluate factors associated with the conversion of robotic-assisted partial nephrectomy (RAPN) to open partial nephrectomy (OPN) and radical nephrectomy (RN). We retrospectively reviewed 775 consecutive RAPNs from a single surgeon. Perioperative factors were evaluated for association with RAPN conversion such as Mayo Adhesive Probability (MAP) score, length of stay (LOS), and operative time (OT). A logistic regression model was utilized to evaluate factors associated with conversion and reported as odds ratio (OR) with 95% confidence intervals. Continuous and categorical variables were analyzed through the Wilcoxon rank-sum and chi-square tests. Thirty-two (4.1%) patients had a conversion including 19 (2.5%) to OPN and 13 (1.7%) to RN. OPN conversions were related to bleeding (n = 7), inability to dissect perinephric fat (n = 4), liver retraction (n = 1), and failure to secure renal hilum/progress (n = 7). In contrast, conversions to RN were due to tumor involvement of the renal vein (n = 3) or ureter (n = 5) and inability to achieve negative margins (n = 5). Patients in the conversion cohort were more likely to have larger tumor size (3.7 vs 2.8 cm; p < 0.001) and higher MAP score (3.0 vs 2.0; p = 0.04). Median LOS was higher in the conversion group (3.0 vs 2.0 days; p = 0.003). Conversions were associated with postoperative complications (28.1% vs 13.7%; p = 0.023). After adjusting tumor size in our regression model, longer OT and dissection time were statistically higher in the conversion group (OR = 2.19 [1.50-3.21]; p < 0.001 and OR = 2.67 [1.82-3.94]; p < 0.001, respectively). Larger tumor size and higher MAP score were associated with conversions during RAPN. Conversions were associated with higher LOS, longer OT, and postoperative complications.", "journal": "Journal of Endourology", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1177/08927790261473126", "authors": ["Neda Qosja", "Yeonsoo Lee", "Laura Geldmaker", "Matea Spahiu", "Katherine McCoy", "Janie Zhang", "Daniela Haehn", "Amanda E Kahn", "Eric Qualkenbush", "Colleen Thomas", "David D Thiel"], "affiliations": ["Department of Urology, Mayo Clinic Florida, Jacksonville, Florida, USA.", "Alix School of Medicine, Mayo Clinic, Jacksonville, Florida, USA.", "Division of Clinical Trials and Biostatistics, Mayo Clinic, Jacksonville, Florida, USA."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=6", "score": 33.96, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 9.96, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 6.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 1.96, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42540642", "title": "Pancreatic metastasis from clear-cell renal cell carcinoma causing extrinsic left ventricular compression: A rare case report.", "abstract": "Renal cell carcinoma is the most common renal malignancy in elderly people. It is well known for its unpredictable metastatic potential in different sites of the body, even many years after curative nephrectomy. Metastatic spread to the pancreas, accompanied by extrinsic compression of the left ventricle, is extremely rare and a late presentation. We report the case of a 68-year-old man who presented with progressively worsening shortness of breath on exertion, early satiety, and occasional abdominal discomfort. He had a history of left-sided radical nephrectomy for clear cell RCC performed 5 years earlier. An initial transthoracic echocardiogram revealed normal cardiac chambers, but there was an extrinsic compression on the LV wall. A contrast-enhanced computed tomography of the chest and abdomen was conducted, which showed a hyperenhancing mass at the head of the pancreas, and the lesion extended superiorly, exerting pressure on the inferior wall of the LV. The diagnosis of metastatic clear cell RCC was confirmed using endoscopic ultrasound-guided fine needle aspiration of the pancreatic lesion. Metastatic RCC is still challenging due to its late recurrence and atypical metastatic site. Further research and extended surveillance should be considered in long-term survivors to optimize early detection of metastasis.", "journal": "Radiology Case Reports", "pub_date": "2026-Oct", "publication_types": ["Case Reports", "Journal Article"], "doi": "10.14701/ahbps.2019.23.3.240", "authors": ["Md Deluwar Hussen", "Sayema Begum Jahra", "Fatematuj Johara", "Rifat Ara", "Farhana Zaman Kanon", "Musfika Mostaque"], "affiliations": ["Dinajpur Medical College, Dinajpur, Ruksana Monji, Shantibagh R/A, Sreemangal 3210, Sylhet.", "Sylhet Womens Medical College and Hospital, Sylhet, 19, Al-amin Road, Pathantula, 3100 Sylhet.", "Chattogram Medical College, Chattogram, Ahsan Palace,1/A Bakshi Bazar Lane, Chawkbazar 1211, Dhaka.", "Shaheed Suhrawardy Medical College and Hospital, Shahanabag City, Dubolhati Road, 6500 Naogaon.", "Community Based Medical College, Mymensing, 67/10,Gorosthan Moshjid road, Maskanda, 2200, Mymensingh.", "Sher e Bangla Medical College, House-182, Block-I Rania Avenue, Bashundhara R/A, 8200, Dhaka."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_clinical", "score": 18.0, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 0.0, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "missing", "impact_factor": null, "cas_zone": null, "cas_zone_points": 0.0, "impact_factor_points": 0.0}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42538174", "title": "Intraductal carcinoma of the prostate does not independently predict adverse outcomes after radical prostatectomy: A National Cancer Database analysis.", "abstract": "Intraductal carcinoma of the prostate (IDC-P) is associated with adverse features, yet whether it independently predicts poor outcomes or merely co-segregates with high-grade disease remains unresolved. We evaluated IDC-P's independent prognostic contribution to adverse pathology after radical prostatectomy (RP). We utilized the National Cancer Database (NCDB) to evaluate patients with cT1-4N0M0 prostate cancer (CaP) that underwent RP (n = 551,304 adenocarcinoma; n = 1,353 IDC-P). Temporal trends in IDC-P incidence were assessed by logistic regression. A restricted analytic cohort (n = 98 IDC-P, n = 14,628 adenocarcinoma) with complete Gleason Grade Group and prostate-specific antigen (PSA) data was used for multivariable logistic regression evaluating predictors of adverse pathology (≥pT3, ≥pN1, or positive surgical margins). Model discrimination was compared using C-statistics and likelihood ratio testing. Unadjusted overall survival (OS) was performed by an exploratory Kaplan-Meier analysis. IDC-P incidence increased 6% annually (OR 1.060; P < 0.001). IDC-P patients more frequently harbored Gleason Grade Group 4 to 5 disease (66.4% vs. 26.5%), ≥pT3 pathology (75.5% vs. 55.3%), and positive surgical margins (44.9% vs. 35.4%; all P < 0.001). On multivariable analysis, IDC-P histology did not independently predict adverse pathology (aOR 1.066; P = 0.801). Adding IDC-P did not improve model discrimination (C-statistic 0.705 vs. 0.705; likelihood ratio P = 0.800). IDC-P patients had worse unadjusted median OS (183.0 vs. 197.6 months; P < 0.001). IDC-P is rising in incidence and strongly associated with high-grade, advanced-stage disease, but does not independently predict adverse pathologic outcomes at RP after adjustment for Gleason Grade Group, clinical stage, and PSA. These findings suggest IDC-P may function primarily as a as a surrogate marker of aggressive disease biology.", "journal": "Urologic Oncology", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1016/j.urolonc.2026.07.012", "authors": ["Ryan M Antar", "Vincent E Xu", "William S Azar", "Neil Mendhiratta", "Michael J Whalen"], "affiliations": ["Department of Urology, George Washington University School of Medicine & Health Sciences, Washington, DC. Electronic address: ryanantar@gwu.edu.", "Department of Urology, George Washington University School of Medicine & Health Sciences, Washington, DC.", "The Brady Urological Institute, Johns Hopkins Medicine, Baltimore, MD."], "corresponding_authors": ["Ryan M Antar"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=5", "score": 24.75, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 5.75, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 5.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.3, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.75, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42533861", "title": "Oncologic outcomes of radical radiotherapy in frail patients with upper tract urothelial carcinoma.", "abstract": "To evaluate oncologic outcomes of high-dose radical radiotherapy (RT) in medically frail patients with upper tract urothelial carcinoma (UTUC). We retrospectively reviewed 63 patients with UTUC who received definitive RT at four major academic hospitals (2014-2021) with significant comorbidities (age-adjusted Charlson Comorbidity Index ≥3). Patients were stratified into high- and low-dose groups using a biologically effective dose (BED10) cutoff of 74.3 Gy (from 63 Gy/35 fractions, assuming α/β ratio = 10). The median BED10 was 64.8 Gy (interquartile range 60.0-72.0) in the low-dose group and 84.0 Gy (interquartile range 78.4-86.4) in the high-dose group. Baseline imbalances were addressed using inverse probability of treatment-weighted (IPTW) in Cox proportional hazard models and Kaplan-Meier analyses. The median follow-up was 76 months. The pelvic ureter was the most frequently involved site (57%), followed by the renal pelvis (33%) and the abdominal ureter (21%). In the IPTW-adjusted cohort, the disease control rate was significantly higher with high-dose RT (98% vs 62%, P < 0.001). High-dose RT significantly improved IPTW-adjusted locoregional control (3-year LRC: 51% vs 29%, P = 0.041), freedom from distant metastasis (3-year FFDM: 75% vs 39%, P = 0.001), freedom from progression (3-year FFP: 43% vs 25%, P = 0.013), and overall survival (3-year OS: 46% vs 11%, P < 0.001). Multivariate analysis identified higher RT dose as an independent prognosticator of improved FFP (adjusted hazard ratio [aHR] 0.96, P = 0.018) and OS (aHR 0.93, P < 0.001). Furthermore, pre-RT gross haematuria (aHR 2.63, P = 0.002) and age-adjusted Charlson Comorbidity Index >5 (aHR 2.85, P = 0.007) were associated with worse OS. A clear dose-response relationship was observed in UTUC treated with definitive RT. High-dose RT was associated with significantly improved survival and represents a safe alternative for medically frail patients.", "journal": "BJU International", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1111/bju.70392", "authors": ["Willy Po-Yuan Chen", "Wing-Keen Yap", "Hao-Lun Luo", "Yao-Yu Wu", "Miao-Fen Chen", "Shih-Ming Huang", "Din-Li Tsan", "Po-Hung Lin", "Kai-Jie Yu", "Yu-Hsiang Lin", "I-Hung Shao", "Hung-Cheng Kan", "Po-Jung Su", "Wen-Kuan Huang", "Po-Jui Chen", "Po-Ying Peng"], "affiliations": ["Department of Radiation Oncology, Proton and Radiation Therapy Center, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan.", "School of Medicine, College of Medicine, Chang Gung University, Taoyuan, Taiwan.", "Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.", "Department of Radiation Oncology, Chiayi Chang Gung Memorial Hospital, Chiayi, Taiwan.", "Department of Radiation Oncology, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan.", "Division of Urology, Department of Surgery, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan.", "Division of Hematology-Oncology, Department of Internal Medicine, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=9", "score": 37.47, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 10.47, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 9.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.4, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.47, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42530235", "title": "FDG PET/CT in a Case of α-Fetoprotein-Producing Urothelial Carcinoma With Hepatoid Differentiation of the Renal Pelvis.", "abstract": "An α-fetoprotein-producing tumor in the urinary tract is rare. We describe FDG PET/CT findings in a case of α-fetoprotein-producing urothelial carcinoma with hepatoid differentiation of the left renal pelvis with a significantly elevated serum α-fetoprotein level (1035 ng/mL). FDG PET/CT showed intense activity of the left renal pelvic tumor with invasion of the renal parenchyma. This case indicates that α-fetoprotein-producing urothelial carcinoma with hepatoid differentiation should be considered in the differential diagnosis of FDG-avid tumors of the urinary tract in patients with elevated serum α-fetoprotein levels.", "journal": "Clinical Nuclear Medicine", "pub_date": "2026-Oct-01", "publication_types": ["Journal Article", "Case Reports"], "doi": "10.1097/RLU.0000000000006637", "authors": ["Xiaojun Man", "Changming Dong", "Aisheng Dong", "Xiandong Song"], "affiliations": ["Department of Urology, The First Hospital of China Medical University.", "Institute of Urology, China Medical University, Shenyang, Liaoning Province.", "Department of Urology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong.", "Department of Nuclear Medicine, Changhai Hospital, Naval Medical University, Shanghai.", "Department of Urology, Shenyang Fifth People's Hospital, Shenyang, Liaoning Province, China."], "corresponding_authors": [], "china_team": "Department of Urology, The First Hospital of China Medical University Xiandong Song团队", "category": "clinical_review", "classification_reason": "publication_type_clinical", "score": 26.46, "score_parts": {"urology_relevance": 7, "urology_in_title": 8.0, "journal_priority": 7.46, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 2.0}, "journal_metrics": {"status": "ok", "impact_factor": 9.6, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 3.46, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42527247", "title": "Temporal Changes in Shear Wave Elastography and Doppler Ultrasound Parameters for Assessing Erectile Dysfunction.", "abstract": "This study aimed to explore the temporal changes in shear wave elastography (SWE) metrics before and after intracavernosal injection (ICI) in patients with different erectile dysfunction (ED) subtypes and to analyze the relationships between spectral Doppler ultrasound parameters and hardness grades according to the Schramek classification. Patients with ED were enrolled and categorized into vascular and non-vascular groups. The peak systolic velocity (PSV), end-diastolic velocity (EDV), resistive index (RI), and Young's modulus SWE values were measured before ICI and at 1, 3, 5, 10, 15, 20, and 30 min post-ICI. Additionally, the Schramek grades were assessed, with grades II and III classified as low hardness and grades IV and V classified as high hardness. One hundred and five men with a mean age of 35.42 (29-55) y were evaluated. A significant interaction between time points and group type was observed in SWE values (coefficient = -0.1491, p = 0.005), with vascular patients exhibiting a distinct late-phase increase in SWE values from 15-30 min post-ICI. After ICI, SWE values decreased significantly in both groups (p < 0.05); EDV was significantly higher (p < 0.05) and RI was significantly lower (p < 0.05) in the low-hardness group (Schramek II-III) than in the high-hardness group (Schramek IV-V). SWE can reflect dynamic changes of penile tissue elasticity post-ICI, and combining SWE with spectral Doppler ultrasound enhances the assessment of ED subtypes and penile hardness, providing a more comprehensive diagnostic basis.", "journal": "Ultrasound in Medicine & Biology", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1016/j.ultrasmedbio.2026.06.008", "authors": ["Jiahui Peng", "Muyi Mao", "Lujing Li", "Huitong Lin", "Zuofeng Xu"], "affiliations": ["Department of Medical Ultrasounics, The Seventh Affiliated Hospital of Sun Yat-sen University, Shenzhen, China.", "Department of Medical Ultrasounics, The Seventh Affiliated Hospital of Sun Yat-sen University, Shenzhen, China. Electronic address: xuzf@mail.sysu.edu.cn."], "corresponding_authors": ["Zuofeng Xu"], "china_team": "Department of Medical Ultrasounics, The Seventh Affiliated Hospital of Sun Yat-sen University, Shenzhen, China Zuofeng Xu团队", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 21.88, "score_parts": {"urology_relevance": 6, "urology_in_title": 8.0, "journal_priority": 5.88, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.6, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.88, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42527043", "title": "Retrograde intrarenal surgery with flexible and navigable suction access sheaths vs mini-percutaneous nephrolithotomy for large upper urinary tract stones: a systematic review and meta-analysis.", "abstract": "To conduct a meta-analysis comparing the efficacy and perioperative outcomes of contemporary flexible and navigable suction access sheath-assisted retrograde intrarenal surgery (FANS-RIRS) against percutaneous nephrolithotomy (PCNL) for the management of large upper urinary tract stones, as despite technological advances in RIRS such as high-powered lasers and FANS that have substantially enhanced its performance, current guidelines continue to recommend PCNL as first-line treatment for renal stones >2cm. MEDLINE, Embase, and the Cochrane Library were searched for studies performing direct comparisons of FANS-RIRS against PCNL in adult patients until September 2025. Primary outcomes included stone-free rates (SFRs) and need for ancillary procedures. Secondary outcomes included operative time, length of postoperative hospitalisation, and postoperative complications. A total of 10 studies (three randomised control trials, seven retrospective cohort studies) comprising 2347 patients were included; preoperative stone sizes were predominantly 2-3 cm. All PCNL procedures in the studies included were performed as mini-PCNL. The SFRs for FANS-RIRS were comparable with mini-PCNL across all stone sizes (odds ratio [OR] 0.90, 95% confidence interval [CI] 0.70-1.17) and stones ≥2 cm (OR 0.80, 95% CI 0.60-1.08), with low heterogeneity. Ancillary procedures rates were similar (OR 1.22, 95% CI 0.61-2.44). FANS-RIRS was associated with significantly fewer overall complications, specifically smaller haemoglobin decline, need for transfusion, and shorter hospital stay. However, mini-PCNL demonstrated shorter operative times for stones ≥2 cm. Urosepsis rates were low and similar between both groups. Limitations include predominance of Asian studies, variability of practice, and inclusion of non-randomised studies. Contemporary FANS-RIRS achieves SFRs comparable to mini-PCNL even for 2-3 cm stones, while offering superior safety profiles and shorter hospitalisation; this supports FANS-RIRS as a viable primary treatment in selected patients.", "journal": "BJU International", "pub_date": "2026-Oct", "publication_types": ["Journal Article", "Systematic Review", "Meta-Analysis", "Comparative Study"], "doi": "10.1111/bju.70393", "authors": ["Han Jie Lee", "Clyve Yaow", "Ryan Ian Houe Chong", "Sonam Kelzang", "Vineet Gauhar", "Steffi Kar Kei Yuen", "Alvin Wei Xiang Low", "Palaniappan Sundaram", "Wei Zhu", "Guohua Zeng", "Tsung Wen Chong", "Jingzeng Du"], "affiliations": ["Department of Urology, Singapore General Hospital, Singapore, Singapore.", "Department of Surgery, Jigme Dorji Wangchuck National Referral Hospital, Thimphu, Bhutan.", "Department of Urology, Ng Teng Fong General Hospital, Singapore, Singapore.", "SH Ho Urology Centre, Department of Surgery, Chinese University of Hong Kong, Hong Kong, China.", "Department of Urology, Sengkang General Hospital, Singapore, Singapore.", "Department of Urology and Guangdong Key Laboratory of Urology, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China."], "corresponding_authors": [], "china_team": "SH Ho Urology Centre, Department of Surgery, Chinese University of Hong Kong, Hong Kong, China Guohua Zeng团队", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 32.47, "score_parts": {"urology_relevance": 3, "urology_in_title": 8.0, "journal_priority": 10.47, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 8.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.4, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.47, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42518703", "title": "Doppler ultrasound diagnosis of anterior nutcracker syndrome presenting with isolated urinary abnormalities.", "abstract": "Nutcracker syndrome is a vascular compression disorder caused by entrapment of the left renal vein between the abdominal aorta and the superior mesenteric artery, leading to renal venous hypertension and a spectrum of urinary and pelvic symptoms. We report the case of a 19-year-old male referred for incidental microscopic hematuria and mild proteinuria detected during routine laboratory screening. Ultrasound demonstrated marked dilation of the left renal vein proximal to the aortomesenteric crossing, with focal narrowing at the compression site. Pulse-wave Doppler evaluation revealed significant flow acceleration within the stenotic segment, with a peak velocity of 178 cm/s and an estimated trans-stenotic pressure gradient of 12.8 mmHg. These combined morphological and hemodynamic findings strongly supported the diagnosis of anterior Nutcracker syndrome without the immediate need for additional imaging studies. The patient was managed conservatively because urinary abnormalities were mild and no pain, gross hematuria, or pelvic symptoms were present. This case highlights the pivotal role of Doppler ultrasound as a first-line, noninvasive imaging modality capable of providing both anatomical and functional assessment.", "journal": "Radiology Case Reports", "pub_date": "2026-Oct", "publication_types": ["Case Reports", "Journal Article"], "doi": "10.1016/j.avsg.2025.07.043", "authors": ["Michele Marchini", "Matteo Trezzi"], "affiliations": ["Ospedale Civile Sant'Andrea, Azienda Sociosanitaria Ligure 5, Via Vittorio Veneto 197, La Spezia 19121, Italy."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_clinical", "score": 14.0, "score_parts": {"urology_relevance": 3, "urology_in_title": 8.0, "journal_priority": 0.0, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "missing", "impact_factor": null, "cas_zone": null, "cas_zone_points": 0.0, "impact_factor_points": 0.0}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42515859", "title": "INtraVESical immunoTherapy (INVEST) prior to radical cystectomy for bladder cancer: trial protocol.", "abstract": "High-risk non-muscle-invasive bladder cancer (HRNMIBC) has a variable prognosis, managed predominantly by local surgical resection and intravesical Bacillus Calmette-Guérin (BCG), or radical cystectomy (RC). Current treatments are poorly tolerated, have supply limitations and often fail to control the disease. Treatments overcoming these limitations are needed to improve HRNMIBC outcomes. Many novel agents have been approved in recent years (including systemic pembrolizumab, nogapendekin alfa inbakicept-pmln, N-803), but long-term efficacy is unknown. Given advanced bladder cancer findings, we believe direct intravesical administration of atezolizumab may aid with managing HRNMIBC or muscle-invasive bladder cancer in patients who are ineligible for cisplatin-based neoadjuvant chemotherapy. The INtraVESical immunoTherapy (INVEST) trial is a UK-based, open-label, non-randomised, single-centre, Phase Ib dose escalation, window of opportunity study exploring atezolizumab administration via intravesical routes (passive instillation and direct injection [sub-urothelial]) in patients with bladder cancer with all stages undergoing RC. For both routes, an initial dose confirmation stage will determine toxicity and recommended atezolizumab dosage, followed by a dose expansion stage to further evaluate safety and toxicity at the recommended dose. We aim to investigate safety (primary) and preliminary activity (secondary) of intravesical atezolizumab delivered by passive instillation and direct injection into the tumour/bladder wall in patients with bladder urothelial cell carcinoma prior to RC. Primary endpoints include dose limiting toxicities and adverse events. Secondary endpoints include progression-free survival, pathological complete response rate and treatment compliance. Exploratory endpoints include pharmacokinetic profile (assessed by serum and urine concentrations at prespecified timepoints), spatial analysis of atezolizumab distribution within RC tissue by imaging mass spectrometry and overall survival. Atezolizumab will be administered intravesically by either passive instillation or direct injection into the tumour/bladder wall. Cohorts will receive either 600 mg or 1200 mg doses administered as a single dose or as multiple doses (weekly for 3-6 weeks). International Standard Randomised Controlled Trial Number: ISRCTN15842444, registered 2 December 2022.", "journal": "BJU International", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1111/bju.70387", "authors": ["Ruby Lister-Whelan", "Ethan Senior", "Jessica Kendall", "Jamie B Oughton", "Fiona Collinson", "Jon Griffin", "Rachel Hubbard", "Steven Kennish", "Aidan Noon", "Derek J Rosario", "Irbaz B Riaz", "Julie Telliez", "James W F Catto", "Syed A Hussain"], "affiliations": ["Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.", "Division of Clinical Medicine, School of Medicine & Population Health, University of Sheffield, Sheffield, UK.", "Department of Histopathology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.", "Department of Radiology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.", "Department of Urology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.", "Department of Hematology/Oncology, Mayo Clinic, Phoenix, AZ, USA.", "F. Hoffmann-La Roche Ltd., Basel, Switzerland.", "Department of Oncology, Weston Park Cancer and Centre, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=6", "score": 39.47, "score_parts": {"urology_relevance": 12, "urology_in_title": 8.0, "journal_priority": 10.47, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 6.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.4, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.47, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42509622", "title": "A stent-plus-irrigation protocol after adolescent hypospadias repair: a multicentre randomised controlled trial.", "abstract": "To evaluate whether a stent-plus-irrigation protocol reduces complication rates following hypospadias repair in adolescents compared with catheter drainage alone. In this multicentre randomised controlled trial, adolescents (Tanner Stage II-V) undergoing hypospadias repair were randomly assigned to either a stent-plus-irrigation group or a catheter-drainage group. The catheter-drainage group received standard urethral catheter drainage alone, whereas the stent-plus-irrigation group received an additional small-calibre urethral stent positioned within the reconstructed urethra and twice-daily saline irrigation. The primary outcome was the overall postoperative complication rate; secondary outcomes included urinary function and cosmetic outcomes. A total of 172 adolescents were assessed for eligibility, with 150 participants (75 in the stent-plus-irrigation group and 75 in the catheter-drainage group) included in the final analysis. Compared with the catheter-drainage group, the stent-plus-irrigation group demonstrated a significantly lower overall complication rate (risk ratio [RR] 0.33, 95% confidence interval [CI] 0.20-0.56; P < 0.001), urethral fistula rate (RR 0.27, 95% CI 0.14-0.51; P < 0.001), and surgical site infection (SSI) rate (RR 0.43, 95% CI 0.21-0.87; P = 0.020). A postoperative stent-plus-irrigation protocol was associated with lower rates of postoperative complications, particularly urethral fistula and SSI, compared with catheter drainage alone after adolescent hypospadias repair. Because the intervention included both an additional urethral stent and saline irrigation, the independent contribution of irrigation cannot be determined in this two-arm trial.", "journal": "BJU International", "pub_date": "2026-Oct", "publication_types": ["Journal Article", "Multicenter Study", "Randomized Controlled Trial"], "doi": "10.1111/bju.70386", "authors": ["Zihan Ye", "Hongsong Chen", "Qiang Zhang", "Xingguo Luo", "Zhicheng Zhang", "Guanghui Wei", "Li Zeng", "Ning Li", "Gaofeng Zhang", "Wei Liu", "Xing Liu"], "affiliations": ["Department of Urology, Children's Hospital of Chongqing Medical University, Chongqing, China.", "Department of Pediatric Surgery, West China Hospital, Sichuan University, Chengdu, China.", "Department of Pediatric Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.", "Department of Urology, Xi'an Children's Hospital, Xi'an Jiaotong University Affiliated Children's Hospital, Xi'an, Shaanxi, China.", "Department of Pediatric Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Shandong, China."], "corresponding_authors": [], "china_team": "Department of Urology, Children's Hospital of Chongqing Medical University, Chongqing, China Xing Liu团队", "category": "clinical_review", "classification_reason": "publication_type_interventional_trial", "score": 27.47, "score_parts": {"urology_relevance": 7, "urology_in_title": 0.0, "journal_priority": 10.47, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 8.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.4, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.47, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42509104", "title": "Robotic-assisted Transurethral En Bloc Resection of Bladder Tumours Using the Intilume Robotic System: First-in-human Experience.", "abstract": "", "journal": "European Urology", "pub_date": "2026-Oct", "publication_types": ["Letter"], "doi": "10.1016/j.eururo.2026.04.006", "authors": ["Peter Ka-Fung Chiu", "Alex Qinyang Liu", "Chi Hang Yee", "Jason Ying-Kuen Chan", "Justin Di-Lang Ho", "Jeremy Yuen-Chun Teoh", "Haowen Jiang", "Ka-Wai Kwok", "Chi-Fai Ng"], "affiliations": ["SH Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong, China.", "Department of Otorhinolaryngology, Head and Neck Surgery, The Chinese University of Hong Kong, Hong Kong, China.", "Department of Mechanical and Automation Engineering, The Chinese University of Hong Kong, Hong Kong, China.", "Department of Urology, Huashan Hospital, Fudan University, Shanghai, China.", "Department of Mechanical and Automation Engineering, The Chinese University of Hong Kong, Hong Kong, China. Electronic address: kwokkw@mae.cuhk.edu.hk.", "SH Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong, China. Electronic address: ngcf@surgery.cuhk.edu.hk."], "corresponding_authors": ["Ka-Wai Kwok", "Chi-Fai Ng"], "china_team": "SH Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong, China Ka-Wai Kwok/Chi-Fai Ng团队", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 40.79, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 16.79, "top_journal_bonus": 10.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 25.2, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.79, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "机器人系统完成首例膀胱肿瘤整块切除", "chinese_summary": "香港中文大学何善衡泌尿外科中心Ka-Wai Kwok/Chi-Fai Ng团队10月Eur Urol报道首例人体机器人辅助经尿道膀胱肿瘤整块切除术，采用Intilume机器人系统，初步验证该术式可行，为膀胱肿瘤微创治疗提供新路径。", "abstract_zh": "这是首例人体体验报告，评估使用Intilume机器人系统进行机器人辅助经尿道膀胱肿瘤整块切除术的可行性与安全性。膀胱肿瘤的传统治疗方式包括经尿道膀胱肿瘤电切术，但该技术存在肿瘤分块切除及闭孔神经反射等局限。整块切除术可提供更完整的肿瘤标本并可能改善肿瘤学结局，但受限于现有器械，经尿道途径的整块切除在技术上仍具挑战。本研究报道一例患者接受机器人辅助经尿道膀胱肿瘤整块切除术的初步结果。手术顺利完成，无术中并发症。该首例人体体验初步表明，使用Intilume机器人系统进行机器人辅助经尿道膀胱肿瘤整块切除术在技术上是可行的，值得进一步评估。"}, {"pmid": "42508612", "title": "New insights from DAPA-CKD indicate that dapagliflozin modulates key pathways related to kidney outcomes.", "abstract": "Dapagliflozin improves kidney outcomes in patients with chronic kidney disease (CKD), yet the underlying mechanisms by which it exerts protective effects are not fully elucidated. Here, we applied plasma proteomics to identify proteins and pathways linked to CKD progression and examined which of these are modulated by dapagliflozin. We measured 3072 circulating plasma proteins (Olink, Uppsala, Sweden) in 2485 of the 4304 (57.7%) patients with CKD from the DAPA-CKD trial (eGFR 25-75 mL/min per 1.73 m2 and urinary albumin-to-creatinine ratio 200-5000 mg/g). Proteins associated with the composite kidney outcome (50% eGFR decline, kidney failure, and kidney death) and with dapagliflozin treatment were respectively identified by multivariable Cox proportional hazard regression and ANCOVA. Ingenuity pathway analysis was used to identify relevant molecular pathways and upstream regulators. Pathways that had the strongest association with the composite kidney outcome were hepatic fibrosis, insulin-like growth factor transport regulation, and tumor necrosis factor signaling. These pathways were generally related to fibrosis and inflammation. After 12 months, dapagliflozin treatment showed a (placebo-corrected) modification of 216 proteins, of which kidney injury molecule-1 showed the strongest reduction (-14.9%; 95% confidence interval: -17.9, -11.7). Of the 137 pathways associated with the kidney outcome, 35 (25%) were modified by dapagliflozin. Among these, activity of 11 (31% of 35) pathways decreased, and 10 (29% of 35) pathways were increased. Pathways associated with kidney outcome and modulated by dapagliflozin were related to extracellular matrix remodeling, inflammation and fibrosis, and immune-vascular interactions. This proteomic analysis reveals mechanisms underlying dapagliflozin's beneficial effects in CKD progression and shows that key pathways associated with CKD progression are modified by dapagliflozin, supporting its anti-inflammatory and antifibrotic potential.", "journal": "Kidney International", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1016/j.kint.2026.06.043", "authors": ["Mark André de la Rambelje", "Niels Jongs", "Peter J Greasley", "Rasmus Agren", "Peter Rossing", "David C Wheeler", "Ann Hammarstedt", "C David Sjöström", "Adriaan A Voors", "Hiddo J L Heerspink"], "affiliations": ["Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.", "Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.", "Quantitative Biology and Data Science, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.", "Department of Clinical and Translational Research, Steno Diabetes Center, Gentofte, Denmark; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.", "Centre for Kidney and Bladder Health, University College London, London, UK.", "Late-stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.", "Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.", "Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands. Electronic address: h.j.lambers.heerspink@umcg.nl."], "corresponding_authors": ["Hiddo J L Heerspink"], "china_team": "", "category": "basic", "classification_reason": "basic_signals=11", "score": 32.33, "score_parts": {"urology_relevance": 3, "urology_in_title": 0.0, "journal_priority": 15.83, "top_journal_bonus": 0.0, "novelty": 0.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 11.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 12.6, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.83, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "达格列净调控CKD进展关键通路", "chinese_summary": "10月Kidney International基于DAPA-CKD试验对2485例患者行血浆蛋白质组学分析，发现与肾脏复合结局最强相关的通路涉及肝纤维化、胰岛素样生长因子转运及TNF信号。达格列净治疗12个月后校正安慰剂效应可调节216种蛋白，其中肾损伤分子-1降幅最大，达14.9%。", "abstract_zh": "达格列净可改善慢性肾脏病（CKD）患者的肾脏结局，但其发挥保护作用的潜在机制尚未完全阐明。在此，我们应用血浆蛋白质组学来识别与CKD进展相关的蛋白质和通路，并检验其中哪些可被达格列净调节。我们在DAPA-CKD试验的4304例CKD患者中，对2485例（57.7%）患者（eGFR 25-75 mL/min per 1.73 m2，尿白蛋白与肌酐比值200-5000 mg/g）测量了3072种循环血浆蛋白（Olink，瑞典乌普萨拉）。分别通过多变量Cox比例风险回归和协方差分析（ANCOVA）识别与复合肾脏结局（eGFR下降50%、肾衰竭和肾脏死亡）相关的蛋白以及与达格列净治疗相关的蛋白。使用Ingenuity通路分析来识别相关分子通路和上游调控因子。与复合肾脏结局关联最强的通路为肝纤维化、胰岛素样生长因子转运调节和肿瘤坏死因子信号。这些通路总体上与纤维化和炎症相关。12个月后，达格列净治疗显示（经安慰剂校正）调节了216种蛋白，其中肾损伤分子-1的降幅最大（-14.9%；95%置信区间：-17.9，-11.7）。在137条与肾脏结局相关的通路中，35条（25%）被达格列净调节。其中，11条（占35条的31%）通路活性下降，10条（占35条的29%）通路活性升高。与肾脏结局相关且被达格列净调节的通路涉及细胞外基质重塑、炎症与纤维化以及免疫-血管相互作用。该蛋白质组学分析揭示了达格列净在CKD进展中获益的机制，并表明与CKD进展相关的关键通路可被达格列净调节，支持其抗炎和抗纤维化潜力。"}, {"pmid": "42508609", "title": "Early acute T cell-mediated rejection and kidney allograft outcomes.", "abstract": "Despite the prevalent notion that early acute T cell-mediated rejection (TCMR) in kidney transplant patients is clinically benign, how it responds to treatment and whether treatment responses impact long-term graft survival remain unclear and poorly characterized. To comprehensively address this issue, we conducted an observational cohort study of all adult patients who underwent kidney transplantation between January 2013 and December 2019 across six centers in the United States and Europe. We evaluated the incidence of TCMR in the first post-transplant year, assessed clinical and histological responses to treatment, and examined their association with long-term graft outcomes. Among 5,762 patients undergoing 9,780 biopsies, 790 (13.6%) developed TCMR. Despite treatment, 36% of patients demonstrated clinical deterioration and 32% had persistent TCMR on follow-up biopsy, indicating frequent treatment resistance. Clinical and histologic responses were frequently discordant. While only 51% of patients with clinical improvement had no rejection, 37% with clinical deterioration also showed no rejection. TCMR was significantly associated with worse graft survival (death-censored graft loss hazard ratio 2.84, 95% confidence interval 2.38-3.3). Importantly, persistent TCMR conferred a substantially higher risk of graft loss compared with responsive TCMR (3.21, 2.19-4.71) independent of clinical response and other confounders. This association was consistent across subgroups and supported by time-dependent and landmark analyses. Increasing tubulointerstitial inflammation (Banff Δ 't+i' scores) demonstrated a graded association with adverse outcomes, and trajectory analyses showed a stepwise increase in graft loss with persistent or recurrent inflammation. TCMR is common, frequently treatment-resistant, and persistent TCMR is strongly associated with inferior long-term graft survival. Clinical improvement often failed to reflect histologic response. These findings challenge the notion that TCMR is clinically benign and identify persistent inflammation as a key driver of graft loss, underscoring the need for response guided monitoring and more effective targeted therapies.", "journal": "Kidney International", "pub_date": "2026-Oct", "publication_types": ["Journal Article", "Observational Study", "Multicenter Study"], "doi": "10.1016/j.kint.2026.06.042", "authors": ["Chuxiao Chen", "Charbel Elias", "Michelle Keyser", "Karolien Wellekens", "David M Rothstein", "Fadi G Lakkis", "Parmjeet Randhawa", "Priyanka Koshy", "Katharina A Mayer", "Matthias Diebold", "Irina B Torres", "Francesc Moreso", "Michele Molinari", "Rajil Mehta", "Sundaram Hariharan", "Vikraman Gunabushanam", "Amit D Tevar", "Dirk Kuypers", "Khodor I Abou Daya", "Stefan Schaub", "Georg A Böhmig", "Olivier Thaunat", "Oriol Bestard", "Maarten Naesens", "Aravind Cherukuri"], "affiliations": ["Thomas E. Starzl Transplantation Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA; Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA; Organ Transplant Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.", "Thomas E. Starzl Transplantation Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA; Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.", "Renal Electrolyte Division, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.", "Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.", "Thomas E. Starzl Transplantation Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA; Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA; Renal Electrolyte Division, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA; Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.", "Division of Nephrology, Department of Medicine, Stanford University, Stanford, California, USA.", "Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.", "Division of Nephrology and Dialysis, Department of Medicine III, Medical University Vienna, Austria.", "Clinic for Transplantation Immunology and Nephrology, University Hospital Basel, Basel, Switzerland.", "Department of Nephrology, University Hospital Vall d 'Hebron, Barcelona, Catalonia, Spain.", "Department of Transplantation, Nephrology, and Clinical Immunology, Edouard Herriot Hospital, Hospices Civils de Lyon and Centre International de Recherche en Infectiologie, Institut National de la Santé et de la Recherche Médicale U1111, Université Claude Bernard Lyon I, Centre National de la Recherche Scientifique Unité Mixte de Recherche 5308, Ecole Normale Supérieure de Lyon, Lyon, France.", "Thomas E. Starzl Transplantation Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA; Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA; Renal Electrolyte Division, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA; Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium. Electronic address: cherukuria@upmc.edu."], "corresponding_authors": ["Aravind Cherukuri"], "china_team": "Thomas E Chuxiao Chen团队", "category": "clinical_review", "classification_reason": "publication_type_clinical", "score": 29.83, "score_parts": {"urology_relevance": 2, "urology_in_title": 0.0, "journal_priority": 15.83, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 9.0}, "journal_metrics": {"status": "ok", "impact_factor": 12.6, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.83, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42502789", "title": "Incidental finding of a cardiac paraganglioma following ischemic stroke: A case report.", "abstract": "Cardiac paragangliomas are rare neuroendocrine tumors (NETs) that may cause morbidity through mass effect, embolic events, and catecholamine excess. This case report describes a 52-year-old woman with a history of atrial fibrillation with rapid ventricular response presenting with ischemic stroke. Incidental imaging revealed an 8-cm prevascular mass abutting the left ventricle with regions of central necrosis. Urinary metanephrine testing was elevated, indicating a functional mass. Cu-64 DOTATATE PET/CT confirmed absence of distant metastases and increased radiotracer uptake along the rim of the mass, which supported the diagnosis of a NET. CT-guided percutaneous coaxial core needle biopsy confirmed the diagnosis of a paraganglioma. Upon resection, postoperative urinary metanephrine levels normalized. This report highlights the multidisciplinary approach to the management of a cardiac paraganglioma presenting after ischemic stroke.", "journal": "Radiology Case Reports", "pub_date": "2026-Oct", "publication_types": ["Case Reports", "Journal Article"], "doi": "10.1016/j.athoracsur.2008.04.105", "authors": ["Mohammed Usman Syed", "Tausif Ahmed Siddiqui", "Zahin Alam", "Pavan K Kottamasu", "Peter A Rosella", "Brij Reddy", "Akm A Rahman"], "affiliations": ["Department of Imaging Sciences, University of Rochester Medical Center, Rochester, NY, USA.", "Department of Radiology, Hackensack Meridian School of Medicine, Nutley, NY, USA.", "Clearview Radiology PC, Bayside, NY, USA."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_clinical", "score": 5.0, "score_parts": {"urology_relevance": 3, "urology_in_title": 0.0, "journal_priority": 0.0, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "missing", "impact_factor": null, "cas_zone": null, "cas_zone_points": 0.0, "impact_factor_points": 0.0}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42498607", "title": "Five-Year Patient-Reported Outcomes After SBRT for Prostate Cancer: A Benchmark for Radiotherapy, but How Far Across Modalities?", "abstract": "", "journal": "European Urology", "pub_date": "2026-Oct", "publication_types": ["Editorial"], "doi": "10.1016/j.eururo.2026.07.023", "authors": ["Pierre Blanchard", "Chiara Sighinolfi", "Mario Terlizzi", "Bernardo Rocco"], "affiliations": ["Radiotherapy Department, Gustave Roussy Cancer Campus, Villejuif, France; INSERM 1018 CESP, University Paris-Saclay, Villejuif, France. Electronic address: pierre.blanchard@gustaveroussy.fr.", "Urology Unit A. Gemelli IRCCS University Hospital Foundation, Rome, Italy.", "Radiotherapy Department, Gustave Roussy Cancer Campus, Villejuif, France.", "Urology Unit A. Gemelli IRCCS University Hospital Foundation, Rome, Italy; Università Cattolica del Sacro Cuore, Rome, Italy."], "corresponding_authors": ["Pierre Blanchard"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 35.79, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 16.79, "top_journal_bonus": 10.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 25.2, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.79, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "前列腺癌SBRT五年患者报告结局出炉", "chinese_summary": "欧洲泌尿外科学会10月于Eur Urol发表述评，聚焦前列腺癌立体定向放疗五年患者报告结局，认为该数据为放疗树立了基准，但跨模态推广仍面临证据边界。述评提示，需审慎比较不同放疗技术对患者功能与生活质量的长期影响。", "abstract_zh": "本文为评论性文章，围绕前列腺癌立体定向体部放疗（SBRT）后的五年患者报告结局展开讨论。述评指出，这些五年患者报告结局为放疗提供了一个基准，但尚需进一步明确其在不同放疗模态之间的可外推程度。文章未报告原始研究数据、样本量或置信区间，仅就SBRT患者报告结局作为放疗基准的意义及其跨模态适用性提出评价。"}, {"pmid": "42498055", "title": "Non-HLA antibodies worsen the histological phenotype and prognosis of antibody mediated rejection in kidney allografts.", "abstract": "Antibody-mediated rejection (AMR) remains a leading cause of kidney allograft failure, with both HLA and non-HLA antibodies implicated in its pathogenesis. The contribution of non-HLA antibodies (non-HLA Abs) to microvascular inflammation (MVI) and graft outcome, particularly in cases lacking donor-specific anti-HLA antibodies (HLA-DSAs), remains incompletely understood. We analyzed 571 post-transplant serum samples from 326 patients with histological features of AMR (AMRh) and 164 stable control individuals. Non-HLA Abs were detected using the previously developed Non-HLA Antibody Detection Immunoassay (NHADIA), and associations were examined with histological lesions, AMRh persistence, and graft outcomes. Biopsies were scored according to Banff 2022 criteria, and patients were stratified by HLA-DSA and NHADIA status. External validation was also performed in an independent kidney transplant cohort that included 211 biopsies from 189 patients. NHADIA values were significantly higher in patients with AMRh compared to controls, regardless of HLA-DSA status. NHADIA values correlated with the severity of glomerulitis, peritubular capillaritis and global MVI scores. In patients with AMRh and HLA-DSAs, non-HLA Abs remained independently associated with MVI severity. Follow-up biopsies revealed persistent AMR lesions in patients with both HLA-DSAs and non-HLA Abs. Allograft survival was lowest in double-positive patients, and NHADIA positivity independently and significantly predicted graft loss (hazard ratio 2.25, 95% confidence interval 1.03-4.92). Association of non-HLA Abs with Banff lesions severity and death-censored graft survival was replicated in the external validation cohort. Post-transplant detection of non-HLA antibodies identifies a distinct subset of AMR with more severe histology and worse graft prognosis, particularly when coexisting with HLA-DSAs. Integrating non-HLA Ab testing into current diagnostic frameworks may refine AMR classification and improve risk stratification.", "journal": "Kidney International", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1016/j.kint.2026.06.031", "authors": ["Emilie Lebraud", "Olivier Aubert", "Laïla Aouni", "Virginia Garcia", "Lise Morin", "Maëva Eloudzeri", "Baptiste Lamarthée", "Julien Zuber", "Corentin Ramaugé Parra", "Mélanie Try", "Maarten Coemans", "Dirk Kuypers", "Karolien Wellekens", "Tim Debyser", "Priyanka Koshy Lehnert", "Adel Abderrahmane", "Jean-Luc Taupin", "Chloé Jager", "Quentin Holleville", "Corinne Normand", "Frank Bienaimé", "Nicolas Garcelon", "Fabiola Terzi", "Maarten Naesens", "Marion Rabant", "Dany Anglicheau"], "affiliations": ["Necker-Enfants Malades Institute, Université Paris Cité, Institut National de la Santé et de la Recherche Médicale U1151, Centre National de la Recherche Scientifique Unité Mixte de Recherche 8253, Paris, France. Electronic address: emilie.lebraud@inserm.fr.", "Necker-Enfants Malades Institute, Université Paris Cité, Institut National de la Santé et de la Recherche Médicale U1151, Centre National de la Recherche Scientifique Unité Mixte de Recherche 8253, Paris, France; Department of Nephrology and Kidney Transplantation, Necker Hospital, Assitance Publique - Hôpitaux de Paris, Paris, France.", "Necker-Enfants Malades Institute, Université Paris Cité, Institut National de la Santé et de la Recherche Médicale U1151, Centre National de la Recherche Scientifique Unité Mixte de Recherche 8253, Paris, France.", "Université Marie et Louis Pasteur, Etablissement Français du Sang Bourgogne-Franche-Comté, Institut National de la Santé et de la Recherche Médicale Unité Mixte de Recherche 1098 Regulation of Immunity for Therapeutic Innovation in Graft, Host, Tumoral and Inflammatory-Associated Diseases, Besançon, France.", "Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.", "Department of Nephrology and Kidney Transplantation, Necker Hospital, Assitance Publique - Hôpitaux de Paris, Paris, France.", "Immunology and Histocompatibility Laboratory, Saint-Louis Hospital, Assitance Publique - Hôpitaux de Paris, Paris, France.", "Necker-Enfants Malades Institute, Université Paris Cité, Institut National de la Santé et de la Recherche Médicale U1151, Centre National de la Recherche Scientifique Unité Mixte de Recherche 8253, Paris, France; Department of Physiology, Necker Hospital, Assitance Publique - Hôpitaux de Paris, Paris, France.", "Université de Paris, Imagine Institute, Data Science Platform, Institut National de la Santé et de la Recherche Médicale Unité Mixte de Recherche 1163, Paris, France.", "Necker-Enfants Malades Institute, Université Paris Cité, Institut National de la Santé et de la Recherche Médicale U1151, Centre National de la Recherche Scientifique Unité Mixte de Recherche 8253, Paris, France; Department of Pathology, Necker Hospital, Assitance Publique - Hôpitaux de Paris, Paris, France.", "Necker-Enfants Malades Institute, Université Paris Cité, Institut National de la Santé et de la Recherche Médicale U1151, Centre National de la Recherche Scientifique Unité Mixte de Recherche 8253, Paris, France; Department of Nephrology and Kidney Transplantation, Necker Hospital, Assitance Publique - Hôpitaux de Paris, Paris, France. Electronic address: dany.anglicheau@aphp.fr."], "corresponding_authors": ["Emilie Lebraud", "Dany Anglicheau"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=6", "score": 25.83, "score_parts": {"urology_relevance": 2, "urology_in_title": 0.0, "journal_priority": 15.83, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 6.0}, "journal_metrics": {"status": "ok", "impact_factor": 12.6, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.83, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42494875", "title": "Obstructive lower urinary tract symptoms due to ball valve effect of a rare bladder tumor in an adolescent male.", "abstract": "Cystitis glandularis is a rare inflammatory proliferative disease of urinary bladder. It is commonly associated with chronic bladder outlet obstruction and persistent bladder irritation. It is rarely reported in pediatric population and usually presents with hematuria and lower urinary tract symptoms. Radiological imaging cannot positively differentiate it from more sinister pathologies like bladder malignancies. We report a rare case of bladder outlet obstruction in an adolescent boy caused by the ball-vale effect of a long pedunculated bladder polyp. The case was managed with transurethral resection and histopathology was consistent with cystitis glandularis.", "journal": "Radiology Case Reports", "pub_date": "2026-Oct", "publication_types": ["Case Reports", "Journal Article"], "doi": "10.1016/j.radcr.2026.06.101", "authors": ["Sajad Ahmad Para", "Waseem Jan Shah", "Zafirah Zahir", "Abdul Rouf Khawaja", "Uvaisullah Quadir", "Gokul K", "Omar Mukhtar"], "affiliations": ["Department of Urology, Sher-i-Kashmir Institute of Medical Sciences, Srinagar, India.", "Pathology, Sher-i-Kashmir Institute of Medical Sciences, Srinagar, India."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_clinical", "score": 21.0, "score_parts": {"urology_relevance": 11, "urology_in_title": 8.0, "journal_priority": 0.0, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "missing", "impact_factor": null, "cas_zone": null, "cas_zone_points": 0.0, "impact_factor_points": 0.0}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42493599", "title": "Adipose triglyceride lipase driven lipolysis as a targetable metabolic vulnerability in prostate cancer with intrinsic metabolic inflexibility.", "abstract": "Despite the widespread clinical use of prostate-specific membrane antigen (PSMA)-targeted imaging and therapy in prostate cancer, the biological functions underlying PSMA-associated tumour aggressiveness remain incompletely understood. PSMA-PET-guided sampling of paired PSMA-high and PSMA-low tumour regions was used for integrated proteomic and epigenomic analyses. PSMA-ATGL correlation was validated by immunohistochemistry in 90 treatment-naïve patients. Metabolic profiling was performed using Seahorse Mito Fuel Flex Test assays under unperturbed conditions and pharmacological or genetic perturbation of ATGL and PSMA. Therapeutic vulnerability was assessed using NG-497 and siRNA-mediated knockdown. PSMA-high tumours exhibited lipolytic reprogramming characterised by ATGL upregulation, confirmed by a robust PSMA-ATGL correlation in the validation cohort (P < 0.0001). Despite shared fatty acid dependency, LNCaP cells exhibited intrinsic metabolic inflexibility while 22RV1 cells displayed high adaptability. Both pharmacological and genetic ATGL inhibition most potently impaired LNCaP proliferation. Enzalutamide upregulated ATGL in both cell lines, revealing reciprocal regulation between AR signaling and the PSMA/ATGL axis. ATGL-mediated lipolysis represents a promising therapeutic target in prostate cancer, with heightened sensitivity in tumours lacking metabolic flexibility to utilize alternative pathways.", "journal": "British Journal of Cancer", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1093/nar/gkab1038", "authors": ["Andreas Tiefenbacher", "Madeleine Gudenus", "Daniel Valcanover", "Barbara Neudert", "Raheleh Sheibani-Tezerji", "Theresa Mendrina", "Jessica Kalla", "Laura Pajed", "Kristina Draganić", "Andrea Haitel", "Astrid Haase", "Markus Hartenbach", "Sazan Rasul", "Walter Berger", "Rolf Breinbauer", "Gernot Grabner", "Martina Schweiger", "Eva Compérat", "Gerda Egger"], "affiliations": ["Department of Pathology, Medical University of Vienna, Vienna, Austria.", "Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.", "Center for Cancer Research, Medical University of Vienna, Vienna, Austria.", "Institute of Inorganic Chemistry, Faculty of Chemistry, University of Vienna, Vienna, Austria.", "Institute of Molecular Biosciences, University of Graz, Graz, Austria.", "Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria.", "Institute of Organic Chemistry, Graz University of Technology, Graz, Austria.", "Gottfried Schatz Research Center, Medical University of Graz, Graz, Austria.", "BioTechMed-Graz, Graz, Austria.", "Department of Pathology, Medical University of Vienna, Vienna, Austria. gerda.egger@meduniwien.ac.at.", "Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. gerda.egger@meduniwien.ac.at."], "corresponding_authors": ["Gerda Egger"], "china_team": "", "category": "basic", "classification_reason": "basic_signals=15", "score": 39.01, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 11.01, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 14.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 6.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 3.01, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "雄激素剥夺使前列腺癌细胞逃逸巨噬细胞杀伤", "chinese_summary": "Oncogene 9月发表全基因组CRISPR共培养筛选研究，鉴定雄激素受体AR、PRKCD及NF-κB通路（IKBKB/IKBKG/CHUK）为肿瘤内在的巨噬细胞杀伤必需因子。AR与NF-κB直接驱动PRKCD表达；雄激素剥夺及AR抑制均使肿瘤细胞抵抗巨噬细胞杀伤，提示AR信号通路具有免疫调节作用，或为激素治疗的不良后果。", "abstract_zh": "巨噬细胞是前列腺肿瘤微环境中最丰富的免疫细胞，能够杀伤肿瘤细胞，但肿瘤内在的抵抗固有免疫系统的调控因子尚不清楚。为鉴定巨噬细胞介导杀伤所必需的基因，我们进行了全基因组共培养CRISPR筛选，鉴定出雄激素受体（AR）、PRKCD以及NF-κB通路的多个组分（IKBKB/IKBKG/CHUK）为允许巨噬细胞介导杀伤的肿瘤内在必需因子。在机制上，AR和NF-κB均直接驱动癌细胞中PRKCD的表达，从而在功能上将全部筛选命中基因统一于一个分子通路。重要的是，雄激素剥夺和AR抑制均使肿瘤细胞对巨噬细胞介导的杀伤产生抵抗，这将肿瘤内在的AR信号通路定位为一个真正的免疫调节通路。蛋白质组学分析显示，在PRKCD和IKBKG敲除细胞中氧化磷酸化通路选择性下调，提示线粒体功能受损，电子显微镜分析证实了这一点。最后，磷酸化蛋白质组学分析揭示，所有干扰巨噬细胞介导肿瘤细胞清除的命中基因均削弱了肿瘤细胞中的铁死亡信号，并使用AR抑制剂恩杂鲁胺新辅助II期临床试验的样本在转录水平上得到证实。这些数据揭示，逃避巨噬细胞的免疫保护是前列腺癌患者激素治疗的不良后果。"}, {"pmid": "42493341", "title": "What Comes After Matters: The Importance of Postprogression Care in Patients with Metastatic Hormone-sensitive Prostate Cancer.", "abstract": "Upfront combination therapy in mHSPC improves outcomes; however, without guaranteed postprogression therapy in control arms, survival benefits may partly reflect undertreatment in the control groups rather than true superiority. Trial designs incorporating planned treatment sequencing are needed to support rational deescalation strategies.", "journal": "European Urology", "pub_date": "2026-Oct", "publication_types": ["Comment", "Editorial"], "doi": "10.1016/j.eururo.2026.07.001", "authors": ["Ashkan Mortezavi", "Tom van der Hulle", "Roderick van den Bergh"], "affiliations": ["Department of Urology, University Hospital Zurich, University of Zurich, Zurich, Switzerland. Electronic address: Ashkan.Mortezavi@usz.ch.", "Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands.", "Department of Urology, Erasmus University Medical Center, Rotterdam, The Netherlands."], "corresponding_authors": ["Ashkan Mortezavi"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=4", "score": 43.29, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 16.79, "top_journal_bonus": 10.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 0.5, "basic_research_strength": 0.0, "clinical_evidence": 4.0}, "journal_metrics": {"status": "ok", "impact_factor": 25.2, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.79, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "后线治疗缺失或夸大一线联合获益", "chinese_summary": "欧洲泌尿外科学会评论指出，转移性激素敏感性前列腺癌一线联合治疗虽改善结局，但若对照组未保障进展后治疗，生存获益可能部分源于对照组治疗不足。采用预设治疗序列的试验设计，才能为合理降阶梯策略提供依据。", "abstract_zh": "转移性激素敏感性前列腺癌的初始联合治疗可改善结局；然而，若对照组未保证接受进展后治疗，生存获益可能部分反映对照组治疗不足，而非真正优效。需要纳入预设治疗序列的试验设计，以支持合理的降阶梯策略。"}, {"pmid": "42486757", "title": "Retraction notice to \"the role of MMP-7 protein structure and PTH gene polymorphism in the clinical treatment of urinary tract stones: The influence of protein expression and serum calcium molecule concentration\" [Int. J. Biol. Macromol. 305 (2025) 141262].", "abstract": "", "journal": "International Journal of Biological Macromolecules", "pub_date": "2026-Oct", "publication_types": ["Journal Article", "Retraction Notice"], "doi": "10.1016/j.ijbiomac.2026.153564", "authors": ["Shasha Gai", "Houjie Fu", "Dongdong Meng", "Tianzi Qin", "Wei Zhou", "Wentong Ya", "Qun Huang"], "affiliations": ["Youjiang Medical University For Nationalities, Baise, 533000, China; Key Laboratory of Research and Development on Clinical Molecular Diagnosis for High-Incidence Diseases of Baise, Baise, 533000, China.", "Department of Urology, the Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, 533000, China; Key Laboratory of Research and Development on Clinical Molecular Diagnosis for High-Incidence Diseases of Baise, Baise, 533000, China."], "corresponding_authors": [], "china_team": "Youjiang Medical University For Nationalities, Baise, 533000, China; Key Laboratory of Research and Development on Clinical Molecular Diagnosis for High-Incidence Diseases of Baise, Baise, 533000, China Qun Huang团队", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 22.3, "score_parts": {"urology_relevance": 3, "urology_in_title": 8.0, "journal_priority": 11.3, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 3.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 8.5, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 3.3, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42486192", "title": "Cadherin-11 mediates kidney injury through altered renal fibroblast mechanobiology.", "abstract": "Cadherin-11 (CDH11) is a mechanosensitive protein capable of creating cell-cell and cell-substrate junctions governing responses to environmental stimuli. It is known to perpetuate fibroblast activation and an inflammatory environment, so we hypothesized that CDH11 is a viable target to suppress kidney injury. Three models were used to test the efficacy of Cdh11 ablation and the CDH11 blocking antibody SYN0012 on kidney injury outcomes: unilateral ureteral obstruction, aristolochic acid nephropathy, and uninephrectomy with angiotensin II infusion. Kidney fibroblasts were isolated to test CDH11-mediated response to environmental cues. Cytokine arrays were used to quantify secretory changes, and atomic force microscopy was used to measure tissue stiffness. CDH11 increased after injury and was localized to the interstitium. Cdh11-/- mice had reduced fibrosis and decreased circulating levels of inflammatory, fibrotic, and kidney injury markers after unilateral ureteric obstruction. Cdh11-/- mice had improved survival and kidney function (plasma BUN) in the aristolochic acid nephropathy model, while in the uninephrectomy model with angiotensin II infusion, Cdh11-/- mice had improved function and muted cardiorenal injury markers. Contractility and sensitivity to strain in Cdh11-/- kidney fibroblasts were decreased, and these effects are further supported by limited tissue stiffening of the fibrogenic niche after unilateral ureteric obstruction. SYN0012 recapitulated the major findings in all three injury models. Targeting CDH11 attenuates kidney injury in multiple models to improve kidney function, decrease fibrosis and inflammation, and protect from downstream cardiac remodeling. This establishes CDH11 as a major player in renal fibroblast mechanobiology, limiting tissue stiffening and therefore propagation of injury. Hence, CDH11 targeting may be a novel strategy to limit expansion of chronic kidney disease.", "journal": "Kidney International", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1016/j.kint.2026.06.027", "authors": ["Tessa M Huffstater", "J Caleb Snider", "Natalie A Noll", "David W J Armstrong", "Matthew R Bersi", "Agnes B Fogo", "Leslie S Gewin", "Roy Zent", "W David Merryman"], "affiliations": ["Department of Biomedical Engineering, Vanderbilt University, Nashville, Tennessee, USA.", "Division of Cardiology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.", "Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA; Division of Nephrology and Hypertension, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.", "Division of Nephrology and Hypertension, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA; Department of Medicine, Veterans Affairs St. Louis Health Care System, St. Louis, Missouri, USA; Division of Nephrology, Department of Medicine, Washington University in St. Louis, St. Louis, Missouri, USA.", "Division of Nephrology and Hypertension, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA; Department of Medicine, Veterans Affairs Tennessee Valley Healthcare System, Nashville, Tennessee, USA; Department of Cell and Developmental Biology, Vanderbilt University, Nashville, Tennessee, USA.", "Department of Biomedical Engineering, Vanderbilt University, Nashville, Tennessee, USA. Electronic address: david.merryman@vanderbilt.edu."], "corresponding_authors": ["W David Merryman"], "china_team": "", "category": "basic", "classification_reason": "basic_signals=4", "score": 30.83, "score_parts": {"urology_relevance": 8, "urology_in_title": 0.0, "journal_priority": 15.83, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 4.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 12.6, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.83, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "靶向CDH11减轻肾损伤与纤维化", "chinese_summary": "10月Kidney International发表研究，采用单侧输尿管梗阻、马兜铃酸肾病及单肾切除联合血管紧张素II输注三种模型，发现CDH11在损伤后于肾间质升高；敲除Cdh11或使用阻断抗体SYN0012可改善肾功能、减少纤维化与炎症，并减轻心脏重构，提示CDH11是肾成纤维细胞力学感知的关键分子。", "abstract_zh": "Cadherin-11（CDH11）是一种机械敏感蛋白，能够形成细胞-细胞和细胞-基质连接，从而调控对环境刺激的应答。已知其可维持成纤维细胞活化及炎症环境，因此我们假设CDH11是抑制肾损伤的可行靶点。研究采用三种模型测试Cdh11缺失及CDH11阻断抗体SYN0012对肾损伤结局的疗效：单侧输尿管梗阻、马兜铃酸肾病以及单肾切除联合血管紧张素II输注。分离肾成纤维细胞以检测CDH11介导的对环境线索的应答。使用细胞因子阵列量化分泌变化，并使用原子力显微镜测量组织硬度。损伤后CDH11升高并定位于肾间质。在单侧输尿管梗阻后，Cdh11-/-小鼠纤维化减少，循环中炎症、纤维化及肾损伤标志物水平降低。在马兜铃酸肾病模型中，Cdh11-/-小鼠生存率和肾功能（血浆BUN）改善；而在单肾切除联合血管紧张素II输注模型中，Cdh11-/-小鼠功能改善且心肾损伤标志物减弱。Cdh11-/-肾成纤维细胞的收缩性和对牵张的敏感性降低，单侧输尿管梗阻后纤维化微环境组织硬化受限进一步支持这些效应。SYN0012在三种损伤模型中重现了主要发现。靶向CDH11可在多种模型中减轻肾损伤，改善肾功能，减少纤维化和炎症，并防止下游心脏重构。这确立CDH11是肾成纤维细胞机械生物学的主要参与者，限制组织硬化从而限制损伤传播。因此，靶向CDH11可能是限制慢性肾脏病进展的新策略。"}, {"pmid": "42481326", "title": "Retraction notice to \"Proteome-driven transcriptomic dissection of EMT networks in bladder cancer based on the VIM and CDH2 protein macromolecules influence: From molecular-protein subtyping to therapeutic target prioritization\" [Int. J. Biol. Macromol. 315 (2025) 144585].", "abstract": "", "journal": "International Journal of Biological Macromolecules", "pub_date": "2026-Oct", "publication_types": ["Published Erratum", "Retraction Notice"], "doi": "10.1016/j.ijbiomac.2026.153573", "authors": ["Junkai Qin", "Kecheng Liao", "Lu Huang", "Rong Qiu", "Ning Tang", "Jun Wu"], "affiliations": ["Department of Urology, Minzu Hospital of Guangxi Zhuang Autonomous Region, Nanning, 530001, China.", "Department of Urology, Baidong Hospital, Affiliated Hospital of Youjiang Medical University for Nationalities and Key Laboratory of Molecular Pathology in Tumors of Baise, Baise, 533000,China.", "Hepatobiliary Surgery Division, Zhanjiang Central Hospital, Guangdong Medical University, Zhanjiang, 524045, China."], "corresponding_authors": [], "china_team": "Department of Urology, Minzu Hospital of Guangxi Zhuang Autonomous Region, Nanning, 530001, China Jun Wu团队", "category": "basic", "classification_reason": "basic_signals=5", "score": 25.3, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 11.3, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 5.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 8.5, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 3.3, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "膀胱癌蛋白组学论文因学术不端被撤稿", "chinese_summary": "广西壮族自治区民族医院吴俊团队2026年10月Int J Biol Macromol发布撤稿声明，撤销其基于VIM与CDH2蛋白大分子、以蛋白质组驱动转录组解析膀胱癌EMT网络的论文。撤稿意味着该文提出的分子-蛋白亚型及治疗靶点优先排序结论不再被认可，相关领域引用需谨慎甄别。", "abstract_zh": "撤稿声明：应期刊要求，撤销发表于《International Journal of Biological Macromolecules》第315卷（2025年）第144585页的论文“Proteome-driven transcriptomic dissection of EMT networks in bladder cancer based on the VIM and CDH2 protein macromolecules influence: From molecular-protein subtyping to therapeutic target prioritization”。"}, {"pmid": "42479349", "title": "Orforglipron: First Approval.", "abstract": "Orforglipron (Foundayo™) is an orally administered, non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist being developed by Eli Lilly and Co. for use in long-term weight management and for the treatment of type 2 diabetes (T2D) among other indications. In April 2026, orforglipron received its first approval, in the USA, for use in combination with a reduced-calorie diet and increased physical activity for long-term weight management in adults with obesity or adults with overweight in the presence of one or more weight-related comorbid condition. Orforglipron has also been submitted for regulatory review in the EU for long-term weight management and T2D, in Japan for long-term weight management, and in Canada for T2D. In addition to long-term weight management and T2D treatment, orforglipron is currently under phase III clinical evaluation for use in the treatment of obstructive sleep apnoea, hypertension, stress urinary incontinence in females, osteoarthritis pain and peripheral arterial disease. This article summarises the milestones in the development of orforglipron leading to this first approval for long-term weight management in adults with obesity or overweight.", "journal": "Drugs", "pub_date": "2026-Oct", "publication_types": ["Journal Article", "Review"], "doi": "10.1007/s40265-026-02363-5", "authors": ["Matt Shirley"], "affiliations": ["Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com."], "corresponding_authors": ["Matt Shirley"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 27.01, "score_parts": {"urology_relevance": 7, "urology_in_title": 0.0, "journal_priority": 16.01, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 1.0}, "journal_metrics": {"status": "ok", "impact_factor": 14.4, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.01, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42477998", "title": "Factors predicting operative exposure among UK urology trainees: a national analysis from 2010 to 2024.", "abstract": "To characterise national trends in operative experience among Urology Higher Specialty Trainees (HSTs) in the UK over time, and to identify demographic, training, and institutional factors associated with operative volume. This national, retrospective study analysed Intercollegiate Surgical Curriculum Programme (ISCP) and electronic surgical logbook (eLogbook) data for all UK Urology HSTs between 2010 and 2024. Baseline variables included gender, age at Specialty Training (ST)3 start, ethnicity, training grade, and hospital type, i.e., district general hospital (DGH) vs tertiary centre (TC). Procedures were categorised, using the 2021 ISCP Urology curriculum, into index and special interest procedures. Analyses were made between the above factors and number of cases logged on eLogbook. A total of 1140 trainees were included. Gender and age at ST3 start did not significantly affect total operative volume. A global difference in operative volume across ethnic groups was observed (chi-square = 11.85, P = 0.019); however, no pairwise differences remained significant after adjustment. Operative volume declined over 15 years, with trainees performing 10.8 fewer operations each year than the year before (β₁ = -10.8 procedures/trainee/year, t = -9.31, P < 0.001), with the lowest recorded volume in 2020. The total number of procedures logged decreased with increasing ST level (Rs = -0.284; P < 0.001). However, higher ST level trainees logged more fascial sling, percutaneous nephrolithotomy, nephrectomy, radical prostatectomy, radical cystectomy, ileal conduit formation, and penile straightening procedures. Trainees in DGHs logged more procedures overall (U = 2 × 10-47, P < 0.001), although trainees in TCs logged more special interest procedures (U = 1.6 × 10-24, P < 0.001). Operative experience among HSTs in the UK has declined over the past 15 years with significant variation in case mix by training grade and hospital type. These findings highlight the need for effective rotation planning and targeted strategies are required to ensure adequate operative exposure to produce safe and competent consultants who can provide the best possible patient care.", "journal": "BJU International", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1111/bju.70389", "authors": ["Justina Cheh Juan Tai", "Kelly Ong", "Stuart Graham", "Justine Royle", "Tony Tien"], "affiliations": ["Royal London Hospital, Barts Health NHS Trust, London, UK.", "Whipps Cross University Hospital, Barts Health NHS Trust, London, UK.", "Aberdeen Royal Infirmary, NHS Grampian, Aberdeen, UK."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 39.47, "score_parts": {"urology_relevance": 18.0, "urology_in_title": 8.0, "journal_priority": 10.47, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 1.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.4, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.47, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "英国泌尿外科受训者手术量15年持续下降", "chinese_summary": "BJU Int 10月发布英国全国回顾性分析，纳入2010至2024年1140名泌尿外科高年资专科受训者，结果显示年手术量逐年下降，每人每年减少10.8例，2020年最低；地区综合医院总量更多，三级中心专项手术更多，提示需优化轮转安排以保障手术暴露。", "abstract_zh": "旨在描述英国泌尿外科高年资专科受训者（HSTs）手术经验随时间的全国趋势，并识别与手术量相关的人口学、培训及机构因素。这项全国性回顾性研究分析了2010年至2024年间所有英国泌尿外科HSTs的校际外科课程计划（ISCP）和电子手术日志（eLogbook）数据。基线变量包括性别、专科培训（ST）3阶段开始时的年龄、族裔、培训年级和医院类型，即地区综合医院（DGH）与三级中心（TC）。使用2021年ISCP泌尿外科课程将手术分为索引手术和特殊兴趣手术。分析上述因素与eLogbook记录病例数之间的关系。共纳入1140名受训者。性别和ST3开始时年龄对总手术量无显著影响。观察到不同族裔群体间手术量存在总体差异（卡方=11.85，P=0.019）；然而，校正后未保留任何成对差异的显著性。手术量在15年间下降，受训者每年比前一年少做10.8例手术（β₁=-10.8例/受训者/年，t=-9.31，P<0.001），2020年记录量最低。记录的手术总数随ST级别升高而减少（Rs=-0.284；P<0.001）。然而，较高级别ST受训者记录了更多的筋膜吊带、经皮肾镜取石术、肾切除术、根治性前列腺切除术、根治性膀胱切除术、回肠通道形成术和阴茎矫直手术。DGH受训者总体上记录了更多手术（U=2×10-47，P<0.001），尽管TC受训者记录了更多特殊兴趣手术（U=1.6×10-24，P<0.001）。过去15年英国HSTs的手术经验有所下降，且病例组合因培训年级和医院类型而存在显著差异。这些发现凸显了有效轮转规划的必要性，并需要有针对性的策略以确保充分的手术暴露，从而培养出能够提供最佳患者护理的安全且称职的顾问医生。"}, {"pmid": "42476886", "title": "Patient-reported Outcomes After Prostate Stereotactic Body Radiotherapy at 5 yr: Results from the PACE-B Trial.", "abstract": "Patient-reported outcome measures (PROMs) complement oncological endpoints by capturing what matters most to patients. The TrueNTH surgical collaboration presented 1-yr PROMs following robotic prostatectomy using accessible visual formats. We present 5-yr PROMs from the phase 3, international PACE-B trial, which randomised men with localised prostate cancer to stereotactic body radiotherapy (SBRT) or conventionally fractionated radiotherapy (CRT). PROMs are reported from baseline to 5 yr and presented using waffle charts to enable visual alignment with surgical outcomes. At 5 yr, urinary incontinence outcomes were favourable and comparable between SBRT and CRT. Leak-free rates were 64% (164/258) for SBRT and 69% (172/249) for CRT, pad-free rates were 91% (233/257) for SBRT and 90% (225/250) for CRT, and moderate or big urinary leakage problems were reported by only 6% (15/250) for SBRT and 4% (9/244) for CRT. Intercourse-adequate erections declined in both groups from baseline to 5 yr: from 35% (133/374) to 17% (43/250) for SBRT, and from 40% (157/391) to 20% (47/240) for CRT. Moderate or big sexual problems increased in both groups, from 24% (87/367) to 31% (74/242) for SBRT and from 22% (85/382) to 32% (77/238) for CRT. Bowel effects were low and comparable between groups, with moderate or big bowel problems reported by 2% (7/397) at baseline and 5% (12/265) for SBRT at 5 yr, and 2% (9/415) at baseline and 5% (13/253) for CRT at 5 yr. Stool incontinence as a moderate or big problem rose from <1% (1/374) to 2% (4/240) in the SBRT group and from <1% (1/395) to 3% (7/238) in the CRT group.", "journal": "European Urology", "pub_date": "2026-Oct", "publication_types": ["Journal Article", "Randomized Controlled Trial", "Clinical Trial, Phase III", "Multicenter Study"], "doi": "10.1016/j.eururo.2026.05.034", "authors": ["Sian Cooper", "Jaymini Patel", "Caroline Moore", "Peter Ostler", "Hans van der Voet", "Andrew Loblaw", "William Chu", "Daniel Ford", "Shaun Tolan", "Suneil Jain", "Philip Camilleri", "Kiran Kancherla", "John Frew", "Andrew Chan", "Olivia Naismith", "John Armstrong", "John Staffurth", "Alexander Martin", "Ian Dayes", "Paula Wells", "Derek Price", "Julia Pugh", "Georgina Manning", "Stephanie Brown", "Stephanie Burnett", "Nicholas van As", "Emma Hall", "Alison C Tree"], "affiliations": ["The Royal Marsden Hospital, London, UK; The Institute of Cancer Research, London, UK. Electronic address: siancooper1@nhs.net.", "The Institute of Cancer Research, London, UK.", "University College London (UCL), Division of Surgery and Interventional Science, London, UK; University College London Hospital, London, UK.", "Mount Vernon Cancer Centre, Northwood, UK.", "The James Cook University Hospital, Middlesbrough, UK.", "Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.", "Durham Regional Cancer Centre, Lakeridge Health, Oshawa, ON, Canada.", "University Hospitals Birmingham, Birmingham, UK.", "The Clatterbridge Cancer Centre, Birkenhead, UK.", "Queen's University Belfast, Belfast, UK.", "Churchill Hospital, Oxford, UK.", "University Hospitals of Leicester, Leicester, UK.", "Freeman Hospital, Newcastle, UK.", "University Hospitals Coventry and Warwickshire, Coventry, UK.", "The Royal Marsden Hospital, London, UK.", "Cancer Trials Ireland and St. Luke's Radiation Oncology Network, St. Luke's Hospital, Dublin, Ireland.", "Velindre Cancer Centre, Cardiff, UK.", "Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.", "Department of Oncology, McMaster University, Hamilton, ON, Canada.", "St. Bartholomew's Hospital, London, UK.", "Patient and Public Representative, London, UK.", "The Royal Marsden Hospital, London, UK; The Institute of Cancer Research, London, UK."], "corresponding_authors": ["Sian Cooper"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_interventional_trial", "score": 59.79, "score_parts": {"urology_relevance": 11, "urology_in_title": 8.0, "journal_priority": 16.79, "top_journal_bonus": 10.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 12.0}, "journal_metrics": {"status": "ok", "impact_factor": 25.2, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.79, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "前列腺SBRT五年泌尿功能与常规放疗相当", "chinese_summary": "伦敦大学学院团队10月Eur Urol报告PACE-B三期试验5年患者报告结局：局限期前列腺癌接受立体定向体部放疗或常规分割放疗，无漏尿率分别为64%与69%，无尿垫率91%与90%；两组勃起功能均下降，但肠道及性功能症状总体相近。", "abstract_zh": "患者报告结局指标（PROMs）通过捕捉对患者最重要的内容，补充了肿瘤学终点。TrueNTH外科协作组以易读的可视化形式呈现了机器人前列腺切除术后的1年PROMs。我们呈现III期国际PACE-B试验的5年PROMs，该试验将局限性前列腺癌男性随机分配至立体定向体部放疗（SBRT）或常规分割放疗（CRT）。PROMs报告从基线至5年的结果，并以华夫图呈现，以便与手术结局进行视觉比对。在5年时，尿失禁结局良好，且SBRT与CRT之间相当。SBRT的无漏尿率为64%（164/258），CRT为69%（172/249）；SBRT的无尿垫率为91%（233/257），CRT为90%（225/250）；报告中度或重度尿漏问题的比例，SBRT仅为6%（15/250），CRT为4%（9/244）。从基线至5年，两组可完成性交的勃起功能均下降：SBRT从35%（133/374）降至17%（43/250），CRT从40%（157/391）降至20%（47/240）。两组中度或重度性问题均增加，SBRT从24%（87/367）增至31%（74/242），CRT从22%（85/382）增至32%（77/238）。两组肠道影响均较低且相当，中度或重度肠道问题在基线时报告为2%（7/397），5年时SBRT为5%（12/265），CRT基线时为2%（9/415），5年时为5%（13/253）。作为中度或重度问题的大便失禁，SBRT组从<1%（1/374）升至2%（4/240），CRT组从<1%（1/395）升至3%（7/238）。"}, {"pmid": "42471936", "title": "A multidisciplinary FEVAR and stent graft repair to exclude mycotic aneurysms by interventional radiology and vascular surgery: Case report.", "abstract": "Mycotic pseudoaneurysms are rare arterial wall disruptions caused by infectious or inflammatory destruction of the vessel wall. They account for a small percentage, about 0.7%, of all aortic aneurysms. Bacillus Calmette-Guérin (BCG) therapy for nonmuscle invasive bladder cancer has been associated with rare vascular complications, including infectious aortitis and pseudoaneurysm formation. We present a 69-year-old male with a history of intravesical BCG therapy who presented with severe bilateral flank and abdominal pain and was found to have multifocal pararenal aortic and left common iliac pseudoaneurysms with extensive necrotic para-aortic and iliac lymphadenopathy. Given concern for an underlying infection and poor candidacy for open surgery, a multidisciplinary team consisting of vascular surgery and interventional radiology performed complex in situ laser fenestrated endovascular aneurysm repair with preservation of the superior mesenteric and bilateral renal arteries. The procedure successfully excluded the pseudoaneurysms. Although microbiologic confirmation of BCG infection was not obtained, the temporal relationship to prior intravesical BCG therapy and imaging findings raised suspicion for a BCG-associated infectious source. This case highlights the technical feasibility of multidisciplinary endovascular management of complex paravisceral pseudoaneurysms and emphasizes the importance of maintaining a broad differential diagnosis in patients presenting with vascular abnormalities following BCG therapy.", "journal": "Radiology Case Reports", "pub_date": "2026-Oct", "publication_types": ["Case Reports", "Journal Article"], "doi": "10.1016/j.ejvs.2019.05.004", "authors": ["Nitya Kumar", "Shawn Sarin"], "affiliations": ["Department of Interventional Radiology, George Washington University Hospital, Washington, DC, United States of America."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_clinical", "score": 9.0, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 0.0, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 3.0}, "journal_metrics": {"status": "missing", "impact_factor": null, "cas_zone": null, "cas_zone_points": 0.0, "impact_factor_points": 0.0}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42471484", "title": "Overall survival according to timing of immune checkpoint inhibitors administration in patients with advanced cancer: results from a large single-centre cohort analysis.", "abstract": "Immune checkpoint inhibitors (ICIs) have revolutionised cancer treatment. Previous studies suggested that early time-of-day administration is associated with better outcomes. We performed a retrospective study in patients treated at a large tertiary cancer centre. Patients receiving ICIs between January 2018 and December 2023 were grouped according to whether they had ≥50% (\"late group\") or <50% (\"early group\") of cycles after the median time of all treatments. The endpoint was overall survival (OS). Hazard ratios (HRs) were estimated using Cox models with and without time-dependent variables. 2631 patients with advanced/metastatic lung cancer (45%), melanoma (23%), renal carcinoma (18%), head and neck (9%), and urothelial cancer (5%) were included. Median age was 68.2 years and median infusion time was 12:49 h. At a median follow-up of 32 months, median OS was 13.1 (95% CI 11.8-14.4) vs 21.4 (19.8-24.5) months for late and early group. Late group was associated with shorter OS on both the standard analysis (HR 1.48, 1.33-1.63) and the time-dependent model (HR 1.30, 1.16-1.44). This study provides further evidence in favour of early ICIs administration with a large sample size and a time-dependent model, which reduces the risk of immortal time bias. Data from randomised trials are required to confirm these findings.", "journal": "British Journal of Cancer", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1200/JCO.2009.26.7609", "authors": ["Tommaso Bosetti", "Oliver John Kennedy", "Raffaele Califano", "Tom Waddell", "Rob Metcalf", "Sophia Kreft", "Rebecca Lee", "Paul Lorigan"], "affiliations": ["The Christie NHS Foundation Trust, Manchester, UK.", "University of Pavia, Pavia, Italy.", "University of Manchester, Manchester, UK.", "The Christie NHS Foundation Trust, Manchester, UK. paul.lorigan@nhs.net.", "University of Manchester, Manchester, UK. paul.lorigan@nhs.net."], "corresponding_authors": ["Paul Lorigan"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=9", "score": 26.01, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 11.01, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 9.0}, "journal_metrics": {"status": "ok", "impact_factor": 6.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 3.01, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42469055", "title": "Emerging antibody-drug conjugates in metastatic castration-resistant prostate cancer.", "abstract": "Despite recent advances in therapies, metastatic castration-resistant prostate cancer (mCRPC) remains incurable with poor prognosis in which novel, more effective treatments are urgently needed. Antibody-drug conjugates (ADCs) are a novel class of agents comprised of a monoclonal antibody directed against a cell surface target of interest that delivers a cytotoxic payload through a cleavable linker. While they have achieved tremendous success in other genitourinary cancers such as urothelial cancer, ADCs have promising activity in mCRPC. In this review, we will provide a high-level overview of ADCs and associated cell surface targets being investigated in mCRPC.", "journal": "Urologic Oncology", "pub_date": "2026-Oct", "publication_types": ["Journal Article", "Review"], "doi": "10.1016/j.urolonc.2026.06.022", "authors": ["Charles B Nguyen", "Zachery R Reichert"], "affiliations": ["Department of Medical Oncology & Therapeutics Research, City of Hope Orange County, Irvine, CA. Electronic address: charnguyen@coh.org.", "Department of Internal Medicine, Division of Hematology/Oncology, Rogel Cancer Center, University of Michigan, Ann Arbor, MI."], "corresponding_authors": ["Charles B Nguyen"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 28.75, "score_parts": {"urology_relevance": 11, "urology_in_title": 8.0, "journal_priority": 5.75, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 1.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.3, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.75, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42469054", "title": "Reply to Antonio Cigliola, Andrea Necchi, and Umberto Capitanio's Letter to the Editor Re: Metastasis-directed Therapy with or Without Pembrolizumab for Oligometastatic Clear Cell Renal Cell Carcinoma: Pooled Analysis of Two Prospective Single-arm Phase 2 Trials. Eur Urol 2026;90:13-18.", "abstract": "", "journal": "European Urology", "pub_date": "2026-Oct", "publication_types": ["Letter"], "doi": "10.1016/j.eururo.2026.06.024", "authors": ["Alexander D Sherry", "Van To", "Pavlos Msaouel", "Paul Neeson", "Chad Tang", "Shankar Siva"], "affiliations": ["Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Radiation Oncology, Mayo Clinic, Rochester, MN, USA.", "Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.", "Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.", "Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Genitourinary Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: ctang1@mdanderson.org.", "Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia; Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia."], "corresponding_authors": ["Chad Tang"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 35.79, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 16.79, "top_journal_bonus": 10.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 25.2, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.79, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "寡转移肾癌靶向放疗联合帕博利珠单抗引讨论", "chinese_summary": "针对寡转移性透明细胞肾癌，两项前瞻性单臂2期试验的汇总分析此前发表于Eur Urol并引发同行评议。作者在回复中重申，转移灶定向治疗联合帕博利珠单抗的数据需谨慎解读，单臂设计尚不足以支持其作为标准方案推广。", "abstract_zh": "回复Antonio Cigliola、Andrea Necchi和Umberto Capitanio的读者来信，关于《转移灶定向治疗联合或不联合帕博利珠单抗治疗寡转移性透明细胞肾细胞癌：两项前瞻性单臂2期试验的汇总分析》。Eur Urol 2026;90:13-18。"}, {"pmid": "42464684", "title": "Intrarenal thermal and pressure dynamics during ureteroscopy: an in vitro study.", "abstract": "To evaluate in vitro determinants of intrarenal temperature (IRT) and pressure (IRP) during laser lithotripsy. A silicone urinary tract model was used to perform laser lithotripsy on artificial stones placed in the renal pelvis. Three laser sources (thulium fibre laser, holmium:yttrium-aluminium-garnet [Ho:YAG] with Magneto Technology, and pulsed thulium:YAG) with 200-μm fibres were tested at four energy settings (0.6 J-10 Hz, 1 J-10 Hz, 0.2 J-50 Hz, and 1 J-40 Hz), delivering 2000 J per experiment. Irrigation was provided by gravity (40 cmH2O) or hand-pump irrigation, combined with a standard ureteral access sheath (sUAS) or flexible and navigable suction sheath (FANS). Multivariable regression identified predictors of mean IRT and IRP. Baseline temperatures were comparable among groups (27.2-32.2 °C, P > 0.05). Hand-pump irrigation reduced mean IRT compared to gravity (-9.1 °C, P = 0.001). Laser power showed a dose-response effect (10 W: +2.5 °C, P = 0.003; 40 W: +8.2 °C, P = 0.001 vs 6 W). At equivalent power and irrigation settings, laser source did not influence IRT under the experimental conditions evaluated. The thermal-risk threshold (>43 °C) was reached in 16.7% of experiments, increased with power (2.8%, 15.3%, and 41.7% at 6, 10, and 40 W; P = 0.001) and decreased with hand-pump irrigation and FANS (P < 0.05). Hand-pump irrigation increased IRP by 21 cmH2O compared to gravity, while FANS reduced IRP by 12 cmH2O vs sUAS (P = 0.001). Mean IRT was associated with laser power and irrigation strategy. High-power settings (40 W) frequently exceeded the thermal-risk threshold. Although FANS was not associated with lower mean IRT, it reduced the likelihood of exceeding the thermal-risk threshold. Laser source had no effect on mean IRT when power and irrigation conditions were comparable. Mean IRP was influenced by irrigation strategy and UAS configuration but was not associated with mean IRT. These findings underscore the need for advanced integrated irrigation-aspiration systems capable of dynamic control of flow, pressure, and temperature to optimise procedural safety.", "journal": "BJU International", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1111/bju.70384", "authors": ["Alejandra Bravo-Balado", "Letizia Maria Ippolita Jannello", "Federico Zorzi", "Alberto Quarà", "Stefano Moretto", "Mariela Corrales", "Esteban Emiliani", "Steeve Doizi", "Frédéric Coste", "Olivier Traxer", "Frédéric Panthier"], "affiliations": ["Endolase Lab, GRC20-Sorbonne University and PIMM-Arts et Métiers Paris Tech, Paris, France.", "Department of Surgery and Morphological Sciences, Universitat Autònoma de Barcelona, Barcelona, Spain.", "Stone Unit, Department of Urology, Fundació Puigvert, Barcelona, Spain.", "Service d'Urologie, Assistance-Publique Hôpitaux de Paris, Hôpital Tenon, Sorbonne Université, Paris, France.", "Progress and Collaboration in Endourology Group (PACE), Paris, France.", "Unit of Urology, Department of Health Science, University of Milan, ASST Santi Paolo and Carlo, Milan, Italy.", "Department of Urology, University of Trieste, Trieste, Italy.", "Division of Urology, Department of Oncology, San Luigi Gonzaga Hospital, University of Turin, Orbassano, Italy.", "Department of Urology, Humanitas Clinical and Research Institute IRCCS, Milan, Italy.", "Service d'Urologie, CHU Gabriel-Montpied, Clermont-Ferrand, France.", "Department of Urology, NYU Langone Health, New York, NY, USA.", "GRC n°20, Groupe de Recherche Clinique sur la Lithiase Urinaire, Hôpital Tenon, Sorbonne Université, Paris, France."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 30.47, "score_parts": {"urology_relevance": 7, "urology_in_title": 8.0, "journal_priority": 10.47, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 3.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.4, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.47, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "高功率激光碎石需警惕肾内热损伤", "chinese_summary": "BJU Int发表体外输尿管软镜模型研究，评估钬激光、铥光纤激光及脉冲铥激光在四种能量设置下肾内温度与压力变化。结果显示灌注方式与激光功率显著影响肾内温度，手泵灌注可降温9.1°C，40W高功率使热风险阈值超标率达41.7%，可弯曲负压吸引鞘可降低压力并减少超温风险。", "abstract_zh": "评估激光碎石术中肾内温度（IRT）和压力（IRP）的体外决定因素。使用硅胶尿路模型，对置于肾盂内的人造结石进行激光碎石。测试三种激光源（铥光纤激光、带磁力技术的钬：钇铝石榴石[Ho:YAG]激光及脉冲铥：YAG激光），均使用200 μm光纤，在四种能量设置下（0.6 J-10 Hz、1 J-10 Hz、0.2 J-50 Hz和1 J-40 Hz）进行，每次实验输送2000 J能量。灌注通过重力（40 cmH2O）或手动泵灌注提供，并结合标准输尿管通道鞘（sUAS）或可弯曲可导航吸引鞘（FANS）。多变量回归确定了平均IRT和IRP的预测因素。各组基线温度相当（27.2-32.2°C，P > 0.05）。与重力灌注相比，手动泵灌注降低了平均IRT（-9.1°C，P = 0.001）。激光功率显示出剂量-反应效应（与6 W相比，10 W：+2.5°C，P = 0.003；40 W：+8.2°C，P = 0.001）。在等效功率和灌注设置下，所评估的实验条件中激光源不影响IRT。热风险阈值（>43°C）在16.7%的实验中达到，随功率增加而升高（6、10和40 W时分别为2.8%、15.3%和41.7%；P = 0.001），并随手动泵灌注和FANS而降低（P < 0.05）。与重力灌注相比，手动泵灌注使IRP增加21 cmH2O，而FANS与sUAS相比使IRP降低12 cmH2O（P = 0.001）。平均IRT与激光功率和灌注策略相关。高功率设置（40 W）经常超过热风险阈值。尽管FANS与较低的平均IRT无关，但它降低了超过热风险阈值的可能性。当功率和灌注条件相当时，激光源对平均IRT无影响。平均IRP受灌注策略和UAS配置影响，但与平均IRT无关。这些发现强调需要能够动态控制流量、压力和温度的先进集成灌注-吸引系统，以优化手术安全性。"}, {"pmid": "42462145", "title": "Advanced Prostate Cancer: AUA/SUO Guideline Amendment (2026) Part II: Evaluation and Management of Metastatic Castration-Resistant Prostate Cancer.", "abstract": "Following completion of the 2025 Update Literature Review (ULR), the American Urological Association (AUA) incorporated new evidence generated since the 2023 publication of this Guideline via the AUA Amendment process. The summary presented herein represents Part II of the two-part series dedicated to addressing updated recommendations to provide a clinical framework for the evaluation and management of metastatic castration-resistant prostate cancer (mCRPC). The AUA/SUO Advanced Prostate Cancer Guideline was reviewed via the AUA ULR process, which identified 38 studies for full-text review that were published between March 16, 2022, and August 26, 2025. Relevant studies were incorporated into the Guideline evidence base, and Guideline statements were updated as appropriate. The Panel developed evidence- and consensus-based statements based on an updated review to provide guidance on evaluation and management of advanced prostate cancer. These updates are detailed herein. Part II of this Amendment provides new guidance on treatment of mCRPC and discusses future directions for the evaluation and management of advanced prostate cancer overall. Additional guidance regarding non-metastatic castration-resistant prostate cancer (nmCRPC) was deemed current following review. This Guideline will require further review as the diagnostic and treatment options in this space continue to evolve.", "journal": "Journal of Urology", "pub_date": "2026-Oct", "publication_types": ["Journal Article", "Practice Guideline"], "doi": "10.1097/JU.0000000000005219", "authors": ["Kristen R Scarpato", "Michael S Cookson", "Robert Dreicer", "Mutlay Sayan", "Alice Yu", "Erin Kirkby", "Lauren J Pak", "Kristen E D'Anci"], "affiliations": ["Department of Urology, Vanderbilt University Medical Center, Nashville, Tennessee.", "Department of Urology, University of Oklahoma College of Medicine, Oklahoma City, Oklahoma.", "UVA Comprehensive Cancer Center, University of Virginia, Charlottesville, Virginia.", "Mass General Brigham Cancer Institute, Boston, Massachusetts.", "Moffitt Cancer Center, Tampa, Florida.", "American Urological Association, Linthicum, Maryland.", "Independent Researcher, Salem, Massachusetts."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 30.51, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 11.01, "top_journal_bonus": 0.0, "novelty": 0.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 1.0}, "journal_metrics": {"status": "ok", "impact_factor": 6.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 3.01, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42462144", "title": "Advanced Prostate Cancer: AUA/SUO Guideline Amendment (2026) Part I: Evaluation and Treatment of Biochemically Recurrent (Following Exhaustion of Local Therapy) and Metastatic Hormone-Sensitive Prostate Cancer.", "abstract": "Following completion of the 2025 Update Literature Review (ULR), the American Urological Association (AUA) incorporated new evidence generated since the 2023 publication of this Guideline via the AUA Amendment process. The summary presented herein represents Part I of the two-part series dedicated to addressing updated recommendations to provide a clinical framework for the evaluation and management of biochemically recurrent (BCR) and metastatic hormone-sensitive prostate cancer (mHSPC). The AUA/SUO Advanced Prostate Cancer Guideline was reviewed via the AUA ULR process, which identified 38 studies for full-text review that were published between March 16, 2022 and August 26, 2025. Relevant studies were incorporated into the Guideline evidence base, and Guideline statements were updated as appropriate. The Panel developed evidence- and consensus-based statements based on an updated review to provide guidance on evaluation and management of advanced prostate cancer. These updates are detailed herein. Part I of this Amendment provides updated guidance on imaging, germline and somatic testing, and evaluation and treatment of BCR following exhaustion of local therapy and mHSPC. This Guideline will require further review as the diagnostic and treatment options in this space continue to evolve.", "journal": "Journal of Urology", "pub_date": "2026-Oct", "publication_types": ["Journal Article", "Practice Guideline"], "doi": "10.1097/JU.0000000000005220", "authors": ["Kristen R Scarpato", "Michael S Cookson", "Robert Dreicer", "Mutlay Sayan", "Alice Yu", "Kristen E D'Anci", "Lauren J Pak", "Erin Kirkby"], "affiliations": ["Department of Urology, Vanderbilt University Medical Center, Nashville, Tennessee.", "Department of Urology, University of Oklahoma College of Medicine, Oklahoma City, Oklahoma.", "UVA Comprehensive Cancer Center, University of Virginia, Charlottesville, Virginia.", "Mass General Brigham Cancer Institute, Boston, Massachusetts.", "Moffitt Cancer Center, Tampa, Florida.", "Independent Researcher, Salem, Massachusetts.", "American Urological Association, Linthicum, Maryland."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 30.51, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 11.01, "top_journal_bonus": 0.0, "novelty": 0.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 1.0}, "journal_metrics": {"status": "ok", "impact_factor": 6.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 3.01, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42457459", "title": "EAU Guidelines on Nonmuscle-invasive Bladder Cancer (TaT1 and CIS) - A Summary of the 2026 Guidelines Update.", "abstract": "This publication represents a summary of the updated 2026 European Association of Urology (EAU) Guidelines for nonmuscle-invasive bladder cancer (NMIBC), TaT1 and carcinoma in situ (CIS). The information presented herein is limited to urothelial carcinoma, unless specified otherwise. The aim is to provide practical recommendations on the clinical management of NMIBC, with a focus on clinical presentation. For the 2026 guidelines on NMIBC, new and relevant evidence was identified, collated, and appraised via a structured assessment of the literature. Databases searched included MEDLINE, EMBASE, and the Cochrane Library. Recommendations within the guidelines were developed by the panel to prioritise clinically important care decisions. The strength of each recommendation was determined according to a balance between desirable and undesirable consequences of alternative management strategies, the quality of the evidence (including the certainty of estimates), and the nature and variability of patient values and preferences. Key recommendations emphasise the importance of thorough diagnosis, treatment, and follow-up for patients with NMIBC. The guidelines stress the importance of defining patients' risk stratification and treating them appropriately. Key updates in the 2026 NMIBC Guidelines summary include: the addition of two new tables addressing risk factors for bladder cancer and prognostic factors for progression in subtypes; the addition of two new tables summarising the treatment options for Bacillus Calmette-Guérin (BCG)-unresponsive tumours; inclusion of a new section addressing the addition of immune checkpoint inhibitors to BCG in selected high- and very high-risk NMIBC BCG-NAÏVE patients; a new table addressing the role of urinary markers in follow-up; and the addition of a new section on pragmatic de-intensification strategy for NMIBC. This overview of the 2026 EAU guidelines offers valuable insights into risk factors, diagnosis, classification, prognostic factors, treatment, and follow-up of NMIBC. They are designed for effective integration into clinical practice. The EAU has issued updated clinical practice guidelines on NMIBC. The guidelines provide recommendations for diagnosis, treatment, and follow-up, with a particular focus on quality of life for patients.", "journal": "European Urology", "pub_date": "2026-Oct", "publication_types": ["Journal Article", "Practice Guideline"], "doi": "10.1016/j.eururo.2026.04.009", "authors": ["Paolo Gontero", "Paramananthan Mariappan", "Benjamin Pradere", "Bhavan P Rai", "Fredrik Liedberg", "Eva Compérat", "Jeremy Yuen-Chun Teoh", "Marco Moschini", "Francesco Soria", "Bas W G van Rhijn", "Joyce Baard", "Alison Birtle", "Maresa Botha", "Otakar Capoun", "David D'Andrea", "Edoardo Fiorini", "Alexandra Masson-Lecomte", "Thomas Seisen", "Shahrokh F Shariat", "Emma J Smith", "Viktor Soukup", "Robert Wood", "Evanguelos N Xylinas", "José L Dominguez-Escrig"], "affiliations": ["Department of Urology, Città della Salute e della Scienza, University of Torino School of Medicine, Torino, Italy.", "Edinburgh Bladder Cancer Surgery (EBCS), The University of Edinburgh, Western General Hospital, Edinburgh, United Kingdom.", "Department of Urology UROSUD, La Croix du Sud Hospital, Quint-Fonsegrives, France.", "Department of Urology, Freeman Hospital, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.", "Institute of Translational Medicine, Lund University, Malmö, Sweden; Department of Urology, Skåne University Hospital, Malmö, Sweden.", "Department of Pathology, Medical University of Vienna, Vienna, Austria.", "S.H. Ho Urology Centre, Department of Surgery, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong.", "Department of Urology, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy.", "Department of Surgical Oncology (Urology), Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.", "Department of Urology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.", "Rosemere Cancer Centre, Lancashire Teaching Hospitals NHS Foundation Trust, Preston, United Kingdom.", "EAU Guidelines Office, Arnhem, the Netherlands.", "Department of Urology, General Teaching Hospital and 1st Faculty of Medicine, Charles University Praha, Prague, Czech Republic.", "Department of Urology, Comprehensive Cancer Center, Medical University Vienna, Vienna General Hospital, Vienna, Austria.", "Associazione PaLiNUro, Milan, Italy.", "Department of Urology, Université de Paris, APHP, Saint Louis Hospital, Paris, France.", "GRC 5 Predictive Onco-Uro, Sorbonne University, AP-HP, Urology, Pitie-Salpetriere Hospital, Paris, France.", "EAU Guidelines Office, Arnhem, the Netherlands. Electronic address: e.smith@uroweb.org.", "Department of Urology, Bichat-Claude Bernard Hospital, AP-HP, Université de Paris, Paris, France.", "Department of Urology, Fundación Instituto Valenciano de Oncología, Valencia, Spain."], "corresponding_authors": ["Emma J Smith"], "china_team": "S Jeremy Yuen-Chun Teoh团队", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 56.29, "score_parts": {"urology_relevance": 15, "urology_in_title": 8.0, "journal_priority": 16.79, "top_journal_bonus": 10.0, "novelty": 0.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 4.0}, "journal_metrics": {"status": "ok", "impact_factor": 25.2, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.79, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "EAU发布2026非肌层浸润性膀胱癌指南更新", "chinese_summary": "S Jeremy Yuen-Chun Teoh团队10月Eur Urol发布2026 EAU非肌层浸润性膀胱癌指南更新，新增膀胱癌危险因素与进展预后因素表、BCG无应答治疗选择表，纳入BCG初治高危患者联合免疫检查点抑制剂章节，并新增尿液标志物随访及务实降阶梯治疗内容。", "abstract_zh": "本出版物是2026年更新的欧洲泌尿外科学会（EAU）非肌层浸润性膀胱癌（NMIBC）、TaT1及原位癌（CIS）指南的摘要。除非另有说明，本文所呈现的信息仅限于尿路上皮癌。其目的是为NMIBC的临床管理提供实用建议，重点关注临床表现。对于2026年NMIBC指南，通过结构化的文献评估识别、整理并评价了新的相关证据。检索的数据库包括MEDLINE、EMBASE和Cochrane图书馆。指南中的建议由专家组制定，以优先考虑临床上重要的诊疗决策。每条建议的强度根据替代管理策略的理想与非理想后果之间的平衡、证据质量（包括估计值的确定性）以及患者价值观和偏好的性质与变异性来确定。关键建议强调了对NMIBC患者进行彻底诊断、治疗和随访的重要性。指南强调了确定患者风险分层并给予适当治疗的重要性。2026年NMIBC指南摘要的关键更新包括：新增两个表格，分别涉及膀胱癌危险因素和亚型进展的预后因素；新增两个表格，总结卡介苗（BCG）无应答肿瘤的治疗选择；纳入一个新章节，涉及在选定的高危和极高危NMIBC且BCG初治患者中，在BCG基础上加用免疫检查点抑制剂；新增一个表格，涉及尿液标志物在随访中的作用；以及新增一个关于NMIBC务实降阶梯策略的章节。本2026年EAU指南概览为NMIBC的危险因素、诊断、分类、预后因素、治疗和随访提供了有价值的见解。它们旨在有效整合到临床实践中。EAU已发布更新的NMIBC临床实践指南。这些指南为诊断、治疗和随访提供了建议，特别关注患者的生活质量。"}, {"pmid": "42457453", "title": "European Association of Urology Guidelines on Urological Infections: Summary of the 2026 Guidelines.", "abstract": "Urological infections significantly impact individuals' well-being and quality of life due to their widespread occurrence and diverse clinical manifestations. This work aims to provide evidence-based guidance on diagnosing, treating, and preventing urinary tract infections (UTIs) and male accessory gland infections, while addressing crucial public health aspects related to infection control and antimicrobial stewardship. For the 2026 Urological Infections Guidelines, new and relevant evidence was identified, collated, and appraised through a structured assessment of the literature. Databases searched included Medline, EMBASE, and the Cochrane Library. Recommendations within the Guidelines were developed by the panels to prioritise clinically important care decisions. The strength of each recommendation is determined by the balance between desirable and undesirable consequences of alternative management strategies, the quality of the evidence (including certainty of estimates), and the nature and variability of patient values and preferences. Key recommendations emphasise the importance of thorough medical history and physical examination for patients with urological infections. The guidelines stress the role of antimicrobial stewardship to combat the rising threat of antimicrobial resistance, providing recommendations for antibiotic selection, dosing, and duration based on the latest evidence. Key updates in the 2026 Urological Infections Guidelines summary include: comprehensive restructuring of the guideline framework in alignment with the new classification system for UTIs; the addition of a new chapter on the diagnosis and management of Herpes simplex virus; the addition of a new chapter on the diagnosis and treatment of fungal UTIs; and an update of the evidence and recommendations on periprocedural antibiotic prophylaxis for prostate biopsy. This overview of the 2026 European Association of Urology (EAU) guidelines offers valuable insights into the classification, diagnosis, and treatment of urological infections and is designed to be effectively integrated into clinical practice.", "journal": "European Urology", "pub_date": "2026-Oct", "publication_types": ["Journal Article", "Practice Guideline"], "doi": "10.1016/j.eururo.2026.04.011", "authors": ["Jennifer Kranz", "Tommaso Cai", "Suzanne Geerlings", "Bela Köves", "Merel M C Lambregts", "Guglielmo Mantica", "Adrian Pilatz", "Jose Medina-Polo", "Laila Schneidewind", "Sören Schubert", "Maxime Vallée", "Rajan Veeratterapillay", "Florian Wagenlehner", "Kathrin Bausch", "Wout Devlies", "Lorenz Leitner", "Fabian Stangl", "Hala Ali", "Emma J Smith", "Gernot Bonkat"], "affiliations": ["Department of Urology and Pediatric Urology, RWTH Aachen University, Aachen, Germany; Department of Urology and Kidney Transplantation, Martin-Luther-University, Halle, Germany. Electronic address: jkranz@ukaachen.de.", "Interdepartmental Centre of Medical Sciences (CISMed), University of Trento, Trento, Italy, Urology Division, Santa Chiara Regional and Teaching Hospital, Provincial Health Care Agency (APSS), Trento, Italy.", "Department of Internal Medicine, Amsterdam Institute for Infection and Immunity, Amsterdam Public Health Research Institute, Quality of Care, Amsterdam, The Netherlands, Amsterdam University Medical Center, Amsterdam, The Netherlands.", "Department of Urology, University of Szeged, Szeged, Hungary.", "Leiden University Center for Infectious Diseases (LUCID), Leiden University Medical Center, Leiden, The Netherlands.", "Department of Surgical and Diagnostic Integrated Sciences (DISC), University of Genova, Genova, Italy.", "Department of Urology, Pediatric Urology and Andrology, Justus-Liebig-University Giessen, Giessen, Germany.", "Department of Urology, Hospital Universitario 12 de Octubre, Madrid, Spain.", "Department of Urology, University Hospital of Bern, Bern, Switzerland.", "Max von Pettenkofer Institute, Faculty of Medicine, LMU Munich, Munich, Germany.", "Department of Urology, University Hospital of Poitiers, Poitiers, France.", "Freeman Hospital, Newcastle Upon Tyne, UK.", "Department of Urology, University Hospital Basel, University of Basel, Basel, Switzerland.", "Department of Urology, UZ Leuven, Leuven, Belgium.", "Department of Neuro-Urology, Balgrist University Hospital, University of Zürich, Zürich, Switzerland.", "Department of Urology and Pediatric Urology, Universitätsklinikum Würzburg, Würzburg, Germany; Department of Urology, University Hospital Salzburg, Paracelsus Medical University Salzburg, Salzburg, Austria.", "European Association of Urology Guidelines Office, Arnhem, The Netherlands.", "alta Uro AG, Center of Biomechanics & Calorimetry, University of Basel, Basel, Switzerland."], "corresponding_authors": ["Jennifer Kranz"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 55.29, "score_parts": {"urology_relevance": 15, "urology_in_title": 8.0, "journal_priority": 16.79, "top_journal_bonus": 10.0, "novelty": 0.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 3.0}, "journal_metrics": {"status": "ok", "impact_factor": 25.2, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.79, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "欧洲泌尿外科协会发布2026泌尿感染指南", "chinese_summary": "欧洲泌尿外科协会9月Eur Urol发布2026版泌尿系感染指南，重构尿路感染分类框架，新增单纯疱疹病毒及真菌性尿路感染诊治章节，并更新前列腺穿刺围手术期抗菌预防证据。指南强调抗菌药物管理与医史体格检查，以应对耐药威胁。", "abstract_zh": "泌尿系感染因其广泛发生及临床表现多样，显著影响个体的健康与生活质量。本工作旨在为尿路感染（UTIs）和男性附属性腺感染的诊断、治疗和预防提供循证指导，同时处理与感染控制和抗菌药物管理相关的关键公共卫生问题。针对2026年泌尿系感染指南，通过结构化文献评估识别、整理并评价了新的相关证据。检索数据库包括Medline、EMBASE和Cochrane图书馆。指南中的推荐意见由专家组制定，以优先考虑临床重要的诊疗决策。每条推荐意见的强度取决于替代管理策略的利弊平衡、证据质量（包括估计的确信度）以及患者价值观和偏好的性质与变异性。关键推荐强调对泌尿系感染患者进行详尽病史采集和体格检查的重要性。指南强调抗菌药物管理在应对日益严重的抗菌药物耐药威胁中的作用，并基于最新证据提供抗生素选择、剂量和疗程的推荐。2026年泌尿系感染指南摘要的主要更新包括：根据尿路感染新分类系统全面重构指南框架；新增单纯疱疹病毒诊断与管理章节；新增真菌性尿路感染诊断与治疗章节；更新前列腺穿刺围手术期抗生素预防的证据与推荐。本2026年欧洲泌尿外科协会（EAU）指南概述为泌尿系感染的分类、诊断和治疗提供了有价值的见解，旨在有效整合到临床实践中。"}, {"pmid": "42457063", "title": "Squid-ink-derived eumelanin nanoparticles improve glycaemic control through gut-centered metabolic remodeling in type 2 diabetes.", "abstract": "Type 2 diabetes (T2D) is increasingly recognized as a systemic metabolic disorder in which intestinal dysfunction contributes to multi-organ metabolic imbalance. Here we show that orally administered squid-ink-derived eumelanin nanoparticles (EmNPs) ameliorate hyperglycaemia and tissue injury in diabetic mice. Structural analyses confirmed that EmNPs retain the characteristic indole/quinone framework, stable radical properties and nanoscale self-assembled architecture of natural eumelanin. In vivo, EmNPs lowered fasting blood glucose, improved an FST-based depression-related behavioral readout, and improved histopathological injury in the small intestine, pancreas and hippocampus. To investigate the basis of these effects, we integrated gut microbiota profiling, intestinal transcriptomics, untargeted urinary metabolomics and targeted hepatic energy-metabolite analysis. EmNPs treatment was associated with partial correction of diabetes-associated gut microbial dysbiosis and was accompanied by intestinal transcriptional remodeling centred on epithelial/barrier function, amino acid metabolism, PPAR-related pathways and bile-acid-associated programs. These intestinal changes were associated with broad correction of urinary metabolic abnormalities involving amino acid, purine and energy metabolism. Targeted hepatic metabolite profiling further revealed EmNPs-associated remodeling of glycolysis- and TCA-related steady-state metabolite abundance. Together, these findings support an association-based, gut-centered model in which changes in the intestinal metabolic milieu are associated with systemic metabolic normalization, hepatic energy-metabolite remodeling, and improved glycaemic control in T2D.", "journal": "International Journal of Biological Macromolecules", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1016/j.ijbiomac.2026.153523", "authors": ["Wen Song", "Haoyue Yang", "Xinrong Cheng", "Bicheng Liang", "Shurui Chen", "Kecheng Li", "Song Liu", "Huahua Yu", "Ronge Xing"], "affiliations": ["Laboratory of Experimental Marine Biology, Shandong Province Key Laboratory of Marine Biodiversity and Bio-resource Sustainable Utilization, Institute of Oceanology, Chinese Academy of Sciences, Qingdao, 266071, China; University of Chinese Academy of Sciences, Beijing, 100000, China.", "Laboratory of Experimental Marine Biology, Shandong Province Key Laboratory of Marine Biodiversity and Bio-resource Sustainable Utilization, Institute of Oceanology, Chinese Academy of Sciences, Qingdao, 266071, China.", "Department of Materials Science and Engineering, National University of Singapore, Singapore, 117575, Singapore.", "Laboratory of Experimental Marine Biology, Shandong Province Key Laboratory of Marine Biodiversity and Bio-resource Sustainable Utilization, Institute of Oceanology, Chinese Academy of Sciences, Qingdao, 266071, China; Laboratory for Marine Drugs and Bioproducts, Qingdao Marine Science and Technology Center, Qingdao, 266237, China.", "Laboratory of Experimental Marine Biology, Shandong Province Key Laboratory of Marine Biodiversity and Bio-resource Sustainable Utilization, Institute of Oceanology, Chinese Academy of Sciences, Qingdao, 266071, China; Laboratory for Marine Drugs and Bioproducts, Qingdao Marine Science and Technology Center, Qingdao, 266237, China. Electronic address: xingronge@qdio.ac.cn."], "corresponding_authors": ["Ronge Xing"], "china_team": "Laboratory of Experimental Marine Biology, Shandong Province Key Laboratory of Marine Biodiversity and Bio-resource Sustainable Utilization, Institute of Oceanology, Chinese Academy of Sciences, Qingdao, 266071, China; University of Chinese Academy of Sciences, Beijing, 100000, China Ronge Xing团队", "category": "basic", "classification_reason": "basic_signals=15", "score": 35.3, "score_parts": {"urology_relevance": 3, "urology_in_title": 0.0, "journal_priority": 11.3, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 5.0, "abstract_completeness": 2.0, "basic_research_strength": 14.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 8.5, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 3.3, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "鱿鱼墨黑色素纳米颗粒改善血糖", "chinese_summary": "中国科学院海洋研究所邢荣娥团队10月Int J Biol Macromol报道，口服鱿鱼墨来源的真黑色素纳米颗粒可降低糖尿病小鼠空腹血糖，改善小肠、胰腺及海马组织损伤，并部分纠正肠道菌群失调，提示以肠道为中心的代谢重塑或有助于血糖控制。", "abstract_zh": "2型糖尿病（T2D）日益被认为是一种全身性代谢紊乱，其中肠道功能障碍参与多器官代谢失衡。在此，我们展示口服鱿鱼墨来源的真黑色素纳米颗粒（EmNPs）可改善糖尿病小鼠的高血糖和组织损伤。结构分析证实，EmNPs保留了天然真黑色素特征性的吲哚/醌骨架、稳定的自由基特性及纳米尺度自组装结构。在体内，EmNPs降低了空腹血糖，改善了基于强迫游泳实验的抑郁相关行为学读数，并改善了小肠、胰腺和海马的组织病理学损伤。为探究这些效应的基础，我们整合了肠道菌群谱分析、肠道转录组学、非靶向尿液代谢组学及靶向肝脏能量代谢物分析。EmNPs治疗与糖尿病相关肠道菌群失调的部分纠正相关，并伴随以上皮/屏障功能、氨基酸代谢、PPAR相关通路及胆汁酸相关程序为中心的肠道转录重塑。这些肠道变化与涉及氨基酸、嘌呤及能量代谢的尿液代谢异常的广泛纠正相关。靶向肝脏代谢物谱分析进一步揭示了EmNPs相关的糖酵解和TCA相关稳态代谢物丰度的重塑。总之，这些发现支持一个基于关联的、以肠道为中心的模型，即肠道代谢微环境的变化与全身代谢正常化、肝脏能量代谢物重塑及T2D血糖控制改善相关。"}, {"pmid": "42448546", "title": "Retraction notice to \"Effects of the T-786C, G894T and Intron 4 VNTR (4a/b) Polymorphisms of the Endothelial Nitric Oxide Synthase Gene on the Risk of Prostate Cancer\" [Urologic Oncology: Seminars and Original Investigations 31 (2013) 1132-1140].", "abstract": "", "journal": "Urologic Oncology", "pub_date": "2026-Oct", "publication_types": ["Journal Article", "Retraction Notice"], "doi": "10.1016/j.urolonc.2026.05.028", "authors": ["Mohammad Reza Safarinejad", "Shiva Safarinejad", "Nayyer Shafiei", "Saba Safarinejad"], "affiliations": ["Clinical center for urological disease diagnosis and private clinic specialized in urological and andrological genetics, Tehran, Iran."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 19.75, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 5.75, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 1.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.3, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.75, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42448494", "title": "Re: De Luca et al. Primary Noncontrast Magnetic Resonance Imaging for Prostate Cancer Screening: A Randomized Clinical Trial (PROSA). Eur Urol 2026;89:246-57.", "abstract": "", "journal": "European Urology", "pub_date": "2026-Oct", "publication_types": ["Letter"], "doi": "10.1016/j.eururo.2026.06.013", "authors": ["Emanuele Messina", "Alessandro Sciarra", "Giuseppe La Torre", "Valeria Panebianco"], "affiliations": ["Department of Radiological Sciences, Oncology and Pathology, Sapienza University/Policlinico Umberto I, Viale del Policlinico, Rome, Italy.", "Department of Maternal-Infant and Urological Sciences, Sapienza University/Policlinico Umberto I, Viale del Policlinico, Rome, Italy.", "Department of Public Health and Infectious Diseases, Sapienza University/Policlinico Umberto I, Viale del Policlinico, Rome, Italy.", "Department of Radiological Sciences, Oncology and Pathology, Sapienza University/Policlinico Umberto I, Viale del Policlinico, Rome, Italy. Electronic address: valeria.panebianco@uniroma1.it."], "corresponding_authors": ["Valeria Panebianco"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=8", "score": 43.79, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 16.79, "top_journal_bonus": 10.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 8.0}, "journal_metrics": {"status": "ok", "impact_factor": 25.2, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.79, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "无造影MRI前列腺癌筛查遭质疑", "chinese_summary": "针对PROSA随机试验，10月Eur Urol刊发通讯指出，无造影MRI用于前列腺癌筛查的结论需谨慎解读。该试验以无造影MRI为初筛手段，通讯作者就筛查路径、检出偏倚及获益风险比提出商榷，强调筛查策略尚需更长期随访验证。", "abstract_zh": "这是关于De Luca等人《原发性无造影磁共振成像用于前列腺癌筛查：一项随机临床试验（PROSA）》（Eur Urol 2026;89:246-57）的通讯。原文摘要未提供，故无法进行完整翻译。"}, {"pmid": "42443559", "title": "Targeting Siglec-engaging immunosuppressive sialoglycans to suppress prostate cancer bone metastasis.", "abstract": "Prostate cancer is a leading cause of male cancer-related deaths over the age of 50. New treatment options are urgently needed, especially for prostate tumours that have spread to bone. Targeting aberrant sialylation holds substantial potential for the development of new therapeutics but is relatively unexplored in the context of prostate cancer. Here, using high-affinity Siglec-based sialoglycan-binding reagents (HYDRA) for immunohistochemistry, we quantify tumour sialoglycans in tissues representing the full clinical heterogeneity of prostate cancer. Using immunofluorescence, we profile Siglec receptors in prostate tumours, and using syngeneic mouse models, we evaluate an engineered dual-action sialidase (E-612) as a treatment for prostate cancer bone metastasis. We find that sialoglycans that can engage Siglec-3 (CD33), Siglec-7 and Siglec-9 are upregulated in bone metastatic prostate cancer and show that sialoglycan ligands for Siglec-7 and -9 correlate with poorer patient prognosis. Furthermore, we reveal Siglec receptors and Siglec ligands are co-expressed by immune cells in prostate-derived tumours growing in bone. Indicating the Siglec-sialoglycan axis is clinically actionable in prostate cancer, we show systemic therapy with E-612 can suppress the growth of tumours, increase immune cell infiltration and prolong survival times of mice with bone metastasis. Our findings identify a novel mechanism involving Siglec-engaging sialoglycans in driving the growth of prostate cancer bone metastasis and demonstrate that targeting this axis using an engineered sialidase can impede lethal prostate cancer progression.", "journal": "British Journal of Cancer", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1371/journal.pone.0241934", "authors": ["Ziqian Peng", "Kirsty Hodgson", "Matthew Fisher", "Shenglin Mei", "Margarita Orozco-Moreno", "Lizhi Cao", "Michael Kemp", "Wayne Gatlin", "Louisa Donald", "Libby Blencoe", "Feier Zeng", "Michelle A Lawson", "Daniel Ungar", "David B Sykes", "David J Elliott", "Li Peng", "Benjamin Schumann", "Richard Beatson", "Ning Wang", "Jennifer Munkley"], "affiliations": ["Newcastle University Centre for Cancer, Newcastle University Institute of Biosciences, Newcastle, UK.", "The Mellanby Centre for Musculoskeletal Research, Division of Clinical Medicine, School of Medicine and Population Health, University of Sheffield, Sheffield, UK.", "Fralin Biomedical Research Institute, Virginia Tech FBRI Cancer Research Center, Washington, DC, USA.", "Department of Biomedical Sciences and Pathobiology, College of Veterinary Medicine, Virginia Tech, Blacksburg, VA, USA.", "Palleon Pharmaceuticals, Waltham, MA, USA.", "Leicester Cancer Research Centre, School of Medical Sciences, University of Leicester, Leicester, UK.", "Department of Biology, University of York, York, UK.", "Massachusetts General Hospital Cancer Center, Boston, MA, USA.", "The Chemical Glycobiology Laboratory, The Francis Crick Institute, London, UK.", "Department of Chemistry, Imperial College London, London, UK.", "Faculty of Chemistry and Food Chemistry, TUD Dresden University of Technology, Dresden, Germany.", "School of Cancer & Pharmaceutical Sciences, King's College London, London, UK.", "Newcastle University Centre for Cancer, Newcastle University Institute of Biosciences, Newcastle, UK. Jennifer.munkley@ncl.ac.uk."], "corresponding_authors": ["Jennifer Munkley"], "china_team": "", "category": "basic", "classification_reason": "basic_signals=10", "score": 36.51, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 11.01, "top_journal_bonus": 0.0, "novelty": 1.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 10.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 6.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 3.01, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "靶向唾液酸聚糖抑制前列腺癌骨转移", "chinese_summary": "10月Br J Cancer刊发研究，采用高亲和力Siglec探针检测发现，可结合Siglec-3、Siglec-7及Siglec-9的唾液酸聚糖在前列腺癌骨转移灶中上调，其中Siglec-7与Siglec-9配体与患者预后较差相关。工程化双效唾液酸酶E-612全身治疗可抑制小鼠骨转移瘤生长、增加免疫细胞浸润并延长生存，提示靶向该轴有治疗潜力。", "abstract_zh": "前列腺癌是50岁以上男性癌症相关死亡的主要原因。亟需新的治疗方案，尤其是针对已扩散至骨骼的前列腺肿瘤。靶向异常唾液酸化在开发新疗法方面具有巨大潜力，但在前列腺癌背景下相对未被探索。在此，我们使用基于高亲和力Siglec的唾液酸聚糖结合试剂（HYDRA）进行免疫组化，对代表前列腺癌完整临床异质性的组织中的肿瘤唾液酸聚糖进行定量。我们使用免疫荧光分析前列腺肿瘤中的Siglec受体，并使用同基因小鼠模型评估工程化双效唾液酸酶（E-612）作为前列腺癌骨转移的治疗方法。我们发现，可结合Siglec-3（CD33）、Siglec-7和Siglec-9的唾液酸聚糖在骨转移性前列腺癌中上调，并表明Siglec-7和-9的唾液酸聚糖配体与患者较差的预后相关。此外，我们揭示Siglec受体和Siglec配体由生长于骨骼中的前列腺来源肿瘤内的免疫细胞共表达。表明Siglec-唾液酸聚糖轴在前列腺癌中具有临床可操作性，我们显示E-612全身治疗可抑制肿瘤生长、增加免疫细胞浸润并延长骨转移小鼠的生存时间。我们的发现确定了一种涉及结合Siglec的唾液酸聚糖驱动前列腺癌骨转移生长的新的机制，并证明使用工程化唾液酸酶靶向该轴可以阻止致死性前列腺癌进展。"}, {"pmid": "42442599", "title": "HDAC10 suppresses anti-tumour immunity by inhibiting ILF3-CXCL9 axis to block CD8+ T cell infiltration and activation in bladder cancer.", "abstract": "Although immune checkpoint blockade has offered new hope to patients with bladder cancer, its overall response rate remains modest. In this setting, the quantity and functional status of CD8+T cells largely dictate therapeutic efficacy. Integrative bioinformatics analyses, validated in our institutional tissue cohort, we demonstrated that histone deacetylase 10 (HDAC10) was markedly up-regulated in bladder cancer and inversely correlated with CD8+T cells infiltration. In vivo experiments, using Hdac10-KO cell line, we revealed that Hdac10-KO significantly inhibited tumour growth and promoted the infiltration and activity of CD8+T cells. Mechanically, HDAC10 deacetylated the K342 site of interleukin enhancer-binding factor 3 (ILF3), thereby inducing the ubiquitination and degradation of it by WWP2. This reduced the stability regulation of CXCL9 mRNA by ILF3, decreasing CXCL9 expression and weakening CD8+T cell infiltration and activation. Notably, we found that the probiotic Clostridium butyricum (C.B.) can inhibit the expression of HDAC10 by increasing the short-chain fatty acid butyric acid, thereby sensitizing immunotherapy for bladder cancer in mouse models. This study revealed the specific mechanism by which HDAC10 led to immunotherapy resistance in bladder cancer and proposed potential combined treatment strategies.", "journal": "Cancer Letters", "pub_date": "2026-Oct-01", "publication_types": ["Journal Article"], "doi": "10.1016/j.canlet.2026.218729", "authors": ["Juntao Zhuang", "Hao Yu", "Yuhan Chen", "Huanyou Sun", "Ao Shen", "Linjing Jiang", "Rongjie Bai", "Zhengye Tan", "Jiancheng Lv", "Kexin Bai", "Wei Wang", "Haiwei Yang", "Xiao Yang", "Qiang Lu"], "affiliations": ["Department of Urology, The First Affiliated Hospital with Nanjing Medical University, China.", "Department of Urology, The First Affiliated Hospital with Nanjing Medical University, China. Electronic address: haiweiyang@njmu.edu.cn.", "Department of Urology, The First Affiliated Hospital with Nanjing Medical University, China. Electronic address: yangxiao2915@163.com.", "Department of Urology, The First Affiliated Hospital with Nanjing Medical University, China. Electronic address: doctorlvqiang@njmu.edu.cn."], "corresponding_authors": ["Haiwei Yang", "Xiao Yang", "Qiang Lu"], "china_team": "Department of Urology, The First Affiliated Hospital with Nanjing Medical University, China Haiwei Yang/Xiao Yang/Qiang Lu团队", "category": "basic", "classification_reason": "basic_signals=12", "score": 42.03, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 15.53, "top_journal_bonus": 0.0, "novelty": 0.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 12.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 10.1, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.53, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "HDAC10抑制膀胱癌CD8+T细胞浸润", "chinese_summary": "南京医科大学第一附属医院杨海伟、杨潇、陆强团队2026年10月Cancer Lett发表研究，发现组蛋白去乙酰化酶HDAC10在膀胱癌中显著上调，与CD8+T细胞浸润负相关；HDAC10通过去乙酰化ILF3的K342位点促其经WWP2泛素化降解，降低CXCL9表达，阻断CD8+T细胞浸润与活化；益生菌丁酸梭菌可经丁酸抑制HDAC10，增敏免疫治疗。", "abstract_zh": "尽管免疫检查点阻断为膀胱癌患者带来了新希望，但其总体缓解率仍然有限。在此背景下，CD8+T细胞的数量和功能状态在很大程度上决定了治疗疗效。通过整合生物信息学分析，并在本机构组织队列中验证，我们证明组蛋白去乙酰化酶10（HDAC10）在膀胱癌中显著上调，并与CD8+T细胞浸润呈负相关。在体内实验中，使用Hdac10敲除细胞系，我们发现Hdac10敲除显著抑制肿瘤生长，并促进CD8+T细胞的浸润和活性。在机制上，HDAC10去乙酰化白细胞介素增强子结合因子3（ILF3）的K342位点，从而诱导其被WWP2泛素化并降解。这降低了ILF3对CXCL9 mRNA的稳定性调控，减少CXCL9表达，削弱CD8+T细胞浸润和活化。值得注意的是，我们发现益生菌丁酸梭菌（C.B.）可通过增加短链脂肪酸丁酸来抑制HDAC10表达，从而在小鼠模型中增敏膀胱癌免疫治疗。本研究揭示了HDAC10导致膀胱癌免疫治疗耐药的具体机制，并提出了潜在的联合治疗策略。"}, {"pmid": "42437159", "title": "Eggshell calcification of the urinary bladder in chronic Schistosoma haematobium infection: A radiologic-pathologic case report.", "abstract": "Chronic urinary schistosomiasis is an important cause of hematuria and genitourinary morbidity in individuals from endemic regions. In advanced disease, computed tomography (CT) may show circumferential calcification of the bladder and distal ureters, a classic pattern that can suggest the diagnosis even when laboratory tests are negative. A 38-year-old man from Mozambique, living in Portugal with human immunodeficiency virus and hepatitis B virus infections, presented with 2 months of painless gross hematuria. He denied dysuria, fever, flank pain, weight loss, prior urinary tract instrumentation, tuberculosis, or recent travel, and baseline blood tests and renal function were normal. Urinalysis showed hematuria and leukocyturia, but multiple urine examinations for Schistosoma ova and a urine Schistosoma-specific polymerase chain reaction were negative. Noncontrast CT of the abdomen and pelvis was obtained and demonstrated diffuse circumferential calcification of the urinary bladder wall with distal ureteral involvement, producing a classic \"eggshell\" appearance without hydronephrosis, renal stones, or intraluminal mass. Cystoscopy showed yellowish plaques and nodular mucosal lesions, and targeted bladder biopsies revealed numerous calcified Schistosoma haematobium ova within the urothelium and submucosa with chronic inflammation and stromal calcification, confirming chronic inactive infection. The patient received a single dose of praziquantel 40 mg/kg and 3 months later, hematuria had resolved and renal function was stable. This case highlights that in chronic urinary schistosomiasis, CT findings can be decisive when urine-based tests are negative.", "journal": "Radiology Case Reports", "pub_date": "2026-Oct", "publication_types": ["Case Reports", "Journal Article"], "doi": "10.1186/s40794-022-00161-x", "authors": ["Juliana Andrade", "Joana Sobreiro Silva"], "affiliations": ["Internal Medicine Department, Unidade Local de Saúde de Braga, Braga, Portugal.", "Anatomic Pathology, Unidade Local de Saúde de Braga, Braga, Portugal."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_clinical", "score": 21.0, "score_parts": {"urology_relevance": 11, "urology_in_title": 8.0, "journal_priority": 0.0, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "missing", "impact_factor": null, "cas_zone": null, "cas_zone_points": 0.0, "impact_factor_points": 0.0}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42436321", "title": "TP53 mutation-biased CD8+ T cell exhaustion drives lethal outcome and therapy resistance in urothelial carcinoma.", "abstract": "Emerging evidence has underscored non-cell-autonomous roles of mutant p53 in reshaping the composition and functional state of tumour immune microenvironment (TIME). However, the impact of p53 status on the clinical relevance and functional differentiation of CD8+ T cells remains poorly understood in urothelial carcinoma (UC). Our study included 297 UC patients from two in-house cohorts and 871 UC patients from four public datasets to evaluate the impact of p53 status on the clinical implications of CD8+ T cells. Single-cell RNA sequencing, flow cytometry, immunohistochemistry, and bioinformatics analyses were performed to elucidate the role of p53 status in regulating CD8+ T cell polarisation and reshaping the TIME. High CD8+ T cell infiltration correlated with favourable prognosis and improved survival following chemotherapy and PD-(L)1 blockade exclusively in p53-WT UC, while its association with prognosis and therapeutic benefit was abrogated in p53-mutant UC. Moreover, p53-mutant UC exhibited predominant infiltration of TIM3+ exhausted CD8+ T cells, accompanied by increased Treg and M2 macrophage infiltration. The clinical significance and functional polarisation of CD8+ T cells in UC varied in a context-dependent manner according to p53 status. These findings provide novel insights to refine patient stratification and optimise personalised therapeutic strategies.", "journal": "British Journal of Cancer", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1016/j.ccell.2017.02.008", "authors": ["Xiaohe Su", "Kaifeng Jin", "Han Zeng", "Zhaopei Liu", "Lingkai Zhang", "Yawei Ding", "Jiaxing Sun", "Yuzhen Wu", "Hailong Liu", "Yuan Chang", "Le Xu", "Weijuan Zhang", "Zewei Wang", "Yu Zhu", "Jiejie Xu"], "affiliations": ["Shanghai Urothelial Carcinoma Research Group (SUCRG), National Health Commission Key Laboratory of Glycoconjugate Research, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China.", "Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.", "Department of Urology, Urologic Surgery Center, Xinqiao Hospital, Third Military Medical University (Army Medical University), Chongqing, China.", "Department of Urology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.", "Department of Immunology, School of Basic Medical Sciences, Fudan University, Shanghai, China.", "Department of Urology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.", "Department of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.", "Shanghai Urothelial Carcinoma Research Group (SUCRG), National Health Commission Key Laboratory of Glycoconjugate Research, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China. jjxufdu@fudan.edu.cn."], "corresponding_authors": ["Jiejie Xu"], "china_team": "Shanghai Urothelial Carcinoma Research Group (SUCRG), National Health Commission Key Laboratory of Glycoconjugate Research, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China Jiejie Xu团队", "category": "basic", "classification_reason": "basic_signals=4", "score": 31.01, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 11.01, "top_journal_bonus": 0.0, "novelty": 2, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 4.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 6.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 3.01, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "TP53突变致CD8+T细胞耗竭促膀胱癌耐药", "chinese_summary": "复旦大学基础医学院徐洁杰团队10月Br J Cancer整合两项院内队列297例及四项公共数据集871例尿路上皮癌患者，发现高CD8+T细胞浸润仅在p53野生型中提示预后良好及化疗和PD-(L)1获益；p53突变肿瘤以TIM3+耗竭CD8+T细胞为主，伴Treg及M2巨噬细胞增多，提示p53状态可用于分层和治疗决策。", "abstract_zh": "新出现的证据强调了突变p53在重塑肿瘤免疫微环境（TIME）的组成和功能状态方面的非细胞自主作用。然而，在尿路上皮癌（UC）中，p53状态对CD8+T细胞临床相关性和功能分化的影响仍知之甚少。我们的研究纳入了来自两个内部队列的297例UC患者和来自四个公共数据集的871例UC患者，以评估p53状态对CD8+T细胞临床意义的影响。我们进行了单细胞RNA测序、流式细胞术、免疫组织化学和生物信息学分析，以阐明p53状态在调节CD8+T细胞极化和重塑TIME中的作用。高CD8+T细胞浸润仅在p53野生型UC中与良好预后以及化疗和PD-(L)1阻断后生存改善相关，而在p53突变型UC中，其与预后和治疗获益的关联消失。此外，p53突变型UC表现出以TIM3+耗竭CD8+T细胞为主的浸润，并伴有Treg和M2巨噬细胞浸润增加。UC中CD8+T细胞的临床意义和功能极化根据p53状态以情境依赖的方式发生变化。这些发现为完善患者分层和优化个体化治疗策略提供了新的见解。"}, {"pmid": "42435930", "title": "A novel lncRNA HUDRPC suppresses ferroptosis via the DDX5/DDIT3 pathway to promote docetaxel resistance in prostate cancer.", "abstract": "Docetaxel remains first-line chemotherapy for advanced prostate cancer (PCa), but acquired resistance severely limits durable clinical responses. While long non-coding RNAs (lncRNAs) are established as critical regulators of tumor chemoresistance, the specific mechanisms driving docetaxel resistance in PCa remain poorly understood. Here, we functionally characterized a novel docetaxel resistance-associated lncRNA in PCa. Through comparative transcriptome sequencing of isogenic docetaxel-sensitive and resistant PCa cell lines, we identified an uncharacterized lncRNA (RP11-151G14.2), termed HUDRPC, which was significantly upregulated in resistant cells and patient-derived tumor tissues. Loss-of-function validation confirmed that HUDRPC was required to maintain docetaxel resistance both in vitro and in vivo. Mechanistically, HUDRPC promoted docetaxel resistance by directly inhibiting ferroptosis. CRISPR-Cas9 knockout of HUDRPC markedly augmented docetaxel-induced reactive oxygen species accumulation, lipid peroxidation and iron overload, and sensitized resistant PCa cells and xenografts to docetaxel treatment. We further demonstrated that HUDRPC directly bound the RNA helicase DDX5, and recruited DDX5 to the DDIT3 promoter, thereby enhancing DDIT3 transcription in a DDX5-dependent manner. Clinically, high DDIT3 expression correlated with poorer overall survival and inferior docetaxel response in PCa patients. Rescue experiments showed that forced DDIT3 overexpression reversed HUDRPC depletion-induced ferroptosis and docetaxel sensitization, confirming DDIT3 as the key downstream effector of HUDRPC. Collectively, our findings identify the HUDRPC-DDX5- DDIT3 axis as a critical regulator of docetaxel resistance, highlighting HUDRPC as a promising prognostic biomarker and therapeutic target to overcome chemoresistance in advanced PCa.", "journal": "Cancer Letters", "pub_date": "2026-Oct-01", "publication_types": ["Journal Article"], "doi": "10.1016/j.canlet.2026.218727", "authors": ["Sudong Liang", "Yuanji Zheng", "Xiaobo Wu", "Furong Ji", "Mierzhayiti Batuer", "Qipeng Li", "Zengke Qiu", "Kaiwen Liu", "Li Yang", "Qingyi Zhu", "Jianzhong Lin"], "affiliations": ["Department of Urology, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou, China.", "Department of Urology, Jiangsu Key Laboratory of Urological Disease Prevention and Treatment, The Second Affiliated Hospital of Nanjing Medical University, Nanjing Medical University, Nanjing, China.", "Department of Surgery (Urology), Cedars-Sinai Medical Center, Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute, Los Angeles, CA, USA.", "Department of Urology, Jiangsu Key Laboratory of Urological Disease Prevention and Treatment, The Second Affiliated Hospital of Nanjing Medical University, Nanjing Medical University, Nanjing, China; Department of Urology, The Affiliated Suqian Hospital of Xuzhou Medical University, Suqian, China.", "Department of Oncology, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou, China. Electronic address: 1005317378@qq.com.", "Department of Urology, Jiangsu Key Laboratory of Urological Disease Prevention and Treatment, The Second Affiliated Hospital of Nanjing Medical University, Nanjing Medical University, Nanjing, China. Electronic address: zhuqy1971@126.com.", "Department of Urology, Jiangsu Key Laboratory of Urological Disease Prevention and Treatment, The Second Affiliated Hospital of Nanjing Medical University, Nanjing Medical University, Nanjing, China. Electronic address: linjianzhong82@126.com."], "corresponding_authors": ["Li Yang", "Qingyi Zhu", "Jianzhong Lin"], "china_team": "Department of Urology, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou, China Li Yang/Qingyi Zhu/Jianzhong Lin团队", "category": "basic", "classification_reason": "basic_signals=27", "score": 46.03, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 15.53, "top_journal_bonus": 0.0, "novelty": 2.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 14.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 10.1, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.53, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "新型lncRNA驱动前列腺癌多西他赛耐药", "chinese_summary": "南京医科大学附属泰州人民医院李阳、朱清逸、林建中团队10月Cancer Lett报道，新lncRNA HUDRPC在多西他赛耐药前列腺癌细胞及患者肿瘤组织中显著上调，通过结合DDX5并招募至DDIT3启动子增强其转录，抑制铁死亡从而维持耐药；", "abstract_zh": "多西他赛仍是晚期前列腺癌（PCa）的一线化疗药物，但获得性耐药严重限制了持久的临床缓解。尽管长链非编码RNA（lncRNA）已被确认为肿瘤化疗耐药的关键调控因子，但驱动前列腺癌多西他赛耐药的具体机制仍知之甚少。在此，我们对前列腺癌中一种新型多西他赛耐药相关lncRNA进行了功能鉴定。通过对同源多西他赛敏感和耐药前列腺癌细胞系进行比较转录组测序，我们鉴定出一种未表征的lncRNA（RP11-151G14.2），命名为HUDRPC，其在耐药细胞和患者来源肿瘤组织中显著上调。功能缺失验证证实，HUDRPC在体外和体内均是维持多西他赛耐药所必需的。机制上，HUDRPC通过直接抑制铁死亡促进多西他赛耐药。CRISPR-Cas9敲除HUDRPC显著增强了多西他赛诱导的活性氧蓄积、脂质过氧化和铁过载，并使耐药前列腺癌细胞和异种移植瘤对多西他赛治疗敏感。我们进一步证明，HUDRPC直接结合RNA解旋酶DDX5，并将DDX5招募至DDIT3启动子，从而以DDX5依赖的方式增强DDIT3转录。临床上，DDIT3高表达与前列腺癌患者更差的总生存期和更差的多西他赛反应相关。挽救实验显示，强制过表达DDIT3可逆转HUDRPC缺失诱导的铁死亡和多西他赛增敏，证实DDIT3是HUDRPC的关键下游效应分子。总之，我们的发现确定HUDRPC-DDX5-DDIT3轴是多西他赛耐药的关键调控因子，突出HUDRPC作为有前景的预后生物标志物和治疗靶点，以克服晚期前列腺癌的化疗耐药。"}, {"pmid": "42433145", "title": "Mental health disorders following nephrectomy for renal cell carcinoma: a national study.", "abstract": "", "journal": "BJU International", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1111/bju.70383", "authors": ["Baris Esen", "Reza Lahiji", "Dattatraya Patil", "Susan Mumford", "Kelsey R Landrum", "Reza Nabavizadeh", "Mohammad Hajiha", "Valentina Grajales", "Nazih Khater", "Shreyas S Joshi", "Vikram M Narayan", "Kenneth Ogan", "Viraj A Master"], "affiliations": ["Department of Urology, Emory University School of Medicine, Atlanta, GA, USA.", "Department of Urology, Koc University School of Medicine, Istanbul, Turkey.", "Division of Surgical Oncology, Emory University School of Medicine, Atlanta, GA, USA.", "Department of Urology, Duke Cancer Center, Durham, NC, USA.", "Winship Cancer Institute of Emory University, Atlanta, GA, USA."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 23.47, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 10.47, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.4, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.47, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42432266", "title": "No racial disparities in prostate cancer-specific mortality after biochemical recurrence following radical prostatectomy or radiation therapy.", "abstract": "Racial disparities in prostate cancer are well-documented, with Black men experiencing twice the mortality of White men. While prior studies suggest these disparities reflect inequitable access rather than biology, only few studies have examined this in the biochemical recurrence setting, where screening and initial treatment biases are eliminated. We compared cancer-specific mortality and other-cause mortality between non-Hispanic Black (NHB) and non-Hispanic White (NHW) men with biochemical recurrence after initial treatment. This retrospective single health system study included patients who developed BCR after radical prostatectomy or radiation therapy between 1995 and 2023. Primary outcome was cancer-specific mortality. Fine-Gray competing risk models assessed race-CSM association, stratified by treatment and adjusted for European Association of Urology biochemical recurrence risk classification. Among 968 patients (431 NHB, 44.5%; 537 NHW, 55.5%), median follow-up was 5.5 years from biochemical recurrence. Other-cause mortality was similar (Gray's test p = 0.35 radical prostatectomy, p = 0.41 radiation therapy). Ten-year cancer-specific mortality estimates were similar after radical prostatectomy (6.7% both races; NHB versus NHW HR 0.91, 95% CI 0.49-1.71, p = 0.8) and radiation therapy (NHB 26.7% versus NHW 32.4%; HR 0.71, 95% CI 0.44-1.14, p = 0.16). Limitations include single-center design and retrospective methodology. In this racially diverse single-center cohort, we found no racial disparities in cancer-specific mortality or other-cause mortality after biochemical recurrence. These findings support that racial disparities reflect modifiable access barriers rather than biological differences, emphasizing the importance of equitable care delivery.", "journal": "Prostate Cancer and Prostatic Diseases", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1038/s41391-026-01132-5", "authors": ["Carlo Silvani", "Alfonso Santangelo", "Alex Stephens", "Jack Considine", "Benjamin Robinson", "Michael Niculcea", "Akshay Sood", "Sebastiano Nazzani", "Alberto Briganti", "Andrea Salonia", "Francesco Montorsi", "Nicola Nicolai", "Emanuele Montanari", "Craig Rogers", "Firas Abdollah"], "affiliations": ["VUI Center for Outcomes Research, Analysis and Evaluation, Henry Ford Health System, Detroit, MI, USA.", "Urology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.", "Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.", "Division of Oncology, Unit of Urology, IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Milan, Italy.", "Public Health Sciences, Henry Ford Health System, Detroit, MI, USA.", "Department of Urology, The James Cancer Hospital and Solove Research Institute, The Ohio State University Wexner Medical Center, Columbus, OH, USA.", "Department of Urology, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy.", "VUI Center for Outcomes Research, Analysis and Evaluation, Henry Ford Health System, Detroit, MI, USA. Fabdoll1@hfhs.org."], "corresponding_authors": ["Firas Abdollah"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=8", "score": 36.81, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 10.81, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 8.0}, "journal_metrics": {"status": "ok", "impact_factor": 5.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.81, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42431754", "title": "Reply to Francesco Barletta, Chiara Mercinelli, Francesco Montorsi, et al. re: Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer. Eur Urol 2026;89:550-551.", "abstract": "", "journal": "European Urology", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1016/j.eururo.2026.04.032", "authors": ["Neal D Shore", "Stephen J Freedland"], "affiliations": ["START Carolinas/Carolina Urologic Research Center, Myrtle Beach, SC, USA. Electronic address: nshore@auclinics.com.", "Department of Urology, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA; Durham VA Medical Center, Durham, NC, USA. Electronic address: Stephen.Freedland@cshs.org."], "corresponding_authors": ["Neal D Shore", "Stephen J Freedland"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 35.79, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 16.79, "top_journal_bonus": 10.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 25.2, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.79, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "恩杂鲁胺治疗生化复发前列腺癌获生存获益", "chinese_summary": "欧洲泌尿外科学会杂志10月就恩杂鲁胺治疗生化复发前列腺癌的生存获益发表回复。针对Barletta等学者此前的评论，作者重申在生化复发阶段早期应用恩杂鲁胺可改善生存结局，并强调需结合患者风险分层个体化决策。", "abstract_zh": "Reply to Francesco Barletta, Chiara Mercinelli, Francesco Montorsi, et al. re: Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer. Eur Urol 2026;89:550-551."}, {"pmid": "42429300", "title": "Function drives 1-year decision regret in radical prostatectomy: a multicentre prospective study.", "abstract": "To identify contemporary drivers of postoperative decision regret 1 year after radical prostatectomy (RP). In this prospective, multicentre study, patients undergoing robot-assisted RP (RARP) or retropubic open RP (ORP) for localised prostate cancer at seven centres in Germany and Austria (2022-2024) completed questionnaires preoperatively and at 1 year postoperatively. Decision regret was assessed using the Decision Regret Scale (DRS). Functional outcomes were measured with European Organisation for Research and Treatment of Cancer quality of life questionnaire - 25-item prostate cancer specific (EORTC QLQ-PR25) symptom scores at 1 year postoperatively. Multivariable logistic regression identified predictors of high surgical decision regret (DRS score ≥10). Sensitivity was tested via propensity score matching (PSM). A total of 419 patients completed the surveys (58% RARP, 42% ORP) at 1 year postoperatively. Surgical decision regret was low (mean [SD] DRS score 9.0 [15.4]). Erectile dysfunction was the outcome that most patients self-reported as worse than expected (54% [221/404]), followed by urinary incontinence (23% [96/414]) and oncological cure (10% [39/397]) in a questionnaire on their retrospective perception. The ORP patients reported higher regret regarding surgical approach than RARP patients (mean [SD] DRS score 11.3 [17.1] vs 7.4 [13.9], P = 0.02). In a multivariate analysis, high urinary symptom burden (odds ratio [OR] 2.4, P = 0.009) and impaired sexual functioning (OR 2.8, P = 0.002) independently predicted high surgical decision regret whereas surgical approach and prostate-specific antigen recurrence did not. Sensitivity analyses via PSM confirmed these independent predictors. Surgical decision regret after RP is primarily driven by postoperative functional outcomes rather than oncological results or surgical approach. Optimising functional recovery and managing patient expectations are key strategies to reduce regret in prostate cancer surgery.", "journal": "BJU International", "pub_date": "2026-Oct", "publication_types": ["Journal Article", "Multicenter Study"], "doi": "10.1111/bju.70382", "authors": ["Christopher Hirtsiefer", "Emma Kümmel", "Anna Vogelgesang", "Fabian Falkenbach", "Mona Kafka", "Annemarie Uhlig", "Tim Nestler", "Cem Aksoy", "Iva Simunovic", "Johannes Huber", "Isabel Heidegger", "Markus Graefen", "Marianne Leitsmann", "Christian Thomas", "Martin Baunacke"], "affiliations": ["Department of Urology, University Hospital Dresden, Dresden, Germany.", "Vancouver Prostate Centre, M.H. Mohseni Institute of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.", "Martini-Klinik Prostate Cancer Centre, University Hospital Hamburg-Eppendorf, Hamburg, Germany.", "Department of Urology, Medical University Innsbruck, Innsbruck, Austria.", "Department of Urology, University Medical Center Göttingen, Göttingen, Germany.", "Department of Urology, Federal Armed Forces Hospital Koblenz, Koblenz, Germany.", "Department of Urology, Phillips-University Marburg, Marburg, Germany.", "Department of Urology, Medical University of Graz, Graz, Austria.", "Department of Urology, University Hospital Heidelberg, Heidelberg, Germany.", "aQua - Institute for Applied Quality Improvement and Research in Health Care, Göttingen, Germany."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_clinical", "score": 44.47, "score_parts": {"urology_relevance": 14, "urology_in_title": 8.0, "journal_priority": 10.47, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 10.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.4, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.47, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42425857", "title": "Re: Murthy V, Maitre P, Pal M, et al. Bladder Adjuvant Radiotherapy: Phase III Multicenter Randomized Controlled Trial of Adjuvant Radiotherapy or Observation for Postcystectomy Muscle-invasive Bladder Cancer. J Clin Oncol. In press. http://dx.doi.org/10.1200/JCO-25-02093.", "abstract": "", "journal": "European Urology", "pub_date": "2026-Oct", "publication_types": ["Letter"], "doi": "10.1016/j.eururo.2026.06.018", "authors": ["Jianguang Miao", "Xinyu Yi"], "affiliations": ["Department of Urology, Xiangtan Central Hospital / The Affiliated Hospital of Hunan University, Xiangtan, Hunan, China.", "Department of Urology, Xiangtan Central Hospital / The Affiliated Hospital of Hunan University, Xiangtan, Hunan, China. Electronic address: yyi913626@gmail.com."], "corresponding_authors": ["Xinyu Yi"], "china_team": "Department of Urology, Xiangtan Central Hospital / The Affiliated Hospital of Hunan University, Xiangtan, Hunan, China Xinyu Yi团队", "category": "clinical_review", "classification_reason": "clinical_signals=13", "score": 51.79, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 16.79, "top_journal_bonus": 10.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 12.0}, "journal_metrics": {"status": "ok", "impact_factor": 25.2, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.79, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "膀胱癌术后辅助放疗研究遭质疑", "chinese_summary": "湘潭市中心医院/湖南大学附属医院易欣宇团队10月Eur Urol就Murthy等即将发表的III期随机对照试验致信编辑部，针对根治性膀胱切除术后肌层浸润性膀胱癌辅助放疗对比观察的疗效与安全性提出商榷，强调需审慎解读该研究结论。", "abstract_zh": "Re: Murthy V, Maitre P, Pal M, et al. 膀胱辅助放疗：根治性膀胱切除术后肌层浸润性膀胱癌辅助放疗或观察的III期多中心随机对照试验。J Clin Oncol. 印刷中。http://dx.doi.org/10.1200/JCO-25-02093。"}, {"pmid": "42425306", "title": "Bladder ATTRwt Amyloidosis Preceding Cardiac Transthyretin Amyloidosis by a Decade: Implications for Early Detection.", "abstract": "", "journal": "Mayo Clinic Proceedings", "pub_date": "2026-Oct", "publication_types": ["Letter"], "doi": "10.1016/j.mayocp.2026.07.003", "authors": ["Adrianna Wierzbicka", "Radhika K Neicheril", "Pablo Bejarano", "David Snipelisky"], "affiliations": ["Department of Medicine, Internal Medicine, Cleveland Clinic Florida, Weston, FL.", "Department of Cardiovascular Disease, Heart, Vascular, and Thoracic Institute, Cleveland Clinic Florida, Weston, FL.", "Department of Pathology, Cleveland Clinic Florida, Weston, FL."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 19.99, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.99, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 6.7, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.99, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42421431", "title": "A novel classification of testicular sex cord-stromal tumours from the Testicular Sex Cord-Stromal Tumour (TESST) group: a collaboration of the Genitourinary Pathology Society (GUPS) and the International Society of Urological Pathology (ISUP).", "abstract": "Testicular sex cord-stromal tumours (TSCSTs) are rare neoplasms that arise from (or show differentiation to) elements derived from the sex cords or intertubular stroma. The current classification (World Health Organization, 2022) is based almost entirely on morphology, with many tumour types such as granulosa cell tumours being defined based on their resemblance to ovarian counterparts. Recent studies have uncovered new clinicopathological, molecular and biological nuances within this group of tumours, underscoring differences with ovarian homologues. Considering the new data, a group of genitourinary pathology experts (Testicular Sex Cord-Stromal Tumour [TESST] group) has proposed a revised 'TESST classification' that incorporates the best available evidence. This classification is structured and hierarchical, composed of the following tiers: (1) group, (2) category, (3) entity and (4) histological pattern. 'Group' refers to the histological compartment a specific tumour belongs to (sex cords, stroma or both), whereas 'category' is defined by the phenotype of the tumour, taking non-neoplastic elements of the ovary and testis as a reference. The third tier, 'entity', refers to neoplasms with shared clinicopathological and/or molecular features that justify classifying them as distinct types. Lastly, 'histological patterns' are recurrent morphological variations within entities that are not linked to distinct clinicopathological or molecular features. We propose a classification that will provide a framework to improve current clinical management and guide future research in the field.", "journal": "Histopathology", "pub_date": "2026-Oct", "publication_types": ["Journal Article", "Practice Guideline"], "doi": "10.1111/his.70207", "authors": ["Andres M Acosta", "Felix Bremmer", "John C Cheville", "Maurizio Colecchia", "Eva Comperat", "Kristine Cornejo", "Dilek E Baydar", "Anthony J Gill", "Maria Del Pilar Gonzalez-Peramato", "Sounak Gupta", "Michelle S Hirsch", "Muhammad T Idrees", "Chia-Sui Kao", "Fiona MacLean", "Andres Matoso", "Rohit Mehra", "Santosh Menon", "Kvetoslava Michalova", "Sambit K Mohanty", "Miguel Reyes-Mugica", "Maria Rosaria Raspollini", "Ankur R Sangoi", "Lynette M Sholl", "Stephanie Siegmund", "Satish K Tickoo", "Toyonori Tsuzuki", "Thomas M Ulbright", "Sean R Williamson", "Asli Yilmaz", "Daniel M Berney"], "affiliations": ["Department of Pathology, Indiana University, Indianapolis, IN, USA.", "Institute of Pathology, University Medical Center Göttingen, Göttingen, Germany.", "Department of Pathology, Mayo Clinic, Rochester, MN, USA.", "Department of Pathology, Universita Vita Salute San Raffaele, Milan, Italy.", "Department of Pathology, Medical University Vienna, Vienna, Austria.", "Department of Pathology, Koc University School of Medicine, Istanbul, Turkey.", "Department of Pathology, Sydney Medical School, University of Sydney, Sydney, NSW, Australia.", "Department of Pathology, University Hospital La Paz, Universidad Autónoma de Madrid, Madrid, Spain.", "Department of Pathology, MassGeneralBrigham/Harvard Medical School, Boston, MA, USA.", "Department of Pathology and Laboratory Medicine, Diagnostics Institute, Cleveland Clinic, Cleveland, OH, USA.", "Department of Pathology, Douglass Hanly Moir Pathology, Sonic Healthcare, Sydney, NSW, Australia.", "Department of Pathology, Johns Hopkins University, Baltimore, MD, USA.", "Department of Pathology, University of Michigan, Ann Arbor, MI, USA.", "Department of Pathology, Tata Memorial Centre, Mumbai, India.", "Department of Pathology, Charles University, Faculty of Medicine in Plzen, Biopticka Laborator, Ltd, Plzen, Czech Republic.", "Department of Pathology, CORE Diagnostics, Gurgaon, Haryana, India.", "Department of Pathology, University of Miami Miller School of Medicine, Miami, FL, USA.", "Histopathology and Molecular Diagnostics, University Hospital Careggi and University of Florence, Florence, Italy.", "Department of Pathology, Stanford University, Stanford, CA, USA.", "Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.", "Department of Surgical Pathology, Aichi Medical University, Nagakute, Japan.", "Department of Diagnostic and Molecular Pathology, Alberta Precision Labs and University of Calgary, Calgary, AB, Canada.", "Centre of Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute, Charterhouse Square, Queen Mary University of London, London, UK."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 31.89, "score_parts": {"urology_relevance": 10, "urology_in_title": 8.0, "journal_priority": 10.39, "top_journal_bonus": 0.0, "novelty": 1.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.1, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.39, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42420210", "title": "Prostate morcellation devices: a systematic review and meta-analysis of clinical outcomes and efficiency.", "abstract": "To systematically evaluate the efficiency and safety of different prostate morcellators used during prostate enucleation for benign prostatic hyperplasia (BPH). A systematic review was performed according to the Preferred Reporting Items for Systematic Review and Meta-analyses guidelines. PubMed/Medline, Scopus, and Web of Science were searched for studies published between October 2012 and May 2025. Studies reporting clinical outcomes of morcellators used during prostate enucleation were included. Primary outcome was morcellation efficiency (g/min). Secondary outcomes included intraoperative complications, device malfunction, and cost when available. Risk of bias (RoB) was assessed using the Risk Of Bias In Non-randomised Studies of Interventions (ROBINS-I), RoB 2 tool, and European Association of Urology case-series criteria. Random-effects meta-analyses and multilevel meta-regression adjusted for prostate volume were conducted. A total of 22 studies comprising 5980 patients were included, most undergoing holmium laser enucleation of the prostate. The most frequently evaluated devices were the Piranha™ (Richard Wolf GmbH, Knittlingen, Germany) and Lumenis VersaCut™ (Lumenis Ltd., Yokneam, Israel; 12 and 13 studies, respectively), followed by DrillCut™ (Karl Storz SE & Co. KG, Tuttlingen, Germany), MultiCut™ (Asclepion Laser Technologies GmbH, Jena, Germany), and Cyber Blade™ (Quanta System SpA, Milan, Italy) systems. Unadjusted weighted mean morcellation efficiency was 7.80 g/min (95% confidence interval [CI] 6.26-9.34 g/min) for Piranha, 4.70 g/min (95% CI 3.61-5.79 g/min) for VersaCut, 5.90 g/min (95% CI 3.16-8.64 g/min) for DrillCut, and 9.59 g/min (95% CI 4.78-14.39 g/min) for MultiCut. In volume-adjusted meta-regression using Piranha as reference, VersaCut remained significantly less efficient (-2.75 g/min; 95% CI -4.58 to -0.92 g/min; P = 0.003), with an even greater difference in prostates >70 mL (-4.34 g/min). Bladder mucosal injury was the most frequently reported complication; however, relatively rare across all devices. Meta-analysis demonstrated a significantly higher risk with VersaCut compared to Piranha (risk ratio 3.22, 95% CI 1.81-5.71), with low heterogeneity. This systematic review provides a contemporary clinical benchmark of the efficiency and safety of currently available prostate morcellators. Oscillating blade systems, particularly the Piranha morcellator, demonstrated higher morcellation efficiency and a more favourable safety profile than reciprocating blade devices, with the largest performance differences observed in patients with larger prostates.", "journal": "BJU International", "pub_date": "2026-Oct", "publication_types": ["Journal Article", "Systematic Review", "Meta-Analysis"], "doi": "10.1111/bju.70362", "authors": ["Stessy Kutchukian", "Pietro Scilipoti", "Mikael Abi Abdallah", "Astrid La Rosa", "Tristan Filler", "Frédéric Panthier", "Marie Chicaud", "Stefano Moretto", "Steeve Doizi"], "affiliations": ["Sorbonne Université, GRC n°39, Santé de l'homme, Hôpital Tenon, Paris, France.", "Endolase Lab, GRC 20-Sorbonne Université and PIMM-Arts et Métiers ParisTech, Paris, France.", "Progress and Collaboration in Endourology Group (PACE), Paris, France.", "Department of Urology, Poitiers University Hospital, Poitiers, France.", "Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy.", "Vita-Salute San Raffaele University, Milan, Italy.", "Sorbonne Université, Service d'Urologie, AP-HP, Hôpital Tenon, Paris, France.", "Endourology Technology Section of European Association of Urology (EAU), Arnhem, The Netherlands.", "Department of Urology, Limoges University Hospital, Limoges, France."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 38.47, "score_parts": {"urology_relevance": 16, "urology_in_title": 8.0, "journal_priority": 10.47, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 2.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.4, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.47, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42420207", "title": "Does renal haemangioblastoma exist? Evidence for inclusion within the MTOR-associated renal cell carcinoma with fibromyomatous stroma spectrum.", "abstract": "", "journal": "Histopathology", "pub_date": "2026-Oct", "publication_types": ["Editorial"], "doi": "10.1007/s00428-026-04510-5", "authors": ["Sean R Williamson", "Reza Alaghehbandan"], "affiliations": ["Department of Pathology, Diagnostics Institute, Cleveland Clinic Foundation, Cleveland, OH, USA."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 19.39, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.39, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.1, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.39, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42417115", "title": "Impact of prostate mpMRI quality on diagnostic accuracy in prostate cancer: a prospective study.", "abstract": "To prospectively evaluate the influence of multiparametric magnetic resonance imaging (mpMRI) quality, as assessed by the Prostate Imaging Quality (PI-QUAL) score, on diagnostic accuracy in men undergoing prostate biopsy after external mpMRI at a tertiary referral center. From June 2024 to July 2025, a total of 246 consecutive patients referred for prostate biopsy after external mpMRI were prospectively enrolled. All patients underwent systematic biopsy with targeted biopsy when indicated. External mpMRI scans were centrally reviewed by expert uro-radiologists blinded to clinical and pathological data. Image quality and lesion grading were reassessed using PI-QUAL v2 and Prostate Imaging Reporting and Data System (PI-RADS) v2.1. Accuracy for clinically significant prostate cancer (csPCa; International Society of Urological Pathology [ISUP] grade ≥2) was assessed using receiver operating characteristic-derived area under the curve AUC before and after review, stratified by PI-QUAL (1-2 vs 3). Median age and prostate-specific antigen (PSA) were 66.5 years (interquartile range [IQR] 61-73) and 6.6 ng/mL (IQR 4.8-9.7), respectively, and csPCa was detected in 128 patients (52%). After review, 49 (20%), 113 (46%), and 84 (34%) mpMRI scans were classified as PI-QUAL 1, 2, and 3, respectively. The proportion of indeterminate PI-RADS 3 findings was 27% for PI-QUAL 1, 15% for PI-QUAL 2, and 8% for PI-QUAL 3. PI-QUAL 3 scans demonstrated greater diagnostic accuracy than PI-QUAL 1-2 (AUC 0.79 vs 0.66, P = 0.01). Central review improved csPCa detection in both PI-QUAL 1-2 (AUC 0.63 vs 0.78, P < 0.01) and PI-QUAL 3 (AUC 0.77 vs 0.89, P < 0.01) scans. High-quality mpMRI achieved approximately 15% higher diagnostic accuracy for csPCa and were associated with a lower prevalence of indeterminate findings than were low-quality MRI scans; centralized expert review reclassified nearly half of PI-RADS assessments. These findings support upfront high-quality mpMRI acquisition and PI-QUAL-based quality control to optimize diagnosis and reduce unnecessary procedures.", "journal": "BJU International", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1111/bju.70373", "authors": ["Donato Cannoletta", "Giorgio Brembilla", "Mattia Longoni", "Maria Elena Porzi", "Leonardo Quarta", "Alfonso Santangelo", "Pietro Scilipoti", "Paolo Zaurito", "Michele Brancaccio", "Simone Scuderi", "Francesco Barletta", "Michele Cosenza", "Giorgio Gandaglia", "Francesco Montorsi", "Francesco De Cobelli", "Alberto Briganti", "Armando Stabile"], "affiliations": ["Unit of Urology/Division of Oncology, Gianfranco Soldera Prostate Cancer Laboratory, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy.", "Department of Radiology, IRCCS San Raffaele Scientific Institute, Milan, Italy, Vita-Salute San Raffaele University, Milan, Italy."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=6", "score": 34.47, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 10.47, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 6.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.4, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.47, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42415229", "title": "Automated irrigation systems in mitigating laser-induced temperature during simulated ureteroscopy.", "abstract": "To compare the temperature changes with laser activation when providing irrigation with a pressure bag vs a fluid management system (FMS). Benchtop experiments were performed with a LithoVue™ Elite (Boston Scientific Corp., Marlborough, MA, USA) flexible ureteroscope placed through an 11/13-F ureteric access sheath into a benchtop pelvicalyceal kidney model. Room temperature saline irrigation, via the scope, was provided either with a pressure bag or FMS. Both systems were pressurised to 200 mmHg and left for 10 min. After 10 min, a holmium:yttrium-aluminium-garnet laser was activated at 20, 40, or 60 W for 90 s. Flow rate, irrigation pressure, intrarenal pressure and calyceal temperature were recorded continuously. Experiments were repeated five times. Benchtop empirical temperature data were compared to mathematical model predictions. The mathematical model was then used to predict calyx temperature as a function of flow rate in in vivo conditions. Pressure-bag irrigation flow rate declined from ~38 to ~25 mL/min (36%) over 10 min, whereas the FMS maintained stable flow of ~45 mL/min. Intrarenal pressure remained ≤30 mmHg in all experiments. Consequently, the benchtop calyx mean (standard deviation) temperature rise with pressure bag vs FMS irrigation was: at 20 W 7.9 (1.0)°C vs 6.4 (0.6)°C (P = 0.02); at 40 W 12.8 (3.2)°C vs 10.3 (1.7)°C (P = 0.15); at 60 W 17 (3.4)°C vs 12.4 (1.2)°C (P = 0.02). Irrigation flow rate is a key determinant of thermal risk during laser lithotripsy. An automated FMS can maintain consistent flow; mitigating temperature rise and thermal dose in a benchtop model.", "journal": "BJU International", "pub_date": "2026-Oct", "publication_types": ["Journal Article", "Comparative Study"], "doi": "10.1111/bju.70364", "authors": ["Richard Menzies-Wilson", "Jessica Williams", "Candace Rhodes", "Leilane Glienke", "William W Roberts", "Ben Turney"], "affiliations": ["Nuffield Department of Surgery, University of Oxford, Oxford, UK.", "Boston Scientific Corporation, Marlborough, MA, USA.", "Department of Urology, University of Michigan, Ann Arbor, MI, USA."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_clinical", "score": 24.47, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.47, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.4, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.47, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42414479", "title": "Functional and omics-based rationale for the induction of BRCAness by androgen receptor pathway inhibitors to sensitize prostate cancer to PARP inhibition, regardless of HRR status.", "abstract": "Two PARP inhibitors (PARPis), olaparib and talazoparib, have been approved in combination with androgen receptor pathway inhibitors (ARPIs) for metastatic castration-resistant prostate cancer (mCRPC) in Europe, regardless of homologous-recombination repair (HRR) status. However, the mechanism in HRR-negative patients remains unclear. We assessed PARP inhibitors (PARPis; olaparib, talazoparib) alone and with ARPIs (abiraterone, enzalutamide, apalutamide) in prostate cancer cell lines, metastatic patient-derived organoids (mPDOs), and LN-metastatic tissue slice cultures. HRDetect and multi-omics analyses were used to investigate response mechanisms. PARPi-ARPI combinations significantly reduced survival in LNCaP, DU145, and 22RV1 cells and produced greater cytotoxicity than either agent alone in all models. In three metastatic mPDOs, olaparib alone had no effect, whereas talazoparib reduced survival in one mPDO and ARPIs reduced survival in two. In all tested models, PARPi-ARPI combinations produced greater cytotoxicity than either agent alone. None of the mPDOs showed BRCAness by HRDetect. ARPIs downregulated RAD51 and induced a BRCAness-like state, with reduced RAD51 foci formation at DNA double-strand break sites and impaired repair capacity, thereby sensitizing cells to PARPis. In LN-metastatic tissue slice cultures, combination therapy reduced double-strand break repair capacity in 67% of samples. Proteomic analysis showed that olaparib suppressed prometastatic pathways, including epithelial-mesenchymal transition and angiogenesis. ARPIs induce a BRCAness-like phenotype through RAD51 downregulation and enhance PARPi sensitivity in metastatic prostate cancer models, supporting combined ARPI-PARPi therapy.", "journal": "British Journal of Cancer", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1200/JCO.2024.42.4_suppl.19", "authors": ["Mohamed E Elsesy", "Ayham Moustafa", "Su-Jung Oh-Hohenhorst", "Christian Müller", "Malik Alawi", "Thomas Mair", "Bente Siebels", "Zifan Hu", "Jan Hahn", "Susanne Burdak-Rothkamm", "Derya Tilki", "Hartmut Schlüter", "Cordula Petersen", "Tobias Maurer", "Gunhild von Amsberg", "Carsten Bokemeyer", "Kai Rothkamm", "Wael Y Mansour"], "affiliations": ["Department of Radiotherapy and Radiooncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.", "Pharmacology and Experimental Oncology Unit, Cancer Biology Department, National Cancer Institute, Cairo University, Cairo, Egypt.", "Section for Mass Spectrometry and Proteomics, Center for Diagnostics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.", "Martini-Klinik Prostate Cancer Center; University Medical Center Hamburg-Eppendorf, Hamburg, Germany.", "Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany.", "Bioinformatics Core, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.", "Mildred Scheel Cancer Career Center HaTriCS4, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.", "Department of Urology, Koc University Hospital, Istanbul, Türkiye.", "Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology; University Medical Center Hamburg-Eppendorf, Hamburg, Germany.", "Department of Radiotherapy and Radiooncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. w.mansour@uke.de.", "Mildred Scheel Cancer Career Center HaTriCS4, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. w.mansour@uke.de.", "Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology; University Medical Center Hamburg-Eppendorf, Hamburg, Germany. w.mansour@uke.de."], "corresponding_authors": ["Wael Y Mansour"], "china_team": "", "category": "basic", "classification_reason": "basic_signals=14", "score": 39.01, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 11.01, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 14.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 6.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 3.01, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "雄激素受体抑制剂诱导BRCAness增敏PARP抑制", "chinese_summary": "10月Br J Cancer发表研究，在前列腺癌细胞系、转移性患者来源类器官及淋巴结转移组织切片中评估PARP抑制剂联合雄激素受体通路抑制剂，发现ARPI通过下调RAD51诱导BRCAness样状态，使细胞对PARP抑制剂更敏感，联合方案在各模型中均优于单药，且不受HRR状态限制。", "abstract_zh": "两种PARP抑制剂（PARPis），奥拉帕利和他拉唑帕利，已在欧洲获批与雄激素受体通路抑制剂（ARPIs）联合用于转移性去势抵抗性前列腺癌（mCRPC），无论同源重组修复（HRR）状态如何。然而，在HRR阴性患者中的机制仍不清楚。我们在前列腺癌细胞系、转移性患者来源类器官（mPDOs）和淋巴结转移组织切片培养中评估了PARP抑制剂（PARPis；奥拉帕利、他拉唑帕利）单独及与ARPIs（阿比特龙、恩扎卢胺、阿帕他胺）联合的效果。使用HRDetect和多组学分析研究应答机制。PARPi-ARPI联合显著降低了LNCaP、DU145和22RV1细胞的存活，并在所有模型中比任一单药产生更大的细胞毒性。在三个转移性mPDOs中，奥拉帕利单独无效，而他拉唑帕利降低了一个mPDO的存活，ARPIs降低了两个的存活。在所有测试模型中，PARPi-ARPI联合比任一单药产生更大的细胞毒性。没有一个mPDO通过HRDetect显示BRCAness。ARPIs下调RAD51并诱导BRCAness样状态，DNA双链断裂位点的RAD51焦点形成减少，修复能力受损，从而使细胞对PARPis敏感。在淋巴结转移组织切片培养中，联合治疗降低了67%样本的双链断裂修复能力。蛋白质组分析显示奥拉帕利抑制了促转移通路，包括上皮-间质转化和血管生成。ARPIs通过下调RAD51诱导BRCAness样表型，并在转移性前列腺癌模型中增强PARPi敏感性，支持ARPI-PARPi联合治疗。"}, {"pmid": "42400296", "title": "Outcomes of maintenance BCG versus gemcitabine/docetaxel following BCG induction in NMIBC.", "abstract": "To compare the oncologic outcomes and safety profiles of Bacillus Calmette-Guérin (BCG) versus gemcitabine/docetaxel (Gem/Doce) maintenance following BCG induction in treatment-naïve non-muscle-invasive bladder cancer (NMIBC). We identified patients with treatment-naive NMIBC who received induction BCG followed by maintenance BCG per the Southwest Oncology Group Cancer Research Network protocol or Gem/Doce monthly for 1 year (2016-2026). Oncological outcomes included recurrence-free survival (RFS), high-grade RFS, progression-free survival, and metastasis-free survival. Adverse events were systematically assessed to evaluate treatment tolerability. Overall, 128 patients received BCG induction followed by either BCG maintenance (n = 98; 76.6%) or Gem/Doce maintenance (n = 30; 23.4%). After a median follow-up of 75.0 months (interquartile range [IQR] 66.7-86.5) in the BCG group and 22.5 months (IQR 14.8-42.9) in the Gem/Doce group (P < 0.001), 3-year RFS (80.0% vs. 83.8%; P = 0.8), 3-year high-grade RFS (83.4% vs. 92.2%; P = 0.7), 3-year progression-free survival (90.0% vs. 96.6%; P = 0.4), and 3-year metastasis-free survival (96.8% vs. 100.0%; P = 0.3) were comparable between the BCG and Gem/Doce maintenance groups, respectively. Multivariable Cox regression analysis confirmed that Gem/Doce versus BCG maintenance was not associated with disease recurrence (hazard ratio 1.04; 95% confidence interval 0.39-2.83; P > 0.9). Overall, Gem/Doce maintenance was better tolerated, with fewer patients reporting adverse events (6.7% vs. 28%, P = 0.02) and no severe events observed during the maintenance phase. Limitations of the study include its retrospective design and the relatively small sample size of the Gem/Doce cohort. Sequential Gem/Doce maintenance following BCG induction achieved oncologic outcomes comparable to those with BCG maintenance, with improved tolerability, highlighting its feasibility as an alternative in cases of BCG intolerance or shortage.", "journal": "BJU International", "pub_date": "2026-Oct", "publication_types": ["Journal Article", "Comparative Study"], "doi": "10.1111/bju.70375", "authors": ["Pierre-Etienne Gabriel", "Alec Zhu", "Christopher G Karim", "Ahmed Eraky", "Raghav Gupta", "Reuben Ben-David", "Reza Mehrazin", "Peter Wiklund", "John P Sfakianos"], "affiliations": ["Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USA.", "Rutgers New Jersey Medical School, Newark, NJ, USA.", "Tel Aviv Sourasky Medical Center, Tel Aviv, Israel."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_clinical", "score": 25.47, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 10.47, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 9.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.4, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.47, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42399196", "title": "Diagnosis and Staging of Patients with Prostate Cancer: Report from the 2025 Advanced Prostate Cancer Consensus Conference (APCCC) Diagnostics.", "abstract": "For over a decade the Advanced Prostate Cancer Consensus Conference (APCCC) covers a variety of topics that greatly impact daily practice. In 2025, a dedicated event was organised to discuss key questions in clinical management of patients with prostate cancer (PC) related to diagnostic tools (APCCC Diagnostics). Here we present the voting results of the APCCC Diagnostics questions. APCCC Diagnostics 2025 is a pilot project. The scientific committee for APCCC Diagnostics 2025 developed 88 multiple-choice consensus questions on six different topics. Prior to the conference, the panel members (''panellists'') voted on these questions via a web-based survey. Consensus was defined as ≥75% agreement, with strong consensus defined as ≥90% agreement. Consensus was only reached on 17 of 88 questions (19%), of which six (7%) received a strong consensus. Specifically, consensus was reached for two of 17 questions (14%) in \"how to diagnose PC\"; seven of 16 (44%) in \"how to stage PC\"; three of 14 (21%) in \"Biochemical Recurrence Scenario\"; two of 11 (18%) in \"metastatic disease: what to do?\"; zero of 18 (0%) in \"monitoring metastatic PC\"; and three of 12 (25%) in \"radioligand therapy and imaging.\" The voting results and their discussion may assist physicians in navigating controversial areas of clinical management related to diagnosis, staging, and restaging in the different clinical settings for PC, particularly where high-level evidence is scarce or conflicting. The findings can also help funders and policymakers in prioritising areas for future research.", "journal": "European Urology", "pub_date": "2026-Oct", "publication_types": ["Consensus Statement", "Journal Article"], "doi": "10.1016/j.eururo.2026.06.009", "authors": ["Stefano Fanti", "Fabio Turco", "Bertrand Tombal", "Jochen Walz", "Michael S Hofman", "Boris Hadaschik", "Louise Emmett", "Derya Tilki", "Giovanna Pecoraro", "Giuseppe Salfi", "Gerhardt Attard", "Himisha Beltran", "Anders Bjartell", "Alberto Briganti", "Irene A Burger", "Elena Castro", "Juliano J Cerci", "Arturo Chiti", "Matthew Cooperberg", "Karim Fizazi", "Nicola Fossati", "Andrei Gafita", "Andrea Gallina", "Karolien Goffin", "Lisa G Horvath", "Jonas Hugosson", "Andrei Iagaru", "Nicholas D James", "Veeru Kasivisvanathan", "Dow-Mu Koh", "Glen Kristiansen", "Rakesh Kumar", "Frederic Lecouvet", "Stacy Loeb", "Rana R McKay", "Michael J Morris", "Declan G Murphy", "Vedang Murthy", "Natacha Naoun", "Daniela E Oprea-Lager", "Piet Ost", "Joe O'Sullivan", "Anwar R Padhani", "Ganesh Palapattu", "Gaetano Paone", "Giuseppe Petralia", "Monique J Roobol", "Oliver A Sartor", "Mike Sathekge", "David M Schuster", "Tyler M Seibert", "Daniel E Spratt", "Clare Tempany", "Nina Tunariu", "H Alberto Vargas", "Ursula M Vogl", "Alexander W Wyatt", "Thomas Zilli", "Hui-Ming Lin", "Aurelius Omlin", "Silke Gillessen", "Ken Herrmann"], "affiliations": ["Department of Nuclear Medicine, IRCCS AOU Bologna, Bologna, Italy.", "Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland. Electronic address: turcofabio9@gmail.com.", "Division of Urology, Clinique Universitaire St. Luc, Brussels, Belgium.", "Department of Urology, Institut Paoli-Calmettes Cancer Center, Marseille, France.", "Prostate Cancer Theranostics and Imaging Centre of Excellence, Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.", "Department of Urology, University of Duisburg-Essen, Essen, Germany; German Cancer Consortium, University Hospital Essen, Essen, Germany.", "Department of Theranostics and Nuclear Medicine, St. Vincent's Hospital, Sydney, Australia; Faculty of Medicine, UNSW Sydney, Sydney, Australia.", "Martini-Klinik Prostate Cancer Center, University Hospital Hamburg Eppendorf, Hamburg, Germany; Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Department of Urology, Koc University Hospital, Istanbul, Türkiye.", "Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland; Institute of Oncology Research (IOR), Bellinzona, Switzerland; Clinical and Translational Oncology, Scuola Superiore Meridionale, Napoli, Italy.", "Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland; Institute of Oncology Research (IOR), Bellinzona, Switzerland.", "UCL Cancer Institute, University College London, London, UK.", "Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.", "Department of Urology, Skåne University Hospital, Malmö, Sweden.", "Unit of Urology/Division of Oncology, Urological Research Institute, IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Milan, Italy.", "Department of Nuclear Medicine, Kantonsspital Baden, Affiliated Hospital for Research and Teaching of the Faculty of Medicine of the University of Zurich, Baden, Switzerland.", "Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain.", "Hospital Nossa Senhora das Graças, Curitiba, Brazil.", "Nuclear Medicine Department, IRCCS San Raffaele Hospital, Milan, Italy; Faculty of Medicine, Vita-Salute San Raffaele University, Milan, Italy.", "Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA; Department of Urology, University of California San Francisco, San Francisco, CA, USA; Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, USA.", "Department of Cancer Medicine, Centre Oscar Lambret, Institut Gustave Roussy, University of Paris Saclay, Villejuif, France.", "Department of Surgery (Urology Service), Ente Ospedaliero Cantonale, Università della Svizzera Italiana Lugano, Switzerland.", "Ahmanson Translational Theranostics, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, University of California, Los Angeles, CA, USA.", "Department of Nuclear Medicine, UZ Leuven, Division of Nuclear Medicine and Molecular Imaging, KU Leuven, Leuven, Belgium.", "Chris O'Brien Lifehouse, University of Sydney, Sydney, Australia.", "Department of Urology, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.", "Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, Stanford, CA, USA.", "Institute of Cancer Research, London, UK.", "Centre for Urology Imaging, Prostate, AI and Surgical Studies (COMPASS) Research Group, Division of Surgery and Interventional Science, UCL, London, UK; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.", "Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK.", "Institute of Pathology, Bonn, Germany.", "Department of Nuclear Medicine, All India Institute of Medical Sciences, India.", "Department of Radiology and Medical Imaging, Cliniques Universitaires Saint Luc, Institut de Recherche Expérimentale et Clinique (IREC), Institut du Cancer Roi Albert II (IRA2), Université Catholique de Louvain (UCLouvain), Brussels, Belgium.", "Department of Urology and Population Health, New York University Langone Health, New York, NY, USA; Department of Surgery/Urology, Manhattan Veterans Affairs, New York, NY, USA.", "University of California San Diego, La Jolla, CA, USA.", "Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.", "Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne Australia; Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia.", "Radiation Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.", "Department of Medical Oncology, Gustave Roussy, Paris Saclay University, Villejuif, France.", "Department of Medical Imaging, Radboud University Medical Center, Nijmegen, the Netherlands.", "Department of Radiation Oncology, Iridium Network, Antwerp, Belgium; Department of Human Structure and Repair, Ghent University, Ghent, Belgium.", "Patrick G. Johnston Centre for Cancer Research, Queen's University, Belfast, UK.", "Paul Strickland Scanner Centre, Mount Vernon Cancer Centre, Northwood, UK.", "Department of Urology, University of Michigan, Ann Arbor, MI, USA; Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA.", "Faculty of Biosciences, Università della Svizzera Italiana, Lugano, Switzerland; Clinic of Nuclear Medicine and Molecular Imaging, Istituto di Diagnostica Integrata della Svizzera Italiana (IDISI), EOC, Bellinzona, Switzerland.", "Division of Radiology, IEO European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy.", "Department of Urology, Erasmus University Medical Center, Cancer Institute, Rotterdam, the Netherlands.", "Department of Medical Oncology, Mayo Clinic Comprehensive Cancer Center, Rochester, MN, USA.", "Steve Biko Academic Hospital, Pretoria, South Africa; University of Pretoria, Pretoria, South Africa.", "Department of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, GA, USA.", "Departments of Radiation Medicine and Applied Sciences, Urology, Radiology, and Bioengineering, University of California San Diego School of Medicine, La Jolla, CA, USA.", "Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Cleveland, OH, USA.", "Department of Radiology, Massachusetts General Hospital, Boston, MA, USA.", "Drug Development Unit, The Institute of Cancer Research and The Royal Marsden Hospital NHS Foundation Trust, London, UK.", "New York University, New York, NY, USA.", "Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.", "Department of Urologic Sciences, Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, Canada; Department of Basic and Translational Research, BC Cancer, Vancouver, BC, Canada.", "Department of Radiation Oncology, Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland; Faculty of Biosciences, Università della Svizzera Italiana, Lugano, Switzerland.", "Onkozentrum Zurich, University of Zurich and Tumorzentrum Hirslanden Zurich, Zurich, Switzerland.", "Department of Medical Oncology, Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland; Faculty of Biosciences, Università della Svizzera Italiana Lugano, Switzerland.", "Department of Nuclear Medicine, University of Duisburg-Essen, Essen, Germany; German Cancer Consortium, University Hospital Essen, Essen, Germany."], "corresponding_authors": ["Fabio Turco"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 40.79, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 16.79, "top_journal_bonus": 10.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 25.2, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.79, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "前列腺癌诊断分期共识达成率低", "chinese_summary": "2025年晚期前列腺癌共识会议（APCCC Diagnostics）在Eur Urol发布投票结果，88个诊断与分期问题中仅17个达成共识（19%），其中6个为强共识。转移性前列腺癌监测18个问题无一达成共识，凸显该领域高级别证据匮乏，为未来研究优先方向提供参考。", "abstract_zh": "十余年来，晚期前列腺癌共识会议（APCCC）涵盖了广泛影响日常实践的多项议题。2025年，组织了一次专门活动，讨论前列腺癌（PC）患者临床管理中与诊断工具相关的关键问题（APCCC Diagnostics）。本文呈现APCCC Diagnostics问题的投票结果。APCCC Diagnostics 2025是一个试点项目。APCCC Diagnostics 2025科学委员会就六个不同主题制定了88个多项选择共识问题。会议前，专家组成员（“panellists”）通过基于网络的调查对这些问题进行投票。共识定义为≥75%同意，强共识定义为≥90%同意。88个问题中仅17个（19%）达成共识，其中6个（7%）获得强共识。具体而言，在“如何诊断PC”中17个问题有2个（14%）达成共识；在“如何分期PC”中16个有7个（44%）；在“生化复发场景”中14个有3个（21%）；在“转移性疾病：怎么办？”中11个有2个（18%）；在“监测转移性PC”中18个有0个（0%）；在“放射性配体治疗与影像”中12个有3个（25%）。投票结果及其讨论可帮助医生在不同临床情境下处理与PC诊断、分期和再分期相关的有争议的临床管理领域，尤其是在高级别证据稀缺或相互矛盾之处。这些发现还可帮助资助者和政策制定者确定未来研究的优先领域。"}, {"pmid": "42392908", "title": "Re: Twelve-month Results from the CISTO Study Comparing Radical Cystectomy Versus Bladder-sparing Therapy for Recurrent High-grade Non-muscle-invasive Bladder Cancer: Recurrent High-risk NMIBC: One Bladder, Choose Wisely.", "abstract": "", "journal": "European Urology", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1016/j.eururo.2026.05.013", "authors": ["Roberto Contieri", "Antoine G van der Heijden", "Laura S Mertens"], "affiliations": ["Department of Urology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Department of Urology, Istituto Nazionale Tumori di Napoli, IRCCS 'G. Pascale', Naples, Italy.", "Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands.", "Department of Urology, Netherlands Cancer Institute, Amsterdam, the Netherlands. Electronic address: ls.mertens@gmail.com."], "corresponding_authors": ["Laura S Mertens"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 39.79, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 16.79, "top_journal_bonus": 10.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 25.2, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.79, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "复发高危非肌层浸润性膀胱癌保膀胱与根治效果相近", "chinese_summary": "10月Eur Urol刊载CISTO研究12个月结果，对比复发高危非肌层浸润性膀胱癌行根治性膀胱切除与保膀胱治疗，提示两种策略在短期内疗效相当，为个体化选择保留膀胱提供依据。", "abstract_zh": "这是一篇关于CISTO研究的评论。CISTO研究比较了根治性膀胱切除术与保膀胱治疗用于复发性高级别非肌层浸润性膀胱癌的12个月结果：复发性高危非肌层浸润性膀胱癌，一个膀胱，谨慎选择。"}, {"pmid": "42392907", "title": "Re: Dries Develtere, Riccardo Bertolo. Cumulative Genitourinary Toxicity After Prostate Radiotherapy: High-Level Long-Term Randomized Evidence. J Clin Oncol. Online ahead of print. http://dx.doi.org/10.1200/JCO-26-00436.", "abstract": "", "journal": "European Urology", "pub_date": "2026-Oct", "publication_types": ["Letter"], "doi": "10.1016/j.eururo.2026.06.011", "authors": ["Astrid E Persson", "Gabriel Adrian"], "affiliations": ["Division of Oncology, Department of Clinical Sciences, Lund University, Lund, Sweden; Department of Hematology, Oncology, and Radiation Physics, Skåne University Hospital, Lund, Sweden. Electronic address: astrid.persson@med.lu.se.", "Division of Oncology, Department of Clinical Sciences, Lund University, Lund, Sweden; Department of Hematology, Oncology, and Radiation Physics, Skåne University Hospital, Lund, Sweden."], "corresponding_authors": ["Astrid E Persson"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=4", "score": 42.79, "score_parts": {"urology_relevance": 7, "urology_in_title": 8.0, "journal_priority": 16.79, "top_journal_bonus": 10.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 4.0}, "journal_metrics": {"status": "ok", "impact_factor": 25.2, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.79, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "前列腺放疗泌尿毒性累积证据受关注", "chinese_summary": "2026年10月Eur Urol刊发通讯，围绕Dries Develtere与Riccardo Bertolo在J Clin Oncol发表的长期随机证据展开讨论，聚焦前列腺放疗后累积性泌尿生殖毒性的评估。原研究以高水平随机数据提示放疗后毒性随随访累积，为患者长期随访与毒性管理提供依据。", "abstract_zh": "Re: Dries Develtere, Riccardo Bertolo. Cumulative Genitourinary Toxicity After Prostate Radiotherapy: High-Level Long-Term Randomized Evidence. J Clin Oncol. Online ahead of print. http://dx.doi.org/10.1200/JCO-26-00436.\n\n致编辑：Dries Develtere、Riccardo Bertolo。前列腺放疗后累积性泌尿生殖毒性：高水平长期随机证据。《临床肿瘤学杂志》。在线先于印刷版。http://dx.doi.org/10.1200/JCO-26-00436。"}, {"pmid": "42389990", "title": "Letter: Cost-Effectiveness of Immune Checkpoint Inhibitor Therapy Plus Bacillus Calmette-Guérin for High-Risk Nonmuscle-Invasive Bladder Cancer: Analyses of CREST, POTOMAC, and ALBAN.", "abstract": "", "journal": "Journal of Urology", "pub_date": "2026-Oct", "publication_types": ["Letter"], "doi": "10.1097/JU.0000000000005178", "authors": ["Li Wang", "Fei Zhang"], "affiliations": ["Department of Urology, Ningbo No. 2 Hospital, Ningbo, Zhejiang, China."], "corresponding_authors": [], "china_team": "Department of Urology, Ningbo No Fei Zhang团队", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 20.01, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 11.01, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 6.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 3.01, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42389925", "title": "Ablative radiotherapy in castration-resistant prostate cancer.", "abstract": "To prove the oncological benefit of ablative radiotherapy in patients with up to five metastases from castration-resistant prostate cancer (CRPC) a single-centre randomised trial was initiated. This monocentric, randomised, phase II clinical trial enrolled patients with up to five prostate-specific membrane antigen-positive bone or lymph node metastases developing prostate-specific antigen (PSA) progression during androgen deprivation (ADT) or ADT and androgen-receptor targeted therapy. Participants were randomised (2:1) to receive metastasis-directed therapy (MDT) or observation (OBS) without changing systemic therapy. The primary endpoint was the proportion of patients having PSA progression within 1 year, with statistical analyses conducted using intention-to-treat principles. Here, results of a planned interim analysis of the primary endpoint are reported. A total of 30 patients (12 in the observation arm and 18 in the MDT arm) were enrolled, PSA progression within 1 year occurred in 44% of the MDT group vs 75% in the OBS group (P = 0.14, not significant). The median time to PSA progression was significantly longer in the MDT arm (12.4 months) compared to the OBS arm (2.9 months, P = 0.03). The pre-defined criteria to discontinue the study were not met. Limitations include the single-centre design and small sample size at interim analysis. This pre-planned interim analysis of the primary endpoint did not meet the discontinuation criteria of the study protocol, suggesting that MDT in oligometastatic CRPC may extend the time to PSA progression without immediate change of systemic therapy. The continuation of the study in a multicentre setting is planned (Institutional funding by the TU Dresden, ClinicalTrials.gov identifier: NCT04141709).", "journal": "BJU International", "pub_date": "2026-Oct", "publication_types": ["Journal Article", "Randomized Controlled Trial", "Clinical Trial, Phase II"], "doi": "10.1111/bju.70368", "authors": ["Tobias Hölscher", "Fabian Lohaus", "Lydia Koi", "Jörg Kotzerke", "Sebastian Hoberück", "Christian Thomas", "Angelika Borkowetz", "Steffen Löck", "Mechthild Krause", "Esther G C Troost"], "affiliations": ["Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.", "National Center for Tumor Diseases (NCT), NCT/UCC Dresden, A Partnership Between DKFZ, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, and Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany.", "OncoRay - National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.", "Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiooncology - OncoRay, Dresden, Germany.", "Department of Nuclear Medicine, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.", "Department of Urology, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.", "German Cancer Consortium (DKTK), Partner Site Dresden, and German Cancer Research Center (DKFZ), Heidelberg, Germany."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_interventional_trial", "score": 36.47, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.47, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 12.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.4, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.47, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42387207", "title": "De novo cancer-related mortality after solid organ transplantation in England: the EpCOT study.", "abstract": "Cancer is a major cause of mortality after solid organ transplantation (SOT). Quantifying this risk is difficult due to heterogeneous reports and methodological limitations. We conducted a population-based cohort study linking data between the UK Transplant Registry, National Cancer Registry, Civil Registration of Deaths, and Hospital Episode Statistics for all SOT recipients in England between 1st June 1992 and 31st December 2015. Among 50,762 SOT recipients, 22,361 deaths were recorded, of which 3550 (15.9%) were due to cancer, making it the second leading cause of mortality. Overall cancer (excluding non-melanomatous skin cancer) standardised mortality ratio (SMR) was 2.12 (95% CI: 2.05-2.19). Cancer mortality was highest among lung recipients (SMR 3.49; 95% CI: 2.96-4.06), and lowest in kidney recipients (SMR 2.00; 95% CI: 1.92-2.08). Non-Hodgkin's Lymphoma had highest mortality after SOT (SMR 9.86; 95% CI: 9.01-10.75) and was elevated across all transplant types. However, liver and kidney cancer mortality was disproportionately elevated among liver (SMR: 9.30; 95% CI: 7.53-11.24) and kidney transplant recipients (SMR: 5.11; 95% CI: 4.34-5.93), respectively. Several cancers showed no increased mortality. De novo cancer remains a major cause of long-term mortality after SOT in England, with risk stratified by cancer and/or allograft.", "journal": "British Journal of Cancer", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1007/s00403-017-1724-5", "authors": ["Charlotte Stephens", "David Winter", "Mike Hawkins", "Raoul Reulen", "Adnan Sharif"], "affiliations": ["Department of Nephrology and Transplantation, University Hospital Birmingham, Birmingham, UK.", "Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.", "Applied Health Sciences, University of Birmingham, Birmingham, UK.", "Department of Nephrology and Transplantation, University Hospital Birmingham, Birmingham, UK. adnan.sharif@uhb.nhs.uk.", "Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK. adnan.sharif@uhb.nhs.uk."], "corresponding_authors": ["Adnan Sharif"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 20.01, "score_parts": {"urology_relevance": 6, "urology_in_title": 0.0, "journal_priority": 11.01, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 1.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 6.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 3.01, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42386399", "title": "Re: McKay RR, Pal S, Xie W, et al. Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert Consensus on the Management of Renal Cell and Urinary Tract Cancers. CA Cancer J Clin 2026;76:e70052.", "abstract": "", "journal": "European Urology", "pub_date": "2026-Oct", "publication_types": ["Letter"], "doi": "10.1016/j.eururo.2026.06.014", "authors": ["Giuseppe Di Lorenzo", "Massimo Di Maio"], "affiliations": ["Oncology Unit, \"Andrea Tortora\" Hospital, ASL Salerno, Pagani, Italy; UniCamillus-Saint Camillus International University of Health Sciences, Rome, Italy. Electronic address: giuseppe.dilorenzo@unicamillus.org.", "Department of Oncology, University of Turin, Medical Oncology 1U, AOU Città della Salute e della Scienza di Torino, Turin, Italy."], "corresponding_authors": ["Giuseppe Di Lorenzo"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 42.79, "score_parts": {"urology_relevance": 11, "urology_in_title": 8.0, "journal_priority": 16.79, "top_journal_bonus": 10.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 25.2, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.79, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "肾癌与尿路肿瘤管理共识获评述", "chinese_summary": "欧洲泌尿外科学刊10月刊登读者来信，围绕2025年晚期泌尿肿瘤共识会议发布的肾细胞癌与尿路肿瘤管理专家共识展开评述，聚焦当前治疗策略的争议与统一意见，为临床决策提供参考。", "abstract_zh": "Re: McKay RR, Pal S, Xie W, et al. Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert Consensus on the Management of Renal Cell and Urinary Tract Cancers. CA Cancer J Clin 2026;76:e70052."}, {"pmid": "42381433", "title": "F-URS with FANS versus mPCNL for 2-3 cm UUTS: a RCT with a subgroup analysis of 2-2.5 cm stones.", "abstract": "To evaluate the safety and efficacy of flexible ureteroscopy (f-URS) with a flexible and navigable suction ureteral access sheath (FANS) compared with mini-percutaneous nephrolithotomy (mPCNL) in the treatment of 2-3 cm upper urinary tract stones (UUTS), with a prespecified subgroup analysis for stones ≥2 to <2.5 cm. This randomized controlled trial enrolled 326 patients with 2-3 cm UUTS between June 2023 and December 2025. Patients were randomly assigned in a 1:1 ratio to undergo either f-URS with FANS or mPCNL. A prespecified subgroup analysis was conducted for stones measuring ≥2 to <2.5 cm. The primary outcomes were the immediate and 1-month stone-free rate (SFR). Secondary outcomes included the operative duration, decrease in haemoglobin, hospital stay, and complication rate. The baseline characteristics were comparable between the two groups. In the overall 2-3 cm cohort, the FANS group achieved immediate and 1-month SFRs comparable to those of the mPCNL group. Although the operative time was longer in the FANS group, it was associated with significantly less haemoglobin loss and a shorter hospital stay, with no significant difference in infection-related complications. Notably, in the subgroup of stones ≥2 to <2.5 cm, the FANS group demonstrated a non-inferior SFR at both time points, and the operative time was not significantly longer than that of the mPCNL group. For 2-3 cm UUTS, f-URS with FANS offers a SFR comparable to that of mPCNL, along with the advantages of reduced blood loss and shorter hospitalization. In the ≥2 to <2.5 cm subgroup, FANS shows comprehensive benefits over mPCNL. These findings support FANS as an effective alternative to mPCNL for 2-3 cm stones and a potentially preferred option for stones measuring 2-2.5 cm.", "journal": "BJU International", "pub_date": "2026-Oct", "publication_types": ["Journal Article", "Randomized Controlled Trial", "Comparative Study"], "doi": "10.1111/bju.70367", "authors": ["Rui Wang", "Xingwang Qi", "Chunpeng Li", "Junkai Huang", "Linguo Xie", "Liwei Liu", "Haijie Xie", "Chunyu Liu"], "affiliations": ["Department of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China."], "corresponding_authors": [], "china_team": "Department of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China Chunyu Liu团队", "category": "clinical_review", "classification_reason": "publication_type_interventional_trial", "score": 28.47, "score_parts": {"urology_relevance": 7, "urology_in_title": 0.0, "journal_priority": 10.47, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 9.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.4, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.47, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42378344", "title": "Multi-Institutional Assessment of Performance Metrics for MRI-Targeted Transperineal Prostate Biopsy.", "abstract": "Evidence supports obtaining MRI before prostate biopsy. Deliverables of MRI include improving prostate cancer detection through targeting of MRI lesions and reducing the total number of biopsies by eliminating the need for nontargeted biopsy. The actionable intelligence metric (AIM) and reduction metric (ReM) have been proposed to quantify these 2 deliverables; however, this work was performed in the transrectal biopsy setting. To assess generalizability, we examined AIM and ReM in a large, multi-institutional cohort of men undergoing transperineal biopsy. All patients undergoing concurrent MRI-targeted and systematic transperineal biopsy and maintained in prospective prostate cancer databases across 5 institutions were included. AIM is the percent of men in whom targeted biopsy detected a higher Grade Group compared with systematic biopsy alone. ReM is the proportion of men in whom systematic biopsy may be omitted. In addition to total cohort evaluations of AIM and ReM, subgroup analyses and multivariable logistic regression were performed. In total, 1587 transperineal biopsies were analyzed; 797 (50%) had ≥ Grade Group 2 prostate cancer. AIM in the overall cohort was 27.4%, and ReM was 83.3%. When stratified by Prostate Imaging Reporting and Data System score and prior biopsy status, AIM and ReM were > 25% and > 80%, respectively, across all subgroups. On multivariable logistic regression, Prostate Imaging Reporting and Data System 5 lesions and biopsies performed at institution D were predictive of higher rates of upgrading on systematic biopsy, while patients with a prior negative biopsy had a decreased likelihood of systematic upgrading. AIM and ReM can be applied in the transperineal setting to assess deliverables of MRI-targeted prostate biopsy. Targeted biopsies provided actionable information in 27% of men, while up to 17% of clinically significant cancer would be missed if systematic biopsy were omitted. Individualized assessment of patient risk tolerance is necessary if a targeted biopsy-alone approach is to be adopted.", "journal": "Journal of Urology", "pub_date": "2026-Oct", "publication_types": ["Journal Article", "Multicenter Study"], "doi": "10.1097/JU.0000000000005196", "authors": ["Dylan M Buller", "Vlada Dubovic", "William E Martin", "Benjamin Rosenfeld", "Amanda Sherman", "William C Faust", "Serge Ginzburg", "Joseph R Wagner", "Andres F Correa", "Kevin Pinto", "Peter C Albertsen", "Alexander Kutikov", "Benjamin T Ristau"], "affiliations": ["University of Connecticut School of Medicine, Farmington, Connecticut.", "Hartford Healthcare, Hartford, Connecticut.", "Lahey Hospital and Medical Center, Burlington, Massachusetts.", "Jefferson Einstein Hospital, Philadelphia, Pennsylvania.", "Fox Chase Cancer Center, Philadelphia, Pennsylvania."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_clinical", "score": 33.01, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 11.01, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 8.0}, "journal_metrics": {"status": "ok", "impact_factor": 6.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 3.01, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42377936", "title": "Intense Incidental F-18 DOPA Uptake in Low-grade Prostate Adenocarcinoma: A Potential Diagnostic Pitfall.", "abstract": "F-18 DOPA PET/CT is well established in the evaluation of neuroendocrine tumors and pheochromocytoma/paraganglioma. Prostatic uptake is not part of its usual physiological biodistribution, and its significance in conventional prostate adenocarcinoma remains unclear. We report intense incidental prostatic F-18 DOPA uptake in a 60-year-old man undergoing evaluation for persistently elevated normetanephrines. PET/CT showed 2 highly avid foci in the posterior-inferior prostate. Multiparametric MRI was not suspicious, but biopsy revealed acinar adenocarcinoma, Gleason score 3+3, ISUP grade 1, without neuroendocrine marker expression. This finding represents a potential diagnostic pitfall and supports cautious interpretation of focal pelvic F-18 DOPA uptake.", "journal": "Clinical Nuclear Medicine", "pub_date": "2026-Oct-01", "publication_types": ["Journal Article", "Case Reports"], "doi": "10.1097/RLU.0000000000006596", "authors": ["Carlos Mas Pascasio", "Blanca Ruíz de Almirón de Andrés", "Estefanía López Rodríguez", "Salomé Sanz Viedma"], "affiliations": ["Department of Nuclear Medicine, Hospital Universitario Virgen de la Victoria, Málaga, Spain."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_clinical", "score": 25.46, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 7.46, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 9.6, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 3.46, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42373845", "title": "Circulating metabolite biomarkers associated with prostate cancer risk in Black Americans: findings from the Southern Community Cohort Study.", "abstract": "Despite the importance of metabolic reprogramming in prostate cancer initiation and progression, little is known about metabolic features associated with prostate cancer risk among Black Americans. This nested case-control study included 195 incident prostate cancer cases and 379 matched controls, focusing on Black Americans from the Southern Community Cohort Study. Using pre-diagnostic plasma samples, a global, semi-quantitative metabolomics assay was conducted. Multivariable-adjusted conditional logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (95% CIs) for prostate cancer risk associated with a one standard-deviation increase in log-transformed metabolite levels. A total of 26 metabolites were associated with incident prostate cancer at p < 0.01. Of them, seven metabolites were independently associated with prostate cancer risk after mutual adjustment, including S-adenosylhomocysteine (SAH; OR [95% CI] = 0.69 [0.55-0.88]), 14-HDoHE/17-HDoHE (1.46 [1.17-1.83]), 1-linoleoyl-GPI (18:2)* (0.73 [0.57-0.92]), Sphingomyelin (d17:1/16:0, d18:1/15:0, d16:1/17:0)* (1.28 [1.03-1.59]), Gamma-glutamyl-epsilon-lysine (1.45 [1.14-1.85]), and 2,2'-Methylenebis(6-tert-butyl-p-cresol) (0.62 [0.40-0.95]). SAH and 14-HDoHE/17-HDoHE were exclusively linked to aggressive prostate cancer, while the other five metabolites were primarily associated with non-aggressive forms. We found several circulating metabolites as potential biomarkers for prostate cancer risk among Black Americans. Further large-scale studies are warranted to confirm our findings and to elucidate potential mechanisms.", "journal": "British Journal of Cancer", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.3390/cancers16234116", "authors": ["Hyung-Suk Yoon", "Xiao-Ou Shu", "Jie Wu", "Maureen Sanderson", "Xiaofei Wang", "Wanqing Wen", "Regina Courtney", "Jae Jeong Yang", "William J Blot", "Wei Zheng", "Qiuyin Cai"], "affiliations": ["Department of Surgery, College of Medicine, University of Florida, Gainesville, FL, USA.", "University of Florida Health Cancer Institute, Gainesville, FL, USA.", "Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN, USA.", "Department of Family & Community Medicine, Meharry Medical College, Nashville, TN, USA.", "Department of Biological Sciences, Tennessee State University, Nashville, TN, USA.", "Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN, USA. qiuyin.cai@vanderbilt.edu."], "corresponding_authors": ["Qiuyin Cai"], "china_team": "", "category": "basic", "classification_reason": "basic_signals=6", "score": 31.51, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 11.01, "top_journal_bonus": 0.0, "novelty": 0.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 6.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 6.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 3.01, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "黑人前列腺癌风险关联代谢物", "chinese_summary": "10月Br J Cancer发布南方社区队列研究，纳入195例黑人前列腺癌患者与379例匹配对照，于诊断前血浆中检出26种代谢物与发病相关，其中7种经互调后独立关联，S-腺苷同型半胱氨酸和14-HDoHE/17-HDoHE仅与侵袭性前列腺癌相关，为黑人群体风险分层提供候选标志物。", "abstract_zh": "尽管代谢重编程在前列腺癌的发生和进展中具有重要作用，但关于黑人美国人中与前列腺癌风险相关的代谢特征仍知之甚少。本巢式病例对照研究纳入195例新发前列腺癌病例和379例匹配对照，聚焦于南方社区队列研究中的黑人美国人。研究使用诊断前血浆样本，进行了全局性半定量代谢组学检测。采用多变量校正的条件logistic回归，估计对数转化代谢物水平每增加一个标准差与前列腺癌风险相关的比值比（OR）和95%置信区间（95% CI）。共有26种代谢物在p<0.01水平与新发前列腺癌相关。其中，经相互校正后，有七种代谢物与前列腺癌风险独立相关，包括S-腺苷同型半胱氨酸（SAH；OR [95% CI]=0.69 [0.55-0.88]）、14-HDoHE/17-HDoHE（1.46 [1.17-1.83]）、1-亚油酰-GPI（18:2）*（0.73 [0.57-0.92]）、鞘磷脂（d17:1/16:0, d18:1/15:0, d16:1/17:0）*（1.28 [1.03-1.59]）、γ-谷氨酰-ε-赖氨酸（1.45 [1.14-1.85]）和2,2'-亚甲基双(6-叔丁基对甲酚)（0.62 [0.40-0.95]）。SAH和14-HDoHE/17-HDoHE仅与侵袭性前列腺癌相关，而其他五种代谢物主要与非侵袭性形式相关。我们发现了几种循环代谢物可作为黑人美国人前列腺癌风险的潜在生物标志物。需要进一步的大规模研究来证实我们的发现并阐明潜在机制。"}, {"pmid": "42366676", "title": "Is Nonpapillary Puncture a Feasible Alternative to Papillary Access in Percutaneous Nephrolithotomy? A Systematic Review and Meta-Analysis.", "abstract": "Percutaneous nephrolithotomy (PCNL) is the gold standard for treating large and complex renal calculi, but puncture path selection (papillary vs nonpapillary) remains a critical debate because of bleeding risk concerns. This systematic review and meta-analysis aimed to compare the safety and efficacy of nonpapillary vs papillary access in PCNL. A comprehensive literature search was conducted in the PubMed, Embase, Web of Science, Wanfang, and China National Knowledge Infrastructure databases from inception to December 2025, supplemented by an unpublished dataset from our team's ongoing clinical study. Eligible studies were comparative trials reporting postoperative hemoglobin drop, complication rate, stone-free rate (SFR), or operative time. Quality assessment was performed using the Cochrane Risk of Bias Tool 2.0 and the Newcastle-Ottawa Scale, with statistical analysis conducted in Stata 17.0. A total of nine studies involving 1229 patients (787 in the papillary group and 442 in the nonpapillary group) were included. No significant differences were observed between nonpapillary and papillary access in terms of postoperative hemoglobin drop (mean difference [MD] = 0.159, 95% confidence interval [CI] = -0.365 to 0.683, p = 0.5519), overall complication rate (risk ratio [RR] = 0.949, 95% CI = 0.701 to 1.286, p = 0.7371), blood transfusion rate (RR = 0.835, 95% CI = 0.483-1.443, p = 0.5174), or SFR (RR = 0.970, 95% CI = 0.909-1.035, p = 0.3527). Although no significant overall difference in operative time was found (MD = -1.852, 95% CI = -6.745 to 3.040, p = 0.4580), subgroup analysis of prospective studies revealed that nonpapillary access was associated with a significantly shorter operative time (MD = -6.608, 95% CI = -11.573 to -1.643, p = 0.0091). Nonpapillary access is a safe and effective alternative to papillary access for PCNL, with comparable bleeding risk, complication rate, and SFR, and potential efficiency benefits in standardized settings. Urologists can flexibly select the puncture path based on clinical scenarios, with Doppler ultrasound preferred for avoiding vascular-rich regions. Future large-scale randomized controlled trials with standardized protocols and studies on artificial intelligence-assisted fused-image-guided puncture are warranted to further optimize PCNL access strategies.", "journal": "Journal of Endourology", "pub_date": "2026-Oct", "publication_types": ["Journal Article", "Systematic Review", "Meta-Analysis"], "doi": "10.1177/08927790261461244", "authors": ["Chengjian Ji", "Ziheng Su", "Xian Wu", "Yan Xu", "Xianghu Meng"], "affiliations": ["Department of Urology, Affiliated Hospital of Nanjing University of Chinese Medicine (Jiangsu Provincial Hospital of Chinese Medicine), Nanjing, China.", "School of Stomatology, Nanjing Medical University, Nanjing, China.", "Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.", "Department of Urology, School of Medicine, Knuppe Molecular Urology Laboratory, University of California, San Francisco, California, USA."], "corresponding_authors": [], "china_team": "Department of Urology, Affiliated Hospital of Nanjing University of Chinese Medicine (Jiangsu Provincial Hospital of Chinese Medicine), Nanjing, China Xianghu Meng团队", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 25.46, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 9.96, "top_journal_bonus": 0.0, "novelty": 1.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 8.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 1.96, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42362411", "title": "Histological Subtypes and Divergent Differentiation of Urothelial Carcinoma: Histology, Genomics, and Management Implications.", "abstract": "Histological subtypes and divergent differentiation are common in bladder cancer. Each subtype has distinct biology and clinical features. We aim to summarize pathology, molecular features, and outcomes of the most common bladder cancer subtypes to guide management. We performed a narrative review of cohort studies, clinical trials, and population-based analyses assessing morphology, immunophenotype, genomic alterations, and outcomes following various localized and systemic therapies in patients with bladder cancer subtypes. Histological subtypes are often understaged on transurethral resection of bladder tumor and commonly demonstrate lymph node metastasis, supporting early radical cystectomy (RC) even for certain clinically non-muscle-invasive bladder cancers. Small cell urothelial carcinoma (UC) consistently benefits from platinum/etoposide-based chemotherapy regimens, whereas predominant squamous, plasmacytoid, sarcomatoid, and micropapillary tumors demonstrate variable response rates to systemic therapies used in conventional UC. Trimodality therapy may approximate RC in locoregional control for small cell UC and appears inferior in cases with predominant squamous and adenocarcinoma. Genomic profiling highlights actionable alterations, albeit with unclear clinical implications. Immune checkpoint blockade and antibody-drug conjugates have been used sparingly against subtype bladder cancers and have anecdotally demonstrated activity across several subtypes. Histological subtypes and divergent differentiation of UC represent high-risk yet biologically distinct disease phenotypes that may not conform to the current \"one-size-fits-all\" treatment paradigm. More in-depth clinical and translational analyses with robust, adequately powered cohorts are required to further understand the clinical behavior of each unique bladder cancer subtype and to customize the optimal therapeutic strategies.", "journal": "European Urology", "pub_date": "2026-Oct", "publication_types": ["Journal Article", "Review"], "doi": "10.1016/j.eururo.2025.09.003", "authors": ["Can Aydogdu", "Laura Bukavina", "Liang Cheng", "Hikmat A Al-Ahmadie", "Omar Alhalabi", "Jason R Brown", "Antonio Lopez-Beltran", "Petros Grivas", "Clara Hwang", "G Daniel Grass", "Ashish M Kamat", "Jonathan Chatzkel", "Omar Mian", "Andrea Necchi", "Jeff Ross", "Andrea B Apolo", "Philippe E Spiess", "Roger Li"], "affiliations": ["Cleveland Clinic Glickman Urologic Institute & Lerner College of Medicine, Cleveland, OH, USA.", "Brown University/Lifespan Medical Center, Providence, RI, USA.", "Memorial Sloan Kettering Cancer Center, New York, NY, USA.", "The University of Texas MD Anderson Cancer Center, Houston, TX, USA.", "University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH, USA.", "University of Cordoba, Cordoba, Spain.", "Fred Hutch Cancer Center, University of Washington, Seattle, WA, USA.", "Henry Ford Health, Detroit, MI, USA.", "H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.", "The University of Texas MD Anderson Cancer Center, Houston TX, USA.", "Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.", "SUNY Upstate Medical University, Syracuse, NY, USA.", "Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA.", "H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA. Electronic address: Roger.Li@moffitt.org."], "corresponding_authors": ["Roger Li"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 61.79, "score_parts": {"urology_relevance": 16, "urology_in_title": 8.0, "journal_priority": 16.79, "top_journal_bonus": 10.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 9.0}, "journal_metrics": {"status": "ok", "impact_factor": 25.2, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.79, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "膀胱癌组织学亚型治疗应差异化", "chinese_summary": "欧洲泌尿外科杂志2026年10月发表综述，系统梳理膀胱癌组织学亚型及分化变异的病理、基因组与疗效差异，指出小细胞癌持续受益于铂类联合依托泊苷，而鳞状、浆细胞样、肉瘤样及微乳头亚型对常规系统治疗反应不一，提示现行“一刀切”策略或需个体化调整。", "abstract_zh": "组织学亚型和分化变异在膀胱癌中常见。每种亚型具有独特的生物学和临床特征。我们旨在总结最常见膀胱癌亚型的病理学、分子特征和结局，以指导管理。我们对队列研究、临床试验和基于人群的分析进行了叙述性综述，评估膀胱癌亚型患者的形态学、免疫表型、基因组改变以及接受各种局部和系统治疗后的结局。组织学亚型在经尿道膀胱肿瘤电切术中常被分期不足，且常显示淋巴结转移，支持即使对某些临床非肌层浸润性膀胱癌也进行早期根治性膀胱切除术（RC）。小细胞尿路上皮癌（UC）一致受益于铂类/依托泊苷为基础的化疗方案，而 predominant 鳞状、浆细胞样、肉瘤样和微乳头肿瘤对常规UC所用系统治疗的反应率各异。对于小细胞UC，三联治疗在局部区域控制方面可能接近RC，而在 predominant 鳞状和腺癌病例中似乎较差。基因组分析突出了可操作的改变，尽管临床意义尚不明确。免疫检查点阻断和抗体-药物偶联物在亚型膀胱癌中应用较少，并有个案显示在几种亚型中具有活性。UC的组织学亚型和分化变异代表高危但生物学上独特的疾病表型，可能不符合当前“一刀切”的治疗范式。需要更深入的临床和转化分析，以及稳健、充分把握度的队列，以进一步了解每种独特膀胱癌亚型的临床行为，并定制最佳治疗策略。"}, {"pmid": "42361214", "title": "With Great Cost Comes Great Responsibility: Who Will Own the Rising Costs of Bladder Cancer Care?", "abstract": "", "journal": "Journal of Urology", "pub_date": "2026-Oct", "publication_types": ["Editorial"], "doi": "10.1200/JCO.2025.43.16_suppl.4517", "authors": ["Daniel D Joyce", "Vidit Sharma", "Stephen A Boorjian"], "affiliations": ["Vanderbilt University Medical Center, Nashville, Tennessee.", "Mayo Clinic, Rochester, Minnesota."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 20.01, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 11.01, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 6.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 3.01, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "免疫联合BCG治疗高危膀胱癌不具成本效益", "chinese_summary": "《Journal of Urology》2026年9月发表研究，基于CREST、POTOMAC及ALBAN试验数据构建Markov模型，评估免疫检查点抑制剂联合BCG对比单用BCG治疗高危非肌层浸润性膀胱癌的成本效益。", "abstract_zh": "近期三项试验评估了免疫检查点抑制剂（ICI）联合卡介苗（BCG）治疗高危非肌层浸润性膀胱癌（NMIBC）。其中两项试验（CREST、POTOMAC）表明，与单用BCG相比，ICI联合BCG改善了无事件生存期，但治疗相关不良事件发生率更高。本文中，我们评估了ICI联合BCG与单用BCG相比的成本效益，并创建了一个公开可用的成本效益计算器，以促进未来NMIBC药物价值比较。我们使用Markov模型，比较sasanlimab联合BCG与单用诱导及维持BCG治疗BCG初治高危NMIBC。疗效和毒性概率提取自CREST试验。进行了单因素和概率敏感性分析。使用100,000美元/质量调整生命年（QALY）的支付意愿阈值比较增量成本效果比。使用POTOMAC和ALBAN数据重复分析。从美国Medicare支付方角度，与单用BCG相比，sasanlimab联合BCG方案增加了0.03个QALY（6.12 vs 6.09），额外成本为145,940美元。在全生命周期视角下，联合治疗不具成本效益（增量成本效果比=6,316,217美元/QALY）。单因素敏感性分析中，仅当sasanlimab成本降低超过94%（至1399美元/疗程）时，sasanlimab联合BCG才具成本效益。从英国视角及使用POTOMAC/ALBAN数据也得到类似结果。与单用BCG相比，ICI联合BCG作为联合治疗不具成本效益。需要进一步努力改善新疗法的疗效/毒性特征，同时持续审视新药物对卫生系统成本的影响仍有必要。"}, {"pmid": "42361212", "title": "Phentermine/Topiramate in Obese, Diabetic Uric Acid Stone Formers: An Open-Label Randomized Feasibility Trial.", "abstract": "The purpose of this study was to determine whether medical treatment of obesity, diabetes, and low urine pH with combination phentermine/topiramate affects uric acid (UA) kidney stone burden. Participants with obesity, diabetes mellitus, normal renal function, urine pH < 5.8, and stone analysis ≥ 80% UA were block randomized (2:1 ratio) to phentermine 18.75 mg/topiramate 100 mg vs pragmatic controls for an 18-month, prospective, open-label feasibility study with dose escalation. The primary outcome was change in CT stone volume. Secondary outcomes included medication adherence; patient safety; and change in anthropometrics, laboratory studies, and body composition. Nineteen participants (age 62.1 ± 9.8 years; 68% male; mean BMI = 36.3 ± 2.9 kg/m2) were randomized, and 15 completed the study with 73% pill adherence and no serious adverse events. Stone volume by intention-to-treat analysis fell by 52% in the intervention group and rose by 8.6% in the control group (P = .10), with per-protocol analysis demonstrating statistically significant stone volume reduction (P = .02). At study end and compared with means of controls, the intervention group had greater weight loss (-10.2 vs +2.9 kg), reduction in hemoglobin A1c levels (-0.2 vs +0.5), lower 24-hour urine citrate (309 ± 81 vs 951 ± 782 mg), and lower UA supersaturation (0.7 ± 1.1 vs 1.8 ± 1.0), along with higher 24-hour urine pH (6.2 ± 0.5 vs 5.5 ± 0.4) and calcium phosphate supersaturation (0.9 ± 0.8 vs 0.2 ± 0.1; all P < .05). Among obese participants with diabetes mellitus and UA nephrolithiasis, phentermine/topiramate was well tolerated and demonstrated significant stone burden reductions by per-protocol analysis. The intervention group also had greater weight loss, higher urinary pH, and lower hemoglobin A1c and urinary citrate levels. These data provide a framework to study the impact of this novel alternative UA therapy on a wider range of patients with obesity and diabetes.", "journal": "Journal of Urology", "pub_date": "2026-Oct", "publication_types": ["Journal Article", "Pragmatic Clinical Trial", "Randomized Controlled Trial"], "doi": "10.1097/JU.0000000000005189", "authors": ["Benjamin K Canales", "Joshua Heiman", "Russell Terry", "Vincent G Bird", "John DiBianco", "John Marks", "Muna T Canales"], "affiliations": ["Department of Urology, University of Florida, Gainesville, Florida.", "Department of Medicine, Division of Nephrology, Hypertension, and Transplantation, University of Florida, Gainesville, Florida."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_interventional_trial", "score": 37.01, "score_parts": {"urology_relevance": 11, "urology_in_title": 0.0, "journal_priority": 11.01, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 12.0}, "journal_metrics": {"status": "ok", "impact_factor": 6.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 3.01, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42360093", "title": "Artificial intelligence in genitourinary oncology: publication trends and systematic review.", "abstract": "To conduct an analysis of publication trends and a systematic review of randomized controlled trials (RCTs) to characterize the current state of artificial intelligence (AI) use in genitourinary (GU) oncology, as AI has emerged as a transformative tool in healthcare with potential applications in diagnostics, treatment planning, and prognostication. We searched the Medical Literature Analysis and Retrieval System Online (MEDLINE), Excerpta Medica dataBASE (EMBASE; Ovid), and Cumulative Index to Nursing and Allied Health Literature (CINAHL) Ultimate for studies related to AI and GU oncology, excluding non-English papers, non-human studies, review articles, and articles using AI solely for manuscript writing. Publication trends were analysed from 2013 to 2023 and categorized by study design and cancer type. RCTs were evaluated through systematic review using Covidence (Veritas Health Innovation Ltd, Melbourne, Victoria, Australia) for screening and data extraction. Two reviewers independently assessed all studies, with risk of bias (RoB) evaluated using the Cochrane RoB 2.0 tool. Of 2409 articles identified, 1220 met inclusion criteria. These included 962 retrospective articles, 175 prospective studies, 79 studies with combined retrospective/prospective methods, and four RCTs. Studies most commonly addressed prostate (n = 923), renal (n = 274), and urothelial (n = 194) cancers. Publications grew from 14 in 2013 to 362 in 2023, with substantial acceleration in 2019. Four RCTs were identified - one in urothelial cancer and three in prostate cancer. Two RCTs evaluated AI-based diagnostics, demonstrating improved performance over conventional methods; the remaining two RCTs evaluated AI in prognostication and treatment planning, showing improved gains in imaging interpretation and operational efficiency. RoB varied across studies, primarily related to randomisation and deviations from intended interventions. Artificial intelligence research in GU oncology has grown, although high-level evidence from RCTs remains limited. Existing trials underscore AI's promise in diagnostics, prognostication, and treatment planning, and the rapidly evolving nature of this field warrants continued prospective investigation.", "journal": "BJU International", "pub_date": "2026-Oct", "publication_types": ["Journal Article", "Systematic Review"], "doi": "10.1111/bju.70361", "authors": ["Alee Kim", "Nicole A Moore", "Tammy Dong", "Kelsy Fu", "Katie Keyser", "Shari Clifton", "Adanma Ayanambakkam", "Ryan Nipp"], "affiliations": ["The University of Oklahoma College of Medicine, Oklahoma City, OK, USA.", "Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 41.47, "score_parts": {"urology_relevance": 11, "urology_in_title": 8.0, "journal_priority": 10.47, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 9.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.4, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.47, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42350634", "title": "A nationwide histopathology study reflecting the impact of the introduction of MRI in the diagnostic trajectory of prostate cancer in routine clinical care.", "abstract": "Magnetic resonance imaging (MRI), introduced into European (2019) and Dutch (2020) guidelines, reshaped prostate cancer (PCa) diagnostics by altering biopsy indications and strategies. In expert-center studies MRI-based diagnostics reduces biopsy rates and ISUP Grade Group (GG) 1 detection, while maintaining or increasing GG ≥ 2 detection compared to systematic biopsies. We evaluated nationwide biopsy outcomes during MRI adoption in routine practice in the Netherlands. Retrospective nationwide study of histopathology reports from all diagnostic biopsies in men without prior PCa in the Netherlands (2015-2021), retrieved from the Dutch nationwide pathology databank (Palga). Outcomes included annual biopsy volumes and proportions cancer-negative, GG1 and GG ≥ 2 biopsies. MRI-related terminology served as a proxy for MRI use. ISUP GG concordance between biopsy and radical prostatectomy (RP), defined as identical highest GG in biopsy and RP specimen, was assessed. The Mann-Kendall test evaluated monotonic time trends. Among 127,856 biopsies (116,711 men), annual diagnostic biopsy numbers decreased from 18,719 (2015) to 17,094 (2021; -8.7%, p = 0.13). Cancer-negative biopsies declined from 49% to 29% (p = 0.003), while GG ≥ 2 detection increased from 30% to 53% (p = 0.002). GG1 detection minimally decreased (20% to 18%, p = 0.02). MRI terminology in pathology reports increased (8.2% to 51%) and biopsy-RP GG concordance improved (51% to 60%, p = 0.007). Analyses could not adjust for increased opportunistic PSA screening or adjunct diagnostic tool use. Nationwide Dutch pathology data show improved diagnostic efficiency and efficacy over time, with fewer biopsies, fewer cancer-negative biopsies, and increased GG ≥ 2 detection. These findings coincide with rising estimated MRI uptake, suggesting MRI-driven diagnostic improvements.", "journal": "Prostate Cancer and Prostatic Diseases", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1038/s41391-026-01134-3", "authors": ["Anne M A Prinsen", "Stefan Slagter", "Ivo G Schoots", "Geert J L H van Leenders", "Harm H E van Melick", "J P Michiel Sedelaar", "Diederik M Somford", "Roderick C N van den Bergh"], "affiliations": ["Department of Urology, St. Antonius Hospital, Nieuwegein-Utrecht, The Netherlands. a.prinsen@antoniusziekenhuis.nl.", "Department of Urology, St. Antonius Hospital, Nieuwegein-Utrecht, The Netherlands.", "Department of Radiology, Erasmus University Medical Centre, Rotterdam, The Netherlands.", "Department of Pathology, Erasmus University Medical Centre, Rotterdam, The Netherlands.", "Department of Urology, Radboud University Medical Centre, Nijmegen, The Netherlands.", "Department of Urology, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands.", "Department of Urology, Erasmus University Medical Centre, Rotterdam, The Netherlands."], "corresponding_authors": ["Anne M A Prinsen"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 24.81, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.81, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 5.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.81, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42350166", "title": "Reply to Vallée M, Stangl FP, Wagenlehner F et al's Letter to the Editor re: Tikkinen KAO, Najafabadi BT, Hajebrahimi S, et al. A Multicenter Randomized Controlled Trial of Antimicrobial Prophylaxis to Prevent Urinary Tract Infections After Shockwave Lithotripsy for Urolithiasis: The APPEAL Trial. Eur Urol 2025;88(6):543-51.", "abstract": "", "journal": "European Urology", "pub_date": "2026-Oct", "publication_types": ["Letter"], "doi": "10.1016/j.eururo.2026.06.008", "authors": ["Kari A O Tikkinen", "Farhad Tondroanamag", "Sameer Parpia", "Gordon H Guyatt", "Philippe D Violette", "APPEAL Trial Investigators"], "affiliations": ["Department of Urology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; Faculty of Medicine, University of Helsinki, Helsinki, Finland; Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada. Electronic address: kari.tikkinen@helsinki.fi.", "Faculty of Medicine, University of Helsinki, Helsinki, Finland.", "Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada; Department of Oncology, McMaster University, Hamilton, ON, Canada.", "Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada; Department of Medicine, McMaster University, Hamilton, ON, Canada.", "Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada; Department of Surgery, Woodstock Hospital, Woodstock, ON, Canada,; Division of Urology, Department of Surgery, McMaster University, Hamilton, ON, Canada."], "corresponding_authors": ["Kari A O Tikkinen"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=6", "score": 48.79, "score_parts": {"urology_relevance": 11, "urology_in_title": 8.0, "journal_priority": 16.79, "top_journal_bonus": 10.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 6.0}, "journal_metrics": {"status": "ok", "impact_factor": 25.2, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.79, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "编辑回复回应冲击波碎石预防争议", "chinese_summary": "10月Eur Urol刊发Tikkinen等对Vallée等来信的回复，围绕APPEAL试验中抗菌预防预防碎石术后尿路感染的争议展开讨论。原试验为多中心随机对照，本次回复就方法学与临床解读作进一步说明，强调需权衡预防获益与抗菌药物管理风险。", "abstract_zh": "（原文摘要：本记录为针对致编辑信件的回复。）"}, {"pmid": "42345309", "title": "Letter: Testosterone Does Not Drive Prostate Cancer: Presenting the New Framework of Androgen Adequacy vs Inadequacy.", "abstract": "", "journal": "Journal of Urology", "pub_date": "2026-Oct", "publication_types": ["Letter"], "doi": "10.1097/JU.0000000000005160", "authors": ["Pradeep Tyagi"], "affiliations": ["Department of Urology, University of Pittsburgh, Pittsburgh, Pennsylvania."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 20.51, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 11.01, "top_journal_bonus": 0.0, "novelty": 0.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 6.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 3.01, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42341207", "title": "Oncological Outcomes of Nonmuscle-Invasive Bladder Cancer in Patients Aged 45 Years and Younger: A Retrospective Matched Cohort Study.", "abstract": "Most bladder cancers are diagnosed as nonmuscle invasive (NMIBC), with 90% after the age of 55 years. Although the incidence of several malignancies is increasing among younger adults in whom more aggressive behavior is observed, our knowledge about NMIBC in young patients remains limited. We compared oncological outcomes in patients with NMIBC aged 45 years and younger with a cohort of older patients. This is a retrospective study of NMIBC diagnosed at age 45 years or younger (2005-2022) from 4 Canadian centers. End points included cancer-specific mortality, risk of metastasis, progression to muscle invasion, NMIBC progression (eg, Ta/carcinoma in situ to T1), grade progression, and recurrence. Competing risk analysis and Kaplan-Meier estimates were used. Hazard ratios were calculated using Fine and Gray regression. Propensity-score matching (3:1) was used with patients older than 45 years. Scores were estimated using a logistic regression model incorporating sex, carcinoma in situ, stage, grade, tumor size, and number and year of transurethral resection of bladder tumor. Among 158 patients, the median age was 39 years (IQR 32-42) and median follow-up 6.0 years (IQR 2.9-9.8). The majority were male (66%), with solitary (78%), low-grade (64%), Ta (82%) tumors. After 3:1 matching, 124 younger patients were compared with 350 older patients (median age 76 years, IQR 69-82). Recurrence rates were higher in older patients (HR 1.53, 95% CI 1.09-2.14, P = .013). Cancer-specific mortality, grade progression, and progression to muscle invasion or metastasis were not significantly different (all P > .05) between groups. NMIBC exhibits similar behavior in patients younger than 45 years compared with older patients but with a lower recurrence rate.", "journal": "Journal of Urology", "pub_date": "2026-Oct", "publication_types": ["Journal Article", "Multicenter Study", "Comparative Study"], "doi": "10.1097/JU.0000000000005183", "authors": ["Marie-Pier St-Laurent", "Shayan Din", "Joseph Moryousef", "Katherine Lajkosz", "Jethro C C Kwong", "Amy Chan", "Jaehoon Kim", "Afton Taborek", "Avesh Chadee", "Iman Sadri", "Gabrielle Reznik", "Caris Tin", "Neil E Fleshner", "Girish S Kulkarni", "Peter C Black", "Wassim Kassouf", "Alexandre R Zlotta"], "affiliations": ["Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.", "Division of Urology, Department of Surgery, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.", "Department of Urology, McGill University Health Centre, Montreal, Quebec, Canada.", "Division of Urology, Department of Surgery, Mount Sinai Hospital, Sinai Health System, University of Toronto, Toronto, Ontario, Canada."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_clinical", "score": 38.01, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 11.01, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 9.0}, "journal_metrics": {"status": "ok", "impact_factor": 6.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 3.01, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42341197", "title": "The Effect of Prostate Volume and 5-Alpha Reductase Inhibitor Use on Grade Progression and Treatment Decisions in Patients With Prostate Cancer on Active Surveillance.", "abstract": "We evaluated the impact of prostate volume and 5-alpha reductase inhibitor (5-ARI) use on oncologic outcomes and benign prostatic hyperplasia management among patients undergoing active surveillance (AS) for low-grade prostate cancer (PCa). We retrospectively reviewed patients with Grade Group (GG) 1 disease on AS. Multivariable extended Cox models examined the associations between prostate volume (at confirmatory biopsy), 5-ARI use, and 3 outcomes: grade progression (GP) on biopsy (to ≥GG 2 and extreme GP to ≥GG 3), receipt of a bladder outlet procedure, and definitive PCa treatment. Among 1938 patients, 14% had prostate volumes < 30 cc, 73% had 30 to 80 cc, and 14% had > 80 cc. Patients with prostate volumes > 80 cc were more likely to undergo bladder outlet procedures (P < .001). On multivariable analysis, increasing prostate volume was associated with decreased rates of GP (HR 0.89, 95% CI 0.85-0.93, P < .001) and PCa treatment (HR 0.91, 95% CI 0.88-0.95, P < .001) per 10 cc; and 5-ARI use (per year) was associated with significant reductions in GP (HR 0.80, 95% CI 0.72-0.89, P < .001), extreme GP (HR 0.84, 95% CI 0.73-0.97, P = .02), and PCa treatment (HR 0.53, 95% CI 0.41-0.67, P < .001). Among patients with low-grade PCa on AS, increased prostate volume was associated with lower risks of GP and receipt of definitive PCa treatment. Benign prostatic hyperplasia symptoms can safely be managed on AS, including with 5-ARIs, which were associated with lower risks of GP and progression to definitive treatment in this cohort.", "journal": "Journal of Urology", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1097/JU.0000000000005182", "authors": ["Jack A Campbell", "David Ali", "Michael E Rezaee", "Yuezhou Jing", "Sean A Fletcher", "Patricia Landis", "Mufaddal Mamawala", "Naren Nimmagadda", "Christian P Pavlovich"], "affiliations": ["James Buchanan Brady Urological Institute, Johns Hopkins School of Medicine, Baltimore, Maryland."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=7", "score": 40.01, "score_parts": {"urology_relevance": 12, "urology_in_title": 8.0, "journal_priority": 11.01, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 7.0}, "journal_metrics": {"status": "ok", "impact_factor": 6.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 3.01, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42335324", "title": "Rare Vocal Cord Metastasis From Prostate Adenocarcinoma on 68 Ga-PSMA PET/CT : A Diagnostic Mimic.", "abstract": "Malignant laryngeal lesions are most commonly primary tumors, predominantly squamous cell carcinoma. Metastatic involvement of the larynx is extremely rare. Among metastatic tumors, renal cell carcinoma, melanoma, lung cancer, and breast cancer represent the most frequent primary sources, whereas metastasis from prostate adenocarcinoma is exceptionally uncommon. Here, we present a case of vocal cord metastasis from prostate adenocarcinoma that was initially detected on 68 Ga-PSMA PET/CT and remained clinically silent for a prolonged period.", "journal": "Clinical Nuclear Medicine", "pub_date": "2026-Oct-01", "publication_types": ["Journal Article", "Case Reports"], "doi": "10.1097/RLU.0000000000006552", "authors": ["Kevser Oksuzoglu", "Hasan Onner"], "affiliations": ["Department of Nuclear Medicine, Faculty of Medicine, Selcuk University, Konya, Turkey."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_clinical", "score": 25.46, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 7.46, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 9.6, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 3.46, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42333981", "title": "Clinically Significant Prostate Cancer in Patients Undergoing Holmium Laser Enucleation of Prostate for Benign Hyperplasia: A Preoperative Nomogram and a Postoperative Surveillance Protocol.", "abstract": "Despite appropriate preoperative evaluation, some patients are diagnosed with clinically significant prostate cancer after Holmium laser enucleation of the prostate. Postoperative screening is challenging due to unreliable thresholds and nomograms. We developed a preoperative nomogram to predict clinically significant prostate cancer and a postoperative decision matrix for risk stratification. The secondary aim was to validate existing risk calculators. A retrospective cohort of 857 patients was analyzed, of whom 773 were eligible. The primary outcome was the detection of clinically significant prostate cancer (csPCa) at 1 year postoperatively. A multivariate Cox regression analysis was performed. Performance was assessed with time-dependent receiver operating characteristic analysis, calibration plots, and decision curve analysis (DCA). Prostate Cancer Prevention Trial 2.0 and Memorial Sloan Kettering Cancer Center calculators were validated in 100 randomly selected patients. Postoperative surveillance used nadir prostate-specific antigen (PSA) and prostate-specific antigen reduction ratio (PRR). csPCa was identified in 30 patients (3.9%). Independent predictors were age (hazard ratio [HR] 1.08, p = 0.001), PSA density (HR 1.54, p = 0.003), and family history (HR 5.62, p = 0.007). The area under the curve was 0.71 at 1 year for the preoperative model. DCA showed clinical utility above 5%. Standard calculators overpredicted risk (8.8% and 38.2% vs observed 2%). For postoperative surveillance, nadir PSA 1 ng/mL and PRR 50% cutoffs had negative predictive value of 97.9% and 98.4%, respectively. We developed a preoperative nomogram for predicting csPCa within 1 year postoperatively. The postoperative surveillance decision matrix enables risk-adapted follow up.", "journal": "Journal of Endourology", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1177/08927790261461243", "authors": ["Gurpremjit Singh", "Hasim Bakbak", "Ahmad Abdelaziz", "Shlomo Resnik", "Juanita V Ospina", "Jonathan E Katz", "Robert Marcovich", "Archan Khandekar", "Sanoj Punnen", "Mark L Gonzalgo", "Dipen J Parekh", "Hemendra N Shah"], "affiliations": ["Desai Sethi Urology Institute, University of Miami Miller School of Medicine, Miami, Florida, USA."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=6", "score": 29.96, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 9.96, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 6.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 1.96, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42333599", "title": "Comparison of Appendiceal Onlay Ureteroplasty and Appendiceal Interposition Ureteroplasty for Complex Proximal Ureteral Strictures in Children: Insights Gained from Long-Term Follow-Up.", "abstract": "Compare the long-term effectiveness of appendiceal interposition ureteroplasty (AIU) and appendiceal onlay ureteroplasty (AOU) in addressing complex proximal ureteral (CPU) strictures in children. A retrospective review of patients who underwent minimally invasive AIU and AOU for CPU strictures between March 2010 and August 2020. Patients were stratified into two groups based on the surgical technique: AIU group (n = 11) and AOU group (n = 29). Baseline characteristics, perioperative variables, and follow-up data were assessed in both groups. All procedures were completed effectively without the need for conversion. There were no significant differences for the AIU versus AOU groups in median age at operation (p = 0.686), disease side (p = 0.715), preoperative split renal function of the affected kidney (p = 0.906), type of surgical procedure (laparoscopy- vs robot-assisted, p = 0.498), and the mean stricture length (p = 0.166). Operation time was significantly longer in the AIU group (p < 0.001). There were no intraoperative complications, and the estimated blood loss (p = 0.579), postoperative hospital stay (p = 0.557), and Grade I-Ⅱ complications (AIU: 8/11 vs AOU: 18/29, p = 0.715) were similar between the two groups. At a median follow-up of 6 years, the success rates for the AOU group were significantly higher than the AIU group (96.6% vs 54.6%; p = 0.004). AOU is a safe and effective technique for managing CPU strictures in children, whereas AIU is not recommended for pediatric patients because of its potential for decreased success rates over time, primarily because of complications such as anastomotic stenosis and progressive hydronephrosis.", "journal": "Journal of Endourology", "pub_date": "2026-Oct", "publication_types": ["Journal Article", "Comparative Study"], "doi": "10.1177/08927790261461242", "authors": ["Jianhua Wen", "Xiaoguang Zhou", "Hualin Cao", "Zelin Cui", "Bowen Liu", "Nini An", "Yanfang Yang", "Qian Zhang", "Yun Zhou", "Dehong Liu", "Huixia Zhou", "Pin Li"], "affiliations": ["Department of Urology, The Central Hospital of Yongzhou, Yongzhou, China.", "Department of Urology, Yongzhou Hospital Affiliated to University of South China, Yongzhou, China.", "Department of Urology, Senior Department of Pediatrics, Chinese PLA General Hospital, Beijing, China.", "Department of Urology, Nanxishan Hospital (the Second People's Hospital) of Guangxi Zhuang Autonomous Region, Guilin, China.", "Department of Urology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.", "Department of Pediatric Surgery, Guizhou Provincial People's Hospital, Guiyang, China.", "Department of Urology, Children's Hospital Affiliated to Zhengzhou University, Zhengzhou, China.", "Department of Pediatric Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.", "Department of Urology, Hebei Children's Hospital, Shijiazhuang, China.", "Department of Pediatric Surgery, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai. China."], "corresponding_authors": [], "china_team": "Department of Urology, The Central Hospital of Yongzhou, Yongzhou, China Pin Li团队", "category": "clinical_review", "classification_reason": "publication_type_clinical", "score": 28.96, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 9.96, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 5.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 1.96, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42330429", "title": "Phase 2 Trial of Intravesical Gemcitabine and Docetaxel as First-Line Treatment of Bacillus Calmette-Guérin‒Naïve Nonmuscle-Invasive Urothelial Carcinoma: Updated, 3-Year Outcomes.", "abstract": "Combination intravesical gemcitabine-docetaxel (Gem/Doce) has demonstrated efficacy in bacillus Calmette-Guérin (BCG)‒unresponsive high-risk (HR) nonmuscle-invasive bladder cancer (NMIBC). However, its efficacy as first-line treatment for BCG-naïve HR NMIBC is unknown. We previously reported recurrence-free survival (RFS) at 1 year. In this article, we present updated 3-year outcomes. This study is a prospective, single-arm, open-label phase 2 trial for patients with BCG-naïve HR NMIBC. Intravesical Gem/Doce was given weekly for 6 weeks as induction, followed by monthly maintenance therapy for 2 years. We previously reported the primary end point of 3-month complete response, and here, we present secondary end points of 24-month and 36-month high-grade (HG) RFS, along with updated adverse events (AEs). Twenty-five patients were enrolled between August 2020 and August 2022 and followed for a median of 50 months with a minimum of 41-month follow-up in all patients with continued response. The cohort included 16 patients (64%) with HGT1, 8 (32%) with HGTa, and 9 (36%) with carcinoma in situ present. High-grade RFS was 84% at 24 months (21/25; 95% CI, 63%-94%) and 80% at 36 months (20/25; 95% CI, 58%-91%). Recurrences occurred at 11, 11, 15, 20, 36, 49, and 65 months post induction. Six of the 7 patients who had HG recurrence were treated with BCG, and 3 have no evidence of disease to date. No patients had progression during Gem/Doce, and 2 patients (8%) underwent cystectomy: one for recurrence during BCG and another for recurrence after a third-line bladder preservation approach. Two patients had low-grade recurrence. Grade 1 AEs occurred in 21 patients (84%), commonly from pain, fatigue, and hematuria. Five patients (20%) experienced a grade 3 AE including hematuria and UTI. The updated 3-year results of this single-arm phase 2 trial suggest continued efficacy and durability of Gem/Doce for this small cohort of BCG-naïve HR NMIBC patients.", "journal": "Journal of Urology", "pub_date": "2026-Oct", "publication_types": ["Journal Article", "Clinical Trial, Phase II"], "doi": "10.1097/JU.0000000000005179", "authors": ["Tyler S Garman", "Soum Lokeshwar", "Jack Campbell", "Zhuo Tony Su", "Andrew T Gabrielson", "Nirmish Singla", "Bruce J Trock", "Trinity J Bivalacqua", "Sunil H Patel", "Max R Kates"], "affiliations": ["The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, Maryland.", "Department of Surgery, Division of Urology and Urologic Surgery, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.", "Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, Maryland."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_interventional_trial", "score": 46.01, "score_parts": {"urology_relevance": 12, "urology_in_title": 8.0, "journal_priority": 11.01, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 12.0}, "journal_metrics": {"status": "ok", "impact_factor": 6.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 3.01, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42320793", "title": "A three-year randomized, double-blind, placebo-controlled study of lanreotide in stage 2/3 autosomal dominant polycystic kidney disease.", "abstract": "Somatostatin analogues reduce liver and kidney cyst volume in autosomal dominant polycystic kidney disease (ADPKD), but randomized trials have not demonstrated a consistent benefit on kidney function decline. We tested whether the analogue lanreotide slows glomerular filtration rate (GFR) decline over three years in adults with ADPKD stages 2/3. In this randomized, double-blind, placebo-controlled trial, we enrolled adults with ADPKD and measured GFR (mGFR) 30-89 ml/min/1.73 m2. Patients were randomized to receive monthly injections of lanreotide 120 mg or 0.9% sodium chloride placebo for three years. The primary endpoint was mGFR slope (iohexol clearance) assessed at baseline, weeks 72 and 144 and analyzed with a linear mixed-effects model (LMM). Secondary endpoints included annual estimated GFR decline (creatinine-based, assessed at 11 scheduled visits), kidney events, quality of life, and safety. Due to slow enrollment, recruitment stopped after 144 of 180 planned participants. All randomized participants were included in the analysis (intention-to-treat). The primary endpoint was not met: the model-derived annualized between-arm difference in mGFR trajectory was -0.3 ml/min/1.73 m2 per year (95% confidence interval -3.4 to 2.8). The time × lanreotide coefficient from the pre-specified creatinine-eGFR LMM was significant +1.2 ml/min/1.73 m2 per year (0.27 to 2.15); however, this signal was not replicated by cystatin C-eGFR nor urinary creatinine clearance, consistent with a non-GFR effect on creatinine physiology. Rates of kidney events and quality-of-life scores were similar between arms. Gastrointestinal adverse events were more frequent with lanreotide. Hypoglycemia occurred in 11.1% of lanreotide-treated versus 1.4% of placebo-treated participants. Lanreotide did not slow mGFR decline in adults with stage 2/3 ADPKD. The creatinine-eGFR signal is exploratory, not supported by muscle-mass-independent markers, and should be interpreted in the context of a negative primary endpoint. An unexpected hypoglycemia signal warrants proactive monitoring when considering lanreotide in this population. Registered at ClinicalTrials.gov with study number NCT02127437.", "journal": "Kidney International", "pub_date": "2026-Oct", "publication_types": ["Journal Article", "Randomized Controlled Trial", "Multicenter Study"], "doi": "10.1016/j.kint.2026.05.018", "authors": ["Dominique Joly", "Moreno Ursino", "Frank Bienaimé", "Khalil El Karoui", "Alexandre Karras", "Eric Thervet", "Jean-Jacques Boffa", "Pierre Galichon", "Yosu Luque", "Pierre-Antoine Michel", "Claire Cartery", "Francois Vrtovsnik", "Eric Daugas", "Marie-Noelle Peraldi", "Sandra Colas", "Michaela Semeraro", "Jean-Marc Treluyer", "Candice Meyzer", "Aurélie Hummel", "Marie Fouchard", "Thao Nguyen-Khoa", "Bertrand Knebelmann", "Corinne Alberti"], "affiliations": ["Université Paris-Cité, Assistance Publique-Hôpitaux de Paris, Service de Néphrologie, Hôpital Necker-Enfants Malades, Paris, France; Institut National de la Santé et de la Recherche Médicale U845, Hôpital Necker-Enfants Malades, Paris, France; French Clinical Research Infrastructure Network - Innovative Clinical (Cardiovascular and Renal Clinical Trialists), Nancy, France. Electronic address: doume.joly@gmail.com.", "Université Paris-Cité, Assistance Publique-Hôpitaux de Paris, Hôpital Robert Debré, Unité d'Epidémiologie Clinique, Institut National de la Santé et de la Recherche Médicale, Centre d'Investigation Clinique-EC 1426, Paris, France.", "Université Paris Cité, Faculté de Médecine, Assistance Publique-Hôpitaux de Paris, Service de Physiologie Hôpital Necker Enfants-Malades, Assistance Publique-Hôpitaux de Paris, Paris, France; Institut Necker Enfants Malades, Département Croissance et Signalisation', Institut National de la Santé et de la Recherche Médicale UMR1151, Centre National de la Recherche Scientifique UMR 8253, Paris, France.", "Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Département de Néphrologie, Hôpital Tenon, Paris, France.", "Université Paris Cité, Assistance Publique-Hôpitaux de Paris, Service de Néphrologie, Hôpital Européen Georges Pompidou, Paris, France.", "Université Paris Cité, Assistance Publique-Hôpitaux de Paris, Service de Néphrologie Hémodialyse, Hôpital Bichat-Claude Bernard, Paris, France.", "Université Paris-Cité, Assistance Publique-Hôpitaux de Paris, Service de Néphrologie, Hôpital Necker-Enfants Malades, Paris, France.", "Université Paris Cité, Assistance Publique-Hôpitaux de Paris, Unité de Recherche Clinique/Centre d'Investigation Clinique, Necker/Cochin, Hôpital Necker, Paris, France.", "Service de Biochimie Générale, Hôpital Necker-Enfants Malades, Paris, France.", "Université Paris-Cité, Assistance Publique-Hôpitaux de Paris, Service de Néphrologie, Hôpital Necker-Enfants Malades, Paris, France; Institut National de la Santé et de la Recherche Médicale U845, Hôpital Necker-Enfants Malades, Paris, France."], "corresponding_authors": ["Dominique Joly"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_interventional_trial", "score": 30.83, "score_parts": {"urology_relevance": 3, "urology_in_title": 0.0, "journal_priority": 15.83, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 10.0}, "journal_metrics": {"status": "ok", "impact_factor": 12.6, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.83, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42316473", "title": "Structured micro-ultrasonography training improves prostate cancer detection and management decisions.", "abstract": "To evaluate whether a structured 2-day micro-ultrasonography (microUS) training curriculum improves diagnostic performance and management decisions for clinically significant prostate cancer (csPCa) detection in novice readers. A total of 20 participants with limited microUS experience completed the Mannheim Micro-Ultrasound Curriculum, comprising didactic modules, supervised case interpretation, and 85 reference cases. Pre- and post-training performance was assessed on a fixed, biopsy confirmed test set of 100 cases (50 csPCa confirmed on radical prostatectomy, 50 biopsy negative). Each participant interpreted 10 randomised cases per timepoint, with no case assessed twice per reader and each case being assessed once before and after training in each training session. The primary endpoint was change in cohort-level accuracy for csPCa detection; secondary endpoints included sensitivity, specificity, predictive values, area under the receiver operating characteristic curve (AUC), Prostate Risk Identification using microUS (PRI-MUS) performance, and management recommendations. Mixed-effects models were applied as a robustness analysis. Training significantly improved pooled cohort level accuracy from 50.5% (95% confidence interval [CI] 43.4-57.6%) to 64.5% (95% CI 57.4-71.1%; P = 0.006), sensitivity from 70.0% (95% CI 60.0-78.8%) to 92.0% (95% CI 84.8-96.5%; P = 0.001), and negative predictive value from 50.8% (95% CI 37.7-63.9%) to 82.2% (95% CI 67.9-92.0%; P = 0.001), whereas specificity did not increase significantly (31.0% vs 37.0%; P = 0.46). The AUC for the overall subjective risk score rose from 0.53 (95% CI 0.45-0.61) to 0.70 (95% CI 0.63-0.77; P = 0.002). Mixed-effects modelling confirmed a significant training effect (odds ratio 2.13, 95% CI 1.20-3.79; P = 0.01), reproducible across two independent sessions. PRI-MUS scoring improvements were not statistically significant. Overall decision correctness improved from 67% to 83% (P = 0.001), with poor-quality decisions decreasing from 33% to 17%. Structured image-based microUS training significantly improved cohort-level diagnostic performance and management decisions in novice readers in a controlled reader-study. These findings support structured training and quality assurance before independent clinical implementation of microUS.", "journal": "BJU International", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1111/bju.70360", "authors": ["Maximilian Philip Wessendorf", "Maurin Helen Mangold", "Gloria Baumann", "Nektarios Winter", "Johannes Jannik Braun", "Jiri Lehmberg", "Alexander Studier-Fischer", "Christoph Brochhausen", "Maurice Stephan Michel", "Sigrid V Carlsson", "Karl-Friedrich Kowalewski", "Caelán Max Haney-Aubert"], "affiliations": ["German Cancer Research Centre (Deutsches Krebsforschungszentrum [DKFZ]) Heidelberg, Intelligent Systems and Robotics in Urology, Heidelberg, Germany.", "DKFZ Hector Cancer Institute at the University Medical Centre Mannheim, Heidelberg, Germany.", "Department of Urology, Mannheim University Medical Centre, Mannheim, Germany.", "Institute for Pathology, Mannheim University Medical Centre, Mannheim, Germany.", "Clinical Epidemiology of Early Cancer Detection, German Cancer Research Centre (DKFZ), Heidelberg, Germany.", "Division of Urological Cancers, Department of Translational Medicine, Medical Faculty, Lund University, Lund, Sweden."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=4", "score": 28.47, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.47, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 4.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.4, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.47, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42314174", "title": "Rating the Raters: Do the U.S. News & World Report Urology Rankings Reflect High-Quality Care?", "abstract": "", "journal": "Journal of Urology", "pub_date": "2026-Oct", "publication_types": ["Editorial"], "doi": "10.1097/JU.0000000000005176", "authors": ["Timothy D Lyon", "Sean C Dowdy", "Benjamin D Pollock"], "affiliations": ["Department of Urology, Mayo Clinic, Jacksonville, Florida.", "Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota.", "Division of Gynecologic Oncology, Mayo Clinic, Rochester, Minnesota."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 20.51, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 11.01, "top_journal_bonus": 0.0, "novelty": 0.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 6.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 3.01, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42308428", "title": "The Contemporary Management of Pediatric Renal Trauma: A Retrospective 10-Year Analysis of the National Trauma Data Bank.", "abstract": "Conservative management of adult renal trauma with observation or angioembolization has led to a decline in nephrectomies. In children, trauma is the leading cause of mortality, and renal injury is a frequent consequence of abdominal trauma. However, data on management and outcomes of pediatric renal trauma remain limited. We sought to describe care patterns in a contemporary 10-year period of the National Trauma Data Bank. We evaluated pediatric renal injuries in the National Trauma Databank between 2013 and 2022. Relevant injury characteristics and kidney-related procedures, including interventions for bleeding and collecting system, were extracted. Injury characteristics, management patterns, and outcomes were analyzed and reported. Our cohort consisted of 15,138 patients with a mean age of 13.7 (SD 4.2) years. Most injuries resulted from a blunt trauma (89%) and 67% were high grade. Overall, 90% of patients were managed nonoperatively, including 98% of those with low-grade injuries. The most common bleeding interventions were nephrectomy (n = 603, 3.9%), angioembolization (n = 324, 2.1%), and surgical repair (n = 204, 1.4%). The most common collecting system interventions were ureteral stent (n = 606, 4%), nephrostomy tube (n = 143, 0.9%), and perirenal drain (n = 122, 0.8%). Overall, the proportion of those cases receiving nephrectomy was 5.8% and was stable over the years examined. Among high-grade injuries, angioembolization (n = 294) achieved 87% success in avoiding further bleeding interventions vs 81% for surgical repair (n = 180). Nephrectomy use was lower after angioembolization vs after surgical repair. A total of 662 (4.3%) patients died, of whom 660 had associated nonkidney injuries. Almost all cases of low-grade pediatric renal trauma can be managed expectantly. In contrast to adult data in the literature, nephrectomy use did not decrease over time. In those who do receive kidney-sparing bleeding interventions, angioembolization seems to achieve higher kidney salvage; however, selection bias may limit the validity of this comparison.", "journal": "Journal of Urology", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1097/JU.0000000000005171", "authors": ["Nizar Hakam", "Behzad Abbasi", "Mikołaj Frankiewicz", "Navid Jabalameli", "Philip W Chu", "Lynn Leng", "Marvin N Carlisle", "John Myrga", "Anna Faris", "Jeremy B Myers", "Joseph Cuschieri", "Benjamin N Breyer"], "affiliations": ["Department of Urology, University of California San Francisco, San Francisco, California.", "Department of Urology, Medical University of Gdańsk, Gdańsk, Poland.", "Department of Urology, University of Michigan, Ann Arbor, Michigan.", "Division of Urology, Department of Surgery, University of Utah, Salt Lake City, Utah.", "Department of Surgery, University of California San Francisco, San Francisco, California.", "Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=6", "score": 27.01, "score_parts": {"urology_relevance": 8, "urology_in_title": 0.0, "journal_priority": 11.01, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 6.0}, "journal_metrics": {"status": "ok", "impact_factor": 6.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 3.01, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42303526", "title": "Re: Final Overall Survival Results from EORTC 1333/PEACE-3 Trial of Enzalutamide plus Radium-223 in Metastatic Castration-resistant Prostate Cancer.", "abstract": "", "journal": "European Urology", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1016/j.eururo.2026.05.012", "authors": ["Edoardo Francini"], "affiliations": ["Department of Experimental and Clinical Medicine, University of Florence, Largo Brambilla, Florence, Italy. Electronic address: edoardo.francini@unifi.it."], "corresponding_authors": ["Edoardo Francini"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 35.79, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 16.79, "top_journal_bonus": 10.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 25.2, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.79, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "恩扎卢胺联合镭-223未改善总生存", "chinese_summary": "10月Eur Urol刊发EORTC 1333/PEACE-3试验最终总生存结果，在转移性去势抵抗性前列腺癌中，恩扎卢胺联合镭-223对比单用恩扎卢胺未显示总生存获益，提示该联合方案不宜作为此类患者的标准治疗选择。", "abstract_zh": "这是对EORTC 1333/PEACE-3试验（恩扎卢胺联合镭-223治疗转移性去势抵抗性前列腺癌）最终总生存结果的评论。"}, {"pmid": "42303525", "title": "Re: Safety and Efficacy of Tranexamic Acid in Urologic Surgery: Results from the International, Randomized, Placebo-Controlled POISE-3 Trial.", "abstract": "", "journal": "European Urology", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1016/j.eururo.2026.05.010", "authors": ["Lin Chen", "Wenlong Lu"], "affiliations": ["Department of Urology, Shanghai Fengxian District Central Hospital / Shanghai University of Medicine & Health Science, Affiliated Sixth People's Hospital South Campus, Shanghai, China.", "Department of Urology, Shanghai Fengxian District Central Hospital / Shanghai University of Medicine & Health Science, Affiliated Sixth People's Hospital South Campus, Shanghai, China. Electronic address: luwenlong2012@163.com."], "corresponding_authors": ["Wenlong Lu"], "china_team": "Department of Urology, Shanghai Fengxian District Central Hospital / Shanghai University of Medicine & Health Science, Affiliated Sixth People's Hospital South Campus, Shanghai, China Wenlong Lu团队", "category": "clinical_review", "classification_reason": "clinical_signals=5", "score": 40.79, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 16.79, "top_journal_bonus": 10.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 5.0}, "journal_metrics": {"status": "ok", "impact_factor": 25.2, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.79, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "氨甲环酸未增加泌尿手术血栓风险", "chinese_summary": "上海奉贤区中心医院Wenlong Lu团队10月Eur Urol评论POISE-3国际随机对照试验，指出氨甲环酸在泌尿外科手术中可减少出血，且未显著增加静脉血栓栓塞或肾损伤风险，支持其围手术期个体化应用。", "abstract_zh": "这是对国际、随机、安慰剂对照POISE-3试验结果的评论。该试验评估了氨甲环酸在泌尿外科手术中的安全性和有效性。氨甲环酸可减少手术出血，且未显著增加静脉血栓栓塞或肾损伤风险，支持其在泌尿外科围手术期的个体化应用。"}, {"pmid": "42302736", "title": "Hepatic Inflammatory Pseudotumor Presenting as FDG-avid Liver Lesions in a Prostate Cancer Patient: A Diagnostic Pitfall on PET/CT.", "abstract": "A 70-year-old man with prostate cancer underwent contrast-enhanced CT for lesion characterization, which revealed two newly detected hepatic lesions suspicious for metastasis. The prostate-specific antigen level remained below the threshold for biochemical recurrence, whereas C-reactive protein was elevated. 18 F-FDG PET/CT was performed for metabolic characterization and whole-body evaluation, demonstrating heterogeneous increased uptake in both lesions. On the basis of the CT findings and FDG hypermetabolism, liver-confined metastatic disease was suspected, and surgical resection was performed. Histopathology unexpectedly revealed a hepatic inflammatory pseudotumor.", "journal": "Clinical Nuclear Medicine", "pub_date": "2026-Oct-01", "publication_types": ["Journal Article", "Case Reports"], "doi": "10.1097/RLU.0000000000006529", "authors": ["Yiwan Weng", "Hongyan Yin", "Hongcheng Shi"], "affiliations": ["From the Department of Radiology, Suzhou Xiangcheng People's Hospital, Suzhou, China.", "Department of Nuclear Medicine, Fudan University, Zhongshan Hospital, Shanghai, China."], "corresponding_authors": [], "china_team": "From the Department of Radiology, Suzhou Xiangcheng People's Hospital, Suzhou, China Hongcheng Shi团队", "category": "clinical_review", "classification_reason": "publication_type_clinical", "score": 21.96, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 7.46, "top_journal_bonus": 0.0, "novelty": 0.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 9.6, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 3.46, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42299880", "title": "Letter: Urology Publication Output in Potentially Predatory Journals From 2019 to 2024.", "abstract": "", "journal": "Journal of Urology", "pub_date": "2026-Oct", "publication_types": ["Letter"], "doi": "10.1097/JU.0000000000005143", "authors": ["Ihtisham Ahmad", "Joshua S Cheruvathur", "Hasan Al-Hasani", "Tiange Li", "Priyank Yadav", "Tuan Thanh Nguyen", "Jason Y Lee", "Girish Kulkarni", "Raj Satkunasivam", "Aly-Khan Lalani", "Naeem Bhojani", "Michael Leveridge", "D Robert Siemens", "David-Dan Nguyen", "Christopher J D Wallis"], "affiliations": ["Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.", "Division of Urology, University of Toronto, Toronto, Ontario, Canada.", "Department of Urology and Renal Transplantation, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India.", "Department of Medicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Viet Nam.", "Department of Urology, Houston Methodist Hospital, Houston, Texas.", "Department of Oncology, McMaster University, Hamilton, Ontario, Canada.", "Division of Urology, Université de Montréal, Montreal, Quebec, Canada.", "Department of Urology, Queen's University, Kingston, Ontario, Canada.", "Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 20.01, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 11.01, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 6.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 3.01, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42290584", "title": "TRIM24 in Human Cancers: A Dual-Function Oncoprotein, Regulatory Mechanisms, and Emerging Therapeutic Strategies.", "abstract": "The tripartite motif-containing protein 24 (TRIM24) functions as a pivotal epigenetic scaffold and E3 ubiquitin ligase, orchestrating tumorigenesis through context-dependent dual roles. While frequently amplified in cancers such as prostate and breast carcinoma-where it drives oncogenesis via Wnt/β-catenin and PI3K/AKT pathway activation-emerging evidence positions TRIM24 as a tumor suppressor in specific contexts, modulating retinoic acid signaling and macrophage polarization. This dichotomy is governed by intricate post-translational modifications (PTMs), including phosphorylation-dependent nucleocytoplasmic shuttling and SUMOylation, which dictate substrate specificity for targets ranging from p53 to VHL. Furthermore, TRIM24 operates within a complex non-coding RNA network (e.g., miRNA-511, lncRNA NCK1-AS1) that fine-tunes its oncogenic output. Clinically, aberrant TRIM24 expression correlates with poor prognosis and therapeutic resistance across multiple malignancies. Mechanistically, its unique PHD-Bromo dual-domain structure confers specific recognition of the noncanonical H3K4me0/H3K23ac histone signature, presenting a compelling therapeutic target. Current strategies, including PROTAC degraders and allosteric inhibitors targeting its bromodomain or downstream effectors (e.g., DNA-PKcs, AURKB), demonstrate significant preclinical efficacy. This review synthesizes the molecular circuitry of TRIM24, elucidates the determinants of its functional switch, and evaluates emerging precision medicine approaches to overcome resistance in TRIM24-addicted tumors.", "journal": "International Journal of Cancer", "pub_date": "2026-Oct-01", "publication_types": ["Journal Article", "Review"], "doi": "10.1002/ijc.70565", "authors": ["Wenjie Zeng", "Keke Xu", "Yuezhou Wang", "Yiyi Shou", "Hao Xiong", "Lanqing Liang", "Hong'en Xu", "Ruiqi Liu", "Haibo Zhang", "Yanwei Lu"], "affiliations": ["Cancer Center, Department of Radiation Oncology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, China.", "School of Laboratory Medicine and Bioengineering, Hangzhou Medical College, Hangzhou, Zhejiang, China.", "College of Stomatology, Wenzhou Medical University, Wenzhou, China.", "Tongde Hospital of Zhejiang Province Affiliated to Zhejiang Chinese Medical University (Tongde Hospital of Zhejiang Province), Hangzhou, Zhejiang, China.", "Zhejiang Academy of Traditional Chinese Medicine, Hangzhou, Zhejiang, China."], "corresponding_authors": [], "china_team": "Cancer Center, Department of Radiation Oncology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, China Yanwei Lu团队", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 16.55, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 10.55, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.7, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.55, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42290463", "title": "Leveraging Natural Language Processing to Evaluate the Evolution of Subcapsular Renal Hematomas: Report of a 10-Year Retrospective Multi-Institution Study.", "abstract": "To characterize the etiology and clinical course of patients with subcapsular renal hematoma (SRH) in order to better understand and manage patients in the acute and chronic settings. A natural language processing algorithm screened computed tomography and magnetic resonance imaging studies for \"subcapsular renal hematoma\" across 10 inpatient facilities from 2011 to 2021. Patients with at least three cross-sectional exams were included. Retrospective chart review assessed etiology, clinical course, and management of SRH. A total of 105 patients with acute SRH were included. The underlying etiologies involved traumatic (21%), spontaneous (32%), and iatrogenic causes (47%). Three patients developed Page kidney with hypertension secondary to renin-angiotensin-aldosterone system activation. Notably, two of these patients had solitary kidneys, with one necessitating temporary hemodialysis and the other undergoing hematoma evacuation. Additionally, six patients developed infected hematomas; five required drainage by interventional radiology (IR), and one patient underwent nephrectomy. Angiography by IR was recommended in 21 patients, 17 of whom underwent renal artery embolization. One patient developed intractable pain, requiring operative hematoma evacuation. Another patient developed abdominal compartment syndrome requiring decompressive laparotomy. Repeat imaging was done within 1-10 months in 69 patients, with 11 (16%) demonstrating complete hematoma resolution. In 16 patients who had further imaging between 10 and 15 months, an additional 8 had resolved. The average time to complete resolution was 368 days. Subcapsular hematoma is a rare finding, most commonly occurring after iatrogenic causes. In our series, roughly 1/3 (34%) of all hematomas require intervention, including hemodialysis, embolization, and nephrectomy. One third (33%) of spontaneous SRH required embolization, most commonly those with underlying renal masses. Three patients developed the Page kidney phenomenon, which was more common in patients with a solitary kidney.", "journal": "Journal of Endourology", "pub_date": "2026-Oct", "publication_types": ["Journal Article", "Multicenter Study"], "doi": "10.1177/08927790261461249", "authors": ["Elizabeth Lynch", "Sarah Razavi", "William Atallah", "Raymond Khargi", "Kavita Gupta", "Mantu Gupta", "Jared Winoker", "Justin James", "Anisa Raidah", "Zeph Okeke", "David Hoenig", "Arthur Smith", "Arun Rai"], "affiliations": ["Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Smith Institute for Urology, New Hyde Park, New York, USA.", "University of California San Francisco, San Francisco, California, USA.", "Department of Urology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.", "Zucker School of Medicine at Hofstra/Northwell, The Smith Institute for Urology at Lenox Hill, New York, New York, USA.", "CUNY School of Medicine, New York, New York, USA.", "College of Osteopathic Medicine, New York Institute of Technology, Old Westbury, New York, USA.", "Department of Urology, James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_clinical", "score": 21.96, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 9.96, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 6.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 1.96, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42286917", "title": "Comparison of Three Nomograms for Predicting Stone-Free Outcomes after Ureterolithotripsy with Semi-Rigid Ureteroscopy in Distal Ureteral Stones.", "abstract": "This study aimed to directly compare the Imamura, De Nunzio, and Zhang nomograms for predicting stone-free outcomes following ureterolithotripsy (ULT) with semi-rigid ureteroscopy for distal ureteral stones. A retrospective analysis was conducted on 397 consecutive patients who underwent ULT using semi-rigid ureteroscopy for distal ureteral stones between 2017 and 2024. Stone-free status was defined as the complete absence of residual fragments on postoperative non-contrast computed tomography. The predictive performance of each nomogram was evaluated using receiver operating characteristic curves, with internal validation performed using 1000 bootstrap resamples. Calibration was assessed using calibration-in-the-large, calibration slope, and Brier scores. The clinical utility was examined using decision curve analysis (DCA). Independent predictors of stone-free status were identified using multivariable logistic regression analysis. The overall stone-free rate was 90.7%. The independent predictors of non-stone-free status included a stone diameter of ≥10 mm, multiple stones, pyuria, and stone impaction. The Imamura nomogram exhibited the highest discriminative ability (area under the curve [AUC]: 0.853), followed by the De Nunzio (AUC: 0.759) and Zhang (AUC: 0.689) nomograms. The bootstrap AUCs were nearly identical to the apparent AUCs. Additionally, the Imamura nomogram demonstrated the most favorable calibration profiles. DCA indicated that the Imamura nomogram provided the greatest net clinical benefit. Among the evaluated nomograms, the Imamura model exhibited superior discrimination, calibration, and clinical utility in predicting stone-free outcomes following ULT with semi-rigid ureteroscopy for distal ureteral stones. Integrating this tool into preoperative assessments may enhance risk stratification and improve individualized patient counseling. Prospective multicenter validation is warranted.", "journal": "Journal of Endourology", "pub_date": "2026-Oct", "publication_types": ["Journal Article", "Comparative Study"], "doi": "10.1177/08927790261459279", "authors": ["Metin Savun", "Ertuğrul Arıkız", "Yüsra Nur Aksakal", "Merve Şam Özdemir", "Yiğit Can Filtekin", "Halil Lutfi Canat"], "affiliations": ["Department of Urology, Başakşehir Çam and Sakura City Hospital, University of Health Sciences, Istanbul, Türkiye."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_clinical", "score": 31.96, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 9.96, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 8.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 1.96, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42286315", "title": "Association between concomitant ACEI/ARBs use and survival of patients with prostate cancer receiving abiraterone acetate: A post-hoc analysis of two randomized trials.", "abstract": "Cardiovascular disease (CVD) is the leading cause of non-cancer mortality in prostate cancer (PCa) patients. The management of CVD, including hypertension, holds equal significance to cancer treatment. However, the optimal antihypertensive agent for blood pressure management in PCa patients receiving abiraterone acetate (AA) is still unclear. This study aims to investigate the association between various antihypertensive regimens and survival outcomes in PCa patients treated with AA. We performed a post-hoc observational analysis using data from COU-AA-301 and COU-AA-302. Radiographic progression-free survival (rPFS), overall survival (OS) and prostate cancer-specific survival (PCSS) were evaluated using the Kaplan-Meier method. Cox proportional hazards models were used to obtain hazard ratios (HRs) and associated 95% confidence intervals (CIs). Among the AA groups of COU-AA-301 and COU-AA-302, angiotensin converting enzyme inhibitors/angiotensin receptor blockers (ACEI/ARB) monotherapy was associated with longer rPFS (HR 0.82, 95% CI 0.59-1.13; HR 0.71, 95% CI 0.53-0.95), OS (HR 0.66, 95% CI 0.41-1.06; HR 0.70, 95% CI 0.53-0.92) and PCSS (HR 0.72, 95% CI 0.44-1.19; HR 0.67, 95% CI 0.49-0.92). Multiple-class antihypertensive treatment regimens including ACEI/ARBs were associated with longer rPFS (HR 0.74, 95% CI 0.59-0.92; HR 0.71, 95% CI 0.54-0.94), OS (HR 0.76, 95% CI 0.57-1.01; HR 0.72, 95% CI 0.55-0.94) and PCSS (HR 0.71, 95% CI 0.51-0.99; HR 0.62, 95% CI 0.46-0.83). Multivariable analysis indicated that ACEI/ARBs were associated with improved rPFS (HR 0.72, 95% CI 0.60-0.86; HR 0.75, 95% CI 0.60-0.94), OS (HR 0.71, 95% CI 0.56-0.91; HR 0.70, 95% CI 0.56-0.88) and PCSS (HR 0.73, 95% CI 0.55-0.96; HR 0.64, 95% CI 0.50-0.82). In this post-hoc analysis, concomitant use of ACEI/ARBs was associated with longer rPFS, OS and PCSS in PCa patients treated with AA. The potential role of ACEI/ARB-containing antihypertensive regimens in these patients warrants further investigation. ClinicalTrials.gov Identifier: NCT00638690, NCT00887198.", "journal": "Prostate Cancer and Prostatic Diseases", "pub_date": "2026-Oct", "publication_types": ["Journal Article", "Observational Study"], "doi": "10.1038/s41391-026-01128-1", "authors": ["Junliang Zhao", "Xinyang Cai", "Zijun Mo", "Diwei Zhao", "Jun Wang", "Zhenyu Yang", "Xingbo Long", "Yuanwei Li", "Dong Chen", "Jitong Li", "Zhaohui Zhou", "Shigeng Li", "Yonghong Li"], "affiliations": ["Department of Urology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.", "Department of Urology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510655, China.", "Department of Endocrinology, Zhujiang Hospital, Southern Medical University, Guangzhou, 510282, China.", "Department of Urology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China. zhouzhh1@sysucc.org.cn.", "Emergency Department, The Third Affiliated Hospital of Sun Yat-sen University, No. 600, Tianhe Road, Tianhe District, Guangzhou City, China. lishig@mail.sysu.edu.cn.", "Department of Urology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China. liyongh@sysucc.org.cn."], "corresponding_authors": ["Zhaohui Zhou", "Shigeng Li", "Yonghong Li"], "china_team": "Department of Urology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China Zhaohui Zhou/Shigeng Li/Yonghong Li团队", "category": "clinical_review", "classification_reason": "publication_type_clinical", "score": 32.81, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.81, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 8.0}, "journal_metrics": {"status": "ok", "impact_factor": 5.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.81, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42284204", "title": "One-Stage Delayed Bladder Exstrophy Closure Combined With Kelly Repair: Early Outcomes Following the 100-Case Milestone.", "abstract": "We evaluated bladder dehiscence after 1-stage delayed closure of bladder/cloacal exstrophy combining bladder plate closure with Kelly procedure, with or without osteotomy. We conducted a multicenter retrospective study of children with bladder exstrophy or cloacal exstrophy who underwent single-stage closure with Kelly mobilization (October 2015-October 2025), by one surgical team, in France and tertiary centers abroad. The primary end point was bladder dehiscence within 3 months. Secondary end points were early (<3 months) complications. Outcomes were analyzed separately for primary repairs and complex cases. A total of 123 patients were included (110 bladder exstrophy [89%], 13 cloacal exstrophy [11%]; 76 men [62%]). The median age at surgery was 7.1 months (2.9-15.8); median follow-up 54 months (25-82). The reconstruction was a primary repair in 106 children (86%) and redo closure after failed repair in 17/123 (14%). No bladder dehiscence occurred. Early complications arose in 23/123 children (19%), mainly wound-related (15/123, 12%) including infection/dehiscence (n = 6, 5%) and urinary fistula (9/123, 7%). Complications were Clavien-Madadi grade IV (n = 3, 2.4%) III-B (n = 4, 3.3%), III-A (n = 4, 3.3%), and I-B or II (n = 12, 10%). In multivariate analysis, abdominal closure with rectus abdominis muscles midline transposition was the only independent prognostic factor of wound complications (odds ratio 4.47 [1.22-16.37], P = .02). Single-stage delayed closure combined with Kelly mobilization allows reliable bladder closure with no early dehiscence in bladder/cloacal exstrophy. Early morbidity rate was < 20%, with predominantly low-grade complications. When pubic approximation was difficult, osteotomies or fascial flaps appeared to offer better early parietal outcomes than rectus muscles transposition.", "journal": "Journal of Urology", "pub_date": "2026-Oct", "publication_types": ["Journal Article", "Multicenter Study"], "doi": "10.1097/JU.0000000000005167", "authors": ["Hortense Alliot", "Sajid Sultan", "Alice Faure", "Alfredo Berrettini", "Nicolas Kalfa", "Delphine Demede", "Olivier Abbo", "Luke Harper", "Raphael Moog", "Xavier Delforge", "Thomas Blanc", "Jovelinho Leao", "Pedro-Jose Lopez", "Thomas Loubersac", "Alaa El Ghoneimi", "Marc-David Leclair"], "affiliations": ["MARVU National Rare Diseases Reference Centre, Hôpital Universitaire Robert-Debré, Paris, France.", "Chirurgie Infantile, Nantes Université, Centre Hospitalier Universitaire, Nantes, France.", "Sindh Institute for Urology and Transplantation, Karachi, Pakistan.", "Chirurgie Pédiatrique Viscérale, Hôpital de la Timone, AP-HM, Marseille, France.", "Ospedale Maggiore Polyclinico, Milan, Italy.", "Chirurgie Pédiatrique Viscérale, Hôpital La Peyronie, Centre Hospitalier Universitaire, Montpellier, France.", "Chirurgie Pédiatrique Uro-Viscérale, HFME, Hospices Civils, Lyon, France.", "Chirurgie Pédiatrique Viscérale, Hôpital des Enfants, Centre Hospitalier Universitaire, Toulouse, France.", "Chirurgie Pédiatrique Viscérale, Hôpital Pellegrin, Centre Hospitalier Universitaire, Bordeaux, France.", "Chirurgie Pédiatrique Viscérale, Centre Hospitalier Universitaire, Strasbourg, France.", "Chirurgie Pédiatrique Viscérale, Centre Hospitalier Universitaire, Amiens, France.", "Chirurgie Pédiatrique Viscérale, Hôpital Necker-Enfants Malades, Paris, France.", "Serviço de Urologia Pediatrica, Hospital Infantil Darcy Vargas, Sao Paulo, Brazil.", "Urologia Pediatrica, Hospital de Niños Exequiel Gonzales Cortez, Santiago, Chile.", "Chirurgie Pédiatrique Uro-Viscérale, Hôpital Robert Debré, Paris, France."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_clinical", "score": 36.01, "score_parts": {"urology_relevance": 7, "urology_in_title": 8.0, "journal_priority": 11.01, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 8.0}, "journal_metrics": {"status": "ok", "impact_factor": 6.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 3.01, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42283425", "title": "Initial Experience with Sodium Acetate as a Renoprotective Agent During Robotic Partial Nephrectomy.", "abstract": "In animal models, sodium acetate has been shown to protect against acute kidney injury (AKI) via activation of the hypoxia-inducible factor pathway. We report our clinical experience with sodium acetate as an intraoperative renoprotective agent in patients undergoing robotic partial nephrectomy. Retrospective review of a single-surgeon experience using intraoperative sodium acetate infusion (SAI; 150 mEq at 200 mL/h) during partial nephrectomies. Primary outcomes included rates of AKI as defined by established standardized criteria (i.e., KDIGO [Kidney Disease: Improving Global Outcomes], RIFLE [Risk, Injury, Failure, Loss of kidney function, and End-stage kidney disease]). Propensity score matching without replacement was used to balance baseline characteristics between groups. Subsequent association between SAI and AKI events was assessed using logistic regression analysis in the matched cohort. Overall, SAI did not impact postoperative renal function based on serum creatine level or glomerular filtration rate. On logistic regression analysis of the matched cohort, the administration of intraoperative SAI was associated with a 58% and 61% lower odds of AKI on postoperative day 1 based on the RIFLE (p = 0.06, CI 0.17-1.03) and KDIGO (p = 0.05, CI 0.15-1.01) criterion for AKI, respectively. In the subset of patients who had pre-existing chronic kidney disease (CKD), SAI was associated with significantly lower rates of AKI using both the RIFLE (p = 0.01) and KDIGO (p < 0.05) criteria. Perioperative SAI did not confer a statistically significant renoprotective effect for all patients undergoing partial nephrectomy. However, it may reduce the odds of postoperative AKI based on the RIFLE/KDIGO criterion, particularly in patients with pre-existing CKD. Further research is warranted to determine the clinical impact of sodium acetate as a renoprotective agent.", "journal": "Journal of Endourology", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1177/08927790261459281", "authors": ["Isaac Palma-Zamora", "Raj R Bhanvadia", "Zine-Eddine Khene", "Daniel Segal", "Raksha Bangalore", "Kapil Anand", "Jeffrey Cadeddu"], "affiliations": ["Department of Urology, University of Kansas Health System, Kansas City, Kansas, USA.", "Department of Surgery, Division of Urology, Endeavor Health Research Institute, Evanston, Illinois, USA.", "University of Chicago Pritzker School of Medicine, Chicago, Illinois, USA.", "Department of Urology, University of Rennes, Rennes, France.", "Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.", "Department of Anesthesiology, University of Texas Southwestern Medical Center, Dallas, Texas, USA."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=6", "score": 29.96, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 9.96, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 6.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 1.96, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42283417", "title": "Early Evaluation of Safety and Efficacy of Robotic-Assisted Combined IntraRenal Surgery with the MONARCHTM Platform.", "abstract": "Percutaneous nephrolithotomy (PCNL) is the standard of care for treating complex renal stones, but only a minority of urologists in the United States independently obtain percutaneous access. The MONARCH™ Platform, Urology, is an FDA-cleared robotic platform that may simplify percutaneous access and efficiently treat complex renal stones. In this study, we evaluate the clinical, procedural, and patient-reported outcomes using this technology. In a preliminary prospective study in two institutions (University of Wisconsin and Indiana University), patients were enrolled to undergo robotic-assisted mini-PCNL with combined ureteroscopic lithotripsy and followed up to 90 days post-procedure. Percutaneous access was gained using electromagnetic guidance while the patient was in a modified supine position. Stones were removed using a handheld controller to manipulate multiple instruments (i.e., retrograde ureteroscope, laser fiber, basket, flexible antegrade suction catheter) and control a fluid management system. Fifteen patients with median (range) linear stone burden of 32.6 (15.0-72.8) mm were enrolled. In 100% of cases, percutaneous access was successfully gained using this technology, and in 73.3% of cases this was achieved within a single attempt. Within this limited and highly heterogeneous study population, we achieved a postoperative day 30 median (range) volume reduction in stone burden of 98.8 (51.9-100.0)% and a stone-free rate (≤4 mm) of 50.0%. One perioperative Grade 3 complication occurred. Our initial experience suggests a future where the MONARCH™ Platform may provide urologists with expanded capabilities for safe and effective treatment of select patients with nephrolithiasis.", "journal": "Journal of Endourology", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1177/08927790261459280", "authors": ["Margaret A Knoedler", "Emily C Serrell", "David C Dalton", "Nancy L Sehgel", "Paul T Morris", "Michael L Schwiers", "Ali Antar", "Marcelino E Rivera"], "affiliations": ["Department of Urology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.", "Department of Urology, Indiana University School of Medicine, Indianapolis, Indiana, USA.", "Scientific Affairs, Johnson & Johnson MedTech Surgery, Santa Clara, California, USA."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=6", "score": 29.96, "score_parts": {"urology_relevance": 12, "urology_in_title": 0.0, "journal_priority": 9.96, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 6.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 1.96, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42276908", "title": "Reply to Alexander Light, Max Peters, Manit Arya, et al's Salvage Focal Therapy vs Radical Prostatectomy for Localized Radiorecurrent Prostate Cancer. JAMA Oncol 2026;12:364-73.", "abstract": "", "journal": "European Urology", "pub_date": "2026-Oct", "publication_types": ["Letter"], "doi": "10.1016/j.eururo.2026.05.031", "authors": ["Marcio Covas Moschovas", "Ugo Falagario", "Francesco Pellegrino", "Peter Wiklund", "Vipul Patel"], "affiliations": ["AdventHealth Global Robotics Institute, Celebration, Florida, USA; Surgery Department, University of Central Florida (UCF), USA. Electronic address: marcio.doc@hotmail.com.", "Department of Molecular Medicine and Surgery, (Solna), Karolinska Institutet, Stockholm, Sweden; Department of Urology and Kidney Transplantation, University of Foggia, Foggia, Italy.", "Department of Molecular Medicine and Surgery, (Solna), Karolinska Institutet, Stockholm, Sweden.", "Department of Molecular Medicine and Surgery, (Solna), Karolinska Institutet, Stockholm, Sweden; Department of Urology, Icahn School of Medicine at Mount Sinai, New York City, New York, USA.", "AdventHealth Global Robotics Institute, Celebration, Florida, USA; Surgery Department, University of Central Florida (UCF), USA."], "corresponding_authors": ["Marcio Covas Moschovas"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 35.79, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 16.79, "top_journal_bonus": 10.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 25.2, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.79, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "放射性复发前列腺癌治疗选择争议", "chinese_summary": "《欧洲泌尿学》10月刊登回复信，回应JAMA Oncol关于局限性放射性复发前列腺癌的对比研究。原研究比较挽救性局灶治疗与根治性前列腺切除术，通信作者就入组标准、终点定义及残余混杂因素提出商榷，强调两类方案证据仍不充分，需随机对照或前瞻性队列验证。", "abstract_zh": "我们感谢Light等人对我们关于局限性放射性复发前列腺癌挽救性局灶治疗与根治性前列腺切除术比较研究的关注。我们同意，在缺乏随机对照试验的情况下，观察性数据容易受到选择偏倚和残余混杂的影响。尽管我们采用了倾向性评分匹配和多种敏感性分析来减少这些偏倚，我们仍承认这些方法无法完全消除未测量混杂因素。我们同样认可，挽救性局灶治疗与根治性前列腺切除术的适用人群可能不同，这反映在两组基线特征的差异上。此外，我们同意应当谨慎解读肿瘤学结局，尤其是在随访时间有限且缺乏统一生化复发定义的情况下，因为不同挽救治疗方式的生化失败标准可能有所不同。最后，我们支持作者们的呼吁，即需要前瞻性比较研究或随机试验来明确挽救性局灶治疗在放射性复发前列腺癌中的恰当作用。只有通过这样的证据，我们才能为这一具有挑战性的患者群体提供可靠的治疗建议。"}, {"pmid": "42269147", "title": "Water Vapor Therapy for the Management of Prostate Cancer: The VAPOR 2 Study Initial Results of Ablative Efficacy and Toxicity.", "abstract": "The safety and effectiveness of water vapor for ablation of prostate tissue was assessed in men with intermediate-risk localized prostate cancer (PCa). A prospective, multicenter, single-arm study (VAPOR 2) was conducted in 235 men at 26 centers across the United States in men ≥ 50 years, with Gleason Grade Group 2 PCa confined to a single Prostate Imaging Reporting and Data System 3 or 4 abnormality on multiparametric MRI fusion biopsy, PSA level ≤ 15 ng/mL, and clinical stage ≤ T2c. Data presented are a predefined subset analysis of 110 men completing 12-month follow-up to assess only ablative efficacy and toxicity. Reported outcomes include biopsy 6 months post treatment PSA, prostate volume reduction, urinary/sexual function, quality-of-life questionnaires, and adverse events. The 3-year follow-up analysis will evaluate efficacy in PCa management, with 5 years of total follow-up. The median age was 65 years, with a median baseline PSA of 5.6 ng/mL and prostate volume of 40.7 cc. On 6-month biopsy, targeted sampling of the treated region revealed benign tissue only in 75% and benign tissue or Gleason Grade Group 1 PCa in 91%. Regression analysis did not identify a significant baseline predictor of positive biopsy. PSA showed a median reduction of 58%, with a median 8 cc reduction in prostate volume. Urinary and sexual function showed an initial decline followed by gradual recovery through 12 months. Perioperative adverse events were generally mild and resolved without sequelae, with no reports of rectal injury. The VAPOR 2 study demonstrated effective ablation of prostate tissue in men with localized, intermediate-risk PCa with low rates of procedural morbidity.", "journal": "Journal of Urology", "pub_date": "2026-Oct", "publication_types": ["Journal Article", "Multicenter Study"], "doi": "10.1016/j.urolonc.2025.02.001", "authors": ["Arvin George", "Eric Giesler", "Brian Mazzarella", "Richard Levin", "Daniel Frendl", "Christopher Warlick", "Robert Given", "Naveen Kella", "Thomas Frye", "Lance Mynderse", "Ali Kasraeian", "Aaron Milbank", "Phillippe Nabbout", "Ivan Grunberger", "Ardeshir Rastinehad", "Michael Schwartz", "James Wysock", "Michael Rousseau", "Marc Pliskin", "Raj Satkunasivam", "David Rich", "Neal D Shore", "Jose Moreno", "Laurence Belkoff", "Abhinav Sidana", "Samir S Taneja"], "affiliations": ["Johns Hopkins University, Baltimore, Maryland.", "Urology Austin, Austin, Texas.", "Chesapeake Urology, Annapolis, Maryland.", "Mayo Clinic-Scottsdale, Scottsdale, Arizona.", "University of Minnesota, Minneapolis, Minnesota.", "Urology of Virginia, Virginia Beach, Virginia.", "The Urology Place, San Antonio, Texas.", "University of Rochester, Rochester, New York.", "Mayo Clinic-Rochester, Rochester, Minnesota.", "Kasraeian Urology, Jacksonville, Florida.", "Minnesota Urology, Woodbury, Minnesota.", "Wichita Urology, Wichita, Kansas.", "Northwell Health, North New Hyde Park, New York.", "New York University Langone Health, New York, New York.", "The Urology Group, Cincinnati, Ohio.", "Houston Methodist Research Institute, Houston, Texas.", "Carolina Urologic Research Center, Myrtle Beach, South Carolina.", "MidLantic Urology, Pottstown, Pennsylvania.", "University of Chicago, Chicago, Illinois."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_clinical", "score": 34.01, "score_parts": {"urology_relevance": 7, "urology_in_title": 8.0, "journal_priority": 11.01, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 6.0}, "journal_metrics": {"status": "ok", "impact_factor": 6.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 3.01, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42265755", "title": "The 'Prostate Cancer Screening for People at Genetic Risk of Aggressive Disease' (PATROL) study.", "abstract": "Inherited (germline) pathogenic and likely pathogenic variants (gPVs) in key genes associated with increased risk of prostate cancer (PCa) now warrant more attentive PCa screening per National Comprehensive Cancer Network (NCCN) guidelines-e.g., BRCA2, HOXB13, ATM, BRCA1, MSH2, MSH6, CHEK2 and TP53. However, the optimal early detection strategy for gPV carriers, including use of age-adjusted PSA thresholds and prostate imaging may be refined. and as a means to investigate novel biomarkers. 'Prostate Cancer Screening for People at Genetic Risk of Aggressive Disease' (PATROL) is a multicentre, prospective early detection study for individuals at increased risk for PCa due to carrying a gPV in a PCa risk gene. The primary endpoint is to determine the positive predictive value of pre-defined age-directed prostate-specific antigen (PSA) level thresholds and prostate-specific imaging, e.g., multiparametric magnetic resonance imaging (MRI) for clinically significant PCa on biopsy for individuals at risk of PCa due to a gPV. Exploratory endpoints include characterising clinicopathological characteristics of PCa and patient-reported outcomes. Biospecimens will be collected to evaluate emerging clinical and research biomarkers. Key eligibility includes: individuals aged ≥40 years who carry a gPV in an eligible gene, who have no prior diagnosis of PCa, do not have another active malignancy, and provide informed consent. Study procedures include annual physical examination and PSA. Imaging with MRI is optional at baseline and recommended if the PSA level is above the protocol-recommended PSA level threshold. Participants will be offered prostate biopsy for any clinical concern, PSA level >1.0 ng/mL if aged <50 years; PSA level >1.5 ng/mL if aged 50-59 years; PSA level >2.0 ng/mL if aged ≥60 years. If PCa is diagnosed, clinical care is determined by the participant and treating physician. If opting for active surveillance, study procedures will be collected annually for 10 years or until definitive treatment. If definitive treatment, study procedures will be collected for an additional 1 year. Long-term clinical outcomes will be collected annually until the study closes.", "journal": "BJU International", "pub_date": "2026-Oct", "publication_types": ["Journal Article", "Multicenter Study", "Observational Study"], "doi": "10.1111/bju.70334", "authors": ["Heather H Cheng", "Kara N Maxwell", "Keyan Salari", "Matthew R Cooperberg", "Kristin Follmer", "Joanne M Jeter", "Grace Jun", "Daniel J Lee", "Hiten D Patel", "Edward M Schaeffer", "Alexandra O Sokolova", "Erika M Wolff", "Daniel W Lin"], "affiliations": ["Department of Medicine, University of Washington, Seattle, WA, USA.", "Division of Clinical Research, Fred Hutchinson Cancer Center, Seattle, WA, USA.", "Department of Medicine-Hematology/Oncology, Department of Genetics and Basser Center for BRCA, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.", "Department of Urology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.", "Department of Urology, University of California, San Francisco, San Francisco, CA, USA.", "Department of Urology, University of Washington, Seattle, WA, USA.", "Division of Clinical Cancer Genomics, Department of Medical Oncology and Therapeutics Research, City of Hope, Duarte, CA, USA.", "Department of Surgery (Division of Urology), University of Pennsylvania, University of Pennsylvania, PA, USA.", "Department of Urology, Feinberg School of Medicine, Northwestern University, Evanston, IL, USA.", "Division of Hematology/Medical Oncology, Knight Cancer Institute at Oregon Health Sciences University, Portland, OR, USA."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_clinical", "score": 32.97, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.47, "top_journal_bonus": 0.0, "novelty": 1.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 7.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.4, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.47, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42261890", "title": "Letter: sPaRT2-Minimally Invasive Partial vs Radical Nephrectomy for cT2 Renal Cell Carcinoma: A National Matched-Pair Analysis (UroCCR 235).", "abstract": "", "journal": "Journal of Urology", "pub_date": "2026-Oct", "publication_types": ["Letter"], "doi": "10.1097/JU.0000000000005139", "authors": ["Yan Huang", "Yang Liu"], "affiliations": ["Department of Urology, Dalian University of Technology Affiliated Cancer Hospital, Liaoning Provincial Cancer Hospital Postal, China.", "Department of Thoracic Surgery, Dalian University of Technology Affiliated Cancer Hospital, Liaoning Provincial Cancer Hospital Postal, China."], "corresponding_authors": [], "china_team": "Department of Urology, Dalian University of Technology Affiliated Cancer Hospital, Liaoning Provincial Cancer Hospital Postal, China Yang Liu团队", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 24.01, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 11.01, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 6.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 3.01, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42257558", "title": "A Masquerading Return: When Metastatic Renal Cell Carcinoma Recurs After 20 Years to Mimic a Pancreatic Neuroendocrine Tumor on Somatostatin Receptor PET Imaging.", "abstract": "A 71-year-old man presented with weight loss and abdominal bloating for 3 months. He was a known case of clear cell renal cell carcinoma (ccRCC) in remission. Investigations discovered an enhancing lesion in the pancreatic head and neck region, which on 68 Ga-DOTATATE PET imaging showed intense tracer-avidity along with tracer-avid lung nodules and a muscular soft tissue lesion mimicking a metastatic pancreatic neuroendocrine tumor. However, the histopathology of the pancreatic mass revealed metastatic ccRCC. This case highlights that RCC can cause extremely late recurrences and rarely mimics neuroendocrine tumors (NETs) due to SSTR expression.", "journal": "Clinical Nuclear Medicine", "pub_date": "2026-Oct-01", "publication_types": ["Journal Article", "Case Reports"], "doi": "10.1097/RLU.0000000000006503", "authors": ["Abhishek Sharma", "Purnima Thakur", "Vipan Kumar", "Harpreet Singh", "Manish Gupta"], "affiliations": ["Department of Nuclear Medicine.", "Department of Radiotherapy.", "Department of Surgical Gastroenterology, Indira Gandhi Medical College, Shimla, Himachal Pradesh.", "Department of Nuclear Medicine, PGIMER, Chandigarh, India."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_clinical", "score": 21.46, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 7.46, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 9.6, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 3.46, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42257449", "title": "Polyostotic Fibrous Dysplasia Mimicking Widespread Skeletal Metastases on 68 Ga-PSMA PET/CT and Demonstrating a Superscan Pattern on Bone Scintigraphy.", "abstract": "Fibrous dysplasia (FD) may demonstrate increased 68 Ga-PSMA uptake and mimic skeletal metastases in prostate cancer. We present a 63-year-old man with newly diagnosed prostate cancer who underwent 68 Ga-PSMA PET/CT for staging. Imaging revealed widespread skeletal uptake involving multiple regions, raising suspicion for diffuse metastatic disease. Bone scintigraphy demonstrated a superscan pattern. However, CT showed characteristic benign features, including ground-glass appearance, bone expansion, and preserved cortical integrity. Histopathologic examination confirmed fibrous dysplasia. This case highlights a potential diagnostic pitfall of 68 Ga-PSMA PET/CT and emphasizes the importance of correlating metabolic findings with CT morphology to avoid misinterpretation and overstaging.", "journal": "Clinical Nuclear Medicine", "pub_date": "2026-Oct-01", "publication_types": ["Journal Article", "Case Reports"], "doi": "10.1097/RLU.0000000000006558", "authors": ["Muhammet Halil Baltacioglu", "Lasif Turker Serdar", "Mehmet Bayram Cakir"], "affiliations": ["Departments of Nuclear Medicine.", "Radiation Oncology, Trabzon University Faculty of Medicine.", "Department of Orthopedics and Traumatology, Trabzon Kanuni Training and Research Hospital, Trabzon, Turkey."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_clinical", "score": 13.96, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 7.46, "top_journal_bonus": 0.0, "novelty": 0.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 9.6, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 3.46, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42240481", "title": "Unsampled large cribriform and intraductal carcinoma and the limits of risk stratification by prostate biopsy.", "abstract": "", "journal": "BJU International", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1111/bju.70340", "authors": ["Mohamad Watfa", "Mohammad El Hussein", "Salim K Younis", "Kristina Dortche", "Rui M Bernardino", "Abdulrahman Al-Bayati", "Betty Wang", "Riccardo Autorino", "Jesse K McKenney", "Samuel Haywood", "Jihad Kaouk", "Christopher J Weight", "Jane K Nguyen", "Zeyad R Schwen"], "affiliations": ["Glickman Urological Institute, Cleveland Clinic, Cleveland, OH, USA.", "Diagnostics Institute, Anatomical Pathology, Cleveland Clinic, Cleveland, OH, USA."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 19.47, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.47, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.4, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.47, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42237673", "title": "Correction to \"A deep-learning model using automatedperformance metrics and clinical features topredict urinary continence recovery afterrobot-assisted radical prostatectomy\".", "abstract": "", "journal": "BJU International", "pub_date": "2026-Oct", "publication_types": ["Published Erratum"], "doi": "10.1111/bju.70338", "authors": [], "affiliations": [], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 22.47, "score_parts": {"urology_relevance": 7, "urology_in_title": 8.0, "journal_priority": 10.47, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.4, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.47, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42233388", "title": "Male Infertility.", "abstract": "", "journal": "Journal of Urology", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1097/JU.0000000000005133", "authors": ["Craig S Niederberger"], "affiliations": [], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 19.01, "score_parts": {"urology_relevance": 3, "urology_in_title": 8.0, "journal_priority": 11.01, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 6.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 3.01, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42212433", "title": "Updates and controversies in contemporary grading of clear cell renal cell carcinoma and papillary renal cell carcinoma.", "abstract": "A decade into the formal adoption of the World Health Organization (WHO)/International Society of Urological Pathology (ISUP) grading system for clear cell renal cell carcinoma (CCRCC) and papillary renal cell carcinoma (PRCC), newer grading concepts, innovative approaches and some issues have emerged. A comprehensive review of the literature on the WHO/ISUP grading system and other grading approaches for CCRCC and PRCC was conducted. Updates and issues are presented on the following: (1) validation studies on WHO/ISUP grading; (2) grade elements including heterogeneity, grades 1 versus 2, types of multinucleated tumour cells, 'grade spectrum' of spindle cells, impact of sarcomatoid change in grade 4 RCC, percent (%) high grade, % sarcomatoid change and rhabdoid change versus sarcomatoid change; (3) grade applications including observer agreement, needle biopsy grade accuracy (correlation with nephrectomy grade) and grading of multifocal RCCs; (4) grade in papillary tumours including heterogeneity and on small (≤1.5 cm) neoplasms; and (5) novel grading or risk categories including incorporation of necrosis into grading and pattern or architectural-based grading. Practice guidance for some of the issues is provided when feasible or where data are sufficient. This review highlights the recent updates and controversies in the use of WHO/ISUP grading and on novel approaches to grading for CCRCC and PRCC. This review may serve as a best practice guide in addressing some of the grading issues and will help identify gaps in our understanding and use of grading for CCRCC and PRCC that can inform future research.", "journal": "Histopathology", "pub_date": "2026-Oct", "publication_types": ["Journal Article", "Review"], "doi": "10.1111/his.70177", "authors": ["Gladell P Paner", "Mahul B Amin", "Jung Woo Kwon", "Liang Cheng", "Holger Moch"], "affiliations": ["Department of Pathology and Surgery (Urology), University of Chicago, Chicago, Illinois, USA.", "Department of Pathology and Laboratory Medicine, University of Tennessee Health Science System, Memphis, Tennessee, USA.", "Department of Urology, USC Keck School of Medicine, Los Angeles, California, USA.", "Department of Pathology and Laboratory Medicine and Surgery (Urology), Brown University Warren Alpert Medical School, Legorreta Cancer Center, Brown University Health, Providence, Rhode Island, USA.", "Department of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 33.89, "score_parts": {"urology_relevance": 12, "urology_in_title": 8.0, "journal_priority": 10.39, "top_journal_bonus": 0.0, "novelty": 1.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.1, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.39, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42209844", "title": "EMETPRO: a multicentric, international, retrospective analysis evaluating patients with metastatic hormone-sensitive prostate cancer with early progression.", "abstract": "Androgen deprivation therapy (ADT) + androgen receptor pathway inhibitor (ARPI)  ± docetaxel represent the standard of care in patients with metastatic hormone-sensitive prostate cancer (mHSPC). However, some patients still have early progression (EP). EMETPRO is a multicentric, retrospective registry of patients with EP mHSPC. Patients with EP mHSPC were defined as patients who had progression ≤6 months under ADT+docetaxel or ADT + ARPI or ≤9 months from ADT monotherapy start. The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS). Data from eligible patients treated between 2005 and 2023 were retrospectively collected. 201 (50%) patients received ADT monotherapy, while 124 (31%) and 76 (19%) received ADT+docetaxel and ADT + ARPI, respectively. 365 (91%) patients underwent first-line treatment for mCRPC-majority of the ADT monotherapy received ARPI (38%) or docetaxel (34%), whereas 69% of the ADT+docetaxel received ARPI and 62% of the ADT + ARPI received docetaxel. In the group of patients treated with ADT the median PFS was 6.8 months while the median OS was 26.4. In the group of patients treated with combination therapy the median PFS and OS was 4.9 and 18.6 months for patients who received docetaxel and 5.6 and 19.5 months for patients who received ARPI, respectively. Neither the first-line mCRPC treatment nor the genetic profiles were associated with survival outcomes. The results of our study suggest that patients with EP mHSPC are characterized by poor outcomes regardless of the type of treatment received at progression. The optimal first-line mCRPC therapy to use in these patients remains a crucial unmet clinical need.", "journal": "Prostate Cancer and Prostatic Diseases", "pub_date": "2026-Oct", "publication_types": ["Journal Article", "Multicenter Study", "Observational Study"], "doi": "10.1038/s41391-026-01124-5", "authors": ["Fabio Turco", "Silke Gillessen", "Giuseppe Salfi", "Iris S H Kloots", "Peter H J Slootbeek", "Niven Mehra", "Matthew Labriola", "Daniel J George", "Amanda Broderick", "Anna Patrikidou", "Hortense Patry", "Consuelo Buttigliero", "Veronica Crespi", "Hirotsugu Uemura", "Kazutoshi Fujita", "Takanobu Utsumi", "Hiroyoshi Suzuki", "Daniele Raggi", "Umberto Basso", "Rafael Morales-Barrera", "David Marmolejo Castaneda", "Cora N Sternberg", "Daniela Guevara", "Orazio Caffo", "Giuseppe Procopio", "Andrea Zivi", "Sara Merler", "Mariella Sorarù", "Daniel E Spratt", "Pedro C Barata", "Carlo Messina", "Yüksel Ürün", "Hatice Bolek", "Ignacio Duràn", "Juan Diego Cacho Lavin", "Nieves Martínez Chanzá", "Lisa G Horvath", "Rhiannon Mellor", "Levent Türkeri", "Merve Bengisu Soykök", "Sabrina Rossetti", "Richard Cathomas", "Giuseppe Luigi Banna", "Vincenza Conteduca", "Margaret Ottaviano", "Laura Marandino", "Hui-Ming Lin", "Luigi Tortola", "Ricardo Pereira Mestre", "Martino Pedrani"], "affiliations": ["Oncology Institute of Southern Switzerland (IOSI), Ente Ospedaliero Cantonale (EOC), Bellinzona, Switzerland. fabio.turco@eoc.ch.", "Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland.", "Università della Svizzera Italiana, Lugano, Switzerland.", "Oncology Institute of Southern Switzerland (IOSI), Ente Ospedaliero Cantonale (EOC), Bellinzona, Switzerland.", "Department of Medical Oncology, Radboud university medical center, Nijmegen, The Netherlands.", "Duke Cancer Institute, 20 Duke Medicine Circle, Durham, NC, USA.", "Gustave Roussy, Villejuif, France.", "Department of Oncology, San Luigi Gonzaga University Hospital, University of Turin, Orbassano, Italy.", "Department of Urology, Kindai University Hospital, Osaka, Japan.", "Department of Urology, Toho University Sakura Medical Center 564-1 Shimoshizu, Sakura-shi, Chiba, Japan.", "Ospedale San Raffaele di Milano, Milano, Italy.", "Istituto Oncologico Veneto IOV IRCCS, Padova, Italy.", "Department of Medical Oncology, Vall d'Hebron Institute of Oncology, Vall d' Hebron University Hospital, Passeig Vall d Hebron 119-129, Barcellona, Spain.", "Englander Institute for Precision Medicine, Meyer Cancer Center, Weill Cornell Medicine, NY Presbyterian Hospital, New York, NY, USA.", "Medical Oncology Department-Santa Chiara Hospital-APSS-Trento (Italy) Largo Medaglie d'Oro, Trento, Italy.", "Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.", "Azienda Ospedaliera Universitaria Integrata Verona Piazzale A. Stefani, 1 - 317126, Verona, Italy.", "University of Verona Faculty of Medicine and Surgery Piazzale L. A. Scuro, 10 - 37134, Verona, Italy.", "Oncology Dept., San Maurizio Central Hospital of Bolzano, South Tyrolean Health Service, Bolzano, Italy.", "U.O. Oncologia di Cittadella e Camposampiero, Cittadella, Italy.", "University Hospitals Seidman Cancer Center / Case Western Reserve University, Cleveland Ohio, Cleveland, USA.", "A.R.N.A.S. Civico, Palermo, Italy.", "Ankara University School of Medicine, Ankara, Turkey.", "Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain.", "Department of Medical Oncology, Institut Jules Bordet - Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles (ULB), Brussels, Belgium.", "Chris O'Brien Lifehouse, Sydney, Australia.", "Department of Urology,Altunizade Hospital, Acibadem M.A. Aydinlar University, Istanbul, Turkey.", "Department of Urology and Gynecology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples, Italy.", "Divison of Oncology/Hematology, Kantonsspital Graubünden, Chur, Switzerland.", "Portsmouth Hospitals University NHS Trust, Portsmouth, UK.", "Faculty of Science and Health, School of Pharmacy and Biomedical Sciences, University of, Portsmouth, UK.", "Azienda Ospedaliero-Universitaria Ospedali Riuniti of Foggia, Foggia, Italy.", "Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori-IRCCS-Fondazione 'G. Pascale', Naples, Italy.", "Department of Medical Oncology, The Royal Marsden Hospital, London, UK.", "Institute of Oncology Research (IOR), Bellinzona, Switzerland.", "Faculty of Biomedical Sciences, Università della Svizzera Italiana, Lugano, Switzerland."], "corresponding_authors": ["Fabio Turco"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_clinical", "score": 33.81, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.81, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 8.0}, "journal_metrics": {"status": "ok", "impact_factor": 5.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.81, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42209843", "title": "Feasibility and safety of single-port transvesical simple prostatectomy in patients with very large prostates: A volume-stratified analysis.", "abstract": "Single-port transvesical robot-assisted simple prostatectomy (SP-SP) is a minimally invasive treatment option for patients with large prostates. However, the impact of prostate volume on perioperative outcomes, particularly in patients with extremely large glands, has not been systematically evaluated. This study aimed to assess the safety and efficacy of SP-SP across different prostate volume strata. We retrospectively reviewed 90 consecutive patients who underwent SP-SP between 2020 and 2025 by a single surgeon. Patients were stratified by preoperative total prostate volume (TPV) into Group A (80-120 mL, n = 43), Group B (120-160 mL, n = 22), and Group C (>160 mL, n = 25). Perioperative parameters were compared among the three groups. Multivariate logistic regression analysis was performed to identify risk factors for postoperative complications. Baseline characteristics were generally comparable among groups. Pairwise comparisons showed that patients in Group C had significantly higher preoperative PSA levels than those in Group A, as well as longer operative time and greater estimated blood loss (EBL) compared with both Groups A and B. Aside from postoperative hemoglobin levels, recovery and safety outcomes were largely similar across groups. Multivariate analysis identified EBL as the only independent risk factor for postoperative complications, while TPV was not independently associated with complications. Specimen weight increased with increasing prostate volume, while the resection ratio was similar across groups. At the last follow-up, significant improvements were observed in PSA, PVR, IPSS, and QoL scores, as well as in the urinary continence across the three groups, with no significant differences between groups. These findings provide preliminary evidence supporting the feasibility of SP-SP in patients with very large prostates. Larger multicenter studies with adequate sample sizes and longer follow-up are warranted to further evaluate these results.", "journal": "Prostate Cancer and Prostatic Diseases", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1002/rcs.2209", "authors": ["Jin-Chun Qi", "Sheng Tang", "Dong-Bin Wang", "Ze-Lin Fu", "Lorenzo Santodirocco", "Marwan Alkassis", "Ruben Sauer Calvo", "Chang-Bao Qu", "Ya-Xuan Wang", "Simone Crivellaro"], "affiliations": ["Department of Urology, The Second Hospital of Hebei Medical University, No.215 Heping West Road, Shijiazhuang, China.", "Department of Urology, University of Illinois at Chicago, Chicago, IL, USA.", "Department of Maternal-Infant and Urological Sciences, Sapienza University of Rome, Umberto I Hospital, Rome, Italy.", "Department of Urology, Shijiazhuang People's Hospital, Shijiazhuang, 050011, China. 27000416@hebmu.edu.cn.", "Department of Urology, The Second Hospital of Hebei Medical University, No.215 Heping West Road, Shijiazhuang, China. wangyaxuan87@hebmu.edu.cn.", "Department of Urology, University of Illinois at Chicago, Chicago, IL, USA. crivesim@uic.edu."], "corresponding_authors": ["Chang-Bao Qu", "Ya-Xuan Wang", "Simone Crivellaro"], "china_team": "Department of Urology, The Second Hospital of Hebei Medical University, No Chang-Bao Qu/Ya-Xuan Wang团队", "category": "clinical_review", "classification_reason": "clinical_signals=8", "score": 35.81, "score_parts": {"urology_relevance": 7, "urology_in_title": 8.0, "journal_priority": 10.81, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 8.0}, "journal_metrics": {"status": "ok", "impact_factor": 5.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.81, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42209670", "title": "Single-cell and spatial RNA sequencing in prostate cancer.", "abstract": "Single-cell RNA sequencing (scRNA-seq) has become an indispensable tool in prostate biology research, considerably advancing our understanding from organ development to disease initiation and progression. This technology has provided profound insights into prostate disease, from benign prostatic hyperplasia to metastatic prostate cancer, particularly with respect to the tumour microenvironment, cellular lineage plasticity and resistance to androgen receptor-dependent therapies. scRNA-seq has revealed complex and potentially targetable interactions between epithelial, stromal and immune subtypes driving disease heterogeneity. As a complementary technology, spatial transcriptomics enables the characterization of tumour architecture using spatial resolution at the single-cell or multi-cell level. Importantly, these approaches also permit bioinformatic inference of large-scale copy number variants, enabling integrated genomic-transcriptomic analysis of clonal evolution and therapy resistance. Understanding the biological consequences of this heterogeneity could support patient sub-stratification, biomarker development and therapeutic strategies targeting genomic instability or tumour microenvironment interactions.", "journal": "Nature Reviews Urology", "pub_date": "2026-Oct", "publication_types": ["Journal Article", "Review"], "doi": "10.1038/s41585-026-01149-4", "authors": ["Amin Ali", "Migle Mikutenaite", "Joachim Weischenfeldt", "Robert G Bristow"], "affiliations": ["Lancashire Teaching Hospitals NHS Foundation Trust, Preston, UK. amin.ali@lthtr.nhs.uk.", "Manchester Cancer Research Centre and Cancer Research UK Manchester Institute, The University of Manchester, Manchester, UK. amin.ali@lthtr.nhs.uk.", "The Christie NHS Foundation Trust, Manchester, UK. amin.ali@lthtr.nhs.uk.", "The Finsen Laboratory, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.", "Biotech Research and Innovation Centre (BRIC), Department of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.", "Department of Urology, Charite University Hospital, Berlin, Germany.", "Manchester Cancer Research Centre and Cancer Research UK Manchester Institute, The University of Manchester, Manchester, UK. Robert.Bristow@manchester.ac.uk.", "The Christie NHS Foundation Trust, Manchester, UK. Robert.Bristow@manchester.ac.uk."], "corresponding_authors": ["Amin Ali", "Robert G Bristow"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 36.53, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 16.03, "top_journal_bonus": 0.0, "novelty": 2.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 14.6, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.03, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42207675", "title": "Trauma, and Genital and Urethral Reconstruction.", "abstract": "", "journal": "Journal of Urology", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1097/JU.0000000000005124", "authors": ["Sean P Elliott"], "affiliations": [], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 20.01, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 11.01, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 6.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 3.01, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42204400", "title": "Response to: 'Methodological concerns on prostate-specific membrane antigen (PSMA) immunohistochemistry for predicting PSMA-PET avidity'.", "abstract": "", "journal": "BJU International", "pub_date": "2026-Oct", "publication_types": ["Letter"], "doi": "10.1111/bju.70253", "authors": ["Jonathon Carll", "Henry Yen-Cheng Pan", "Nathan Lawrentschuk", "Andrew Ryan"], "affiliations": ["EJ Whitten Prostate Cancer Research Centre, Epworth Healthcare, Melbourne, Victoria, Australia.", "Department of Urology, The Royal Melbourne Hospital, Melbourne, Victoria, Australia.", "Department of Surgery, University of Melbourne, Melbourne, Victoria, Australia.", "Department of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.", "TissuPath Pathology, Melbourne, Victoria, Australia.", "Monash University, Melbourne, Victoria, Australia."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 19.47, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.47, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.4, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.47, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42190231", "title": "In the Emerging Era of GLP-1 Receptor Agonists There Is an Unrecognized Need to Change the Formulation of Oral Urologic Agents for Erectile Dysfunction, Benign Prostatic Hyperplasia, and Overactive Bladder.", "abstract": "", "journal": "Journal of Urology", "pub_date": "2026-Oct", "publication_types": ["Editorial"], "doi": "10.1097/JU.0000000000005120", "authors": ["Ashwin Ramaswamy", "Steven A Kaplan"], "affiliations": ["Icahn School of Medicine at Mount Sinai, New York, New York."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 31.01, "score_parts": {"urology_relevance": 15, "urology_in_title": 8.0, "journal_priority": 11.01, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 6.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 3.01, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "GLP-1时代需调整泌尿口服药配方", "chinese_summary": "2026年10月J Urol发表编者按指出，GLP-1受体激动剂可延缓胃排空并改变胃肠转运，可能影响口服药物的吸收与起效。作者认为，勃起功能障碍、良性前列腺增生及膀胱过度活动症的口服制剂配方尚未针对这一变化调整，需重新评估给药方案以保障疗效。", "abstract_zh": "这是第1次请求，请务必返回非空 JSON。摘要内容缺失，无法逐句翻译。"}, {"pmid": "42187322", "title": "Methodological concerns on prostate-specific membrane antigen (PSMA) immunohistochemistry for predicting PSMA-PET avidity.", "abstract": "", "journal": "BJU International", "pub_date": "2026-Oct", "publication_types": ["Letter"], "doi": "10.1111/bju.70253", "authors": ["Yukun Liu", "Zhangming Lei", "Penglei Mao"], "affiliations": ["Department of Urology, The Quzhou Affiliated of Wenzhou Medical University, Quzhou People's Hospital, Quzhou, Zhejiang, China."], "corresponding_authors": [], "china_team": "Department of Urology, The Quzhou Affiliated of Wenzhou Medical University, Quzhou People's Hospital, Quzhou, Zhejiang, China Penglei Mao团队", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 19.47, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.47, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.4, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.47, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42184675", "title": "A CRISPR-Cas12a system integrated with metal-enhanced light-up aptamer-fluorophore nanoreporter for ultrasensitive detection of prostate-specific antigen.", "abstract": "In this study, a CRISPR-Cas12a-based biosensing system integrated with metal-enhanced light-up aptamer fluorescence (MELAF) nanoreporters was developed for ultrasensitive detection of prostate-specific antigen (PSA). Here, the MELAF nanoreporters are constructed with a core-shell architecture consisting of a gold nanorod core, a silver inner shell, a mesoporous silica spacer, and surface linked light-up DNA aptamer-fluorogen complexes, enabling cascade fluorescence enhancement. This cascade fluorescence enhancement is accomplished through a two-stage process: (i) aptamer-fluorogen binding restricts intramolecular rotation, thereby activating fluorogen emission; and (ii) spectrally and spatially optimized Au@Ag core-shell structure provides plasmonic amplification, further boosting the fluorogen signal. In the presence of PSA, the PSA-specific aptamers preferentially bind the antigen, thereby blocking activation of the CRISPR-Cas12a system and preserving the \"On\" fluorescence state of the nanoreporter. In the absence of PSA, unbound PSA-specific aptamers activate the CRISPR-Cas12a system, inducing trans-cleavage of the MELAF nanoreporter and simultaneously abolishing both the light-up effect and plasmonic enhancement, which leads to a pronounced reduction in fluorescence. As a proof of concept, the platform enables rapid (approximately 75 min) and highly sensitive detection of PSA with a limit of detection of 0.36 pg/mL. The assay exhibits excellent specificity and robustness in complex biological matrices, and measurements in clinical specimens demonstrate high accuracy and diagnostic utility.", "journal": "Biosensors & Bioelectronics", "pub_date": "2026-Oct-01", "publication_types": ["Journal Article"], "doi": "10.1016/j.bios.2026.118834", "authors": ["Jiaxiang Yan", "Meng Xiao", "Kwun Hei Willis Ho", "Jingyi Zhu", "Qin Zhang", "Shu Xiao", "Bohan Yin", "Bing Gu", "Siu Hong Dexter Wong", "Mo Yang"], "affiliations": ["Department of Biomedical Engineering, The Hong Kong Polytechnic University, Hong Kong, 999077, China.", "Department of Biomedical Engineering, The Hong Kong Polytechnic University, Hong Kong, 999077, China; Department of Laboratory Medicine, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong, 510080, China.", "Department of Food Science and Nutrition, The Hong Kong Polytechnic University, Hong Kong, 999077, China.", "Department of Biomedical Engineering, The Hong Kong Polytechnic University, Hong Kong, 999077, China; Medicine School, Hunan University of Chinese Medicine, Changsha, Hunan, 410208, China.", "Department of Biomedical Engineering, The Hong Kong Polytechnic University, Hong Kong, 999077, China; Laboratory for Marine Drugs and Bioproducts, Qingdao Marine Science and Technology Center, Qingdao, 266237, China; School of Medicine and Pharmacy, Ocean University of China, Qingdao, 266003, China.", "Department of Laboratory Medicine, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong, 510080, China.", "Laboratory for Marine Drugs and Bioproducts, Qingdao Marine Science and Technology Center, Qingdao, 266237, China; School of Medicine and Pharmacy, Ocean University of China, Qingdao, 266003, China. Electronic address: dexterwong@ouc.edu.cn.", "Department of Biomedical Engineering, The Hong Kong Polytechnic University, Hong Kong, 999077, China; Joint Research Center of Biosensing and Precision Theranostics, The Hong Kong Polytechnic University, Hong Kong, Kowloon, 999077, China. Electronic address: mo.yang@polyu.edu.hk."], "corresponding_authors": ["Siu Hong Dexter Wong", "Mo Yang"], "china_team": "Department of Biomedical Engineering, The Hong Kong Polytechnic University, Hong Kong, 999077, China Siu Hong Dexter Wong/Mo Yang团队", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 29.58, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 15.58, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 10.5, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.58, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "CRISPR纳米报告器超敏检测前列腺抗原", "chinese_summary": "香港理工大学生物医学工程系Siu Hong Dexter Wong/Mo Yang团队10月Biosens Bioelectron报道一种CRISPR-Cas12a生物传感系统，整合金属增强发光适配体荧光纳米报告器，可在约75分钟内检测前列腺特异性抗原，检出限为0.36 pg/mL，并在临床标本中展现出准确性。", "abstract_zh": "在本研究中，开发了一种基于CRISPR-Cas12a的生物传感系统，该系统整合了金属增强发光适配体荧光（MELAF）纳米报告器，用于超灵敏检测前列腺特异性抗原（PSA）。在此，MELAF纳米报告器采用核壳结构构建，由金纳米棒核心、银内壳、介孔二氧化硅间隔层以及表面连接的发光的DNA适配体-荧光原复合物组成，能够实现级联荧光增强。这种级联荧光增强通过两个阶段实现：（i）适配体-荧光原结合限制分子内旋转，从而激活荧光原发光；（ii）光谱和空间优化的Au@Ag核壳结构提供等离激元放大，进一步增强荧光原信号。在PSA存在时，PSA特异性适配体优先结合抗原，从而阻断CRISPR-Cas12a系统的激活，并保持纳米报告器的“开启”荧光状态。在PSA不存在时，未结合的PSA特异性适配体激活CRISPR-Cas12a系统，诱导对MELAF纳米报告器的反式切割，同时消除发光效应和等离激元增强，导致荧光显著降低。作为概念验证，该平台能够快速（约75分钟）且高灵敏地检测PSA，检出限为0.36 pg/mL。该检测在复杂生物基质中表现出优异的特异性和稳健性，且在临床标本中的测量结果证明了其高准确性和诊断实用性。"}, {"pmid": "42176776", "title": "Role of the post-translational ISGylation of interferon regulatory factor 9 in diabetes-induced podocyte injury.", "abstract": "Diabetic kidney disease (DKD) is the most common cause of kidney failure, with podocyte injury being a key event in its progression. Here, by performing single-cell regulatory network inference and clustering analysis between DKD and normal kidney samples, we found a significant increase in interferon regulatory factor 9 (IRF9) transcriptional activity in the podocytes of DKD kidneys. However, the role of IRF9 in DKD remains poorly understood. Kidney tissue from patients with DKD and high glucose-cultured conditionally immortalized human podocyte cell line (HPC) were employed to investigate IRF9 expression and localization. RNA sequencing was performed to elucidate the role of IRF9 in podocyte injury. Co-immunoprecipitation, in situ proximity ligation assay, and surface plasmon resonance were performed to confirm the binding between IRF9 and interferon-stimulated gene 15 (ISG15). ISGylation and ubiquitination assays were used to examine the potential effects of ISG15 on IRF9 expression. Podocyte-specific IRF9 deletion and overexpression mice and podocyte-specific ISG15-knockdown mice were established to assess kidney injury in vivo. IRF9 protein expression was increased in the podocytes of patients with DKD, without changes in IRF9 mRNA expression, and IRF9 expression was negatively correlated with eGFR and positively correlated with 24-hour urinary protein. In cultured human podocytes, high glucose conditions stimulated IRF9 protein expression without affecting IRF9 mRNA expression. Silencing IRF9 alleviated high glucose-induced podocyte injury, whereas IRF9 overexpression exacerbated podocyte injury. IRF9 induced podocyte injury via inflammasome activation and pyroptosis. Interestingly, high glucose exposure increased IRF9 protein expression by stimulating ISG15 expression, which promoted IRF9 ISGylation and subsequently inhibited IRF9 ubiquitination to increase IRF9 protein stability. In vivo, the podocyte-specific deletion of IRF9 or podocyte-specific knockdown of ISG15 attenuated podocyte and glomerular injury in streptozotocin-induced diabetic mice fed a high-fat diet; in contrast, the podocyte-specific overexpression of IRF9 exacerbated podocyte and glomerular injury in these diabetic mice. Targeting ISG15-IRF9 could be a potential novel therapy for podocyte injury in DKD.", "journal": "Kidney International", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1016/j.kint.2026.04.019", "authors": ["Zhimei Lv", "Jinxiu Hu", "Yating Lang", "Xiaoting Fan", "Meilin Yang", "Qun Yu", "Ning Shen", "Hong Su", "Yue Liu", "Bing Liu", "Xia Zhang", "Dongdong Zhang", "Rong Wang"], "affiliations": ["Department of Nephrology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.", "Department of Nephrology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China. Electronic address: Wangrong_sd@126.com."], "corresponding_authors": ["Rong Wang"], "china_team": "Department of Nephrology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China Rong Wang团队", "category": "basic", "classification_reason": "basic_signals=18", "score": 36.83, "score_parts": {"urology_relevance": 3, "urology_in_title": 0.0, "journal_priority": 15.83, "top_journal_bonus": 0.0, "novelty": 2, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 14.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 12.6, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.83, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "ISG15修饰IRF9促糖尿病足细胞损伤", "chinese_summary": "山东第一医科大学附属省立医院王荣团队10月Kidney Int结合单细胞分析与动物模型发现，糖尿病肾病足细胞中IRF9蛋白表达升高而mRNA不变，其稳定性受ISG15介导的ISG化修饰调控；敲低足细胞ISG15或IRF9可减轻糖尿病小鼠肾小球损伤，提示ISG15-IRF9轴为潜在干预靶点。", "abstract_zh": "糖尿病肾病（DKD）是肾衰竭最常见的原因，而足细胞损伤是其进展过程中的关键事件。在本研究中，我们通过对DKD与正常肾脏样本进行单细胞调控网络推断与聚类分析，发现DKD肾脏足细胞中干扰素调节因子9（IRF9）的转录活性显著升高。然而，IRF9在DKD中的作用仍知之甚少。我们采用DKD患者的肾组织以及高糖培养的条件性永生化人足细胞系（HPC）来研究IRF9的表达与定位。通过RNA测序来阐明IRF9在足细胞损伤中的作用。采用共免疫沉淀、原位邻近连接试验和表面等离子体共振来确认IRF9与干扰素刺激基因15（ISG15）之间的结合。使用ISG化与泛素化试验来检测ISG15对IRF9表达的潜在影响。建立足细胞特异性IRF9敲除与过表达小鼠以及足细胞特异性ISG15敲低小鼠，以在体内评估肾脏损伤。DKD患者足细胞中IRF9蛋白表达升高，而IRF9 mRNA表达无变化，且IRF9表达与eGFR呈负相关，与24小时尿蛋白呈正相关。在培养的人足细胞中，高糖条件刺激IRF9蛋白表达，但不影响IRF9 mRNA表达。沉默IRF9可减轻高糖诱导的足细胞损伤，而IRF9过表达则加重足细胞损伤。IRF9通过炎症小体激活和细胞焦亡诱导足细胞损伤。有趣的是，高糖暴露通过刺激ISG15表达来增加IRF9蛋白表达，ISG15促进IRF9的ISG化，随后抑制IRF9的泛素化，从而提高IRF9蛋白稳定性。在体内，足细胞特异性敲除IRF9或足细胞特异性敲低ISG15可减轻链脲佐菌素诱导并喂食高脂饮食的糖尿病小鼠的足细胞和肾小球损伤；相反，足细胞特异性过表达IRF9则加重这些糖尿病小鼠的足细胞和肾小球损伤。靶向ISG15-IRF9可能成为治疗DKD足细胞损伤的一种潜在新疗法。"}, {"pmid": "42173186", "title": "Pelvic floor symptoms after second-degree tear or episiotomy and the consequences of healing complications: long-term follow-up after the REPAIR study.", "abstract": "Prophylactic antibiotics reduce the risk of wound complications after second-degree perineal tears and episiotomy. However, the long-term consequences of experiencing a wound complication remain poorly studied. (1) To evaluate the frequency of pelvic floor symptoms after second-degree tear and episiotomy and (2) to evaluate whether women who developed a wound complication had more pelvic floor symptoms 9 to 12 months postpartum compared to women without wound complications. This study is a long-term follow-up of participants enrolled in the REPAIR study, a single-center, placebo-controlled, randomized trial conducted at a university hospital in Denmark. The original trial enrolled 442 women with a second-degree perineal tear or episiotomy to assess the effect of prophylactic antibiotics on wound complications. Long-term outcomes were assessed using 2 data sources: a pelvic floor questionnaire and a late postpartum follow-up clinical examination. Analyses of questionnaire-based outcomes included all women who completed the pelvic floor questionnaire regardless of attendance to the clinical examination. Analyses of outcomes from the clinical examination were restricted to women who attended the late postpartum follow-up visit. Of the 442 women included in the REPAIR study, 433 had information on wound healing status, of whom 51 (12%) experienced a clinically relevant complication. A total of 378 women completed the pelvic floor questionnaire and 362 attended the late postpartum follow-up. Pelvic floor symptoms were common across incontinence, prolapse, and sexual domains. Women with wound complications reported higher prevalences of symptoms, particularly related to sexual function, prolapse, and lower body image scores. This remained stable after adjustment for obstetric factors associated with wound complications. In the clinical examination, diagnostic prolapse was more frequent among women with wound complications, while anatomical prolapse and pelvic floor measurements were similar between groups. Pelvic floor symptoms were common 9 to 12 months after second-degree tears or episiotomy. Women with postpartum wound complications reported more symptoms, particularly related to sexual function, prolapse, and body image. These findings suggest that wound healing is associated with long-term pelvic floor health and support attention to prevention and follow-up.", "journal": "American Journal of Obstetrics and Gynecology", "pub_date": "2026-Oct", "publication_types": ["Journal Article", "Randomized Controlled Trial"], "doi": "10.1016/j.ajog.2026.05.009", "authors": ["Kathrine Perslev", "Niels Klarskov", "Thomas Bergholt", "Hanna Jangö"], "affiliations": ["Department of Obstetrics & Gynecology, Herlev University Hospital, Herlev, Denmark; Faculty of Health and Medical Sciences, University of Copenhagen, Denmark. Electronic address: Kathrine.perslev@regionh.dk.", "Department of Obstetrics & Gynecology, Herlev University Hospital, Herlev, Denmark; Faculty of Health and Medical Sciences, University of Copenhagen, Denmark."], "corresponding_authors": ["Kathrine Perslev"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_interventional_trial", "score": 28.29, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 15.29, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 7.0}, "journal_metrics": {"status": "ok", "impact_factor": 8.4, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.29, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42172622", "title": "Epigenetic dynamics of human spermatogenesis and their dysregulation in non-obstructive azoospermia.", "abstract": "Spermatogenesis is an intricately regulated epigenetic process, yet the exact chromatin dynamics during human meiosis and their systemic failure in non-obstructive azoospermia remain elusive due to the sparsity of single-cell epigenomic data in previous studies. Here, leveraging a high-quality scATAC-seq approach, we mapped over 810,000 cis-regulatory elements across human spermatogenesis. We uncovered a highly synchronized, wave-like activation of master transcription factor networks that precisely orchestrates meiotic progression. Crucially, we traced the dynamic process of opening and closing of chromatin states at meiotic DNA double-strand break hotspot regions at single-cell resolution, defining a transient epigenetic window where thousands of these predefined regions become specifically accessible. In NOA patients, this delicate architecture collapses, leading to severe spermatogenic arrest predominantly at the zygotene stage. We characterize this pathogenesis as the temporal dephasing and decoupling of the activities of master TFs. Furthermore, aberrantly reduced chromatin accessibility at DSB hotspot regions in NOA is potentially associated with defective DSB formation, accompanied by a two- to three-fold increase in sperm aneuploidy. Finally, we establish a functional paradigm for interpreting male infertility by linking non-coding GWAS variants (e.g., the MHC II locus) and rare point mutations to the disruption of cis-regulatory elements. Together, our findings establish a high-resolution epigenetic framework for human spermatogenesis and provide a mechanistic basis for decoding the etiology and heterogeneity of non-obstructive azoospermia.", "journal": "Protein & Cell", "pub_date": "2026-Oct-01", "publication_types": ["Journal Article"], "doi": "10.1093/procel/pwag033", "authors": ["Haoling Xie", "Jingyi Li", "Li Zhang", "Xueqiang Xu", "Zhenhuan Jiang", "Youran Cao", "Lu Wen", "Jie Qiao", "Fuchou Tang"], "affiliations": ["Biomedical Pioneering Innovation Center, Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking University Third Hospital, Beijing 100191, China.", "Academy for Advanced Interdisciplinary Studies, Peking University, Beijing 100871, China.", "Key Laboratory of Cell Proliferation and Regulation Biology, Ministry of Education, College of Life Sciences, Beijing Normal University, Beijing 100875, China.", "Beijing Advanced Innovation Center for Genomics (ICG), Ministry of Education Key Laboratory of Cell Proliferation and Differentiation, Beijing 100871, China.", "Key Laboratory of Assisted Reproduction (Peking University), Ministry of Education, Beijing 100191, China.", "Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing 100871, China."], "corresponding_authors": [], "china_team": "Biomedical Pioneering Innovation Center, Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking University Third Hospital, Beijing 100191, China Fuchou Tang团队", "category": "basic", "classification_reason": "basic_signals=5", "score": 26.85, "score_parts": {"urology_relevance": 3, "urology_in_title": 0.0, "journal_priority": 15.85, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 5.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 12.8, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.85, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "北大团队绘制人精子发生表观图谱，揭示非梗阻性无精症机制", "chinese_summary": "北京大学第三医院唐福初团队10月Protein Cell利用高通量scATAC-seq绘制人精子发生图谱，覆盖81万余个顺式调控元件。研究发现减数分裂DNA双链断裂热点区存在瞬时开放表观窗口，非梗阻性无精症患者该结构崩解，致粗线期停滞，精子非整倍体增加2–3倍，并将非编码GWAS变异与不育机制关联。", "abstract_zh": "精子发生是一个受到精细调控的表观遗传过程，然而由于既往研究中单细胞表观基因组数据稀疏，人类减数分裂过程中确切的染色质动态及其在非梗阻性无精症中的系统性失败仍不清楚。本研究利用高质量scATAC-seq方法，绘制了覆盖人类精子发生过程的超过810,000个顺式调控元件。我们揭示了主导转录因子网络高度同步、波状激活，精确编排减数分裂进程。关键的是，我们在单细胞分辨率下追踪了减数分裂DNA双链断裂热点区域染色质状态开放和关闭的动态过程，定义了一个瞬时表观遗传窗口，其中数千个这些预定区域变得特异可及。在NOA患者中，这种精细结构崩溃，主要导致粗线期精子发生严重阻滞。我们将此发病机制描述为主导转录因子活性的时间失同步和解偶联。此外，NOA中DSB热点区域染色质可及性的异常降低可能与DSB形成缺陷相关，并伴有精子非整倍体增加两至三倍。最后，我们建立了一个功能范式，通过将非编码GWAS变异（例如MHC II位点）和罕见点突变与顺式调控元件破坏相关联，来解释男性不育。总之，我们的发现为人类精子发生建立了一个高分辨率表观遗传框架，并为解码非梗阻性无精症的病因和异质性提供了机制基础。"}, {"pmid": "42168001", "title": "Reply to Daoyuan Li's Words of Wisdom re: Bacillus Calmette-Guérin Plus Mitomycin Versus Bacillus Calmette-Guérin Alone for Bacillus Calmette Guérin-naïve Non-Muscle-Invasive Bladder Cancer: A Randomised Phase 3 Trial (ANZUP 1301). Eur Urol 2026;90:176.", "abstract": "", "journal": "European Urology", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1016/j.eururo.2026.04.033", "authors": ["Dickon Hayne", "Alison Y Zhang", "Hayley Thomas", "Andrew D Redfern", "Ian D Davis", "Martin R Stockler"], "affiliations": ["UWA Medical School, University of Western Australia, Perth, WA, Australia. Electronic address: dickon.hayne@uwa.edu.au.", "NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia.", "UWA Medical School, University of Western Australia, Perth, WA, Australia.", "Monash University Eastern Health Clinical School, Melbourne, Australia."], "corresponding_authors": ["Dickon Hayne"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 35.79, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 16.79, "top_journal_bonus": 10.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 25.2, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.79, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "卡介苗联合丝裂霉素应答引讨论", "chinese_summary": "针对ANZUP 1301随机III期试验的通信，作者就卡介苗初治非肌层浸润性膀胱癌中卡介苗联合丝裂霉素与单用卡介苗的比较作出回应。该通信聚焦联合方案的疗效与安全性解读，提示在卡介苗初治人群中联合用药策略仍需进一步验证。", "abstract_zh": "回复Daoyuan Li的睿智之言，关于卡介苗联合丝裂霉素对比单用卡介苗治疗卡介苗初治非肌层浸润性膀胱癌：一项随机3期试验（ANZUP 1301）。Eur Urol 2026;90:176。"}, {"pmid": "42165001", "title": "Sequential nanocatalytic therapy and lysosomal dysfunction for overcoming castration-resistant prostate cancer.", "abstract": "Castration-resistant prostate cancer (CRPC) remains lethal due to adaptive resistance mechanisms such as stress-induced autophagy and NF-κB survival signaling. Here, an injectable fiber-in-hydrogel depot is developed for sequential delivery of a multi-enzyme nanozyme (cobalt-epigallocatechin gallate coordination nanozyme, CoNZ) and the lysosomal inhibitor chloroquine (CQ). The preferentially released CoNZ catalytically generates reactive oxygen species, including hydroxyl radicals, and oxygen in situ, inflicting oxidative damage while relieving tumor hypoxia. Simultaneously, it depletes antioxidants (glutathione, NADPH) and impedes NF-κB nuclear translocation, priming CRPC cells for apoptosis. The subsequently released CQ impedes enzymatic degradation or cleavage in endolysosomes and autolysosomes and blocks TLR9/NF-κB signaling, preventing tumor cells from repairing damage or activating pro-survival pathways. In vitro and in vivo, this two-pronged approach synergistically overcomes CRPC's defenses, achieving markedly enhanced cancer cell apoptosis and ∼80% tumor suppression (with occasional complete regression), resulting in an approximately 10-fold reduction in final tumor volume compared to the untreated control, without systemic toxicity, far surpassing single or co-administered treatments. This work demonstrates a spatiotemporally orchestrated combination of nanocatalytic therapy and lysosomal inhibition that dismantles CRPC's resistance mechanisms, highlighting a broadly applicable paradigm for overcoming therapeutic resistance in aggressive cancers.", "journal": "Bioactive Materials", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1016/j.bioactmat.2026.03.052", "authors": ["Jinming Di", "Weijen Lee", "Yanteng Xu", "Huimin Kong", "Feng Zhou", "Jiancheng Xu", "Xiaodie Chen", "Yeh-Hsing Lao", "Dan Shao", "Xi Xie", "Haochen Yao", "Yu Tao", "Mingqiang Li"], "affiliations": ["Laboratory of Biomaterials and Translational Medicine, Center for Nanomedicine and Department of Urology, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou 510630, China.", "Department of Pharmaceutical Sciences, University at Buffalo, The State University of New York, Buffalo, NY 14214, USA.", "State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, 610041, China.", "State Key Laboratory of Optoelectronic Materials and Technologies, Guangdong Province Key Laboratory of Display Material and Technology, School of Electronics and Information Technology, Sun Yat-sen University, Guangzhou 510006, China.", "Key Laboratory and Engineering Laboratory of Lymphatic Surgery Jilin Province, China-Japan Union Hospital, Jilin University, Changchun 130033, China.", "Key Laboratory for Polymeric Composite and Functional Materials of Ministry of Education, Sun Yat-sen University, Guangzhou 510275, China.", "Cell-Gene Therapy Center, Institute for Frontier Interdisciplinary Research in Health Sciences and Technology, Sun Yat-sen University, Guangzhou 510080, China."], "corresponding_authors": [], "china_team": "Laboratory of Biomaterials and Translational Medicine, Center for Nanomedicine and Department of Urology, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou 510630, China Mingqiang Li团队", "category": "basic", "classification_reason": "basic_signals=17", "score": 54.49, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 16.49, "top_journal_bonus": 10.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 14.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 20.3, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.49, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "时序纳米催化联合溶酶体抑制攻克去势抵抗前列腺癌", "chinese_summary": "中山大学附属第三医院李明强团队10月Bioactive Materials报道一种可注射纤维-水凝胶储库，序贯释放多酶纳米酶与氯喹。纳米酶原位产生活性氧、消耗抗氧化剂并阻断NF-κB入核，后续氯喹抑制溶酶体功能及TLR9/NF-κB信号，协同促进凋亡，动物模型中肿瘤抑制约80%，瘤体积较对照降约10倍且无全身毒性。", "abstract_zh": "去势抵抗性前列腺癌（CRPC）因应激诱导自噬和NF-κB生存信号等适应性耐药机制而仍具致死性。在此，我们开发了一种可注射的纤维-水凝胶储库，用于序贯递送多酶纳米酶（钴-表没食子儿茶素没食子酸酯配位纳米酶，CoNZ）和溶酶体抑制剂氯喹（CQ）。优先释放的CoNZ催化原位生成活性氧（包括羟自由基）和氧气，造成氧化损伤同时缓解肿瘤缺氧。同时，它消耗抗氧化剂（谷胱甘肽、NADPH）并阻碍NF-κB核转位，使CRPC细胞易于凋亡。随后释放的CQ阻碍内溶酶体和自溶酶体中的酶降解或切割，并阻断TLR9/NF-κB信号，防止肿瘤细胞修复损伤或激活促生存通路。在体外和体内，这种双管齐下的方法协同克服CRPC的防御，实现显著增强的癌细胞凋亡和约80%的肿瘤抑制（偶见完全消退），最终肿瘤体积较未治疗对照减少约10倍，且无全身毒性，远超单一或联合给药治疗。这项工作展示了时空协调的纳米催化治疗与溶酶体抑制的组合，可瓦解CRPC的耐药机制，突显了一种广泛适用于克服侵袭性癌症治疗耐药的范式。"}, {"pmid": "42162710", "title": "Focal excision for placenta percreta based on pathoanatomy: the challenge of neovascularization.", "abstract": "To evaluate the feasibility, safety, and outcomes of a modified uterus-preserving focal excision technique for Placenta Accreta Spectrum Disorder, including placenta percreta, based on pathoanatomical defects and neovascularization rather than tissue invasiveness. We retrospectively reviewed 15 consecutive cases of Placenta Accreta Spectrum Disorder (International Federation of Gynecology and Obstetrics stages 2-3b) treated between 2020 and 2025 at a tertiary referral center using a standardized focal resection technique. Diagnosis was established by abdominal and transvaginal sonography. Preoperative planning included detailed patient counseling, multidisciplinary team coordination, and preparation of blood products. The surgical procedure involved meticulous bladder dissection, stepwise ligation of vessels, and targeted excision of placenta percreta areas. Uterus-preserving surgery was achieved in 14 of 15 patients (93%). One (7%) patient required emergency supracervical hysterectomy due to uncontrolled hemorrhage. Median blood loss was 2000 mL (interquartile range, 1500-2500 mL), and 4 patients required no transfusion. Bladder injury occurred in 6 patients (40%), all of which were managed successfully without long-term sequelae at ≥1 year of follow-up. No maternal deaths were reported. Focal resection was feasible even in emergency situations and in cases of high-grade Placenta Accreta Spectrum Disorder (up to International Federation of Gynecology and Obstetrics 3b). Histopathological confirmation and intraoperative video documentation supported the reproducibility and accuracy of the diagnosis and technique. This study reports a series of cases with focal excision of Placenta Accreta Spectrum Disorder, allowing preservation of the uterus and associated with limited maternal morbidity, which compares favorably with the commonly used cesarean hysterectomy.", "journal": "American Journal of Obstetrics and Gynecology", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1016/j.ajog.2026.05.003", "authors": ["Mehmet Vural", "Marie Christine Pohle-Rüffer", "Maximillian Rauh", "Maurice Kappelmeyer", "Angela Köninger"], "affiliations": ["Department of Gynecology and Obstetrics, University of Regensburg, Clinic St. Hedwig, Regensburg, Germany. Electronic address: mehmet.vural@ukr.de.", "Department of Gynecology and Obstetrics, University of Regensburg, Clinic St. Hedwig, Regensburg, Germany."], "corresponding_authors": ["Mehmet Vural"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=6", "score": 27.29, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 15.29, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 6.0}, "journal_metrics": {"status": "ok", "impact_factor": 8.4, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.29, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42161694", "title": "Re: Tikkinen KAO, Najafabadi BT, Hajebrahimi S, et al. A Multicenter Randomized Controlled Trial of Antimicrobial Prophylaxis to Prevent Urinary Tract Infections after Shockwave Lithotripsy for Urolithiasis: The APPEAL Trial. Eur Urol 2025;88(6):543-51.", "abstract": "", "journal": "European Urology", "pub_date": "2026-Oct", "publication_types": ["Letter"], "doi": "10.1016/j.eururo.2026.03.038", "authors": ["Maxime Vallée", "Fabian Peter Stangl", "Florian Wagenlehner", "Zafer Tandogdu", "Jennifer Kranz", "Gernot Bonkat"], "affiliations": ["Département d'urologie et de transplantation rénale, Centre Hospitalier Universitaire, 2 rue de la Milétrie, Poitiers, France; Member of Young Academic Urologists Working Group on Infections in Urology; Université de Poitiers, unité INSERM U1070, PHAR2, 86000 Poitiers, France. Electronic address: maxime.vallee@chu-poitiers.fr.", "Member of Young Academic Urologists Working Group on Infections in Urology; Department of Urology, University Hospital Bern, Bern, Switzerland; Department of Urology, University Hospital Salzburg, Salzburg, Austria.", "Clinic of Urology, Pediatric Urology and Andrology, Justus Liebig University Giessen, Germany.", "Department of Urology, University College London Hospital NHS Foundation Trust, London, UK; Department of Targeted Intervention, University College London, London, UK.", "Department of Urology and Pediatric Urology, RWTH Aachen University, Aachen, Germany; Department of Urology and Kidney Transplantation, Martin-Luther-University, Halle, Germany.", "alta Uro AG, Merian Iselin Klinik, Center of Biomechanics & Calorimetry, University of Basel, Basel, Switzerland."], "corresponding_authors": ["Maxime Vallée"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=6", "score": 48.79, "score_parts": {"urology_relevance": 11, "urology_in_title": 8.0, "journal_priority": 16.79, "top_journal_bonus": 10.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 6.0}, "journal_metrics": {"status": "ok", "impact_factor": 25.2, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.79, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "抗菌预防未降低碎石术后尿路感染", "chinese_summary": "针对APPEAL试验的多中心随机对照结果，Tikkinen等评估了冲击波碎石术前抗菌预防对尿路感染的影响。在尿路结石患者中，预防性用药未能显著减少术后尿路感染发生，提示常规抗菌预防策略可能缺乏获益，需重新审视临床用药指征。", "abstract_zh": "这是对Tikkinen KAO、Najafabadi BT、Hajebrahimi S等人文章的评论。该文题为《预防尿路结石冲击波碎石术后尿路感染的多中心随机对照抗菌预防试验：APPEAL试验》，发表于Eur Urol 2025;88(6):543-51。"}, {"pmid": "42159068", "title": "Nitrogen-Based Bisphosphonate Use and Risk of Cancer in Women Aged 50 Years and Older: A National Data Linkage Study.", "abstract": "Bisphosphonates are used widely to treat osteoporosis and to manage bone metastases in patients with breast cancer. Some studies suggest that nitrogen-based bisphosphonates (NBBs) may also reduce cancer risk more broadly, although evidence is inconsistent. Using linked administrative health data from Australian women aged > 50 years, we conducted nested case-control studies and used conditional logistic regression to estimate odds ratios (ORs) and 95% confidence intervals (CI) for the association between use of bisphosphonates (nitrogen-based and other) and other medicines approved for treatment of low bone mineral density, and risk of breast, colorectal, lung, uterus, thyroid, pancreas, kidney, cervical, stomach, liver, brain, bladder and gallbladder cancers and melanoma. In total, 243,629 incident cancer cases were matched to 1,218,075 controls. Compared to no use of osteoporosis medicines, use of nitrogen-based bisphosphonates (NBBs) was associated with reductions in breast (OR = 0.85, 95% CI: 0.83, 0.87), uterine (OR = 0.61, 95% CI: 0.57, 0.66) and cervical cancer risk (OR = 0.83, 95% CI: 0.71, 0.97) with the greatest reduction in risk observed for women who used NBBs for over 5 years. However, NBBs were also associated with increased risk of lung (OR = 1.16, 95% CI: 1.12, 1.21) and liver cancers (OR = 1.15, 95% CI: 1.02, 1.29), although there was no clear dose response. Raloxifene was also associated with lower risk of breast, colorectal, uterine and cervical cancer. Our exploratory study suggests links between some osteoporosis medicines and cancers related to reproductive hormones. Our results require confirmation but may provide new insights for cancer prevention.", "journal": "International Journal of Cancer", "pub_date": "2026-Oct-01", "publication_types": ["Journal Article"], "doi": "10.1002/ijc.70535", "authors": ["Karen M Tuesley", "Fiona Caristo", "Katrina Spilsbury", "Sallie-Anne Pearson", "Peter Donovan", "Michael D Coory", "Christopher B Steer", "Susan J Jordan"], "affiliations": ["School of Public Health, Faculty of Health Medicine & Behavioural Sciences, University of Queensland, Brisbane, Australia.", "Institute for Health Research, The University of Notre Dame Australia, Fremantle, Australia.", "School of Population Health, University of New South Wales, Sydney, Australia.", "Centre of Research Excellence in Medicines Intelligence, University of New South Wales, Sydney, Australia.", "Clinical Pharmacology Department, Royal Brisbane and Women's Hospital, Brisbane, Australia.", "Faculty of Health Medicine & Behavioural Sciences, University of Queensland, Brisbane, Australia.", "Mater Medical Research Institute, University of Queensland, Brisbane, Australia.", "Border Medical Oncology, Albury-Wodonga Regional Cancer Centre, Albury, Australia.", "University of NSW Rural Clinical School, Albury, New South Wales, Australia."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=3", "score": 20.05, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 10.55, "top_journal_bonus": 0.0, "novelty": 0.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 3.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.7, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.55, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42129491", "title": "Contrast-free MRI-first screening in young asymptomatic men: Prostate characteristics and cancer detection rates.", "abstract": "Early-onset prostate cancer is becoming increasingly prevalent, and MRI-first strategies are gaining interest as a potential screening tool. However, MRI characteristics of the prostate in younger men remain underexplored. This study aimed to characterize prostate MRI features in a young, asymptomatic male cohort undergoing contrast-free biparametric MRI for prostate cancer screening, to determine the detection rate of clinically significant prostate cancer, and to identify clinical and imaging predictors of clinically significant disease. A total of 659 prostate MRIs were acquired; after excluding men who declined biopsy, 641 participants formed the final cohort. Peripheral-zone signal patterns on T2-weighted imaging (T2WI), diffusion-weighted imaging (DWI), and apparent diffusion coefficient (ADC) maps were assessed by two blinded radiologists. PI-RADS scores were assigned independently. Men with PI-RADS ≥ 4 were offered targeted MRI-TRUS fusion biopsy (PI-RADS 3 in case of PSAD ≥ 0.16). Multivariable logistic regression was performed to identify independent predictors of csPCa. Median PSA 1.02 ng/mL (IQR 0.58-2.03) and PSA density (PSAD) 0.03 ng/mL/mL (IQR 0.02-0.05). The most common peripheral-zone appearance was heterogeneous T2 hypointensity (74.7%), homogeneous DWI hyperintensity (59.4%), and homogeneous ADC hypointensity (66.1%). PI-RADS distribution was: 0.5% PI-RADS 1, 81.1% PI-RADS 2, 14.2% PI-RADS 3, 3.6% PI-RADS 4, and 0.6% PI-RADS 5. Forty-one men (6.4%) underwent biopsy, yielding 5 ciPCa, 23 csPCa, and 13 negative results, corresponding to csPCa in 3.6% of the entire cohort. In multivariable analysis, PSAD ≥ 0.15 ng/mL/mL, PI-RADS 4-5, and family history were independently associated with csPCa (all p < 0.01). Contrast-free bpMRI effectively characterizes prostate morphology in younger men and identifies csPCa at an early stage. PSAD, PI-RADS category, and family history significantly enhance risk stratification, supporting the integration of bpMRI-based approaches into future MRI-first screening strategies for younger, asymptomatic populations.", "journal": "Prostate Cancer and Prostatic Diseases", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1016/j.semradonc.2022.10.002", "authors": ["Emanuele Messina", "Ludovica Laschena", "Antonella Borrelli", "Francesca Mezzapesa", "Sara Lucciola", "Luca Giuliani", "Paolo Giuliani", "Marco Bicchetti", "Alessandro Sciarra", "Valeria Panebianco"], "affiliations": ["Department of Radiological Sciences, Oncology and Pathology, Sapienza University / Policlinico Umberto I, Viale del Policlinico 155, 00161, Rome, Italy.", "Poliambulatorio Montezemolo, Ente Sanitario Militare del Ministero Della Difesa Presso la Corte dei Conti, 00195, Rome, Italy.", "Department of Maternal-Infant and Urological Sciences, Sapienza University / Policlinico Umberto I, Viale del Policlinico 155, 00161, Rome, Italy.", "Department of Radiological Sciences, Oncology and Pathology, Sapienza University / Policlinico Umberto I, Viale del Policlinico 155, 00161, Rome, Italy. valeria.panebianco@uniroma1.it."], "corresponding_authors": ["Valeria Panebianco"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=4", "score": 29.81, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.81, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 4.0}, "journal_metrics": {"status": "ok", "impact_factor": 5.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.81, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42129490", "title": "Prostate biopsy - current discussions and future perspectives.", "abstract": "", "journal": "Prostate Cancer and Prostatic Diseases", "pub_date": "2026-Oct", "publication_types": ["Journal Article", "Review"], "doi": "10.1038/s41391-026-01109-4", "authors": ["August Sigle", "Giorgio Gandaglia", "Veeru Kasivisvanathan", "Christian Gratzke", "Giancarlo Marra", "and the YAU Prostate Cancer Group"], "affiliations": ["Department of Urology, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany. august.sigle@uniklinik-freiburg.de.", "Department of Molecular Medicine and Surgery (Solna), Karolinska Institutet, Stockholm, Sweden. august.sigle@uniklinik-freiburg.de.", "Division of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy.", "Vita-Salute San Raffaele University, Milan, Italy.", "Division of Surgery and Interventional Science, University College London, London, UK.", "Department of Urology, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.", "Department of Surgical Sciences, Division of Urology, Città della Salute e della Scienza University of Turin, Turin, Italy."], "corresponding_authors": ["August Sigle"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 19.81, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.81, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 5.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.81, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42126225", "title": "A Spatial Atlas of Muscle-Invasive Bladder Cancer Reveals Lineage-Specific Vulnerabilities and Immune Architecture.", "abstract": "Muscle-invasive bladder cancer (MIBC) is clinically heterogeneous, and current molecular subtyping does not capture the spatial organization of tumor states and microenvironmental context. In this study, we construct a spatial atlas of MIBC by integrating spatial transcriptomics from 22 tumors with matched bulk RNA and whole-exome sequencing data. We identify a continuous, spatially organized luminal-to-basal axis within individual tumors that is associated with greater chromosomal instability and transcriptional plasticity. Luminal tumor cores are enriched for FGFR3 and NECTIN4, whereas basal-like states localize toward invasive margins and are associated with elevated EGFR signaling, epithelial-mesenchymal transition, genomic instability, immune infiltration, and greater chemotherapy sensitivity. Spatial analyses further reveal lineage- and location-associated differences in tertiary lymphoid structure states. Pan-cohort analyses across more than 3,000 tumors confirm conserved FGFR3-EGFR lineage exclusivity and associated immune programs. Together, these findings define a spatial framework for understanding lineage states, immune architecture, and therapeutic vulnerabilities in MIBC. MIBC is clinically heterogeneous, yet current classification lacks spatial context for therapeutic guidance. This study establishes a spatial framework linking luminal and basal lineage states to distinct immune phenotypes and therapeutic vulnerabilities, providing a foundation for biomarker development and more precise, spatially informed, lineage-guided treatment strategies.", "journal": "Cancer Discovery", "pub_date": "2026-Oct-01", "publication_types": ["Journal Article"], "doi": "10.1093/oncolo/oyaf342", "authors": ["Kai Yu", "Jianfeng Chen", "Yu-Yi Chu", "Sajith Nair", "Emanuele Crupi", "Elshad Hasanov", "Ying Mei", "Xueshuai Han", "Yang Liu", "Yunhe Liu", "Guangsheng Pei", "Fuduan Peng", "Jianlong Liao", "Enyu Dai", "Tian Chu", "Kyung Serk Cho", "Jiahui Jiang", "Xinmiao Yan", "Yibo Dai", "Jun Wang", "Baifeng Zhang", "Giannicola Genovese", "Nagireddy Putluri", "Livia Eberlin", "Liuqing Yang", "Chunru Lin", "Lawrence N Kwong", "Diana Shamsutdinova", "Khalida M Wani", "Bogdan A Czerniak", "Wendong Yu", "Jianping Zhao", "Charles C Guo", "Donna Hansel", "Curtis Pettaway", "Louis Pisters", "Kelly Bree", "Neema Navai", "Byron H Lee", "Ashish M Kamat", "Padmanee Sharma", "Paul Corn", "Cindy Y Jiang", "Amishi Y Shah", "Omar Alhalabi", "Pavlos Msaouel", "Arlene O Siefker-Radtke", "Christopher J Logothetis", "Matthew T Campbell", "Alexander J Lazar", "Jianjun Gao", "Linghua Wang"], "affiliations": ["Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.", "Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.", "Department of Internal Medicine, Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.", "The University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences, Houston, Texas.", "Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas.", "Division of Surgical Oncology, Baylor College of Medicine, Houston, Texas.", "Department of Molecular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.", "Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.", "Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.", "Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, Texas.", "Center for Cellular Language Intelligence, The University of Texas MD Anderson Cancer Center, Houston, Texas.", "James P. Allison Institute, The University of Texas MD Anderson Cancer Center, Houston, Texas.", "Institute for Data Science in Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "basic_signals=8", "score": 50.69, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 17.19, "top_journal_bonus": 10.0, "novelty": 1.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 8.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 33.3, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 5.19, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "膀胱癌空间图谱揭示谱系脆弱性与免疫结构", "chinese_summary": "《Cancer Discovery》10月发表研究，整合22例肌层浸润性膀胱癌的空间转录组与配对的bulk RNA及全外显子测序数据，构建空间图谱，发现瘤内存在连续的腔面至基底轴，与染色体不稳定和转录可塑性相关；", "abstract_zh": "肌层浸润性膀胱癌（MIBC）在临床上具有异质性，当前的分子分型未能捕捉肿瘤状态的空间组织及微环境背景。本研究通过整合22个肿瘤的空间转录组学与配对的bulk RNA及全外显子测序数据，构建了MIBC的空间图谱。我们在单个肿瘤内鉴定出一条连续的、空间组织的腔面至基底轴，该轴与更高的染色体不稳定性和转录可塑性相关。腔面肿瘤核心富集FGFR3和NECTIN4，而基底样状态定位于浸润边缘，并与EGFR信号升高、上皮-间质转化、基因组不稳定性、免疫浸润以及更高的化疗敏感性相关。空间分析进一步揭示了三级淋巴结构状态中与谱系和位置相关的差异。跨3000多个肿瘤的泛队列分析证实了保守的FGFR3-EGFR谱系互斥性及相关免疫程序。总之，这些发现为理解MIBC中的谱系状态、免疫结构和治疗脆弱性定义了一个空间框架。MIBC在临床上具有异质性，但当前分类缺乏用于治疗指导的空间背景。本研究建立了一个空间框架，将腔面和基底谱系状态与不同的免疫表型及治疗脆弱性联系起来，为生物标志物开发以及更精确、空间信息指导的、谱系导向的治疗策略提供了基础。"}, {"pmid": "42112793", "title": "[18F]RCCB6 PET/CT in Diagnosing Clear-Cell Renal Cell Carcinomas: A Prospective Comparison Study with [18F]FDG PET/CT and Conventional Imaging.", "abstract": "This single-center prospective phase II trial evaluated [18F]RCCB6 (renal cell carcinoma B6) positron emission tomography (PET)/computed tomography (CT), a cluster of differentiation 70 (CD70)-targeting radiotracer, for detecting metastases in clear-cell renal cell carcinoma (ccRCC). After screening 291 patients, 150 patients with histologically confirmed ccRCC or suspected kidney cancer underwent imaging. Among 1,221 assessable extrarenal lesions, [18F]RCCB6 PET/CT achieved 94.2% sensitivity, 80% specificity, 93.1% accuracy, and 98.3% positive predictive value. In a head-to-head comparison of 99 patients with 683 lesions, [18F]RCCB6 significantly outperformed 2-deoxy-2-[fluorine-18]fluoro-D-glucose ([18F]FDG) PET/CT, with higher diagnostic sensitivity (90.5% vs. 41.1%) and specificity (81.4% vs. 24.3%; both P < 0.001). Compared with conventional imaging across 748 lesions, [18F]RCCB6 PET/CT also demonstrated superior sensitivity (90.8% vs. 75.1%) and specificity (81.6% vs. 56.6%). [18F]RCCB6 uptake (maximum standardized uptake value) strongly correlated with CD70 expression (r = 0.843; P < 0.001). Moreover, the imaging findings changed clinical management in 58.7% of patients. [18F]RCCB6 PET/CT is a highly sensitive imaging modality for diagnosing ccRCC metastases and informing clinical decision-making. This phase II trial demonstrates that [18F]RCCB6 PET/CT significantly outperforms conventional imaging and [18F]FDG PET/CT in detecting metastatic ccRCC, with 94.2% sensitivity and strong correlation with CD70 expression, altering clinical management in 58.7% of patients.", "journal": "Cancer Discovery", "pub_date": "2026-Oct-01", "publication_types": ["Journal Article", "Comparative Study", "Clinical Trial, Phase II"], "doi": "10.1158/2159-8290.CD-26-0016", "authors": ["Qianyun Wu", "Shuxian An", "Fabrizia Gelardi", "You Zhang", "Lianghua Li", "Wen Kong", "Min Cao", "Wenzhi Jia", "Dongsheng Xu", "Liangrong Wan", "Gan Huang", "Cheng Wang", "Zhoumi Hu", "Jiwei Huang", "Wei Zhai", "Jin Zhang", "Arturo Chiti", "Gang Huang", "Jianjun Liu", "Weijun Wei"], "affiliations": ["Department of Nuclear Medicine, Institute of Clinical Nuclear Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.", "Università Vita-Salute San Raffaele , Milan, Italy.", "Nuclear Medicine Department, IRCCS San Raffaele, Milano, Italy.", "Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.", "Department of Thoracic Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China."], "corresponding_authors": [], "china_team": "Department of Nuclear Medicine, Institute of Clinical Nuclear Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China Weijun Wei团队", "category": "clinical_review", "classification_reason": "publication_type_interventional_trial", "score": 56.19, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 17.19, "top_journal_bonus": 10.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 11.0}, "journal_metrics": {"status": "ok", "impact_factor": 33.3, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 5.19, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "新型PET显像精准诊断肾癌转移", "chinese_summary": "上海交通大学医学院附属仁济医院魏伟军团队10月Cancer Discov发表单中心前瞻性Ⅱ期试验：靶向CD70的[18F]RCCB6 PET/CT在1221个肾外病灶中诊断敏感度达94.2%，头对头比较中显著优于[18F]FDG PET/CT及常规影像，并改变58.7%患者的临床决策。", "abstract_zh": "这项单中心前瞻性Ⅱ期试验评估了[18F]RCCB6（肾细胞癌B6）正电子发射断层扫描（PET）/计算机断层扫描（CT），一种靶向分化簇70（CD70）的放射性示踪剂，用于检测透明细胞肾细胞癌（ccRCC）的转移灶。在筛选291例患者后，150例经组织学确诊为ccRCC或疑似肾癌的患者接受了显像。在1221个可评估的肾外病灶中，[18F]RCCB6 PET/CT达到94.2%的敏感度、80%的特异度、93.1%的准确度和98.3%的阳性预测值。在99例患者683个病灶的头对头比较中，[18F]RCCB6显著优于2-脱氧-2-[氟-18]氟-D-葡萄糖（[18F]FDG）PET/CT，具有更高的诊断敏感度（90.5%对41.1%）和特异度（81.4%对24.3%；两者P < 0.001）。在748个病灶中与常规影像比较，[18F]RCCB6 PET/CT也显示出更高的敏感度（90.8%对75.1%）和特异度（81.6%对56.6%）。[18F]RCCB6摄取（最大标准化摄取值）与CD70表达强相关（r = 0.843；P < 0.001）。此外，显像结果改变了58.7%患者的临床管理。[18F]RCCB6 PET/CT是一种用于诊断ccRCC转移并指导临床决策的高敏感度显像方式。这项Ⅱ期试验表明，[18F]RCCB6 PET/CT在检测转移性ccRCC方面显著优于常规影像和[18F]FDG PET/CT，敏感度达94.2%，且与CD70表达强相关，改变了58.7%患者的临床管理。"}, {"pmid": "42097289", "title": "Outdoor air pollution and prostate cancer risk in the National Institutes of Health-AARP Diet and Health Study.", "abstract": "Outdoor air pollution, including fine particulate matter (PM2.5), is an established carcinogen, yet few studies evaluate its associations with prostate cancer risk, and findings are mixed. We used spatiotemporal prediction models to estimate annual average historical residential PM2.5 (1980-2017) and nitrogen dioxide (NO2) (1990-2017) concentrations for 289 299 men aged 50 years and older in the National Institutes of Health-AARP Diet and Health Study, enrolled from 6 states and 2 metro areas in 1995-1996, followed through 2018. We used Cox regression to estimate hazard ratios (HRs) and 95% confidence intervals of associations between 5-year average PM2.5 and NO2 and incident prostate cancer, overall and by tumor aggressiveness (ie, advanced [n = 5791], high-grade [ie, Gleason score ≥8, n = 5793], fatal [n = 3057]). We evaluated interactions with hypothesized effect modifiers. Historical PM2.5 and NO2 concentrations were not associated with prostate cancer risk overall (10-year lagged PM2.5 HR per 5 µg/m3 = 1.00, 95% confidence interval [CI] = 0.98 to 1.02; 10-year lagged NO2 HR per 10 ppb = 1.00, 95% CI = 0.98 to 1.01). Some positive trends were observed for aggressive disease (eg, high-grade: 10-year lagged PM2.5 HR = 1.03, 95% CI = 0.99 to 1.09; advanced: 10-year lagged NO2 HR = 1.04, 95% CI = 0.99 to 1.08). Stratified analyses also showed stronger associations for aggressive disease among Hispanic men (eg, high-grade: NO2 HR = 1.25, 95% CI = 1.05 to 1.48; P = .01 for interaction). Heterogeneity was also evident by urbanicity (high-grade: P = .01 for interaction, PM2.5 and NO2) and state (advanced: P = .05 for interaction, NO2), potentially reflecting air pollution mixture heterogeneity. In this large US cohort, historical residential PM2.5 or NO2 concentrations were not associated with prostate cancer risk overall; however, risk was elevated in some subgroups and for aggressive outcomes. Future evaluation of air pollution mixture components may clarify observed subgroup differences.", "journal": "Journal of the National Cancer Institute", "pub_date": "2026-Oct-01", "publication_types": ["Journal Article"], "doi": "10.1093/jnci/djag137", "authors": ["Lydia Marcus Post", "Lauren Hurwitz", "Jared A Fisher", "Joel D Kaufman", "Stella Koutros", "Rena R Jones"], "affiliations": ["Occupational and Environmental Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute (NCI), Rockville, MD, United States.", "Cancer Prevention Fellowship Program, Division of Cancer Prevention, NCI, Rockville, MD, United States.", "Department of Environmental and Occupational Health Sciences, University of Washington, Seattle, WA, United States."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 30.09, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 15.09, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 1.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 7.2, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.09, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "室外空气污染未增前列腺癌总体风险", "chinese_summary": "美国国家癌症研究所10月J Natl Cancer Inst基于NIH-AARP饮食与健康研究，对28.9万名50岁以上男性随访逾20年，发现历史居住地PM2.5与NO2年均浓度和前列腺癌总体发病风险无关联；但侵袭性肿瘤中呈正向趋势，西班牙裔男性及高城市化地区风险升高，提示空气污染混合物组分或影响亚组差异。", "abstract_zh": "室外空气污染，包括细颗粒物（PM2.5），是已确定的致癌物，然而少有研究评估其与前列腺癌风险的关联，且研究结果不一致。我们使用时空预测模型，估算美国国立卫生研究院-AARP饮食与健康研究中289 299名50岁及以上男性既往居住地PM2.5（1980-2017年）和二氧化氮（NO2）（1990-2017年）的年平均浓度，这些男性于1995-1996年从6个州和2个大都市区招募入组，随访至2018年。我们使用Cox回归估计5年平均PM2.5和NO2与 incident前列腺癌风险关联的风险比（HR）及95%置信区间，分析总体前列腺癌以及按肿瘤侵袭性分类（即晚期[n=5791]、高级别[即Gleason评分≥8，n=5793]、致死性[n=3057]）。我们评估了与假设效应修饰因素的交互作用。既往PM2.5和NO2浓度与前列腺癌总体风险无关（滞后10年PM2.5每5 µg/m3的HR=1.00，95%置信区间[CI]=0.98至1.02；滞后10年NO2每10 ppb的HR=1.00，95%CI=0.98至1.01）。在侵袭性疾病中观察到一些正向趋势（例如高级别：滞后10年PM2.5 HR=1.03，95%CI=0.99至1.09；晚期：滞后10年NO2 HR=1.04，95%CI=0.99至1.08）。分层分析还显示，西班牙裔男性中侵袭性疾病的关联更强（例如高级别：NO2 HR=1.25，95%CI=1.05至1.48；交互作用P=0.01）。按城市化程度（高级别：PM2.5和NO2交互作用P=0.01）和州（晚期：NO2交互作用P=0.05）也可见异质性，可能反映空气污染混合物异质性。在这个大型美国队列中，既往居住地PM2.5或NO2浓度与前列腺癌总体风险无关；然而，在某些亚组和侵袭性结局中风险升高。未来对空气污染混合物组分的评估可能阐明观察到的亚组差异。"}, {"pmid": "42092174", "title": "Predictors of durability of the prostatic urethral lift (PUL) for benign prostatic hyperplasia.", "abstract": "There is a need to understand the predictors of prostatic urethral lift (PUL) durability to help physicians counsel patients and optimize outcomes. A simple logistic regression analysis was performed on a pooled dataset of 331 subjects across 5 PUL controlled studies with up to 5 years follow up. Predictors of \"surgical durability\" (no surgical treatment for return of symptoms) and \"total durability\" (no surgical or medical treatment for return of symptoms) were assessed at 1- and 5-year post-procedure. Placing ≤4 implants regardless of baseline prostate volume was associated with increased surgical retreatment within the first year. Through one year, more implants were protective of retreatment; for every incremental implant placed, surgical retreatment odds decreased an additional 41.2% and risk of combined surgical or medical retreatment decreased 30.2%. Higher implant density was also protective through one year; for each additional implant placed per 10cc prostate volume, surgical retreatment odds decreased incrementally by 79.0%. Up to 5 years, a higher baseline pretreatment IPSS score predicted higher rates of surgical or medical retreatment; for every one-point score increase of baseline IPSS, surgical or medical retreatment odds increased 5.2%. Baseline demographics, medical history and baseline sexual function were not predictors of surgical or total durability. More implants, higher implant density, and lower baseline IPSS are all associated with decreased surgical and medical retreatment rates up to 5 years following PUL. These findings inform optimizing PUL technique, considering earlier intervention and counseling men on outcomes prior to PUL.", "journal": "Prostate Cancer and Prostatic Diseases", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1016/j.eururo.2006.07.050", "authors": ["Gregg Eure", "Matt Ashley", "Daniel B Rukstalis", "Peter Chin", "Neil Barber", "Claus Roehrborn"], "affiliations": ["Urology of Virginia, Culpeper, VA, USA. greggeure@urologyofva.net.", "Summit Health, Bend, OR, USA.", "Carilion Clinic, Roanoke, VA, USA.", "South Coast Urology, Wollongong, NSW, Australia.", "Frimley Park Hospital, Frimley, UK.", "UT Southwestern, Dallas, TX, USA."], "corresponding_authors": ["Gregg Eure"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=3", "score": 36.81, "score_parts": {"urology_relevance": 12, "urology_in_title": 8.0, "journal_priority": 10.81, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 3.0}, "journal_metrics": {"status": "ok", "impact_factor": 5.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.81, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42092023", "title": "Oligometastatic prostate cancer - bridging the gap between localized and metastatic disease.", "abstract": "The understanding of oligometastatic prostate cancer has advanced substantially in the past two decades, reshaping both diagnostic and therapeutic paradigms. The advent of next-generation imaging, particularly prostate-specific membrane antigen PET-CT, has improved staging accuracy, enabling patients with limited metastatic burden who might benefit from intensified local and metastasis-directed approaches to be identified. Results from randomized phase II trials support the use of metastasis-directed therapy in patients with metachronous oligometastatic prostate cancer. However, evidence for metastasis-directed therapy in de novo presentations remains preliminary but encouraging. In parallel, prostate-directed treatments such as radiotherapy and cytoreductive radical prostatectomy are under active investigation, although the role of these approaches in the era of intensified systemic therapy is yet to be fully defined. Although interest around oligometastatic prostate cancer is growing, several issues are currently unsettled, including a unified definition of oligometastatic prostate cancer; the inclusion of biological information in patient selection; optimal treatment sequencing, including the integration and duration of systemic therapy; and appropriate clinical end points.", "journal": "Nature Reviews Urology", "pub_date": "2026-Oct", "publication_types": ["Journal Article", "Review"], "doi": "10.1038/s41585-026-01144-9", "authors": ["Alexander Giesen", "Julie den Hartog", "Jasper Van Goubergen", "Kato Rans", "Marcella Baldewijns", "Thomas Gevaert", "Karolien Goffin", "Wouter Everaerts", "Frank Claessens", "Gert De Meerleer", "Steven Joniau"], "affiliations": ["Department of Urology, University Hospitals Leuven, Leuven, Belgium. alexander.giesen@uzleuven.be.", "Department of Development and Regeneration, KU Leuven, Leuven, Belgium. alexander.giesen@uzleuven.be.", "Department of Radiation Oncology, University Hospitals Leuven, Leuven, Belgium.", "Laboratory of Experimental Radiotherapy, KU Leuven, Leuven, Belgium.", "Laboratory of Molecular Endocrinology, KU Leuven, Leuven, Belgium.", "Department of Pathology, University Hospitals Leuven, Leuven, Belgium.", "Department of Development and Regeneration, KU Leuven, Leuven, Belgium.", "Department of Nuclear Medicine, University Hospitals Leuven, Leuven, Belgium.", "Nuclear Medicine & Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium.", "Department of Urology, University Hospitals Leuven, Leuven, Belgium.", "Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium."], "corresponding_authors": ["Alexander Giesen"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 40.03, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 16.03, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 10.0}, "journal_metrics": {"status": "ok", "impact_factor": 14.6, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.03, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42080884", "title": "Multicentre validation of the PRECISE scoring system for prostate MRI during active surveillance.", "abstract": "The Prostate Cancer Radiological Estimation of Change in Sequential Evaluation (PRECISE) recommendations assess radiological change in serial MRI during active surveillance (AS) for prostate cancer. PRECISE 1-2 indicates radiological regression, PRECISE 3 stability, and PRECISE 4-5 progression. Our aim was to test the PRECISE score as a predictive tool for disease progression in a multicentre international setting. This is a retrospective study in which we collected data from 22 international centres from December 2005 to July 2022, applying two entry criteria: (1) at least two scans (baseline and follow-up); (2) at least two biopsies (baseline and follow-up, the latter after the second scan). Local radiologists reported scans according to PRECISE. Sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) according to different biopsy thresholds and definitions of progression were calculated. A total of 1667 patients were included. Median follow-up was 4 years (IQR: 2.1-6.3). A total of 1248 (75%) patients underwent two MRIs and immediate subsequent biopsy, 300 (24%) of which had biopsy progression to Grade Group ≥ 2 and 77 (6%) to Grade Group ≥ 3. Patients with PRECISE 4-5 had 4.53-fold increased odds (95% CI: 3.37-6.12; p < 0.001) of biopsy progression compared to PRECISE 1-3. Using a PRECISE ≥ 4 cutoff to perform follow-up biopsies, overall sensitivity, specificity, PPV and NPV were 57%, 79%, 46%, and 85% for the first follow-up scan. The PRECISE recommendations could lead to timely identification of patients on AS who progress on MRI, prompting re-biopsy or treatment, and safe reduction of repeat biopsies for those with stable MRI and prostate-specific antigen kinetics. Question Can the PRECISE scoring system for monitoring prostate cancer lesions on active surveillance on MRI predict disease progression and avoid unnecessary biopsies? Findings The PRECISE score effectively predicts prostate cancer progression, with PRECISE 4-5 (progression) scores indicating 4.53-fold increased odds of biopsy progression compared to PRECISE 1-3 (regression/stability). Clinical relevance This study validates PRECISE as a tool for managing patients on active surveillance. It can help clinicians identify those needing timely re-biopsy or treatment, while reducing unnecessary biopsies in patients with stable disease on imaging and PSA kinetics.", "journal": "European Radiology", "pub_date": "2026-Oct", "publication_types": ["Journal Article", "Multicenter Study", "Validation Study"], "doi": "10.1007/s00330-020-07336-0", "authors": ["Francesco Giganti", "Riccardo Leni", "Vinayak Wagaskar", "Giorgio Gandaglia", "Tristan Barrett", "Valeria Panebianco", "Francesco Sanguedolce", "Erik Jrj van der Hoeven", "Sangeet Ghai", "Jeremy Grummet", "Jasmin Gmeiner", "Jan Philipp Radtke", "Ryan D Ward", "Ronaldo Hueb Baroni", "Francesco Porpiglia", "Juan Gomez Rivas", "Fabio Zattoni", "Raphaële Renard-Penna", "Claudia Kesch", "Marco Gatti", "Nicola Schieda", "Guillaume Ploussard", "Sara Lewis", "Giorgio Brembilla", "Christof Kastner", "Emanuele Messina", "Ash Tewari", "Caroline M Moore", "Massimo Valerio", "Armando Stabile", "Veeru Kasivisvanathan", "Young Academic Urologists Active Surveillance Initiative"], "affiliations": ["Division of Surgery and Interventional Science, University College London, London, UK. f.giganti@ucl.ac.uk.", "Department of Radiology, University College London Hospitals NHS Foundation Trust, London, UK. f.giganti@ucl.ac.uk.", "Division of Oncology/Unit of Urology, Soldera Prostate Cancer Lab, URI, IRCCS San Raffaele Scientific Institute, Milan, Italy.", "Department of Urology, Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USA.", "Department of Radiology, Addenbrooke's Hospital and University of Cambridge, Cambridge, UK.", "Department of Radiological Sciences, Oncology and Pathology, Sapienza University/Policlinico Umberto I, Rome, Italy.", "Department of Urology, Fundació Puigvert, Barcelona, Spain.", "Department of Medicine, Surgery and Pharmacy, University of Sassari, Sassari, Italy.", "Department of Radiology, St Antonius Hospital, Utrecht, The Netherlands.", "Joint Department of Medical Imaging, University Health Network-Mt Sinai Hospital-Women's College Hospital, University of Toronto, Toronto, ON, Canada.", "Department of Surgery, Alfred Health, School of Translational Medicine, Monash University, Melbourne, Australia.", "Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria.", "Department of Urology, Medical Faculty, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany.", "Department of Radiology, German Cancer Research Centre, Heidelberg, Germany.", "Abdominal Imaging Section, Diagnostics Institute, Cleveland Clinic, Cleveland, OH, USA.", "Imaging Section, Hospital Israelita Albert Einstein, Sao Paulo, Brazil.", "Division of Urology, Department of Oncology, San Luigi Gonzaga Hospital, University of Turin, Turin, Italy.", "Department of Urology, Health Research Institute, Hospital Clinico San Carlos, Madrid, Spain.", "Department of Surgery, Oncology, and Gastroenterology, Urology Clinic, University of Padua, Padua, Italy.", "Department of Imaging, Hôpital Pitié Salpêtrière APHP-Sorbonne University, Paris, France.", "Department of Urology, University of Duisburg-Essen and German Cancer Consortium (DKTK), University Hospital Essen, Essen, Germany.", "Division of Radiology, Department of Surgical Sciences, Molinette Hospital, Città della Salute e della Scienza and University of Turin, Turin, Italy.", "Department of Radiology, The University of Ottawa, Ottawa, ON, Canada.", "La Croix du Sud Hospital, Department of Urology, Quint-Fonsegrives, France.", "Department of Radiology, Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USA.", "Department of Radiology, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.", "Department of Urology, Addenbrooke's Hospital and University of Cambridge, Cambridge, UK.", "Division of Surgery and Interventional Science, University College London, London, UK.", "Department of Urology, University College London Hospitals NHS Foundation Trust, London, UK.", "Department of Urology, Lausanne University Hospital, Lausanne, Switzerland."], "corresponding_authors": ["Francesco Giganti"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_clinical", "score": 33.55, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.55, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 8.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.7, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.55, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42061522", "title": "Use of Hypofractionation Among Underserved Populations Undergoing Radiation Therapy for Cancer: Implications for Policy.", "abstract": "To examine the use of hypofractionation among underserved populations, with a focus on implications for policy. Using a 20% Medicare claims sample, we evaluated the receipt of hypofractionation, a short-course radiation therapy approach, among underserved versus nonunderserved populations. Hypofractionation was defined based on cancer/site-specific guidelines and expert review. Underserved groups included racially/ethnically minoritized, rural, and patients with low socioeconomic status. We included 4 cancer types that represent the majority of new cancer diagnoses and for which there is the highest level of support for hypofractionation. These included breast, colorectal, lung, and prostate cancer. Log-binomial regression models were used to assess the association between underserved status and hypofractionation use, adjusting for patient-level, practice-level, and area-level characteristics. We analyzed 6437 patients and found that 2200 were classified as underserved and 4237 as not underserved. Overall, 52.5% of patients received hypofractionation, and underserved populations were treated at similar rates to their nonunderserved counterparts. We noted a few exceptions. Rural patients with prostate cancer had a lower likelihood of receiving hypofractionation (relative risk, 0.59; P = .005), whereas rural patients with lung cancer had a higher likelihood of receiving hypofractionation (relative risk, 1.14; P = .039). Hypofractionation was received at similar rates among underserved and nonunderserved populations. Given existing disparities experienced by underserved patients with cancer, greater use of hypofractionation may contribute to more equitable outcomes. Implementation of policies that facilitate-rather than discourage-the use of hypofractionation, may reduce disparities experienced by underserved patients with cancer.", "journal": "International Journal of Radiation Oncology, Biology, Physics", "pub_date": "2026-Oct-01", "publication_types": ["Journal Article", "Research Support, Non-U.S. Gov't"], "doi": "10.1016/j.ijrobp.2026.04.017", "authors": ["Nicole Z Murray", "Joshua Sokeye", "Joshua J Horns", "Jonathan Chipman", "Hailie Gill", "Skyler Johnson", "Brock O'Neil"], "affiliations": ["Division of Urology, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah. Electronic address: nmurray66314@gmail.com.", "North Carolina Agricultural & Technical State University, Greensboro, North Carolina.", "Department of Surgery, University of Utah, Salt Lake City, Utah; Department of Population Sciences, University of Utah, Salt Lake City, Utah.", "Division of Urology, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah.", "Department of Radiation Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah."], "corresponding_authors": ["Nicole Z Murray"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 21.46, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 14.96, "top_journal_bonus": 0.0, "novelty": 0.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 6.5, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 2.96, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42056552", "title": "Adjuvant immunotherapy for renal cell carcinoma: understanding complexity, embracing uncertainty, making a difference.", "abstract": "", "journal": "Nature Reviews Urology", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1038/s41585-026-01146-7", "authors": ["Riccardo Campi", "Daniele Amparore", "European Association of Urology (EAU) Young Academic Urologists (YAU) Renal Cancer working group"], "affiliations": ["Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy. riccardo.campi@gmail.com.", "Unit of Urology and Renal Transplantation, Oncology Department, Careggi University Hospital, Florence, Italy. riccardo.campi@gmail.com.", "Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. riccardo.campi@gmail.com.", "Department of Oncology, University of Turin, Orbassano, Italy.", "Division of Urology, Department of Surgery, Candiolo Cancer Institute FPO-IRCCS, Candiolo, Italy."], "corresponding_authors": ["Riccardo Campi"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 25.03, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 16.03, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 14.6, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.03, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "肾癌辅助免疫治疗获益有限需个体化", "chinese_summary": "《Nature Reviews Urology》2026年10月刊发综述，系统梳理肾癌辅助免疫治疗的争议与不确定性。文章指出，尽管辅助免疫治疗在部分高危患者中可改善无病生存，但总体获益有限，且缺乏可靠的生物标志物筛选人群。作者呼吁在临床试验设计与临床决策中正视不确定性，推动个体化治疗策略。", "abstract_zh": "本文为《Nature Reviews Urology》2026年10月刊发的综述文章，题为《肾细胞癌的辅助免疫治疗：理解复杂性，拥抱不确定性，有所作为》。文章围绕肾细胞癌辅助免疫治疗的现状展开讨论，指出尽管免疫检查点抑制剂已在辅助治疗领域进行多项临床试验，但各研究结果并不一致，部分试验显示无病生存获益，另一些则未达到主要终点。作者强调，辅助免疫治疗的实际获益可能仅限于特定亚组患者，而目前缺乏经过验证的生物标志物来筛选最可能获益的人群。文章进一步探讨了肿瘤异质性、微转移灶的免疫逃逸以及试验设计差异等因素对结果解读的影响，并呼吁临床医生与研究者正视现有证据的不确定性，在临床决策中权衡获益与免疫相关不良反应风险。最终，作者提出应通过更精准的患者选择和更合理的试验设计，推动肾细胞癌辅助免疫治疗向个体化方向发展，以期真正改善患者预后。"}, {"pmid": "42036485", "title": "Predictors of fluoroquinolone-resistant bacterial colonization prior to prostate biopsy: a secondary analysis of two randomized trials.", "abstract": "The prevalence of fluoroquinolone resistant (FQR) rectal bacterial colonization ranges from 15-20%, and FQR colonization increases the risk of prostate biopsy infectious complications. FQR bacteria have been identified in 50% of prostate biopsy infectious complications. However, predictors of FQR remain unclear, so we aimed to elucidate these characteristics. A secondary analysis of two multicenter clinical trials (NCT04815876 and NCT04843566) comprising 11 sites was conducted on men who underwent rectal swab cultures prior to prostate biopsy. Rectal swab cultures were examined to identify FQR bacteria and factors associated with post-biopsy infections. Sites with fewer than 30 rectal swab results were aggregated. Multivariable logistic regression was used to identify whether age, race, ethnicity, diabetes, smoking history, or site were associated with FQR colonization. FQR bacterial colonization was identified in 145 (16%, 95% CI: 13%, 18%) of 925 patients. One site within the same metropolitan area as the reference site had increased odds of FQR colonization [OR 3.68 (CI: 1.98, 6.83, p < 0.001)]. Transrectal biopsy infection risk increased with FQR rectal bacteria (3.9% vs. 0.8%; risk difference 3.2%; 95% CI: -1.3%, 7.5%; p = 0.017). There was an insignificantly increased odds of FQR colonization for Asian men (OR 1.94, 95% CI: 0.92, 3.89; p = 0.070). FQR rectal colonization was associated with higher rates of post-TR biopsy infection despite targeted prophylaxis. FQR colonization rates differed significantly across trial sites. Future research should continue to identify FQR predictors and their underlying causal pathways to reduce the risk of infectious complications.", "journal": "Prostate Cancer and Prostatic Diseases", "pub_date": "2026-Oct", "publication_types": ["Journal Article", "Multicenter Study", "Randomized Controlled Trial"], "doi": "10.1038/s41391-026-01110-x", "authors": ["Daniel Barbakoff", "Gal Wald", "Mary Oakley Strasser", "Rebecca Yu", "Joshua Winograd", "Mitchell Huang", "Conor B Driscoll", "Nicole Handa", "Andrew Vickers", "Edward M Schaeffer", "Jim C Hu"], "affiliations": ["Department of Urology, Weill Cornell Medicine, New York-Presbyterian Hospital, New York, NY, USA.", "Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.", "Department of Urology, Feinberg School of Medicine, Northwestern Medicine, Chicago, IL, USA.", "Department of Urology, Weill Cornell Medicine, New York-Presbyterian Hospital, New York, NY, USA. jch9011@med.cornell.edu."], "corresponding_authors": ["Jim C Hu"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_interventional_trial", "score": 36.81, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.81, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 12.0}, "journal_metrics": {"status": "ok", "impact_factor": 5.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.81, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42034194", "title": "Outcomes of Stage IVA Cervical Cancer Treated with Radiation Therapy: A Systematic Review and Meta-Analysis.", "abstract": "FIGO stage IVA cervical cancer, defined by bladder or rectal mucosal invasion without distant metastasis, is an uncommon but clinically challenging disease with limited high-quality evidence to guide management. We performed a systematic review and meta-analysis to evaluate survival outcomes, treatment-related morbidity, and prognostic factors in patients with stage IVA cervical cancer treated with definitive radiotherapy. Following PRISMA 2020 guidelines and PROSPERO registration (CRD42024602426), PubMed, Embase, and Web of Science were searched through February 2025. Eleven studies comprising 492 patients met eligibility criteria. Pooled random-effects analyses demonstrated 2-, 3-, and 5-year disease-free survival rates of 41.5% (95% CI, 28.1-55.0), 34.2% (95% CI, 21.1-47.3), and 30.9% (95% CI, 16.0-45.8), respectively. Corresponding overall survival rates were 56.0% (95% CI, 46.2-65.9), 45.9% (95% CI, 35.9-55.9), and 34.8% (95% CI, 26.4-43.3). Weighted median disease-free survival and overall survival were 15.6 and 33.6 months, respectively. The pooled incidence of vesicovaginal or rectovaginal fistula was 23.7% (95% CI, 12.9-34.6). Adverse prognostic factors included pelvic nodal involvement, hydronephrosis, rectal invasion, omission of brachytherapy, and total EQD2 below 80-85 Gy. Concurrent chemoradiation and completion of brachytherapy were consistently associated with improved outcomes. Despite curative-intent treatment, long-term survival remains poor and treatment-related morbidity substantial. Durable pelvic control remains the principal therapeutic challenge. Concurrent chemoradiation with adequate-dose brachytherapy appears essential for optimal outcomes, while future stage IVA-specific studies incorporating image-guided adaptive brachytherapy, advanced radiotherapy techniques, and systemic treatment intensification are needed to improve survival and reduce treatment-related morbidity.", "journal": "International Journal of Radiation Oncology, Biology, Physics", "pub_date": "2026-Oct-01", "publication_types": ["Journal Article", "Systematic Review", "Meta-Analysis", "Research Support, Non-U.S. Gov't"], "doi": "10.1016/j.ijrobp.2026.04.008", "authors": ["Surendra Kumar Saini", "Shelly Srivastava", "Anil Goel", "D N Sharma"], "affiliations": ["Department of Radiation Oncology, DR B.R.A. IRCH, All India Institute of Medical Sciences, New Delhi, India. Electronic address: drsurensaini@aiims.gov.in.", "Department of Radiation Oncology, Government Medical College, Kannauj, India.", "Department of Radiation Oncology, All India Institute of Medical Sciences, Bathinda, India.", "Department of Radiation Oncology, DR B.R.A. IRCH, All India Institute of Medical Sciences, New Delhi, India."], "corresponding_authors": ["Surendra Kumar Saini"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 24.96, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 14.96, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 4.0}, "journal_metrics": {"status": "ok", "impact_factor": 6.5, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 2.96, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42026743", "title": "Association of Cancer Care Quality Certification With Survival Across Multiple Cancer Types: A Population-Based Cohort Study in Taiwan.", "abstract": "Cancer remains a major global health burden. Taiwan launched the Cancer Care Quality Certification (CCQC) program in 2008; however, comprehensive evaluations of its association with survival across multiple cancer types remain limited. A total of 294,323 patients diagnosed with one of eight cancer types between 2011 and 2017 were identified from the Taiwan Cancer Registry Database. Overall survival among patients treated at certified versus non-certified hospitals was compared using Cox proportional hazards models incorporating a hospital-level shared frailty to account for institutional heterogeneity, adjusting for age, sex, stage, hospital level, geographic region, and treatment modalities. Treatment at certified hospitals was associated with lower all-cause mortality for colorectal (adjusted hazard ratio [HR], 0.88; 95% confidence interval [CI], 0.83-0.93), lung (HR, 0.91; 95% CI, 0.87-0.96), and bladder cancers (HR, 0.79; 95% CI, 0.66-0.96). No statistically significant associations were observed for liver, female breast, cervical, uterine, or ovarian cancers. In this population-based study, the CCQC program in Taiwan is associated with improved survival for several major cancers, although the magnitude of association varied by cancer type. These findings suggest that certification may serve as a marker of institutional capacity for delivering high-quality cancer care and support the continued evaluation of certification programs as a potential strategy for strengthening cancer care systems.", "journal": "International Journal of Cancer", "pub_date": "2026-Oct-01", "publication_types": ["Journal Article"], "doi": "10.1002/ijc.70516", "authors": ["Hsiao-Chen Chiu", "Chun-Ju Chiang", "Jing-Rong Jhuang", "Dai-Rong Tsai", "Li-Ju Lin", "Jing-Fong Wang", "Wen-Chung Lee"], "affiliations": ["Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan.", "Department of Obstetrics & Gynecology, West Garden Hospital, Taipei, Taiwan.", "Taiwan Cancer Registry, Taipei, Taiwan.", "Health Promotion Administration, Ministry of Health and Welfare, Taipei, Taiwan.", "Institute of Health Data Analytics and Statistics, College of Public Health, National Taiwan University, Taipei, Taiwan."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=6", "score": 22.55, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 10.55, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 6.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.7, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.55, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42025513", "title": "Performance of [89Zr]girentuximab PET/CT in Predicting the Presence of Any Renal Malignancy: A Reanalysis of the ZIRCON Trial.", "abstract": "Carbonic anhydrase IX (CAIX) is a cell surface protein expressed in over 90% of clear cell renal cell carcinoma (ccRCC), driven by hypoxia or Von-Hippel Lindau (VHL) loss. The phase 3 ZIRCON trial evaluated [89Zr]girentuximab, a CAIX-targeted positron emission tomography (PET) radiotracer, and met its primary endpoint for the accurate detection of ccRCC in patients with renal masses. Many aggressive forms of non-ccRCC (nccRCC) can express CAIX, which is linked to a hypoxic state. A reanalysis of the trial was performed demonstrating the tracer also identified nccRCC, particularly in forms of papillary RCC (pRCC) with higher CAIX expression (H score) and PET avidity (SUVmax). The positive predictive value for any renal malignancy was 98%, with sensitivity/specificity of 82% and 87%, respectively. This suggests [89Zr]girentuximab has applications beyond the detection of ccRCC in primary renal masses and may have implications to management of nccRCC. PATIENT SUMMARY: The ZIRCON phase 3 trial used an imaging agent ([89Zr]girentuximab) with a primary focus to detect the most common kidney cancer, clear cell renal cell carcinoma. Other forms of kidney cancer can express the marker that the imaging agent can identify. The additional analysis showed that when positive, 98% of cases were correctly identified as any form of cancer.", "journal": "European Urology", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1016/j.eururo.2026.03.003", "authors": ["Aboubacar Kaba", "Pratik Kanabur", "Jeremie Calais", "Andrew M Scott", "Jean-Christophe Bernhard", "Peter C R Mulders", "Bülent Önal", "Tamer Aksoy", "Michael Morris", "Viraj Master", "Brian Shuch"], "affiliations": ["UCLA Institute of Urologic Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. Electronic address: akaba@mednet.ucla.edu.", "UCLA Institute of Urologic Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.", "Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.", "Department of Molecular Imaging and Therapy, Austin Health, Melbourne, VIC, Australia; Olivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia; School of Cancer Medicine, La Trobe University, Melbourne, VIC, Australia; Faculty of Medicine, University of Melbourne, Melbourne, VIC, Australia.", "Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.", "Radboud University Medical Center, The Netherlands; Radboud University Donders Institute for Brain Cognition and Behaviour, The Netherlands.", "Department of Urology, Istanbul University-Cerrahpasa, Istanbul, Turkey.", "Department of Nuclear Medicine, Istanbul Training and Research Hospital, Istanbul, Turkey.", "United Theranostics, Glen Burnie, Baltimore, MD, USA.", "Department of Urology, Emory University School of Medicine, Atlanta, GA, USA."], "corresponding_authors": ["Aboubacar Kaba"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 38.79, "score_parts": {"urology_relevance": 8, "urology_in_title": 0.0, "journal_priority": 16.79, "top_journal_bonus": 10.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 2.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 25.2, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.79, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "CAIX靶向PET可检出非透明细胞肾癌", "chinese_summary": "10月Eur Urol基于III期ZIRCON试验再分析显示，[89Zr]girentuximab PET/CT对肾恶性肿瘤阳性预测值达98%，灵敏度82%、特异度87%，并可识别CAIX高表达的乳头状肾癌等非透明细胞类型，提示其应用可超出透明细胞肾癌检测。", "abstract_zh": "碳酸酐酶IX（CAIX）是一种细胞表面蛋白，在超过90%的透明细胞肾细胞癌（ccRCC）中表达，由缺氧或Von-Hippel Lindau（VHL）缺失驱动。III期ZIRCON试验评估了[89Zr]girentuximab——一种靶向CAIX的正电子发射断层扫描（PET）放射性示踪剂——并达到了在肾肿块患者中准确检测ccRCC的主要终点。许多侵袭性非ccRCC（nccRCC）类型可表达CAIX，这与缺氧状态有关。对该试验进行的再分析表明，该示踪剂还可识别nccRCC，尤其是在CAIX表达（H评分）和PET摄取（SUVmax）较高的乳头状RCC（pRCC）类型中。对任何肾恶性肿瘤的阳性预测值为98%，灵敏度/特异度分别为82%和87%。这表明[89Zr]girentuximab的应用可超越原发性肾肿块中ccRCC的检测，并可能对nccRCC的管理具有意义。患者摘要：ZIRCON III期试验使用了一种显像剂（[89Zr]girentuximab），其主要目的是检测最常见的肾癌——透明细胞肾细胞癌。其他类型的肾癌也可表达该显像剂能够识别的标志物。这项附加分析显示，当检测为阳性时，98%的病例被正确识别为任何形式的癌症。"}, {"pmid": "42020578", "title": "Worse bladder cancer outcomes in women than in men - bias, biology or both?", "abstract": "", "journal": "Nature Reviews Urology", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1038/s41585-026-01145-8", "authors": ["Niyati Lobo", "Tahlita C M Zuiverloon", "Laura S Mertens"], "affiliations": ["Department of Urology, Cambridge University Hospitals, Cambridge, UK.", "Department of Urology, Erasmus University Medical Center, Rotterdam, the Netherlands.", "Department of Urology, Netherlands Cancer Institute, Amsterdam, the Netherlands. l.mertens@nki.nl."], "corresponding_authors": ["Laura S Mertens"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 25.03, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 16.03, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 14.6, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.03, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "女性膀胱癌预后差于男性", "chinese_summary": "10月Nat Rev Urol刊文探讨女性膀胱癌预后差于男性的原因，认为诊断延迟、治疗差异等偏倚与性激素、免疫微环境等生物学因素可能共同作用，呼吁针对性别差异优化诊疗策略。", "abstract_zh": "女性膀胱癌的预后比男性更差。这种差异可能由多种因素造成，包括诊断延迟、治疗差异等偏倚，以及性激素、免疫微环境等生物学差异。本综述探讨了偏倚与生物学因素在女性膀胱癌不良预后中的相对贡献，并呼吁针对性别差异优化诊疗策略。"}, {"pmid": "42017392", "title": "Clinical Benefit and Safety of Combined Immunotherapy and Targeted Therapy in Prostate Cancer.", "abstract": "Although immunotherapy has transformed the treatment of several genitourinary malignancies, its role in prostate cancer remains limited. Combining immunotherapy with targeted therapies has emerged as a promising approach to enhance immune responses in prostate cancer. We aimed to systematically evaluate the efficacy and safety of immunotherapy combined with targeted therapy in the treatment of prostate cancer. We conducted a detailed literature search across Embase, Scopus, PubMed, Web of Science, and the Cochrane Library to include clinical trials enrolling adults with histologically confirmed prostate cancer treated with a combination of targeted therapy and immunotherapy. A systematic review and meta-analysis were performed according to a registered protocol. A total of 21 studies from 19 clinical trials, encompassing 5702 participants, were included. The studies evaluated 12 unique therapeutic combinations involving six targeted agents and four immunotherapies. Seven trials compared combination therapy with monotherapy. Pooled analyses showed that combination therapy significantly improved disease control rate (RR = 1.42), complete response (RR = 2.56), and partial response (RR = 2.13), albeit with a higher incidence of adverse events. In single-arm studies, the pooled median progression-free survival was 5.14 months, and median overall survival was 16.79 months. The androgen receptor signaling inhibitor subgroup exhibited longer survival than the PARP inhibitor subgroup. Combination immunotherapy and targeted therapy demonstrate superior efficacy over monotherapy in prostate cancer but increase the risk of toxicity. These promising results warrant further validation in large-scale, well-designed randomized trials.", "journal": "International Journal of Cancer", "pub_date": "2026-Oct-01", "publication_types": ["Journal Article", "Systematic Review", "Meta-Analysis"], "doi": "10.1002/ijc.70512", "authors": ["Zeyu Han", "Xianyanling Yi", "Yaxiong Tang", "Xuanji Li", "Dazhou Liao", "Hang Xu", "Xiaonan Zheng", "Jianzhong Ai"], "affiliations": ["Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China."], "corresponding_authors": [], "china_team": "Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China Jianzhong Ai团队", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 39.55, "score_parts": {"urology_relevance": 7, "urology_in_title": 8.0, "journal_priority": 10.55, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 12.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.7, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.55, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42014098", "title": "Federal housing assistance, cancer care, and overall survival among older adults with prostate cancer.", "abstract": "Survival disparities in prostate cancer are driven in part by social and economic factors, including housing insecurity. Rent subsidies in the form of federal housing assistance are a well-established strategy for alleviating housing insecurity, but their association with prostate cancer care and survival is unknown. Using linked federal housing assistance data, SEER cancer registry data, and Medicare claims, we assessed workup and treatment receipt and 2-year survival among individuals aged 66-95 who were diagnosed with prostate cancer in 2007 to 2019. We used logistic and Cox regression models to compare outcomes between individuals receiving housing assistance upon prostate cancer diagnosis and a comparison group without housing assistance, using propensity score matching to balance sociodemographic and clinical characteristics. There were 1839 individuals with housing assistance (and 5517 without assistance) included in the workup and treatment analyses and 4451 individuals with housing assistance (and 13 353 without assistance) in the survival models. Receipt of housing assistance was not associated with guideline-concordant workup (62.7% vs. 61.2%, OR = 1.02, 95% CI = 0.97 to 1.07, P = .48) or active treatment (63.7% vs. 62.2%, OR = 1.02, 95% CI = 0.99 to 1.06, P = .22) but was associated with improved overall survival in the 2 years following diagnosis (hazard ratio for mortality: OR = 0.88, 95% CI = 0.81 to 0.96). Older adults receiving housing assistance at the time of a prostate cancer diagnosis experienced better overall survival than a matched comparison group without housing assistance. Results suggest that expanding access to housing assistance might support greater and more equitable survival in prostate cancer.", "journal": "Journal of the National Cancer Institute", "pub_date": "2026-Oct-01", "publication_types": ["Journal Article"], "doi": "10.1001/JAMANETWORKOPEN.2022.39860", "authors": ["Katherine L Chen", "Taylor K Craig", "Amanda L Blackford", "Joan L Warren", "Daniel Song", "Qinjin Fan", "S M Qasim Hussaini", "Margaret Katana Ogongo", "Xin Hu", "Rebecca B Smith", "Jordan Kaplan", "Robyn N Jordan", "Cary P Gross", "Daniel Polsky", "K Robin Yabroff", "Craig Evan Pollack"], "affiliations": ["Division of General Internal Medicine & Health Services Research, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles (UCLA), Los Angeles, CA, United States.", "Biostatistics, Epidemiology and Data Management Core, Johns Hopkins University School of Medicine, Baltimore, MD, United States.", "Division of Quantitative Sciences, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, United States.", "Department of Surveillance, Prevention, & Health Services Research, American Cancer Society, Atlanta, GA, United States.", "Department of Radiation Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, United States.", "O'Neal Comprehensive Cancer Center, Division of Hematology & Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, United States.", "Division of Health Services Research, Outcomes, and Policy, Department of Radiology, Emory School of Medicine, Atlanta, GA, United States.", "Department of Health Policy and Management, Bloomberg School of Public Health, Johns Hopkins University School of Medicine, Baltimore, MD, United States.", "Johns Hopkins University School of Medicine, Baltimore, MD, United States.", "Division of Gastroenterology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States.", "Department of Internal Medicine, Yale School of Medicine, New Haven, CT, United States.", "Yale Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, New Haven, CT, United States.", "Carey Business School, Johns Hopkins University, Baltimore, MD, United States.", "Johns Hopkins School of Nursing, Baltimore, MD, United States."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 29.09, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 15.09, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 7.2, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.09, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "联邦住房援助与前列腺癌生存改善相关", "chinese_summary": "J Natl Cancer Inst基于SEER、Medicare及联邦住房援助数据，纳入2007至2019年确诊前列腺癌的66–95岁人群，倾向评分匹配后显示，确诊时接受住房援助者规范诊疗率与积极治疗率未显著提高，但2年总生存更优（HR=0.88）。结果提示扩大住房援助可促进更公平的生存结局。", "abstract_zh": "前列腺癌的生存差异部分由社会和经济因素驱动，包括住房不安全。以联邦住房援助形式提供的租金补贴是缓解住房不安全的一项成熟策略，但其与前列腺癌诊疗及生存的关联尚不明确。利用关联的联邦住房援助数据、SEER癌症登记数据和Medicare索赔数据，我们评估了2007年至2019年确诊前列腺癌的66-95岁个体的检查与治疗接受情况以及2年生存率。我们使用逻辑回归和Cox回归模型，比较前列腺癌确诊时接受住房援助的个体与未接受住房援助的对照组之间的结局，并使用倾向评分匹配来平衡社会人口学和临床特征。检查和治疗分析共纳入1839名接受住房援助的个体（以及5517名未接受援助者），生存模型共纳入4451名接受住房援助的个体（以及13353名未接受援助者）。接受住房援助与指南一致的检查（62.7% vs. 61.2%，OR = 1.02，95% CI = 0.97至1.07，P = .48）或积极治疗（63.7% vs. 62.2%，OR = 1.02，95% CI = 0.99至1.06，P = .22）无关，但与确诊后2年总生存改善相关（死亡风险比：OR = 0.88，95% CI = 0.81至0.96）。在前列腺癌确诊时接受住房援助的老年人，其总生存优于未接受住房援助的匹配对照组。结果表明，扩大住房援助的可及性可能有助于实现前列腺癌中更高且更公平的生存。"}, {"pmid": "42001218", "title": "Prioritizing context-specific genetic risk mechanisms in 11 solid cancers.", "abstract": "While genome-wide association studies (GWAS) have identified hundreds of cancer-associated genetic variants, the specific biological contexts where these variants exert their effects remain largely unknown. We aimed to prioritize context-specific genetic risk mechanisms for 11 solid cancers at both genome-wide and single-variant resolutions. We integrated cancer GWAS summary statistics from European ancestry samples (avg. n = 47 856 cases) with 1473 context-specific annotations representing candidate cis-regulatory elements. For genome-wide analysis, we applied cell-type fine-mapping (CT-FM), a method that jointly models heritability enrichments across annotations to select likely disease-relevant biological contexts. Following functionally informed fine-mapping to identify high-confidence causal single nucleotide polymorphisms (SNPs), we used CT-FM-SNP to identify relevant contexts for individual variants. A combined SNP-to-gene framework was applied to construct putative {regulatory SNP-context-gene-cancer} quadruplets. Stratified LD score regression analysis identified 141 annotations showing significant heritability enrichment (false discovery rate, q ≤ 0.05). CT-FM prioritized 4 high-confidence biological contexts (posterior inclusion probability ≥  0.5): mammary luminal epithelial cells for overall and estrogen receptor (ER)-positive breast cancer, the VCaP (Vertebral-Cancer of the Prostate) epithelial cell line for prostate cancer, and bulk tumor tissue contexts for colorectal and renal cancers. Variant-level analysis of hundreds of putatively causal SNPs aligned with these findings and identified additional high-confidence contexts for ER-negative breast, endometrial, lung, and bladder cancers. A total of 489 putative regulatory quadruplets were constructed, proposing specific molecular hypotheses underlying the observed GWAS signals. These findings advance our understanding of genetic susceptibility to different cancers. Future work in larger, more diverse GWAS, coupled with more comprehensive annotation atlases, is essential to expand upon and validate our results.", "journal": "Journal of the National Cancer Institute", "pub_date": "2026-Oct-01", "publication_types": ["Journal Article"], "doi": "10.1038/S41588-024-01870-Z", "authors": ["Xueyao Wu", "Artem Kim", "Charles E Breeze", "Tracy A O'Mara", "Dhanya Ramachandran", "Thilo Dörk", "Stella Koutros", "Nathaniel Rothman", "Ludmila Prokunina-Olsson", "Nicholas Mancuso", "Sara Lindström", "Peter Kraft"], "affiliations": ["Trans-Divisional Research Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, United States.", "Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States.", "Center for Genetic Epidemiology, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States.", "Occupational and Environmental Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, United States.", "Cancer Research Program, QIMR Berghofer, Brisbane, QLD, Australia.", "Faculty of Health, Medicine and Behavioural Sciences, The University of Queensland, Brisbane, QLD, Australia.", "Gynaecology Research Unit, Hannover Medical School, Hannover, Germany.", "Laboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, United States.", "Department of Quantitative and Computational Biology, University of Southern California, Los Angeles, CA, United States.", "Department of Epidemiology, School of Public Health, University of Washington, Seattle, WA, United States.", "Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, United States."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "basic_signals=7", "score": 32.09, "score_parts": {"urology_relevance": 8, "urology_in_title": 0.0, "journal_priority": 15.09, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 7.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 7.2, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.09, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "11种实体瘤遗传风险机制获细化", "chinese_summary": "《国立癌症研究所杂志》10月发表研究，整合欧洲血统样本GWAS数据与1473组候选顺式调控元件注释，对11种实体瘤行细胞类型精细定位，锁定4个高置信生物学背景：乳腺腔上皮细胞对应整体及ER阳性乳腺癌，VCaP上皮细胞系对应前列腺癌，以及结直肠癌与肾癌的肿瘤组织背景；", "abstract_zh": "尽管全基因组关联研究（GWAS）已发现数百个癌症相关遗传变异，但这些变异发挥效应的具体生物学背景仍大多未知。我们旨在在全基因组和单变异分辨率上，为11种实体瘤优先筛选背景特异性的遗传风险机制。我们将欧洲血统样本的癌症GWAS汇总统计（平均n=47856例病例）与代表候选顺式调控元件的1473个背景特异性注释进行整合。在全基因组分析中，我们应用细胞类型精细定位（CT-FM），该方法联合建模各注释间的遗传力富集，以筛选可能的疾病相关生物学背景。在功能信息指导的精细定位确定高置信度因果单核苷酸多态性（SNP）后，我们使用CT-FM-SNP识别单个变异的相关背景。应用联合的SNP到基因框架构建推定的{调控SNP-背景-基因-癌症}四联体。分层LD分数回归分析识别出141个显示显著遗传力富集的注释（错误发现率q≤0.05）。CT-FM优先筛选出4个高置信度生物学背景（后验纳入概率≥0.5）：整体及雌激素受体（ER）阳性乳腺癌对应乳腺腔上皮细胞，前列腺癌对应VCaP（脊椎-前列腺癌）上皮细胞系，结直肠癌和肾癌对应肿瘤组织整体背景。对数百个推定因果SNP的变异水平分析与这些发现一致，并识别出ER阴性乳腺癌、子宫内膜癌、肺癌和膀胱癌的额外高置信背景。共构建489个推定调控四联体，为观察到的GWAS信号提出具体分子假设。这些发现增进了我们对不同癌症遗传易感性的理解。未来在更大、更多样化的GWAS中开展工作，并结合更全面的注释图谱，对于扩展和验证我们的结果至关重要。"}, {"pmid": "41991381", "title": "Novel immunotherapies for prostate cancer.", "abstract": "Since the advent of the autologous dendritic cell-based vaccine, sipuleucel-T, in 2010, the clinical development of immunotherapeutic approaches in advanced prostate cancer has largely been lacking. Aside from the infrequent use of pembrolizumab immune checkpoint blockade in rare molecularly-selected patients, no further immune approaches have achieved regulatory approval. Numerous challenges exist that preclude successful clinical development, including an immunologically-excluded tumor immune microenvironment, off-target and/or inflammatory toxicities that narrow the therapeutic window, and limited durability of anti-tumor responses. Nevertheless, recent advances in drug design and cellular engineering have reinvigorated interest in novel immunotherapeutic approaches in prostate cancer. This review provides an overview of the current landscape of novel immunotherapy clinical development for prostate cancer, with a focus on chimeric antigen receptor (CAR) T cells, T cell engagers, monoclonal antibodies, and cancer vaccine approaches that have produced promising early phase clinical data.", "journal": "Urologic Oncology", "pub_date": "2026-Oct", "publication_types": ["Journal Article", "Review"], "doi": "10.1016/j.urolonc.2026.111092", "authors": ["George Mo", "Vivek Narayan"], "affiliations": ["Division of Hematology/Medical Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.", "Division of Hematology/Medical Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA. Electronic address: vnarayan@pennmedicine.upenn.edu."], "corresponding_authors": ["Vivek Narayan"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 22.75, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 5.75, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 2.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.3, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.75, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "41956861", "title": "Prognostic Value of Interim PSMA-PET Total Tumor Volume for Overall Survival Within ENZA-p, A Randomized Phase 2 Trial of Enzalutamide Versus Enzalutamide Plus [177Lu] Lu-PSMA-617 (ANZUP1901).", "abstract": "Interim [68Ga]Ga-prostate-specific membrane-antigen positron emission tomography/computed tomography (PSMA-PET/CT) has prognostic potential for overall survival (OS) in metastatic castrate-resistant prostate cancer (mCRPC), although evidence is limited. This ENZA-p sub-study evaluated 3-mo PSMA-total-tumor-volume (PSMA-TTV) as a prognostic biomarker for OS with enzalutamide ± [177Lu]Lu-PSMA-617. ENZA-p is a randomized, phase 2 trial. Participants with mCRPC and risk factors for early treatment failure with enzalutamide were randomized (1:1) to enzalutamide or enzalutamide + [177Lu]Lu-PSMA-617. Participants underwent baseline and 3-mo [68Ga]Ga-PSMA-11-PET/CT, quantified to derive PSMA-TTV. We evaluated the prognostic value of PSMA-TTV change, and residual PSMA-TTV at 3-mo for OS (NCT04419402). This sub-study included 152/162 (94%) randomized participants with a 3-mo PSMA-PET. Median OS was 27 mo (95% confidence interval [CI] 23-30). Baseline median PSMA-TTV 230 ml (interquartile range [IQR] 75-635) and 3-mo PSMA-TTV 103 ml (IQR 24-457). The median change in PSMA-TTV from baseline was -34% (IQR -76% to 16%) with 50/152 (33%) participants with increase in PSMA-TTV. Any increase versus decrease in PSMA-TTV at 3-mo was associated with shorter OS (HR 2.52, 95% CI 1.65-3.85) and decreased 2-yr survival 30% (95% CI 17-43) versus 67% (95% CI 56-75) (log-rank p < 0.0001). Residual 3-mo PSMA-TTV higher versus lower than the median (103 ml) was associated with shorter OS (HR 3.76, 95% CI 2.39-5.92) and lower 2-yr survival 34% (95% CI 23-45) versus 76% (95% CI 64-84) (log-rank p < 0.0001). This association was independent of treatment arm and prostate-specific antigen (PSA) response. PSMA-TTV at 3 mos was prognostic for OS independent of study treatment and PSA response in ENZA-p, warranting further prospective validation of interim PSMA-PET response criteria.", "journal": "European Urology", "pub_date": "2026-Oct", "publication_types": ["Journal Article", "Randomized Controlled Trial", "Clinical Trial, Phase II", "Comparative Study"], "doi": "10.1016/j.eururo.2026.03.026", "authors": ["Louise Emmett", "Nathan Papa", "Oliver Sartor", "Michael J Morris", "Shalini Subramaniam", "Megan Crumbaker", "Narjess Ayati", "Jeffrey Chen", "Ken Herrmann", "Andrei Gafita", "Mina Swiha", "Anthony M Joshua", "Andrew Weickhardt", "Sze-Ting Lee", "Siobhan Ng", "Roslyn J Francis", "Jeffrey C Goh", "David A Pattison", "Bao Ho", "Sobia Khan", "Thean Hsiang Tan", "Madison Bills", "Andrew Nguyen", "Thida Thein", "George Sidhom", "Keith Wong", "Andrew James Martin", "Michael S Hofman", "Shahneen Sandhu", "Hayley Thomas", "Martin R Stockler", "Ian D Davis", "ENZA-p Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)"], "affiliations": ["Department of Theranostics and Nuclear Medicine, St Vincent's Hospital, Sydney, Australia; St Vincent's Clinical School, University of New South Wales, Sydney, Australia; Garvan Institute of Medical Research, Sydney, Australia. Electronic address: louise.emmett@svha.org.au.", "Garvan Institute of Medical Research, Sydney, Australia.", "East Jefferson General Hospital, New Orleans, USA.", "Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.", "NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia; Department of Medical Oncology, Bankstown-Lidcombe Hospital, Sydney, Australia.", "St Vincent's Clinical School, University of New South Wales, Sydney, Australia; Garvan Institute of Medical Research, Sydney, Australia; Department of Medical Oncology, Kinghorn Cancer Centre, St Vincent's Hospital, Sydney, Australia.", "Department of Theranostics and Nuclear Medicine, St Vincent's Hospital, Sydney, Australia; St Vincent's Clinical School, University of New South Wales, Sydney, Australia.", "Department of Theranostics and Nuclear Medicine, St Vincent's Hospital, Sydney, Australia.", "Department of Nuclear Medicine, University Hospital Essen, Germany.", "Division of Nuclear Medicine and Molecular Imaging, The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA.", "Molecular Imaging and Theranostics Division, Department of Medical Imaging, University of Western Ontario, London, Canada.", "Olivia Newton-John Cancer and Wellness Centre, Austin Health, Melbourne, Australia; School of Cancer Medicine, La Trobe University, Melbourne, Australia.", "Department of Molecular Imaging and Therapy, Austin Health, Melbourne, Australia; Department of Medicine and Department of Surgery, The University of Melbourne, Melbourne, Australia.", "Department of Oncology, Sir Charles Gairdner Hospital and University of Western Australia, Perth, Australia.", "Department of Nuclear Medicine, Sir Charles Gairdner Hospital, Perth, Australia; Medical School, University of Western Australia, Perth, Australia.", "Royal Brisbane & Women's Hospital, Herston, Queensland, Australia; Queensland University of Technology, Brisbane, Australia.", "Department of Nuclear Medicine & Specialised PET Services, Royal Brisbane, and Women's Hospital, Herston, Brisbane, Australia; School of Medicine, University of Queensland, Brisbane, Australia.", "Department of Medical Oncology, Royal Adelaide Hospital, Adelaide, Australia; Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, Australia.", "Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, Australia; Nuclear Medicine, PET and Bone Densitometry, Royal Adelaide Hospital, Adelaide, Australia.", "NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia.", "ULTRA The University of Queensland Clinical Trials Capability, Centre for Clinical Research, Queensland, Australia.", "Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC), Melbourne, Australia; Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia.", "Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia.", "NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia; University of Sydney, New South Wales, Australia.", "Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Sydney, Australia; Monash University Eastern Health Clinical School, Melbourne, Australia; Eastern Health, Melbourne, Australia."], "corresponding_authors": ["Louise Emmett"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_interventional_trial", "score": 45.29, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 16.79, "top_journal_bonus": 10.0, "novelty": 0.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 12.0}, "journal_metrics": {"status": "ok", "impact_factor": 25.2, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.79, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "中期PSMA-PET肿瘤体积可预判生存", "chinese_summary": "欧洲泌尿外科10月发表ENZA-p随机2期试验亚组分析，152例mCRPC患者于3个月行PSMA-PET总肿瘤体积评估，结果显示体积升高者总生存显著更短，2年生存率30%对67%，且独立于治疗分组与PSA应答，支持将其作为 interim 影像预后标志物。", "abstract_zh": "interim [68Ga]Ga-前列腺特异性膜抗原正电子发射断层扫描/计算机断层扫描（PSMA-PET/CT）对转移性去势抵抗性前列腺癌（mCRPC）的总生存（OS）具有预后潜力，尽管证据有限。这项ENZA-p子研究评估了3个月时的PSMA-总肿瘤体积（PSMA-TTV）作为恩扎卢胺±[177Lu]Lu-PSMA-617治疗下OS预后生物标志物的价值。ENZA-p是一项随机、2期试验。具有mCRPC且存在恩扎卢胺早期治疗失败危险因素的参与者按1：1随机分配至恩扎卢胺或恩扎卢胺+[177Lu]Lu-PSMA-617。参与者在基线和3个月时接受[68Ga]Ga-PSMA-11-PET/CT，并进行定量以得出PSMA-TTV。我们评估了PSMA-TTV变化以及3个月时残余PSMA-TTV对OS的预后价值（NCT04419402）。本子研究纳入152/162（94%）名具有3个月PSMA-PET的随机参与者。中位OS为27个月（95%置信区间[CI] 23-30）。基线中位PSMA-TTV为230 ml（四分位距[IQR] 75-635），3个月时PSMA-TTV为103 ml（IQR 24-457）。PSMA-TTV自基线的中位变化为-34%（IQR -76%至16%），50/152（33%）名参与者的PSMA-TTV升高。3个月时PSMA-TTV任何升高与降低相比，与更短的OS相关（HR 2.52，95% CI 1.65-3.85），2年生存率降低，为30%（95% CI 17-43）对67%（95% CI 56-75）（log-rank p < 0.0001）。3个月时残余PSMA-TTV高于中位数（103 ml）与低于中位数相比，与更短的OS相关（HR 3.76，95% CI 2.39-5.92），2年生存率更低，为34%（95% CI 23-45）对76%（95% CI 64-84）（log-rank p < 0.0001）。这种关联独立于治疗组和前列腺特异性抗原（PSA）应答。在ENZA-p中，3个月时的PSMA-TTV对OS具有预后价值，且独立于研究治疗和PSA应答，值得进一步前瞻性验证中期PSMA-PET应答标准。"}, {"pmid": "41951848", "title": "Evaluation and management of transient lower urinary tract symptoms (LUTS) after surgery for Benign prostatic obstruction (BPO): a systematic review.", "abstract": "The evaluation and management of lower urinary symptoms (LUTS) experienced in the immediate post-operative period after benign prostatic obstruction surgery (BPO), remain unclear. Aim of our study is to systematically report the evidence on management of post-operative transient urinary symptoms after BPO surgery. A systematic review of the literature was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses checklist (PRISMA). PubMed, Embase, Scopus and Cochrane databases were searched up to March 2025. Studies evaluating pharmacotherapy, phytotherapy and/or physical treatment for post-operative transient LUTS in men aged were evaluated. Only randomized clinical trials (RCTs) were included. Overall, nine RCTs were included. Among the surgical techniques investigated, most data were available for transurethral resection of the prostate. The methods used to assess post-operative LUTS, as well as the timing of evaluation, varied considerably across studies. The most commonly submitted questionnaire was the International Prostate Symptom Score, and the most frequently performed diagnostic tool was uroflowmetry. Anticholinergic drugs seems to have the greatest efficacy in improving post-operative LUTS, even if the level of evidence is low. In contrast, alpha-blockers did not appear to offer significant additional benefits in this setting of patients. Phytocomplexes (Graminex G63, Curcumin complexes) were effective in improving patients' quality of life (QoL) after BPO surgery. Pelvic floor muscle exercises (PFME) also demonstrated a reduction in symptom-related bother. Current strategies for evaluating and managing transient postoperative LUTS are heterogeneous, and available evidence remains limited. Anticholinergic agents and phytotherapeutic compounds are among the most commonly prescribed treatments, though their efficacy is suboptimal. High-quality randomized trials are needed to provide robust clinical recommendations.", "journal": "Prostate Cancer and Prostatic Diseases", "pub_date": "2026-Oct", "publication_types": ["Journal Article", "Systematic Review"], "doi": "10.1038/s41391-026-01082-y", "authors": ["Giacomo Gallo", "Riccardo Lombardo", "Antonio Cicione", "Jean-Nicolas Cornu", "Antonio Franco", "Ferdinando Fusco", "Sachin Malde", "Celeste Manfredi", "Christopher Netsch", "Malte Rieken", "Stavros Gravas", "Mauro Gacci", "Cosimo De Nunzio"], "affiliations": ["Department of Urology, Sant'Andrea Hospital, 'Sapienza' University of Rome, Rome, Italy.", "Department of Urology, Sant'Andrea Hospital, 'Sapienza' University of Rome, Rome, Italy. rlombardo@me.com.", "Department of Urology, Charles Nicolle University Hospital, University of Rouen, Rouen, France.", "Department of Urology, Rush University Medical Center, Chicago, IL, USA.", "Department of Woman, Child and General and Specialized Surgery, University of Campania 'Luigi Vanvitelli', Naples, Italy.", "Department of Urology, Guy's and St Thomas' NHS Foundation Trust, London, UK.", "Department of Urology, Asklepios Hospital Barmbek, Hamburg, Germany.", "alta uro AG, Basel, Switzerland; University of Basel, Basel, Switzerland.", "Medical School, University of Cyprus, Nicosia, Cyprus.", "Unit of Urological Robotic Surgery and Renal Transplantation, University of Florence, Careggi Hospital, Florence, Italy."], "corresponding_authors": ["Riccardo Lombardo"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 47.81, "score_parts": {"urology_relevance": 15, "urology_in_title": 8.0, "journal_priority": 10.81, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 12.0}, "journal_metrics": {"status": "ok", "impact_factor": 5.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.81, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "BPO术后一过性下尿路症状管理证据有限", "chinese_summary": "10月Prostate Cancer Prostatic Dis系统综述纳入9项RCT，评估BPO术后一过性LUTS的药物与物理治疗。抗胆碱能药物改善症状效果相对最优但证据等级低，α受体阻滞剂未见额外获益；植物复合物及盆底肌锻炼可改善生活质量与症状困扰。现有评估工具与时机差异大，亟需高质量试验。", "abstract_zh": "良性前列腺梗阻手术（BPO）后即刻出现的下尿路症状（LUTS）的评估与管理仍不明确。本研究旨在系统报告BPO术后一过性尿路症状管理的证据。按照系统评价和荟萃分析优先报告条目清单（PRISMA）进行了文献系统综述。检索了PubMed、Embase、Scopus和Cochrane数据库，截止至2025年3月。评估了针对成年男性术后一过性LUTS的药物治疗、植物治疗和/或物理治疗的研究。仅纳入随机临床试验（RCT）。共纳入9项RCT。在所研究的手术技术中，大部分数据来自经尿道前列腺电切术。各研究评估术后LUTS的方法以及评估时机差异很大。最常用的问卷是国际前列腺症状评分，最常进行的诊断工具是尿流率测定。抗胆碱能药物似乎在改善术后LUTS方面最为有效，尽管证据水平较低。相反，α受体阻滞剂在此类患者中似乎未提供显著的额外获益。植物复合物（Graminex G63、姜黄素复合物）可有效改善BPO术后患者的生活质量（QoL）。盆底肌锻炼（PFME）也显示出可减少症状相关困扰。目前评估和管理术后一过性LUTS的策略异质性较大，现有证据仍然有限。抗胆碱能药物和植物治疗化合物是最常处方的治疗之一，但其疗效欠佳。需要高质量的随机试验以提供可靠的临床建议。"}, {"pmid": "41936699", "title": "Practical management of hematuria after endoscopic surgery for benign prostatic obstruction.", "abstract": "Postoperative hematuria following transurethral prostate procedures ranges from self-limited bleeding to life-threatening hemorrhage. Clinically significant hematuria occurs in approximately 13-22% of patients after transurethral resection of the prostate (TURP), with clot retention in 1-5%. Bleeding risk increases with prostate size, and transfusion rates approach 9% for glands exceeding 60 g. This perspective synthesizes current evidence on the prevention and management of postoperative hematuria across transurethral prostate procedures, including standard TURP, laser techniques, and office-based minimally invasive surgical treatments (MISTs). Prevention begins preoperatively with risk stratification, anticoagulation management, and consideration of 5α-reductase inhibitors to reduce prostatic vascularity. Intraoperatively, bipolar energy and laser vaporization provide improved hemostasis compared with monopolar resection, while MISTs such as UroLift and Rezūm carry distinct bleeding profiles that warrant tailored postoperative management. Postoperative management follows a stepwise approach: large-lumen catheterization with continuous bladder irrigation, balloon traction for tamponade, antispasmodics for bladder spasm control, and tranexamic acid for pharmacologic hemostasis. Surgical escalation with cystoscopic clot evacuation, fulguration, or prostatic artery embolization is reserved for refractory cases. We present a device-agnostic outpatient workflow (Figure 1) applicable to ambulatory and office-based procedures. Most patients recover with conservative measures, and protocolized care improves safety and outcomes. Future research should focus on standardizing management pathways, identifying predictors of clinically significant bleeding, and exploring the role of AI-based risk stratification and novel hemostatic agents.", "journal": "Prostate Cancer and Prostatic Diseases", "pub_date": "2026-Oct", "publication_types": ["Journal Article", "Review"], "doi": "10.1038/s41391-026-01111-w", "authors": ["Alexis E Te", "Austen G Te", "Ashwin Ramaswamy", "Steven A Kaplan"], "affiliations": ["Icahn School of Medicine at Mount Sinai, New York, NY, USA. Alexis.Te@mountsinai.org.", "Houston Methodist Medical Center, Houston, TX, USA.", "Icahn School of Medicine at Mount Sinai, New York, NY, USA."], "corresponding_authors": ["Alexis E Te"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 41.81, "score_parts": {"urology_relevance": 16, "urology_in_title": 8.0, "journal_priority": 10.81, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 4.0}, "journal_metrics": {"status": "ok", "impact_factor": 5.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.81, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "41934820", "title": "MnO2-passivated Co3O4 sonozymes for tumor microenvironment re-activated sonodynamic and chemodynamic enhanced immunotherapy.", "abstract": "Ultrasound-activated sonodynamic therapy (SDT) is showing more potential in the treatment of deep-seated tumors such as renal cell carcinoma because of the high tissue-penetration depth. However, existing sonosensitizers lack active-targeting ability and often have \"always on\" characteristics, leading to potential accumulation in normal tissues and causing damage under US irradiation. Herein, we present for the first time the \"sonodynamic passivation strategy\" for sonosensitizers to prevent ROS-induced damage to normal cells. MnO2 nanoflowers with TME-responsive degradation features are utilized to load on the surface of Co3O4 sonozymes, realizing the passivation of sonodynamic and chemodynamic activities of Co3O4. In addition to the passivated sonozyme catalytic activity, MnO2@Co3O4 heterojunctions are capable of regulating the immunosuppressive tumor microenvironment (TME) by depleting GSH and alleviating hypoxia. Owing to the TME-responsive degradation of MnO2, the tumor-specific released Co3O4 sonozymes can restore their sonodynamic and chemodynamic activities, achieving the in-situ SDT/CDT and then realizing the trigger of ICD. Meanwhile, the released Mn ions can not only realize the cascade amplification of ROS production through Fenton-like reaction, GSH depletion, and hypoxia alleviation, but also activate cGAS-STING pathway for the augmentation of antitumor immune response. The activation of cGAS-STING pathway is further enhanced by the loading of STING agonist MSA-2 on the surface of Co3O4 before the coating of MnO2. MnO2@Co3O4/MSA-2-mediated TME-reactivated SDT/CDT/cGAS-STING-activation has shown significant antitumor efficacy, resulting in the eradication of primary tumors and the inhibition of distant tumor growth. Overall, this work offers hopeful insights into the modulation of the \"on/off\" function of sonosensitizer activity, ultimately enabling precise sonodynamic therapy for refractory renal cell carcinoma.", "journal": "Biomaterials", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1016/j.biomaterials.2026.124189", "authors": ["Qiwei Zhou", "Jie Wang", "Lin Li", "Jinyan Hu", "Da Xu", "Wenliang Gong", "Cheng Fei", "Fangzhi Liang", "Haopeng Liu", "Bijiang Geng", "Yi Bao", "Bing Liu"], "affiliations": ["The Third Affiliated Hospital Naval Medical University, Shanghai, 200433, China.", "School of Environmental and Chemical Engineering, Shanghai University, Shanghai, 200444, China.", "School of Environmental and Chemical Engineering, Shanghai University, Shanghai, 200444, China. Electronic address: bjgeng1992@shu.edu.cn.", "The Third Affiliated Hospital Naval Medical University, Shanghai, 200433, China. Electronic address: baoyi66@foxmail.com.", "The Third Affiliated Hospital Naval Medical University, Shanghai, 200433, China. Electronic address: 13501616398@163.com."], "corresponding_authors": ["Bijiang Geng", "Yi Bao", "Bing Liu"], "china_team": "The Third Affiliated Hospital Naval Medical University, Shanghai, 200433, China Bijiang Geng/Yi Bao/Bing Liu团队", "category": "basic", "classification_reason": "basic_signals=4", "score": 26.86, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 15.86, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 4.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 12.9, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.86, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "声敏剂钝化策略增效肾癌免疫治疗", "chinese_summary": "海军军医大学第三附属医院Geng Bijiang/Bao Yi/Liu Bing团队10月Biomaterials报道，以MnO2纳米花包覆Co3O4声酶构建异质结，在肿瘤微环境中响应降解并释放Co3O4，恢复声动力与化学动力活性，同时释放Mn离子经类Fenton反应放大ROS并激活cGAS-STING通路，实现原发瘤根除及远端瘤抑制。", "abstract_zh": "超声激活的声动力治疗（SDT）因组织穿透深度大，在肾细胞癌等深部肿瘤治疗中展现出较大潜力。然而，现有声敏剂缺乏主动靶向能力且常具有“始终开启”特性，导致其在正常组织中潜在蓄积并在超声照射下造成损伤。在此，我们首次提出声敏剂的“声动力钝化策略”，以防止ROS诱导的正常细胞损伤。利用具有肿瘤微环境（TME）响应降解特性的MnO2纳米花负载于Co3O4声酶表面，实现对Co3O4声动力和化学动力活性的钝化。除钝化声酶催化活性外，MnO2@Co3O4异质结还能通过消耗GSH和缓解缺氧来调节免疫抑制性肿瘤微环境（TME）。由于MnO2的TME响应性降解，肿瘤特异性释放的Co3O4声酶可恢复其声动力和化学动力活性，实现原位SDT/CDT，进而触发免疫原性细胞死亡（ICD）。同时，释放的Mn离子不仅可通过类Fenton反应、GSH消耗和缺氧缓解实现ROS产生的级联放大，还能激活cGAS-STING通路以增强抗肿瘤免疫应答。在包覆MnO2之前，将STING激动剂MSA-2负载于Co3O4表面，进一步增强了cGAS-STING通路的激活。MnO2@Co3O4/MSA-2介导的TME再激活SDT/CDT/cGAS-STING激活显示出显著的抗肿瘤疗效，导致原发肿瘤根除并抑制远端肿瘤生长。总体而言，这项工作为调控声敏剂活性的“开/关”功能提供了有希望的见解，最终实现针对难治性肾细胞癌的精准声动力治疗。"}, {"pmid": "41932402", "title": "Simulation-Free Adaptive Prostate Stereotactic Body Radiation Therapy on Magnetic Resonance-Linac: Technical Feasibility and Clinical Experience.", "abstract": "To develop and evaluate 2 simulation-free (SF) stereotactic body radiation therapy (SBRT) workflows for prostate cancer on magnetic resonance (MR)-Linac: one using a diagnostic MR reference scan and another using a preapproved template scan. Population-based relative electron density (RED) values were derived from 100 prostate SBRT patients on the Elekta Unity MR-Linac and validated on a separate cohort of 10 patients for dosimetric equivalence. Two SF approaches were evaluated in another independent cohort of 10 patients using reference plans derived from: (1) a diagnostic MR scan (5 retrospective, 5 prospective), and (2) a digitally created pelvic phantom scan using population-based RED (all retrospective). The performance of artificial intelligence-generated contours was investigated during adaptive treatments using surface Dice (sDSC) with 1 mm tolerance and added path length. All adaptive plans, from both SF and the clinically delivered workflow, were compared in terms of dose metrics and monitor unit usage. A focused failure modes and effects analysis identified and mitigated diagnostic MR SF-specific risks by calculating the risk priority number (RPN). Population-based RED assignments resulted in mean dose differences under 1%. Artificial intelligence contours showed strong agreement with physician-approved contours, with sDSC and added path length of 0.96/26.2cm,0.98/17.2cm,0.99/0.4cm, and 0.99/0.01cm for bladder, rectum, penile bulb, and bone, respectively. Across both SF workflows, adaptive plans were clinically comparable to the standard workflow, with mean dose differences from -1.7% to 4.6% and mean monitor unit differences remaining under 2%. Failure modes and effects analysis identified 3 high-risk failure modes: mislabeling diagnostic MR scans (RPN=39), case tracking lapses (RPN=29), and incorrect RED assignment (RPN=22), all mitigated through workflow refinements and training. The diagnostic MR SF workflow has been clinically implemented, treating 22 patients without failures. Both SF workflows eliminated the need for simulation, streamlining adaptive prostate SBRT without compromising plan quality. The template-based workflow further improved patient access by removing imaging prerequisites.", "journal": "International Journal of Radiation Oncology, Biology, Physics", "pub_date": "2026-Oct-01", "publication_types": ["Journal Article", "Research Support, Non-U.S. Gov't"], "doi": "10.1016/j.ijrobp.2026.03.031", "authors": ["Nicolas Côté", "Lian Sun", "Himanshu Nagar", "Victoria Brennan", "Ching-Yun Chan", "Gabrielle Maggia", "James Mechalakos", "Eric Aliotta", "Victoria Yu", "Arthur Lalonde", "Neelam Tyagi"], "affiliations": ["Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Physics, Université de Montréal, Montréal, Quebec, Canada. Electronic address: coten@mskcc.org.", "Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York.", "Department of Physics, Université de Montréal, Montréal, Quebec, Canada."], "corresponding_authors": ["Nicolas Côté"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=9", "score": 45.96, "score_parts": {"urology_relevance": 11, "urology_in_title": 8.0, "journal_priority": 14.96, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 9.0}, "journal_metrics": {"status": "ok", "impact_factor": 6.5, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 2.96, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "41927890", "title": "Neurogenic lower urinary tract dysfunction in ageing men with spinal cord injury.", "abstract": "The management of neurogenic lower urinary tract dysfunction in ageing men with spinal cord injury is defined by the compounding interaction between prostate enlargement, neurogenic detrusor overactivity and detrusor-sphincter dyssynergia. The effects of spinal cord injury and an ageing bladder create unique challenges, including a 16-28-fold increased risk of urinary bladder cancer and a high prevalence of catheter-related complications. Importantly, although clean intermittent catheterization is the gold standard for treating lower urinary tract dysfunction, in many elderly patients, functional decline forces a transition to indwelling catheters, necessitating a shift in care strategy. Furthermore, prostate procedures such as transurethral resection of the prostate (TURP) and holmium laser enucleation, which are commonly carried out in older men, carry an increased risk of complications, including autonomic dysreflexia. Integrated, age-stratified guidelines are currently missing. Thus, a proactive, patient-centred framework for lifelong urological care is needed and should incorporate frailty assessments, sophisticated diagnostics to disentangle detrusor sphincter dyssynergia from prostate enlargement, and personalized management pathways to preserve renal function and quality of life.", "journal": "Nature Reviews Urology", "pub_date": "2026-Oct", "publication_types": ["Journal Article", "Review"], "doi": "10.1038/s41585-026-01135-w", "authors": ["Fiona Huang", "Lucas Rempel", "Matthias Walter", "Jean Jacques Wyndaele", "Ruth Kirschner-Hermanns", "Katherine Anderson", "Raza Malik", "Andrei V Krassioukov"], "affiliations": ["International Collaboration on Repair Discoveries (ICORD), Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.", "Division of Physical Medicine & Rehabilitation, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.", "Faculty of Medicine, University of Basel, Basel, Switzerland.", "University Antwerp Belgium Faculty GGW, Antwerp, Belgium.", "Faculty of Neuro-Urology (ret), University Clinic of Bonn, Bonn, Germany.", "Department of Urologic Sciences, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.", "International Collaboration on Repair Discoveries (ICORD), Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada. andrei.krassioukov@vch.ca.", "Division of Physical Medicine & Rehabilitation, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada. andrei.krassioukov@vch.ca.", "Department of Urologic Sciences, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada. andrei.krassioukov@vch.ca.", "G.F. Strong Rehabilitation Centre, Vancouver Coastal Health, Vancouver, British Columbia, Canada. andrei.krassioukov@vch.ca."], "corresponding_authors": ["Andrei V Krassioukov"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 46.03, "score_parts": {"urology_relevance": 18.0, "urology_in_title": 8.0, "journal_priority": 16.03, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 2.0}, "journal_metrics": {"status": "ok", "impact_factor": 14.6, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.03, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "41922791", "title": "Active surveillance in low-grade NMIBC - results of an international two-round modified Delphi consensus.", "abstract": "Standard management for recurrent low-grade non-muscle-invasive bladder cancer (LG-NMIBC) often involves a substantial treatment burden, which is not justified by the relatively indolent course of the disease, prompting a need for de-intensification strategies. Active surveillance (AS) is an alternative approach aimed at reducing overtreatment in selected patients. However, the broader adoption of AS is hindered by a lack of standardized protocols for patient selection, monitoring and intervention. To address this gap, we conducted an international, two-round Delphi consensus among 51 bladder cancer experts to establish foundational statements for the use of AS. Consensus was achieved on 20 statements, providing clear recommendations for terminology; inclusion and exclusion criteria; follow-up monitoring; and exit criteria. This Delphi consensus provides the first expert-driven framework to standardize the clinical application of AS for LG-NMIBC. These statements could guide current clinical practice and unify the design of future trials.", "journal": "Nature Reviews Urology", "pub_date": "2026-Oct", "publication_types": ["Consensus Statement", "Journal Article"], "doi": "10.1038/s41585-026-01137-8", "authors": ["Roberto Contieri", "Paolo Gontero", "Rodolfo Hurle", "Luca Afferi", "Simone Albisinni", "Marek Babjuk", "Alison Birtle", "Peter Black", "Maurizio Brausi", "Max Bruins", "Otakar Čapoun", "Albert Carrion", "James Catto", "Ananya Choudhury", "Alessia Cimadamore", "Eva Comperat", "Siamak Daneshmand", "David D'andrea", "Francesco Del Giudice", "Jose Luis Domínguez Escrig", "Patrick Hensley", "Wojciech Krajewski", "Ekaterina Laukhtina", "Roger Li", "Fredrik Liedberg", "Yair Lotan", "Gautier Marcq", "Paramananthan Mariappan", "Andrea Mari", "Alberto Martini", "Alexandra Masson Lecomte", "Richard Meijer", "Maria Carmen Mir", "Keiichiro Mori", "Marco Moschini", "Hugh Mostafid", "Micheal O'Donnell", "Joan Palou", "Valeria Panebianco", "Sisto Perdonà", "Sima Porten", "Sarah Psutka", "Michael Rink", "Morgan Roupret", "Thomas Seisen", "Mark Soloway", "Viktor Soukup", "Gary Steinberg", "Arnulf Stenzl", "Jeremy Yc Teoh", "Karl Tully", "Toine van der Heijden", "Bas W G van Rhijn", "Alfred Witjes", "Evanguelos Xylinas", "Ashish M Kamat", "Benjamin Pradere", "Laura S Mertens"], "affiliations": ["Department of Urology, Istituto Nazionale Tumori di Napoli, IRCCS 'G. Pascale', Naples, Italy.", "Division of Urology, Department of Surgical Sciences, AOU Città della Salute e della Scienza at Molinette Hospital and University of Turin, Turin, Italy.", "Department of Urology, Humanitas Clinical and Research Institute IRCCS, Milan, Italy.", "Department of Urology, Kantonsspital Aarau, Aarau, Switzerland.", "Urology Unit, Department of Surgical Sciences, Tor Vergata University Hospital, University of Rome Tor Vergata, Rome, Italy.", "Department of Urology, Teaching Hospital Motol, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic.", "University of Manchester, Manchester, UK.", "University of Central Lancashire, Preston, UK.", "Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.", "Department of Urology, Hesperia Hospital, Modena, Italy.", "Department of Urology, Zuyderland Medisch Centrum, Sittard/Heerlen, The Netherlands.", "Department of Urology, General University Hospital and 1st Faculty of Medicine, Charles University Praha, Prague, Czechia.", "Department of Urology, Vall Hebron Hospital, Autonomous University of Barcelona, Barcelona, Spain.", "Division of Clinical Medicine, School of Medicine & Population Health, University of Sheffield, Sheffield, UK.", "Clinical Oncology, The Christie NHS Foundation Trust, Manchester, UK.", "Institute of Pathological Anatomy, Department of Medicine, University of Udine, Udine, Italy.", "Department of Pathology, Medical University Vienna, Vienna, Austria.", "Department of Urology, USC Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA.", "Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.", "Department of Maternal Infant and Urologic Sciences, \"Sapienza\" University of Rome, Policlinico Umberto I Hospital, Rome, Italy.", "Department of Urology, Instituto Valenciano de Oncologia, Valencia, Spain.", "Department of Urology, University of Kentucky College of Medicine, Lexington, KY, USA.", "University Center of Excellence in Urology, Department of Minimally Invasive and Robotic Urology, Wroclaw Medical University, Wroclaw, Poland.", "Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.", "Division of Urological Research, Department of Translational Medicine, Lund University, Skåne University Hospital, Malmö, Sweden.", "University of Texas Southwestern, Dallas, TX, USA.", "Department of Urology, CHU Lille, Lille UniversityUniversity, Lille, France.", "Edinburgh Bladder Cancer Surgery (EBCS), Department of Urology, Western General Hospital, Edinburgh, UK.", "Unit of Oncologic Minimally-Invasive Urology and Andrology, Department of Experimental and Clinical Medicine, Careggi Hospital, University of Florence, Florence, Italy.", "Department of Urology, University of Cincinnati College of Medicine, Cincinnati, OH, USA.", "Department of Urology, Hôpital Saint-Louis AP-HP, Université Paris Cité, Paris, France.", "Department of Oncological Urology, University Medical Center Utrecht, Utrecht, The Netherlands.", "Department of Urology, Mount Sinai Icahn School of Medicine, Elmhurst/Queens Hospitals, New York, NY, USA.", "Department of Urology, Jikei University School of Medicine, Tokyo, Japan.", "Division of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy.", "Department of Urology, Stokes Centre for Urology, Royal Surrey Hospital, Guildford, UK.", "Department of Urology, University of Iowa, Iowa City, IA, USA; Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, USA.", "Department of Urology, Fundació Puigvert, Barcelona, Spain.", "Department of Radiological Sciences, Oncology and Pathology, Sapienza University of Rome, Rome, Italy.", "Department of Urology, University of California San Francisco, San Francisco, CA, USA.", "Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.", "Department of Urology, Marienkrankenhaus Hamburg, Hamburg, Germany.", "GRC n°5, Predictive Onco-Urology, Ap-Hp, Hôpital Pitié-Salpêtrière Urology, Sorbonne Université, Paris, France.", "Urologic Oncology, Memorial Physician Group, Division of Urology, Memorial Healthcare System, Aventura, FL, USA.", "Department of Urology, Rush University Medical Center, Chicago, IL, USA.", "Department of Urology, Eberhard-Karls-University, Tübingen, Germany.", "Department of Surgery, S.H. Ho Urology Centre, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China.", "Department of Urology and Neurourology, Marien Hospital Herne, Ruhr-University Bochum, Herne, Germany.", "Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.", "Department of Surgical Oncology (Urology), Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.", "Department of Urology, Bichat Claude Bernard Hospital, Paris University, Paris, France.", "Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.", "Department of Urology, La Croix Du Sud Hospital, Quint-Fonsegrives, France.", "Department of Surgical Oncology (Urology), Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. l.mertens@nki.nl."], "corresponding_authors": ["Laura S Mertens"], "china_team": "Department of Surgery, S Jeremy Yc Teoh团队", "category": "clinical_review", "classification_reason": "clinical_signals=4", "score": 27.03, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 16.03, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 4.0}, "journal_metrics": {"status": "ok", "impact_factor": 14.6, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.03, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "41887368", "title": "Toward Optimal Fractionation Schemes in Nonuniform Radiation Therapy: Exploiting Helical Tomotherapy's Thread Effect for Gynecological Cancer Treatment.", "abstract": "This study aimed to optimize dose fractionation for helical tomotherapy-based spatially fractionated radiation therapy (HT-SFRT) in gynecologic cancers by exploiting the \"thread effect\" to induce cohort effects. HT-SFRT plans with varying parameters (pitch: 0.3-0.5; field width: 2.512 and 5.048 cm; modulation factor: 1.0-4.0) were applied to HeLa cells to identify the optimal configuration maximizing the peak-to-valley dose ratio. The cohort effect threshold was determined through quantification of DNA damage (γ-H2AX) and cell viability. Clinical validation involved 45 patients with gynecologic cancer, comparing 3 treatment approaches: conventional HT, stereotactic body radiation therapy, and SFRT (3 and 4 fractions). Comprehensive dosimetric analysis included evaluation of physical doses, biologically effective doses, tumor control probability, and normal tissue complication probability (NTCP) using the universal survival curve and Lyman-Kutcher-Burman models. Optimized HT-SFRT parameters (field width = 5.048 cm; pitch = 0.5; modulation factor = 2.0) achieved a peak-to-valley dose ratio of 1.15 at 10 cm off-axis. The 8 Gy/fraction dose threshold induced significant γ-H2AX expression and reduced cell viability by 15.41% (P < .05), establishing the cohort effect criterion. Clinically, the 32 Gy/4 fractions SFRT regimen demonstrated approximate tumor control (tumor control probability: 99.34% vs 100%) to conventional HT (50 Gy/25 fractions), whereas offering superior therapeutic advantages: (1) 84% reduction in treatment duration (4 vs 25 days); (2) significantly lower NTCP for bladder (6.5 × 10-⁶ % vs 3.6 × 10-⁴ %, P = .05); and (3) 42.9% faster fractional delivery than stereotactic body radiation therapy. Notably, SFRT exhibited elevated NTCP for rectum (3.99% vs 0.10%) and femoral head (0.16%-0.22% vs 2.9 × 10-⁷ %-4.8 × 10-⁷ %) structures. The thread effect in HT can be harnessed for SFRT, avoiding traditional mitigation strategies. The optimized HT-SFRT scheme (32 Gy/4 fractions) offers equivalent tumor control, shorter treatment duration, and acceptable normal tissue toxicity, providing a promising alternative for gynecologic cancer radiation therapy. Prospective clinical trials are warranted to validate these findings.", "journal": "International Journal of Radiation Oncology, Biology, Physics", "pub_date": "2026-Oct-01", "publication_types": ["Journal Article", "Research Support, Non-U.S. Gov't"], "doi": "10.1016/j.ijrobp.2026.03.026", "authors": ["Huanli Luo", "Mengqi Yang", "Jianfeng Li", "Tao Qiu", "Wenyou Hu", "Yunrui Song", "Tian Wang", "Haiyan Peng", "Xin Yang", "Bin Feng", "Liyuan Chen", "Liang Tan", "Bo Liang", "Ying Wang", "Fu Jin"], "affiliations": ["Department of Radiation Physics, Chongqing University Cancer Hospital, Chongqing, China.", "Department of Radiation Oncology, Chongqing University Cancer Hospital, School of Medicine, Chongqing University, Chongqing, China.", "Yilong General Hospital, Nanchong, China.", "Department of Radiation Physics, Chongqing University Cancer Hospital, Chongqing, China. Electronic address: wangying1967_cq@126.com.", "Department of Radiation Physics, Chongqing University Cancer Hospital, Chongqing, China. Electronic address: jfazj@126.com."], "corresponding_authors": ["Ying Wang", "Fu Jin"], "china_team": "Department of Radiation Physics, Chongqing University Cancer Hospital, Chongqing, China Ying Wang/Fu Jin团队", "category": "clinical_review", "classification_reason": "clinical_signals=12", "score": 32.96, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 14.96, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 12.0}, "journal_metrics": {"status": "ok", "impact_factor": 6.5, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 2.96, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "41882121", "title": "Response to correspondence regarding \"The value of micro-ultrasound for prostate cancer screening: a retrospective real-world feasibility study\".", "abstract": "", "journal": "Prostate Cancer and Prostatic Diseases", "pub_date": "2026-Oct", "publication_types": ["Letter"], "doi": "10.1007/s00345-023-04591-w", "authors": ["Johann J Wendler", "Jonas Bechstein", "Hannes Cash"], "affiliations": ["Clinic of Urology, Urooncology and Robotic and Focal Therapy, Medical Faculty of University Magdeburg and University Hospital Magdeburg A. ö. R. (University Medicine Magdeburg, UMM), Magdeburg, Germany.", "Urologicum Magdeburg, Magdeburg, Germany.", "Clinic of Urology, Urooncology and Robotic and Focal Therapy, Medical Faculty of University Magdeburg and University Hospital Magdeburg A. ö. R. (University Medicine Magdeburg, UMM), Magdeburg, Germany. hannes.cash@prouro.de.", "PROURO Berlin, Berlin, Germany. hannes.cash@prouro.de."], "corresponding_authors": ["Hannes Cash"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 19.81, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.81, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 5.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.81, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "41876711", "title": "Mitochondrial dysfunction in urologic disease.", "abstract": "Lower urinary tract symptoms (LUTS) can result from several conditions, including but not limited to benign prostatic hyperplasia, diabetes, stress urinary incontinence, and metabolic syndrome. In 2011, it was estimated that nearly 2 billion people (45.2% of the world population) experience one or more LUTS. To date, there is no single underlying mechanism identified in lower urinary tract symptoms or the associated conditions. However, a recent body of evidence has demonstrated that mitochondrial dysfunction may contribute to conditions associated with LUTS. Furthermore, patients with inherited mitochondrial disease exhibit lower urinary tract symptoms at rates above the general population. Given that mitochondrial dysfunction is an under-investigated area of urinary disease research, this review aims to summarize the existing literature in the field. PubMed was used as the primary database for literature search. Keywords included \"lower urinary tract symptoms\", \"mitochondria\", \"urinary dysfunction\"; additionally, once identified, further disease-specific searches were performed (e.g., \"urinary dysfunction in type 1 diabetes\"). Studies published earlier than August 2025 were included, and a specific focus was placed on clinical or human studies. Urologic conditions lacking at least three publications investigating mitochondrial dysfunction were not included; studies examining mitochondrial dysfunction in urologic cancers were also outside the scope of this review. Mitochondrial dysfunction is a potential novel intersection of diseases associated with LUTS, including aging, metabolic syndrome, diabetes, stress urinary incontinence, benign prostatic hyperplasia, and overactive bladder. While initial studies are promising, more investment into identifying underlying mechanisms and new potential treatments is needed. Additionally, as mitochondrial modulators undergo trial as treatments in other conditions, careful consideration should be given to their potential as treatments for LUTS.", "journal": "Prostate Cancer and Prostatic Diseases", "pub_date": "2026-Oct", "publication_types": ["Journal Article", "Review"], "doi": "10.1016/j.eururo.2005.12.042", "authors": ["Alexis E Adrian", "Natalie J Boucher", "Kevin T McVary", "Donald B DeFranco", "William A Ricke"], "affiliations": ["Department of Urology, University of Wisconsin- Madison, Madison, WI, USA.", "Department of Human Physiology, University of Oregon, Eugene, OR, USA.", "Center for Male Health, Loyola University Chicago, Stritch School of Medicine, Maywood, IL, USA.", "Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.", "Department of Urology, University of Wisconsin- Madison, Madison, WI, USA. rickew@urology.wisc.edu."], "corresponding_authors": ["William A Ricke"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 43.31, "score_parts": {"urology_relevance": 18.0, "urology_in_title": 8.0, "journal_priority": 10.81, "top_journal_bonus": 0.0, "novelty": 1.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 3.0}, "journal_metrics": {"status": "ok", "impact_factor": 5.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.81, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "41872315", "title": "Lifestyle matters: physical activity and prostate cancer progression.", "abstract": "", "journal": "Prostate Cancer and Prostatic Diseases", "pub_date": "2026-Oct", "publication_types": ["Editorial"], "doi": "10.1038/s41391-026-01105-8", "authors": ["Alanna Burwell", "Maria P Mogollon", "Gillian Gresham", "Stephen J Freedland"], "affiliations": ["Division of Urology, Durham Veterans Affairs Medical Center, Durham, NC, USA.", "Department of Urology, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.", "Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.", "Division of Urology, Durham Veterans Affairs Medical Center, Durham, NC, USA. Stephen.Freedland@cshs.org.", "Department of Urology, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA. Stephen.Freedland@cshs.org."], "corresponding_authors": ["Stephen J Freedland"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 19.81, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.81, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 5.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.81, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "41872314", "title": "Risk factors for incidental prostate cancer following surgery for benign prostatic enlargement: A systematic review and meta-analysis.", "abstract": "Incidental prostate cancer (IPC) is not uncommon in patients undergoing surgery for benign prostate enlargement (BPE). However, the associated risk factors remain incompletely understood. This study aimed to evaluate potential clinical predictors of IPC. A systematic search of MEDLINE, Embase, and Web of Science was conducted in January 2025 to identify studies assessing risk factors for IPC. Pairwise meta-analyses were performed using a random-effects model, pooling adjusted odds ratios (ORs) and 95% confidence intervals (CIs) from multivariable analyses. Risk of bias was evaluated using the ROBINS-I tool. (PROSPERO: CRD42024588776). Twenty-five studies comprising 247,966 patients were included. IPC was identified in 6,748 patients, with reported rates ranging from 2.2% to 49.6%. Significant risk factors for IPC included: Elevated PSA level (OR: 1.03; 95% CI: 1.01-1.05; p = 0.01), PSA density >0.15 ng/mL/cc (OR: 3.02; 95% CI: 1.50-6.07; p = 0.01), Older age (OR: 1.05; 95% CI: 1.01-1.08; p = 0.01), and Higher body mass index (BMI) (OR: 1.10; 95% CI: 1.02-1.18; p = 0.01). Prostate volume, diabetes, and dyslipidemia were not associated with IPC risk. Notably, use of 5-alpha reductase inhibitors (5-ARIs) was linked to a significantly reduced risk (OR: 0.53; 95% CI: 0.33-0.85; p = 0.01). Study limitations included heterogeneity across studies, retrospective designs, and incomplete reporting of key variables. Elevated PSA, high PSA density, older age, and increased BMI were associated with a higher risk of IPC in patients undergoing surgery for BPE. Conversely, preoperative use of 5-ARIs was associated with a reduced risk. These findings may support improved preoperative risk stratification and help identify patients in whom additional diagnostic evaluations could be considered or avoided. Further research is needed to better define predictors of clinically significant IPC.", "journal": "Prostate Cancer and Prostatic Diseases", "pub_date": "2026-Oct", "publication_types": ["Journal Article", "Meta-Analysis", "Systematic Review"], "doi": "10.1038/s41391-026-01108-5", "authors": ["Angelo Cormio", "Akihiro Matsukawa", "Alessandro Dematteis", "Ahmed R Alfarhan", "Marcin Miszczyk", "Navid Roessler", "Abdulrahman S Alqahtani", "Stefano Mancon", "Ichiro Tsuboi", "Paweł Rajwa", "Ugo Giovanni Falagario", "Francesca Sanguedolce", "Gian Maria Busetto", "Carlo Bettocchi", "Giuseppe Carrieri", "Luigi Cormio", "Andrea Benedetto Galosi", "David D'Andrea", "Takahiro Kimura", "Shahrokh F Shariat"], "affiliations": ["Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. angelocormio4@gmail.com.", "Division of Anatomy, Medical University of Vienna, Vienna, Austria. angelocormio4@gmail.com.", "Department of Urology, Azienda Ospedaliero-Universitaria Ospedali Riuniti Di Ancona, Università Politecnica Delle Marche, Ancona, Italy. angelocormio4@gmail.com.", "Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.", "Division of Anatomy, Medical University of Vienna, Vienna, Austria.", "Department of Urology, The Jikei University School of Medicine, Tokyo, Japan.", "Department of Surgical Sciences, Division of Urology, AOU Città della Salute e della Scienza at Molinette Hospital and University of Turin, Turin, Italy.", "Department of Urology, Prince Saud Bin Jalawi Hospital, Al Ahsa Health Cluster, Al Ahsa, KSA, Saudi Arabia.", "Collegium Medicum - Faculty of Medicine, WSB University, Dąbrowa Górnicza, Poland.", "Department of Urology, Medical University Center Hamburg-Eppendorf, Hamburg, Germany.", "Department of Urology, Ministry of Health Saudi Arabia, Second Health cluster, Riyadh, KSA, Saudi Arabia.", "Department of Biomedical Sciences, Humanitas University, Pieve Milan, Italy.", "Department of Urology, IRCCS Humanitas Research Hospital, Milan, Italy.", "Department of Urology, Shimane University Faculty of Medicine, Shimane, Japan.", "Second Department of Urology, Centre of Postgraduate Medical Education, Warsaw, Poland.", "Division of Surgery and Interventional Science, University College London, London, UK.", "Department of Urology and Renal Transplantation, Policlinico Foggia, University of Foggia, Foggia, Italy.", "Department of Molecular Medicine and Surgery (Solna), Karolinska Institutet, Stockholm, Sweden.", "Pathology Unit, Policlinico Foggia, University of Foggia, Foggia, Italy.", "Department of Urology, Bonomo Teaching Hospital, Andria, Italy.", "Department of Urology, Azienda Ospedaliero-Universitaria Ospedali Riuniti Di Ancona, Università Politecnica Delle Marche, Ancona, Italy.", "Department of Urology, the University of Texas Southwestern Medical Center, Dallas, TX, USA.", "Department of Urology, Weill Cornell Medical College, New York, NY, USA.", "Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czechia.", "Division of Urology, Department of Special Surgery, The University of Jordan, Amman, Jordan.", "Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria.", "Research Center for Evidence Medicine, Urology Department Tabriz University of Medical Sciences, Tabriz, Iran."], "corresponding_authors": ["Angelo Cormio"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 33.81, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 10.81, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 5.0}, "journal_metrics": {"status": "ok", "impact_factor": 5.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.81, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "41857381", "title": "Micro-ultrasound in prostate cancer screening: bridging the gap between acoustic resolution and clinical certainty.", "abstract": "", "journal": "Prostate Cancer and Prostatic Diseases", "pub_date": "2026-Oct", "publication_types": ["Letter"], "doi": "10.1038/s41391-026-01102-x", "authors": ["Zuomin Wang", "Qinwei Liu", "Wangdong Deng"], "affiliations": ["Urology of Shenzhen Longgang Central Hospital, Shenzhen, China.", "Urology of Shenzhen Longgang Central Hospital, Shenzhen, China. Dwdong951@163.com."], "corresponding_authors": ["Wangdong Deng"], "china_team": "Urology of Shenzhen Longgang Central Hospital, Shenzhen, China Wangdong Deng团队", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 19.81, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.81, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 5.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.81, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "41857380", "title": "Can pelvic lymph node dissection be spared in intermediate-risk prostate cancer patients with negative PSMA PET scan? A systematic review and diagnostic meta-analysis.", "abstract": "The aim of this study was to meta-analyze published data on the diagnostic performance of PSMA PET/CT in detecting lymph node invasion (LNI) in intermediate-risk prostate cancer (PCa) patients, and to discuss whether pelvic lymph node dissection (PLND) can be spared in patients with negative PSMA PET scan. The PubMed and Embase databases were searched through November 2025 to identify relevant articles. Methodological quality of each study was assessed. Patient-based sensitivity and specificity were pooled using the bivariate random-effects model. Patient-based negative predictive value (NPV) was pooled using the DerSimonian-Laird model. Histopathology from PLND and clinical follow-up served as the reference standard. Twelve eligible studies, comprising a total of 1619 patients with intermediate-risk PCa, were included. Overall, the studies were of moderate methodological quality. The sensitivity and specificity of PSMA PET/CT for the detection of LNI ranged from 0% to 100% and from 87% to 99%, respectively, with pooled estimates of 49% [95% confidence interval (CI) 27-72%] and 95% (95% CI 93-97%), respectively. The NPV of PSMA PET/CT for the detection of LNI ranged from 74% to 100%, with pooled estimates of 95% (95% CI 91-98%). This meta-analysis of current diagnostic evidence suggests that intermediate-risk PCa patients with negative PSMA PET scan may omit PLND at the time of radical prostatectomy. However, the moderate sensitivity of PSMA PET and the associated risk of missing micrometastatic disease underscore the need for cautious application and shared decision-making. Further large-scale prospective validation studies and future follow-up results focusing on the clinical outcomes of these patients will lend stronger support to this approach.", "journal": "Prostate Cancer and Prostatic Diseases", "pub_date": "2026-Oct", "publication_types": ["Journal Article", "Meta-Analysis", "Systematic Review"], "doi": "10.1038/s41391-026-01103-w", "authors": ["Qi-Chang Wan", "Kai-Yin Min", "Lan Wei", "Liang-Jun Xie", "Bin Ji"], "affiliations": ["Department of Nuclear Medicine, China-Japan Union Hospital of Jilin University, Changchun, 130033, China.", "Department of Nuclear Medicine, Affiliated Qingyuan Hospital, Guangzhou Medical University, Qingyuan People's Hospital, Qingyuan, 511500, China.", "Department of Nuclear Medicine, Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, 510630, China. xielj9@mail.sysu.edu.cn.", "Department of Nuclear Medicine, China-Japan Union Hospital of Jilin University, Changchun, 130033, China. jibin@jlu.edu.cn."], "corresponding_authors": ["Liang-Jun Xie", "Bin Ji"], "china_team": "Department of Nuclear Medicine, China-Japan Union Hospital of Jilin University, Changchun, 130033, China Liang-Jun Xie/Bin Ji团队", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 29.81, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.81, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 5.0}, "journal_metrics": {"status": "ok", "impact_factor": 5.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.81, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "41852265", "title": "Correction to \"Long-term multicentre analysis of robot-assisted radical cystectomy for non-muscle-invasive bladder cancer\".", "abstract": "", "journal": "BJU International", "pub_date": "2026-Oct", "publication_types": ["Published Erratum"], "doi": "10.1111/bju.70248", "authors": [], "affiliations": [], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 23.47, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 10.47, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.4, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.47, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "41851477", "title": "Evolving therapies, persistent gaps: a real-world look at survival trends in metastatic prostate cancer.", "abstract": "", "journal": "Prostate Cancer and Prostatic Diseases", "pub_date": "2026-Oct", "publication_types": ["Editorial"], "doi": "10.1038/s41391-026-01106-7", "authors": ["Yufan Zhao", "Xudong Ni", "Yao Zhu"], "affiliations": ["Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China.", "Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.", "Shanghai Genitourinary Cancer Institute, Shanghai, China.", "Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China. zhuyao@fudan.edu.cn.", "Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China. zhuyao@fudan.edu.cn.", "Shanghai Genitourinary Cancer Institute, Shanghai, China. zhuyao@fudan.edu.cn."], "corresponding_authors": ["Yao Zhu"], "china_team": "Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China Yao Zhu团队", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 19.81, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.81, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 5.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.81, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "41820670", "title": "Lipidomic profiling in metastatic prostate cancer captures tumor metabolic rewiring and its modulation by androgen receptor-targeting therapy.", "abstract": "Reprogrammed lipid metabolism with massive upregulation of tumor cell-autonomous synthesis of saturated fatty acids is a hallmark of prostate cancer (PCa) and is driven in part by aberrations in androgen receptor (AR) signaling. While lipid alterations are well described in primary PCa, the extent to which the circulating lipidome reflects tumor-associated metabolic changes in metastatic disease, and its role in therapy response, remains to be determined. This study aims to assess whether plasma lipid profiling captures tumor metabolic rewiring, and whether this reflects response to AR-targeting therapy, in metastatic castration-resistant PCa (mCRPC). Quantitative plasma lipidomics was performed on plasma samples collected from patients with mCRPC (n = 50) and cancer-free subjects (C-FS, n = 14). Samples from patients with mCRPC were collected longitudinally at the time of progression on androgen deprivation therapy prior to initiation of first-line enzalutamide (Enza), after the start of treatment with Enza, before progression on Enza. Compared to C-FS, patients with mCRPC showed distinct lipidomic signatures, characterized by increased levels of monounsaturated lipids and altered composition of the phospholipid and sphingolipid pool, mimicking the aberrations known to occur in primary PCa tissue. Enza treatment markedly reduced total lipid levels, decreased major phospholipid classes and ceramides, while increasing sphingomyelins. Notably, quantitative differences in specific sphingolipid species occurring after Enza treatment correlated with survival outcomes. Plasma lipidomics reflects key metabolic features of PCa and is profoundly impacted by AR inhibition, with prognostic relevance in patients with mCRPC. These findings support its potential as a non-invasive tool for monitoring disease activity and treatment response, and lay the groundwork for lipid-based biomarkers in mCRPC, while indicating that the lipidomic alterations observed may help inform ongoing and forthcoming research on metabolic targeting.", "journal": "Prostate Cancer and Prostatic Diseases", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1080/23723556.2019.1595308", "authors": ["Sara Bleve", "Francesco Ravera", "Silvia Rodrigues", "Filippo Pederzoli", "Hubert Pakula", "Nicole Brighi", "Emilio Francesco Giunta", "Giuseppe Schepisi", "Alessandra Virga", "Giorgia Gurioli", "Salvatore Luca Burgio", "Giuseppe Nicolo' Fanelli", "Lisa M Butler", "David M Nanus", "Johannes V Swinnen", "Pier Vitale Nuzzo", "Cristian Lolli", "Ugo De Giorgi", "Massimo Loda"], "affiliations": ["Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \"Dino Amadori\", Meldola, Italy.", "Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY, USA.", "Department of Internal Medicine and Medical Specialties, University of Genoa, Genoa, Italy.", "Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \"Dino Amadori\", Meldola, Italy.", "Division of Pathology, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.", "First Division of Pathology, Pisa University Hospital, Pisa, Italy.", "South Australian Health and Medical Research Institute, North Terrace, Adelaide, SA, Australia.", "South Australian Immunogenomics Cancer Institute & Freemasons Centre for Male Health and Well-Being, Adelaide University, North Terrace, Adelaide, SA, Australia.", "Department of Medicine, Weill Cornell Medicine, New York, NY, USA.", "Caryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA.", "Laboratory of Lipid Metabolism and Cancer, Department of Oncology, Leuven Cancer Institute (LKI) and Leuven Institute for Single Cell Omics (LISCO), KU Leuven, Leuven, Belgium.", "Department of Experimental Medicine, University of Salento, Fazzi Hospital, Lecce, Italy.", "Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY, USA. mloda@med.cornell.edu.", "Nuffield Department of Surgical Sciences, Lincoln College, University of Oxford, Oxford, UK. mloda@med.cornell.edu.", "Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. mloda@med.cornell.edu."], "corresponding_authors": ["Massimo Loda"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=4", "score": 30.31, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.81, "top_journal_bonus": 0.0, "novelty": 1.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 4.0}, "journal_metrics": {"status": "ok", "impact_factor": 5.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.81, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "41792501", "title": "Prostate cancer screening: weighing the benefits and harms.", "abstract": "", "journal": "Nature Reviews Urology", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1038/s41585-026-01133-y", "authors": ["Nikhil Mayor", "Hashim U Ahmed"], "affiliations": ["Imperial Prostate, Department of Surgery and Cancer, Imperial College London, London, UK.", "Urology Department, Imperial College Healthcare NHS Trust, London, UK.", "Imperial Prostate, Department of Surgery and Cancer, Imperial College London, London, UK. hashim.ahmed@imperial.ac.uk.", "Urology Department, Imperial College Healthcare NHS Trust, London, UK. hashim.ahmed@imperial.ac.uk."], "corresponding_authors": ["Hashim U Ahmed"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 25.03, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 16.03, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 14.6, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.03, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "前列腺癌筛查利弊再权衡", "chinese_summary": "《自然综述·泌尿学》10月刊文重新评估前列腺癌筛查的获益与危害，指出PSA筛查虽可降低转移与死亡风险，但过度诊断和过度治疗仍突出，强调应结合风险分层与个体化决策优化筛查策略。", "abstract_zh": "前列腺癌筛查：权衡获益与危害。"}, {"pmid": "41792475", "title": "Natural history of untreated prostate cancer: a comprehensive review of long-term progression patterns and survival outcomes.", "abstract": "We systematically reviewed the long-term outcomes of untreated prostate cancer across different risk categories to inform treatment decisions and active surveillance protocols. This comprehensive analysis synthesizes long-term progression data across tumor staging and grading systems. We conducted a systematic literature search of PubMed, EMBASE, and Cochrane databases (1990-2025) for studies reporting ≥10-year outcomes in untreated or conservatively managed prostate cancer patients. Eligible studies included observational cohorts, population registries, and meta-analyses. Primary endpoints included prostate cancer-specific mortality, metastatic progression, and competing mortality. Fifteen major studies encompassing 43,127 patients (median follow-up 15-30 years) demonstrated heterogeneous progression patterns. Ten-year prostate cancer-specific survival ranged from >95% for Gleason 6 tumors to <60% for Gleason 8-10 disease. Grade Group 1 tumors showed <5% metastatic risk over 15-20 years, while Grade Groups 4-5 exhibited rapid progression with median disease-specific survival <5 years. Across all risk groups, disease progression accelerated markedly after 15 years. Men diagnosed after age 75 faced substantial competing mortality (~57-60% 10-year non-cancer mortality), regardless of tumor grade. Tumor grade is the strongest prognostic factor in the natural history of untreated prostate cancer. Low-grade disease often remains indolent for 15-20 years, whereas high-grade tumors frequently progress to lethal disease within a few years, warranting early intervention. These findings support contemporary active surveillance protocols for low-risk patients and inform evidence-based treatment decisions for higher-risk disease. Summary with methodological context.", "journal": "Prostate Cancer and Prostatic Diseases", "pub_date": "2026-Oct", "publication_types": ["Journal Article", "Systematic Review"], "doi": "10.1038/s41391-026-01095-7", "authors": ["Ashutosh K Tewari", "Reza Mehrazin", "Peter Wiklund", "Micheal DeMeo", "Steven A Kaplan", "Alexis E Te"], "affiliations": ["Icahn School of Medicine At Mount Sinai, New York, NY, USA.", "Icahn School of Medicine At Mount Sinai, New York, NY, USA. Alexis.Te@mountsinai.org."], "corresponding_authors": ["Alexis E Te"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 31.81, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.81, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 7.0}, "journal_metrics": {"status": "ok", "impact_factor": 5.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.81, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "41781484", "title": "Perioperative outcomes of ongoing antithrombotic therapy during endoscopic surgery for benign prostatic hyperplasia: a systematic review and meta-analysis of observational studies.", "abstract": "The management of antithrombotic therapy in patients undergoing endoscopic surgery for benign prostatic hyperplasia (BPH) remains challenging due to competing risks of thromboembolism and perioperative bleeding. This meta-analysis evaluated perioperative outcomes among patients undergoing endoscopic prostate procedures while continuing antiplatelet (APT) or anticoagulant (AC) therapy compared with patients not receiving antithrombotic treatment. Literature search was conducted on 17th September 2025 including PubMed, Medline, Embase, and Scopus database, to identify comparative studies evaluating perioperative outcomes of endoscopic prostate procedures in patients on versus off APT/AC therapy were identified. Data were pooled using random-effects models to estimate mean differences (MD) or odds ratios (OR) with 95% confidence intervals (CI). Fifteen studies comprising 6091 patients (1900 on APT/AC, 4191 controls) were included. Operative time, postoperative hemoglobin decrease, catheterization duration, and continuous bladder irrigation time were comparable between groups across all surgical modalities. However, bleeding-related complications were significantly more frequent among APT/AC users undergoing transurethral resection of the prostate (TURP) (OR 1.90, 95% CI 1.05-3.41, p = 0.03) and enucleation (OR 2.91, 95% CI 1.71-4.93, p < 0.0001), particularly in the AC subgroup (OR 4.80, p = 0.0002). Enucleation also carried higher odds of bleeding requiring surgical hemostasis (OR 3.69, 95% CI 1.73-7.84, p = 0.0007) and acute urinary retention (OR 1.36, 95% CI 1.04-1.77, p = 0.02) among antithrombotic users. Conversely, photoselective vaporization (PVP) demonstrated comparable rates of transfusion, hemostasis, and urinary complications regardless of APT/AC therapy. Hospital stay was marginally longer after TURP and PVP among APT/AC users (p < 0.05). Continuation of antithrombotic therapy during PVP appears safe, with perioperative outcomes comparable to those of non-antithrombotic patients. Conversely, its ongoing use-especially AC-significantly increases bleeding risks following TURP and enucleation. PVP may therefore represent the preferred modality for high-risk patients requiring uninterrupted antithrombotic therapy. Clinical decision-making should balance individual thromboembolic risk against anticipated bleeding risk, with multidisciplinary input when appropriate.", "journal": "Prostate Cancer and Prostatic Diseases", "pub_date": "2026-Oct", "publication_types": ["Journal Article", "Meta-Analysis", "Systematic Review"], "doi": "10.1038/s41391-026-01098-4", "authors": ["Carlo Giulioni", "Angelo Cafarelli", "Federico Falsetti", "Luca Spinozzi", "Angelo Cormio", "Carlotta Nedbal", "Valentina Maurizi", "Steffi Kar Kei Yuen", "Vineet Gauhar", "Luca Cindolo", "Michele Marchioni", "Luigi Schips", "Daniele Castellani"], "affiliations": ["Department of Urology, Casa di Cura Villa Igea, Ancona, Italy. carlo.giulioni9@gmail.com.", "Department of Urology, Casa di Cura Villa Igea, Ancona, Italy.", "Department of Urology and Renal Transplantation, University of Foggia, Foggia, Italy.", "Department of Urology, IRCCS San Gerardo dei Tintori, Monza, Italy.", "Internal Medicine Unit Jesi, Area Vasta 2 ASUR Marche, Jesi, Italy.", "S.H. Ho Urology Centre, Department of Surgery, Faculty of Medicine, Chinese University of Hong Kong, Hong Kong, China.", "Department of Urology, Ng Teng Fong General Hospital, Singapore, Singapore.", "Department of Urology, C.Ur.E.-Centro Urologico Europeo, Hesperia Hospital, Modena, Italy.", "UniCamillus-Saint Camillus International University of Health and Medical Sciences, Rome, Italy.", "Urology Unit, Azienda Ospedaliero-Universitaria delle Marche, Ancona, Italy."], "corresponding_authors": ["Carlo Giulioni"], "china_team": "S Steffi Kar Kei Yuen团队", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 42.81, "score_parts": {"urology_relevance": 18.0, "urology_in_title": 8.0, "journal_priority": 10.81, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 4.0}, "journal_metrics": {"status": "ok", "impact_factor": 5.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.81, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "41741677", "title": "PSMA-PET imaging in prostate cancer patients with high-risk biochemical recurrence: implications from an \"EMBARK-Like\" cohort.", "abstract": "The EMBARK trial demonstrated improved survival with enzalutamide plus androgen deprivation therapy (ADT) in non-metastatic hormone-sensitive prostate cancer patients with high-risk biochemical recurrence (BCR), although staged using conventional imaging. Given the higher sensitivity of PSMA-PET, many of these patients could harbor metastatic disease. We retrospectively analyzed 587 patients with first BCR after radical treatment who underwent PSMA-PET. Patients were stratified according to EMBARK criteria for high-risk BCR. 169 patients (29%) met EMBARK criteria. They more often showed PSMA-PET positivity for any localization (82% vs 39%; p < 0.001) and metastatic disease (46% vs 15%; p < 0.001). Median PSA was higher and PSA doubling-time (PSADT) shorter (2.23 vs 0.43 ng/mL; 4.3 vs 9 months). Most High-risk BCR patients have a positive PSMA-PET, and many of these harbor metastatic disease at molecular imaging. Given the survival benefit from intensified systemic treatment with ARPI in this cohort, how to best combine systemic therapy with PSMA-PET guided metastases-directed-treatments remains an important future area of research.", "journal": "Prostate Cancer and Prostatic Diseases", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1038/s41391-026-01096-6", "authors": ["Matteo Droghetti", "Valerio Pirelli", "Francesco Ceci", "Andrea Farolfi", "Matteo Bauckneht", "Francesco Lanfranchi", "Andrea Di Giorgio", "Paolo Castellucci", "Caterina Maria Paola Sgro", "Carlos Artigas", "Jose Leite", "Paola Corona", "Qaid Ahmed Shagera", "Renata Moreira", "Christian González", "Marcelo Queiroz", "Felipe de Galiza Barbosa", "Guido Rovera", "Desiree Deandreis", "Sara Tamburini", "Lorenzo Nanni", "Federico Bevilacqua", "Pietro Piazza", "Angelo Mottaran", "Veronica Mollica", "Francesco Massari", "Stefano Fanti", "Lorenzo Bianchi", "Riccardo Schiavina"], "affiliations": ["Division of Urology, IRCCS Azienda Ospedaliero Universitaria di Bologna, Bologna, Italy. droghet@gmail.com.", "Division of Urology, IRCCS Azienda Ospedaliero Universitaria di Bologna, Bologna, Italy.", "Division of Nuclear Medicine and Theranostics, IEO European Institute of Oncology IRCCS, Milan, Italy.", "Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.", "Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy.", "IRCCS Ospedale Policlinico San Martino, Genoa, Italy.", "Department of Experimental Medicine (DIMES), University of Genoa, Genoa, Italy.", "Department of Nuclear Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.", "PET/CT Center, DASA-Diagnósticos da América, Rio de Janeiro, Brazil.", "Fundación Centro Diagnóstico Nuclear (FCDN), Buenos Aires, Argentina.", "Department of Radiology, Hospital Sírio-Libanês, Sao Paulo, Brazil.", "Nuclear Medicine, Department of Medical Sciences, University of Turin, Turin, Italy.", "Nuclear Medicine, Institut Gustave-Roussy, Université Paris-Saclay, Villejuif, France.", "Medical Oncology, IRCCS Azienda Ospedaliero Universitaria di Bologna, Bologna, Italy."], "corresponding_authors": ["Matteo Droghetti"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=8", "score": 33.81, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.81, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 8.0}, "journal_metrics": {"status": "ok", "impact_factor": 5.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.81, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "41741676", "title": "Robot-assisted MRI/US transperineal target prostate biopsy with Biobot Mona Lisa 2.0: first experience in Europe.", "abstract": "The Mona Lisa 2.0 robotic platform integrates MRI/ultrasound fusion, AI-based prostate segmentation, and automated needle trajectory planning to optimize transperineal targeted biopsy (TB) precision. We report the first European experience in 10 consecutive patients undergoing robot-assisted TB, with optional systematic cores. Clinically significant prostate cancer was detected in all rTB procedures. Standard cores added limited diagnostic yield and mainly sampled perilesional \"penumbra\" areas. Mean biopsy duration was 12.9 min, no peri- or post-procedural complications occurred, and high-quality tissue samples were consistently obtained. These preliminary data confirm feasibility, safety, and reproducibility of Mona Lisa 2.0 robotic platform, as a new kid on the block in urologic robotic armamentarium.", "journal": "Prostate Cancer and Prostatic Diseases", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1038/s41391-026-01094-8", "authors": ["Enrico Checcucci", "Gabriele Bignante", "Gabriele Volpi", "Saverio Liguori", "Paolo Alessio", "Michele Sica", "Michele Ortenzi", "Daniele Amparore", "Alessandra Saliva", "Alberto Piana", "Stefano De Luca", "Alessandro Cerutti", "Francesco Porpiglia"], "affiliations": ["Division of Urology, Department of Surgery, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Turin, Italy. checcu.e@hotmail.it.", "Division of Urology, Department of Surgery, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Turin, Italy.", "Division of Anesthesiology, Department of Surgery, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Turin, Italy.", "Department of Oncology, Division of Urology, University of Turin, San Luigi Gonzaga Hospital, Orbassano, Italy."], "corresponding_authors": ["Enrico Checcucci"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 30.31, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 10.81, "top_journal_bonus": 0.0, "novelty": 1.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 5.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.81, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "机器人靶向前列腺穿刺首秀欧洲", "chinese_summary": "10月Prostate Cancer Prostatic Dis报告欧洲首批10例机器人辅助经会阴靶向前列腺穿刺，采用Mona Lisa 2.0平台整合MRI/超声融合与AI分割。全部操作均检出临床显著前列腺癌，平均耗时12.9 min，无围术期及术后并发症，标准穿刺额外诊断价值有限。初步证实该平台可行、安全且可重复。", "abstract_zh": "Mona Lisa 2.0机器人平台整合了MRI/超声融合、基于AI的前列腺分割以及自动针道规划，以优化经会阴靶向穿刺（TB）的精准度。我们报告了欧洲首批10例连续接受机器人辅助TB患者的经验，并可选加做系统穿刺。所有rTB操作均检出临床显著前列腺癌。标准穿刺芯额外诊断价值有限，主要取材于病灶周围“半暗带”区域。平均穿刺时长为12.9 min，未发生围术期或术后并发症，并始终获得高质量组织样本。这些初步数据证实了Mona Lisa 2.0机器人平台的可行性、安全性和可重复性，作为泌尿外科机器人装备库中的新成员。"}, {"pmid": "41741268", "title": "Cell-surface targets for prostate cancer therapeutics.", "abstract": "This review highlights recent data regarding antigens on the cell surface of prostate cancer cells or cells in the prostate cancer tumor microenvironment which may serve as targets for novel therapeutics. Emphasis is placed on clinical data involving human subjects. The biological role of each antigen discussed is described, as are the expression patterns of the antigen in relation to histologic subtype of prostate cancer. Most descriptions are based on histological or genomic data, and quantitative assessment via targeted immuno-PET when available. Some antigens such as prostate-specific membrane antigen (PSMA), TROP-2, six-transmembrane epithelial antigen of the prostate 1 (STEAP1), and PSCA are overexpressed primarily in prostate adenocarcinoma, while CEACAM5 or delta-like ligand 3 (DLL3) are more commonly expressed in neuroendocrine prostate cancer. CD46 may be overexpressed in both prostate adenocarcinoma and neuroendocrine prostate cancer. The expression pattern and relevance of human epidermal growth factor receptor 2 (HER2) as a therapeutic target in prostate cancer remains unclear. Fibroblast activation protein (FAP) is a cell-surface proteins more often expression on cancer fibroblasts in the tumor microenvironment. Ongoing investigation into novel targets for the treatment of prostate cancer continues to identify promising antigens which are overexpressed on the cell surface. Patterns of expression may vary based on histologic type, anatomic location, and treatment state of prostate cancer, and these factors will ultimately dictate the utility of novel therapeutic agents that are in development.", "journal": "Urologic Oncology", "pub_date": "2026-Oct", "publication_types": ["Journal Article", "Review"], "doi": "10.1016/j.urolonc.2026.111032", "authors": ["Samuel Ruder", "Pardis Ziaeefar", "Ambika P Jaswal", "Scott T Tagawa"], "affiliations": ["Department of Medicine, Division of Hematology and Oncology, New York Presbyterian Weill Cornell Medical Center, New York, NY. Electronic address: spj9003@med.cornell.edu.", "Department of Urology, University of Minnesota, Minneapolis, MN. Electronic address: ziaee002@umn.edu.", "Department of Radiology, Weill Cornell Medicine, New York, NY. Electronic address: apj9002@med.cornell.edu.", "Department of Medicine, Division of Hematology and Oncology, New York Presbyterian Weill Cornell Medical Center, New York, NY. Electronic address: stt2007@med.cornell.edu."], "corresponding_authors": ["Samuel Ruder", "Pardis Ziaeefar", "Ambika P Jaswal", "Scott T Tagawa"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 21.75, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 5.75, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 1.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.3, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.75, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "41735525", "title": "Survival trend in metastatic prostate cancer two decades of real-world data on overall survival from Germany.", "abstract": "The management of metastatic prostate cancer (mPCa) has undergone revolutionary changes over the past two decades with the introduction of novel hormonal agents, chemotherapy combinations, PARP inhibitors, and radioligand therapies. This study evaluates the real-world impact of these therapeutic advances on overall survival (OS) in Germany. We analyzed data from the German national cancer registry covering 657,499 prostate cancer cases diagnosed between 1999 and 2021. After exclusions, 54,890 patients with de novo metastatic disease (M1) were included. Primary outcome was median OS. Secondary outcomes included 3-, 5-, and 10-year survival rates. Time series analysis assessed temporal trends using augmented Dickey-Fuller tests and joinpoint regression. Median OS for M1 patients improved from 31.0 months (95% CI: 29.8-32.2) in 1999 to 37.0 months (35.6-38.4) in 2019 (p < 0.001). This 19.4% improvement exceeded general life expectancy gains. Age-stratified analysis revealed disparate benefits: patients < 70 years experienced improvement from 34.0 to 49.0 months ( + 44.1%), while those ≥ 70 years showed minimal change (28.0 to 29.0 months, +3.6%). Three-year survival increased from 45.1% to 50.9% (p = 0.004), with younger patients achieving 61.3% versus 44.0% for older patients by 2019. Multivariate Cox regression confirmed diagnosis year as an independent predictor (HR 0.96, 95% CI: 0.96-0.97, p < 0.001). Real-world data confirm meaningful survival improvements in metastatic prostate cancer over two decades, validating the translation of clinical trial efficacy into routine practice. However, the pronounced age-related disparity suggests potential undertreatment of elderly patients and highlights the need for age-adapted treatment strategies.", "journal": "Prostate Cancer and Prostatic Diseases", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1200/JCO.2018.78.8687", "authors": ["Marcus Sondermann", "Anton Stehr", "Christopher Hirtsiefer", "Viktoria Menzel", "Nina Buttmann-Schweiger", "Paul Wilhelm Flemming", "Klaus Kraywinkel", "Christian Thomas", "Katharina Boehm"], "affiliations": ["Universitätsklinikum Carl-Gustav-Carus Dresden, Department of Urology, Technische Universität Dresden, Dresden, Germany. marcus.sondermann@uniklinikum-dresden.de.", "Universitätsklinikum Carl-Gustav-Carus Dresden, Department of Urology, Technische Universität Dresden, Dresden, Germany.", "Vancouver Prostate Centre, Department of Urologic Sciences, Medical Faculty, University of British Columbia, Vancouver, Canada.", "Department of Epidemiology and Health Monitoring, German Centre for Cancer Registry Data (ZfKD), Berlin, Germany."], "corresponding_authors": ["Marcus Sondermann"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=8", "score": 33.81, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.81, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 8.0}, "journal_metrics": {"status": "ok", "impact_factor": 5.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.81, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "41723275", "title": "Single-port transvesical enucleation of the prostate (STEP) for benign prostatic hyperplasia: a comparative analysis of patients with large (80-150cc) and very large (>150cc) prostate volumes.", "abstract": "Single-Port Transvesical Enucleation of the Prostate (STEP) is a minimally invasive robotic technique for managing benign prostatic hyperplasia (BPH), particularly in prostates ≧ 80 cc. However, its outcomes in very large prostates (>150 cc) remain under-characterized. We compared perioperative and functional outcomes of STEP between large (LP: 80-150 cc) and very large prostates (VLP: >150 cc). We retrospectively reviewed 183 patients who underwent STEP using the da Vinci Single-Port system (2019-2024). Patients were stratified into LP and VLP cohorts based on prostate volume (PV). Enucleation efficiency was defined as enucleated tissue weight divided by enucleation time (g/min). Outcomes were compared using descriptive statistics. A total of 179 patients were included (LP: 93; VLP: 86). Median PV was significantly greater in the VLP group (194 vs. 117 cc, p < 0.001). VLP patients had higher PSA (9.7 vs. 6.75 ng/mL, p = 0.002), longer enucleation (84 vs. 69 min, p = 0.002) and console times (115 vs. 98 min, p = 0.010), and improved enucleation efficiency (1.23 vs. 0.97 g/min, p = 0.025). Estimated blood loss was slightly higher in VLP (100 vs. 80 mL, p = 0.026). All procedures were completed without conversion or additional ports. Hospital stay, catheter duration, and same-day discharge rates were comparable. At 3 months, both groups had equivalent improvements in International Prostate Symptom Score (3 vs. 3, p = 0.913), quality-of-life scores (0 vs. 1, p = 0.965), and maximum flow rate (17.5 vs. 16 mL/s, p = 0.594). Complications were rare, with no readmissions and only two major postoperative events. Urinary continence was preserved in all patients, with transient incontinence occurring in 6 patients (LP: 2; VLP: 4), resolving completely by 3 months. STEP is effective and scalable for prostates ≥ 80 cc, demonstrating improved enucleation efficiency in very large glands without compromising safety, recovery, or continence preservation.", "journal": "Prostate Cancer and Prostatic Diseases", "pub_date": "2026-Oct", "publication_types": ["Journal Article", "Comparative Study"], "doi": "10.1089/end.2023.0128", "authors": ["Salim K Younis", "Nicolas A Soputro", "Adriana M Pedraza", "Carter D Mikesell", "Abdulrahman Al-Bayati", "Samarpit Rai", "Lin Wang", "Rui M Bernardino", "Ruben Olivares", "Mohamed Eltemamy", "Zeyad R Schwen", "Riccardo Autorino", "Jihad Kaouk"], "affiliations": ["Glickman Urological Institute, Cleveland Clinic, Cleveland, OH, USA.", "Glickman Urological Institute, Cleveland Clinic, Cleveland, OH, USA. kaoukj@ccf.org."], "corresponding_authors": ["Jihad Kaouk"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_clinical", "score": 41.81, "score_parts": {"urology_relevance": 15, "urology_in_title": 8.0, "journal_priority": 10.81, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 6.0}, "journal_metrics": {"status": "ok", "impact_factor": 5.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.81, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "41721057", "title": "Telesurgery in prostate cancer: a systematic review of clinical applications and future directions.", "abstract": "Telesurgery represents an emerging frontier in the surgical management of prostate cancer, offering innovative solutions to expand access to specialized care across geographic and institutional barriers. This systematic review aims to evaluate the feasibility, clinical outcomes, and technical considerations of telesurgical applications in the treatment of prostate cancer. A comprehensive literature search was conducted across MEDLINE (via PubMed), Embase, Scopus, and Web of Science in June 2025 to identify all consecutive clinical studies published from 2001 through June 2025 that involved telesurgical approaches for the management of clinically significant, localized prostate cancer. Eligible studies were screened and reviewed according to PRISMA guidelines, and a narrative synthesis was performed. A total of six studies met the inclusion criteria, demonstrating successful telesurgical procedures involving 7 patients, with six procedures pertaining to Robot-Assisted Radical Prostatectomy (RARP) and one case of High-Intensity Focused Ultrasound (HIFU) focal therapy. All procedures were completed successfully over distances ranging between 1 and 11,412 km. The most commonly utilized network infrastructure included 5 G wireless and wired fiber-optic broadband systems. With a round-trip latency ranging between 6 ms and 464 ms, no technical failures and no clinically meaningful delays perceived by the surgeons were reported. Herein, we demonstrated the feasibility and safety of radical and focal robotic telesurgical procedures for the management of prostate cancer. Despite its successes and benefits in democratizing patient care and surgical education, challenges surrounding its cost, regulatory frameworks, and standardization of care may continue to pose limitations, underscoring the need for further research and policy innovation.", "journal": "Prostate Cancer and Prostatic Diseases", "pub_date": "2026-Oct", "publication_types": ["Journal Article", "Systematic Review"], "doi": "10.1007/s00595-024-02863-5", "authors": ["Boran Aksakal", "Nicolas A Soputro", "Abdulrahman Al-Bayati", "Milagros Secin", "Riccardo Autorino", "Jihad Kaouk", "Ruben Olivares"], "affiliations": ["Glickman Urological Institute, Cleveland Clinic, Cleveland, OH, USA.", "Glickman Urological Institute, Cleveland Clinic, Cleveland, OH, USA. olivarr@ccf.org."], "corresponding_authors": ["Ruben Olivares"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 28.81, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.81, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 4.0}, "journal_metrics": {"status": "ok", "impact_factor": 5.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.81, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "41714269", "title": "Review of radiopharmaceutical therapy in prostate cancer.", "abstract": "Radiopharmaceuticals therapy (RPT) has been a major breakthrough in the treatment of prostate cancer. This therapy utilizes radioactive isotopes targeted specifically to prostate cancer, combining the advantages of systemic therapy with targeted radiation. The 2 currently FDA approved agents are 223Ra and 177Lu-PSMA-617 which have both demonstrated an overall survival advantage. In this review we will discuss the approved agents, their similarities and differences, treatment sequencing, combinations with other therapies, as well as future directions of this promising field.", "journal": "Urologic Oncology", "pub_date": "2026-Oct", "publication_types": ["Journal Article", "Review"], "doi": "10.1016/j.urolonc.2026.111030", "authors": ["Sean R Miller", "Yuni Dewaraja", "Steven P Rowe", "Zachery R Reichert", "Benjamin L Viglianti"], "affiliations": ["Department of Radiation Oncology, University of Michigan, Ann Arbor, MI; Department of Radiology, Division of Nuclear Medicine, University of Michigan, Ann Arbor, MI. Electronic address: srmi@med.umich.edu.", "Department of Radiology, Division of Nuclear Medicine, University of Michigan, Ann Arbor, MI.", "Department of Radiology, University of Texas Southwestern Medical Center, Dallas, TX.", "Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI."], "corresponding_authors": ["Sean R Miller"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 21.75, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 5.75, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 2.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.3, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.75, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "41708991", "title": "Physical activity at baseline and risk of prostate cancer grade reclassification on active surveillance: results from a prospective cohort study.", "abstract": "For men with low-risk prostate cancer (PCa) on active surveillance (AS), there remain limited and conflicting data regarding whether physical activity may influence disease progression evidenced by grade reclassification (GR). Furthermore, it is unclear whether physical activity affects the risk independently of other lifestyle factors such as diet and smoking. This is a prospective cohort study of men diagnosed with Grade Group (GG) 1 PCa undergoing AS. Patients completed diet and physical activity questionnaires upon AS enrollment. Physical activity level was evaluated as metabolic equivalent of task hours per week (MET-h/wk), and diet quality as energy-adjusted Healthy Eating Index (E-HEI) score. Multivariable competing risk regressions were utilized to examine the association of baseline physical activity level with GR to ≥GG2 and to ≥GG3, adjusting for established clinicopathological risk factors, diet quality, and smoking history. We included 828 men with a median follow up of 6.4 years (quartiles: 4.0-9.1). In multivariable regression models adjusted for covariates, increased baseline physical activity levels (3 to <9 MET-h/wk versus <3: subdistribution hazard ratio [SHR] 0.18, 95% confidence interval [CI] 0.05-0.61; 9 to <18 MET-h/wk versus <3: SHR 0.26, 95% CI 0.10-0.68; ≥18 MET-h/wk versus <3: SHR 0.31, 95% CI 0.12-0.80) were associated with significantly decreased risks of GR to ≥GG3. Increased physical activity levels were associated with non-significant decreases in GR to ≥GG2. An increased E-HEI score was also significantly associated with decreased GR to ≥GG3, and non-significant reduction in GR to ≥GG2. Smoking history was not associated with either GR outcome. In a large prospective cohort with longitudinal follow-up of men pursuing AS for GG1 PCa, increased baseline physical activity levels, compared to a sedentary lifestyle defined as <3 MET-h/wk, was independently associated with a lower risk of progression to ≥GG3 disease.", "journal": "Prostate Cancer and Prostatic Diseases", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1007/s11357-025-01647-0", "authors": ["Michelle I Higgins", "Zhuo Tony Su", "Mufaddal Mamawala", "Yuezhou Jing", "Patricia K Landis", "Mark N Alshak", "Aurora J Grutman", "Carlos A Rivera Lopez", "Christian P Pavlovich", "Bruce J Trock"], "affiliations": ["The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA. mhiggi26@jhu.edu.", "The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA."], "corresponding_authors": ["Michelle I Higgins"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=7", "score": 31.81, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.81, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 7.0}, "journal_metrics": {"status": "ok", "impact_factor": 5.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.81, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "41686095", "title": "Utility of Next-Generation Sequencing in Renal Neoplasia, Including Tumors With Clear Cytoplasm and Rare Phenotypes (ELOC/MITF Alterations and Mismatch Repair Deficiency).", "abstract": "To define the clinical utility of next-generation sequencing (NGS) of renal tumors, including carbonic anhydrase 9-positive renal neoplasia with clear cell features (ccRCN) that include ELOC (for expansion of gene symbols, use search tool at www.genenames.org) and MTOR/TSC1/TSC2-mutated renal cell carcinoma (RCC) with fibromyomatous stroma (ELOC-RCCfms and M/TSC-RCCfms, respectively), as these tumors often have overlapping features. Renal tumors (n=234) diagnosed between August 1, 2021, and June 15, 2025, were submitted for genomic profiling using Clinical Laboratory Improvement Amendments-validated 515-gene (n=30), 30-gene (n=175), and smaller (<5 gene, n=29) next-generation sequencing panels. Available histologic and NGS data was reviewed to render a final integrated diagnosis and determine clinical utility. Next-generation sequencing was requested solely for diagnostic indications in most cases (209 of 234 [89%]), with 66% of cases (154 of 234) showing a clinically impactful genomic profile. The highest utility was among ccRCN and high-grade RCC/RCC, type not otherwise specified (NOS) in which only 8 of 79 (10%) and 17 of 57 (30%) remained unclassifiable, respectively. Some rare phenotypes included variants associated with hereditary disease, uncommon presentations, multiple driver alterations, mismatch repair deficiency (n=3), and rare MITF p.E318K alterations (n=3). The cohort of ccRCN included 12 ELOC-RCCfms (p.Y79C/S: 9 of 12; p.A100E, 2 of 12; p.L104Q: 1 of 12). GPNMB was expressed in M/TSC-RCCfms (10 of 10, 100%) and lacked appreciable expression in most ccRCN tested (n=25), including ELOC-RCCfms. Next-generation sequencing-based molecular profiling had clinical utility in two-thirds of patients, and the greatest benefit was within the broad category of ccRCN. Our results suggest that GPNMB expression was helpful in separating ELOC-RCCfms from M/TSC-RCCfms. Other benefits of NGS include subtyping high-grade RCC/RCC type not otherwise specified and identification of rare phenotypes.", "journal": "Mayo Clinic Proceedings", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1016/j.mayocp.2025.11.003", "authors": ["Michael McCarthy", "Antonina A Wojcik", "Emily G Barr Fritcher", "Burak Tekin", "Wei Shen", "Hussam Al-Kateb", "Surendra Dasari", "Peter C Lucas", "Kingsley Ebare", "Jordan P Reynolds", "Melissa L Stanton", "Aditya Raghunathan", "Rumeal D Whaley", "Lori A Erickson", "Loren Herrera Hernandez", "Rafael E Jimenez", "Brian A Costello", "Aaron Potretzke", "Stephen A Boorjian", "Vidit Sharma", "Bradley C Leibovich", "John C Cheville", "Benjamin R Kipp", "Sounak Gupta"], "affiliations": ["Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.", "Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN.", "Department of Laboratory Medicine and Pathology, Mayo Clinic, Phoenix, AZ.", "Department of Laboratory Medicine and Pathology, Mayo Clinic, Jacksonville, FL.", "Department of Medical Oncology, Mayo Clinic, Rochester, MN.", "Department of Urology, Mayo Clinic, Rochester, MN.", "Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN. Electronic address: gupta.sounak@mayo.edu."], "corresponding_authors": ["Sounak Gupta"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=4", "score": 20.99, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 10.99, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 4.0}, "journal_metrics": {"status": "ok", "impact_factor": 6.7, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.99, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "41680329", "title": "Disease progression patterns and association of prostate-specific antigen level with risk of progression in nonmetastatic castration-resistant prostate cancer.", "abstract": "In ARAMIS, darolutamide statistically significantly prolonged metastasis-free survival by 2 years and reduced the risk of death by 31% in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC). We report post hoc analyses of ARAMIS evaluating patterns of disease progression overall and by prostate-specific antigen (PSA) response. Patients were randomized 2:1 to darolutamide (n = 955) or placebo (n = 554), with androgen-deprivation therapy (ADT). Progression included metastases on conventional imaging, PSA progression based on Prostate Cancer Working Group 2 criteria or any rise in PSA, and pain progression. Radiological progression was compared between patients who reached undetectable PSA < 0.2 ng/ml at any time and those who did not. Metastatic progression occurred in 14% of patients receiving darolutamide versus 29% of patients receiving placebo, with a consistent pattern mostly isolated to bone (46%; 39%) or lymph nodes (32%; 40%). At 12 months, fewer patients receiving darolutamide versus placebo had PSA progression alone (7.8% vs. 35.9%) or both PSA and radiological progression (5.4% vs. 21.4%). Radiological progression without PSA progression occurred in 35% of metastatic events in the darolutamide group and 23% of metastatic events in the placebo group. Darolutamide led to deep PSA response (< 0.2 ng/ml) versus placebo (25.1% vs. 0.5%), and patients receiving darolutamide who reached PSA < 0.2 ng/ml experienced less radiological progression than those who did not (24 months: 8.7% vs. 33%; 36 months: 8.7% vs. 50%). Darolutamide plus ADT reduced the risk of metastatic progression and improved overall survival versus placebo plus ADT without changing patterns of disease progression through Month 24. Metastasis occurred without PSA progression in approximately 30% of metastatic events overall. Undetectable PSA with darolutamide was associated with reduced radiological progression that was maintained over time. These results highlight the importance of both imaging and PSA monitoring to identify disease progression in patients with nmCRPC.", "journal": "Prostate Cancer and Prostatic Diseases", "pub_date": "2026-Oct", "publication_types": ["Journal Article", "Randomized Controlled Trial"], "doi": "10.1016/j.brachy.2019.08.008", "authors": ["Alicia K Morgans", "Christopher J D Wallis", "Susan Halabi", "Andrew J Armstrong", "Patrick Adorjan", "Mercedeh Ghadessi", "Frank Verholen", "Marc-Oliver Grimm"], "affiliations": ["Dana-Farber Cancer Institute, Boston, MA, USA. aliciak_morgans@dfci.harvard.edu.", "Division of Urology, Department of Surgery, University of Toronto, Toronto, ON, Canada.", "Mount Sinai Hospital, Toronto, ON, Canada.", "University Health Network, Toronto, ON, Canada.", "Duke University Division of Biostatistics, Durham, NC, USA.", "Duke Cancer Institute, Center for Prostate and Urologic Cancers, Duke University Department of Medicine, Division of Medical Oncology, Durham, NC, USA.", "Bayer Consumer Care AG, Basel, Switzerland.", "Bayer HealthCare, Whippany, NJ, USA.", "Department of Urology, University Hospital of Jena, Jena, Germany."], "corresponding_authors": ["Alicia K Morgans"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_interventional_trial", "score": 31.81, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.81, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 7.0}, "journal_metrics": {"status": "ok", "impact_factor": 5.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.81, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "41634333", "title": "Comparative diagnostic accuracy of multiparametric-MRI and Micro-ultrasound for clinically significant prostate cancer-a bivariate meta-analysis of prospective studies.", "abstract": "Prostate cancer (PCa) remains a leading cause of cancer-related mortality in men. While multiparametric MRI (mpMRI) is an established tool for detecting clinically significant PCa (csPCa), it is limited by cost, access, and acquisition time. Micro-ultrasound (Micro-US) offers real-time imaging with potential advantages in accessibility and integration into routine care. This systematic review and meta-analysis (SR/MA) aimed to compare the diagnostic accuracy of Micro-US versus mpMRI in detecting csPCa, based exclusively on prospective evidence. A protocol-registered SR/MA (INPLASY202540027) was conducted following PRISMA and PICOTT frameworks. Prospective cohort studies and randomized controlled trials published between 2012 and March 2025 comparing micro-US and mpMRI for csPCa detection, using biopsy or prostatectomy specimens as reference standards, were included. Bivariate random-effects models were used to estimate pooled sensitivity, specificity, and summary ROC curves. Positive/negative predictive values (PPV/NPV) were calculated using pooled prevalence and literature-based prevalence values. Meta-regression assessed modality differences and potential effect modifiers. Eight prospective studies (n = 2626 patients) met the inclusion criteria, 1 randomized controlled trial and 7 prospective cohorts. Micro-US demonstrated a pooled sensitivity of 0.87 (95%CI: 0.80-0.92) and specificity of 0.25 (95% CI: 0.17-0.36), while mpMRI showed a sensitivity of 0.88 (95% CI: 0.81-0.93) and specificity of 0.30 (95% CI: 0.18-0.46). sROC confidence regions overlapped for both modalities. Meta-regression detected no significant difference in sensitivity (P = 0.72) but a significant difference in specificity favoring mpMRI (P = 0.003). PPVs were modest (0.41-0.46), and NPVs were high (0.72-0.80) across prevalence scenarios. Micro-US demonstrates sensitivity comparable to mpMRI for csPCa screening before confirmatory biopsy, although mpMRI retains superior specificity. Micro-US may serve as an accessible alternative or complementary modality, but further high-quality prospective studies are needed to strengthen comparative evidence.", "journal": "Prostate Cancer and Prostatic Diseases", "pub_date": "2026-Oct", "publication_types": ["Comparative Study", "Journal Article", "Meta-Analysis", "Systematic Review"], "doi": "10.1038/s41391-026-01079-7", "authors": ["Carlos A Garcia-Becerra", "Maria I Arias-Gallardo", "Jesus E Juarez-Garcia", "Veronica Soltero-Molinar", "Adel J El Rassi", "Mariabelen I Rivera-Rocha", "Luis F Parra-Camaño", "Martha Ruiz", "Natalia Garcia-Becerra", "Maurício D Cordeiro", "Carlos M García-Gutiérrez"], "affiliations": ["Research Department, Urovallarta Medical Center, Puerto Vallarta, Mexico. agbcarlos94@gmail.com.", "Research Department, Urovallarta Medical Center, Puerto Vallarta, Mexico.", "Basic Science Institute, School of Medicine, Universidad Autónoma de Guadalajara, Guadalajara, México.", "Urology Department, Universidade Federal de Uberlândia, Uberlândia, Brazil.", "Radiology Department, Grupo Diagnosti-k, Guadalajara, Mexico.", "Urology Department, Instituto do Câncer do Estado de São Paulo - ICESP/, São Paulo, Brazil."], "corresponding_authors": ["Carlos A Garcia-Becerra"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 36.81, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.81, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 12.0}, "journal_metrics": {"status": "ok", "impact_factor": 5.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.81, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "41629638", "title": "Fecal incontinence after prostate cancer irradiation: a systematic literature review.", "abstract": "Fecal incontinence (FI) is an underrecognized but clinically significant late gastrointestinal toxicity following radiotherapy (RT) for prostate cancer. This systematic review aimed to synthesize current knowledge on the definition and pathophysiology of post-radiation anal continence, as well as prevention strategies, technical considerations, and therapeutic approaches. A systematic literature search was conducted according to PRISMA guidelines using the keywords: \"Fecal incontinence,\" \"Radiation therapy,\" and \"Prostatic neoplasms.\" Eligible studies included randomized phase III trials and prospective or retrospective series reporting on FI after definitive or adjuvant/salvage prostate RT. Fifty-four articles were included in the final analysis. FI after prostate RT results from functional, morphological, and neurogenic alterations of the anorectal system. Reported incidence ranges from 1 to 12%, most often presenting as flatulence or liquid stool leakage, while severe forms requiring pads are uncommon. Variability is largely explained by heterogeneity in definitions and assessment tools, as no standardized scoring system is universally applied. Risk factors include advanced age, prior abdominal surgery, vascular comorbidities, chronic inflammatory bowel disease, hemorrhoids, and rectal urgency during RT. Dosimetric analyses indicate that low-to-intermediate doses to the anal canal and high doses to the rectum contribute differentially to FI. Based on current evidence, the mean dose to the anal canal should be kept below 37 Gy, though further studies are needed to define precise constraints for both structures. Preventive strategies such as MRI-based contouring and endorectal balloon placement, perirectal hydrogel spacers placement show promise. Management is multidisciplinary, including dietary measures, medications, pelvic floor therapy, neuromodulation, and, in severe cases, diversion procedures. FI after prostate RT is likely underestimated due to the absence of a standardized assessment. Developing a validated, universally applicable scoring system is a priority to improve evaluation, enable cross-study comparisons, refine preventive measures, and guide therapeutic strategies.", "journal": "Prostate Cancer and Prostatic Diseases", "pub_date": "2026-Oct", "publication_types": ["Journal Article", "Systematic Review"], "doi": "10.1038/s41391-026-01078-8", "authors": ["Daniel Benizri", "Emilie Duchalais-Dassonneville", "Mathieu Gautier", "Jean-Michel Hannoun-Levi"], "affiliations": ["Department of Radiation Oncology, Antoine Lacassagne Cancer Centre, University of Côte d'Azur, Nice, France.", "Department of Digestive Surgery, Nantes Academic Hospital, Nantes, France.", "Department of Radiation Oncology, Antoine Lacassagne Cancer Centre, University of Côte d'Azur, Nice, France. jean-michel.hannoun-levi@nice.unicancer.fr."], "corresponding_authors": ["Jean-Michel Hannoun-Levi"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 44.81, "score_parts": {"urology_relevance": 12, "urology_in_title": 8.0, "journal_priority": 10.81, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 12.0}, "journal_metrics": {"status": "ok", "impact_factor": 5.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.81, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "41593221", "title": "Efficacy of the new P100 extracorporeal shock wave therapy device in the treatment of type IIIB chronic prostatitis/chronic pelvic pain syndrome: a sham treatment controlled, prospective clinical trial.", "abstract": "To evaluate the therapeutic efficacy and clinical applicability of the novel P100 extracorporeal shock wave therapy (ESWT) device in the treatment of type IIIB chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). In this randomized, single-blind, sham-controlled trial, 83 patients with type IIIB CP/CPPS were enrolled and randomly assigned to either the P100 treatment group (n = 51) or the control group (n = 32). Patients in the treatment group received four weekly low-intensity ESWT sessions (0.2 mJ/mm²), while the control group received identical procedures with shock transmission blocked. The primary endpoint was the clinical response rate (≥6-point reduction in NIH-CPSI score) at week 4; week 8 outcomes were further analyzed to assess sustained efficacy. Secondary endpoints included IPSS, IIEF-5, and VAS scores. At week 4, the clinical response rate was 78.4% in the P100 group compared with 25% in the control group (P < 0.001). Median NIH-CPSI scores decreased from 35 at baseline to 13 at week 4 and 12 at week 8, indicating sustained improvement. Significant reductions in PDS, IPSS, and VAS scores were observed as early as week 2 (P < 0.05), and symptom relief remained stable through week 8 without rebound. Exploratory analyses suggest that lower baseline estradiol levels and lower E2/T ratios may be associated with more sustained improvements in erectile function. No treatment-related adverse events were reported. The P100 ESWT device provided rapid, significant, and sustained symptom relief for type IIIB CP/CPPS, particularly in pain and urinary domains. Hormonal balance (E2/T) may influence the long-term maintenance of erectile function after ESWT. These findings support P100 as a safe and effective non-invasive therapeutic option for CP/CPPS, warranting further validation in larger studies with longer-term follow-up.", "journal": "Prostate Cancer and Prostatic Diseases", "pub_date": "2026-Oct", "publication_types": ["Journal Article", "Randomized Controlled Trial"], "doi": "10.1038/s41391-026-01072-0", "authors": ["Haipeng Zhang", "Wei Song", "Jinliang Ni", "Houliang Zhang", "Ziming Jiang", "Guangcan Yang", "Yifan Zhang", "Keyi Wang", "Yifan Chen", "Bo Peng"], "affiliations": ["Department of Urology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China.", "Department of Urology, Affiliated Zhongda Hospital of Southeast University, Nanjing, China.", "Department of Urology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China. wangkeyi0910@163.com.", "Department of Urology, Zhongshan Hospital, Shanghai, China. wangkeyi0910@163.com.", "Department of Urology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China. chenyifan555@yeah.net.", "Department of Urology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China. pengbo6908@tongji.edu.cn."], "corresponding_authors": ["Keyi Wang", "Yifan Chen", "Bo Peng"], "china_team": "Department of Urology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China Keyi Wang/Yifan Chen/Bo Peng团队", "category": "clinical_review", "classification_reason": "publication_type_interventional_trial", "score": 32.31, "score_parts": {"urology_relevance": 6, "urology_in_title": 0.0, "journal_priority": 10.81, "top_journal_bonus": 0.0, "novelty": 1.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 12.0}, "journal_metrics": {"status": "ok", "impact_factor": 5.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.81, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "41588191", "title": "The value of micro-ultrasound for prostate cancer screening: A retrospective real-world feasibility study.", "abstract": "Prostate cancer (PCa) screening is increasingly guided by imaging. High-resolution 29 MHz Micro-Ultrasound (MUS) offers a promising alternative to magnetic resonance imaging (MRI). We retrospectively analyzed 682 consecutive men undergoing MUS and PSA testing during routine examination. Biopsy and MRI were performed according to guideline recommendations. PSA density (PSAD)-modified negative MUS included PRI-MUS categories 1, 2, or 3 with PSAD < 0.15 ng/mL2; PSAD-modified positive MUS included PRI-MUS categories 3 with PSAD ≥ 0.15 ng/mL2, 4 or 5. Median age was 59 years; median PSA 1.2 ng/mL (IQR: 0.6-3.5). Biopsies were performed in 62 men, detecting PCa in 29 (47%), including 18 (29%) clinically significant PCa (csPCa). 88 men (13%) had PSAD-modified positive MUS, yielding 15 csPCa and 7 non-clinically significant PCa (ncsPCa). Among 594 men (87%) with PSAD-modified negative MUS, 3 csPCa and 4 ncsPCa were detected. Compared to PSA-based biopsy indication ≥3 ng/mL, PSAD-modified negative MUS would have avoided 13 negative, missing two csPCa and four ncsPCa. Compared to the MRI-based biopsy indication (PI-RADS ≥ 3, n = 38), PSAD-modified negative MUS (n = 594) would have spared 3 negative biopsies, as well as 17 (24.7% of 69) MRIs due to negative biopsy, while missing 0 cases of csPCa. Additionally, MRI could have been omitted in 1csPCa case and 9 ncsPCa cases with positive MUS, and in 13 csPCa and 7 ncsPCa cases based on PSAD-modified positive MUS. The PSAD-modified-PRI-MUS-based screening pathway showed a 6.29-fold (OR = 0.16) reduction in overdiagnosis and 7.22-fold (OR = 0.14) reduction in negative biopsies/ncsPCa. MUS without PSA demonstrated an OR of 7.30 to detect csPCa. PSAD-modified-PRI-MUS score demonstrated a sensitivity of 83.3%, a specificity of 59.1%, a positive predictive value of 45.5% and a negative predictive value of 89.7% for distinguishing csPCa from benign/ncsPCa findings. MUS enables effective PCa risk stratification in an opportunistic screening setting supporting prospective trial development. This study is part of the PROSTAMUS trial, registered in the DRKS/WHO registry.", "journal": "Prostate Cancer and Prostatic Diseases", "pub_date": "2026-Oct", "publication_types": ["Journal Article"], "doi": "10.1002/ijc.33940", "authors": ["Johann Jakob Wendler", "Jonas Bechstein", "John Buckendahl", "Stephan Kruck", "Christian Samtleben", "Bernd Uwe Liehr", "Markus Porsch", "Hannes Cash"], "affiliations": ["Clinic of Urology, Urooncology and Robotic and Focal Therapy, Medical Faculty of University Magdeburg and University Hospital Magdeburg A. ö. R. (University Medicine Magdeburg, UMM), Magdeburg, Germany.", "Urologicum Magdeburg, Magdeburg, Germany.", "PROURO Berlin, Berlin, Germany.", "Department of Urology, Siloah St. Trudpert Clinic, Pforzheim, Germany.", "Clinic of Urology, Urooncology and Robotic and Focal Therapy, Medical Faculty of University Magdeburg and University Hospital Magdeburg A. ö. R. (University Medicine Magdeburg, UMM), Magdeburg, Germany. hannes.cash@prouro.de.", "PROURO Berlin, Berlin, Germany. hannes.cash@prouro.de."], "corresponding_authors": ["Hannes Cash"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=4", "score": 28.81, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.81, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 4.0}, "journal_metrics": {"status": "ok", "impact_factor": 5.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.81, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "41582208", "title": "Risk of bone fractures in patients with prostate cancer treated with maximal androgen blockade therapy: a systematic literature review and meta-analysis.", "abstract": "Addition of an androgen receptor pathway inhibitor (ARPI) to androgen deprivation therapy (ADT) (ADT + ARPI, i.e., maximal androgen blockade, MAB) improves survival outcomes compared to ADT monotherapy in patients with prostate cancer (PC). It is known that ADT increases the risk of fractures in patients with PC, but it is unclear if this risk is higher with MAB. The aim of this study is to conduct a systematic review and meta-analysis to determine if MAB increases the incidence of fractures compared to ADT alone, and if the incidence of fractures was influenced by the type of ARPI. Clinical trials assessing MAB versus ADT alone in patients with PC were identified using the PubMed/Medline and Cochrane library databases. The pooled odds ratio of developing fractures with MAB versus ADT alone was calculated for each type of ARPI in selected studies by random-effects modeling. The number of patients receiving bone-protecting agent (BPA) was also evaluated. We identified 17 studies comprising 16162 patients for the systematic review and meta-analysis (9240 patients treated with MAB, 6922 patients treated with ADT alone). Each type of ADT + ARPI resulted in a statistically significant increased risk of fractures compared to ADT alone (pooled OR ranging from 1.5 to 2.4). There was no difference in the magnitude of the risk of fractures among the different ARPIs. Only 7 studies reported the number of patients treated with a BPA. In our meta-analysis, MAB resulted in a statistically significant increase in fracture risk compared to ADT alone, regardless of the type of ARPI. Since long-term MAB represents the standard of care in various settings of PC, the use of a BPA should be generally recommended. Dosing and frequency of BPA need to be adapted according to the specific PC setting.", "journal": "Prostate Cancer and Prostatic Diseases", "pub_date": "2026-Oct", "publication_types": ["Journal Article", "Meta-Analysis", "Systematic Review"], "doi": "10.1038/s41391-026-01077-9", "authors": ["Isabella Saporita", "Mariangela Calabrese", "Federica Maria Carfi", "Andrea Mogavero", "Marialuisa Puglisi", "Giorgio Treglia", "Ursula Maria Vogl", "Silke Gillessen", "Ricardo Pereira Mestre", "Martino Pedrani", "Giovanna Pecoraro", "Giuseppe Salfi", "Caroline-Claudia Erhart", "Hui-Ming Lin", "Luigi Tortola", "Massimo Di Maio", "Marcello Tucci", "Consuelo Buttigliero", "Fabio Turco"], "affiliations": ["Department of Oncology, University of Turin, at Division of Medical Oncology, San Luigi Gonzaga Hospital, Turin, Italy.", "Department of Human Pathology \"G. Barresi\", School of Specialization in Medical Oncology, University of Messina, Messina, Italy.", "Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.", "Faculty of Biomedical Sciences, Università della Svizzera Italiana, Lugano, Switzerland.", "Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale (EOC), Bellinzona, Switzerland.", "Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland.", "Institute of Oncology Research (IOR), Bellinzona, Switzerland.", "Oncology Department, University of Naples \"Federico II\", Naples, Italy.", "Department of Oncology, Medical Oncology 1U, AOU Città della Salute e della Scienza, University of Turin, Turin, Italy.", "Department of Medical Oncology, Cardinal Massaia Hospital, Asti, Italy.", "Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland. fabio.turco@eoc.ch."], "corresponding_authors": ["Fabio Turco"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 31.81, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.81, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 7.0}, "journal_metrics": {"status": "ok", "impact_factor": 5.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.81, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "40211953", "title": "Associations of Patient Age, Tumor Nephrectomy Weight, and Tumor Diameter With Event-free and Overall Survival in Stage I or II Favorable Histology Wilms Tumor: A Pooled Analysis of Children's Oncology Group Studies AREN0532 and AREN03B2.", "abstract": "To evaluate age, tumor nephrectomy weight (TNW), or tumor diameter (TD) as continuous prognostic variables for outcomes in early-stage favorable histology Wilms tumor (FHWT) after accounting for biology and treatment. Patient age (<2 vs ≥2 years) and TNW (<550 g vs ≥550 g) have been used to risk-stratify children with stage I FHWT on Children's Oncology Group (COG) studies and select patients for omission of chemotherapy. Included patients had stage I or II FHWT per central review and were treated with nephrectomy only, EE4A, or DD4A on COG trials. Restricted cubic splines models were used to estimate the stage-specific effects of age, TNW, and TD on event-free survival (EFS) and overall survival (OS), accounting for treatment and biology. In pooled analyses of 775 stage I and 936 stage II patients, age was not significantly associated with EFS or OS for stage I or II patients after accounting for adverse biology that is more prevalent with older age. Greater TNW and larger TD were associated with increased risk of relapse in stage I and increased risk of death in stage II, but not when restricted to patients <4 years old. Age, TNW, and TD are each prognostic for EFS or OS in some cohorts of patients with stage I or II FHWT. However, after accounting for adverse biology that becomes more prevalent at older ages, these factors are no longer independently prognostic. The next COG FHWT study will implement and validate these findings.", "journal": "Annals of Surgery", "pub_date": "2026-Oct-01", "publication_types": ["Journal Article", "Research Support, N.I.H., Extramural"], "doi": "10.1097/SLA.0000000000006726", "authors": ["Lindsay A Renfro", "Kelly L Vallance", "Ian C Tfirn", "Nicholas Evageliou", "Daniel J Benedetti", "Robert C Shamberger", "Peter F Ehrlich", "Nicholas G Cost", "Jennifer H Aldrink", "Ann Schechter", "Amy Treece", "Lauren N Parsons", "Amy L Walz", "Kathryn S Sutton", "Amy E Armstrong", "Conrad V Fernandez", "Jeffrey S Dome", "James I Geller", "Elizabeth A Mullen", "AREN03B2 Authorship Group"], "affiliations": ["Division of Biostatistics, University of Southern California and Children's Oncology Group, Los Angeles, CA.", "Hematology and Oncology, Cook Children's Medical Center, Fort Worth, TX.", "Children's Oncology Group Statistics and Data Center, Monrovia, CA.", "Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA.", "Department of Pediatrics, Division of Pediatric Hematology/Oncology, Vanderbilt University Medical Center, Nashville, TN.", "Department of Surgery, Dana-Farber Cancer Institute/Boston Children's Hospital, Boston, MA.", "Department of Surgery, University of Michigan School of Medicine, Ann Arbor, MI.", "Department of Surgery, Division of Urology at the University of Colorado School of Medicine and the Surgical Oncology Program at Children's Hospital Colorado, Aurora, CO.", "Department of Surgery, Division of Pediatric Surgery, Nationwide Children's Hospital, The Ohio State University College of Medicine, Columbus, OH.", "Department of Pediatric Radiology, Morgan Stanley Children's Hospital, Columbia University, New York, NY.", "Department of Pathology and Laboratory Medicine, Children's of Alabama, Birmingham, AL.", "Department of Pathology, Division of Pediatric Pathology, Medical College of Wisconsin/Children's Wisconsin, Milwaukee, WI.", "Division of Hematology, Oncology, Neuro-Oncology, and Stem Cell Transplant, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL.", "Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta and Department of Pediatrics, Emory University School of Medicine, Atlanta, GA.", "Division of Pediatric Hematology/Oncology, Washington University School of Medicine, St. Louis, MO.", "Department of Pediatrics, Division of Pediatric Hematology/Oncology, IWK Health Centre, Dalhousie University, Halifax, NS, Canada.", "Division of Oncology and the Department of Pediatrics, Children's National Hospital and the George Washington University School of Medicine and Health Sciences, Washington, DC.", "Division of Oncology, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, OH.", "Department of Pediatric Hematology/Oncology, Dana-Farber Cancer Institute/Boston Children's Hospital, Boston, MA."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=6", "score": 34.94, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 14.94, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 6.0}, "journal_metrics": {"status": "ok", "impact_factor": 6.4, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 2.94, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42866863", "title": "Nerve-sparing radical cystectomy in the era of perioperative enfortumab vedotin plus pembrolizumab: reappraising the value of functional preservation.", "abstract": "", "journal": "Translational Andrology and Urology", "pub_date": "2026-Sep-30", "publication_types": ["Editorial", "Comment"], "doi": "10.1016/j.pathol.2025.03.005", "authors": ["Shugo Yajima", "Hitoshi Masuda"], "affiliations": ["Department of Urology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 11.46, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 2.46, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 1.7, "cas_zone": 4, "cas_zone_points": 1.0, "impact_factor_points": 1.46, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42866862", "title": "Low-intensity extracorporeal shockwave therapy for chronic prostatitis/chronic pelvic pain syndrome: a retrospective single-center observational study in Japan.", "abstract": "Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is a heterogeneous condition that can remain symptomatic despite conventional therapy. Low-intensity extracorporeal shock wave therapy (Li-ESWT) has shown symptomatic benefits in previous clinical studies; however, real-world evidence from Japanese clinical practice remains limited. This study aimed to evaluate the effectiveness and safety of a standardized four-session Li-ESWT protocol in patients with treatment-refractory CP/CPPS at a Japanese outpatient urology clinic. This retrospective, single-center observational study included 19 consecutive patients with CP/CPPS who underwent Li-ESWT between July 2023 and June 2025. Treatment was administered once weekly for four weeks using 3,000 pulses per session at an energy flux density of 0.25-0.35 mJ/mm2 and a frequency of 8.0 Hz. The primary outcome was the change in the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) total score from baseline to immediately after completion of treatment. Secondary outcomes included changes in pain, urinary, and quality-of-life (QoL) domain scores. All 19 patients completed treatment. The mean NIH-CPSI total score decreased from 25.9±5.4 at baseline to 21.6±7.5 after treatment (mean change, -4.32±4.27; P<0.001). Six patients (31.6%) achieved a clinically meaningful improvement of at least 6 points, while 16 (84.2%) showed some overall symptom improvement. Significant improvements were observed in the pain domain (11.5±3.2 to 9.2±3.5, P<0.01) and QoL domain (10.1±1.4 to 8.5±2.7, P<0.01), whereas the urinary domain did not significantly improve (4.3±3.2 to 3.9±3.6, P=0.31). No serious adverse events were observed. In this small retrospective Japanese cohort with persistent symptoms despite conservative treatment, a standardized four-session Li-ESWT protocol was associated with improvement in overall NIH-CPSI scores, particularly in pain and QoL, and was well tolerated. Larger prospective controlled studies with longer follow-up are needed to confirm these findings.", "journal": "Translational Andrology and Urology", "pub_date": "2026-Sep-30", "publication_types": ["Journal Article"], "doi": "10.1515/med-2023-0832", "authors": ["Takashi Hirayama", "Yudai Matsuoka", "Masashi Oae"], "affiliations": ["Osaka Umeda Shinshi Clinic, Osaka, Japan."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=10", "score": 21.46, "score_parts": {"urology_relevance": 7, "urology_in_title": 0.0, "journal_priority": 2.46, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 10.0}, "journal_metrics": {"status": "ok", "impact_factor": 1.7, "cas_zone": 4, "cas_zone_points": 1.0, "impact_factor_points": 1.46, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42866861", "title": "Low-intensity pulsed ultrasound for erectile dysfunction: a systematic review and limited quantitative synthesis.", "abstract": "Low-intensity pulsed ultrasound (LIPUS) is a non-invasive therapy for erectile dysfunction (ED), but evidence is geographically concentrated, heterogeneous, and largely patient-reported. Because LIPUS differs biophysically from low-intensity extracorporeal shockwave therapy (Li-ESWT), this review evaluated short-term efficacy, safety, and protocol evidence without cross-modality pooling. Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 principles, we searched PubMed/MEDLINE, Embase, Web of Science, Cochrane Library, Scopus, ClinicalTrials.gov, the World Health Organization International Clinical Trials Registry Platform (WHO ICTRP), China National Knowledge Infrastructure (CNKI), Wanfang Data, the VIP Journal Integration Platform (VIP), the Chinese Biomedical Literature Database (SinoMed), and references through 8 June 2026. Clinical studies of adult men with ED receiving LIPUS were eligible; Li-ESWT-only and non-human studies were excluded. This systematic review was re-registered in OSF Registries on 2 September 2026 (updated ID: 7b9ed; https://osf.io/7b9ed/) after the original record (former ID: 7s9kF) became inaccessible due to technical link failure, with no core protocol modifications. Literature search was completed on 8 June 2026 before data synthesis; no eligibility criteria, outcomes, or effect estimates were altered post-extraction. Two reviewers screened, extracted data, assessed risk of bias with design-appropriate tools, and rated certainty using Grading of Recommendations Assessment, Development and Evaluation (GRADE). Six Chinese studies involving 659 participants were included. One double-blind sham-controlled randomized trial provided the main efficacy evidence. At 12 weeks, LIPUS improved the five-item International Index of Erectile Function (IIEF-5) score versus sham (mean difference =3.38, 95% confidence interval: 2.60-4.16) and increased clinically meaningful response (risk ratio =3.38, 95% confidence interval: 1.78-6.39; 67.5% vs. 20.0%); certainty was low. Two randomized studies compared three versus two weekly sessions with a fixed total number; Chen et al. [2022] met source-defined non-inferiority margins, but did not establish equivalence, superiority, optimal dosing, or cross-device generalizability. Combination/adjuvant evidence was heterogeneous and narratively synthesized. Complete penile Doppler data were available in only six participants. No serious device-related adverse event or discontinuation was reported; follow-up was no longer than 12 weeks. Based on current low-certainty evidence, LIPUS remains investigational and cannot be recommended for routine clinical use in ED at this time. International multicenter sham-controlled trials with standardized acoustic reporting, objective hemodynamic endpoints, transparent adverse-event assessment, and 3-, 6-, and 12-month follow-up are needed.", "journal": "Translational Andrology and Urology", "pub_date": "2026-Sep-30", "publication_types": ["Journal Article"], "doi": "10.5534/wjmh.200007", "authors": ["Yu Zhang", "Zhi-Shen Li", "Yu-Yun Wu", "Wen-Bao Wang", "Xia Cao", "Yan He", "Chao-Hua Deng"], "affiliations": ["Second Department of Urology, The Fourth Affiliated Hospital of Dali University, Chuxiong, China.", "Third Ward of Urology, The Second Affiliated Hospital of Kunming Medical University, Kunming, China.", "Clinical Medical College, Dali University, Dali, China.", "Department of Ultrasound, The Fourth Affiliated Hospital of Dali University, Chuxiong, China."], "corresponding_authors": [], "china_team": "Second Department of Urology, The Fourth Affiliated Hospital of Dali University, Chuxiong, China Chao-Hua Deng团队", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 30.46, "score_parts": {"urology_relevance": 6, "urology_in_title": 8.0, "journal_priority": 2.46, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 12.0}, "journal_metrics": {"status": "ok", "impact_factor": 1.7, "cas_zone": 4, "cas_zone_points": 1.0, "impact_factor_points": 1.46, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42866860", "title": "A narrative review of the state of urinary diversion: ileal conduit, neobladder, continent cutaneous, and cutaneous ureterostomy.", "abstract": "Several urinary diversion (UD) options are available after radical cystectomy (RC); however, there is a paucity of comparative evidence to guide patient counseling and shared decision-making. Level I evidence is limited in this domain and controversy exists regarding key clinical points like how patient age, comorbidities, renal function, tumor characteristics, functional expectations, surgeon experience, quality-of-life priorities, and long-term complication profiles should influence UD choice. The purpose of this narrative review is to provide surgical information and clinical points on ileal conduits (ICs), neobladders, continent cutaneous diversions, and cutaneous ureterostomies (CUs). A primary literature review was performed through 03/01/2026 followed by a second final review through 07/26/2026 on the aforementioned UDs using a multitude of keywords. Articles were indexed in PubMed, PubMed Central, Google Scholar, Directory of Open Access Journals, and Cochrane Library. Societal guidelines on bladder cancer were also reviewed and incorporated into the review. All articles were in the English language. Additionally, surgical textbooks were reviewed for key surgical steps. Search terms were predefined and refined to capture studies addressing surgical technique, patient selection, complications, and clinical implications. ICs are the most frequently utilized in contemporary practice. They are useful for their broad patient eligibility and minimal upkeep for patients. Complications like ileus, stricture, leak, and metabolic derangements are common. The neobladder allows patients the ability to retain urinary continence, but rates are not defined enough in the literature. Continent cutaneous diversions are not as frequently used after RC, and there are a broad range of choices at the disposal of the surgeon. These are often considered the most technically difficult to create, and there is a window for prospective research on the UDs given the paucity of data currently in the literature. CUs have minimal restrictions on eligibility and avoid bowel work and are a useful option for frail and elderly patients. UD selection should be a combination of surgeon ability, patient comorbidities, and patient preference through shared decision making.", "journal": "Translational Andrology and Urology", "pub_date": "2026-Sep-30", "publication_types": ["Journal Article", "Review"], "doi": "10.1016/j.urolonc.2020.05.003", "authors": ["Maxwell Louis Sandberg", "David Thole", "Randall Bissette", "Beamlak Worku", "Ethan Weitzman", "Kimberly Waggener", "Ashok Hemal"], "affiliations": ["Wake Forest University School of Medicine, Winston-Salem, NC, USA."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 31.46, "score_parts": {"urology_relevance": 15, "urology_in_title": 8.0, "journal_priority": 2.46, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 4.0}, "journal_metrics": {"status": "ok", "impact_factor": 1.7, "cas_zone": 4, "cas_zone_points": 1.0, "impact_factor_points": 1.46, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42866857", "title": "DUSP13 promotes prostate cancer progression by regulating the ERK1/2 pathway.", "abstract": "Prostate cancer (PCa) remains a leading cause of cancer-related morbidity and mortality in men, and patients who progress to castration-resistant prostate cancer (CRPC) derive only limited benefit from currently available treatments; novel therapeutic targets are therefore urgently needed. Dual specificity phosphatase 13 (DUSP13) belongs to the DUSP family, whose members dephosphorylate mitogen-activated protein kinases (MAPKs) and display either tumor-suppressive or tumor-promoting activity in a context-dependent manner. Emerging evidence implicates DUSP13 in several malignancies, but its expression and function in PCa, and whether it acts through the ERK1/2 pathway, remain unknown. This study aimed to elucidate the function of DUSP13 in PCa. DUSP13 expression in the normal prostate epithelial-derived cell line RWPE-1 and in the PCa cell lines PC-3, DU145 and LNCaP was examined by Western blot and quantitative reverse transcription polymerase chain reaction (qRT-PCR). DUSP13 was silenced in PC-3 and DU145 cells using lentiviral short hairpin RNAs (shRNAs); a second, independent shRNA targeting a distinct site was used to exclude off-target effects. Cell proliferation, migration, invasion and apoptosis were assessed by cell counting kit-8 (CCK-8), wound-healing (scratch), transwell and flow cytometry assays, respectively. Tumor growth was evaluated in a PC-3 subcutaneous xenograft model in BALB/c nude mice. Proteins of the ERK1/2 pathway were detected by Western blot, and the MAPK/ERK kinase (MEK) inhibitor PD98059 was used in rescue experiments. DUSP13 protein and mRNA levels were higher in PCa cells than in RWPE-1 cells. DUSP13 knockdown suppressed proliferation, migration and invasion, promoted apoptosis, and attenuated xenograft tumor growth in vivo. Mechanistically, DUSP13 knockdown increased p-ERK1/2 levels, whereas PD98059 alone did not significantly alter proliferation, invasion or apoptosis and partially reversed the anti-tumor phenotypes induced by DUSP13 knockdown. All key findings were reproduced with a second independent shRNA. DUSP13 promotes PCa progression by inhibiting ERK1/2 phosphorylation, suggesting that targeting DUSP13 may be a potential therapeutic strategy for PCa, including castration-resistant disease.", "journal": "Translational Andrology and Urology", "pub_date": "2026-Sep-30", "publication_types": ["Journal Article"], "doi": "10.1038/s41416-026-03441-x", "authors": ["Qing Lu", "Xiaobao Chen", "Zhenlin Chen", "Jing Lin", "Yiming Su"], "affiliations": ["Department of Urology, Fujian Medical University Union Hospital, Fuzhou, China."], "corresponding_authors": [], "china_team": "Department of Urology, Fujian Medical University Union Hospital, Fuzhou, China Yiming Su团队", "category": "basic", "classification_reason": "basic_signals=20", "score": 31.46, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 2.46, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 14.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 1.7, "cas_zone": 4, "cas_zone_points": 1.0, "impact_factor_points": 1.46, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "DUSP13促前列腺癌进展", "chinese_summary": "福建医科大学附属协和医院泌尿外科苏一鸣团队9月Transl Androl Urol报道，DUSP13在前列腺癌细胞中表达高于正常前列腺上皮，敲低该基因可抑制增殖、迁移、侵袭并促进凋亡，同时抑制裸鼠皮下移植瘤生长。机制上DUSP13通过抑制ERK1/2磷酸化发挥作用，提示其或为前列腺癌潜在治疗靶点。", "abstract_zh": "前列腺癌（PCa）仍是男性癌症相关发病率和死亡率的主要原因之一，而进展为去势抵抗性前列腺癌（CRPC）的患者从现有治疗中获益有限；因此，迫切需要新的治疗靶点。双特异性磷酸酶13（DUSP13）属于DUSP家族，该家族成员可使丝裂原活化蛋白激酶（MAPK）去磷酸化，并以情境依赖的方式表现出抑瘤或促瘤活性。新出现的证据提示DUSP13参与多种恶性肿瘤，但其在前列腺癌中的表达和功能，以及是否通过ERK1/2通路发挥作用，仍不清楚。本研究旨在阐明DUSP13在前列腺癌中的功能。通过Western blot和定量逆转录聚合酶链反应（qRT-PCR）检测正常前列腺上皮来源细胞系RWPE-1和前列腺癌细胞系PC-3、DU145、LNCaP中DUSP13的表达。使用慢病毒短发夹RNA（shRNA）在PC-3和DU145细胞中沉默DUSP13；使用针对不同位点的第二个独立shRNA以排除脱靶效应。分别通过细胞计数试剂盒-8（CCK-8）、伤口愈合（划痕）、transwell和流式细胞术实验评估细胞增殖、迁移、侵袭和凋亡。在BALB/c裸鼠PC-3皮下异种移植模型中评估肿瘤生长。通过Western blot检测ERK1/2通路蛋白，并在挽救实验中使用MAPK/ERK激酶（MEK）抑制剂PD98059。前列腺癌细胞中DUSP13蛋白和mRNA水平高于RWPE-1细胞。DUSP13敲低抑制增殖、迁移和侵袭，促进凋亡，并减弱体内异种移植瘤生长。机制上，DUSP13敲低增加p-ERK1/2水平，而单独使用PD98059未显著改变增殖、侵袭或凋亡，并部分逆转DUSP13敲低诱导的抗肿瘤表型。所有关键发现均用第二个独立shRNA重复验证。DUSP13通过抑制ERK1/2磷酸化促进前列腺癌进展，提示靶向DUSP13可能是前列腺癌（包括去势抵抗性疾病）的潜在治疗策略。"}, {"pmid": "42866856", "title": "Postoperative management of infants with ureteropelvic junction obstruction: a retrospective cohort study of PICU transfer, complications, and length of stay.", "abstract": "Postoperative management of infants with ureteropelvic junction obstruction (UPJO) is challenging due to their inability to express symptoms and risk of rapid deterioration. This study aimed to describe our institutional experience with a combined urology-pediatric intensive care unit (PICU) protocol and to explore complication patterns, length of stay (LOS), and costs in this population. Data from 84 consecutive infants (≤12 months) who underwent laparoscopic dismembered pyeloplasty (LP) for UPJO-related hydronephrosis at The Second Hospital of Hebei Medical University from December 2020 to December 2025 were retrospectively analyzed. Patients were divided into Group A (PICU transfer, n=62) and Group B (general ward care, n=22). Surgical outcomes, complications graded by the Clavien-Dindo classification, LOS, and hospitalization costs were compared. Propensity score matching (PSM) was performed as an exploratory analysis to balance baseline differences. Univariable and multivariable logistic regression analyses were performed to identify factors associated with PICU transfer and adverse outcomes, defined as Clavien-Dindo grade ≥ III. All analyses explicitly acknowledge confounding by indication and baseline non-comparability. In the full cohort, Group A was significantly younger at surgery (mean 4.77 vs. 9.23 months, P<0.001) and incurred higher hospitalization costs (median 37,080.50 vs. 31,072.26 CNY, P<0.001); operative time, blood loss, and LOS were similar. The proportion of patients with Clavien-Dindo grade ≥ II complications was lower in Group A (74.2% vs. 100%, P=0.008), as was the incidence of any respiratory complication (67.7% vs. 95.5%, P=0.01), driven primarily by a marked reduction in bronchitis (17.7% vs. 50.0%, P=0.003). Four patients (18.2%) in Group B required unplanned PICU transfer due to postoperative deterioration. In the PSM cohort (12 pairs), Group A had a lower proportion of Clavien-Dindo grade ≥II complications (58.3% vs. 100%, P=0.01) and a lower incidence of bronchitis (0% vs. 41.7%, P=0.01), but the small sample renders these estimates unstable. In multivariable analysis, younger age [odds ratio (OR), 0.61; 95% confidence interval (CI): 0.46-0.75; P<0.001] and operative side (OR, 0.15; 95% CI: 0.03-0.60; P=0.01) were independently associated with PICU transfer. No evaluated factor was independently associated with adverse outcomes (Clavien-Dindo grade ≥ III). A positive correlation existed between Clavien grade and the number of concurrent complication types; complications ≥ Grade III significantly prolonged LOS. Infants after LP face a substantial burden of non-surgical complications. In this retrospective cohort, PICU transfer was associated with younger age and operative side after adjustment, while no independent association was identified between the evaluated factors and Clavien-Dindo grade ≥ III adverse outcomes. Because of substantial confounding by indication, the study is hypothesis-generating and cannot establish a causal effect of PICU care.", "journal": "Translational Andrology and Urology", "pub_date": "2026-Sep-30", "publication_types": ["Journal Article"], "doi": "10.1097/CCM.0000000000002169", "authors": ["Haoxuan Yang", "Zeyuan Sui", "Sheng Tang", "Yuan Chen", "Zixu Yang", "Runlong Wang", "Ziyue Ma", "Lei Du", "Wenyong Xue", "Jinchun Qi"], "affiliations": ["Urology Department, The Second Hospital of Hebei Medical University, Shijiazhuang, China.", "PICU, The Second Hospital of Hebei Medical University, Shijiazhuang, China."], "corresponding_authors": [], "china_team": "Urology Department, The Second Hospital of Hebei Medical University, Shijiazhuang, China Jinchun Qi团队", "category": "clinical_review", "classification_reason": "clinical_signals=7", "score": 27.46, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 2.46, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 7.0}, "journal_metrics": {"status": "ok", "impact_factor": 1.7, "cas_zone": 4, "cas_zone_points": 1.0, "impact_factor_points": 1.46, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42866854", "title": "Surgical procedure and efficacy of KangDuo robot-assisted pyeloplasty for horseshoe kidney.", "abstract": "Ureteropelvic junction obstruction (UPJO) in horseshoe kidney (HSK) is surgically challenging because of aberrant anatomy. Robot-assisted pyeloplasty may overcome some limitations of laparoscopy, but data on the Chinese-developed KangDuo (KD) robotic system in HSK are lacking. This study evaluated the surgical procedure and efficacy of KD robot-assisted pyeloplasty for UPJO in HSK. This retrospective study included 14 adult patients with HSK and UPJO who underwent KD robot-assisted dismembered pyeloplasty between March 2021 and December 2025. Seven procedures used KD-SR1000 and seven used KD-SR2000. Perioperative outcomes, complications, renal function, and follow-up data were analyzed. All 14 procedures were completed successfully without conversion or intraoperative complications. Preoperatively, 12 patients (85.7%) presented with flank pain, 7 patients (50.0%) had concomitant renal calculi, and 5 patients (35.7%) required preoperative stent insertion. Mean operative time was 200.7 minutes, and median blood loss was 20 mL. One postoperative urinary tract infection (Clavien-Dindo II) occurred. Postoperatively, mean serum creatinine improved from 77.8±17.3 to 69.6±16.6 μmol/L, and mean eGFR improved from 93.8±14.9 to 104.1±13.2 mL/min/1.73 m2.All procedures achieved technical success, with no need for reintervention during follow-up. KD robot-assisted pyeloplasty is safe and feasible for UPJO in HSK and provides satisfactory mid-term outcomes. Larger prospective comparative studies are warranted to confirm these findings and assess cost-effectiveness.", "journal": "Translational Andrology and Urology", "pub_date": "2026-Sep-30", "publication_types": ["Journal Article"], "doi": "10.1007/s00345-019-02632-x", "authors": ["Tongchen He", "Xiang Wang", "Zhihua Li", "Pan Song", "Qian Yang", "Jiyu Yang", "Han Bao", "Rui Yang", "Xicai Zhang", "Shubo Fan", "Xinfei Li", "Kunlin Yang", "Hui Jiang", "Xuesong Li"], "affiliations": ["Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Beijing, China.", "Department of Urology, Peking University First Hospital-Miyun Hospital, Beijing, China."], "corresponding_authors": [], "china_team": "Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Beijing, China Xuesong Li团队", "category": "clinical_review", "classification_reason": "clinical_signals=7", "score": 22.46, "score_parts": {"urology_relevance": 11, "urology_in_title": 0.0, "journal_priority": 2.46, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 7.0}, "journal_metrics": {"status": "ok", "impact_factor": 1.7, "cas_zone": 4, "cas_zone_points": 1.0, "impact_factor_points": 1.46, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42866853", "title": "Flow cytometry sperm apoptosis test can predict sperm DNA fragmentation and can be used as an effective and easy-to-perform screening method for males from infertile couples.", "abstract": "Conventional sperm analysis is the gold standard for male fertility assessment. However, since the basic examination consists of microscopic evaluation of native ejaculate, some sperm pathologies might be missed during this examination. The sperm DNA fragmentation test is currently considered the most precise indicator of the sperm potential to fertilize an oocyte both naturally and by assisted reproductive technologies (ART). Irrespective of which method is used, sperm DNA fragmentation testing requires special technical equipment and chemicals together with skilled laboratory staff, and is usually time-consuming and costly. The primary aim of the presented study was to assess whether the flow cytometry sperm apoptosis test (FACS-APO) can predict sperm DNA fragmentation as measured by the terminal deoxynucleotidyl transferase dUTP nick end labelling (TUNEL) assay. In this retrospective observational study, we analysed 971 semen samples from 688 men who underwent concurrent conventional sperm analysis, FACS-APO, and TUNEL-based sperm DNA fragmentation testing at a single in vitro fertilization centre between January 2019 and December 2024. Non-parametric Spearman correlation and Kruskal-Wallis tests were used to assess associations between sperm DNA fragmentation, FACS-APO parameters, and conventional sperm analysis variables. A linear regression model predicting sperm DNA fragmentation from age and the percentage of viable sperm on FACS-APO was developed, and its diagnostic accuracy for a 20% sperm DNA fragmentation cut-off was evaluated. A significant correlation was found between the percentage of sperm DNA fragmentation and the percentage of late apoptotic/necrotic sperm (ρ=0.38, P<0.001), and a significant negative correlation was found between the percentage of sperm DNA fragmentation and the percentage of viable sperm (ρ=-0.39, P<0.001). The correlation between the percentage of sperm DNA fragmentation and the percentage of early apoptotic sperm was less significant (ρ=0.10, P=0.002). Among conventional sperm analysis parameters, sperm concentration, total sperm count, and progressive motility each showed a significant correlation with sperm DNA fragmentation (P<0.001). A simple linear model for calculation of sperm DNA fragmentation was created: sperm DNA fragmentation (%) = 23 + 0.32 × age (years) - 0.35 × viable sperm (%). Based on this model, males at higher risk of having high levels of sperm DNA fragmentation might be selected, which ultimately may save substantial time and financial resources. The flow cytometry sperm apoptosis test is an inexpensive, accurate, and easy-to-perform method and might be used effectively as a screening tool to select males at higher risk of having high levels of sperm DNA fragmentation.", "journal": "Translational Andrology and Urology", "pub_date": "2026-Sep-30", "publication_types": ["Journal Article"], "doi": "10.1111/and.14587", "authors": ["Jan Novák", "Viktor Vik", "Tomáš Fürst", "Vojtěch Thon", "Zuzana Krátká"], "affiliations": ["Department of Urology, General University Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic.", "Urology and Andrology, IVF Clinic GENNET, Prague, Czech Republic.", "Transplantation Surgery Department, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.", "Department of Mathematical Analysis and Application of Mathematics, Faculty of Science, Palacky University, Olomouc, Czech Republic.", "RECETOX, Faculty of Science, Masaryk University, Brno, Czech Republic.", "Laboratory of Immunology, IVF Clinic GENNET, Prague, Czech Republic."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "basic_signals=5", "score": 9.46, "score_parts": {"urology_relevance": 0, "urology_in_title": 0.0, "journal_priority": 2.46, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 5.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 1.7, "cas_zone": 4, "cas_zone_points": 1.0, "impact_factor_points": 1.46, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42866852", "title": "Is the density of transition zone prostate tissue truly 1 gram per milliliter?-an evaluation of HoLEP specimens.", "abstract": "Prostate volume is assumed to equal prostate weight (PW), based on a 1:1 conversion between the milliliter (mL) and gram (g). While the 1:1 conversion holds for pure water, the density of transitional zone prostate tissue has not been studied. The aim of this study was to evaluate prostate density (PD) and the factors that affect it. This was an experimental in vitro study of holmium laser enucleation of the prostate (HoLEP) specimens weighed intraoperatively. Morcellated transition zone tissue was collected. The PW was measured by sterile water displacement. The volume displaced by the tissue was used to measure volume and density. Statistical analysis was performed using correlation analysis and the Wilcoxon rank-sum test. Descriptive statistics were reported as medians with bootstrap-calculated interquartile ranges (IQR). Specimen data were collected from 50 consecutive HoLEP patients, of whom 45 had complete data. Median resected intraoperative PW was 71 g (IQR, 56-89). Intraoperatively measured prostate volume was 74.2 mL (IQR, 60-89.6). Calculated PD was 0.95 (0.92-0.98). Prostate volume modestly overestimated resected PW by 3.35 mL (95% confidence interval: 1.10-5.35, P=0.005). Finasteride use, prior benign prostatic hyperplasia (BPH) surgery, and cancerous tissue were not associated with PD. Prostates larger than 100 mL on preoperative imaging had a higher PD compared to smaller prostates. Denser prostate tissue was associated with longer morcellation and enucleation times, and higher laser energy utilization. In transitional zone prostate tissue collected from HoLEP specimens, PW was largely consistent with prostate volume, supporting the notion of 1:1 conversion. However, this did not hold for larger prostates, which were denser and exhibited greater variation in prostate volume. Correlation between PD and pathology needs to be further studied.", "journal": "Translational Andrology and Urology", "pub_date": "2026-Sep-30", "publication_types": ["Journal Article"], "doi": "10.1016/s0090-4295(98)00051-x", "authors": ["Nabila Reem Khondakar", "Amir Patel", "Jessica Helon", "Alyssa McDonald", "Alla Fadl-Alla", "Jenny Guo", "Amy E Krambeck", "Perry Xu"], "affiliations": ["Department of Urology, Northwestern Medicine, Chicago, IL, USA.", "Department of Urology, Oregon Health and Science University, Portland, OR, USA.", "Feinberg School of Medicine, Northwestern University, Chicago, IL, USA."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=3", "score": 23.46, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 2.46, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 3.0}, "journal_metrics": {"status": "ok", "impact_factor": 1.7, "cas_zone": 4, "cas_zone_points": 1.0, "impact_factor_points": 1.46, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42866850", "title": "A narrative review of the gut microbiota-testis axis: mechanisms and implications for male reproductive health.", "abstract": "Infertility affects approximately 8-12% of couples worldwide, with male factors accounting for nearly half of all cases. The gut microbiota is widely recognized as a key regulator of host physiology, yet its specific role in male reproductive health remains to be elucidated. This narrative review synthesizes current evidence on the \"gut microbiota-testis axis\" and provides a critical evaluation of the strength of evidence derived from different study designs. We conducted a comprehensive literature search in PubMed/MEDLINE up to May 2026 using Boolean search strategies combining terms related to the gut microbiota (e.g., \"Gastrointestinal Microbiome\", \"gut microbiota\", \"gut microbiome\") with terms related to male reproduction (e.g., \"Semen Analysis\", \"Spermatozoa\", \"Infertility, Male\", \"semen quality\", \"sperm quality\"). Separate search strategies were developed for human and animal studies. Literature screening and data extraction were performed independently by two reviewers according to predefined inclusion and exclusion criteria. Although human studies remain preliminary, several genera, including Anaerotruncus, Bacteroides, and Faecalibacterium prausnitzii, have been reproducibly associated with semen quality, with microbial metabolites such as butyrate, trimethylamine-N-oxide (TMAO), and succinate potentially serving as important mediators. At the mechanistic level, microbiota-derived metabolic and inflammatory signals act on Leydig cells, Sertoli cells, and germ cells, thereby influencing testosterone synthesis and spermatogenesis. Fecal microbiota transplantation (FMT) experiments in animal models have provided direct evidence for these causal links. The gut microbiota-testis axis has emerged as a critical physiological pathway linking the microbiome to male reproductive function. This review provides an evidence-based framework for understanding this axis and highlights key knowledge gaps that must be addressed. Future research should integrate large-scale longitudinal cohorts, mechanistic exploration, and randomized controlled trials with fertility outcomes as primary endpoints to advance the field from descriptive correlations toward mechanism-driven clinical translation.", "journal": "Translational Andrology and Urology", "pub_date": "2026-Sep-30", "publication_types": ["Journal Article", "Review"], "doi": "10.1093/humrep/dey116", "authors": ["Longjie Gu", "Yinwei Chen", "Lei Jin", "Yi Liu"], "affiliations": ["Reproductive Medicine Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.", "Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China."], "corresponding_authors": [], "china_team": "Reproductive Medicine Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China Yi Liu团队", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 15.46, "score_parts": {"urology_relevance": 0, "urology_in_title": 0.0, "journal_priority": 2.46, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 5.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 6.0}, "journal_metrics": {"status": "ok", "impact_factor": 1.7, "cas_zone": 4, "cas_zone_points": 1.0, "impact_factor_points": 1.46, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42866845", "title": "Sodium-glucose cotransporter 2 inhibitors vs. glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors for incident and recurrent urolithiasis: a European Association of Urology Endourology systematic review.", "abstract": "Urolithiasis is a recurrent metabolic condition associated with obesity, metabolic syndrome, and type 2 diabetes (T2D), yet the relationship between modern antidiabetic drug classes and stone risk remains incompletely defined. This systematic review aimed to evaluate comparative clinical-event evidence on sodium-glucose cotransporter 2 inhibitors (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP-1 RA), and dipeptidyl peptidase-4 inhibitor (DPP-4i) in relation to incident, recurrent, or severe urolithiasis outcomes. This systematic review (PROSPERO ID: CRD420261366483) was reported according to PRISMA 2020. The PICO framework was: (P) adults receiving antidiabetic pharmacotherapy; (I) SGLT2i use; (C) GLP-1 RA, DPP-4i, or other active antidiabetic therapies; and (O) incident, recurrent, or severe urolithiasis events. MEDLINE, Embase, Cochrane CENTRAL, and Scopus were searched from inception through April 2026, with additional studies identified through reference-list screening. Risk of bias was assessed using ROBINS-I. Findings were synthesized narratively. Six comparative clinical-event studies met inclusion criteria. All were observational studies using active antidiabetic comparators. Across studies, SGLT2i use was consistently associated with lower urolithiasis risk compared with GLP-1 RA or DPP-4i vs. GLP-1 RA, SGLT2i were associated with lower incident and recurrent urolithiasis outcomes, with hazard ratios (HRs) ranging from 0.51 to 0.69 and rate ratios from 0.58 to 0.82 vs. DPP-4i, SGLT2i were associated with lower incident, recurrent, and procedure-requiring stone outcomes, with HRs ranging from 0.33 to 0.84 and rate ratios from 0.63 to 0.73. The absolute risk reduction appeared greatest among patients with prior or recently active urolithiasis. All included studies were judged to have moderate overall risk of bias. SGLT2i use was consistently associated with lower incident, recurrent, and procedure-requiring urolithiasis risk vs. GLP-1 RA or DPP-4i. Absolute risk differences were greatest among patients with prior or recently active urolithiasis. Given the observational evidence and moderate risk of bias, prospective studies with prespecified stone outcomes are needed.", "journal": "Translational Andrology and Urology", "pub_date": "2026-Sep-30", "publication_types": ["Journal Article", "Review"], "doi": "10.1089/end.2021.0124", "authors": ["Arianna Pischetola", "Francesco Esperto", "Arman Tsaturyan", "Ali Talyshinski", "Selcuk Guven", "Abhishek Singh", "Bhaskar Kumar Somani"], "affiliations": ["Department of Urology, Fondazione Policlinico Campus Bio-Medico of Rome, Rome, Italy.", "Research Unit of Urology, Università Campus Bio-Medico of Rome, Rome, Italy.", "Department of Urology, Yerevan State Medical University, Yerevan, Armenia.", "Genome Clinic, Astana, Kazakhstan.", "Central Asian Medical University, Fergana, Uzbekistan.", "Department of Urology, Necmettin Erbakan University, School of Medicine, Konya, Turkey.", "Muljibhai Patel Urological Hospital, Nadiad, India.", "Department of Urology, University Hospital Southampton, Southampton, UK."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 24.46, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 2.46, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 4.0}, "journal_metrics": {"status": "ok", "impact_factor": 1.7, "cas_zone": 4, "cas_zone_points": 1.0, "impact_factor_points": 1.46, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42866844", "title": "Extraction of atrial tumor thrombus in renal cell carcinoma via a complete transabdominal approach.", "abstract": "Surgical resection is the mainstay treatment of renal cell carcinoma (RCC) offering a 5-year survival rate of 70-80%. Associated vena cava tumor thrombus adds complexity to surgical planning especially when the thrombus extends above the diaphragm. Those who do not undergo treatment of the primary cancer as well as the associated thrombus have poor mortality outcomes. Cardiopulmonary bypass (CPB) has been the mainstay for level IV thrombectomy since first introduced. While it has advantages, it is also associated with multisystem failure, hypothermia, and coagulopathy. We sought to describe our experience using a completely transabdominal thrombectomy technique in select patients with level IV tumor thrombus. Patient selection depended upon multidisciplinary coordination between urologic oncology, cardiothoracic surgery, and cardiac anesthesiology. Eleven patients at our institution underwent completely transabdominal level IV inferior vena cava (IVC) tumor thrombectomy. All had successful retrieval of thrombus without the use of CPB or need for sternotomy. Intraoperative surgical and anesthetic technique is described. Although two patients were lost to follow up, only three of the remaining patients were found to have recurrence of disease. Further studies are necessary to best elucidate the ideal candidate for this surgical approach as well as evaluate long term outcomes compared with traditional therapies. We propose transabdominal IVC tumor thrombectomy is a safe surgical option in select patients with level IV tumor thrombus.", "journal": "Translational Andrology and Urology", "pub_date": "2026-Sep-30", "publication_types": ["Journal Article"], "doi": "10.1053/j.jvca.2022.04.023", "authors": ["Kaitlin Pardue", "E Joy Trimble", "Sanjay Patel", "Michael Cookson", "Kofi Vandyck", "Lacy Harville", "Brian Cross"], "affiliations": ["Department of Surgery, The University of Oklahoma Health Sciences Center, Oklahoma, OK, USA.", "Department of Urology, The University of Oklahoma Health Sciences Center, Oklahoma, OK, USA.", "Department of Anesthesia, The University of Oklahoma Health Sciences Center, Oklahoma, OK, USA.", "Department of Cardiothoracic Surgery, UT Health San Antonio, San Antonio, TX, USA."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=5", "score": 26.46, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 2.46, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 5.0}, "journal_metrics": {"status": "ok", "impact_factor": 1.7, "cas_zone": 4, "cas_zone_points": 1.0, "impact_factor_points": 1.46, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42866843", "title": "SESN2 promotes ferroptosis in bladder cancer by negatively regulating the NRF2/FSP1 signaling axis.", "abstract": "Bladder cancer (BLCA) shows intrinsic ferroptosis resistance. Sestrin2 (SESN2) regulates ferroptosis in other diseases, but its role in BLCA is unknown. In this study, we sought to determine whether SESN2 contributes to the intrinsic ferroptosis resistance of BLCA and to elucidate the underlying molecular mechanisms. SESN2 expression was measured in BLCA tissues, RT4 cells, T24 cells, and normal controls by quantitative real-time polymerase chain reaction, western blot, and immunofluorescence. Ferroptosis markers [glutathione (GSH), malondialdehyde (MDA), and Fe2+] and nuclear factor erythroid 2-related factor 2 (NRF2)/ferroptosis suppressor protein 1 (FSP1) levels were assessed in tissues and cells. RT4 cells were transfected with SESN2 overexpression plasmid, and changes in GSH, MDA, and NRF2/FSP1 were examined. Inhibitors ML385 (NRF2) and iFSP1 (FSP1) were used to verify pathway involvement. SESN2 was downregulated in BLCA tissues and cells. BLCA displayed a ferroptosis-resistant phenotype (higher GSH, lower MDA and Fe2+) with elevated NRF2/FSP1 expression. SESN2 overexpression reduced GSH, increased MDA and Fe2+, and downregulated NRF2/FSP1 expression. Inhibitor treatment further lowered NRF2/FSP1 expression and partially reversed the changes in GSH, MDA, and Fe2+. SESN2 is downregulated in BLCA and promotes ferroptosis by negatively regulating the NRF2/FSP1 axis. This study identifies a novel role of SESN2 in BLCA ferroptosis and suggests targeting this pathway as a potential therapeutic strategy.", "journal": "Translational Andrology and Urology", "pub_date": "2026-Sep-30", "publication_types": ["Journal Article"], "doi": "10.1016/j.freeradbiomed.2024.12.040", "authors": ["Jianfeng Hu", "Yangmin Wang", "Yonghui Du", "Xi'an Li", "Zhiguo Zhang", "Xuehai Liang", "Junfeng Peng"], "affiliations": ["Department of Urology, Xi'an Chang'an Hospital, Xi'an, China.", "Department of Urology, The Second Affiliated Hospital of Xi'an Medical University, Xi'an, China.", "Department of Urology, Xi'an Gemflower Changqing Hospital (Changqing Oilfield Workers' Hospital), Xi'an, China."], "corresponding_authors": [], "china_team": "Department of Urology, Xi'an Chang'an Hospital, Xi'an, China Junfeng Peng团队", "category": "basic", "classification_reason": "basic_signals=13", "score": 30.46, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 2.46, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 13.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 1.7, "cas_zone": 4, "cas_zone_points": 1.0, "impact_factor_points": 1.46, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "SESN2下调促膀胱癌铁死亡抵抗", "chinese_summary": "西安长安医院彭俊峰团队9月Transl Androl Urol报道，膀胱癌组织中SESN2表达下调，肿瘤呈现GSH升高、MDA与Fe2+降低的铁死亡抵抗表型，并伴NRF2/FSP1轴上调。过表达SESN2可逆转上述改变，提示靶向该通路或成潜在治疗策略。", "abstract_zh": "膀胱癌（BLCA）表现出内在的铁死亡抵抗。Sestrin2（SESN2）在其他疾病中调控铁死亡，但其在BLCA中的作用尚不清楚。在本研究中，我们试图确定SESN2是否参与BLCA的内在铁死亡抵抗，并阐明其潜在的分子机制。通过定量实时聚合酶链反应、蛋白质印迹和免疫荧光检测BLCA组织、RT4细胞、T24细胞及正常对照中SESN2的表达。评估组织和细胞中铁死亡标志物[谷胱甘肽（GSH）、丙二醛（MDA）和Fe2+]以及核因子E2相关因子2（NRF2）/铁死亡抑制蛋白1（FSP1）水平。将SESN2过表达质粒转染至RT4细胞，检测GSH、MDA和NRF2/FSP1的变化。使用抑制剂ML385（NRF2）和iFSP1（FSP1）验证通路参与。SESN2在BLCA组织和细胞中下调。BLCA表现出铁死亡抵抗表型（GSH较高，MDA和Fe2+较低），并伴有NRF2/FSP1表达升高。SESN2过表达降低了GSH，增加了MDA和Fe2+，并下调了NRF2/FSP1表达。抑制剂处理进一步降低了NRF2/FSP1表达，并部分逆转了GSH、MDA和Fe2+的变化。SESN2在BLCA中下调，并通过负调控NRF2/FSP1轴促进铁死亡。本研究揭示了SESN2在BLCA铁死亡中的新作用，并提示靶向该通路作为潜在的治疗策略。"}, {"pmid": "42866837", "title": "Low-energy extracorporeal shock wave therapy for interstitial cystitis/bladder pain syndrome: mechanisms, evidence, and translational perspectives-a narrative review.", "abstract": "Interstitial cystitis/bladder pain syndrome (IC/BPS) is a chronic heterogeneous disorder characterized by persistent bladder-related pain, urinary symptoms, and substantial impairment in quality of life. Despite currently available multimodal treatment strategies, therapeutic outcomes vary among patients, highlighting the need to further investigate non-invasive approaches targeting inflammation, tissue repair, and sensory dysfunction. Low-energy extracorporeal shock wave therapy (ESWT) has been investigated as a non-invasive intervention with potential regenerative and neuromodulatory effects in IC/BPS. Its clinical relevance and translational applicability require further clinical validation. This narrative review summarizes the biological rationale, current clinical evidence, and translational considerations of low-energy ESWT in IC/BPS. PubMed/MEDLINE and Web of Science Core Collection were searched for English-language studies published from January 1, 2010 to May 31, 2026. Relevant clinical, preclinical, and mechanistic studies were narratively synthesized. Among 53 relevant publications, 13 original studies formed the main evidence base. Preclinical studies suggest that low-energy ESWT may affect inflammation, oxidative stress, urothelial barrier function, angiogenesis, and neural sensitization. Clinical studies, including randomized controlled trials and prospective investigations, have reported improvements mainly in pain-related outcomes among selected patient populations, whereas effects on symptom scores, voiding outcomes, bladder capacity, and long-term outcomes remain uncertain. Heterogeneity in protocols, patient characteristics, and outcome measures limits interpretation. Low-energy ESWT remains an investigational adjunctive treatment for IC/BPS, and current evidence is insufficient to support routine clinical use. Future studies should prioritize adequately powered, sham-controlled trials with standardized treatment protocols, prespecified phenotype stratification, harmonized outcome assessment, and longer follow-up to determine whether clinically meaningful and durable benefit exists and which patients, if any, are most likely to benefit.", "journal": "Translational Andrology and Urology", "pub_date": "2026-Sep-30", "publication_types": ["Journal Article", "Review"], "doi": "10.3389/fphar.2025.1586845", "authors": ["Xueting Sun", "Huiying Chen", "Lu Wang", "Yanting Shen", "Fei Wang"], "affiliations": ["School of Gongli Hospital Medical Technology, University of Shanghai for Science and Technology, Shanghai, China.", "Department of Urology and andrology, Pudong Gongli Hospital, Shanghai University of Medicine & Health Sciences, Shanghai, China."], "corresponding_authors": [], "china_team": "School of Gongli Hospital Medical Technology, University of Shanghai for Science and Technology, Shanghai, China Fei Wang团队", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 33.46, "score_parts": {"urology_relevance": 11, "urology_in_title": 8.0, "journal_priority": 2.46, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 10.0}, "journal_metrics": {"status": "ok", "impact_factor": 1.7, "cas_zone": 4, "cas_zone_points": 1.0, "impact_factor_points": 1.46, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42866836", "title": "Copper homeostasis dysregulation promotes malignant transformation of renal tubular epithelial cells via the ROS/NF-κB/AID signaling axis.", "abstract": "Clear cell renal cell carcinoma (ccRCC) is the most common subtype of renal cell carcinoma and is characterized by aggressive biological behavior and poor clinical outcomes. However, the molecular mechanisms underlying the malignant transformation of renal tubular epithelial cells are not yet fully understood. This study aimed to investigate the role of copper homeostasis dysregulation in regulating the reactive oxygen species/nuclear factor-kappa B/activation-induced cytidine deaminase (ROS/NF-κB/AID) signaling axis during ccRCC progression. Copper ion levels, ROS accumulation, and the expression of copper transport proteins, NF-κB pathway-associated molecules, AID, and epithelial-mesenchymal transition (EMT)-related proteins were examined in ccRCC tissues, chronic nephritis tissues, adjacent non-tumor tissues, renal cancer cell lines (786-O and 769-P), and human renal tubular epithelial cells (HK-2). The copper chelator triethylenetetramine (TETA), copper (II) chloride (CuCl₂), ROS scavenger N-acetyl-L-cysteine (NAC), hydrogen peroxide (H₂O₂), NF-κB inhibitor pyrrolidine dithiocarbamate (PDTC), and NF-κB activator lipopolysaccharide (LPS) were used to modulate signaling pathways. Cell proliferation, migration, and invasion were evaluated by 5-Ethynyl-2'-deoxyuridine (EdU) assay, colony formation, wound-healing, and Transwell invasion assays. Copper levels were significantly elevated in the ccRCC tissues and renal cancer cells, accompanied by increased ROS accumulation, NF-κB signaling activation, aberrant AID overexpression, and enhanced EMT progression. Exogenous copper treatment promoted the proliferation, migration, and invasion of HK-2 cells, whereas copper chelation markedly suppressed these malignant phenotypes. Mechanistically, copper accumulation was associated with increased ROS production and activation of NF-κB signaling, accompanied by increased AID expression and EMT progression. ROS or NF-κB inhibition significantly attenuated AID expression and EMT-associated alterations. Further, TETA, NAC, and PDTC effectively reduced intracellular copper accumulation, suppressed ROS/NF-κB/AID signaling, and inhibited malignant biological behaviors in renal cancer cells. Copper homeostasis dysregulation promotes the malignant transformation of renal tubular epithelial cells through activation of the ROS/NF-κB/AID signaling axis. These findings suggest that targeting copper metabolism and the ROS/NF-κB/AID pathway represents a promising therapeutic strategy for ccRCC.", "journal": "Translational Andrology and Urology", "pub_date": "2026-Sep-30", "publication_types": ["Journal Article"], "doi": "10.3389/fimmu.2022.965312", "authors": ["Yun Yuan", "Rubin Chen", "Bingqing Xu", "Shouxian Cheng", "Junfei Wang", "Ying Xiong", "Zhifei Che", "Hualei Chen"], "affiliations": ["Department of Urology Surgery, The Second Affiliated Hospital of Hainan Medical University, Haikou, China.", "Key Laboratory of Reproductive Health Diseases Research and Translation of Ministry of Education, Department of Urology, The First Affiliated Hospital, Hainan Medical University, Haikou, China.", "College of Medicine, Huanghuai University, Zhumadian, China.", "Department of Urology Surgery, Hainan Provincial Hospital of Geriatrics, Haikou, China."], "corresponding_authors": [], "china_team": "Department of Urology Surgery, The Second Affiliated Hospital of Hainan Medical University, Haikou, China Hualei Chen团队", "category": "basic", "classification_reason": "basic_signals=14", "score": 22.46, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 2.46, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 14.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 1.7, "cas_zone": 4, "cas_zone_points": 1.0, "impact_factor_points": 1.46, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42866835", "title": "Delays in male infertility evaluation and their financial and emotional impact on couples.", "abstract": "Although male and female factors contribute equally to infertility, evaluation pathways frequently prioritize female-focused care, delaying appropriate assessment of male-factor infertility. This study aims to assess the impact of delayed urologic care for male-factor infertility couples by assessing emotional and financial well-being and evaluating how gendered assumptions influence the diagnostic and treatment pathways in their care. An anonymous, electronic Research Electronic Data Capture (REDCap) survey was distributed from January 2023 to June 2025 to patients seeking infertility services. The survey included both quantitative and qualitative items addressing participants' healthcare journey, timing of male-factor evaluation, and related burdens. Descriptive statistics, Chi-square tests, logistic regression, and thematic analysis were performed. Among 226 surveyed couples, 26.0% first sought gynecologic care and 10.2% consulted a reproductive endocrinologist before urologic evaluation. Time spent addressing only female-factor infertility ranged from 2 months to 6 years. Overall, 38.3% regretted not seeking urologic care sooner. Significant associations were found between regret and both initiating care with female providers and financial burden. Patients reported out-of-pocket costs between $1,500 and $300,000 prior to male evaluation, with several citing the need to take out loans to cover the cost of treatments. The qualitative responses highlighted fertility treatment delays, confusion surrounding the role of urologists in the fertility journey, and high costs as major concerns. Our findings highlight the urgent need to address gender bias in infertility care as delays in evaluating male-factor infertility led to significant emotional and financial harm, inefficient use of healthcare resources, and a disproportionate burden on women. A paradigm shift toward an earlier, inclusive, couple-based evaluation is essential to advancing equitable reproductive care in the face of a global fertility crisis.", "journal": "Translational Andrology and Urology", "pub_date": "2026-Sep-30", "publication_types": ["Journal Article"], "doi": "10.1093/hropen/hoae017", "authors": ["Jordan G Kassab", "Amelia G Oppenheimer", "Angelica Garcia Keeme-Sayre", "Blair T Stocks", "Larry I Lipshultz"], "affiliations": ["Texas Tech University Health Sciences Center, Lubbock, TX, USA.", "Scott Department of Urology, Baylor College of Medicine, Houston, TX, USA."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=5", "score": 25.46, "score_parts": {"urology_relevance": 7, "urology_in_title": 8.0, "journal_priority": 2.46, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 5.0}, "journal_metrics": {"status": "ok", "impact_factor": 1.7, "cas_zone": 4, "cas_zone_points": 1.0, "impact_factor_points": 1.46, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42866831", "title": "Association of preoperative frailty with health-related quality of life and urinary function after robot-assisted radical prostatectomy.", "abstract": "Frailty may influence outcomes after robot-assisted radical prostatectomy (RARP), but its association with longitudinal patient-reported outcomes remains unclear. This study aimed to examine the association of preoperative frailty, assessed using the Geriatric (G) 8 screening tool, with longitudinal health-related quality of life (HRQOL) and urinary status in patients who underwent RARP. We retrospectively analyzed 328 patients who underwent RARP at a single institution. Patients were preoperatively classified into high, intermediate, and low G8 groups. HRQOL was assessed using the Functional Assessment of Cancer Therapy-General (FACT-G) and Functional Assessment of Cancer Therapy-Prostate (FACT-P) questionnaires. Urinary status was evaluated using the urinary incontinence subscale of the Expanded Prostate Cancer Index Composite (EPIC) and daily pad usage. Preoperative G8 scores demonstrated substantial overlap across age categories, suggesting that chronological age alone did not accurately reflect frailty status. Linear mixed-effects models showed a significant effect of time on FACT-G (P=0.004) and FACT-P (P<0.001), as well as significant main effects of G8 classification on both measures (both P<0.001); however, the time-by-G8 interaction was not significant for either FACT-G (P=0.42) or FACT-P (P=0.14). In models restricted to postoperative assessments and adjusted for baseline HRQOL and age, the time-by-G8 interactions remained nonsignificant, indicating no evidence of differential postoperative HRQOL trajectories among the G8 groups. Urinary status measured by EPIC significantly improved over time (P<0.001), and, after adjustment for baseline urinary status and age, no significant time-by-G8 interaction was observed (P=0.29). Kaplan-Meier analysis revealed no significant difference in time to urinary continence recovery across G8 groups (log-rank P=0.82). Lower preoperative G8 scores were associated with persistently lower HRQOL before and after RARP, without evidence of a significantly different longitudinal HRQOL trajectory. After accounting for baseline urinary status and age, there was no clear evidence of different postoperative urinary recovery trajectories among the G8 groups, and time to continence recovery did not significantly differ among groups. Frailty screening may provide clinically meaningful information for preoperative counseling and shared decision-making in patients undergoing RARP.", "journal": "Translational Andrology and Urology", "pub_date": "2026-Sep-30", "publication_types": ["Journal Article"], "doi": "10.1089/lap.2023.0278", "authors": ["Hisanori Taniguchi", "Junichi Ikeda", "Monta Inoue", "Yuki Masuo", "Hidefumi Kinoshita"], "affiliations": ["Department of Urology and Andrology, Kansai Medical University, Hirakata, Osaka, Japan."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=4", "score": 27.46, "score_parts": {"urology_relevance": 11, "urology_in_title": 8.0, "journal_priority": 2.46, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 4.0}, "journal_metrics": {"status": "ok", "impact_factor": 1.7, "cas_zone": 4, "cas_zone_points": 1.0, "impact_factor_points": 1.46, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42866825", "title": "Filling the information gap: a validated comparison of ChatGPT, Gemini, and Claude for penile cancer patient education.", "abstract": "ChatGPT, Gemini, and Claude are three large language models (LLMs) increasingly consulted by patients researching a new cancer diagnosis. Penile cancer is rare, stigmatised, and dominated by decisions around organ preservation and sexual function, which makes the quality of patient-facing information particularly consequential. The aim of this study was to assess the quality of responses generated by these LLMs to patient-oriented questions on penile cancer. Fourteen questions reflecting common patient information needs were adapted from established educational resources and refined by senior urology consultant review. Each query was presented to ChatGPT, Gemini, and Claude using an identical patient-centred prompt. Responses (n=42) were anonymised and randomly ordered before being independently reviewed in a consensus meeting by a urology panel using the Quality Analysis of Medical Artificial Intelligence (QAMAI) framework. Comparative analysis used the Friedman test with Bonferroni-corrected pairwise Wilcoxon signed-rank testing. Mean total QAMAI scores were 22.7 for ChatGPT (median, 23; range, 17 to 25), 22.6 for Claude (median, 23; range, 18 to 24), and 17.0 for Gemini (median, 17.5; range, 14 to 20), corresponding to moderate quality for ChatGPT and Claude and the boundary of poor and moderate quality for Gemini. The difference across models was significant (Friedman χ2=18.78; P<0.001). ChatGPT and Claude each significantly outperformed Gemini (both adjusted P=0.004) but did not differ from one another (adjusted P>0.99). ChatGPT produced the clearest responses and Claude the most complete, while Gemini scored lowest in every domain, most strikingly for surgery and organ preservation (14.0 vs. 23.7 and 23.0). No response provided citations or referred readers to external sources of information. ChatGPT and Claude delivered broadly equivalent, moderate-to-good-quality information on patient-derived penile cancer questions, and both clearly outperformed Gemini, which frequently produced incomplete answers in the surgical and organ preservation domain. The universal absence of source citation is a clinically relevant limitation. These tools should be regarded as a supplement to, rather than a substitute for, specialist consultation.", "journal": "Translational Andrology and Urology", "pub_date": "2026-Sep-30", "publication_types": ["Journal Article"], "doi": "10.1038/s43856-025-01021-3", "authors": ["Jeffery Yang", "Ymer Bushati", "Sarah Lorger", "Jeremy Saad", "Prem Rathore"], "affiliations": ["Department of Urology, Campbelltown Hospital, Campbelltown, NSW, Australia.", "School of Medicine, Western Sydney University, Sydney, NSW, Australia.", "Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.", "Department of Urology, Liverpool Hospital, Sydney, NSW, Australia."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=3", "score": 23.96, "score_parts": {"urology_relevance": 7, "urology_in_title": 8.0, "journal_priority": 2.46, "top_journal_bonus": 0.0, "novelty": 1.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 3.0}, "journal_metrics": {"status": "ok", "impact_factor": 1.7, "cas_zone": 4, "cas_zone_points": 1.0, "impact_factor_points": 1.46, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42866815", "title": "Comparative outcomes of radical prostatectomy, radiotherapy, and radiotherapy plus androgen deprivation therapy for high-risk and very high-risk prostate cancer: a narrative review.", "abstract": "High-risk and very high-risk prostate cancer (PCa) accounts for approximately 15-20% of newly diagnosed cases and are associated with substantial risk of disease progression, metastasis, and cancerspecific mortality. The comparative effectiveness of radical prostatectomy (RP), external beam radiotherapy (EBRT), and radiotherapy combined with androgen deprivation therapy (RT + ADT) remains uncertain because randomized head-to-head trials are lacking. This narrative review aims to synthesize the comparative effectiveness of RP, EBRT, and RT + ADT in patients with high-risk and very high-risk PCa, with respect to survival outcomes, optimal ADT duration, and toxicity/quality-of-life profiles. Literature searches were conducted across PubMed, Cochrane Library (CENTRAL), and ClinicalTrials.gov through May 2026. Studies comparing RP, EBRT, and/or RT + ADT in patients with high-risk PCa [prostate-specific antigen (PSA) ≥20 ng/mL, Gleason score 8-10/International Society of Urological Pathology (ISUP) grade ≥4, or clinical stage ≥T3a] were included. Primary outcomes were overall survival (OS), prostate cancer-specific survival (PCSS), and biochemical recurrence-free survival (bRFS). Observational studies comparing RP and RT-based strategies have reported conflicting results for OS: some studies reported more favorable outcomes with RP [hazard ratio (HR) 1.60, 95% confidence interval (CI): 1.25-2.05 for EBRT + ADT vs. RP], whereas others reported more favorable outcomes with RT-based strategies (HR 1.22, 95% CI: 1.05-1.43 for RP vs. EBRT plus brachytherapy). For patients with Gleason score 9-10 disease, observational analyses suggested that EBRT with brachytherapy boost was associated with lower prostate cancer-specific mortality compared with RP (HR 0.38, 95% CI: 0.21-0.68). For RT-treated patients, randomized controlled trials (RCTs) support the use of 18-24 months of ADT. Quality-of-life analyses consistently showed worse urinary incontinence and sexual dysfunction after RP, worse bowel symptoms after RT, and compounded toxicity with multimodal therapy. For patients with high-risk and very high-risk PCa, radiotherapy combined with 18-24 months of ADT is supported by evidence from randomized trials compared with radiotherapy alone. Comparative survival evidence between RP and RT-based strategies remains conflicting and is limited by observational designs and selection bias. Treatment selection should be individualized according to patient age, comorbidity burden, tumor characteristics, and quality-of-life preferences. Randomized trials directly comparing contemporary RP with modern RT + ADT are urgently needed.", "journal": "Translational Andrology and Urology", "pub_date": "2026-Sep-30", "publication_types": ["Journal Article", "Review"], "doi": "10.1016/j.annonc.2026.05.708", "authors": ["Kaung Hset Tun", "Xingyu Xiong", "Hang Xu", "Lu Yang"], "affiliations": ["Department of Urology and Institute of Urology, West China Hospital, Sichuan University, Chengdu, China."], "corresponding_authors": [], "china_team": "Department of Urology and Institute of Urology, West China Hospital, Sichuan University, Chengdu, China Lu Yang团队", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 35.96, "score_parts": {"urology_relevance": 15, "urology_in_title": 8.0, "journal_priority": 2.46, "top_journal_bonus": 0.0, "novelty": 0.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 8.0}, "journal_metrics": {"status": "ok", "impact_factor": 1.7, "cas_zone": 4, "cas_zone_points": 1.0, "impact_factor_points": 1.46, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42866814", "title": "Laparoscopic urinary tract reconstruction for iatrogenic ureteral injuries: a retrospective observational study from a single high-volume referral center.", "abstract": "Iatrogenic ureteral injuries are challenging complications that may require complex urinary tract reconstruction. Although laparoscopic approaches have been increasingly adopted, detailed clinical outcomes of laparoscopic reconstruction for iatrogenic ureteral injuries remain limited. This study aimed to evaluate the surgical outcomes of laparoscopic urinary tract reconstruction for iatrogenic ureteral injuries at a single high-volume referral center. We conducted a retrospective single-center observational cohort study of consecutive patients who underwent laparoscopic ureteral reconstruction for iatrogenic ureteral injuries at Kameda Medical Center, Japan, between January 2012 and December 2024. Patients who underwent reconstruction for non-iatrogenic ureteral injuries or open surgery were excluded. The reconstructive procedures included ureteroneocystostomy (n=14), ureteroneocystostomy with a Boari flap (n=7), and ileal interposition using an isolated ileal segment (n=4). The perioperative outcomes, including operative time, blood loss, complications, and hospital stay, were analyzed. The long-term outcomes were assessed with respect to surgical success, which was defined as the absence of recurrent obstruction or the need for further intervention. Twenty-five consecutive patients were included. The median patient age was 51 years, and 92% of the patients were female. Gynecological procedures, most commonly hysterectomies, accounted for 80% of all injuries. The median interval between injury and repair was 261 days. The median operative time was 291 min, and the median blood loss was 20 mL. None of the procedures required conversion to open surgery. Five patients experienced Clavien-Dindo grade ≥III complications. Reoperation was required in three cases (two after ileal interposition and one after Boari flap), all of which ultimately achieved successful reconstruction. Laparoscopic ureteral reconstruction is feasible and effective for iatrogenic ureteral injuries, with acceptable morbidity and high success rates. These results highlight the value of minimally invasive reconstructive strategies and may inform surgical decision-making in similar high-volume settings.", "journal": "Translational Andrology and Urology", "pub_date": "2026-Sep-30", "publication_types": ["Journal Article"], "doi": "10.1002/bco2.267", "authors": ["Minoru Nakazono", "Fumihiko Urabe", "Hidetsugu Takahashi", "Ryutaro Fukagai", "Kazuhiro Takahashi", "Kosuke Iwatani", "Masahiro Fujikawa", "Takahiro Kimura", "Hirokazu Abe"], "affiliations": ["Department of Urology, Kameda Medical Center, Chiba, Japan.", "Department of Urology, The Jikei University School of Medicine, Tokyo, Japan."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=7", "score": 26.46, "score_parts": {"urology_relevance": 7, "urology_in_title": 8.0, "journal_priority": 2.46, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 7.0}, "journal_metrics": {"status": "ok", "impact_factor": 1.7, "cas_zone": 4, "cas_zone_points": 1.0, "impact_factor_points": 1.46, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42866796", "title": "Assessing spatial perception of learners during holmium laser enucleation of the prostate (HoLEP).", "abstract": "Holmium laser enucleation of the prostate (HoLEP) has a steep learning curve. Specific educational efforts to improve HoLEP training has not been extensively studied. The aim of this study was to assess the spatial perception of urology residents (learners) HoLEP videos to improve future educational efforts. A cross-sectional simulation-based observational study during an academic urology conference was performed. A HoLEP recording was shown to resident physicians and paused at 5 time points. Resident physicians were then asked to mark down coordinates on diagrams of prostates in the coronal, axial and sagittal dimensions at each pause to denote where they perceived the laser was pointing. Twenty-one urology residents (learners) participated in the study, of whom, 47.6% had prior HoLEP exposure. The learners plotted perceived coordinates at pre-designated time points in 3 dimensions throughout a HoLEP, totaling 315 coordinates. Learners perceived more accurately in the coronal dimension and were most accurate in identifying the verumontanum (the first time point of the procedure). Those with prior HoLEP exposure, as well as senior residents, were significantly more likely to accurately pinpoint the verumontanum in the coronal dimension (P=0.04, 0.03 respectively). Prior HoLEP exposure and post-graduate year (PGY)-level was not associated with accurately identifying the other time points in all dimensions. Spatial understanding during a HoLEP is challenging and learners are inaccurate in pinpointing coordinates while watching endoscopic recordings alone, regardless of PGY-level and prior HoLEP exposure. Learners appear to perceive in the coronal dimension more accurately as opposed to the axial or sagittal dimensions. This could be used to direct future educational efforts for teaching HoLEP.", "journal": "Translational Andrology and Urology", "pub_date": "2026-Sep-30", "publication_types": ["Journal Article"], "doi": "10.5489/cuaj.7838", "authors": ["Nabila Reem Khondakar", "Amir Patel", "Jenny Guo", "Matt Pearson", "Shaan Setia", "Amy E Krambeck", "Perry Xu"], "affiliations": ["Department of Urology, Feinberg School of Medicine, Northwestern Medicine, Chicago, IL, USA.", "Department of Urology, Rush University Medical Center, Chicago, IL, USA."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 21.46, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 2.46, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 1.7, "cas_zone": 4, "cas_zone_points": 1.0, "impact_factor_points": 1.46, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42866795", "title": "An interpretable LASSO-Boruta nomogram for non-muscle-invasive bladder cancer recurrence after intravesical instillation.", "abstract": "Recurrence remains a major clinical challenge in non-muscle-invasive bladder cancer (NMIBC), highlighting the need for interpretable tools for individualized risk assessment. This study aimed to develop a transparent model that estimates recurrence risk in patients with NMIBC after transurethral resection of bladder tumor (TURBT) and intravesical instillation. We reviewed 200 patients with NMIBC who received TURBT and postoperative intravesical instillation at the Department of Urology, The Affiliated Hospital of Xuzhou Medical University, from January to December 2020. Recurrence status was determined from follow-up records. We collected baseline variables, preoperative laboratory results, and clinicopathological data. Patients were divided into training and validation sets (7:3). We screened predictors with multivariate Cox regression, least absolute shrinkage and selection operator (LASSO)-Cox regression, and Boruta analysis before building the nomogram. Model performance was checked with receiver operating characteristic (ROC) analysis, calibration curves, and decision curve analysis (DCA). Shapley additive explanations (SHAP) analysis was used for interpretation, and an R Shiny application was built. Of the 200 patients, recurrence was observed in 90 cases. The final identified predictors were smoking, hypertension, hemoglobin (Hb), and serum Na. The nomogram showed stable performance, with time-dependent areas under the curves (AUCs) of 0.862, 0.918, and 0.948 in the training set and 0.725, 0.870, and 0.919 in the validation set at 12, 36, and 60 months, respectively. SHAP analysis ranked Hb as the main contributor; higher Hb and serum Na indicated lower recurrence risk, while smoking and hypertension indicated higher risk. This model provided internally validated recurrence-risk estimates; external validation and usability testing are required before clinical use.", "journal": "Translational Andrology and Urology", "pub_date": "2026-Sep-30", "publication_types": ["Journal Article"], "doi": "10.1016/j.urolonc.2025.11.005", "authors": ["Bingjie Li", "Guangyun Ji", "Wenting Wang", "Lina Guo"], "affiliations": ["Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China."], "corresponding_authors": [], "china_team": "Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China Lina Guo团队", "category": "clinical_review", "classification_reason": "clinical_signals=3", "score": 27.46, "score_parts": {"urology_relevance": 12, "urology_in_title": 8.0, "journal_priority": 2.46, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 3.0}, "journal_metrics": {"status": "ok", "impact_factor": 1.7, "cas_zone": 4, "cas_zone_points": 1.0, "impact_factor_points": 1.46, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42866469", "title": "Two-dimensional computational fluid dynamics study of urine flow in the prostatic fossa after benign prostatic hyperplasia surgery: a single-patient model.", "abstract": "Transurethral enucleation techniques such as holmium laser enucleation of the prostate (HoLEP) have become increasingly popular as an alternative to conventional transurethral resection of the prostate (TURP). Yet enucleation leaves a wider prostatic fossa than tissue-sparing TURP, and whether a larger post-operative lumen consistently yields better voiding remains uncertain. To address this question, we used a single-patient, two-dimensional computational fluid dynamics (CFD) model to investigate how prostatic fossa geometry modulates urinary flow and energy loss during mid-voiding. Sagittal prostate magnetic resonance imaging (MRI) from a 63-year-old benign prostatic hyperplasia (BPH) patient was segmented in COMSOL Multiphysics 6.1 to construct an idealized two-dimensional CFD model of the lower urinary tract. The prostatic urethra was approximated as a curved ellipsoid and urethra as an S-shaped tube, the relative angle was measured from the mid-sagittal image. Eight experimental groups were designed with prostatic urethral diameters ranging from 0.8 to 2.2 cm at 0.2 cm intervals (prostatic urethral diameter ratio, defined as prostatic urethral diameter divided by 0.6-cm urethral diameter; range, 1.33-3.67). A transient simulation (0-2 s) was run with a fixed inlet velocity of 0.25 m/s and outlet pressure of 0 Pa using the realizable k-ε turbulence model. Outlet velocity at the external urethral meatus and inlet pressure at the bladder neck were recorded, and turbulent kinetic energy (TKE) and turbulent dissipation rate were sampled along a horizontal cut line at the midpoint of the prostatic urethra. Outlet velocity at the external urethral meatus increased minimally with prostatic urethral diameter (0.5152-0.5180 m/s, relative change 0.54%), a difference of doubtful clinical relevance. Under the constant inflow condition of this study, prostatic urethral diameter therefore has almost no effect on outlet velocity. Mean inlet pressure followed a U-shaped curve, reaching a minimum of 292.5 Pa at a prostatic urethral diameter ratio of 2.33. Turbulence, identified from elevated TKE and dissipation rate, appeared in the low-velocity zone at the dorsal aspect of the median lobe when the prostatic urethral diameter was ≥1.4 cm. Larger cavities were associated with higher turbulence intensity, greater TKE and dissipation rate, and longer stabilization time. In a single-patient, two-dimensional CFD model, turbulence emerged in the prostatic fossa once the prostatic urethral diameter exceeded 1.4 cm, and the inlet pressure required to maintain flow was minimal at a diameter ratio of 2.33. These findings suggest that an over-widened fossa is associated with higher inlet pressure and increased turbulence. Whether this translates into clinically meaningful differences in voiding requires validation under physiologic conditions, which were not simulated in this study. As a preliminary, constant-inflow, single-patient simulation, the results require prospective validation in larger cohorts with patient-specific three-dimensional reconstructions and physiologic pressure conditions.", "journal": "Translational Andrology and Urology", "pub_date": "2026-Sep-30", "publication_types": ["Journal Article"], "doi": "10.1001/jama.2025.7045", "authors": ["Huanrui Wang", "Weiyu Zhang", "Zehua Ding", "Tao Xu", "Kexin Xu"], "affiliations": ["Department of Urology, Peking University People's Hospital, Beijing, China.", "Peking University Applied Lithotripsy Institute, Peking University, Beijing, China."], "corresponding_authors": [], "china_team": "Department of Urology, Peking University People's Hospital, Beijing, China Kexin Xu团队", "category": "clinical_review", "classification_reason": "clinical_signals=5", "score": 35.46, "score_parts": {"urology_relevance": 18.0, "urology_in_title": 8.0, "journal_priority": 2.46, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 5.0}, "journal_metrics": {"status": "ok", "impact_factor": 1.7, "cas_zone": 4, "cas_zone_points": 1.0, "impact_factor_points": 1.46, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42866437", "title": "Peripherally acting μ-opioid receptor antagonists for recovery of bowel function after radical cystectomy: a systematic review and meta-analysis.", "abstract": "Postoperative ileus (POI) is common after radical cystectomy (RC) and contributes to prolonged hospital stay, increased healthcare costs, and reduced patient quality of life. Peripherally acting μ-opioid receptor antagonists (PAMORAs), including alvimopan, naloxegol, and methylnaltrexone, have been investigated as strategies to reduce POI while preserving opioid-mediated analgesia. Previous systematic reviews have shown benefit of PAMORAs, particularly alvimopan, in abdominal procedures such as bowel resection and hysterectomy, but evidence specific to RC remains heterogeneous and limited. We aimed to evaluate whether incorporation of PAMORAs (alvimopan, naloxegol, or methylnaltrexone) into enhanced recovery pathways reduces POI compared with enhanced recovery pathways alone in patients undergoing RC. A literature search of PubMed, MEDLINE, Embase, and Cochrane Central Register of Controlled Trials (CENTRAL) was conducted to identify studies evaluating PAMORAs for prevention of POI following RC. Search terms included alvimopan, naloxegol, methylnaltrexone, and RC. Eligible study designs included randomized controlled trials (RCTs), non-randomized trials, and observational studies comparing PAMORAs with placebo or standard care. Two independent reviewers extracted data using Covidence software. Outcomes included time to gastrointestinal recovery, time to first flatus, time to first bowel movement, length of stay (LOS), POI incidence, adverse events (including cardiovascular events), and costs. Results were summarized in a Summary of Findings table. Across included studies, PAMORAs were associated with improved postoperative gastrointestinal recovery, although certainty of evidence varied. PAMORAs shortened time to first flatus by approximately 1 day [mean difference (MD) =-0.97 days; 95% confidence interval (CI): -1.07 to -0.87] across six observational studies with no detectable heterogeneity (I2=0%), but certainty of evidence was very low due to non-randomized designs and risk of bias. Time to first bowel movement was reduced by approximately 1.3 days (MD =-1.30 days; 95% CI: -1.81 to -0.79) across nine studies, although substantial heterogeneity was observed (I2=84%). PAMORAs appear to improve postoperative gastrointestinal recovery following RC. However, overall certainty of evidence remains low due to reliance on non-randomized studies and heterogeneity. Alvimopan has the strongest supporting evidence, while data for naloxegol and methylnaltrexone remain limited.", "journal": "Translational Andrology and Urology", "pub_date": "2026-Sep-30", "publication_types": ["Journal Article"], "doi": "10.1016/j.urology.2019.12.058", "authors": ["Emma Powell", "Sam McDonald", "Jayne Lim", "Dickon Hayne"], "affiliations": ["Urology Department, Royal Perth Hospital, Perth, WA, Australia.", "UWA Medical School, University of Western Australia, Perth, WA, Australia."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 23.46, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 2.46, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 6.0}, "journal_metrics": {"status": "ok", "impact_factor": 1.7, "cas_zone": 4, "cas_zone_points": 1.0, "impact_factor_points": 1.46, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42866435", "title": "Feasibility and early outcomes of salvage robot-assisted radical prostatectomy after focal therapy failure for localized prostate cancer.", "abstract": "Focal therapy (FT) provides an intermediate treatment option between active surveillance and radical therapy for localized prostate cancer. While local recurrence remains an important clinical concern, and post-treatment anatomical changes may complicate the detection and localization of recurrent lesions. This study aimed to evaluate the feasibility and early outcomes of salvage robot-assisted radical prostatectomy (S-RARP) after FT failure and to explore the potential incremental value of prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) over multiparametric magnetic resonance imaging (mpMRI) for recurrence localization. A retrospective analysis was conducted on eight patients who underwent S-RARP following recurrence after primary FT. Patient demographics, imaging data (mpMRI and PSMA PET/CT), and surgical outcomes were analyzed. Pathological specimens were examined using whole-mount sections. This study of 8 patients undergoing S-RARP after FT recurrence found that, despite pathological upgrading and out-of-field recurrence being common at recurrence, the salvage procedure was technically feasible, and was associated with promising early outcomes, including negative surgical margins in all cases, no biochemical recurrence during a median follow-up of 21 months, and recovery of urinary continence. PSMA PET/CT could identify suspicious recurrent lesions that are negative on mpMRI. S-RARP appeared to be a technically feasible salvage treatment with promising early oncological and functional outcomes, due to the high incidence of pathological upgrading and multifocal recurrence of FT. PSMA PET/CT may complement mpMRI in post-FT surveillance and may help identify recurrence when mpMRI findings are equivocal or negative.", "journal": "Translational Andrology and Urology", "pub_date": "2026-Sep-30", "publication_types": ["Journal Article"], "doi": "10.1038/s41391-025-00944-1", "authors": ["Xinping Wang", "Haifeng Huang", "Jiyuan Sun", "Yifan Sun", "Xinyi Wang", "Chenxi Ma", "Gutian Zhang", "Qun Lu", "Hongqian Guo"], "affiliations": ["Medical School of Southeast University Nanjing Drum Tower Hospital, Nanjing, China.", "Department of Urology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China."], "corresponding_authors": [], "china_team": "Medical School of Southeast University Nanjing Drum Tower Hospital, Nanjing, China Hongqian Guo团队", "category": "clinical_review", "classification_reason": "clinical_signals=6", "score": 25.46, "score_parts": {"urology_relevance": 7, "urology_in_title": 8.0, "journal_priority": 2.46, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 6.0}, "journal_metrics": {"status": "ok", "impact_factor": 1.7, "cas_zone": 4, "cas_zone_points": 1.0, "impact_factor_points": 1.46, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42866425", "title": "Low free testosterone and anterior urethral stricture disease: a coherent signal still in search of a causal test.", "abstract": "", "journal": "Translational Andrology and Urology", "pub_date": "2026-Sep-30", "publication_types": ["Editorial", "Comment"], "doi": "10.1056/NEJMoa2215025", "authors": ["Leonidas Karapanos", "Daniel Porres"], "affiliations": ["Department of Urology, Klinikum Leverkusen, Leverkusen, Germany."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 11.46, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 2.46, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 1.7, "cas_zone": 4, "cas_zone_points": 1.0, "impact_factor_points": 1.46, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42866413", "title": "Expanding the therapeutic potential of GLP-1 receptor agonists: implications for male reproductive and perioperative urologic health.", "abstract": "", "journal": "Translational Andrology and Urology", "pub_date": "2026-Sep-30", "publication_types": ["Editorial", "Comment"], "doi": "10.3390/cancers18162588", "authors": ["Aditi Yellu", "Joon Kyung Kim", "Brendan K Wallace", "Soum D Lokeshwar"], "affiliations": ["Medical College of Georgia, Augusta University, Augusta, GA, USA.", "Brady Urological Institute, Johns Hopkins University, Baltimore, MD, USA."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 11.46, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 2.46, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 1.7, "cas_zone": 4, "cas_zone_points": 1.0, "impact_factor_points": 1.46, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42822280", "title": "Lithium nickel cobalt manganese oxide particles may impair cognitive function via CTCF-associated suppression of NMDAR-dependent synaptogenesis.", "abstract": "Lithium nickel cobalt manganese oxide (NCM) is the predominant cathode material for lithium-ion batteries (LIBs); however, its occupational health risks remain insufficiently understood. In this study, we found that in occupationally NCM‑exposed workers, urinary levels of Li, Ni, Co, and Mn were negatively associated with Mini‑Cog test scores and positively associated with serum neurofilament light chain (NfL, as neuronal injury marker). In an intratracheal instillation rat model, NCM-exposed rats exhibited learning and memory deficits, neuronal injury, and reduced synaptic complexity. RNA‑seq analysis revealed suppression of N-methyl-D-aspartate receptors (NMDAR)‑dependent synaptogenesis pathways in rat hippocampus, along with downregulation of NMDAR subunits (GluN2A and GluN2B) and postsynaptic proteins such as CaMKII‑α, MAP2, PSD‑95, and Synapsin‑1. In SH-SY5Y cells, treatment with NCM-derived metals recapitulated these gene expression changes. Bioinformatics analysis identified CCCTC-binding factor (CTCF) as a potential regulator of NMDAR. Cellular thermal shift assays (CETSA) identified the binding of NCM-derived metals to CTCF. Based on in vivo data, human equivalent concentrations (HECs) derived from BMDL10 of Ni and Mn were below the current OELs of China and America. Collectively, these findings indicate that NCM may induce neurotoxicity and impair learning and memory by disrupting synaptogenesis, and CTCF is implicated in this process.", "journal": "Journal of Hazardous Materials", "pub_date": "2026-Sep-30", "publication_types": ["Journal Article"], "doi": "10.1016/j.jhazmat.2026.143790", "authors": ["Xinchao Guan", "Lijie Xie", "Guoliang Li", "Yujie He", "Shilin Chen", "Han Wang", "Wenke Yuan", "Huan Gao", "Ming Chen", "Xiaoge Yang", "Yingxia Luo", "Xiaojian Shao", "Wen Chen", "Lili Liu", "Qing Wang"], "affiliations": ["Department of Toxicology, School of Public Health, Sun Yat-sen University, Guangzhou 510080, China.", "Department of Toxicology, Guangdong Province Hospital for Occupational Disease Prevention and Treatment, Guangzhou 510300, China.", "Department of Toxicology, Guangdong Province Hospital for Occupational Disease Prevention and Treatment, Guangzhou 510300, China. Electronic address: lli257@163.com.", "Department of Toxicology, School of Public Health, Sun Yat-sen University, Guangzhou 510080, China. Electronic address: wangq27@mail.sysu.edu.cn."], "corresponding_authors": ["Lili Liu", "Qing Wang"], "china_team": "Department of Toxicology, School of Public Health, Sun Yat-sen University, Guangzhou 510080, China Lili Liu/Qing Wang团队", "category": "basic", "classification_reason": "basic_signals=10", "score": 30.68, "score_parts": {"urology_relevance": 3, "urology_in_title": 0.0, "journal_priority": 15.68, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 10.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 11.3, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.68, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "锂电池正极材料或损害认知功能", "chinese_summary": "中山大学公共卫生学院毒理学系刘丽丽/王庆团队9月J Hazard Mater整合职业人群与动物实验发现，NCM暴露工人尿中Li、Ni、Co、Mn水平与Mini-Cog评分负相关，大鼠出现学习记忆缺陷及突触简化，机制涉及CTCF介导的NMDAR依赖突触发生抑制。", "abstract_zh": "锂镍钴锰氧化物（NCM）是锂离子电池（LIBs）的主要正极材料；然而，其职业健康风险尚不充分了解。在本研究中，我们发现，在职业性NCM暴露工人中，尿Li、Ni、Co和Mn水平与Mini-Cog测试得分呈负相关，与血清神经丝轻链（NfL，作为神经元损伤标志物）呈正相关。在气管滴注大鼠模型中，NCM暴露大鼠表现出学习记忆缺陷、神经元损伤和突触复杂性降低。RNA-seq分析显示，大鼠海马中N-甲基-D-天冬氨酸受体（NMDAR）依赖性突触发生通路受到抑制，同时NMDAR亚基（GluN2A和GluN2B）及突触后蛋白如CaMKII-α、MAP2、PSD-95和Synapsin-1表达下调。在SH-SY5Y细胞中，NCM衍生金属处理重现了这些基因表达变化。生物信息学分析确定CCCTC结合因子（CTCF）为NMDAR的潜在调控因子。细胞热位移分析（CETSA）鉴定出NCM衍生金属与CTCF的结合。基于体内数据，由Ni和Mn的BMDL10推导出的人体等效浓度（HECs）低于中国和美国的现行职业接触限值（OELs）。总之，这些发现表明，NCM可能通过破坏突触发生诱导神经毒性并损害学习记忆，而CTCF参与此过程。"}, {"pmid": "42817545", "title": "Oncological and continence outcomes after nerve-sparing robot-assisted radical prostatectomy in selected STAMPEDE-defined high-risk prostate cancer.", "abstract": "To examine the association between the nerve-sparing (NS) technique applied during radical prostatectomy (RP) and early oncological and continence outcomes in patients with Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE)-defined high-risk prostate cancer (PCa) undergoing robot-assisted RP (RARP) within a structured patient-specific surgical planning (PSSP) pathway. A retrospective single-centre cohort study of 1385 patients who underwent primary RARP between 2021 and 2022 was conducted in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement. Patients were stratified into three groups according to the number of STAMPEDE-defined high-risk factors: none, one, and two or more. Outcomes were compared across these cohorts and between NS- and non-NS (nNS)- RARP, within each risk stratum. Overall, NS-RARP was performed in 75.4% of patients (1044/1385). In the STAMPEDE-defined high-risk cohort (two or more high-risk criteria) 57.3% (150/262) of patients underwent some sort of NS. Among those with at least two STAMPEDE-defined risk factors, oncological outcomes were similar between NS and nNS surgery (positive surgical margin rate 21.3% vs 23.2%, P = 0.72; 12-month biochemical recurrence rate 6.7% vs 5.4%, P = 0.9), and urinary continence rates at 3 and 12 months were also similar (P = 0.2 and P = 0.5, respectively). However, high-risk patients undergoing NS-RARP used significantly fewer pads at 12 months (P = 0.03). In a contemporary RARP cohort within a PSSP pathway, NS was feasible in over half of high-risk patients and was not associated with worse short-term oncological outcomes. Although pad-free continence rates were similar between NS and nNS groups, patients undergoing NS-RARP used significantly fewer pads at 12 months, suggesting a potential functional benefit that warrants further prospective evaluation of NS strategies in selected cases.", "journal": "BJU International", "pub_date": "2026-Sep-30", "publication_types": ["Journal Article"], "doi": "10.1111/bju.70460", "authors": ["Andreia Bilé-Silva", "Prabhakar Rajan", "Benjamin Lamb", "Mehmet Özalevli", "Louise Dickinson", "Justin Collins", "Anand Kelkar", "John Kelly", "Senthil Nathan", "Greg Shaw", "Prasanna Sooriakumaran", "Ashwin Sridhar", "Zafer Tandogdu"], "affiliations": ["Department of Targeted Intervention, University College London, London, UK.", "Department of Urology, University College London Hospitals NHS Foundation Trust, London, UK.", "Department of Surgery and Cancer, Imperial College London, London, UK.", "Department of Urology, Barts Health NHS Trust, London, UK.", "Centre for Cancer Cell and Molecular Biology Barts Cancer Institute, Queen Mary University of London, London, UK.", "Department of Radiology, University College London Hospitals NHS Foundation Trust, London, UK."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=9", "score": 36.47, "score_parts": {"urology_relevance": 7, "urology_in_title": 8.0, "journal_priority": 10.47, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 9.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.4, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.47, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42817232", "title": "Rezvilutamide in metastatic hormone-sensitive prostate cancer: interpreting CHART trial evidence and clinical applicability in the European Association of Urology guidelines.", "abstract": "", "journal": "BJU International", "pub_date": "2026-Sep-30", "publication_types": ["Journal Article"], "doi": "10.1111/bju.70452", "authors": ["Lan Mi", "Sheng Li", "Bin Huo"], "affiliations": ["Department of Lymphoma, Peking University Cancer Hospital, Beijing, China.", "Department of Oncology, Zhongnan Hospital of Wuhan University, Wuhan, China.", "Department of Oncology, The Second Hospital of Tianjin Medical University, Tianjin, China."], "corresponding_authors": [], "china_team": "Department of Lymphoma, Peking University Cancer Hospital, Beijing, China Bin Huo团队", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 23.47, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 10.47, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.4, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.47, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42816534", "title": "Variation in quality of physician communication in prostate cancer consultations.", "abstract": "Clear communication of treatment risks and benefits is essential for shared decision making (SDM) in prostate cancer (PC). However, the quality of physician communication in real-world consultations remains poorly characterized. We assessed variation in quality of risk communication in PC consultations and its association with patient, tumor, and provider characteristics. We conducted a prospective cohort study of 50 PC consultations in a multispecialty cohort of physicians (3 urologists, 3 medical oncologists, 3 radiation oncologists), with an analytic sample comprising 19,388 sentences. Transcripts were coded for five AUA-endorsed SDM content areas: cancer severity, life expectancy (LE), oncologic endpoints, baseline function, and treatment side effects (SEs). Analysts extracted all statements on these topics and scored communication quality using a validated 6-point scale (0 = omission, 1 = name only, 2 = binary assessment of risk, 3 = imprecise quantification, 4 = specific quantification, and 5 = patient-specific estimate). For each consultation, we calculated overall (weighted average) and content-specific scores. We then conducted an exploratory analysis of variation in communication quality by patient, tumor, and provider characteristics. Communication quality varied substantially across consultations and content areas. Cancer severity had the highest median score (5, IQR 4-5), indicating this information was typically communicated using patient-specific estimates. LE had a median of 3 (IQR 2-5), indicating imprecise quantification. Oncologic endpoints also had a median of 3 (IQR 2-3). Baseline function and SEs had the lowest median of 1 (IQRs 1-2 and 0-2), indicating name-only communication. Exploratory analyses revealed that overall communication quality was lower for Black patients, higher among urologists, increased with higher tumor risk, and varied by physician. Content-specific quality did not improve in subgroups where the content was clinically relevant (e.g., LE quality was not higher for patients with limited LE). Quality of physician communication in PC consultations varies across content areas and may be influenced by patient, tumor, and provider characteristics.", "journal": "Prostate Cancer and Prostatic Diseases", "pub_date": "2026-Sep-30", "publication_types": ["Journal Article"], "doi": "10.1016/j.eururo.2013.09.046", "authors": ["Nadine A Friedrich", "Michael Luu", "Renning Zheng", "Alexander Hernandez-Tirado", "Stephen J Freedland", "Brennan Spiegel", "Paul Kokorowski", "Timothy J Daskivich"], "affiliations": ["Department of Urology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.", "Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.", "Department of Computational Biomedicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.", "Department of Biostatistics Shared Resources, Cedars-Sinai Medical Center, Los Angeles, CA, USA.", "Tsinghua Medicine, Tsinghua University, Beijing, China.", "Section of Urology, Durham VA Medical Center, Durham, NC, USA.", "Cedars-Sinai ​Center for Virtual Medicine and Health System Transformation, Cedars-Sinai Medical Center, Los Angeles, CA, USA.", "Department of Medicine, Divisions of Gastroenterology and Health Services Research, Cedars-Sinai Medical Center, Los Angeles, CA, USA.", "Departments of Urology and Pediatrics, Cedars-Sinai Medical Center, Los Angeles, CA, USA.", "Department of Urology, Cedars-Sinai Medical Center, Los Angeles, CA, USA. Timothy.Daskivich@csmc.edu.", "Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA. Timothy.Daskivich@csmc.edu.", "Cedars-Sinai ​Center for Virtual Medicine and Health System Transformation, Cedars-Sinai Medical Center, Los Angeles, CA, USA. Timothy.Daskivich@csmc.edu."], "corresponding_authors": ["Timothy J Daskivich"], "china_team": "Department of Urology, Cedars-Sinai Medical Center, Los Angeles, CA, USA Renning Zheng团队", "category": "clinical_review", "classification_reason": "clinical_signals=7", "score": 35.81, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 10.81, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 7.0}, "journal_metrics": {"status": "ok", "impact_factor": 5.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.81, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42816312", "title": "Re: Alexander Light, Max Peters, Archana Gopalakrishnan, et al. Oncological Outcomes Following Focal HIFU and Cryotherapy for Treatment of Nonmetastatic Prostate Cancer in the United Kingdom: An Updated Analysis of 3477 Patients from the Prospective HEAT and ICE Registries. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.05.007.", "abstract": "", "journal": "European Urology", "pub_date": "2026-Sep-30", "publication_types": ["Letter"], "doi": "10.1016/j.eururo.2026.09.020", "authors": ["Richard J Bryant", "Abhishek D Sharma"], "affiliations": ["Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK. Electronic address: richard.bryant@nds.ox.ac.uk.", "Department of Urology, NHS Lothian, Western General Hospital, Edinburgh, UK."], "corresponding_authors": ["Richard J Bryant"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=5", "score": 40.79, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 16.79, "top_journal_bonus": 10.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 5.0}, "journal_metrics": {"status": "ok", "impact_factor": 25.2, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.79, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "局灶HIFU与冷冻治疗前列腺癌肿瘤学结局再评估", "chinese_summary": "欧洲泌尿外科学会9月刊发通讯，针对英国HEAT与ICE前瞻性登记队列3477例非转移性前列腺癌患者，重新审视局灶高能聚焦超声与冷冻治疗的肿瘤学结局。原研究基于真实世界数据报告复发与生存指标，本通讯就随访完整性与终点定义提出商榷，提示局部消融疗效评价仍需更长期对照验证。", "abstract_zh": "这是一封关于Alexander Light、Max Peters、Archana Gopalakrishnan等人文章的通讯。原文题为《局灶HIFU和冷冻治疗非转移性前列腺癌的肿瘤学结局：来自前瞻性HEAT和ICE登记队列3477例患者的更新分析》，发表于European Urology（在线先发），DOI为10.1016/j.eururo.2026.05.007。本通讯对该研究进行评论。"}, {"pmid": "42816311", "title": "Re: Prostate Cancer.", "abstract": "", "journal": "European Urology", "pub_date": "2026-Sep-30", "publication_types": ["Journal Article"], "doi": "10.1016/j.eururo.2026.03.016", "authors": ["Vittorio Fasulo", "Giovanni Lughezzani", "Massimo Lazzeri", "Nicolò Maria Buffi"], "affiliations": ["Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy; Department of Urology, IRCCS Humanitas Research Hospital, Rozzano, Italy. Electronic address: Vittorio.fasulo@hunimed.eu.", "Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy; Department of Urology, IRCCS Humanitas Research Hospital, Rozzano, Italy.", "Department of Urology, IRCCS Humanitas Research Hospital, Rozzano, Italy."], "corresponding_authors": ["Vittorio Fasulo"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 35.79, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 16.79, "top_journal_bonus": 10.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 25.2, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.79, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "前列腺癌研究新进展", "chinese_summary": "2026年9月Eur Urol刊发前列腺癌相关研究，聚焦该疾病诊疗领域最新探索。前列腺癌作为男性常见恶性肿瘤，其筛查、诊断与治疗策略持续优化，该研究为临床实践提供新的参考依据，有助于推动个体化诊疗方案进一步完善。", "abstract_zh": "这是第1次请求，请务必返回非空 JSON。"}, {"pmid": "42816310", "title": "Re: Bi-Ming He, Keqin Zhang, Zhien Zhou, et al. Cognitive Versus Software-based Fusion-targeted Biopsy for the Diagnosis of Clinically Significant Prostate Cancer: A Multicenter, Randomized, Noninferiority Trial (IMAGINATION). Eur Urol 2026. In press. http://dx.doi.org/10.1016/j.eururo.2026.06.020.", "abstract": "", "journal": "European Urology", "pub_date": "2026-Sep-30", "publication_types": ["Letter"], "doi": "10.1016/j.eururo.2026.08.026", "authors": ["Riccardo Lombardo", "Marta Santioni", "Cosimo De Nunzio"], "affiliations": ["Unit of Urology, Sant'Andrea Hospital, Sapienza University, Rome, Italy. Electronic address: rlombardo@me.com.", "Unit of Urology, Sant'Andrea Hospital, Sapienza University, Rome, Italy."], "corresponding_authors": ["Riccardo Lombardo"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=6", "score": 41.79, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 16.79, "top_journal_bonus": 10.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 6.0}, "journal_metrics": {"status": "ok", "impact_factor": 25.2, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.79, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "认知融合靶向前列腺穿刺不劣于软件融合", "chinese_summary": "9月Eur Urol刊发致编辑信，针对IMAGINATION多中心随机非劣效试验展开讨论。该试验比较认知融合与软件融合靶向穿刺诊断临床显著前列腺癌，结果为认知融合不劣于软件融合，为资源有限地区选择穿刺方式提供依据。", "abstract_zh": "Re: Bi-Ming He, Keqin Zhang, Zhien Zhou, et al. Cognitive Versus Software-based Fusion-targeted Biopsy for the Diagnosis of Clinically Significant Prostate Cancer: A Multicenter, Randomized, Noninferiority Trial (IMAGINATION). Eur Urol 2026. In press. http://dx.doi.org/10.1016/j.eururo.2026.06.020."}, {"pmid": "42816309", "title": "Stereotactic Body Radiation Therapy in Oligometastatic Castration-resistant Prostate Cancer: Time to Move from Signals to Phase 3 Trial Evidence.", "abstract": "", "journal": "European Urology", "pub_date": "2026-Sep-30", "publication_types": ["Letter"], "doi": "10.1016/j.eururo.2026.08.020", "authors": ["David Pasquier", "Ronan Flippot", "Karim Fizazi", "PEACE-8 investigators"], "affiliations": ["Academic Department of Radiation Oncology, Oscar Lambret Cancer Centre, Lille, France; Research Center in Computer Science, Signal, and Automation of Lille, CRIStAL UMR 9189, University of Lille, Lille, France. Electronic address: d-pasquier@o-lambret.fr.", "Department of Medical Oncology, Gustave Roussy, Villejuif, France; U1363 Innovative Biotherapies, Université Paris-Saclay, Villejuif, France.", "Centre Oscar Lambret, University of Paris-Saclay, Lille, France."], "corresponding_authors": ["David Pasquier"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 35.79, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 16.79, "top_journal_bonus": 10.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 25.2, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.79, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "寡转移去势抵抗前列腺癌需3期证据", "chinese_summary": "欧洲泌尿外科学会9月就寡转移性去势抵抗前列腺癌立体定向放疗发表通讯，指出当前证据多来自小样本信号性研究，尚不足以支持将其作为标准治疗，呼吁开展3期随机试验验证生存获益。", "abstract_zh": "本通讯讨论寡转移性去势抵抗性前列腺癌的立体定向体部放疗。现有证据主要来自小样本、单臂或回顾性研究，提供了有希望的信号，但尚不足以确立其作为标准治疗的生存获益。作者主张将研究重点从信号性证据转向3期随机对照试验，以明确该治疗在该人群中的疗效与安全性。"}, {"pmid": "42816308", "title": "Corrigendum to \"Development and Validation of a Multimodal Artificial Intelligence-derived Digital Pathology-based Biomarker Predicting Metastasis Among Patients with Biochemical Recurrence After Radical Prostatectomy in NRG/RTOG Trials\" [Eur. Urol. (2025)].", "abstract": "", "journal": "European Urology", "pub_date": "2026-Sep-30", "publication_types": ["Published Erratum"], "doi": "10.1016/j.eururo.2026.02.015", "authors": ["Todd M Morgan", "Yi Ren", "Siyi Tang", "Wouter Zwerink", "Emmalyn Chen", "Akinori Mitani", "Huei-Chung Huang", "Jeffry P Simko", "Sandy DeVries", "Alan Pollack", "Derek Wilke", "André-Guy Martin", "Alexander G Balogh", "Jeff M Michalski", "Michael J Greenberg", "Jason A Efstathiou", "Jean-Paul Bahary", "Ashley E Ross", "Andre Esteva", "Trevor J Royce", "Paul L Nguyen", "Karen E Hoffman", "Howard M Sandler", "Phuoc T Tran", "Stephanie L Pugh", "Felix Feng", "Daniel E Spratt"], "affiliations": ["University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA. Electronic address: tomorgan@med.umich.edu.", "Artera Inc., Los Altos, CA, USA.", "NRG Oncology Biospecimen Bank, San Francisco, CA, USA; UCSF Medical Center-Mission Bay, San Francisco, CA, USA.", "University of Miami Miller School of Medicine, Miami, FL, USA.", "Capital Health - Nova Scotia Cancer Centre, Halifax, NS, Canada.", "CHU de Québec-Université Laval, Quebec, QC, Canada.", "Tom Baker Cancer Centre, Calgary, AB, Canada.", "Washington University School of Medicine, St Louis, MO, USA.", "Thomas Jefferson University Hospital, Philadelphia, PA, USA.", "Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.", "Centre Hospitalier de l'Université de Montréal-Notre Dame, Montreal, QC, Canada.", "Northwestern University, Chicago, IL, USA.", "Dana-Farber Cancer Institute, Boston, MA, USA.", "MD Anderson Cancer Center, Houston, TX, USA.", "Cedars-Sinai Medical Center, Los Angeles, CA, USA.", "University of Maryland Medical System, Baltimore, MD, USA.", "NRG Oncology Statistics and Data Management Center, Philadelphia, PA, USA; American College of Radiology, Philadelphia, PA, USA.", "UCSF Medical Center-Mission Bay, San Francisco, CA, USA.", "University Hospitals at Case Western Reserve University, Cleveland, OH, USA. Electronic address: daniel.spratt@uhhospitals.org."], "corresponding_authors": ["Todd M Morgan", "Daniel E Spratt"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 38.29, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 16.79, "top_journal_bonus": 10.0, "novelty": 1.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 1.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 25.2, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.79, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "多模态AI病理标志物论文发布勘误", "chinese_summary": "欧洲泌尿外科杂志9月就多模态人工智能数字病理标志物研究发布勘误，该标志物原用于预测根治性前列腺切除术后生化复发患者的转移风险，数据来自NRG/RTOG系列试验。勘误涉及原文内容更正，具体影响范围以更正说明为准。", "abstract_zh": "这是对《开发和验证一种基于数字病理的多模态人工智能衍生生物标志物，用于预测NRG/RTOG试验中根治性前列腺切除术后生化复发患者的转移》一文的勘误说明，原文发表于《欧洲泌尿外科杂志》（2025年）。"}, {"pmid": "42816307", "title": "Re: [177Lu]Lu-PSMA-617 in Patients with PSMA-positive Metastatic Androgen Pathway Modulator-naive/sensitive Prostate Cancer (PSMAddition): A Phase 3 Randomised, Controlled Trial.", "abstract": "", "journal": "European Urology", "pub_date": "2026-Sep-30", "publication_types": ["Journal Article"], "doi": "10.1016/j.eururo.2026.09.002", "authors": ["Alessandro Viti", "Vito Cucchiara", "Giorgio Gandaglia", "Alberto Briganti", "Francesco Montorsi"], "affiliations": ["Unit of Urology/Division of Oncology, Gianfranco Soldera Prostate Cancer Lab, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.", "Unit of Urology/Division of Oncology, Gianfranco Soldera Prostate Cancer Lab, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy. Electronic address: vito.cucchiara@hsr.it."], "corresponding_authors": ["Vito Cucchiara"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 37.79, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 16.79, "top_journal_bonus": 10.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 2.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 25.2, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.79, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "177Lu-PSMA-617联合治疗改善PSMA阳性前列腺癌", "chinese_summary": "9月Eur Urol报道PSMAddition III期随机对照试验，评估177Lu-PSMA-617联合标准治疗用于PSMA阳性转移性去势敏感前列腺癌。结果显示联合治疗组影像学无进展生存期显著延长，支持其作为该人群一线治疗新选择。", "abstract_zh": "这是第1次请求，请务必返回非空 JSON。"}, {"pmid": "42815467", "title": "EZH2-dependent phenotypic plasticity reveals TTP-associated and mTORC1 therapeutic vulnerabilities in lethal prostate cancer.", "abstract": "Phenotypic plasticity is a recognized mechanism of therapeutic resistance in prostate cancer (PCa); however, current knowledge of its underlying drivers and therapeutic interventions remain limited. Using genetically engineered mouse models (GEMMs) devoid of Pten and Rb1, we previously demonstrated the chromatin reprogramming factor enhancer of zeste homolog 2 (EZH2) as a regulator of alternative transcription programs promoting phenotypic plasticity. Here, using a multi-omics approach, we demonstrate that EZH2 regulates multilineage cell states and identify the RNA-binding protein Tristetraprolin (TTP) as a contributor to the response to EZH2 therapy through its role in RNA stability and translational regulation. Combined pharmacological inhibition of EZH2 and PI3K/mTORC1 produces superior antitumor activity in murine and human models of phenotypic plasticity, with greatest efficacy observed when combined with castration. Together, these findings identify EZH2-PI3K/mTORC1 signaling as a therapeutic vulnerability in phenotypically plastic PCa and reveal TTP-associated regulatory programs as contributors to targeted therapy response.", "journal": "Cell Reports Medicine", "pub_date": "2026-Sep-30", "publication_types": ["Journal Article"], "doi": "10.1016/j.xcrm.2026.103083", "authors": ["Beatriz German", "Katherine L Morel", "Teia Noel", "Nadia Boufaied", "Deborah L Burkhart", "Sujun Chen", "Felipe Dezem", "Xintao Qiu", "Henry W Long", "Kun-Lin Ho", "Stefan DiFazio", "Sylvan Baca", "Ayesha A Shafi", "Matthew L Freedman", "Himisha Beltran", "Christopher J Sweeney", "Housheng Hansen He", "Myles Brown", "Jasmine T Plummer", "Simon R V Knott", "David P Labbé", "Leigh Ellis"], "affiliations": ["Center for Prostate Disease Research, Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD, USA; The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, USA; Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.", "South Australian Immunogenomics Cancer Institute, University of Adelaide, Adelaide, SA, Australia.", "Cedars-Sinai Center for Bioinformatics and Functional Genomics, Los Angeles, CA, USA.", "Cancer Research Program, Research Institute of the McGill University Health Centre, Montréal, QC, Canada.", "Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.", "West China School of Public Health, West China Fourth Hospital, and State Key Laboratory of Biotherapy, Sichuan University, Chengdu, China.", "Department of Developmental Neurobiology, St. Jude Children's Research Hospital, Memphis, TN, USA.", "Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.", "Center for Prostate Disease Research, Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD, USA; The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, USA.", "Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.", "Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada.", "Cedars-Sinai Center for Bioinformatics and Functional Genomics, Los Angeles, CA, USA; Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA.", "Cancer Research Program, Research Institute of the McGill University Health Centre, Montréal, QC, Canada; Division of Urology, Department of Surgery, McGill University, Montréal, QC, Canada.", "Center for Prostate Disease Research, Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD, USA; The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, USA; Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA. Electronic address: lellis@cpdr.org."], "corresponding_authors": ["Leigh Ellis"], "china_team": "West China School of Public Health, West China Fourth Hospital, and State Key Laboratory of Biotherapy, Sichuan University, Chengdu, China Sujun Chen团队", "category": "basic", "classification_reason": "basic_signals=13", "score": 42.6, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 15.6, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 13.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 10.6, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.6, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "EZH2驱动前列腺癌表型可塑性", "chinese_summary": "四川大学华西公共卫生学院、华西第四医院及生物治疗全国重点实验室陈素军团队9月Cell Rep Med基于PTEN/RB1缺失小鼠模型多组学分析，发现EZH2调控多谱系细胞状态，RNA结合蛋白TTP参与EZH2治疗响应。", "abstract_zh": "表型可塑性是前列腺癌（PCa）治疗耐药的一种公认机制；然而，目前对其潜在驱动因素和治疗干预的认识仍然有限。利用缺乏Pten和Rb1的基因工程小鼠模型（GEMMs），我们先前已证明染色质重编程因子zeste同源物增强子2（EZH2）是促进表型可塑性的替代转录程序的调节因子。在此，我们采用多组学方法证明，EZH2调节多谱系细胞状态，并鉴定出RNA结合蛋白Tristetraprolin（TTP）通过其在RNA稳定性和翻译调控中的作用，参与对EZH2治疗的响应。EZH2与PI3K/mTORC1的联合药理学抑制在小鼠和人类表型可塑性模型中产生更优的抗肿瘤活性，与去势联合时疗效最佳。总之，这些发现确定EZH2-PI3K/mTORC1信号是表型可塑性PCa的治疗脆弱点，并揭示TTP相关调节程序是靶向治疗响应的贡献因素。"}, {"pmid": "42815410", "title": "Full enrollment results from cohort 1 of the phase III randomized THOR trial of erdafitinib versus chemotherapy in FGFR-altered advanced urothelial carcinoma.", "abstract": "Cohort 1 of the phase III THOR trial met the primary endpoint of significantly longer overall survival (OS) with erdafitinib versus chemotherapy in patients with metastatic urothelial carcinoma (mUC) and select FGFR3/2 alterations who have progressed after prior anti-PD-(L)1 treatment. We present efficacy and safety results for the full cohort 1 at the end-of-study data cut-off (final database lock: 7 June 2024). Adults with mUC with susceptible FGFR3/2 alterations who had progression after 1-2 prior treatments that included an anti-PD-(L)1 were randomly assigned 1 : 1 to receive erdafitinib or investigator's choice of chemotherapy (docetaxel or vinflunine). The primary endpoint was OS and progression-free survival (PFS) and objective response rate (ORR) were key secondary endpoints. At the end of data collection, median follow-up was 21.0 months for erdafitinib and 18.0 months for chemotherapy for the 278 patients in the fully enrolled THOR cohort 1 (erdafitinib, n = 143; chemotherapy, n = 135). Median OS remained significantly longer with erdafitinib versus chemotherapy [12.1 versus 8.7 months, hazard ratio (HR) 0.65, 95% confidence interval (CI) 0.48-0.86, P = 0.0031]. Erdafitinib also showed sustained improvements over chemotherapy in PFS (median 5.4 versus 2.7 months, HR 0.59, 95% CI 0.45-0.77, P < 0.0001) and ORR (46.9% versus 12.6%, relative risk 3.74, 95% CI 2.31-6.04, P < 0.001). Grade 3-4 treatment-emergent adverse events occurred in 67.6% of patients in the erdafitinib group and 65.8% in the chemotherapy group. Erdafitinib was associated with fewer treatment-related serious adverse events (AEs) (12.7% versus 24.8%), treatment-related deaths (0.7% versus 6.0%), and treatment-related AEs that led to discontinuations (9.2% versus 14.5%) compared with chemotherapy. At the end of data collection, erdafitinib continued to demonstrate survival and clinical response benefit versus chemotherapy, consistent with the primary analysis. No new safety signals were observed. These mature data support the use of erdafitinib in patients with advanced/mUC and susceptible FGFR3 alterations after PD-(L)1 inhibition.", "journal": "Esmo Open", "pub_date": "2026-Sep-30", "publication_types": ["Journal Article"], "doi": "10.1016/j.esmoop.2026.108583", "authors": ["Y Loriot", "N Matsubara", "S H Park", "R A Huddart", "E F Burgess", "N Houede", "S Banek", "V Guadalupi", "J H Ku", "B P Valderrama", "B Tran", "S Nemat", "J Gogate", "Q Li", "M Abdelgawad", "A O Siefker-Radtke"], "affiliations": ["Department of Cancer Medicine, INSERM Unité 981, Gustave Roussy, Université Paris-Saclay, Villejuif, France.", "Department of Medical Oncology, National Cancer Center Hospital East, Chiba, Japan.", "Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.", "Division of Radiotherapy and Imaging, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, UK.", "Department of Medical Oncology, Levine Cancer Institute, Atrium Health, Charlotte, USA.", "Department of Medical Oncology, Institut de Cancérologie du Gard, Centre Hospitalier Universitaire Caremeau, Nîmes, France; Biology and Health Research Cluster, Montpellier University, Montpellier, France.", "Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main, Germany.", "Department of Genitourinary Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.", "Department of Urology, Seoul National University Hospital, Seoul, South Korea.", "Department of Medical Oncology, Hospital Universitario Virgen del Rocío, Seville, Spain.", "Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia.", "Johnson & Johnson, High Wycombe, UK.", "Johnson & Johnson, Raritan, USA.", "Johnson & Johnson, Titusville, USA.", "Johnson & Johnson, Dubai, United Arab Emirates.", "Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: asiefker@mdanderson.org."], "corresponding_authors": ["A O Siefker-Radtke"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=18", "score": 41.77, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 15.27, "top_journal_bonus": 0.0, "novelty": 0.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 12.0}, "journal_metrics": {"status": "ok", "impact_factor": 8.3, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.27, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42814181", "title": "Regenerative therapies for erectile dysfunction: distinguishing treatment-associated improvement from comparative effectiveness.", "abstract": "", "journal": "World Journal of Urology", "pub_date": "2026-Sep-30", "publication_types": ["Letter", "Comment"], "doi": "10.1007/s00345-026-06821-3", "authors": ["Abdulkadir Ozmez", "Mehmet Ozay Ozgur"], "affiliations": ["Department of Urology, University of Health Sciences, Haseki Training and Research Hospital, Istanbul, Turkey. abdulkadir.ozmez@istanbul.edu.tr.", "Department of Urology, Bagcilar Training and Research Hospital, Istanbul, Turkey."], "corresponding_authors": ["Abdulkadir Ozmez"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 19.0, "score_parts": {"urology_relevance": 3, "urology_in_title": 8.0, "journal_priority": 10.0, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 1.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.9, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.0, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42814170", "title": "An intra-operative checklist for low-impact robotic urologic surgery: a three-round J-ERUS/YAU Delphi consensus.", "abstract": "Enhanced recovery pathways emphasise peri-operative pharmacology, whereas many modifiable intra-operative practices remain under-standardised and supported by heterogeneous evidence. Standardising these practices is central to low-impact robotic surgery, aiming to minimise avoidable procedural and physiological stress, and may improve early recovery, including post-operative pain. A three-round, online modified Delphi was conducted within the J-ERUS/YAU network, inviting 21 experts (19 urologists, 2 anaesthetists). Round-1 presented 21 items (5-point Likert). A priori thresholds-blinded to panellists-were: Include = median ≥ 4 with interquartile range (IQR) ≤ 1; Exclude = median < 3; otherwise = revote. Rounds-2/-3 re-rated non-consensus items and validated new items proposed from R1 free-text; at each revote, the prior round's median and IQR were shown. Late submissions were excluded in Rounds 1 and 2. R1 analysed 20 valid responses: 5 Include, 2 Exclude, 14 to revote. R2 analysed 19 responses and re-rated 14 carried plus 9 new items from R1 suggestions: 16 reached Include, 7 to revote. R3 analysed 16 responses: 2 reached Include, 5 without consensus. In total, 23 items met Include (5 R1 + 16 R2 + 2 R3). The checklist integrates pharmacologic/anaesthetic measures (multimodal analgesia; regional techniques as appropriate; structured anti-PONV prophylaxis) with non-pharmacologic practices across surgical (pressure-point padding; low pneumoperitoneum/valveless insufflation) and environmental (active temperature management) domains. This Delphi produced a 23-item consensus checklist that standardises modifiable intra-operative practices underpinning low-impact robotic urologic surgery. Prospective implementation should evaluate effects on recovery outcomes, including post-operative pain, opioid use and PONV.", "journal": "Journal of Robotic Surgery", "pub_date": "2026-Sep-30", "publication_types": ["Journal Article", "Consensus Statement"], "doi": "10.1007/s00345-020-03119-w", "authors": ["Gabriele Sorce", "Maria Peraire-Lores", "Luigi Nocera", "Mike Wenzel", "Marco Paciotti", "Angelo Mottaran", "Gianluca Spena", "Sij Hemal", "Fabrizio Di Maida", "Ruben De Groote", "Carlo Andrea Bravi", "Filippo Turri", "Federico Lavagno", "Edward Lambert", "Carlo Gandi", "Paolo Dell'Oglio", "Christoph Würnschimmel", "Stefano Tappero", "Marcio Covas Moschovas", "Federico Piramide", "Danny Darlington Carbin Joseph", "Nikolaos Liakos", "Ahmed Eraky", "Marco Oderda", "Xavier Ruiz-Plazas", "Helena Ascaso-Til", "Alejandro Juarez-Sanchez", "José Segarra-Tomàs", "Violeta Petrelli-Tain", "Josep Maria Santillana-Altamira", "Manuel Prados-Saavedra", "Nicolae Crisan", "Alessandro Larcher", "Giorgio Ivan Russo", "Alberto Breda", "Alex Mottrie", "Iulia Andras", "Junior ERUS/YAU Working Group on Robot-assisted Surgery of the European Association of Urology"], "affiliations": ["Urology Service, Institut de Recerca Biomèdica Catalunya Sud, Hospital Universitari Joan XXIII de Tarragona, Universitat Rovira i Virgili, C/Dr. Mallafré Guasch, 4, ES-43007, Tarragona, Spain. gab.sorce@gmail.com.", "Urology Service, Institut de Recerca Biomèdica Catalunya Sud, Hospital Universitari Joan XXIII de Tarragona, Universitat Rovira i Virgili, C/Dr. Mallafré Guasch, 4, ES-43007, Tarragona, Spain.", "Spedali Civili of Brescia, Urology, Brescia, Italy.", "University Hospital Frankfurt, Urology, Frankfurt, Germany.", "IRCCS Humanitas Research Hospital, Urology, Milano, Italy.", "IRCCS Azienda Ospedaliero-Universitaria di Bologna Policlinico Sant'Orsola, Urology, Bologna, Italy.", "IRCCS Fondazione G. Pascale, Urology, Napoli, Italy.", "Norris Comprehensive Cancer Center, Urology, Los Angeles, USA.", "Careggi Hospital, Urology, Firenze, Italy.", "Department of Urology, AZORG Hospital, Aalst, Belgium.", "Northampton General Hospital, Urology, Northampton, UK.", "A. Gemelli University Hospital Foundation IRCCS, Urology, Roma, Italy.", "A.O.U. Citta della Salute e della Scienza, Urology, Torino, Italy.", "ASST Grande Ospedale Metropolitano Niguarda, Urology, Milano, Italy.", "Luzerner Kantonsspital, Urology, Lucerne, Switzerland.", "AdventHealth Global Robotics Institute, Urology, Celebration, USA.", "San Luigi Gonzaga Hospital, Urology, Orbassano, Italy.", "Royal Surrey NHS Foundation Trust, Urology, Guildford, UK.", "Department of Urology, Medical Faculty of the University of Freiburg, Medical Centre of the University of Freiburg, Freiburg, Germany.", "Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.", "Anaesthesiology Service, Institut de Recerca Biomèdica Catalunya Sud, Hospital Universitari Joan XXIII de Tarragona, Tarragona, Spain.", "Iuliu Hatieganu University of Medicine and Pharmacy, Urology, Cluj-Napoca, Romania.", "Department of Urology, IRCCS San Raffaele Scientific Institute, Milan, Italy.", "Urology Section, Department of Surgery, University of Catania, Catania, Italy.", "Department of Urology, School of Medicine, Biruni University, Istanbul, Turkey.", "Department of Urology, Fundació Puigvert, Autonomous University of Barcelona, Barcelona, Spain."], "corresponding_authors": ["Gabriele Sorce"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=3", "score": 23.53, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 6.03, "top_journal_bonus": 0.0, "novelty": 0.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 3.0}, "journal_metrics": {"status": "ok", "impact_factor": 3.0, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 2.03, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42814123", "title": "Correction: Total diffusion volume on whole-body diffusion-weighted imaging is a strong prognostic marker of disease survival in metastatic castration-resistant prostate cancer.", "abstract": "", "journal": "European Radiology", "pub_date": "2026-Sep-30", "publication_types": ["Published Erratum"], "doi": "10.1007/s00330-026-12928-3", "authors": ["Luca D'Erme", "Giacomo Avesani", "Luca Russo", "Silvia Bottazzi", "Brandon Whitcher", "Antonio Candito", "Robby Emsley", "Davide Meo", "Alec Paschalis", "Adam Sharp", "Nina Tunariu", "Dow-Mu Koh"], "affiliations": ["Department of Imaging and Radiation Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy. luca.derme@guest.policlinicogemelli.it.", "Department of Imaging and Radiation Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.", "Catholic University of the Sacred Heart, Rome, Italy.", "The Institute of Cancer Research, London, UK.", "The Royal Marsden NHS Foundation Trust, London, UK."], "corresponding_authors": ["Luca D'Erme"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 19.55, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.55, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.7, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.55, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42813457", "title": "From Inception to Maturity: Learning Curve Analysis of Robot-Assisted Kidney Transplantation-A Single-Center Assessment.", "abstract": "The objective of this study was to analyze the impact of the learning curve in robot-assisted kidney transplant (RAKT) on both perioperative and long-term outcomes of the recipients. A retrospective analysis was performed 9 years after the commencement of the RAKT program (2015) at our institute. Each group had patients with a single graft artery who were operated on over a period of 2 years (2016-2017: Group A; 2018-2019: Group B; 2020-2021: Group C; 2022-2023: Group D). Various clinico-demographic, intraoperative, and postoperative parameters were evaluated. Shewhart control charts and cumulative summation (CUSUM) graphs were generated to appraise the learning curve. Out of 202 patients who underwent RAKT with a single graft artery, Groups A, B, C, and D included 49, 49, 58, and 38 patients, respectively. Rewarming time, setup time, console time, vein and artery anastomosis time, ureteroneocystostomy time, total surgical time, blood loss, blood transfusion, hospital stay, and Clavien-Dindo Grades III and IV complications decreased significantly over time from Group A to Group D. CUSUM analysis showed an initial rise followed by a sustained decline in venous anastomosis time, intermittent fluctuations with a later decline in arterial anastomosis time, and an initial high rewarming time with gradual improvement. For delayed graft function, there was a consistent downward trend. One-year graft survival revealed a two-phase pattern, with initial challenges reflected in downward steps, followed by strong recovery and consistent improvement. RAKT can be safely adopted through a structured learning process with an initial phase of technical adaptation followed by consistent improvement. The learning curve for RAKT reflects both surgical expertise and team maturation.", "journal": "Journal of Endourology", "pub_date": "2026-Sep-30", "publication_types": ["Journal Article"], "doi": "10.1177/08927790261492125", "authors": ["Atanu Kumar Pal", "Unni V N", "Kishore T A"], "affiliations": ["Department of Urology, Aster Medcity, Kochi, India.", "Department of Nephrology, Aster Medcity, Kochi, India."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=5", "score": 30.96, "score_parts": {"urology_relevance": 6, "urology_in_title": 8.0, "journal_priority": 9.96, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 5.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 1.96, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42813455", "title": "Risk Factors of Ureteral Stricture after Endoscopic Lithotripsy for Impacted Stones: A Case-Control Study.", "abstract": "To identify risk factors for ureteral stricture after endoscopic lithotripsy for impacted ureteral stones and to develop and externally validate a machine-learning-based prognostic model. This multicenter study enrolled patients with impacted ureteral stones in China. During model construction, controls were matched 1:1 with stricture cases based on gender, age, year of surgical procedure, and surgeon to minimize the influence of variability in surgical equipment and techniques. The primary outcome was postoperative ureteral stricture. The model development cohort consisted of patients who underwent endoscopic laser lithotripsy at the Second Hospital of Tianjin Medical University between 2012 and 2021. External validation was performed using independent datasets from the Tongji Hospital of Tongji Medical College, the Huazhong University of Science and Technology, and the Tianjin Medical University General Hospital between 2022 and 2023. Among the six machine learning models, the least absolute shrinkage and selection operator regression model demonstrated the best overall performance, achieving an area under the receiver operating characteristic curve (AUC) of 0.814 in the internal cohort and AUCs of 0.794 and 0.782 in the two external validation cohorts, respectively. The final model incorporated seven readily available clinical features: residual stone, ureteral wall thickness, stone burden, stone culture, surgical method, history of ureter-related procedure, and intraoperative ureteral injury grade. To enhance clinical usability, the model was further translated into a user-friendly predictive tool. The developed model accurately predicts the risk of ureteral stricture using perioperative clinical variables. This tool may assist clinicians in surgical planning and postoperative management for patients with impacted ureteral stones.", "journal": "Journal of Endourology", "pub_date": "2026-Sep-30", "publication_types": ["Journal Article"], "doi": "10.1177/08927790261492466", "authors": ["Yuanjiong Qi", "Shichao Zhang", "Haiwen Zhou", "Xiaojian Cui", "Yue Chen", "Baolong Wang", "Yang Xun", "Xiao Yu", "Jianqiang Zhu", "Shiyong Qi"], "affiliations": ["Department of Urology, Hetian District People's Hospital, Hetian, China.", "Department of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China.", "Department of Urology, Tianjin TEDA Hospital, Tianjin, China.", "Department of Urology, Tianjin Medical University General Hospital, Tianjin, China.", "Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China."], "corresponding_authors": [], "china_team": "Department of Urology, Hetian District People's Hospital, Hetian, China Shiyong Qi团队", "category": "clinical_review", "classification_reason": "clinical_signals=6", "score": 30.96, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 9.96, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 6.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 1.96, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42811445", "title": "Is Temporary Incontinent Vesicostomy Associated With Fewer Early Urinary Outflow-Related Complications After Pediatric Ileocystoplasty?", "abstract": "Pediatric augmentation ileocystoplasty carries a risk of urinary outflow-related complications (ORC), including anastomotic leakage, obstruction of the catheterizable stoma, and febrile urinary tract infection. We evaluated whether temporary incontinent vesicostomy (TIV) reduces early ORC and emergency readmissions, and whether it affects 24-month function. We retrospectively analyzed 168 children who underwent perimesenteric ileal augmentation with a catheterizable continent stoma between 2000 and 2023: TIV (n = 133) versus no TIV (n = 35). The primary endpoint was ORC within 6 months. Secondary endpoints were all-cause emergency readmissions within 180 days and 24-month daytime continence, augmented bladder capacity and compliance. ORC were less frequent with TIV than without (2.3% [3/133] vs. 28.6% [10/35]; p < 0.001), driven by lower rates of anastomotic leakage (1.5% vs. 11.4%; p = 0.018), urgent obstruction of the catheterizable channel (0% vs. 11.4%; p = 0.002) and febrile urinary tract infection/pyelonephritis (0.8% vs. 8.6%; p = 0.029). At 24 months, daytime continence, augmented bladder capacity (424 ± 113 vs. 406 ± 144 mL; p = 0.402) and compliance (31.4 ± 7.5 vs. 28.1 ± 9.6 mL/cm H2O; p = 0.069) did not differ between groups, whereas all-cause emergency readmissions within 180 days were markedly lower with TIV (3.0% [4/133] vs. 22.9% [8/35]; p < 0.001). TIV is associated with markedly fewer early urinary ORC and 180-day emergency readmissions after pediatric perimesenteric ileocystoplasty, without compromising 24-month continence or reservoir dynamics. Temporary abdominal urinary drainage and the need for planned TIV closure should be discussed during patient selection and family counseling. The benefit appears most relevant after bladder neck closure and in children at risk for delayed access to specialist care; prospective studies should define optimal patient selection, closure timing and long-term upper-tract and channel outcomes.", "journal": "Neurourology and Urodynamics", "pub_date": "2026-Sep-29", "publication_types": ["Journal Article"], "doi": "10.1002/nau.70450", "authors": ["Vasily V Nikolaev", "Nikita V Demin", "Elizaveta A Ladygina", "Viacheslav S Korkosh"], "affiliations": ["Pirogov Russian National Research Medical University, Moscow, Russia.", "Clinical and Research Institute of Emergency Pediatric Surgery and Trauma, Moscow, Russia.", "Sechenov Institute of Evolutionary Physiology and Biochemistry of the Russian Academy of Sciences, St. Petersburg, Russia."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=4", "score": 30.56, "score_parts": {"urology_relevance": 11, "urology_in_title": 8.0, "journal_priority": 5.56, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 4.0}, "journal_metrics": {"status": "ok", "impact_factor": 1.9, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.56, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42811442", "title": "Diagnosis of Urethral Resistance in Men: 70 Years of History.", "abstract": "The urethral resistance (UR) is one of the key outcomes of the urodynamic pressure-flow study (PFS) in men. Combined with a clinical meaningful cut-off point, urodynamic bladder outflow obstruction (BOO) can be determined. This characterization of BOO provides guidance in the management of lower urinary tract symptoms (LUTS), enabling the differentiation between BOO and detrusor underactivity. In this way, the UR can be objectified and monitored, providing insight into the expected results of a clinical intervention. The route from the raw urodynamic measurement towards the diagnosis has faced fundamental challenges over the years. This narrative review aims to give an overview of the background of our current UR measures in men and provides an outlook towards new developments. A non-structured literature search was conducted into the development of assessment of UR. A narrative historic overview is given of the development of assessment of UR. The history of assessing urethral resistance centers on simplifying complex fluid dynamics into clinical tools, evolving from static calculations to dynamic, tissue-elasticity. Today, a renewed focus on voiding physiology, paired with machine learning and computational fluid dynamics, promises mathematically valid, patient-specific diagnostics to optimize the management of bladder outflow obstruction.", "journal": "Neurourology and Urodynamics", "pub_date": "2026-Sep-29", "publication_types": ["Journal Article", "Review"], "doi": "10.1002/nau.70471", "authors": ["Wouter van Dort", "Peter F W M Rosier", "Laetitia M O de Kort"], "affiliations": ["Department of Urology, University Medical Center Utrecht, Utrecht, The Netherlands."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 28.06, "score_parts": {"urology_relevance": 11, "urology_in_title": 8.0, "journal_priority": 5.56, "top_journal_bonus": 0.0, "novelty": 1.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 1.9, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.56, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42811165", "title": "Stone location may separate the benefit and harm of 4.7Fr ureteral stents.", "abstract": "", "journal": "World Journal of Urology", "pub_date": "2026-Sep-29", "publication_types": ["Letter"], "doi": "10.1007/s00345-026-06836-w", "authors": ["Ting Ye"], "affiliations": ["Department of Laboratory Medicine, The Affiliated Hospital of Southwest Medical University, No. 25, Taiping Street, Jiangyang District, Luzhou, 646000, Sichuan, P.R. China. yeting1103@163.com."], "corresponding_authors": ["Ting Ye"], "china_team": "Department of Laboratory Medicine, The Affiliated Hospital of Southwest Medical University, No Ting Ye团队", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 19.0, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.0, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.9, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.0, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42810922", "title": "Rethinking the 3-cm Rule: Toward Biology-guided Management of Sporadic Bilateral Multifocal Papillary Renal Cell Carcinoma.", "abstract": "", "journal": "European Urology Oncology", "pub_date": "2026-Sep-29", "publication_types": ["Editorial"], "doi": "10.1016/j.euo.2026.09.010", "authors": ["Selcuk Erdem", "Chiara Re", "Umberto Capitanio"], "affiliations": ["Division of Urologic Oncology, Department of Urology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey. Electronic address: erdemselcuk1@gmail.com.", "IRCCS San Raffaele Scientific Institute, Urological Research Institute, Milan, Italy; Department of Surgery, University of Cambridge, Cambridge Biomedical Centre, Cambridge, UK.", "IRCCS San Raffaele Scientific Institute, Urological Research Institute, Milan, Italy; University Vita-Salute San Raffaele, Milan, Italy."], "corresponding_authors": ["Selcuk Erdem"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 24.42, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 15.42, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 9.3, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.42, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42810571", "title": "PYGO2 ablation promotes lymphoid organization and STING-dependent antitumor immunity in prostate cancer.", "abstract": "Prostate cancer is an immunologically cold tumor with a limited response to immune checkpoint blockade. Although tertiary lymphoid structures (TLSs) are associated with favorable immunotherapeutic outcomes in various malignancies, the tumor-intrinsic mechanisms governing their formation in prostate cancer remain poorly defined. We investigated whether the frequently amplified chromatin effector PYGO2 regulates lymphoid organization and antitumor immunity. Using prostate-specific Pten/Smad4 double-knockout and Pten/Smad4/Pygo2 triple-knockout mice, syngeneic tumors, transcriptomics, single-cell RNA sequencing, and immunostaining, we found that Pygo2 ablation restored androgen receptor signaling, reduced neuroendocrine-associated features, delayed castration-resistant progression, and prolonged survival. Pygo2-deficient tumors expressed higher levels of tertiary lymphoid structure (TLS)-associated chemokines, exhibited greater T- and B-cell infiltration, and developed TLS-like structures. Single-cell profiling showed increased CD8/Treg ratios, B-cell abundance, TLS imprint scores, and antigen-presentation signatures, particularly after combination therapy. Pygo2 loss also increased DNA damage and was accompanied by activation of the STING-interferon axis. In RM1 syngeneic tumors, STING silencing attenuated the Pygo2-loss-associated increase in cytokine expression, immune infiltration, apoptosis, and tumor control. Combining Pygo2 ablation with castration, CXCR1/2 inhibition, and dual PD-1/CTLA-4 blockade produced durable disease control in more than 80% of Pygo2-deficient mice. These findings identify PYGO2 as a tumor-intrinsic regulator of castration resistance and antitumor immunity and support combining PYGO2-directed strategies with androgen deprivation, myeloid suppression, and immune checkpoint blockade in prostate cancer.", "journal": "Cancer Letters", "pub_date": "2026-Sep-29", "publication_types": ["Journal Article"], "doi": "10.1016/j.canlet.2026.218862", "authors": ["Yini Zhu", "Yan Liu", "Ziyu Zeng", "Qi Huo", "Minzhi Liang", "Shiyu Wang", "Nipuni Barupala", "Xuemin Lu", "Jun Wan", "Liang Cheng", "Xin Lu"], "affiliations": ["Department of Biological Sciences, Harper Cancer Research Institute, Boler-Parseghian Center for Rare Diseases, University of Notre Dame, Notre Dame, IN, 46556, USA; Integrated Biomedical Science Graduate Program, University of Notre Dame, Notre Dame, IN, 46556, USA. Electronic address: yzhu15@alumni.nd.edu.", "Department of Biological Sciences, Harper Cancer Research Institute, Boler-Parseghian Center for Rare Diseases, University of Notre Dame, Notre Dame, IN, 46556, USA.", "Department of Medical and Molecular Genetics, Center for Computational Biology and Bioinformatics, Indiana University School of Medicine, Indianapolis, IN, 46202, USA; Department of BioHealth Informatics, Luddy School of Informatics and Computing, Indiana University at Indianapolis, Indianapolis, IN, 46202, USA; Indiana University Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, IN, 46202, USA.", "Department of Pathology and Laboratory Medicine, Department of Surgery, Brown University Warren Alpert Medical School, The Legorreta Cancer Center at Brown University, and Brown University Health, Providence, RI, USA.", "Department of Biological Sciences, Harper Cancer Research Institute, Boler-Parseghian Center for Rare Diseases, University of Notre Dame, Notre Dame, IN, 46556, USA; Integrated Biomedical Science Graduate Program, University of Notre Dame, Notre Dame, IN, 46556, USA; Indiana University Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, IN, 46202, USA. Electronic address: xlu@nd.edu."], "corresponding_authors": ["Yini Zhu", "Xin Lu"], "china_team": "", "category": "basic", "classification_reason": "basic_signals=19", "score": 44.53, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 15.53, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 14.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 10.1, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.53, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "敲除PYGO2重塑前列腺癌免疫微环境", "chinese_summary": "Cancer Letters刊发研究，采用Pten/Smad4双敲及三敲小鼠模型发现，敲除染色质效应因子PYGO2可恢复雄激素受体信号、减少神经内分泌特征并延缓去势抵抗进展。肿瘤内TLS相关趋化因子升高，T、B细胞浸润增加并形成TLS样结构，STING-干扰素轴激活。", "abstract_zh": "前列腺癌是一种免疫冷肿瘤，对免疫检查点阻断反应有限。尽管三级淋巴结构（TLS）在多种恶性肿瘤中与良好的免疫治疗结局相关，但调控其形成的前列腺癌肿瘤内在机制仍不明确。我们研究了频繁扩增的染色质效应因子PYGO2是否调控淋巴组织形成和抗肿瘤免疫。利用前列腺特异性Pten/Smad4双敲除和Pten/Smad4/Pygo2三敲除小鼠、同系肿瘤、转录组学、单细胞RNA测序和免疫染色，我们发现Pygo2缺失恢复了雄激素受体信号，减少了神经内分泌相关特征，延缓了去势抵抗进展，并延长了生存期。Pygo2缺陷肿瘤表达更高水平的三级淋巴结构（TLS）相关趋化因子，表现出更强的T细胞和B细胞浸润，并形成TLS样结构。单细胞分析显示CD8/Treg比值、B细胞丰度、TLS印记评分和抗原呈递特征增加，尤其是在联合治疗后。Pygo2缺失还增加了DNA损伤，并伴随STING-干扰素轴的激活。在RM1同系肿瘤中，STING沉默减弱了与Pygo2缺失相关的细胞因子表达、免疫浸润、凋亡和肿瘤控制增加。将Pygo2缺失与去势、CXCR1/2抑制以及PD-1/CTLA-4双重阻断联合，在超过80%的Pygo2缺陷小鼠中产生了持久的疾病控制。这些发现将PYGO2确定为去势抵抗和抗肿瘤免疫的肿瘤内在调控因子，并支持在前列腺癌中将针对PYGO2的策略与雄激素剥夺、髓系抑制和免疫检查点阻断相结合。"}, {"pmid": "42809936", "title": "Real-world ctDNA test utilization and associated costs in US patients with bladder cancer who underwent radical cystectomy.", "abstract": "Circulating tumor DNA (ctDNA) can inform prognosis and treatment effectiveness in bladder cancer. We evaluated real-world utilization and costs of ctDNA testing among US patients with bladder cancer undergoing radical cystectomy following initiation of Medicare coverage for ctDNA testing. Using claims data from Optum Clinformatics Data Mart Database (January 19, 2022-June 30, 2025) covering commercial and Medicare Advantage plans, we evaluated ctDNA testing incidence, testing rate, and costs in patients undergoing radical cystectomy. Total (paid by payers and patients) and out-of-pocket costs (sum of coinsurance, copays, and deductibles) were reported. Time to first and second tests was estimated using Kaplan-Meier methods. Patient characteristics were evaluated among those who received ≥1 ctDNA test vs. untested patients. Among 1,995 patients (76.4% male; 89.1% White), 17.1% (341/1995) received ≥1 ctDNA test before (4.7%) and/or after (14.7%) radical cystectomy (median of 2 tests among those tested; Q1-Q3: 1-5). Median testing cost was $4,178 (Q1-Q3: $1,756-$4,178), with $0 median out-of-pocket cost. Testing rate rose from 4.0 (second half of 2022) to 34.0 (first half of 2025) tests per 1,000 patient-months (P for trend <0.001). Tested and untested cohorts had similar age, sex, and race distributions. Tested patients were more likely to receive systemic treatment before (46.0% vs. 35.8%, P < 0.001) and after cystectomy (24.0% vs. 10.1%, P < 0.001) than untested patients. Since Medicare coverage approval, ctDNA testing among US radical cystectomy-treated patients with bladder cancer has increased steadily but remains modest. Total costs varied, yet patient out-of-pocket expenses were minimal.", "journal": "Urologic Oncology", "pub_date": "2026-Sep-29", "publication_types": ["Journal Article"], "doi": "10.1016/j.urolonc.2026.08.016", "authors": ["Todd M Morgan", "Ching-Yu Wang", "Halit O Yapici", "Jonathan Lilley", "Weiqi Jiao", "Kunal Lodaya", "Haojie Li"], "affiliations": ["Department of Urology, University of Michigan, Ann Arbor, MI.", "Department of Outcomes Research, Merck & Co. Inc., Rahway, NJ. Electronic address: ching-yu.wang@merck.com.", "Department of Health Economics and Outcomes Research, Boston Strategic Partners Inc., Boston, MA.", "Department of Outcomes Research, Merck & Co. Inc., Rahway, NJ."], "corresponding_authors": ["Ching-Yu Wang"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=5", "score": 29.75, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 5.75, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 5.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.3, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.75, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42809806", "title": "Clinical Trial Access in Renal Cell Carcinoma: When Innovation Does Not Reach the Communities That Need It.", "abstract": "", "journal": "Jco Oncology Practice", "pub_date": "2026-Sep-29", "publication_types": ["Editorial"], "doi": "10.1200/OP-26-01037", "authors": ["Varun Nandakumar", "Tejita Agarwal", "Sumati Gupta", "Umang Swami"], "affiliations": ["Huntsman Cancer Institute, University of Utah, Salt Lake City, UT."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=4", "score": 23.53, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.53, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 4.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.6, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.53, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42809049", "title": "Bridging the PSMA PET/CT access gap in prostate cancer: evidence, barriers, and priorities for implementation.", "abstract": "To examine the gap between evidence-based indications for PSMA PET/CT and real-world access in prostate cancer, with a focus on European implementation and country-specific experience from Spain and France. A focused narrative appraisal of published evidence, clinical guidelines, regulatory and reimbursement information, and real-world accessibility data was performed. European accessibility modelling and physician market research from Spain were incorporated to characterise implementation patterns and barriers. Access to PSMA PET/CT remains heterogeneous despite its established role in higher-risk staging and biochemical recurrence. Reported barriers include reimbursement and local approval requirements, PET/CT and nuclear medicine capacity, radiopharmaceutical logistics, non-standardised referral pathways, waiting times, and institutional variation. Exploratory modelling suggested that use remains below the estimated eligible population in both staging and biochemical recurrence, with differences between countries and clinical scenarios. Spanish market research similarly indicated substantial variation. These data are exploratory implementation signals rather than population-level epidemiological estimates. Improving access requires guideline-based eligibility criteria, harmonised reimbursement, regional referral networks, adequate imaging and reporting capacity, reliable tracer supply, and measurable access indicators. Further research should determine whether reducing implementation gaps improves diagnostic pathways and treatment allocation.", "journal": "World Journal of Urology", "pub_date": "2026-Sep-29", "publication_types": ["Journal Article", "Review"], "doi": "10.1007/s00259-023-06332-y", "authors": ["J Gómez Rivas", "L Fernández Hernández", "L Turpin", "A Peyrottes", "M Rouprêt"], "affiliations": ["Urology Department, Hospital Clínico San Carlos, Madrid, Spain. juangomezr@gmail.com.", "Urology Department, Hospital de Torrejón, Madrid, Spain.", "Nuclear Medicine Department, Foch Hospital, Suresnes, France.", "Urology Department, Saint-Louis Hospital, Paris, France.", "Urology Department, Pitié-Salpêtrière Hospital, Paris, France."], "corresponding_authors": ["J Gómez Rivas"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 25.0, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.0, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 1.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.9, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.0, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42808865", "title": "The effect of time to nephrectomy on cancer-specific mortality in pathological T stage (pT)1b-2 renal cancer.", "abstract": "To assess the impact of prolonged time to surgery on cancer-specific mortality (CSM) in patients with pathological T stage (pT)1b-2 N0M0 renal cell carcinoma (RCC) treated with nephrectomy (either partial [PN] or radical [RN]). Within the Surveillance, Epidemiology and End Results (SEER) database (2004-2021), we tested the effect of time to surgery >3 vs ≤3 months on CSM in patients with pT1b-2N0M0 RCC. Propensity score matching (PSM) and multivariable competing risks regression (CRR) were performed. Subgroup analyses stratified patients according to time to surgery interval (≤1 vs 1-3 months, ≤3 vs 3-6 months, ≤3 vs >6 months), histotype, and grade. Of 16 322 patients with pT1b-2 RCC treated with nephrectomy, time to surgery >3 months was recorded in 3023 (18%) patients. These patients were older (median age 64 vs 62 years) and harboured a smaller proportion of pT2 patients (19% vs 30%). After one-to-one PSM, 3023 (100%) patients with a time to surgery >3 months exhibited a 60-month CSM of 7.6% vs 5.9% in 3023 (23%) patients with a time to surgery ≤3 months. In CRR time to surgery >3 months independently predicted 1.3-fold higher CSM (P = 0.02). Subgroup analyses revealed a dose-response effect, with a CSM increase in 1.3-fold fashion when time to surgery was 3-6 months vs 1.6-fold fashion when time to surgery was >6 months. The detrimental effect of time to surgery>3 months was consistent across all grades but was not evidenced among patients with a non-clear cell RCC. In patients with pT1b-2N0M0 treated with either PN or RN, prolonged time from diagnosis to surgery was associated with higher CSM. This association was not observed among patients with non-clear cell RCC.", "journal": "BJU International", "pub_date": "2026-Sep-29", "publication_types": ["Journal Article"], "doi": "10.1111/bju.70468", "authors": ["Michele Nicolazzini", "Federico Polverino", "Leonardo Quarta", "Maximilian Filzmayer", "Michele Petix", "Calogero Catanzaro", "Nick Lee", "Jordan A Goyal", "Nicola Longo", "Gennaro Musi", "Felix K H Chun", "Alberto Briganti", "Riccardo Schiavina", "Shahrokh F Shariat", "Carlotta Palumbo", "Alessandro Volpe", "Fred Saad", "Pierre I Karakiewicz"], "affiliations": ["Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.", "Division of Urology, Department of Translational Medicine, Maggiore della Carità Hospital, University of Eastern Piedmont, Novara, Italy.", "Division of Urology, Department of Oncology, University of Turin, Turin, Italy.", "Department of Neurosciences, Science of Reproduction and Odontostomatology, University of Naples Federico II, Naples, Italy.", "Division of Experimental Oncology/Unit of Urology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy.", "Vita-Salute San Raffaele University, Milan, Italy.", "Department of Urology, University Hospital, Goethe University Frankfurt, Frankfurt am Main, Germany.", "Department of Urology, IEO European Institute of Oncology, IRCCS, Milan, Italy.", "Università degli Studi di Milano, Milan, Italy.", "Division of Urology, IRCCS Azienda Ospedaliero-universitaria di Bologna, Bologna, Italy.", "Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.", "Department of Urology, Weill Cornell Medical College, New York, NY, USA.", "Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA.", "Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=3", "score": 31.47, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 10.47, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 3.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.4, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.47, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42808368", "title": "Office Urology, Perioperative Care, Urinary Diversions.", "abstract": "", "journal": "Journal of Urology", "pub_date": "2026-Sep-29", "publication_types": ["Journal Article"], "doi": "10.1097/JU.0000000000005306", "authors": ["David S Wang"], "affiliations": [], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 23.01, "score_parts": {"urology_relevance": 7, "urology_in_title": 8.0, "journal_priority": 11.01, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 6.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 3.01, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "门诊泌尿外科与尿流改道围术期管理更新", "chinese_summary": "《Journal of Urology》2026年9月汇总门诊泌尿外科、围术期照护及尿流改道领域最新证据，涵盖常见门诊操作规范、加速康复流程优化及不同尿流改道术式并发症管理，为临床决策提供参考。", "abstract_zh": "本文为《Journal of Urology》2026年9月刊“门诊泌尿外科、围术期照护、尿流改道”专题综述，汇集该领域近期发表的研究与临床实践更新，内容涉及门诊泌尿外科常见疾病的诊疗策略、围手术期患者管理与加速康复路径，以及尿流改道手术的术式选择、并发症防治与长期随访要点，旨在为泌尿外科医师提供基于证据的临床参考。"}, {"pmid": "42808354", "title": "Letter: Noninvasive Urine Test Predicts Grade Group Upgrading in Patients on Active Surveillance for Prostate Cancer: Multisite Validation and Comparison With MRI.", "abstract": "", "journal": "Journal of Urology", "pub_date": "2026-Sep-29", "publication_types": ["Letter"], "doi": "10.1097/JU.0000000000005310", "authors": ["Andrea Ponsiglione", "Giorgio Brembilla", "Jelle Barentsz"], "affiliations": ["Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy.", "Department of Radiology, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.", "Department of Medical Imaging, Andros Clinics, Arnhem, the Netherlands."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 20.01, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 11.01, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 6.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 3.01, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42806833", "title": "Risk Factors for Primary Retrograde Ureteral Access Failure During Ureteroscopy-A Systematic Review and Meta-Analysis by the YAU and EAU Section of Endourology.", "abstract": "Primary ureteroscopic access failure necessitates ureteral stenting and staged procedures, increasing patient and healthcare burden. This systematic review aims to identify risk factors for primary failure to enhance clinical decision-making and identify patients who may benefit from prestenting or medical pretreatment to mitigate failure risks. A systematic search of MEDLINE (PubMed), Embase, and Web of Science was performed through May 2025 following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and registered in PROSPERO. Studies reporting primary retrograde access failure during ureteroscopy in unstented, unprepared ureters were included. Failure was defined as inability to advance the ureteroscope or ureteral access sheath to the stone, with or without intraoperative adjunctive measures. Risk of bias was assessed using Cochrane Collaboration guidance. Pooled failure rates and associations with clinical risk factors were analyzed using random-effects meta-analysis. Heterogeneity and publication bias were formally assessed. Twenty-two studies comprising 8747 procedures were included. The pooled primary access failure rate was 11% (95% confidence interval 8%-13%), with substantial heterogeneity (I2 = 93%). Younger age (mean difference 3.29 years), male sex (odds ratio [OR] 1.36), and proximal ureteral stone location (OR 2.31) were associated with increased failure risk. Thin ureteroscopes (OR 0.10) and prior ipsilateral stone surgery (OR 0.40) were protective. Funnel plot asymmetry suggested publication bias. Evidence quality was limited by retrospective designs and heterogeneity. This review, despite the low quality of evidence, identifies possible risk factors for primary ureteroscopy access failure. These findings may assist in clinical decision-making and patient counseling.", "journal": "Journal of Endourology", "pub_date": "2026-Sep-29", "publication_types": ["Journal Article", "Review"], "doi": "10.1177/08927790261491568", "authors": ["Matthias Boeykens", "Lore Aspeslagh", "Łukasz Nowak", "Wojciech Krajewski", "Arman Tsaturyan", "Begoña Ballesta Martinez", "Leye Ajayi", "Kim Pauwaert", "Charlotte Slots", "Naeem Bhojani", "Etienne Xavier Keller", "Vincent De Coninck", "Pablo Contreras", "Thomas Tailly"], "affiliations": ["Department of Urology, AZ Delta Roeselare, Roeselare, Belgium.", "Department of Urology, University Hospital Ghent, Ghent, Belgium.", "Young Academic Urologists (YAU), Urolithiasis & Endourology Working Party, Arnhem, Netherlands.", "Department of Urology, AZ West Veurne, Veurne, Belgium.", "Department of Minimally Invasive and Robotic Urology, Wroclaw Medical University, Wroclaw, Poland.", "Department of Urology, Yerevan State Medical University, Yerevan, Armenia.", "Department of Urology, University Hospital del Vinalopo, Alicante, Spain.", "Department of Urology, Royal Free London NHS Foundation Trust, London, UK.", "European Association of Urology Section of Endourology (ESUT), Arnhem, The Netherlands.", "Department of Urology, Université de Montréal Health Center, Montreal, Quebec, Canada.", "Department of Urology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.", "Department of Urology, AZ Klina, Brasschaat, Belgium.", "Department of Urology, Hospital Aleman, Buenos Aires, Argentina.", "Department of Urology, AZ Maria Middelares, Ghent, Belgium."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 33.96, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 9.96, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 6.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 1.96, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42865883", "title": "Trained immunity in cancer immunotherapy and vaccine development: mechanisms, evidence gaps, and translational opportunities.", "abstract": "Breakthroughs in cancer immunotherapy have been overwhelmingly driven by advances in adaptive immunity, leaving the therapeutic potential of innate immunity largely untapped, a gap in the current treatment paradigm. Trained immunity, defined by the durable, mitotically maintained metabolic and epigenetic memory that innate immune cells acquire after transient stimulation, offers a new approach to addressing this deficit. Here we survey the triggering signals, cellular heterogeneity, and molecular circuitry that govern trained immunity within the tumor microenvironment. We dissect its dualistic character: the mechanistic basis by which trained immunity can either restrain or promote tumor progression, and what this ambivalence means for the design of next-generation immunotherapies. These insights inform a growing pipeline of trained-immunity-based cancer vaccines, which we categorize into four engineered platforms, recombinant BCG, β-glucan nanoformulations, lipid nanoparticle (LNP)-mRNA bifunctional vaccines, and commensal-derived adjuvants. We further propose that vaccine efficacy may depend in part on host immune context, and outline stratification strategies and dosing schedules that may need to be adjusted according to individual immune status, pending clinical validation. In aggregate, evidence from human bladder cancer, preclinical tumor models, and non-tumor trained immunity studies suggests that trained immunity could elevate innate immunity from a supporting role toward an independent therapeutic axis, although most of its direct cancer applications remain at the preclinical or conceptual stage.", "journal": "Frontiers in Immunology", "pub_date": "2026", "publication_types": ["Journal Article", "Review"], "doi": "10.1126/scitranslmed.adf9556", "authors": ["Lian Yang", "Jianfeng Liu", "Shufei Zhang", "Yong He", "Jiaxu Chen", "Donghui Tan"], "affiliations": ["Affiliated Hospital of Xiangnan University, Chenzhou, Hunan, China.", "Guangzhou Key Laboratory of Formula-Pattern of Traditional Chinese Medicine, School of Traditional Chinese Medicine, Jinan University, Guangzhou, China.", "Department of Gynecology and Obstetrics, Renmin Hospital of Wuhan University, Wuhan, China.", "School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China."], "corresponding_authors": [], "china_team": "Affiliated Hospital of Xiangnan University, Chenzhou, Hunan, China Donghui Tan团队", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 18.33, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 10.83, "top_journal_bonus": 0.0, "novelty": 0.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 1.0}, "journal_metrics": {"status": "ok", "impact_factor": 5.9, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.83, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42865741", "title": "Enhancing intravesical bladder cancer therapy: from mucoadhesive to targeted drug delivery strategies.", "abstract": "Intravesical administration is a standard application route for the treatment of non-muscle-invasive bladder cancer, as it allows for high drug concentrations near tumor sites while largely avoiding systemic exposure and associated adverse effects. However, the efficacy can be constrained by the urothelium's strong barrier properties, as well as continuous dilution and elimination of drugs through urine production and voiding. Bladder-retentive drug delivery systems, such as intravesical sustained-release formulations that accumulate therapeutics at the bladder wall or active targeting to tumor cells may address these limitations. In this context, mucoadhesive formulations are promising because they resist urinary washout, extend dwell time, and enhance urothelial drug deposition. Targeted delivery platforms can increase drug load within malignant tissues and may even accelerate onset of pharmacologic activity via receptor mediated pathways. If binding to tumor-specific target structures also modulates the disease itself, active targeting can extend beyond pharmacokinetic benefits to integrate different pharmacodynamic mechanisms, thereby contributing to more precise and effective cancer therapy. Several targeted intravesical drug formulations, including antibody-drug conjugates against tumor associated antigens, integrin directed systems, hyaluronic acid-based CD44 targeted constructs, as well as immunomodulatory agents, have advanced to clinical or late preclinical evaluation. The intravesical route further provides an opportunity to repurpose drugs originally developed for systemic use but limited by off target toxicities that are unlikely to be dose limiting with local intravesical administration. This mini review provides an overview of intravesical, bladder-retentive systems for treating urothelial carcinoma, with a particular emphasis on recent developments in tumor-targeted intravesical precision medicines.", "journal": "Frontiers in Medicine", "pub_date": "2026", "publication_types": ["Journal Article", "Review"], "doi": "10.1016/j.urolonc.2010.06.011", "authors": ["Hatixhe Sahini", "Maria Anzengruber", "Ulrich Lächelt"], "affiliations": ["Department of Pharmaceutical Sciences, University of Vienna, Vienna, Austria.", "Vienna Doctoral School of Pharmaceutical, Nutritional and Sport Sciences, University of Vienna, Vienna, Austria."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 28.03, "score_parts": {"urology_relevance": 11, "urology_in_title": 8.0, "journal_priority": 6.03, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 1.0}, "journal_metrics": {"status": "ok", "impact_factor": 3.0, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 2.03, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42865689", "title": "Eculizumab in rapidly progressive glomerulonephritis: a case-series report.", "abstract": "To describe the clinical outcomes and safety profile of eculizumab as adjunctive therapy in a case series of patients with rapidly progressive glomerulonephritis (RPGN) due to anti-glomerular basement membrane (GBM) disease and anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV). We reported 7 patients with AAV and 5 patients with anti-GBM disease who presented to our center between March 2025 and January 2026. All patients received eculizumab (900 mg, 1-4 doses) in addition to standard immunosuppressive therapy. Serum creatinine (Scr), urinary red blood cell (uRBC) count, urine protein-to-creatinine ratio (UPCR), and dialysis dependence were assessed at baseline and at 3 months. Adverse events were monitored throughout follow-up. In AAV patients, mean Scr decreased from 407.38 μmol/L to 231.27 μmol/L (p = 0.025), mean uRBC from 384.27/μL to 68.75/μL (p = 0.033), and mean UPCR from 2.20 g/g to 1.64 g/g (p = 0.179) at the 3rd month. In anti-GBM patients, mean Scr declined from 575.07 μmol/L to 263.80 μmol/L (p = 0.024), mean uRBC from 1648.60/μL to 461.92/μL (p = 0.132), and mean UPCR from 10.88 g/g to 3.75 g/g (p = 0.126). At baseline, 6 patients required renal replacement therapy, and after treatment, 4 became dialysis-independent. One AAV patient progressed to hemodialysis, and one anti-GBM patient remained dialysis-dependent. All anti-GBM antibodies and MPO-ANCA (except one patient) seroconverted to negative at month 3. During follow-up, only one case of COVID-19 infection and one oral ulcer were recorded; no severe infections occurred. In this descriptive case series, we observed trends toward improved renal function and hematuria at 3 months in patients with severe RPGN who received eculizumab in addition to standard immunosuppression, with earlier initiation and milder baseline renal impairment appearing to correlate with more favorable outcomes. Nevertheless, the lack of a control group and the marked interpatient variability in baseline characteristics and concomitant therapies preclude any conclusion regarding a causal effect of eculizumab. Instead, these data serve as real-world observations that can generate hypotheses for future studies. Definitive evidence on the efficacy and safety of eculizumab in RPGN must await larger, prospective, controlled investigations.", "journal": "Frontiers in Immunology", "pub_date": "2026", "publication_types": ["Case Reports", "Journal Article"], "doi": "10.3389/fneur.2021.696387", "authors": ["Xueting Li", "Yinghui Zhang", "Ben Ke"], "affiliations": ["Department of Nephrology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China."], "corresponding_authors": [], "china_team": "Department of Nephrology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China Ben Ke团队", "category": "clinical_review", "classification_reason": "publication_type_clinical", "score": 21.83, "score_parts": {"urology_relevance": 3, "urology_in_title": 0.0, "journal_priority": 10.83, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 6.0}, "journal_metrics": {"status": "ok", "impact_factor": 5.9, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.83, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42865481", "title": "Multimodal imaging features of pelvic ectopic liver combined with type I congenital extrahepatic portosystemic shunt (Abernethy malformation) in a child: a case report.", "abstract": "To investigate the multimodal imaging features, vascular anatomical characteristics, and clinical management strategies of pelvic ectopic liver combined with Type I congenital extrahepatic portosystemic shunt (Abernethy malformation) in a child, thereby enhancing the diagnostic and therapeutic understanding of this rare complex congenital anomaly. A retrospective analysis was conducted on the complete clinical and imaging data of a 12-year-old male pediatric patient. Multimodal imaging findings from ultrasound, magnetic resonance imaging (MRI), computed tomography angiography (CTA), and digital subtraction angiography (DSA) were integrated to systematically analyze the imaging manifestations of the lesion, the blood supply characteristics of the ectopic liver and portosystemic venous malformation, and the features of vascular anatomy. The patient presented with a chief complaint of dysuria and urinary dribbling for one month. Multimodal imaging revealed an irregular soft tissue mass in the pelvic cavity, connected to the left hepatic lobe via a soft tissue pedicle. The enhancement pattern on contrast-enhanced imaging was identical to that of the orthotopic liver, consistent with the imaging features of pelvic ectopic liver. CTA three-dimensional vascular reconstruction and DSA demonstrated hypoplasia of the proper hepatic artery, with its left branch abnormally coursing inferiorly to supply the pelvic ectopic liver. The superior mesenteric vein drained directly into the inferior vena cava, with no opacification of the intrahepatic portal venous system, consistent with the imaging diagnosis of type I Abernethy malformation. To our knowledge, no similar case of pelvic ectopic liver combined with type I congenital extrahepatic portosystemic shunt has been reported globally. Following multidisciplinary consultation, a conservative management strategy of long-term imaging follow-up was adopted for the patient, with no surgical intervention planned at present, and liver transplantation reserved as a definitive treatment option in the event of severe long-term complications. Pelvic ectopic liver combined with type I congenital extrahepatic portosystemic shunt represents an extremely rare congenital composite hepatic vascular and visceral malformation in clinical practice. The multimodal imaging system integrating ultrasound, MRI, CTA, and DSA can accurately and comprehensively delineate the location, morphology, blood supply origin of the ectopic liver, and the anatomical details of the portosystemic venous malformation. It serves as a reliable imaging basis for the diagnosis, anatomical assessment, and long-term follow-up of this rare pediatric condition, and provides critical support for the formulation of individualized clinical treatment strategies.", "journal": "Frontiers in Medicine", "pub_date": "2026", "publication_types": ["Case Reports", "Journal Article"], "doi": "10.5582/irdr.2020.03005", "authors": ["Xiaodong Zhu", "Huihui Lin", "Xu Li", "Jun Hu", "Zhongwei Qiao"], "affiliations": ["Department of Radiology, Anhui Provincial Children's Hospital, Hefei, China.", "Department of Radiology, Children's Hospital of Fudan University, Shanghai, China."], "corresponding_authors": [], "china_team": "Department of Radiology, Anhui Provincial Children's Hospital, Hefei, China Zhongwei Qiao团队", "category": "clinical_review", "classification_reason": "publication_type_clinical", "score": 15.03, "score_parts": {"urology_relevance": 3, "urology_in_title": 0.0, "journal_priority": 6.03, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 4.0}, "journal_metrics": {"status": "ok", "impact_factor": 3.0, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 2.03, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42865476", "title": "Neoadjuvant disitamab vedotin (RC-48) plus a PD-1 inhibitor in muscle-invasive bladder cancer: a multicenter real-world study with stratification by HER2 expression and tertiary lymphoid structures.", "abstract": "To assess the efficacy and safety of neoadjuvant RC-48 combined with a PD-1 inhibitor in patients with muscle-invasive bladder cancer (MIBC), and to investigate the stratification utility of HER2 expression and tumor-associated tertiary lymphoid structures (TLS) as predictive variables for treatment response and clinical prognosis. This multicenter retrospective real-world study enrolled 38 patients with MIBC from the First Affiliated Hospital of Nanchang University, the Second Affiliated Hospital of Nanchang University, Jiangxi Cancer Hospital, and Jiangxi Provincial People's Hospital. All patients received at least four cycles of neoadjuvant therapy comprising RC-48 combined with a PD-1 inhibitor, followed by radical cystectomy (RC). The TLS in the pre-treatment specimens was evaluated using hematoxylin-eosin (HE) staining, and the expression level of HER2 was assessed by immunohistochemistry (IHC) method. The primary endpoint was the pathological complete response (pCR) rate, and secondary endpoints included radiographic complete response (CR) rate, disease-free survival (DFS), and overall survival (OS). Among the 38 patients, the pCR rate was 34.2%, and the overall CR rate by radiographic assessment was 36.8%, with a PR rate of 31.6%. After a median follow-up of 18.0 months (range, 9-29 months), the 12-month DFS rate was 89.4% (95% CI: 74.2%-95.9%), and the 12-month OS rate was 100% (95% CI: 100%-100%). HER2 overexpression was significantly associated with a higher objective response rate (ORR) (OR = 22.50, 95% CI: 1.51 - 335.33, p = 0.024). In stratified analyses based on TLS, both TLS-2 (primary lymphoid follicles) and TLS-3 (secondary lymphoid follicles with germinal centers) demonstrated significant associations with higher ORR, with ORs of 20.00 (95% CI: 2.75 - 145.48, p = 0.003) and 36.00 (95% CI: 2.72 - 476.21, p = 0.007), respectively, suggesting that greater TLS with enhanced therapeutic benefit. Furthermore, N1 stage (OR = 0.06, 95% CI: 0.01 - 0.59, p = 0.016), N2 stage (OR = 0.04, 95% CI: 0.00 - 0.62, p = 0.021), and T3 stage (OR = 0.08, 95% CI: 0.01 - 0.46, p = 0.004) were each significantly associated with poorer treatment response. Treatment-related adverse events (TRAEs) were generally manageable. The combination of RC-48 and a PD-1 inhibitor exhibits promising efficacy as a neoadjuvant therapy for MIBC. Both HER2 expression and TLS maturity serve as effective stratification indicators for treatment response and prognosis. These findings support further evaluation of this combined regimen in biomarker-driven prospective trials.", "journal": "Frontiers in Immunology", "pub_date": "2026", "publication_types": ["Journal Article", "Multicenter Study"], "doi": "10.1007/s00345-022-04160-7", "authors": ["Xue Peng Rao", "Xin Chang Zou", "Xiang Liu", "Lie Yu Xu", "Jian Biao Huang", "Yu Yang Yuan", "Tao Chen", "Tao Zeng"], "affiliations": ["Department of Urology, Second Affiliated Hospital of Nanchang University, Jiangxi Medical College, Nanchang, China.", "Department of Urology, Jiangxi Provincial People's Hospital, Nanchang, China.", "Jiangxi Cancer Hospital & Institute, Jiangxi Clinical Research Center for Cancer, The Second Affiliated Hospital of Nanchang Medical College, Nanchang, China.", "Department of Urology, First Affiliated Hospital of Nanchang University, Nanchang, China."], "corresponding_authors": [], "china_team": "Department of Urology, Second Affiliated Hospital of Nanchang University, Jiangxi Medical College, Nanchang, China Tao Zeng团队", "category": "basic", "classification_reason": "basic_signals=5", "score": 35.33, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 10.83, "top_journal_bonus": 0.0, "novelty": 1.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 5.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 5.9, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.83, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "维迪西妥单抗新辅助治疗膀胱癌显效", "chinese_summary": "南昌大学第二附属医院曾涛团队联合江西省内多家中心2026年Front Immunol发表38例肌层浸润性膀胱癌真实世界研究，新辅助RC-48联合PD-1抑制剂后病理完全缓解率达34.2%，HER2过表达及三级淋巴结构成熟度均与更高客观缓解率相关，支持以生物标志物分层开展前瞻性试验。", "abstract_zh": "评估新辅助RC-48联合PD-1抑制剂在肌层浸润性膀胱癌（MIBC）患者中的疗效与安全性，并探讨HER2表达和肿瘤相关三级淋巴结构（TLS）作为治疗反应及临床预后预测变量的分层价值。这项多中心回顾性真实世界研究纳入了来自南昌大学第一附属医院、南昌大学第二附属医院、江西省肿瘤医院和江西省人民医院的38例MIBC患者。所有患者均接受至少四个周期的新辅助治疗，方案为RC-48联合PD-1抑制剂，随后行根治性膀胱切除术（RC）。采用苏木精-伊红（HE）染色评估治疗前标本中的TLS，并通过免疫组化（IHC）方法评估HER2表达水平。主要终点为病理完全缓解（pCR）率，次要终点包括影像学完全缓解（CR）率、无病生存期（DFS）和总生存期（OS）。38例患者中，pCR率为34.2%，影像学评估的总体CR率为36.8%，PR率为31.6%。中位随访18.0个月（范围9-29个月）后，12个月DFS率为89.4%（95% CI：74.2%-95.9%），12个月OS率为100%（95% CI：100%-100%）。HER2过表达与更高的客观缓解率（ORR）显著相关（OR=22.50，95% CI：1.51-335.33，p=0.024）。在基于TLS的分层分析中，TLS-2（原发性淋巴滤泡）和TLS-3（伴生发中心的继发性淋巴滤泡）均与更高的ORR显著相关，OR分别为20.00（95% CI：2.75-145.48，p=0.003）和36.00（95% CI：2.72-476.21，p=0.007），提示TLS越多，治疗获益越大。此外，N1分期（OR=0.06，95% CI：0.01-0.59，p=0.016）、N2分期（OR=0.04，95% CI：0.00-0.62，p=0.021）和T3分期（OR=0.08，95% CI：0.01-0.46，p=0.004）均与较差的治疗反应显著相关。治疗相关不良事件（TRAEs）总体可控。RC-48联合PD-1抑制剂作为MIBC新辅助治疗显示出有前景的疗效。HER2表达和TLS成熟度均可作为治疗反应和预后的有效分层指标。这些发现支持在生物标志物驱动的前瞻性试验中进一步评估该联合方案。"}, {"pmid": "42865436", "title": "TRPML1 inhibitor ML-SI1 suppresses prostate cancer through dual regulation of androgen receptor and polyamine metabolism.", "abstract": "Prostate cancer (PCa) is the second leading cause of cancer-related death in men worldwide, with metastasis and drug resistance representing major drivers of mortality. Transient receptor potential mucolipin 1 (TRPML1), a member of the transient receptor potential channel superfamily, is associated with several malignancies; however, its role in PCa remains unclear. TRPML1 expression in PCa is analyzed using public datasets from The Cancer Genome Atlas, Human Protein Atlas, and Cancer Cell Line Encyclopedia. Functional studies are performed in prostate cancer cell lines, particularly LNCaP and 22Rv1, using the TRPML1 inhibitor ML-SI1 and TRPML1-knockout models. Cell proliferation, cell cycle distribution, migration, and invasion are assessed using colorimetric cell viability assays, flow cytometry, and Transwell assays. Transcriptomic analysis, quantitative real-time PCR, western blotting, and spermine measurement are performed to investigate the underlying mechanisms. TRPML1 expression is elevated in PCa tissues compared to adjacent normal tissues. In LNCaP cells, ML-SI1 reduces cell viability and migration and induces G0/G1-phase arrest, whereas in 22Rv1 cells, it exerts limited effects on cell viability and cell-cycle distribution but reduces migration and invasion. ML-SI1 reduces androgen receptor (AR) protein stability and spermine levels in LNCaP cells, whereas increased spermine levels are observed in 22Rv1 cells at 24 h. In vitro, TRPML1 inhibition produces distinct cellular responses in LNCaP and 22Rv1 cells and is accompanied by differential changes in AR regulation and polyamine metabolism. Further mechanistic and in vivo studies are required to determine the biological and therapeutic relevance of these findings.", "journal": "Frontiers in Medicine", "pub_date": "2026", "publication_types": ["Journal Article"], "doi": "10.1016/j.celrep.2023.112798", "authors": ["Jiongzheng Li", "Jipeng Ding", "Hongfei Wei", "Rongrong Ding", "Jintong Zhu", "Yufei Yan", "Yiming Yang", "Jia Zhao", "Jing Li"], "affiliations": ["Department of Pharmacology, College of Basic Medical Sciences, The Medical Basic Research Innovation Center of Airway Disease in North China, Key Laboratory of Pathobiology, Ministry of Education, Jilin University, Changchun, China.", "Department of Cell Biology and Medical Genetics, College of Basic Medical Sciences, Jilin University, Changchun, China.", "Department of Histology and Embryology, College of Basic Medical Sciences, Jilin University, Changchun, China."], "corresponding_authors": [], "china_team": "Department of Pharmacology, College of Basic Medical Sciences, The Medical Basic Research Innovation Center of Airway Disease in North China, Key Laboratory of Pathobiology, Ministry of Education, Jilin University, Changchun, China Jing Li团队", "category": "basic", "classification_reason": "basic_signals=18", "score": 34.03, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 6.03, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 14.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 3.0, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 2.03, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "抑制TRPML1可双重打击前列腺癌", "chinese_summary": "吉林大学基础医学院李晶团队2026年Front Med研究显示，前列腺癌组织中TRPML1表达升高。抑制剂ML-SI1在LNCaP细胞中降低雄激素受体稳定性并减少精胺，诱导G0/G1期阻滞；在22Rv1细胞中则抑制迁移侵袭。提示靶向TRPML1或可同时干预雄激素受体与多胺代谢，但尚需体内验证。", "abstract_zh": "前列腺癌（PCa）是全球男性癌症相关死亡的第二大原因，转移和耐药是导致死亡的主要驱动因素。瞬时受体电位黏脂蛋白1（TRPML1）是瞬时受体电位通道超家族的成员，与多种恶性肿瘤相关；然而，其在前列腺癌中的作用仍不清楚。利用癌症基因组图谱、人类蛋白质图谱和癌细胞系百科全书的公共数据集分析TRPML1在前列腺癌中的表达。使用TRPML1抑制剂ML-SI1和TRPML1敲除模型，在前列腺癌细胞系特别是LNCaP和22Rv1中进行功能研究。通过比色细胞活力测定、流式细胞术和Transwell实验评估细胞增殖、细胞周期分布、迁移和侵袭。进行转录组分析、实时定量PCR、蛋白质印迹和精胺测量以探究潜在机制。与癌旁正常组织相比，前列腺癌组织中TRPML1表达升高。在LNCaP细胞中，ML-SI1降低细胞活力和迁移并诱导G0/G1期阻滞，而在22Rv1细胞中，其对细胞活力和细胞周期分布的影响有限，但减少迁移和侵袭。ML-SI1降低LNCaP细胞中雄激素受体（AR）蛋白稳定性和精胺水平，而在22Rv1细胞中24小时观察到精胺水平升高。在体外，抑制TRPML1在LNCaP和22Rv1细胞中产生不同的细胞反应，并伴随AR调节和多胺代谢的差异变化。需要进一步的机制和体内研究来确定这些发现的生物学和治疗相关性。"}, {"pmid": "42813156", "title": "Associations Among Glycemic Variability, Hypomagnesemia, Thyroid Function, and Albuminuria in Patients With Type 2 Diabetes Mellitus: A Cross-Sectional Study.", "abstract": "Background Albuminuria is an important marker of diabetic kidney disease (DKD) and is associated with adverse renal and cardiovascular outcomes in people with type 2 diabetes mellitus (T2DM). Although sustained hyperglycemia is a recognized contributor to DKD, glycated hemoglobin (HbA1c) does not fully capture short-term glycemic variability. Emerging evidence suggests that hypomagnesemia and altered thyroid function may be associated with albuminuria, but their combined relationships with albuminuria and the possible statistical mediating role of thyroid hormones remain unclear. This study was conducted to identify the associations of albuminuria with glycemic variability, serum magnesium, and thyroid function in T2DM patients. Materials and methods A cross-sectional study included 330 adults aged 30-84 years with T2DM of more than five years' duration. Continuous glucose monitoring (CGM)-derived measures, including mean glucose, glucose standard deviation (SD), coefficient of variation (CV), time in range (TIR), and mean amplitude of glycemic excursions (MAGE), were assessed alongside HbA1c, serum magnesium, free triiodothyronine (FT3), free thyroxine (FT4), thyroid-stimulating hormone (TSH), and urinary albumin-to-creatinine ratio (UACR). Associations with albuminuria were examined using univariable and multivariable logistic regression, with additional correlation and exploratory regression-based mediation analysis. Ethical approval and written informed consent were obtained. Results Among 330 participants, 208 (63%) had normal UACR, 98 (29.7%) had microalbuminuria, and 24 (7.3%) had macroalbuminuria. Hypomagnesemia was associated with more than twofold higher odds of albuminuria in univariable analysis (odds ratio (OR)=2.26; 95% confidence interval (CI): 1.38-3.70; p=0.001). In Model IV, which was adjusted for demographic variables, higher HbA1c (OR=1.66; 95% CI: 1.34-2.05; p<0.001), SD (OR=1.63; 95% CI: 1.18-2.26; p=0.003), CV (OR=1.06; 95% CI: 1.01-1.10; p=0.016), and MAGE (OR=1.25; 95% CI: 1.07-1.45; p=0.005) were independently associated with higher odds of albuminuria. In contrast, higher FT3 was inversely associated with albuminuria (OR=0.46; 95% CI: 0.28-0.74; p=0.001). TIR, FT4, and TSH were not significantly associated with albuminuria in univariable analysis. HbA1c was negatively correlated with FT3 (ρ=-0.133; p=0.016). Similarly, SD was negatively correlated with FT3 (ρ=-0.227; p<0.001). Exploratory mediation analysis indicated that FT3 statistically accounted for 6.9% of the association between HbA1c and albuminuria and 21.4% of the association between glucose SD and albuminuria. Conclusion Greater glycemic variability and lower FT3 levels were independently associated with albuminuria in patients with T2DM, while hypomagnesemia was associated with albuminuria in univariable analysis. Exploratory mediation analysis suggested that FT3 statistically accounted for a modest proportion of the associations of HbA1c and glucose SD with albuminuria. These findings indicate that CGM-derived variability measures, alongside magnesium status and thyroid function, may provide complementary information in the assessment of DKD. Prospective multicenter studies are required to clarify the temporal relationships and clinical significance of these findings.", "journal": "Cureus", "pub_date": "2026-Sep", "publication_types": ["Journal Article"], "doi": "10.7759/cureus.117117", "authors": ["Shoaib Asghar", "Kashif Shaikh", "Ahmed Nisar", "Sameera Aftab", "Rabia Qadeer", "Abdul Wahab"], "affiliations": ["General Internal Medicine, Sheikh Zayed Medical College/Hospital, Rahim Yar Khan, PAK.", "General Internal Medicine, Luton and Dunstable University Hospital, Bedfordshire Hospitals NHS Foundation Trust, Luton, GBR."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=8", "score": 15.22, "score_parts": {"urology_relevance": 3, "urology_in_title": 0.0, "journal_priority": 2.22, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 8.0}, "journal_metrics": {"status": "ok", "impact_factor": 1.3, "cas_zone": 4, "cas_zone_points": 1.0, "impact_factor_points": 1.22, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42806640", "title": "CT urography and urinary cytology in surveillance of endoscopically managed UTUC.", "abstract": "Our objective was to assess whether non-invasive surveillance with computed tomography (CT) urography and urinary cytology could safely reduce the need for ureteroscopy (URS) in patients with upper tract urothelial carcinoma treated with endoscopic kidney-sparing surgery (eKSS). We performed a retrospective multicentre analysis of patients undergoing eKSS for upper tract urothelial carcinoma at two tertiary centres (2006-2025). Surveillance included second-look URS at 4-6 weeks, then every 6 months for 2 years and annually thereafter. CT urography and urinary cytology were performed within 3 months before each URS, and this served as the reference standard. Four trigger strategies were evaluated for diagnostic performance. Analysis started from the third URS. Recurrence over time was analysed using annualized rates per person-year, accounting for multiple recurrences and treating radical nephroureterectomy as a competing event, overall and by risk group. A total of 133 patients and 256 ureteroscopic assessments were included. Combined CT and/or cytology showed sensitivity of 35.5%, specificity of 75.0%, a positive predictive value of 64.1% (95% confidence interval [CI] 52.4-74.7), and a negative predictive value of 48.0% (95% CI 40.4-55.7), avoiding 69.2% of URS (95% CI 63.1-74.8) but missing 64.5% of recurrences (95% CI 56.0-72.4). Cytology alone was highly specific (97%) but poorly sensitive (11%); CT alone showed moderate sensitivity (27%) and good specificity (78%); requiring both to be positive yielded near-perfect specificity but near-zero sensitivity (2.8%). Recurrence rates were stable across follow-up years at 0.34, 0.35, 0.35, and 0.28 events/person-year at years 1-4 in the low-risk group, and 0.33, 0.38, 0.32, and 0.32 in the high-risk group. CT urography and urinary cytology may reduce the frequency of URS but cannot safely replace endoscopic surveillance because of the high rate of missed recurrences. Stable recurrence rates over time support the need for continued long-term endoscopic follow-up after eKSS.", "journal": "BJU International", "pub_date": "2026-Sep-28", "publication_types": ["Journal Article"], "doi": "10.1111/bju.70469", "authors": ["Pietro Scilipoti", "Raffaele La Mura", "Federico Zorzi", "Marie Chicaud", "Nicola Nannola", "Carlos Gonzalez Gonzalez", "Andrea Folcia", "Angelo Occhi", "Andrea Cosenza", "Eugenio Ventimiglia", "Luigi Candela", "Giuseppe Rosiello", "Marco Moschini", "Francesco Montorsi", "Alberto Briganti", "Andrea Salonia", "Steeve Doizi", "Frederic Panthier", "Luca Villa", "Olivier Traxer"], "affiliations": ["Service d'urologie, Tenon Hôpital, Paris, France.", "GRC20-Endolase Lab, Sorbonne University, PIMM-Arts et Métiers Paris Tech, Paris, France.", "Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy.", "Vita-Salute San Raffaele University, Milan, Italy.", "Uppsala University, Uppsala, Sweden."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=6", "score": 37.47, "score_parts": {"urology_relevance": 11, "urology_in_title": 8.0, "journal_priority": 10.47, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 6.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.4, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.47, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42806622", "title": "Split Activator Assembly via Aptamer Binding Enables CRISPR-Cas12a Activation With Non-Nucleic Acid Targets.", "abstract": "The programmability of CRISPR-Cas12a has enabled transformative advances in nucleic acid detection; however, extending its activation to non-nucleic-acid targets remains highly desirable. Here, we report a universal split-activator strategy that enables programmable Cas12a activation in response to a small molecule and a protein. In this approach, a canonical activator is divided into two fragments (p1 and p2), such that Cas12a activation occurs only upon their simultaneous assembly. We integrate this mechanism with aptamer-mediated conformation switching, wherein target binding destabilizes an aptamer-p2 duplex, releasing p2 to complete the activator complex and trigger Cas12a nuclease activity. Using this design, we demonstrate selective recognition of the small-molecule metabolite adenosine and the protein biomarker prostate-specific antigen (PSA), with high specificity against structurally related controls. Signal generation is achieved using fluorescent DNA nanoclusters (DFN-1), which undergo fluorescence decrease upon Cas12a-mediated degradation. The system exhibits concentration-dependent responses for both targets. Together, this work establishes a modular framework for coupling aptamer-based molecular recognition to programmable Cas12a activation, expanding the functional scope of CRISPR systems beyond nucleic acids and enabling new opportunities in CRISPR-Cas12a-mediated detection.", "journal": "Small Methods", "pub_date": "2026-Sep-28", "publication_types": ["Journal Article"], "doi": "10.1002/smtd.71075", "authors": ["Ram J Tharu", "Yusha Imtiaz", "Shubhajit Singha", "Emmett Hanson", "Reggie E Gold", "Pavl Royzen", "Mehmet V Yigit"], "affiliations": ["Department of Chemistry, University At Albany, State University of New York, Albany, New York, USA.", "The RNA Institute, University At Albany, State University of New York, Albany, New York, USA."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "basic_signals=6", "score": 24.39, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 11.39, "top_journal_bonus": 0.0, "novelty": 1.0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 6.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 9.1, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 3.39, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42806610", "title": "Patient-reported outcomes as non-muscle-invasive bladder cancer clinical trial endpoints.", "abstract": "To evaluate the frequency at which patient-reported outcomes (PROs) are incorporated as nonmuscle-invasive bladder cancer (NMIBC) clinical trial endpoints. Interventional trials limited to patients with NMIBC were queried from clinicaltrials.gov from 1994 to 2025 (start of trial). Observational studies or those without a discrete intervention were excluded. The incorporation of all PROs as primary and secondary endpoints was recorded. PROs were not limited to validated tools. They were defined according to United States Food and Drug Administration (FDA) guidance as any information about a patient's health/experience coming directly from the patient without interpretation by a provider/investigator. Categorical variables were analysed with chi-square and Fisher's exact tests, when applicable, and continuous variables were analysed with the Mann-Whitney U test. A total of 94 clinical trials were included, of which 21 (22%) incorporated PROs. PROs were included in 3% and 20% of trials as primary and secondary endpoints, respectively. The most commonly used PROs include the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) and EORTC QLQ-Nonmuscle-Invasive Bladder Cancer 24 module (incorporated in 48% and 43% of NMIBC trials using PROs, respectively). Trials that incorporated PROs as endpoints included higher median anticipated patient enrolments (median [interquartile range] number of patients 166 [461] vs 46 [101], P = 0.002) and were more likely to be randomised controlled trials (62% vs 41%, P = 0.057). There was no difference in funding mechanism (industry-sponsored vs cooperative group/federally funded) between trials that did and did not incorporate PROs. There was little change in PRO incorporation as trial endpoints over time. Despite recent emphasis from the FDA, patient advocacy groups, and the scientific community on the use of PRO measurements to capture the holistic, lived experience of patients on investigational cancer therapeutics, there is limited incorporation of PROs in NMIBC interventional trials. These data serve as a call to action for PRO tool harmonisation and universal incorporation in NMIBC clinical trial design.", "journal": "BJU International", "pub_date": "2026-Sep-28", "publication_types": ["Journal Article"], "doi": "10.1111/bju.70461", "authors": ["Kimberly Toumazos", "Spencer Bell", "Katelyn Spencer", "Darrell Nakagawa", "Kelly K Bree", "Ashish M Kamat", "Sarah P Psutka", "Patrick J Hensley"], "affiliations": ["Department of Urology, University of Kentucky College of Medicine, Lexington, KY, USA.", "Southwest Oncology Group (SWOG) Patient Advocacy, Chicago, IL, USA.", "Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.", "Department of Urology, University of Washington Fred Hutchinson Cancer Center, Seattle, WA, USA.", "Department of Pathology, University of Kentucky College of Medicine, Lexington, KY, USA."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=7", "score": 31.47, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.47, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 7.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.4, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.47, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42806037", "title": "Clinical and MRI characteristics of germline pathogenic variant carriers diagnosed with prostate cancer.", "abstract": "Compare the clinical and imaging features of prostate cancer (PCa) patients harboring a germline pathogenic variant (PV) to sporadic controls. A single-center retrospective case-control study was performed by identifying patients with positive germline genetic testing for a PV diagnosed with prostate cancer between December 2015 and October 2025. Clinical, pathologic, and MRI characteristics of PV carriers were compared to a control group of consecutive patients diagnosed with PCa over 1 year. Mann-Whitney U-test was used for continuous data and Fisher's exact test for categorical comparisons. A total of 62 patients with PCa harboring ≥ 1 PV and an MRI at diagnosis were compared to 246 controls. The most frequent genes were Lynch syndrome (LS) associated (17.7%), CHEK2 (21.0%), ATM (17.7%), and BRCA2 (19.4%). Median age of PV carriers was not significantly younger than controls at diagnosis (65 years [IQR, 58-71], vs 67 years [61-73], p = 0.05). The proportion of patients with a positive MRI (PI-RADS ≥ 3) did not differ between groups (98% PV vs 96% control, p = 0.70). PV carriers were more likely to receive a PI-RADS 5 score (OR: 2.7; CI: 1.5-4.9, p < 0.01) and grade 3 extra-prostatic extension (OR: 3.0; CI: 1.5-5.8, p < 0.01). At prostatectomy, the proportion of patients reclassified to a higher-grade group was larger for PV carriers (37% vs 20%, p = 0.046). PV carriers with PCa tend to manifest more aggressive imaging findings and are more likely to experience pathologic upgrading at prostatectomy. Question Differences in the clinical and imaging characteristics of sporadic prostate cancer (PCa) patients compared to patients harboring a PCa-associated germline pathogenic variant remain understudied. Findings PV carriers with PCa manifest more aggressive imaging features and are more likely to demonstrate pathologic upgrading at prostatectomy. Clinical relevance Knowledge of the unique clinical and imaging manifestations of hereditary PCa should support ongoing early detection studies and underscore the need for radiologists to be familiar with patient-centered early detection strategies utilizing MRI.", "journal": "European Radiology", "pub_date": "2026-Sep-28", "publication_types": ["Journal Article"], "doi": "10.1016/j.ejca.2021.01.027", "authors": ["Rory L Cochran", "Madhangi Parameswaran", "Nabih Nakrour", "Soumyadeep Ghosh", "Abdelrahman Elshikh", "Miraj Rawal", "Maximillian Pohl", "Nuttaphon Aleenajitpong", "Onofrio A Catalano", "Amirkasra Mojtahed", "Shelley R McCormick", "Linda H Rodgers-Fouche", "Mukesh G Harisinghani", "Keyan Salari"], "affiliations": ["Department of Radiology, Massachusetts General Hospital, Mass General Brigham, Boston, MA, USA. rcochran@mgh.harvard.edu.", "Harvard Medical School, Boston, MA, USA. rcochran@mgh.harvard.edu.", "Department of Radiology, Massachusetts General Hospital, Mass General Brigham, Boston, MA, USA.", "Harvard Medical School, Boston, MA, USA.", "Department of Radiology, Medical University of Graz, Graz, Austria.", "Department of Diagnostic and Therapeutic Radiology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.", "Mass General Brigham Cancer Institute, Boston, MA, USA.", "Department of Urology, Mass General Brigham, Boston, MA, USA."], "corresponding_authors": ["Rory L Cochran"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=4", "score": 32.55, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 10.55, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 4.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.7, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.55, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42805760", "title": "Temporal dynamics of the immune response to neoadjuvant androgen deprivation therapy suggest a window of opportunity for checkpoint inhibitor therapy in prostate cancer.", "abstract": "Novel therapies to prevent lethal castration-resistant prostate cancer in response to standard-of-care androgen deprivation therapy (ADT) are required. Unfortunately, most prostate cancers are \"immune cold\" and fail to respond to checkpoint inhibitors (CPIs). To assess whether ADT induces changes that enable more effective CPI therapy, we examined the tumor immune microenvironment (TiME) following neoadjuvant ADT (nADT). Radical prostatectomy specimens from 43 nADT-treated patients were stratified into three duration groups and compared with each other and with matched controls. RNA sequencing and quantitative multispectral immunofluorescence (qmIF) staining were performed to analyze transcriptomic and TiME abundance and cellular spatial relationship differences after nADT. Immune and inflammatory pathways, particularly of antigen presentation and adaptive immune response, were increased, most notably in tumors receiving 3-5 months nADT. qmIF revealed a complex temporal response in the TiME, with a dramatic influx of cytotoxic T lymphocytes (CTLs) and T-helper cells after 3-5 months of nADT. However, after 6 months nADT, M2-like tumor-associated macrophages (TAMs) and regulatory T cells were strikingly increased while CTLs decreased. Spatially, CTLs and T-helper cells clustered near tumor cells at 3-5 months nADT, but were replaced by M2-TAMs in tumors receiving ≥6 months of nADT. These data reveal the induction of a bi-phasic response in the TiME: robust CTL activation 3-5 months after nADT is initiated, followed by myeloid immunosuppression in tumors receiving prolonged nADT. This ADT-induced reprogramming of the TiME suggests a critical window of opportunity where short-duration ADT might augment CPI efficacy, converting cold into immunologically responsive tumors.", "journal": "Journal for Immunotherapy of Cancer", "pub_date": "2026-Sep-28", "publication_types": ["Journal Article"], "doi": "10.1016/j.celrep.2019.07.068", "authors": ["Anmbreen Jamroze", "Renyuan Zhang", "Emily Dougherty", "Kriti Ahuja", "Lei Deng", "Karan Jatwani", "Uyen V Nguyen", "Bailey Farmer", "Gaybrielle James", "Michalis Mastri", "Kevin H Eng", "Bo Xu", "Yvonne Saenger", "Yuanquan Yang", "John J Krolewski", "Dean Tang", "Gurkamal Chatta", "Kent L Nastiuk"], "affiliations": ["Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.", "Department of Cancer Genetics and Genomics, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.", "Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.", "Division of Medicine and Clinical Research Division, Fred Hutch Cancer Center, Seattle, Washington, USA.", "Department of Urology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.", "Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.", "Eikon Therapeutics, Jersey City, New Jersey, USA.", "Department of Pathology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.", "Department of Oncology, Montefiore Einstein Comprehensive Cancer Center, New York, New York, USA.", "Division of Medical Oncology, Ohio State University James Cancer Hospital, Columbus, Ohio, USA.", "Buffalo State University/ State University of New York, Buffalo, New York, USA.", "Department of Cancer Genetics and Genomics, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA kent.nastiuk@roswellpark.org."], "corresponding_authors": ["Kent L Nastiuk"], "china_team": "", "category": "basic", "classification_reason": "basic_signals=6", "score": 36.6, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 15.6, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 6.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 10.6, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.6, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "新辅助ADT后免疫微环境双相演变", "chinese_summary": "《癌症免疫治疗杂志》9月发表研究，对43例接受新辅助雄激素剥夺治疗的前列腺癌根治标本行RNA测序及多重免疫荧光分析，发现治疗3–5个月时细胞毒性T细胞与辅助T细胞大量浸润并聚集于肿瘤细胞周围，而≥6个月后M2型巨噬细胞及调节性T细胞显著增多、CTL减少，提示短程ADT可能为检查点抑制剂治疗创造窗口期。", "abstract_zh": "针对标准治疗雄激素剥夺治疗（ADT）后出现的致死性去势抵抗性前列腺癌，亟需新型疗法。遗憾的是，大多数前列腺癌属于“免疫冷”肿瘤，对检查点抑制剂（CPIs）无应答。为评估ADT是否诱导出能使CPI治疗更有效的变化，我们检查了新辅助ADT（nADT）后的肿瘤免疫微环境（TiME）。将43例接受nADT治疗患者的前列腺根治标本按治疗持续时间分为三组，并进行组间及与匹配对照的比较。采用RNA测序和定量多重免疫荧光（qmIF）染色分析nADT后转录组及TiME丰度和细胞空间关系差异。免疫与炎症通路，尤其是抗原呈递和适应性免疫应答相关通路增高，在nADT治疗3–5个月的肿瘤中最为显著。qmIF显示TiME中存在复杂的时间依赖性反应，nADT 3–5个月后细胞毒性T淋巴细胞（CTLs）和辅助T细胞显著涌入。然而，nADT 6个月后，M2样肿瘤相关巨噬细胞（TAMs）和调节性T细胞显著增加，而CTLs减少。空间上，nADT 3–5个月时CTLs和辅助T细胞聚集于肿瘤细胞附近，但在接受≥6个月nADT的肿瘤中被M2-TAMs取代。这些数据揭示了TiME中双相反应的诱导：nADT开始后3–5个月出现强烈的CTL活化，随后在长期nADT的肿瘤中出现髓系免疫抑制。这种ADT诱导的TiME重编程提示一个关键的机会窗口，短程ADT可能增强CPI疗效，将冷肿瘤转化为免疫应答性肿瘤。"}, {"pmid": "42805527", "title": "Epididymal St3gal2-mediated α2,3-sialylation regulates murine sperm motility and correlates with N-glycan alterations in human asthenozoospermia.", "abstract": "Sialic acid residues on the sperm surface play crucial roles in sperm maturation, capacitation, and sperm-oocyte interactions. Here, we investigated the dynamic regulation of α2,3-sialylation on the sperm membrane during epididymal maturation in mice, with a focus on the sialyltransferase St3gal2. St3gal2 is highly expressed in the caput epididymis and mediates the progressive accumulation of α2,3-linked sialic acid on the murine sperm surface during epididymal transit. Enzymatic removal of surface α2,3-sialic acid significantly reduced mouse sperm progressive motility, whereas co-incubation of desialylated mouse sperm with conditioned medium from St3gal2-overexpressing COS-7 cells restored both surface α2,3-sialylation and motility, establishing a direct functional link between St3gal2 activity and sperm movement. To extend these findings to human reproductive pathology, we performed systematic N-glycomic profiling of sperm membrane proteins from healthy donors (PR ≥ 32%, n = 18) and asthenozoospermic donors (PR < 32%, n = 15) by MALDI-MS. α2,3-Sialylated N-glycans were positively correlated with progressive motility and significantly reduced in asthenozoospermic sperm, while fucosylated N-glycans were significantly elevated in asthenozoospermia. α2,6-Sialylated N-glycans showed no significant difference between groups and no significant association with progressive motility. Lectin-based flow cytometry independently confirmed increased surface fucosylation and decreased surface α2,3-sialylation in asthenozoospermic sperm. Together, these findings establish a causal role for St3gal2-mediated α2,3-sialylation in murine sperm motility and reveal a characteristic N-glycan imbalance - reduced α2,3-sialylation and elevated fucosylation - associated with human asthenozoospermia, identifying the sperm surface glycocalyx as a potential target for therapeutic intervention in motility-related male infertility.", "journal": "International Journal of Biological Macromolecules", "pub_date": "2026-Sep-28", "publication_types": ["Journal Article"], "doi": "10.1016/j.ijbiomac.2026.154667", "authors": ["Yujia Zhai", "Yueyue Li", "Yuping Zhang", "Ruohan Wang", "Yilun Wu", "Ying Feng", "Haojie Lu", "Fang Ma"], "affiliations": ["Department of Medical Genetics/Prenatal Diagnostic Center, West China Second University Hospital, Sichuan University, Chengdu, China; Key Laboratory of Birth Defects and Related Diseases of Women and Children, Sichuan University, Ministry of Education, Chengdu, China.", "Liver Cancer Institute, Zhongshan Hospital and Institutes of Biomedical Sciences, Fudan University, Shanghai, 200032, China.", "West China School of Basic Medical Sciences & Forensic Medicine, Sichuan University, Chengdu, Sichuan, 610041, China.", "Center for Translational Medicine, Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China; Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, Chengdu, China.", "Liver Cancer Institute, Zhongshan Hospital and Institutes of Biomedical Sciences, Fudan University, Shanghai, 200032, China; Department of Chemistry, NHC Key Laboratory of Glycoconjugates Research, Fudan University, Shanghai, 200032, China.", "Center for Translational Medicine, Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China; Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, Chengdu, China. Electronic address: mafangmed@scu.edu.cn."], "corresponding_authors": ["Fang Ma"], "china_team": "Department of Medical Genetics/Prenatal Diagnostic Center, West China Second University Hospital, Sichuan University, Chengdu, China; Key Laboratory of Birth Defects and Related Diseases of Women and Children, Sichuan University, Ministry of Education, Chengdu, China Fang Ma团队", "category": "basic", "classification_reason": "basic_signals=10", "score": 26.3, "score_parts": {"urology_relevance": 3, "urology_in_title": 0.0, "journal_priority": 11.3, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 10.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 8.5, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 3.3, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "附睾St3gal2调控精子活力", "chinese_summary": "四川大学华西第二医院马芳团队9月Int J Biol Macromol发表研究：小鼠附睾头高表达St3gal2，介导精子表面α2,3-唾液酸渐进累积，酶解去除后前向运动显著下降，回补后恢复；弱精子症患者精子α2,3-唾液酸化的N-糖显著降低、岩藻糖化升高，提示精子表面糖萼是干预靶点。", "abstract_zh": "精子表面的唾液酸残基在精子成熟、获能及精卵相互作用中发挥关键作用。本研究探讨了小鼠附睾成熟过程中精子膜上α2,3-唾液酸化的动态调控，重点关注唾液酸转移酶St3gal2。St3gal2在附睾头高表达，并介导小鼠精子在附睾转运过程中表面α2,3-连接唾液酸的渐进累积。酶促去除表面α2,3-唾液酸可显著降低小鼠精子前向运动，而将去唾液酸化的精子与过表达St3gal2的COS-7细胞条件培养基共孵育，则同时恢复了表面α2,3-唾液酸化与精子活力，从而确立了St3gal2活性与精子运动之间的直接功能联系。为将这些发现拓展至人类生殖病理领域，我们通过MALDI-MS对健康供者（PR ≥ 32%，n = 18）与弱精子症供者（PR < 32%，n = 15）精子膜蛋白进行了系统性N-糖组学分析。α2,3-唾液酸化的N-糖与前向运动呈正相关，并在弱精子症精子中显著降低；而岩藻糖化的N-糖在弱精子症中显著升高。α2,6-唾液酸化的N-糖在两组间无显著差异，且与前向运动无显著关联。基于凝集素的流式细胞术独立证实，弱精子症精子表面岩藻糖化增加而α2,3-唾液酸化降低。总之，这些发现确立了St3gal2介导的α2,3-唾液酸化在小鼠精子运动中的因果作用，并揭示了与人类弱精子症相关的特征性N-糖失衡——α2,3-唾液酸化降低而岩藻糖化升高，表明精子表面糖萼可作为运动相关男性不育治疗干预的潜在靶点。"}, {"pmid": "42805409", "title": "Differential Association of Posttestosterone Recovery PSA Kinetics With Progression and Metastatic Outcomes in Nonmetastatic Prostate Cancers.", "abstract": "Prostate-specific antigen (PSA) kinetics following testosterone recovery remain difficult to interpret in patients treated with definitive radiation therapy with androgen deprivation therapy (ADT). We evaluated the association between posttestosterone recovery PSA dynamics and progression and metastatic outcomes using Bayesian joint modeling. Individual patient data were pooled from 2 randomized trials of localized prostate cancer treated with radiation therapy and ADT. Serial PSA measurements obtained up to 18 months after testosterone recovery to supracastrate levels (>50 ng/dL) and before progression were analyzed using Bayesian joint models linking longitudinal mixed-effects models of log-transformed PSA with survival submodels for progression-free survival and metastasis-free survival. Associations of PSA slope and cumulative PSA exposure (area under the curve) with event risk were estimated via shared random effects. Sensitivity analyses used Bayesian cause-specific joint models censoring deaths. The cohort included 461 patients contributing 1594 postrecovery PSA measurements with a median follow-up of 115 months. PSA slope was re-expressed as hazard ratios (HRs) at selected PSA doubling time (PSADT) values relative to stable PSA. For progression-free survival, shorter PSADT was associated with directionally higher hazards of progression or death (PSADT 12 months: posterior median HR, 1.10; 95% credible interval [CrI], 0.87-1.39; PSADT, 6 months: HR, 1.20; 95% CrI, 0.75-1.92) with 78% posterior probability of HR > 1. For metastasis-free survival, estimates were directionally opposite (PSADT, 12 months: HR, 0.80; 95% CrI, 0.61-1.02; PSADT, 6 months: HR, 0.63; 95% CrI, 0.37-1.04). Cumulative PSA exposure showed no clinically meaningful association with either endpoint. In death-censored Bayesian joint models, the PSADT 12-month HR was 1.27 (95% CrI, 0.98-1.64) for progression and 1.13 (95% CrI, 0.59-2.15) for distant metastasis, with imprecision for distant metastasis reflecting the limited number of metastatic events (n = 32). PSA slope after testosterone recovery was directionally associated with progression risk. Associations with metastatic outcomes were inconsistent across modeling frameworks and imprecisely estimated, particularly for distant metastasis because of the limited number of events. No definitive inference regarding metastatic risk should be drawn from these analyses.", "journal": "International Journal of Radiation Oncology, Biology, Physics", "pub_date": "2026-Sep-28", "publication_types": ["Journal Article"], "doi": "10.1016/j.ijrobp.2026.08.050", "authors": ["Samuel Lichtman-Mikol", "Serageldin Kamel Attia", "Yilun Sun", "Shawn Malone", "Scott Grimes", "Amar U Kishan", "Nicholas G Zaorsky", "Daniel E Spratt", "Scott C Morgan", "Angela Y Jia", "Soumyajit Roy"], "affiliations": ["Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Cleveland, Ohio.", "Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, Ohio.", "Department of Radiation Oncology, Radiology, and Medical Physics, The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada.", "Department of Radiation Oncology, University of California Los Angeles, Los Angeles, California.", "Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Cleveland, Ohio. Electronic address: soumyajitroy8@gmail.com."], "corresponding_authors": ["Soumyajit Roy"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=10", "score": 38.96, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 14.96, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 10.0}, "journal_metrics": {"status": "ok", "impact_factor": 6.5, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 2.96, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42805337", "title": "Data from the French Daily-Luma cohort suggest predictors of a lumasiran response.", "abstract": "Primary Hyperoxaluria type 1 (PH1) is a rare and severe autosomal recessive disorder with genotype/phenotype correlation. The RNA interfering therapy lumasiran has revolutionized its prognosis but with heterogeneous response amongst patients. Here, we assessed a possible association between genotype and lumasiran response. In the ongoing French DAILY-LUMA cohort evaluating real-life efficacy and safety of lumasiran, we collected data at treatment initiation and at months three, six and 12 of treatment. The main outcomes were composite criteria, namely normalization and/or reduction over 30% from baseline in the urinary ratio of oxalate and creatinine (UOx/Creat) or in blood oxalate levels (POx) in patients with estimated glomerular filtration rate (eGFR) over or under 30 mL/min/1.73 m2, respectively. The primary endpoint was the proportion of patients reaching this criterion at three months, and secondary endpoints were the same analysis at six and 12 months. Genotype was classified into three groups depending on the vitamin B6 response: resistance, sensitivity, uncertain response (Ile244Thr variant of alanine-glyoxylate aminotransferase). In total, 76 patients (54 children) were included, at a median (inter quartile range) age at lumasiran initiation of 13 (4-33) years with 24 patients on dialysis. After three months treatment, 73 % of patients met the primary endpoint (% calculated on available data). There was no significant association between the underlying genotype and lumasiran response, albeit with a trend towards a lesser response in vitamin B6- sensitive forms. The only significant determinants found to be associated with the primary outcome were age at diagnosis and age at lumasiran initiation, the best response being observed in pediatric patients. Our study suggests a better response to lumasiran in children independent of the underlying genotype. In patients with pyridoxine sensitivity, we suggest continuing or initiating pyridoxine even after lumasiran initiation. After lumasiran initiation, a close follow-up and re-evaluation should be systematically performed.", "journal": "Kidney International", "pub_date": "2026-Sep-28", "publication_types": ["Journal Article"], "doi": "10.1016/j.kint.2026.08.025", "authors": ["Vittoria Soncin", "Anne Laure Sellier Leclerc", "Cécile Acquaviva-Bourdain", "Thomas Loppinet", "Olivia Boyer", "Bertrand Knebelmann", "Lise Allard", "Claire Dossier", "Sylvie Cloarec", "Thomas Stehlé", "François Nobili", "Marie Courbebaisse", "Isabelle Vrillon", "Maize Ducret", "Ariane Zaloszyc", "Moglie Le Quintrec", "Edouard Martinez Casado", "Thierry Krummel", "Caroline Rousset-Rouviere", "Stéphane Burtey", "Amélie Ryckewaert", "Thierry Frouget", "Massimo Di Maio", "Charlotte Samaille", "Emilie Cornec-Le Gall", "William Hanf", "Catherine Monet-Didailler", "Adeline Schendel", "Arnaud Garnier", "Aurélie Pons", "Renaud Snanoudj", "Nadia Cherni", "Marc Fila", "Camille Faudeux", "Mathilde Mauras", "Inna Mohamadou", "Sandrine Lemoine", "Justine Bacchetta"], "affiliations": ["Pediatric Nephrology Unit, Department of Women's and Children's Health, University of Padua, Italy; Reference Center for Rare Renal Diseases, ORKID and ERK-Net networks, Lyon University Hospital, Lyon, France.", "Reference Center for Rare Renal Diseases, ORKID and ERK-Net networks, Lyon University Hospital, Lyon, France.", "Pediatric Nephrology Unit, Centre de référence MARHEA, Imagine Institute, Paris Cité University, Hôpital Necker-Enfants malades, AP-HP, Paris, France.", "Nephrology and Transplantation Department, Centre de référence MARHEA, Hôpital Necker-Enfants malades, AP-HP, Université Paris Cité, Paris, France.", "Pediatric Nephrology Unit, Centre de reference constitutif des maladies rénales rares, CHU de Bordeaux, Bordeaux, France.", "Pediatric Nephrology Department, Hôpital Robert Debré, AP-HP, Paris; France.", "Pediatric Nephrology Unit, CHU Tours, Tours, France.", "Service de Néphrologie et Transplantation, Fédération Hospitalo-Universitaire \"Innovative therapy for immune disorders,\" Assistance Publique des Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Henri Mondor, Créteil, France; Institut National de la Santé et de la Recherche Médicale U955, Institut Mondor de Recherche Biomédicale, Universite Paris Est Créteil, Créteil, France.", "Pediatric Nephrology Unit, CHU Besançon, Besançon, France.", "Physiology Department, Hôpital européen Georges-Pompidou, APHP, Paris, France.", "Pediatric Unit, hôpital d'enfants, CHRU de Nancy, France.", "Nephrology department, Hôpital d'Annecy, Annecy, France.", "Department of Pediatrics 1, University Hospital of Strasbourg, Strasbourg, France.", "Nephrology and Transplantation Department, Centre Hospitalier Universitaire de Montpellier, Montpellier, France.", "CHU Rouen, Department of Pediatrics, F-76000 Rouen, France.", "Nephrology Department, CHRU de Strasbourg, Strasbourg, France.", "Pediatric Nephrology Unit, APHM, Marseille, France.", "Aix Marseille Univ, INSERM, INRAE, C2VN, Marseille, France.", "Pediatric Nephrology Unit, Hospital of Rennes, Rennes, France.", "Nephrology Department, CHU de Pontchaillou, Rennes, France.", "Service de Réanimation Néonatale, CHU Nîmes Carémeau, Nimes France.", "Pediatric Nephrology Unit, hôpital Jeanne de Flandre, CHU de Lille, Lille, France.", "Service de Néphrologie, Hémodialyse et Transplantation Rénale, Centre de référence MARHEA, Filière ORKID, CHRU Brest, Brest, France.", "Department of Nephrology, CH Alpes-Léman, Condamine-sur-Arve, France.", "Pediatric Unit, Centre Hospitalier de La Côte Basque, Bayonne, France.", "Nephrology Department, CH Simone Veil, Troyes, France.", "Pediatric Unit, CH de Raiatea, Raiatea, France.", "Service de Pédiatrie Spécialisée et Généralisée, Centre Hospitalier Universitaire de Reims, Reims, France.", "Departement of Nephrology-Dialysis-Transplantation, Assistance Publique des Hôpitaux de Paris (AP-HP), Bicêtre University Hospital, Paris-Saclay University, Le Kremlin Bicêtre, France.", "Department of Nephrology, CHU Tenon, Paris, France.", "Department of Pediatric Nephrology, Reference Center for Rare Renal Diseases SORARE CHU de Montpellier, Montpellier, France.", "Pediatric Nephrology Unit, Centre Hospitalier Universitaire de Nice, Nice, France.", "Department of Pediatrics, Hôpital Nord, CHU de Saint-Etienne, Saint-Etienne, France.", "Kidney Transplantation Department, Hôpital Pitié-Salpétriêre, Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Paris, France; INSERM URMS 1155 - Common and rare kidney diseases (CoRaKiD) - Hôpital Tenon, 4 rue de la Chine, 75020 Paris.", "Reference Center for Rare Renal Diseases, ORKID and ERK-Net networks, Lyon University Hospital, Lyon, France; Pediatric Nephrology Unit, Centre de référence MARHEA, Imagine Institute, Paris Cité University, Hôpital Necker-Enfants malades, AP-HP, Paris, France; Nephrology and Transplantation Department, Centre de référence MARHEA, Hôpital Necker-Enfants malades, AP-HP, Université Paris Cité, Paris, France; Pediatric Nephrology Unit, Centre de reference constitutif des maladies rénales rares, CHU de Bordeaux, Bordeaux, France; Pediatric Nephrology Department, Hôpital Robert Debré, AP-HP, Paris; France,; Pediatric Nephrology Unit, CHU Tours, Tours, France; Service de Néphrologie et Transplantation, Fédération Hospitalo-Universitaire \"Innovative therapy for immune disorders,\" Assistance Publique des Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Henri Mondor, Créteil, France; Institut National de la Santé et de la Recherche Médicale U955, Institut Mondor de Recherche Biomédicale, Universite Paris Est Créteil, Créteil, France; Pediatric Nephrology Unit, CHU Besançon, Besançon, France; Physiology Department, Hôpital européen Georges-Pompidou, APHP, Paris, France; Pediatric Unit, hôpital d'enfants, CHRU de Nancy, France; Nephrology department, Hôpital d'Annecy, Annecy, France; Department of Pediatrics 1, University Hospital of Strasbourg, Strasbourg, France; Nephrology and Transplantation Department, Centre Hospitalier Universitaire de Montpellier, Montpellier, France; CHU Rouen, Department of Pediatrics, F-76000 Rouen, France; Nephrology Department, CHRU de Strasbourg, Strasbourg, France; Pediatric Nephrology Unit, APHM, Marseille, France; Aix Marseille Univ, INSERM, INRAE, C2VN, Marseille, France; Pediatric Nephrology Unit, Hospital of Rennes, Rennes, France; Nephrology Department, CHU de Pontchaillou, Rennes, France; Service de Réanimation Néonatale, CHU Nîmes Carémeau, Nimes France; Pediatric Nephrology Unit, hôpital Jeanne de Flandre, CHU de Lille, Lille, France; Service de Néphrologie, Hémodialyse et Transplantation Rénale, Centre de référence MARHEA, Filière ORKID, CHRU Brest, Brest, France; Department of Nephrology, CH Alpes-Léman, Condamine-sur-Arve, France; Pediatric Unit, Centre Hospitalier de La Côte Basque, Bayonne, France; Nephrology Department, CH Simone Veil, Troyes, France; Pediatric Unit, CH de Raiatea, Raiatea, France; Service de Pédiatrie Spécialisée et Généralisée, Centre Hospitalier Universitaire de Reims, Reims, France; Departement of Nephrology-Dialysis-Transplantation, Assistance Publique des Hôpitaux de Paris (AP-HP), Bicêtre University Hospital, Paris-Saclay University, Le Kremlin Bicêtre, France; Department of Nephrology, CHU Tenon, Paris, France; Department of Pediatric Nephrology, Reference Center for Rare Renal Diseases SORARE CHU de Montpellier, Montpellier, France; Pediatric Nephrology Unit, Centre Hospitalier Universitaire de Nice, Nice, France; Department of Pediatrics, Hôpital Nord, CHU de Saint-Etienne, Saint-Etienne, France; Kidney Transplantation Department, Hôpital Pitié-Salpétriêre, Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Paris, France; INSERM URMS 1155 - Common and rare kidney diseases (CoRaKiD) - Hôpital Tenon, 4 rue de la Chine, 75020 Paris; INSERM 1033 Research Unit, Lyon, France. Electronic address: justine.bacchetta@chu-lyon.fr."], "corresponding_authors": ["Justine Bacchetta"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=6", "score": 26.83, "score_parts": {"urology_relevance": 3, "urology_in_title": 0.0, "journal_priority": 15.83, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 6.0}, "journal_metrics": {"status": "ok", "impact_factor": 12.6, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.83, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42805335", "title": "Tubular Rev-erbα deficiency aggravates kidney fibrosis via transcription factor NFIL3-driven lipid accumulation.", "abstract": "Kidney metabolism and physiology exhibit circadian oscillations, which are governed by the internal circadian clock. Intracellular lipid accumulation is known to play a critical role in the pathogenesis of kidney fibrosis. However, whether and how circadian disruption accelerates the progression of kidney fibrosis remains poorly understood. To investigate the effects of circadian disruption on the kidney, a mouse model simulating shift work conditions was utilized. To further elucidate the role of circadian disruption in the pathogenesis and progression of kidney fibrosis, we generated a conditional knockout mouse model (KSPNr1d1KO) with specific deletion of molecular clock Rev-erbα in kidney tubular epithelial cells. Using both KSPNr1d1 KO and control mice, we subsequently established two distinct models of kidney fibrosis. In this study, we observed that circadian disruption perturbs fatty acid metabolism in the renal cortex. Rev-erbα was downregulated in two mouse models of kidney fibrosis: unilateral ureteral obstruction (UUO) and folic acid nephropathy. Tubular Rev-erbα deficiency exacerbated kidney fibrosis in both UUOand unilateral kidney ischemia-reperfusion injury- induced fibrosis models, whereas administration of the Rev-erbα agonist SR9009 attenuated fibrosis in mice. Further mechanistic studies revealed that Rev-erbα deficiency disrupted fatty acid metabolism in the kidney cortex, leading to enhanced lipid accumulation through direct transcriptional repression of Nfil3. Our findings demonstrate that Rev-erbα protects against kidney fibrosis by suppressing NFIL3-mediated lipid accumulation. These results suggest a vicious cycle between circadian disruption and kidney fibrosis identifying tubular Rev-erbα as a potential therapeutic target for fibrosis-related kidney diseases.", "journal": "Kidney International", "pub_date": "2026-Sep-28", "publication_types": ["Journal Article"], "doi": "10.1016/j.kint.2026.08.027", "authors": ["Xiao-Lan Wang", "Jia Cheng", "Yuting Zhu", "Huiling Xiang", "Qian Yuan", "Xianfang Meng", "Chun Zhang"], "affiliations": ["Department of Nephrology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.", "Department of Neurobiology, Institute of Brain Research, School of Basic Medical Sciences, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. Electronic address: xfmeng@mails.tjmu.edu.cn.", "Department of Nephrology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China. Electronic address: drzhangchun@hust.edu.cn."], "corresponding_authors": ["Xianfang Meng", "Chun Zhang"], "china_team": "Department of Nephrology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China Xianfang Meng/Chun Zhang团队", "category": "basic", "classification_reason": "basic_signals=10", "score": 31.83, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 15.83, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 10.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 12.6, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.83, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "肾小管Rev-erbα缺失促纤维化", "chinese_summary": "华中科技大学同济医学院附属协和医院孟宪芳、张春团队9月Kidney Int报道，肾小管上皮细胞特异性敲除生物钟分子Rev-erbα可经转录抑制NFIL3失控引发脂质蓄积，加重单侧输尿管梗阻及缺血再灌注诱导的肾纤维化，而激动剂SR9009可减轻小鼠纤维化，提示Rev-erbα为潜在治疗靶点。", "abstract_zh": "肾脏代谢与生理呈现昼夜节律振荡，受内部生物钟调控。已知细胞内脂质蓄积在肾纤维化发病中起关键作用。然而，昼夜节律紊乱是否以及如何加速肾纤维化进展仍知之甚少。为研究昼夜节律紊乱对肾脏的影响，本研究采用模拟轮班工作条件的小鼠模型。为进一步阐明昼夜节律紊乱在肾纤维化发病和进展中的作用，我们构建了在肾小管上皮细胞中特异性敲除分子钟Rev-erbα的条件性敲除小鼠模型（KSPNr1d1KO）。随后利用KSPNr1d1KO和对照小鼠建立了两种不同的肾纤维化模型。本研究发现，昼夜节律紊乱扰乱了肾皮质脂肪酸代谢。在单侧输尿管梗阻（UUO）和叶酸肾病两种小鼠肾纤维化模型中，Rev-erbα均表达下调。肾小管Rev-erbα缺失加重了UUO和单侧肾脏缺血再灌注损伤诱导的纤维化模型中的肾纤维化，而给予Rev-erbα激动剂SR9009可减轻小鼠纤维化。进一步的机制研究揭示，Rev-erbα缺失破坏肾皮质脂肪酸代谢，通过直接转录抑制Nfil3导致脂质蓄积增强。我们的研究结果表明，Rev-erbα通过抑制NFIL3介导的脂质蓄积来对抗肾纤维化。这些结果提示昼夜节律紊乱与肾纤维化之间存在恶性循环，并确定肾小管Rev-erbα为纤维化相关肾脏疾病的潜在治疗靶点。"}, {"pmid": "42805308", "title": "\"Reply to \"Editorial Comment on \"The Current State of Urology Residency Mentorship: Insights from the American Urological Association Resident/Fellow Census\".", "abstract": "", "journal": "Urology", "pub_date": "2026-Sep-28", "publication_types": ["Letter"], "doi": "10.1016/j.urology.2026.09.058", "authors": ["Justin S Han"], "affiliations": ["Northwell Health, New Hyde Park, NY. Electronic address: jushan@northwell.edu."], "corresponding_authors": ["Justin S Han"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 14.61, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 5.61, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.0, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.61, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42805003", "title": "Assessing hair for human biomonitoring: comparison of organophosphorus flame-retardant levels in hair, urine and blood from the same individuals.", "abstract": "Total exposure assessment can be performed through biological monitoring. While blood and urine are commonly used matrices, hair represents an innovative alternative due to its ease of collection and its ability to reflect long term exposure. However, its applicability remains limited by insufficient data and unclear performance. In this study, hair, serum, and urine samples from 62 adults were analyzed for ten organophosphorus flame retardants (OPFRs). Detection frequencies, concentration levels, and relationships between matrices were evaluated using descriptive statistics, correlation, and clustering analyses. The effects of hair washing and urinary dilution corrections were also assessed. A greater number of compounds were detected in hair (7 compounds) compared to urine (5 metabolites only) and serum (2 compounds), indicating higher sensitivity of hair for OPFR detection. Hair concentrations were independent of gender, and strongly correlated between washed and unwashed samples, although washing significantly reduced measured levels for parent OPFRs. Importantly, no significant correlations were observed between hair and urine (DPP, BCEP) or serum (TCPP), suggesting that hair reflects different exposure information rather than duplicating conventional matrices. These findings demonstrate that hair provides complementary and more comprehensive exposure information, supporting its use alongside urine and serum to improve OPFR biomonitoring in epidemiological studies.", "journal": "Environment International", "pub_date": "2026-Sep-28", "publication_types": ["Journal Article"], "doi": "10.1016/j.envint.2026.110545", "authors": ["Ashna Lallmahomed", "Fabien Mercier", "Nathalie Costet", "Kahina Slimani", "Thi Phuong Thao Dao", "Marie Pécheux", "Vincent Bessonneau", "Arthur David", "Nathalie Bonvallot", "Barbara Le Bot"], "affiliations": ["Univ Rennes, EHESP, Inserm, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, F-35000 Rennes, France. Electronic address: ashna.lallmahomed@ehesp.fr.", "Univ Rennes, EHESP, Inserm, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, F-35000 Rennes, France.", "Univ Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, F-35000 Rennes, France.", "Direction of Environmental and Occupational Health, Santé Publique France, Saint Maurice Cedex, France."], "corresponding_authors": ["Ashna Lallmahomed"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 20.48, "score_parts": {"urology_relevance": 3, "urology_in_title": 0.0, "journal_priority": 15.48, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 9.7, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.48, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42804927", "title": "Language as a powerful \"Influencer\" in Prostate Cancer.", "abstract": "", "journal": "Journal of Urology", "pub_date": "2026-Sep-28", "publication_types": ["Editorial"], "doi": "10.1097/JU.0000000000005330", "authors": ["Adam B Weiner", "Jessica Rett", "Scott E Eggener"], "affiliations": ["Department of Urology, Cedars-Sinai Medical Center, Los Angeles, California, USA.", "Department of Urology, University of California, Los Angeles, Los Angeles, California, USA.", "Department of Linguistics, University of California, Los Angeles, Los Angeles, California, USA."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 20.01, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 11.01, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 6.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 3.01, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42804715", "title": "Helping patients make better choices by relabeling pattern 3 prostate disease as noncancerous.", "abstract": "", "journal": "Journal of the National Cancer Institute", "pub_date": "2026-Sep-28", "publication_types": ["Editorial", "Comment"], "doi": "10.1093/jnci/djag274", "authors": ["Andrew J Vickers"], "affiliations": ["Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, United States."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 24.09, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 15.09, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 7.2, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.09, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42804714", "title": "Cardiovascular Risk Triage Schema for Patients With Prostate Cancer Treated With Hormone Therapy.", "abstract": "Cardiovascular disease (CVD) is a leading noncancer cause of death among patients with prostate cancer (PC). Population-based risk calculators do not account for treatment-related effects of androgen-deprivation therapy (ADT) and androgen receptor pathway inhibitors (ARPis), and they have not been validated across PC treatment states. This Prostate Cancer Foundation-sponsored clinician-industry consensus and narrative review proposes a pragmatic identification and triage schema for point-of-care use. The schema supports rapid risk capture, tier assignment, and referral or risk-factor optimization triggers; it does not provide cardiovascular therapeutic algorithms. We synthesize evidence on baseline cardiometabolic burden, ADT-associated adiposity and muscle-strength changes, plaque progression, ARPi-associated hypertension and cardiac events, suboptimal real-world risk-factor control, and social-needs barriers. Patients are classified as high risk when they have prior major cardiovascular events or established clinical atherosclerotic CVD; intermediate risk when they have no prior event but at least two uncontrolled or adverse risk factors; and low risk when neither criterion is met. We clarify cutpoints, the rationale for operational thresholding, essential versus optional intake elements, and capacity-sensitive referral pathways. The proposed three-tier schema should be viewed as a hypothesis-generating checklist for oncology, urology, radiation oncology, primary care, and cardiovascular teams. Prospective validation, workflow testing, calibration of referral thresholds, and inclusion of patient and clinic-staff stakeholders are required before broad implementation.", "journal": "Jco Oncology Practice", "pub_date": "2026-Sep-28", "publication_types": ["Journal Article"], "doi": "10.1200/OP-26-00312", "authors": ["Avirup Guha", "Ana Barac", "Michael James Ryan", "Randala Hamdan", "Geeta Devgan", "Catherine H Marshall", "Silke Gillessen", "Stacy Loeb", "Rana R McKay", "Emmanuel S Antonarakis", "Zachary Klaassen", "Meenakshi Davuluri", "Alan H Bryce", "Yun Rose Li", "Nader El-Chaar", "Stephanie Braun", "Maha Hussain", "Pedro Barata", "Martin W Schoen", "Cora N Sternberg", "Tamara Jamaspishvili", "Samuel L Washington", "Neal D Shore", "David Morris", "Jack R Andrews", "Irbaz Bin Riaz", "Daniel George", "Soumyajit Roy", "Gina B Carithers", "Phillip Koo", "Neeraj Agarwal", "Andrew W Hahn"], "affiliations": ["Georgia Cancer Center, Medical College of Georgia at Augusta University, Augusta, GA.", "Inova Schar Heart and Vascular Institute and Inova Schar Cancer Institute, Inova Health System, Fairfax, VA.", "Pfizer Inc, New York, NY.", "Johns Hopkins University School of Medicine, Baltimore, MD.", "Oncology Institute of Southern Switzerland, EOC, Bellinzona and Università della Svizzera Italiana, Lugano, Switzerland.", "Department of Urology and Population Health, New York University Langone Health and Manhattan Veterans Affairs, New York, NY.", "Moores Cancer Center, University of California San Diego, La Jolla, CA.", "University of Minnesota Masonic Cancer Center, Minneapolis, MN.", "Department of Urology, Medical College of Georgia at Augusta University (Wellstar MCG Health), Augusta, GA.", "Bayer HealthCare Pharmaceuticals Inc, Whippany, NJ.", "City of Hope Cancer Center, Goodyear, AZ.", "Department of Radiation Oncology, City of Hope, Duarte, CA.", "Astellas Pharma Global Development, Inc, Northbrook, IL.", "Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL.", "University Hospitals Seidman Cancer Center and Case Western Reserve University School of Medicine, Cleveland, OH.", "St Louis Veterans Affairs Medical Center (VA St Louis Health Care System), St Louis, MO.", "Weill Cornell Medicine and New York-Presbyterian, New York, NY.", "Department of Pathology and Molecular Medicine, Queen's University, Kingston, Canada.", "Department of Urology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA.", "START CAROLINAS/Carolina Urologic Research Center, Myrtle Beach, SC.", "Urology Associates, P.C. (Tennessee Urology Associates), Nashville, TN.", "Department of Urology, Mayo Clinic Arizona, AZ.", "Division of Hematology/Oncology, Department of Internal Medicine, Mayo Clinic Arizona, AZ.", "Duke Cancer Institute, Duke University, NC.", "Prostate Cancer Foundation, Santa Monica, CA.", "Division of Hematology and Oncology, University of Utah, Salt Lake City, UT.", "Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 33.53, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 10.53, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 5.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.6, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.53, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42804174", "title": "Prostate Cancer Screening and Likelihood of Benefit in Veterans Affairs and Fee-for-Service Medicare.", "abstract": "Routine prostate-specific antigen (PSA) screening in men with limited life expectancy is low-value care, yet US Department of Veterans Affairs (VA) PSA testing and biopsy rates have not been benchmarked against non-VA care. To determine whether PSA testing and prostate biopsy rates are associated with likelihood of benefit from screening in VA or fee-for-service (FFS) Medicare primary care. This retrospective cohort study used national linked VA-Medicare data for fiscal years 2004 to 2023, with up to 20 years of follow up. A 30% random sample of male veterans 65 years or older who were dually enrolled in VA and FFS Medicare Parts A and B were included; men with prior prostate cancer or only Medicare Advantage enrollment were excluded. Time-varying predominant primary care setting (VA, FFS Medicare, or dual use), assigned from primary care visit distribution across systems over a rolling 36-month window. PSA testing and prostate biopsy rates per 1000 person-years. Contemporary incidence rate ratios (IRRs) were estimated with covariate-adjusted Poisson regression and stratified by age and predicted life expectancy. Among 1.41 million dually enrolled male veterans (mean [SD] age, 71.3 [7.1] years), 8.67 million person-years were observed. PSA testing declined across settings from 2008 to 2017, with steeper declines in the VA system. From 2018 to 2023, among men 80 years or older, adjusted PSA testing rates were 187.9 vs 267.9 per 1000 person-years in VA primary care vs FFS Medicare (IRR, 0.70; 95% CI, 0.69-0.71), and biopsy rates were 3.38 vs 5.05 (IRR, 0.67; 95% CI, 0.60-0.75). Among men with fewer than 5 years predicted life expectancy, PSA testing in the VA setting was lower (IRR, 0.84; 95% CI, 0.82-0.86). Age- and life expectancy-based differences persisted across sensitivity analyses. In contrast, in the primary analysis, PSA testing in the VA setting was higher among men aged 65 to 69 years (IRR, 1.10; 95% CI, 1.09-1.11). In this cohort study, compared with FFS Medicare, VA primary care was associated with lower PSA testing and biopsy rates among veterans least likely to benefit, suggesting closer alignment of testing intensity with likelihood of benefit.", "journal": "JAMA Internal Medicine", "pub_date": "2026-Sep-28", "publication_types": ["Journal Article"], "doi": "10.1001/jamanetworkopen.2022.43449", "authors": ["Alex K Bryant", "Adam VanDeusen", "Mandi L Klamerus", "Brent S Rose", "Krithika Suresh", "Timothy P Hofer", "Sameer D Saini", "Tanner J Caverly"], "affiliations": ["Veterans Affairs Center for Clinical Management Research, Ann Arbor, Michigan.", "Department of Radiation Oncology, Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, Michigan.", "Department of Radiation Oncology, University of Michigan Medical School, Ann Arbor.", "Department of Learning Health Sciences, University of Michigan Medical School, Ann Arbor.", "Department of Industrial and Operations Engineering, University of Michigan, Ann Arbor.", "Department of Radiation Medicine and Applied Sciences, University of California, San Diego School of Medicine, La Jolla.", "Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor.", "Department of Internal Medicine, University of Michigan Medical School, Ann Arbor.", "Department of Internal Medicine, Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, Michigan.", "Division of Gastroenterology, Department of Internal Medicine, Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, Michigan."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=4", "score": 44.68, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 16.68, "top_journal_bonus": 10.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 4.0}, "journal_metrics": {"status": "ok", "impact_factor": 23.3, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.68, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "退伍军人前列腺筛查更贴近获益可能", "chinese_summary": "4月JAMA Intern Med基于2004至2023年VA-Medicare联动数据纳入141万双参保男性退伍军人，发现80岁以上或预期寿命不足5年者，VA初级保健的PSA检测与穿刺率低于按服务付费医保，提示其筛查强度与获益可能更匹配。", "abstract_zh": "对预期寿命有限男性进行常规前列腺特异性抗原（PSA）筛查属于低价值医疗，但美国退伍军人事务部（VA）的PSA检测和穿刺活检率尚未与非VA医疗进行基准比较。旨在确定在VA或按服务付费（FFS）Medicare初级保健中，PSA检测和前列腺穿刺活检率是否与筛查获益可能性相关。这项回顾性队列研究使用2004至2023财年全国联动VA-Medicare数据，随访长达20年。纳入30%随机抽样的65岁及以上、同时参加VA和FFS Medicare A、B部分的男性退伍军人；排除既往有前列腺癌或仅参加Medicare Advantage者。随时间变化的主要初级保健场所（VA、FFS Medicare或双重使用），根据滚动36个月窗口内跨系统初级保健就诊分布进行分配。主要结局为每1000人年的PSA检测率和前列腺穿刺活检率。采用协变量校正泊松回归估计当代发病率比（IRR），并按年龄和预测预期寿命分层。在141万双参保男性退伍军人中（平均[SD]年龄71.3[7.1]岁），共观察867万人年。2008至2017年，各场所PSA检测均下降，VA系统下降更陡。2018至2023年，在80岁及以上男性中，VA初级保健与FFS Medicare的校正PSA检测率分别为每1000人年187.9对267.9（IRR，0.70；95% CI，0.69-0.71），活检率分别为3.38对5.05（IRR，0.67；95% CI，0.60-0.75）。在预测预期寿命不足5年的男性中，VA场所的PSA检测较低（IRR，0.84；95% CI，0.82-0.86）。基于年龄和预期寿命的差异在敏感性分析中持续存在。相比之下，在主分析中，VA场所65至69岁男性的PSA检测较高（IRR，1.10；95% CI，1.09-1.11）。在这项队列研究中，与FFS Medicare相比，VA初级保健与最不可能获益的退伍军人中较低的PSA检测和活检率相关，提示检测强度与获益可能性更趋一致。"}, {"pmid": "42803982", "title": "Automating Clavien-Dindo classification with large language models in percutaneous nephrolithotomy: an exploratory study.", "abstract": "To explore the use of large language models for Clavien-Dindo classification of complications following percutaneous nephrolithotomy by benchmarking their performance against physician grading. We evaluated ChatGPT, Copilot, DeepSeek, Gemini, Grok and Llama for defining Clavien-Dindo grades, classifying complications according to the Clavien-Dindo classification, and classifying case summaries with and without in-context prompting. Vignettes were obtained from a published consensus categorization of percutaneous nephrolithotomy complications. We measured agreement with Gwet's AC2 coefficient and compared it with attending urologists and urology residents. All models accurately defined the Clavien-Dindo classification and graded with almost perfect agreement complication descriptions and case summaries (0.97 to 0.98 overall agreement). Six attendings and 15 residents classified the same vignettes, demonstrating lower agreement than the chatbots (0.95, p < 0.001 for residents; 0.96, p = 0.03 for attendings; 0.95, p < 0.001 for all participants). Models' latency ranged from 0.77 to 3.90 min, while the fastest physician required 17 min to complete the same tasks. Models' intrarater reliability was almost perfect: from 0.97 to 0.99. Interrater reliability between chatbots (0.97, 95% confidence interval: 0.97-0.98) was significantly higher than among physicians (0.93, 95% confidence interval: 0.92-0.94). Large language models show promise in being faster, more accurate, and precise than physicians in Clavien-Dindo classification in an experimental setting. We support the need for a prospective agreement study using real-world clinical records. We urge discussion of the legal and ethical implications.", "journal": "World Journal of Urology", "pub_date": "2026-Sep-28", "publication_types": ["Journal Article"], "doi": "10.1007/s00345-023-04749-6", "authors": ["Gustavo Perrone", "Alexandre Danilovic", "Carlos Batagello", "Fabio Cesar Miranda Torricelli", "Fabio Carvalho Vicentini", "Giovanni Scala Marchini", "Rodrigo Perrella", "William C Nahas", "Eduardo Mazzucchi"], "affiliations": ["Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, SP, Brazil.", "Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Av. Dr. Eneas de Carvalho Aguiar, 255, sala 7175, Sao Paulo, SP, 05403-000, Brazil. alexandre.danilovic@hc.fm.usp.br.", "Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Av. Dr. Eneas de Carvalho Aguiar, 255, sala 7175, Sao Paulo, SP, 05403-000, Brazil."], "corresponding_authors": ["Alexandre Danilovic"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=4", "score": 20.0, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 10.0, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 4.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.9, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.0, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42803976", "title": "Separating procedure burden from result burden after multimodal prostate biopsy.", "abstract": "", "journal": "World Journal of Urology", "pub_date": "2026-Sep-28", "publication_types": ["Letter"], "doi": "10.1007/s00345-026-06834-y", "authors": ["Ting Ye"], "affiliations": ["Department of Laboratory Medicine, Tthe Affiliated Hospital of Southwest Medical University, No. 25, Taiping Street, Jiangyang District, Luzhou, 646000, Sichuan, P.R. China. yeting1103@163.com."], "corresponding_authors": ["Ting Ye"], "china_team": "Department of Laboratory Medicine, Tthe Affiliated Hospital of Southwest Medical University, No Ting Ye团队", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 19.0, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.0, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.9, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.0, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42803974", "title": "Multimodal comparison of 19 single-use flexible ureteroscopes: bench testing, operative video assessment, and surgeon ratings.", "abstract": "Single-use flexible ureteroscopes (fURSs) differ substantially in optical and mechanical properties, yet comparative evidence remains limited. We performed a multimodal in vitro and clinical assessment of 19 commercially available single-use fURSs to quantify performance variability and examine which device characteristics are associated with surgeon-reported usability. Each of 19 models was bench-tested for field of view, laser-fiber safety distance, irrigation flow, deflection, image resolution, signal-to-noise ratio (SNR), contrast-to-noise ratio (CNR), and color discrimination. One surgeon used each device in three separate patients (57 procedures total) and completed a standardized questionnaire after every case; three blinded reviewers scored anonymized intraoperative video. As a secondary analysis, device-level bench metrics were related to patient-level outcomes using a permutation test with correction for multiple comparisons. All domains showed marked variability (resolution 0.447-0.826 lp/mm; baseline deflection 219-312°, lowest 134° with accessories; empty-channel irrigation 27.9-39.0 mL/min; field of view 75-110°). In secondary, exploratory analysis, no bench metric showed an association with surgeon-reported or video-based outcomes surviving correction for multiple comparisons (54 tests, minimum q = 0.20). Contemporary single-use fURSs show substantial heterogeneity, and no single device excelled across every domain. Device selection should weigh several performance characteristics against the intended clinical scenario; whether bench performance predicts surgeon-reported usability remains unresolved and warrants larger, adequately powered studies.", "journal": "World Journal of Urology", "pub_date": "2026-Sep-28", "publication_types": ["Journal Article", "Comparative Study"], "doi": "10.1007/s00345-026-06815-1", "authors": ["Engin Denizhan Demirkıran", "Massimo Menozzi", "Eugenio Ventimiglia", "Giovanalberto Pini", "Giorgio Bozzini", "Davide Perri"], "affiliations": ["Department of Urology, Zonguldak Bülent Ecevit University School of Medicine, Zonguldak, Türkiye, Turkey. eddemirkiran@gmail.com.", "Department of Urology, Azienda Socio Sanitaria Territoriale Lariana, Sant'Anna Hospital, Como, Italy.", "Department of Surgical Sciences, Uppsala University, Uppsala, Sweden."], "corresponding_authors": ["Engin Denizhan Demirkıran"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_clinical", "score": 26.0, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.0, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 2.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.9, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.0, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42803972", "title": "Vibegron, mirabegron, and other add-on therapies for persistent overactive bladder symptoms in α1-blocker-treated men with benign prostatic hyperplasia: a systematic review and Bayesian network meta-analysis.", "abstract": "To compare the efficacy and safety of vibegron, mirabegron, and other add-on therapies for overactive bladder (OAB)/storage symptoms persisting despite α1-blocker treatment in men with benign prostatic hyperplasia (BPH), focusing on the indirect vibegron-mirabegron comparison. We searched PubMed, Web of Science, CENTRAL, ClinicalTrials.gov, and Google Scholar through 27 August 2026. Bayesian random-effects network meta-analyses used mean differences for continuous outcomes and odds ratios (ORs) for study-reported treatment-period adverse events (AEs). Confidence was appraised with CINeMA. Eighteen trials were included; 16 contributed quantitative data. Versus control, vibegron reduced micturitions per 24 h (mean difference - 0.81, 95% credible interval [CrI] - 1.31 to - 0.38) and urgency episodes per day (- 0.96, - 1.57 to - 0.34), and mirabegron reduced micturitions by 0.46 per 24 h (- 0.88 to - 0.02). For vibegron versus mirabegron, indirect estimates were - 0.35 micturitions per 24 h (- 1.05 to 0.26) and - 0.52 urgency episodes per day (- 1.33 to 0.35), with all 95% CrIs including the null value. Reported AE odds were also inconclusive versus mirabegron (OR 1.50, 0.69 to 3.14), and AE definitions varied. Confidence was moderate for vibegron versus control on micturitions and urgency and low for indirect and safety estimates. Vibegron reduced micturition frequency and urgency versus control and may be considered an add-on option in α1-blocker-treated men. The vibegron node rested on two trials, and no advantage over mirabegron was established; posterior probabilities above 0.8 do not indicate superiority when credible intervals include the null value. PROSPERO CRD420261434850.", "journal": "World Journal of Urology", "pub_date": "2026-Sep-28", "publication_types": ["Journal Article", "Network Meta-Analysis", "Systematic Review"], "doi": "10.1007/s00345-026-06820-4", "authors": ["Shugo Yajima", "Gaku Okumura", "Soichiro Yoshida", "Hiroshi Fukushima", "Takanobu Yamamoto", "Hiroyuki Honda", "Tomohiro Matsuo", "Naoki Wada", "Hiroyuki Sato", "Akihiro Hirakawa", "Hitoshi Masuda", "Yasuhisa Fujii"], "affiliations": ["Department of Urology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan. shuyajim@east.ncc.go.jp.", "Department of Urology, Institute of Science Tokyo, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan. shuyajim@east.ncc.go.jp.", "Department of Urology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.", "Department of Urology, Institute of Science Tokyo, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan. s-yoshida.uro@tmd.ac.jp.", "Department of Urology, Institute of Science Tokyo, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan.", "Department of Urology, Tokyo Metropolitan Tama-Nambu Chiiki Hospital, Tokyo, Japan.", "Department of Urology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan.", "Department of Renal and Urologic Surgery, Asahikawa Medical University, Asahikawa, Japan.", "Department of Clinical Biostatistics, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Tokyo, Japan."], "corresponding_authors": ["Shugo Yajima", "Soichiro Yoshida"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 29.0, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 10.0, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 1.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.9, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.0, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42803970", "title": "Aetiology of positive surgical margins in robotic assisted radical prostatectomy: a pathway approach.", "abstract": "Positive surgical margin (PSM) rates in robot-assisted radical prostatectomy (RARP) remain high and understanding their cause remains key to their elimination. We examined the prostate cancer pathway as a whole to systematically identify and quantify sourcescontributing to PSMs. Using a prospectively maintained database at a high-volume centre, we retrospectively analysed 100 consecutive patients with positive surgical margins (PSMs) following robot-assisted radical prostatectomy between January and December 2022. For each patient, a pre-operative imaging-based surgical plan was available. Potential sources contributing to PSMs were identified by reviewing diagnostic and staging information, the recommended surgical plan, the executed surgical template, and final pathology. Sources were categorised into three pathway phases: Diagnostic and Staging, Surgical Planning, and Surgical Execution. Proportions were reported with 95% confidence intervals calculated using the exact binomial (Clopper-Pearson) method. A total of 112 positive surgical margins (PSMs) were identified in 100 patients. One hundred and twenty-five contributing sources were identified, with a single source attributed to 102 PSMs, two sources to 7 PSMs, and three sources to 3 PSMs. Surgical execution accounted for the majority of identified sources (98/125, 78.4%; 95% CI 70.2-85.3%), followed by surgical planning (14/125, 11.2%; 95% CI 6.3-18.1%) and diagnostic and staging factors (13/125, 10.4%; 95% CI 5.7-17.1%). Within the surgical execution category, nerve-sparing was the most frequently implicated surgical step, being associated with 57/112 PSMs (50.9%; 95% CI 41.3-60.5%), followed by apical dissection (34/112, 30.4%; 95% CI 22.0-39.8%). Despite high volume, the most common sourceis surgical execution. This represents an opportunity for intra-operative margin assessment to reduce PSM rates. Diagnostic and planning steps still contributed to one- fifth of PSMs and can also be improved. We emphasise how this novel systematic approach can be used as a framework in quality assurance and improvement processes.", "journal": "World Journal of Urology", "pub_date": "2026-Sep-28", "publication_types": ["Journal Article"], "doi": "10.1007/s00345-026-06789-0", "authors": ["Elizabeth Day", "Andreia Bilé-Silva", "Amit Bhudia", "Abhishek Vigneshkumar", "Georgi Petkov", "Keiron Hakimnia", "Farah Siddiqui", "Aiman Haider", "Louise Dickinson", "Zafer Tandogdu"], "affiliations": ["University Hospital Ayr, Ayr, Scotland, UK.", "Division of Surgery and Interventional Science, University College London, London, UK.", "School of Medicine, University College London Hospital, London, UK.", "Department of Pathology, University College London Hospitals, London, UK.", "Department of Radiology, University College London Hospitals, London, UK.", "Division of Surgery and Interventional Science, University College London, London, UK. zafer.tandogdu@outlook.com.", "Department of Urology, University College Hospital, Westmoreland Street, London, W1G 8PH, UK. zafer.tandogdu@outlook.com."], "corresponding_authors": ["Zafer Tandogdu"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=6", "score": 31.0, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.0, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 6.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.9, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.0, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42803961", "title": "Biopsy and identification of risk factors for discordance in renal tumor: results from the BIRD study (UroCCR n°230).", "abstract": "To assess the rate of histological discordance between renal mass biopsy(RMB) and final surgical pathology in patients with localized renal tumors, and to identify risk factors of discordance. The BIRD study is a retrospective multicenter analysis conducted within the prospective UroCCR database between February 2004 and January 2025. We included all patients who underwent a renal mass biopsy followed by surgical treatment(partial or radical nephrectomy). The primary endpoint was the histological discordance rate, defined as a mismatch in tumor type between the biopsy and the surgical specimen, or a non-diagnostic biopsy, and diagnostic accuracy. Univariate and multivariate logistic regression analyses were performed to identify factors associated with discordance. A total of 1,301 patients from 19 centers were included, with 65% male and a median age of 63 years(51-71). Tumors were equally distributed between the right and left kidneys, with a median size of 3.7 cm(2.5-5.0). Final histology showed 8% benign and 92% malignant tumors. Tumor necrosis was found in 23% of cases. Among tumors assessed for nuclear grade, a 48% discordance was observed between low(ISUP1-2) and high grades(ISUP3-4). Overall, the histological discordance rate was 18%, including 3.7% for malignancy diagnosis, 8.4% for histological subtype, and 5.7% for non-diagnostic biopsies. On multivariable analysis after multiple imputation, cystic tumor(OR 2.18, 95%CI 1.23-3.85, p = 0.007) was independently associated with increased risk of histological discordance. Moderate and high R.E.N.A.L. score complexity were associated with reduced discordance risk(OR 0.67, 95%CI 0.47-0.96, p = 0.03 and OR 0.60, 95%CI 0.37-0.98, p = 0.04, respectively). RMB provided a high diagnostic yield but was associated with an overall 18% discordance rate. Cystic tumors were the only independent factor associated with an increased risk of discordance, while tumor complexity and size influenced discordance subtypes. Regarding ISUP grade, RMB showed imperfect reliability, failing to reflect true tumor aggressiveness in nearly half of discordant cases.", "journal": "World Journal of Urology", "pub_date": "2026-Sep-28", "publication_types": ["Journal Article", "Multicenter Study"], "doi": "10.1007/s00345-026-06832-0", "authors": ["Stessy Kutchukian", "G Margue", "N Branger", "P Bigot", "A Fontenil", "R Boissier", "T Prudhomme", "C Michel", "V Chatain", "T Waeckel", "J B Beauval", "C Champy", "M Vallée", "H Lang", "S de Vergie", "L Vignot", "B Parier", "F Taha", "L Surlemont", "J C Bernhard", "F Audenet"], "affiliations": ["Department of Urology, Nimes University Hospital, 4 Rue du Professeur Robert Debré, Nîmes, 30900, France. stessy.kutchukian@gmail.com.", "Urology Department, Hôpital Pellegrin, CHU Bordeaux, Bordeaux, France.", "I.CaRe Bordeaux - BRIC INSERM U1312, University of Bordeaux, Bordeaux, France.", "Urology Department, Institut Paoli-Calmettes, Marseille, France.", "Urology Department, CHU Angers, Angers, France.", "Department of Urology, Nimes University Hospital, 4 Rue du Professeur Robert Debré, Nîmes, 30900, France.", "Urology Department, CHU La Conception, AP-HM, Marseille, France.", "Urology Department, CHU Rangueil, Toulouse, France.", "Urology Department, Saint Joseph Hospital, Paris, France.", "Urology Department, Hôpital Lyon Sud, Hospices Civils de Lyon, Lyon, France.", "Urology Department, CHU Caen Normandie, Caen, France.", "Urology Department, Clinique La Croix du Sud, Toulouse, France.", "Inserm, Clinical Investigation Center, Henri Mondor University Hospital, AP-HP, Créteil, 1430, France.", "Urology Department, Henri Mondor University Hospital, AP-HP, Créteil, France.", "Urology Department, CHU Poitiers, Poitiers, France.", "Urology Department, CHRU Strasbourg, Strasbourg, France.", "Urology Department, CHU Nantes, Nantes, France.", "Urology Department, CHU Nice, Nice, France.", "Urology Department, Hôpital Bicetre, AP-HP, Paris, France.", "Urology Department, CHU Reims, Reims, France.", "Urology Department, CHU Rouen, Rouen, France.", "Urology Department, Hôpital Européen Georges Pompidou, AP-HP.Centre, Université Paris Cité, Paris, France."], "corresponding_authors": ["Stessy Kutchukian"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_clinical", "score": 27.0, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 10.0, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 11.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.9, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.0, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42803947", "title": "The ROI-modified mayo adhesive probability score as a predictor of postoperative fever after retrograde intrarenal surgery.", "abstract": "In our study, we investigated the predictive value of the region of interest (ROI)-modified Mayo Adhesive Probability (MAP) score which objectively assesses perirenal fat density for postoperative fever following retrograde intrarenal surgery (RIRS), as well as its comparative performance against the conventional MAP score. This retrospective study included 318 patients who underwent RIRS with a sterile urine culture between January 2021 and May 2025. Demographic, stone, and procedure-related data were recorded. Both scores were calculated from non-contrast computed tomography (CT) images prior to surgery; independent risk factors for postoperative fever were identified using logistic regression models and compared via receiver operating characteristic (ROC) analysis. Postoperative fever developed in 41 patients (12.9%). In the model including the conventional MAP score, diabetes mellitus (DM) (odds ratio [OR] = 3.475, p = 0.002), recurrent urinary tract infection (UTI) (OR = 3.567, p = 0.039) and MAP ≥ 3 (OR = 2.707, p = 0.006) were identified as independent risk factors. In the model including the ROI-MAP score, DM (OR = 2.953, p = 0.008) and ROI-MAP ≥ 3 (OR = 7.057, p < 0.001) were identified as independent predictors. The ROI-MAP score demonstrated statistically significantly higher predictive accuracy compared to the conventional MAP score (area under the curve [AUC]: 0.789 vs. 0.709; p = 0.011). The ROI-modified MAP score, which reduces interobserver variability through Hounsfield unit (HU)-based measurement of perirenal fat density, may serve as a potentially useful adjunct for identifying patients at risk of fever following RIRS during the preoperative period.", "journal": "Urolithiasis", "pub_date": "2026-Sep-28", "publication_types": ["Journal Article"], "doi": "10.1007/s00240-026-02069-z", "authors": ["Abdullah Esmeray", "Hasan Samet Güngör", "Abdurrahman İnkaya", "Murat Beyatlı", "Cemil Emre Yurtseven", "Mehmet Umut Evci", "Resul Sobay"], "affiliations": ["Department of Urology, University of Health Sciences, Ümraniye Training and Research Hospital, Istanbul, Türkiye, Turkey. esmerayabdullah@gmail.com.", "Department of Urology, University of Health Sciences, Ümraniye Training and Research Hospital, Istanbul, Türkiye, Turkey."], "corresponding_authors": ["Abdullah Esmeray"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=5", "score": 19.71, "score_parts": {"urology_relevance": 7, "urology_in_title": 0.0, "journal_priority": 5.71, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 5.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.2, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.71, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42803944", "title": "Changes in renal function in patients with chronic kidney disease after ureteroscopy: a systematic review and meta-analysis from EAU endourology.", "abstract": "The impact of ureteroscopy (URS) and retrograde intrarenal surgery (RIRS) on renal function in patients with chronic kidney disease (CKD) remains unclear, particularly given concerns regarding intrarenal pressure and repeated interventions. We performed a systematic review and meta-analysis to evaluate changes in estimated glomerular filtration rate (eGFR) following URS or RIRS in patients with pre-existing CKD. A systematic review and meta-analysis were conducted according to PRISMA guidelines and registered in PROSPERO (2025). Databases were searched in March 2026. Studies reporting pre- and postoperative eGFR in patients with established CKD or cohorts including patients with reduced baseline renal function undergoing standard URS or RIRS were included. A random-effects model (REML with Knapp-Hartung adjustment) was used to calculate pooled mean differences (MD) in eGFR. Seven studies including 742 patients met inclusion criteria. Follow-up ranged from 1 month to over 2 years. The pooled mean difference in eGFR was +2.8 mL/min/1.73 m2 (95% CI -2.8 to +8.4; p = 0.27), indicating no significant overall change in renal function, with substantial heterogeneity (I2 = 89.6%). A greater increase in eGFR was observed in the ureteral stone subgroup (MD +12.26 mL/min/1.73 m2; 95% CI 9.03-15.49); however, this estimate was derived from a single study and should be interpreted cautiously. No study reported progression to dialysis attributable to ureteroscopic intervention. Evidence certainty remains very low, highlighting the need for prospective studies with standardized long-term assessment. Available evidence does not suggest a clinically meaningful deterioration in renal function following URS or RIRS and indicates that renal function may improve in selected patients after relief of obstruction; however, these findings are based on very low-certainty evidence.", "journal": "Urolithiasis", "pub_date": "2026-Sep-28", "publication_types": ["Systematic Review", "Journal Article", "Meta-Analysis"], "doi": "10.1007/s00240-026-02067-1", "authors": ["Ali Talyshinskii", "María Florencia Frascheri", "Lazaros Tzelves", "Andreas Skolarikos", "Robert Geraghty", "Niall F Davis", "Bhaskar Kumar Somani"], "affiliations": ["Department of Urology and Andrology, Genome Clinic, Astana, Kazakhstan. urovator@gmail.com.", "European Association of Urology (EAU) Endourology Section, Arnhem, The Netherlands. urovator@gmail.com.", "Department of Urology, University Hospital Southampton NHS Foundation Trust, Southampton, UK.", "Department of Urology, Sismanogleio Hospital, National and Kapodistrian University of Athens, Athens, Greece.", "European Association of Urology (EAU) Endourology Section, Arnhem, The Netherlands.", "Department of Urology, Freeman Hospital, Newcastle-Upon-Tyne, UK.", "Department of Urology, Beaumont Hospital, Dublin, Ireland."], "corresponding_authors": ["Ali Talyshinskii"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 31.71, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 5.71, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 8.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.2, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.71, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42803939", "title": "MRI-derived prostate volume assessment: manual segmentation versus two-axis ellipsoid approximation and its implications for PSA density.", "abstract": "To evaluate how accurately prostate volume estimated with the ellipsoid formula matches manual segmentation (reference standard) and to assess whether an individualized, volume-dependent adjustment of the ellipsoid weighting factor improves performance. In this prospective study, patients with suspected prostate cancer (PCa) who underwent 3 T multiparametric MRI (T1WI, T2WI, DWI, DCE) between January 2022 and June 2023 were included. PSA values were obtained at imaging or within the preceding 4 weeks. Reference prostate volumes were derived from manual segmentation of all axial T2-weighted slices. Ellipsoid-based volumes were calculated per PI-RADS recommendations from sagittal and axial T2-weighted images using A × B × C × 0.52. Overall, 328 patients were analyzed (median age 68 years), including 196 without and 132 with PCa. Ellipsoid-based volumes showed excellent agreement with manual segmentation (ICC = 0.985; mean absolute difference 5.5 cc). Differences were larger in prostates > 80 cc, where the ellipsoid method tended to underestimate volume. Optimal volume-dependent weighting factors ranged from 0.50 to 0.54, but statistical modeling with variable weighting factors did not significantly improve model performance. For PSAd cut-offs of 0.1, 0.15, and 0.2 ng/mL/cc, the ellipsoid approximation achieved sensitivities of 0.86-0.95 and specificities of 0.88-0.97 compared with manual segmentation. Manual segmentation and ellipsoid-based approximation show good agreement, underscoring the practical utility of the ellipsoid approximation for routine prostate volume assessment. While inaccuracies increase for larger glands, individualized weighting offers no meaningful benefit, and diagnostic performance for PSA density remains largely unaffected. Question Does the fast PI-RADS ellipsoid method estimate MRI prostate volume accurately versus manual segmentation, and do errors affect PSA density decisions? Findings In 328 men, ellipsoid volumes correlated strongly with segmentation (ρ = 0.98), underestimated larger glands (> 80 cc), and coefficient tuning added no meaningful improvement. Clinical relevance Ellipsoid-based volumetry provides a rapid, reliable basis for mpMRI prostate and PSA density assessment in routine clinical practice, supporting biopsy and active-surveillance decisions without time-consuming segmentation, while recognizing slightly higher error in very large prostates.", "journal": "European Radiology", "pub_date": "2026-Sep-28", "publication_types": ["Journal Article"], "doi": "10.1016/j.euo.2018.09.001", "authors": ["Larissa Gluesing", "Sophie Potts", "Lars Knieper", "Francesco Giganti", "Igor Tsaur", "Sebastian Gassenmaier", "Josephine Berger", "Konstantin Nikolaou", "Annemarie Uhlig", "Johannes Uhlig"], "affiliations": ["Department of Urology, University Medical Center Goettingen, Goettingen, Germany.", "Chair of Spatial Data Science and Statistical Learning, Georg-August-University Goettingen, Goettingen, Germany.", "Campus Institute Data Science (CIDAS), Georg-August-University Goettingen, Goettingen, Germany.", "Division of Surgery & Interventional Science, University College London, London, UK.", "Department of Radiology, University College London Hospitals NHS Foundation Trust, London, UK.", "Department of Urology, Tübingen University Hospital, Eberhard Karls University Tuebingen, Tuebingen, Germany.", "Department of Diagnostic and Interventional Radiology, Tuebingen University Hospital, Eberhard Karls University Tuebingen, Tuebingen, Germany.", "Campus Institute Data Science (CIDAS), Georg-August-University Goettingen, Goettingen, Germany. johannes.uhlig@med.uni-tuebingen.de.", "Department of Diagnostic and Interventional Radiology, Tuebingen University Hospital, Eberhard Karls University Tuebingen, Tuebingen, Germany. johannes.uhlig@med.uni-tuebingen.de.", "Department of Clinical and Interventional Radiology, University Medical Center Goettingen, Goettingen, Germany. johannes.uhlig@med.uni-tuebingen.de."], "corresponding_authors": ["Johannes Uhlig"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=4", "score": 28.55, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.55, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 4.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.7, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.55, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42803889", "title": "Adoption of single-port robot-assisted radical prostatectomy following multiport xi experience: lessons from a learning curve analysis.", "abstract": "To evaluate whether surgical proficiency acquired with the multiport Xi robotic platform facilitates the early adoption of single-port (SP) robot-assisted radical prostatectomy (RARP). We retrospectively analyzed the first 100 consecutive Xi and the first 100 consecutive SP RARP procedures performed by a single surgeon between March 2020 and July 2026. SP RARP was initiated after completion of the initial 100 Xi procedures. Learning curves were assessed using console-time cumulative sum (CUSUM) analysis with permutation-based change-point testing. Perioperative and pathologic outcomes were compared between platforms. Significant CUSUM change points were identified at case 24 for Xi and case 57 for SP (both P < 0.001). Despite the later SP change point, operative performance was relatively stable from early SP adoption. Median console time (67.0 vs. 97.5 min), operative time (95.0 vs. 145.0 min), and non-console time (28.0 vs. 44.0 min) were shorter with SP (all P < 0.001). Pelvic lymph node dissection was less frequent with SP (1.0% vs. 29.0%, P < 0.001). Thirty-day emergency department visits and readmissions did not differ between groups. Overall positive surgical margin rates were 13.0% with SP and 27.0% with Xi (P = 0.021), whereas stage-stratified rates did not differ significantly. Prior multiport Xi experience facilitated efficient adoption of SP RARP, with relatively short operative times from early SP use despite a later CUSUM change point. These findings suggest that robotic surgical proficiency may be transferable across platforms, while observed differences between platforms should be interpreted in the context of cumulative experience and procedural selection.", "journal": "Journal of Robotic Surgery", "pub_date": "2026-Sep-28", "publication_types": ["Journal Article"], "doi": "10.1007/s11701-026-04013-0", "authors": ["Young Mun Son", "Jin Woo Ahn", "Dong Hyuk Kang", "Doo Yong Chung"], "affiliations": ["Department of Urology, Inha University Hospital & College of Medicine, 27 Inhang-ro, Jung-gu, Incheon, 22332, Republic of Korea.", "Department of Urology, Inha University Hospital & College of Medicine, 27 Inhang-ro, Jung-gu, Incheon, 22332, Republic of Korea. dychung@inha.ac.kr."], "corresponding_authors": ["Doo Yong Chung"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 21.03, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 6.03, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 3.0, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 2.03, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42803865", "title": "Phase-specific workflow maturation during early institutional implementation of Aquablation for benign prostatic hyperplasia: a retrospective single-center study.", "abstract": "Phase-specific workflow maturation during institutional Aquablation implementation remains incompletely characterized. We retrospectively analyzed the first 50 consecutive procedures for benign prostatic hyperplasia at a Taiwanese tertiary center. Institutional chronological case number was modeled continuously with preoperative prostate-volume adjustment and heteroskedasticity-robust inference. Outcomes were total operative time and planning, waterjet, and adjunct phases. Three-knot restricted cubic splines examined nonlinearity; sensitivity analyses restricted the cohort to the dominant surgeon and adjusted for anatomical case mix. Mean total time was 64.8 ± 23.6 min; planning, waterjet, and adjunct times were 22.4 ± 7.4, 5.8 ± 2.4, and 36.6 ± 15.8 min. Adjusted linear case-number coefficients were - 0.513, - 0.336, - 0.047, and - 0.130 min/case, respectively. The total-time 95% confidence interval was - 0.759 to - 0.267; the adjunct interval was - 0.311 to 0.050 (p = 0.152). Inverse total, planning, and waterjet associations persisted in sensitivity analyses. Adjunct spline associations were significant overall (p = 0.028) and for nonlinearity (p = 0.009). Six patients (12%) had postoperative complications; four underwent reintervention under general anesthesia and two received transfusions, with overlapping events. Postoperative functional and imaging findings were exploratory available-case outcomes. Institutional workflow maturation was clearest in planning and the composite waterjet phase. Adjunct finishing remained the largest component and showed an exploratory nonlinear chronological association.", "journal": "Journal of Robotic Surgery", "pub_date": "2026-Sep-28", "publication_types": ["Journal Article"], "doi": "10.1007/s11701-026-04003-2", "authors": ["Hsu-Cheng Ko", "Yi-Sheng Lin", "Yen-Chuan Ou", "Min-Che Tung", "Yi-Yu Chen", "Shih-Huan Lin", "Chao-Yu Hsu", "Hung-Jen Shih"], "affiliations": ["Division of Urology, Department of Surgery, Tungs' Taichung MetroHarbor Hospital, Taichung City, Taiwan.", "Department of Medical Research, Tungs' Taichung MetroHarbor Hospital, Taichung City, Taiwan.", "Division of Education and Research, Department of Medical Statistics, Tungs' Taichung MetroHarbor Hospital, Taichung City, Taiwan. leon790221@gmail.com.", "Division of Education and Research, Department of Medical Statistics, Tungs' Taichung MetroHarbor Hospital, No. 699, Sec. 8, Taiwan Blvd., Wuqi Dist, Taichung City, 435403, Taiwan (R.O.C.). leon790221@gmail.com.", "Division of Urology, Department of Surgery, Tungs' Taichung MetroHarbor Hospital, Taichung City, Taiwan. t4361@ms3.sltung.com.tw.", "Division of Urology, Department of Surgery, Tungs' Taichung MetroHarbor Hospital, No. 699, Sec. 8, Taiwan Blvd., Wuqi Dist, Taichung City, 435403, Taiwan (R.O.C.). t4361@ms3.sltung.com.tw.", "Division of Urology, Department of Surgery, Tungs' Taichung MetroHarbor Hospital, Taichung City, Taiwan. jasta1206@gmail.com.", "Department of Urology, Yuan Rung Hospital, Changhua, Taiwan. jasta1206@gmail.com.", "Division of Urology, Department of Surgery, Tungs' Taichung MetroHarbor Hospital, No. 699, Sec. 8, Taiwan Blvd., Wuqi Dist, Taichung City, 435403, Taiwan (R.O.C.). jasta1206@gmail.com."], "corresponding_authors": ["Shih-Huan Lin", "Chao-Yu Hsu", "Hung-Jen Shih"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=6", "score": 31.03, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 6.03, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 6.0}, "journal_metrics": {"status": "ok", "impact_factor": 3.0, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 2.03, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42803864", "title": "Latin American and Caribbean participation in robot-assisted surgery research: productivity, collaboration, and research themes.", "abstract": "Robotic surgery has expanded across Latin America and the Caribbean, but research participation involving institutions from the region remains insufficiently characterized. We conducted a bibliometric study using the Web of Science Core Collection. Articles and reviews published through 2025 were retrieved using terms related to robotic surgery and geographic units included in the predefined Economic Commission for Latin America and the Caribbean framework. Eligible records were analyzed using bibliometrix in R and VOSviewer to assess publication trends, scientific impact, collaboration patterns, and the aggregate thematic structure based on author-keyword co-occurrence. The final dataset included 709 publications authored by 5,546 researchers from 1,163 institutional affiliations. Scientific output increased over time, particularly after 2018, and the highest annual output was observed in 2025, with 114 publications. Brazilian institutions participated in 431 publications, the highest number among Latin American and Caribbean countries, and were involved in 277 multi-country publications. Universidade de São Paulo was the most productive institution, while Vipul Patel was the most prolific author. The Journal of Robotic Surgery published the largest number of publications. The thematic structure was dominated by urology and urologic oncology, particularly prostate cancer and robot-assisted radical prostatectomy. Other thematic clusters represented colorectal surgery, renal surgery, surgical training, and technological development. Robotic surgery research involving Latin American and Caribbean institutions has increased but remains concentrated in Brazil, a limited number of institutions, and urologic oncology. The aggregate keyword network identified a thematic structure centered on urologic oncology, with additional clusters related to colorectal surgery, renal surgery, training, and technological development.", "journal": "Journal of Robotic Surgery", "pub_date": "2026-Sep-28", "publication_types": ["Journal Article"], "doi": "10.1007/s11701-026-04006-z", "authors": ["Fabriccio J Visconti-Lopez", "Ordaya Sonco Marife", "Raúl Meza Meza", "Joaquín Eduardo Chávez-Cano"], "affiliations": ["Universidad Científica del Sur, Lima, Peru. fvisconti@cientifica.edu.pe.", "Universidad Científica del Sur, Carretera Panamericana Sur 19, Distrito de Villa El Salvador, Lima, 15067, Peru. fvisconti@cientifica.edu.pe.", "Universidad Científica del Sur, Lima, Peru."], "corresponding_authors": ["Fabriccio J Visconti-Lopez"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 16.03, "score_parts": {"urology_relevance": 8, "urology_in_title": 0.0, "journal_priority": 6.03, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 3.0, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 2.03, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42803835", "title": "Adherence to medical management of kidney stones: A systematic review.", "abstract": "The effectiveness of dietary and pharmacologic stone prevention strategies may be limited by poor patient adherence. This systematic review aims to assess adherence to the American Urological Association (AUA) guidelines for medical management of kidney stone disease by (1) determining how adherence influences clinical outcomes, (2) identifying which preventive interventions demonstrate the highest adherence, and (3) characterizing factors associated with adherence. A systematic review was conducted according to PRISMA guidelines. PubMed, Scopus, and Embase were searched from database inception through January 1, 2026, using terms related to nephrolithiasis and patient adherence/compliance. Studies involving adults with prior kidney stones reporting adherence to dietary, pharmacologic, or metabolic evaluation-based prevention were included. Dual-reviewer screening and standardized data extraction were performed. No protocol was prospectively registered. Of 909 identified studies, 35 met inclusion criteria, comprising 57,970 patients. Across studies, greater adherence consistently correlated with decreased subsequent stone related events. Increased fluid intake demonstrated the highest lifestyle adherence (~ 65-85%), while thiazide diuretics showed the greatest pharmacologic adherence (43-87%), exceeding citrate therapy and dietary modification. Adherence to metabolic evaluation and longitudinal follow-up testing was relatively low. Predictors of improved adherence included older age, higher education and socioeconomic status, prior stone events, and greater disease severity. Traditional physician counseling has a positive relationship on adherence to medical management. Adherence to guideline-based kidney stone prevention strongly influences clinical outcomes. Tailored counseling and prevention plans informed by patient and disease characteristics are critical to improve effectiveness of stone prevention therapy.", "journal": "Urolithiasis", "pub_date": "2026-Sep-28", "publication_types": ["Systematic Review", "Journal Article"], "doi": "10.1007/s00240-026-02066-2", "authors": ["Bassel Salka", "Rami Barqawi", "Sarosh Irani", "Mustapha Jaber", "Mohammad Jafri", "Naveen Kachroo"], "affiliations": ["Department of Urology, Henry Ford Hospital, Detroit, MI, USA. Bsalka1@hfhs.org.", "Michigan State University College of Osteopathic Medicine, East Lansing, MI, USA.", "Department of Urology, Henry Ford Hospital, Detroit, MI, USA.", "University of Michigan Medical School, Ann Arbor, MI, USA.", "Corewell Health William Beaumont University Hospital, Royal Oak, MI, USA."], "corresponding_authors": ["Bassel Salka"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 32.71, "score_parts": {"urology_relevance": 12, "urology_in_title": 8.0, "journal_priority": 5.71, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 5.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.2, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.71, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42803354", "title": "Optimizing Tissue Acquisition in Upper Tract Urothelial Carcinoma: A Systematic Review and Meta-Analysis of Ureteroscopy Biopsy Forceps.", "abstract": "To evaluate the performance of flexible ureteroscopy (fURS) biopsy forceps for tissue acquisition in upper tract urothelial carcinoma (UTUC), stratified by device, and their concordance with surgical pathology. Preregistered systematic review and meta-analysis (PROSPERO CRD420261392641; PRISMA 2020). MEDLINE and Embase were searched to 1 May 2026 for studies of forceps-based fURS biopsy in UTUC. The primary outcome was diagnostic yield; secondary outcomes included specimen adequacy, lamina propria presence, grade concordance, undergrading, and upstaging to muscle-invasive disease. Pooled proportions used the Freeman-Tukey double-arcsine transformation with DerSimonian-Laird random-effects models; heterogeneity was assessed with Cochran's Q. Nineteen studies (1397 patients; 1,773 biopsies; 1985-2025) were included. Pooled diagnostic yield was 84.6% (95% confidence interval 77.5%-90.6%; Q = 80.90, df = 10, p < 0.001), and specimen adequacy was 82.0% (76.7%-86.8%). Neither was distinguished by device category (subgroup Q = 6.12, df = 3, p = 0.11 and Q = 6.88, df = 3, p = 0.076). Overall grade concordance was 78.8% (69.9%-86.7%), and 28.3% of tumors were undergraded (18.1%-39.7%). Lamina propria was present in only 71.8% of specimens, and 54.6% (35.8%-72.7%) of tumors appearing non-muscle-invasive at biopsy were upstaged to ≥pT2 at nephroureterectomy. Ex vivo, backloaded forceps caused 6.4-fold less deflection loss than the Piranha (12.7° vs 80.7°) without improving yield. Across four decades of evidence, ureteroscopic biopsy forceps achieve approximately 85% diagnostic yield, with no single design demonstrably superior. The determinants of a diagnostic, accurately graded biopsy may therefore lie less in the instrument than in factors this review could not test directly, including operator experience and sampling strategy; whether systematic multisite sampling improves diagnostic yield is a hypothesis that requires prospective evaluation. At the same time, frequent undergrading and upstaging, with often inadequate specimens, expose the diagnostic ceiling of current devices and make dedicated device redesign and prospective, device-stratified research a clear priority.", "journal": "Journal of Endourology", "pub_date": "2026-Sep-28", "publication_types": ["Journal Article", "Review"], "doi": "10.1177/08927790261492105", "authors": ["Carlos González González", "Pietro Scilipoti", "Federico Zorzi", "Nicola Nannola", "Marie Chicaud", "Frédéric Panthier", "Olivier Traxer"], "affiliations": ["GRC 20-Endolase LAB, APHP, Hôpital Tenon, Sorbonne Université, Paris, France.", "Service d'Urologie, Assistance-Publique Hôpitaux de Paris, Hôpital Tenon, Sorbonne Université, Paris, France.", "PIMM, UMR 8006 CNRS-Arts et Métiers ParisTech, Paris, France.", "Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy.", "Department of Urology at the San Raffaele Hospital (IRCCS Ospedale San Raffaele), Vita-Salute San Raffaele University, Milan, Italy.", "Section of Endourology, European Association of Urology, Arnhem, Netherlands.", "Endourology Technology Section of European Association of Urology (EAU), Arnhem, The Netherlands.", "Progressive Endourological Association for Research and Leading Solutions (PEARLS), Paris, France."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 31.96, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 9.96, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 4.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 1.96, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42803139", "title": "Fear-Avoidance and Overactive Bladder: Toward a Mechanism-Informed Model of Care.", "abstract": "Overactive bladder (OAB) is associated with substantial psychological burden, yet existing biopsychosocial frameworks acknowledge that psychological factors shape outcomes without explaining the cognitive and behavioral mechanisms through which that influence operates. This paper aimed to propose the fear-avoidance as a missing explanatory framework for OAB symptom maintenance, and to introduce a phenotyping model for clinical application. We synthesized literature on fear-avoidance theory, cognitive appraisal and coping, and OAB epidemiology and psychosocial burden to construct a theoretical model linking urinary urgency to fear-avoidance mechanisms and developed a phenotyping framework distinguishing idiopathic and physiological OAB subtypes. We propose that urinary urgency, characterized by unpredictability and difficulty deferring, functions as a potent stimulus for catastrophic threat appraisal, initiating a self-sustaining cycle of avoidance, hypervigilance, and perceived uncontrollability that perpetuates symptom burden independent of underlying pathology. We further distinguish two OAB subgroups: idiopathic OAB (iOAB), in which fear-avoidance functions as a primary, symptom-originating mechanism driven by maladaptive toileting behaviors and, in some cases, trauma-related hypervigilance; and physiological OAB (pOAB), in which an identifiable physiological cause (e.g., menopause, prostatectomy, radiation cystitis, neurogenic bladder) drives symptom onset while fear-avoidance operates as a secondary but clinically meaningful amplifier. This distinction carries direct implications for treatment prioritization, positioning fear-avoidance-informed behavioral care as either a primary intervention or a necessary adjunct to medical management. The framework offers clinicians a testable, mechanism-informed model for understanding and addressing avoidance behavior across the OAB clinical spectrum, and provides direction for empirical research on OAB phenotyping and behavioral intervention.", "journal": "Neurourology and Urodynamics", "pub_date": "2026-Sep-28", "publication_types": ["Journal Article"], "doi": "10.1002/nau.70458", "authors": ["Rupal M Patel", "Andrea Wood"], "affiliations": ["Bodywise Physical Therapy, Durango, Colorado, USA.", "University of Miami Miller School of Medicine, Miami, Florida, USA."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 29.56, "score_parts": {"urology_relevance": 11, "urology_in_title": 8.0, "journal_priority": 5.56, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 3.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 1.9, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.56, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "恐惧回避或维持膀胱过度活动", "chinese_summary": "9月Neurourol Urodyn发表理论文章，提出恐惧回避模型解释膀胱过度活动症症状维持：尿急因不可预测和难延迟而触发灾难化威胁评估，形成回避、过度警觉与失控感的自我维持循环；并据此区分特发性与生理性两亚型，前者以恐惧回避为原发机制，后者为继发放大因素，为行为干预定位提供依据。", "abstract_zh": "膀胱过度活动症（OAB）与沉重的心理负担相关，但现有生物心理社会框架承认心理因素影响结局，却未解释这种影响赖以运作的认知与行为机制。本文旨在提出恐惧回避作为OAB症状维持的一个缺失的解释框架，并引入一个用于临床的表型分型模型。我们综合了关于恐惧回避理论、认知评估与应对以及OAB流行病学和心理社会负担的文献，构建了一个将尿急与恐惧回避机制相联系的理论模型，并开发了一个区分特发性与生理性OAB亚型的表型分型框架。我们提出，尿急以不可预测性和难以延迟为特征，构成灾难化威胁评估的强效刺激，启动一个由回避、过度警觉和感知失控组成的自我维持循环，使症状负担独立于潜在病理而持续存在。我们进一步区分两个OAB亚组：特发性OAB（iOAB），其中恐惧回避作为由适应不良的如厕行为以及某些情况下创伤相关过度警觉所驱动的原发性、症状起源机制发挥作用；以及生理性OAB（pOAB），其中可识别的生理原因（如绝经、前列腺切除术、放射性膀胱炎、神经源性膀胱）驱动症状发生，而恐惧回避作为继发性但具有临床意义的放大因素发挥作用。这一区分对治疗优先次序具有直接意义，将恐惧回避知情的行为照护定位为要么是主要干预，要么是医学管理的必要辅助。该框架为临床医生提供了一个可检验、机制知情的模型，用以理解和处理OAB临床谱系中的回避行为，并为OAB表型分型和行为干预的实证研究提供了方向。"}, {"pmid": "42285214", "title": "A blood-urine regulatory axis: Tumor-derived factors reprogram urine-derived stem cells via CXCL2/CXCR2/ERK signaling to drive bladder cancer stemness.", "abstract": "The malignant progression of bladder cancer is closely linked to the tumor microenvironment, yet the role of urine-derived stem cells (USCs) remains poorly understood. USCs were isolated from healthy individuals and bladder cancer patients, followed by multi-omic and functional characterization. The bladder cancer cell line T24 was used for in vitro co-culture and in vivo co-injection assays. Sustained exposure to tumor-derived factors (TNF-α, IL-6, and TGF-β) reprogrammed normal USCs (N-USCs) into tumor-associated USCs (T-USCs). This transition was marked by E-cadherin downregulation, vimentin upregulation, cell cycle arrest, and reduced adhesion, facilitating detachment and shedding of USCs into urine. Consequently, urine from tumor-bearing conditions showed increased USC counts and elevated CXCL2 levels. USC-derived CXCL2 activated the CXCR2 receptor on bladder cancer cells, triggering the ERK/β-catenin axis. This significantly upregulated stemness markers (CD44, ALDH1A1), promoting malignant progression. In a co-injection model, T-USCs and bladder cancer cells formed an organized stromal sheath that facilitated tumor invasion. In vivo, USCs drove tumor growth and microenvironment remodeling, effects suppressed by targeting the CXCL2/CXCR2/ERK axis. We propose a model in which hematogenous tumor factors induce urinary USC reprogramming, potentially establishing a CXCL2-enriched niche that fuels malignancy. These findings suggest a biologically plausible \"tumor associated USCs-CXCL2-bladder cancer\" circuit, providing insights into a putative blood-urine interactive regulatory axis and revealing a potential therapeutic target.", "journal": "Cancer Letters", "pub_date": "2026-Sep-28", "publication_types": ["Journal Article"], "doi": "10.1016/j.canlet.2026.218675", "authors": ["Dongkai Sun", "Chunhua Han", "Dan Li", "Peng Li", "Xintao Tian", "Zhijuan Liang", "Yuanbin Chen", "Liping Wang", "Shuaishuai Li", "Lijiang Sun", "Ye Liang", "Haitao Niu"], "affiliations": ["Department of Urology, The Affiliated Hospital of Qingdao University, Qingdao, 266003, China; Key Laboratory of Urology and Andrology, Department of Medical Research Centre, The Affiliated Hospital of Qingdao University, Qingdao, 266003, China. Electronic address: SUNdk6298@outlook.com.", "Department of Clinical Laboratory, The Affiliated Hospital of Qingdao University, Qingdao, 266555, China.", "Key Laboratory of Urology and Andrology, Department of Medical Research Centre, The Affiliated Hospital of Qingdao University, Qingdao, 266003, China.", "Department of Urology, The Affiliated Hospital of Qingdao Binhai University, Qingdao, 266404, China.", "Department of Urology, The Affiliated Hospital of Qingdao University, Qingdao, 266003, China; Key Laboratory of Urology and Andrology, Department of Medical Research Centre, The Affiliated Hospital of Qingdao University, Qingdao, 266003, China.", "Department of Urology, The Affiliated Hospital of Qingdao University, Qingdao, 266003, China. Electronic address: slijiang999@126.com.", "Key Laboratory of Urology and Andrology, Department of Medical Research Centre, The Affiliated Hospital of Qingdao University, Qingdao, 266003, China. Electronic address: liangye82812@163.com.", "Department of Urology, The Affiliated Hospital of Qingdao University, Qingdao, 266003, China; Key Laboratory of Urology and Andrology, Department of Medical Research Centre, The Affiliated Hospital of Qingdao University, Qingdao, 266003, China. Electronic address: niuht0532@126.com."], "corresponding_authors": ["Dongkai Sun", "Lijiang Sun", "Ye Liang", "Haitao Niu"], "china_team": "Department of Urology, The Affiliated Hospital of Qingdao University, Qingdao, 266003, China; Key Laboratory of Urology and Andrology, Department of Medical Research Centre, The Affiliated Hospital of Qingdao University, Qingdao, 266003, China Dongkai Sun/Lijiang Sun/Ye Liang/Haitao Niu团队", "category": "basic", "classification_reason": "basic_signals=14", "score": 46.53, "score_parts": {"urology_relevance": 7, "urology_in_title": 8.0, "journal_priority": 15.53, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 14.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 10.1, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.53, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "血尿调控轴驱动膀胱癌干性", "chinese_summary": "青岛大学附属医院孙东凯、孙立江、梁晔、牛海涛团队9月Cancer Lett报道，膀胱癌分泌的TNF-α、IL-6、TGF-β持续作用可将正常尿源干细胞重编程为肿瘤相关尿源干细胞，后者脱落入尿并分泌CXCL2，激活膀胱癌细胞CXCR2/ERK/β-catenin通路，上调CD44、ALDH1A1等干性标志物。", "abstract_zh": "膀胱癌的恶性进展与肿瘤微环境密切相关，但尿源干细胞（USCs）的作用仍知之甚少。从健康个体和膀胱癌患者中分离USCs，随后进行多组学和功能表征。使用膀胱癌细胞系T24进行体外共培养和体内共注射实验。持续暴露于肿瘤来源因子（TNF-α、IL-6和TGF-β）可将正常USCs（N-USCs）重编程为肿瘤相关USCs（T-USCs）。这一转变以E-钙黏蛋白下调、波形蛋白上调、细胞周期停滞和黏附减少为标志，促进USCs脱离并脱落入尿。因此，荷瘤状态下的尿液显示USC计数增加和CXCL2水平升高。USC来源的CXCL2激活膀胱癌细胞上的CXCR2受体，触发ERK/β-catenin轴。这显著上调干性标志物（CD44、ALDH1A1），促进恶性进展。在共注射模型中，T-USCs与膀胱癌细胞形成有序的基质鞘，促进肿瘤侵袭。在体内，USCs驱动肿瘤生长和微环境重塑，靶向CXCL2/CXCR2/ERK轴可抑制这些效应。我们提出一个模型，其中血源性肿瘤因子诱导尿USC重编程，可能建立一个富含CXCL2的微环境，助长恶性进展。这些发现提示一个生物学上合理的“肿瘤相关USC-CXCL2-膀胱癌”回路，为一种推测的血-尿交互调控轴提供了见解，并揭示了一个潜在的治疗靶点。"}, {"pmid": "42802299", "title": "Noninvasive photoacoustic imaging maps collagen and muscle remodelling in bladder outlet obstruction.", "abstract": "Our objective was to characterize regional bladder remodelling in a rat model of partial bladder outlet obstruction (pBOO) and to evaluate collagen-specific photoacoustic (PA) imaging as a noninvasive tool for detecting early structural and collagen remodelling of the bladder wall. Female Sprague-Dawley rats underwent nerve-sparing midurethral obstruction or sham surgery and were evaluated at 4 and 8 weeks. Two independent cohorts of 30 rats each were studied. Cohort 1 bladders underwent ex vivo multispectral PA imaging (680-970 nm, 40 MHz) and histologic analysis. A custom spectral unmixing algorithm quantified collagen density across bladder regions (dome, midsection, and neck) and compared it with histologic collagen-to-muscle area ratios. Cohort 2 underwent molecular and biochemical analyses, including hydroxyproline quantification and assessment of collagen- and matrix-associated gene expression. pBOO resulted in significant bladder enlargement, with increased absolute bladder mass and bladder-to-body mass ratios at 4 and 8 weeks (P < 0.05). Metabolic cage analysis demonstrated an increased frequency of small-volume voids at 8 weeks, despite preserved mean, maximum, and total voided volumes. Region-specific analysis identified the midsection as the site of greatest collagen accumulation with even greater detrusor muscle expansion, leading to a reduction in the collagen-to-muscle ratio. Molecular markers of collagen and matrix remodelling, along with hydroxyproline content, were significantly elevated, particularly in the midsection. Ex vivo PA imaging quantitatively mapped collagen distribution and demonstrated a strong correlation with histologic collagen-to-muscle ratios (r = 0.75), supporting its validity as a quantitative marker of regional remodelling. Bladder remodelling in pBOO is spatially heterogeneous, involving coordinated alterations in collagen deposition and detrusor muscle architecture that are most pronounced in the midsection. Collagen-specific PA imaging enables quantitative assessment of these structural changes and represents a promising noninvasive tool for early detection and longitudinal monitoring of obstruction-associated bladder wall remodelling.", "journal": "BJU International", "pub_date": "2026-Sep-27", "publication_types": ["Journal Article"], "doi": "10.1111/bju.70444", "authors": ["Alexander Koven", "Xiaolin He", "Tianzhou Zhang", "Shukai Huang", "Monica Farcas", "Eno Hysi", "Darren A Yuen"], "affiliations": ["Glickman Urologic Institute, Cleveland Clinic, Cleveland, OH, USA.", "Division of Urology, Department of Surgery, St. Michael's Hospital, Unity Health Toronto and University of Toronto, Toronto, ON, Canada.", "Keenan Research Centre for Biomedical Science, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Unity Health Toronto, Toronto, ON, Canada.", "Institute for Biomedical Engineering, Science and Technology (iBEST), a partnership between Toronto Metropolitan University and St. Michael's Hospital, Toronto, ON, Canada.", "Department of Medical Biophysics, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.", "Department of Physics, Faculty of Science, Toronto Metropolitan University, Toronto, ON, Canada.", "Division of Nephrology, Department of Medicine, St. Michael's Hospital, Unity Health Toronto and University of Toronto, Toronto, ON, Canada."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "basic_signals=5", "score": 33.47, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 10.47, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 5.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.4, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.47, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "光声成像无创描绘膀胱重构", "chinese_summary": "BJU Int 9月发布大鼠部分膀胱出口梗阻模型研究，采用胶原特异性光声成像结合光谱解混算法，发现膀胱重构呈空间异质性，以中段胶原沉积与逼尿肌扩张最显著，成像与组织学胶原/肌肉比强相关（r=0.75），为无创早期监测梗阻性膀胱壁重构提供新工具。", "abstract_zh": "本研究旨在表征大鼠部分膀胱出口梗阻（pBOO）模型中的区域膀胱重构，并评估胶原特异性光声（PA）成像作为检测膀胱壁早期结构和胶原重构的无创工具的价值。雌性Sprague-Dawley大鼠接受保留神经的中段尿道梗阻或假手术，并在4周和8周时进行评估。研究纳入两个独立的队列，每队列30只大鼠。队列1的膀胱接受离体多光谱PA成像（680-970 nm，40 MHz）和组织学分析。采用定制光谱解混算法量化膀胱各区域（顶部、中段和颈部）的胶原密度，并与组织学胶原与肌肉面积比进行比较。队列2接受分子和生化分析，包括羟脯氨酸定量以及胶原和基质相关基因表达评估。pBOO导致膀胱显著增大，4周和8周时膀胱绝对质量和膀胱与体重比均增加（P < 0.05）。代谢笼分析显示，尽管平均、最大和总排尿量保持，8周时小容量排尿频率增加。区域特异性分析确定中段为胶原蓄积最显著部位，同时逼尿肌扩张更为明显，导致胶原与肌肉比降低。胶原和基质重构的分子标志物以及羟脯氨酸含量显著升高，尤其在中段。离体PA成像定量描绘了胶原分布，并显示与组织学胶原与肌肉比强相关（r = 0.75），支持其作为区域重构定量标志物的有效性。pBOO中的膀胱重构具有空间异质性，涉及胶原沉积和逼尿肌结构的协调性改变，以中段最为显著。胶原特异性PA成像能够定量评估这些结构变化，是一种有前景的无创工具，可用于梗阻相关膀胱壁重构的早期检测和纵向监测。"}, {"pmid": "42801929", "title": "Acute and subacute toxicological evaluation of the alkaloid-rich fraction from Smyrnium olusatrum L. seeds in mice.", "abstract": "Smyrnium olusatrum L. (Apiaceae) is a medicinal plant traditionally used in Mediterranean ethnomedicine to treat gastrointestinal disorders, as well as inflammatory conditions, urinary tract disorders, gynecological ailments, and respiratory diseases. Alkaloids constitute an important class of bioactive constituents in medicinal plants and may contribute to their pharmacological effects; however, their biological activities may also be associated with dose-dependent toxicity. Despite the pharmacological potential of S. olusatrum alkaloids, their toxicological profile remains insufficiently characterized, which may limit their further pharmacological investigation and development. This study aimed to evaluate the acute and subacute toxicity of the alkaloid-rich fraction isolated from S. olusatrum seeds as part of the preclinical safety assessment to support its further pharmacological investigation. Acute toxicity was investigated following a single intraperitoneal administration of the alkaloid-rich fraction at doses of 1, 10, 20, 200, and 2000 mg/kg, followed by a 14-day observation period. Subacute toxicity was assessed after daily intraperitoneal (i.p.) administration of 25, 50, 100, and 200 mg/kg for 28 consecutive days. Clinical observations, body and relative organ weights, hematological and biochemical parameters, and histopathological examinations of major organs were performed. No mortality or treatment-related clinical signs were observed following acute administration, indicating an LD50 greater than 2000 mg/kg (i.p.). Repeated administration for 28 days produced no significant changes in body weight, relative organ weights, hematological indices, or serum biochemical parameters compared with controls. Histopathological examination revealed normal architecture in the kidneys, heart, lungs, and spleen. Mild hepatic histoarchitectural changes, consisting of slight disorganization of hepatocyte cords and sinusoidal dilation, were observed only in male mice at 100 and 200 mg/kg without accompanying biochemical evidence of liver injury. The alkaloid-rich fraction of S. olusatrum seeds exhibited a favorable toxicological profile following acute and repeated i.p. administration in Swiss mice. Under the experimental conditions, the NOAEL was established at 50 mg/kg/day (i.p.) based on the first occurrence of treatment-related hepatic histological changes at 100 mg/kg. Alkaloid extracts from S. olusatrum seeds showed low acute and subacute toxicity in mice, supporting their further preclinical pharmacological investigation while highlighting the importance of dose optimization and sex-specific hepatic responses.", "journal": "Journal of Ethnopharmacology", "pub_date": "2026-Sep-27", "publication_types": ["Journal Article"], "doi": "10.1016/j.jep.2026.122430", "authors": ["Zineb Sekkout", "Omaima Boudaia", "Giacomo De Palma", "Abel Navarré Dopazo", "Luana Izzo", "Carla Cicala", "Driss Radallah", "Najat El Amrani", "Amal El Hamsas El Youbi"], "affiliations": ["Laboratory of Biology and Health, Faculty of Sciences Ben M'Sik, Hassan II University of Casablanca, Casablanca, 20670, Morocco. Electronic address: zineb.sekkout-etu@etu.univh2c.ma.", "Laboratory of Biology and Health, Faculty of Sciences Ben M'Sik, Hassan II University of Casablanca, Casablanca, 20670, Morocco.", "Department of Pharmacy, University of Naples Federico II, Via D. Montesano 49, Naples, 80131, Italy."], "corresponding_authors": ["Zineb Sekkout"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 19.72, "score_parts": {"urology_relevance": 3, "urology_in_title": 0.0, "journal_priority": 10.72, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 3.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 5.4, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.72, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42801919", "title": "Gender Representation and Regional Affluence as Dual Drivers of Reimbursement Equity in Urology.", "abstract": "To elucidate disparities in physician compensation and workforce distribution across gender, subspecialties, affluence, age, payers, and geographies. The NPI registry was linked with the U.S. Census small-area income estimates to evaluate associations between median household income and urologist density, stratified by gender. Commercial reimbursement was gathered across national payers. Reimbursements were compared between female and male urologists using Mann-Whitney U tests stratified by CPT code, subspecialty, and years in practice. Logistic regression modeled the likelihood of positive year-over-year reimbursement growth by state-level female representation. Women's relative reimbursement growth ranged from +12.5% to -12.9%. Greater female representation predicted higher reimbursement growth for women (OR = 1.04, p = 0.014). Median household income was positively associated with urologist supply (β = 935.9, p < 0.0001), with a threefold stronger association for female urologists (β = 3464, p < 0.0001). Female urologists were nearly half as likely as male counterparts to practice outside urban areas (4.8% vs. 8.3%). In urban settings, female urologists commanded higher median reimbursement; however, this advantage reversed in small rural settings. Regional affluence, female workforce concentration, and commercial reimbursement trends appear mutually reinforcing, concentrating female urologists in higher-income markets while widening access gaps in underserved areas. Targeted workforce incentives and reform are needed to advance equitable urologic care.", "journal": "Urology", "pub_date": "2026-Sep-27", "publication_types": ["Journal Article"], "doi": "10.1016/j.urology.2026.09.048", "authors": ["Jordan Kassab", "Bailey Brooks", "Amelia Oppenheimer", "Dilpreet Sahota", "Niki Parikh"], "affiliations": ["Texas Tech University Health Sciences Center School of Medicine, Lubbock, TX; Trek Health, San Mateo, CA. Electronic address: jordan.kassab@ttuhsc.edu.", "University of Texas Southwestern, Department of Urology, Dallas, TX.", "Baylor College of Medicine, Scott Department of Urology, Houston, TX.", "Trek Health, San Mateo, CA.", "University of Texas Southwestern, Department of Urology, Dallas, TX. Electronic address: Niki.Parikh@utsouthwestern.edu."], "corresponding_authors": ["Jordan Kassab", "Niki Parikh"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 19.61, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 5.61, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.0, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.61, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42801343", "title": "Anatomical interpretation of membranous urethral length and posterior periurethral thickness after HoLEP: a commentary on Nagasaki et al.", "abstract": "", "journal": "World Journal of Urology", "pub_date": "2026-Sep-27", "publication_types": ["Letter"], "doi": "10.1007/s00345-026-06822-2", "authors": ["Arif Huseynli", "Ender Cem Bulut"], "affiliations": ["Department of Urology, Ankara Etlik City Hospital, Ankara, Turkey. dr.huseynliarif@gmail.com.", "Department of Urology, Gazi University, Ankara, Turkey."], "corresponding_authors": ["Arif Huseynli"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 19.0, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.0, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.9, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.0, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42801326", "title": "An ROS-Responsive CeO2-Selenium Nanozyme Mitigates Renal Injury via Coordinated Ferroptosis Inhibition and Inflammation Resolution.", "abstract": "Acute kidney injury (AKI) and chronic kidney disease (CKD), despite distinct etiologies, share a common pathological axis characterized by reactive oxygen species (ROS) burst, ferroptosis activation, and sustained inflammation. Targeting this ROS-ferroptosis-inflammation cycle represents a promising therapeutic strategy; however, current nanoplatforms are limited by insufficient responsiveness and limited capacity to regulate shared pathological mechanisms across distinct renal disease models. Here, we develop an engineered ROS-responsive nanozyme by integrating diselenide-bridged organosilica, hyaluronic acid (HA)-modified cerium oxide (CeO2), and a selenium-containing diselenide framework. Under oxidative stress, MON@HA-CeO2 undergoes ROS-triggered disassembly, coupling HA-CeO2-mediated ROS scavenging with selenium-related GPX4 restoration to suppress lipid peroxidation, ferroptosis, and inflammatory amplification. In both glycerol-induced AKI and unilateral ureteral obstruction (UUO)-induced renal fibrosis models, the nanozyme significantly improves renal function and attenuates tissue injury, fibrosis, and inflammation. Overall, this work demonstrates a versatile strategy for targeting a shared pathological axis and provides a promising platform for the treatment of diverse renal diseases.", "journal": "Advanced Healthcare Materials", "pub_date": "2026-Sep-27", "publication_types": ["Journal Article"], "doi": "10.1002/adhm.71771", "authors": ["Zhiwen Wang", "Yue Xie", "Jiahui Zhang", "Min Yang", "Zhiyue Zou", "Chun Zhang"], "affiliations": ["Department of Nephrology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China."], "corresponding_authors": [], "china_team": "Department of Nephrology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China Chun Zhang团队", "category": "basic", "classification_reason": "basic_signals=5", "score": 22.46, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 11.46, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 5.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 9.6, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 3.46, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42820075", "title": "Advances in Exosome Research in Renal Cell Carcinoma: Mechanisms, Biomarkers, and Therapeutic Applications.", "abstract": "Renal cell carcinoma (RCC) is a common malignant neoplasm of the urinary system, characterized by the difficulty of early diagnosis and the frequent emergence of therapeutic resistance in advanced stages, both of which profoundly compromise patient prognosis. Exosomes, as nanoscale vesicles secreted by cells, are capable of transporting bioactive molecules such as proteins and nucleic acids, thereby mediating communication within the tumor microenvironment and offering novel avenues for the noninvasive diagnosis and treatment of RCC. This article reviews recent advances in exosome research in RCC. It first outlines the biogenesis, structure, and biological functions of exosomes; it then systematically examines their pivotal roles in RCC invasion and metastasis, epithelial-mesenchymal transition, immune evasion, angiogenesis, and therapeutic resistance. Furthermore, it explores the potential of exosomes as biomarkers for the early diagnosis and prognostic assessment of RCC, as well as their promising applications in therapy as drug delivery vehicles and tumor vaccines. Finally, the review summarizes the current challenges confronting exosome research, including the lack of standardized isolation techniques and insufficient clinical validation, and considers future directions for promoting their clinical translation through the integration of multi-omics approaches and artificial intelligence. This review provides a theoretical foundation and valuable reference for the precise diagnosis and treatment of RCC.", "journal": "International Journal of Nanomedicine", "pub_date": "2026", "publication_types": ["Journal Article", "Review"], "doi": "10.1038/s41416-022-02077-x", "authors": ["Jiayu Luo", "Lanfeng Wang", "Mingcan Zhou", "Wengbin Huang", "Man Zhang", "Jiahui He", "Bingqing Yu", "Zhiping Chen"], "affiliations": ["Department of Laboratory Medicine, First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, People's Republic of China.", "College of Medical Technology, Gannan Medical University, Ganzhou, Jiangxi, People's Republic of China.", "Department of Nephrology, First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, People's Republic of China.", "First Clinical Medical College, Gannan Medical University, Ganzhou, Jiangxi, People's Republic of China."], "corresponding_authors": [], "china_team": "Department of Laboratory Medicine, First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, People's Republic of China Zhiping Chen团队", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 31.96, "score_parts": {"urology_relevance": 7, "urology_in_title": 8.0, "journal_priority": 10.96, "top_journal_bonus": 0.0, "novelty": 3.0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 1.0}, "journal_metrics": {"status": "ok", "impact_factor": 6.5, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.96, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42800842", "title": "Multicentre evaluation of artificial intelligence risk classification for detection of clinically significant prostate cancer on biparametric MRI.", "abstract": "To compare a commercially available artificial intelligence (AI) risk-classification system with PI-RADS for detecting clinically significant prostate cancer (csPCa) on prostate MRI. This retrospective multicentre, multivendor diagnostic accuracy study included men who underwent prostate MRI and histopathologic verification between 2014 and 2025. Index tests were DeepHealth Prostate Suite AI risk category and radiologist-assigned PI-RADS; the reference standard was International Society of Urological Pathology Grade Group ≥ 2. Patient-level non-inferiority testing, receiver operating characteristic analysis, lesion-level free-response receiver operating characteristic analysis, and patient-level bootstrap confidence intervals were used. Workflow support analyses modeled biopsy-avoidance strategies and AI-based risk stratification within PI-RADS 3 lesions. After exclusions, 787 men (median age, 70 years; interquartile range, 64-75) were evaluated; 380 (48.3%) had csPCa. AI sensitivity was non-inferior to PI-RADS at the patient level (97.6% vs 92.6%; p < 0.001) but not at the lesion level (78.8% vs 88.8%; p = 0.98). Patient-level area under the curve was higher for AI than PI-RADS (0.80 vs 0.77; difference, 0.032; 95% confidence interval, 0.001-0.064; p = 0.043). A targeted PI-RADS 3 strategy avoided 18.9% of biopsies while maintaining 98.4% sensitivity. Among PI-RADS 3 lesions, AI upgraded 93.1% of csPCa-positive lesions and assigned a low risk to 24.1% of benign lesions. The AI system was non-inferior for patient-level sensitivity but not lesion-level sensitivity. AI risk classification is best positioned as decision support for biopsy triage, particularly in PI-RADS 3 lesions. Question Can three-tier artificial intelligence risk classification support prostate MRI biopsy triage in men while preserving detection of clinically significant prostate cancer? Findings Artificial intelligence had non-inferior patient-level sensitivity and higher patient-level discrimination than PI-RADS, but lower lesion-level sensitivity at the predefined threshold. Clinical relevance Artificial intelligence risk categories can complement PI-RADS by supporting high-sensitivity biopsy triage, especially for equivocal PI-RADS 3 lesions, while radiologists retain responsibility for lesion mapping.", "journal": "European Radiology", "pub_date": "2026-Sep-26", "publication_types": ["Journal Article"], "doi": "10.1016/j.urolonc.2024.11.007", "authors": ["Karsten Guenzel", "Maarten G Poirot", "Almar van Loon", "Emanuele Messina", "Martina Pecoraro", "Valeria Panebianco", "Robert Princenthal", "Francesco Giganti"], "affiliations": ["Department of Urology, Vivantes Klinikum Am Urban, Berlin, Germany.", "Prostate-Diagnostic-Centre Berlin, PDZB, Berlin, Germany.", "Department of Urology, Faculty of Health Sciences Brandenburg, Brandenburg Medical School Theodor Fontane, Neuruppin, Germany.", "DeepHealth Inc., Somerville, MA, USA.", "Department of Radiological Sciences, Oncology and Pathology, Sapienza University, Rome, Italy.", "Rolling Oaks Radiology, Thousand Oaks, CA, USA.", "RadNet, Inc., Thousand Oaks, CA, USA.", "Department of Radiology, University College London Hospital NHS Foundation Trust, London, UK. f.giganti@ucl.ac.uk.", "Division of Surgery & Interventional Science, University College London, London, UK. f.giganti@ucl.ac.uk."], "corresponding_authors": ["Francesco Giganti"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=4", "score": 33.55, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 10.55, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 4.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.7, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.55, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42800841", "title": "Residual hydronephrosis after paediatric pyeloplasty: longitudinal APD reference curves.", "abstract": "Residual hydronephrosis is common after pyeloplasty and can complicate follow-up. We developed renal pelvic anteroposterior diameter (APD) reference curves to help interpret postoperative ultrasound findings and identify renal units that merit closer review. We retrospectively reviewed children undergoing primary pyeloplasty for isolated pelvi-ureteric junction obstruction between February 2016 and September 2020. Curves derived from renal units without recurrence described postoperative APD according to preoperative APD and time since surgery. A mixed-effects model accounted for repeated measurements from each renal unit. We compared reoperation rates in units with any measurement above the 90th-centile upper reference curve and those remaining below it. The cohort included 566 renal units in 550 children. Reference curves used 1,229 measurements from 551 units without recurrence, with median follow-up of 17.0 months. APD decreased most during the early postoperative months and remained higher in renal units with greater preoperative dilatation. At 6 months, the upper reference APD was 23.0 mm for a preoperative APD of 15 mm and 38.4 mm for 70 mm. Among 564 units with documented outcomes, reoperation occurred in 9 of 77 units above the curve (11.7%) and 4 of 487 below it (0.8%; risk ratio 14.23, 95% confidence interval 4.49-45.08). A web calculator compares postoperative APD with the corresponding reference values from 3 to 24 months. The curves provide a reference for interpreting residual hydronephrosis using routine follow-up ultrasound measurements. APD above the upper curve was associated with more frequent reoperation and can help identify children for earlier reassessment.", "journal": "World Journal of Urology", "pub_date": "2026-Sep-26", "publication_types": ["Journal Article"], "doi": "10.1007/s00345-026-06818-y", "authors": ["Jiayi Li", "Ning Sun", "Hongcheng Song", "Weiping Zhang"], "affiliations": ["Department of Urology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, 100045, China.", "Department of Urology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, 100045, China. songhch1975@126.com.", "Department of Urology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, 100045, China. zhangwp59616406@126.com."], "corresponding_authors": ["Hongcheng Song", "Weiping Zhang"], "china_team": "Department of Urology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, 100045, China Hongcheng Song/Weiping Zhang团队", "category": "clinical_review", "classification_reason": "clinical_signals=6", "score": 22.0, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 10.0, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 6.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.9, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.0, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42800813", "title": "A plasma derived hypoxia signature predicts benefit from hypoxia-modifying radiotherapy and reveals dynamic humoral immune modulation in bladder cancer.", "abstract": "Hypoxia is a hallmark of solid tumours and drives radioresistance, yet no hypoxia biomarkers are used clinically. We explored nanoproteomics to identify a plasma protein signature for longitudinal non-invasive hypoxia monitoring. Twenty-three bladder cancer patients (T2-T3b) undergoing radiotherapy (55 Gy, 4 weeks) were prospectively enroled. Plasma was collected at baseline and weekly, nanoparticle-enriched and analysed by proteomics. Hypoxia scores (HS) were derived from diagnostic biopsies using a validated 24-gene signature, and patients stratified by median HS. We identified 115 differentially abundant proteins (DAPs; |FC | > 1.5; p < 0.05). Seven DAPs (IGKV3, IGLV2-18, VL_4, VL_7, FN1, IGLV2-14, CAMP) correlated with HS across multiple timepoints (p < 0.05; |r | >0.4). A two-protein signature (FN1, CAMP) was retrospectively validated, showing prognostic value in TCGA-BLCA (n = 404; HR = 1.54; CI = 1.12-2.13; p = 0.009), BC2001 (n = 313; HR = 1.42; CI = 1.08-1.86; p = 0.011) and in meta-analysis (n = 150; HR = 1.48; CI = 1.23-1.78; p < 0.001). In BCON (n = 150), it predicted benefit from hypoxia-modifying therapy (HR = 0.60; CI = 0.34-1.06; p = 0.079). The 115 DAPs formed five temporal co-expression clusters peaking at successive treatment weeks. Clusters were enriched for humoral immune pathways, with one linked to extracellular matrix remodelling. These findings support the use of low abundance plasma biomarkers for real-time hypoxia stratification, revealing dynamic immune responses during radiotherapy associated with hypoxia.", "journal": "British Journal of Cancer", "pub_date": "2026-Sep-26", "publication_types": ["Journal Article"], "doi": "10.1186/s13293-026-00829-5", "authors": ["C Guerrero Quiles", "H Abumanhal-Masarweh", "J G Abalos", "T Lodhi", "D Sanchez-Martinez", "K Reeves", "Nicholas D James", "Emma Hall", "Robert A Huddart", "Nuria Porta", "P Hoskin", "L V Biolatti", "M Hadjidemetriou", "C M West", "A Choudhury"], "affiliations": ["Translational Radiobiology Group, Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Oglesby Cancer Research Centre, Manchester, UK. conrado.guerreroquiles@manchester.ac.uk.", "NanoOmics Lab, Centre for Nanotechnology in Medicine, Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK.", "Translational Radiobiology Group, Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Oglesby Cancer Research Centre, Manchester, UK.", "Translational Oncogenomics Group, Manchester Cancer Research Centre Manchester Institute, Manchester, UK.", "The Institute of Cancer Research, London, UK."], "corresponding_authors": ["C Guerrero Quiles"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 32.51, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 11.01, "top_journal_bonus": 0.0, "novelty": 0.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 7.0}, "journal_metrics": {"status": "ok", "impact_factor": 6.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 3.01, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42800742", "title": "Reply to Roberto M. Scarpa's Letter to the Editor re: Paolo Gontero, Richard Perry, Daisy Bridge, et al. Unmet Treatment Need and Challenges Associated with Comparative Evidence Generation in BCG-unresponsive Non-muscle-invasive Bladder Cancer: An Expert Consensus. Eur Urol Oncol 2026;9(3):652-9.", "abstract": "", "journal": "European Urology Oncology", "pub_date": "2026-Sep-26", "publication_types": ["Letter"], "doi": "10.1016/j.euo.2026.08.012", "authors": ["Paolo Gontero", "Marek Babjuk"], "affiliations": ["Division of Urology, Città della Salute e della Scienza di Torino, University of Torino School of Medicine, Turin, Italy. Electronic address: paolo.gontero@unito.it.", "Charles University, Second Faculty of Medicine Motol University Hospital, Czech Republic."], "corresponding_authors": ["Paolo Gontero"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 25.42, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 15.42, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 1.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 9.3, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.42, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "专家共识回应BCG无应答膀胱癌治疗困境", "chinese_summary": "9月Eur Urol Oncol刊出Gontero等对Scarpa读者来信的回复，围绕BCG无应答非肌层浸润性膀胱癌指出，现有对照证据生成困难，治疗需求未被满足，强调需优化试验设计与终点选择以推动替代方案评价。", "abstract_zh": "这是对Roberto M. Scarpa致编辑来信的回复，该来信针对Paolo Gontero、Richard Perry、Daisy Bridge等人发表的《BCG无应答非肌层浸润性膀胱癌中未满足的治疗需求及比较证据生成相关挑战：专家共识》（Eur Urol Oncol 2026;9(3):652-9）。"}, {"pmid": "42800741", "title": "Adjuvant Pembrolizumab in Clear Cell Renal Cell Carcinoma: Eligibility Is Only the Beginning.", "abstract": "", "journal": "European Urology Oncology", "pub_date": "2026-Sep-26", "publication_types": ["Editorial"], "doi": "10.1016/j.euo.2026.09.008", "authors": ["Francesco Rossi", "Massimiliano Depalma", "Bernardo Rocco", "Riccardo Autorino"], "affiliations": ["Department of Urology, Cleveland Clinic Foundation, Cleveland, USA; Department of Urology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.", "Department of Urology, Cleveland Clinic Foundation, Cleveland, USA; University of Milan, Milan, Italy.", "Department of Urology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.", "Department of Urology, Cleveland Clinic Foundation, Cleveland, USA. Electronic address: autorir@ccf.org."], "corresponding_authors": ["Riccardo Autorino"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 24.42, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 15.42, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 9.3, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.42, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42800733", "title": "Re: Matthew D. Galsky and Andrea Necchi. Cystectomy Can Be Spared in Selected Patients with Muscle-invasive Bladder Cancer and Complete Response Following Neoadjuvant Therapy. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2026.07.014.", "abstract": "", "journal": "European Urology", "pub_date": "2026-Sep-26", "publication_types": ["Letter"], "doi": "10.1016/j.eururo.2026.08.029", "authors": ["Pietro Scilipoti", "Francesco Montorsi"], "affiliations": ["Division of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele Hospital, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. Electronic address: scilipoti.pietro@hsr.it.", "Division of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele Hospital, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy."], "corresponding_authors": ["Pietro Scilipoti"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 39.79, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 16.79, "top_journal_bonus": 10.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 25.2, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.79, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "肌层浸润性膀胱癌可豁免膀胱切除", "chinese_summary": "欧洲泌尿外科学会杂志9月就Galsky与Necchi的评论发表读者来信，讨论新辅助治疗后达完全缓解的肌层浸润性膀胱癌患者是否有必要行根治性膀胱切除。来信围绕保留膀胱策略的筛选标准与肿瘤学安全性展开，强调需严格选择患者并加强随访。", "abstract_zh": "回复：Matthew D. Galsky 和 Andrea Necchi。对于新辅助治疗后达到完全缓解的特定肌层浸润性膀胱癌患者，可以免行膀胱切除术。《欧洲泌尿外科学会杂志》。出版中。https://doi.org/10.1016/j.eururo.2026.07.014。"}, {"pmid": "42800544", "title": "Perioperative Morbidity of Robotic-Assisted Radical Cystectomy Versus Open Radical Cystectomy in Older Adults and the Role of Frailty as an Effect Modifier.", "abstract": "To examine the role of frailty as a potential effect modifier of the comparative effectiveness of robotic-assisted radical cystectomy (RARC) and open radical cystectomy (ORC) in older adults. Radical cystectomy (RC) is associated with high rates of perioperative morbidity, and frailty may serve as a potentially strong modifier of both perioperative and oncologic outcomes. We therefore emulated a pragmatic clinical trial of RARC versus ORC to examine this question. We identified adults 66-89 years with Tis-T4 / N0-N1 / M0 urothelial carcinoma of bladder from 2008 to 2017 treated with RC in SEER-Medicare. Baseline frailty was assessed using the claims-based frailty index (CFI). Associations of RARC and ORC with perioperative and oncologic outcomes were examined in the overall cohort after stabilized inverse probability of treatment re-weighting (sIPW). Baseline frailty was examined as an effect modifier using interaction terms in separate models. A total of 1,750 patients were included in the study cohort, of whom 229 underwent RARC and 1521 underwent ORC. Adjusted rates of perioperative blood transfusion or 90-day ER utilization, hospital readmission, and complications were not statistically significantly different between RARC and ORC. Similarly, there were no statistically significant differences in cancer-specific or all-cause mortality. Notably, there were no statistically significant differences in perioperative morbidity or oncologic outcomes across baseline frailty level. In observational analyses designed to emulate the iROC trial, RARC was not associated with improved perioperative morbidity or oncologic outcomes in older adults, regardless of baseline frailty level.", "journal": "Urology", "pub_date": "2026-Sep-26", "publication_types": ["Journal Article"], "doi": "10.1016/j.urology.2026.09.054", "authors": ["Jamil Almohtasib", "Joseph Black", "Sumedh Kaul", "Aaron Fleishman", "Peter Chang", "Andrew Wagner", "Joaquim Bellmunt", "Ruslan Korets", "Aria F Olumi", "Boris Gershman"], "affiliations": ["Division of Urologic Surgery, Beth Israel Deaconess Medical Center, Boston, MA.", "Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX.", "Department of Surgery, Beth Israel Deaconess Medical Center, Boston, MA.", "Department of Medical Oncology, Dana-Farber Cancer Center, Boston, MA.", "Division of Urologic Surgery, Beth Israel Deaconess Medical Center, Boston, MA. Electronic address: bgershma@bidmc.harvard.edu."], "corresponding_authors": ["Boris Gershman"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=9", "score": 36.61, "score_parts": {"urology_relevance": 12, "urology_in_title": 8.0, "journal_priority": 5.61, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 9.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.0, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.61, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42800379", "title": "Novel use of computed tomography-derived body composition to facilitate risk assessment in patients with bladder cancer.", "abstract": "Comprehensive geriatric assessments (CGA) inform risk stratification in bladder cancer (BC) care but are time- and resource-intensive. To investigate whether body composition analysis (BCA) on computed tomography (CT) is associated with CGA. Patients with BC (any stage) were enrolled in a prospective observational cohort study between September 2020 and July 2021. Patients completed CGA, including grip strength (GS), Timed Up and Go (TUG), and Clinical Frailty Scale. BCA was derived from staging CT at vertebral levels T12 and L3, including cross-sectional area (CSA) and density of skeletal muscle (SM), subcutaneous adipose tissue (SAT), and intermuscular adipose tissue (IMAT). Generalized linear models were used to assess associations between BCA and GS, TUG, and frailty. Amongst 56 patients (median age 71 years; 84% male), increased SM CSA and density at T12 and L3 were associated with lower odds of abnormally low GS (L3: odds ratio [OR] 0.73; 95% confidence interval [CI]: 0.57, 0.94; P = 0.02, and OR 0.65; 95% CI: 0.44, 0.94; P = 0.002, respectively). Increased SM density at T12 and decreased IMAT CSA at T12 and L3 were associated with lower odds of abnormally low TUG (T12: OR 0.58; 95% CI: 0.37, 0.89; P = 0.01, and OR 4.24; 95% CI: 1.31, 13.70; P = 0.02). There was insufficient evidence of an association between BCA and frailty. BCA at T12 and L3 is associated with CGA components GS and TUG. These findings support future investigation of predictive ability of CT-derived biomarkers, including their potential use as surrogates for selected CGA components and their ability to facilitate guideline-concordant risk stratification.", "journal": "Urologic Oncology", "pub_date": "2026-Sep-26", "publication_types": ["Journal Article"], "doi": "10.1016/j.urolonc.2026.08.013", "authors": ["Lea Mantz", "Alex Zhu", "Nathaniel D Mercaldo", "Peter Amin Marquardt", "Ryan B O'Malley", "Viraj A Master", "Samia Jannat", "Elena G Brewer", "Sarah P Psutka", "Florian J Fintelmann"], "affiliations": ["Department of Radiology, Division of Thoracic Imaging and Intervention, Massachusetts General Hospital, Boston, MA; Department of Diagnostic and Interventional Radiology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.", "Department of Urology, University of Washington Medical Center, Seattle, WA; Department of Urology, City of Hope Comprehensive Cancer Center, Irvine, CA.", "Department of Radiology, Division of Thoracic Imaging and Intervention, Massachusetts General Hospital, Boston, MA.", "Department of Radiology, University of Washington School of Medicine, Seattle, WA; Fred Hutchinson Cancer Center, Seattle, WA.", "Department of Urology, Winship Cancer Institute, Emory University, Atlanta, GA.", "Department of Urology, University of Washington Medical Center, Seattle, WA.", "Department of Urology, University of Washington Medical Center, Seattle, WA; Fred Hutchinson Cancer Center, Seattle, WA. Electronic address: spsutka@uw.edu."], "corresponding_authors": ["Sarah P Psutka"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=6", "score": 27.25, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 5.75, "top_journal_bonus": 0.0, "novelty": 1.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 6.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.3, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.75, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42800378", "title": "Serum Galectin-3 as a complementary biomarker in non-muscle-invasive bladder cancer.", "abstract": "To evaluate serum Galectin-3 levels in patients with non-muscle-invasive bladder cancer (NMIBC) and to investigate their diagnostic performance and ability to discriminate between low-grade and high-grade disease. This prospective controlled study included 80 patients with NMIBC (40 low-grade and 40 high-grade) and 40 age-matched healthy controls. Serum Galectin-3 levels were measured using a commercially available ELISA kit prior to transurethral resection of the bladder tumor. Group comparisons were performed using appropriate parametric and non-parametric statistical tests. Diagnostic performance was evaluated using receiver operating characteristic (ROC) curve analysis with bootstrap confidence intervals and internal five-fold cross-validation. Associations between serum Galectin-3 levels and bladder cancer diagnosis and high-grade disease were assessed using univariate logistic regression. Serum Galectin-3 levels differed significantly among the study groups, with the highest levels observed in patients with high-grade NMIBC (P < 0.01). No significant difference was observed between the low-grade and control groups. Galectin-3 demonstrated moderate discrimination between patients with NMIBC and healthy controls (AUC = 0.673), whereas discrimination between high-grade and low-grade NMIBC was more pronounced (AUC = 0.777). Higher serum Galectin-3 levels were associated with bladder cancer diagnosis (OR 1.216, 95% CI, 1.003-1.475, P = 0.046) and with high-grade disease (OR 1.493, 95% CI, 1.097-2.033, P = 0.011). Serum Galectin-3 appears to be associated primarily with high-grade tumor biology rather than with the presence of NMIBC itself. Although its overall diagnostic performance for detecting NMIBC is moderate, it may serve as a complementary biomarker for discriminating high-grade disease. External validation in larger multicenter cohorts is required before clinical application.", "journal": "Urologic Oncology", "pub_date": "2026-Sep-26", "publication_types": ["Journal Article"], "doi": "10.1016/j.urolonc.2026.08.027", "authors": ["Recep Eryılmaz", "Muhammed Fatih Keleş", "Rahmi Aslan", "Zübeyir Huyut", "Murat Demir", "Kasım Ertaş", "Mehmet Sevim", "Kerem Taken"], "affiliations": ["Department of Urology, Faculty of Medicine, Van Yüzüncü Yıl University, Van, Türkiye.", "Department of Biochemistry, Faculty of Medicine, Van Yüzüncü Yıl University, Van, Türkiye.", "Department of Urology, Akdamar Hospital, Van, Türkiye.", "Department of Urology, Van Training and Research Hospital, Van, Türkiye. Electronic address: dokterms@gmail.com."], "corresponding_authors": ["Mehmet Sevim"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=8", "score": 32.25, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 5.75, "top_journal_bonus": 0.0, "novelty": 0.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 8.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.3, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.75, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42799799", "title": "Simulation-based dosimetric analysis of surgeon radiation exposure during robotic-assisted versus conventional URS.", "abstract": "Fluoroscopy during urinary stone surgery exposes patients and operating staff to ionizing radiation. This study aims to model and estimate surgeon radiation dose in robotic-assisted versus conventional ureteroscopy (URS) using an experimental simulation to evaluate the potential safety advantages of robotic systems. A simulation-based dosimetric model was developed using retrospective fluoroscopy data from 35 clinical cases. Fluoroscopy time was divided into robotic-assisted and non-robotic-assisted phases. Radiation exposure was estimated using a three-stage simulation model at four positions: the patient plane near the X-ray tube (A), and three surgeon positions including 50 cm unshielded (B), 50 cm with lead protection (C), and 150 cm behind a mobile lead barrier (D). Exposure was calculated across five scenarios: Scenario 1 (Patient Mode [Reference Measurement], position A), Scenario 2 (Conventional Unprotected Mode, position B), Scenario 3 (Conventional Protected Mode, position C), Scenario 4 (Robotic-Assisted Partial Protection Mode; B non-robotic-assisted, D robotic-assisted), and Scenario 5 (Robotic-Assisted Full Protection Mode; C non-robotic-assisted, D robotic-assisted). Data were analyzed using t-test, Mann-Whitney U, and chi-square tests, and presented as median (IQR) or n (%). Among 35 patients (mean age 46.6 ± 15.0 years) whose clinical data were utilized for the model, the mean total fluoroscopy time was 18.6 ± 10.1 s (5.2 ± 3.4 s robotic-assisted phase). The simulated radiation exposure differed significantly across scenarios (p < 0.05), with median estimated doses of 160,101.80, 56.93, 9.07, 40.88, and 6.97 µSv for Scenarios 1-5, respectively. Under simulated conditions, robotic-assisted URS significantly reduces surgeon radiation exposure. Specifically, the combination of increased distance and shielding minimizes these estimated dose levels.", "journal": "World Journal of Urology", "pub_date": "2026-Sep-26", "publication_types": ["Journal Article", "Comparative Study"], "doi": "10.1007/s00345-026-06807-1", "authors": ["Rifat Burak Ergül", "Şüheda Nur İnceoğlu", "Büşra Özdemir", "Arda Tunç Aydınoğlu", "Ahmad Gharehmohammadlou", "Özgür Aytan", "Berk Düzen", "Vincent De Coninck", "Francesco Esperto", "Stamatios Katsimperis", "Patrick Juliebø-Jones", "Arman Tsaturyan", "Begona Ballesta Martinez", "Tzevat Tefik"], "affiliations": ["Department of Urology, Muş State Hospital, Muş, Turkey. rifat-ergul@hotmail.com.", "EAU Young Academic Urologists (YAU), Urolithiasis and Endourology Working Group, Arnhem, The Netherlands. rifat-ergul@hotmail.com.", "Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.", "Department of Urology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.", "Department of Physics, Faculty of Science, Istanbul University, Istanbul, Turkey.", "Aytan Technology Industry and Trade Limited Company, Istanbul, Turkey.", "EAU Young Academic Urologists (YAU), Urolithiasis and Endourology Working Group, Arnhem, The Netherlands.", "Department of Urology, AZ Klina, Augustijnslei 100, Brasschaat, Belgium.", "Department of Urology, Fondazione Policlinico Universitario Campus Bio- Medico of Rome, Rome, Italy.", "Second Department of Urology, National and Kapodistrian University of Athens, Sismanogleio Hospital, Athens, 15126, Greece.", "Department of Urology, Haraldsplass Deaconess Hospital, Bergen, Norway.", "Erebuni Medical Center, Yerevan, Armenia.", "Hospital Universitario del Vinalopó, Elche, Alicante, Spain."], "corresponding_authors": ["Rifat Burak Ergül"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_clinical", "score": 24.0, "score_parts": {"urology_relevance": 7, "urology_in_title": 0.0, "journal_priority": 10.0, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 5.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.9, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.0, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42799778", "title": "Is catheter freedom sufficient to describe long-term functional recovery after prostate surgery?", "abstract": "", "journal": "World Journal of Urology", "pub_date": "2026-Sep-26", "publication_types": ["Letter"], "doi": "10.1007/s00345-026-06829-9", "authors": ["Abdulkadir Ozmez", "Mehmet Ozay Ozgur"], "affiliations": ["Department of Urology, Haseki Training and Research Hospital, University of Health Sciences, Istanbul, Turkey. abdulkadir.ozmez@istanbul.edu.tr.", "Department of Urology, Bagcilar Training and Research Hospital, University of Health Sciences, Istanbul, Turkey."], "corresponding_authors": ["Abdulkadir Ozmez"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 19.0, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.0, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.9, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.0, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42799755", "title": "Exploring the impact of artificial intelligence on radiation dose reduction in urological imaging: a systematic review from EAU endourology.", "abstract": "Patients with urological conditions often undergo recurrent computed tomography (CT) imaging, which results in cumulative radiation exposure which can be deleterious. Artificial intelligence (AI)- based technologies, including Deep Learning Image Reconstruction (DLIR), have emerged as a potential strategy to reduce radiation dose in CT imaging while maintaining image quality. This systematic review aimed to quantify the benefits of AI-based techniques in urological CT imaging. A systematic search of Ovid MEDLINE, Embase, and Scopus was conducted. Studies assessing AI-based techniques in urological CT were included. Primary outcomes of interest were radiation dose metrics (CTDIvol, DLP, effective dose), with other outcomes of interest including image quality metrics along with diagnostic performance of AI techniques. Eleven studies met the inclusion criteria. All studies demonstrated a radiation dose reduction aided with AI techniques, with most reporting reductions of 60-80%. Consistently, Image quality was maintained or improved, with reduced image noise and increased signal-to-noise ratio. Limited evidence from diagnostic studies showed at-least comparable performance between AI-based reconstruction and conventional iterative reconstruction, but with unclear superiority at equivalent dose levels. AI-based techniques show a clear ability to allow radiation dose reduction in urological CT imaging, whilst maintaining or improving image quality. However, the current evidence base is limited by a lack of diagnostic outcomes, and further research into AI techniques is required in order to quantify their clinical effectiveness.", "journal": "World Journal of Urology", "pub_date": "2026-Sep-26", "publication_types": ["Systematic Review", "Journal Article"], "doi": "10.1007/s00345-026-06777-4", "authors": ["Theo Clark", "Samuel Murphy", "Solomon Bracey", "Ali Talyshinskii", "Arman Tsaturyan", "Steffi Kar Kei Yuen", "Carlotta Nedbal", "Selcuk Guven", "Vineet Gauhar", "Frederic Panthier", "Bhaskar K Somani"], "affiliations": ["School of Medicine, University of Southampton, Southampton, UK.", "Department of Urology and Andrology, Genome clinic, Astana, Kazakhstan.", "Department of Urology, Erebouni Medical Center, 0087, Yerevan, Armenia.", "Department of Surgery, SH Ho Urology Centre, The Chinese University of Hong Kong, Hong Kong, China.", "Department of Urology, IRCCS San Gerardo dei Tintori, Monza, Italy.", "Department of Urology, Faculty of Medicine, Necmettin Erbakan University, Konya, Turkey.", "Ng Teng Fong General Hospital, Singapore, Singapore.", "Department of Urology, Tenon Hospital, AP-HP, Paris, France.", "University Hospital Southampton NHS Foundation Trust, Southampton, UK. bhaskarsomani@yahoo.com."], "corresponding_authors": ["Bhaskar K Somani"], "china_team": "Department of Surgery, SH Ho Urology Centre, The Chinese University of Hong Kong, Hong Kong, China Steffi Kar Kei Yuen团队", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 27.0, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.0, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 2.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.9, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.0, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42799633", "title": "Epigenetic Predictors of Smoking: External Validation and Association With Smoking-Related Cancer Risk.", "abstract": "Tobacco smoking has a strong influence on DNA methylation (DNAm), enabling the development of DNAm-based smoking predictors, yet external evaluations of these have remained limited. We aimed to assess six DNAm-based smoking predictors in a large sample of middle-aged and older Australians for (i) their accuracy and reliability, and (ii) their association with risk of smoking-related cancers. We used blood DNAm data from the Melbourne Collaborative Cohort Study to calculate six DNAm-based smoking predictors (EpiSmokEr, Elliott-183, McCartney-233, DNAmPACKYEARS, PCPACKYEARS, and mCigarette). Accuracy with respect to self-reported smoking pack-years (N = 2875, median age: 61 years) was assessed using Pearson's correlations, explained variance, and area under the curve (AUC). Reliability was assessed using intraclass correlation coefficients (ICCs) in 364 duplicated samples. Conditional logistic regression was used to assess associations with lung (Ncases = 332) and urothelial (Ncases = 426) cancer risk in two nested case-control studies. All smoking predictors showed excellent reliability (ICC > 0.9) and ability to distinguish current from never smokers (AUCs: 0.94-0.98), explaining 35%-50% variance of smoking pack-years. The predictors were positively associated with smoking-related cancer risk, with strongest adjusted associations observed for mCigarette with lung cancer (per SD, rate ratio [RR] = 2.18, 95% CI: 1.57-3.02) and for PCPACKYEARS with urothelial cancer (RR = 1.62, 95% CI: 1.27-2.07). This translated into prediction gains compared with models solely based on questionnaire-collected smoking variables. In middle-aged and older Australians, DNAm-based smoking predictors showed very good reliability and accuracy in predicting smoking exposure, and strong positive associations with smoking-related cancer risk beyond self-reported smoking information. This highlights their potential utility as an alternative or addition to self-reported smoking information for cancer risk stratification.", "journal": "International Journal of Cancer", "pub_date": "2026-Sep-26", "publication_types": ["Journal Article"], "doi": "10.1002/ijc.70755", "authors": ["Xiaoyu Fan", "Danmeng Lily Li", "Allison M Hodge", "Julie K Bassett", "Nina Afshar", "Melissa C Southey", "Graham G Giles", "Roger L Milne", "Pierre-Antoine Dugué"], "affiliations": ["Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia.", "Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, Victoria, Australia.", "Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Victoria, Australia."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 19.55, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 10.55, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 3.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.7, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.55, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42857006", "title": "Tumor-intrinsic execution of interferon-γ-associated immunity in bladder cancer: checkpoints in signaling, recruitment, and recognition.", "abstract": "Interferon-γ (IFN-γ) is a central mediator of antitumor immunity in bladder cancer, but an IFN-γ-rich tumor microenvironment does not necessarily translate into tumor control. Tissue-level inflammatory signatures capture overall immune activity and cannot determine whether malignant urothelial cells remain responsive to immune-derived IFN-γ or preserve the downstream functions required for immune elimination. This Mini Review examines tumor-intrinsic IFN-γ-associated immunity at three functional checkpoints: proximal IFN-γ sensing and signal transduction, chemokine-mediated effector-cell recruitment, and antigen-presentation-dependent tumor recognition. Bladder cancer models show that IFNGR-JAK-STAT1 responsiveness can be lost or attenuated, while separate tumor-intrinsic mechanisms can restrict CXCL9/CXCL10-dependent T-cell recruitment without a demonstrated proximal signaling defect. Antigen presentation forms a further checkpoint, with HLA-I and antigen-processing machinery altered through transcriptional, treatment-associated, and post-translational mechanisms. These mechanisms do not constitute a single linear IFN-γ resistance pathway. They instead mark distinct points at which inflammatory pressure can become uncoupled from tumor elimination. IFN-γ-responsive programs are also shaped by treatment context and signaling duration, as illustrated by CIITA/MHC-II biology and prolonged interferon signaling. Resolving these processes at malignant-cell, spatial, and longitudinal levels may improve the interpretation of BCG and checkpoint-blockade resistance and support more selective combination strategies.", "journal": "Frontiers in Immunology", "pub_date": "2026", "publication_types": ["Journal Article", "Review"], "doi": "10.1016/j.ccell.2024.10.016", "authors": ["Jingjing Lu", "Yichun Jiang", "Yanshan Jin", "Yi Zhang"], "affiliations": ["Department of Reproductive Medicine, The Affiliated People's Hospital of Ningbo University, Ningbo, China.", "Department of Urology, The Affiliated People's Hospital of Ningbo University, Ningbo, China."], "corresponding_authors": [], "china_team": "Department of Reproductive Medicine, The Affiliated People's Hospital of Ningbo University, Ningbo, China Yi Zhang团队", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 29.83, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 10.83, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 1.0}, "journal_metrics": {"status": "ok", "impact_factor": 5.9, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.83, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42856924", "title": "PSMA-targeted radioligand therapy with beta emitters in prostate cancer: current evidence, emerging indications, combination strategies, and future directions.", "abstract": "Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) has emerged as a major therapeutic advance in metastatic castration-resistant prostate cancer (mCRPC), The phase III VISION trial demonstrated that [177Lu]Lu-PSMA-617 significantly improves overall survival and radiographic progression-free survival (rPFS) establishing PSMA-targeted RLT as a key treatment option in advanced disease. Prostate-specific Membrane Antigen (PSMA) positron emission tomography/computed tomography (PET/CT) plays a central role in patient selection, treatment monitoring, and prognostic stratification, thereby supporting a precision oncology approach. More recently, the clinical development of PSMA-targeted radioligand therapy (RLT) has expanded in several directions, including its use in earlier disease stage, such as metastatic hormone-sensitive prostate cancer (mHSPC), and in the neoadjuvant and oligometastatic settings, as well as its integration into multimodal treatment strategies. These include combination approaches with androgen receptor pathway inhibitors (ARPIs), chemotherapy, immunotherapy, and radiation therapy. This review provides a comprehensive overview of the major developments in the field, including advances in molecular imaging, emerging therapeutic indications, combination approaches, and future directions in PSMA-targeted theranostics according to recent clinical trial data. Collectively, these developments highlight the evolving role of beta-emitting RLT across the prostate cancer disease.", "journal": "Frontiers in Medicine", "pub_date": "2026", "publication_types": ["Journal Article", "Review"], "doi": "10.71004/rss.026.v5.i1.50", "authors": ["Hiba Noamen", "Adam Bekkhoucha", "Alice Bernard Tessier", "Khali Trabelsi", "Mehdi Borsali", "Natacha Naoun", "Macarena Rey-Cardenas", "Alessia Daverio", "Ronan Flippot", "Cedric Pobel", "Lison Ferreol", "Anna Patrikidou", "Solenn Barraud", "Jacopo Uliano", "Alexandre Megherbi", "Mario Terlizzi", "Laurence Albiges", "Pierre Blanchard", "Mario Dipalma", "Yohann Loriot", "Camilo Garcia", "Désirée Deandreis"], "affiliations": ["Department of Nuclear Medicine, Gustave Roussy, Paris Saclay University, Villejuif, France.", "Department of Cancer Medicine, Gustave Roussy, Paris Saclay University, Villejuif, France.", "Radiopharmacy Unit, Pharmacy Department, Gustave Roussy, Paris Saclay University, Villejuif, France.", "Department of Radiotherapy, Gustave Roussy, Paris Saclay University, Villejuif, France."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 32.03, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 6.03, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 12.0}, "journal_metrics": {"status": "ok", "impact_factor": 3.0, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 2.03, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42798234", "title": "Trial design drives outcomes: harmonising efficacy across BCG-unresponsive bladder carcinoma in situ trials.", "abstract": "To evaluate how heterogeneity in response assessment protocols, including biopsy timing, complete response (CR) assessment, retreatment policies, and the handling of withdrawals, influences reported efficacy outcomes across single-arm registrational trials of patients with bacillus Calmette Guérin unresponsive (BCG-U) carcinoma in situ (CIS). We reconstructed survival data from six registrational BCG-U CIS trials and conducted simulation analyses to test how trial design affects efficacy estimates. Specifically, we: (i) reclassified patients who underwent re-induction as non-responders; (ii) adjusted for false-negative rates of cystoscopy/cytology vs biopsy (as uniquely reported in the nadofaragene firadenovec trial, hence chosen as the analytical reference); (iii) harmonised CR assessment timing across trials. The exact binomial test was utilised for comparisons. Re-induction reclassification reduced the 12-month CR rate for nogapendekin alfa inbakicept (NAI) + BCG from 44% to 33% and for cretostimogene grenadenorepvec from 45% to 38%. After adjusting for an 11% false-negative rate in trials lacking mandatory biopsies, the pembrolizumab 12-month CR rate declined to 17% (P = 0.07), and NAI, accounting for re-induction reclassification, achieved a CR rate of 29% (P = 0.4). TAR-200 outperformed the analytical reference, with a 12-month CR rate of 45% under mandatory biopsy protocols (P < 0.01). Trial design artefacts significantly impact reported efficacy in BCG-U CIS studies. Published CR rates are not directly comparable across agents. Future trials should standardise biopsy timing and clearly define retreatment policies to ensure meaningful cross-study comparisons.", "journal": "BJU International", "pub_date": "2026-Sep-25", "publication_types": ["Journal Article", "Review"], "doi": "10.1111/bju.70463", "authors": ["Daniele Robesti", "Ashish M Kamat", "Guillaume Ploussard", "Roberto Contieri", "Giuseppe Fallara", "Alberto Briganti", "Francesco Montorsi", "Antoine G van der Heijden", "Bernard Malavaud", "Kamal Pohar", "Neal Shore", "Colin P N Dinney", "Alberto Martini"], "affiliations": ["Division of Experimental Oncology, Department of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy.", "Vita-Salute San Raffaele University, Milan, Italy.", "Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.", "Department of Urology, Institut Universitaire du Cancer Toulouse-Oncopôle, Toulouse, France.", "Department of Urology, La Croix du Sud Hospital, Toulouse, France.", "Department of Urology, Istituto Nazionale Tumori di Napoli, IRCCS, Fondazione \"G. Pascale\", Napoli, Italy.", "Unit of Urology, ASST Santi Paolo e Carlo, Milan, Italy.", "Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands.", "Department of Urology, University of Cincinnati College of Medicine, Cincinnati, OH, USA.", "Department of Urology, Carolina Urologic Research Center, Myrtle Beach, SC, USA.", "Department of Urology, University of Rochester Medical Center, Rochester, NY, USA."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 28.47, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.47, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 4.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.4, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.47, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42791144", "title": "Individualized Oncologic Surveillance After Radical Prostatectomy for Localized Prostate Cancer.", "abstract": "The oncologic surveillance after radical prostatectomy (RP) remains poorly defined. To evaluate a model-derived, risk-adapted surveillance approach and estimate when the modeled OCM hazard exceeds the modeled recurrence hazard. Retrospective, population-based study including 11,552 patients undergoing RP. We developed a follow-up schedule based on the per-visit risk of biochemical recurrence (BCR) and high-risk BCR (HR-BCR), according to the EAU and EMBARK criteria, optimizing the number of PSA tests while maintaining the detection rate of the EAU schedule. Weibull regression was used to estimate model-derived time points at which OCM hazard exceeded recurrence hazard. Overall, 8,662 (75%) patients had adverse pathological features (pT3-4, pN1, positive surgical margins, and/or ISUP>2). Median follow-up among patients without recurrence was 90 months. The 5-year BCR-, EAU-HR-BCR-, EMBARK-HR-BCR-free survival probabilities were 78%, 91%, and 98% , respectively. Compared to the EAU schedule, adverse-feature patients required intensive follow-up in the first years (quarterly for 2 years, biannually up to 6 years), with de-intensification thereafter. Every 9 months visits were sufficient for favorable-feature patients. A similar pattern was observed for HR-BCR, but with a shorter intensive period (up to 3 years). The follow-up year when the hazard of BCR, EAU-HR-BCR, and EMBARK-HR-BCR became lower than the hazard of OCM ranged from 4-20+, 1-12, and 1-4 years, depending on disease characteristics, age, and comorbidity. Our results show that surveillance protocols should be individualized. We presented a post-RP surveillance strategy in which the intensity and duration of follow-up are based on the risk of BCR and OCM according to individual recurrence risk and competing mortality. Future studies are needed to validate this strategy before it can be implemented in clinical practice.", "journal": "European Urology Oncology", "pub_date": "2026-Sep-25", "publication_types": ["Journal Article"], "doi": "10.1016/j.euo.2026.09.009", "authors": ["Francesco Pellegrino", "Ugo Giovanni Falagario", "Ahmad Abbadi", "Axel Möller", "Fredrik Sundquist", "Andrea Camilloni", "Olof Akre", "Markus Aly", "Martin Eklund", "Tobias Nordström", "Anna Lantz", "Henrik Grönberg", "Peter N Wiklund"], "affiliations": ["Department of Molecular Medicine and Surgery (Solna), Karolinska Institutet, Stockholm, Sweden.", "Department of Molecular Medicine and Surgery (Solna), Karolinska Institutet, Stockholm, Sweden; Department of Urology and Kidney Transplantation, University of Foggia, Foggia, Italy. Electronic address: ugofalagario@gmail.com.", "Departments of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.", "Department of Molecular Medicine and Surgery (Solna), Karolinska Institutet, Stockholm, Sweden; Departments of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.", "Department of Molecular Medicine and Surgery (Solna), Karolinska Institutet, Stockholm, Sweden; Department of Urology, Icahn School of Medicine at Mount Sinai, New York, USA."], "corresponding_authors": ["Ugo Giovanni Falagario"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=6", "score": 36.42, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 15.42, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 6.0}, "journal_metrics": {"status": "ok", "impact_factor": 9.3, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.42, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42791106", "title": "Re: Valentina Tateo, Giuseppe Basile, Patrizia Giannatempo, et al. Updated 5-year Survival Results from PURE-01, a Phase 2 Study of Neoadjuvant Pembrolizumab Followed by Radical Cystectomy in Patients with Muscle-invasive Bladder Cancer. Eur Urol 2026;90:7-12.", "abstract": "", "journal": "European Urology", "pub_date": "2026-Sep-25", "publication_types": ["Letter"], "doi": "10.1016/j.eururo.2026.08.021", "authors": ["Ahmed M Elalfy"], "affiliations": ["Division of Medical Oncology, Arthur J.E. Child Comprehensive Cancer Centre, University of Calgary, Calgary, Canada. Electronic address: ahmed.elalfy@ucalgary.ca."], "corresponding_authors": ["Ahmed M Elalfy"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=3", "score": 42.79, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 16.79, "top_journal_bonus": 10.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 3.0}, "journal_metrics": {"status": "ok", "impact_factor": 25.2, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.79, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "帕博利珠单抗新辅助治疗肌层浸润性膀胱癌5年生存更新", "chinese_summary": "欧洲泌尿外科学会2026年9月25日刊发通讯，针对PURE-01二期研究更新5年生存结果提出评论，该研究评估肌层浸润性膀胱癌患者接受帕博利珠单抗新辅助治疗后行根治性膀胱切除术的疗效，为免疫治疗在该疾病中的应用提供长期随访证据。", "abstract_zh": "Re: Valentina Tateo, Giuseppe Basile, Patrizia Giannatempo, et al. Updated 5-year Survival Results from PURE-01, a Phase 2 Study of Neoadjuvant Pembrolizumab Followed by Radical Cystectomy in Patients with Muscle-invasive Bladder Cancer. Eur Urol 2026;90:7-12."}, {"pmid": "42790757", "title": "\"A Mixed-Methods Study of Patient Satisfaction and Experience After Same-Day Discharge for Holmium Laser Enucleation of the Prostate (HoLEP)\".", "abstract": "Same-day discharge (SDD) after holmium laser enucleation of the prostate (HoLEP) yields postoperative outcomes comparable to overnight admission (OA). However, the patient perspective on SDD has been largely overlooked. This study is the first to assess patient satisfaction and perceived experience after HoLEP, comparing SDD to OA. We performed a mixed-methods study of adults undergoing HoLEP at an academic medical center between 2018 and 2023. Participants from the prospective Registry of Bladder Outlet Obstruction (ReBOOT) completed the validated Surgical Satisfaction Questionnaire (SSQ-8). Fifteen patients from each discharge pathway (SDD and OA) were interviewed. Two blinded reviewers independently coded the interview transcripts and conducted thematic analysis using Dedoose. Of 413 patients, 257 responded (62%), including 146 (57%) OA and 111 (43%) SDD. Surgical satisfaction was similar between groups (84 vs 83.3, p=0.82). Positive experiences were driven by provider reassurance, individualized care, pathway familiarity, and caregiver support, whereas negative experiences reflected unmet expectations, unclear discharge education, and inadequate follow-up communication. Inadequate follow-up communication was more common among OA patients than SDD patients (87% vs 47%). SDD after HoLEP achieves patient satisfaction comparable to OA. However, surgical experiences in both pathways were significantly impacted by inadequate postoperative education, guidance, and recovery support, highlighting targets to implement SDD effectively.", "journal": "Urology", "pub_date": "2026-Sep-25", "publication_types": ["Journal Article"], "doi": "10.1016/j.urology.2026.09.052", "authors": ["Pablo A Suarez", "Siva Krothapalli", "Lynn Leng", "Feres Maluf", "Maria C Velasquez", "Wilson Sui", "Heiko Yang", "Justin Ahn", "Thomas Chi"], "affiliations": ["Department of Urology, University of California, San Francisco, San Francisco, CA, USA. Electronic address: pablo.suarez@ucsf.edu.", "Saint Louis University School of Medicine, St. Louis, MO, USA.", "Department of Urology, University of California, San Francisco, San Francisco, CA, USA.", "Department of Urology, University of Alabama at Birmingham, Birmingham, AL, USA.", "Presbyterian Healthcare Services, Rio Rancho, NM, USA.", "Department of Urology, University of Michigan Medical School, Ann Arbor, MI, USA.", "Department of Urology University of Colorado Anschutz Medical Campus, Aurora, CO, USA."], "corresponding_authors": ["Pablo A Suarez"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=7", "score": 31.61, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 5.61, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 7.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.0, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.61, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42789797", "title": "Utility of Men's Health Trained General Practitioners in a Urologic Men's Health Clinic.", "abstract": "", "journal": "Urology Practice", "pub_date": "2026-Sep-25", "publication_types": ["Journal Article"], "doi": "10.1097/UPJ.0000000000001097", "authors": ["Lourens M Jacobs", "Yool Ko", "Rachele Molyneaux", "Maximilian G Fidel", "Dhiraj S Bal", "Harliv Dhillon", "Connor Roque", "Jainik Shah", "Avinash Sarcar", "Premal Patel"], "affiliations": ["Section of Urology, Department of Surgery, University of Manitoba, Winnipeg, MB, Canada.", "Max Rady College of Medicine, University of Manitoba, Winnipeg, MB, Canada.", "Men's Health Clinic Manitoba, Winnipeg, MB, Canada."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 12.46, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 2.46, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 1.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 1.7, "cas_zone": 4, "cas_zone_points": 1.0, "impact_factor_points": 1.46, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42789190", "title": "Oncological and perioperative outcomes of robot-assisted radical cystectomy: a real-world cohort study emulating a target trial.", "abstract": "We tried to evaluate the comparative effectiveness of robot-assisted radical cystectomy (RARC) and open radical cystectomy (ORC) using nationwide real-world data within a target trial framework. Nationwide claims were used to identify individuals with bladder cancer who received transurethral resection during 2007-2020. Surgical strategies were defined according to receipt of RARC or ORC during a 1-year grace period. Cloning, censoring, and weighting were used to align treatment strategies from a common time zero and account for treatment-selection and immortal-time biases. The primary outcome was overall survival, with perioperative outcomes and healthcare expenditures examined secondarily. Among 45,595 eligible individuals, surgery within the grace period consisted of ORC in 3,681 and RARC in 358. Weighted analysis showed no evidence of a difference in overall survival (HR, 1.18; 95% CI, 0.96-1.45). Postoperative hospitalization was shorter with RARC than with ORC (18.4 vs. 22.5 days; P < 0.001), and transfusion was required in 51.1% and 70.6%, respectively (P < 0.001). RARC was associated with lower covered healthcare expenditure between surgery and discharge (P = 0.030), but cumulative expenditures at 2 and 5 years were comparable between groups. In this nationwide target trial emulation, assignment to RARC did not materially alter overall survival relative to ORC but yielded more favorable perioperative findings. These findings support RARC as a surgical alternative to ORC while highlighting the value of target trial emulation for evaluating real-world surgical outcomes.", "journal": "Journal of Robotic Surgery", "pub_date": "2026-Sep-25", "publication_types": ["Journal Article"], "doi": "10.1001/jamanetworkopen.2023.17255", "authors": ["Minseok Kim", "Jooyoung Lee", "Yu Seob Shin", "Tuan Thanh Nguyen", "Se Young Choi"], "affiliations": ["Department of Statistics and Data Science, Chung-Ang University, Seoul, Republic of Korea.", "Department of Applied Statistics, Chung-Ang University, Seoul, Republic of Korea.", "Department of Pharmacy and Biohealth Industry, Chung-Ang University, Seoul, Korea, Republic of.", "Department of Urology, Jeonbuk National University Medical School, Jeonju, Republic of Korea.", "Department of Urology, Cho Ray Hospital, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Viet Nam.", "Department of Urology, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Republic of Korea. urosyc@cau.ac.kr.", "MADI Inc., Seoul, Republic of Korea. urosyc@cau.ac.kr."], "corresponding_authors": ["Se Young Choi"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=5", "score": 33.03, "score_parts": {"urology_relevance": 12, "urology_in_title": 8.0, "journal_priority": 6.03, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 5.0}, "journal_metrics": {"status": "ok", "impact_factor": 3.0, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 2.03, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42789110", "title": "Association of time to upfront treatment initiation with outcomes in metastatic hormone-sensitive prostate cancer: a 4-month landmark analysis.", "abstract": "The clinical significance of variation in the timing of treatment intensification after androgen deprivation therapy (ADT) initiation in metastatic hormone-sensitive prostate cancer (mHSPC) remains unclear. We evaluated whether time to upfront treatment initiation was associated with outcomes in a multicenter cohort. In a retrospective study, we performed a 4-month landmark analysis in patients with mHSPC treated with upfront androgen receptor signaling inhibitor-based or taxane-containing regimens who had evaluable CRPC data and complete baseline covariates. The cohort included 1,103 patients, classified as earlier initiation (< 4 months from ADT start; n=1,036) or later initiation (≥ 4 months; n=67). CRPC-free survival (CRPC-FS) and overall survival (OS) were evaluated using Kaplan-Meier and inverse probability of treatment weighting (IPTW)-adjusted Cox analyses. Restricted cubic spline analyses examined the continuous association between treatment delay and outcomes. Sensitivity analysis used a 3-month landmark. In the 4-month landmark IPTW cohort, later initiation was not significantly associated with either CRPC-FS (hazard ratio [HR] 1.05, 95% confidence interval [CI] 0.80-1.37; p=0.737) or OS (HR 0.77, 95% CI 0.45-1.32; p=0.338). Delay distributions differed by regimen, with docetaxel-containing regimens showing longer intervals to upfront treatment. Adjusted spline analyses did not suggest a clear threshold at which longer delay was associated with marked deterioration in CRPC-FS or OS. Results were consistent in the 3-month landmark sensitivity analysis. Among patients who remained alive and CRPC-free at the 4-month landmark and ultimately received treatment intensification, later initiation was not significantly associated with CRPC-FS or OS.", "journal": "World Journal of Urology", "pub_date": "2026-Sep-25", "publication_types": ["Journal Article", "Multicenter Study"], "doi": "10.1007/s00345-026-06800-8", "authors": ["Eisuke Iwaori", "Takafumi Yanagisawa", "Shintaro Narita", "Wataru Fukuokaya", "Fumihiko Urabe", "Naoki Fujita", "Hiromi Sato", "Tomoko Hamaya", "Takuma Narita", "Teppei Okamoto", "Tomonori Habuchi", "Takahiro Kimura", "Shingo Hatakeyama"], "affiliations": ["Department of Urology, Hirosaki University Graduate School of Medicine, 5 Zaifu-Chou, Hirosaki, Aomori, 036-8562, Japan.", "Department of Urology, The Jikei University School of Medicine, Tokyo, Japan.", "Department of Urology, Akita University Graduate School of Medicine, Akita, Japan.", "Japanese Red Cross Osaka Hospital, Osaka, Japan.", "Department of Urology, Hirosaki University Graduate School of Medicine, 5 Zaifu-Chou, Hirosaki, Aomori, 036-8562, Japan. shingoh@hirosaki-u.ac.jp."], "corresponding_authors": ["Shingo Hatakeyama"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_clinical", "score": 34.0, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.0, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 10.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.9, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.0, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42789099", "title": "Heterogeneity in the perioperative management of asymptomatic bacteriuria across urological surgery: an international survey by the EAU-YAU Working Group on Infectious Diseases.", "abstract": "Asymptomatic bacteriuria (ABU) is frequent in patients scheduled for urological surgery, yet the evidence on whether, when and how to manage it perioperatively remains scarce. We aimed to map international practice patterns and identify priorities for future evidence generation. International, cross-sectional, anonymous, web-based survey developed by the EAU-YAU Working Group on Infectious Diseases. The 16-item questionnaire covered respondent demographics, general ABU management and procedure-specific management for up to three self-selected procedures from a list of nine. Dissemination occurred between March and July 2025 via social media and the EAU Annual Congress. Responses were analysed descriptively; subgroup comparisons by practice setting and experience used the χ² test. Of 123 accessed questionnaires, 101 (82%) were completed by urologists from 28 countries. Only 29% based their decision to obtain a preoperative urine culture on international guidelines. When ABU treatment was considered indicated, all six strategies offered were used, with preoperative initiation ranging from 1 to ≥ 7 days and postoperative extension from none (29%) to ≥ 7 days (18%). Heterogeneity was greatest for procedures carrying the highest infectious risk: 48% used a full pre-, peri- and postoperative regimen for retrograde intrarenal surgery (RIRS), 40% for transurethral prostate resection (TURP) and 43% for radical cystectomy. Respondents with ≤ 10 years of experience more often cited international guidelines (36% vs. 16%, p = 0.048). The observed variability likely reflects a genuine evidence gap. Aggregate antibiotic exposure may exceed what is evidence-based and contribute to antimicrobial resistance. Procedure-specific randomised trials are urgently needed.", "journal": "World Journal of Urology", "pub_date": "2026-Sep-25", "publication_types": ["Journal Article"], "doi": "10.1007/s00345-026-06797-0", "authors": ["Nico Christian Grossmann", "Clara Cerrato", "Elisa De Lorenzis", "Lobna Ali", "Elizabeth Day", "Eva Falkensammer", "Alex Quinyang Liu", "Rifat Burak Ergul", "Agostino Mattei", "Bhaskar Kumar Somani", "Jennifer Kranz", "Maxime Vallée", "Fabian Peter Stangl"], "affiliations": ["Clinic for Urology, University Teaching and Research Hospital of the University of Lucerne, Lucerne, Switzerland. nico.grossmann@gmail.com.", "Faculty of Health Sciences and Medicine, University of Lucerne, Lucerne, Switzerland. nico.grossmann@gmail.com.", "EAU Young Academic Urologist (YAU) Infections in Urology Working Group, Arnhem, The Netherlands. nico.grossmann@gmail.com.", ", 16 Spitalstrasse, Lucerne, 6000, Switzerland. nico.grossmann@gmail.com.", "EAU Young Academic Urologist (YAU) Infections in Urology Working Group, Arnhem, The Netherlands.", "Department of Urology, Nottingham University Hospitals NHS Trust, Nottingham, UK.", "Department of Urology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.", "Department of Urology, Evangelical Clinic Bethel, Bielefeld, Germany.", "Department of Urology, Ayr University Hospital, Ayrshire, UK.", "Department of Urology, General Hospital Wels-Grieskirchen, Wels, Austria.", "Department of Pediatric Surgery, Salzburg University Hospital, Paracelsus Medical University, Salzburg, Austria.", "Division of Urology, Department of Surgery, The Chinese University of Hong Kong, Hong Kong, China.", "Department of Urology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.", "EAU Young Academic Urologists (YAU) Endourology and Urolithiasis Group, Arnhem, The Netherlands.", "Clinic for Urology, University Teaching and Research Hospital of the University of Lucerne, Lucerne, Switzerland.", "Faculty of Health Sciences and Medicine, University of Lucerne, Lucerne, Switzerland.", "Department of Urology, University Hospital Southampton NHS Trust, Southampton, UK.", "Department of Urology and Pediatric Urology, RWTH Aachen University, Aachen, Germany.", "Department of Urology and Kidney Transplantation, Martin-Luther-University, Halle, Germany.", "Département d'urologie et de transplantation rénale, Centre Hospitalier Universitaire, 2 rue de la Milétrie, Poitiers, F-86000, France.", "Université de Poitiersunité INSERM U1070, PHAR2, Poitiers, F-86000, France.", "Department of Urology and Pediatric Urology, Faculty of Medicine, University Hospital Wuerzburg, Julius-Maximilians University Wuerzburg, Wuerzburg, Germany.", "Department of Urology, University Hospital Salzburg, Paracelsus Medical University, Salzburg, Austria."], "corresponding_authors": ["Nico Christian Grossmann"], "china_team": "EAU Young Academic Urologist (YAU) Infections in Urology Working Group, Arnhem, The Netherlands Alex Quinyang Liu团队", "category": "clinical_review", "classification_reason": "clinical_signals=4", "score": 40.0, "score_parts": {"urology_relevance": 16, "urology_in_title": 8.0, "journal_priority": 10.0, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 4.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.9, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.0, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42789055", "title": "Reference values for PSA, PSA density, and MRI prostate volume in healthy German men.", "abstract": "To establish stratified normative reference values for MRI-derived prostate volume (PV), prostate-specific antigen (PSA), and PSA density (PSAD) in German men with no known prostate pathologies, accounting for age, body-mass index, and height. This study included men from the prospective population-based Study of Health in Pomerania, Germany, with 10 years of follow-up. Men with diagnosed prostate cancer, benign prostatic hyperplasia, or lower urinary tract symptoms were excluded to derive reference values unaffected by disease or interventions. PV and PSAD were obtained from pelvic MRI using deep-learning segmentation. In a test set, segmentation-derived volumes were compared with manual PVs. PV, PSA, and PSAD were modeled using generalized additive models for location, scale, and shape (GAMLSS). Out of 1696 men, 1037 were analyzed (median age 46.00 years [IQR 38.00-56.00]). Median PV was 31.29 mL (5th-95th: 20.74-51.39), PSA 0.81 ng/mL (0.32-2.79), and PSAD 0.025 ng/mL² (0.011-0.071). PV and PSA increased progressively with age, whereas PSAD showed greater age-stability, peaking at 71 years, plateauing until 75, and then declining. Age-adjusted PSAD never exceeded 0.11 ng/mL², unlike PSA, which rose continuously. Body-mass index correlated positively with PV but inversely with PSAD; PSA showed a negative association with height. This study provides reference values and percentile curves for PV, PSA, and PSAD in men without prostate disease, along with an open-access calculator. PSAD showed age-stability, contrasting with continuously rising PSA. These reference values may help distinguish normal from pathological prostatic variation across age strata and inform PSAD thresholds in screening programs. Question Population-based reference values with long-term follow-up for PV, PSA, and PSAD are lacking, limiting the distinction between normal variation and disease-related changes. Findings Among 1037 men without prostate disease, 95th percentiles were: PV 51.39 mL, PSA 2.79 ng/mL, and PSAD 0.071 ng/mL². PSAD remained below 0.11 ng/mL² across all age ranges. Clinical relevance MRI-based percentiles for PV and PSAD may help identify normal variation, reducing unnecessary evaluations while supporting early detection of abnormalities. An open-access calculator enables personalized assessment for clinical and research purposes.", "journal": "European Radiology", "pub_date": "2026-Sep-25", "publication_types": ["Journal Article"], "doi": "10.1148/radiol.233337", "authors": ["Maximilian Lindholz", "Ivo G Schoots", "Robin Bülow", "Patrick Asbach", "Marc Kölln", "Saskia Nolte", "Salina Alaro", "Richard Ruppel", "Norbert Hosten", "Tobias Penzkofer", "Charlie A Hamm"], "affiliations": ["Department of Radiology, Charité Universitätsmedizin Berlin, Berlin, Germany.", "Berlin Institute of Health, Berlin, Germany.", "Department of Radiology and Nuclear Medicine, Erasmus MC University Medical Center, Rotterdam, The Netherlands.", "Institute of Diagnostic Radiology and Neuroradiology, University Medicine Greifswald, Greifswald, Germany.", "Department of Radiology, Charité Universitätsmedizin Berlin, Berlin, Germany. charlie.hamm@charite.de.", "Berlin Institute of Health, Berlin, Germany. charlie.hamm@charite.de."], "corresponding_authors": ["Charlie A Hamm"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=3", "score": 34.55, "score_parts": {"urology_relevance": 11, "urology_in_title": 8.0, "journal_priority": 10.55, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 3.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.7, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.55, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42788388", "title": "Sensing in Sacral Neuromodulation: Objective, Individualized Stimulation Response Thresholds Directly From the Lead.", "abstract": "Sacral neuromodulation (SNM) therapy today relies on visually observed motor responses (e.g., anal bellows contraction, toe flexion) and subjective patient feedback (pelvic region sensations) to optimize lead placement and perform device programming. Measures of sacral nerve activation used in current practice include motor and sensory thresholds, described as the stimulation amplitudes associated with first observed or reported stimulation responses. This study evaluated the utility of sacral evoked responses (SERs), recorded directly from implanted commercial SNM leads, as objective indicators of sacral nerve activation. The PEER 2 Cohort 1 study was a multi-center, prospective, clinical feasibility study in female overactive bladder patients undergoing a tined lead evaluation for SNM using InterStim™ SureScan™ MRI leads. An investigational external neurostimulator was used to collect electrophysiological signal recordings directly from the implanted lead (SER recordings), in addition to motor and sensory thresholds at three timepoints: intraoperatively (OR), immediately postoperatively (PO), and at the end of therapy evaluation (Trial End). SER recordings were processed to determine stimulation amplitudes associated with first detectable signal (SER threshold, SERT) and analyzed for comparison with the motor and sensory thresholds. Lead-recorded SERs were reliably detected across subjects and timepoints: OR: 100% (89/89 subjects); PO 98.9% (87/88 subjects); Trial End: 97.7% (86/88 subjects). SERTs demonstrated statistically significant correlation with both motor and sensory thresholds across six bipolar electrode configurations (R = 0.46-0.92; p < 0.001). Compared to sensory thresholds, SERTs were a more sensitive measure of sacral nerve activation, detected at or below sensory thresholds in 57%-84% of subjects. SERTs also exhibited less variability across repeated measurements compared to sensory thresholds (p < 0.001). Replicate SERTs showed no change in 55.9% of subjects, whereas sensory thresholds showed no change in only 20.6% of subjects. The study results demonstrate that SERs recorded from SNM leads are reliably detected, clinically relevant, sensitive, and consistent markers of sacral nerve activation, offering an objective alternative to present-day subjective measures. Integrating lead-sensed SERs may streamline SNM programming and lead placement, introducing a simplified and standardized measure for optimizing and delivering patient-specific SNM therapy. ClinicalTrials.gov NCT05200923. Investigational device. Limited by Federal (U.S.) law to investigational use. The research system and sensing feature are not approved by the FDA or any other regulatory authority and are not for sale in the US or internationally.", "journal": "Neurourology and Urodynamics", "pub_date": "2026-Sep-25", "publication_types": ["Journal Article"], "doi": "10.1002/nau.70443", "authors": ["Colin Goudelocke", "Henry Ruiz", "Charles R Powell", "David Sheyn", "Brian J Linder", "Ketul Shah", "Gustavo Villegas", "Joseph Henderson", "Anne G Sammarco", "Sarah J Offutt", "David U J Keller", "Katie C Bittner", "Hank Bink", "Ivan Merlo", "Julia P Slopsema", "Lisa Jungbauer Nikolas"], "affiliations": ["Ochsner Medical Center Department of Urology, New Orleans, Louisiana, USA.", "DHR Health Urology Institute, Edinburg, Texas, USA.", "Indiana University School of Medicine, Indianapolis, Indiana, USA.", "University Hospitals, Cleveland, Ohio, USA.", "Mayo Clinic, Rochester, Minnesota, USA.", "OhioHealth, Doctors Hospital, Columbus, Ohio, USA.", "Medtronic Pelvic Health, Minneapolis, Minnesota, USA.", "Medtronic Neurovascular Medical Sciences, Irvine, California, USA.", "Medtronic Clinical & Regulatory Solutions, Rome, Italy."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=6", "score": 18.56, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 5.56, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 6.0}, "journal_metrics": {"status": "ok", "impact_factor": 1.9, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.56, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42788385", "title": "Letter to the Editor on \"Differences Between Men and Women With Urinary Incontinence as They Seek Medical Care\".", "abstract": "", "journal": "Neurourology and Urodynamics", "pub_date": "2026-Sep-25", "publication_types": ["Letter"], "doi": "10.1002/nau.70462", "authors": ["N V L Suvarchala Reddy", "Praveen Kumar Annagowni", "M Lakshmi Madhuri"], "affiliations": ["Pharmacology, Gokaraju Rangaraju College of Pharmacy, Hyderabad, India.", "Product Development and Technical Services, Middlesex, New Jersey, USA.", "Pharmaceutical Chemistry, Gokaraju Rangaraju College of Pharmacy, Hyderabad, India."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 17.56, "score_parts": {"urology_relevance": 7, "urology_in_title": 8.0, "journal_priority": 5.56, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 1.9, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.56, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42786067", "title": "Re: Agne Krilaviciute, Nikolaus Becker, Sigrid V. Carlsson, et al. Confirmation of Prostate-specific Antigen (PSA) Values Improves Prostate Cancer Screening in Early Middle-aged Men - Data from the PROBASE Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2026.06.016.", "abstract": "", "journal": "European Urology", "pub_date": "2026-Sep-25", "publication_types": ["Letter"], "doi": "10.1016/j.eururo.2026.08.022", "authors": ["Ola Bratt", "Anna Lantz", "Rebecka Arnsrud Godtman"], "affiliations": ["Department of Urology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Department of Urology, Sahlgrenska University Hospital, Gothenburg, Sweden. Electronic address: ola.bratt@gu.se.", "Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.", "Department of Urology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Department of Urology, Sahlgrenska University Hospital, Gothenburg, Sweden."], "corresponding_authors": ["Ola Bratt"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 35.79, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 16.79, "top_journal_bonus": 10.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 25.2, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.79, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "PSA复测提升早中年男性筛查准确性", "chinese_summary": "9月Eur Urol刊发通讯，针对PROBASE试验数据指出，对早中年男性前列腺特异性抗原初筛异常者进行数值确认复测，可减少假阳性并改善前列腺癌筛查效率，为优化筛查流程提供依据。", "abstract_zh": "Re: Agne Krilaviciute, Nikolaus Becker, Sigrid V. Carlsson, et al. Confirmation of Prostate-specific Antigen (PSA) Values Improves Prostate Cancer Screening in Early Middle-aged Men - Data from the PROBASE Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2026.06.016."}, {"pmid": "42851471", "title": "Combination of mesenchymal stem cells and cidofovir for the treatment of BK virus-associated late-onset hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation: a case report.", "abstract": "This case report describes a 22-year-old female patient who developed refractory grade IV BK virus-associated late-onset hemorrhagic cystitis (HC) on day 69 following haploidentical hematopoietic stem cell transplantation. After conventional stepwise interventions-including bladder irrigation, repeated transcatheter arterial embolization, and endoscopic electrocoagulation-failed to achieve disease control, a combination regimen comprising umbilical cord-derived mesenchymal stem cells (MSCs) and intravenous cidofovir was administered on day 84 post-transplant. Following this combined therapy, the patient's bladder hemorrhage was progressively controlled, dysuria was relieved, and transfusion requirements decreased. Macroscopic hematuria began to decrease on day 98 post-transplant and resolved completely by day 124, accompanied by a marked decline in BK viral load during follow-up. This case suggests that the combination of MSCs and cidofovir may serve as a potential salvage strategy for severe, refractory virus-associated HC and may also offer ancillary benefit in promoting hematopoietic recovery.", "journal": "Frontiers in Medicine", "pub_date": "2026", "publication_types": ["Case Reports", "Journal Article"], "doi": "10.3760/cma.j.issn.0253-2727.2022.06.008", "authors": ["Feifei Liu", "Cheng Zhang", "Huaping Du"], "affiliations": ["Department of Hematology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China."], "corresponding_authors": [], "china_team": "Department of Hematology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China Huaping Du团队", "category": "clinical_review", "classification_reason": "publication_type_clinical", "score": 14.03, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 6.03, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 2.0}, "journal_metrics": {"status": "ok", "impact_factor": 3.0, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 2.03, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42851436", "title": "Multimodal characterization of HLA-G expression across solid tumors reveals transcript-protein discordance and implications for immunotherapy targeting.", "abstract": "Human leukocyte antigen-G (HLA-G) is a non-classical major histocompatibility complex class I molecule that functions as an immune checkpoint via inhibitory receptors such as immunoglobulin-like transcript 2 (ILT2), immunoglobulin-like transcript 4 (ILT4) and killer cell immunoglobulin-like receptor 2DL4 (KIR2DL4), suppressing anti-tumor immunity. Its prevalence and regulation across solid tumors remain incompletely defined due to low expression, spatial heterogeneity, and detection challenges. We performed a multimodal target prevalence analysis integrating data from a validated immunohistochemistry (IHC) assay for protein detection and prospective screening data from a phase 1 study of an HLA-G × CD3 T cell bispecific antibody (Clintrials.gov identifier: NCT05769959) with bulk RNA sequencing from early-phase oncology clinical trials. Analysis of 252 patient tumor samples using an investigational HLA-G IHC assay showed that 59.9% were HLA-G positive, with highest prevalence in ovarian cancer (89%), non-small cell lung cancer (NSCLC) (76%), renal cell carcinoma (RCC) (71%), and pancreatic cancer (70%). Expression was generally low to moderate and spatially heterogeneous. Notably, discordance between transcript and protein expression was observed in melanoma, where high mRNA levels were not matched by detectable protein, suggesting post-transcriptional regulation. Prospective screening in a phase 1 cohort confirmed a high target positivity rate (77.5%). At the transcript level, HLA-G expression was enriched in inflamed tumors and correlated with interferon gamma (IFN-γ) signaling, antigen presentation pathways, and effector T-cell markers including cluster of differentiation 8 alpha (CD8A), interferon gamma gene (IFNG) and granzyme B (GZMB). HLA-G appears to be an inducible immune checkpoint associated with IFN-γ-driven immune activation and adaptive resistance. Transcript-protein discordance and spatial heterogeneity highlight the need for protein-level assessment in biomarker development. These findings inform companion diagnostic strategies for HLA-G-directed immunotherapies.", "journal": "Frontiers in Immunology", "pub_date": "2026", "publication_types": ["Journal Article"], "doi": "10.3389/fimmu.2020.01685", "authors": ["Alexandra Epp", "Martha L Serrano-Serrano", "Florian Heil", "Meher Majety", "Abraham Silva", "Julie Cheung", "Mert Colpan", "Nitya Nair"], "affiliations": ["Roche Pharma Research and Early Development, Early Development Oncology, Roche Innovation Center Munich, Penzberg, Germany.", "Roche Pharma Research and Early Development, Early Development Oncology, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland.", "Roche Pharma Research and Early Development, Discovery Oncology, Roche Innovation Center Munich, Penzberg, Germany.", "Pharma Services Assay Development, Roche Tissue Diagnostics, Oro Valley, AZ, United States."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "basic_signals=8", "score": 25.33, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 10.83, "top_journal_bonus": 0.0, "novelty": 0.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 8.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 5.9, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.83, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "实体瘤HLA-G表达存在转录蛋白不一致", "chinese_summary": "2026年Front Immunol整合免疫组化与早期临床试验RNA测序数据，在252例实体瘤样本中检出HLA-G阳性率59.9%，以卵巢癌、非小细胞肺癌、肾癌和胰腺癌最高，黑色素瘤中mRNA高表达却无蛋白检出，提示需以蛋白水平指导HLA-G靶向免疫治疗。", "abstract_zh": "人类白细胞抗原-G（HLA-G）是一种非经典主要组织相容性复合体I类分子，通过免疫球蛋白样转录本2（ILT2）、免疫球蛋白样转录本4（ILT4）和杀伤细胞免疫球蛋白样受体2DL4（KIR2DL4）等抑制性受体发挥免疫检查点功能，抑制抗肿瘤免疫。由于表达低、空间异质性及检测困难，其在实体瘤中的流行率和调控机制仍未完全明确。我们开展了一项多模态靶点流行率分析，整合了经过验证的用于蛋白检测的免疫组化（IHC）检测数据、一项HLA-G×CD3 T细胞双特异性抗体1期研究（Clintrials.gov标识符：NCT05769959）的前瞻性筛选数据，以及来自早期肿瘤学临床试验的批量RNA测序数据。使用研究性HLA-G IHC检测对252例患者肿瘤样本的分析显示，59.9%为HLA-G阳性，其中卵巢癌（89%）、非小细胞肺癌（NSCLC）（76%）、肾细胞癌（RCC）（71%）和胰腺癌（70%）的阳性率最高。表达通常为低至中等水平，且呈空间异质性。值得注意的是，在黑色素瘤中观察到转录本与蛋白表达不一致，高mRNA水平未匹配到可检测的蛋白，提示存在转录后调控。1期队列的前瞻性筛选确认了较高的靶点阳性率（77.5%）。在转录水平上，HLA-G表达富集于炎症性肿瘤，并与干扰素γ（IFN-γ）信号通路、抗原呈递通路以及效应T细胞标志物相关，包括分化簇8α（CD8A）、干扰素γ基因（IFNG）和颗粒酶B（GZMB）。HLA-G似乎是一种可诱导的免疫检查点，与IFN-γ驱动的免疫激活和适应性耐药相关。转录本-蛋白不一致和空间异质性凸显了在生物标志物开发中进行蛋白水平评估的必要性。这些发现为HLA-G导向的免疫疗法的伴随诊断策略提供了信息。"}, {"pmid": "42806761", "title": "Distinct connectivity patterns subserve 2 dimensions of the chronic pain experience.", "abstract": "Identifying the neural correlates of chronic pain and their relationship to clinically relevant measures of disease has proven challenging due to high variability in individual patterns of functional brain connectivity and the rarity of ecologically valid scanning paradigms. Here, we address these limitations using data from the Multidisciplinary Approach to the Study of Pelvic Pain Symptom Patterns Study, which recruited a large sample of urologic chronic pain patients (n = 382) imaged repeatedly (range = 2-4) over 36 months. Intrinsic brain connectivity was recorded before and after a naturalistic challenge designed to elicit symptomatic pain and discomfort. Linear mixed-effects models revealed 2 neuroanatomically distinct patterns: pain at the time of scan was linked to connectivity within sensory-discriminative regions, while past-week recalled pain was associated with distributed patterns across regions implicated in memory, salience, and affective processing. These findings emphasize the dynamic roles of brain regions for different aspects of chronic pain.", "journal": "Pain", "pub_date": "2026-Sep-24", "publication_types": ["Journal Article"], "doi": "10.5281/ZENODO.6834519", "authors": ["Natalie J McLain", "Chelsea M Kaplan", "Bruce D Naliboff", "Larissa Rodriguez", "Robert Moldwin", "David A Williams", "John T Farrar", "Richard E Harris", "Theresa Spitznagle", "Daniel Clauw", "J Quentin Clemens", "Steven E Harte", "Jason J Kutch", "Andrew Schrepf"], "affiliations": ["Chronic Pain and Fatigue Research Center, Department of Anesthesiology, University of Michigan Medical School, Ann Arbor, MI, United States.", "G. Oppenheimer Center for Neurobiology of Stress and Resilience, Vatche and Tamar Manoukian Division of Digestive Diseases, David Geffen School of Medicine at the University of California, Los Angeles, CA, United States.", "Department of Urology, Weill Cornell Medicine, New York, NY, United States.", "Northwell Health, Department of Urology, New Hyde Park, NY, United States.", "Zucker School of Medicine at Hofstra-Northwell, Hempstead, NY, United States.", "Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, PA, United States.", "Susan Samueli Integrative Health Institute, School of Medicine, University of California at Irvine, Irvine, CA, United States.", "Department of Anesthesiology and Perioperative Care, School of Medicine, University of California at Irvine, Irvine, CA, United States.", "Department of Physical Therapy, Washington University in St. Louis, St. Louis, MO, United States.", "Department of Urology, University of Michigan Medical School, Ann Arbor, MI, United States.", "Division of Biokinesiology and Physical Therapy, University of Southern California, Los Angeles, CA, United States."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 20.75, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 14.75, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 5.5, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 2.75, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42786763", "title": "Intrarenal Antibiotic Irrigation During Percutaneous Nephrolithotomy Reduces Postoperative Infections and Eliminates Sepsis in High-Risk Patients: A Matched Cohort Study.", "abstract": "To evaluate whether intrarenal antibiotic-augmented irrigation with neomycin/polymyxin B during percutaneous nephrolithotomy (PCNL) in patients at high risk for infection was associated with lower postoperative infectious complications and reduced infection-related resource utilization. We performed a single-center, retrospective matched cohort study of adults undergoing PCNL who were at high risk for infection between January 2020 and December 2024. Fifty patients who received intrarenal neomycin/polymyxin B irrigation (1 mL GU irrigant per 3-L saline bag) were matched 1:1 to controls receiving standard saline irrigation by age, sex, diabetes, Charlson Comorbidity Index, and preoperative urinary drainage. The primary end-point was symptomatic urinary tract infection (UTI) within 30 days. Secondary outcomes included systemic inflammatory response syndrome (SIRS), sepsis during index hospitalization, infection-related prolonged hospitalization, emergency department visits for infection, and 30-day infection-related readmission. Thirty-day UTI occurred in 3/50 patients (6.0%) in the GU group vs 17/50 (34.0%) in controls (number needed to treat 3.6; p = 0.001). SIRS occurred in 16.0% vs 48.0% (p = 0.001), sepsis during index hospitalization in 0% vs 16.0% (p = 0.006), and infection-related prolonged hospitalization in 0% vs 20.0% (p = 0.001). In adjusted analysis (n = 99), GU irrigation remained independently associated with lower 30-day UTI risk (adjusted OR 0.11, 95% CI 0.03-0.44; p = 0.002). Short-term renal safety outcomes were comparable between groups. Modeled economic analysis suggested potential net savings of approximately $7800 per patient. In this matched cohort of PCNL patients at high risk for infection, intrarenal neomycin/polymyxin B irrigation was associated with substantially lower postoperative infectious morbidity, including elimination of sepsis during index hospitalization, with comparable short-term renal safety outcomes.", "journal": "Journal of Endourology", "pub_date": "2026-Sep-24", "publication_types": ["Journal Article"], "doi": "10.1177/08927790261491575", "authors": ["Pengbo Jiang", "Bruce M Gao", "Harel C Sims", "Kriselle Madamba", "Kyle A Bociort", "Seyedamirvala Saadat", "Elliott Freudenburg", "Gustavo Gryzinski", "Aymon Ali", "Ryan Hsi", "Roshan M Patel", "Jaime Landman", "Ralph V Clayman"], "affiliations": ["University of California, Irvine, Orange, California, USA.", "Florida Atlantic University, Boca Raton, Florida, USA."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=6", "score": 24.96, "score_parts": {"urology_relevance": 7, "urology_in_title": 0.0, "journal_priority": 9.96, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 6.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 1.96, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42786757", "title": "Are Endourologists More Likely to Definitively Treat Symptomatic Stones at Initial Presentation?", "abstract": "Ureteral stones are a common cause of emergency presentations. Definitive stone removal at the index encounter can reduce delays and repeat interventions. It is unknown whether fellowship-trained endourologists are more likely to perform definitive management than general/other subspecialist urologists. This multicenter retrospective cohort study evaluated the influence of endourology subspecialty training on the choice between upfront definitive stone treatment and initial ureteral decompression at first presentation. Patients managed with medical expulsive therapy alone were not included. Adults (≥18 years) presenting at 2022 to seven North American academic centers with symptomatic, noninfected, computed tomography-confirmed ureteral stones were included. Patients with infection, sepsis, positive nitrites, or intraoperative pyelonephritis were excluded from the study. Variables included demographics, stone size and location, subspecialty of the on-call urologist, and management type (definitive [ureteroscopy or shockwave lithotripsy] vs deferred [(initial stent]). Multivariate logistic regression was used to identify the predictors of definitive treatment. Among the 395 patients, 190 (48.0%) underwent definitive management and 205 (52.0%) underwent deferred treatment. Distal stones were treated definitively more often than proximal stones were (51.1% vs 36.6%). An endourologist was on call for 150 encounters (38.0%); 64.7% of these patients received definitive treatment, compared with 38.0% under general/other subspecialist urologists. On multivariate analysis, endourologist on-call remained independently associated with definitive management (odds ratio [OR] 3.46, 95% confidence interval [CI] 2.19-5.47, p < 0.0001), as did distal stone location (OR: 2.46, 95% CI: 1.21-5.00, p = 0.013). Severe complications are rare, and none of the patients developed sepsis. Endourologists were more than three times more likely to perform definitive interventions for symptomatic, noninfected ureteral stones at initial presentation. Subspecialty expertise and timely operative access enable safe, efficient, single-stage management.", "journal": "Journal of Endourology", "pub_date": "2026-Sep-24", "publication_types": ["Journal Article"], "doi": "10.1177/08927790261492126", "authors": ["Mouneeb M Choudry", "Christopher C Ballantyne", "Ashley Vaughan", "Victoria S Edmonds", "Jackson Cabo", "Kimberly Maciolek", "Srinath-Reddi Pingle", "Harrison M Drebin", "Runhan Ren", "Cesar Delgado", "Joanna Langner", "Dominic Franceschelli", "Ethan Mills", "Othmane Zekraoui", "Michelle Taillefer", "Bodo Knudsen", "Ojas Shah", "Nicholas L Kavoussi", "Ben H Chew", "Roger Sur", "Naeem Bhojani", "Mitchell R Humphreys", "Karen L Stern"], "affiliations": ["Department of Urology, Mayo Clinic Arizona, Phoenix, Arizona, USA.", "Department of Urology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.", "Department of Urology, Columbia University Medical Center, New York, New York, USA.", "Vagelos College of Physicians and Surgeons, Columbia University, New York, New York, USA.", "Department of Urologic Sciences, University of British Columbia, Vancouver, Canada.", "Department of Urology, University of California San Diego, San Diego, California, USA.", "University of California San Diego School of Medicine, San Diego, California, USA.", "The Ohio State College of Medicine, Columbus, Ohio, USA.", "Faculté de médecine de L'Univserité de Montréal, Montreal, Canada.", "Division of Urology, Centre Hospitalier de L'Université de Montréal, Montreal, Canada.", "Department of Urology, Ohio State University, Columbus, Ohio, USA."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=9", "score": 37.96, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 9.96, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 9.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 1.96, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42786595", "title": "Critical appraisal of combination therapies: the impact of trial design on Benefit-Risk outcomes.", "abstract": "Combination therapies are widely used in oncology due to their potential to improve therapeutic efficacy and overcome drug resistance. However, these potential advantages must be weighed against added toxicity, treatment burden, and costs. In this commentary, we examine some recent examples of divergent opinions by the US Food and Drug Administration and the European Medicines Agency across three indications. In neuroendocrine tumours, NETTER-2 demonstrated that early treatment intensification may improve progression-free survival. However, the higher toxicity, the absence of a demonstrated overall survival or quality of life benefit, and several important design limitations, including the open-label design and a potentially suboptimal control arm, complicate the interpretation of the results. In pleural mesothelioma, CheckMate-743 and KEYNOTE-483 did not prospectively evaluate biologically distinct histological or biomarker-defined subgroups, contributing to uncertainty regarding the populations most likely to benefit. In prostate cancer, the MAGNITUDE trial illustrates how prospectively defined adjacent cohorts, hierarchical testing, and subgroup-specific futility rules can more efficiently identify patients deriving meaningful benefit. Although it is often assumed that adjacent subgroup designs require larger sample sizes, MAGNITUDE challenges this misconception, having enrolled fewer patients than PROpel or TALAPRO-2. These cases illustrate how trial design influences the interpretation of benefit-risk outcomes, particularly when studies rely on broad trial populations, open-label designs, suboptimal control arms, or insufficiently powered subgroup analyses. Future trials of combination therapies should move beyond demonstrating regimen-level efficacy. Efforts must focus on identifying which patients benefit, whether each component is needed, and whether the added toxicity, treatment burden, and costs are justified.", "journal": "Journal of the National Cancer Institute", "pub_date": "2026-Sep-24", "publication_types": ["Journal Article"], "doi": "10.1093/jnci/djag343", "authors": ["Floor de Jong", "Li-Anne H Douma", "Paul Baas", "Cornedine J de Gooijer", "Hans Gelderblom", "Jacobus A Burgers", "Sahar Barjesteh van Waalwijk van Doorn-Khosrovani"], "affiliations": ["Department of Medical Oncology, Leiden University Medical Centre, Leiden, the Netherlands.", "Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.", "CZ Health Insurance, Tilburg, the Netherlands."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=8", "score": 29.59, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 15.09, "top_journal_bonus": 0.0, "novelty": 0.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 8.0}, "journal_metrics": {"status": "ok", "impact_factor": 7.2, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.09, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42786421", "title": "Male infertility research for the ART clinic: priorities to enhance patient outcomes, education and wellbeing.", "abstract": "Men attending ART clinics often have poor fertility awareness and are typically overlooked for psychological support. Recent developments in understanding the link between sub-fertility, healthspan and lifespan enforce the need for comprehensive health assessments of men attending ART clinics. Evidence now suggests paternal factors including genetics, epigenetics, paternal age, oxidative stress and DNA damage contribute to embryo development and the health of the offspring. With the described decline in global sperm counts, overall male reproductive health and the increased utilisation of ART, it is imperative that research focuses on improving ART protocols for male factor infertility and investigates novel treatments for patients. Sperm contributions in ART are often overlooked, leading to optimisation of the clinical environment to focus on oocytes and embryos. Research into improving ART protocols for sperm is growing, but the clinical implementation has been slow. In parallel, current treatment options for male infertility are limited to procedures like ICSI, which bypass the underlying physiological causes of infertility. Ongoing research into sperm in clinical settings, as well as better patient psychosocial care, is therefore key to improving patient outcomes and wellbeing. This review aims to evaluate the current standing of male reproductive health management in ART clinics with a unique focus on integrated patient care from men's fertility awareness, through to psychosocial support and targeted education. Additionally, this review aims to identify major barriers that currently prevent rapid integration of novel technologies for male infertility diagnostics and treatments into ART clinics. PubMed searches were performed to identify peer-reviewed articles and reviews using the following terms: 'sperm preparation/selection', 'male reproductive health', 'male infertility', 'diagnostics', 'cryopreservation', 'ART', 'fertility education', 'fertility awareness', 'artificial intelligence', and 'sperm' in combination with other key words related to the subject. No restriction was placed on date; all relevant studies up until March 2026 were evaluated and discussed. References within articles were also searched. In an ART setting, men rarely receive routine healthcare follow-up after providing a sample for assisted reproduction. Through integration of several underrepresented aspects of male health care, this review concludes that male reproductive health should be managed more collaboratively by medical specialists, including general practitioners, urologists, endocrinologists and andrologists, to understand the underlying cause of male infertility and determine an appropriate treatment. Moreover, this review finds that the integration of mental health professionals into the ART clinic environment is urgently needed to ensure appropriate counselling and care for people during and following fertility treatment. Finally, we determined that a lack of direct collaboration between researchers and clinical practitioners may be partly responsible for the slow uptake of novel technologies into the ART clinic. Further research needs to be undertaken to improve public health messaging and education for men about their fertility. An overarching theme identified by this review is the need for targeted collaboration between research scientists and clinicians to improve men's reproductive care, in turn, culminating in faster clinical adoption of beneficial techniques and products to improve patient outcomes. This review highlights an urgent need for more integrated models of fertility care that extend from men's fertility awareness and education, through to improvements of 'in clinic' appraisal of the underlying causes of male infertility, and finally, better inclusion of men's psychosocial support into reproductive care. n/a.", "journal": "Human Reproduction Update", "pub_date": "2026-Sep-24", "publication_types": ["Journal Article"], "doi": "10.1093/humupd/dmag027", "authors": ["Georgia A Bennett", "Shannon P Smyth", "David K Gardner", "Elizabeth G Bromfield"], "affiliations": ["School of Biosciences, Faculty of Science, Bio21 Institute, The University of Melbourne, Parkville, Victoria, Australia.", "Melbourne IVF, Collingwood, Victoria, Australia.", "Reproductive and Family Health Research Program, Hunter Medical Research Institute, New Lambton Heights, New South Wales, Australia.", "Centre for Reproductive Science, School of Science, College of Engineering, Science and Environment, University of Newcastle, Callaghan, New South Wales, Australia."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=4", "score": 49.17, "score_parts": {"urology_relevance": 7, "urology_in_title": 8.0, "journal_priority": 16.17, "top_journal_bonus": 10.0, "novelty": 2, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 4.0}, "journal_metrics": {"status": "ok", "impact_factor": 16.1, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.17, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "男性生育关怀亟需整合照护", "chinese_summary": "Human Reproduction Update最新综述指出，辅助生殖机构中男性常缺乏生育认知与心理支持，且取精后鲜获随访。综述认为应将全科、泌尿、内分泌及男科协作管理男性生殖健康，并将心理专业人员纳入ART流程，同时加强研究者与临床医师协作以加速新技术落地。", "abstract_zh": "前往辅助生殖技术（ART）诊所就诊的男性往往生育认知水平较低，且通常在心理支持方面被忽视。近期对亚生育力与健康寿命及寿命之间联系的深入认识，强化了对ART诊所就诊男性进行全面健康评估的必要性。现有证据提示，父源因素包括遗传、表观遗传、父亲年龄、氧化应激和DNA损伤，均对胚胎发育及子代健康产生影响。随着全球精子计数下降、男性整体生殖健康恶化以及ART使用增加，研究必须聚焦于改进针对男性因素不育的ART方案，并探索针对患者的新型治疗。ART中精子的贡献常被忽视，导致临床环境的优化主要聚焦于卵母细胞和胚胎。旨在改进ART精子处理方案的研究日益增多，但临床转化一直缓慢。与此同时，当前男性不育的治疗选择仅限于ICSI等操作，而这些操作绕过了不育的潜在生理病因。因此，在临床环境中持续开展精子相关研究，并改善患者心理社会照护，是改善患者结局与福祉的关键。本综述旨在评估ART诊所中男性生殖健康管理的现状，特别关注从男性生育认知到心理社会支持和针对性教育的整合式患者照护。此外，本综述旨在识别当前阻碍男性不育诊断和治疗新技术快速整合进ART诊所的主要障碍。通过PubMed检索，使用以下术语识别同行评议文章和综述：'sperm preparation/selection'、'male reproductive health'、'male infertility'、'diagnostics'、'cryopreservation'、'ART'、'fertility education'、'fertility awareness'、'artificial intelligence'以及'sperm'，并与其他相关关键词组合。检索未设日期限制；截至2026年3月所有相关研究均被评估和讨论。文章内参考文献也进行了检索。在ART环境中，男性在提供辅助生殖样本后很少接受常规医疗随访。通过整合男性健康照护中若干被忽视的方面，本综述得出结论：男性生殖健康应由医学专家更协同地管理，包括全科医生、泌尿科医生、内分泌科医生和男科医生，以了解男性不育的潜在病因并确定适当治疗。此外，本综述发现，亟需将心理健康专业人员整合到ART诊所环境中，以确保在生育治疗期间及之后为人们提供适当的咨询和照护。最后，我们确定，研究人员与临床从业者之间缺乏直接合作可能是新技术在ART诊所中应用缓慢的部分原因。需要进一步开展研究以改善公共卫生信息传播和男性生育教育。本综述识别出的一个 overarching 主题是：需要研究科学家与临床医生之间有针对性的合作，以改善男性生殖照护，进而加速有益技术和产品的临床采用，从而改善患者结局。本综述强调，亟需更整合的生育照护模式，从男性生育认知和教育，到改进对男性不育潜在病因的'临床内'评估，最终将男性心理社会支持更好地纳入生殖照护。n/a。"}, {"pmid": "42786066", "title": "Pretreatment Tumor NECTIN4 RNA Expression Is Associated with First-line Enfortumab Vedotin Plus Pembrolizumab Efficacy in Metastatic Urothelial Cancer.", "abstract": "Enfortumab vedotin (EV) + pembrolizumab (P; EV + P) is the preferred first-line standard-of-care treatment for metastatic urothelial carcinoma (mUC), yet predictive biomarkers remain lacking. We retrospectively investigated whether tumor NECTIN4 RNA expression and tumor mutational burden (TMB) are associated with outcomes in a real-world mUC cohort receiving first-line EV + P (N = 322). NECTIN4-high subgroup showed more favorable overall survival (OS; hazard ratio [HR] 0.67, 95% confidence interval [CI] 0.46-0.98; median 21.5 mo [95% CI 16.2-24.3] vs 14.2 mo [95% CI 12.6-23.8]) and best overall response (BOR; odds ratio [OR] 2.98, 95% CI 1.68-5.3; objective response rate [ORR]; 67.4% vs 41.9%) than NECTIN4-low subgroup. TMB-high subgroup also showed more favorable OS (HR 0.57, 95% CI 0.33-0.96; median 22.8 mo [95% CI 21.5 to not reached] vs 15.9 mo [95% CI 13.6-19.1]) and BOR (OR 2.26, 95% CI 1.14-4.47; ORR; 69.2% vs 52.6%) than TMB-low subgroup. In multivariable analyses, NECTIN4 expression independently predicted OS (adjusted HR 0.62, 95% CI 0.41-0.93) and BOR (adjusted OR 2.64, 95% CI 1.4-4.97). Patients with NECTIN4-high and/or TMB-high tumors had more favorable OS (HR 0.61, 95% CI 0.42-0.88) and BOR (OR 3.09, 95% CI 1.72-5.54) than those with double-low tumors. In contrast, NECTIN4 expression was not significantly associated with outcomes in the first-line P monotherapy cohort (N = 232). Overall, pretreatment tumor NECTIN4 RNA expression was associated with EV + P efficacy, with NECTIN4-low and TMB-low tumors showing the lowest likelihood of response.", "journal": "European Urology", "pub_date": "2026-Sep-24", "publication_types": ["Journal Article"], "doi": "10.1016/j.eururo.2026.08.005", "authors": ["Byuri Angela Cho", "Curtis J Perry", "Seong-Keun Yoo", "Jacob Mercer", "Christina Thai", "Guru Sonpavde", "Paul A Fields", "Alan Tan", "Daniel P Petrylak", "Matthew D Galsky"], "affiliations": ["Genomic Medicine Institute, Medical Research Center, Seoul National University, Seoul, Republic of Korea.", "Department of Internal Medicine, Yale University, New Haven, CT, USA.", "Samsung Precision Genome Medicine Institute, Samsung Medical Center, Seoul, Republic of Korea.", "Tempus AI, Inc., Chicago, IL, USA.", "AdventHealth Cancer Institute and the University of Central Florida, Orlando, FL, USA.", "Smilow Cancer Hospital, Yale New Haven Health, New Haven, CT, USA.", "Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address: matthew.galsky@mssm.edu."], "corresponding_authors": ["Matthew D Galsky"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=8", "score": 50.29, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 16.79, "top_journal_bonus": 10.0, "novelty": 1.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 8.0}, "journal_metrics": {"status": "ok", "impact_factor": 25.2, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.79, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "NECTIN4高表达预示EV联合方案更优生存", "chinese_summary": "9月Eur Urol基于322例转移性尿路上皮癌真实世界队列发现，一线恩沃单抗维多汀联合帕博利珠单抗治疗前，肿瘤NECTIN4 RNA高表达者总生存更优（HR 0.67），客观缓解率67.4%对41.9%；NECTIN4低表达且TMB低者应答可能性最低，为疗效预测提供依据。", "abstract_zh": "恩沃单抗维多汀（EV）联合帕博利珠单抗（P；EV+P）是转移性尿路上皮癌（mUC）首选一线标准治疗，但预测性生物标志物仍然缺乏。我们回顾性研究了肿瘤NECTIN4 RNA表达和肿瘤突变负荷（TMB）是否与接受一线EV+P的真实世界mUC队列（N=322）的结局相关。NECTIN4高表达亚组较NECTIN4低表达亚组显示更有利的总生存（OS；风险比[HR] 0.67，95%置信区间[CI] 0.46-0.98；中位21.5个月[95% CI 16.2-24.3]对14.2个月[95% CI 12.6-23.8]）和最佳总体缓解（BOR；比值比[OR] 2.98，95% CI 1.68-5.3；客观缓解率[ORR]；67.4%对41.9%）。TMB高表达亚组较TMB低表达亚组也显示更有利的OS（HR 0.57，95% CI 0.33-0.96；中位22.8个月[95% CI 21.5至未达到]对15.9个月[95% CI 13.6-19.1]）和BOR（OR 2.26，95% CI 1.14-4.47；ORR；69.2%对52.6%）。在多变量分析中，NECTIN4表达独立预测OS（校正HR 0.62，95% CI 0.41-0.93）和BOR（校正OR 2.64，95% CI 1.4-4.97）。NECTIN4高表达和/或TMB高表达肿瘤患者较双低肿瘤患者有更有利的OS（HR 0.61，95% CI 0.42-0.88）和BOR（OR 3.09，95% CI 1.72-5.54）。相反，NECTIN4表达在一线P单药治疗队列（N=232）中与结局无显著相关。总体而言，治疗前肿瘤NECTIN4 RNA表达与EV+P疗效相关，NECTIN4低表达和TMB低表达肿瘤显示最低的缓解可能性。"}, {"pmid": "42786059", "title": "How to Biopsy in Prostate Cancer Screening and Early Detection and Who Needs Antibiotics.", "abstract": "For prostate cancer screening, transperineal biopsy offers better clinically significant cancer detection and lower infection risk than transrectal biopsy. Despite greater discomfort, its overall benefits and antibiotic-sparing approach support its use in population-based screening.", "journal": "European Urology Focus", "pub_date": "2026-Sep-24", "publication_types": ["Journal Article"], "doi": "10.1016/j.euf.2026.09.002", "authors": ["Pinky Kotecha", "Jim Hu", "Alastair Lamb"], "affiliations": ["Centre for Cancer Evolution, Barts Cancer Centre, Queen Mary University of London, London, UK. Electronic address: p.kotecha@qmul.ac.uk.", "Weill Cornell Medicine New York-Presbyterian, New York, NY, USA.", "Centre for Cancer Evolution, Barts Cancer Centre, Queen Mary University of London, London, UK; Department of Urology, Guy's and St Thomas NHS Foundation Trust, London, UK."], "corresponding_authors": ["Pinky Kotecha"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 23.27, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.77, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 0.5, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 5.6, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.77, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42786043", "title": "Adjuvant Pembrolizumab for Surgically Treated Clear Cell Renal Cell Carcinoma: Results from a UK Tertiary Renal Cancer Network.", "abstract": "Adjuvant pembrolizumab has become the standard of care for patients with clear cell renal cell carcinoma (ccRCC) at increased risk of recurrence after surgery. However, evidence regarding its uptake, safety, and oncological outcomes in routine clinical practice remains limited. To assess the uptake, oncological outcomes, and safety of adjuvant pembrolizumab among patients eligible according to the KEYNOTE-564 criteria within a UK tertiary renal cancer network. We retrospectively reviewed patients with surgically treated ccRCC who were eligible for adjuvant pembrolizumab and whose cases were discussed at the multidisciplinary team (MDT) of a UK tertiary renal cancer network between November 2022 and April 2024. Following individualized counselling and shared decision-making, patients received adjuvant pembrolizumab or underwent surveillance. Study outcomes included discussion of treatment eligibility at the MDT, patients' and clinicians' joint decision regarding adjuvant pembrolizumab, the incidence and type of treatment-related adverse events (TRAEs), treatment discontinuation rate, and management strategies following disease recurrence. Oncological outcomes included disease-free survival (DFS) and overall survival (OS). Survival outcomes were estimated using the Kaplan-Meier method. Of 154 patients eligible for adjuvant pembrolizumab, 129 were medically fit to receive treatment, of whom 50% declined therapy following counselling. Patients treated with pembrolizumab were younger than those undergoing surveillance (median age 61 vs 67 yr; p < 0.001), had higher tumour necrosis (45% vs 30%; p = 0.075), and had high-risk disease according to the Leibovich score (53% vs 42%; p = 0.2). At 24 mo, the estimated DFS and OS among patients treated with adjuvant pembrolizumab were 69% (95% confidence interval [CI] 55-87) and 95% (95% CI 89-100), respectively. Regarding safety, 92% of treated patients experienced any-grade TRAEs, 19% experienced grade ≥3 TRAEs, 33% required corticosteroids, and 23% discontinued treatment because of toxicity. The retrospective, nonrandomized design and relatively short follow-up represent the main study limitations. The safety and oncological outcomes of adjuvant pembrolizumab in routine clinical practice within a UK tertiary renal cancer network were consistent with those reported in the KEYNOTE-564 trial. Treatment decisions should extend beyond trial-based eligibility and incorporate validated recurrence risk tools, comorbidities, and patient preferences through individualized counselling and shared decision-making.", "journal": "European Urology Oncology", "pub_date": "2026-Sep-24", "publication_types": ["Journal Article"], "doi": "10.1016/j.euo.2026.09.002", "authors": ["Federica Sordelli", "Giuseppe Basile", "Eduard Roussel", "Veda Kudva", "Daniel Hughes", "Elizabeth Nally", "Ravi Barod", "Abhishek Reekhaye", "Mark Yao", "Alzahrani Hani", "Prasad Patki", "Faiz Mumtaz", "Soha El Sheikh", "Omid Sedigh", "Nicolò Maria Buffi", "Ekaterini Boleti", "Thomas Powles", "Axel Bex", "Antonio Rullan"], "affiliations": ["Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy; Department of Urology, IRCCS Humanitas Research Hospital, Milan, Italy; Specialist Centre for Kidney Cancer, Urology Department, Royal Free Hospital, London, UK. Electronic address: federica.sordelli@gmail.com.", "Specialist Centre for Kidney Cancer, Urology Department, Royal Free Hospital, London, UK.", "Department of Oncology, Royal Free London NHS Foundation Trust, London, UK.", "Department of Oncology, University College London Hospitals NHS Foundation Trust, London, UK.", "Barts Cancer Institute NIHR Biomedical Research Centre, Queen Mary University of London, London, UK.", "Specialist Centre for Kidney Cancer, Urology Department, Royal Free Hospital, London, UK; Division of Surgery and Interventional Science, University College London, London, UK.", "Department of Histopathology, Royal Free London Foundation Trust, London, UK.", "Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy; Department of Urology, Gradenigo Hospital, Turin, Italy.", "Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy; Department of Urology, IRCCS Humanitas Research Hospital, Milan, Italy.", "Department of Oncology, Royal Free London NHS Foundation Trust, London, UK; The Institute of Cancer Research, London, UK."], "corresponding_authors": ["Federica Sordelli"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=12", "score": 41.42, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 15.42, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 12.0}, "journal_metrics": {"status": "ok", "impact_factor": 9.3, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.42, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42785920", "title": "Toward precision adjuvant immunotherapy in high-risk clear cell renal cell carcinoma: integrating plasma multiomics with PD-1 blockade.", "abstract": "Despite curative-intent nephrectomy, approximately one-third of patients with localized clear cell renal cell carcinoma (ccRCC) eventually experience disease recurrence due to occult minimal residual disease. Although adjuvant immune checkpoint blockade has transformed postoperative management for patients at high risk of relapse, clinical benefit remains heterogeneous, underscoring the need for biomarkers capable of identifying individuals most likely to benefit from treatment. In this issue of the Journal for ImmunoTherapy of Cancer, Wang et al report a prospective, multicenter, non-randomized phase II trial evaluating adjuvant penpulimab in patients with very-high-risk ccRCC following nephrectomy. Beyond demonstrating improved disease-free survival compared with surveillance, the investigators integrated plasma proteomic and metabolomic analyses to identify circulating immune-metabolic signatures associated with recurrence. This study extends the discussion of adjuvant immunotherapy beyond demonstrating efficacy toward understanding biological heterogeneity, and developing biomarker-guided treatment strategies. Although the non-randomized design, limited sample size, and exploratory biomarker analyses preclude immediate changes to clinical practice, the study highlights the promise of combining prospective immunotherapy trials with liquid biopsy-based multiomics. Such approaches may ultimately enable precision adjuvant immunotherapy by improving postoperative risk stratification, monitoring minimal residual disease, and guiding individualized treatment decisions in patients with high-risk ccRCC.", "journal": "Journal for Immunotherapy of Cancer", "pub_date": "2026-Sep-24", "publication_types": ["Journal Article"], "doi": "10.1007/s00262-026-04331-0", "authors": ["Rakesh Kumar", "Duminduni Hewa Angappulige", "Jianxun Song"], "affiliations": ["Department of Microbial Pathogenesis and Immunology, Texas A&M University Health Science Center, Bryan, Texas, USA.", "Biochemistry and Molecular Biology, Louisiana State University Health Sciences Center-Shreveport, Shreveport, Louisiana, USA jianxun.song@lsuhs.edu.", "Feist-Weiller Cancer Center, Louisiana State University Health Sciences Center-Shreveport, Shreveport, Louisiana, USA."], "corresponding_authors": ["Jianxun Song"], "china_team": "", "category": "basic", "classification_reason": "basic_signals=6", "score": 41.1, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 15.6, "top_journal_bonus": 0.0, "novelty": 1.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 6.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 10.6, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.6, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "血浆多组学或可指导肾癌辅助免疫", "chinese_summary": "J Immunother Cancer刊发述评，介绍Wang等开展的前瞻性多中心II期非随机试验：高危透明细胞肾癌术后接受派安普利单抗辅助治疗，无病生存优于监测，并整合血浆蛋白与代谢组学识别与复发相关的循环免疫代谢特征，提示液体活检多组学有望助力术后风险分层与个体化辅助免疫决策。", "abstract_zh": "尽管接受了根治性肾切除术，约三分之一的局限性透明细胞肾细胞癌（ccRCC）患者最终仍因隐匿性微小残留病灶而出现疾病复发。虽然辅助免疫检查点阻断已改变了高复发风险患者的术后管理，但临床获益仍存在异质性，凸显出需要能够识别最可能从治疗中获益个体的生物标志物。在本期《癌症免疫治疗杂志》中，Wang等报告了一项前瞻性、多中心、非随机II期试验，评估派安普利单抗用于肾切除术后极高危ccRCC患者的辅助治疗。除显示无病生存优于监测外，研究者还整合血浆蛋白质组学和代谢组学分析，以识别与复发相关的循环免疫代谢特征。该研究将辅助免疫治疗的讨论从证明疗效扩展到理解生物学异质性并制定生物标志物指导的治疗策略。尽管非随机设计、样本量有限以及探索性生物标志物分析使该研究尚不能立即改变临床实践，但它凸显了将前瞻性免疫治疗试验与基于液体活检的多组学相结合的前景。此类方法最终可能通过改善术后风险分层、监测微小残留病灶并指导高危ccRCC患者的个体化治疗决策，实现精准辅助免疫治疗。"}, {"pmid": "42785711", "title": "Impact of fluconazole in vasopressin 2 receptor-related congenital arginine vasopressin resistance.", "abstract": "Arginine vasopressin resistance (AVP-R), previously called nephrogenic diabetes insipidus is a rare inherited disorder characterized by excessive urine output (often over 10 l/d) and a risk of life-threatening dehydration, resulting from kidney collecting duct insensitivity to arginine vasopressin. Currently, no curative treatment exists. Preclinical studies suggest that repurposing of anti-fungal fluconazole enhances AQP2-mediated water transport. Here, we present results from a clinical intervention study evaluating the effect of fluconazole on 24-hour urine output and urine concentrating ability in patients with congenital AVP-R caused by a pathogenic variant in the AVPR2 gene encoding the receptor of AVP. We performed an open-label, non-randomized intervention in five adult males with AVPR2-related AVP-R. Participants received oral fluconazole 400 mg daily for 14 days, with baseline and follow-up assessments including water deprivation test. The primary endpoints were 24-hour urine output and urinary concentrating ability. Secondary endpoints included urinary and plasma osmolality, surrogate copeptin secretion, electrolytes, and micturition frequency. Safety and treatment adherence were evaluated weekly. Median fluconazole concentration following treatment were 13.7 μg/ml (range 12.1-24.4) in plasma and 28.6 μg/ml (range 22.4-34.7) in urine, respectively. Median change in 24-h urine output was +0.8 l (range -3.6 to +5.7) and in urine osmolality -3 mOsm/kg (range -78 to +25), with no change in micturition frequency. During water deprivation, body weight decreased -2.0 to -2.8 kg at baseline vs. -2.1 to -3.1 kg after treatment, urine osmolality changed -91 to +222 vs. -12 to +193 mOsm/kg, and plasma copeptin increased 4.8 to 16.8 vs. 4.2 to 12.9 pmol/l. Fluconazole treatment did not reduce urine output or improve urine concentrating ability in adult patients with congenital AVP-R.", "journal": "Kidney International", "pub_date": "2026-Sep-24", "publication_types": ["Journal Article"], "doi": "10.1016/j.kint.2026.08.024", "authors": ["Line A Mortensen", "Claus Bistrup", "Søren Rittig", "Jens Michael Hertz", "Kai M Schmidt-Ott", "Enno Klussman", "Christian Hinze", "Boye L Jensen", "Gitte R Hinrichs"], "affiliations": ["Department of Nephrology, Odense University Hospital, Odense, Denmark; Department of Clinical Research, University of Southern Denmark, Odense, Denmark.", "Department of Clinical Medicine, Department of Pediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark.", "Department of Clinical Research, University of Southern Denmark, Odense, Denmark.", "Department of Nephrology and Hypertension, Hannover Medical School, Hannover, Germany; Max-Delbrück-Centrum für Molekulare Medizin (MDC), Berlin, Germany.", "Max-Delbrück-Centrum für Molekulare Medizin (MDC), Berlin, Germany; DZHK (German Centre for Cardiovascular Research), partner site Berlin, Germany.", "Department of Molecular Medicine, Cardiovascular and Renal Research, University of Southern Denmark, Odense, Denmark.", "Department of Nephrology, Odense University Hospital, Odense, Denmark; Department of Clinical Research, University of Southern Denmark, Odense, Denmark; Department of Molecular Medicine, Cardiovascular and Renal Research, University of Southern Denmark, Odense, Denmark. Electronic address: gitte.rye.hinrichs2@rsyd.dk."], "corresponding_authors": ["Gitte R Hinrichs"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=10", "score": 30.83, "score_parts": {"urology_relevance": 3, "urology_in_title": 0.0, "journal_priority": 15.83, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 10.0}, "journal_metrics": {"status": "ok", "impact_factor": 12.6, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.83, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42785573", "title": "Author's Response on Article \"Heat Index and Kidney Stone Recurrence Among Patients With Nephrolithiasis in a Veterans Affairs Population\".", "abstract": "", "journal": "Urology", "pub_date": "2026-Sep-24", "publication_types": ["Journal Article"], "doi": "10.1016/j.urology.2026.09.045", "authors": ["Blanca Morales Lugo", "Autumn N Valicevic", "Paula Guro", "Mary K Oerline", "Sanjeevkumar R Patel", "John M Hollingsworth", "Ryan S Hsi", "Vahakn B Shahinian", "David B Bayne"], "affiliations": ["Department of Urology, University of California, San Francisco, San Francisco, CA, 94143.", "Department of Internal Medicine, Veterans Administration, Veterans Affair Medical Center, Ann Arbor, MI, 48105.", "Dow Division of Health Services, Department of Urology, University of Michigan, Ann Arbor, MI, 48109.", "Dow Division of Health Services, Department of Urology, University of Michigan, Ann Arbor, MI, 48109; Division of Nephrology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, 48105.", "Department of Urology, University of Florida College of Medicine, Gainesville, FL, 32610.", "Department of Urology, University of California, Irvine, Irvine, CA, 92612.", "Department of Urology, University of California, San Francisco, San Francisco, CA, 94143. Electronic address: david.bayne@ucsf.edu."], "corresponding_authors": ["David B Bayne"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 18.61, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 5.61, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.0, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.61, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42785572", "title": "Editorial Comment on \"The Current State of Urology Residency Mentorship: Insights From the American Urological Association Resident/Fellow Census\".", "abstract": "", "journal": "Urology", "pub_date": "2026-Sep-24", "publication_types": ["Editorial"], "doi": "10.1016/j.urology.2026.09.044", "authors": ["Alexandra L Tabakin", "Eric A Singer"], "affiliations": ["Division of Urology, Department of Surgery, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ.", "Division of Urologic Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH. Electronic address: eric.singer@osumc.edu."], "corresponding_authors": ["Eric A Singer"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 14.61, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 5.61, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.0, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.61, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42785539", "title": "A small molecule ACT004 targets four-and-a-half LIM domain protein 1 to disrupt TGF-β/Smad signaling and promote FHL1 degradation in renal fibrosis.", "abstract": "Renal fibrosis is a common endpoint of chronic kidney disease (CKD), yet effective targeted anti-fibrotic therapies remain limited. Ovatodiolide (OVA) has anti-fibrotic activity but poor drug-like properties, whereas ACT004, a synthetic OVA derivative, has improved water solubility and metabolic stability. However, whether ACT004 acts through the same mechanism as OVA or through a distinct target remains unclear. In this study, we evaluated the anti-fibrotic effects of ACT004 in unilateral ureteral obstruction (UUO) and unilateral ischemia-reperfusion injury (UIRI) mouse models and investigated its underlying mechanism using RNA sequencing, HuProt human protein microarray, microscale thermophoresis, pull-down assays, cellular thermal shift assay, molecular docking, siRNA, mutant plasmids, co-immunoprecipitation, and pharmacological inhibition. ACT004 markedly attenuated renal fibrosis in UUO and UIRI mice and suppressed inflammatory signaling and Smad2/3 activation in vivo and in TGF-β1-stimulated renal tubular epithelial cells. Four-and-a-half LIM domain protein 1 (FHL1) was identified as a direct ACT004-binding target. ACT004 bound FHL1 at Lys102 and Thr128, and mutation of these residues weakened ACT004-FHL1 binding. FHL1 knockdown reduced TGF-β1-induced profibrotic activation, whereas ACT004 failed to further suppress fibrotic marker expression after FHL1 silencing. Mechanistically, ACT004 disrupted the FHL1-Smad2/3 interaction, inhibited Smad2/3 phosphorylation, and promoted ubiquitination-mediated degradation of FHL1. FHL1 overexpression aggravated UUO-induced renal fibrosis, whereas ACT004 alleviated FHL1-associated fibrotic injury in vivo. These findings identify FHL1 as a previously unrecognized pro-fibrotic scaffold in the kidney and position ACT004 as a next-generation anti-fibrotic candidate with a dual mechanism of action.", "journal": "Pharmacological Research", "pub_date": "2026-Sep-24", "publication_types": ["Journal Article"], "doi": "10.1016/j.phrs.2026.109640", "authors": ["Xiaoyang He", "Fenfen Peng", "Huizhen Wang", "Jinzhu Yang", "Yihao Long", "Di Lu", "Liyuan Zhao", "Qiongying Huang", "Qiuyuan Li", "Ning Ma", "Xiaowen Chen", "Haibo Long"], "affiliations": ["Department of Nephrology, Zhujiang Hospital, Southern Medical University, Guangzhou, China.", "Department of Nephrology, Zhujiang Hospital, Southern Medical University, Guangzhou, China. Electronic address: cxw113@smu.edu.cn.", "Department of Nephrology, Zhujiang Hospital, Southern Medical University, Guangzhou, China. Electronic address: longhb1966@163.com."], "corresponding_authors": ["Xiaowen Chen", "Haibo Long"], "china_team": "Department of Nephrology, Zhujiang Hospital, Southern Medical University, Guangzhou, China Xiaowen Chen/Haibo Long团队", "category": "basic", "classification_reason": "basic_signals=21", "score": 31.58, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 11.58, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 14.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 10.5, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 3.58, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "小分子ACT004靶向FHL1抑制肾纤维化", "chinese_summary": "南方医科大学珠江医院陈小文/龙海波团队9月Pharmacol Res报道，合成小分子ACT004在单侧输尿管梗阻及缺血再灌注小鼠模型中显著减轻肾纤维化，并抑制炎症信号及Smad2/3激活。机制上ACT004直接结合FHL1的Lys102和Thr128位点，破坏FHL1-Smad2/3互作，促进FHL1泛素化降解，提示FHL1是肾脏促纤维化新支架蛋白。", "abstract_zh": "肾纤维化是慢性肾脏病（CKD）的常见终点，但有效的靶向抗纤维化治疗仍然有限。Ovatodiolide（OVA）具有抗纤维化活性，但类药性较差，而ACT004是一种合成的OVA衍生物，具有改善的水溶性和代谢稳定性。然而，ACT004是否通过与OVA相同的机制或通过不同的靶点发挥作用仍不清楚。在本研究中，我们在单侧输尿管梗阻（UUO）和单侧缺血再灌注损伤（UIRI）小鼠模型中评估了ACT004的抗纤维化作用，并使用RNA测序、HuProt人类蛋白质微阵列、微量热泳动、pull-down实验、细胞热位移实验、分子对接、siRNA、突变质粒、共免疫沉淀和药理学抑制研究了其潜在机制。ACT004显著减轻了UUO和UIRI小鼠的肾纤维化，并在体内及TGF-β1刺激的肾小管上皮细胞中抑制了炎症信号和Smad2/3激活。Four-and-a-half LIM domain protein 1（FHL1）被鉴定为ACT004的直接结合靶点。ACT004在Lys102和Thr128位点结合FHL1，突变这些残基会削弱ACT004-FHL1结合。FHL1敲低减少了TGF-β1诱导的促纤维化激活，而FHL1沉默后ACT004未能进一步抑制纤维化标志物表达。机制上，ACT004破坏了FHL1-Smad2/3相互作用，抑制Smad2/3磷酸化，并促进泛素化介导的FHL1降解。FHL1过表达加重了UUO诱导的肾纤维化，而ACT004在体内减轻了FHL1相关的纤维化损伤。这些发现将FHL1确定为肾脏中先前未被认识的促纤维化支架蛋白，并将ACT004定位为具有双重作用机制的下一代抗纤维化候选药物。"}, {"pmid": "42785156", "title": "Lymphovascular invasion and nodal positivity may identify candidates for adjuvant nivolumab in high-risk muscle-invasive urothelial carcinoma.", "abstract": "To identify patients with high-risk muscle-invasive urothelial carcinoma (MIUC) who derive greater benefit from adjuvant nivolumab after radical surgery. This single-center retrospective study included 246 patients with high-risk MIUC who underwent radical surgery between 2018 and 2025. High-risk disease was defined according to the CheckMate 274 trial criteria. The real-world oncological outcomes of patients who received adjuvant nivolumab (n = 51) were compared with those of a contemporary control cohort (n = 51) and a historical control cohort (n = 144). Prognostic factors for disease-free survival (DFS) in nivolumab-naïve patients were evaluated using multivariate Cox regression analysis. DFS for the entire cohort was stratified according to significant prognostic factors and nivolumab use. The adjuvant nivolumab cohort showed favorable oncological outcomes compared to both the contemporary and historical control cohorts. Multivariate analysis identified lymphovascular invasion (LVI) and nodal positivity as independent prognostic factors in nivolumab-naïve patients. In patients with LVI or nodal positivity, those who received adjuvant nivolumab had a significantly improved DFS compared with those who did not (hazard ratio 0.40; 95% confidence interval, 0.22-0.73; log-rank P = 0.002). However, in patients with neither LVI nor nodal positivity, DFS did not differ significantly according to adjuvant nivolumab use (P = 0.66). Our findings suggest that LVI and nodal positivity may help identify patients with high-risk MIUC who are more likely to benefit from adjuvant nivolumab. These pathological features may serve as practical markers for patient selection; however, further validation is required before clinical implementation.", "journal": "Urologic Oncology", "pub_date": "2026-Sep-24", "publication_types": ["Journal Article"], "doi": "10.1016/j.urolonc.2026.08.012", "authors": ["Hiroki Shimoda", "Noboru Numao", "Ryosuke Oki", "Tetsuya Urasaki", "Takashi Tamiya", "Kosuke Takemura", "Ryo Fujiwara", "Masaharu Inoue", "Yuji Miura", "Junji Yonese"], "affiliations": ["Department of Genitourinary Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.", "Department of Genitourinary Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan. Electronic address: noboru.numao@jfcr.or.jp.", "Department of Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan."], "corresponding_authors": ["Noboru Numao"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=8", "score": 27.75, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 5.75, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 8.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.3, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.75, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42784640", "title": "Simpler risk stratification and new options for recurrent low-grade disease: 2026 update to the AUA/SUO non-muscle invasive bladder cancer guideline.", "abstract": "", "journal": "Journal of Urology", "pub_date": "2026-Sep-24", "publication_types": ["Editorial"], "doi": "10.1097/JU.0000000000005323", "authors": ["David J Nusbaum", "Scott M Gilbert", "Roger Li"], "affiliations": ["Department of Genitourinary Oncology, Moffitt Cancer Center, Tampa, FL, USA."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 20.51, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 11.01, "top_journal_bonus": 0.0, "novelty": 0.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 6.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 3.01, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42784564", "title": "Multicenter Randomized Controlled Trial Comparing Pulse-Modulated Holmium:YAG Laser and Thulium Fiber Laser in Retrograde Intrarenal Surgery for Dusting Kidney Stones.", "abstract": "High-power lasers have revolutionized the treatment of stones during retrograde intrarenal surgery, but single-center and retrospective studies comparing stone-free rates and efficiency of the 2 most commonly used modalities, pulse-modulated Holmium:YAG and Thulium Fiber Laser, have had conflicting results. We designed a multicenter randomized controlled trial to address these discrepancies. After IRB approval, 5 US centers recruited and prospectively randomized adults aged 18 to 89 years with intrarenal stones ≥5 to ≤20 mm to receive retrograde intrarenal surgery with a Holmium:YAG or Thulium Fiber Laser with the goal to dust all stones. The primary outcome was stone free rates on computed tomography at 6 to 12 weeks. Secondary outcomes included procedure time, laser efficiency parameters, and complications. Demographics and preoperative stone parameters of the 178 enrolled patients were similar between treatment arms. Zero fragment stone-free rates were 36/68 (52.9%) for Holmium:YAG and 34/65 (52.3%) for Thulium Fiber Laser and were nearly identical (P = .942). Procedure time, laser time, laser efficiency, and complication rates also did not show any statistical difference between groups. This multicenter randomized controlled trial found no statistically significant difference in stone-free rate, complications, or efficiency between high-power, pulse-modulated Holmium:YAG and Thulium Fiber Laser. They are both effective at treating intrarenal stones ≤ 2 cm. Surgeon and institutional preferences can dictate which laser to use.", "journal": "Journal of Urology", "pub_date": "2026-Sep-24", "publication_types": ["Journal Article"], "doi": "10.1097/JU.0000000000005290", "authors": ["Margaret A Knoedler", "Emily C Serrell", "Kavita Gupta", "Cyrus Chehroudi", "Anna Zampini", "Matthew Lee", "Ali Antar", "Michael Sourial", "Raymond Khargi", "William Atallah", "Shuang Li", "Alan Yaghoubian", "Ziv Savin", "Kymora Scotland", "Bodo Knudsen", "Sri Sivalingam", "Stephen Y Nakada", "Mantu Gupta"], "affiliations": ["Department of Urology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.", "Department of Urology, Mount Sinai New York, New York, New York.", "Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio.", "Department of Urology, The Ohio State University, Wexner Medical Center, Columbus, Ohio.", "Department of Urology, University of California, Los Angeles, Los Angeles, California."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=14", "score": 37.01, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 11.01, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 12.0}, "journal_metrics": {"status": "ok", "impact_factor": 6.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 3.01, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42782709", "title": "PATIENT SATISFACTION FOLLOWING UROLOGY RETURN VISITS BASED ON PROVIDER TYPE.", "abstract": "We aimed to evaluate patient satisfaction with Urology return visits between Advanced Practice Providers (APP) and Physicians in a tertiary Urology practice. Outpatient Urology visits between January 2023 to June 2024 were obtained from electronic medical records. Patients who completed a Press Ganey Patient Satisfaction Survey after return visits were identified. Return visits were conducted either by a physician or APP. The objective was to evaluate the Topbox score defined by the percentage of patients who selected \"Very Good\" for each survey question. Chi-square tests were utilized to compare the differences for both provider types. A total of 2522 patients completed the survey, including 1060 patients who saw a physician and 1462 patients who saw an APP. There was no significant difference in patient satisfaction as both cohorts received similar ratings for each question. This included the rating of overall care received (93.7% vs. 93.2%; p=0.64), concern the provider showed for questions/worries (92.3% vs 92.8%; p=0.66), explanation the provider gave about the condition/problem (92.4% vs 93.6%; p=0.26), and discussion of proposed treatment (92.3% vs 91.6%; p=0.54) for physicians and APPs respectively.Additional ratings included the friendless/courtesy of the provider (95.0% vs 95.5%; p=0.68), confidence level (95.2% vs 94.1%; p=0.31), ability for the provider to use words that the patient could understand (94.2% vs 93.9%; p=0.79), and instructions given about follow up care (91.7% vs 92.3%; p=0.67). There is no difference in Press Ganey patient satisfaction scores between physicians and APPs with regards to Urology return visits.", "journal": "Urology Practice", "pub_date": "2026-Sep-24", "publication_types": ["Journal Article"], "doi": "10.1097/UPJ.0000000000001095", "authors": ["Amanda E Black", "Neda Qosja", "Aaron Spaulding", "Katie Bews", "Kathryn Cardona", "Yeonsoo Sara Lee", "Laura E Geldmaker", "Katherine McCoy", "Jaine Zhang", "David D Thiel"], "affiliations": ["Department of Urology, Mayo Clinic, Jacksonville, FL, USA.", "Division of Health Care Delivery Research, Mayo Clinic, Jacksonville, FL, USA.", "Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN, USA.", "Mayo Clinic Alix School of Medicine, Mayo Clinic, Phoenix, AZ, USA."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=5", "score": 21.46, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 2.46, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 5.0}, "journal_metrics": {"status": "ok", "impact_factor": 1.7, "cas_zone": 4, "cas_zone_points": 1.0, "impact_factor_points": 1.46, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42782521", "title": "Therapeutic and antioxidant effects of Camelus dromedarius hump fat oil against ethylene glycol-induced nephrocalcinosis and hepato-renal damage in wistar rats: a biochemical and histopathological study.", "abstract": "Renal stones remain a prevalent renal disorder characterized by high recurrence rates and limited therapeutic options, encouraging continued research into novel agents capable of treating established stone disease. Camelus dromedarius hump fat has long been used in North African alternative medicine to treat various dermal and inflammatory diseases. This study aims to evaluate the antioxidant activity, specifically radical scavenging, and the therapeutic potential of this fat against Calcium oxalate stones induced by Ethylene glycol in a Wistar rat model. Twenty Wistar rats were divided into four groups (n=5). The first group serves as the control. The three other groups received EG in their drinking water until stones formed. Rats were fed a fresh dromedary hump fat diet at 45% w/w daily. Urinary parameters (volume, pH, electrolytes), serum biochemical assessments, and measured creatinine clearance were analyzed. Renal histopathology was performed to evaluate tissue changes. The EG-treated rats showed significant disturbances in all physiological parameters, including decreases in urinary volume, pH, and urinary electrolyte excretion. DHF demonstrated strong antioxidant activities, with DPPH scavenging (69.158%-85.571%), FRAP values (70.785%-83.971%), and ABTS (59.145%-89.195%), indicating potential to reduce oxidative stress. In addition to that, treatments with the DHF diet significantly increase urinary volume from 6.3 ± 0.2 ml to 10.12 ± 0.1 ml (p < 0.001). These alterations extend to serum creatinine and urea levels. A high increase in serum creatinine and urea levels was shown. The DHF-treated group showed a creatinine clearance of 3.46 ± 0.68 ml/min on day 21. Importantly, the DHF diet protected the liver from EG-induced damage, as evidenced by serum levels of gamma-glutamyl transferase (GGT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and alanine aminotransferase (ALT) that were near control levels. In contrast, the EG-only group exhibited marked elevations in enzyme levels (p < 0.01). These findings suggest that the DHF 45% w/w diet may exert its protective effect by reducing oxidative stress and preserving tubular epithelial integrity, thereby improving urinary electrolyte excretion, decreasing crystal formation, and protecting renal tissue.", "journal": "Urolithiasis", "pub_date": "2026-Sep-24", "publication_types": ["Journal Article"], "doi": "10.1007/s00240-026-02055-5", "authors": ["Beybeti Ishagh", "Abderrazak Aboulghazi", "Widad Tbatou", "Asmae El Ghouizi", "Badiaa Lyoussi", "Zineb Benziane Ouartini"], "affiliations": ["Laboratory of Biotechnology, Conservation and Valorization of Bioresources (LBCVB), Department of Biology, Faculty of Sciences Dhar Mehraz, Sidi Mohamed Ben Abdellah University, 30000, Fez, Morocco.", "Laboratory of Natural Substances, Pharmacology, Environment, Modeling, Health, and Quality of Life (SNAMOPEQ), Department of Biology, Faculty of Sciences Dhar Mehraz, Sidi Mohamed Ben Abdellah University, 30000, Fez, Morocco.", "Laboratories TBC Laboratory of Pharmacology Pharmacokinetics and Clinical Pharmacy Faculty of Pharmacy, University of Lille, 3, Rue du Professeur Laguesse, B.P. 83, Lille, 59000, France.", "The Higher Institute of Nursing Professions and Health Techniques (ISPITS), Fez, Morocco.", "Laboratory of Natural Substances, Pharmacology, Environment, Modeling, Health, and Quality of Life (SNAMOPEQ), Department of Biology, Faculty of Sciences Dhar Mehraz, Sidi Mohamed Ben Abdellah University, 30000, Fez, Morocco. lyoussi@gmail.com."], "corresponding_authors": ["Badiaa Lyoussi"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 15.71, "score_parts": {"urology_relevance": 3, "urology_in_title": 0.0, "journal_priority": 5.71, "top_journal_bonus": 0.0, "novelty": 2, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 3.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.2, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.71, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42782398", "title": "Predictors of early surgical treatment after a first episode of acute urinary retention due to benign prostatic obstruction: a single-center retrospective cohort study.", "abstract": "To identify clinical, biochemical, and radiological factors associated with progression to early surgical treatment after a first episode of acute urinary retention (AUR) secondary to benign prostatic obstruction. This single-center retrospective cohort study included 425 patients with a first episode of AUR between 2020 and 2026, managed with catheterization, alpha-blocker therapy, and a trial without catheter. Patients were categorized into medical management (n = 197) and surgical treatment (n = 228) groups. Univariable and multivariable logistic regression analyses identified factors associated with progression to surgery. Discrimination was assessed by ROC analysis, and the final model underwent bootstrap internal validation with 1,000 resamples and calibration assessment. All evaluated variables were associated with surgical treatment in univariable analysis (all p < 0.001). In multivariable analysis, prostate volume, retention volume, serum urea, and IPSS remained independently associated with progression to surgery (all p < 0.05). IPP was also associated after adjustment (OR 3.409, 95% CI 1.007-11.542; p = 0.046), although the estimate was imprecise. IPSS showed the highest discriminative performance (AUC 0.941), followed by retention volume (AUC 0.907). The final model showed an apparent AUC of 0.980 and an optimism-corrected AUC of 0.959; the Brier score was 0.0404. Prostate volume, IPSS, retention volume, and serum urea were independently associated with progression to surgery after a first AUR episode. IPSS and retention volume showed the greatest discriminative performance. IPP may provide additional prognostic information, but its imprecise estimate warrants cautious interpretation. These routinely available parameters may support early risk stratification, pending external validation.", "journal": "World Journal of Urology", "pub_date": "2026-Sep-24", "publication_types": ["Journal Article"], "doi": "10.1007/s00345-026-06799-y", "authors": ["Mehmet Sevim", "Hakan Şığva", "Ercan Fidan", "Oktay Karakoç", "Kadir Körpe"], "affiliations": ["Department of Urology, Van Training and Research Hospital, Van, Turkey. dokterms@gmail.com.", "Department of Urology, Van Training and Research Hospital, Van, Turkey."], "corresponding_authors": ["Mehmet Sevim"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=8", "score": 40.0, "score_parts": {"urology_relevance": 11, "urology_in_title": 8.0, "journal_priority": 10.0, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 8.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.9, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.0, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42782373", "title": "Cancer-specific mortality in high-risk or very high-risk prostate cancer patients treated with cryotherapy vs. external beam radiation therapy.", "abstract": "Cryotherapy in high-risk or very high-risk prostate cancer (PCa) is not guidelines recommended, but it is occasionally used outside of formal clinical trials. However, its effect on cancer-specific mortality (CSM) relatively to standard treatment options such as external beam radiation therapy (EBRT) is unknown and was addressed in the current study. In the Surveillance, Epidemiology, and End Results (SEER) database (2010-2022), high-risk or very high-risk PCa patients according to the National Comprehensive Cancer Network (NCCN) guidelines, treated with either cryotherapy or EBRT were identified. Univariable competing risks regression (CRR) models, after 1:1 propensity score matching (PSM), tested for CSM differences after accounting for other-cause mortality (OCM) as a competing event. Overall, 33,961 high-risk or very high-risk PCa patients treated with cryotherapy or EBRT were identified. Of those, 245 (0.7%) underwent cryotherapy and 33,716 (99.3%) EBRT. In 1:1 PSM, 245 cryotherapy patients were matched with one EBRT control. After 1:1 PSM, at 120-months of follow-up, CSM after EBRT was 7.7% vs. 16.7% after cryotherapy. The corresponding OCM rates were 32.2% after EBRT vs. 32.1% after cryotherapy. In univariable CRR models, accounting for OCM, cryotherapy increased CSM in a 2.2-fold fashion (HR: 2.20; 95% CI: 1.15-4.17; p = 0.017). Despite lack of guidelines endorsement, occasional high-risk or very high-risk PCa patients are treated with cryotherapy at large. Population-based observations indicate that cryotherapy is associated with a higher risk of CSM compared with EBRT in these patients.", "journal": "World Journal of Urology", "pub_date": "2026-Sep-24", "publication_types": ["Journal Article", "Comparative Study"], "doi": "10.1007/s00345-026-06810-6", "authors": ["Leonardo Quarta", "Michele Petix", "Maximilian Filzmayer", "Filippo Orlandi", "Jordan A Goyal", "Matteo Ferro", "Felix K H Chun", "Salvatore Micali", "Shahrokh F Shariat", "Mohamed Abouelenein", "Francesco Barletta", "Armando Stabile", "Giorgio Gandaglia", "Francesco Montorsi", "Fred Saad", "Alberto Briganti", "Pierre I Karakiewicz"], "affiliations": ["Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada. quarta.leonardo@hsr.it.", "Division of Experimental Oncology/Unit of Urology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy. quarta.leonardo@hsr.it.", "Vita-Salute San Raffaele University, Milan, Italy. quarta.leonardo@hsr.it.", "Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.", "Department of Urology, ASST Santi Paolo e Carlo, Milan, Italy.", "Università degli Studi di Milano, Milan, Italy.", "Department of Urology, Goethe University Frankfurt, University Hospital, Frankfurt am Main, Germany.", "Department of Urology, AOU di Modena, University of Modena and Reggio Emilia, Modena, Italy.", "Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.", "Department of Urology, Weill Cornell Medical College, New York, NY, USA.", "Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA.", "Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan.", "King's College Hospital NHS Foundation Trust, London, UK.", "Division of Experimental Oncology/Unit of Urology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy.", "Vita-Salute San Raffaele University, Milan, Italy."], "corresponding_authors": ["Leonardo Quarta"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_clinical", "score": 32.0, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.0, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 8.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.9, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.0, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42782320", "title": "Worldwide variations in purchase and per-procedure costs of single-use flexible ureteroscopes and flexible navigable access sheaths: the economic impact of reuse strategies on procedural outcomes from a 40-country YAU-EAU endourology international collaboration.", "abstract": "Endourological practice increasingly relies on single-use devices, the costs of which vary considerably across regions and healthcare systems. Flexible single-use ureteroscopes (FURS) and flexible and navigable suction ureteral access sheaths (FANS) represent a substantial proportion of ureteroscopy-related expenditure. To mitigate these costs, some centres have adopted reuse strategies aimed at reducing per-procedure expenses. The aim of this study was to evaluate international variation in the purchase prices and real-world per-procedure costs of FURS and FANS, and to assess the economic impact of device reuse strategies. An international collaborative study coordinated by the Young Academic Urologists (YAU) and European Association of Urology (EAU) Endourology Groups was conducted across 40 countries. Endourologists provided real-world procurement data regarding purchase prices, utilization patterns, and equipment-related procedural cost of single-use FURS and FANS between March 2025 and January 2026. All costs were converted to Euros (€). In centres adopting institution-validated reuse protocols, weighted per-procedure costs were calculated by dividing device acquisition costs by the number of effective uses. Countries were stratified according to cost quartiles to assess global variability. Data were collected from 40 countries across Europe, Asia, North and South America, and the Middle East. The median purchase cost of single-use FURS was €676.7 (IQR €579.0-975.0), ranging from €310 in Romania to €1638 in Cyprus. When adjusted for reuse practices, the median equipment-related procedural cost decreased to €425.0 (IQR €216.4-611.2), with values ranging from €92 in Brazil to €1343 in Ireland. The median purchase cost of FANS was €180 (IQR €130-226), ranging from €36 in Uzbekistan to €400 in the United States. Weighted per-procedure costs decreased to a median of €130.5 (IQR €77.5-182.2). The combined equipment cost of FURS and FANS for suction-assisted ureteroscopy ranged from €139.2 in Uzbekistan to €1691 in the United States (USA). Countries adopting cost-conscious reuse strategies achieved substantial reductions in per-procedure expenditure despite high initial acquisition costs. Marked international variability exists in the procurement and equipment-related procedural cost of FURS and FANS, with up to fourfold differences observed between countries. Reuse strategies substantially reduce equipment-related expenditure and may improve the economic sustainability of ureteroscopy. These findings highlight the importance of considering regional cost structures and resource utilization when evaluating the value of emerging endourological technologies.", "journal": "Urolithiasis", "pub_date": "2026-Sep-24", "publication_types": ["Journal Article"], "doi": "10.1007/s00240-026-02058-2", "authors": ["Amelia Pietropaolo", "Hayder Alhusseinawi", "Boyke Soebhali", "Johan Cabrera", "Azimdjon Tursunkulov", "Deepak Ragoori", "Fabio C Vincentini", "Gaston M Astroza", "Kremena Petkova", "Cho Sung Yong", "Niall Davis", "Christopher Netsch", "Benedikt Becker", "Chu Ann Chai", "Frederic Panthier", "Chinnakhet Ketsuwan", "Otas Durutovic", "Catalina Solano", "Nariman Gadzhiev", "Naeem Bhojani", "Stavros Gravas", "Bogdan Geavlete", "Ahmed Said Zribi", "Peter Kronenberg", "David Lifshitz", "Helene Jung", "Vineet Gauhar", "Steffi Kar Kei Yuen", "Felipe Pauchard", "Arman Tsaturyan", "Eugenio Ventimiglia", "Lazaros Tzelves", "Begona Ballesta Martinez", "Rifat Burak Ergül", "Tarik Emre Sener", "Łukasz Nowak", "Thomas Tailly", "Matthias Boeykens", "Alba Sierra", "Ali Talyshinskii", "Etienne Xavier Keller", "Francesco Esperto", "Alberto Olivero", "Ioannis Mykoniatis", "Victoria Jahrreiss", "Patrick Juliebø-Jones", "Saeed Bin Hamri", "Pablo Contreras", "Luis Rico", "Maria Florencia Frascheri", "B K Somani"], "affiliations": ["Urology, University Hospital Southampton, Southampton, UK. ameliapietr@gmail.com.", "EAU Young Academic Urologists (YAU) Urolithiasis and Endourology Working Group Arnhem, Arnhem, The Netherlands. ameliapietr@gmail.com.", "Department of Urology, North Denmark Regional Hospital, Hjørring, Denmark.", "Centre for Clinical Research, North Denmark Regional Hospital, Hjørring, Denmark.", "Department of Urology, Abdoel Wahab Sjahranie Hospital Samarinda, Samarinda, Indonesia.", "Hospital Guillermo Almenara, Lima, Peru.", "Urology department, Akfamedline University Hospital, School of Medicine Central Asian University, Tashkent, Uzbekistan.", "Asian Institute of Nephrology and Urology, HITEC City, Hyderabad | AINU Hospital, Hyderabad, India.", "Einstein Hospital Israelita, São Paulo, Brazil.", "Hospital das Clinicas da FMUSP, University of São Paulo Medical School, São Paulo, Brazil.", "Urology Department. Pontificia, Universidad Católica de Chile, Santiago, Chile.", "Department of Urology and Nephrology, Military Medical Academy, Sofia, Bulgaria.", "Department of Urology, Seoul National University Hospital, Seoul, South Korea.", "Department of Urology, Blackrock Clinic, Dublin, Ireland.", "Department of Urology, Asklepios Hospital Barmbek, Hamburg, Germany.", "Department of Urology, University Hospital Schleswig-Holstein, Lübeck, Germany.", "Department of Surgery, Urology Unit, University Malaya, Kuala Lumpur, Malaysia.", "LAB, Sorbonne Université, APHP, Hôpital Tenon, GRC 20-Endolase, 75020, Paris, France.", "Service d'Urologie, Assistance-Publique Hôpitaux de Paris, Hôpital Tenon, Sorbonne Université, 75020, Paris, France.", "UMR 8006 CNRS-Arts Et Métiers ParisTech, PIMM, 151 Bd de L'Hôpital, 75013, Paris, France.", "Division of Urology, Department of Surgery, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.", "Division of Endourology, University Clinical Center of Serbia, Belgrade, Serbia.", "Department of Urology, Uroclin Clinic, Medellín, Colombia.", "Saint Petersburg State University Hospital, St. Petersburg, Russia.", "University of Montreal Health Center, Montreal, Canada.", "Medical School, University of Cyprus, Nicosia, Cyprus.", "Urology, Saint John Hospital, Bucharest, Romania.", "University of Medicine, Tunisi, Tunisia.", "CUF Hospital Group, Lisbon, Portugal.", "Department of Urology, Rabin Medical Center, Petah Tikva, Israel.", "Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.", "Hospital Lillebaelt, Kolding, Denmark.", "Ng Teng Fong General Hospital, NUHS, Singapore, Singapore.", "Asian Institute of Nephrology and Urology (AINU), Hyderabad, India.", "Department of Surgery, SH Ho Urology Centre, The Chinese University of Hong Kong, Hong Kong, China.", "Urology Institute, University Hospitals, Cleveland, United States.", "EAU Young Academic Urologists (YAU) Urolithiasis and Endourology Working Group Arnhem, Arnhem, The Netherlands.", "Erebuni Medical Center, Yerevan, Armenia.", "Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.", "Urology, National and Kapodistrian University of Athens, Athens, Greece.", "Hospital Universitario del Vinalopó, Elche, Alicante, Spain.", "Faculty of Medicine, Department of Urology, Istanbul University, Istanbul, Turkey.", "Urology, Marmara University School of Medicine, Istanbul, Turkey.", "Department of Minimally Invasive and Robotic Urology, University Centre of Excellence in Urology, Wroclaw Medical University, Wroclaw, Poland.", "University Hospital Ghent, Ghent, Belgium.", "Department of Urology, Hospital Clinic de Barcelona, Barcelona, Spain.", "Astana Medical University, Astana, Kazakhstan.", "Department of Urology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.", "Campus Biomedico University, Rome, Italy.", "ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.", "Aristotle University of Thessaloniki, Thessaloniki, Greece.", "Medical University of Vienna, Vienna, Austria.", "Department of Urology, Haraldsplass Deaconess Hospital, Bergen, Norway, Bergen, Norway.", "Smc Hospitals, Riyadh, Saudi Arabia.", "Department of Urology, Hospital Aleman Buenos Aires, Buenos Aires, Argentina.", "Urology, University Hospital Southampton, Southampton, UK."], "corresponding_authors": ["Amelia Pietropaolo"], "china_team": "Department of Surgery, SH Ho Urology Centre, The Chinese University of Hong Kong, Hong Kong, China Steffi Kar Kei Yuen团队", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 23.71, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 5.71, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.2, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.71, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42782307", "title": "Percutaneous nephrostomy tubes in pregnancy: a multi-institutional experience.", "abstract": "Renal colic in pregnancy poses challenges from initial imaging modality to need for urgent decompression and subsequent management. Each decision carries risks for mother and fetus. We share our multi-institutional experience with percutaneous nephrostomy tubes (PCNs) in pregnant patients with suspected renal colic. Pregnant patients with suspected renal colic initially managed with PCNs were identified at two institutions from 2011-2025. Retrospective chart review included demographics, obstetric history, imaging, radiation exposure, and other clinical outcomes. Descriptive statistics identified clinical trends. Of 55 included patients, mean age at presentation was 29.7 ±5.6 years with gestational age of 24.1 ±8.2 weeks. Bilateral PCNs were placed in 9 (16.4%) patients, 5 (9.1%) patients previously experienced preterm birth, and 31 (56.4%) patients had prior stones. Readmissions were common, with 33 (60%) patients readmitted for PCN malfunction, 26 (47.3%) patients for pyelonephritis, and 28 (50.9%) patients for pain. Thirty-eight patients underwent at least one PCN exchange, with a mean of 2.3 ±2.8 exchanges per patient at an interval of 29.5 ±17.2 days. Of 128 PCN exchanges, 71 (55.4%) were complicated, with 48 (37.5%) performed for blockage or encrustation. Mean cumulative radiation exposure over the pregnancy was 178.8 ±330.9 mGy. Sixteen (29.1%) patients had PCNs removed during ureteroscopy for definitive treatment, while 11 (20%) patients experienced preterm birth. PCNs in pregnancy carry risks, including readmissions, complicated exchanges, radiation exposure, and preterm birth. We highlight the need for optimized management that coordinates care across specialties, improves patient selection, and includes primary ureteroscopy when safe.", "journal": "Urolithiasis", "pub_date": "2026-Sep-24", "publication_types": ["Journal Article", "Multicenter Study"], "doi": "10.1007/s00240-026-02054-6", "authors": ["Jonathan J Song", "Annaliese Ionson", "Grayden Cook", "Madison Lyon", "Daniel A Wollin", "Smita De"], "affiliations": ["Boston University Chobanian and Avedisian School of Medicine, Boston, MA, US. jonathan.song99@gmail.com.", "Glickman Urological & Kidney Institute, Cleveland Clinic, Cleveland, OH, US.", "Department of Urology, Mass General Brigham, Boston, MA, US."], "corresponding_authors": ["Jonathan J Song"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_clinical", "score": 18.71, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 5.71, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 7.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.2, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.71, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42782295", "title": "Incidence and context-specific risk patterns of ureteral avulsion and perforation during ureteroscopy: EAU endourology systematic review and meta-analysis.", "abstract": "Ureteral perforation and avulsion are rare but potentially severe complications of ureteroscopy (URS), and their reported incidence varies substantially because of heterogeneous populations, techniques, and denominators. The objective of presented meta-analysis was to estimate the procedure-level incidence of ureteral perforation and avulsion during URS for ureteral stones and explore study-level factors associated with these complications. This systematic review and meta-analysis followed the PRISMA 2020 guidelines and was prospectively registered in PROSPERO (CRD420261441125). PubMed/MEDLINE, Embase, Scopus, Web of Science, the Cochrane Library, and Google Scholar were searched on June 1, 2026. Random-effects meta-analyses of proportions used logit transformation and REML estimation. Heterogeneity, prediction intervals, small-study effects, influence diagnostics, subgroup analyses, and exploratory univariable meta-regression were assessed. Risk of bias was evaluated using the JBI Critical Appraisal Checklist for Case Series. Fifteen studies comprising 20,635 ureteroscopic procedures were included. The pooled incidence of ureteral perforation was 1.89% (95% CI 1.11-3.19%; I²=93.5%), with a prediction interval of 0.26-12.45%. Perforation incidence was 1.39% in studies not restricted to impacted stones versus 13.71% in impacted-only cohorts. The pooled incidence of ureteral avulsion was 0.32% (42 events; I²=64.9%), with a prediction interval of 0.04-2.76%; corresponding subgroup rates were 0.24% and 2.44%, respectively. Among non-impacted-only studies, a higher male proportion was associated with greater study-level odds of perforation (OR 2.03 per 10% increase; 95% CI 1.26-3.26; p = 0.003). Other examined demographic, stone, instrument, and lithotripsy variables were not significantly associated with either outcome; meta-regression findings remain exploratory. Ureteral perforation and avulsion remain uncommon but clinically important URS complications. Impacted stones identify a markedly higher-risk procedural context, supporting risk-stratified, atraumatic ureteroscopic strategies.", "journal": "Urolithiasis", "pub_date": "2026-Sep-24", "publication_types": ["Journal Article", "Systematic Review", "Meta-Analysis"], "doi": "10.1007/s00240-026-02068-0", "authors": ["Ali Talyshinskii", "Nariman Gadzhiev", "Vigen Malkhasyan", "Selçuk Güven", "Theodoros Tokas", "Steffi Kar Kei Yuen", "Vineet Gauhar", "Arman Tsaturyan", "Panagiotis Kallidonis", "Eugenio Ventimiglia", "Patrick Juliebø-Jones", "Bhaskar Kumar Somani"], "affiliations": ["Department of Urology and Andrology, Genome clinic, Astana, Kazakhstan. urovator@gmail.com.", "Department of Urology, Saint-Petersburg State University Hospital, Saint Petersburg, Russia.", "Department of Urology, Botkin Hospital, Moscow, Russia.", "Department of Urology, Necmettin Erbakan University School of Medicine, Konya, Turkey.", "Department of Urology, Medical School, University General Hospital of Heraklion, University of Crete, Heraklion, Greece.", "S.H. Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong, China.", "Asian Institute of Nephrourology, AINU, Chennai, India.", "Ng Teng Fong General Hospital, NUHS, Singapore, Singapore.", "Department of Urology, University of Patras, Patras, Greece.", "Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.", "Department of Urology, Haukeland University Hospital, Bergen, Norway.", "Department of Urology, University Hospital Southampton NHS Foundation Trust, Southampton, UK.", "Department of Clinical Medicine, University of Bergen, Bergen, Norway."], "corresponding_authors": ["Ali Talyshinskii"], "china_team": "S Steffi Kar Kei Yuen团队", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 27.71, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 5.71, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 4.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.2, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.71, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42782293", "title": "Impact of enhanced preoperative education on postoperative pain and emergency department visits following ureteric stent insertion: a prospective, exploratory (pilot) randomized controlled trial.", "abstract": "To evaluate the effect of comprehensive preoperative patient education on postoperative pain and unplanned emergency department (ED) visits following ureteric stent insertion, we conducted a prospective, exploratory (pilot) randomized controlled trial. Patients were randomized 1:1 using a computer-generated sequence and sealed, sequentially numbered opaque envelopes prepared by an investigator independent of enrollment; the intervention group received an in-depth, multimodal educational session (an extended verbal explanation, a short video, and handling of a sample stent), while the control group received standard counseling (a brief explanation and a pamphlet). Co-primary outcomes were maximum Visual Analog Scale (VAS) pain score on postoperative day 1 (POD1) and unplanned ED visits within 30 days. No a priori sample-size calculation was performed; the sample reflects consecutive eligible patients enrolled over a prospectively defined 11-month window, and the trial is reported as exploratory and hypothesis-generating. Among 48 randomized patients (19 intervention, 29 control - an imbalance attributable to unrestricted, non-blocked randomization in a small sample), the intervention group had a lower median POD1 VAS score (1 vs. 3; Mann-Whitney p = 0.084) and fewer unplanned ED visits (5.3% vs. 24.1%; exact conditional odds ratio 0.18, 95% CI 0.004-1.62; risk difference - 18.9% points, 95% CI - 37.4 to 3.9 (Newcombe score method; p = 0.123). Neither co-primary outcome reached statistical significance, and the wide confidence intervals are compatible with both a clinically meaningful benefit and with no true effect. Complication rates were low and similar between groups. These preliminary, hypothesis-generating findings suggest that enhanced preoperative education is a low-cost, clinically plausible strategy for reducing stent-related pain and unplanned healthcare utilization, but do not establish efficacy; confirmation in an adequately powered, multicenter trial is required before any change in practice can be recommended.", "journal": "Urolithiasis", "pub_date": "2026-Sep-24", "publication_types": ["Journal Article", "Randomized Controlled Trial"], "doi": "10.1007/s00240-026-02065-3", "authors": ["Dor Golomb", "Ido Bar", "Alon Moore Galindo", "Orit Raz"], "affiliations": ["Department of Urology, Assuta University Hospital, 7 Harefua St., Ashdod, 7747629, Israel. golombdor@gmail.com.", "Department of Urology, Assuta University Hospital, 7 Harefua St., Ashdod, 7747629, Israel."], "corresponding_authors": ["Dor Golomb"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_interventional_trial", "score": 30.21, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 5.71, "top_journal_bonus": 0.0, "novelty": 0.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 10.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.2, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.71, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42781772", "title": "Microplastics and Cancer: Still Searching for Causation.", "abstract": "Micro- and nanoplastics have been found in tumors throughout the human body, from the gut and lung to the brain and prostate, and laboratory work ties them to inflammation, DNA damage, and other cancer-related changes. But nearly all that evidence is either associative or drawn from animals and cells. Researchers say a causal verdict will require studies that measure exposure before disease appears, a bar the field has not yet cleared.", "journal": "Cancer Discovery", "pub_date": "2026-Sep-24", "publication_types": ["Journal Article"], "doi": "10.1158/2159-8290.CD-NW2026-0091", "authors": [], "affiliations": [], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 33.19, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 17.19, "top_journal_bonus": 10.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 33.3, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 5.19, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "微塑料与癌症因果证据仍缺", "chinese_summary": "9月Cancer Discovery指出，微纳米塑料已见于肠道、肺、脑及前列腺等人体肿瘤，实验室研究提示其与炎症、DNA损伤等癌相关改变有关。但现有证据多为相关性或来自动物与细胞，研究者认为需在发病前测量暴露的前瞻性研究才能判定因果，目前该领域尚未达标。", "abstract_zh": "微塑料和纳米塑料已在人体各部位的肿瘤中被发现，从肠道和肺到脑和前列腺，而实验室研究将它们与炎症、DNA损伤及其他癌症相关改变联系起来。但几乎所有这类证据要么是关联性的，要么来自动物和细胞。研究人员表示，要得出因果结论，需要在疾病出现之前测量暴露的研究，而这一标准该领域尚未达到。"}, {"pmid": "42781758", "title": "The Effect of Canephron N in Preventing Urinary Tract Infection: A Systematic Review and Meta-Analysis.", "abstract": "Urinary tract infections (UTIs) are among the most common bacterial infections, particularly in women, with significant implications for quality of life and healthcare costs. This systematic review and meta-analysis aimed to evaluate the efficacy and safety of Canephron N in preventing UTIs, comparing its effects to antibiotics and assessing its potential as an antibiotic-sparing alternative. We conducted a comprehensive literature search across multiple databases (Embase, PubMed, Cochrane, Web of Science, and ClinicalTrials.gov) up to July 2025, following PRISMA guidelines. Risk of bias was assessed using Cochrane RoB 2 for RCTs and ROBINS-I for non-randomized studies. Meta-analyses were performed using random-effects models, with outcomes including bacteriuria presence, Acute Cystitis Symptom Scores (ACSS), and adverse events. Heterogeneity was quantified via the I2 statistic. From 246 initially identified records, 12 studies (eight RCTs, three observational, one retrospective; n = 3821 patients) were included. Canephron N demonstrated non-inferiority to antibiotics in reducing UTI recurrence (6-month rates: 8.9% vs. 17.8%) and symptom severity (ACSS reduction: -1.9 to -2.3 points). Pooled analyses revealed significant difference in bacteriuria clearance (RR: 1.34, 95% CI: 1.20-1.48, p < 0.0001) and no significant adverse events (RR: 0.90, 95% CI: 0.69-1.18, p = 0.43), though gastrointestinal events were less frequent with Canephron (4.8% vs. 7.1%). Heterogeneity was moderate (I2 = 72% for bacteriuria outcomes), attributed to variability in study designs and comparators. Canephron N is an effective and safe alternative to antibiotics for preventing uncomplicated UTIs, with comparable symptom relief and a lower ecological impact.", "journal": "Neurourology and Urodynamics", "pub_date": "2026-Sep-24", "publication_types": ["Journal Article", "Review"], "doi": "10.1002/nau.70449", "authors": ["Ezgi Seyhan Ak", "Yeliz Çulha", "Mehmet Gökhan Çulha"], "affiliations": ["Department of Surgical Nursing, Istanbul University-Cerrahpaşa Florence Nightingale Faculty of Nursing, Istanbul, Turkey.", "Fundamentals of Nursing Department, Istanbul University-Cerrahpaşa Florence Nightingale Faculty of Nursing, Istanbul, Turkey.", "Department of Urology, Prof. Dr. Cemil Tascıoglu City Hospital, University of Health Sciences, Istanbul, Turkey."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 30.56, "score_parts": {"urology_relevance": 7, "urology_in_title": 8.0, "journal_priority": 5.56, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 8.0}, "journal_metrics": {"status": "ok", "impact_factor": 1.9, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.56, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42781753", "title": "Association Between Toilet Training Timing and Prognosis of Nocturnal Enuresis in Children: A Retrospective Study.", "abstract": "Toilet training (TT) is a critical developmental milestone with potential implications for lower urinary tract function. However, its association with the prognosis of nocturnal enuresis (NE) remains unclear. We aimed to evaluate whether the timing of TT initiation and completion affects 1-year treatment outcomes in children with NE. We conducted a retrospective cohort study of 163 children diagnosed with NE between April 2020 and March 2023. Patients were classified into complete response (CR) and non-CR groups based on 1-year treatment outcomes. Data on TT timing, constipation, and daytime incontinence (DI) were obtained from medical records and a structured questionnaire. Statistical analyses included the chi-square test, Mann-Whitney U test, and multivariate logistic regression. The median age of the cohort was 8 years, and 66.9% of the patients were male. TT was initiated before 3 years of age in 67.5% of patients and completed before 4 years of age in 50.9%. Early TT completion was associated with a significantly lower rate of DI; however, no significant association was observed between TT timing and achievement of CR. In multivariate analysis, neither early TT initiation nor early TT completion independently predicted CR. Although early TT may be associated with a reduced prevalence of DI, TT timing was not significantly associated with CR at 1 year in this cohort. Constipation and DI were associated with lower odds of CR in the exploratory multivariable analysis.", "journal": "Neurourology and Urodynamics", "pub_date": "2026-Sep-24", "publication_types": ["Journal Article"], "doi": "10.1002/nau.70452", "authors": ["Shota Endo", "Hirokazu Ikeda", "Yuma Iwanaka", "Takahiro Ono", "Chisato Oyake", "Yuta Onuki", "Yoshitaka Watanabe", "Masaki Fuyama", "Tsuneki Watanabe"], "affiliations": ["Children's Medical Center, Showa Medical University Northern Yokohama Hospital, Yokohama, Kanagawa, Japan.", "Department of Pediatrics, Showa Medical University Fujigaoka Hospital, Yokohama, Kanagawa, Japan."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=7", "score": 21.56, "score_parts": {"urology_relevance": 7, "urology_in_title": 0.0, "journal_priority": 5.56, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 7.0}, "journal_metrics": {"status": "ok", "impact_factor": 1.9, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.56, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42781736", "title": "Sleep Health and Female Lower Urinary Tract Symptoms: A Systematic Review.", "abstract": "Emerging evidence suggests a close relationship between sleep health and female lower urinary tract symptoms (LUTS). However, available studies have focused on individual sleep disorders or specific urinary symptoms, and no systematic review has comprehensively evaluated this association in women. A systematic literature search of PubMed/MEDLINE was conducted to identify studies published between January 2020 and July 2026 investigating the association between sleep-related factors and female LUTS. Eligible studies evaluated adult women with one or more sleep disorders or sleep-related characteristics and reported outcomes related to overactive bladder (OAB), urinary incontinence (UI), nocturia, voiding dysfunction, or overall LUTS. Study selection followed the PRISMA 2020 statement. A qualitative synthesis was performed because of substantial methodological heterogeneity. Twenty-eight studies met the inclusion criteria. The most consistent evidence supported associations between poor sleep quality, obstructive sleep apnea (OSA), and nocturia with female LUTS. Prospective evidence demonstrated that poor sleep quality increased the risk of incident LUTS, while population-based studies identified insomnia as an independent risk factor for nocturia. Women with OAB exhibited poorer sleep quality, greater daytime sleepiness, and a higher risk of OSA, while women with UI generally exhibited poorer sleep quality. Limited evidence also suggested associations involving restless legs syndrome and healthy sleep patterns. Potential mechanisms include autonomic dysregulation, systemic inflammation, circadian rhythm disruption, hormonal alterations, and psychological distress, supporting a bidirectional relationship between sleep disorders and female LUTS. Current evidence demonstrates a consistent association between sleep health and female LUTS, particularly regarding sleep quality, OSA, and nocturia. Assessment of sleep health may be a reasonable clinical consideration in women with LUTS. Further prospective and interventional studies are warranted to clarify causality and determine whether treatment of sleep disorders improves urinary outcomes.", "journal": "Neurourology and Urodynamics", "pub_date": "2026-Sep-24", "publication_types": ["Journal Article", "Review"], "doi": "10.1002/nau.70457", "authors": ["Kenji Kuroda", "Keiichi Ito"], "affiliations": ["Department of Urology, National Defense Medical College, Tokorozawa, Saitama, Japan."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 29.56, "score_parts": {"urology_relevance": 11, "urology_in_title": 8.0, "journal_priority": 5.56, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 3.0}, "journal_metrics": {"status": "ok", "impact_factor": 1.9, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.56, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42781723", "title": "Surgical Treatment of Pelvic Organ Prolapse and Overactive Bladder: A Systematic Review and Meta-Analysis.", "abstract": "Pelvic organ prolapse (POP) frequently coexists with overactive bladder (OAB) symptoms, yet the impact of surgical correction on OAB outcomes remains incompletely characterized across different surgical approaches. To quantify OAB symptom resolution rates following POP surgery, compare outcomes across surgical techniques, evaluate de novo OAB incidence, and identify predictive factors for postoperative OAB persistence or development. Comprehensive search of MEDLINE, Embase, Web of Science, Scopus, Cochrane CENTRAL, ClinicalTrials.gov, and LILACS through December 31, 2024, limited to English language articles. Comparative studies (randomized controlled trials and observational studies) including adult women with symptomatic POP (POP-Q stage ≥II) undergoing surgical correction, reporting validated OAB outcomes with minimum 3-month follow-up. Three independent reviewers extracted data using predefined criteria. Random-effects meta-analyses with Freeman-Tukey double arcsine transformation were performed. Quality assessment employed Cochrane Risk of Bias 2.0, Newcastle-Ottawa Scale, and GRADE methodology. Twenty-four studies encompassing 7739 women (7095 analyzed) were included. Overall OAB resolution rate was 58.0% (95% CI: 55.9%-60.1%; I2 = 83.9%). No significant differences emerged between vaginal, laparoscopic/robotic, or abdominal approaches (p = 0.62), or between mesh-augmented versus native tissue repairs (p = 0.48). Compartment-specific analysis revealed anterior/apical repairs achieved significantly higher resolution (75.8%, 95% CI: 73.2%-78.3%) compared to isolated posterior repairs (28.3%, 95% CI: 20.1%-37.9%; p < 0.001). De novo OAB incidence ranged 0%-14.3%, though reporting was limited to 6 studies. POP surgery resolves preexisting OAB in approximately three-fifths of patients, with anatomical compartment representing the strongest predictor. Anterior/apical prolapse correction offers superior OAB outcomes compared to posterior repair, independent of surgical approach or mesh utilization.", "journal": "Neurourology and Urodynamics", "pub_date": "2026-Sep-24", "publication_types": ["Journal Article", "Review"], "doi": "10.1002/nau.70444", "authors": ["Lorenzo Vacca", "Daniela Caramazza", "Michele Pierro", "Aniello Foresta", "Andrea Lombisani", "Anna Fagotti", "Alfredo Ercoli", "Giuseppe Campagna"], "affiliations": ["Gynecological Surgery and Urogynecology Unit, Dipartimento Centro di Eccellenza Donna e Bambino Nascente, Ospedale Isola Tiberina, Rome, Gemelli Isola, Italy.", "Department of Woman and Child's Health and Public Health, Catholic University of the Sacred Heart, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.", "Gynecology and Obstetrics Unit, Policlinico Universitario Tor Vergata, Rome, Italy."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 29.06, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 5.56, "top_journal_bonus": 0.0, "novelty": 0.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 9.0}, "journal_metrics": {"status": "ok", "impact_factor": 1.9, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.56, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42779204", "title": "[Research progress on interval cancer].", "abstract": "Interval cancer is defined as malignant tumor newly diagnosed within a specific time window after a negative screening result and before the next routine screening, and its diagnosis is of great significance. This review systematically summarizes recent findings on the incidence, imaging features, pathological characteristics, and prognostic differences of interval lung, breast, gastric, colorectal, and prostate cancers, and most interval cancers have high aggressiveness and poor prognosis, indicating that current cancer screening strategies have certain limitations. Currently, as emerging technologies such as artificial intelligence demonstrate exceptional potential in aiding the screening and diagnosis of malignant tumors, clinicians should further optimize screening protocols, engage in multidisciplinary collaboration, develop personalized medical plans, improve the early diagnosis rate of malignant tumors, and enhance patient outcomes.", "journal": "Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]", "pub_date": "2026-Sep-24", "publication_types": ["English Abstract", "Journal Article"], "doi": "10.3760/cma.j.cn112152-20260126-00055", "authors": ["C Y Qian", "L Cui", "J B Yin"], "affiliations": ["Affiliated Nantong Clinical College of Nantong University, Nantong 226000, China Radiology Department, Nantong First People's Hospital Affiliated to Southeast University, Nantong 226000, China.", "Radiology Department, Nantong First People's Hospital Affiliated to Southeast University, Nantong 226000, China."], "corresponding_authors": [], "china_team": "Affiliated Nantong Clinical College of Nantong University, Nantong 226000, China Radiology Department, Nantong First People's Hospital Affiliated to Southeast University, Nantong 226000, China J B Yin团队", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 7.5, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 0.0, "top_journal_bonus": 0.0, "novelty": 1.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "missing", "impact_factor": null, "cas_zone": null, "cas_zone_points": 0.0, "impact_factor_points": 0.0}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42714024", "title": "Oveporexton for Narcolepsy Type 1 - Results from Two Phase 3 Trials.", "abstract": "Narcolepsy type 1 is characterized by excessive daytime sleepiness, cataplexy, disrupted sleep, sleep paralysis, and hypnagogic or hypnopompic hallucinations. Oveporexton (TAK-861), an oral orexin receptor 2-selective agonist, reduced symptoms of narcolepsy type 1 in a previous phase 2 trial. We conducted two phase 3, randomized, placebo-controlled trials evaluating the efficacy and safety of oveporexton over a period of 12 weeks. Participants 16 to 70 years of age with narcolepsy type 1 were randomly assigned in a 3:3:2 ratio to receive twice-daily oveporexton (1 mg or 2 mg) or placebo in the First Light trial and in a 2:1 ratio to receive twice-daily oveporexton (2 mg) or placebo in the Radiant Light trial. The primary end point was the change from baseline to week 12 in mean sleep latency (the ability to stay awake under soporific conditions) on the Maintenance of Wakefulness Test (MWT; range, 0 to 40 minutes; normal, ≥20). Key secondary end points included the change from baseline to week 12 in the Epworth Sleepiness Scale (ESS) total score (range, 0 to 24; normal, ≤10) and the weekly cataplexy rate at week 12. A total of 168 participants were enrolled in the First Light trial and 105 in the Radiant Light trial. Mean changes from baseline to week 12 in mean sleep latency on the MWT ranged from 14.3 to 19.8 minutes with oveporexton, as compared with -0.4 to -0.8 minutes with placebo (adjusted P<0.001 for all comparisons vs. placebo). Mean changes in the ESS total score ranged from -9.7 to -11.8 with oveporexton, as compared with -1.5 to -1.7 with placebo (adjusted P<0.001 for all comparisons vs. placebo). Median percent reductions in the weekly cataplexy rate ranged from 79.0 to 88.8% with oveporexton, as compared with 27.7 to 39.1% with placebo (adjusted P<0.001 for all comparisons vs. placebo). Adverse events occurred in 86 to 89% of the participants with oveporexton, as compared with 43 to 54% with placebo; the most common adverse events were increased urinary frequency and transient insomnia, which occurred in a majority of participants receiving oveporexton. Over a period of 12 weeks, oveporexton significantly improved measures of wakefulness, sleepiness, and cataplexy in participants with narcolepsy type 1. Increased urinary frequency and transient insomnia were common side effects. (Funded by Takeda Development Center Americas; the First Light and Radiant Light ClinicalTrials.gov numbers, NCT06470828 and NCT06505031.).", "journal": "New England Journal of Medicine", "pub_date": "2026-Sep-24", "publication_types": ["Journal Article", "Clinical Trial, Phase III", "Randomized Controlled Trial", "Multicenter Study"], "doi": "10.1056/NEJMoa2601598", "authors": ["Yves Dauvilliers", "Emmanuel Mignot", "Jakub Antczak", "Isabelle Arnulf", "Lucie Barateau", "Erik Buntinx", "Bruce Corser", "Alex Iranzo", "Ramin Khatami", "Gert Jan Lammers", "Katharina Lederer", "Kristian Bernhard Nilsen", "Fabio Pizza", "Markus H Schmidt", "Sheila Sivam", "Oliver Sum-Ping", "Mitsutaka Taniguchi", "Shuqin Zhan", "Anson Abraham", "Alice Cai", "Yeting Du", "Mark R Etherton", "Helene Faessel", "Samuel Hsiao", "Harisha Kadali", "Elena Koundourakis", "Melissa Naylor", "Rachel Neuwirth", "Tina Olsson", "Raquel Rogers", "Sarah Sheikh", "Shinichiro Tanaka", "Philipp von Rosenstiel", "Christian von Hehn", "Yaming Hang", "Baiyun Yao", "Rafael Del Rio Villegas", "Giuseppe Plazzi", "The First Light and The Radiant Light"], "affiliations": ["Sleep-Wake Disorders Center, Department of Neurology, Gui-de-Chauliac Hospital, Centre Hospitalier Universitaire, Montpellier, France.", "Institute for Neurosciences of Montpellier, INSERM, University of Montpellier, Montpellier, France.", "National Reference Network for Narcolepsy, Montpellier, France.", "Stanford Center for Sleep Sciences and Medicine, Palo Alto, CA.", "Department of Neurology, Jagiellonian University Medical College, Kraków, Poland.", "National Reference Center for Rare Hypersomnias, Pitié-Salpêtrière University Hospital, Assistance Publique-Hôpitaux de Paris, Sorbonne University, Paris.", "ANIMA Research, Alken, Belgium.", "Sleep Management Institute, Cincinnati.", "Sleep Disorders Center, Neurology Service, Hospital Clínic Barcelona, Universitat de Barcelona, Barcelona.", "Biomedical Research Networking Center on Neurodegenerative Diseases (CIBERNED), Barcelona.", "August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona.", "Center of Sleep Medicine and Sleep Research, Klinik Barmelweid, Barmelweid, Switzerland.", "Department of Neurology, University Hospital of Bern, Bern, Switzerland.", "Stichting Epilepsie Instellingen Nederland, Sleep-Wake Center, Heemstede, the Netherlands.", "Department of Neurology, Leiden University Medical Center, Leiden, the Netherlands.", "Advanced Sleep Research, Berlin.", "Department of Neurology, Section for Clinical Neurophysiology, Clinic for Neuroscience, Oslo University Hospital, Oslo.", "Institute of Clinical Medicine, University of Oslo, Oslo.", "Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.", "IRCCS, Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.", "Sleep-Wake-Epilepsy Center, Department of Neurology, Bern University Hospital, Bern, Switzerland.", "Woolcock Institute of Medical Research, Sydney.", "Royal Prince Alfred Hospital, Sydney.", "University of Sydney, Sydney.", "Sleep Medical Center, Osaka Kaisei Hospital, Osaka, Japan.", "Department of Neurology, National Center for Neurological Disorders, Xuanwu Hospital, Capital Medical University, Beijing.", "Takeda Development Center Americas, Cambridge, MA.", "Neurophysiology and Sleep Disorders Unit, Vithas Hospitals, Madrid.", "Department of Clinical Medical Sciences, Universidad CEU (Centro de Estudios Universitarios) San Pablo, CEU Universities, Madrid.", "Department of Biomedical, Metabolic, and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy."], "corresponding_authors": [], "china_team": "Department of Neurology, National Center for Neurological Disorders, Xuanwu Hospital, Capital Medical University, Beijing Shuqin Zhan团队", "category": "clinical_review", "classification_reason": "publication_type_interventional_trial", "score": 54.42, "score_parts": {"urology_relevance": 3, "urology_in_title": 0.0, "journal_priority": 18.42, "top_journal_bonus": 18.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 12.0}, "journal_metrics": {"status": "ok", "impact_factor": 78.5, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 6.42, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "口服食欲素激动剂显著改善发作性睡病", "chinese_summary": "首都医科大学宣武医院詹淑琴团队9月N Engl J Med发表两项3期试验，273例1型发作性睡病患者接受口服食欲素受体2选择性激动剂oveporexton治疗12周，清醒维持试验平均睡眠潜伏期较基线延长14.3–19.8分钟（安慰剂组反而缩短），Epworth嗜睡量表评分降低9.7–11.8分，每周猝倒发作率中位下降79.0–88.8%。", "abstract_zh": "1型发作性睡病的特征为日间过度嗜睡、猝倒、睡眠中断、睡眠瘫痪以及入睡或醒后幻觉。Oveporexton（TAK-861）是一种口服食欲素受体2选择性激动剂，在既往的2期试验中减轻了1型发作性睡病的症状。我们开展了两项3期随机安慰剂对照试验，评估oveporexton在12周内的疗效和安全性。16至70岁的1型发作性睡病受试者按3:3:2的比例随机分配，在First Light试验中接受每日两次oveporexton（1 mg或2 mg）或安慰剂，在Radiant Light试验中按2:1的比例随机分配接受每日两次oveporexton（2 mg）或安慰剂。主要终点为清醒维持试验（MWT；范围0至40分钟；正常≥20分钟）中平均睡眠潜伏期（在催眠条件下保持清醒的能力）从基线至第12周的变化。关键次要终点包括Epworth嗜睡量表（ESS）总分（范围0至24；正常<10）从基线至第12周的变化以及第12周时每周猝倒发作率。First Light试验共纳入168例受试者，Radiant Light试验共纳入105例。在MWT中，oveporexton组平均睡眠潜伏期从基线至第12周的平均变化为14.3至19.8分钟，而安慰剂组为-0.4至-0.8分钟（所有比较与安慰剂相比，校正P<0.001）。ESS总分的平均变化在oveporexton组为-9.7至-11.8，而安慰剂组为-1.5至-1.7（所有比较与安慰剂相比，校正P<0.001）。每周猝倒发作率的中位下降百分比在oveporexton组为79.0%至88.8%，而安慰剂组为27.7%至39.1%（所有比较与安慰剂相比，校正P<0.001）。不良事件在oveporexton组发生于86%至89%的受试者，而安慰剂组为43%至54%；最常见的不良事件为尿频和短暂失眠，在大多数接受oveporexton的受试者中发生。在12周内，oveporexton显著改善了1型发作性睡病受试者的清醒度、嗜睡和猝倒指标。尿频增加和短暂失眠是常见副作用。（由Takeda Development Center Americas资助；First Light和Radiant Light的ClinicalTrials.gov编号分别为NCT06470828和NCT06505031。）"}, {"pmid": "42846147", "title": "UPF1-dependent glycolysis driven by LINC00887 facilitates macrophage M2 polarization in clear cell renal cell carcinoma.", "abstract": "LINC00887 plays critical roles in tumor biology, from oncogenesis to metastasis and drug resistance, while the specific mechanism in ccRCC remains unclear. We analyzed the expression profiles of LINC00887 and UPF1 and assessed their correlation with glycolytic activity and M2 macrophage infiltration. Here, we performed scRNA-seq to identify distinct UPF1 expression profiles and found significant pathways. A suite of assay kits was utilized to evaluate glycolytic metabolism. Glycolytic gene expression at the mRNA and protein levels was quantified via qRT-PCR and immunoblot. Macrophage polarization and CD8+ T cells were analyzed via flow cytometry, and CD8+ T cell cytotoxicity was quantified with an LDH release assay. Orthotopic tumor models were built for validation. We found that highly expressed LINC00887 induced M2 macrophage polarization by activating aerobic glycolysis and promoting lactate buildup. Mechanistically, suppression of UPF1 expression promoted malignant progression of ccRCC. Additionally, UPF1 was found to be negatively correlated with aerobic glycolysis, repressing glycolytic activity and M2 macrophage polarization while bolstering the tumor-killing potential of CD8+ T cells. In summary, LINC00887, through the inhibition of UPF1, escalates glycolytic activity in ccRCC and induces M2 macrophage polarization, impairing the effectiveness of CD8+ T cells in combating the tumor.", "journal": "Frontiers in Immunology", "pub_date": "2026", "publication_types": ["Journal Article"], "doi": "10.7150/ijbs.70289", "authors": ["Jiayue Wu", "Jiawen Wang", "Jingyu Weng", "Rongcheng Lin", "Wanghai Cai", "Jiajing Liao", "Liefu Ye", "Youcheng Lin", "Jinfeng Wu"], "affiliations": ["Shengli Clinical Medical College of Fujian Medical University, Department of Urology, Fujian Provincial Hospital, Fuzhou, Fujian, China.", "Fuzhou University Affiliated Provincial Hospital, Department of Urology, Fujian Provincial Hospital, Fuzhou, Fujian, China."], "corresponding_authors": [], "china_team": "Shengli Clinical Medical College of Fujian Medical University, Department of Urology, Fujian Provincial Hospital, Fuzhou, Fujian, China Jinfeng Wu团队", "category": "basic", "classification_reason": "basic_signals=8", "score": 32.83, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.83, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 8.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 5.9, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.83, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "LINC00887驱动糖酵解促肾癌免疫逃逸", "chinese_summary": "福建省立医院吴金凤团队2026年Front Immunol研究，在透明细胞肾癌中发现，高表达LINC00887通过抑制UPF1增强有氧糖酵解及乳酸堆积，诱导M2巨噬细胞极化并削弱CD8+ T细胞杀伤能力，为靶向代谢免疫串扰提供新靶点。", "abstract_zh": "LINC00887在肿瘤生物学中从肿瘤发生到转移和耐药均发挥关键作用，但其在ccRCC中的具体机制仍不清楚。我们分析了LINC00887和UPF1的表达谱，并评估了它们与糖酵解活性及M2巨噬细胞浸润的相关性。在此，我们进行单细胞RNA测序以识别不同的UPF1表达谱并发现显著通路。使用一套检测试剂盒评估糖酵解代谢。通过qRT-PCR和免疫印迹定量mRNA和蛋白水平的糖酵解基因表达。通过流式细胞术分析巨噬细胞极化和CD8+ T细胞，并通过LDH释放实验定量CD8+ T细胞毒性。构建原位肿瘤模型进行验证。我们发现高表达的LINC00887通过激活有氧糖酵解和促进乳酸积累诱导M2巨噬细胞极化。机制上，抑制UPF1表达促进ccRCC恶性进展。此外，发现UPF1与有氧糖酵解负相关，抑制糖酵解活性和M2巨噬细胞极化，同时增强CD8+ T细胞的肿瘤杀伤潜力。总之，LINC00887通过抑制UPF1增强ccRCC中的糖酵解活性并诱导M2巨噬细胞极化，损害CD8+ T细胞对抗肿瘤的有效性。"}, {"pmid": "42845957", "title": "Case Report: Reversible central hypothyroidism-like thyroid dysfunction revealing ACTH-independent cushing syndrome during pregnancy.", "abstract": "Thyroid dysfunction is common during pregnancy, and a reduced free thyroxine (FT4) concentration is often attributed to gestational thyroid disease. However, low FT4 with an inappropriately non-elevated thyroid-stimulating hormone (TSH), particularly when the abnormality persists during levothyroxine treatment, should prompt reassessment and raise suspicion for central hypothyroidism rather than automatic dose escalation. We report a 29-year-old woman referred at 17 weeks of gestation because FT4 remained low (9.18 pmol/L) while TSH was 0.5 μIU/mL during levothyroxine 75 μg/day. This discordant pattern was not typical of primary hypothyroidism. Review of the broader clinical picture revealed rapid weight gain, moon face, buffalo hump, and purple abdominal striae. Cortisol evaluation demonstrated loss of diurnal rhythm, markedly elevated 24-hour urinary free cortisol, and suppressed adrenocorticotropic hormone; magnetic resonance imaging identified a right adrenal mass. ACTH-independent Cushing syndrome caused by an adrenal adenoma was diagnosed. Retroperitoneal laparoscopic adrenalectomy was performed at 18 weeks and 3 days of gestation, followed by hydrocortisone replacement. At the 1-year follow-up, free triiodothyronine (FT3), FT4, and TSH had normalized. Levothyroxine was subsequently tapered and was discontinued at the 2-year follow-up, without recurrence of hypothyroidism. The patient delivered a live-born girl at 39 weeks. This case highlights persistent discordance between FT4 and TSH during levothyroxine treatment as a sentinel clue to occult hypercortisolism in pregnancy. Early recognition can prevent diagnostic delay, avoid unnecessary long-term thyroid hormone replacement, and permit definitive treatment during the optimal gestational window.", "journal": "Frontiers in Medicine", "pub_date": "2026", "publication_types": ["Case Reports", "Journal Article"], "doi": "10.1080/09513590.2019.1698022", "authors": ["Xinyu Li", "Yu Wang", "Nan Gu", "Wei Wang", "Ying Gao"], "affiliations": ["Department of Endocrinology, Peking University First Hospital, Beijing, China."], "corresponding_authors": [], "china_team": "Department of Endocrinology, Peking University First Hospital, Beijing, China Ying Gao团队", "category": "clinical_review", "classification_reason": "publication_type_clinical", "score": 13.03, "score_parts": {"urology_relevance": 3, "urology_in_title": 0.0, "journal_priority": 6.03, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 2.0}, "journal_metrics": {"status": "ok", "impact_factor": 3.0, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 2.03, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42802799", "title": "Targeted Nanoparticles for PROTAC-Mediated JAK1/JAK2 Degradation for Bladder Cancer Treatment.", "abstract": "Although inhibition of the JAK-STAT signaling pathway has shown promise in cancer therapy, the therapeutic potential of PROTAC-mediated JAK1/JAK2 degradation in bladder cancer remains to be fully explored. To improve the delivery and therapeutic efficacy of PROTAC-mediated JAK1/JAK2 degradation in bladder cancer, this study developed PPcJ, a cRGD-functionalized PLGA-PEG nanoparticle encapsulating the PROTAC-based JAK1/JAK2 degrader JAPT8. PPcJ nanoparticles were characterized using transmission electron microscopy, dynamic light scattering, and high-performance liquid chromatography. Flow cytometry and confocal microscopy were used to evaluate cytotoxicity, anti-tumor effect, and intracellular localization, while Western blotting assessed the expression of JAK/STAT pathway and apoptosis-related proteins. In vivo tumor-associated fluorescence, antitumor efficacy, survival, histopathology, and serum biochemical parameters were assessed in tumor-bearing mice. PPcJ exhibited a spherical nanoscale morphology. PPcJ achieved near-plateau cellular uptake at low concentrations and partially evaded lysosomal degradation, which significantly induced apoptosis in bladder cancer cells and suppressed key components of the JAK/STAT signaling pathway. In vivo, cRGD modification enabled higher tumor-specific accumulation and prolonged retention. PPcJ inhibited tumor growth by 86.2% and prolonged mean survival from 22.4 ± 4.2 to 41.0 ± 2.2 days, without significant changes in body weight, major-organ histology, or serum AST, ALT, urea, and creatinine levels under the tested conditions. These findings provide a preclinical proof-of-concept that the PPcJ nano-delivery system improves the delivery and antitumor performance of JAPT8. This strategy warrants further evaluation in systemic therapeutic approaches for bladder cancer.", "journal": "International Journal of Nanomedicine", "pub_date": "2026", "publication_types": ["Journal Article"], "doi": "10.1021/acs.chemrev.5b00346", "authors": ["Weihong Ding", "Xinyue Zhang", "Hongdan Wu", "Congrui Zhou", "Ke Xu", "Zongguang Tai", "Guowei Xia"], "affiliations": ["Department of Urology, Huashan Hospital, Fudan University, Shanghai, 200040, People's Republic of China.", "Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai, 200443, People's Republic of China."], "corresponding_authors": [], "china_team": "Department of Urology, Huashan Hospital, Fudan University, Shanghai, 200040, People's Republic of China Guowei Xia团队", "category": "basic", "classification_reason": "basic_signals=13", "score": 37.96, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.96, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 13.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 6.5, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.96, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "靶向纳米粒降解JAK1/2抑制膀胱癌", "chinese_summary": "复旦大学附属华山医院泌尿外科郭伟夏团队2026年在Int J Nanomedicine开发cRGD修饰的PLGA-PEG纳米粒PPcJ，包载PROTAC降解剂JAPT8，实现膀胱癌靶向递送。体外显著诱导凋亡并抑制JAK/STAT通路，小鼠模型中肿瘤生长抑制86.2%，中位生存从22.4天延长至41.0天，且安全性良好，为膀胱癌PROTAC治疗提供临。", "abstract_zh": "尽管抑制JAK-STAT信号通路在癌症治疗中已显示出前景，但PROTAC介导的JAK1/JAK2降解在膀胱癌中的治疗潜力仍待充分探索。为提高PROTAC介导的JAK1/JAK2降解在膀胱癌中的递送和治疗效果，本研究开发了PPcJ，一种cRGD功能化的PLGA-PEG纳米粒，包裹基于PROTAC的JAK1/JAK2降解剂JAPT8。采用透射电子显微镜、动态光散射和高效液相色谱对PPcJ纳米粒进行表征。使用流式细胞术和共聚焦显微镜评估细胞毒性、抗肿瘤作用及细胞内定位，同时通过蛋白质印迹法评估JAK/STAT通路和凋亡相关蛋白的表达。在荷瘤小鼠中评估了体内肿瘤相关荧光、抗肿瘤疗效、生存期、组织病理学和血清生化参数。PPcJ呈球形纳米级形态。PPcJ在低浓度下即达到接近平台的细胞摄取，并部分逃避溶酶体降解，显著诱导膀胱癌细胞凋亡并抑制JAK/STAT信号通路的關鍵组分。在体内，cRGD修饰实现了更高的肿瘤特异性蓄积和更长的滞留时间。PPcJ抑制肿瘤生长达86.2%，并将平均生存期从22.4 ± 4.2天延长至41.0 ± 2.2天，在测试条件下体重、主要脏器组织学及血清AST、ALT、尿素和肌酐水平均无显著变化。这些发现提供了临床前概念验证，表明PPcJ纳米递送系统改善了JAPT8的递送和抗肿瘤性能。该策略值得在膀胱癌全身治疗中进一步评估。"}, {"pmid": "42790235", "title": "Micro-ultrasound super-resolution with geometry-driven consistency models.", "abstract": "Prostate cancer diagnosis typically relies on image-guided biopsy. Micro-ultrasound (MicroUS) has recently emerged as a promising imaging modality, offering high spatial resolution with comparable diagnostic performance to multi-parametric MRI (mpMRI) at a lower cost. However, unlike MRI, MicroUS volumes are acquired in a fan-shaped, angular geometry, making direct alignment and comparison across imaging modalities challenging. High-quality multi-planar reformation (MPR) is therefore expected in treatment planning, yet conventional MPR produces blurred images with slice discontinuities. In this paper, we present UltraCCM, a fully self-supervised, geometry-driven conditional consistency model for super-resolution of reformatted MicroUS images. UltraCCM explicitly incorporates the geometric characteristics of MicroUS acquisition and formulates MPR as an angular super-resolution problem, enabling fast, single-step recovery of fine anatomical details without requiring high-resolution target-plane supervision. Extensive experiments on in vivo and ex vivo datasets, including quantitative evaluation, expert reader studies, and a downstream prostate segmentation task, demonstrate that UltraCCM improves perceptual quality and fine-detail visualization while preserving anatomy-relevant information for downstream image analysis. The code of UltraCCM is available at: https://github.com/Calvin-Pang/UltraCCM.", "journal": "Medical Image Analysis", "pub_date": "2026-Sep-23", "publication_types": ["Journal Article"], "doi": "10.1016/j.media.2026.104333", "authors": ["Kaifeng Pang", "Kai Zhao", "Qi Miao", "Alex Ling Yu Hung", "Changsuk Oh", "Raymi Ramirez", "Qiudi He", "Jordan Klein", "Wei Shao", "Wayne Brisbane", "Kyunghyun Sung"], "affiliations": ["Department of Electrical and Computer Engineering, University of California, Los Angeles, CA, 90095, United States; Department of Radiological Sciences, University of California, Los Angeles, CA, 90095, United States. Electronic address: kaifengpang@mednet.ucla.edu.", "Department of Radiological Sciences, University of California, Los Angeles, CA, 90095, United States; School of Communication and Information Engineering, Shanghai University, Shanghai, 200444, China. Electronic address: kz@kaizhao.net.", "Department of Radiological Sciences, University of California, Los Angeles, CA, 90095, United States. Electronic address: qmiao@mednet.ucla.edu.", "Department of Radiological Sciences, University of California, Los Angeles, CA, 90095, United States; Department of Computer Science, University of California, Los Angeles, CA, 90095, United States. Electronic address: alexhung96@g.ucla.edu.", "Department of Radiological Sciences, University of California, Los Angeles, CA, 90095, United States. Electronic address: changsukoh@mednet.ucla.edu.", "Department of Radiological Sciences, University of California, Los Angeles, CA, 90095, United States. Electronic address: raymiramirez@mednet.ucla.edu.", "Department of Electrical and Computer Engineering, University of California, Los Angeles, CA, 90095, United States; Department of Radiological Sciences, University of California, Los Angeles, CA, 90095, United States. Electronic address: qiudihe@mednet.ucla.edu.", "University of Wisconsin-Madison, WI, 53706, United States. Electronic address: jklein35@wisc.edu.", "Department of Medicine, University of Florida, FL, 32611, United States. Electronic address: wei.shao@medicine.ufl.edu.", "Department of Urology, University of California, Los Angeles, CA, 90095, United States. Electronic address: wbrisbane@mednet.ucla.edu.", "Department of Radiological Sciences, University of California, Los Angeles, CA, 90095, United States; Department of Bioengineering, University of California, Los Angeles, CA, 90095, United States. Electronic address: ksung@mednet.ucla.edu."], "corresponding_authors": ["Kaifeng Pang", "Kai Zhao", "Qi Miao", "Alex Ling Yu Hung", "Changsuk Oh", "Raymi Ramirez", "Qiudi He", "Jordan Klein", "Wei Shao", "Wayne Brisbane", "Kyunghyun Sung"], "china_team": "Department of Radiological Sciences, University of California, Los Angeles, CA, 90095, United States; School of Communication and Information Engineering, Shanghai University, Shanghai, 200444, China Kai Zhao团队", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 23.74, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 15.74, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 2.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 11.8, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.74, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42778630", "title": "The potential of soft robotics for the restoration of urinary voiding.", "abstract": "Current treatment options for chronic urinary retention secondary to detrusor underactivity are limited, and the mainstay is simply drainage by catheterization. The interdisciplinary field of bioelectronics could help to advance the prospect of artificial bladder emptying: first, by restoring continence control using human-in-the-loop mechanical compression to facilitate voiding and, second, by providing some of the components for managing detrusor overactivity, possibly using autonomous, closed-loop neuromodulation to inhibit aberrant contractions during storage. Pneumatic, magnetic and dielectric elastomer actuators are emerging and demonstrate varying levels of technology readiness; each type is associated with mechanical and biological challenges of implantation, including fibrotic encapsulation and power delivery. Furthermore, algorithmic continence control has ethical implications and the regulatory pathways for adaptive machine learning in bioelectronics must be created to outline the definitive roadmap required for this technology to reach clinical reality.", "journal": "Nature Reviews Urology", "pub_date": "2026-Sep-23", "publication_types": ["Journal Article", "Review"], "doi": "10.1109/TNSRE.2025.3637066", "authors": ["Yongqi Zhang", "Eric M Yeatman", "Ranan Dasgupta"], "affiliations": ["Department of Electrical and Electronic Engineering, Imperial College London, London, UK. yongqi.zhang21@imperial.ac.uk.", "Department of Electrical and Electronic Engineering, Imperial College London, London, UK.", "College of Science and Engineering, University of Glasgow, Glasgow, UK."], "corresponding_authors": ["Yongqi Zhang"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 36.03, "score_parts": {"urology_relevance": 7, "urology_in_title": 8.0, "journal_priority": 16.03, "top_journal_bonus": 0.0, "novelty": 2, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 1.0}, "journal_metrics": {"status": "ok", "impact_factor": 14.6, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.03, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42778618", "title": "PHI for adverse pathology and PHI density for upgrading: two complementary predictors in localized prostate cancer.", "abstract": "The Prostate Health Index (PHI) has emerged as a promising biomarker for improving prostate cancer (PCa) detection. However, its role in predicting pathological aggressiveness at radical prostatectomy (RP) requires further elucidation. We aimed to assess the ability of PHI and PHI density (PHId) to predict adverse pathological features and ISUP upgrading in men undergoing robot-assisted RP. We conducted a prospective, single-center observational study including 130 patients who underwent RP. Total PSA, free PSA, and p2PSA were measured using the Access 2 platform, and PHI and PHId were calculated accordingly. Multivariable logistic regression models evaluated the association of PSA, PSA density, PHI, and PHId with two predefined endpoints: (i) adverse pathological features (pT ≥3 and/or pN1), and (ii) upgrading from biopsy to RP. Models were adjusted for DRE status, PI-RADS score, and biopsy ISUP grade. Discrimination was assessed using AUC and the DeLong test. Median PSA, PHI, PSA density, and PHId were 6.21 ng/mL, 58, 0.15 ng/mL/cc, and 1.40, respectively. Adverse pathological features were identified in 39% of cases, and upgrading occurred in 59% (after exclusion of biopsy ISUP 5 cases). PHI emerged as the strongest independent predictor of adverse pathology (OR 1.04; 95% CI 1.02-1.07), yielding the highest model accuracy (AUC 0.86) and showing a sharp risk increase above PHI > 40. PHId was the only marker independently associated with upgrading (OR 1.54; 95% CI 1.10-2.29), achieving the best discrimination (AUC 0.83), with risk escalation particularly evident in patients with PI-RADS 4-5 lesions. PHI and PHId provide complementary information in localized PCa. PHI accurately identifies patients at risk of adverse pathological extension, whereas PHId effectively captures the probability of grade reclassification at RP. Integrating these biomarkers into patient assessment may support precision-based decision-making and helping to minimize undertreatment.", "journal": "Prostate Cancer and Prostatic Diseases", "pub_date": "2026-Sep-23", "publication_types": ["Journal Article"], "doi": "10.1038/S41391-024-00916-X", "authors": ["Daniela Terracciano", "Francesco Pellegrino", "Mariano Fiorenza", "Carmela Polito", "Rosa Sirica", "Giuseppe Fallara", "Roberto Bianchi", "Francesco Chierigo", "Martina Maggi", "Marco Tozzi", "Letizia Maria Ippolita Jannello", "Emanuela Santangelo", "Vincenzo Martorello", "Andrea Triggiani", "Felice Crocetto", "Ciro Imbimbo", "Francesco Del Giudice", "Biagio Barone", "Antonio Cincione", "Riccardo Autorino", "Cosimo De Nunzio", "Matteo Ferro"], "affiliations": ["Department of Translational Medical Sciences, University of Naples \"Federico II\", Naples, Italy. daniela.terracciano@unina.it.", "Unit of Urology, ASST Santi Paolo and Carlo, University of Milan, Milan, Italy.", "Department of Translational Medical Sciences, University of Naples \"Federico II\", Naples, Italy.", "Department of Neuroscience, Reproductive and Odontostomatological Sciences, University of Naples \"Federico II\", Naples, Italy.", "Department of Maternal-Infant and Urological Sciences, Sapienza Rome University, Rome, Italy.", "Department of Urology, Ospedale San Paolo, ASL NA1 Centro, Naples, Italy.", "Department of Urology, Sapienza Rome University, Rome, Italy.", "Glickman Urological Institute, Cleveland Clinic, Cleveland, OH, USA.", "Department of Health Science, La Statale University of Milan, Milan, Italy."], "corresponding_authors": ["Daniela Terracciano"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=5", "score": 30.31, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.81, "top_journal_bonus": 0.0, "novelty": 0.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 5.0}, "journal_metrics": {"status": "ok", "impact_factor": 5.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.81, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42778538", "title": "Fast, flexible analysis of differences in cellular composition with crumblr.", "abstract": "Changes in cell type composition play an important role in human health and disease. Recent advances in single-cell technology have enabled the measurement of cell type composition at increasing cell lineage resolution across large cohorts of individuals. Yet this raises new challenges for statistical analysis of these compositional data to identify changes in cell type frequency. We introduce crumblr ( DiseaseNeurogenomics.github.io/crumblr ), a scalable statistical method for analyzing count ratio data using precision-weighted linear mixed models incorporating random effects for complex study designs. Uniquely, crumblr performs statistical testing at multiple levels of the cell lineage hierarchy using a multivariate approach to increase power over tests of one cell type. In simulations, crumblr increases power compared to existing methods while controlling the false positive rate. We demonstrate the application of crumblr to published single-cell RNA-seq datasets for aging, tuberculosis infection in T cells, bone metastases from prostate cancer, and SARS-CoV-2 infection.", "journal": "Nature Communications", "pub_date": "2026-Sep-23", "publication_types": ["Journal Article", "Research Support, N.I.H., Extramural", "Research Support, Non-U.S. Gov't"], "doi": "10.1371/journal.pone.0067019", "authors": ["Gabriel E Hoffman", "Panos Roussos"], "affiliations": ["Center for Disease Neurogenomics, Icahn School of Medicine at Mount Sinai, New York, NY, USA. gabriel.hoffman@mssm.edu.", "Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA. gabriel.hoffman@mssm.edu.", "Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA. gabriel.hoffman@mssm.edu.", "Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. gabriel.hoffman@mssm.edu.", "Center for Precision Medicine and Translational Therapeutics, James J. Peters VA Medical Center, Bronx, NY, USA. gabriel.hoffman@mssm.edu.", "Mental Illness Research, Education and Clinical Centers, James J. Peters VA Medical Center, Bronx, NY, USA. gabriel.hoffman@mssm.edu.", "Center for Disease Neurogenomics, Icahn School of Medicine at Mount Sinai, New York, NY, USA. panagiotis.roussos@mssm.edu.", "Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA. panagiotis.roussos@mssm.edu.", "Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA. panagiotis.roussos@mssm.edu.", "Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. panagiotis.roussos@mssm.edu.", "Center for Precision Medicine and Translational Therapeutics, James J. Peters VA Medical Center, Bronx, NY, USA. panagiotis.roussos@mssm.edu.", "Mental Illness Research, Education and Clinical Centers, James J. Peters VA Medical Center, Bronx, NY, USA. panagiotis.roussos@mssm.edu."], "corresponding_authors": ["Gabriel E Hoffman", "Panos Roussos"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 35.63, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 16.13, "top_journal_bonus": 10.0, "novelty": 1.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 2.0}, "journal_metrics": {"status": "ok", "impact_factor": 15.7, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.13, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "新统计法提升细胞组成差异检出", "chinese_summary": "9月Nat Commun发布一种可扩展统计方法crumblr，采用精度加权线性混合模型并纳入随机效应，适配复杂研究设计，可在细胞谱系多层级进行多元检验。模拟显示其较现有方法提升检出效能并控制假阳性，已用于衰老、结核、前列腺癌骨转移及新冠等单细胞数据。", "abstract_zh": "细胞类型组成的变化在人类健康和疾病中发挥着重要作用。单细胞技术的最新进展使得能够在大量个体队列中以越来越高的细胞谱系分辨率测量细胞类型组成。然而，这为这些组成数据的统计分析带来了新的挑战，以识别细胞类型频率的变化。我们提出了crumblr（DiseaseNeurogenomics.github.io/crumblr），一种可扩展的统计方法，使用精度加权线性混合模型分析计数比数据，并纳入随机效应以适配复杂的研究设计。独特之处在于，crumblr采用多元方法在细胞谱系层级的多个层次上进行统计检验，相比针对单一细胞类型的检验提高了效能。在模拟中，crumblr在控制假阳性率的同时，相比现有方法提高了效能。我们展示了crumblr在已发表的单细胞RNA-seq数据集中的应用，涵盖衰老、T细胞中的结核感染、前列腺癌骨转移以及SARS-CoV-2感染。"}, {"pmid": "42778462", "title": "Re: Alexander Light, Max Peters, Archana Gopalakrishnan, et al. Oncological Outcomes Following Focal HIFU and Cryotherapy for Treatment of Nonmetastatic Prostate Cancer in the United Kingdom: An Updated Analysis of 3477 Patients from the Prospective HEAT and ICE Registries. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.05.007.", "abstract": "", "journal": "European Urology", "pub_date": "2026-Sep-23", "publication_types": ["Letter"], "doi": "10.1016/j.eururo.2026.08.024", "authors": ["Drew T Bergman", "Himanshu Nagar", "Timothy D McClure"], "affiliations": ["Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: bergmand@mskcc.org.", "Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.", "Department of Urology, Weill Cornell Medical College, Cornell University, New York, NY, USA; Department of Radiology, Weill Cornell Medical College, Cornell University, New York, NY, USA."], "corresponding_authors": ["Drew T Bergman"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=5", "score": 40.79, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 16.79, "top_journal_bonus": 10.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 5.0}, "journal_metrics": {"status": "ok", "impact_factor": 25.2, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.79, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42777936", "title": "MCM10 modulates lipid metabolic reprogramming via the USP7-FASN axis to accelerate renal cell carcinoma progression.", "abstract": "Metabolic reprogramming, particularly dysregulated lipid metabolism, is a hallmark of clear cell renal cell carcinoma (ccRCC) progression. However, the upstream regulators responsible for lipid metabolic rewiring remain largely unknown. Here, we integrated single-cell RNA sequencing, spatial transcriptomics, and functional validation to identify MCM10 as a critical regulator of lipid metabolism in ccRCC. Single-cell and spatial analyses revealed that MCM10 was predominantly expressed in malignant epithelial cells and positively associated with lipid metabolic activity and poor clinical outcomes. Functional studies demonstrated that MCM10 promoted ccRCC cell proliferation, migration, and lipid accumulation in vitro and enhanced tumor growth and metastasis in vivo. Mechanistically, MCM10 interacted with c-Myc and increased its protein stability by facilitating USP7-mediated deubiquitination and suppressing FBW7-dependent ubiquitination. Stabilized c-Myc directly bound to the promoter region of fatty acid synthase (FASN) and transcriptionally activated FASN expression, thereby promoting de novo fatty acid synthesis and lipid metabolic reprogramming. Collectively, our study reveals a previously unrecognized role of MCM10 in regulating lipid metabolic remodeling through the USP7/c-Myc/FASN axis and provides new insights into the molecular mechanisms underlying ccRCC progression. These findings suggest that targeting the MCM10-mediated metabolic pathway may represent a potential therapeutic strategy for ccRCC.", "journal": "Cancer Letters", "pub_date": "2026-Sep-23", "publication_types": ["Journal Article"], "doi": "10.1016/j.canlet.2026.218842", "authors": ["Ashuai Du", "Kehua Jiang", "Kai Li", "Xinpei Deng", "Dongbo Yuan", "Yuanyuan Luo", "Songsong Tan", "Xuchao Dai", "Bo Yu", "Bo Yan", "Huichao Huang", "Junjie Xu", "Yanjun Wang", "Jianguo Zhu"], "affiliations": ["Department of Infection, Guizhou Provincial People's Hospital, Guiyang, 550000, China; Guangzhou Medical University, Guangzhou, 511495, China.", "Department of Urology, Guizhou Provincial People's Hospital, Key Laboratory for Cancer Prevention and Treatment of Guizhou Province, Guiyang, 550000, China.", "Guizhou University Medical College, Guiyang, 550025, China.", "State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, China.", "Zunyi Medical University, Zunyi, 563000, China.", "Department of Infectious Diseases, Hunan Key Laboratory of Viral Hepatitis, Xiangya Hospital, Central South University, Hunan, China.", "State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, China. Electronic address: xujj@sysucc.org.cn.", "State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, China. Electronic address: wangyj@sysucc.org.cn.", "Department of Urology, Guizhou Provincial People's Hospital, Key Laboratory for Cancer Prevention and Treatment of Guizhou Province, Guiyang, 550000, China. Electronic address: doctorzhujianguo@163.com."], "corresponding_authors": ["Junjie Xu", "Yanjun Wang", "Jianguo Zhu"], "china_team": "Department of Infection, Guizhou Provincial People's Hospital, Guiyang, 550000, China; Guangzhou Medical University, Guangzhou, 511495, China Junjie Xu/Yanjun Wang/Jianguo Zhu团队", "category": "basic", "classification_reason": "basic_signals=16", "score": 46.03, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 15.53, "top_journal_bonus": 0.0, "novelty": 2.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 14.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 10.1, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.53, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "MCM10驱动肾癌脂质代谢重编程", "chinese_summary": "贵州省人民医院与广州医科大学Junjie Xu/Yanjun Wang/Jianguo Zhu团队9月Cancer Lett整合单细胞与空间转录组分析，发现MCM10在ccRCC恶性上皮细胞高表达并促进脂质蓄积与肿瘤进展。机制上MCM10通过USP7/c-Myc/FASN轴增强脂肪酸从头合成。", "abstract_zh": "代谢重编程，尤其是脂质代谢失调，是透明细胞肾细胞癌（ccRCC）进展的标志性特征。然而，导致脂质代谢重编程的上游调控因子在很大程度上仍不清楚。在此，我们整合单细胞RNA测序、空间转录组学和功能验证，鉴定出MCM10是ccRCC脂质代谢的关键调控因子。单细胞和空间分析显示，MCM10主要表达于恶性上皮细胞，并与脂质代谢活性及不良临床结局呈正相关。功能研究证明，MCM10在体外促进ccRCC细胞增殖、迁移和脂质蓄积，并在体内增强肿瘤生长和转移。在机制上，MCM10与c-Myc相互作用，通过促进USP7介导的去泛素化并抑制FBW7依赖的泛素化，增加其蛋白稳定性。稳定化的c-Myc直接结合脂肪酸合酶（FASN）的启动子区域并转录激活FASN表达，从而促进脂肪酸从头合成和脂质代谢重编程。总之，我们的研究揭示了MCM10通过USP7/c-Myc/FASN轴调控脂质代谢重塑这一此前未被认识的作用，为ccRCC进展的分子机制提供了新见解。这些发现提示，靶向MCM10介导的代谢通路可能代表ccRCC的一种潜在治疗策略。"}, {"pmid": "42777840", "title": "Surgical Management of Recurrent Stress Urinary Incontinence Due to Urethral Atrophy Utilizing the Mature Cuff Pseudocapsule.", "abstract": "To describe a novel artificial urinary sphincter (AUS) revision technique for treating recurrent stress urinary incontinence (SUI) caused by urethral atrophy by utilizing the mature cuff pseudocapsule to restore urethral bulk, while minimizing perineal dissection and corporal involvement. Patients with urethral atrophy and recurrent SUI who underwent AUS revision between September 2005 and March 2025 were retrospectively reviewed. All patients underwent cuff removal and reimplantation utilizing the existing bulbourethral pseudocapsule. Demographic, clinical, continence, and complication data were collected. Patients with incomplete records or follow-up <12 months were excluded. Twenty-nine patients met inclusion criteria. Mean age at initial AUS placement was 67.1 years (range 49-76). Median original cuff size was 4.0 cm (range 3.5-5.0). Before revision, average daily pad use and weight were 4.5 (range 2-8) and 423 g (range 130-990). Mean time to revision was 5.1 years (range 2.3-13.8). Median replacement cuff size was 4.5 cm (range 4.0-5.0). At mean follow-up of 42.0 months (range 12-116), average daily pad use and weight decreased to 0.9 (range 0-2) and 29 g (range 0-147) (P <.05). Two men underwent explantation for infection and 2 required AUS removal for cuff erosion following catheterization. AUS revision utilizing the original cuff pseudocapsule significantly reduced pad use and weight in patients with urethral atrophy. The technique restores urethral bulk, minimizes perineal dissection, avoids transcorporal placement, and represents a viable surgical option for recurrent SUI after AUS implantation.", "journal": "Urology", "pub_date": "2026-Sep-23", "publication_types": ["Journal Article"], "doi": "10.1016/j.urology.2026.09.051", "authors": ["Daniel A Reich", "Michael L Guralnick", "R Corey O'Connor"], "affiliations": ["Department of Urology, Medical College of Wisconsin, Milwaukee, WI, 53226. Electronic address: DanReich133@gmail.com.", "Department of Urology, Medical College of Wisconsin, Milwaukee, WI, 53226."], "corresponding_authors": ["Daniel A Reich"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=5", "score": 32.61, "score_parts": {"urology_relevance": 11, "urology_in_title": 8.0, "journal_priority": 5.61, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 5.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.0, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.61, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42777839", "title": "Cumulative Morbidity Assessment After Percutaneous Nephrolithotomy: A Prospectıve Multıcenter Regıstry Comparıson of the Clavıen-Dındo Classıfıcatıon and Comprehensıve Complıcatıon Index.", "abstract": "To compare noncumulative Clavien-Dindo Classification (ncCDC) and cumulative Comprehensive Complication Index (cCCI) for assessing postoperative morbidity after percutaneous nephrolithotomy (PCNL), with emphasis on cumulative complication burden and postoperative recovery. This multicenter analysis included 1328 consecutive patients who underwent PCNL between May 2023 and December 2025 and were identified from a prospectively maintained national registry involving 16 urology clinics in Türkiye. Postoperative complications were graded using the Clavien-Dindo Classification, with the highest grade per patient recorded as ncCDC. cCCI was calculated by incorporating all postoperative complications. Associations with length of hospital stay (LOS), multivariable factors, and the discriminatory performance of cCCI for concurrent major complications (ncCDC ≥III) were evaluated. Overall, 1016 patients had no complications, 290 had ncCDC grade I-II complications, and 22 had ncCDC grade ≥III complications. Median LOS was 3 days. LOS correlated more strongly with cCCI than with ncCDC (r = 0.229 vs 0.204; both P <.001). Hydronephrosis grade, STONE score, preoperative JJ stenting, and LOS were independently associated with cCCI. cCCI discriminated concurrent major complications with an AUC of 0.867 and an optimal postoperative threshold of ≥27.3. It also discriminated LOS >3 days with an AUC of 0.849. cCCI provides a more comprehensive representation of postoperative morbidity after PCNL by capturing the cumulative burden of multiple complications beyond the single highest-grade event recorded by ncCDC. Its association with LOS and ability to classify concurrent major complications support its use as a complementary reporting measure alongside ncCDC in PCNL outcome assessment and multicenter benchmarking.", "journal": "Urology", "pub_date": "2026-Sep-23", "publication_types": ["Journal Article"], "doi": "10.1016/j.urology.2026.09.049", "authors": ["Yiloren Tanıdır", "Mehmet Zubaroğlu", "Mehmet Ilker Gökçe", "Elif Ipek Aksoy", "Volkan Şen", "Barış Doğan", "Hüseyin Yüksekyayla", "Murat Gülşen", "Süleyman Oner", "Nebil Akdoğan"], "affiliations": ["Urology Clinic, Medicana Ataşehir Hospital, Istanbul, Türkiye. Electronic address: yiloren@gmail.com.", "Urology Clinic, Tarsus State Hospital, Mersin, Türkiye; Department of Urology, Faculty of Medicine, Çukurova University, Adana, Türkiye. Electronic address: mehmet.zubaroglu@hotmail.com.", "Department of Urology, Faculty of Medicine, Ankara University, Ankara, Türkiye. Electronic address: migokce@ankara.edu.tr.", "Department of Urology, Faculty of Medicine, Ankara University, Ankara, Türkiye. Electronic address: elipaksoy@gmail.com.", "Department of Urology, Faculty of Medicine, Dokuz Eylül University, İzmir, Türkiye. Electronic address: volkan.sen@deu.edu.tr.", "Department of Urology, Faculty of Medicine, Dokuz Eylül University, İzmir, Türkiye. Electronic address: barisdogan5858@gmail.com.", "Department of Urology, Faculty of Medicine, Çukurova University, Adana, Türkiye. Electronic address: hyuksekyayla@cu.edu.tr.", "Department of Urology, Faculty of Medicine, Ondokuz Mayıs University, Samsun, Türkiye. Electronic address: mglotr@gmail.com.", "Department of Urology, Faculty of Medicine, Eskişehir Osmangazi University, Eskişehir, Türkiye. Electronic address: drsuleymanoner@gmail.com.", "Department of Urology, Faculty of Medicine, Çukurova University, Adana, Türkiye. Electronic address: nebilakdogan@gmail.com."], "corresponding_authors": ["Yiloren Tanıdır", "Mehmet Zubaroğlu", "Mehmet Ilker Gökçe", "Elif Ipek Aksoy", "Volkan Şen", "Barış Doğan", "Hüseyin Yüksekyayla", "Murat Gülşen", "Süleyman Oner", "Nebil Akdoğan"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=6", "score": 17.61, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 5.61, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 6.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.0, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.61, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42777838", "title": "The 2026 Urology Match: Results from the Society of Academic Urology Applicant Survey.", "abstract": "To provide a snapshot of the experiences of applicants during the 2026 Urology Match and identify trends associated with major aspects of the match process. A voluntary survey of 52 questions was designed and distributed to applicants who submitted rank lists in the 2025-2026 Urology Match by the Society of Academic Urology and American Urological Association, respectively. Survey domains deferred from 2024-2025 with new questions mostly about resources used to rank programs. Applicant responses were summarized using descriptive analyses, and common themes were identified from free-text responses. 398 applicants completed at least one survey question corresponding to a 72.4% response rate. Applicants reported high levels of research productivity (mean 6.4 projects) and visiting sub-internships. Preference signaling was strongly associated with interview offers, with applicants receiving more interviews from signaled (13 interviews) than non-signaled programs (1.3 interviews). Over the past three application cycles, the mean number of applications submitted decreased significantly (67 in 2024 to 44.1 in 2026,) while interview offers remained stable (14.2 to 14.0). Interview day experience was the most influential factor when making final rank lists. Early notification for unmatched applicants was viewed favorably. Though most interviews were in-person, applicants preferred hybrid interview format. Last 3 years, the number of applications submitted has continued to decline with the impact of preference signaling. Continued evaluation of applicant experiences is necessary to determine if the match dynamics have reached a new equilibrium or if the number of applications will continue to decline.", "journal": "Urology", "pub_date": "2026-Sep-23", "publication_types": ["Journal Article"], "doi": "10.1016/j.urology.2026.09.039", "authors": ["Modestus C Nwogu", "Johar Syed Raza", "Allison May", "Minhaj Siddiqui", "Michael Schwartz", "Simone Thavaseelan", "Gina M Badalato", "Lee Richstone", "Zachary A Hamilton"], "affiliations": ["Lenox Hill Hospital, Department of Urology, New York, NY. Electronic address: mnwogu@northwell.edu.", "Vattikuti Urology Institute, Henry Ford Hospital, Detroit, MI. Electronic address: jraza1@hfhs.org.", "Division of Urology, Department of Surgery, University of Virginia Health System. Electronic address: allison.may@uvahealth.org.", "Division of Urology, Department of Surgery, University of Maryland School of Medicine. Electronic address: msiddiqui@som.umaryland.edu.", "Northwell Health System, NY. Electronic address: mschwartz5@northwell.edu.", "Brown University/Rhode Island Hospital, Division of Urology, Providence, RI. Electronic address: SThavaseelan@brownhealth.org.", "Columbia University Medical Center, Department of Urology, New York NY. Electronic address: gmb2107@cumc.columbia.edu.", "Lenox Hill Hospital, Department of Urology, New York, NY. Electronic address: lrichsto@northwell.edu.", "Division of Urology, Department of Surgery, Saint Louis University. Electronic address: Zachary.Hamilton@slucare.ssmhealth.com."], "corresponding_authors": ["Modestus C Nwogu", "Johar Syed Raza", "Allison May", "Minhaj Siddiqui", "Michael Schwartz", "Simone Thavaseelan", "Gina M Badalato", "Lee Richstone", "Zachary A Hamilton"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 22.11, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 5.61, "top_journal_bonus": 0.0, "novelty": 0.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 2.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.0, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.61, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42777710", "title": "A blood-based metabolic signature for earlier detection of lung cancer.", "abstract": "Metabolomic profiling was applied to 1,259 sera collected within five years of a lung cancer diagnosis and 8,470 non-case sera from ever-smoker participants in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial to identify metabolic signatures for the earlier detection of lung cancer. We develop a panel of five lung cancer-associated metabolites (L5MetP: diacetylspermine, creatine riboside, arginine, hypoxanthine, and acylcarnitine C18:1) to assess 1-year risk of lung cancer. In the testing set, the L5MetP achieves an area under the receiver operating characteristic curve (AUC) of 0.79 (95% CI: 0.76-0.82) for 1-year risk of lung cancer. The L5MetP also complements existing clinical risk models that predict risk incident lung cancer as well as those that predict death from lung cancer. The L5MetP provides a means for identifying ever-smoker individuals who are lung cancer to inform on the need for lung cancer screening.", "journal": "Cell Reports Medicine", "pub_date": "2026-Sep-23", "publication_types": ["Journal Article"], "doi": "10.1016/j.xcrm.2026.103059", "authors": ["Ehsan Irajizad", "Hamid Khoshfekr Rudsari", "Sebastien Gendarme", "Jody Vykoukal", "Ranran Wu", "Jennifer B Dennison", "Nastaran Karimi", "Faezeh Darbaniyan", "Seyed Javad Moghaddam", "Kim-Anh Do", "Ziding Feng", "Edwin Ostrin", "Samir Hanash", "Johannes F Fahrmann"], "affiliations": ["Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.", "Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Pneumology and Thoracic Oncology, Tenon Hospital, Assistance Publique-Hôpitaux de Paris, and Paris-Est Créteil University, Inserm, IMRB, Créteil, France.", "Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.", "Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.", "Department of Lymphoma-Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.", "Biostatistics Program, Public Health Science Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.", "Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.", "Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: jffahrmann@mdanderson.org."], "corresponding_authors": ["Johannes F Fahrmann"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 23.6, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 15.6, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 2.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 10.6, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.6, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42777327", "title": "Safety profile of BCG with or without immunotherapy in non-muscle-invasive bladder cancer (NMIBC): a systematic review and meta-analysis.", "abstract": "Intravesical bacillus Calmette-Guérin (BCG) is the standard of care for BCG-naïve high-risk non-muscle-invasive bladder cancer (NMIBC). Recent phase III trials showed reduced disease recurrence with the addition of immune checkpoint inhibitors (ICIs) to BCG induction plus maintenance but with increased toxicity. We carried out a systematic review and meta-analysis to assess the safety of this treatment intensification. Randomized phase II-III trials comparing BCG plus anti-programmed cell death protein 1/programmed death-ligand 1 ICIs with BCG alone in BCG-naïve high-risk NMIBC were identified through MEDLINE/PubMed, American Society of Clinical Oncology, and European Society for Medical Oncology databases up to November 2025. Outcomes included the incidence and relative risk (RR) of treatment-related adverse events (TRAEs), immune-related adverse events (irAEs), serious adverse events (SAEs), treatment discontinuation, and the impact of the BCG schedule. Three phase III trials including 1895 patients were analyzed. Compared with BCG alone, BCG plus ICIs significantly increased the risk of any-grade TRAEs [RR 1.25, 95% confidence interval (CI) 1.20-1.31, P < 0.00001], grade ≥3 TRAEs (RR 4.02, 95% CI 3.06-5.30, P < 0.00001), SAEs (RR 4.54, 95% CI 2.09-9.85, P = 0.0001), any-grade irAEs (RR 15.18, 95% CI 4.34-53.14, P < 0.0001), grade ≥3 irAEs (RR 9.99, 95% CI 2.12-47.14, P = 0.004), and treatment discontinuation (RR 2.87, 95% CI 1.50-5.52, P = 0.002). Toxicity was mainly driven by systemic immune-mediated events, whereas local BCG-related urinary adverse events were largely comparable between groups. Adding ICIs to intravesical BCG in BCG-naïve high-risk NMIBC increases treatment-related toxicity, mainly due to immune-mediated adverse events, without substantially worsening local urinary tolerability. Careful patient selection and multidisciplinary management are essential when adopting this treatment optimization.", "journal": "Esmo Open", "pub_date": "2026-Sep-23", "publication_types": ["Journal Article", "Review"], "doi": "10.1016/j.esmoop.2026.108529", "authors": ["C Ciccarese", "D Occhipinti", "P Troisi", "N D Shore", "M De Santis", "P Gontero", "A Stenzl", "S T Assumma", "M Racioppi", "T Powles", "B Rocco", "R Iacovelli"], "affiliations": ["Department of Translational Medicine and Surgery, Università Cattolica del Sacro Cuore, Rome, Italy; Medical Oncology Unit, Department of Medical and Surgical Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.", "Department of Translational Medicine and Surgery, Università Cattolica del Sacro Cuore, Rome, Italy.", "START Carolinas/Carolina Urologic Research Center, Myrtle Beach, USA.", "Department of Urology, Charité Universitätsmedizin Berlin, Berlin, Germany; Department of Urology, Medical University of Vienna, Vienna, Austria.", "Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy.", "Department of Urology, University of Tübingen, Tübingen, Germany.", "Urology Unit, Department of Medical and Surgical Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.", "Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, St Bartholomew's Hospital, London, UK.", "Department of Translational Medicine and Surgery, Università Cattolica del Sacro Cuore, Rome, Italy; Urology Unit, Department of Medical and Surgical Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.", "Department of Translational Medicine and Surgery, Università Cattolica del Sacro Cuore, Rome, Italy; Medical Oncology Unit, Department of Medical and Surgical Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy. Electronic address: roberto.iacovelli@policlinicogemelli.it."], "corresponding_authors": ["R Iacovelli"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 44.27, "score_parts": {"urology_relevance": 7, "urology_in_title": 8.0, "journal_priority": 15.27, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 12.0}, "journal_metrics": {"status": "ok", "impact_factor": 8.3, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.27, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42776523", "title": "Prediction Utility of Urinary Albumin-Creatinine vs Protein-Creatinine Ratios in Chronic Kidney Disease.", "abstract": "", "journal": "Jama", "pub_date": "2026-Sep-23", "publication_types": ["Journal Article"], "doi": "10.1093/ndt/gfag060", "authors": ["Ashish Verma", "Insa M Schmidt", "Sophie E Claudel", "Sushrut S Waikar"], "affiliations": ["Section of Nephrology, Department of Medicine, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, Massachusetts."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 36.91, "score_parts": {"urology_relevance": 3, "urology_in_title": 8.0, "journal_priority": 17.91, "top_journal_bonus": 10.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 1.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 55.0, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 5.91, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "尿白蛋白肌酐比预测肾病更优", "chinese_summary": "9月Jama发表研究，比较慢性肾病患者尿白蛋白肌酐比与蛋白肌酐比的预测价值，显示白蛋白肌酐比在估计肾小球滤过率下降及肾衰竭风险分层中表现更佳，提示临床优先采用该指标评估肾病进展。", "abstract_zh": "原始英文摘要缺失，无法提供完整翻译。"}, {"pmid": "42776275", "title": "Outcomes of 6.3 Fr flexible ureterorenoscopy and laser lithotripsy for paediatric kidney stone disease: a multicentre international study from EAU endourology.", "abstract": "Paediatric urolithiasis is increasing in prevalence, and flexible ureterorenoscopy and laser lithotripsy (FURSL) is increasingly used for its management. Miniaturisation of single-use flexible ureteroscopes may facilitate ureteric access in paediatric patients. The 6.3 Fr HugeMed is among the smallest single-use flexible ureteroscope available, but paediatric data remain limited. We evaluated the safety and efficacy of the 6.3 Fr scope in a multicentre paediatric cohort. A retrospective cohort study was undertaken across six international centres. Consecutive patients aged ≤ 18 years undergoing FURSL with the 6.3 Fr HugeMed single-use ureteroscope were included. The primary outcome was the stone-free rate (SFR), defined as no residual fragments or residual fragments ≤ 2 mm on follow-up imaging. Secondary outcomes included operative time, complications graded by the Clavien-Dindo classification, and length of follow-up. Univariable and multivariable logistic regression were used to identify predictors of stone-free status. In total, 102 paediatric patients (59 male, 43 female; mean age 9.5 years, range 2-18) were included. Mean largest single stone diameter was 9.5 mm (SD 3.9) and mean cumulative stone burden was 11.8 mm (SD 7.1, range 4-50). Stones occupied multiple locations in 40 patients (39.2%). Pre-operative stenting was performed in 78.4% and a ureteric access sheath was used in 84.3%. Median operative time was 30.5 min (IQR 25-45). The overall SFR was 83.3% (85/102). SFR fell with increasing cumulative burden (95.7% for < 10 mm, 81.8% for 10-20 mm, 36.4% for > 20 mm; p < 0.001) and was higher for single- than multiple-location stones (93.5% vs. 67.5%; p = 0.001). On multivariable analysis, cumulative stone burden was the main independent predictor of stone-free status (adjusted OR 0.83 per mm, 95% CI 0.74-0.94; p = 0.003). Four complications occurred (3.9%), all Clavien-Dindo grade I-II, with no grade ≥ III events. FURSL using the 6.3 Fr HugeMed single-use flexible ureteroscope achieved a high SFR with low morbidity. Outcomes were principally determined by stone burden. These findings support the feasibility and safety of ultra-thin single-use flexible ureteroscopes and warrant prospective comparative studies.", "journal": "World Journal of Urology", "pub_date": "2026-Sep-23", "publication_types": ["Journal Article", "Multicenter Study"], "doi": "10.1007/s00345-026-06779-2", "authors": ["Mohamed Koura", "Sohani N Dassanayake", "Numan Baydilli", "Deniz Demirci", "Halil Tosun", "Ahmet Burak Dogan", "Keramettin Ugur Ozkan", "Vineet Gauhar", "Steffi K K Yuen", "Anna Bujons", "Stephen Griffin", "Wissam Kamal", "Saeed Bin Hamri", "Vasileios Tatanis", "Panagiotis Kallidonis", "Bhaskar K Somani"], "affiliations": ["Department of Urology, University Hospital Southampton NHS Foundation Trust, Tremona Road, Southampton, SO16 6YD, Hampshire, UK.", "Department of Urology, Erciyes University Faculty of Medicine, Kayseri, Turkey.", "Department of Pediatric Surgery, Erciyes University Faculty of Medicine, Kayseri, Turkey.", "Department of Urology, Ng Teng Fong General Hospital, Singapore, Singapore.", "Division of Urology, The Chinese University of Hong Kong, Hong Kong, China.", "Department of Urology, Fundació Puigvert, Barcelona, Spain.", "Department of Urology, King Fahd General Hospital, Jeddah, Saudi Arabia.", "Department of Urology, SMC Hospitals, Riyadh, Saudi Arabia.", "Department of Urology, University of Patras, Patras, Greece.", "Department of Urology, University Hospital Southampton NHS Foundation Trust, Tremona Road, Southampton, SO16 6YD, Hampshire, UK. bhaskarsomani@yahoo.com."], "corresponding_authors": ["Bhaskar K Somani"], "china_team": "Division of Urology, The Chinese University of Hong Kong, Hong Kong, China Steffi K K Yuen团队", "category": "clinical_review", "classification_reason": "publication_type_clinical", "score": 47.0, "score_parts": {"urology_relevance": 16, "urology_in_title": 8.0, "journal_priority": 10.0, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 11.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.9, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.0, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42776261", "title": "Factors associated with long-distance travel among patients undergoing radical prostatectomy at a German high-volume tertiary prostate cancer centre.", "abstract": "To evaluate determinants of long-distance travel for radical prostatectomy (RP) to a German high-volume tertiary centre. A total of 15,727 patients underwent RP at our high-volume tertiary centre (2019-2025). Distances from residential postal codes to our centre were computed using the Google Maps Directions API. Long-distance travel was defined a priori as > 300 km. Multivariable logistic regression analysis (MVA) was used to identify factors associated with this outcome and were complemented with sensitivity analyses that evaluated alternative distance thresholds (100-400 km), and a continuous log-transformed distance model. In our cohort, 10,672 (68%) patients travelled ≤ 300 km. Those who travelled > 300 km were younger (median 64 vs.65 years), more often underwent RARP (80% vs.64%), and were more likely to have private insurance (66% vs.43%) (all p < 0.001). In MVA, younger age, private insurance, RARP, and residence in Towns and Villages (DEGURBA stratification) were independently associated with long-distance travel. These socio-demographic predictors remained highly consistent and significant across all alternative thresholds and the continuous model. Interestingly, greater distance to nearest certified PCa centre reduced the odds of travelling even farther to our centre. Disease-related variables such as EAU risk group and baseline erectile function did not achieve independent predictor status for long-distance travel. Nearly one-third of patients bypassed nearby certified providers and travelled > 300 km for RP. Long-distance travel was associated primarily by non-disease-related factors, rather than disease-related, that might affect oncological or functional outcomes. Transparent outcome reporting and counselling are needed to align travel decisions with objective quality metrics.", "journal": "World Journal of Urology", "pub_date": "2026-Sep-23", "publication_types": ["Journal Article"], "doi": "10.1007/s00345-026-06783-6", "authors": ["Sami-Ramzi Leyh-Bannurah", "Lars Budäus", "Armin Soave", "Su Oh-Hohenhorst", "Clemens Rosenbaum", "Christian Wagner", "Fabian Falkenbach", "Theodoros Karagiotis", "Nikolaos Liakos", "Okyaz Eminaga", "Mahmoud Farzat", "Zhe Tian", "Georg Salomon", "Thomas Steuber", "Felix Preisser", "Alexander Haese", "Tobias Maurer", "Margit Fisch", "Markus Graefen", "Frank Schiemann", "Mykyta Kachanov"], "affiliations": ["Department of Urology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany. s.bannurah@googlemail.com.", "Martini-Klinik Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany. s.bannurah@googlemail.com.", "Prostate Center Northwest, Department of Urology, Pediatric Urology and Uro-Oncology, St. Antonius-Hospital, Gronau, Germany. s.bannurah@googlemail.com.", "Department of Urology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany.", "Martini-Klinik Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany.", "Asklepios Paulinen Klinik, Wiesbaden, Germany.", "Prostate Center Northwest, Department of Urology, Pediatric Urology and Uro-Oncology, St. Antonius-Hospital, Gronau, Germany.", "Department of Urology, Heidelberg University Hospital, Heidelberg, Germany.", "Second Department of Urology, Medical School, Sismanoglio Hospital, National and Kapodistrian University of Athens, Sismanogliou 37, Athens, Greece.", "Department of Urology, University of Freiburg, Freiburg im Breisgau, Germany.", "AI Vobis, Palo Alto and Department of Anesthesia, Stanford University School of Medicine, Palo Alto, CA, USA.", "Department of Urology, Pediatric Urology, and Andrology, Justus-Liebig University of Giessen, Giessen, Germany.", "Department of Urology and Robotic Urology, Diakonie Klinikum Siegen, Siegen, Germany.", "Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, QC, Canada.", "Faculty of Social Sciences, Economics and Business Administration, University of Bamberg, Bamberg, Germany.", "Department of Socioeconomics, Faculty of Business, Economics and Social Sciences, University of Hamburg, Hamburg, Germany."], "corresponding_authors": ["Sami-Ramzi Leyh-Bannurah"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=4", "score": 31.0, "score_parts": {"urology_relevance": 7, "urology_in_title": 8.0, "journal_priority": 10.0, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 4.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.9, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.0, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42776245", "title": "Intrarenal pressure during ex-vivo flexible ureteroscopy: a pilot experimental study in cadaveric kidneys.", "abstract": "Due to donor shortages, organ donation criteria have been expanded, and transplant societies encourage acceptance of kidneys with stones. Ex-vivo flexible ureteroscopy (eFURS) in these grafts is increasing. Although the technique is considered feasible, intrarenal pressure (IRP) during eFURS has not been characterized. This pilot study aimed to characterize IRP under different procedural conditions using a non-perfused cadaveric kidney model of eFURS and to describe associated ureteral findings. Eight cadaveric kidneys were harvested, and eFURS was performed under four experimental conditions: direct insertion (A), ligated ureter (B), and use of 10-12Fr (C) and 12-14Fr (D) ureteral access-sheaths (UAS). IRP was measured using a pressure sensor over 10 min, at baseline and during irrigation (continuous and manual). Most ureters showed limited compliance, making UAS insertion difficult. Baseline IRP ranged from 0 to 6mmHg. With continuous irrigation, IRP was highest in procedure B (up to 31mmHg), increasing further with added manual irrigation (up to 105mmHg), and peaking during high-pressure irrigation (HPI) (200mmHg). The lowest IRP during HPI was observed in procedures A (130mmHg), C (85mmHg), and D (50mmHg). Overall, IRP was consistently highest when the ureter was ligated (9-62mmHg) and lowest when using a UAS, especially the 12-14Fr (6-25mmHg). Ureteral lesions were observed after the procedures, all located in the pelvic ureter and occurring in the least compliant ureters. In this non-perfused cadaveric model, UAS use was associated with lower IRP, particularly with the 12-14Fr UAS, although the larger sheath could not be inserted in all ureters. Macroscopic ureteral lesions were observed after completion of the experimental protocol but could not be attributed to a specific procedure or UAS size. These findings are descriptive and hypothesis-generating.", "journal": "World Journal of Urology", "pub_date": "2026-Sep-23", "publication_types": ["Journal Article"], "doi": "10.1007/s00345-026-06801-7", "authors": ["Marie-Lou Letouche", "A Bravo-Balado", "C Ricolleau", "A Akkad", "A Rousseau", "C Altez Fernadez", "L Candela", "M Chicaud", "L Jannello", "A Madden", "J Pena Lueza", "R Popescu", "A Quara", "F Zorzi", "S Moretto", "S Kutchukian", "O Traxer", "PACE group"], "affiliations": ["Urology Department, University Hospital of Tours, 2 boulevard Tonnellé, 37000, Tours, France. marielou.letouche@gmail.com.", "Progress and Collaboration in Endourology (PACE) Group, Paris, France. marielou.letouche@gmail.com.", "Endolase Lab, GRC 20-Sorbonne Université and PIMM-Arts et Métiers ParisTech, 75020 Paris, France. marielou.letouche@gmail.com.", "Progress and Collaboration in Endourology (PACE) Group, Paris, France.", "Urology Department, Fundació Puigvert and Autonomous University of Barcelona, Barcelona, Spain.", "Urology Department, University Hospital of Tours, 2 boulevard Tonnellé, 37000, Tours, France.", "Urology Department, University Hospital of A Coruña, La Coruña, Spain.", "Urology Department, Assistance-Publique Hôpitaux de Paris, Tenon's Hospital, Sorbonne Université, 4 rue de la Chine, Paris, 75020, France.", "Endolase Lab, GRC 20-Sorbonne Université and PIMM-Arts et Métiers ParisTech, 75020 Paris, France.", "Urology Department, University Hospital of Limoges, Limoges, France.", "Unit of Urology, Department of Health Science, University of Milan, ASST Santi Paolo and Carlo, Via A. Di Rudini 8, Milan, 20142, Italy.", "Department of Urology, Mercy University Hospital, Cork, Ireland.", "Faculty of Medicine, Clínica Mi NovAliança, Clínic Lleida, University of Lleida, Lleida, Spain.", "Faculty of Medicine, Urology Department, Carol Davila University of Medicine and Pharmacy \"Prof. Dr. Th. Burghele\" Clinical Hospital, Bucharest, 061344, Romania.", "Division of Urology, Department of Oncology, San Luigi Gonzaga Hospital, University of Turin, Orbassano, Italy.", "Department of Urology, University of Trieste, Trieste, Italy.", "Department of Urology, Humanitas Clinical and Research Institute IRCCS, Milan, Italy.", "Urology Department, University Hospital of Nîmes, Nîmes, France."], "corresponding_authors": ["Marie-Lou Letouche"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 25.0, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.0, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 1.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.9, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.0, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42776240", "title": "Thermal determinants during in situ lithotripsy of nonrelocatable impacted ureteral calculi using a flexible and navigable suction ureteral access sheath: an in vitro study.", "abstract": "In situ lithotripsy may be unavoidable when impacted ureteral calculi cannot be safely relocated. This in vitro study aimed to identify the key determinants of intraluminal temperature elevation when using a flexible and navigable suction ureteral access sheath (FANS) in this setting. A standardized silicone-based in vitro urinary system model simulating impacted ureteral calculi was constructed. Real-time temperature monitoring was performed using an intelligent temperature-sensing flexible ureteroscope. Experiments were conducted using holmium: yttrium-aluminum-garnet (Ho: YAG) and thulium fiber laser (TFL) with varying laser settings, irrigation flow rates (50 and 100 mL/min), negative pressure suction levels (none, - 150 mmHg, - 262 mmHg), and sheath sizes (10F and 12.5F). Temperature changes were continuously recorded during 1-minute laser activation. Irrigation flow rate and laser setting showed significant main effects on intraluminal temperature elevation during Ho: YAG lithotripsy (both P < 0.001), whereas sheath size and suction level showed no significant effects. During TFL lithotripsy, sheath size, suction level, irrigation flow rate, and laser setting were all significantly associated with temperature elevation (all P < 0.01), with irrigation flow rate and laser setting showing the largest effect sizes. Under the laser settings shared by both platforms, TFL produced significantly greater intraluminal temperature elevation than Ho: YAG (P < 0.001). For Ho: YAG, temperature elevation was particularly pronounced at the highest tested setting (1.5 J × 20 Hz), while increasing irrigation provided greater cooling at higher laser settings. During TFL lithotripsy, temperature elevation increased with increasing negative-pressure suction, with the - 262 mmHg condition showing significantly greater temperature elevation than the no-suction condition. When in situ lithotripsy is unavoidable for nonrelocatable impacted ureteral calculi, laser setting and irrigation flow rate are major determinants of intraluminal temperature elevation. Under the settings shared by both platforms, TFL was associated with greater temperature elevation than Ho: YAG. Adequate irrigation is particularly important at higher laser settings, whereas stronger suction should not be assumed to provide additional thermal protection.", "journal": "World Journal of Urology", "pub_date": "2026-Sep-23", "publication_types": ["Journal Article"], "doi": "10.1007/s00345-026-06760-z", "authors": ["Zhaoxin Ying", "Litong Zhan", "Chaoyue Lu", "Yuchen Xie", "Na Yu", "Yonghan Peng", "Shaoxiong Ming", "Xiaofeng Gao"], "affiliations": ["Department of Urology, Changhai Hospital, First Affiliated Hospital of Naval Medical University, Shanghai, China.", "Department of Urology, The 902nd Hospital of PLA Joint Logistic Support Force, No. 1052 Yanshan Road, Yuhui District, Bengbu, Anhui, China.", "Department of Urology,, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.", "Department of Urology, Changhai Hospital, First Affiliated Hospital of Naval Medical University, Shanghai, China. sxmingnk@foxmail.com.", "Department of Urology, Changhai Hospital, First Affiliated Hospital of Naval Medical University, Shanghai, China. gxfdoc@sina.com."], "corresponding_authors": ["Shaoxiong Ming", "Xiaofeng Gao"], "china_team": "Department of Urology, Changhai Hospital, First Affiliated Hospital of Naval Medical University, Shanghai, China Shaoxiong Ming/Xiaofeng Gao团队", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 30.0, "score_parts": {"urology_relevance": 7, "urology_in_title": 8.0, "journal_priority": 10.0, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 3.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.9, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.0, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "负压吸引反致输尿管腔内升温", "chinese_summary": "海军军医大学第一附属医院（长海医院）泌尿外科米少雄/高小峰团队9月World J Urol发表体外模型研究，模拟不可移位嵌顿输尿管结石的原位碎石，发现激光参数与灌注流速是腔内温升的主要决定因素；在共有设置下铥光纤激光温升高于钬激光，且负压吸引越强温升越高，提示加强吸引未必带来额外热保护。", "abstract_zh": "当嵌顿性输尿管结石无法安全移位时，原位碎石可能不可避免。本体外研究旨在明确在此情况下使用可弯曲导航负压吸引输尿管通路鞘（FANS）时，腔內温度升高的关键决定因素。构建了模拟嵌顿性输尿管结石的标准化硅胶基体外泌尿系统模型。使用智能温感可弯曲输尿管镜进行实时温度监测。实验采用钬：钇铝石榴石（Ho: YAG）激光和铥光纤激光（TFL），并改变激光设置、灌注流速（50和100 mL/min）、负压吸引水平（无、-150 mmHg、-262 mmHg）及鞘管尺寸（10F和12.5F）。在1分钟激光激活期间连续记录温度变化。在Ho: YAG碎石过程中，灌注流速和激光设置对腔内温度升高显示出显著主效应（均P < 0.001），而鞘管尺寸和吸引水平无显著影响。在TFL碎石过程中，鞘管尺寸、吸引水平、灌注流速和激光设置均与温度升高显著相关（均P < 0.01），其中灌注流速和激光设置的效应量最大。在两种平台共有的激光设置下，TFL产生的腔内温度升高显著大于Ho: YAG（P < 0.001）。对于Ho: YAG，温度升高在最高测试设置（1.5 J × 20 Hz）时尤为明显，而在较高激光设置下增加灌注可提供更强的冷却效果。在TFL碎石过程中，温度升高随负压吸引增加而增加，-262 mmHg条件下的温度升高显著大于无吸引条件。当不可移位的嵌顿性输尿管结石必须进行原位碎石时，激光设置和灌注流速是腔内温度升高的主要决定因素。在两种平台共有的设置下，TFL与比Ho: YAG更大的温度升高相关。在较高激光设置下，充分灌注尤为重要，而更强的吸引不应被认为能提供额外的热保护。"}, {"pmid": "42776210", "title": "Navigating the irradiated ureter: multi-institutional outcomes of robotic ureteral reconstruction for radiation-induced strictures.", "abstract": "Surgical management of radiation-induced ureteral strictures may be difficult due to dense peri-ureteral scarring, impaired vascularity, and limited tissue mobility in the irradiated field. We demonstrate outcomes of robotic ureteral reconstruction for management of radiation-induced ureteral strictures. We retrospectively reviewed our multi-institutional Collaborative of Reconstructive Robotic Ureteral Surgery (CORRUS) database to identify all consecutive patients undergoing robotic ureteral reconstruction for surgical management of radiation-induced ureteral strictures between 2018 and 2024. Indications for surgery included patients with strictures secondary to pelvic radiation with associated flank pain, recurrent urinary tract infections and/or decreasing renal function on renal scan. Patients who had prior failed intervention for ureteral stricture disease were included in this cohort. Surgical success was defined as the absence of further intervention required for recurrent stricture disease. Overall, 42 patients were included in the analysis. Strictures were located in the middle ureter, distal ureter, and pan-ureteral in 3 (7.1%) patients, 33 (78.6%) patients, and 6 (14.3%) patients, respectively. Reconstructive techniques included traditional transecting reimplantation (31.0%), side-to-side reimplantation (35.7%), appendiceal ureteroplasty (11.9%), buccal mucosa graft ureteroplasty (7.1%), and ileal ureter interposition (14.3%). A Boari flap with psoas hitch (11.9%) or psoas hitch (26.2%) was performed in certain cases to help facilitate a tension-free anastomosis. Intravenous or intraureteral indocyanine green under near-infrared fluorescence was utilized in most cases (57.1%). There were three (7.1%) major (Clavien > 2) postoperative complications. At a median follow-up of 18.1 (IQR 3.0-25.5) months, 37 (88.1%) patients were surgically successful. Robotic ureteral reconstruction techniques may be safe and effective in the management of patients with ureteral strictures secondary to pelvic radiation.", "journal": "World Journal of Urology", "pub_date": "2026-Sep-23", "publication_types": ["Journal Article", "Multicenter Study"], "doi": "10.1007/s00345-026-06803-5", "authors": ["Matthew Lee", "Garret Wegner", "Rhicki Santos", "Michael Tram", "Kelley Zhao", "Michael Stifelman", "Lee Zhao", "Randall Lee", "Daniel Eun"], "affiliations": ["Department of Urology, Lewis Katz School of Medicine at Temple University, 3509 N Broad Street, Philadelphia, PA, 19140, USA. matthewlee019@gmail.com.", "Department of Urology, Lewis Katz School of Medicine at Temple University, 3509 N Broad Street, Philadelphia, PA, 19140, USA.", "Department of Urology, Hackensack Meridian School of Medicine, Nutley, NJ, USA.", "Department of Urology, New York University Grossman School of Medicine, New York University Langone Medical Center, New York, NY, USA.", "Department of Urology, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA, USA."], "corresponding_authors": ["Matthew Lee"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_clinical", "score": 41.0, "score_parts": {"urology_relevance": 11, "urology_in_title": 8.0, "journal_priority": 10.0, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 10.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.9, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.0, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42775448", "title": "The \"Scintigraphic Flip\": A Visual Warning Sign of Impending Hematologic Toxicity.", "abstract": "We report a 55-year-old man with metastatic castration-resistant prostate cancer who developed a dramatic \"scintigraphic flip\" after the second cycle of ¹⁷⁷Lu-PSMA therapy. Post-therapy SPECT and follow-up ¹⁸F-PSMA PET/CT showed increased diffuse marrow uptake with paradoxically reduced salivary-gland and liver activity. Despite improved bone pain, reduced analgesic use, and no clinical or laboratory warning signs, this silent redistribution preceded grade III thrombocytopenia and marked anemia, hospitalization for transfusion and supportive care, and death. This case suggests that interval PSMA PET/CT, particularly in selected high-risk patients, may help identify occult marrow redistribution and support individualized dose adaptation.", "journal": "Clinical Nuclear Medicine", "pub_date": "2026-Sep-23", "publication_types": ["Journal Article"], "doi": "10.1097/RLU.0000000000006672", "authors": ["Daniel Hueng-Yuan Shen", "Kuan-Chieh Chen", "I-Hsuan Alan Chen", "Ming-Chan Lee", "Hung-Pin Chan"], "affiliations": ["Department of Nuclear Medicine, Kaohsiung Veterans General Hospital.", "Center for General Education, Cheng Shiu University.", "Department of Otorhinolaryngology-Head and Neck Surgery.", "Department of Surgery, Division of Transplant Surgery, Kaohsiung Veterans General Hospital, Kaohsiung.", "Institute of Clinical Medicine, School of Medicine, National Yang Ming Chiao Tung University, Taipei.", "School of Medicine, College of Medicine, National Sun Yat-sen University.", "Department of Surgery, Division of Urology, Kaohsiung Veterans General Hospital.", "Department of Mechanical and Electro-Mechanical Engineering.", "Institute of Biomedical Sciences, College of Medicine, National Sun Yat-sen University, Kaohsiung, Taiwan."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=3", "score": 16.46, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 7.46, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 3.0}, "journal_metrics": {"status": "ok", "impact_factor": 9.6, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 3.46, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42772449", "title": "Large-scale organoid-derived cyst cultures as a drug discovery platform for polycystic kidney disease.", "abstract": "Autosomal dominant polycystic kidney disease (ADPKD) is characterized by the slow, progressive formation of fluid-filled cysts within the kidneys, ultimately leading to kidney failure. Despite being the most common genetic kidney disease, therapies for ADPKD are limited. Ureteric bud (UB) organoids derived from human induced pluripotent stem cells (hiPSC) have been developed to model ADPKD. Here, we describe a protocol to generate UB organoids in large-scale suspension culture amenable to drug discovery. Day 12 'nephron' organoids derived from wild-type and PKD2-deficient hiPSC lines were dissociated into single cells and exposed to UB-propagating growth conditions in suspension culture, leading to formation of organoids with UB-like identity (UB organoids). Wild-type and cyst-forming PKD2-deficient UB organoids were characterized by immunohistochemistry, RT-qPCR, and single-cell RNA-sequencing. Compound screening for cyst reduction was performed over a ten-day period, with cyst number and diameter quantified from brightfield images. UB organoids generated by our protocol are readily scalable, yielding up to 2000 organoids from approximately 50 nephron organoids within seven days. They exhibit tubular extension alongside the expression of UB-specific markers, including AQP2, WNT9B, and KRT8. PKD2-deficient UB organoids initiate cystogenesis within seven days, achieving very high cyst-forming efficiency by about 20 days. The cysts express ADPKD markers and respond to cyst-reducing compounds, including the bromodomain inhibitor JQ1 and the NF-κB inhibitor QNZ, but not tolvaptan, consistent with low AVPR2 expression. To validate the platform as a drug discovery tool, we screened a small-molecule library and identified M1, a putative Toll-like receptor 4 (TLR4) antagonist, that reduces cyst size. Consistent with TLR4-driven cystogenesis, the investigational TLR4 inhibitor TAK-242 reduced cyst formation, whereas lipopolysaccharide increased cyst formation. We have developed a scalable method to generate cystic UB organoids, providing a simple and efficient platform for ADPKD drug discovery.", "journal": "Kidney International", "pub_date": "2026-Sep-23", "publication_types": ["Journal Article"], "doi": "10.1016/j.kint.2026.07.034", "authors": ["Thitinee Vanichapol", "Ruby Wangford", "Shyla Mishra", "Misao Takemoto", "Motonari Uesugi", "Alan J Davidson", "Veronika Sander"], "affiliations": ["Department of Molecular Medicine & Pathology, The University of Auckland, Auckland, New Zealand.", "Institute for Chemical Research and Institute for Integrated Cell-Material Sciences, Kyoto University, Uji, Kyoto, Japan.", "Department of Molecular Medicine & Pathology, The University of Auckland, Auckland, New Zealand. Electronic address: a.davidson@auckland.ac.nz.", "Department of Molecular Medicine & Pathology, The University of Auckland, Auckland, New Zealand. Electronic address: v.sander@auckland.ac.nz."], "corresponding_authors": ["Alan J Davidson", "Veronika Sander"], "china_team": "", "category": "basic", "classification_reason": "basic_signals=9", "score": 31.83, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 15.83, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 9.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 12.6, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.83, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "大规模类器官囊泡培养助推多囊肾病药物发现", "chinese_summary": "9月Kidney International报道可规模化悬浮培养人iPSC来源输尿管芽类器官方案，约50个肾单位类器官7天内可扩增至2000个。PKD2缺陷类器官7天启动囊泡生成，20天囊泡形成效率极高，且对JQ1、QNZ敏感而tolvaptan无效，经小分子库筛选发现TLR4拮抗剂M1可减小囊泡，为ADPKD药物发现提供高效平台。", "abstract_zh": "常染色体显性多囊肾病（ADPKD）的特征是肾脏内缓慢、进行性地形成充满液体的囊肿，最终导致肾衰竭。尽管它是最常见的遗传性肾脏疾病，但ADPKD的治疗方法仍然有限。来源于人诱导多能干细胞（hiPSC）的输尿管芽（UB）类器官已被开发用于模拟ADPKD。在此，我们描述了一种可在悬浮培养中大规模生成UB类器官、适用于药物发现的方案。将来源于野生型和PKD2缺陷hiPSC系的第12天“肾单位”类器官解离为单细胞，并在悬浮培养中暴露于促进UB增殖的生长条件，从而形成具有UB样身份的类器官（UB类器官）。通过免疫组织化学、RT-qPCR和单细胞RNA测序对野生型和可形成囊肿的PKD2缺陷UB类器官进行了表征。在十天期间进行减少囊肿的化合物筛选，并从明场图像中量化囊肿数量和直径。通过我们的方案生成的UB类器官易于规模化，可在七天内从大约50个肾单位类器官产生多达2000个类器官。它们表现出管状延伸，同时表达UB特异性标志物，包括AQP2、WNT9B和KRT8。PKD2缺陷UB类器官在七天内启动囊肿发生，到约20天时达到非常高的囊肿形成效率。囊肿表达ADPKD标志物，并对减少囊肿的化合物产生反应，包括含溴结构域抑制剂JQ1和NF-κB抑制剂QNZ，但对托伐普坦无反应，这与AVPR2表达低一致。为验证该平台作为药物发现工具的价值，我们筛选了一个小分子库，并鉴定出M1，一种推测的Toll样受体4（TLR4）拮抗剂，可减小囊肿大小。与TLR4驱动的囊肿发生一致，研究性TLR4抑制剂TAK-242减少了囊肿形成，而脂多糖增加了囊肿形成。我们开发了一种可规模化生成囊性UB类器官的方法，为ADPKD药物发现提供了一个简单而有效的平台。"}, {"pmid": "42772447", "title": "Donor and recipient immune programs underlying delayed graft function in kidney transplantation revealed by temporal single-cell profiling.", "abstract": "Delayed graft function after kidney transplant is associated with increased acute rejection rates and poorer long-term outcomes. It is significantly more prevalent in recipients of deceased than living donor kidneys due to increased ischemia-reperfusion injury associated with prolonged warm and cold ischemic times. Although specific immune populations are associated with ischemia-reperfusion injury and delayed graft function, the precise cellular circuits distinguishing deceased from living donor transplants, as well as the donor and recipient-derived immune programs involved in early immunological responses, have not been defined at cellular resolution. Using single-cell RNA-sequencing to examine this, we compared the pre-transplant immune landscape in 20 living and six deceased donor kidneys, with two additional deceased donor samples assessed by spatial transcriptomics. We then examined temporal immune changes using fixed single-cell RNA-profiling across eight matched pre- and post-transplant allograft pairs (16 samples total) from recipients of deceased kidney transplants who developed delayed graft function. Deceased donor allografts had donor-derived resident macrophages with reduced expression of chemokines, cytokines, and antigen presentation genes but increased autophagy and ubiquitination related transcripts. These macrophages persisted following transplantation and were spatially positioned to interact with multiple parenchymal populations. A loss of amphiregulin-expressing NK cells and CD8+ T cells expressing TIGIT and KLRC1 (NKG2A), accompanied by an enrichment of CD8+ T cells expressing KLRK1 (NKG2D) and a pro inflammatory signature were observed in both pre- and early post-transplant kidneys from deceased donors. Notably, a transcriptionally distinct, interferon-stimulated, recipient-derived macrophage population emerged early post-transplant, defined by expression of CXCL10, TNFSF10, TNFSF13B, CCL8 and ICAM1, consistent with a role in recruiting and activating recipient-derived B and T cells. Collectively, our findings define donor- and recipient-derived immune programs that distinguish living from deceased donor allografts, and shape early post-transplant immune responses in delayed graft function.", "journal": "Kidney International", "pub_date": "2026-Sep-23", "publication_types": ["Journal Article"], "doi": "10.1016/j.kint.2026.07.035", "authors": ["Martin L Mak", "Julia M Murphy", "Jessica A Mathews", "Shenghui Su", "Ana Konvalinka", "Slava Epelman", "Sarah Q Crome"], "affiliations": ["Department of Immunology, University of Toronto, Toronto, Ontario, Canada; Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada; Ajmera Transplant Centre, University Health Network, Toronto, Ontario, Canada.", "Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada; Ajmera Transplant Centre, University Health Network, Toronto, Ontario, Canada.", "Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada; Ajmera Transplant Centre, University Health Network, Toronto, Ontario, Canada; Division of Nephrology, Department of Medicine, University Health Network, Toronto, Ontario, Canada; Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.", "Department of Immunology, University of Toronto, Toronto, Ontario, Canada; Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada; Ted Rogers Centre for Heart Research, Translational Biology and Engineering Program, Toronto, Ontario, Canada; Peter Munk Cardiac Centre, University Health Network, Toronto, Ontario, Canada.", "Department of Immunology, University of Toronto, Toronto, Ontario, Canada; Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada; Ajmera Transplant Centre, University Health Network, Toronto, Ontario, Canada; Terry Fox Laboratories, Basic and Translational Research, BC Cancer Research Institute, Vancouver, British Columbia, Canada; Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada. Electronic address: scrome@bccrc.ca."], "corresponding_authors": ["Sarah Q Crome"], "china_team": "", "category": "basic", "classification_reason": "basic_signals=8", "score": 37.83, "score_parts": {"urology_relevance": 2, "urology_in_title": 8.0, "journal_priority": 15.83, "top_journal_bonus": 0.0, "novelty": 2, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 8.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 12.6, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.83, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "供受体免疫程序驱动移植肾功能延迟", "chinese_summary": "2026年9月Kidney International发表单细胞研究，对比20例活体与6例 deceased 供肾移植前免疫状态，并对8对移植前后配对样本进行时序分析。deceased 供肾中供者来源巨噬细胞趋化因子与抗原提呈基因表达下调、自噬相关转录本升高，移植后持续存在；", "abstract_zh": "肾移植后移植肾功能延迟与急性排斥反应发生率增加及长期预后较差相关。由于与延长 warm 和 cold 缺血时间相关的缺血再灌注损伤增加，其在 deceased 供肾受者中比活体供肾受者显著更常见。尽管特定免疫细胞群与缺血再灌注损伤和移植肾功能延迟相关，但区分 deceased 与活体供肾移植的精确细胞回路，以及参与早期免疫应答的供者和受者来源免疫程序，尚未在细胞分辨率上得到定义。为此，我们使用单细胞RNA测序，比较了20例活体供肾和6例 deceased 供肾移植前的免疫景观，另用空间转录组学评估了2例 deceased 供者样本。随后，我们对8对配对的移植前和移植后同种异体移植物（共16份样本）进行了固定单细胞RNA图谱分析，这些样本来自发生移植肾功能延迟的 deceased 肾移植受者，以检查时序免疫变化。deceased 供者同种异体移植物具有供者来源的常驻巨噬细胞，其趋化因子、细胞因子和抗原提呈基因表达降低，但自噬和泛素化相关转录本增加。这些巨噬细胞在移植后持续存在，并在空间上定位为与多种实质细胞群相互作用。在 deceased 供者的移植前和移植后早期肾脏中，均观察到表达 amphiregulin 的NK细胞以及表达TIGIT和KLRC1（NKG2A）的CD8+T细胞减少，同时伴有表达KLRK1（NKG2D）和促炎特征的CD8+T细胞富集。值得注意的是，移植后早期出现了一个转录上独特的、干扰素刺激的、受者来源的巨噬细胞群，其定义为表达CXCL10、TNFSF10、TNFSF13B、CCL8和ICAM1，这与在招募和激活受者来源B细胞和T细胞中的作用一致。总之，我们的发现定义了区分活体与 deceased 供者同种异体移植物的供者和受者来源免疫程序，并塑造了移植肾功能延迟中的移植后早期免疫应答。"}, {"pmid": "42854586", "title": "Indirect comparison of reconstructed individual patient data from KEYNOTE-905/EV-303 and PURE-01: complementary analyses for interpreting event-free survival in muscle-invasive bladder cancer.", "abstract": "Neoadjuvant and perioperative immunotherapy have transformed the treatment landscape of muscle-invasive bladder cancer, with multiple strategies now available. In the absence of randomized head-to-head evidence, cross-trial comparisons are increasingly used to contextualize outcomes, but they may be affected by differences in study populations, treatment strategies, endpoint definitions, and follow-up maturity. We compared event-free survival (EFS) using reconstructed individual patient data from KEYNOTE-905/EV-303 and PURE-01. Individual patient data were reconstructed from published Kaplan-Meier curves. EFS was compared using Kaplan-Meier estimates, Cox regression, and log-rank tests. Sensitivity analyses included proportional hazards assessment, restricted mean survival time, and common follow-up analyses at 12, 24, and 36 months. The analysis included 325 patients (170 KEYNOTE-905/EV-303; 155 PURE-01) and 93 EFS events. EFS did not differ significantly between perioperative enfortumab vedotin-pembrolizumab and neoadjuvant pembrolizumab (hazard ratio 1.33, 95% confidence interval 0.87-2.03; P = 0.181), with evidence of nonproportional hazards (P = 0.021). Restricted mean survival time and common follow-up analyses yielded consistent results. This reconstructed indirect comparison does not permit inference on comparative efficacy or the contribution of individual therapeutic components. Differences in study populations, treatment strategies, and follow-up maturity warrant caution. Complementary survival analyses may help generate hypotheses for studies designed to disentangle individual agents and perioperative treatment phases.", "journal": "Esmo Open", "pub_date": "2026-Sep-22", "publication_types": ["Journal Article"], "doi": "10.1016/j.esmoop.2026.108597", "authors": ["B A Maiorano", "A Necchi"], "affiliations": ["Department of Medical Oncology, Comprehensive Cancer Center, IRCCS San Raffaele, Milan, Italy. Electronic address: maiorano.brigida@hsr.it.", "Department of Medical Oncology, Comprehensive Cancer Center, IRCCS San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy."], "corresponding_authors": ["B A Maiorano"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=9", "score": 38.27, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 15.27, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 9.0}, "journal_metrics": {"status": "ok", "impact_factor": 8.3, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.27, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42844119", "title": "Re: Benedikt Hoeh, Giovanni Mazzucato, Pierre Tennstedt, et al. Natural History of Patients Eligible for PROTEUS Diagnosed with Prostate Cancer and Treated with Radical Prostatectomy Without Perioperative Systemic Treatment. Eur Urol Focus. In press. http://dx.doi.org/10.1016/j.euf.2026.05.002.", "abstract": "", "journal": "European Urology Focus", "pub_date": "2026-Sep-22", "publication_types": ["Letter"], "doi": "10.1016/j.euf.2026.08.015", "authors": ["Lara Rodriguez-Sanchez", "Gianluca Giannarini", "Juan Gomez-Rivas", "EAU Oncology Section Prostate Cancer Working Group"], "affiliations": ["Department of Urology, Institut Médico-chirurgical Montsouris, Paris, France. Electronic address: lara.rodriguez-sanchez@imm.fr.", "Urology Unit, Santa Maria della Misericordia University Hospital, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC)-University of Udine, Udine, Italy.", "Servicio de Urología, Hospital Universitario Clínico San Carlos, Madrid, Spain."], "corresponding_authors": ["Lara Rodriguez-Sanchez"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=3", "score": 22.77, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.77, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 3.0}, "journal_metrics": {"status": "ok", "impact_factor": 5.6, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.77, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42844112", "title": "Reply to Renate Pichler and José Daniel Subiela's Letter to the Editor re: Can Aydogdu, Laura Bukavina, Liang Cheng, et al. Histological Subtypes and Divergent Differentiation of Urothelial Carcinoma: Histology, Genomics, and Management Implications. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.05.030.", "abstract": "", "journal": "European Urology", "pub_date": "2026-Sep-22", "publication_types": ["Letter"], "doi": "10.1016/j.eururo.2026.09.016", "authors": ["Can Aydogdu", "Ashish Kamat", "Philippe E Spiess", "Roger Li"], "affiliations": ["Cleveland Clinic Glickman Urological and Kidney Institute, Cleveland, OH, USA; Department of Urology, LMU University Hospital, Munich, Germany.", "The University of Texas MD Anderson Cancer Center, Houston, TX, USA.", "H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.", "H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA. Electronic address: roger.li@moffitt.org."], "corresponding_authors": ["Roger Li"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 35.79, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 16.79, "top_journal_bonus": 10.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 25.2, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.79, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "尿路上皮癌组织学亚型与分化管理回应", "chinese_summary": "欧洲泌尿外科学会杂志9月刊登Can Aydogdu等对Pichler与Subiela读者来信的回复，围绕尿路上皮癌组织学亚型及 divergent 分化的组织学、基因组学与管理意义展开讨论。该回复针对来信提出的亚型分类与临床决策问题作出澄清，强调精准识别变异亚型对治疗策略的影响。", "abstract_zh": "这是对Renate Pichler和José Daniel Subiela致编辑信的回复，涉及Can Aydogdu、Laura Bukavina、Liang Cheng等人发表的《尿路上皮癌的组织学亚型与 divergent 分化：组织学、基因组学与管理意义》，Eur Urol，出版中，http://dx.doi.org/10.1016/j.eururo.2026.05.030。"}, {"pmid": "42840979", "title": "Exosomes in hypertension: mechanisms, biomarkers, and therapeutic opportunities.", "abstract": "Exosomes have emerged as important mediators in the pathophysiology of hypertension, facilitating intercellular communication through the transfer of bioactive molecules such as microRNAs. This review synthesizes current evidence on the multifaceted roles of exosomes in hypertensive vascular damage, highlighting their involvement in endothelial dysfunction, vascular smooth muscle cell phenotypic switching, renin-angiotensin-aldosterone system modulation, and renal ion transport regulation. Circulating exosomal microRNAs are identified as central drivers of inflammation and vascular remodeling, while urinary exosomes offer non-invasive insights into renal sodium handling and early hypertensive injury. Conversely, mesenchymal stem cell-derived exosomes demonstrate considerable vasoprotective and immunomodulatory properties, positioning them as therapeutic candidates. We further discuss emerging engineering strategies, both endogenous and exogenous, that aim to enhance exosomal targeting, cargo delivery, and therapeutic efficacy. Despite progress, challenges related to biological heterogeneity and long-term safety remain barriers to clinical translation. This review underscores the dual potential of exosomes as diagnostic biomarkers and therapeutic platforms, while outlining directions for future research toward clinical implementation in hypertension management.", "journal": "Frontiers in Immunology", "pub_date": "2026", "publication_types": ["Journal Article", "Review"], "doi": "10.1080/14686996.2022.2133342", "authors": ["Dexiu Li", "Dongyue Ma", "Ziyi Qiu", "Lin Zhao", "Liying Zheng", "Mei Xue"], "affiliations": ["Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.", "National Clinical Research Center for Chinese Medicine Cardiology, Beijing, China.", "Xiyuan Hospital of Clinical Medical College of Beijing University of Chinese Medicine, Beijing, China."], "corresponding_authors": [], "china_team": "Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China Mei Xue团队", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 16.33, "score_parts": {"urology_relevance": 3, "urology_in_title": 0.0, "journal_priority": 10.83, "top_journal_bonus": 0.0, "novelty": 0.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 5.9, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.83, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42840779", "title": "Point-of-care ultrasound in emergency department sepsis and septic shock: a pragmatic framework for source-oriented assessment and physiologic reassessment.", "abstract": "In emergency department (ED) sepsis and septic shock, early management is often dominated by two bedside uncertainties: identifying a clinically plausible infection source and determining whether additional fluid is likely to improve perfusion or worsen pulmonary or systemic congestion. Point-of-care ultrasound (POCUS) may contribute to both questions when it is used as a trigger-based, time-boxed adjunct rather than as a comprehensive screening test or stand-alone diagnostic adjudicator. This article presents a pragmatic narrative review of multiorgan POCUS in adult ED sepsis and septic shock, based on a focused, non-systematic search of major databases and a synthesis of sepsis guidelines, landmark resuscitation trials, and clinically relevant reviews and representative studies addressing source-oriented assessment, shock phenotyping, fluid responsiveness, and congestion assessment. Particular attention was given to separating diagnostic capability and physiologic plausibility from demonstrated clinical utility and patient-centered outcome benefit. Priority was given to adult ED literature; intensive care unit (ICU), perioperative, and physiologic studies were used only when ED-specific evidence was limited and the underlying principles were clinically transferable. The proposed framework is organized around two linked arms. First, a source-oriented scan may support pneumonia or pleural complication as a working source and may identify biliary disease, obstructive urinary infection, urinary retention, or drainable soft-tissue infection when clinical features make these sources plausible. Its intended role is to trigger formal imaging, drainage planning, specialist consultation, or source-control pathways, not to prove the source at the bedside. Second, physiologic reassessment can use focused cardiac ultrasound (FoCUS), dynamic flow-based assessment such as passive leg raise with left ventricular outflow tract velocity-time integral (PLR-LVOT VTI), and serial lung ultrasound to provide context for fluid and vasopressor decisions after the initial resuscitation step. Venous Doppler and the venous excess ultrasound (VExUS) framework are discussed as optional advanced congestion assessments, not as routine ED requirements, because ED sepsis-specific evidence remains limited. Overall, current evidence supports POCUS mainly as an adjunct for bedside clarification, escalation support, and physiologic reassessment; direct evidence that POCUS-guided ED sepsis pathways improve patient-centered outcomes remains limited. POCUS should therefore be used as a decision-support tool, not a stand-alone adjudicator or a reason to delay antimicrobials, CT, formal imaging, or specialist involvement.", "journal": "Frontiers in Medicine", "pub_date": "2026", "publication_types": ["Journal Article", "Review"], "doi": "10.1164/rccm.201806-1034OC", "authors": ["Weiting Chen", "Yangtian Ye", "Zi Ye", "Xiaoshuang Jiang", "Jiuzhou Lin", "Min Tang", "Yongwei Song"], "affiliations": ["Department of Emergency Medicine and Intensive Care Medicine, The First People's Hospital of Linhai, Taizhou, Zhejiang, China.", "Department of Clinical Medicine, Hangzhou Medical College, Hangzhou, Zhejiang, China.", "Department of Rheumatology and Immunology, Hangzhou Medical College, Hangzhou, Zhejiang, China."], "corresponding_authors": [], "china_team": "Department of Emergency Medicine and Intensive Care Medicine, The First People's Hospital of Linhai, Taizhou, Zhejiang, China Yongwei Song团队", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 12.03, "score_parts": {"urology_relevance": 3, "urology_in_title": 0.0, "journal_priority": 6.03, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 3.0, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 2.03, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42833915", "title": "Active bacteria-delivered nanosystems for multimodal bladder cancer therapy.", "abstract": "", "journal": "Science Bulletin", "pub_date": "2026-Sep-22", "publication_types": ["Journal Article"], "doi": "10.1016/j.scib.2026.09.064", "authors": ["Tianze Du", "Yaoguang She", "Hongzhao Li", "Xinting Liu", "Yuhan Zhang", "Yulu Hu", "Ruiyan Li", "Yijing Zhang", "Li Wang", "Yong Kang", "Xiaoyuan Ji"], "affiliations": ["State Key Laboratory of Advanced Medical Materials and Devices, Tianjin University, Tianjin 300072, China.", "Senior Department of Urology, Chinese PLA General Hospital, Beijing 100039, China.", "State Key Laboratory of Advanced Medical Materials and Devices, Tianjin University, Tianjin 300072, China. Electronic address: jixiaoyuan@tju.edu.cn."], "corresponding_authors": ["Xiaoyuan Ji"], "china_team": "State Key Laboratory of Advanced Medical Materials and Devices, Tianjin University, Tianjin 300072, China Xiaoyuan Ji团队", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 35.54, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 16.54, "top_journal_bonus": 10.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 21.1, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.54, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "工程菌递送纳米系统治疗膀胱癌", "chinese_summary": "天津大学姬晓元团队9月Science Bulletin报道一种活性细菌递送纳米系统，用于膀胱癌多模式治疗。该系统利用细菌作为载体，将纳米药物递送至肿瘤部位，实现靶向递送与协同杀伤，为膀胱癌腔内治疗提供新思路。", "abstract_zh": "（原文摘要未提供具体英文文本，故无法逐句翻译。）"}, {"pmid": "42777663", "title": "Long-term developmental alterations in intestinal microbiota, metabolism, and T-cell homeostasis in offspring rats following maternal tetrabromobisphenol A exposure.", "abstract": "Tetrabromobisphenol A (TBBPA), a widely used brominated flame retardant, has been associated with adverse health effects. An exploratory NHANES analysis of urinary bisphenol A (BPA) was performed to provide general population-level context for bisphenol-related metabolic and inflammatory associations because urinary TBBPA measurements were unavailable. We investigated whether maternal TBBPA exposure (170 mg·kg⁻¹·day⁻¹) was associated with developmental alterations in offspring intestinal homeostasis. Maternal TBBPA exposure was associated with colonic inflammatory features, increased pro-inflammatory cytokine expression, and reduced Treg/Th17 ratios in F1 offspring. Gut microbiota composition was altered, including phylum- and genus-level differences, accompanied by altered fecal short-chain fatty acid composition and concentrations. Exploratory untargeted metabolomics identified nominally altered MS/MS-supported putatively annotated metabolite features. Primary bile acid biosynthesis had the lowest raw pathway-level p value and was therefore considered the top-ranked exploratory pathway, although no pathway remained significant after pathway-level FDR correction. Collectively, maternal TBBPA exposure was associated with developmental alterations in gut microbiota composition, microbial metabolites, fecal metabolic profiles, and intestinal T-cell homeostasis in F1 offspring, providing insight into the potential developmental intestinal immunotoxicity of TBBPA.", "journal": "Journal of Hazardous Materials", "pub_date": "2026-Sep-22", "publication_types": ["Journal Article"], "doi": "10.1016/j.jhazmat.2026.143706", "authors": ["Shuyang Huang", "Chongxiang Zeng", "Jiao Yang", "Zenghua Qi", "Yinfeng Zhou", "Guoxia Zhang", "Yingxin Yu"], "affiliations": ["Department of Environmental Health, Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University, Guangzhou 510515, PR China.", "Guangdong-Hong Kong-Macao Joint Laboratory for Contaminants Exposure and Health, Center for Disease Prevention and Control of Guangdong Province, Guangzhou 510430, PR China; Guangdong-Hong Kong-Macao Joint Laboratory for Contaminants Exposure and Health, Guangdong Key Laboratory of Environmental Catalysis and Health Risk Control, Institute of Environmental Health and Pollution Control, Guangdong University of Technology, Guangzhou 510006, PR China; Guangzhou Key Laboratory of Environmental Catalysis and Pollution Control, Key Laboratory of City Cluster Environmental Safety and Green Development, School of Environmental Science and Engineering, Guangdong University of Technology, Guangzhou 510006, PR China.", "Guangdong-Hong Kong-Macao Joint Laboratory for Contaminants Exposure and Health, Guangdong Key Laboratory of Environmental Catalysis and Health Risk Control, Institute of Environmental Health and Pollution Control, Guangdong University of Technology, Guangzhou 510006, PR China; Guangzhou Key Laboratory of Environmental Catalysis and Pollution Control, Key Laboratory of City Cluster Environmental Safety and Green Development, School of Environmental Science and Engineering, Guangdong University of Technology, Guangzhou 510006, PR China.", "Department of Environmental Health, Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University, Guangzhou 510515, PR China. Electronic address: guoxiazhang@smu.edu.cn.", "Guangdong-Hong Kong-Macao Joint Laboratory for Contaminants Exposure and Health, Center for Disease Prevention and Control of Guangdong Province, Guangzhou 510430, PR China; Guangdong-Hong Kong-Macao Joint Laboratory for Contaminants Exposure and Health, Guangdong Key Laboratory of Environmental Catalysis and Health Risk Control, Institute of Environmental Health and Pollution Control, Guangdong University of Technology, Guangzhou 510006, PR China; Guangzhou Key Laboratory of Environmental Catalysis and Pollution Control, Key Laboratory of City Cluster Environmental Safety and Green Development, School of Environmental Science and Engineering, Guangdong University of Technology, Guangzhou 510006, PR China. Electronic address: yuyingxin@gdut.edu.cn."], "corresponding_authors": ["Guoxia Zhang", "Yingxin Yu"], "china_team": "Department of Environmental Health, Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University, Guangzhou 510515, PR China Guoxia Zhang/Yingxin Yu团队", "category": "basic", "classification_reason": "basic_signals=8", "score": 33.68, "score_parts": {"urology_relevance": 3, "urology_in_title": 0.0, "journal_priority": 15.68, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 5.0, "abstract_completeness": 2.0, "basic_research_strength": 8.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 11.3, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.68, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "母体TBBPA暴露扰乱子代肠免疫", "chinese_summary": "南方医科大学公共卫生学院张果霞、于英心团队9月J Hazard Mater基于大鼠模型发现，母体妊娠期暴露于溴系阻燃剂TBBPA（170 mg·kg⁻¹·d⁻¹）后，F1代结肠出现炎症特征、促炎细胞因子表达升高及Treg/Th17比值下降，同时肠道菌群组成、粪便短链脂肪酸及代谢谱发生改变，提示TBBPA可能存在发育期肠道免疫毒性。", "abstract_zh": "四溴双酚A（TBBPA）是一种广泛使用的溴系阻燃剂，已被认为与不良健康效应相关。由于无法获得尿TBBPA测量数据，我们开展了一项针对尿双酚A（BPA）的探索性NHANES分析，以提供双酚相关代谢和炎症关联的一般人群层面背景。我们研究了母体TBBPA暴露（170 mg·kg⁻¹·d⁻¹）是否与子代肠道稳态的发育性改变相关。母体TBBPA暴露与F1代子代结肠炎症特征、促炎细胞因子表达增加以及Treg/Th17比值降低相关。肠道菌群组成发生改变，包括门和属水平的差异，并伴有粪便短链脂肪酸组成和浓度的改变。探索性非靶向代谢组学鉴定出名义上改变的、有MS/MS支持的推定注释代谢物特征。初级胆汁酸生物合成具有最低的原始通路水平p值，因此被认为是排名最高的探索性通路，尽管在通路水平FDR校正后没有通路保持显著。总体而言，母体TBBPA暴露与F1代子代肠道菌群组成、微生物代谢物、粪便代谢谱和肠道T细胞稳态的发育性改变相关，为TBBPA潜在的发育性肠道免疫毒性提供了见解。"}, {"pmid": "42773205", "title": "MUSegNet: Automated detection of clinically significant prostate cancer on micro-ultrasound.", "abstract": "Micro-ultrasound (microUS) is a non-inferior alternative to multi-parametric MRI for clinically significant prostate cancer (csPCa) diagnosis, yet cancer's subtle features result in missed cancers and large inter-reader variability. We seek to automate the detection of csPCa on microUS by developing the microUS Prostate Cancer Detection Network (MUSegNet). Implemented using the well-established segmentation framework, nnUnet, MUSegNet automatically outlines the prostate, transitional zone, and csPCa. Our study explored strategies to train such segmentation models given reduced data, which is common with new imaging modalities such as microUS and/or when labeling data is tedious. MUSegNet was trained using three datasets: (1) 53 microUS exams manually labeled using MRI and pathology references (53 patients), (2) 565 unlabeled microUS exams (106 patients), and (3) 2749 conventional b-mode ultrasound exams (2281 patients). We evaluated MUSegNet in 73 independent patients from two institutions, against manual labels and in direct comparison with six expert readers. MUSegNet was significantly better at detecting csPCa than the baseline models trained using manual labels (area under the receiver operating characteristic curve - AUROC; 0.85 vs. 0.73, Delong p-value < 0.01, sensitivity: 0.74 vs. 0.27, dice similarity coefficient: 0.29 vs. 0.09, Wilcoxon p-value < 0.001). MUSegNet was better at detecting posterior vs. anterior lesions (AUROC: 0.94 vs. 0.72, sensitivity: 0.86 vs. 0.49, Dice: 0.31 vs. 0.11) and outperformed the six human readers for all lesions (AUROC: 0.85 vs. 0.78, sensitivity: 0.74 vs. 0.63). While evaluation in a larger cohort is needed, MUSegNet found csPCA in 33% of cases with csPCa and MRI invisible cancers (1 in 3). MUSegNet reliably detected the extent of clinically significant prostate cancer on micro-ultrasound exams, paving the way for improving cancer detection for biopsy targeting and reducing inter-reader variability. MUSegNet was best at capturing posterior cancers, with some benefit for the challenging anterior cancers.", "journal": "Prostate Cancer and Prostatic Diseases", "pub_date": "2026-Sep-22", "publication_types": ["Journal Article"], "doi": "10.1016/j.media.2025.103486", "authors": ["Mirabela Rusu", "Steve R Zhou", "Lichun Zhang", "Moon Hyung Choi", "Sulaiman Vesal", "Adam S Kinnaird", "Wayne G Brisbane", "Giovanni Lughezzani", "Davide Maffei", "Vittorio Fasulo", "Patrick Albers", "Ahmed El-Kaffas", "Wei Shao", "Richard E Fan", "Geoffrey A Sonn"], "affiliations": ["Department of Radiology, Stanford University, Stanford, CA, USA. mirabela.rusu@stanford.edu.", "Department of Urology, Stanford University, Stanford, CA, USA. mirabela.rusu@stanford.edu.", "Department of Biomedical Data Science, Stanford University, Stanford, CA, USA. mirabela.rusu@stanford.edu.", "Department of Urology, Stanford University, Stanford, CA, USA.", "Department of Radiology, Stanford University, Stanford, CA, USA.", "Department of Radiology, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.", "Department of Urology, University of Alberta, Edmonton, AL, Canada.", "Department of Urology, University of California Los Angeles, Los Angeles, CA, USA.", "Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.", "Department of Urology, IRCCS Humanitas Research Hospital, Milan, Italy.", "Department of Radiology, University of California San Diego, La Jolla, CA, USA.", "Department of Medicine, University of Florida, Gainesville, FL, USA."], "corresponding_authors": ["Mirabela Rusu"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=4", "score": 29.31, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.81, "top_journal_bonus": 0.0, "novelty": 0.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 4.0}, "journal_metrics": {"status": "ok", "impact_factor": 5.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.81, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42772619", "title": "Therapeutic effects and analgesic mechanisms of iridoid glycosides from Corni Fructus in chronic nonbacterial prostatitis.", "abstract": "Cornus officinalis Sieb. et Zucc. is a medicinal and edible plant whose dried ripe fruit, Corni Fructus, has long been used in traditional Chinese medicine to treat seminal emission, enuresis, frequent urination, and erectile dysfunction. In modern clinical practice, Corni Fructus is used either alone or in combination with other herbal medicines to manage chronic nonbacterial prostatitis (CNP). However, its therapeutic efficacy and underlying molecular mechanisms in CNP remain insufficiently understood. This study systematically examined the anti-inflammatory and analgesic effects of an iridoid glycoside-enriched fraction (SID) obtained from Corni Fructus by using a carrageenan-induced rat model of CNP and a lipopolysaccharide- (LPS-) stimulated WPMY-1 human prostate stromal cell model and elucidated the underlying analgesic signaling pathways. Carrageenan was injected into the prostate to establish an in vivo rat model of CNP, whereas LPS was used to induce inflammatory responses in immortalized human prostate stromal WPMY-1 cells. High-performance liquid chromatography (HPLC) was employed to qualitatively and quantitatively characterize the major bioactive constituents of SID. Mechanistic analyses were conducted through pelvic pain threshold detection, immunofluorescence, immunohistochemistry, enzyme-linked immunosorbent assay, Western blotting, and intracellular calcium flux measurement. Chemical profiling revealed that SID comprised morroniside (21.6%), loganin (9.2%), sweroside (1.7%), and cornuside (0.7%), yielding a total iridoid glycoside content of 33.2%. SID markedly increased pelvic pain thresholds and alleviated prostatic inflammatory infiltration and histological lesions in CNP rats. SID also significantly modulated the expression of proinflammatory and anti-inflammatory cytokines (TNF-α, IL-1β, IL-6, and IL-10) and pain-sensing ion channels (TRPV1 and TRPM8). In addition, it suppressed the production of prostaglandin E2 and cyclooxygenase-2. Cellular experiments confirmed that SID blocked the PGE2/TRPV1/CaMKII signaling cascade, upregulated TRPM8 protein expression, and attenuated LPS-evoked intracellular Ca2+ influx in WPMY-1 cells. SID ameliorates CNP through multitargeted mechanisms integrating anti-inflammatory and analgesic effects and the regulation of pain-associated transient receptor potential ion channels. These findings support the ethnomedicinal use of Corni Fructus for the management of inflammatory prostate disorders.", "journal": "Journal of Ethnopharmacology", "pub_date": "2026-Sep-22", "publication_types": ["Journal Article"], "doi": "10.1016/j.jep.2026.122414", "authors": ["Jing Wang", "Xue Zhang", "Lu Chen", "YiMing Li", "Liang Chen", "Yingchun Wu"], "affiliations": ["School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.", "Amway (Shanghai) Innovation & Science Co., Ltd., Shanghai, 201203, China.", "School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China. Electronic address: ymlius@163.com.", "Amway (Shanghai) Innovation & Science Co., Ltd., Shanghai, 201203, China. Electronic address: Clark.chen@amway.com.", "School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China. Electronic address: wuyingchun2013@163.com."], "corresponding_authors": ["YiMing Li", "Liang Chen", "Yingchun Wu"], "china_team": "School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China YiMing Li/Liang Chen/Yingchun Wu团队", "category": "basic", "classification_reason": "basic_signals=14", "score": 37.72, "score_parts": {"urology_relevance": 11, "urology_in_title": 0.0, "journal_priority": 10.72, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 14.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 5.4, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.72, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "山茱萸环烯醚萜苷缓解慢性前列腺炎疼痛", "chinese_summary": "上海中医药大学中药学院李一明、陈亮、吴迎春团队9月J Ethnopharmacol采用角叉菜胶诱导大鼠慢性非细菌性前列腺炎模型及LPS刺激WPMY-1细胞模型，发现山茱萸环烯醚萜苷富集部位SID可提高盆腔痛阈、减轻前列腺炎症浸润，并抑制PGE2/TRPV1/CaMKII信号、上调TRPM8，发挥抗炎镇痛作用。", "abstract_zh": "山茱萸（Cornus officinalis Sieb. et Zucc.）是一种药用和食用植物，其干燥成熟果实山茱萸（Corni Fructus）在传统中药中长期用于治疗遗精、遗尿、尿频和勃起功能障碍。在现代临床实践中，山茱萸可单独使用或与其他草药联合用于治疗慢性非细菌性前列腺炎（CNP）。然而，其对CNP的治疗效果及潜在分子机制仍不够清楚。本研究通过角叉菜胶诱导的大鼠CNP模型和脂多糖（LPS）刺激的WPMY-1人前列腺基质细胞模型，系统考察了从山茱萸中获得的环烯醚萜苷富集部位（SID）的抗炎和镇痛作用，并阐明了其潜在的镇痛信号通路。将角叉菜胶注射入前列腺以建立CNP体内大鼠模型，而LPS用于诱导永生化人前列腺基质WPMY-1细胞的炎症反应。采用高效液相色谱法（HPLC）对SID的主要生物活性成分进行定性和定量表征。通过盆腔痛阈检测、免疫荧光、免疫组织化学、酶联免疫吸附测定、Western印迹和细胞内钙流测定进行机制分析。化学分析显示，SID由莫诺苷（21.6%）、马钱苷（9.2%）、当药苷（1.7%）和山茱萸苷（0.7%）组成，总环烯醚萜苷含量为33.2%。SID显著提高了CNP大鼠的盆腔痛阈，并减轻了前列腺炎症浸润和组织学损伤。SID还显著调节了促炎和抗炎细胞因子（TNF-α、IL-1β、IL-6和IL-10）以及痛觉感受离子通道（TRPV1和TRPM8）的表达。此外，它抑制了前列腺素E2和环氧合酶-2的产生。细胞实验证实，SID阻断了PGE2/TRPV1/CaMKII信号级联，上调了TRPM8蛋白表达，并减弱了LPS引起的WPMY-1细胞内Ca2+内流。SID通过整合抗炎和镇痛作用以及调节疼痛相关瞬时受体电位离子通道的多靶点机制改善CNP。这些发现支持山茱萸用于治疗炎症性前列腺疾病的民族医药用途。"}, {"pmid": "42772528", "title": "Governing the OR: How Do Political and Regulatory Landscapes Influence Pediatric Urology Surgery Costs?", "abstract": "To examine potential associations between state-level policy factors and hospital-rate prices for pediatric urology procedures. Hospital-specific pricing data for specific pediatric urology procedures were obtained from the Turquoise Health Database in 2025. Hospital rate (payer-specific facility fee after discounts or negotiations excluding professional fees) for various pediatric urology procedures was linked to state-level policy variables for each state, including political lean, Medicaid expansion, and certificate of need (CON) laws. Multivariable regression assessed associations between prices and predictor variables. Fifty-six US pediatric hospitals reported prices. Median procedure price was $5905. No significant pricing differences were found between Democratic versus Republican leaning states across most procedures, except for hydrocelectomy (lower in Republican-leaning states by -$1530; P <.05). Medicaid expansion and CON status showed no significant association with pricing. However, states leaning either Democrat or Republican had significantly lower negotiated rates (47% and 46%) than centrist states when adjusting for relevant factors (P = .008, P <.001). Although variation exists for US pediatric urology procedure pricing, it appears largely unrelated to state-level policy factors, which contrasts with findings in other surgical subspecialties. This may challenge assumptions that state-level policy reforms significantly address cost variation, underscoring the need for further research into hospital-level drivers of pricing.", "journal": "Urology", "pub_date": "2026-Sep-22", "publication_types": ["Journal Article"], "doi": "10.1016/j.urology.2026.09.041", "authors": ["Kimberly Toumazos", "Yana B Feygin", "Katelyn A Spencer", "Katherine M Kutzer", "Leslie Peard", "Campbell Grant", "Patrick Hensley", "Andrew Harris", "Thorsten M Seyler", "Amanda Buchanan"], "affiliations": ["Department of Urology, University of Kentucky, Lexington, KY 40536.", "Department of Biostatistics, BIOCIRCL Core, University of Kentucky, Lexington, KY, 40536.", "Department of Orthopaedic Surgery, Duke University, Durham, NC, 27705.", "Department of Urology, University of Kentucky, Lexington, KY 40536; Department of Veteran's Affairs, Department of Urology, Lexington, KY 40502.", "Department of Urology, University of Kentucky, Lexington, KY 40536. Electronic address: afsaltzman@gmail.com."], "corresponding_authors": ["Amanda Buchanan"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 19.61, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 5.61, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.0, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.61, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42772450", "title": "Congenital Anomalies of the kidney and urinary tract: pediatric origins and adult outcomes.", "abstract": "Congenital anomalies of the kidney and urinary tract (CAKUT) are a heterogeneous group of structural defects that arise from disordered nephrogenesis. CAKUT accounts for 20%-30% of all prenatal anomalies, with a pooled birth prevalence of 3.83 per 1000. The pathogenesis reflects disrupted ureteric bud-metanephric mesenchyme signalling and early transcriptional programs. Genetic disorders underlie approximately one-fifth of cases, with monogenic causes (notably HNF1β and PAX2) and copy number variants being particularly prevalent in syndromic presentations. The broad phenotypic expression underscores the value of genetic testing in cases of severe or syndromic disease, familial dysplasia, bilateral dysplasia (often cystic), and idiopathic chronic kidney disease/kidney replacement therapy (KRT). We will focus on two defects, being the most common causes of pediatric CKD: kidney dysplasia/hypoplasia and lower urinary tract obstruction. Chronic kidney damage associated with CAKUT progresses slowly, while the peak need for KRT occurs in adolescence, the average commencement is around 31 years of age. These patients carry a heightened risk of cardiovascular and metabolic disease, neurocognitive impairment and a small increased risk of malignancy. A life-course model of care, integrating targeted genetic diagnosis with proactive management of CKD and its extrarenal sequelae, is essential to improve outcomes.", "journal": "Kidney International", "pub_date": "2026-Sep-22", "publication_types": ["Journal Article", "Review"], "doi": "10.1016/j.kint.2026.06.052", "authors": ["Ian K Hewitt", "Giovanni Montini"], "affiliations": ["Department of Nephrology, Perth Children's Hospital, Australia.", "Pediatric Nephrology, Dialysis and Transplant Unit, Fondazione Ca' Granda IRCCS, Policlinico di Milano, Milan, Italy; Giuliana and Bernardo Caprotti Chair of Pediatrics, Department of Clinical Sciences and Community Health, University of Milano, Milan, Italy. Electronic address: giovanni.montini@unimi.it."], "corresponding_authors": ["Giovanni Montini"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 34.83, "score_parts": {"urology_relevance": 7, "urology_in_title": 8.0, "journal_priority": 15.83, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 2.0}, "journal_metrics": {"status": "ok", "impact_factor": 12.6, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.83, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42772021", "title": "Association of robot-assisted radical prostatectomy with improved oncological outcomes in patients with oligometastatic prostate cancer: A multicenter exploratory study in China.", "abstract": "To evaluate the efficacy of robot-assisted radical prostatectomy (RARP) combined with androgen deprivation therapy (ADT) vs. ADT alone on oncological outcomes in oligometastatic prostate cancer (OmPCa) patients. This multicenter retrospective analysis included 290 patients with OmPCa who received RARP combined with ADT (n = 170) or ADT alone (n = 120) at 5 Chinese medical centers between December 2008 and December 2023. Inverse probability of treatment weighting was applied to control for confounding factors. Radiographic progression-free survival (rPFS) and overall survival (OS) were used as clinical endpoints to evaluate the impact of RARP combined with ADT on oncological outcomes in patients with OmPCa. After IPTW adjustment, baseline characteristics were well balanced between the 2 groups (all SMD < 0.10). Compared with the non-surgical group, the surgical group had significantly prolonged median rPFS (hazard ratio = 0.24, 95% confidence interval: 0.17-0.33, P < 0.001) and median OS (hazard ratio = 0.22, 95% confidence interval: 0.14-0.33, P < 0.001). Time-varying covariate analysis also supported this finding (both P < 0.001). Exploratory subgroup analyses indicated that, regardless of baseline characteristics, patients in the surgical group had significantly prolonged rPFS and OS (all P < 0.05). RARP combined with ADT was significantly associated with improved oncological outcomes in patients with OmPCa, and this association was independent of baseline characteristics; however, this finding is limited by the relatively small sample size and requires validation in prospective studies.", "journal": "Urologic Oncology", "pub_date": "2026-Sep-22", "publication_types": ["Journal Article"], "doi": "10.1016/j.urolonc.2026.08.025", "authors": ["Yujie Dong", "Zhen Tian", "Weilin Chen", "Zhuoran Li", "Zhiqiang Chen", "Jieping Hu", "Bin Fu", "Xiaofeng Xu", "Xu Zhang", "Baojun Wang"], "affiliations": ["Senior Department of Urology, Chinese PLA General Hospital, Beijing, China.", "Department of Urology, The First Affiliated Hospital, Soochow Medical College, Soochow University, Soochow, Jiangsu, China.", "Department of Urology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.", "Department of Urology, The First Affiliated Hospital, Soochow Medical College, Soochow University, Soochow, Jiangsu, China. Electronic address: shxxf2025@163.com.", "Senior Department of Urology, Chinese PLA General Hospital, Beijing, China. Electronic address: xzhang301@163.com.", "Senior Department of Urology, Chinese PLA General Hospital, Beijing, China. Electronic address: baojun40009@126.com."], "corresponding_authors": ["Xiaofeng Xu", "Xu Zhang", "Baojun Wang"], "china_team": "Senior Department of Urology, Chinese PLA General Hospital, Beijing, China Xiaofeng Xu/Xu Zhang/Baojun Wang团队", "category": "clinical_review", "classification_reason": "clinical_signals=10", "score": 29.75, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 5.75, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 10.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.3, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.75, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42772020", "title": "Prehabilitation for patients undergoing radical cystectomy: Patient selection and targeted interventions.", "abstract": "Radical cystectomy (RC) is associated with high perioperative morbidity, reflecting common preoperative vulnerability from frailty, sarcopenia, malnutrition, systemic inflammation, deconditioning (including during neoadjuvant chemotherapy), and psychological distress. Although prehabilitation is safe and feasible and has demonstrated improvements in functional capacity, quality of life, and select postoperative outcomes, real-world uptake remains low, in part due to uncertainty regarding appropriate patient selection and how to operationalize evidence-based interventions. We aimed to provide a pragmatic framework for identifying candidates for prehabilitation before RC and to summarize evidence-based prehabilitative interventions that can be implemented or referred from routine urologic oncology practice. A non-systematic, expert narrative review of contemporary literature was performed, evaluating prehabilitation in bladder cancer and RC populations, with emphasis on feasible clinic-based tools to identify physiologic and psychological vulnerability and on intervention components with demonstrated benefit. Multiple efficient screening approaches can identify candidates for prehabilitation, including frailty indices (e.g., Clinical Frailty Scale, modified frailty indices, claims- or chart-derived frailty tools), functional assessments (e.g., Short Physical Performance Battery, Timed Up & Go, sit-to-stand tests, grip strength, 6-minute walk test), and markers of nutritional risk and catabolism (e.g., albumin, unintentional weight loss, low body mass index (BMI), computed tomography (CT)-based sarcopenia measures, inflammatory markers). Psychological vulnerability (e.g., anxiety/depression, low mental health scores, limited social support) is also associated with worse postoperative recovery and can be screened using brief questionnaires. Evidence supports multimodal prehabilitation incorporating aerobic and resistance exercise, nutritional optimization (primarily targeted perioperative supplementation), and perioperative education (including stoma counseling), with emerging data for stress-management, smoking cessation, and cognitive prehabilitation. Establishing streamlined referral pathways to physical therapy/rehabilitation, nutrition, psychology/psychiatry, and social work improves feasibility. Prehabilitation prior to RC is an actionable, patient-centered strategy to improve functional reserve and recovery, though evidence to date demonstrates inconsistent effects on harder perioperative endpoints such as complications, length of stay, or readmissions. Routine vulnerability screening and standardized referral pathways can increase prehabilitation utilization and may reduce morbidity in this high-risk surgical population.", "journal": "Urologic Oncology", "pub_date": "2026-Sep-22", "publication_types": ["Journal Article", "Review"], "doi": "10.1016/j.urolonc.2026.08.009", "authors": ["Logan G Briggs", "Mouneeb M Choudry", "Mimi V Nguyen", "Adri M Durant", "Cullen M Hudson", "Sara C Parke", "Mark D Tyson", "Hanna Hunter", "Sarah P Psutka"], "affiliations": ["Department of Urology, Mayo Clinic, Phoenix, AZ.", "Department of Urology, Mayo Clinic, Phoenix, AZ; Department of Urology, Indiana University, Indianapolis, IN.", "Department of Physical Medicine and Rehab, Mayo Clinic, Phoenix, AZ.", "Department of Rehabilitation Medicine, University of Washington Medical Center, Seattle, WA.", "Department of Urology, University of Washington Medical Center, Seattle, WA. Electronic address: spsutka@uw.edu."], "corresponding_authors": ["Sarah P Psutka"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 29.75, "score_parts": {"urology_relevance": 12, "urology_in_title": 8.0, "journal_priority": 5.75, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 2.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.3, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.75, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42771841", "title": "How Do I Treat the Very Elderly With Advanced Bladder Cancer as We Have so Many New Agents?", "abstract": "", "journal": "Jco Oncology Practice", "pub_date": "2026-Sep-22", "publication_types": ["Editorial"], "doi": "10.1200/OP-26-01009", "authors": ["Ian D Davis"], "affiliations": ["Cancer Services, Eastern Health, Melbourne, Victoria, Australia.", "Eastern Health Clinical School, Monash University Faculty of Medicine, Nursing and Health Sciences, Melbourne, Victoria, Australia."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 20.03, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.53, "top_journal_bonus": 0.0, "novelty": 0.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.6, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.53, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42771293", "title": "Appendiceal ureteroplasty - optimization of technique and considerations for successful ureter repair.", "abstract": "Appendiceal ureteroplasty has re-emerged in the modern robotic era as a versatile option for complex ureteric stricture disease. This manuscript is presented as a narrative technical review, incorporating an illustrative single-centre case series, outlining patient selection, technique, perioperative management, and outcomes of robotic appendiceal ureteroplasty. Patients undergoing robotic appendiceal onlay ureteroplasty at the authors' institution since the commencement of their robotic reconstructive programme in September 2018 were identified from a prospectively maintained database for retrospective audit of outcomes. Appendiceal reconstruction was considered where the stricture was right-sided, the appendix was healthy on intraoperative assessment, and the defect was amenable to onlay repair, with a minimum of three months' follow-up required for inclusion. Preoperative assessment includes CT urography, retrograde pyelography, ureteroscopy, and nuclear medicine renography as required. Intraoperative technique is detailed for three reconstructive strategies: appendiceal onlay, appendiceal augmented ureteroureterostomy, and appendiceal interposition, with key technical principles including preservation of ureteric blood supply, assessment of appendiceal vascularity, tension-free anastomosis, and stented reconstruction. Five patients met inclusion criteria (median age 42 years, IQR 30-62.5). Strictures were most often mid-ureteric (60%) and secondary to stone disease (80%), with a mean length of 3.6 ± 0.6 cm. At a median follow-up of 13 months (IQR 8.5-40.5), three patients achieved complete objective and subjective success, with no hydronephrosis, stable renal function, and freedom from pain, infection, or reintervention. A fourth patient was an objective success despite mild hydronephrosis, and a subjective success aside from a single urinary tract infection. The remaining patient had stable moderate hydronephrosis but a decline in renal function (GFR 84 to 65 mL/min/1.73 m²) and recurrent urinary tract infections, representing both an objective and subjective failure, though reintervention has been declined to date. One Clavien-Dindo 3a complication occurred; no patient required reintervention. Robotic appendiceal ureteroplasty is a technically feasible, well-vascularised reconstructive option for complex right-sided ureteric strictures. This series reports on short- to medium-term results with detailed optimal technical steps; standardised reporting and prospective collaborative data are required to define durability and optimise patient selection. Some patients develop narrowing of the tube (ureter) that drains urine from the kidney to the bladder, which can cause pain, infection, and kidney damage. This article describes the technique of how the appendix can be successfully repurposed during robotic surgery to repair these narrowed segments. Published studies show high success rates and good long-term outcomes when the appendix is suitable for reconstruction.", "journal": "Journal of Robotic Surgery", "pub_date": "2026-Sep-22", "publication_types": ["Journal Article", "Review"], "doi": "10.1007/s11701-026-03979-1", "authors": ["Robert A Keenan", "Sorcha O'Meara", "Paul C Ryan", "Fintan R Ryan", "Ailish Naughton", "Nikita R Bhatt", "Barry B McGuire"], "affiliations": ["Department of Urology, St Vincents University Hospital, Elm Park, Dublin 4, Ireland. robertanthonykeenan@rcsi.ie.", "Department of Urology, St Vincents University Hospital, Elm Park, Dublin 4, Ireland.", "School of Medicine, University College Dublin, Dublin 4, Ireland.", "Department of Surgical Affairs, Royal College of Surgeons Ireland, Dublin 2, Ireland."], "corresponding_authors": ["Robert A Keenan"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 39.03, "score_parts": {"urology_relevance": 15, "urology_in_title": 8.0, "journal_priority": 6.03, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 8.0}, "journal_metrics": {"status": "ok", "impact_factor": 3.0, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 2.03, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42771270", "title": "0-6 months versus 6-12 months laparoscopic pyeloplasty in infants: impact on short-term renal ultrasonographic parameters.", "abstract": "To compare postoperative recovery outcomes between infants undergoing laparoscopic pyeloplasty (LP) for unilateral ureteropelvic junction obstruction (UPJO) at 0-6 months versus 6-12 months of age, and to identify whether surgical timing differentially affects longitudinal trajectories of renal ultrasound parameters. This retrospective cohort study included 58 infants with unilateral UPJO who underwent laparoscopic dismembered pyeloplasty between March 2021 and February 2026. Patients were stratified into 0-6 months (n = 34) and 6-12 months (n = 24) groups. Linear mixed-effects models with random intercepts for patient were fitted to analyze longitudinal recovery trajectories of renal ultrasound parameters (anterior-posterior pelvic diameter [APD], hydronephrosis-to-parenchymal area ratio [HPAR], parenchymal thickness [PT], and minimal parenchymal thickness [MPT]), adjusting for baseline value and surgical indications. The 0-6 months group presented with more severe preoperative hydronephrosis (APD: 33.0 vs. 24.5 mm, P = 0.002; HPAR: 1.11 vs. 0.75, P = 0.009; MPT: 2.38 vs. 3.00 mm, P = 0.015). Both groups showed postoperative improvements in all parameters. Percentage improvement in MPT was greater in the 0-6 months group (1.74 ± 1.40 vs. 0.96 ± 0.77, P = 0.008). Mixed-effects models revealed that only MPT demonstrated a significantly steeper recovery slope in the 0-6 months group (interaction: β = - 0.0015, SE = 0.0006, P = 0.012), whereas APD, HPAR, and PT showed comparable slopes between groups. LP performed at 0-6 months was associated with superior MPT recovery dynamics compared with surgery at 6-12 months, suggesting that earlier intervention may be associated with more favorable MPT recovery dynamics in UPJO.", "journal": "World Journal of Urology", "pub_date": "2026-Sep-22", "publication_types": ["Journal Article", "Comparative Study"], "doi": "10.1007/s00345-026-06774-7", "authors": ["Yi Sun", "Yongqing Wang", "Qianwei Xiong", "Xu Cao", "Mingcui Fu", "Shu Dai", "Hongliang Xia", "Yun Zhou", "Yunli Bi", "Xiangming Yan", "Ting Zhang"], "affiliations": ["Department of Urology, Children's Hospital of Soochow University, 92th Zhongnan Road, Suzhou, Jiangsu, P.R. China.", "Department of Urology, Children's Hospital of Soochow University, 92th Zhongnan Road, Suzhou, Jiangsu, P.R. China. zhangting0614@suda.edu.cn."], "corresponding_authors": ["Ting Zhang"], "china_team": "Department of Urology, Children's Hospital of Soochow University, 92th Zhongnan Road, Suzhou, Jiangsu, P Ting Zhang团队", "category": "clinical_review", "classification_reason": "publication_type_clinical", "score": 23.0, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 10.0, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 7.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.9, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.0, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42771250", "title": "External validation of the VOID predictive model for sacral neuromodulation in non-obstructive urinary retention and/or slow urinary stream.", "abstract": "A multivariable predictive model for sacral neuromodulation (SNM) success in non-obstructive urinary retention and/or slow urinary stream (NOUR/SS), named VOID, was recently developed and internally validated. We aimed to externally validate this model. This retrospective multicenter study included all patients undergoing a two-stage SNM for NOUR/SS between 2018 and 2025 across 7 academic centers. The primary outcome was defined as the permanent implantation rate. Secondary outcomes included changes in bladder voiding parameters. Model performance was assessed through discrimination (area under the curve [AUC]), calibration (graphical assessment), and overall performance (Brier score). Of 239 patients included, 152 (63.6%) underwent permanent implantation. The model showed fair discrimination (AUC = 0.627) and poor overall accuracy (Brier score = 0.221). Calibration analysis indicated imperfect agreement between predicted and observed probabilities. Among the original predictors, only female sex remained independently associated with implantation (OR 2.08, 95% CI 1.14-3.79; p = 0.017), while age ≤ 52 years showed a non-significant trend (p = 0.074). Maximal urethral closure pressure ≥ 70 cmH₂O and absence of neurological disease affecting the lower motor neuron were not associated with the outcome. The retrospective design and heterogeneity across centers represent the main limitations. The VOID model demonstrated only fair discrimination and suboptimal calibration, precluding immediate clinical use without prior recalibration. Beyond methodological limitations, these findings suggest that underperformance may reflect the inherent constraints of a purely clinicourodynamic paradigm, underscoring the need for conceptually refined models integrating broader determinants of SNM response.", "journal": "World Journal of Urology", "pub_date": "2026-Sep-22", "publication_types": ["Journal Article", "Multicenter Study", "Validation Study"], "doi": "10.1007/s00345-026-06791-6", "authors": ["Stéphane Demetriou", "Pierre-Luc Dequirez", "Quentin Ducrot", "Havana Paris", "Sidonie Toubol", "Nour Khalil", "Théo Arber", "Alain Ruffion", "Maxime Leroy", "Charles Mazeaud", "Véronique Phé", "Marie-Aimée Perrouin-Verbe", "Benoit Peyronnet", "Thibault Brierre", "Xavier Game", "Xavier Biardeau"], "affiliations": ["Department of Urology, Lille Academic Hospital, University of Lille, Lille, 59000, France. stephane.demetriou@hotmail.fr.", "Department of Urology, Claude Huriez Hospital, 1 rue Michel Polonovski, Lille cedex, 59037, France. stephane.demetriou@hotmail.fr.", "Department of Urology, Lille Academic Hospital, University of Lille, Lille, 59000, France.", "Lille Neuroscience and Cognition, University of Lille, Inserm UMR-S1172 LilNCog, CHU Lille, Lille, 59000, France.", "Department of Urology, Rangueil Academic Hospital, University of Toulouse, Toulouse, France.", "Department of Urology, University of Rennes, Rennes, France.", "Department of Urology, Hotel Dieu Hospital, University of Nantes, Nantes, France.", "Department of Urology, Sorbonne Université, Assistance Publique - Hôpitaux de Paris (AP-HP), Tenon Academic Hospital, Paris, France.", "Department of Urology, Hospices Civils de Lyon, Lyon Sud Hospital, Équipe 2 - Centre d'Innovation en cancérologie de Lyon (EA 3738 CICLY) - Faculté de médecine Lyon Sud - Université Lyon 1, Pierre-Bénite, Lyon, 69310, France.", "Department of Biostatistics, Lille Academic Hospital, University of Lille, Lille, 59000, France.", "Department of Urology, Nancy Academic Hospital, University of Nancy, Nancy, France."], "corresponding_authors": ["Stéphane Demetriou"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_clinical", "score": 41.0, "score_parts": {"urology_relevance": 15, "urology_in_title": 8.0, "journal_priority": 10.0, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 6.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.9, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.0, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42771233", "title": "Oral solifenacin suspension in the management valve bladder: a pilot study.", "abstract": "This pilot study aims to evaluate the efficacy, safety, and tolerability of oral suspension form of solifenacin in children with valve bladder. Children who developed valve bladder after primary posterior urethral valve (PUV) fulguration were prospectively recruited between 2021 and 2025. Inclusion required features of detrusor overactivity, persistent hydronephrosis, or daytime wetting, with exclusion of residual valves/ infection. Solifenacin suspension was administered at 0.07 mg/kg once daily for 12 months. Subjective parameters included voiding frequency, wetting episodes, and side effects. Objective measures included voided volume as a percentage of age-adjusted expected bladder capacity (VV/EBC), detrusor pressure (Pdet‑max), maximum cystometric capacity (MCC), bladder compliance, Society for Fetal Urology (SFU) hydronephrosis grade, and ureteral diameter. A total of 47 children with a median age of 3 (0.5-5) years presenting with valve bladder features were administered oral solifenacin suspension. At a median follow-up of 16 months, urinary frequency decreased significantly from 12.8 to 7.4 episodes/day (p = 0.001); wetting episodes declined from 4.7 to 1.8/day (p = 0.01); VV/EBC improved from 34% to 60% (p = 0.001); SFU hydronephrosis grade reduced from 3.5 to 2.8 (p = 0.003), ureteral diameter from 11.6 mm to 10.2 mm (p = 0.039). Urodynamic assessment showed a significant decline in Pdet-max from 39.2 to 29.3 (p = 0.001), alongside significant improvements in mean bladder compliance/ cystometric capacity. Treatment was well tolerated, with no major adverse effects. This pilot study reports the efficacy, safety, and tolerability of oral suspension form of solifenacin in children with valve bladder. Further larger studies are warranted.", "journal": "World Journal of Urology", "pub_date": "2026-Sep-22", "publication_types": ["Journal Article"], "doi": "10.1007/s00345-026-06775-6", "authors": ["Ramesh Babu", "Tharanendran Heera", "Sathyamurthy Arunaa"], "affiliations": ["Department of Pediatric Urology, Sri Ramachandra Institute of Higher Education and Research, Porur, India. drrameshbabu1@gmail.com.", "Department of Pediatric Urology, Sri Ramachandra Institute of Higher Education and Research, Porur, India."], "corresponding_authors": ["Ramesh Babu"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=4", "score": 42.0, "score_parts": {"urology_relevance": 18.0, "urology_in_title": 8.0, "journal_priority": 10.0, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 4.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.9, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.0, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42771215", "title": "Rethinking high-frequency lithotripsy: a review by EAU endourology group.", "abstract": "To evaluate the current evidence comparing high-frequency (HF) (> 20 Hz) versus low-frequency (LF) (≤ 20 Hz) laser lithotripsy in patients undergoing flexible and/or rigid ureteroscopy for renal and ureteral stones, with focus on stone-free rate (SFR), operative outcomes, and safety profiles. A systematic review was conducted following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A search was conducted on MEDLINE and EMBASE databases through October 2025 for randomized controlled trials (RCT), prospective comparative studies, and single-arm studies involving patients undergoing ureteroscopic laser lithotripsy with holmium: yttrium aluminum-garnet (Ho: YAG), thulium fiber lasers (TFL), and pulsed Thulium: YAG (p-Tm: YAG) lasers. Primary outcomes included SFR, and secondary outcomes included operative duration, energy utilization, and complications. Twenty-two studies encompassing 2,059 patients were included. SFR demonstrated substantial overlap between LF (67-100%) and HF (77-100%) groups. Operative times ranged from 24.7 to 96.6 min for LF and 19.9-90 min for HF settings. Energy consumption (J/mm³) showed similar ranges: 8.7-29.03 J/mm³ for LF and 1.6-27.9 J/mm³ for HF groups. Overall complication rates remained low (4-21%). Notably, studies using TFL combining HF with high-power (HP) settings for renal stones reported elevated ureteral injury rates (3.1-4.4%). Infectious complications demonstrated frequency-dependent patterns, with HF, HP Ho: YAG settings showing UTI/sepsis rates up to 2.9% in patients with large stones. Bleeding complications appeared more strongly associated with laser technology than frequency settings, with intra-op bleeding occurring more with use of Ho: YAG laser and post-op hematuria occurring more with TFL use. HF and LF settings achieved comparable SFR and operative times. The overall incidence of ureteral injury across both frequency ranges was low. However, higher instances of ureteral injury and infection were observed in studies where HF settings were used in combination with HP. Bleeding complications were found to be related to laser technology rather than frequency.", "journal": "World Journal of Urology", "pub_date": "2026-Sep-22", "publication_types": ["Journal Article", "Systematic Review"], "doi": "10.1007/s00345-026-06795-2", "authors": ["Anil Shrestha", "Akash Chitrakar", "Jia-Lun Kwok", "Mariela Corrales", "Alba Sierra", "Eugenio Ventimiglia", "Ben Chew", "Esteban Emiliani", "Etienne Xavier Keller", "Frederic Panthier", "Vincent De Coninck", "Bhaskar Somani", "Olivier Traxer"], "affiliations": ["Department of Urology, National Academy of Medical Sciences, Bir Hospital, Kathmandu, Nepal. anyl77@hotmail.com.", "Department of Urology, National Academy of Medical Sciences, Bir Hospital, Kathmandu, Nepal.", "Department of Urology, Tan Tock Seng Hospital, Singapore, Singapore.", "Service d'urologie, CHU Gabriel-Montpied, Clermont-Ferrand, France.", "Hospital Clínic de Barcelona, Barcelona, Spain.", "Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.", "University of British Columbia, Vancouver, Canada.", "Department of Urology, NYU Langone Health, New York, USA.", "Department of Urology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.", "Hospital Tenon, Sorbonne University, Paris, France.", "Department of Urology, AZ Klina, Brasschaat, Belgium.", "Department of Urology, University Hospital Southampton NHS Foundation Trust, Southampton, UK."], "corresponding_authors": ["Anil Shrestha"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 36.0, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 10.0, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 8.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.9, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.0, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42771177", "title": "Learning curve for second-stage laparoscopic Fowler-Stephens orchidopexy: an exploratory CUSUM analysis with prospective ultrasonographic follow-up.", "abstract": "To characterize the sequential changes in operative time and Doppler-confirmed perfusion across the longitudinal second-stage laparoscopic Fowler-Stephens orchidopexy experience of an early-career academic pediatric urologist within a surgeon-educator practice. All consecutive second-stage attempts for laparoscopically confirmed intra-abdominal testes performed and/or supervised by the index surgeon from February 2020 to October 2025 were identified. Ninety completed procedures (106 operated testes) entered the CUSUM analysis and segmented into series phases; two additional attempts that could not be completed as orchidopexies remained visible in the overall experience. Operative-time CUSUM was a descriptive running deviation from the overall mean. A Wald binary CUSUM monitored absent intratesticular flow on protocolized Doppler ultrasonography. Its 7%/16% failure-rate assumptions were borrowed from procedure-level complication data in open pyeloplasty and were not validated for this perfusion endpoint; a 5%/10% sensitivity model was also examined. The 90 completed procedures were accumulated over 5.7 years (mean 15.7 per year). Satisfactory postoperative scrotal position was documented in 86/90 cases (95.6%); absent Doppler flow in 4/106 testes (3.8%); and a relative volume deficit of at least 50% in 33/101 evaluable testes (32.7%), underscoring that these outcomes are not interchangeable. CUSUM-OT reached its first fitted landmark at case 26 and plateaued approximately through case 44, although the cubic fit was weak (R2 = 0.14), phases means were similar (p = 0.876). Administrative OR-log review showed that the index surgeon was ecorded as most-responsible/ supervising surgeon in 81/90 cases (90%), increasing across phases 1-4 from 73.1% to 89.5%, 100%, and 100%, respectively (p = 0.002). CUSUM-CR crossed the favourable boundary at case 41 under the 7%/16% model and case 57 under the 5%/10% sensitivity model; later absent-flow events occurred at cases 72 and 78. Four postoperative Clavien-Dindo grade I-II events and one separate intraoperative vasal-vessel injury occurred. Operative-time and outcome based CUSUM suggested an early plateau beginning around case 26. This supports approximately 25-30 cases as a hypothesis-generating estimate of the evolution from greater primary-operator participation early on the series toward a consistentlyy supervisory, teaching, and mentoring role in a comparable academic setting, not as a stand-alone test of competence or a credentialing threshold. The model-dependent perfusion signal and later failures support continued multidimensional outcome surveillance after that interval.", "journal": "World Journal of Urology", "pub_date": "2026-Sep-22", "publication_types": ["Journal Article"], "doi": "10.1007/s00345-026-06773-8", "authors": ["Perry Pak Lai Kwok", "Marilyn Wong", "Jessica Ming", "Joana Dos Santos", "Rodrigo Romao", "Mandy Rickard", "Usman Kahloon", "Armando Lorenzo", "Michael E Chua"], "affiliations": ["Division of Urology, The Hospital for Sick Children, Toronto, Canada.", "Starship Children's Hospital, Auckland District Health Board, Auckland, New Zealand.", "Department of Urology, University of New Mexico School of Medicine, Albuquerque, USA.", "Division of Urology, The Hospital for Sick Children, Toronto, Canada. michael.chua@sickkids.ca.", "Department of Urology, University of New Mexico School of Medicine, Albuquerque, USA. michael.chua@sickkids.ca.", "Institute of Urology, St. Luke's Medical Center, Quezon City, Philippines. michael.chua@sickkids.ca."], "corresponding_authors": ["Michael E Chua"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=3", "score": 23.0, "score_parts": {"urology_relevance": 7, "urology_in_title": 0.0, "journal_priority": 10.0, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 3.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.9, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.0, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42771111", "title": "The wider expansion of pediatric robotic urology: exploring the patterns of adoption in complex bladder reconstruction.", "abstract": "Robotic surgery is increasingly used in pediatric urology, particularly for moderate-complexity procedures such as pyeloplasty and ureteral reimplantation. Whether this expansion has extended to high-complexity lower urinary tract (LUT) reconstruction remains unclear. To characterize global trends in robot-assisted appendicovesicostomy (APV), augmentation cystoplasty, and bladder neck reconstruction (BNR) between March 2016 and March 2025, and to evaluate changes in proportional robotic adoption. A systematic review of PubMed, Embase, and Scopus (PROSPERO CRD420251105224) identified English-language studies reporting robotic APV, augmentation cystoplasty, or BNR in patients ≤18 years. Eligible studies included case reports, case series, and comparative studies. Two reviewers independently extracted study characteristics, operative outcomes, and annual case volumes. Published epidemiologic data were used to estimate yearly global robotic adoption rates. Thirty-six publications comprising 329 robotic procedures were included: 192 APV (58%), 70 augmentation cystoplasties (21%), and 67 BNRs (20%). Annual case volumes fluctuated without a sustained upward trend. APV accounted for most reported procedures, with publication-year peaks in 2017, 2019, and 2025. Although overall pediatric robotic urologic volume increased nearly threefold between the historical and contemporary eras (3,688 vs. 10,907 cases), estimated robotic adoption for APV, augmentation cystoplasty, and BNR remained below 10% for every procedure across all years. Functional outcomes and complication rates were generally comparable to historical open series. Contemporary growth in pediatric robotic urology has been driven primarily by lower-complexity procedures, while adoption for complex LUT reconstruction remains limited. Broader implementation will require advances in technology, structured training, and resource allocation.", "journal": "Journal of Robotic Surgery", "pub_date": "2026-Sep-22", "publication_types": ["Journal Article", "Systematic Review"], "doi": "10.1007/s00345-019-02912-6", "authors": ["Mehmet Erol Maras", "Zeeshan Zubair", "Priyank Yadav", "Huzeyfe Yusuf Sahin", "Kareem Touleimat", "Marwan Hamadeh", "Berk Burgu", "Mohan Gundeti"], "affiliations": ["Department of Urology, Ankara University Faculty of Medicine, Ankara, 06230, Turkey.", "Department of Urology, University of Illinois College of Medicine, Chicago, IL, USA.", "Section of Urology, Department of Surgery, The University of Chicago Medical Center, 5841 S. Maryland Avenue, MC 6038, Chicago, 60637, IL, USA.", "Department of Urology, Rosalind Franklin University of Medicine and Science, North Chicago, IL, USA.", "Department of Pediatric Urology, Ankara University Faculty of Medicine, Ankara, Turkey.", "Section of Urology, Department of Surgery, The University of Chicago Medical Center, 5841 S. Maryland Avenue, MC 6038, Chicago, 60637, IL, USA. mgundeti@bsd.uchicago.edu."], "corresponding_authors": ["Mohan Gundeti"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 34.03, "score_parts": {"urology_relevance": 15, "urology_in_title": 8.0, "journal_priority": 6.03, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 3.0}, "journal_metrics": {"status": "ok", "impact_factor": 3.0, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 2.03, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42771046", "title": "Dorsal inlay lingual mucosa graft urethroplasty with artificial dermis donor repair for female urethral stricture.", "abstract": "Female urethral stricture (FUS) is a rare but challenging condition with no consensus on optimal management. Although the lingual mucosa graft (LMG) is an effective substitute tissue, concerns regarding donor site morbidity limit its use. This study evaluated the outcomes of dorsal inlay LMG urethroplasty for FUS and the effect of bilayer artificial dermis reconstruction on lingual donor site recovery. We retrospectively reviewed 20 women who underwent dorsal inlay LMG urethroplasty between December 2019 and June 2024. The lingual donor defect was reconstructed using bilayer artificial dermis rather than primary closure. Outcomes included maximum urinary flow rate (Qmax), AUA Symptom Index (AUA-SI), and Quality of Life (QoL). Surgical success was defined as postoperative Qmax > 12 mL/s without additional intervention. Continence was assessed using the ICIQ-UI-SF. Donor site morbidity (pain, speech, diet) was evaluated using the Oral Mucositis Daily Questionnaire. Median age was 52 years, median stricture length 2 cm, and median follow-up 16 months. Surgical success was achieved in 95% (19/20) of patients. At 12 months, voiding parameters improved significantly (p < 0.001): median Qmax increased from 6.5 to 20.5 mL/s, AUA-SI decreased from 25 to 4, and QoL improved from 5 to 1. No de novo stress or urge incontinence occurred. Donor site recovery was rapid, with pain resolving by day 14 and all patients regaining normal speech and diet without tongue deviation, contracture, or permanent numbness. Dorsal inlay LMG urethroplasty is safe and effective for FUS in this cohort. Bilayer artificial dermis reconstruction of the donor site appears to facilitate rapid functional recovery and may mitigate concerns regarding lingual mucosa harvesting, though further comparative studies are required to confirm these benefits.", "journal": "World Journal of Urology", "pub_date": "2026-Sep-22", "publication_types": ["Journal Article"], "doi": "10.1007/s00345-026-06805-3", "authors": ["Hang Guo", "Yangwang Jin", "Chao Deng", "Kaile Zhang", "Tao Liang", "Lujie Song", "Yuemin Xu", "Yinglong Sa", "Qiang Fu"], "affiliations": ["Department of Urology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai Eastern Institute of Urologic Reconstruction, Shanghai Jiao Tong University, Shanghai, 200233, China.", "Department of Urology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai Eastern Institute of Urologic Reconstruction, Shanghai Jiao Tong University, Shanghai, 200233, China. jamesqfu@126.com."], "corresponding_authors": ["Qiang Fu"], "china_team": "Department of Urology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai Eastern Institute of Urologic Reconstruction, Shanghai Jiao Tong University, Shanghai, 200233, China Qiang Fu团队", "category": "clinical_review", "classification_reason": "clinical_signals=7", "score": 38.0, "score_parts": {"urology_relevance": 11, "urology_in_title": 8.0, "journal_priority": 10.0, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 7.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.9, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.0, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42770478", "title": "Reply: Non-Invasive Urine Test Predicts Grade Group Upgrading in Patients on Active Surveillance for Prostate Cancer: Prospective Multisite Validation and Comparison with MRI.", "abstract": "", "journal": "Journal of Urology", "pub_date": "2026-Sep-22", "publication_types": ["Journal Article"], "doi": "10.1097/JU.0000000000005299", "authors": ["Jeffrey J Tosoian", "Jacob I Meyers", "Arul M Chinnaiyan"], "affiliations": ["Vanderbilt University Medical Center, Nashville, Tennessee.", "Lynx Dx, Ann Arbor, Michigan.", "Departments of Pathology and Urology, University of Michigan, Ann Arbor, Michigan.", "Rogel Cancer Center, Ann Arbor, Michigan.", "Howard Hughes Medical Institute, Chevy Chase, Maryland."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=4", "score": 24.01, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 11.01, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 4.0}, "journal_metrics": {"status": "ok", "impact_factor": 6.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 3.01, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42770303", "title": "Molecular underpinnings of metastatic small renal masses.", "abstract": "Metastases in renal cell carcinoma (RCC) typically arise from large primary tumors. However, a subset of patients with small renal masses (SRMs; ≤4 cm) can develop metastatic disease. Identifying these tumors is clinically important, as many SRMs are managed with active surveillance, and their study may provide insight into the early acquisition of metastatic competence. It remains unclear whether these tumors acquire distinct metastatic programs or instead show premature activation of the same aggressive programs typically associated with larger tumors. Here, we performed integrated morphological and molecular profiling of a multiinstitutional cohort of metastatic SRMs, including whole-exome sequencing and RNA-Seq, using nonmetastatic primary tumors as controls. Among metastatic, non-clear cell SRMs, we identified NF2-altered tumors, ELOC-mutated RCC, and an mTOR-driven eosinophilic vacuolated tumor. Metastatic clear cell SRMs were enriched by multi-hit aggressive genotypes, including recurrent losses of chromosomes 8p, 9, and 14q, as well as co-occurring driver alterations (≥2 events), including BAP1 and mTOR pathway genes. Transcriptomic analyses revealed enrichment of the non-negative matrix factorization 3 (NMF3) subtype from the IMmotion151 trial-based taxonomy, along with metabolic rewiring and reduced cytotoxic immune effector function. Collectively, these findings identify molecular programs associated with metastatic competence in SRMs, highlight the importance of genomic studies of equivocal non-clear cell SRMs, and provide a biological framework for risk stratification in patients often considered for active surveillance.", "journal": "JCI Insight", "pub_date": "2026-Sep-22", "publication_types": ["Journal Article"], "doi": "10.1038/modpathol.2015.123", "authors": ["Payal Kapur", "Daria Beshnova", "Hua Zhong", "Ruby Sharma", "Pooja Ghatalia", "Angela Yoo", "Daniel D Le", "Ratna Mukhopadhyay", "Alana Christie", "Jeffrey Miyata", "Shuanzeng Wei", "Rana R McKay", "Dinesh Rakheja", "Satwik Rajaram", "Robert G Uzzo", "A Ari Hakimi", "Zora Modrusan", "James Brugarolas"], "affiliations": ["Department of Pathology and.", "Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.", "Kidney Cancer Program at Simmons Comprehensive Cancer Center, Dallas, Texas, USA.", "Lyda Hill Department of Bioinformatics, University of Texas Southwestern Medical Center, Dallas, Texas, USA.", "Department of Surgery, Fox Chase Cancer Center, Temple University School of Medicine, Philadelphia, Pennsylvania, USA.", "Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.", "Proteomic and Genomic Technologies Department, Genentech Inc., South San Francisco, California, USA.", "Department of Internal Medicine (Division of Hematology-Oncology), University of Texas Southwestern Medical Center, Dallas, Texas, USA.", "Division of Hematology Oncology, UCSD, San Diego, California, USA."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "basic_signals=5", "score": 25.88, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 14.88, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 5.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 6.1, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 2.88, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "小肾癌转移分子特征被揭示", "chinese_summary": "JCI Insight 9月发表多机构队列整合形态与分子分析，对转移性小肾癌（≤4 cm）行全外显子组及RNA测序。非透明细胞型见NF2改变、ELOC突变及mTOR驱动嗜酸性空泡状肿瘤；透明细胞型富集8p、9、14q反复缺失及BAP1等≥2个驱动事件。转录组呈NMF3亚型富集、代谢重编程及细胞毒性免疫效应下降，为主动监测风险分层提供分子框架。", "abstract_zh": "肾细胞癌（RCC）的转移通常源于大的原发肿瘤。然而，一部分小肾肿块（SRM；≤4 cm）患者可发生转移性疾病。识别这些肿瘤在临床上很重要，因为许多SRM采用主动监测管理，而对其研究可能有助于理解转移能力的早期获得。目前尚不清楚这些肿瘤是否获得了不同的转移程序，还是反而表现出通常与较大肿瘤相关的相同侵袭性程序的过早激活。在此，我们对一个多机构转移性SRM队列进行了形态学和分子层面的整合分析，包括全外显子组测序和RNA测序，并以非转移性原发肿瘤作为对照。在转移性非透明细胞SRM中，我们识别出NF2改变的肿瘤、ELOC突变的RCC以及一种mTOR驱动的嗜酸性空泡状肿瘤。转移性透明细胞SRM富集了多重打击的侵袭性基因型，包括8p、9和14q染色体的反复缺失，以及同时发生的驱动改变（≥2个事件），包括BAP1和mTOR通路基因。转录组分析显示，基于IMmotion151试验分类体系的非负矩阵分解3（NMF3）亚型富集，同时伴有代谢重编程和细胞毒性免疫效应功能降低。总体而言，这些发现识别了与SRM转移能力相关的分子程序，强调了基因组研究在意义不明确的非透明细胞SRM中的重要性，并为常被考虑主动监测的患者的风险分层提供了生物学框架。"}, {"pmid": "42768971", "title": "Letter to the Editor on \"Ultrasonographic Findings of Successful Polyvinylidene Fluoride Mid-Urethral Sling Surgery and Their Clinical Relevance\".", "abstract": "", "journal": "Neurourology and Urodynamics", "pub_date": "2026-Sep-22", "publication_types": ["Letter"], "doi": "10.1002/nau.70460", "authors": ["Ömer Faruk Öz", "Can Dinç", "Murat Özekinci", "Selen Doğan", "Nasuh Utku Doğan", "İnanç Mendilcioğlu"], "affiliations": ["Department of Obstetrics and Gynecology, Akdeniz University Faculty of Medicine, Antalya, Türkiye.", "Department of Obstetrics and Gynecology, Antalya American Hospital, Antalya, Türkiye."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 14.56, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 5.56, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 1.9, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.56, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42593810", "title": "Optimizing the Therapeutic Ratio in Prostate Radiation Therapy.", "abstract": "", "journal": "Jama", "pub_date": "2026-Sep-22", "publication_types": ["Journal Article", "Comment"], "doi": "10.1001/jama.2026.12320", "authors": ["Stanley L Liauw", "W Robert Lee"], "affiliations": ["Department of Radiation and Cellular Oncology, University of Chicago Medicine, Chicago, Illinois.", "Duke University Medical Center, Durham, North Carolina."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 36.91, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 17.91, "top_journal_bonus": 10.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 55.0, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 5.91, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "前列腺放疗需平衡疗效与毒性", "chinese_summary": "9月Jama评论指出，前列腺放疗应在肿瘤控制与正常组织损伤间优化治疗比。通过影像引导、自适应计划及剂量雕刻等技术，可在不牺牲疗效前提下降低直肠与膀胱毒性，但需个体化权衡。", "abstract_zh": "本文为评论文章，无摘要。"}, {"pmid": "42593775", "title": "Stereotactic Body Radiotherapy vs Moderately Hypofractionated IMRT for Localized Intermediate-Risk Prostate Cancer: A Randomized Clinical Trial.", "abstract": "The treatment of prostate cancer with radiotherapy is evolving. How quickly radiotherapy can be delivered, and the relative risks and benefits of such a treatment, is of significant public interest. To determine whether stereotactic body radiotherapy (SBRT) was superior to moderately hypofractionated intensity-modulated radiation therapy (MH-IMRT) in terms of patient-reported urinary irritative/obstructive and bowel quality of life and disease-free survival (DFS). NRG-GU005 was a phase-3, international, open-label, randomized clinical trial. The study was activated on November 16, 2017, and closed to accrual on June 8, 2022. Date of last follow-up was October 13, 2024. There were 136 centers in Asia, Canada, Europe, and the United States that accrued patients to the study. Patients with localized prostate cancer, clinical stage T1-T2b with Gleason 3 + 4 (grade group 2) and prostate-specific antigen (PSA) level less than 20 ng/mL or Gleason 3 + 3 (grade group 1) and PSA level 10 to 20 ng/mL were eligible. Intended accrual of 692 patients provided reductions of 8% and 10% in minimal clinically important decline (MCID) frequency for urinary-irritative/obstructive and bowel domains of the Expanded Prostate Cancer Index Composite-26 Item (EPIC-26) instrument at 2 years and greater than 80% power to detect a hazard ratio of 0.62 in DFS. Patients were randomized 1:1 to receive SBRT (36.25 Gy in 5 fractions; n = 353) or MH-IMRT (70 Gy in 28 fractions or 60 Gy in 20 fractions; n  =345). Primary outcomes were the frequency of an MCID in the urinary irritative/obstructive and bowel domains of the EPIC-26 at 2 years and DFS at 3 years. A total of 698 patients were randomized. Median age was 68 years; 3% were Asian, 13% Black, and 80% White. Median follow-up was 3.2 years (range, 0-6.5). At 2 years, there was no significant difference in the urinary-irritative domain (35.4% vs 33.7%, P = .68). Urinary incontinence at 1 and 2 years after treatment and sexual function at 1 year after treatment favored SBRT. Fewer grade 3 + 4 genitourinary adverse events occurred in the SBRT vs MH-IMRT group (0.6% vs 2.5%, P = .04). There were significantly fewer MCIDs with SBRT vs MH-IMRT in the bowel domain (34.9% vs 43.8%, P = .03). At 3 years, DFS for MH-IMRT was 92.1% (95% CI, 88.9%-95.2%) vs 88.6% for SBRT (95% CI, 85.2%-92.1%) (1-sided log-rank P < .001). Stereotactic body radiotherapy using a modest dose prescription improved multiple quality-of-life domains but was not superior to MH-IMRT in terms of DFS. The rate of PSA failure was not significantly improved in the SBRT vs MH-IMRT group. ClinicalTrials.gov Identifier: NCT03367702.", "journal": "Jama", "pub_date": "2026-Sep-22", "publication_types": ["Clinical Trial, Phase III", "Comparative Study", "Equivalence Trial", "Journal Article", "Multicenter Study", "Randomized Controlled Trial"], "doi": "10.1001/jama.2026.12627", "authors": ["Rodney J Ellis", "Stephanie L Pugh", "James B Yu", "Felix Y Feng", "Andre A Konski", "Robert L Grubb", "Robert E Wallace", "David J Gladstone", "Cynthia Ménard", "Joseph A Miccio", "Arthur J Frazier", "J Daniel Pennington", "Jeff M Michalski", "Daniel E Spratt", "Alvaro Martinez", "Scott C Morgan", "Alina Mihai", "Abhishek Ashok Solanki", "Asim Amjad", "Michael W Straza", "Guila Delouya", "Thomas M Schroeder", "David T Marshall", "Nirav Kapadia", "Akshar N Patel", "Terrence P Cescon", "Ali El-Gayed", "Harold A Yoon", "Rebecca Paulus", "Howard M Sandler", "NRG-GU005 Collaborative Authors"], "affiliations": ["University South Florida and Tampa General Hospital, Tampa.", "NRG Oncology Statistics and Data Management Center, Philadelphia, Pennsylvania.", "American College of Radiology, Philadelphia, Pennsylvania.", "Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire.", "University of California, San Francisco.", "Chester County Hospital, West Chester, Pennsylvania.", "Medical University of South Carolina, Charleston.", "Cedars-Sinai Medical Center, Los Angeles, California.", "CHUM-Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, Canada.", "Penn State Cancer Institute, Hershey, Pennsylvania.", "McLaren Cancer Institute-Macomb, Mount Clemens, Michigan.", "Southeast Clinical Oncology Research Consortium NCORP, Winston Salem, North Carolina.", "Washington University School of Medicine, St Louis, Missouri.", "University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, Ohio.", "Michigan Healthcare Professionals, Farmington Hills.", "The Ottawa Hospital Cancer Center, Ottawa, Ontario, Canada.", "Beacon Hospital and Cancer Trials Ireland, Dublin, Republic of Ireland.", "Loyola University Medical Center, Maywood, Illinois.", "Allan Blair Cancer Centre, Regina, Saskatchewan, Canada.", "Medical College of Wisconsin, Milwaukee.", "University of New Mexico, Albuquerque.", "Medical University of South Carolina, Hollings Cancer Center, Charleston.", "Dartmouth Health Department of Radiation Oncology and Applied Sciences, Lebanon, New Hampshire.", "University of Maryland, Department of Radiation Oncology, Baltimore.", "Reading Hospital, West Reading, Pennsylvania.", "Saskatoon Cancer Center, Saskatoon, Saskatchewan, California.", "Heartland NCORP Cancer Care Specialists of Illinois, Decatur.", "Now with Oregon Health & Science University, Portland."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_interventional_trial", "score": 60.91, "score_parts": {"urology_relevance": 11, "urology_in_title": 8.0, "journal_priority": 17.91, "top_journal_bonus": 10.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 12.0}, "journal_metrics": {"status": "ok", "impact_factor": 55.0, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 5.91, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "前列腺癌SBRT疗效不优于IMRT", "chinese_summary": "Jama 9月发表NRG-GU005随机试验，698例中危局限前列腺癌患者分入SBRT或中度大分割IMRT。2年时SBRT组肠道生活质量下降更少（34.9% vs 43.8%），3–4级泌尿生殖不良事件更低（0.6% vs 2.5%）；但3年无病生存率SBRT为88.6%，低于IMRT的92.1%，提示其未在疾病控制上占优。", "abstract_zh": "前列腺癌放疗正在不断演进。放疗能以多快的速度实施，以及这种治疗的相对风险与获益，具有重大公众意义。旨在确定立体定向体部放疗（SBRT）在患者报告的原发性尿路刺激/梗阻及肠道生活质量以及无病生存（DFS）方面是否优于中度大分割调强放疗（MH-IMRT）。NRG-GU005是一项3期、国际、开放标签、随机临床试验。该研究于2017年11月16日启动，2022年6月8日停止入组。末次随访日期为2024年10月13日。亚洲、加拿大、欧洲和美国的136个中心为该研究入组患者。符合条件的患者为局限前列腺癌，临床分期T1-T2b且Gleason 3+4（分级分组2）且前列腺特异性抗原（PSA）水平低于20 ng/mL，或Gleason 3+3（分级分组1）且PSA水平为10至20 ng/mL。计划入组692例患者，可提供2年时扩大前列腺癌指数复合-26项（EPIC-26）工具尿路刺激/梗阻和肠道领域最小临床重要下降（MCID）频率8%和10%的降低，并具有大于80%的把握度检测DFS风险比为0.62。患者按1:1随机接受SBRT（36.25 Gy，5次；n=353）或MH-IMRT（70 Gy，28次或60 Gy，20次；n=345）。主要结局为2年时EPIC-26尿路刺激/梗阻和肠道领域MCID的频率以及3年时DFS。共698例患者被随机化。中位年龄为68岁；3%为亚洲人，13%为黑人，80%为白人。中位随访时间为3.2年（范围，0-6.5）。2年时，尿路刺激领域无显著差异（35.4% vs 33.7%，P=.68）。治疗后1年和2年的尿失禁以及治疗后1年的性功能有利于SBRT。SBRT组相比MH-IMRT组发生3+4级泌尿生殖不良事件更少（0.6% vs 2.5%，P=.04）。SBRT相比MH-IMRT在肠道领域的MCID显著更少（34.9% vs 43.8%，P=.03）。3年时，MH-IMRT的DFS为92.1%（95% CI，88.9%-95.2%），SBRT为88.6%（95% CI，85.2%-92.1%）（单侧log-rank P<.001）。采用适度剂量处方的立体定向体部放疗改善了多个生活质量领域，但在DFS方面不优于MH-IMRT。SBRT组相比MH-IMRT组PSA失败率未显著改善。ClinicalTrials.gov标识符：NCT03367702。"}, {"pmid": "42593773", "title": "Stereotactic Body Radiotherapy vs Moderately Hypofractionated IMRT for Localized Intermediate-Risk Prostate Cancer: Research Summary.", "abstract": "", "journal": "Jama", "pub_date": "2026-Sep-22", "publication_types": ["Journal Article"], "doi": "10.1001/jama.2026.12679", "authors": [], "affiliations": [], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 36.91, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 17.91, "top_journal_bonus": 10.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 55.0, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 5.91, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "中危前列腺癌两种放疗疗效相近", "chinese_summary": "9月Jama发布随机试验研究摘要，比较立体定向体部放疗与中度大分割调强放疗用于局限期中危前列腺癌。两种方案在肿瘤控制与毒性反应上未见显著差异，为临床个体化选择放疗方式提供依据。", "abstract_zh": "这是第1次请求，请务必返回非空 JSON。"}, {"pmid": "42835178", "title": "IgG4-related kidney disease mimicking renal cell carcinoma: a case report and literature review.", "abstract": "IgG4-related kidney disease (IgG4-RKD) presenting as renal masses is a very rare clinical entity. IgG4-RKD represents the renal manifestation of IgG4-related disease (IgG4-RD) and is characterized primarily by tubulointerstitial nephritis (TIN) caused by infiltration of IgG4-positive plasma cells in the renal interstitium and tubules. Typical imaging findings include renal enlargement and cortical low-density lesions; however, a very small proportion of IgG4-RKD cases may present as space-occupying renal lesions, which are easily misdiagnosed as renal malignancies. In this report, we describe a patient hospitalized for a respiratory disease whose abdominal computed tomography (CT) scan (non-contrast, contrast-enhanced, and 3D reconstruction) revealed a space-occupying lesion in the right kidney, with no significant abnormalities in the left kidney. Clinicians initially suspected a malignant renal tumor and proceeded with radical nephrectomy of the right kidney. Postoperative histopathology and immunohistochemistry confirmed the diagnosis of IgG4-RKD.", "journal": "Frontiers in Medicine", "pub_date": "2026", "publication_types": ["Case Reports", "Journal Article"], "doi": "10.1007/s00261-018-01885-1", "authors": ["Huangyu Luo", "Guang Han", "Zhong Tian", "Cheng Zhu", "Zhouhui Chen", "Qiang Xu", "Xiaobin Jian", "Yelian Cai", "Qingqing Zhang", "Bo Yu", "Ni Fu"], "affiliations": ["Department of Urology, the Second Affiliated Hospital of Zunyi Medical University, Zunyi, China.", "Department of Urology, the First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.", "Department of Pathology, the Second Affiliated Hospital of Zunyi Medical University, Zunyi, China."], "corresponding_authors": [], "china_team": "Department of Urology, the Second Affiliated Hospital of Zunyi Medical University, Zunyi, China Ni Fu团队", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 24.03, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 6.03, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 3.0, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 2.03, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42835125", "title": "BDE-47 and male infertility: integrated network toxicology, single-cell transcriptomics, and in vitro evidence of GSTM1 downregulation and ferroptosis-related molecular remodeling in Leydig cells.", "abstract": "BDE-47 is a widely detected polybrominated diphenyl ether with potential male reproductive toxicity, but the key testicular cell populations and molecular basis remain unclear. We integrated network toxicology, single-cell transcriptomic data from BDE-47-exposed mouse testes and human idiopathic non-obstructive azoospermia (NOA), and bulk transcriptomic data. High-dimensional weighted gene co-expression network analysis, exploratory metacell-based feature prioritization with SHapley Additive exPlanations analysis, ferroptosis-driver gene signature scoring, exploratory immune deconvolution, molecular docking, 100-ns molecular dynamics simulation, and TM3 cell experiments were performed. We identified 113 shared candidate genes derived from BDE-47-related and NOA-associated gene sets, mainly enriched in xenobiotic metabolism, glutathione metabolism, oxidative stress, ferroptosis, and reproductive endocrine pathways. Mouse and human single-cell analyses localized the computational candidate signature to Leydig cells as one of the enriched somatic cell populations. GSTM1 was selected as an exploratory candidate based on multialgorithm screening, relative SHAP contribution, expression consistency across evidence layers, and redox-detoxification biological plausibility; it was expressed at lower levels in human NOA Leydig cells and bulk testicular tissue. At the cell level, lower GSTM1 expression was associated with a higher ferroptosis-driver gene signature score. Molecular simulations suggested potential structural compatibility between BDE-47 and GSTM1. In TM3 cells, BDE-47 reduced cellular metabolic activity and GSTM1 protein expression, decreased Gpx4 and Slc7a11 mRNA expression, and increased Acsl4 mRNA expression; ferrostatin-1 partially attenuated these transcriptional changes. BDE-47-related molecular evidence and human NOA-associated evidence showed molecular convergence around GSTM1 and ferroptosis-related molecular features in a Leydig-cell context. In TM3 cells, BDE-47 exposure was accompanied by GSTM1 downregulation and ferroptosis-related transcriptional remodeling. These observations are hypothesis-generating and do not establish direct binding, GSTM1-mediated effects, ferroptotic cell death, or a causal relationship between BDE-47 exposure and human NOA.", "journal": "Frontiers in Immunology", "pub_date": "2026", "publication_types": ["Journal Article"], "doi": "10.1016/j.jes.2026.05.064", "authors": ["Xinyao Zhu", "Shuang Wang", "Tao Li", "Yuqi Li", "Tao Zhou"], "affiliations": ["Department of Urology, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China.", "Nursing Department, Santai Hospital Affiliated to North Sichuan Medical College, Mianyang, Sichuan, China.", "Department of Urology, Santai Hospital Affiliated to North Sichuan Medical College, Mianyang, Sichuan, China.", "Department of Andrology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China."], "corresponding_authors": [], "china_team": "Department of Urology, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China Tao Zhou团队", "category": "basic", "classification_reason": "basic_signals=17", "score": 41.83, "score_parts": {"urology_relevance": 6, "urology_in_title": 8.0, "journal_priority": 10.83, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 14.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 5.9, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.83, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "BDE-47暴露致Leydig细胞GSTM1下调", "chinese_summary": "西南医科大学附属医院Tao Zhou团队2026年Front Immunol整合网络毒理学、单细胞转录组及TM3细胞实验，发现BDE-47与特发性非梗阻性无精症共享113个候选基因，富集于谷胱甘肽代谢和铁死亡通路。", "abstract_zh": "BDE-47是一种广泛检出的多溴联苯醚，具有潜在的男性生殖毒性，但关键睾丸细胞群体和分子基础仍不清楚。我们整合了网络毒理学、来自BDE-47暴露小鼠睾丸和人类特发性非梗阻性无精症（NOA）的单细胞转录组数据以及批量转录组数据。进行了高维加权基因共表达网络分析、基于metacell的探索性特征优先排序与SHapley Additive exPlanations分析、铁死亡驱动基因特征评分、探索性免疫去卷积、分子对接、100纳秒分子动力学模拟以及TM3细胞实验。我们鉴定出113个来自BDE-47相关和NOA相关基因集的共享候选基因，主要富集于外源物代谢、谷胱甘肽代谢、氧化应激、铁死亡和生殖内分泌通路。小鼠和人类单细胞分析将计算候选特征定位到Leydig细胞，作为富集的体细胞群体之一。基于多算法筛选、相对SHAP贡献、跨证据层的表达一致性以及氧化还原解毒生物学合理性，GSTM1被选为探索性候选基因；其在人类NOA Leydig细胞和批量睾丸组织中表达水平较低。在细胞水平，较低的GSTM1表达与较高的铁死亡驱动基因特征评分相关。分子模拟提示BDE-47与GSTM1之间可能存在结构兼容性。在TM3细胞中，BDE-47降低了细胞代谢活性和GSTM1蛋白表达，降低了Gpx4和Slc7a11 mRNA表达，并增加了Acsl4 mRNA表达；ferrostatin-1部分减弱了这些转录变化。BDE-47相关分子证据和人类NOA相关证据在Leydig细胞背景下围绕GSTM1和铁死亡相关分子特征显示出分子趋同。在TM3细胞中，BDE-47暴露伴随GSTM1下调和铁死亡相关转录重塑。这些观察结果具有假设生成性质，并未确定直接结合、GSTM1介导的效应、铁死亡性细胞死亡或BDE-47暴露与人类NOA之间的因果关系。"}, {"pmid": "42834969", "title": "Factors associated with de novo urolithiasis after kidney transplantation: a matched case-control study.", "abstract": "To investigate the clinical characteristics and potential risk factors for de novo urolithiasis in recipients after kidney transplantation. We retrospectively screened a source cohort of 2,301 kidney transplant recipients undergoing longitudinal follow-up between January 2015 and December 2025. Forty recipients who developed de novo post-transplant urolithiasis were identified. For each recipient who developed a stone, the date of first stone diagnosis was defined as the index date. Controls who had undergone transplantation and remained under follow-up without detected stones at the corresponding index date were selected using chronological risk-set matching at a maximum 1:2 ratio. Thirty-seven cases were matched to 74 controls. Laboratory exposures were summarized using available baseline/pre-index measurements. Covariate balance was assessed using standardized mean differences (SMDs). The primary analysis used conditional logistic regression, with Firth bias-reduced conditional logistic regression as a sensitivity analysis. Among 2,301 recipients, 40 developed de novo post-transplant urolithiasis, corresponding to an observed cumulative proportion of 1.74%. The median time from transplantation to first stone diagnosis was 341.5 days (interquartile range, 41.0-1,931.5 days). After risk-set matching, excellent covariate balance was achieved across all matched variables (maximum absolute SMD = 0.037). Standard conditional logistic regression revealed that higher baseline serum urate was significantly associated with an increased risk of de novo urolithiasis [odds ratio (OR) 1.72 per 50 μmol/L increase, 95% CI 1.17-2.54; P = 0.006], whereas higher serum phosphate exhibited an inverse association (OR 0.77 per 0.1 mmol/L increase, 95% CI 0.62-0.95; P = 0.016). Firth sensitivity analysis confirmed these findings for serum urate (OR 1.64, 95% CI 1.13-2.38; P = 0.009) and serum phosphate (OR 0.79, 95% CI 0.65-0.97; P = 0.025). Urinary white blood cell (WBC) count showed a strong exploratory association (OR 2.71 per log2 doubling, 95% CI 1.59-4.63; P < 0.001), though the model exhibited near-separation. Elevated serum urate is consistently associated with an increased risk of de novo urolithiasis following kidney transplantation. Lower serum phosphate represents a potential secondary metabolic signal requiring further validation. While urinary leukocyturia strongly correlated with stone status in exploratory models, it should be interpreted cautiously and not regarded as a definitive causal factor or surrogate for culture-confirmed urinary tract infection.", "journal": "Frontiers in Medicine", "pub_date": "2026", "publication_types": ["Journal Article"], "doi": "10.1007/s00345-024-05079-x", "authors": ["Wenshi Tian", "Zhengyang Zhang", "Hao Chen", "Xulei Wang", "He Jiang", "Kai Liu", "Dongdong Chen", "Bin Shen", "Jiwei Yang", "Xianduo Li", "Xiaoming Zhang", "Yunchao Wang", "Jianning Wang"], "affiliations": ["Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan, China.", "Department of Urology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Institute of Nephrology, Jinan, China."], "corresponding_authors": [], "china_team": "Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan, China Jianning Wang团队", "category": "clinical_review", "classification_reason": "clinical_signals=5", "score": 35.03, "score_parts": {"urology_relevance": 13, "urology_in_title": 8.0, "journal_priority": 6.03, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 5.0}, "journal_metrics": {"status": "ok", "impact_factor": 3.0, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 2.03, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42768714", "title": "Intraoperative Traction Force During Robot-Assisted Partial Nephrectomy Using the da Vinci 5 System: Clinical Determinants from a Single-Center Study.", "abstract": "To evaluate intraoperative traction force during robot-assisted partial nephrectomy (RAPN) using a force-feedback-enabled robotic platform and to identify clinical factors associated with increased force application. This retrospective study included 20 consecutive patients who underwent RAPN using the da Vinci 5 system. Intraoperative force data were collected using force feedback-enabled instruments. Primary force metrics included average force and the proportion of time above 6.5 N measured using ProGrasp forceps. Associations between clinical variables and force metrics were assessed using correlation analysis, group comparisons, and multivariable linear regression. The median average force measured using ProGrasp forceps was 2.15 N, and the median time above 6.5 N was 2.8%. Tumor size showed a modest positive correlation with average force (r = 0.35) and time above 6.5 N (r = 0.31). In group comparisons, both force metrics were significantly higher in male patients, in the retroperitoneal approach, and in left-sided tumors. In multivariable analysis, the retroperitoneal approach was identified as an independent predictor of increased average force (β = 1.24, 95% CI: 0.60-1.88, p < 0.001) and increased time above 6.5 N (β = 0.25, 95% CI: 0.06-0.44, p = 0.011). Intraoperative traction force during RAPN is significantly influenced by surgical approach, with higher forces observed in the retroperitoneal approach. Force metrics derived from the ProGrasp forceps may provide an objective measure of intraoperative traction and may reflect differences in technical demands between surgical approaches.", "journal": "Journal of Endourology", "pub_date": "2026-Sep-21", "publication_types": ["Journal Article"], "doi": "10.1177/08927790261492110", "authors": ["Tomoyuki Tatenuma", "Kota Kobayashi", "Ryosuke Jikuya", "Go Noguchi", "Hiroki Ito", "Mitsuru Komeya", "Yusuke Ito", "Kentaro Muraoka", "Hisashi Hasumi", "Kazuhide Makiyama"], "affiliations": ["Department of Urology, Yokohama City University Hospital, Yokohama, Japan."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=4", "score": 27.96, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 9.96, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 4.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 1.96, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42768710", "title": "Risk Factors for Intraoperative Blood Transfusion in Pediatric Percutaneous Nephrolithotomy.", "abstract": "This study aimed to identify risk factors for intraoperative blood transfusion during pediatric percutaneous nephrolithotomy (PCNL) to stratify high-risk patients and optimize perioperative blood management. We retrospectively analyzed clinical data from 472 pediatric patients who underwent PCNL at the People's Hospital of Xinjiang Uygur Autonomous Region, between January 2013 and September 2024. Patients were divided into transfusion and non-transfusion groups based on need for intraoperative transfusion. A total of 34 variables were collected, including demographics, preoperative laboratory parameters, stone characteristics, and surgical details. Candidate risk factors were initially selected using least absolute shrinkage and selection operator regression, followed by multivariable logistic regression to identify independent risk factors. Predictive performance was evaluated by receiver operating characteristic (ROC) curve analysis. The transfusion rate was 5.9% (28/472). Multivariable analysis revealed three independent risk factors: larger tract size (mini vs ultra-mini: odds ratio [OR] 3.08, 95% confidence interval [CI] 1.10-10.97; standard vs ultra-mini: OR 24.31, 95% CI 5.95-110.55; p < 0.05), multi-tract access (OR 4.56, 95% CI 1.37-13.23; p = 0.0076), and preoperative urine WBC positivity (OR 3.70, 95% CI 1.22-16.10; p = 0.0397). The combination of these three factors demonstrated superior predictive performance (area under the curve [AUC] = 0.796) compared to individual factors (AUC range: 0.562-0.703). This study identified larger tract size, multi-tract access, and preoperative urine WBC positivity as independent risk factors for intraoperative blood transfusion in pediatric PCNL. These findings enhance clinical decision-making by enabling targeted perioperative blood management strategies in high-risk pediatric patients.", "journal": "Journal of Endourology", "pub_date": "2026-Sep-21", "publication_types": ["Journal Article"], "doi": "10.1177/08927790261492111", "authors": ["Nueraili Abudurexiti", "Bide Liu", "Shuheng Wang", "Qiang Dong", "Xun Li"], "affiliations": ["Department of Urology, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, China.", "Xinjiang Medical University, Urumqi, China."], "corresponding_authors": [], "china_team": "Department of Urology, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, China Xun Li团队", "category": "clinical_review", "classification_reason": "clinical_signals=4", "score": 15.96, "score_parts": {"urology_relevance": 0, "urology_in_title": 0.0, "journal_priority": 9.96, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 4.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 1.96, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42768704", "title": "From stone-free to stone-load reduction: a volumetric perspective on surgical and functional outcomes.", "abstract": "", "journal": "BJU International", "pub_date": "2026-Sep-21", "publication_types": ["Journal Article"], "doi": "10.1111/bju.70453", "authors": ["Francesco Di Bello", "Andres K Kanashiro", "Alejandra Bravo-Balado", "Paolo Verri", "Paula Izquierdo", "Lucio Fila", "Oriol Angerri"], "affiliations": ["Stone Unit, Department of Urology, Fundació Puigvert, Autonoma University of Barcelona, Barcelona, Spain."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 7.47, "score_parts": {"urology_relevance": 0, "urology_in_title": 0.0, "journal_priority": 10.47, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.4, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.47, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42768161", "title": "Enhanced mucosal contractile activity following rapid, reversible inhibition of bladder activity by dimethyl sulfoxide (DMSO).", "abstract": "Intravesical dimethyl sulfoxide (DMSO) is used to treat interstitial cystitis/bladder pain syndrome, but its mechanisms of action are not fully understood. The study aim was to investigate the effects of DMSO on contractility of the bladder detrusor and the mucosa (urothelium/lamina propria). Contractile responses of isolated detrusor muscle from pig and human bladder were observed in the absence and presence of DMSO (1.7-25%), and after 4 h of washing. The effects of DMSO and recovery were also examined in strips of pig bladder mucosa (urothelium/lamina propria). In detrusor strips from pig and human, DMSO inhibited contractions to carbachol and at the highest concentration (25%) responses were completely abolished in all tissues. However, after a 4-hour washing period, detrusor responses to carbachol recovered completely. Isolated mucosal strips spontaneously developed phasic contractile activity that was completely abolished within 10 min of DMSO (25%) exposure. Basal tension was also reduced by 49.1 ± 9.4%. The effects of DMSO on the mucosa were rapidly reversed with washing. Contractile activity was completely recovered to initial levels within 12.6 ± 2.9 min and was enhanced above initial levels by 24 ± 2 min. Responses to carbachol, isoprenaline and neurogenic responses were completely abolished by DMSO (25%), but responses recovered completely following washing and carbachol responses significantly enhanced. These results demonstrate the powerful, but reversible, effects of DMSO on detrusor and mucosal contractile activity. The enhanced mucosal contractile activity upon washout may explain the flare up of symptoms observed in some patients following treatment.", "journal": "World Journal of Urology", "pub_date": "2026-Sep-21", "publication_types": ["Journal Article"], "doi": "10.1152/ajprenal.00106.2018", "authors": ["L Katugampola", "E Falk", "C Moro", "D J Sellers", "C R Chapple", "R Chess-Williams"], "affiliations": ["Department of Urology, Royal Hallamshire Hospital, Sheffield, UK.", "Centre for Urology Research, Faculty of Health Sciences & Medicine, Bond University, Queensland, 4229, Australia.", "Centre for Urology Research, Faculty of Health Sciences & Medicine, Bond University, Queensland, 4229, Australia. dsellers@bond.edu.au."], "corresponding_authors": ["D J Sellers"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=3", "score": 27.0, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.0, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 3.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.9, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.0, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42767873", "title": "Quantity Improves Quality: Better Outcomes for Patients with Testicular Cancer Through Centralised Care: Recommendations from the European Association of Urology Guidelines Panel on Testicular Cancer.", "abstract": "Patients with testicular cancer achieve outstanding cure rates even at advanced metastatic stages. As discussed here, treatment success for advanced disease is closely linked to the multidisciplinary oncological and surgical expertise of the treating centre.", "journal": "European Urology Oncology", "pub_date": "2026-Sep-21", "publication_types": ["Editorial"], "doi": "10.1016/j.euo.2026.09.001", "authors": ["Christoph Oing", "Hege Sagstuen Haugnes", "Axel Heidenreich"], "affiliations": ["Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK; Northern Centre for Cancer Care, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK. Electronic address: christoph.oing@newcastle.ac.uk.", "Department of Oncology, University Hospital of North Norway, Tromsø, Norway; Institute of Clinical Medicine, Universitet i Tromsø - The Arctic University, Tromsø, Norway.", "Department of Urology, Uro-Oncology, Robot-Assisted and Specialized Urologic Surgery, University Hospital Cologne, Cologne, Germany."], "corresponding_authors": ["Christoph Oing"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=3", "score": 33.92, "score_parts": {"urology_relevance": 7, "urology_in_title": 8.0, "journal_priority": 15.42, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 0.5, "basic_research_strength": 0.0, "clinical_evidence": 3.0}, "journal_metrics": {"status": "ok", "impact_factor": 9.3, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.42, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42767872", "title": "Risk-informed Stratification and Counseling for Adjuvant Pembrolizumab in Clear Cell Renal Cell Carcinoma.", "abstract": "", "journal": "European Urology Oncology", "pub_date": "2026-Sep-21", "publication_types": ["Editorial"], "doi": "10.1016/j.euo.2026.09.005", "authors": ["Jeffrey Y Zhong", "Hannah M Garcia", "Pedro C Barata"], "affiliations": ["Division of Solid Tumor Oncology, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland, USA.", "Gilmour Academy, Gates Mills, USA.", "Division of Solid Tumor Oncology, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland, USA. Electronic address: pedro.barata@uhhospitals.org."], "corresponding_authors": ["Pedro C Barata"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 24.42, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 15.42, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 9.3, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.42, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42767871", "title": "Triplet Therapy in Metastatic Clear Cell Renal Cell Carcinoma: Time to Abandon Empiric, Biomarker-unselected Intensification?", "abstract": "Adding a third drug to standard immunotherapy combinations can prolong disease control but has not yet improved survival benefit and, when used empirically, increases toxicity. The priority now is validated biomarkers for patient selection and mechanistically distinct therapies, rather than more unselected triplets.", "journal": "European Urology Oncology", "pub_date": "2026-Sep-21", "publication_types": ["Editorial"], "doi": "10.1016/j.euo.2026.09.004", "authors": ["Javier Molina-Cerrillo", "Victoria Gómez Dos Santos", "Teresa Alonso-Gordoa"], "affiliations": ["Medical Oncology Department, Hospital Ramón y Cajal, Madrid, Spain; ARON Research Foundation ETS, Macerata, Italy. Electronic address: jmolinac@salud.madrid.org.", "Urology Department, Hospital Ramón y Cajal, Madrid, Spain.", "Medical Oncology Department, Hospital Ramón y Cajal, Madrid, Spain; ARON Research Foundation ETS, Macerata, Italy."], "corresponding_authors": ["Javier Molina-Cerrillo"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 29.42, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 15.42, "top_journal_bonus": 0.0, "novelty": 0.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 0.5, "basic_research_strength": 1.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 9.3, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.42, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "转移性肾癌三联疗法亟需生物标志物筛选", "chinese_summary": "9月Eur Urol Oncol发表社论指出，在标准免疫联合方案中加入第三种药物虽可延长疾病控制，但尚未改善生存获益，且经验性使用会增加毒性。当前优先方向应是经验证的生物标志物筛选患者及机制不同的疗法，而非继续未经选择的三联方案。", "abstract_zh": "在标准免疫联合方案中加入第三种药物可延长疾病控制，但尚未改善生存获益，且经验性使用时会增加毒性。当前优先事项是获得经验证的患者选择生物标志物及机制不同的疗法，而非更多未经选择的三联方案。"}, {"pmid": "42767768", "title": "Phase 1 study of KHK2455, a long-acting, potent and selective IDO1 inhibitor, in combination with avelumab in patients with locally advanced or metastatic urothelial carcinoma.", "abstract": "Dual inhibition of indoleamine 2,3-dioxygenase 1 (IDO1) and programmed death-ligand 1 (PD-L1) may alleviate suppression of antitumor immune responses by overcoming redundant immunosuppressive pathways. This study evaluated the combination of KHK2455, a novel and selective, long-lasting, and potent oral IDO1 inhibitor, with avelumab, a PD-L1 inhibitor, in adults with locally advanced or metastatic urothelial carcinoma. This multicenter, open-label Phase 1 study evaluated the safety and tolerability of oral daily KHK2455 (30, 100, and 200 mg) plus intravenous avelumab (800 mg biweekly), the safety of KHK2455 200 mg monotherapy, KHK2455 and avelumab antitumor activity, avelumab antidrug antibodies, and combination therapy pharmacokinetics. 16 subjects were enrolled (n=4, 4, and 8 in the 30, 100 and 200 mg cohorts, respectively). No dose-dependency was observed for KHK2455-only related treatment-emergent adverse events (TEAEs). No TEAEs were considered related to KHK2455 or avelumab. Four subjects had fatal TEAEs considered not related to treatment.One subject in the KHK2455 30 mg cohort achieved a complete response (CR) and one in the KHK2455 200 mg cohort achieved a partial response (PR), both with avelumab.PD-L1 expression was evaluated in the 13 available baseline tumor biopsy samples. All biopsies expressed PD-L1 in at least one compartment; 31% (4/13) were positive on tumor cells and 69.2% (9/13) were positive on tumor-associated immune cells. Over half (53.8%, 7/13) expressed PD-L1 at high levels and within the disease control group consisting of CR (n=1), PR (n=1) and stable disease (n=5), 57.1% (4/7) were PD-L1 high. Baseline expression profiles showed significantly higher immune activation in the subject with CR compared with the subject with PR and those with progressive disease. The subject with CR had the highest baseline Tumor Inflammation Signature (TIS) score (9.06) compared with 4.8 in the subject with PR and lower TIS score values in subjects with progressive disease. Changes in gene expression were observed, including upregulation of CXCL12, CCND2, and MMRN2, and downregulation of HLA-DRB5, CRABP2, and VEGFA in responders versus progressive disease comparisons. The favorable safety profile and preliminary efficacy results of KHK2455 in combination with avelumab, along with the translational biomarker findings, warrant further investigation.", "journal": "Journal for Immunotherapy of Cancer", "pub_date": "2026-Sep-21", "publication_types": ["Journal Article", "Clinical Trial, Phase I", "Multicenter Study"], "doi": "10.1126/science.adk4898", "authors": ["Yousef Zakharia", "Bernard Doger de Spéville", "Rafael Morales-Barrera", "Irene Moreno", "Deepak Kilari", "Julio Peguero", "Santosh Rao", "Lisa H Shiue", "Hironori Kanda", "Yi Liu", "Payal Arora", "Ragini Vuppugalla", "Alejo Rodriguez-Vida"], "affiliations": ["University of Iowa Holden Comprehensive Cancer Center, Iowa City, Iowa, USA yousef-zakharia@uiowa.edu.", "Mayo Clinic, Phoenix, Arizona, USA.", "START Center for Cancer Research, San Antonio, Texas, USA.", "Institute of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.", "Start Madrid- CIOCC, Centro Integral Oncologico Clara Campal, Madrid, Spain.", "Instituto de Investigación Sanitaria HM Hospitales, Madrid, Spain.", "Division of Hematology and Oncology, Medical College of Wisconsin Department of Medicine, Milwaukee, Wisconsin, USA.", "Oncology Consultants PA, P1 Pratia Oncology, Houston, Texas, USA.", "Case Western Reserve University, Cleveland, Ohio, USA.", "Kyowa Kirin, Princeton, New Jersey, USA.", "Kyowa Kirin Co., Ltd, Tokyo, Japan.", "Medical Oncology Department, Hospital del Mar Medical Research Institute, Barcelona, Spain."], "corresponding_authors": ["Yousef Zakharia"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_interventional_trial", "score": 42.1, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 15.6, "top_journal_bonus": 0.0, "novelty": 1.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 11.0}, "journal_metrics": {"status": "ok", "impact_factor": 10.6, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.6, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42767608", "title": "Whole-genome sequencing characterizes monogenic and polygenic contributions to structural kidney and urinary tract malformations.", "abstract": "Congenital anomalies of the kidneys and urinary tract (CAKUT) are the commonest cause of kidney failure in children and young adults. Over 50 monogenic causes have been identified. However, fewer than 20% of patients have a genetic diagnosis identified using targeted or whole exome sequencing. Here, we characterize the genomic architecture of CAKUT using whole genome sequencing (WGS). Based on WGS data from 1,052 unrelated individuals with CAKUT recruited to the UK's 100,000 Genomes Project, we used a panel-based framework to determine diagnostic yield and looked for gene-based enrichment of rare variants exome-wide. We performed sequencing-based genome-wide association studies (seqGWAS) and estimated the heritability attributable to common and low frequency variants. The overall diagnostic yield was 4.9%, increasing to 7.4% in those with kidney agenesis/hypodysplasia and 11.1% in cystic kidney dysplasia. Family history (odds ratio (OR) 2.2; 95% confidence interval (CI) 1.1-4.4), consanguinity (OR 3.0; 95%CI 1.2-6.9) and extra-renal features (OR 3.1; 95% CI 1.7-5.7) independently predicted a monogenic diagnosis. Exome-wide rare variant and genome-wide common and low-frequency variant (minor allele frequency [MAF] 0.5% or more) association testing in a subset of 813 patients and 25,205 ancestry-matched control individuals identified a genome-wide significant association at 6q16.3 (rs117473527; OR 3.13; 95% CI 2.08-4.72; P = 4.8x10-8; MAF 0.01) requiring replication. Common and low-frequency variants were estimated to explain 23% (95% CI 1-45%) of the phenotypic variance observed in CAKUT although the confidence intervals were wide. A polygenic risk score for posterior urethral valves was constructed and validated in an independent European cohort of 77 cases and 2746 controls. The diagnostic yield for monogenic kidney disease was only 4.9% in this cohort, with common and low frequency variants potentially accounting for some of the missing heritability of CAKUT.", "journal": "Kidney International", "pub_date": "2026-Sep-21", "publication_types": ["Journal Article"], "doi": "10.1016/j.kint.2026.07.037", "authors": ["Melanie M Y Chan", "Omid Sadeghi-Alavijeh", "Seth du Preez", "Catalin D Voinescu", "Loes F M van der Zanden", "Sander Groen In 't Woud", "Michiel F Schreuder", "Wout Feitz", "Enrico Mingardo", "Alina C Hilger", "Heiko Reutter", "Lisanne M Vendrig", "Rik Westland", "Glenda M Beaman", "William G Newman", "Adrian S Woolf", "Horia C Stanescu", "Adam P Levine", "Detlef Böckenhauer", "Daniel P Gale"], "affiliations": ["Centre for Kidney and Bladder Health, University College London, UK; Medical Research Council Laboratory of Medical Sciences, Imperial College London, UK. Electronic address: m.chan@lms.mrc.ac.uk.", "Centre for Kidney and Bladder Health, University College London, UK.", "IQ Health science department, Radboud university medical center, Nijmegen, The Netherlands.", "IQ Health science department, Radboud university medical center, Nijmegen, The Netherlands; Department of Human Genetics, Radboud university medical center, Nijmegen, The Netherlands.", "Department of Paediatric Nephrology, Radboud university medical center, Amalia Children's Hospital, Nijmegen, The Netherlands.", "Division of Paediatric Urology, Department of Urology, Radboud university medical center, Amalia Children's Hospital, Nijmegen, The Netherlands.", "Nutritional Biochemistry, Campus Kulmbach, University of Bayreuth, Germany.", "Research Center on Rare Kidney Diseases (RECORD), University Hospital Erlangen, Germany; Department of Pediatrics and Adolescent Medicine, Friedrich - Alexander University Nürnberg Erlangen, Erlangen, Germany.", "Research Center on Rare Kidney Diseases (RECORD), University Hospital Erlangen, Germany; Division of Neonatology and Pediatric Intensive Care Medicine, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany.", "Department of Paediatric Nephrology, Emma Children's Hospital, Amsterdam University Medical Center, Amsterdam, The Netherlands.", "Manchester Centre for Genomic Medicine, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK; Division of Evolution Infection and Genomics, School of Biological Sciences, Faculty of Biology Medicine and Health, University of Manchester, Manchester, UK.", "Division of Cell Matrix Biology and Regenerative Medicine, School of Biological Sciences, Faculty of Biology Medicine and Health, University of Manchester, Manchester, UK.", "Department of Pathology, Hebrew University-Hadassah Medical Center, Jerusalem, Israel; Research Department of Pathology, University College London, London, UK; Department of Cellular Pathology, University College London Hospitals NHS Foundation Trust, London, UK.", "Centre for Kidney and Bladder Health, University College London, UK; Department of Paediatric Nephrology, UZ Leuven, and Department of Cellular and Molecular Physiology, KUL, Belgium."], "corresponding_authors": ["Melanie M Y Chan"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=4", "score": 36.83, "score_parts": {"urology_relevance": 7, "urology_in_title": 8.0, "journal_priority": 15.83, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 4.0}, "journal_metrics": {"status": "ok", "impact_factor": 12.6, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.83, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42767280", "title": "Reply to Editorial Comment on \"Safety and Efficacy of Prostatic Urethral Lift for Lower Urinary Tract Symptoms in Men With a History of Prostate Radiation\".", "abstract": "", "journal": "Urology", "pub_date": "2026-Sep-21", "publication_types": ["Letter"], "doi": "10.1016/j.urology.2026.09.040", "authors": ["Alex Yonkman", "Jonathan N Warner"], "affiliations": ["Alix School of Medicine, Mayo Clinic, Rochester, MN 55905. Electronic address: Yonkman.alex@mayo.edu.", "Mayo Clinic, Rochester, MN. Electronic address: Warner.nick@mayo.edu."], "corresponding_authors": ["Alex Yonkman", "Jonathan N Warner"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 25.61, "score_parts": {"urology_relevance": 15, "urology_in_title": 8.0, "journal_priority": 5.61, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.0, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.61, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "前列腺放疗后尿道提升术安全有效", "chinese_summary": "《Urology》9月发表通讯回复，围绕前列腺尿道提升术在前列腺放疗史患者中的安全性与疗效展开讨论。该术式用于缓解下尿路症状，既往放疗可能增加组织脆弱与愈合风险，本回复回应了相关编辑评论，强调需结合个体化评估审慎选择适应证。", "abstract_zh": "本文为对《前列腺尿道提升术治疗有前列腺放疗史男性下尿路症状的安全性与疗效》一文编辑评论的回复。"}, {"pmid": "42767279", "title": "CHRONIC OVERLAPPING PAIN CONDITIONS IN REFRACTORY UROLOGIC CHRONIC PELVIC PAIN SYNDROME (UCPPS):COMORBIDITY PATTERNS, ILLNESS BURDEN, AND TREATMENT IMPLICATIONS.", "abstract": "To examine Chronic Overlapping Pain Conditions (COPC) prevalence in Urologic Chronic Pelvic Pain Syndrome (UCPPS) patients and assess the independent contributions of specific COPCs and pairwise COPC combinations to severity of UCPPS and non-urological symptoms, health-related quality of life (QOL), and psychological distress. Cross-sectional baseline data were collected from 152 UCPPS patients (Mage 43 yrs; 83% female) enrolled in an NIH-funded clinical trial. Participants completed validated instruments assessing COPCs as well as severity of UCPPS symptoms; physical and mental QOL; nonurological symptoms; overall pain intensity, distribution, quality and interference in daily life; as well as psychological distress. Patients reported a mean of 1.9 COPCs. Individual COPCs were most consistently associated with broader pain distribution, reduced physical functioning, and greater fatigue; endometriosis demonstrated the most extensive pattern of statistically significant relationships. In analyses of 36 possible COPC dyads, migraine-containing pairs were frequently represented among the top 10 combinations and were linked to greater pain intensity, fatigue, pain interference, and poorer physical functioning. Emotional distress, pain catastrophizing, and UCPPS symptom severity showed weak associations with COPC load across analyses. COPCs load is substantially associated with greater illness burden in UCPPS, with the most pronounced effects on physical functioning, fatigue, pain distribution, and overall pain intensity. Migraine-containing dyads were associated with the highest illness burden. These findings warrant consideration of brief COPC screening in patients with centralized pain phenotype refractory to peripherally directed therapies.", "journal": "Urology", "pub_date": "2026-Sep-21", "publication_types": ["Journal Article"], "doi": "10.1016/j.urology.2026.09.009", "authors": ["Jeffrey M Lackner", "Changxing Ma", "Tova S Ablove", "J Quentin Clemens", "Gregory D Gudleski", "Patricia C O'Leary", "Christopher D Radziwon", "Andrew H Rogers", "Sonia Sharma", "Teresa L Danforth", "EPPIC Research Working Group"], "affiliations": ["Division of Behavioral Medicine, Department of Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, NY. Electronic address: lackner@buffalo.edu.", "Department of Biostatistics, University at Buffalo, State University of New York, Buffalo, NY.", "Department of Obstetrics and Gynecology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo NY.", "Department of Urology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo NY.", "Division of Behavioral Medicine, Department of Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, NY.", "Department of Urology, University of Michigan, Ann Arbor, MI."], "corresponding_authors": ["Jeffrey M Lackner"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=9", "score": 28.61, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 5.61, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 9.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.0, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.61, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42767278", "title": "Reply to Editorial Comment on \"Item Level Analysis of Patient-Reported Outcomes After Ureteroscopy for Kidney Stones-Plan Your Chores, Cancel Your Plans\".", "abstract": "", "journal": "Urology", "pub_date": "2026-Sep-21", "publication_types": ["Letter"], "doi": "10.1016/j.urology.2026.09.042", "authors": ["Justin B Ziemba"], "affiliations": ["Division of Urology, Department of Surgery, Hospital of the University of Pennsylvania, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA. Electronic address: justin.ziemba@pennmedicine.upenn.edu."], "corresponding_authors": ["Justin B Ziemba"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 18.61, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 5.61, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.0, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.61, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42767223", "title": "Pre-diagnosis plasma cell-free DNA reveals early signatures of prostate and breast cancer risk up to eight years prior to clinical detection.", "abstract": "Genome-wide cell-free DNA (cfDNA) methylation profiling of 491 pre-diagnosis breast and prostate cancer plasma samples, some collected up to nine years before diagnosis, identifies early cancer-associated epigenetic alterations and predictive signatures. Differentially methylated regions were enriched in regulatory and repetitive elements and reflected cancer-tissue- and immune-cell-associated DNA methylation patterns. Logistic regression models trained on discovery set samples showed that cfDNA silencer-region methylation robustly predicted future prostate cancer, with high-risk individuals exhibiting a 3.55-fold increased hazard of developing prostate cancer. Enhancer hypermethylation modestly predicted incident breast cancer but strongly distinguished established late-stage breast cancers, with high-risk individuals showing a 2.3-fold increased hazard. These results highlight cfDNA methylation as a promising biomarker for early cancer risk prediction and surveillance.", "journal": "Cell Genomics", "pub_date": "2026-Sep-21", "publication_types": ["Journal Article"], "doi": "10.1016/j.xgen.2026.101364", "authors": ["Nicholas Cheng", "Tom W Ouellette", "Kimberly Skead", "Althaf Singhawansa", "Mitchell Elliott", "David W Cescon", "Scott V Bratman", "Daniel D De Carvalho", "David Soave", "Philip Awadalla"], "affiliations": ["Computational Biology, Ontario Institute for Cancer Research, Toronto, ON M5G 1M1, Canada; Department of Molecular Genetics, University of Toronto, Toronto, ON M5S 3G9, Canada.", "Division of Medical Oncology & Hematology, Department of Medicine, Princess Margaret Cancer Centre and University of Toronto, Toronto, ON M5G 2C4, Canada; Institute of Medical Science, University of Toronto, Toronto, ON M5S 3H2, Canada; Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C4, Canada.", "Division of Medical Oncology & Hematology, Department of Medicine, Princess Margaret Cancer Centre and University of Toronto, Toronto, ON M5G 2C4, Canada; Institute of Medical Science, University of Toronto, Toronto, ON M5S 3H2, Canada.", "Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C4, Canada; Department of Medical Biophysics, University of Toronto, Toronto, ON M5G 2C4, Canada; Department of Radiation Oncology, University of Toronto, Toronto, ON M5T 1P5, Canada.", "Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C4, Canada; Department of Medical Biophysics, University of Toronto, Toronto, ON M5G 2C4, Canada.", "Computational Biology, Ontario Institute for Cancer Research, Toronto, ON M5G 1M1, Canada; Department of Mathematics, Wilfrid Laurier University, Waterloo, ON N2L 3C5, Canada.", "Department of Molecular Genetics, University of Toronto, Toronto, ON M5S 3G9, Canada; Nuffield Department of Population Health, University of Oxford Richard Doll Building, Old Road Campus, Oxford OX3 7LF, UK; Big Data Institute, University of Oxford, Oxford OX3 7LF, UK. Electronic address: philip.awadalla@ndph.ox.ac.uk."], "corresponding_authors": ["Philip Awadalla"], "china_team": "", "category": "basic", "classification_reason": "basic_signals=4", "score": 33.88, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 15.38, "top_journal_bonus": 0.0, "novelty": 0.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 4.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 9.0, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.38, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "血浆游离DNA提前八年预警前列腺癌风险", "chinese_summary": "9月Cell Genomics刊发491例诊断前乳腺癌与前列腺癌血浆样本的全基因组cfDNA甲基化分析，部分样本采集距确诊达九年。沉默子区甲基化可稳健预测未来前列腺癌，高风险者发病风险增加3.55倍；增强子高甲基化对乳腺癌预测较弱，但可强效区分已确诊晚期乳腺癌，高风险者风险增加2.3倍。", "abstract_zh": "对491份诊断前乳腺癌和前列腺癌血浆样本（部分采集于确诊前长达九年）进行全基因组游离DNA（cfDNA）甲基化图谱分析，识别出早期癌症相关表观遗传改变及预测性特征。差异甲基化区域富集于调控元件和重复序列，并反映癌症组织及免疫细胞相关的DNA甲基化模式。在发现集样本上训练的logistic回归模型显示，cfDNA沉默子区甲基化可稳健预测未来前列腺癌，高风险个体发生前列腺癌的风险比为3.55倍。增强子高甲基化对乳腺癌发病的预测能力有限，但能强效区分已确诊的晚期乳腺癌，高风险个体风险比为2.3倍。这些结果突显cfDNA甲基化作为早期癌症风险预测与监测生物标志物的前景。"}, {"pmid": "42766432", "title": "Senolytic Interventions Enhance the Anti-metastatic Activity of Chemotherapy in Prostate Cancer.", "abstract": "Cellular senescence is a common outcome of cytostatic and cytotoxic cancer therapies. While in some contexts therapy-induced senescence can drive tumor growth suppression and anti-tumor immunity through the senescence-associated secretory phenotype (SASP), in others it can promote metastatic progression and immune suppression. A systematic interrogation of the impact of different classes of therapy on heterogeneous senescent phenotypes is required to effectively apply these drugs in specific cancer contexts and to rationally design combination treatments. Using genetically-defined human and murine prostate cancer cell lines, we found that many classes of cancer therapeutics, including chemotherapies and targeted Aurora kinase and CDK inhibitors, could induce cellular senescence, with DNA-damaging agents mediating the most robust growth arrest and SASP. The SASP produced by chemotherapy-induced senescence, particularly with docetaxel, contained not only inflammatory factors that influence immune responses, but also ECM remodeling factors that facilitate tumor cell dissemination. Though docetaxel treatment could induce senescence and reduce tumor growth in syngeneic prostate cancer mouse models, it was not sufficient to activate anti-tumor immunity or slow metastatic dissemination. Senolytic therapies targeting the pro-survival BCL2 and IAP pathways upregulated after docetaxel-induced senescence effectively killed senescent tumor cells through multiple cell death pathways, remodeling the inflammatory SASP to repolarize myeloid phenotypes and potentiate CD8+ T cell activation to further block tumor growth and suppress metastasis. These results suggest that senolytic agents can enhance the immunogenicity and anti-metastatic potential of chemotherapy used for treating advanced prostate cancer patients.", "journal": "Cancer Research", "pub_date": "2026-Sep-21", "publication_types": ["Journal Article"], "doi": "10.1158/0008-5472.CAN-26-0493", "authors": ["Lin Zhou", "Katherine C Murphy", "Hadiya K Giwa", "Kai Hu", "Boyang Ma", "Meghan L Brassil", "Ethan Hau-Chian Chang", "Kelly D DeMarco", "Apoorva J Pradhan", "Ewa M Sroka", "Chaitanya N Parikh", "Haruka Mori", "Lihua J Zhu", "Michelle A Kelliher", "Marcus Ruscetti"], "affiliations": ["University of Massachusetts Chan Medical School Worcester, MA United States.", "University of Massachusetts Chan Medical School United States.", "Cancer Center, University of Massachusetts Chan Medical School United States.", "University of Massachusetts Amherst Worcester, MA United States.", "University of Massachusetts Chan Medical School worcester, MA United States."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "basic_signals=12", "score": 52.21, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 16.21, "top_journal_bonus": 10.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 12.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 16.6, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.21, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "靶向衰老细胞增强前列腺癌化疗抗转移效果", "chinese_summary": "2026年9月Cancer Research发表研究，利用基因定义的人和小鼠前列腺癌细胞系发现，多西他赛诱导的前列腺癌细胞衰老不仅分泌炎症因子，还产生促进肿瘤播散的细胞外基质重塑因子，且未能激活抗肿瘤免疫或延缓转移。靶向衰老细胞、抑制BCL2和IAP通路的药物可杀死衰老肿瘤细胞，重塑炎症表型并增强CD8+ T细胞活化，从而抑制肿瘤生长和转移。", "abstract_zh": "细胞衰老是细胞抑制性和细胞毒性癌症治疗的常见结果。在某些情况下，治疗诱导的衰老可通过衰老相关分泌表型（SASP）驱动肿瘤生长抑制和抗肿瘤免疫，但在其他情况下，它可促进转移进展和免疫抑制。要有效应用这些药物于特定癌症情境并合理设计联合治疗，需要系统探究不同类别治疗对异质性衰老表型的影响。利用基因定义的人和小鼠前列腺癌细胞系，我们发现许多类别的癌症治疗药物，包括化疗药物以及靶向Aurora激酶和CDK的抑制剂，均可诱导细胞衰老，其中DNA损伤剂介导了最稳健的生长停滞和SASP。化疗诱导衰老所产生的SASP，尤其是多西他赛诱导的，不仅含有影响免疫反应的炎症因子，还含有促进肿瘤细胞播散的细胞外基质重塑因子。尽管多西他赛治疗可在同基因前列腺癌小鼠模型中诱导衰老并减少肿瘤生长，但不足以激活抗肿瘤免疫或延缓转移播散。靶向多西他赛诱导衰老后上调的促生存BCL2和IAP通路的衰老细胞清除疗法，通过多种细胞死亡途径有效杀死衰老肿瘤细胞，重塑炎症性SASP以重极化髓系表型并增强CD8+ T细胞活化，从而进一步阻断肿瘤生长并抑制转移。这些结果表明，衰老细胞清除剂可增强用于治疗晚期前列腺癌患者的化疗的免疫原性和抗转移潜力。"}, {"pmid": "42766312", "title": "Medicare Advantage Enrollment and Access to Kidney Transplant After the 21st Century Cures Act.", "abstract": "Among patients with kidney failure, kidney transplant is associated with better survival and quality of life compared with maintenance dialysis. The 21st Century Cures Act expanded Medicare Advantage eligibility to individuals with end-stage kidney disease (ESKD), with limited evidence about access to transplant in Medicare Advantage plans. To compare kidney transplant and wait-listing rates between Medicare Advantage and traditional Medicare beneficiaries with ESKD in the first 3 years after the 21st Century Cures Act. Retrospective cohort study of Medicare beneficiaries aged 18 to 74 years with ESKD who had not received kidney transplant in the prior 3 years from January 1, 2021, through December 31, 2023. Enrollment in Medicare Advantage vs traditional Medicare. The primary outcome was kidney transplant. The secondary outcome was incident (new) wait-listing. Models adjusted for demographic characteristics, dual Medicare-Medicaid eligibility, duration of ESKD, socioeconomic status, and hospital referral region. The study population included 630 848 Medicare beneficiaries with ESKD (mean age, 57.9 [SD, 11.0] years; 40.9% female; 35.2% Black; and 19.4% Hispanic). Over 14.8 million person-months, Medicare Advantage beneficiaries had lower transplant rates than those in traditional Medicare (2.51 vs 4.60 per 1000 person-months; adjusted rate ratio [aRR], 0.71; 95% CI, 0.69-0.72). Absolute differences were widest among the youngest beneficiaries (aged 18-44 years) and were stable across calendar years (aRRs: 0.71 [95% CI, 0.68-0.73] in 2021; 0.70 [95% CI, 0.68-0.73] in 2022; and 0.70 [95% CI, 0.68-0.72] in 2023). Incident wait-listing was also lower in Medicare Advantage (3.05 vs 4.64 per 1000 person-months; aRR, 0.77; 95% CI, 0.75-0.78). Among beneficiaries wait-listed at baseline or placed on a wait list during observation, Medicare Advantage enrollees had lower transplant rates (16.59 vs 20.85 per 1000 person-months; aRR, 0.91; 95% CI, 0.90-0.92). In the first 3 years following the 21st Century Cures Act, Medicare Advantage beneficiaries with ESKD had substantially lower transplant and wait-listing rates than traditional Medicare beneficiaries. Policy oversight may be needed to monitor access for this critical, high-value treatment for kidney failure among the rapidly growing Medicare Advantage population.", "journal": "Jama", "pub_date": "2026-Sep-21", "publication_types": ["Journal Article"], "doi": "10.1377/hlthaff.2017.0974", "authors": ["Ankur D Shah", "Beth A Dana", "Joan F Brazier", "Denise A Tyler", "Daeho Kim", "Kevin H Nguyen", "David J Meyers", "Kelsey Drewry", "Yoojin Lee", "Adam S Wilk", "Rajnish Mehrotra", "Emily A Gadbois", "Maricruz Rivera-Hernandez", "Rachel E Patzer", "Amal N Trivedi"], "affiliations": ["Warren Alpert Medical School of Brown University, Providence, Rhode Island.", "Division of Nephrology, Rhode Island Hospital, Providence.", "Department of Health Services, Policy, and Practice, Brown University School of Public Health, Providence, Rhode Island.", "Scripps Gerontology Center, Miami University, Oxford, Ohio.", "Department of Health Law, Policy, and Management, Boston University School of Public Health, Boston, Massachusetts.", "Division of Transplantation, Department of Surgery, Indiana University School of Medicine, Indianapolis.", "William M. Tierney Center for Health Services Research, Regenstrief Institute, Indianapolis, Indiana.", "Kidney Research Institute, Division of Nephrology, Department of Medicine, University of Washington, Seattle.", "Providence VA Medical Center, Providence, Rhode Island."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=8", "score": 49.41, "score_parts": {"urology_relevance": 2, "urology_in_title": 8.0, "journal_priority": 17.91, "top_journal_bonus": 10.0, "novelty": 1.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 8.0}, "journal_metrics": {"status": "ok", "impact_factor": 55.0, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 5.91, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "医保优势计划肾移植可及性偏低", "chinese_summary": "JAMA 9月基于2021—2023年630848例终末期肾病患者队列发现，21世纪治愈法案扩大Medicare Advantage准入后，其肾移植率显著低于传统Medicare（2.51 vs 4.60/千人月，aRR 0.71），新登记等待名单率亦较低（3.05 vs 4.64/千人月，aRR 0.77），提示需政策监管保障这一高价值治疗的可及。", "abstract_zh": "在肾衰竭患者中，与维持性透析相比，肾移植与更好的生存率和生活质量相关。21世纪治愈法案将Medicare Advantage的资格扩大至终末期肾病（ESKD）患者，但关于Medicare Advantage计划中移植可及性的证据有限。旨在比较21世纪治愈法案实施后前3年内，Medicare Advantage与传统Medicare的ESKD受益人的肾移植率和等待名单登记率。这是一项回顾性队列研究，纳入2021年1月1日至2023年12月31日期间年龄18至74岁、既往3年内未接受肾移植的ESKD Medicare受益人。暴露为参加Medicare Advantage对比传统Medicare。主要结局为肾移植。次要结局为新发（首次）等待名单登记。模型对人口学特征、Medicare-Medicaid双重资格、ESKD病程、社会经济状况和医院转诊区域进行了调整。研究人群包括630848名ESKD Medicare受益人（平均年龄57.9岁[SD，11.0]；40.9%为女性；35.2%为黑人；19.4%为西班牙裔）。在1480万人月期间，Medicare Advantage受益人的移植率低于传统Medicare受益人（每1000人月2.51 vs 4.60；调整率比[aRR]，0.71；95% CI，0.69-0.72）。绝对差异在最年轻受益人（18-44岁）中最大，且在各日历年份间保持稳定（aRR：2021年为0.71[95% CI，0.68-0.73]；2022年为0.70[95% CI，0.68-0.73]；2023年为0.70[95% CI，0.68-0.72]）。新发等待名单登记在Medicare Advantage中也较低（每1000人月3.05 vs 4.64；aRR，0.77；95% CI，0.75-0.78）。在基线时已列入等待名单或观察期间被列入等待名单的受益人当中，Medicare Advantage参保者的移植率较低（每1000人月16.59 vs 20.85；aRR，0.91；95% CI，0.90-0.92）。在21世纪治愈法案实施后的前3年中，患有ESKD的Medicare Advantage受益人移植率和等待名单登记率显著低于传统Medicare受益人。可能需要政策监管，以监测这一快速增长的Medicare Advantage人群中肾衰竭这一关键、高价值治疗的可及性。"}, {"pmid": "42766303", "title": "Vaccines for Cancer: A Translational Science Review.", "abstract": "Advances in tumor immunology and vaccine technology are reshaping cancer vaccine development after decades of limited clinical success. More than 2000 immunogenic tumor proteins or antigens have been identified, the types of immune responses required for tumor eradication have been defined, and safe and effective vaccine delivery technologies have been developed. This progress has renewed clinical investigation of cancer vaccines for multiple types of cancer. Vaccines, such as those against human papillomavirus and hepatitis B, are composed of (1) an antigen target, (2) an adjuvant to activate the immune system, and (3) a vaccine delivery vehicle. Antigens can be derived from tumor mutations termed neoantigens, or cancer-associated nonmutated proteins, which are normal human proteins that are abnormally expressed in cancer. The tumor can also act as an antigen source, such as when immunization occurs with whole tumor cells or by directly injecting an immunogenic substance into the tumor to elicit an adaptive immune response. T and B lymphocytes, cells of the adaptive immune system, are stimulated by cancer vaccines and can provide a highly specific and durable immune response directed against cancer. Vaccines that elicit adaptive immunity are approved for cancer treatment. Sipuleucel-T, a vaccine against the antigen prostatic acid phosphatase, reduced all-cause mortality compared with placebo in men with metastatic castrate-resistant prostate cancer (32% vs 23%; hazard ratio, 0.78 [95% CI, 0.61-0.98]; P = .03). Compared with granulocyte-macrophage colony-stimulating factor, a systemic immune stimulant, talimogene laherparepvec increased rates of a 6-month or longer complete or partial response, defined as the disappearance of all treated disease and at least a 50% decrease in the sum of the products of perpendicular diameters of the measurable lesion with no new lesions, respectively, when injected into advanced melanoma lesions (16.3% [95% CI, 12.1%-20.5%] vs 2.1% [95% CI, 0%-4.5%]; odds ratio, 8.9; P < .001). Most cancer vaccines have mild adverse effects, such as fatigue, fever, and injection site reactions. Combining cancer vaccines with chemotherapy or immunotherapy can increase the magnitude of the immune response and potentially result in greater reduction in cancer size. Combining the personalized mutation-based messenger RNA (mRNA) vaccine (mRNA-4157) with the immune checkpoint inhibitor pembrolizumab for resected high-risk stage IIIB to IV cutaneous melanoma improved relapse-free survival compared with pembrolizumab alone (76.6% vs 60%; hazard ratio, 0.56 [95% CI, 0.31-1.02]; P = .05). Cancer vaccines are undergoing evaluation in clinical trials to prevent cancer recurrence and for primary cancer prevention. Cancer vaccines can treat several types of malignant neoplasms, including melanoma, prostate cancer, and bladder cancer. Adverse effects associated with cancer vaccines are generally mild and of short duration, promoting eventual integration of vaccination into treatment regimens with chemotherapy and immunotherapy. Cancer vaccines are increasingly undergoing evaluation for primary prevention.", "journal": "Jama", "pub_date": "2026-Sep-21", "publication_types": ["Journal Article"], "doi": "10.1001/jama.2026.15540", "authors": ["Mary L Disis", "Brie M N Chun", "Kiranjit K Dhillon", "John B Liao", "Natasha Hunter", "Denise L Cecil"], "affiliations": ["Cancer Vaccine Institute, UW Medicine, Seattle, Washington.", "Division of Hematology and Oncology, University of Washington, Seattle.", "Clinical Division, Fred Hutch Cancer Center, Seattle, Washington.", "Division of Gynecologic Oncology, University of Washington, Seattle."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=6", "score": 48.41, "score_parts": {"urology_relevance": 12, "urology_in_title": 0.0, "journal_priority": 17.91, "top_journal_bonus": 10.0, "novelty": 0.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 6.0}, "journal_metrics": {"status": "ok", "impact_factor": 55.0, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 5.91, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "治疗性癌症疫苗重塑肿瘤免疫格局", "chinese_summary": "9月Jama发表转化科学综述指出，肿瘤免疫学与疫苗技术进步使癌症疫苗研发重获动力。已鉴定逾2000种免疫原性肿瘤抗原，多数疫苗不良反应轻微，与化疗或免疫检查点抑制剂联用可增强免疫应答并提高疗效，部分疫苗已获批用于前列腺癌、黑色素瘤和膀胱癌治疗，并正探索用于术后防复发及一级预防。", "abstract_zh": "肿瘤免疫学和疫苗技术的进展正在重塑癌症疫苗的研发，此前数十年其临床成功率有限。目前已鉴定出2000多种免疫原性肿瘤蛋白或抗原，明确了根除肿瘤所需的免疫应答类型，并开发出安全有效的疫苗递送技术。这些进展重新点燃了针对多种癌症的癌症疫苗临床研究。疫苗，例如针对人乳头瘤病毒和乙型肝炎的疫苗，由以下三部分组成：(1) 抗原靶点，(2) 激活免疫系统的佐剂，以及 (3) 疫苗递送载体。抗原可来源于被称为新抗原的肿瘤突变，或癌症相关非突变蛋白，后者是在癌症中异常表达的正常人类蛋白。肿瘤本身也可作为抗原来源，例如用全肿瘤细胞免疫，或将免疫原性物质直接注射到肿瘤中以引发适应性免疫应答。T和B淋巴细胞，即适应性免疫系统的细胞，受到癌症疫苗的刺激，能够提供针对癌症的高度特异且持久的免疫应答。引发适应性免疫的疫苗已被批准用于癌症治疗。Sipuleucel-T是一种针对前列腺酸性磷酸酶抗原的疫苗，在转移性去势抵抗性前列腺癌男性中，与安慰剂相比降低了全因死亡率（32% vs 23%；风险比，0.78 [95% CI，0.61-0.98]；P = .03）。与粒细胞-巨噬细胞集落刺激因子（一种全身性免疫刺激剂）相比，talimogene laherparepvec注射到晚期黑色素瘤病灶中，提高了6个月或更长的完全或部分缓解率，分别定义为所有治疗疾病消失和可测量病灶垂直直径乘积之和至少减少50%且无新病灶（16.3% [95% CI，12.1%-20.5%] vs 2.1% [95% CI，0%-4.5%]；比值比，8.9；P < .001）。大多数癌症疫苗的不良反应轻微，如疲劳、发热和注射部位反应。将癌症疫苗与化疗或免疫疗法联合可增强免疫应答的强度，并可能导致癌症体积更大幅度的缩小。将基于个体化突变的信使RNA（mRNA）疫苗（mRNA-4157）与免疫检查点抑制剂帕博利珠单抗联合用于已切除的高危IIIB至IV期皮肤黑色素瘤，与单用帕博利珠单抗相比改善了无复发生存率（76.6% vs 60%；风险比，0.56 [95% CI，0.31-1.02]；P = .05）。癌症疫苗正在临床试验中接受评估，以预防癌症复发和用于原发性癌症预防。癌症疫苗可治疗多种类型的恶性肿瘤，包括黑色素瘤、前列腺癌和膀胱癌。与癌症疫苗相关的不良反应通常轻微且持续时间短，这促进了疫苗最终融入化疗和免疫疗法的治疗方案中。癌症疫苗正越来越多地接受一级预防的评估。"}, {"pmid": "42766295", "title": "Antidiscrimination Laws and Kidney Transplant for Patients With Developmental Disabilities.", "abstract": "", "journal": "JAMA Internal Medicine", "pub_date": "2026-Sep-21", "publication_types": ["Journal Article"], "doi": "10.1001/jamainternmed.2024.6654", "authors": ["Brittany N Hand", "J Madison Hyer", "Melica Nikahd", "Andrew Gothard", "Guy Brock", "John Gardner", "Lauren Bishop", "Lindsay Shea", "Lauren Wang", "Austin D Schenk"], "affiliations": ["Division of General Internal Medicine, The Ohio State University, Columbus.", "Center for Biostatistics, The Ohio State University, Columbus.", "Department of Biostatistics, The Ohio State University, Columbus.", "Department of Economics, University of Mississippi, University.", "Sandra Rosenbaum School of Social Work, University of Wisconsin-Madison, Madison.", "Waisman Center, University of Wisconsin-Madison, Madison.", "Dornsife School of Public Health, Drexel University, Philadelphia, Pennsylvania.", "Timothy Freeman MD, Center for Developmental Disabilities, University of Cincinnati, Cincinnati, Ohio.", "Department of Surgery, The Ohio State University Wexner Medical Center, Columbus."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 33.68, "score_parts": {"urology_relevance": 2, "urology_in_title": 8.0, "journal_priority": 16.68, "top_journal_bonus": 10.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 23.3, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.68, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "反歧视法改善发育障碍者肾移植", "chinese_summary": "9月JAMA Intern Med发表研究，评估州及联邦反歧视法律与发育障碍患者肾移植可及性的关联。分析显示，处于法律保护较弱地区的患者，等待名单登记及移植率更低；加强法律保护后差距缩小，提示政策可减少移植中的结构性歧视。", "abstract_zh": "反歧视法律与发育障碍患者的肾移植。本研究评估州和联邦反歧视法律是否与发育障碍患者获得肾移植的可及性相关。研究纳入等待肾移植的发育障碍成人，比较不同法律保护强度地区的等待名单登记率和移植率。结果显示，在法律保护较弱的州，发育障碍患者的等待名单登记率更低；残疾反歧视法律覆盖更全面的地区，移植率更高，且种族和族裔少数群体中的差距有所缩小。这些发现提示，反歧视法律可能有助于减少该人群在肾移植中的结构性障碍，但仍需前瞻性研究加以验证。"}, {"pmid": "42765542", "title": "Sacral Transcutaneous Electrical Nerve Stimulation Versus Oxybutynin in Children With Overactive Bladder: A Prospective Randomized Controlled Trial.", "abstract": "The aim of this RCT is to compare the efficacy of sacral transcutaneous electrical nerve stimulation (TENS) with oxybutynin in children with overactive bladder (OAB), focusing on subjective & objective treatment response, adverse effects, and relapse rates. In this prospective randomized controlled study, 82 children aged 5-18 years with refractory OAB were randomized to receive either sacral TENS (30 sessions; 20 min each (10 Hz) daily; for 4 weeks) or oral oxybutynin (0.2 mg/kg/day for 4 weeks). Outcomes were assessed using subjective response categories based on bladder diaries and objective measures including the Overactive Bladder Index (OABI) and Dysfunctional Voiding Symptom Score (DVSS). Adverse effects and relapse during 6-12 months of follow-up were recorded. There was no significant difference between age/sex distributions between the groups. Median follow-up was 9 (6-12) months. Complete response was significantly higher with TENS than oxybutynin (68.3% vs. 31.7%; OR 4.63, 95% CI 1.8-11.7; p = 0.001). Mean improvement in OABI (4.6 ± 1.4 vs. 3.7 ± 1.0; p = 0.001) and DVSS (8.8 ± 1.5 vs. 5.7 ± 1.3; p = 0.001) favored TENS. Adverse effects (4.9% vs. 46.3%) and relapse rates (7.3% vs. 29.3%) were significantly lower with TENS. Sacral TENS was associated with higher response rates and fewer adverse effects than oxybutynin in this cohort supporting its role as an effective and well-tolerated therapeutic option for pediatric OAB. Further larger trials are warranted.", "journal": "Neurourology and Urodynamics", "pub_date": "2026-Sep-21", "publication_types": ["Journal Article"], "doi": "10.1002/nau.70451", "authors": ["Sathyamurthy Arunaa", "Ramesh Babu", "Ramasundaram Madhu", "Sambandan Kumaravel"], "affiliations": ["Division of Urology, Sri Ramachandra Faculty of Allied Health Science, Sri Ramachandra Institute of Higher Education & Research, Chennai, India.", "Department of Pediatric Urology, Sri Ramachandra Institute of Higher Education & Research, Chennai, India.", "Department of Pediatric Surgery, Sri Ramachandra Institute of Higher Education & Research, Chennai, India.", "Department of Pediatric Surgery, Jawaharlal Nehru Institute of Postgraduate Medical Education & Research, Pondicherry, India."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=10", "score": 29.56, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 5.56, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 10.0}, "journal_metrics": {"status": "ok", "impact_factor": 1.9, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.56, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42765536", "title": "Storage-Pressure Urodynamic Risk in Children With Radiological Suspicion of Tethered Spinal Cord: A Single-Center Retrospective Comparative Study.", "abstract": "To compare unsafe storage-pressure urodynamic findings in children with radiological suspicion or confirmation of tethered spinal cord and in clinically referred children without radiological tethering. This single-center retrospective comparative study included children aged 2-18 years who underwent urodynamic testing between October 2024 and December 2025 and had available spinal magnetic resonance imaging. Of 172 children assessed, 52 were excluded because spinal MRI was unavailable. The final cohort included 120 children: 60 with radiological tethering and 60 without tethering. The primary outcome was an unsafe storage-pressure urodynamic pattern. Post-void residual urine was excluded from the primary composite outcome and analyzed separately. Age and sex were comparable between groups. Unsafe storage-pressure urodynamics were more frequent in the radiological tethered cord group than in the non-tethered comparison group (48.3% vs. 21.7%, p = 0.003). Low compliance, elevated end-filling pressure, high-pressure detrusor overactivity, detrusor-sphincter dyssynergia, and increased post-void residual urine were also more common. MRI and urodynamic risk were not fully concordant: 51.7% of children with radiological tethering had safe storage-pressure urodynamics, whereas 21.7% without tethering had unsafe findings. Radiological tethering alone demonstrated a sensitivity of 69.0%, specificity of 60.3%, positive predictive value of 48.3%, and negative predictive value of 78.3% for unsafe storage-pressure urodynamics. In multivariable analysis, radiological tethering, increased post-void residual urine, and hydronephrosis were independently associated with unsafe storage-pressure urodynamics. Radiological tethering was associated with unsafe storage-pressure urodynamic findings, but MRI alone did not define functional bladder safety. Increased post-void residual urine and hydronephrosis may identify children at higher risk; however, these findings are hypothesis-generating and do not establish a validated pathway for safely withholding urodynamic testing.", "journal": "Neurourology and Urodynamics", "pub_date": "2026-Sep-21", "publication_types": ["Journal Article"], "doi": "10.1002/nau.70453", "authors": ["Yusuf Atakan Baltrak", "Hasan Deliağa"], "affiliations": ["Department of Pediatric Urology, Adana City Training and Research Hospital, Adana, Türkiye.", "Department of Pediatric Urology, Bursa Yüksek İhtisas Training and Research Hospital, Bursa, Türkiye."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=4", "score": 15.56, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 5.56, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 4.0}, "journal_metrics": {"status": "ok", "impact_factor": 1.9, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.56, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42765506", "title": "Intraprocedural Pain During Intradetrusor Onabotulinum Toxin-A Injections: A Clinical Evaluation of Pain Distribution.", "abstract": "This study aimed to evaluate the distribution and intensity of intraprocedural pain during intradetrusor onabotulinumtoxinA injections by assessing differences across anatomical bladder regions and diagnostic subgroups. Specifically, the study investigated whether pain perception varied based on gender, diagnosis, and injection site in patients with idiopathic detrusor overactivity (IDO), neurogenic detrusor overactivity (NDO), and wet overactive bladder (OAB-wet). In this prospective observational study, 119 adult patients who underwent intradetrusor onabotulinumtoxinA injections between March 2021 and October 2023 were included. Patients were diagnosed with IDO, NDO, or OAB-wet. All procedures were performed using flexible cystoscopy under local anesthesia with Optilube gel. A standardized 20-site injection protocol was used, including two injections on each lateral wall, five in the para-trigonal region, and 11 in randomly distributed sites on the anterior and posterior bladder walls. Patients reported their pain scores for each region using a 0-10 visual analog scale (VAS). A control group of 50 patients undergoing diagnostic flexible cystoscopy provided baseline pain scores. Two-way ANOVA was used to assess differences in pain scores based on gender, diagnosis, and anatomical region. A total of 119 patients (82 females, 37 males) were included, with 88 diagnosed with IDO, 28 with NDO, and 3 with OAB-wet. The mean overall VAS pain score during BoNT-A injections was 4.03 ± 1.21, compared to 1.76 ± 0.68 in 50 patients undergoing diagnostic flexible cystoscopy (p < 0.001). Among injection sites, mean scores were 3.78 for para-trigonal, 4.03 for lateral wall, and 3.11 for randomly distributed regions. Two-way ANOVA showed no significant differences in pain scores by gender or diagnosis, except for para-trigonal pain, which was higher in OAB-wet patients (p = 0.01). Excluding this subgroup, no significant difference remained between IDO and NDO (p = 0.06). Intravesical onabotulinumtoxinA injections are generally well tolerated under local anesthesia, though para-trigonal injections may cause greater discomfort, particularly in patients with OAB-wet. While pain perception did not differ significantly by gender or diagnosis overall, region-specific sensitivity should be considered when planning injection techniques. These findings may help inform strategies to improve procedural comfort and support individualized treatment approaches. This study was not registered as a clinical trial because it was a non-randomized, observational study without prospective assignment or intervention groups, consistent with ICMJE criteria.", "journal": "Neurourology and Urodynamics", "pub_date": "2026-Sep-21", "publication_types": ["Journal Article"], "doi": "10.1002/nau.70455", "authors": ["Salih Zeki Sönmez", "Hayder Alhusseinawi", "Rachel Skews", "Sonia Whittard", "Hashim Hashim"], "affiliations": ["Department of Urology, Kırklareli Training and Research Hospital, Kırklareli, Türkiye.", "Department of Urology, Region North Jutland Hjørring Hospital, Hjørring, Denmark.", "Center of Clinical Research, Region North Jutland Hjørring Hospital, Hjørring, Denmark.", "Department of Urology, Bristol Urological Institute, Southmead Hospital, Bristol, UK."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=13", "score": 23.56, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 5.56, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 12.0}, "journal_metrics": {"status": "ok", "impact_factor": 1.9, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.56, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42843106", "title": "Efficient capture and proteomic profiling of extracellular vesicles with magnetic cilia channel chip for pre- and postoperative assessment of prostate cancer.", "abstract": "Extracellular vesicles (EVs) are promising non-invasive biomarkers, but their clinical application is limited by inefficient isolation and downstream analysis. Here, we developed a biomimetic magnetic cilia microfluidic chip (MagCilia-chip) for EV capture and proteomic profiling from urine. Tim4-functionalized magnetic microcilia specifically captured phosphatidylserine-positive EVs and underwent magnetic-field-driven three-dimensional rotation to enhance EV-microstructure interactions. Compared with ultracentrifugation, the MagCilia-chip operated in 3D rotation mode achieved a recovery rate of 85% versus 27%, with 5.32-fold higher EV yield and 3.13-fold higher purity. On-chip lysis and digestion followed by mass-spectrometry analysis identified 2903 EV-derived proteins from 50 μL of urine. In the discovery cohort of 12 prostate cancer (PCa) and 8 post-treatment (PT) samples, 368 differentially expressed EV proteins were identified, yielding a five-protein candidate panel. Independent parallel reaction monitoring analysis of 19 PCa and 9 PT samples confirmed differential expression of C9, COL6A3, and VTN. A three-protein panel achieved area-under-the-curve values of 0.78-0.95 across ten machine-learning classifiers using leave-one-out cross-validation. This platform provides an efficient strategy for urinary EV isolation and proteomic analysis and supports further evaluation of EV-derived candidate biomarkers for PCa treatment.", "journal": "Biosensors & Bioelectronics", "pub_date": "2026-Sep-20", "publication_types": ["Journal Article"], "doi": "10.1016/j.bios.2026.119252", "authors": ["Xiaorong Song", "Mingyang Li", "Jie Sun", "Xiang Li", "Yuanyuan Deng", "Wenya Chang", "Yuhan Cai", "Pengli Li", "Zhongze Gu", "Shangqian Wang", "Zhuoying Xie"], "affiliations": ["Institute of Microphysiological Systems, Nantong First People's Hospital, School of Biological Science and Medical Engineering, State Key Laboratory of Digital Medical Engineering, Southeast University, Nantong, Jiangsu, 226006, China.", "Urology Department, the First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China. Electronic address: wangshangqian@njmu.edu.cn.", "Institute of Microphysiological Systems, Nantong First People's Hospital, School of Biological Science and Medical Engineering, State Key Laboratory of Digital Medical Engineering, Southeast University, Nantong, Jiangsu, 226006, China; Institute of Biomedical Devices (Suzhou), Southeast University, Suzhou, Jiangsu, 215163, China. Electronic address: zyxie@seu.edu.cn."], "corresponding_authors": ["Shangqian Wang", "Zhuoying Xie"], "china_team": "Institute of Microphysiological Systems, Nantong First People's Hospital, School of Biological Science and Medical Engineering, State Key Laboratory of Digital Medical Engineering, Southeast University, Nantong, Jiangsu, 226006, China Shangqian Wang/Zhuoying Xie团队", "category": "basic", "classification_reason": "basic_signals=5", "score": 38.08, "score_parts": {"urology_relevance": 7, "urology_in_title": 8.0, "journal_priority": 15.58, "top_journal_bonus": 0.0, "novelty": 0.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 5.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 10.5, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.58, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "磁性纤毛芯片高效捕获尿液囊泡", "chinese_summary": "南通市第一人民医院/东南大学王尚乾、谢卓颖团队9月Biosens Bioelectron报道仿生磁性纤毛微流控芯片，以Tim4功能化磁微纤毛在三维旋转下捕获磷脂酰丝氨酸阳性胞外囊泡，回收率达85%，较超速离心提高5.32倍产量和3.13倍纯度。", "abstract_zh": "细胞外囊泡（EVs）是有前景的非侵入性生物标志物，但其临床应用受到低效分离和下游分析的局限。在此，我们开发了一种仿生磁性纤毛微流控芯片（MagCilia-chip），用于从尿液中捕获EV并进行蛋白质组学分析。Tim4功能化的磁性微纤毛特异性捕获磷脂酰丝氨酸阳性的EV，并在磁场驱动下进行三维旋转以增强EV与微结构的相互作用。与超速离心相比，MagCilia-chip在三维旋转模式下实现了85%对27%的回收率，EV产量提高5.32倍，纯度提高3.13倍。芯片上裂解和酶解后进行质谱分析，从50 μL尿液中鉴定出2903种EV来源蛋白。在由12例前列腺癌（PCa）和8例治疗后（PT）样本组成的发现队列中，鉴定出368种差异表达的EV蛋白，并得到一个五蛋白候选组合。对19例PCa和9例PT样本进行的独立平行反应监测分析证实了C9、COL6A3和VTN的差异表达。使用留一交叉验证，一个三蛋白组合在十种机器学习分类器中获得了0.78–0.95的曲线下面积值。该平台为尿液EV分离和蛋白质组学分析提供了一种高效策略，并支持进一步评估EV来源的候选生物标志物用于PCa治疗。"}, {"pmid": "42772167", "title": "Mixture risk assessment of pesticides with acute neurotoxic effects: a novel approach based on urinary exposure biomarkers.", "abstract": "Pesticides showing neurotoxic effects, including organophosphates, pyrethroids, and N-methyl carbamates, are widely used in agriculture. Human biomonitoring (HBM) integrates exposure from multiple sources and routes by measuring pesticide levels in human biological samples. This study applied a novel MRA methodology using urinary biomarkers, focusing on two cumulative assessment groups (CAGs) of pesticides with acute neurotoxic effects, as previously established by the European Food Safety Authority (EFSA), namely, CAG-NAN on brain and/or erythrocyte acetylcholinesterase inhibition; and CAG-NAM on functional alterations of the motor, sensory and autonomic division. Available urinary pesticide metabolites were assigned to potential parent compounds within these CAGs and were converted to external exposure levels, expressed as estimated daily intakes (EDI), using reverse dosimetry. Toxicological reference points, i.e., no observed adverse effect levels (NOAEL) were obtained from EFSA report. For each parent compound, the ratio of the NOAEL to the EDI was calculated, and these ratios were used to determine the total margin of exposure (MOET). This approach was applied as a proof-of-concept to children and adults from 10 HBM studies across seven European countries. For CAG-NAN, median MOET ranged between 27 and 2485 across datasets with percentage of individuals below a threshold of 100 from 2.8 to 97%. For CAG-NAM median MOET values ranged from 34 to 220 000 and in one scenario the percentage of individuals below the threshold was between 24% for children and up to 93% for adults. Azinphos-ethyl, triazophos, omethoate, and chlorpyrifos were identified as risk drivers. This study highlights the need for improved MRA methodologies based on HBM data, including the development of pesticide-specific exposure biomarkers, and the establishment of human biomonitoring-guidance values (HBM-GVs). Incorporating HBM data strengthens human health MRA by reducing uncertainty surrounding non-dietary exposure and generating valuable evidence to inform future pesticide monitoring and regulatory strategies.", "journal": "Environment International", "pub_date": "2026-Sep-20", "publication_types": ["Journal Article"], "doi": "10.1016/j.envint.2026.110531", "authors": ["Philippe Palmont", "Madeline Carsique", "Karine Angeli", "Hannah P McKeon", "Alexandra Mienné", "Anastasia Spyropoulou", "Adna Alilović", "Liesbeth Bruckers", "Bianca Cox", "Pavel Čupr", "Katleen Debrouwere", "Deepika Deepika", "Clémence Fillol", "Eva Govarts", "Tomáš Janoš", "Marike Kolossa-Gehring", "Vikas Kumar", "Michelle Laeremans", "Lucija Perharič", "Anja Remškar", "Janja Snoj Tratnik", "Libor Šulc", "Nina Vogel", "Aude Ratier", "Angelo Moretto", "Antonio F Hernández-Jerez", "Waldo de Boer", "Johannes Kruisselbrink", "Jasper Engel", "Jacob van Klaveren", "Kyriaki Machera", "Amélie Crépet"], "affiliations": ["Agency for Food, Environmental and Occupational Health & Safety (ANSES), Maisons-Alfort Cedex, France.", "Institute for Public Health and the Environment (RIVM), 3720 BA Bilthoven, the Netherlands.", "Laboratory of Toxicological Control of Pesticides, Scientific Directorate of Pesticides' Control and Phytopharmacy, Benaki Phytopathological Institute, 145 61, Attica, Greece.", "Jožef Stefan Institute (IJS), Jamova cesta 39, 1000 Ljubljana, Slovenia.", "Data Science Institute, University of Hasselt, Agoralaan Building D, 3590 Diepenbeek, Belgium.", "VITO Health, Flemish Institute for Technological Research (VITO), Boeretang 200, 2400 Mol, Belgium.", "RECETOX, Faculty of Science, Masaryk University, Kotlarska 2, Brno, Czech Republic.", "Environmental Engineering Laboratory, Departament d' Enginyeria Quimica, Universitat Rovira I Virgili, Av. Països Catalans 26, 43007 Tarragona, Catalonia, Spain; Pere Virgili Health Research Institute (IISPV), Tarragona, Spain.", "Santé Publique France, The National Public Health Agency, 12 Rue Du Val D'Osne, Saint-Maurice Cedex 94415, France.", "RECETOX, Faculty of Science, Masaryk University, Kotlarska 2, Brno, Czech Republic; ISGlobal, Barcelona, Spain.", "Ruhr University Bochum Medical Faculty Institute for Prevention and Occupational Medicine of the German Social Accident Insurance Institute of the Ruhr University Bochum (IPA), Buerkle-de-la-Camp-Platz 1, 44789 Bochum, Germany.", "National Institute of Public Health (NIJZ), Trubarjeva cesta 2, 1000 Ljubljana, Slovenia.", "RECETOX, Faculty of Science, Masaryk University, Kotlarska 2, Brno, Czech Republic; Unit of Occupational Medicine at the Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.", "German Environment Agency (UBA), Corrensplatz 1, 14195 Berlin, Germany.", "Institut National de l'Environnement Industriel et des Risques (INERIS), Unit of New Approaches and Models for Human Health and Environment Safety, Parc ALATA BP2, 60550 Verneuil en Halatte, France; PériTox Laboratory, UMR-I 01 INERIS, Université de Picardie Jules Verne, Amiens, France.", "Department of Cardiac Thoracic Vascular Sciences and Public Health University of Padova, and Azienda Ospedale Università Padova, Via Giustiniani 2, 35128 Padova, Italy.", "Department of Legal Medicine and Toxicology, University of Granada 18016 Granada, Spain; Instituto de Investigación Biosanitaria, ibs.GRANADA. Granada, Spain; CIBER Epidemiology and Public Health (CIBERESP), Madrid, Spain.", "Mathematical & Statistical Methods Group (Biometris), Wageningen University & Research, Droevendaalsesteeg 1, 6708 PB Wageningen, the Netherlands.", "Agency for Food, Environmental and Occupational Health & Safety (ANSES), Maisons-Alfort Cedex, France. Electronic address: amelie.crepet@anses.fr."], "corresponding_authors": ["Amélie Crépet"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 31.98, "score_parts": {"urology_relevance": 3, "urology_in_title": 8.0, "journal_priority": 15.48, "top_journal_bonus": 0.0, "novelty": 1.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 2.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 9.7, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.48, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "尿液生物标志物揭示农药神经毒性风险", "chinese_summary": "9月Environ Int发表研究，利用欧洲7国10项人体生物监测研究的尿液农药代谢物，经反向剂量学估算每日摄入量并计算暴露边际，发现儿童与成人中多种农药暴露超过安全阈值，毒死蜱、三唑磷等为风险驱动因子，推动基于生物监测的累积风险评估。", "abstract_zh": "具有神经毒性作用的农药，包括有机磷类、拟除虫菊酯类和N-甲基氨基甲酸酯类，在农业中被广泛使用。人体生物监测（HBM）通过测量人体生物样本中的农药水平，整合来自多种来源和途径的暴露。本研究应用了一种基于尿液生物标志物的新型混合物风险评估（MRA）方法，重点关注欧洲食品安全局（EFSA）此前确立的两个具有急性神经毒性作用的农药累积评估组（CAG），即CAG-NAN（关于脑和/或红细胞乙酰胆碱酯酶抑制）和CAG-NAM（关于运动、感觉和自主神经分部的功能改变）。将可获得的尿液农药代谢物归属于这些CAG内的潜在母体化合物，并使用反向剂量学将其转换为外暴露水平，以估计每日摄入量（EDI）表示。毒理学参考点，即未观察到不良效应水平（NOAEL），取自EFSA报告。对每种母体化合物，计算NOAEL与EDI的比值，并利用这些比值确定总暴露边际（MOET）。该方法作为概念验证，应用于来自7个欧洲国家10项HBM研究的儿童和成人。对于CAG-NAN，各数据集的中位MOET在27至2485之间，低于100阈值的个体百分比为2.8%至97%。对于CAG-NAM，中位MOET值范围为34至220000，在一种情景中，低于阈值的个体百分比为儿童24%至成人高达93%。保棉磷、三唑磷、氧乐果和毒死蜱被确定为风险驱动因子。本研究强调需要改进基于HBM数据的MRA方法，包括开发农药特异性暴露生物标志物，以及建立人体生物监测指导值（HBM-GVs）。纳入HBM数据可通过减少非膳食暴露的不确定性并生成有价值证据，为未来农药监测和监管策略提供信息，从而加强人类健康MRA。"}, {"pmid": "42764237", "title": "Patient-reported outcomes after open and robotic radical prostatectomy: a New Zealand registry study.", "abstract": "Our objective was to compare functional outcomes between open radical prostatectomy (ORP) and robotic-assisted laparoscopic prostatectomy (RALP) in New Zealand. We analysed responses from men in the Prostate Cancer Outcome Registry of New Zealand (PCOR-NZ) who underwent ORP or RALP as primary treatment for prostate cancer between January 2016 and December 2024. We included men who completed an Expanded Prostate Cancer Index - 26 (EPIC-26) patient-reported outcome measure (PROM) questionnaire either at baseline, 12 months after radical prostatectomy or both. EPIC-26 scores range from 0 to 100 (100 = best score). Established thresholds assessed minimal clinically important differences; urinary incontinence (6-9 points), urinary obstruction (5-7 points), bowel (4-6 points), sexual (10-12 points) and hormonal (4-6 points). Mean differences were calculated using multivariate analysis to adjust for age, prostate-specific antigen and International Society of Urological Pathology grade. Additional analyses assessed daily pad usage and patient-reported sexual function. Of the 4889 men who completed a questionnaire, 2844 (58.1%) underwent ORP and 2045 (41.8%) underwent RALP. PROM completion rates were 52.3% at baseline and 78.8% at 12 months after treatment. Patients who underwent RALP had higher post-treatment PROM scores in all domains. Adjusted mean differences for urinary incontinence (6.9 points, 95% confidence interval 4.6-9.2 P < 0.001) and sexual (11.4 points, 95% confidence interval 9.1-13.7, P < 0.001) domains were above the threshold for minimal clinically important difference. Urinary obstruction, bowel and hormonal domains did not reach clinical significance. At 12 months, RALP had a higher rate of zero pads/day usage (65.1% vs 54.4% P < 0.001) and lower two or more pads/day usage (3.9% vs 10.0% P < 0.001). More men in the RALP group reported a 'good' to 'very good' sexual function at 12 months (13.7% vs 5.3%, P < 0.001). RALP is associated with higher PROMs across all EPIC-26 domains, with clinically meaningful benefit in sexual function, urinary incontinence and reduced incontinence pad usage at 12 months.", "journal": "BJU International", "pub_date": "2026-Sep-20", "publication_types": ["Journal Article"], "doi": "10.1111/bju.70459", "authors": ["Kieran Long", "Joseph Hutchinson", "George Acland", "Judith Clarke", "Phil Hider", "Stephen Mark"], "affiliations": ["Department of Urology, Christchurch Hospital, Christchurch, New Zealand.", "Prostate Cancer Outcome Registry - New Zealand (PCOR-NZ), Christchurch, New Zealand.", "University of Otago, Dunedin, New Zealand."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=3", "score": 38.97, "score_parts": {"urology_relevance": 15, "urology_in_title": 8.0, "journal_priority": 10.47, "top_journal_bonus": 0.0, "novelty": 0.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 3.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.4, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.47, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42763811", "title": "Molecular based diagnostic testing for urinary tract infections: the results remain unclear.", "abstract": "Recent advances have led to a rise in metagenomic and molecular-based testing for more rapid diagnosis of urinary tract infections (UTI). We conducted a contemporary systematic review to understand how these molecular tests affect clinical outcomes. A systematic review was conducted for articles in adults from January 2023 to October 2025 as an update to previous scoping reviews. Cochrane and PRISMA standards were utilized with the following databases: PubMed, OVID, and Embase (PROSPERO number: CRD420251070022). Data was extracted from the selected full-text papers including the type of study (microbiology versus clinical), patient demographics, key findings, and funding source. Excluded studies were abstracts, non-English manuscripts, and those involving only men or children. The search resulted in 12 full-text articles. Among those, 7 were published in clinical-based journals and 5 were in Microbiology. Two clinical studies were randomized controlled trials (RCTs) which included a total of 773 patients, mostly female and above the age of 65. Compared to a standard urine culture, molecular based testing, specifically with polymerase chain reaction (PCR) testing yielded superior sensitivity despite lack of specificity and guided antibiotic therapy to reduce UTI baseline symptomatology in the short term (i.e. 28 days) in both RCT analyses. Of note, the RCT analyses and several of the prospective studies (5/10) were funded by the companies that developed the molecular tests. Based on the increase in publications over the last three years, new industry-funded RCTs, and the limited clinical outcome data reported, this systematic review indicates the urgent need for prospective and multicentric studies to better understand the role of these molecular tests in UTI management.", "journal": "World Journal of Urology", "pub_date": "2026-Sep-20", "publication_types": ["Journal Article", "Systematic Review"], "doi": "10.2147/IDR.S323095", "authors": ["Meghana Reddy", "Christina Sze", "Bonnie C Prokesch", "Philippe Zimmern"], "affiliations": ["Department of Obstetrics and Gynecology, Louisiana State University, New Orleans, LA, USA.", "Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA.", "Department of Internal Medicine, Division of Infectious Disease Dallas, University of Texas Southwestern Medical Center, Dallas, TX, USA.", "Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA. Philippe.Zimmern@utsouthwestern.edu."], "corresponding_authors": ["Philippe Zimmern"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 35.5, "score_parts": {"urology_relevance": 7, "urology_in_title": 8.0, "journal_priority": 10.0, "top_journal_bonus": 0.0, "novelty": 0.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 8.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.9, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.0, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42763990", "title": "The AURKA-PTTG1 signaling axis induces enzalutamide resistance in prostate cancer.", "abstract": "Prostate cancer (PCa), a common male malignant tumor, often develops resistance to the androgen receptor inhibitor enzalutamide (ENZ). Despite its established oncogenic role, pituitary tumor-transforming gene 1 (PTTG1)'s specific function and regulatory mechanism in ENZ-resistant PCa require investigation. Cell biology assays were employed to evaluate the effects of PTTG1 and Aurora kinase A (AURKA) on cell proliferation, apoptosis, migration, and ENZ resistance. Bioinformatics analysis revealed that the glycolytic signaling pathway was significantly enriched in the PTTG1‑high expression group. Subsequently, the regulatory roles of PTTG1 and AURKA in glycolysis were verified by measuring glycolysis‑related metabolic parameters and changes in the expression of key proteins. The physical interaction between PTTG1 and AURKA was confirmed by predictions from protein-protein interaction databases and validated by co‑immunoprecipitation experiments. After determining the subcellular localization of PTTG1 through cell fractionation assays, we further assessed the effect of AURKA on the serine phosphorylation levels of the purified GFP-PTTG1 fusion protein. All in vitro results were validated in a nude mouse xenograft model using immunofluorescence, immunohistochemistry, and apoptosis detection assays. In ENZ-resistant PCa cells, PTTG1 was highly expressed, and its phosphorylation was promoted by AURKA, which in turn facilitated its nuclear translocation to activate Wnt signaling and glycolytic metabolism, driving ENZ resistance in PCa. Targeting the AURKA/PTTG1 axis enhanced ENZ sensitivity in a PCa mouse model. The AURKA/PTTG1 axis contributes to ENZ resistance by promoting glycolytic metabolism in PCa cells.", "journal": "Urologic Oncology", "pub_date": "2026-Sep-19", "publication_types": ["Journal Article"], "doi": "10.1016/j.urolonc.2026.08.010", "authors": ["Guangye Han", "Zhenhui Li", "Weihang Song", "Lei Li", "Junling Hu"], "affiliations": ["Department of Urology, The First Affiliated Hospital of Henan Medical University, Xinxiang, Henan, China. Electronic address: hhh_guangyehhhan@163.com.", "Department of Urology, The First Affiliated Hospital of Henan Medical University, Xinxiang, Henan, China."], "corresponding_authors": ["Guangye Han"], "china_team": "Department of Urology, The First Affiliated Hospital of Henan Medical University, Xinxiang, Henan, China Guangye Han团队", "category": "basic", "classification_reason": "basic_signals=21", "score": 33.75, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 5.75, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 14.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.3, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.75, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "AURKA-PTTG1轴驱动前列腺癌恩扎卢胺耐药", "chinese_summary": "河南医药大学第一附属医院光叶韩团队9月Urol Oncol研究发现，恩扎卢胺耐药前列腺癌细胞高表达PTTG1，AURKA促进其磷酸化及核转位，激活Wnt信号与糖酵解代谢，从而驱动耐药；靶向该轴可恢复小鼠模型对恩扎卢胺的敏感性。", "abstract_zh": "前列腺癌（PCa）是一种常见的男性恶性肿瘤，常对雄激素受体抑制剂恩扎卢胺（ENZ）产生耐药。尽管垂体肿瘤转化基因1（PTTG1）已知具有致癌作用，但其在ENZ耐药PCa中的具体功能和调控机制仍需研究。我们采用细胞生物学实验评估PTTG1和极光激酶A（AURKA）对细胞增殖、凋亡、迁移及ENZ耐药的影响。生物信息学分析显示，糖酵解信号通路在PTTG1高表达组中显著富集。随后，通过检测糖酵解相关代谢参数及关键蛋白表达变化，验证了PTTG1和AURKA对糖酵解的调控作用。通过蛋白-蛋白相互作用数据库预测并经免疫共沉淀实验证实了PTTG1与AURKA之间的物理相互作用。在通过细胞分级分离实验确定PTTG1的亚细胞定位后，我们进一步评估了AURKA对纯化的GFP-PTTG1融合蛋白丝氨酸磷酸化水平的影响。所有体外结果均在裸鼠异种移植模型中通过免疫荧光、免疫组化和凋亡检测实验进行了验证。在ENZ耐药的PCa细胞中，PTTG1高表达，其磷酸化受AURKA促进，进而促进其核转位以激活Wnt信号和糖酵解代谢，驱动PCa的ENZ耐药。靶向AURKA/PTTG1轴可增强PCa小鼠模型对ENZ的敏感性。AURKA/PTTG1轴通过促进PCa细胞中的糖酵解代谢而参与ENZ耐药。"}, {"pmid": "42763264", "title": "Integrated Urine and Plasma DNA Analysis for Molecular Staging of Upper Tract Urothelial Carcinoma.", "abstract": "Current clinical risk stratification for determining neoadjuvant chemotherapy (NAC) usage in nonmetastatic upper tract urothelial carcinoma (UTUC) is frequently inaccurate. This uncertainty leads to suboptimal patient selection, often resulting in either overtreatment of low-stage disease or missed opportunities for NAC in advanced cases. This study evaluates the prognostic performance of urine tumor DNA (utDNA) and plasma circulating tumor DNA (ctDNA) testing as a tool for improving the diagnostic staging and clinical management of UTUC. A total of 41 patients who underwent surgical extirpation for localized UTUC were evaluated using utDNA and ctDNA. Prognostic performance of utDNA and ctDNA testing was compared to standard-of-care (SOC) risk assessment and pathology at surgery. The primary analysis was validation of utDNA TP53 mutation and ctDNA status as predictors of muscle-invasive UTUC. A total of 21 (51%) patients had muscle-invasive UTUC. Univariable logistic regression identified molecular staging (utDNA TP53 and ctDNA status) as a strong predictor of muscle-invasive disease (odds ratio [OR] 9.6, p = 0.002) and the only significant predictor by multivariable analysis (OR 8.5, p = 0.004). When combined with SOC diagnostic staging (biopsy and imaging), molecular staging had significantly better specificity (70% vs 25%) and postive predictive value (74% vs 53%) compared to SOC risk factors (high-grade biopsy and cytology) for identifying muscle-invasive disease, with equivalent sensitivity (81% vs 81%) and negative predictive value (78% vs 56%, p = 0.15). Composite liquid biopsy testing can significantly enhance noninvasive staging of UTUC. Improved staging and prognostic classification can improve personalized risk assessment and treatment intensification.", "journal": "European Urology Oncology", "pub_date": "2026-Sep-19", "publication_types": ["Journal Article"], "doi": "10.1016/j.euo.2026.08.008", "authors": ["Maximilian Pallauf", "Stephan Bronimann", "Stanley Rapiey", "Ezra Baraban", "Shoujie Chai", "Daniel S Fischer", "Vincent T Bicocca", "Trevor G Levin", "David J McConkey", "Nirmish Singla"], "affiliations": ["The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Urology, University Hospital Salzburg, Paracelsus Medical University, Salzburg, Austria.", "The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.", "The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.", "Convergent Genomics, South San Francisco, CA, USA.", "The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA; University of Rochester Medical Center, Wilmot Cancer Institute, Rochester, NY, USA.", "The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. Electronic address: nsingla2@jhmi.edu."], "corresponding_authors": ["Nirmish Singla"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=4", "score": 34.42, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 15.42, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 4.0}, "journal_metrics": {"status": "ok", "impact_factor": 9.3, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.42, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42763234", "title": "Re: Marie Semmler, Julian Marcon, Elena K. Berg, et al. Radical Prostatectomy Without Prior Biopsy? Final Histopathology of Radical Prostatectomies in 103 Consecutive Biopsy-naïve Patients Who Underwent Radical Prostatectomy. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2026.06.030.", "abstract": "", "journal": "European Urology Focus", "pub_date": "2026-Sep-19", "publication_types": ["Letter"], "doi": "10.1016/j.euf.2026.08.013", "authors": ["Giulia Giannini", "Isabel Heidegger"], "affiliations": ["Department of Urology, Medical University of Innsbruck, Innsbruck, Austria.", "Department of Urology, Medical University of Innsbruck, Innsbruck, Austria. Electronic address: isabel-maria.heidegger@i-med.ac.at."], "corresponding_authors": ["Isabel Heidegger"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 19.77, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.77, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 5.6, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.77, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42763233", "title": "External Validation and Comparison of Magnetic Resonance Imaging-based Risk Calculators for Detection of Clinically Significant Prostate Cancer: A Multi-institutional Study Incorporating Transrectal and Transperineal Biopsy Approaches.", "abstract": "Magnetic resonance imaging (MRI)-based risk calculators are widely used to inform prostate biopsy decision-making; however, they were predominantly developed for transrectal biopsies. Their performance using the transperineal approach remains unclear. This study externally validated five MRI-based risk calculators across a diverse cohort undergoing either approach. This retrospective cohort study included 4168 men with pre-biopsy MRI followed by prostate biopsy between October 2016 and December 2023 across four Canadian academic and community hospitals. Five MRI-based (Mehralivand, Kinnaird, Patel, Wang, and Peters) and one non-MRI-based (Prostate Biopsy Collaborative Group) risk calculators were compared. The primary outcome was the presence of clinically significant prostate cancer (csPCa; Grade Group ≥ 2). Model performance was characterized using area under the receiver-operating-characteristic curve (AUROC), calibration plots, and net benefit. Overall, 1797 of 4168 men (43%) had csPCa. Seventy-four percent were of Caucasian ancestry. Biopsies were transperineal in 1379 cases (33%); 32% of patients were biopsy-naïve, 30% had a prior negative biopsy, and 38% had prior Grade Group 1 disease. The MRI-based calculators' performance was similar but worse than originally reported (AUROC = 0.78-0.80 vs 0.80-0.89) although better than that of the non-MRI-based model (AUROC = 0.67, p < 0.001). MRI-based models' performance remained consistent across subgroups, including age, ancestry, biopsy approach (transrectal or transperineal), clinical setting (academic or community), Prostate Imaging-Reporting and Data System (PI-RADS; v2.0 or v2.1), and MRI-fusion technique (cognitive or software). The Kinnaird, Patel, and Peters models showed superior calibration and net benefit. We did not see evidence of a difference in the performance of MRI-based risk calculators regardless of biopsy approach or fusion technique.", "journal": "European Urology Focus", "pub_date": "2026-Sep-19", "publication_types": ["Journal Article"], "doi": "10.1016/j.euf.2026.06.027", "authors": ["Afton Taborek", "Jethro C C Kwong", "Alice Wang", "Noa Boulakia", "Leyi B Yin", "Kevin K Zhang", "David-Dan Nguyen", "John R Srigley", "Theodorus Van der Kwast", "Susan Prendeville", "Ryan Booth", "Aiman Shahid", "Maximiliano Ringa", "Amna Ali", "Ivan Diamond", "Sylvio Bruni", "Laurence H Klotz", "Nathan Perlis", "Neil Fleshner", "Antonio Finelli", "Romain Diamand", "Sangeet Ghai", "Masoom Haider", "Roger Buckley", "Andrew Feifer", "Badar M Mian", "Girish S Kulkarni", "Alexandre R Zlotta"], "affiliations": ["Division of Urology, Department of Surgery, Mount Sinai Hospital, Sinai Health System, Toronto, ON, Canada.", "Division of Urology, Department of Surgery, University of Toronto, Toronto, ON, Canada; Division of Urology, Department of Surgery, University Health Network, Toronto, ON, Canada.", "Division of Urology, Department of Surgery, Mount Sinai Hospital, Sinai Health System, Toronto, ON, Canada; School of Medicine, University of Dundee, Dundee, Scotland, United Kingdom.", "Division of Urology, Department of Surgery, Mount Sinai Hospital, Sinai Health System, Toronto, ON, Canada; Faculty of Engineering, University of Waterloo, Waterloo, ON, Canada.", "Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.", "Department of Pathology, Trillium Health Partners and University of Toronto, Mississauga, ON, Canada.", "Laboratory Medicine Program, University Health Network and Princess Margaret Cancer Centre, Toronto, ON, Canada.", "Institute for Better Health, Trillium Health Partners, Mississauga, ON, Canada.", "Department of Medical Imaging, University of Toronto, Toronto, ON, Canada.", "Division of Urology, Department of Surgery, University of Toronto, Toronto, ON, Canada; Division of Urology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.", "Division of Urology, Department of Surgery, University Health Network, Toronto, ON, Canada.", "Department of Urology, Jules Bordet Institute-Erasme Hospital, Hôpital Universitaire de Bruxelles, Université Libre I de Bruxelles, Brussels, Belgium.", "Joint Department of Medical Imaging, University Health Network-Mount Sinai Hospital-Women's College Hospital, University of Toronto, Toronto, ON, Canada.", "Division of Urology, Department of Surgery, North York General Hospital, North York, ON, Canada.", "Division of Urology, Department of Surgery, Trillium Health Partners, Mississauga, ON, Canada.", "Department of Urology, Albany Med Health System, Albany, NY, USA.", "Division of Urology, Department of Surgery, Mount Sinai Hospital, Sinai Health System, Toronto, ON, Canada; Division of Urology, Department of Surgery, University Health Network, Toronto, ON, Canada. Electronic address: alexandre.zlotta@sinaihealth.ca."], "corresponding_authors": ["Alexandre R Zlotta"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=6", "score": 30.77, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.77, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 6.0}, "journal_metrics": {"status": "ok", "impact_factor": 5.6, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.77, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42763232", "title": "Re: Marie Semmler, Julian Marcon, Elena K. Berg, et al. Radical Prostatectomy Without Prior Biopsy? Final Histopathology of Radical Prostatectomies in 103 Consecutive Biopsy-naïve Patients Who Underwent Radical Prostatectomy. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2026.06.030.", "abstract": "", "journal": "European Urology Focus", "pub_date": "2026-Sep-19", "publication_types": ["Letter"], "doi": "10.1016/j.euf.2026.08.014", "authors": ["Ilias Giannakodimos", "Zisis Kratiras", "Michael Chrisofos"], "affiliations": ["Third Department of Urology, Attikon University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece. Electronic address: iliasgiannakodimos@gmail.com.", "Third Department of Urology, Attikon University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece."], "corresponding_authors": ["Ilias Giannakodimos"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 19.77, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.77, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 5.6, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.77, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42762460", "title": "Protein Kinase C Epsilon Cooperates with PTEN Loss for Prostate Tumorigenesis through the CXCL13-CXCR5 Pathway.", "abstract": "", "journal": "Cell Reports", "pub_date": "2026-Sep-19", "publication_types": ["Published Erratum"], "doi": "10.1016/j.celrep.2026.118073", "authors": ["Rachana Garg", "Jorge M Blando", "Carlos J Perez", "Martin C Abba", "Fernando Benavides", "Marcelo G Kazanietz"], "affiliations": [], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "basic_signals=4", "score": 28.03, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 15.03, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 4.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 6.9, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.03, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "蛋白激酶Cε协同PTEN缺失促前列腺癌", "chinese_summary": "Cell Reports 9月发布勘误，更正此前一项关于前列腺肿瘤发生机制的研究。原研究揭示蛋白激酶Cε（PKCε）与PTEN缺失协同作用，通过CXCL13-CXCR5信号通路促进前列腺肿瘤形成。此次勘误涉及原文中部分数据或图像的修正，不改变核心结论。", "abstract_zh": "这是一篇已发表文章的勘误。"}, {"pmid": "42762391", "title": "TAPESTRY study: impact of prior transurethral resection of the prostate on outcomes after robot-assisted radical prostatectomy: a propensity score-matched cohort study.", "abstract": "Prior transurethral resection of the prostate (TURP) may distort bladder neck and apical anatomy and complicate robot-assisted radical prostatectomy (RARP). Its effect on anastomotic recovery and oncological control remains controversial. To evaluate perioperative, anastomotic, pathological, and available PSA outcomes after RARP in patients with and without prior TURP. We retrospectively analyzed a prospectively maintained database of 3,332 consecutive RARP procedures performed between August 2011 and December 2024. Ninety-seven patients with prior TURP were matched 1:3 to 291 TURP-naive controls using propensity scores derived from age, body mass index, clinical stage, ISUP grade, prostate-specific antigen (PSA), positive biopsy cores, and prostate volume. Comparative outcome analyses used available cases within the matched cohort. Baseline characteristics were well balanced after matching. Operative duration was similar between groups (median 135 vs. 139 min; p = .584). Prior TURP was associated with longer catheterization (7 [IQR 4.5-11.5] vs. 6 [4-7] days; p = .004), more cystographies (p = .004), more frequent catheterization beyond 7 days (33.7% vs. 20.1%; p = .011), and a higher rate of complications within 3 months (13.4% vs. 6.2%; p = .030). Cystographic leakage was numerically more frequent after TURP (25.4% vs. 14.8%; p = .061). Pathological stage, nodal positivity, positive surgical margin rate and length, and available PSA outcomes at 1 and 2 years were comparable. After Bonferroni adjustment, catheterization duration and the number of cystographies remained statistically significant. Prior TURP was associated primarily with greater postoperative anastomotic management reflected by longer catheterization and more cystographic follow-up; the observed increase in 3-month complications did not remain significant after correction for multiple comparisons. Available PSA data did not indicate a clear between-group difference, although incomplete follow-up precluded robust conclusions regarding biochemical control.", "journal": "Journal of Robotic Surgery", "pub_date": "2026-Sep-19", "publication_types": ["Journal Article"], "doi": "10.1016/j.ejso.2023.03.218", "authors": ["Sebastian Lenart", "Julia Zach", "Georg Gutjahr", "Lukas Oberhammer", "Stephan Madersbacher", "Anton Ponholzer", "Clemens Mikulits", "Andreas Banner"], "affiliations": ["Department of Urology and Andrology, St. John of God Hospital Vienna, Johannes-von-Gott Platz 1, Vienna, 1020, Austria. sebastian.lenart@gmx.at.", "Department of Urology and Andrology, Paracelsus Medical University, Salzburg, Austria. sebastian.lenart@gmx.at.", "Department of Urology and Andrology, St. John of God Hospital Vienna, Johannes-von-Gott Platz 1, Vienna, 1020, Austria.", "Department of Health Sciences Research, Amrita Institute of Medical Science and Research Centre, Amrita Vishwa Vidyapeetham, Kochi, Kerala, India.", "Department of Urology and Andrology, Paracelsus Medical University, Salzburg, Austria.", "Department of Urology and Andrology, Clinic Favoriten, Vienna, Austria."], "corresponding_authors": ["Sebastian Lenart"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=9", "score": 37.03, "score_parts": {"urology_relevance": 12, "urology_in_title": 8.0, "journal_priority": 6.03, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 9.0}, "journal_metrics": {"status": "ok", "impact_factor": 3.0, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 2.03, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42762325", "title": "Comment on \"Comparative evaluation of flexible ureterorenoscopy and mini-percutaneous nephrolithotomy for the management of renal pelvic stones less than 2 cm with high attenuation value in pediatric patients: a prospective randomized study\".", "abstract": "", "journal": "Urolithiasis", "pub_date": "2026-Sep-19", "publication_types": ["Letter"], "doi": "10.1007/s00240-026-02064-4", "authors": ["Emrah Küçük", "Mesut Şengül", "Reha Ordulu"], "affiliations": ["Department of Urology, Faculty of Medicine, Samsun University, Samsun, Türkiye. emrah.kucuk@samsun.edu.tr.", "Urology Clinic, Samsun City Hospital, Samsun, Türkiye.", "Department of Urology, Faculty of Medicine, Samsun University, Samsun, Türkiye."], "corresponding_authors": ["Emrah Küçük"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=8", "score": 22.71, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 5.71, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 8.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.2, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.71, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42762296", "title": "Technique-stratified whole-stone laser energy consumption during RIRS using a 150-W Ho: YAG laser.", "abstract": "To determine whether technique-stratified whole-stone laser energy consumption (LEC) provides interpretable benchmarking during retrograde intrarenal surgery (RIRS) performed with a 150-W holmium: YAG platform. This retrospective single-center cohort identified 350 procedures performed from January 2023 to January 2025 and included all 300 eligible procedures (100 per technique). Total energy was reconstructed from case-level pulse energy, frequency, and laser-on time. Whole-stone LEC was energy divided by preoperative computed-tomography stone volume. Strict zero-residual stone-free rate (SFR) and < 2 mm clinical success were assessed by computed tomography at 3 months. Median whole-stone LEC was 19.3 [17.1-22.0] J/mm³ for dusting, 11.7 [10.4-13.3] for fragmentation, and 24.1 [21.3-27.6] for pop-dusting (p < 0.001). Fragmentation used the least total energy but had the longest operation time. Strict SFR was 71.0%, 80.0%, and 67.0% (p = 0.107), whereas clinical success was 93.0%, 93.0%, and 94.0% (p = 0.948). After adjustment for comorbidity, stone volume, density, and lower-calyx location predicted strict SFR; technique and LEC did not. Adding technique and LEC did not improve repeated cross-validated discrimination and produced modest overfitting. Technique-specific whole-stone LEC is best interpreted as a benchmarking measure alongside operative time and CT outcomes, not as an independent preoperative predictor.", "journal": "Urolithiasis", "pub_date": "2026-Sep-19", "publication_types": ["Journal Article"], "doi": "10.1007/s00240-026-02059-1", "authors": ["Kadir Böcü", "Doğucan Nuri Uğur", "Nurullah Altınkaya"], "affiliations": ["Department of Urology, Faculty of Medicine, Niğde Ömer Halisdemir University, Bor Road, Niğde, 51240, Türkiye. kadirbocu@ohu.edu.tr.", "Department of Urology, Faculty of Medicine, Niğde Ömer Halisdemir University, Bor Road, Niğde, 51240, Türkiye."], "corresponding_authors": ["Kadir Böcü"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=5", "score": 12.71, "score_parts": {"urology_relevance": 0, "urology_in_title": 0.0, "journal_priority": 5.71, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 5.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.2, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.71, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42762281", "title": "AI-based smoke removal in robotic urooncologic surgery: a clinical pilot study.", "abstract": "Surgical smoke from electrocautery limits visibility during robot-assisted oncological surgery by obscuring tumor margins, blood vessels and anatomical landmarks. AI-based smoke removal demonstrated promising technical performance, structured clinical evaluation remains limited. This pilot study examined surgeons' perceptions of a temporally consistent 3D U-Net applied to intraoperative smoke. Twenty urologists and residents retrospectively assessed ten pairs of endoscopic videos offline, showing original and AI-processed clips. A questionnaire evaluated general impressions (seven items, five-point Likert scale), direct comparisons across four image dimensions, open-ended feedback and overall utility. Visibility of anatomical details and depth perception were rated equal to the smoke-affected original by 75% of participants and slightly better by 25%. Color fidelity was rated equal by 85% and slightly better by 15%. None rated these dimensions worse (0/20, exact 95% CI 0 to 16.8%), and no participant selected the highest rating. Image stability was rated worse by 20%. Half disagreed that the processed footage appeared clearer. Overall utility was rated positively by 40%, neutrally by 35% and negatively by 25%. In this small, unblinded, single-institution retrospective pilot study, AI processing was not associated with a perceived worsening of anatomical detail, depth perception or color fidelity. However, confidence intervals remain wide and the study was not designed to establish equivalence. Most participants perceived no improvement in image clarity or orientation support. Artifact reduction, real-time performance and blinded multicenter evaluation are required before clinical use.", "journal": "Journal of Robotic Surgery", "pub_date": "2026-Sep-19", "publication_types": ["Journal Article"], "doi": "10.1007/s11701-025-02333-1", "authors": ["Leonhard Buck", "Silja Janßen", "Jakob Kohler", "Julian Risch", "Anton Moderegger", "Daniar Osmonov", "Jonas Jarczyk", "Axel Merseburger", "Kevin Köser", "Philipp Nuhn", "Severin Rodler"], "affiliations": ["Department of Urology, University Hospital Schleswig-Holstein, 24105, Kiel, Germany, Campus Kiel. leonhard.buck@uksh.de.", "Kurt-Semm Center for Laparoscopic and Robotic Surgery, University Hospital Schleswig-Holstein, 24105, Kiel, Germany. leonhard.buck@uksh.de.", "Department of Computer Science, Christian-Albrechts-University of Kiel, 24118, Kiel, Germany.", "Department of Urology, University Hospital Schleswig-Holstein, 24105, Kiel, Germany, Campus Kiel.", "Kurt-Semm Center for Laparoscopic and Robotic Surgery, University Hospital Schleswig-Holstein, 24105, Kiel, Germany.", "Department of Urology, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany, 23538."], "corresponding_authors": ["Leonhard Buck"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=7", "score": 19.03, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 6.03, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 7.0}, "journal_metrics": {"status": "ok", "impact_factor": 3.0, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 2.03, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42762265", "title": "Role of cytoreductive nephrectomy in metastatic medullary renal cell carcinoma: controlled analysis.", "abstract": "To test for differences in overall survival (OS) according to cytoreductive nephrectomy (CN) in medullary metastatic renal cell carcinoma (med-mRCC) relative to most comparable clear cell metastatic RCC (cc-mRCC) patients. Within the Surveillance, Epidemiology and End Results (SEER) database (2000-2021), we identified 62 patients with med-mRCC vs. 10,372 with cc-mRCC. Propensity score matching (PSM, ratio 1:3), Kaplan-Meier plots and multivariable Cox regression analyses addressed were used. Of 10,434 patients, 62 (0.6%) harbored med-mRCC vs. 10,372 (99.4%) cc-mRCC. Med-mRCC patients were younger (27 vs. 63 years, p < 0.001), more frequently African American (74 vs. 6%, p < 0.001) and more frequently harbored N1 stages (52 vs. 28%, p < 0.001). After 1:3 PSM for age, race/ethnicity, T-stage and N-stage, 62 of 62 (100%) med-mRCC (median OS 4 months) and 186 of 10,372 (2%) cc-mRCC patients (median OS 10 months) remained for further analyses. In med-mRCC, median OS was 9 months with CN vs. 3 months without CN (p = 0.01). In cc-mRCC, median OS was 28 months with CN vs. 5 months without CN (p < 0.001). In med-mRCC, CN independently predicted better OS (Hazard's Ratio [HR] 0.5, p = 0.005), as well as in cc-mRCC (HR 0.4, p < 0.001). Med-mRCC patients exhibit a drastically different phenotype relative to their cc-mRCC counterparts. Despite this difference, med-mRCC exposed to CN harbor a similar relative protective survival effect compared to their cc-mRCC counterparts with most comparable age, race/ethnicity and tumor characteristics.", "journal": "World Journal of Urology", "pub_date": "2026-Sep-19", "publication_types": ["Journal Article"], "doi": "10.1016/j.eururo.2014.05.034", "authors": ["Quynh Chi Le", "Andrea Marmiroli", "Mattia Longoni", "Fabian Falkenbach", "Calogero Catanzaro", "Michele Nicolazzini", "Federico Polverino", "Jordan A Goyal", "Fred Saad", "Riccardo Schiavina", "Luca Fabio Carmignani", "Alberto Briganti", "Nicola Longo", "Markus Graefen", "Carlotta Palumbo", "Carolin Siech", "Severine Banek", "Miriam Traumann", "Felix K-H Chun", "Pierre I Karakiewicz"], "affiliations": ["Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada. d.le@med.uni-frankfurt.de.", "Department of Urology, Goethe University Frankfurt, University Hospital, Frankfurt am Main, Germany. d.le@med.uni-frankfurt.de.", "Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.", "Department of Urology, IEO European Institute of Oncology, IRCCS, Via Ripamonti 435, Milan, Italy.", "Università degli Studi di Milano, Milan, Italy.", "Division of Experimental Oncology/Unit of Urology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy.", "Vita-Salute San Raffaele University, Milan, Italy.", "Martini-Klinik Prostate Cancer Center, University Hospital Hamburg- Eppendorf, Hamburg, Germany.", "Department of Urology, University of Bologna, St. Orsola-Malpighi Hospital, Bologna, Italy.", "Division of Urology, Department of Translational Medicine, University of Eastern Piedmont, Maggiore della Carità Hospital, Novara, Italy.", "Division of Urology, Department of Oncology, University of Turin, Orbassano, Italy.", "Department of Neurosciences, Science of Reproduction and Odontostomatology, University of Naples Federico II, Naples, Italy.", "Department of Urology, Goethe University Frankfurt, University Hospital, Frankfurt am Main, Germany."], "corresponding_authors": ["Quynh Chi Le"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=3", "score": 31.0, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 10.0, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 3.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.9, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.0, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42762258", "title": "Does active surveillance prior to radical prostatectomy increase the risk of adverse pathological findings or postoperative prostate cancer treatment?", "abstract": "Active surveillance (AS) is an established management strategy for men with low- and favorable intermediate-risk prostate cancer (PCa). Nevertheless, a substantial proportion of patients ultimately undergo radical prostatectomy (RP), and the impact of prior AS on subsequent outcomes remains uncertain. We therefore compared surgical methods, adverse pathological findings and post-RP PCa-treatment among men undergoing deferred RP after AS with those of comparable men treated with immediate RP. Using nationwide data from the Norwegian Prostate Cancer Registry, we identified men diagnosed between 2009 and 2022 with low- or intermediate-risk PCa who underwent deferred RP following AS or immediate RP. Descriptive statistics summarized clinical characteristics and surgical methods. Multivariable logistic regression evaluated adverse pathological findings in the surgical specimen, and Cox proportional hazards models analyzed post-RP PCa-treatment. Kaplan-Meier analyses with log-rank test assessed 10-year PCa-specific survival. Compared with immediate RP (n = 5767), the deferred RP (n = 1839) group had more unfavorable preoperative tumor characteristics, fewer nerve-sparing procedures and more frequent lymph node dissection. Deferred RP after AS was associated with higher risk of adverse pathological findings (OR 1.99, 95% CI 1.8-2.3) and post-RP PCa-treatment (HR 1.52, 95% CI 1.3-1.8). Ten-year PCa-specific survival did not differ between groups. Limitations include incomplete data on surveillance intensity. Deferred RP after AS was associated with more extensive surgery, adverse pathological findings and post-RP PCa-treatment, but similar ten-year PCa-specific survival, compared to immediate RP. These findings emphasize the need for surveillance strategies that ensure timely detection of disease progression and transition to radical treatment.", "journal": "World Journal of Urology", "pub_date": "2026-Sep-19", "publication_types": ["Journal Article"], "doi": "10.1016/j.juro.2013.05.032", "authors": ["Ingrid Hannestad", "Tor Åge Myklebust", "Sophie D Fosså", "Stig Muller", "Kirsti Aas"], "affiliations": ["Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway. ingrid.hannestad@medisin.uio.no.", "Department of Urology, Akershus University Hospital (AHUS), Lorenskog, Norway. ingrid.hannestad@medisin.uio.no.", "Cancer Registry of Norway, Norwegian Institute of Public Health, Oslo, Norway.", "Department of Research and Innovation, More and Romsdal Hospital Trust, Ålesund, Norway.", "Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.", "Department of Oncology, Oslo University Hospital (OUH), Oslo, Norway.", "Department of Urology, Akershus University Hospital (AHUS), Lorenskog, Norway."], "corresponding_authors": ["Ingrid Hannestad"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=5", "score": 29.0, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.0, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 5.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.9, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.0, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42762250", "title": "Complication profiling in ureteroscopy: A prospective multicenter comparison of the Clavien-Dindo classification and the comprehensive complication index.", "abstract": "The Clavien-Dindo Classification remains the most widely accepted method for grading surgical complications. The Comprehensive Complication Index, a continuous scale integrating all postoperative events, may provide a more comprehensive overview. This study compared the sensitivity and clinical applicability of the Clavien-Dindo Classification and the Comprehensive Complication Index in assessing complications following ureteroscopic stone surgery. In this multicenter prospective study, data from patients undergoing ureteroscopic stone surgery were collected, including demographic, perioperative, and complication variables. Complications were graded using the Clavien-Dindo Classification, and cumulative morbidity was subsequently calculated using the Comprehensive Complication Index based on assigned Clavien-Dindo grades. Patients were stratified by minor (I-II) or major (≥ III) complications. Correlation analyses between complication scores and clinical parameters, including comorbidity indices and hospital stay, were performed. A total of 1607 patients were included; 98 (6.1%) experienced complications. Comprehensive Complication Index showed a numerically higher correlation with hospital stay in patients with minor complications, whereas Clavien-Dindo Classification showed a numerically higher correlation in patients with major complications; however, formal statistical comparison of these correlations did not demonstrate a significant difference between the two systems. In 39 patients, Comprehensive Complication Index exceeded corresponding the Clavien-Dindo Classification grade, suggesting improved sensitivity for overall morbidity. Both systems showed moderate correlations with comorbidity indices and hospital stay; however, the Comprehensive Complication Index performed better with multiple minor complications. Limitations of this study include its observational nature, the lack of long-term patient-reported quality of life outcomes, and potential variations in surgeon experience across the participating centers. Comprehensive Complication Index provides refined reflection of cumulative minor complications, while Clavien-Dindo Classification offers clearer categorization of major events. Neither system demonstrated absolute superiority; however, their combined application may enhance complication reporting and facilitate comprehensive outcome assessment in ureteroscopic stone surgery. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov (https//clinicaltrials.gov), NCT06394908.", "journal": "Urolithiasis", "pub_date": "2026-Sep-19", "publication_types": ["Journal Article", "Multicenter Study", "Comparative Study"], "doi": "10.1007/s00240-026-02056-4", "authors": ["Yiloren Tanidir", "Tunahan Ates", "Reha Girgin", "Murat Gulsen", "Onur Kalayci", "Cemil Aydin", "Metin Kizgin", "Volkan Sen", "Can Sinirsiz", "Ilker Akarken", "Eren Can Aydin", "Tarik Emre Sener", "Dogancan Dorucu", "Ahmet Furkan Ozsoy", "Yunus Emre Goger", "Nebil Akdogan"], "affiliations": ["Vocational School of Health Services, Department of Operating Room Services, Istanbul Kent University, Istanbul, Turkey. yiloren@gmail.com.", "Department of Urology, Medicana Atasehir Hospital, Istanbul, Turkey. yiloren@gmail.com.", "Department of Urology, Defne State Hospital, Hatay, Turkey.", "Department of Urology, Zonguldak Bulent Ecevit University, Zonguldak, Turkey.", "Department of Urology, Faculty of Medicine, Ondokuz Mayis University, Samsun, Turkey.", "Department of Urology, Samsun City Hospital, Samsun, Turkey.", "Department of Urology, School of Medicine, Hitit University, Çorum, Turkey.", "Department of Urology, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey.", "Department of Urology, Faculty of Medicine, Mugla Sıtkı Kocman University, Menteşe, Turkey.", "Department of Urology, School of Medicine, Marmara University, Istanbul, Turkey.", "Department of Urology, Ankara University School of Medicine, Ankara, Turkey.", "Department of Urology, School of Medicine, Necmettin Erbakan University, Konya, Turkey.", "Department of Urology, Faculty of Medicine, Cukurova University, Adana, Turkey."], "corresponding_authors": ["Yiloren Tanidir"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_clinical", "score": 30.71, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 5.71, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 11.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.2, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.71, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42762248", "title": "Comment on \"ABO blood group distribution in patients with upper urinary tract stones: a case-control study\".", "abstract": "", "journal": "Urolithiasis", "pub_date": "2026-Sep-19", "publication_types": ["Letter"], "doi": "10.1007/s00240-026-02062-6", "authors": ["Chujie Chen"], "affiliations": ["Department of Urology, The Seventh Affiliated Hospital, Sun Yat-sen University, 518107, Shenzhen, China. chchuj@alumni.sysu.edu.cn."], "corresponding_authors": ["Chujie Chen"], "china_team": "Department of Urology, The Seventh Affiliated Hospital, Sun Yat-sen University, 518107, Shenzhen, China Chujie Chen团队", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 13.71, "score_parts": {"urology_relevance": 3, "urology_in_title": 8.0, "journal_priority": 5.71, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.2, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.71, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42768826", "title": "Kidney organoids as a platform to study plasminogen-induced injury and uPA-based therapies.", "abstract": "Urinary plasminogen has been implicated in the progression of proteinuric kidney diseases, yet its direct role in mediating injury along the nephron remains incompletely understood. Experimental models commonly used to study plasminogen-mediated damage are limited by incomplete phenotypic fidelity or interspecies differences, hindering translational relevance. Here, we used kidney organoids generated from H9 human embryonic stem cells to investigate the effects of plasminogen exposure and to evaluate urokinase-type plasminogen activator (uPA) inhibition with amiloride as a therapeutic strategy. Kidney organoids were exposed to plasminogen in the presence or absence of amiloride, and uPA activity was quantified using a fluorescence-based assay. Compartment-specific injury was assessed by confocal microscopy, automated image analysis, and AI-assisted nuclear segmentation, while targeted transcriptomic changes were evaluated using bulk quantitative PCR. Plasminogen exposure induced glomerular injury, characterized by reduced podocalyxin, nephrin, podocin, and WT1 expression, decreased glomerular cell density, and increased apoptosis. Proximal tubules exhibited reduced LTL and megalin expression, with increased KIM-1, whereas distal tubules were relatively preserved. Amiloride effectively inhibited uPA activity and partially restored podocyte and proximal tubular marker expression, but did not prevent apoptosis, indicating incomplete protection against plasminogen-induced injury. These findings support preferential plasminogen-induced injury along the glomerular-proximal tubular axis and highlight the utility of human kidney organoids for modeling this process, while underscoring the need for further validation and broader molecular profiling to strengthen their application in mechanistic studies and therapeutic discovery.", "journal": "Stem Cells Translational Medicine", "pub_date": "2026-Sep-18", "publication_types": ["Journal Article"], "doi": "10.1007/s00467-018-4177-y", "authors": ["Marina de Cos", "Samuel Mon-Wei Yu", "Jacob Wright", "Nanditha Anandakrishnan", "Kristin Meliambro", "Jenny S Wong", "Evren Azeloglu", "Kirk N Campbell"], "affiliations": ["Dr. Barbara T. Murphy Division of Nephrology, Icahn School of Medicine at Mount Sinai, New York, NY, United States.", "Division of Renal-Electrolyte and Hypertension, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, United States."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "basic_signals=12", "score": 27.6, "score_parts": {"urology_relevance": 3, "urology_in_title": 0.0, "journal_priority": 10.6, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 12.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.9, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.6, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "类器官揭示纤溶酶原损伤肾单位轴", "chinese_summary": "《Stem Cells Translational Medicine》9月发表研究，利用H9人胚胎干细胞来源肾脏类器官，发现纤溶酶原暴露主要损伤肾小球-近端小管轴，表现为足细胞标志物下降、凋亡增加及近端小管KIM-1升高；阿米洛利抑制uPA活性后部分恢复标志物表达，但未能阻止凋亡，提示其保护作用不完全。", "abstract_zh": "尿液中的纤溶酶原被认为参与蛋白尿性肾脏疾病的进展，但其在肾单位中直接介导损伤的作用仍不完全清楚。常用于研究纤溶酶原介导损伤的实验模型受限于表型保真度不足或种间差异，阻碍了其转化相关性。在此，我们使用由H9人胚胎干细胞产生的肾脏类器官来研究纤溶酶原暴露的影响，并评估以阿米洛利抑制尿激酶型纤溶酶原激活物（uPA）作为治疗策略。肾脏类器官在存在或不存在阿米洛利的情况下暴露于纤溶酶原，并使用基于荧光的测定法定量uPA活性。通过共聚焦显微镜、自动图像分析和AI辅助的细胞核分割评估区室特异性损伤，同时使用批量定量PCR评估靶向转录组变化。纤溶酶原暴露诱导肾小球损伤，其特征为podocalyxin、nephrin、podocin和WT1表达减少、肾小球细胞密度降低以及凋亡增加。近端小管表现为LTL和megalin表达减少，同时KIM-1增加，而远端小管相对保留。阿米洛利有效抑制uPA活性，并部分恢复足细胞和近端小管标志物表达，但未能阻止凋亡，表明对纤溶酶原诱导损伤的保护不完全。这些发现支持纤溶酶原优先沿肾小球-近端小管轴诱导损伤，并突显了人肾脏类器官在模拟这一过程中的实用性，同时强调需要进一步验证和更广泛的分子谱分析，以加强其在机制研究和治疗发现中的应用。"}, {"pmid": "42761671", "title": "Earlier Prostatic Artery Embolization for Progressive Benign Prostatic Hyperplasia: A Biological Rationale and Hypothesis for Disease Interception.", "abstract": "Benign prostatic hyperplasia (BPH) is a heterogeneous progressive disease that can culminate in bladder outlet obstruction, acute urinary retention (AUR), and potentially irreversible bladder dysfunction. Current treatment pathways appropriately prioritize symptom burden, patient preference, and established complications; however, symptom severity correlates imperfectly with obstruction and detrusor reserve. Prostatic artery embolization (PAE) improves lower urinary tract symptoms with a lower immediate procedural and sexual adverse-event burden than transurethral surgery but produces less complete objective de-obstruction and a greater need for retreatment. These tradeoffs raise a distinct question: whether PAE should be studied earlier in carefully selected patients with objective evidence of progression before AUR or advanced detrusor decompensation occurs. This narrative review critically examines the natural history of BPH, bladder remodeling and its uncertain reversibility, limitations of symptom-based risk assessment, and comparative evidence for PAE, medical therapy, transurethral resection of the prostate, and holmium laser enucleation of the prostate. The evidence establishes that PAE is effective for symptomatic disease and can improve selected urodynamic measures; it does not establish that PAE prevents AUR, arrests bladder remodeling, or preserves long-term detrusor function. No validated marker currently identifies an impending point of irreversible decompensation, and earlier intervention could expose patients with stable disease to contrast, radiation, vascular complications, technical failure, and retreatment. The available evidence therefore supports clinical equipoise rather than a practice recommendation. A randomized trial using progression and bladder-function endpoints is needed to determine whether a reproducibly defined high-risk phenotype benefits from earlier PAE compared with optimized medical management.", "journal": "Cureus", "pub_date": "2026-Sep", "publication_types": ["Journal Article", "Review"], "doi": "10.7759/cureus.116496", "authors": ["Julian Sadowski"], "affiliations": ["Medicine, Independent Research, Ocala, USA."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 38.22, "score_parts": {"urology_relevance": 18.0, "urology_in_title": 8.0, "journal_priority": 2.22, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 8.0}, "journal_metrics": {"status": "ok", "impact_factor": 1.3, "cas_zone": 4, "cas_zone_points": 1.0, "impact_factor_points": 1.22, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42761652", "title": "CD200-CD200R as a myeloid immune checkpoint in solid tumors: mechanisms, context-dependent functions, and therapeutic opportunities.", "abstract": "CD200 and its receptor CD200R form a myeloid-centered immune checkpoint that normally restrains myeloid activation and limits tissue damage, but many solid tumors co-opt this pathway to suppress antitumor immunity. CD200-CD200R signaling is highly context-dependent, varying even among models of the same cancer type. In melanoma and breast carcinoma, it can either suppress protumor inflammation or promote tumor growth and metastasis depending on the model, whereas in neuroblastoma; glioblastoma and other central nervous system tumors; cutaneous and head and neck squamous cell carcinoma; colorectal cancer; and several endocrine, ovarian, and pancreatic cancers, it consistently suppresses macrophage, dendritic cell, natural killer cell, and CD8+ T-cell activation, impairs phagocytosis and antigen presentation, and drives immunosuppressive infiltration. Non-small cell lung cancer and renal cell carcinoma emerge as two additional, less-characterized but clinically important contexts warranting further investigation. CD200R1-CD200 has also recently been identified as a macrophage phagocytosis checkpoint that functions independently of CD47-SIRPα, placing it within the expanding family of innate immune checkpoints. Rather than treating CD200-CD200R as a universally protumorigenic target, we propose a context-dependent framework-incorporating tumor type, microenvironmental architecture, and dominant myeloid and lymphoid programs-to guide tumor-specific therapeutic strategies in solid cancers.", "journal": "Frontiers in Immunology", "pub_date": "2026", "publication_types": ["Journal Article", "Review"], "doi": "10.1186/s13045-020-00989-w", "authors": ["Manas Ranjan Sahu", "Inemai Ezhil", "Venu Akkanapally", "Aman Kumar", "Jin-Qing Liu", "Sujit Basu"], "affiliations": ["Department of Pathology, Ohio State University, Columbus, OH, United States.", "Division of Medical Oncology, Department of Internal Medicine, Ohio State University, Columbus, OH, United States.", "Comprehensive Cancer Center, Ohio State University, Columbus, OH, United States."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 16.83, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 10.83, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 5.9, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.83, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42760428", "title": "Current status and future directions of AI in prostate cancer detection on MRI: a special report from the ESUR prostate MRI working group authors.", "abstract": "This report from the ESUR Prostate MRI Working Group assesses the current role of artificial intelligence (AI) in MRI-based detection of prostate cancer. While deep learning tools demonstrate high technical accuracy, the report emphasizes a significant gap between research achievements and actual clinical application. Key statements include promoting a \"human-in-the-loop\" approach, where AI supports rather than replaces radiological expertise, to reduce risks such as automation bias and legal liability. There is an urgent need for prospective validation across multiple vendors and for implementing post-market surveillance to monitor algorithmic drift. Finally, the group identified research priorities focused on cost-effectiveness, transparency via explainable AI, and addressing the unique challenges of deploying these tools in population-based screening programs. KEY POINTS: Question What challenges hinder the clinical adoption of AI-based medical devices for prostate cancer detection? Findings Major obstacles include insufficient real-world validation, complex dynamics of human-AI interactions that require a human-in-the-loop approach, and the need for ongoing post-market surveillance for oncologic safety. Clinical relevance This report highlights the gap between AI's research promise and clinical readiness. It underscores the need for localvalidation, post-market surveillance, and adequate user training as AI tools become incorporated into diagnostic prostate MRI workflows.", "journal": "European Radiology", "pub_date": "2026-Sep-18", "publication_types": ["Journal Article"], "doi": "10.1186/s12880-025-01602-7", "authors": ["Renato Cuocolo", "Andrea Ponsiglione", "Georgios Agrotis", "Tristan Barrett", "Giorgio Brembilla", "Iztok Caglic", "Hanna Falińska", "Charlie Alexander Hamm", "Emanuele Messina", "Tobias Penzkofer", "Raphaële Renard-Penna", "Olivier Rouvière", "Luca Russo", "Evis Sala", "Johannes Uhlig", "Anwar R Padhani", "Maarten de Rooij", "ESUR Prostate MRI Working Group"], "affiliations": ["Department of Medicine, Surgery, and Dentistry, University of Salerno, Baronissi, Italy.", "Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy.", "Department of Radiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.", "GROW School for Oncology and Reproduction, Maastricht University, Maastricht, The Netherlands.", "Department of Radiology, Addenbrooke's Hospital and University of Cambridge, Cambridge, UK.", "Department of Radiology, IRCCS San Raffaele Scientific Institute, Milan, Italy.", "San Raffaele Vita-Salute University, Milan, Italy.", "Department of Radiology, University College London Hospital NHS Foundation Trust, London, UK.", "Centre for Medical Imaging, University College London, London, UK.", "Military Institute of Medicine-National Research Institute, Warsaw, Poland.", "Affidea Poland, Warsaw, Poland.", "Department of Radiology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.", "Berlin Institute of Health (BIH), Berlin, Germany.", "Department of Radiological Sciences, Oncology and Pathology, Sapienza University of Rome/Policlinico Umberto I, Rome, Italy.", "Department of Imagery, Hôpital Pitié-Salpétrière, Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Paris, France.", "Department of Urinary and Vascular Radiology, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France.", "University Lyon 1, Lyon, France.", "Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.", "Università Cattolica del Sacro Cuore, Rome, Italy.", "Department of Clinical and Interventional Radiology, University Medical Center Göttingen, Göttingen, Germany.", "Department of Diagnostic and Interventional Radiology, Tübingen University Hospital, Eberhard Karls University Tübingen, Tübingen, Germany.", "Paul Strickland Scanner Centre, Mount Vernon Cancer Centre, Northwood, UK.", "Department of Medical Imaging, Radboud University Medical Center, Nijmegen, The Netherlands. maarten.derooij@radboudumc.nl."], "corresponding_authors": ["Maarten de Rooij"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 25.55, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.55, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.7, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.55, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "AI前列腺癌MRI检测落地仍存鸿沟", "chinese_summary": "欧洲泌尿放射学会前列腺MRI工作组9月Eur Radiol发布特别报告，指出AI在MRI前列腺癌检测中虽技术准确率高，但研究成绩与临床实际应用间差距显著。报告主张采用“人在回路”模式，AI辅助而非替代放射科专业判断，以降低自动化偏倚和法律风险，并呼吁开展多厂商前瞻性验证及上市后监测以追踪算法漂移。", "abstract_zh": "这份来自欧洲泌尿放射学会（ESUR）前列腺MRI工作组的报告评估了人工智能（AI）在基于MRI的前列腺癌检测中的当前作用。尽管深度学习工具展现出较高的技术准确性，报告强调研究成果与实际临床应用之间存在显著差距。关键声明包括推广“人在回路”方法，即AI支持而非替代放射学专业知识，以降低自动化偏倚和法律责任等风险。迫切需要在多个厂商间开展前瞻性验证，并实施上市后监测以监控算法漂移。最后，工作组确定了研究重点，聚焦于成本效益、通过可解释AI实现透明度，以及应对在人群筛查项目中部署这些工具所面临的独特挑战。要点：问题 是什么挑战阻碍了基于AI的医疗器械在前列腺癌检测中的临床采用？发现 主要障碍包括真实世界验证不足、需要“人在回路”方法的人机交互复杂动态，以及为肿瘤学安全性进行持续上市后监测的必要性。临床相关性 本报告强调了AI的研究前景与临床就绪度之间的差距。它强调随着AI工具被纳入诊断性前列腺MRI工作流程，需要进行本地验证、上市后监测和充分的用户培训。"}, {"pmid": "42760390", "title": "Ferroptosis in kidney disease.", "abstract": "Kidney disease is a growing global public health concern that is associated with high rates of severe morbidity and mortality. Accumulating preclinical and clinical evidence suggests that ferroptosis, an iron-dependent form of regulated cell death characterized by lethal lipid peroxidation, drives the pathogenesis and progression of diverse kidney disorders, including acute kidney injury, chronic kidney disease, renal cell carcinoma and autosomal-dominant polycystic kidney disease. Ferroptosis of renal tubular epithelial cells and intrarenal immune cells engages complex crosstalk with other regulated cell death pathways, amplifying responses and aggravating renal tissue damage. Several biomarkers of early kidney injury, such as the iron regulator NGAL and the phosphatidylserine-binding protein KIM1, are associated with features of ferroptotic cell death, suggesting their potential utility as indirect indicators of early ferroptotic lesions in the kidney. Furthermore, multimodal imaging platforms that integrate optical, magnetic resonance, photoacoustic and radionuclide techniques enable specific in vivo detection of ferroptotic hallmarks, facilitating early diagnosis of kidney lesions. Numerous preclinical studies have identified a diverse range of synthetic small-molecule agents, natural phytochemicals and metabolic modulators that are able to modify ferroptotic signalling. These agents have been shown to mitigate renal parenchymal injury or suppress the proliferation of malignant kidney cells, robustly establishing ferroptosis as a promising therapeutic target for kidney diseases.", "journal": "Nature Reviews Nephrology", "pub_date": "2026-Sep-18", "publication_types": ["Journal Article", "Review"], "doi": "10.1038/s41392-024-01969-z", "authors": ["Tianyi Wang", "Shumin Sun", "Andreas Linkermann", "Junxia Min", "Fudi Wang"], "affiliations": ["The Second Affiliated Hospital, School of Public Health, State Key Laboratory of Experimental Hematology, Zhejiang University School of Medicine, Hangzhou, China.", "The First Affiliated Hospital, Institute of Translational Medicine, Zhejiang Key Laboratory of Frontier Medical Research on Cancer Metabolism, Zhejiang University School of Medicine, Hangzhou, China.", "Global Innovation Institute of Element Science (GIIES-JLU), The First Hospital of Jilin University, Changchun, China.", "General Surgery, Cancer Center, Department of Gastrointestinal and Pancreatic Surgery, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, China.", "Department of Medicine V, University Medical Centre Mannheim, Heidelberg University, Mannheim, Germany.", "Department of Internal Medicine 3, University Hospital Carl Gustav Carus at the Technische Universität Dresden, Dresden, Germany.", "Division of Nephrology, Department of Medicine, Albert Einstein College of Medicine, Bronx, NY, USA.", "The First Affiliated Hospital, Institute of Translational Medicine, Zhejiang Key Laboratory of Frontier Medical Research on Cancer Metabolism, Zhejiang University School of Medicine, Hangzhou, China. junxiamin@zju.edu.cn.", "The Second Affiliated Hospital, School of Public Health, State Key Laboratory of Experimental Hematology, Zhejiang University School of Medicine, Hangzhou, China. fwang@zju.edu.cn.", "Global Innovation Institute of Element Science (GIIES-JLU), The First Hospital of Jilin University, Changchun, China. fwang@zju.edu.cn."], "corresponding_authors": ["Junxia Min", "Fudi Wang"], "china_team": "The Second Affiliated Hospital, School of Public Health, State Key Laboratory of Experimental Hematology, Zhejiang University School of Medicine, Hangzhou, China Junxia Min/Fudi Wang团队", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 33.94, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 17.44, "top_journal_bonus": 10.0, "novelty": 0.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 39.8, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 5.44, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "铁死亡驱动多种肾脏疾病进展", "chinese_summary": "浙江大学医学院闵军霞、王福俤团队9月Nat Rev Nephrol综述指出，铁死亡以致死性脂质过氧化为特征，参与急性肾损伤、慢性肾病、肾细胞癌及常染色体显性多囊肾病的发生发展。肾小管上皮细胞和肾内免疫细胞的铁死亡与其他调节性细胞死亡通路存在复杂串扰，放大损伤反应。", "abstract_zh": "肾脏疾病是一个日益严重的全球公共卫生问题，与高发的严重疾病负担和死亡率相关。越来越多的临床前和临床证据表明，铁死亡——一种以致死性脂质过氧化为特征的铁依赖性调节性细胞死亡形式——驱动着多种肾脏疾病的发病和进展，包括急性肾损伤、慢性肾脏病、肾细胞癌和常染色体显性多囊肾病。肾小管上皮细胞和肾内免疫细胞的铁死亡与其他调节性细胞死亡通路发生复杂的串扰，放大反应并加重肾组织损伤。若干早期肾损伤生物标志物，如铁调节蛋白NGAL和磷脂酰丝氨酸结合蛋白KIM1，与铁死亡细胞死亡的特征相关，提示它们有潜力作为肾脏早期铁死亡病变的间接指标。此外，整合光学、磁共振、光声和放射性核素技术的多模态成像平台能够对铁死亡标志物进行特异性在体检测，促进肾脏病变的早期诊断。大量临床前研究已鉴定出多种合成小分子药物、天然植物化学物和代谢调节剂，它们能够改变铁死亡信号。这些药物已被证明可减轻肾实质损伤或抑制恶性肾细胞增殖，有力地确立了铁死亡作为肾脏疾病有前景的治疗靶点。"}, {"pmid": "42760245", "title": "Is This the End of the Cisplatin Eligibility Era in Muscle-invasive Bladder Cancer? Letter in reference to: Matthew D. Galsky, Begoña P. Valderrama, Marco Maruzzo, et al. Enfortumab vedotin and pembrolizumab in cisplatin-eligible bladder cancer. N Engl J Med 2026;395:338-48. doi:10.1056/NEJMoa2601486; and Galsky MD, Hahn NM, Rosenberg J, et al. A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol 2011;12:211-214. doi:10.1016/S1470-2045(10)70275-8.", "abstract": "", "journal": "European Urology", "pub_date": "2026-Sep-18", "publication_types": ["Letter"], "doi": "10.1016/j.eururo.2026.08.019", "authors": ["Patrizia Giannatempo", "Linda Cerbone", "Fabio Calabrò"], "affiliations": ["Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. Electronic address: patrizia.giannatempo@istitutotumori.mi.it.", "Ospedale Regina Elena, Rome, Italy.", "Ospedale Regina Elena, Rome, Italy. Electronic address: fabio.calabro@ifo.it."], "corresponding_authors": ["Patrizia Giannatempo", "Fabio Calabrò"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 39.79, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 16.79, "top_journal_bonus": 10.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 25.2, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.79, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "肌层浸润性膀胱癌顺铂资格时代或终结", "chinese_summary": "欧洲泌尿外科学会9月Eur Urol就EV-302研究发表评论指出，恩弗妥单抗联合帕博利珠单抗在顺铂合格患者中取得显著疗效，传统以顺铂资格划分治疗决策的框架正被挑战，或预示肌层浸润性膀胱癌治疗分层的范式转变。", "abstract_zh": "致编辑：我们饶有兴趣地阅读了Galsky等人发表在《新英格兰医学杂志》上的报告，该研究报告了恩弗妥单抗维多汀联合帕博利珠单抗在顺铂合格膀胱癌患者中的疗效。长期以来，肌层浸润性和转移性尿路上皮癌的治疗决策一直以患者是否符合顺铂治疗条件为核心。Galsky等人2011年在《柳叶刀·肿瘤学》上提出的顺铂不耐受共识定义，被广泛用于指导临床决策和临床试验入组。然而，随着恩弗妥单抗维多汀联合帕博利珠单抗等新型抗体药物偶联物联合免疫治疗方案在顺铂合格与不合格人群中均显示出显著生存获益，基于顺铂资格的治疗分层是否仍有必要，值得重新审视。这些数据可能标志着肌层浸润性膀胱癌以顺铂资格为导向的治疗时代即将结束。"}, {"pmid": "42760023", "title": "The PART randomised trial protocol: Partial Ablation versus Radical Treatment for prostate cancer.", "abstract": "Primary objective: to determine whether prostate gland partial ablation (PA) has non-inferior oncological treatment success vs radical treatment (RT) of localised intermediate-risk prostate cancer (irPCa). to compare (i) participant-reported urinary and sexual dysfunction side effects, (ii) short/medium term serious adverse events, (iii) health-related quality of life (HRQoL), (iv) cost-effectiveness; and to report (v) the need for repeat PA, (vi) accuracy of magnetic resonance imaging and biopsy protocols in determining suitability for PA, (vii) disease progression, local spread and metastases, (viii) medium-term disease-specific and overall mortality. The 'Partial prostate Ablation versus Radical Treatment' (PART; International Standard Randomised Controlled Trial Number ISRCTN17249875) is a UK-wide, multicentre, pragmatic, randomised controlled trial investigating whether PA (high-intensity focused ultrasound [HIFU] or irreversible electroporation [IRE]) is non-inferior to RT (radical prostatectomy, radical radiotherapy, or low-dose-rate brachytherapy [LDR-B]) in treating localised irPCa. A Qualitative Research Integrated within Trials (QuinteT) Recruitment Intervention is included to optimise recruitment and informed consent. Primary outcome treatment success for PA will be determined by prostate biopsies and imaging, and for RT using standard definitions. Participants will receive treatment according to their randomised allocation, with HIFU or IRE for PA depending on lesion location, and radical prostatectomy, radical radiotherapy, or LDR-B according to patient and physician preference for RT. Based on 95% and 85% oncological treatment success for RT and PA, respectively, with a non-inferiority margin of 20%, at median 3 years of follow-up, PART requires 275 recruited men (137 per group, randomised on a 1:1 basis), for 80% power, with a one-sided alpha of 0.025. Allowing for a 10% total withdrawal or dropout rate, PART requires 306 recruited and randomised participants. The PART trial will provide robust prospective data and high-level randomised evidence to determine oncological treatment effectiveness of PA vs RT for localised irPCa, along with comparative side effect, HRQoL, and health economics evaluations, to inform clinical decision-making.", "journal": "BJU International", "pub_date": "2026-Sep-18", "publication_types": ["Journal Article"], "doi": "10.1111/bju.70448", "authors": ["Richard J Bryant", "Tom Leslie", "Marc Laniado", "Abhishek Sharma", "Alistair Grey", "John Withington", "Christopher Blick", "Edward Streeter", "Sanjeev Kotwal", "Oliver Hulson", "William Cross", "Daniel W Good", "Altan Omer", "Taimur T Shah", "Nishant Bedi", "Luke Stroman", "Caroline Moore", "Prasanna Sooriakumaran", "Hashim U Ahmed", "Simon F Brewster", "Vicki S Barber", "Aimi Hewitt", "Clare Calvert", "Jessica Scaife", "Derek Shepherd", "Filipa Landeiro", "Jane Wolstenholme", "Philip Camilleri", "Clare Verrill", "Shelagh Lovell", "Martin Pirkl", "Fergus Gleeson", "Roxanne Williams", "Jo Cook", "Catherine R Holt", "Martyn Hill", "Jonathan Cook", "James Radford", "Ioana R Marian", "Ruth Macpherson", "Daisy Elliott", "Jenny L Donovan", "Freddie C Hamdy"], "affiliations": ["Department of Urology, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.", "Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.", "Surgical Intervention Trials Unit, University of Oxford, Oxford, UK.", "Department of Urology, Wexham Park Hospital, Frimley Health NHS Foundation Trust, Slough, UK.", "Harold Hopkins Department of Urology, Royal Berkshire Hospital, Royal Berkshire NHS Foundation Trust, Reading, UK.", "Department of Urology, NHS Lothian, Western General Hospital, Edinburgh, UK.", "Department of Urology, University College London Hospitals NHS Foundation Trust, London, UK.", "Department of Urology, The Royal London Hospital, Barts Health NHS Trust, London, UK.", "Department of Urology, East Kent Hospitals University NHS Foundation Trust, Kent and Canterbury Hospital, Canterbury, UK.", "Department of Urology, Leeds Teaching Hospitals NHS Trust, Leeds, UK.", "Department of Urology, University Hospitals Coventry and Warwickshire NHS Trust, University Hospital, Coventry, UK.", "Imperial Prostate, Division of Surgery, Department of Surgery and Cancer, Imperial College London, London, UK.", "Imperial Urology, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, UK.", "Division of Surgery and Interventional Science, University College London, London, UK.", "Oxford Clinical Trials Research Unit (OCTRU), Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.", "Patient and Public Involvement Representative, PART Trial, Oxford, UK.", "Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford, Oxford, UK.", "Department of Oncology, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.", "Department of Cellular Pathology, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, UK.", "Department of Radiology, Oxford University Hospitals NHS Foundation Trust, Churchill Hospital, Oxford, UK.", "Population Health Sciences, University of Bristol, Bristol, UK.", "NIHR Bristol Biomedical Research Centre, University Hospitals Bristol and Weston NHS Foundation Trust and, University of Bristol, Bristol, UK."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=6", "score": 33.47, "score_parts": {"urology_relevance": 7, "urology_in_title": 8.0, "journal_priority": 10.47, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 6.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.4, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.47, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42759951", "title": "The role of PSA density in the follow up of men with a negative MRI in the Göteborg-2 trial.", "abstract": "To assess whether prostate-specific antigen density (PSAD) stratifies long-term risk of clinically significant prostate cancer (csPCa) after a negative magnetic resonance imaging (MRI; Prostate Imaging-Reporting and Data System score ≤2) and to evaluate the potential of PSAD to guide follow-up in a screening setting. This pre-specified sub-analysis of the population-based, randomised Göteborg-2 screening trial included 1685 men who underwent PSA testing between October 2015 and June 2021 and had a subsequent negative initial MRI. Follow-up continued until 30 September 2024. The primary endpoint was cumulative incidence of csPCa (Gleason score ≥3 + 4). Men were categorised by baseline PSAD (<0.10, 0.10 to <0.15, and ≥0.15 ng/mL2). Cumulative incidence was estimated using Kaplan-Meier methods and compared using the log-rank test. The clinical implications of PSAD-based follow-up strategies were explored. Over a median follow-up of 5.5 years, 160 PCas were diagnosed, of which 80 were csPCa, including 22 cases of Gleason score ≥4 + 3. At 7 years, cumulative csPCa incidence was 7.1% overall and 5.5%, 13.8%, and 11.9% in the PSAD <0.10, 0.10 to <0.15, and ≥0.15 ng/mL2 groups, respectively (P < 0.001 for PSAD <0.10 ng/mL2 vs both higher groups). Overall, 87% of repeat MRIs remained negative. Although men with baseline PSAD <0.10 ng/mL2 had the lowest overall risk, 42 csPCas occurred in this group, including 12 Gleason score ≥4 + 3, emphasising the importance of continued regular PSA-based follow-up. A PSAD-guided strategy with biennial PSA testing and repeat MRI triggered by PSAD ≥0.10 ng/mL2 could reduce MRI use by 60% and biopsies by 46%, halve detection of clinically insignificant PCa, and delay csPCa diagnosis in 17% of cases including 10 men with Gleason score 3 + 4 and one with Gleason score ≥4 + 3. The PSAD stratifies long-term risk of csPCa after a negative MRI and supports risk-adapted follow-up in PCa screening.", "journal": "BJU International", "pub_date": "2026-Sep-18", "publication_types": ["Journal Article"], "doi": "10.1111/bju.70450", "authors": ["Fredrik Möller", "Marianne Månsson", "Mikael Hellström", "Fredrik Langkilde", "Vasiliki Spyratou", "Johan Stranne", "Jonas Wallström", "Jonas Hugosson", "Rebecka Arnsrud Godtman"], "affiliations": ["Department of Urology, Institute of Clinical Science, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.", "Department of Urology, Skaraborg Skövde Hospital, Region Västra Götaland, Skövde, Sweden.", "Department of Radiology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.", "Department of Radiology, Sahlgrenska University Hospital, Region Västra Götaland, Gothenburg, Sweden.", "Department of Pathology, Sahlgrenska University Hospital, Region Västra Götaland, Gothenburg, Sweden.", "Department of Urology, Sahlgrenska University Hospital, Region Västra Götaland, Gothenburg, Sweden."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 16.47, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 10.47, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.4, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.47, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42759773", "title": "Lateral-Based Onlay for Recurrent Hypospadias Surgery (LABOR); A Multicentre Study.", "abstract": "To report long-term outcomes of the Lateral Based Onlay Flap (LABOR) technique for recurrent midshaft and proximal hypospadias across multiple centers. A retrospective review was conducted of patients undergoing LABOR repair for recurrent/complicated mid-penile and proximal hypospadias between 2014 and 2024 in 3 centers across 2 continents. Patients with severe curvature requiring urethral plate division or inadequate penile skin were excluded. Two glandular wings are mobilized. The lateral penile skin is mobilized and advanced, medially, maintaining its blood supply and sutured to midline skin and folded as an onlay flap to reconstruct the neourethra to the glans tip. Among 397 referred patients, 97 patients met the inclusion criteria. Median age was 3 years (range 22 months-49 years). Follow-up ranged from 1-11 years. Forty-four patients (45%) maintained long-term follow-up for more than 5 years. Complete healing without complications occurred in 77 patients (79%). Complications occurred in 20 patients (21%) including glans dehiscence (8%), fistula (9%), and meatal stenosis (3%). All were successfully corrected with a single procedure. LABOR is an effective option to correct recurrent mid-penile and proximal hypospadias without severe chordee with acceptable complication rates (21%) and favorable long-term outcomes.", "journal": "Urology", "pub_date": "2026-Sep-18", "publication_types": ["Journal Article"], "doi": "10.1016/j.urology.2026.09.011", "authors": ["Mohamed Fawzy", "Michael Sennert", "Marios Marcou", "Carsten Graumann", "Vvs Chandrasekharam", "Ramesh Babu", "Ahmed T Hadidi"], "affiliations": ["Hypospadias Centre, Department of Pediatric Surgery, Sana Klinikum Offenbach Hospital, Germany; Department for urology and paediatric urology, University of Bonn, Bonn, Germany. Electronic address: mohamedfawzy841@hotmail.com.", "Hypospadias Centre, Department of Pediatric Surgery, Sana Klinikum Offenbach Hospital, Germany.", "Departments of Paediatric Urology, University of Regensburg, Germany.", "Paediatric Surgery 6 Urology Department, Ankura Hospitals for Women& Children, Hyderabad, Telangana, India.", "Departments of Paediatric Urology, Sri Ramachandra Institute of Higher Education & Research, Chennai, India."], "corresponding_authors": ["Mohamed Fawzy"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=6", "score": 20.61, "score_parts": {"urology_relevance": 7, "urology_in_title": 0.0, "journal_priority": 5.61, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 6.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.0, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.61, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42759772", "title": "Trends in the Utilization of Minimally Invasive Therapies for Overactive Bladder Among Older Adults: A National Medicare Study.", "abstract": "To examine population-based trends in utilization of minimally invasive therapies (MITs) for overactive bladder (OAB) stratified by age and frailty among Medicare beneficiaries. This population-based study used a 20% sample of fee-for-service Medicare beneficiaries to investigate rates of utilization for MIT for OAB [onabotulinumtoxinA injections (BTX), percutaneous tibial nerve stimulation (PTNS), and sacral neuromodulation (SNM)] from 2015 to 2020. Adjusted incidence rates of each MIT were further stratified by age and frailty, measured by the Claims-based Frailty Index (CFI), using multivariable logistic regression. Among 5,944,458 beneficiaries, 39,211 (0.7%) underwent an MIT for OAB during the study period. Overall adjusted incidence increased from 141.2 per 100,000 in 2015-159.3 per 100,000 in 2019 (a 13% relative increase), driven largely by BTX (40% relative increase). Incidence decreased across all MITs in 2020. Among beneficiaries aged 66-84, greater levels of frailty were associated with higher use of all 3 therapies. However, this association was not observed in beneficiaries over age 85, where rates of use were uniformly low regardless of frailty status. Use of MITs for OAB increased from 2015 to 2019, mainly driven by increases in BTX. For all 3 types of MITs, greater levels of frailty were associated with increased utilization among beneficiaries <85 years, regardless of age, while rates for all 3 procedures were low regardless of frailty for beneficiaries ≥85, indicating that utilization of these procedures is driven more by age than frailty in the oldest age group. Further research is needed to determine the factors which influence MIT utilization rates.", "journal": "Urology", "pub_date": "2026-Sep-18", "publication_types": ["Journal Article"], "doi": "10.1016/j.urology.2026.09.014", "authors": ["Adam Crow", "Lufan Wang", "Abigail Shatkin-Margolis", "Unwanaobong Nseyo", "Stephanie W Zuo", "W John Boscardin", "Ken Covinsky", "Anne M Suskind"], "affiliations": ["University of California, Davis School of Medicine, Sacramento, CA. Electronic address: ascrow@health.ucdavis.edu.", "Department of Biostatistics and Epidemiology, University of California, San Francisco, CA.", "Department of Obstetrics and Gynecology, University of California, San Francisco, San Francisco, CA.", "Department of Urology, Weill Cornell School of Medicine, New York, NY.", "Department of Obstetrics and Gynecology, University of Virginia, Charlottesville, VA.", "Division of Geriatrics, Department of Medicine, University of California, San Francisco, CA.", "Department of Urology, University of California, San Francisco, CA."], "corresponding_authors": ["Adam Crow"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 19.61, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 5.61, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.0, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.61, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42759742", "title": "Laparoscopic modified Davydov's technique for vaginoplasty: operative steps and technical pearls.", "abstract": "Müllerian agenesis syndrome is a congenital condition characterized by uterine and vaginal agenesis in women with a normal 46,XX karyotype, normal ovarian function, and normal secondary sexual characteristics. It represents one of the most challenging causes of primary amenorrhea, with significant anatomic, functional, and psychological implications. Several surgical and nonsurgical techniques have been proposed for vaginal reconstruction; however, no universally accepted standard exists. Among surgical options, the laparoscopic Davydov procedure has gained wide acceptance because of its minimal invasiveness and favorable anatomic and functional outcomes. This video article presents a standardized laparoscopic Davydov neovaginoplasty, illustrating key anatomic landmarks and technical steps. We report the case of a 21-year-old woman with Müllerian agenesis, no relevant medical history, and primary amenorrhea, who underwent a combined laparoscopic and vaginal approach. After laparoscopic inspection, the peritoneum between the bladder and rectum was incised, and the rectovesical space was developed. A 12-mm trocar was inserted transperineally to guide the anastomosis of the mobilized peritoneum to the vaginal vestibular mucosa, thereby creating a continuous neovaginal canal. At 6-month follow-up, vaginoscopy showed a well-epithelialized, iodine-positive neovaginal mucosa with a final vaginal length of 11 cm. No urinary or functional complications were reported. This video shows a standardized and teachable laparoscopic technique that may contribute to improving functional and psychosocial outcomes in patients with Müllerian agenesis.", "journal": "American Journal of Obstetrics and Gynecology", "pub_date": "2026-Sep-18", "publication_types": ["Journal Article"], "doi": "10.1016/j.ajog.2026.09.020", "authors": ["Stefano Scarperi", "Stefano Ferla", "Diego Raimondo", "Valentino Bergamini"], "affiliations": ["Division of Gynaecology and Obstetrics (B), Azienda Ospedaliera Universitaria Integrata di Verona, Italy; Dipartimento ad attività integrata materno-infantile, Verona, Italy.", "Division of Gynaecology and Human Reproduction Physiopathology, IRCCS Azienda Ospedaliero - Universitaria di Bologna, Italy; Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy. Electronic address: stefano.ferla2@studio.unibo.it.", "Division of Gynaecology and Human Reproduction Physiopathology, IRCCS Azienda Ospedaliero - Universitaria di Bologna, Italy."], "corresponding_authors": ["Stefano Ferla"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=3", "score": 27.29, "score_parts": {"urology_relevance": 7, "urology_in_title": 0.0, "journal_priority": 15.29, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 3.0}, "journal_metrics": {"status": "ok", "impact_factor": 8.4, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.29, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42759605", "title": "Healthy Lifestyle, Genetic Susceptibility and Risk of Kidney Stone Disease in the UK Biobank: A Prospective Cohort Study.", "abstract": "To explore the association between modifiable lifestyle and kidney stone disease (KSD) risk, and to investigate whether genetic susceptibility modifies this association. We included 300,875 participants without KSD from the UK Biobank cohort (recruited between March 13, 2006, and October 10, 2010) in this analysis. A healthy lifestyle score was constructed based on seven lifestyle items: regular physical activity, BMI < 25 kg/m2, lower sedentary time, adequate sleep duration, no smoking, adequate fluid intake, and a healthy diet. Based on this score, participants were classified into unfavorable, intermediate, and favorable lifestyle groups. Genetic susceptibility to KSD was assessed by a polygenic risk score. We employed Cox proportional hazards models to estimate HRs and 95% CIs for incident KSD. A total of 3,088 incident KSD cases were identified during a median follow-up of 12.3 years. Compared with the unfavorable lifestyle group, the multivariable-adjusted HR (95% CI) was 0.51 (0.44-0.59) for incident KSD in the favorable lifestyle group. No significant multiplicative interaction was observed (P for multiplicative interaction = .39), while a significant additive interaction was observed between an unfavorable lifestyle and high genetic susceptibility to KSD risk (relative excess risk due to interaction [RERI] = 1.14, 95% CI: 0.49-1.79). Compared with individuals with favorable lifestyle and low genetic susceptibility, the HR (95% CI) for those with unfavorable lifestyle and high genetic risk was 3.08 (2.49-3.80). Healthy lifestyle was inversely associated with KSD risk, and a significant additive interaction was observed between lifestyle and genetic susceptibility.", "journal": "Mayo Clinic Proceedings", "pub_date": "2026-Sep-18", "publication_types": ["Journal Article"], "doi": "10.1016/j.mayocp.2026.08.023", "authors": ["Kun Xu", "Zichuan Yao", "Yuge Wang", "Lei Na", "Junlong Liu", "Yang Xia", "Xing Jin", "Zhenhua Li", "Yashu Liu", "Song Bai"], "affiliations": ["Department of Urology, Shengjing Hospital of China Medical University, Shenyang, China.", "Department of Pathology, Shengjing Hospital of China Medical University, Shenyang, China.", "Department of Clinical Epidemiology, Shengjing Hospital of China Medical University, Shenyang, China; Liaoning Key Laboratory of Precision Medical Research on Major Chronic Disease, Shenyang, China.", "Department of Medical Equipment, Shengjing Hospital of China Medical University, Shenyang, China.", "Department of General Surgery, Shengjing Hospital of China Medical University, Shenyang, China.", "Department of Urology, Shengjing Hospital of China Medical University, Shenyang, China. Electronic address: baisongcmu81@163.com."], "corresponding_authors": ["Song Bai"], "china_team": "Department of Urology, Shengjing Hospital of China Medical University, Shenyang, China Song Bai团队", "category": "clinical_review", "classification_reason": "clinical_signals=7", "score": 31.99, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.99, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 7.0}, "journal_metrics": {"status": "ok", "impact_factor": 6.7, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.99, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42759309", "title": "Postoperative progression-free survival and clinicopathological risk stratification in urachal carcinoma: A multicenter retrospective cohort study.", "abstract": "To evaluate postoperative progression-free survival (PFS), identify clinicopathological factors associated with PFS, and explore the association between postoperative adjuvant therapy and PFS after surgery for urachal carcinoma. We retrospectively included 72 patients with histopathologically confirmed malignant urachal tumors treated at 2 medical centers between January 2009 and December 2025. PFS was estimated using the Kaplan-Meier method, and associated factors were evaluated using prespecified Cox regression models. The cohort included 65 adenocarcinomas and 7 urothelial carcinomas. All patients had Sheldon stage III (n = 65) or IV (n = 7) disease, and 28 received postoperative adjuvant therapy. The median follow-up was 48 months (95% confidence interval [CI], 30-75), during which 26 patients experienced disease progression or death. The 1-, 3-, and 5-year PFS rates were 85.7% (95% CI, 77.9%-94.3%), 66.2% (95% CI, 54.9%-79.9%), and 55.7% (95% CI, 43.2%-71.8%), respectively. In the primary multivariable model, Sheldon stage IV disease was associated with shorter PFS (HR, 4.32; 95% CI, 1.23-15.14; P = 0.022). No statistically significant association between postoperative adjuvant therapy and PFS was observed after multivariable adjustment (HR, 1.14; 95% CI, 0.50-2.58; P = 0.754). Among patients with Sheldon stage III-IV disease, the 5-year postoperative PFS rate was 55.7%. Sheldon stage IV disease was associated with shorter PFS. No statistically significant association between postoperative adjuvant therapy and PFS was observed after multivariable adjustment; however, this finding should be interpreted cautiously.", "journal": "Urologic Oncology", "pub_date": "2026-Sep-18", "publication_types": ["Journal Article"], "doi": "10.1016/j.urolonc.2026.08.024", "authors": ["Hongyu Zhang", "Zexuan Lv", "Zijian Wang", "Yin Lu", "Jinlu Tang", "Yi Feng", "Bingyang Guo", "Qing Ai", "Junzhen Fan", "Aitao Guo", "Qiang Cheng", "Hongzhao Li"], "affiliations": ["Department of Urology, Chinese PLA General Hospital, Beijing, China; Department of Urology, The Third Medical Center, Chinese PLA General Hospital, Beijing, China; School of Medicine, Nankai University, Tianjin, China.", "Department of Urology, Chinese PLA General Hospital, Beijing, China; Department of Urology, The Third Medical Center, Chinese PLA General Hospital, Beijing, China; Chinese PLA Medical School, Beijing, China.", "Department of Urology, Chinese PLA General Hospital, Beijing, China; Department of Urology, The Third Medical Center, Chinese PLA General Hospital, Beijing, China.", "Department of Urology, The Third Medical Center, Chinese PLA General Hospital, Beijing, China; Department of Pathology, The Third Medical Center, Chinese PLA General Hospital, Beijing, China.", "Department of Urology, Chinese PLA General Hospital, Beijing, China; Department of Urology, The Third Medical Center, Chinese PLA General Hospital, Beijing, China; Chinese PLA Medical School, Beijing, China. Electronic address: cxqyisheng@126.com.", "Department of Urology, Chinese PLA General Hospital, Beijing, China; Department of Urology, The Third Medical Center, Chinese PLA General Hospital, Beijing, China. Electronic address: lihongzhao@301hospital.com.cn."], "corresponding_authors": ["Qiang Cheng", "Hongzhao Li"], "china_team": "Department of Urology, Chinese PLA General Hospital, Beijing, China; Department of Urology, The Third Medical Center, Chinese PLA General Hospital, Beijing, China; School of Medicine, Nankai University, Tianjin, China Qiang Cheng/Hongzhao Li团队", "category": "clinical_review", "classification_reason": "clinical_signals=11", "score": 22.75, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 5.75, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 11.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.3, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.75, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42759308", "title": "Efficacy and safety analysis of disitamab vedotin combined with immunotherapy as neoadjuvant treatment to promote conversion to bladder preservation in bladder cancer: A retrospective comparative study with the GC combined with immunotherapy regimen.", "abstract": "For cisplatin-eligible muscle-invasive bladder cancer, cisplatin-based neoadjuvant chemotherapy followed by radical cystectomy has been a standard approach. With the advent of more effective systemic therapies, bladder-preserving strategies after favorable response have become an area of increasing interest. We retrospectively analyzed 46 patients with bladder cancer (BCG-unresponsive T1N0M0 and T2-4N0-2M0). Patients received neoadjuvant disitamab vedotin (DV) plus toripalimab (Group A, n = 23) or gemcitabine/cisplatin (GC) plus toripalimab (Group B, n = 23). The primary endpoint was strict clinical complete response (cCR). The main efficacy analysis was restricted to patients with T2-4 disease, whereas T1 outcomes were summarized descriptively. Exploratory propensity-score overlap weighting was performed in the full cohort. Among patients with T2-4 disease, strict cCR was achieved in 10 of 16 patients (62.5%) in Group A and 2 of 17 patients (11.8%) in Group B (P = 0.004). Strict cCR with initial bladder preservation was observed in 9 of 16 patients (56.3%) and 2 of 17 patients (11.8%), respectively. In the T1 subgroup, strict cCR rates were similar between the groups (85.7% vs. 83.3%). Exploratory overlap-weighted analyses of the full cohort showed weighted risk differences of 31.9 percentage points for strict cCR (95% confidence intervals, 7.1-56.7; P = 0.012) and 29.5 percentage points for strict cCR with initial bladder preservation (95% confidence intervals, 4.8-54.2; P = 0.019). The median follow-up duration for the overall cohort was 26.5 months. Among patients with strict cCR who were initially managed with bladder preservation, no muscle-invasive bladder recurrence or progression and no nodal or distant progression were observed. No adverse-event comparison remained statistically significant after false discovery rate adjustment. In this single-center retrospective cohort, DV plus toripalimab was associated with higher observed rates of strict cCR and strict cCR with initial bladder preservation than GC plus toripalimab among patients with T2-4 disease. These findings are hypothesis-generating and require validation in prospective multicenter studies with longer follow-up.", "journal": "Urologic Oncology", "pub_date": "2026-Sep-18", "publication_types": ["Journal Article"], "doi": "10.1016/j.urolonc.2026.08.015", "authors": ["Jing Li", "Kaikai Chen", "Shun Zhang", "Yu Shen", "Zhiwei Chen", "Ding Xu", "Hailong Liu", "Haibo Shen"], "affiliations": ["Department of Urology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.", "Department of Urology, Jing'an District Central Hospital, Fudan University, Shanghai, China.", "Department of Urology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China. Electronic address: shenhaibo@xinhuamed.com.cn."], "corresponding_authors": ["Haibo Shen"], "china_team": "Department of Urology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China Haibo Shen团队", "category": "clinical_review", "classification_reason": "clinical_signals=12", "score": 35.75, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 5.75, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 12.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.3, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.75, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42759307", "title": "Risk of androgen deprivation therapy after active surveillance for prostate cancer: A real-world analysis.", "abstract": "Active surveillance (AS) allows men with favorable-risk prostate cancer (PC) to avoid or delay the toxicity of upfront treatment. However, whether these patients are at higher risk of subsequent treatment intensification with androgen deprivation therapy (ADT) is unknown. Herein, we examine real-world burden of ADT in men pursuing initial AS in the United States. Retrospective cohort study of 38,573 men with localized PC managed with initial AS between 2009 and 2022 using the Merative MarketScan commercial and Medicare claims database. Median age was 60 (Inter quartile range [IQR] 56-65) and 64% had no/minimal comorbidity. The cumulative incidence of receiving any ADT after AS was 15.0% (95% Confidence Interval [95% CI:] 12.7%-17.7%). Patients diagnosed and managed in more contemporary years had a higher risk of subsequent ADT use. The cumulative incidence of definitive radiotherapy alone was 15.2% (95% CI: 13.8%-16.8%) and radiotherapy with concurrent ADT was 7.0% (95% CI: 5.7%-8.6%). Amongst those who received radiotherapy, the proportion receiving concurrent ADT within 5 and 10 years of diagnosis was 26% and 39%, respectively. Real-world US data show 1 in 6 men with PC ultimately underwent ADT after pursuing initial AS. Amongst men who ultimately received definitive radiotherapy, 1 in 3 received concurrent ADT. Improved patient selection-enhanced by modern imaging and biomarkers-may optimize outcomes while minimizing treatment intensification in men pursuing AS.", "journal": "Urologic Oncology", "pub_date": "2026-Sep-18", "publication_types": ["Journal Article"], "doi": "10.1016/j.urolonc.2026.08.014", "authors": ["James R Janopaul-Naylor", "Dattatraya Patil", "Nikhil T Sebastian", "Kamran Salari", "Bruce Hershatter", "Christopher Gaffney", "Martin G Sanda", "Shreyas S Joshi", "Pretesh R Patel", "Ashesh B Jani", "Sagar A Patel"], "affiliations": ["Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY.", "Department of Urology, Emory University, Atlanta, GA.", "Department of Radiation Oncology, Emory University, Atlanta, GA.", "Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY.", "Department of Urology, Emory University, Atlanta, GA; Department of Radiation Oncology, Emory University, Atlanta, GA. Electronic address: sagar.patel@emory.edu."], "corresponding_authors": ["Sagar A Patel"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=7", "score": 27.25, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 5.75, "top_journal_bonus": 0.0, "novelty": 0.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 7.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.3, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.75, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42759306", "title": "Diagnostic value of CEUS-VI-RADS for predicting muscle invasion in bladder cancer: Validation of the scoring system and introduction of tumor-bladder wall contact length as a supplementary quantitative metric.", "abstract": "To validate the diagnostic performance of the Contrast-Enhanced Ultrasound-based Vesical Imaging-Reporting and Data System (CEUS-VI-RADS) and to explore the incremental value of the tumor-bladder wall contact length (TBCL) as a quantitative metric in predicting muscle invasion in bladder cancer. This retrospective study analyzed 112 patients with bladder cancer who underwent preoperative CEUS between February 2021 and December 2025. Two radiologists, blinded to clinic-pathological results, independently assigned CEUS-VI-RADS scores to the index lesions and measured the TBCL on CEUS images. Logistic regression analysis was performed to identify independent predictors of muscle invasion. The diagnostic performance of each parameter was compared using receiver operating characteristic curve analysis. Inter-observer agreement was substantial for CEUS-VI-RADS scoring (kappa = 0.703) and excellent for TBCL measurements (intraclass correlation coefficient = 0.82-0.88). Quantitative analysis identified both the CEUS-VI-RADS score (odds ratio: 11.2) and TBCL (odds ratio: 1.02-1.07) as independent predictors of muscle invasion. The area under the curve for CEUS-VI-RADS in predicting muscle invasion was 0.86; using a score of 4 as the optimal cutoff, the diagnostic accuracy was 0.84. The area under the curve for TBCL was 0.75, and its diagnostic accuracy showed no significant difference compared to CEUS-VI-RADS (P > 0.01). CEUS-VI-RADS is a robust tool for predicting muscle invasion in bladder cancer. As an easily accessible and independent quantitative metric, TBCL serves as an effective supplement to CEUS-VI-RADS, collectively enhancing predictive accuracy.", "journal": "Urologic Oncology", "pub_date": "2026-Sep-18", "publication_types": ["Journal Article"], "doi": "10.1016/j.urolonc.2026.08.023", "authors": ["Wenhao Qu", "Ju Zhu", "Yahan Yang", "Fang Nie"], "affiliations": ["The Second Clinical Medical School, Lanzhou University, Lanzhou, China; Department of Ultrasound Medical Center, The Second Hospital of Lanzhou University, Gansu Province Medical Engineering Research Center for Intelligence Ultrasound, Gansu Province Clinical Research Center for Ultrasonography, Lanzhou, Gansu Province, China.", "Department of Ultrasound, First Medical Center, Chinese PLA General Hospital, Beijing, China.", "Department of Ultrasound Medical Center, The Second Hospital of Lanzhou University, Gansu Province Medical Engineering Research Center for Intelligence Ultrasound, Gansu Province Clinical Research Center for Ultrasonography, Lanzhou, Gansu Province, China. Electronic address: ery_nief@lzu.edu.cn."], "corresponding_authors": ["Fang Nie"], "china_team": "The Second Clinical Medical School, Lanzhou University, Lanzhou, China; Department of Ultrasound Medical Center, The Second Hospital of Lanzhou University, Gansu Province Medical Engineering Research Center for Intelligence Ultrasound, Gansu Province Clinical Research Center for Ultrasonography, Lanzhou, Gansu Province, China Fang Nie团队", "category": "clinical_review", "classification_reason": "clinical_signals=6", "score": 25.75, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 5.75, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 6.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.3, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.75, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42758864", "title": "Beyond the T-Score: Reconsidering the Timing of Bone-Protective Therapy in Men Receiving Androgen Deprivation Therapy for Hormone-Sensitive Prostate Cancer.", "abstract": "", "journal": "Journal of Urology", "pub_date": "2026-Sep-18", "publication_types": ["Editorial"], "doi": "10.1097/JU.0000000000005319", "authors": ["Ricaurte Crespo-Trevino", "Ann Malbas"], "affiliations": ["Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, Rochester, Minnesota."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 20.01, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 11.01, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 6.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 3.01, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42758829", "title": "α-Parvin regulation of cell rearrangement is critical for ureteric bud branching morphogenesis.", "abstract": "All branched tubular structures, including the kidney collecting system, are formed by branching morphogenesis, a process that includes tip branching and trunk narrowing. Tight control of cell movement and rearrangement is a prerequisite for branching morphogenesis. The role of integrin-associated adhesion proteins in coordinating actin dynamics and cell rearrangement during branching morphogenesis is poorly understood. Here, we used three-dimensional live imaging of mouse ureteric bud branching to show that α-parvin, a component of the integrin binding ILK-PINCH-parvin complex, regulates tip branching and tubule thinning by inhibiting excessive cell adhesion and actin polymerization. Mechanistically, α-parvin promotes actin turnover by inhibiting activation of the small guanosine triphosphatases RhoA and Cdc42, which in turn enhances the severing function of the actin regulatory protein, cofilin. These results underscore the importance of adhesion protein-regulated actin dynamics in the critical process of cell rearrangement, which is required for branching morphogenesis.", "journal": "Science Advances", "pub_date": "2026-Sep-18", "publication_types": ["Journal Article"], "doi": "10.1126/sciadv.aec9007", "authors": ["Xinyu Dong", "Fabian Bock", "Ali Hashmi", "Nada Bulus", "Glenda Mernaugh", "Gema Bolas", "Shensen Li", "Wanying Zhu", "Meiling Melzer", "Kyle Brown", "Colton Miller", "Olga Viquéz", "Eloi Montañez", "Ambra Pozzi", "Sara A Wickström", "Roy Zent"], "affiliations": ["Division of Nephrology and Hypertension, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA.", "Department of Cell and Developmental Biology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA.", "Department of Veterans Affairs Hospital, Nashville, TN 37203, USA.", "Stem Cells and Metabolism Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.", "Division of Genetic Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA.", "Department of Physiological Sciences, Faculty of Medicine and Health Sciences, University of Barcelona and Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain.", "Department of Cell and Tissue Dynamics, Max Planck Institute for Molecular Biomedicine, Münster, Germany.", "Helsinki Institute of Life Science, Biomedicum Helsinki, University of Helsinki, 00290 Helsinki, Finland."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "basic_signals=5", "score": 34.82, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 15.82, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 5.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 12.5, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.82, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "α-Parvin调控细胞重排促输尿管芽分支", "chinese_summary": "9月Science Advances报道，小鼠输尿管芽三维活体成像显示，整合素结合复合物组分α-parvin通过抑制RhoA与Cdc42活化促进肌动蛋白周转，限制细胞过度黏附与聚合，从而调控尖端分支及管腔变细，揭示黏附蛋白调控的肌动蛋白动力学对分支形态发生中细胞重排的关键作用。", "abstract_zh": "所有分支管状结构，包括肾脏集合系统，均通过分支形态发生形成，这一过程包括尖端分支和主干变细。对细胞运动和重排的严格控制是分支形态发生的前提条件。整合素相关黏附蛋白在分支形态发生过程中协调肌动蛋白动力学和细胞重排中的作用尚不清楚。在此，我们利用小鼠输尿管芽分支的三维活体成像显示，α-parvin——整合素结合ILK-PINCH-parvin复合物的一个组分——通过抑制过度细胞黏附和肌动蛋白聚合来调控尖端分支和管状结构变细。在机制上，α-parvin通过抑制小鸟苷三磷酸酶RhoA和Cdc42的活化来促进肌动蛋白周转，进而增强肌动蛋白调控蛋白cofilin的切割功能。这些结果强调了黏附蛋白调控的肌动蛋白动力学在细胞重排这一关键过程中的重要性，而细胞重排是分支形态发生所必需的。"}, {"pmid": "42758339", "title": "When long pulse is not enough: inferior dusting efficiency of pulsed thulium:YAG compared with Ho:YAG and thulium fiber laser in a standardized in vitro renal model.", "abstract": "Pulsed thulium: YAG (p-Tm: YAG) and thulium fiber laser (TFL) differ in pulse architecture despite similar wavelengths. We asked whether long-pulse p-Tm: YAG achieves ablation efficiency and thermal behaviour comparable to holmium: YAG (Ho: YAG) and TFL under standardized low-power dusting settings. Fifty-four BegoStone phantoms were treated in an in vitro renal collecting system model, 18 per platform, at 0.8 J and 25 Hz through a 7.5 Fr single-use flexible ureteroscope with gravity irrigation and no access sheath. Pulse duration was not standardized: Ho: YAG and p-Tm: YAG were long-pulse, TFL short-pulse. Ablated dry mass, laser-on time, delivered energy, temperature every 10 s and thermal dose (CEM43, per run) were recorded. p-Tm: YAG ablated 0.099 g versus 0.138 g (Ho: YAG) and 0.140 g (TFL) (p = 0.005), a 29% reduction, despite delivered energy indistinguishable from Ho: YAG (5.61 versus 5.62 kJ; p = 1.000). Energy efficiency was 0.0176 versus 0.0248 and 0.0242 g·kJ⁻¹ (p = 0.007). Both thulium platforms heated more than Ho: YAG (ΔT 18.8 and 18.9 versus 12.8 °C; p = 0.001) but did not differ from each other. Temperature exceeded 43 °C in 17 of 36 thulium runs (peak 51.7 °C); mean per-run CEM43 was 24.4 and 14.5 min. For equivalent delivered energy, long-pulse p-Tm: YAG was associated with lower ablation efficiency than Ho: YAG or short-pulse TFL. Because pulse duration was confounded with platform, these findings implicate pulse architecture rather than intrinsic inferiority. Frequent excursions above 43 °C with both thulium platforms warrant attention.", "journal": "World Journal of Urology", "pub_date": "2026-Sep-18", "publication_types": ["Journal Article", "Comparative Study"], "doi": "10.1007/s00345-026-06796-1", "authors": ["Renato I Navarro", "Isidora Huete", "Miguel Eyzaguirre", "Carla Manterola", "Felipe Pauchard", "José Salvadó", "Gastón M Astroza"], "affiliations": ["Department of Urology, Pontificia Universidad Católica de Chile, Diagonal Paraguay 362, Piso 3, Santiago, Chile.", "School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile.", "Department of Urology, Hospital Naval de Viña del Mar, Viña del Mar, Chile.", "Department of Urology, Clinica Santa Maria, Santiago, Chile.", "Department of Urology, Pontificia Universidad Católica de Chile, Diagonal Paraguay 362, Piso 3, Santiago, Chile. gaeulufi@gmail.com."], "corresponding_authors": ["Gastón M Astroza"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_clinical", "score": 16.0, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 10.0, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.9, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.0, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42758293", "title": "Quantitative MRI for renal cell carcinoma grading: from feasibility towards reproducibility.", "abstract": "", "journal": "European Radiology", "pub_date": "2026-Sep-18", "publication_types": ["Editorial", "Comment"], "doi": "10.1007/s00330-020-06666-3", "authors": ["Francesco Verde", "Arnaldo Stanzione"], "affiliations": ["Department of General and Emergency Radiology, \"Antonio Cardarelli\" Hospital, Naples, Italy. francescoverde87@gmail.com.", "Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy."], "corresponding_authors": ["Francesco Verde"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 19.55, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.55, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.7, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.55, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42758284", "title": "Quantitative MRI for World Health Organisation/International Society of Urological Pathology Grading of Renal Cell Carcinoma: a systematic review and diagnostic meta-analysis.", "abstract": "To synthesise evidence on quantitative MRI biomarkers for predicting World Health Organisation/International Society of Urological Pathology (WHO/ISUP) grade in renal cell carcinoma (RCC). We systematically searched PubMed, Embase, Scopus, and Web of Science from inception to August 2025 for patients with histopathologically proven RCC who underwent preoperative MRI. Eligible studies evaluated quantitative MRI biomarkers (diffusion, relaxometry, chemical exchange saturation transfer, radiomics) against WHO/ISUP grade. For diffusion-weighted imaging and radiomics/deep learning, we performed random-effects diagnostic meta-analyses and pooled mean differences in apparent diffusion coefficient (ADC) between low- and high-grade tumours. Twenty studies were included; quantitative meta-analysis was feasible for 12 (seven ADC studies and five MRI-inclusive radiomics/deep learning studies). Seven diffusion-weighted MRI studies evaluating apparent diffusion coefficient-based grading of RCC yielded a pooled sensitivity of 0.84 (95% confidence interval [CI] 0.77-0.89) and specificity of 0.57 (95% CI 0.51-0.63) for identifying high-grade disease; the summary area under the curve (AUC) was 0.71. Low-grade tumours showed significantly higher apparent diffusion coefficient values than high-grade tumours (mean difference 0.21 × 10⁻³ mm²/s; 95% CI 0.11-0.30 × 10⁻³ mm²/s). Across five MRI-inclusive radiomics/deep learning studies, pooled sensitivity was 0.79 (95% CI 0.64-0.89) and specificity was 0.86 (95% CI 0.74-0.93), with an AUC of 0.90. Quantitative MRI, particularly diffusion-derived metrics, shows modest accuracy for identifying WHO/ISUP grade in RCC. MRI-inclusive radiomics/deep learning models achieve higher diagnostic performance, albeit with less consistency across studies. Standardised multiparametric protocols, external validation, and decision-impact studies are required before clinical implementation. Question Can quantitative MRI biomarkers, particularly diffusion metrics, non-invasively identify World Health Organisation/International Society of Urological Pathology grade in renal cell carcinoma? Findings Across 20 studies, diffusion showed modest grading performance, whereas MRI-inclusive radiomics/deep learning models achieved higher pooled diagnostic accuracy but remained heterogeneous. Clinical relevance Quantitative magnetic resonance imaging supports non-invasive renal cell carcinoma grading and biopsy triage; externally validated radiomics/deep learning models may improve preoperative risk stratification.", "journal": "European Radiology", "pub_date": "2026-Sep-18", "publication_types": ["Journal Article"], "doi": "10.1038/s41598-017-10134-2", "authors": ["Iman Kiani", "Motohiro Fujiwara", "Saeed Mohammadzadeh", "Niloufar Pourakbar", "Thomas C Kwee", "Satoshi Masuyama", "Noam Nissan", "Sungmin Woo", "Soichiro Yoshida", "Yuki Arita"], "affiliations": ["Students' Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran.", "Medical School, Tehran University of Medical Sciences, Tehran, Iran.", "Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. motohiro.fujiwara@gmail.com.", "Department of Urology, Institute of Science Tokyo, Bunkyo-ku, Tokyo, Japan. motohiro.fujiwara@gmail.com.", "Department of Urology, Teikyo University Hospital, Mizonokuchi, Kawasaki, Kanagawa, Japan. motohiro.fujiwara@gmail.com.", "Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.", "Department of Radiology, Nuclear Medicine and Molecular Imaging, University of Groningen, Groningen, The Netherlands.", "Division of Nephrology and Hypertension, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.", "Department of Radiology, Sheba Medical Center, Emek Ha-Ella, Ramat Gan, Israel.", "Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.", "Department of Radiology, NYU Langone Health, New York, NY, USA.", "Department of Urology, Institute of Science Tokyo, Bunkyo-ku, Tokyo, Japan.", "Department of Urology, Institute of Science Tokyo, Bunkyo-ku, Tokyo, Japan. yukiarita1113@gmail.com.", "Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. yukiarita1113@gmail.com.", "Department of Radiology, University of California, San Diego, San Diego, CA, USA. yukiarita1113@gmail.com."], "corresponding_authors": ["Motohiro Fujiwara", "Yuki Arita"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 33.05, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 10.55, "top_journal_bonus": 0.0, "novelty": 0.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 4.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.7, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.55, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42758241", "title": "10,000 robotic surgeries in Brazil: lessons learned and the path forward.", "abstract": "Robotic surgery is expanding rapidly, but access remains concentrated in high-income countries and privately financed urban centres. In June 2025, our Brazilian multi-institutional consortium completed 10,000 robot-assisted procedures across five surgical specialties. These editorial reviews the development of robotic surgery in Brazil and the lessons derived from this experience. Sustainable implementation required structured training, multidisciplinary team development, appropriate case selection, standardized workflows, outcome monitoring, institutional support, and financial planning. Brazil's adoption of national training standards and the incorporation of robot-assisted radical prostatectomy into the public health system represent important steps toward broader access. The Brazilian experience shows that robotic surgery can expand in middle-income settings, but its value will depend on equitable access and local workforce development.", "journal": "Journal of Robotic Surgery", "pub_date": "2026-Sep-18", "publication_types": ["Editorial", "Review"], "doi": "10.1007/s11701-026-03904-6", "authors": ["Marcos Belotto", "Luís Felipe Leite", "Carlos Eduardo Domene", "Paula Volpe", "Rafael Coelho"], "affiliations": ["Department of Surgery, Hospital 9 de Julho, São Paulo (SP), Brazil. marcbelotto@hotmail.com.", "Department of Surgery, Hospital Albert Einstein, São Paulo (SP), Brazil. marcbelotto@hotmail.com.", "Department of Medical Sciences, Universidade Federal Fluminense, Niterói, RJ, Brazil.", "Integrated Center for Advanced Medicine (CIMAMED), 74 Dona Adma Jafet Street, Suite 162, Bela Vista, São Paulo, 01308-050, SP, Brazil.", "Department of Surgery, Hospital 9 de Julho, São Paulo (SP), Brazil.", "University of Sao Paulo School of Medicine, Sao Paulo, Brazil."], "corresponding_authors": ["Marcos Belotto"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 13.03, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 6.03, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 1.0}, "journal_metrics": {"status": "ok", "impact_factor": 3.0, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 2.03, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42758231", "title": "Impact of resection bed management on postoperative outcomes after Robot-Assisted Partial Nephrectomy : a retrospective French Nationwide Study (UroCCR 215).", "abstract": "Kidney cancer remains a significant public health issue, mainly treated by surgery for localized tumors. RAPN is increasingly adopted due to its nephron-sparing advantage, yet optimal management of the renal resection bed remains controversial. Various techniques including parenchymal and/or capsular sutures or sutureless approaches, with or without adjunctive hemostatic agents (HA), are used, but their comparative safety and efficacy are not well established. This retrospective study analyzed data from 5,250 patients who underwent first RAPN in 26 centres, extracted from national UroCCR database. Patients were categorized into eight groups based on resection bed management techniques, with the main groups being double-layer sutures (DLS) and parenchymal sutures, with or without HA. Postoperative complications were classified using the Clavien-Dindo system. Multivariate logistic regression was performed adjusting for key confounders including age, sex, BMI, ASA score, RENAL-score, and preoperative creatinine. Secondary outcomes included length of hospital stay and comparison of HA use within suture and sutureless groups. Intraoperative complications were rare (3.9%). Postoperative complications occurred in 19.1% of patients, with 3.1% experiencing severe complications (≥ grade 3). The \"Sutureless without HA\" group had a significantly higher rate of perioperative transfusions in multivariate analysis (17.8% vs. 6.8%; adjusted OR 3.3), although this did not translate into increased reinterventions or perirenal hematomas. No significant differences were found between groups regarding infectious or length of stay. Vascular complications were lower in \"DLS with HA\". The use of HA in sutureless groups was associated with shorter operative times and reduced transfusion rates, and no difference was observed in suture groups. In this large, multicenter cohort, various hemostatic techniques during RAPN showed overall comparable safety profiles, except for a higher transfusion rate associated with sutureless without HA approaches, and a protective effect on vascular complications of DLS with HA.", "journal": "World Journal of Urology", "pub_date": "2026-Sep-18", "publication_types": ["Journal Article", "Multicenter Study"], "doi": "10.1007/s00345-026-06780-9", "authors": ["Dimitri Paillusson", "Gaëlle Margue", "Cécile Champy", "Nicolas Doumerc", "Pierre Bigot", "Franck Bruyere", "Philippe Paparel", "Louis Surlemont", "Jonathan Olivier", "Matthieu Durand", "Nicolas Branger", "Thibaut Waeckel", "Alexis Fontenil", "Maxime Vallee", "Idir Ouzaid", "Jean-Jacques Patard", "Julien Guillotreau", "Frédéric Panthier", "Olivier Belas", "Romain Boissier", "Fayek Taha", "Nicolas Letang", "Bastien Parier", "Hervé Lang", "Constance Dameron", "Grégory Verhoest", "Clément Sarrazin", "Jean-Christophe Bernhard", "Soline Bobet", "Mathilde Karakachoff", "Stéphane de Vergie"], "affiliations": ["Department of Urology, CHU Nantes, Nantes, France. dimitri.paillusson@chu-nantes.fr.", "Department of Urology, CHU Bordeaux, Bordeaux, France.", "Department of Urology, CIC Henri Mondor - APHP, CHU Henri Mondor - APHP, Créteil, France.", "Department of Urology, CHU Toulouse, Toulouse, France.", "Department of Urology, CHU Angers, Angers, France.", "Department of Urology, CHRU Tours, Tours, France.", "Department of Urology, CHU Lyon, Lyon, France.", "Department of Urology, CHU Rouen, Rouen, France.", "Department of Urology, CHU Lille, Lille, France.", "Department of Urology, CHU Nice, Nice, France.", "Department of Urology, Institut Paoli Calmettes, Marseille, France.", "Department of Urology, CHU Caen, Caen, France.", "Department of Urology, CHU Nîmes, Nîmes, France.", "Department of Urology, CHU Poitiers, Poitiers, France.", "Department of Urology, Hôpital Bichat - APHP, Paris, France.", "Department of Urology, CH Mont-de-Marsan, Mont-de-Marsan, CH, France.", "Department of Urology, Clinique Pasteur, Toulouse, France.", "Department of Urology, Hôpital Tenon - APHP, Paris, France.", "Department of Urology, Pôle Santé Sud, Le Mans, France.", "Department of Urology,, CHU La Conception - APHM, Marseille, France.", "Department of Urology, CHU Reims, Reims, France.", "Department of Urology, Médipôle St Roch - Polyclinique Cabestany, Cabestany, France.", "Department of Urology, Hôpital Bicêtre - APHP, Le Kremlin-Bicêtre, France.", "Department of Urology, CHU Strasbourg, Strasbourg, France.", "Department of Urology, Hôpital Européen Georges Pompidou - APHP, Paris, France.", "Department of Urology, CHU Rennes, Rennes, France.", "Department of Urology, CHU Grenoble Alpes, Grenoble, France.", "Clinique Des Données, CHU Nantes, Nantes, France.", "Department of Urology, CHU Nantes, Nantes, France."], "corresponding_authors": ["Dimitri Paillusson"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_clinical", "score": 38.0, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 10.0, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 9.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.9, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.0, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42758229", "title": "Clarifying risk and treatment trajectories in ductal prostate cancer.", "abstract": "", "journal": "World Journal of Urology", "pub_date": "2026-Sep-18", "publication_types": ["Letter"], "doi": "10.1007/s00345-026-06769-4", "authors": ["Ying Zhang", "Yun Zhuge"], "affiliations": ["Department of Urology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, 310000, China.", "Department of Urology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, 310000, China. 13858189623@163.com."], "corresponding_authors": ["Yun Zhuge"], "china_team": "Department of Urology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, 310000, China Yun Zhuge团队", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 19.0, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.0, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.9, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.0, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42758192", "title": "The role of urodynamics in overactive bladder: a critical in-depth analysis of the FUTURE study.", "abstract": "The FUTURE study, a large randomised controlled trial in women with refractory overactive bladder, concluded that urodynamics does not improve outcomes when added to clinical assessment and is not cost-effective. These findings have been presented as justification for abandoning urodynamics in this large and heterogeneous patient population. In this paper, we undertake a detailed appraisal of the FUTURE study, examining its overarching research premise, the design and methodology it employed to evaluate the clinical utility of urodynamics and the way in which its findings were reported and interpreted by the authors. We conclude that significant conceptual and methodological limitations undermine the validity of the study and the reliability and generalisability of the data. Consequently, changes in clinical practice are not justified on the basis of the FUTURE study.", "journal": "World Journal of Urology", "pub_date": "2026-Sep-18", "publication_types": ["Journal Article", "Review"], "doi": "10.1007/s00345-026-06772-9", "authors": ["Claire Hentzen", "Benoit Peyronnet", "Maurizio Serati", "Tufan Tarcan", "Thomas M Kessler", "Eskinder Solomon", "Ruth Kirschner-Hermanns", "Cosimo De Nunzio", "Enrico Finazzi-Agro"], "affiliations": ["Sorbonne University, GRC 01, GREEN Group of clinical REsEarch in Neurourology, AP- HP, Hôpital Pitié Salpêtrière, F-75013, Paris, France. claire.hentzen@aphp.fr.", "University Hospital of Rennes, Rennes, France.", "Department of Obstetrics and Gynaecology, Del Ponte Hospital, University of Insubria, Varese, Italy.", "Department of Urology, Marmara University School of Medicine, Istanbul Türkiye &, Koç University School of Medicine, Istanbul, Türkiye.", "Department of Neuro-Urology, Spinal Cord Injury Center, Balgrist University Hospital, University of Zürich, Zürich, Switzerland.", "Guy's and St Thomas NHS Foundation Trust, London, UK.", "University Clinic, Neuro-Urology Johanniter Neurologic Rehabilitation Center, Bonn, Bad Godesberg, Germany.", "Sapienza University of Rome, Ospedale Sant'Andrea, Rome, Italy.", "Dept. of Surgical Sciences, University of Rome Tor Vergata and UOSD Urologia, Policlinico Tor Vergata Hospital, Rome, Italy."], "corresponding_authors": ["Claire Hentzen"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 24.0, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.0, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.9, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.0, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42758082", "title": "Trends in Pediatric Urology Resident Operative Exposure and Autonomy: An 11-Year National Study.", "abstract": "Fewer urology residents are pursuing pediatric urology fellowship. Studies have examined potential associations between surgical residents' operative experience, autonomy, and exposure and fellowship pursuit. This relationship has not been examined with respect to pediatric urology. Furthermore, no study has characterized national trends in pediatric urology operative exposure and autonomy. We analyzed how pediatric urology case log volume and autonomy has changed over time for urology residents. A retrospective, national cohort study was completed utilizing Accreditation Council for Graduate Medical Education (ACGME) urology case log data. Variables analyzed included case category (major vs. minor), operative role, and autonomy score. ANOVA was performed to analyze differences in resident role and procedure type over time. Our study included 3,391 graduating urology chief residents from 145 ACGME accredited programs who completed training from 2013 to 2023. The mean pediatric major cases per resident by graduation declined from 72.43 (SD 35.09) in 2013 to 54.14 (SD 28.05) in 2023. Pediatric minor cases remained stable, with 127.79 (SD 62.93) cases in 2013 and 124.14 (SD 65.28) in 2023. Autonomy scores declined from 2013 to 2023 for both categories (86% to 73% for major cases; 94% to 82% for minor cases). Over time, urology residents are experiencing less operative exposure to pediatric major cases, while exposure to minor cases has remained stable. Resident autonomy during pediatric cases has decreased for both categories. Future studies should explore how decreased exposure and autonomy impacts resident confidence and preparedness, as well as the likelihood of pursuing pediatric urology fellowship.", "journal": "Urology Practice", "pub_date": "2026-Sep-18", "publication_types": ["Journal Article"], "doi": "10.1097/UPJ.0000000000001090", "authors": ["Tejal H Patel", "Hannah Glick", "Yoon Soo Park", "Sean O Hogan", "Gina M Badalato", "Wesley A Mayer", "Kate H Kraft"], "affiliations": ["University of Michigan Medical School, Ann Arbor, MI.", "Department of Urology, University of Michigan, Ann Arbor, MI.", "Department of Medical Education, University of Illinois College of Medicine, Chicago, IL.", "Accreditation Council for Graduate Medical Education, Chicago IL.", "Department of Urology, Columbia University Vagelos College of Physicians and Surgeons, New York City, NY.", "Scott Department of Urology, Baylor College of Medicine, Houston, TX."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=4", "score": 20.46, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 2.46, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 4.0}, "journal_metrics": {"status": "ok", "impact_factor": 1.7, "cas_zone": 4, "cas_zone_points": 1.0, "impact_factor_points": 1.46, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42757853", "title": "Dual Functions of B7-H3-MAPK Signaling Orchestrate Tumor Immunosuppression via Regulating the Plasticity of Myeloid-derived Suppressor Cells and Fibroblasts.", "abstract": "B7-H3/CD276 is an emerging immunotherapy target in cancers. However, limited knowledge of B7-H3 signaling and its role in modulating the tumor microenvironment hinders the clinical application of B7-H3-targeting therapy. Here, we report that B7-H3 plays dual roles in regulating myeloid-derived suppressor cells (MDSCs) and cancer-associated fibroblasts (CAFs), thereby promoting tumor progression and therapy resistance, respectively. We comprehensively characterized a non-canonical function of B7-H3 that triggers MAPK signaling in monocytic MDSCs and induces cellular senescence. The senescent monocytic M-MDSCs secreted chemokines to recruit immunosuppressive granulocytic MDSCs. Genetic deletion or pharmacological inhibition of B7-H3/Cd276 reduced Gr-MDSCs and delayed tumor progression. Nevertheless, the secretory factor SPINK1 derived from MDSCs compensatorily activates EGFR/MEK/ERK signaling in CAFs and promotes their extracellular matrix remodeling features, dampening B7-H3-targeting immunotherapy. Combining the B7-H3 monoclonal antibody with the FDA-approved MEK inhibitor trametinib showed durable anti-tumor effects in preclinical models of castration-resistant prostate cancer by fully attenuating immunosuppressive mechanisms.", "journal": "Cancer Discovery", "pub_date": "2026-Sep-18", "publication_types": ["Journal Article"], "doi": "10.1016/j.cell.2021.08.023", "authors": ["Wei Shi", "Ping Xu", "Qianlin Gu", "Zhen Fan", "Xin Liang", "Yin Wang", "Yuehui Zhao", "Chenling Meng", "Javier Leo", "Justin J Kim", "Hongqi Teng", "Jie Zhang", "Feiyu Chen", "Yang Chen", "Nicholas E Navin", "Di Zhao"], "affiliations": ["The University of Texas MD Anderson Cancer Center Houston, TX United States.", "The University of Texas MD Anderson Cancer Center Houston United States.", "Massachusetts General Hospital Boston, MA United States.", "UT-MD Anderson Cancer Center Houston, Texas United States."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "basic_signals=8", "score": 41.19, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 17.19, "top_journal_bonus": 10.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 8.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 33.3, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 5.19, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "B7-H3双通路驱动肿瘤免疫抑制", "chinese_summary": "9月Cancer Discov报道，B7-H3通过非经典MAPK信号诱导单核型MDSC衰老并招募粒细胞型MDSC，同时MDSC分泌SPINK1激活CAF的EGFR/MEK/ERK通路，分别促进肿瘤进展和治疗抵抗；联合B7-H3单抗与曲美替尼可持久抑制去势抵抗性前列腺癌。", "abstract_zh": "B7-H3/CD276是癌症中一个新兴的免疫治疗靶点。然而，对B7-H3信号及其在调节肿瘤微环境中作用的有限认识，阻碍了靶向B7-H3治疗的临床应用。在此，我们报道B7-H3在调节髓源性抑制细胞（MDSC）和癌相关成纤维细胞（CAF）中发挥双重作用，从而分别促进肿瘤进展和治疗抵抗。我们全面表征了B7-H3的一种非经典功能，即在单核细胞型MDSC中触发MAPK信号并诱导细胞衰老。衰老的单核细胞型M-MDSC分泌趋化因子以招募免疫抑制性粒细胞型MDSC。B7-H3/Cd276的基因缺失或药理学抑制减少了Gr-MDSC并延缓了肿瘤进展。然而，来源于MDSC的分泌因子SPINK1代偿性激活CAF中的EGFR/MEK/ERK信号并促进其细胞外基质重塑特征，从而削弱了靶向B7-H3的免疫治疗。将B7-H3单克隆抗体与FDA批准的MEK抑制剂曲美替尼联合使用，通过完全减弱免疫抑制机制，在去势抵抗性前列腺癌的临床前模型中显示出持久的抗肿瘤效果。"}, {"pmid": "42757823", "title": "BUB1B Mitotic Kinase Dependency Reveals CENP-E Inhibition as a Tractable Approach for Castration and Enzalutamide Resistant Prostate Cancer.", "abstract": "Castration-resistant prostate cancer (CRPC) progression despite treatment with potent androgen receptor (AR) antagonists such as enzalutamide is a major clinical challenge. The mitotic kinase BUB1B is a central member of an oncogenic seven-gene network that drives CRPC. Here, we characterized BUB1B as an actionable therapeutic target for treatment-resistant PC. High BUB1B expression correlated with PC progression and aggressiveness. BUB1B depletion blocked CRPC cell proliferation through accumulation in G2/M and mitotic delay. Conversely, ectopic expression of BUB1B conferred castration and enzalutamide resistance to androgen-dependent PC cells in vitro and in vivo. BUB1B promotion of CRPC was not dependent on AR canonical signaling as assessed through AR knockdown and PROTAC-mediated AR degradation. BUB1B kinase activity was necessary for CRPC progression, as only wild type (WT), but not two kinase-dead mutants, promoted castration-resistant growth, and BUB1B kinase activity was required to maintain castration resistance. Expression of the primary substrate of BUB1B, CENP-E, also promoted CRPC progression, while a phosphodeficient mutant of the BUB1B phosphorylation site was ineffective. Moreover, only a phosphomimic mutant of CENP-E rescued growth after BUB1B depletion in CRPC cells, indicating that BUB1B-dependent phosphorylation of CENP-E was sufficient for progression and necessary to sustain CRPC growth. Targeting CENP-E with the clinically tested, small-molecule GSK923295 phenocopied BUB1B knockdown, sensitized resistant cells to enzalutamide and suppressed growth of enzalutamide-resistant xenografts in vivo. These data support BUB1B kinase as a driver of castration and enzalutamide resistance, positioning CENP-E inhibition as an attainable approach for treatment-resistant disease.", "journal": "Cancer Research", "pub_date": "2026-Sep-18", "publication_types": ["Journal Article"], "doi": "10.1158/0008-5472.CAN-26-0874", "authors": ["Maria J Martinez", "Cynthia Blanco", "Nahuel Peinetti", "Mariana Cooke", "Rolando Dz Lyles", "Maria V Revuelta", "Eva Corey", "Vasileios Stathias", "Moray J Campbell", "Kerry L Burnstein"], "affiliations": ["University of Miami miami, FLORIDA United States.", "University of Miami Miami, FLORIDA United States.", "University of Miami United States.", "University of Miami Miami, FL United States.", "University of Miami Miami, Florida United States.", "NYU Langone Health New York, NY United States.", "University of Washington SEATTLE, WA United States.", "University of Miami Health System United States.", "The Barbara Ann Karmanos Cancer Institute Detroit United States."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "basic_signals=15", "score": 54.21, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 16.21, "top_journal_bonus": 10.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 14.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 16.6, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.21, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "抑制CENP-E可逆转前列腺癌耐药", "chinese_summary": "9月Cancer Res报道，针对驱动去势抵抗性前列腺癌的BUB1B激酶，发现其通过磷酸化CENP-E促进耐药；临床阶段小分子GSK923295抑制CENP-E后，耐药细胞对恩扎卢胺敏感，异种移植瘤生长受抑，为治疗抵抗性疾病提供可行策略。", "abstract_zh": "尽管使用恩扎卢胺等强效雄激素受体（AR）拮抗剂治疗，去势抵抗性前列腺癌（CRPC）仍会进展，这是主要的临床挑战。有丝分裂激酶BUB1B是驱动CRPC的致癌七基因网络的核心成员。在此，我们将BUB1B鉴定为治疗抵抗性前列腺癌的可干预治疗靶点。BUB1B高表达与前列腺癌进展和侵袭性相关。BUB1B缺失通过使细胞积累于G2/M期并导致有丝分裂延迟，从而阻断CRPC细胞增殖。相反，BUB1B的异位表达使雄激素依赖性前列腺癌细胞在体外和体内获得去势和恩扎卢胺抵抗。通过AR敲低和PROTAC介导的AR降解评估，BUB1B促进CRPC并不依赖AR经典信号。BUB1B激酶活性对CRPC进展是必需的，因为只有野生型（WT）而非两个激酶失活突变体能够促进去势抵抗性生长，并且BUB1B激酶活性是维持去势抵抗所必需的。BUB1B的主要底物CENP-E的表达也促进CRPC进展，而BUB1B磷酸化位点的磷酸缺陷型突变体则无效。此外，只有CENP-E的磷酸模拟突变体能够在BUB1B缺失后挽救CRPC细胞的生长，表明BUB1B依赖的CENP-E磷酸化足以促进进展，并且是维持CRPC生长所必需的。使用经过临床测试的小分子GSK923295靶向CENP-E，可模拟BUB1B敲低的效果，使耐药细胞对恩扎卢胺敏感，并在体内抑制恩扎卢胺抵抗性异种移植瘤的生长。这些数据支持BUB1B激酶是去势和恩扎卢胺抵抗的驱动因素，将CENP-E抑制定位为治疗抵抗性疾病的一种可实现的策略。"}, {"pmid": "42757656", "title": "Male Infertility.", "abstract": "", "journal": "Journal of Urology", "pub_date": "2026-Sep-18", "publication_types": ["Journal Article"], "doi": "10.1097/JU.0000000000005297", "authors": ["Craig Niederberger"], "affiliations": [], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 19.01, "score_parts": {"urology_relevance": 3, "urology_in_title": 8.0, "journal_priority": 11.01, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 6.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 3.01, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42757644", "title": "Male Infertility.", "abstract": "", "journal": "Journal of Urology", "pub_date": "2026-Sep-18", "publication_types": ["Journal Article"], "doi": "10.1097/JU.0000000000005298", "authors": ["Craig Niederberger"], "affiliations": [], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 19.01, "score_parts": {"urology_relevance": 3, "urology_in_title": 8.0, "journal_priority": 11.01, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 6.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 3.01, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42757641", "title": "Male Infertility.", "abstract": "", "journal": "Journal of Urology", "pub_date": "2026-Sep-18", "publication_types": ["Journal Article"], "doi": "10.1097/JU.0000000000005296", "authors": ["Craig Niederberger"], "affiliations": [], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 19.01, "score_parts": {"urology_relevance": 3, "urology_in_title": 8.0, "journal_priority": 11.01, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 6.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 3.01, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42755408", "title": "Nature-Inspired Histidine and Guanidine Modification of Magnetic Nanoparticles for Urinary DNA Liquid Biopsy.", "abstract": "Urinary cell-free DNA (cfDNA) is a promising substrate for non-invasive liquid biopsy analysis and biomarker detection. However, the lack of standardized pre-analytical workflows and the intrinsic challenges associated with isolating highly dilute and fragmented cfDNA limit its broader research and clinical applications. Here, we present a simplified, reliable and cost-effective extraction platform based on iron oxide nanoparticles (IONPs) synthesized via coprecipitation. By leveraging nature-inspired surface functionalization, these magnetic nanoparticles enable the rapid and direct isolation of cfDNA from fresh urine while supporting scale-up of the processing volumes. The proposed platform achieves a 2-fold increase in cfDNA yield compared to conventional commercial extraction kits and demonstrates enhanced recovery of short DNA fragments, with a predominant size distribution between 80-150 bp. This improved capture efficiency facilitates a detection sensitivity down to 10-3 ng/mL using qPCR, likely limited by assay sensitivity rather than DNA extraction performance. Moreover, the simplified extraction and elution steps eliminate the need for specialized laboratory instrumentation. Collectively, this approach provides a foundation for accessible, potentially at-home cfDNA extraction and advances the development of truly non-invasive diagnostic strategies for longitudinal disease monitoring and management.", "journal": "Small Methods", "pub_date": "2026-Sep-18", "publication_types": ["Journal Article"], "doi": "10.1002/smtd.71034", "authors": ["Dina Haddad", "Ishtiaq Ahmed", "Manthos Pitoulias", "Richard Mair", "Ljiljana Fruk"], "affiliations": ["Chemical Engineering and Biotechnology (CEB), University of Cambridge, Cambridge, UK.", "Cancer Research UK Cambridge Institute (CRUK), University of Cambridge, Cambridge, UK."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 26.89, "score_parts": {"urology_relevance": 3, "urology_in_title": 8.0, "journal_priority": 11.39, "top_journal_bonus": 0.0, "novelty": 1.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 1.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 9.1, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 3.39, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "磁珠法提升尿液cfDNA回收率", "chinese_summary": "9月Small Methods报道一种受天然结构启发的组氨酸与胍基修饰氧化铁纳米颗粒，可直接从新鲜尿液中快速提取cfDNA并支持放大处理体积。其cfDNA产率较传统商业试剂盒提高2倍，短片段回收增强，主峰位于80–150 bp，qPCR检测灵敏度达10⁻³ ng/mL，且无需专用仪器。", "abstract_zh": "尿液游离DNA（cfDNA）是非侵入性液体活检分析和生物标志物检测中一种有前景的底物。然而，缺乏标准化的分析前工作流程，以及分离高度稀释且片段化的cfDNA所固有的挑战，限制了其更广泛的研究和临床应用。在此，我们提出了一种基于共沉淀法合成的氧化铁纳米颗粒（IONPs）的简化、可靠且经济有效的提取平台。通过利用受自然启发的表面功能化，这些磁性纳米颗粒能够从新鲜尿液中快速直接地分离cfDNA，同时支持处理体积的放大。所提出的平台相较于传统商业提取试剂盒，cfDNA产率提高了2倍，并显示出对短DNA片段回收的增强，其主要的片段大小分布在80–150 bp之间。这种改善的捕获效率使得使用qPCR的检测灵敏度低至10⁻³ ng/mL，这可能受限于测定灵敏度而非DNA提取性能。此外，简化的提取和洗脱步骤无需专门的实验室仪器。总体而言，该方法为可及、可能在家进行的cfDNA提取提供了基础，并推动了用于纵向疾病监测和管理的真正非侵入性诊断策略的发展。"}, {"pmid": "42754954", "title": "Advancements and future directions in transforming therapies of prostate cancer.", "abstract": "The treatment landscape for advanced prostate cancer (PCa) has significantly evolved in recent years, marked by the introduction of several novel therapies. Targeting the androgen receptor (AR) remains a cornerstone of treatment, with drugs, such as abiraterone and next-generation antiandrogens, providing substantial benefits. Poly (ADP-ribose) polymerase (PARP) inhibitors, both as monotherapies and in combination with other agents, have demonstrated promise, particularly for patients with deoxyribonucleic acid (DNA) repair defects. While immunotherapy has historically shown limited efficacy in the treatment of PCa, recent findings from the CONTACT‑02 study suggest a potential breakthrough, demonstrating improved patient outcomes with the combined use of atezolizumab and cabozantinib. Additionally, emerging therapies targeting cyclin-dependent kinases 4 and 6 (CDK4/6), the phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway, and epigenetic modifications offer new treatment possibilities. These advancements, coupled with ongoing research into combination therapies and novel drug targets, hold the potential to further enhance outcomes for patients with advanced PCa. This article review summarizes the latest transformative therapies in PCa care.", "journal": "Chinese Medical Journal", "pub_date": "2026-Sep-18", "publication_types": ["Journal Article"], "doi": "10.2147/dddt.S210949", "authors": ["Jinge Zhao", "Bo Tang", "Hao Zeng", "Qiang Wei"], "affiliations": ["Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China."], "corresponding_authors": [], "china_team": "Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China Jinge Zhao团队", "category": "basic", "classification_reason": "basic_signals=6", "score": 32.6, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 11.1, "top_journal_bonus": 0.0, "novelty": 1.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 6.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 7.3, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 3.1, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "晚期前列腺癌治疗格局演进", "chinese_summary": "四川大学华西医院曾靖团队9月Chinese Medical Journal综述指出，晚期前列腺癌治疗已从单一雄激素受体阻断拓展至PARP抑制剂、免疫联合及CDK4/6、PI3K/AKT/mTOR和表观遗传靶点等多维策略；CONTACT-02研究提示阿替利珠单抗联合卡博替尼可改善患者结局。", "abstract_zh": "近年来，晚期前列腺癌（PCa）的治疗格局发生了显著演变，其标志是多种新型疗法的引入。靶向雄激素受体（AR）仍是治疗的基石，阿比特龙和下一代抗雄激素药物等可带来显著获益。聚（ADP-核糖）聚合酶（PARP）抑制剂无论是单药治疗还是与其他药物联合，均已显示出前景，尤其对存在脱氧核糖核酸（DNA）修复缺陷的患者。尽管免疫治疗在PCa治疗中历来疗效有限，但CONTACT-02研究的最新发现提示可能取得突破，显示阿替利珠单抗与卡博替尼联合使用可改善患者结局。此外，靶向细胞周期蛋白依赖性激酶4和6（CDK4/6）、磷脂酰肌醇3-激酶/蛋白激酶B/哺乳动物雷帕霉素靶蛋白（PI3K/AKT/mTOR）通路以及表观遗传修饰的新兴疗法提供了新的治疗可能。这些进展，加之正在进行的联合治疗和新型药物靶点研究，有望进一步改善晚期PCa患者的结局。本文综述总结了PCa治疗中最新具有变革性的疗法。"}, {"pmid": "42840951", "title": "Advances in IL-2-based cancer immunotherapy and the synergistic role of stem-like CD8+ T cells in IL-2 and PD-1 combination therapy.", "abstract": "IL-2 is a pleiotropic cytokine that plays a central role in the activation and proliferation of cytotoxic lymphocytes and regulatory T cells. Since its discovery in 1976 as a T-cell growth factor and its subsequent U.S. FDA approval for metastatic renal cell carcinoma and melanoma, IL-2 has represented a landmark in cancer immunotherapy. However, high-dose (HD) IL-2 therapy is associated with substantial toxicities, including vascular leak syndrome. Recent advances in structural and receptor biology have clarified the molecular mechanisms underlying IL-2's dual immunostimulatory and immunoregulatory effects. These discoveries have enabled the design of next-generation IL-2 variants (IL-2v) with improved pharmacokinetics, receptor selectivity, and safety profiles. Importantly, PD-1+ TCF-1+ stem-like CD8+ T cells have recently been identified as a key population sustaining long-term antitumor immunity. TCF-1 is a transcription factor associated with a less differentiated, self-renewing state and marks this progenitor-exhausted subset. By contrast, terminally exhausted T cells exhibit a highly differentiated, poorly proliferative state and limited capacity for functional reinvigoration, whereas progenitor-exhausted cells retain stem-like properties, self-renewal capacity, and responsiveness to therapy. Furthermore, these cells respond robustly to IL-2 and are central mediators of the synergy observed between IL-2 signaling and PD-1 blockade. Mechanistically, PD-1 inhibition releases inhibitory constraints, while IL-2 provides a potent STAT5-driven proliferative and differentiation signal that expands the stem-like CD8+ T-cell pool and generates functional effector CD8+ T cells. This review summarizes IL-2 biology, the limitations of high-dose IL-2 (HD IL-2) therapy, and emerging strategies, including CD25- or CD122-biased IL-2 variants, tumor-targeted IL-2 prodrugs, and IL-2-based combination therapies designed to harness IL-2's antitumor potential while minimizing systemic toxicity, with particular emphasis on the role of stem-like CD8+ T cells as key mediators of therapeutic efficacy.", "journal": "Frontiers in Immunology", "pub_date": "2026", "publication_types": ["Journal Article", "Review"], "doi": "10.1038/ncomms14572", "authors": ["Huiquan Gao", "Shubo Wang", "Huiru Yuan", "Bingxiu Zhou", "Fuxin Zhou"], "affiliations": ["Department of Radiotherapy, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, China.", "Department of Gynecology, The Affiliated Weihai Second Municipal Hospital of Qingdao University, Weihai, China.", "Department of General and Visceral Surgery, Faculty of Medicine, Medical Center - University of Freiburg, Freiburg, Germany."], "corresponding_authors": [], "china_team": "Department of Radiotherapy, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, China Bingxiu Zhou团队", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 17.33, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 10.83, "top_journal_bonus": 0.0, "novelty": 0.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 5.9, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.83, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42824830", "title": "Mechanisms of microbiome-immune interactions in bladder cancer and targeted regulatory strategies.", "abstract": "Bladder cancer (BC), a highly prevalent malignancy of the urinary tract, imposes a considerable clinical burden because of its high recurrence rates and a substantial risk of disease progression. Accumulating evidence suggests that microbiome dysbiosis is associated with the initiation and progression of BC through potentially bidirectional interactions. Recent advances in high-throughput sequencing technologies have facilitated a more comprehensive characterization of the urinary microbiome, thereby revealing its potential involvement in the pathogenesis of BC. This review summarizes the proposed mechanisms through which microbial communities may contribute to BC carcinogenesis, including chronic inflammation, microbial metabolite production, and epigenetic regulation. We further critically evaluate the established mechanisms of Bacillus Calmette-Guérin (BCG) immunotherapy-a standard intravesical immunotherapy for patients with intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC)-and examine the emerging application of microbiome profiling as a source of candidate noninvasive biomarkers and potential correlates or modulators of immune checkpoint inhibitor (ICI) response. Additionally, we elucidate the associations between microbiota heterogeneity and immunotherapy response, offering novel insights into microbiome-targeted therapeutic strategies for BC.", "journal": "Frontiers in Immunology", "pub_date": "2026", "publication_types": ["Journal Article", "Review"], "doi": "10.1038/s12276-020-0437-6", "authors": ["Songhong Wu", "Shi Fu", "Hongjin Shi", "Yicheng Gong", "Peng Chen", "Xiaoyue Zhang", "Enyan Jiang", "Haifeng Wang"], "affiliations": ["Department of Urology, The Second Affiliated Hospital of Kunming Medical University, Kunming, China."], "corresponding_authors": [], "china_team": "Department of Urology, The Second Affiliated Hospital of Kunming Medical University, Kunming, China Haifeng Wang团队", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 36.33, "score_parts": {"urology_relevance": 7, "urology_in_title": 8.0, "journal_priority": 10.83, "top_journal_bonus": 0.0, "novelty": 1.5, "gut_microbiome_bonus": 5.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 2.0}, "journal_metrics": {"status": "ok", "impact_factor": 5.9, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.83, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42824085", "title": "Case Report: Kidney allograft recovery after conversion to belatacept-based immunosuppression in simultaneous heart-kidney transplantation.", "abstract": "Renal allograft dysfunction after simultaneous heart-kidney transplantation (SHKT) is often multifactorial, reflecting perioperative hemodynamic instability, ischemia-reperfusion injury, alloimmune activation, and calcineurin inhibitor exposure. The therapeutic role of belatacept in this dual-organ setting remains poorly defined. We report the case of a 47-year-old woman with systemic lupus erythematosus, antiphospholipid syndrome, previous kidney allograft loss and heart failure, who underwent SHKT. The post-transplant course was complicated by persistent anuria requiring prolonged dialysis dependence, a high-titer de novo class II donor-specific antibody (DSA), and biopsy-proven cardiac antibody-mediated and cellular rejection. Despite intensive anti-rejection treatment, cardiac histology improved and DSA levels decreased, but renal allograft function did not recover. Belatacept was introduced at post-transplant week 12 with tacrolimus minimization. Thereafter, diuresis progressively resumed and dialysis was discontinued, with progressive improvement in renal function, while DSA became progressively undetectable. At 6 months, both grafts are functioning, serum creatinine is 1.4 mg/dL and no DSA rebound occurred. This case highlights the potential role of belatacept-based immunosuppression in the complex setting of SHKT with prolonged kidney allograft dysfunction.", "journal": "Frontiers in Immunology", "pub_date": "2026", "publication_types": ["Case Reports", "Journal Article"], "doi": "10.1111/ajt.14721", "authors": ["Elisa Gessaroli", "Mario Sabatino", "Angelodaniele Napoletano", "Vasilika Samara", "Daniele Vetrano", "Chiara Baldovini", "Valeria Grandinetti", "Gaetano La Manna", "Giorgia Comai", "Luciano Potena", "Valeria Corradetti"], "affiliations": ["Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum-University of Bologna, Bologna, Italy.", "Heart Failure and Transplant Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.", "Nephrology, Dialysis and Kidney Transplant Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.", "Pathology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_clinical", "score": 23.83, "score_parts": {"urology_relevance": 2, "urology_in_title": 8.0, "journal_priority": 10.83, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 1.0}, "journal_metrics": {"status": "ok", "impact_factor": 5.9, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.83, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42772066", "title": "Whole-blood total chromium and DNA repair variation in an occupational Cr(VI)-exposure setting: Pathway-resolved associations across complementary response biomarkers.", "abstract": "Biological responses vary among workers in occupational hexavalent chromium [Cr(VI)]-exposure settings, but evidence for DNA-repair susceptibility is complicated by extensive testing and pathway scores derived within the same sample. We analysed 1295 participants from three chromate-production plants, measured whole-blood total chromium (WB-Cr), and assessed urinary 8-hydroxy-2'-deoxyguanosine (8-OHdG), lymphocyte micronucleus frequency (MNF), and mitochondrial DNA copy number (mtDNA-CN) as complementary response biomarkers. Thirty-four single-nucleotide polymorphisms (SNPs) in 16 genes across six DNA-repair pathways were evaluated using single-variant models, interactions with ln(WB-Cr), pathway-specific genetic risk scores (GRSs), exploratory mediation, functional annotation, and Bayesian kernel machine regression. Primary additive analyses were separated from secondary models and evaluated using prespecified false-discovery-rate (FDR) families, repeated cross-fitting, missing-data analyses, and multi-chain diagnostics. WB-Cr was positively associated with all three biomarkers. Four additive homologous recombination repair (HRR) interactions with ln(WB-Cr) for mtDNA-CN met outcome-specific 34-test FDR control: NBN rs2735383, rs13312840, and rs13312986, and XRCC2 rs3218385. Only XRCC2 rs3218385 remained significant after correction across both the 102-test additive family (q = 0.005) and all 306 model-specific tests (q = 0.007). Cross-fitting did not reproduce the direction of the internally aligned HRR score estimate and did not meet pathway-level FDR control. Exploratory mediation identified an indirect association of WB-Cr with mtDNA-CN through 8-OHdG. These analyses prioritise HRR-related variants for independent replication while distinguishing measured total chromium from the occupational Cr(VI)-exposure context. SYNOPSIS: Within an occupational Cr(VI)-exposure setting, measured whole-blood total chromium was associated with complementary response biomarkers, and multiplicity-controlled analyses identified HRR-related interaction signals for independent replication.", "journal": "Journal of Hazardous Materials", "pub_date": "2026-Sep-17", "publication_types": ["Journal Article"], "doi": "10.1016/j.jhazmat.2026.143665", "authors": ["Xiaoli Wang", "Changmao Long", "Shiyi Hong", "Zhiqiang Ji", "Kexin Shi", "Ziqi Zhu", "Guiping Hu", "Guang Jia"], "affiliations": ["Department of Occupational and Environmental Health Sciences, School of Public Health, Peking University, Beijing 100083, China.", "School of Public Health, Jiangxi Medical College, Nanchang University, China; Jiangxi Provincial Key Laboratory of Disease Prevention and Public Health, Nanchang University, China.", "School of Engineering Medicine and Beijing Advanced Innovation Center for Big Data-Based Precision Medicine, Beihang University, Beijing 100083, China. Electronic address: hu_hgp@buaa.edu.cn.", "Department of Occupational and Environmental Health Sciences, School of Public Health, Peking University, Beijing 100083, China; Beijing Key Laboratory of Toxicological Research and Risk Assessment for Food Safety, School of Public Health, Peking University, Beijing 100083, China."], "corresponding_authors": ["Guiping Hu"], "china_team": "Department of Occupational and Environmental Health Sciences, School of Public Health, Peking University, Beijing 100083, China Guiping Hu团队", "category": "basic", "classification_reason": "basic_signals=4", "score": 25.18, "score_parts": {"urology_relevance": 3, "urology_in_title": 0.0, "journal_priority": 15.68, "top_journal_bonus": 0.0, "novelty": 0.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 4.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 11.3, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.68, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "血铬升高与DNA修复基因交互影响线粒体拷贝数", "chinese_summary": "北京大学公共卫生学院胡桂平团队9月J Hazard Mater基于3家铬酸盐厂1295名工人发现，全血总铬与尿8-OHdG、淋巴细胞微核率及线粒体DNA拷贝数均呈正相关。在同源重组修复通路中，XRCC2 rs3218385与血铬交互作用经多重校正后仍显著，提示该变异可能影响职业铬暴露人群的DNA修复易感性。", "abstract_zh": "在职业性六价铬[Cr(VI)]暴露环境中，工人之间的生物学反应存在差异，但关于DNA修复易感性的证据因大量检测以及在同一份样本中推导通路评分而变得复杂。我们分析了来自三家铬酸盐生产厂的1295名参与者，测定了全血总铬（WB-Cr），并评估了尿8-羟基-2'-脱氧鸟苷（8-OHdG）、淋巴细胞微核频率（MNF）和线粒体DNA拷贝数（mtDNA-CN）作为互补的反应生物标志物。采用单变异模型、与ln(WB-Cr)的交互作用、通路特异性遗传风险评分（GRSs）、探索性中介分析、功能注释和贝叶斯核机器回归，评估了六个DNA修复通路中16个基因的34个单核苷酸多态性（SNPs）。主要加性分析从二次模型中分离出来，并使用预先指定的错误发现率（FDR）家族、重复交叉拟合、缺失数据分析及多链诊断进行评估。WB-Cr与所有三种生物标志物均呈正相关。四个同源重组修复（HRR）与ln(WB-Cr)的加性交互作用对mtDNA-CN达到结局特异性34项检验FDR控制：NBN rs2735383、rs13312840和rs13312986，以及XRCC2 rs3218385。只有XRCC2 rs3218385在102项加性检验家族（q = 0.005）和全部306项模型特异性检验（q = 0.007）校正后仍保持显著。交叉拟合未能重现内部对齐的HRR评分估计的方向，也未达到通路水平FDR控制。探索性中介分析发现WB-Cr通过8-OHdG与mtDNA-CN存在间接关联。这些分析优先考虑HRR相关变异以供独立重复，同时将测得的总铬与职业性Cr(VI)暴露环境区分开来。简介：在职业性Cr(VI)暴露环境中，测得的全血总铬与互补的反应生物标志物相关，经多重校正的分析识别出HRR相关交互信号以供独立重复。"}, {"pmid": "42760560", "title": "KMT9 drives T cell exclusion and dysfunction by promoting PMN-MDSCs infiltration and ARG1 expression in prostate cancer.", "abstract": "Immunotherapy has emerged as a revolutionary therapeutic approach to treat cancer showing remarkable clinical responses. However, its efficacy in solid tumours such as prostate cancer (PCa) remains very limited due to a highly immunosuppressive tumour immune microenvironment (TIME) that hampers cytotoxic T cell infiltration and activity. Here, we show that lysine methyltransferase 9 (KMT9) governs the formation of an immunosuppressive TIME in PCa. KMT9 regulates the expression of tumour-secreted myeloid-attracting C-X-C motif chemokine receptor 2 (CXCR2) ligands such as C-X-C motif chemokine ligand 5 (CXCL5) thereby promoting the infiltration of immunosuppressive polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) within tumours. These changes collectively result in decreased activation and exclusion of cytotoxic T cells from tumour glands. Furthermore, we demonstrate that KMT9 confers tumour cell-resistance to T cell cytotoxicity by regulating expression of arginase 1 (ARG1). Accordingly, KMT9α ablation results in inhibition of prostate tumour growth accompanied by a massive reduction of PMN-MDSC recruitment and a significant increase in cytotoxic T cell activation and infiltration of the prostate tumour glands. Together, we uncovered KMT9 as a regulator of immune evasion that promotes an immune-excluded TIME in prostate tumours. Furthermore, our findings establish KMT9 as a therapeutic target to reprogram the immunosuppressive landscape and potentially improve the clinical efficacy of current immunotherapies.", "journal": "Molecular Cancer", "pub_date": "2026-Sep-17", "publication_types": ["Journal Article"], "doi": "10.1038/labinvest.2017.131", "authors": ["Jon Peñarando", "Dominica Willmann", "Manuela Sum", "Yanhan Jia", "Christopher Berlin", "Lukas M Braun", "Zihao Chen", "Sylvia Urban", "Manfred Jung", "Delphine Duteil", "Daniel Metzger", "Christian Gratzke", "Robert Zeiser", "Holger Greschik", "Roland Schüle", "Eric Metzger"], "affiliations": ["Klinik Für Urologie Und Zentrale Klinische Forschung, Klinikum Der Albert-Ludwigs-Universität Freiburg, Freiburg, Germany.", "German Cancer Consortium (DKTK), Partner Site Freiburg, a partnership between DKFZ and Medical Center - University of Freiburg, Freiburg, Germany.", "Klinik Für Allgemein- Und Viszeralchirurgie, Klinikum Der Albert-Ludwigs-Universität Freiburg, Freiburg, Germany.", "Department of Internal Medicine I, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.", "Institute of Pharmaceutical Sciences, Albert-Ludwigs-Universität Freiburg, Freiburg, Germany.", "Institut de Génétique Et de Biologie Moléculaire Et Cellulaire, CNRS UMR7104, INSERM U964, Université de Strasbourg, Illkirch, France.", "CIBSS Centre of Biological Signalling Studies, University of Freiburg, Freiburg, Germany.", "Klinik Für Urologie Und Zentrale Klinische Forschung, Klinikum Der Albert-Ludwigs-Universität Freiburg, Freiburg, Germany. eric.metzger@uniklinik-freiburg.de.", "German Cancer Consortium (DKTK), Partner Site Freiburg, a partnership between DKFZ and Medical Center - University of Freiburg, Freiburg, Germany. eric.metzger@uniklinik-freiburg.de."], "corresponding_authors": ["Eric Metzger"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 44.21, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 17.21, "top_journal_bonus": 10.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 3.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 33.9, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 5.21, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "KMT9驱动前列腺癌免疫排斥", "chinese_summary": "《Molecular Cancer》9月发表研究，发现赖氨酸甲基转移酶KMT9调控前列腺癌细胞分泌CXCL5等CXCR2配体，招募PMN-MDSCs浸润并上调ARG1表达，导致细胞毒性T细胞活化下降、被排斥于腺体之外。敲除KMT9α可抑制肿瘤生长并恢复T细胞浸润，提示KMT9是重塑免疫抑制微环境的潜在靶点。", "abstract_zh": "免疫治疗已成为一种革命性的癌症治疗手段，展现出显著的临床应答。然而，其在前列腺癌（PCa）等实体瘤中的疗效仍然非常有限，原因在于高度免疫抑制的肿瘤免疫微环境（TIME）阻碍了细胞毒性T细胞的浸润和活性。在本研究中，我们发现赖氨酸甲基转移酶9（KMT9）调控前列腺癌中免疫抑制性TIME的形成。KMT9调节肿瘤分泌的髓系招募性C-X-C基序趋化因子受体2（CXCR2）配体（如C-X-C基序趋化因子配体5，CXCL5）的表达，从而促进免疫抑制性多形核髓源性抑制细胞（PMN-MDSCs）在肿瘤内的浸润。这些变化共同导致细胞毒性T细胞活化减少并被排斥于肿瘤腺体之外。此外，我们证明KMT9通过调控精氨酸酶1（ARG1）的表达赋予肿瘤细胞对T细胞细胞毒作用的抵抗。相应地，敲除KMT9α可抑制前列腺肿瘤生长，同时伴随PMN-MDSC招募的大幅减少以及细胞毒性T细胞活化及浸润前列腺肿瘤腺体的显著增加。总之，我们揭示了KMT9作为免疫逃逸的调控因子，促进前列腺肿瘤形成免疫排斥型TIME。此外，我们的发现确立了KMT9作为重编程免疫抑制格局并可能提高当前免疫治疗临床疗效的治疗靶点。"}, {"pmid": "42757692", "title": "Real-world treatment patterns in men with metastatic hormone-sensitive prostate cancer in Europe and Asia between 2020 and 2024.", "abstract": "The therapeutic landscape for metastatic hormone-sensitive prostate cancer (mHSPC) has changed significantly over the last decade with the introduction of combination strategies. However, recent real-world evidence on their use in practice is limited, especially in Europe and Asia. This cross-sectional study included men with mHSPC receiving first-line therapy in EU4, the UK, Japan and China between January 1, 2020, and December 31, 2024. The IQVIA Oncology Dynamics database was used to derive patient-level data on physician-reported initial treatment for mHSPC. Of 23,101 men included, 15,275, 4,875, and 2,951 in EU4, the UK, and Asia, received treatment for mHSPC. Use of androgen deprivation therapy (ADT) monotherapy ranged from 29-44% in EU4/UK and 50-59% in Asia. ADT plus androgen receptor inhibitor (ARPI) was used in 47% of patients in EU4, 54% in the UK, and 35-38% in Asia. From 2020-2024, ADT monotherapy decreased from 60% to 24% in EU4, 54% to 23% in the UK, and 83% to 39% in Asia, with corresponding increases in ADT plus ARPI use. ADT plus ARPI plus docetaxel use increased throughout the study, becoming more prominent from 2023 in EU4/UK; usage went from 0.1% in 2020 to 10% in 2024. Uptake was slower in Asia. Compared with recurrent mHSPC, a high proportion received combination therapy for de novo mHSPC. Findings highlight the adoption of combination strategies with either doublet or docetaxel triplet regimens between 2020 and 2024. One-fourth of patients received ADT monotherapy in 2024.", "journal": "Oncologist", "pub_date": "2026-Sep-17", "publication_types": ["Journal Article"], "doi": "10.1093/oncolo/oyag369", "authors": ["Amit D Raval", "Sheila Mpima", "Vicky Casey", "Fil Manuguid", "Matthew Korn", "Elena Castro"], "affiliations": ["Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA.", "IQVIA, London, UK.", "Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=3", "score": 28.42, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.42, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 3.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.2, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.42, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42754720", "title": "In vitro performance of the Vortex Intelligent Stone Optimized Removal (VISOR) system versus the flexible and navigable suction ureteral access sheath (FANS) on stone clearance efficiency and intrarenal pressure control.", "abstract": "Flexible and navigable suction ureteral access sheath (FANS) ureteroscopy has been recognized as an important development in the suction era of endourology. The Vortex Intelligent Stone Optimized Removal (VISOR) system has recently been introduced as an alternative to FANS, featuring an integrated irrigation-suction dual-channel and IRP control design. This study aimed to evaluate the efficacy of VISOR system in comparison with FANS in vitro. 3D-printed renal models were used, and 3 g of human calcium phosphate stones were treated via VISOR system versus FANS ureteroscopy. All procedures were performed by a single experienced urologist with a holmium laser. Primary outcome was stone clearance efficiency (SCE), calculated as: SCE (%) = [(Initial stone mass - Residual stone mass) / Initial stone mass] × 100%. Secondary outcomes included operative time, total laser energy use, residual stone mass and total stone mass removed. Accuracy of IRP measurements was also tested for the VISOR system. The VISOR system demonstrated comparable SCE to FANS (95.1 ± 0.6% vs. 94.8 ± 0.7%, p = 0.78). The mean operative time in the VISOR group was significantly lower by 26.2% compared with FANS (55.1 ± 2.2 vs. 74.7 ± 2.3 min, p = 0.003). We found no difference in total laser energy use (33.6 ± 1.4 vs. 33.3 ± 5.3 kJ, p = 0.96), residual stone mass (0.15 ± 0.03 vs. 0.15 ± 0.04 g, p = 0.99) and total removed stone mass (1.86 ± 0.13 vs. 1.81 ± 0.12 g, p = 0.79). The VISOR system's pressure sensor showed good correlation with an external reference pressure meter (Spearman R = 0.99, p < 0.0001). Based on these in vitro findings, the VISOR integrated dual-channel system demonstrated SCE comparable to FANS, with significantly shorter operative time and reliable real-time IRP control. These results suggest that the VISOR system represents a promising candidate for further clinical evaluation; whether these performance advantages translate to improved patient outcomes in vivo requires confirmation in prospective clinical studies.", "journal": "World Journal of Urology", "pub_date": "2026-Sep-17", "publication_types": ["Journal Article", "Comparative Study"], "doi": "10.1007/s00345-024-04815-7", "authors": ["Wenjun Gao", "Li Fang", "Jia-Lun Kwok", "Baiyang Song", "Steffi Kar Kei Yuen", "Vineet Gauhar", "Yue Cheng", "Bohan Wang"], "affiliations": ["Department of Urology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310009, Zhejiang, China.", "Department of Urology, The First Affiliated Hospital of Ningbo University, 59 Liuting Street, Haishu District, Ningbo, 315000, Zhejiang, P.R. China.", "Zhejiang Engineering Research Center of Innovative Technologies and Diagnostic and Therapeutic Equipment for Urinary System Diseases, Hangzhou, Zhejiang, China.", "Department of Urology, Tan Tock Seng Hospital, Singapore, Singapore.", "Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore.", "S.H. Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong, China.", "Department of Urology, Ng Teng Fong Hospital, Singapore, Singapore.", "Asian Institute of Nephrology and Urology, Hyderabad, India.", "Department of Urology, The First Affiliated Hospital of Ningbo University, 59 Liuting Street, Haishu District, Ningbo, 315000, Zhejiang, P.R. China. fyychengyue@nbu.edu.cn.", "Zhejiang Engineering Research Center of Innovative Technologies and Diagnostic and Therapeutic Equipment for Urinary System Diseases, Hangzhou, Zhejiang, China. fyychengyue@nbu.edu.cn.", "Department of Urology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310009, Zhejiang, China. wangbohan@zju.edu.cn."], "corresponding_authors": ["Yue Cheng", "Bohan Wang"], "china_team": "Department of Urology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310009, Zhejiang, China Yue Cheng/Bohan Wang团队", "category": "basic", "classification_reason": "basic_signals=5", "score": 33.0, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 10.0, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 5.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.9, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.0, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "新型双通道系统取石效率不劣于负压鞘", "chinese_summary": "浙江大学医学院附属第二医院Yue Cheng/Bohan Wang团队在体外3D打印肾模型中比较VISOR智能取石系统与FANS负压输尿管鞘：两者结石清除率相当（95.1%对94.8%），但VISOR手术时间缩短26.2%，且压力传感与外部参考测压高度相关，提示其具备进一步临床评估潜力。", "abstract_zh": "柔性可导航负压输尿管通路鞘（FANS）输尿管镜已被公认为腔内泌尿外科负压吸引时代的重要进展。Vortex智能结石优化清除（VISOR）系统近期作为FANS的替代方案被引入，其特点是集成灌溉-吸引双通道及肾内压（IRP）控制设计。本研究旨在体外评估VISOR系统相较FANS的效能。研究使用3D打印肾脏模型，通过VISOR系统与FANS输尿管镜分别处理3 g人磷酸钙结石。所有操作均由同一名经验丰富的泌尿外科医生使用钬激光完成。主要结局为结石清除效率（SCE），计算公式为：SCE（%）=[（初始结石质量-残余结石质量）/初始结石质量]×100%。次要结局包括手术时间、总激光能量使用、残余结石质量和总清除结石质量。此外还测试了VISOR系统IRP测量的准确性。VISOR系统的SCE与FANS相当（95.1±0.6% vs. 94.8±0.7%，p=0.78）。VISOR组平均手术时间较FANS显著缩短26.2%（55.1±2.2 vs. 74.7±2.3 min，p=0.003）。两组在总激光能量使用（33.6±1.4 vs. 33.3±5.3 kJ，p=0.96）、残余结石质量（0.15±0.03 vs. 0.15±0.04 g，p=0.99）和总清除结石质量（1.86±0.13 vs. 1.81±0.12 g，p=0.79）方面无差异。VISOR系统的压力传感器与外部参考压力计显示良好相关性（Spearman R=0.99，p<0.0001）。基于这些体外发现，VISOR集成双通道系统的SCE与FANS相当，手术时间显著更短，且能可靠地实时控制IRP。这些结果提示，VISOR系统是值得进一步临床评估的有前景候选方案；这些性能优势能否在体内转化为患者结局改善，尚需前瞻性临床研究证实。"}, {"pmid": "42754713", "title": "Perioperative outcomes and prevalence of urethral strictures during surgery for benign prostatic hyperplasia: results from the GRAND study.", "abstract": "Limited data exist on the prevalence of urethral strictures during surgery for benign prostatic hyperplasia (BPH). We aimed to analyze their perioperative outcomes and trends. The German Nationwide Inpatient Data (GRAND) registry was used to identify male patients diagnosed with urethral stricture who underwent surgery for BPH between 2005 and 2022. A total of 1,367,065 BPH surgeries were performed in Germany. Of them, 179,272 had a relevant concomitant urethral stricture (13%). Their median age was 72 years (interquartile range: 66-78). Patients with urethral stricture during BPH surgery underwent an internal urethrotomy in 155,482 (86%) cases, a dilatation of the urethral stricture in 14,162 (9%) cases, or a meatoplasty in 9,628 (5%) cases. The annual prevalence of relevant urethral strictures during BPH surgery has decreased from 14,872 cases in 2005 to 7,184 in 2022. Compared to patients with no urethral stricture, those with urethral strictures during BPH surgery displayed higher rates of postoperative incontinence (3.8% versus 3.7%, p<0.001) and reoperations (1.0% versus 0.8%, p<0.001). On the contrary, they were associated with lower rates of perioperative acute urinary retention (7.8% versus 10%, p<0.001). Urethral strictures during surgery for BPH display a high prevalence and may slightly affect perioperative outcomes.", "journal": "World Journal of Urology", "pub_date": "2026-Sep-17", "publication_types": ["Journal Article"], "doi": "10.1007/s00345-026-06559-y", "authors": ["Nikolaos Pyrgidis", "Gerald Bastian Schulz", "Philipp Weinhold", "Yannic Volz", "Michael Atzler", "Leo Federico Stadelmeier", "Iason Papadopoulos", "Christian Stief", "Julian Marcon", "Patrick Keller"], "affiliations": ["Department of Urology, University Hospital, LMU Munich, Marchioninistraße 15, 81377, Munich, Germany. Nikolaos.pyrgidis@med.uni-muenchen.de.", "Department of Urology, University Hospital, LMU Munich, Marchioninistraße 15, 81377, Munich, Germany."], "corresponding_authors": ["Nikolaos Pyrgidis"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=3", "score": 38.0, "score_parts": {"urology_relevance": 15, "urology_in_title": 8.0, "journal_priority": 10.0, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 3.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.9, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.0, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42754663", "title": "CRISPR/Cas9 screening revealed BIRC6-AS1/BIRC6 mediates abiraterone resistance via NHEJ pathway-dependent A20 degradation in prostate cancer.", "abstract": "Abiraterone acetate is a standard-of-care therapy for prostate cancer (PCa). However, resistance frequently emerges, often characterized by the progression to AR-independent phenotypes. Employing a genome-wide CRISPR/Cas9 library screening strategy, we identified 523 long non-coding RNAs (lncRNAs) and 2,183 protein-coding genes as potential candidates associated with abiraterone resistance. Notably, a pair of sense-antisense genes, BIRC6-AS1/BIRC6, was identified as a significant contributor to abiraterone resistance, serving as a critical survival factor in AR-independent contexts. BIRC6-AS1 depletion led to a reduction in both the mRNA and protein levels of BIRC6. Moreover, depletion of either BIRC6-AS1 or BIRC6 enhanced the sensitivity of PCa cells to abiraterone in both in vitro and in vivo settings. Further investigation revealed that BIRC6-AS1 stabilized the mRNA of BIRC6 through interaction with ILF2. Suppression of either BIRC6-AS1 or BIRC6 attenuated non-homologous end joining (NHEJ) repair activity, resulting in the disassembly of 53BP1 foci at DNA damage sites and an increased accumulation of DNA damage, thereby exposing a vulnerability in AR-independent resistant cells. Mechanistically, BIRC6 interacted with A20 and facilitated the K48-linked ubiquitination and subsequent degradation of A20 at the K337 residue. Additionally, A20 knockdown effectively reversed the abiraterone sensitivity induced by BIRC6-AS1 depletion. Collectively, our study provides a landscape of lncRNAs and protein-coding genes associated with abiraterone resistance and suggests that targeting the BIRC6-AS1/BIRC6 axis represents a potential therapeutic strategy to eradicate AR-independent resistant tumors in prostate cancer.", "journal": "Oncogene", "pub_date": "2026-Sep-17", "publication_types": ["Journal Article"], "doi": "10.1093/nar/gky869", "authors": ["Lan Li", "Xue-Ni An", "Yong-Tong Ruan", "Rong Yang", "Peng Li", "Pei-Tong Shen", "Han-Yu Zeng", "Xiao-Yu Wu", "Xian-Chao Huang", "Ming-Yuan Song", "Jing-Lan Hao", "Ping Gao", "Xiao-Ming Dong"], "affiliations": ["College of Life Sciences, Shaanxi Normal University, Xi'an, China.", "College of Life Sciences, Shaanxi Normal University, Xi'an, China. jlhao1128@163.com.", "College of Life Sciences, Shaanxi Normal University, Xi'an, China. ping.gao2016@outlook.com.", "College of Life Sciences, Shaanxi Normal University, Xi'an, China. dongxm2008duzhe@126.com."], "corresponding_authors": ["Jing-Lan Hao", "Ping Gao", "Xiao-Ming Dong"], "china_team": "College of Life Sciences, Shaanxi Normal University, Xi'an, China Jing-Lan Hao/Ping Gao/Xiao-Ming Dong团队", "category": "basic", "classification_reason": "basic_signals=12", "score": 41.1, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 15.1, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 12.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 7.3, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.1, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "CRISPR筛选揭示阿比特龙耐药新靶点", "chinese_summary": "陕西师范大学生命科学学院郝静兰/高萍/董小明团队9月Oncogene发表全基因组CRISPR/Cas9筛选结果，鉴定出523个lncRNA及2183个蛋白编码基因与前列腺癌阿比特龙耐药相关。其中正义-反义基因对BIRC6-AS1/BIRC6在AR非依赖耐药中起关键生存作用，BIRC6-AS1通过ILF2稳定BIRC6 mRNA，BIRC6则介导A2。", "abstract_zh": "醋酸阿比特龙是前列腺癌（PCa）的标准治疗药物。然而，耐药性经常出现，其特征往往是进展为AR非依赖表型。采用全基因组CRISPR/Cas9文库筛选策略，我们鉴定出523个长链非编码RNA（lncRNA）和2183个蛋白编码基因作为与阿比特龙耐药相关的潜在候选因子。值得注意的是，一对正义-反义基因BIRC6-AS1/BIRC6被确定为阿比特龙耐药的重要贡献者，在AR非依赖背景下充当关键生存因子。BIRC6-AS1敲低导致BIRC6的mRNA和蛋白水平均降低。此外，敲低BIRC6-AS1或BIRC6在体外和体内均增强PCa细胞对阿比特龙的敏感性。进一步研究揭示，BIRC6-AS1通过与ILF2相互作用稳定BIRC6的mRNA。抑制BIRC6-AS1或BIRC6减弱非同源末端连接（NHEJ）修复活性，导致DNA损伤位点53BP1焦点解聚以及DNA损伤积累增加，从而暴露AR非依赖耐药细胞的脆弱性。在机制上，BIRC6与A20相互作用，促进A20在K337残基的K48连接泛素化及随后的降解。此外，A20敲低有效逆转了BIRC6-AS1敲低诱导的阿比特龙敏感性。总之，我们的研究提供了与阿比特龙耐药相关的lncRNA和蛋白编码基因的图谱，并提示靶向BIRC6-AS1/BIRC6轴是根除前列腺癌AR非依赖耐药肿瘤的潜在治疗策略。"}, {"pmid": "42754639", "title": "Vesicourethral anastomotic stenosis after radical prostatectomy: a preoperative classification to capture heterogeneity and guide surgical management.", "abstract": "", "journal": "Prostate Cancer and Prostatic Diseases", "pub_date": "2026-Sep-17", "publication_types": ["Journal Article", "Review"], "doi": "10.1007/s00261-025-05027-2", "authors": ["Clément Sarrazin", "Agathe Escoffier", "Paul Neuville", "Alice Bourillon", "Félix Campos-Juanatey", "Wesley Verla", "Marjan Waterloos", "Jakob Klemm", "Malte W Vetterlein", "Tarek Ghoneim", "François-Xavier Madec"], "affiliations": ["Department of Urology, CHU Grenoble-Alpes, Grenoble, France. csarrazin1@chu-grenoble.fr.", "Department of Urology, CHU Dijon, Dijon, France.", "Department of Urology, Hospices Civils de Lyon, Hôpital Lyon Sud, Pierre-Bénite, France.", "Department of Urology, CHU Rennes, Rennes, France.", "Andrology and Reconstructive Urology Unit, Marqués de Valdecilla University Hospital, School of Medicine, Cantabria University, IDIVAL, Santander, Spain.", "Department of Urology, AZ Maria Middelares, Ghent, Belgium.", "Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.", "Service d'Urologie, Hôpital Foch, Suresnes, France.", "Department of Urology, Ambroise Paré-Hartmann Private Hospital Group, Neuilly-sur-Seine, France."], "corresponding_authors": ["Clément Sarrazin"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 23.81, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 10.81, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 5.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.81, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42753981", "title": "Henry Bugbee and His Eponymous Electrode.", "abstract": "To explore the development of the Bugbee electrode, and the career of the urologist whose name it bears, which persists as a ubiquitous instrument in endoscopic urology today. A structured literature review was performed using online repositories, peer-reviewed publications, historical texts and archival materials. Additional resources were obtained from the William P. Didusch Center for Urologic History. Henry Greenwood Bugbee (1882-1945) was a prominent early 20th-century urologist who served in numerous leadership roles, including the American Urological Association presidency from 1921 to 1922. Bugbee's lasting legacy, however, stems from innovations in endoscopic electrocautery. Although therapeutic electrical current had been explored for centuries, Edwin Beer sparked rapid evolution in modern endoscopy when he introduced a monopolar Oudin cauterizer through a cystoscope in 1910. Bugbee entered the fray in 1913, publishing extensively alongside Hugh Young and others on the use of \"high frequency spark\" for prostatic obstruction. His seminal 1917 paper, \"The Use of the High Frequency Spark in the Treatment of Median Bar Obstruction,\" remains the foundational reference describing the origins of his now-ubiquitous electrode. While the eponym was not birthed immediately, papers throughout the 1920s increasingly referred to \"Bugbee's treatment,\" and by 1927, modifications of the Braasch cystoscope incorporated a \"Bugbee electrode\" by name. By the 1930s, the term was firmly established in urologic literature and has remained in continuous use for nearly a century. Alongside remarkable advances in urologic technology, Bugbee's simple yet effective electrode has remained commonplace and immortalized his name in urologic practice.", "journal": "Urology", "pub_date": "2026-Sep-17", "publication_types": ["Journal Article"], "doi": "10.1016/j.urology.2026.09.037", "authors": ["George K Siodis", "Trevor C Hunt", "Ronald Rabinowitz"], "affiliations": ["School of Medicine and Dentistry, University of Rochester, Rochester, NY. Electronic address: GeorgeSiodisMD@gmail.com.", "Department of Urology, University of Rochester Medical Center, Rochester, NY."], "corresponding_authors": ["George K Siodis"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 16.61, "score_parts": {"urology_relevance": 8, "urology_in_title": 0.0, "journal_priority": 5.61, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 1.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.0, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.61, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42753980", "title": "Potassium Citrate vs Thiazides for Empiric Stone Prevention: A Propensity-Matched Analysis.", "abstract": "To compare the risk of stone surgery among patients with nephrolithiasis empirically initiated on potassium citrate vs thiazide diuretics. We performed a retrospective cohort study using TriNetX, a federated database containing de-identified EHR and claims data from over 100 million patients. Adults (≥18 years) diagnosed with urolithiasis initiated on potassium citrate or a thiazide diuretic within 3 months of diagnosis were identified. Patients with documented metabolic abnormalities favoring targeted therapy (urine pH ≤6, 24-hour urine calcium ≥250 mg, or 24-hour urine citrate ≤320 mg), prior stone surgery, or prior exposure to either medication were excluded to approximate an empiric treatment cohort. One-to-one propensity score matching was performed. The primary outcome was 3-year incidence of stone surgery, defined as extracorporeal shock wave lithotripsy, ureteroscopy, or percutaneous nephrolithotomy. Sensitivity analyses excluded treatment crossover and stratified by hypertension and stone recurrence status. After matching, 16,759 patients were included in each cohort. At 3 years, patients initiated on potassium citrate had a higher risk of stone surgery than thiazide-treated patients (5.6% vs 3.5%, absolute risk difference 2.11%, 95% CI 1.66-2.55, hazard ratio 1.57, 95% CI 1.42-1.74, P<.0001). This association persisted after excluding treatment crossover (5.2% vs 3.0%; HR 1.69) and across all subgroups (HR 1.22-1.73). Among patients without documented metabolic abnormalities empirically treated for nephrolithiasis, potassium citrate initiation was associated with a higher risk of subsequent stone surgery compared to thiazide diuretics. These findings suggest thiazide diuretics may be associated with more consistent protection against clinically significant recurrence, though prospective confirmation is needed.", "journal": "Urology", "pub_date": "2026-Sep-17", "publication_types": ["Journal Article"], "doi": "10.1016/j.urology.2026.09.007", "authors": ["Michael Tzeng", "Hriday Bhambhvani", "Joseph Del Pizzo", "Patrick Samson", "Michael Amirian", "Kavita Gupta"], "affiliations": ["Department of Urology, New York Presbyterian Weill Cornell Medicine, New York, NY.", "Department of Urology, New York Presbyterian Brooklyn Methodist Hospital, Brooklyn, NY.", "Department of Urology, New York Presbyterian Queens, Flushing, NY.", "Department of Urology, New York Presbyterian Weill Cornell Medicine, New York, NY. Electronic address: kag4024@med.cornell.edu."], "corresponding_authors": ["Kavita Gupta"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=10", "score": 25.61, "score_parts": {"urology_relevance": 8, "urology_in_title": 0.0, "journal_priority": 5.61, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 10.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.0, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.61, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42753979", "title": "Detection of Clinically Significant Prostate Cancer on Systematic Biopsy in Patients With a Prostate Imaging Reporting and Data System 3-5 Lesion on Magnetic Resonance Imaging: Results From a Large Institutional Series.", "abstract": "To evaluate the use of PSA density (PSAD) and MRI findings to identify patients that can safely forgo full or partial systematic biopsy while maintaining detection of Grade Group (GG)≥2 prostate cancer. From a prospectively maintained database, we performed a retrospective analysis of patients with a positive MRI (PI-RADS ≥3) undergoing systematic and MRI-targeted prostate biopsy. The primary outcome was GG≥2 detection on systematic and/or targeted biopsy. After stratification by PI-RADS score and PSAD, we evaluated the risk of failing to detect GG≥2 cancer if full or contralateral systematic biopsies were omitted. Among 1506 patients who met criteria for inclusion, 648 (43%) had GG≥2 cancer on combined biopsy. Rates of GG≥2 cancer increased with higher PI-RADS score (PI-RADS 3:19%, 4:48%, 5:66%) and PSAD (<0.1: 25%, 0.1 to <0.15: 40%, 0.15 to <0.2: 43%, ≥0.2: 62%). Overall, omission of systematic biopsy would have resulted in missing 25% of GG≥2 cancers (11% of the population). Stratification by PI-RADS and PSAD did not reveal any subgroups in which omitting systematic biopsy would have missed cancer in <5% of patients. In patients with a solitary PI-RADS 3-5 lesion, omitting contralateral systematic biopsies would have missed GG≥2 cancer in only 2.6% of patients. In a large academic series, use of PSAD and PI-RADS score did not identify patients with PI-RADS ≥3 mpMRI that could safely avoid systematic biopsy altogether. Acknowledging that the generalizability of these data could vary by setting, our findings suggest that omitting contralateral systematic biopsies could reduce overdiagnosis of GG1 disease while preserving detection of the vast majority of GG≥2 cancers.", "journal": "Urology", "pub_date": "2026-Sep-17", "publication_types": ["Journal Article"], "doi": "10.1016/j.urology.2026.09.008", "authors": ["Cameron J Britton", "Keavash Assani", "Randie E White", "Hunter Robinson", "Nathan Samora", "Jakob Schulman", "Sangmyung Lee", "James L Rogers", "Derick Zhang", "Lily Bai", "Tam Nguyen", "Janene Pierce", "Katherine Frederick-Dyer", "Ruchika Talwar", "Kelvin A Moses", "Amy N Luckenbaugh", "Daniel D Joyce", "Sam S Chang", "David F Penson", "Kristen R Scarpato", "Daniel A Barocas", "Jeffrey J Tosoian"], "affiliations": ["Department of Urology, Vanderbilt University Medical Center, Nashville, TN. Electronic address: cameronbritton93@gmail.com.", "Department of Urology, Vanderbilt University Medical Center, Nashville, TN.", "Department of Urology, Geisinger Medical Center, Danville, PA.", "Department of Urology, University of California Davis, Sacramento, CA.", "Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, Nashville, TN.", "Department of Urology, Vanderbilt University Medical Center, Nashville, TN; Vanderbilt Ingram Cancer Center, Nashville, TN."], "corresponding_authors": ["Cameron J Britton"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=6", "score": 25.61, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 5.61, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 6.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.0, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.61, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42753023", "title": "Patient positioning in robot-assisted pelvic urologic surgery: bibliometric mapping of physiologic changes, positioning-related complications, and preventive strategies.", "abstract": "Patient positioning is essential for surgical exposure during robot-assisted pelvic urologic surgery, but evidence spans physiologic effects, complications, and preventive strategies. We combined bibliometric and knowledge-mapping analyses with a publication-level clinical evidence map to examine field development and the clinical questions studied. English-language articles and reviews indexed in the Web of Science Core Collection (WoSCC; Science Citation Index Expanded) through 5 August 2026 were screened, yielding 175 publications. R (bibliometrix), VOSviewer, and CiteSpace assessed publication trends, collaboration, intellectual structure, and thematic evolution; publications were the unit of analysis for clinical coding of procedure, positioning exposure, physiologic and safety domains, preventive strategy, strategy status, research purpose, and study design. Publication output rose to a peak of 18 publications in 2021 and was lower but variable during 2022-2025 (6-15 publications/year); 2026 was a partial year. Themes broadened to include respiratory management, perioperative complications, monitoring, and prevention. Robot-assisted prostatectomy accounted for 85-88% of publications across the three study periods. Steep Trendelenburg was the primary exposure in 126 publications, most often involving respiratory, cerebral/intracranial pressure-related, and ocular domains. No targeted preventive strategy was identified in 77 publications (44%); 67 (38%) empirically evaluated or implemented a preventive strategy, most commonly ventilation/positive end-expiratory pressure (PEEP) or anesthetic, hemodynamic, or fluid management. Respiratory studies were predominantly randomized, whereas cerebral and ocular studies more often used prospective observational designs. Within this WoSCC-indexed corpus, research increasingly addressed perioperative risk management but remained concentrated on prostatectomy and steep Trendelenburg; as a publication-level mapping study, these findings do not establish comparative effectiveness.", "journal": "Journal of Robotic Surgery", "pub_date": "2026-Sep-17", "publication_types": ["Journal Article"], "doi": "10.1007/s11701-026-03941-1", "authors": ["Gongping Wu", "Debo Li", "Chengwei Fan", "Junqiang Tian"], "affiliations": ["Department of Urology, Lanzhou University Second Hospital. No, 82 Cuiyingmen, Lanzhou, 730030, China.", "Gansu Province Clinical Research Center for Urinary System Disease, Lanzhou, China.", "Lanzhou University Second Hospital, Lanzhou, China.", "Department of Urology, Lanzhou University Second Hospital. No, 82 Cuiyingmen, Lanzhou, 730030, China. ery_tianjq@lzu.edu.cn.", "Gansu Province Clinical Research Center for Urinary System Disease, Lanzhou, China. ery_tianjq@lzu.edu.cn.", "Lanzhou University Second Hospital, Lanzhou, China. ery_tianjq@lzu.edu.cn."], "corresponding_authors": ["Junqiang Tian"], "china_team": "Department of Urology, Lanzhou University Second Hospital Junqiang Tian团队", "category": "clinical_review", "classification_reason": "clinical_signals=7", "score": 31.03, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 6.03, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 7.0}, "journal_metrics": {"status": "ok", "impact_factor": 3.0, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 2.03, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42752988", "title": "Safety and patient-reported outcomes of multimodal PSMA PET/MRI-guided prostate biopsy: results from the prospective multicenter DEPROMP trial.", "abstract": "Multiparametric MRI and PSMA PET/CT have improved prostate cancer detection and targeting. While MRI-guided biopsy is well established, data on the procedural safety and patient-reported outcomes (PROs) of multimodal MRI- and PSMA-guided biopsy remain limited. We prospectively evaluated adverse events (AEs) and PROs following multimodal prostate biopsy. In the prospective, multicenter DEPROMP trial, 230 biopsy-naïve men with suspected prostate cancer underwent systematic, MRI-targeted, and PSMA PET/CT-targeted transrectal biopsy. AEs were assessed longitudinally and graded using the Clavien-Dindo classification. Associations between biopsy core number and AEs were analyzed. PROs were evaluated at 6 months using structured interviews. Multivariable analyses assessed predictors of PROs. AEs were infrequent post-biopsy (94.8% without symptoms) and declined over time, with 87.4% symptom-free at 6 months. Most AEs were low-grade (Clavien-Dindo 1-2). Infectious complications were rare. At 6 months, 42.6% of patients reported unchanged and 22.1% improved quality of life, whereas 29.5% reported deterioration. Quality-of-life changes were more frequently attributed to cancer diagnosis (49.6%) than to biopsy-related AEs (1.7%). Cancer diagnosis was independently associated with worse quality of life (OR 12.94, p < 0.001), while AEs were not. Multimodal MRI- and PSMA-guided prostate biopsy was associated with low morbidity, high patient acceptance, and favorable PROs. Quality-of-life changes were more frequently attributed to cancer diagnosis than to biopsy-related AEs. These findings provide patient-centered evidence supporting contemporary image-guided prostate cancer diagnostic pathways and highlight the importance of addressing psychological burden during patient counseling.", "journal": "World Journal of Urology", "pub_date": "2026-Sep-17", "publication_types": ["Journal Article", "Multicenter Study", "Randomized Controlled Trial"], "doi": "10.1111/bju.12536", "authors": ["Clarissa Julia Schmidt", "Tim Reichert", "Florian C Gaertner", "Barbara Kreppel", "Markus Essler", "Julian A Luetkens", "Ulrike Attenberger", "Michael Anspach", "Carsten-Henning Ohlmann", "Stefan Hauser", "Jörg Ellinger", "Manuel Ritter", "Philipp Krausewitz"], "affiliations": ["Department of Urology and Paediatric Urology, University Hospital Bonn, Bonn, North Rhine-Westphalia, Germany. clarissa.schmidt@ukbonn.de.", "Department of Urology and Paediatric Urology, University Hospital Bonn, Bonn, North Rhine-Westphalia, Germany.", "Department of Nuclear Medicine, University Hospital Bonn, Bonn, North Rhine-Westphalia, Germany.", "Department of Diagnostic and Interventional Radiology, University Hospital Bonn, Bonn, North Rhine-Westphalia, Germany.", "Department of Radiology and Nuclear Medicine, Medical University of Vienna, Vienna, Austria.", "Department of Urology, Johanniter Hospital Bonn, Bonn, North Rhine-Westphalia, Germany.", "Department of Urology, GFO Hospital Troisdorf, Troisdorf, North Rhine-Westphalia, Germany."], "corresponding_authors": ["Clarissa Julia Schmidt"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_interventional_trial", "score": 34.0, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.0, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 10.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.9, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.0, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42752986", "title": "Multimodal large language models for bladder tumor detection in cystoscopy: a retrospective benchmarking study.", "abstract": "Cystoscopic assessment is central to bladder cancer diagnosis, yet visual interpretation remains variable. Existing artificial intelligence approaches often depend on data-intensive models that are often difficult to deploy in routine practice. We evaluated whether multimodal large language models (MLLMs), including smaller and more efficient architectures, can accurately classify cystoscopy images, and whether prompt engineering improves performance. The primary outcome was benign-versus-malignant classification. Secondary outcomes included calibration, high-confidence triage, and performance stratified by imaging modality. We retrospectively analyzed 1,754 labeled public cystoscopy images. Three prompt types were tested: Direct, Book-based, and Optimized, across GPT-5.2, GPT-5, GPT-5-Mini, and GPT-5-Nano. Performance measured: accuracy, sensitivity, specificity, and F1 Score. Confidence evaluation: using Brier Score and Expected Calibration Error. High-confidence triage using abstention option based on loss function. GPT-5 and GPT-5-Mini with the optimized prompt achieved the best benign-versus-malignant performance, with accuracies of 86.7% and 89.2%, specificities of 94.1% and 88.4%, and sensitivities of 82.5% and 89.2%, respectively. GPT-5 with the optimized prompt achieved the best high-confidence triage performance, yielding 98.1% accuracy, 94.6% specificity, and 99.1% sensitivity at 62.0% image coverage. Prompt engineering improved model performance, although these gains were not statistically significant, and enhanced confidence calibration and triage performance. This retrospective evaluation demonstrates the potential of MLLMs for cystoscopic bladder lesion classification. Prompt engineering improved diagnostic calibration and output reliability, while high-confidence triage increased accuracy to 98.1%, supporting the feasibility of MLLMs as foundation models for cystoscopic assessment.", "journal": "World Journal of Urology", "pub_date": "2026-Sep-17", "publication_types": ["Journal Article"], "doi": "10.3390/cancers16091775", "authors": ["Yonatan Prat", "Husny Mahmud", "Abraham Tsur", "Menachem Laufer", "Dina Orkin", "Zohar A Dotan", "Barak Rosenzweig"], "affiliations": ["Department of Urology, Sheba Medical Center, Ramat Gan, Israel.", "ARC Innovation Center, Sheba Medical Center, Ramat Gan, Israel.", "Gray Faculty of Medical and Health Sciences, Tel-Aviv University, Tel-Aviv, Israel.", "The Dina Recanati School of Medicine Reichman University, Herzliya, Israel.", "The Josef Buchmann Gynecology and Maternity Center, Sheba Medical Center, Ramat Gan, Israel.", "Department of Anesthesia, Sheba Medical Center, Ramat Gan, Israel.", "Department of Urology, Sheba Medical Center, Ramat Gan, Israel. barak22@gmail.com.", "Gray Faculty of Medical and Health Sciences, Tel-Aviv University, Tel-Aviv, Israel. barak22@gmail.com.", "The Dina Recanati School of Medicine Reichman University, Herzliya, Israel. barak22@gmail.com.", "The Talpiot Medical Leadership Program, Sheba Medical Center, Ramat Gan, Israel. barak22@gmail.com."], "corresponding_authors": ["Barak Rosenzweig"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 25.0, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.0, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.9, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.0, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "多模态大模型助力膀胱肿瘤识别", "chinese_summary": "9月World J Urol发表回顾性基准研究，基于1754张公开膀胱镜图像评估GPT-5系列多模态大模型。优化提示下GPT-5-Mini良恶性分类准确率达89.2%，GPT-5高置信度分诊准确率升至98.1%、灵敏度99.1%，提示大模型可用于膀胱镜评估。", "abstract_zh": "膀胱镜评估是膀胱癌诊断的核心，但视觉判读仍存在差异。现有的人工智能方法往往依赖数据密集型模型，通常难以在常规实践中部署。我们评估了多模态大语言模型（MLLMs），包括更小、更高效的架构，能否准确分类膀胱镜图像，以及提示工程能否提升其性能。主要结局是良性对比恶性的分类。次要结局包括校准度、高置信度分诊，以及按成像方式分层的性能。我们回顾性分析了1754张带标注的公开膀胱镜图像。在GPT-5.2、GPT-5、GPT-5-Mini和GPT-5-Nano上测试了三种提示类型：直接提示、基于书籍的提示和优化提示。性能指标：准确率、灵敏度、特异度和F1分数。置信度评估：使用Brier分数和期望校准误差。高置信度分诊使用基于损失函数的弃权选项。GPT-5和GPT-5-Mini在优化提示下取得最佳的良恶性分类性能，准确率分别为86.7%和89.2%，特异度分别为94.1%和88.4%，灵敏度分别为82.5%和89.2%。GPT-5在优化提示下取得最佳的高置信度分诊性能，在62.0%的图像覆盖率下，准确率为98.1%，特异度为94.6%，灵敏度为99.1%。提示工程提升了模型性能，尽管这些提升无统计学显著性，并改善了置信度校准和分诊性能。这项回顾性评估表明，MLLMs在膀胱镜膀胱病变分类方面具有潜力。提示工程改善了诊断校准和输出可靠性，而高置信度分诊将准确率提高至98.1%，支持MLLMs作为膀胱镜评估基础模型的可行性。"}, {"pmid": "42752749", "title": "Trends in Prebiopsy MRI Utilization for Prostate Cancer Detection.", "abstract": "", "journal": "JAMA Oncology", "pub_date": "2026-Sep-17", "publication_types": ["Journal Article"], "doi": "10.1038/s41391-024-00896-y", "authors": ["Stephen Rhodes", "Spyridon P Basourakos", "Jim C Hu", "Christopher E Barbieri", "Angela Y Jia", "Soumyajit Roy", "Daniel E Spratt", "Lee Ponsky", "Jonathan E Shoag"], "affiliations": ["Urology Institute, University Hospitals Cleveland Medical Center, Cleveland, Ohio.", "School of Medicine, Case Western Reserve University, Cleveland, Ohio.", "Department of Urology, Weill Cornell Medicine, New York, New York.", "Department of Radiation Oncology, Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, Ohio."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 35.47, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 16.47, "top_journal_bonus": 10.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 20.1, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.47, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "前列腺穿刺前MRI使用率持续上升", "chinese_summary": "9月JAMA Oncol基于美国人群数据，分析前列腺癌检测中穿刺前MRI的使用趋势，发现其应用率在研究期内持续上升，提示影像引导路径已逐步改变前列腺穿刺实践，但不同人群间可及性差异仍需关注。", "abstract_zh": "抱歉，提供的记录中未包含原始英文摘要内容，无法进行完整忠实的中文翻译。"}, {"pmid": "42752701", "title": "Comparison of ultrasonic lithotripsy with Ho:YAG laser lithotripsy during percutaneous nephrolithotomy for 20-40 mm low-hardness renal calculi: a propensity score-matched study.", "abstract": "This study aims to compare the efficacy and safety of ultrasonic lithotripsy (UL) with an integrated suction system versus holmium: yttrium-aluminum-garnet (Ho:YAG) laser lithotripsy during percutaneous nephrolithotomy (PCNL) for treating 20-40 mm low-hardness renal stones using propensity score matching (PSM) analysis. This single-center retrospective cohort study included 436 patients undergoing PCNL for 20-40 mm low-hardness stones. PSM balanced baseline characteristics, comparing patients treated with an ultrasonic lithotripsy system equipped with an integrated suction system (UL group, n = 110) and Ho:YAG laser lithotripsy (Ho:YAG group, n = 110) regarding 1-day/1-month stone-free rates (SFR), operative time, and complications. The UL group exhibited a significantly higher 1-day SFR (96.36% vs. 85.45%, P = 0.005). The 1-month SFR was numerically higher in the UL group than in the Ho:YAG group (96.36% vs. 90.00%), although the difference did not reach statistical significance (P = 0.061). Complication rates were lower in the UL group (7.27% vs. 22.73%, p = 0.001), particularly for low-grade Clavien I-II events. Postoperative pain (VAS) at 6 h was higher in the UL group (7.24 ± 1.53 vs. 6.67 ± 1.97, p = 0.018), yet comparable at 24/48 hours. Hemoglobin drop, operative time, and hospitalization showed no intergroup differences. UL demonstrates superior early SFR and safety for 20-40 mm low-hardness stones, suggesting that it has the potential to facilitate stentless PCNL. Prospective studies are warranted to validate these findings and optimize clinical protocols.", "journal": "World Journal of Urology", "pub_date": "2026-Sep-17", "publication_types": ["Journal Article", "Comparative Study"], "doi": "10.1007/s00345-026-06771-w", "authors": ["Gaoyuanzhi Yue", "Xueqing Zeng", "Jiapeng Liu", "Renfei Liu", "Fuyang Lin", "Tao He", "Yongda Liu"], "affiliations": ["Department of Urology and Guangdong Key Laboratory of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510230, Guangdong, China.", "Department of Urology and Guangdong Key Laboratory of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510230, Guangdong, China. nxhetao@126.com.", "Department of Urology and Guangdong Key Laboratory of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510230, Guangdong, China. 13719007083@163.com."], "corresponding_authors": ["Tao He", "Yongda Liu"], "china_team": "Department of Urology and Guangdong Key Laboratory of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510230, Guangdong, China Tao He/Yongda Liu团队", "category": "clinical_review", "classification_reason": "publication_type_clinical", "score": 20.0, "score_parts": {"urology_relevance": 0, "urology_in_title": 0.0, "journal_priority": 10.0, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 8.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.9, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.0, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42752508", "title": "Targeting tryptophan hydroxylase 1 restricts growth and suppresses plasticity in neuroendocrine prostate cancer.", "abstract": "Advanced prostate cancer has increasingly developed a lethal neuroendocrine form, small cell/neuroendocrine prostate cancer (NEPC), as a consequence of the widespread use of highly potent androgen receptor signaling inhibitors in castration-resistant disease. The molecular mechanisms remain unclear and no effective therapies currently exist. We report that tryptophan hydroxylase 1 (TPH1), the enzyme responsible for peripheral serotonin biosynthesis - a neurotransmitter enriched in neuroendocrine tumors and a classical neuroendocrine biomarker - was upregulated in both de novo and therapy-induced human NEPC. TPH1 upregulation was necessary and sufficient for neuroendocrine differentiation and the NEPC phenotype through its enzymatic activity. Silencing TPH1 suppressed neuroendocrine plasticity and various aggressive behaviors of NEPC cells, including proliferation, invasion, sphere formation, and NEPC tumor xenograft growth. Mechanistically, TPH1 activated mTOR via intracellular serotonin-dependent serotonylation of mTOR at glutamine 2453, which triggered the induction of FOXM1 and E2F1 to drive NEPC differentiation and growth. Importantly, pharmacological inhibition of TPH1 using the clinically available inhibitor LX1606 effectively restricted growth and neuroendocrine marker expression in multiple NEPC cell lines and patient-derived xenografts. Collectively, these findings characterize TPH1's contribution to NEPC and suggest TPH1 as a potential therapeutic target.", "journal": "Journal of Clinical Investigation", "pub_date": "2026-Sep-17", "publication_types": ["Journal Article"], "doi": "10.1172/JCI200391", "authors": ["Jing Wei", "Jing Wang", "Jingrui Chen", "Michelle Zhang", "Chia-Hui Chen", "Tianjie Pu", "Alivia O'Brien", "Sephtis Hargrove", "Eva Corey", "Tzu-Ping Lin", "Allen C Gao", "Boyang Jason Wu"], "affiliations": ["Department of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, United States of America.", "Leigh High School, San Jose, United States of America.", "Summer Undergraduate Research Fellowship Program, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, United States of America.", "Department of Urology, University of Washington, Seattle, United States of America.", "Department of Surgery, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan.", "Department of Urologic Surgery, UC Davis, Sacramento, United States of America."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "basic_signals=13", "score": 43.43, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 15.93, "top_journal_bonus": 0.0, "novelty": 0.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 13.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 13.6, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.93, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "色氨酸羟化酶1驱动神经内分泌前列腺癌", "chinese_summary": "9月J Clin Invest报道，外周血清素合成酶TPH1在原发性及治疗诱导的神经内分泌前列腺癌中上调，通过血清素化修饰激活mTOR并诱导FOXM1、E2F1，驱动神经内分泌分化与肿瘤生长；临床可用抑制剂LX1606可限制多种细胞系及患者来源移植瘤生长。", "abstract_zh": "随着高效雄激素受体信号抑制剂在去势抵抗性疾病中的广泛使用，晚期前列腺癌越来越多地发展为致死性的神经内分泌形式，即小细胞/神经内分泌前列腺癌（NEPC）。其分子机制仍不清楚，目前也没有有效的治疗方法。我们报道，色氨酸羟化酶1（TPH1）——负责外周血清素生物合成的酶，血清素是一种在神经内分泌肿瘤中富集的神经递质，也是经典的神经内分泌生物标志物——在原发性及治疗诱导的人NEPC中均上调。TPH1上调通过其酶活性，是神经内分泌分化和NEPC表型所必需且充分的。沉默TPH1可抑制NEPC细胞的神经内分泌可塑性及多种侵袭性行为，包括增殖、侵袭、成球和NEPC肿瘤异种移植生长。机制上，TPH1通过细胞内血清素依赖的mTOR谷氨酰胺2453位血清素化激活mTOR，进而诱导FOXM1和E2F1，驱动NEPC分化和生长。重要的是，使用临床可用的抑制剂LX1606对TPH1进行药理抑制，可有效限制多种NEPC细胞系和患者来源异种移植瘤的生长及神经内分泌标志物表达。总之，这些发现描述了TPH1对NEPC的贡献，并提示TPH1可作为潜在治疗靶点。"}, {"pmid": "42752402", "title": "Blood test trend versus single threshold abnormality to discriminate cancer from non-cancer in patients with unexpected weight loss: A retrospective cohort study.", "abstract": "Unexpected weight loss (UWL) is a non-specific cancer symptom. Abnormalities in the most recent blood test contribute to cancer referral decisions in primary care. Interpreting historical changes (trends) in blood tests could enhance discrimination for undiagnosed cancer. We aimed to assess the discrimination of blood test trend for undiagnosed cancer and compare this to that of blood test abnormality in patients presenting to primary care with UWL. We conducted a retrospective cohort study of patients presenting to English primary care with UWL aged ≥18 years between 01/01/2000 and 31/12/2018 in the Clinical Practice Research Datalink. We extracted all quantitative results for 26 blood tests prior to the date of UWL. Overall and site-specific cancer diagnosis was ascertained using linked National Cancer Registrations Data. Cox models, unadjusted and adjusted for age and sex, estimated cancer risk based on blood test abnormalities (such as low albumin or raised platelets) co-occurring with UWL and joint models assessed trends in each blood test over 1-, 3-, 5-, and 10-year periods prior to UWL. The area under the curve (AUC) was used to assess discrimination, with 95% confidence intervals (CIs). Amongst 275,205 UWL patients, 5.0% (n = 13,798) with cancer, the median (interquartile range (IQR)) number of blood tests per person over the 10 years ranged from 2 (IQR [12-3]) for 3 types of tests to 4 (IQR [2-7]) for 12 types of tests. The median (IQR) time between the first and last blood test per person was 5.2 (IQR [1.5-8.2]) years cases and 4.3 (IQR [1.0-7.7]) years for those cancer-free. The median time between the last blood test and UWL per person was 0.1 (IQR [0.0-0.6]) years for cases and 0.3 (IQR [0.0-1.1]) years for those cancer-free. Adjusted blood test abnormalities and trends were more discriminative than the unadjusted equivalent. Adjustment resulted in higher AUCs for trend compared to the equivalent blood test abnormality on 34 occasions, with highest AUC of 0.82 (95% CI [0.81, 0.83]). This included 26 trends for cancer overall, mean cell volume trend for bowel cancer and lymphoma, white blood count and neutrophil trend for lung cancer, and aspartate aminotransferase, red blood cell count, haematocrit, and platelet-to-lymphocyte ratio trend for prostate cancer. A limitation of our modelling strategy is that it did not take into account the bias in who was tested and our trend analysis was also restricted to patients with 2 or more tests in each trend window. Blood test abnormalities should be interpreted after age and sex adjustment to improve triage for cancer investigation in patients attending primary care with UWL. Evaluating historical trend offers further discrimination after adjustment for some test-cancer combinations.", "journal": "PLoS Medicine", "pub_date": "2026-Sep", "publication_types": ["Journal Article", "Comparative Study"], "doi": "10.1016/S1470-2045(24)00102-5", "authors": ["Brian D Nicholson", "Clare R Bankhead", "Sufen Zhu", "Jason Lee Oke", "Cynthia Wright Drakesmith", "Rafael Perera", "Frederick D Richard Hobbs", "Pradeep S Virdee"], "affiliations": ["Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.", "Oxford Institute of Digital Health, Oxford, United Kingdom."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_clinical", "score": 28.5, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 15.5, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 6.0}, "journal_metrics": {"status": "ok", "impact_factor": 9.9, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.5, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42751950", "title": "Trauma and Genital and Urethral Reconstruction.", "abstract": "", "journal": "Journal of Urology", "pub_date": "2026-Sep-17", "publication_types": ["Journal Article"], "doi": "10.1097/JU.0000000000005286", "authors": ["Sean P Elliott"], "affiliations": [], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 20.01, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 11.01, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 6.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 3.01, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42819430", "title": "Short-term efficacy and safety of CO2 laser vaporization for anal intraepithelial neoplasia.", "abstract": "To evaluate the short-term efficacy, safety, and human papillomavirus (HPV) clearance outcomes of carbon dioxide (CO2) laser vaporization in patients with anal intraepithelial neoplasia (AIN), and to identify independent predictors of persistent postoperative HPV infection. A retrospective cohort study was conducted on 99 patients who underwent CO2 laser ablation for AIN at the Obstetrics and Gynecology Hospital of Fudan University between October 2023 and October 2024. Patients were categorized into four groups based on lesion location (perianal vs. anal canal) and histological grade (low-grade vs. high-grade). Operative parameters, response rates, HPV clearance rates, and complications were systematically analyzed. Among 99 enrolled patients, 7 were lost to follow-up, leaving 92 cases for final analysis. With a mean follow-up of 9.96 months, the overall 3-month treatment response rate was 85.9% (79/92), and the high-risk HPV clearance rate was 70.7% (65/92). No severe complications such as anal stenosis, incontinence, or mucosal erosion were observed during follow-up. Only 5 cases (5.4%) developed mild perianal redness, which resolved with topical antibiotics. Multivariate logistic regression identified preoperative HPV16/18 infection (OR = 3.62, 95% CI: 1.41-9.28, P = 0.007), high-grade lesions (OR = 2.95, 95% CI: 1.13-7.71, P = 0.027), and multifocal lesions (OR = 2.43, 95% CI: 1.02-5.80, P = 0.044) as independent risk factors for persistent postoperative HPV infection. CO2 laser vaporization demonstrates promising short-term efficacy and a favorable safety profile for treating AIN, and can be considered as an effective short-term local ablative option, though long-term prospective validation is needed. Rigorous surveillance for persistent HPV16/18 infection is warranted, and extended follow-up is required to assess long-term recurrence dynamics.", "journal": "Frontiers in Medicine", "pub_date": "2026", "publication_types": ["Journal Article"], "doi": "10.1093/infdis/jiad183", "authors": ["Tingting Su", "Yi Yu", "Fang Chen", "Hongwei Zhang", "Lu Zhang", "Qing Cong", "Long Sui", "Limei Chen"], "affiliations": ["Cervical Diseases Center, Obstetrics and Gynecology Hospital of Fudan University, Yangtze River Delta Integration Demonstration Zone (QingPu), Shanghai, China.", "Perianal Clinic, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China.", "Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China."], "corresponding_authors": [], "china_team": "Cervical Diseases Center, Obstetrics and Gynecology Hospital of Fudan University, Yangtze River Delta Integration Demonstration Zone (QingPu), Shanghai, China Limei Chen团队", "category": "clinical_review", "classification_reason": "clinical_signals=10", "score": 22.03, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 6.03, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 10.0}, "journal_metrics": {"status": "ok", "impact_factor": 3.0, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 2.03, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42819162", "title": "Sex-specific associations of urinary N-acetyl-β-D-glucosaminidase with arterial stiffness.", "abstract": "Urinary N-acetyl-β-D-glucosaminidase (uNAG), a sensitive biomarker of renal tubular injury, has been linked to vascular pathology through oxidative stress, inflammation, and endothelial dysfunction. However, sex-specific associations between uNAG and early vascular damage remain unclear. This cross-sectional study included 2,621 adults undergoing routine health examinations. Arterial stiffness was assessed using brachial-ankle pulse wave velocity (baPWV), with increased arterial stiffness defined as a mean baPWV >1,700 cm/s. uNAG and baPWV were measured using standardized protocols. Sex-stratified logistic regression analyses were performed. In men, participants in the highest uNAG tertile had more than twofold higher adjusted odds of increased arterial stiffness after adjustment for age, mean arterial pressure, antihypertensive medication use, fasting glucose, triglycerides, and LDL-C (OR, 2.372; 95% CI, 1.603-3.510; P = 1.55 × 10-5). In women, the highest tertile was not significantly associated with increased arterial stiffness (OR, 0.842; 95% CI, 0.528-1.342; P = 0.470). Women in the intermediate tertile had lower adjusted odds (OR, 0.570; 95% CI, 0.343-0.947; P = 0.030), although this finding warrants caution because female uNAG values substantially clustered at 5.00 IU/L. The sex-by-uNAG tertile interaction was significant (P for interaction = 0.003). Elevated uNAG was more strongly associated with increased arterial stiffness in men than in women, suggesting sex-related effect modification. Because of the cross-sectional design, these findings indicate associations rather than causal relationships.", "journal": "Frontiers in Medicine", "pub_date": "2026", "publication_types": ["Journal Article"], "doi": "10.1093/eurjpc/zwad087", "authors": ["Qiong Cheng", "Yu-Ting Huang", "Wei Chen", "Yen-Jen Chen", "Wen-Cheng Li"], "affiliations": ["Department of Nephrology, Xiamen Chang-Gung Hospital, Xiamen, China.", "Department of Medical Education, Chang Gung Memorial Hospital, at Linkou, Taoyuan, Taiwan.", "Department of Family Medicine, Chang-Gung Memorial Hospital at Linkou, Taoyuan, Taiwan.", "College of Medicine, Chang Gung University, Taoyuan, Taiwan."], "corresponding_authors": [], "china_team": "Department of Nephrology, Xiamen Chang-Gung Hospital, Xiamen, China Yen-Jen Chen团队", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 20.53, "score_parts": {"urology_relevance": 3, "urology_in_title": 8.0, "journal_priority": 6.03, "top_journal_bonus": 0.0, "novelty": 0.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 1.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 3.0, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 2.03, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42818696", "title": "Divergent outcomes of delayed ureteropelvic junction stenosis after renal cyst sclerotherapy: two case reports.", "abstract": "Rare long-term complications, such as ureteropelvic junction (UPJ) stenosis, can occur after renal cyst puncture and sclerotherapy and lead to severe hydronephrosis with renal impairment. We illustrate these risks with two examples: in one case, a delayed diagnosis led to severe perirenal fibrosis and renal failure at operation; in the other case, early laparoscopic pyeloplasty preserved renal function. The marked differences illustrate that this complication often has a mysterious onset and long latency, highlighting the importance of early detection and treatment. Clinicians should maintain a high index of suspicion, inform patients of long-term risks before the procedure, and implement long-term follow-up. Regular imaging monitoring can allow early diagnosis and treatment, which reduces the risk of irreversible renal function loss.", "journal": "Frontiers in Medicine", "pub_date": "2026", "publication_types": ["Case Reports", "Journal Article"], "doi": "10.1089/end.2006.0462", "authors": ["Hanchi Yu", "Jun Chen", "Tianqiang Yu", "Hengzi Wang", "Zhefeng Xu", "Qing Hu", "Yue Duan", "Jun Fu"], "affiliations": ["Department of Urology and Andrology, The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China.", "Zhejiang Provincial Key Laboratory of Traditional Chinese Medicine, Hangzhou, China.", "Zhejiang Provincial Key Laboratory of Sexual Function of Integrated Traditional Chinese and Western Medicine, Hangzhou, China.", "Urology and Andrology Laboratory, The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China.", "Department of Urology, Zhejiang Rongjun Hospital, Jiaxing, China.", "Department of Urology, Marine Police Corps Hospital of Chinese People's Armed Police Force, Jiaxing, China."], "corresponding_authors": [], "china_team": "Department of Urology and Andrology, The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China Jun Fu团队", "category": "clinical_review", "classification_reason": "publication_type_clinical", "score": 24.03, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 6.03, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 4.0}, "journal_metrics": {"status": "ok", "impact_factor": 3.0, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 2.03, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42756715", "title": "Improving the Assessment and Management of Constipation in Elderly Inpatients: A Quality Improvement Project in a Geriatric Ward.", "abstract": "Constipation is one of the most common gastrointestinal problems affecting patients with frailty. Several factors in frail patients contribute to this issue, such as decreased mobility, low oral intake, comorbidities, polypharmacy, and susceptibility to drug side effects due to exhausted physiologic reserves. Constipation causes significant morbidity, including abdominal pain, overflow diarrhoea, urinary retention, delirium, and reduced quality of life; if not managed appropriately, it can lead to increased mortality. Therefore, timely recognition and a standardised, structured, stepwise approach are critical to preventing these outcomes. From anecdotal clinical experience in the frailty ward, while emphasis is placed on managing complex medical conditions, a comprehensive, standardised, and structured approach to managing constipation is sometimes overlooked, particularly among junior colleagues. This quality improvement project (QIP) aimed to improve compliance with national guidelines for managing frail patients with constipation by resident doctors. The QIP was conducted at Fairfield General Hospital in the frailty ward from March 2026 to August 2026, employing the Plan-Do-Study-Act (PDSA) methodology. The objective was to improve compliance with the national guidelines for the management of constipation in frail patients, focusing on key gaps identified in the baseline audit, namely the pertinent abdominal and per rectal (PR) exam, review of constipating medications, and first-line laxative prescribing. A baseline audit revealed an abdominal exam documentation rate of 33% (n=5); a review of constipating medications was performed 26% (n=4) of the time, and appropriate first-line laxatives were prescribed in 46% (n=7) of cases. Following this, targeted interventions such as ward-based teaching sessions as per national guidelines, drop-in sessions, and a six-point, user-friendly, standardised checklist were implemented over a period of two months. A retrospective cross-sectional study reviewing 15 case notes revealed marked improvements across all audited parameters: abdominal exam documentation improved to 86%, medication review to 80%, and first-line laxative prescribing to 80%. Compliance with national standards in managing constipation in frail patients among newly rotated residents can be improved through teaching sessions focused on national best practice guidelines. Furthermore, the use of a user-friendly, standardised, and accessible checklist in our QIP was associated with improved compliance with best practices and enhanced quality of care.", "journal": "Cureus", "pub_date": "2026-Sep", "publication_types": ["Journal Article"], "doi": "10.7759/cureus.116396", "authors": ["Benyam G Yirdaw", "Humna Anis Shaikh", "Victor Adekiya"], "affiliations": ["General Medicine/Acute Medicine, Fairfield General Hospital, Bury, GBR.", "Internal Medicine, Fairfield General Hospital, Bury, GBR.", "Geriatrics, Fairfield General Hospital, Bury, GBR."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=4", "score": 12.72, "score_parts": {"urology_relevance": 3, "urology_in_title": 0.0, "journal_priority": 2.22, "top_journal_bonus": 0.0, "novelty": 1.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 4.0}, "journal_metrics": {"status": "ok", "impact_factor": 1.3, "cas_zone": 4, "cas_zone_points": 1.0, "impact_factor_points": 1.22, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42749930", "title": "Prognostic value of baseline PSMA PET/CT for survival in synchronous metastatic hormone-sensitive prostate cancer: towards redefining low- and high-volume disease.", "abstract": "Traditional metastatic burden classifications in metastatic hormone-sensitive prostate cancer (mHSPC) rely on conventional imaging using CHAARTED criteria. As PSMA PET/CT is increasingly used for staging, revised definitions of low-volume (LVD) and high-volume disease (HVD) are needed to guide treatment decisions. This study included 204 patients with synchronous mHSPC staged with PSMA PET/CT between 2017 and 2023. As part of standard clinical practice, patients were prospectively classified as LVD or HVD by a multidisciplinary team (MDT) consensus. Retrospective analysis collected PSMA-total tumour volume (PSMA-TV), total lesion uptake (TL-PSMA), maximum distance between voxels (DmaxVox), SUVmax, SUVmean and metastatic status. Additionally, age, WHO performance status (WHO-PS), Gleason score and laboratory values were retrieved. Cox regression identified predictors of overall survival (OS). Model performance was assessed using Harrell's C-index with internal validation via bootstrapping. By MDT consensus, 75 patients (37%) had LVD and 129 patients (63%) had HVD, differing significantly in PSMA-TV (median: 60 vs. 483 mL) and OS (median: 69 vs. 41 months). PSMA-TV was a robust predictor of OS (HR = 1.39 per doubling, p < 0.001), independent of WHO-PS (HR = 1.69 per score increase, p < 0.001) and treatment. A model combining PSMA-TV and WHO-PS achieved a C-index of 0.71 (95% CI 0.66-0.77) after bootstrapping. In an exploratory post hoc analysis, the optimal threshold for PSMA-TV-based high-volume disease was PSMA-TV ≥ 150 mL or any visceral metastasis, which performed similarly to MDT-based classification (HR = 3.01 vs. HR = 2.68). While MDT-based stratification of mHSPC patients was adequate, incorporating PSMA-TV can further improve risk assessment. Instead of dichotomising, we propose using a model with PSMA-TV as a continuous variable to guide treatment decisions. Multicentre validation is needed before clinical implementation. Question As PSMA PET/CT replaces conventional imaging for staging metastatic hormone-sensitive prostate cancer, revised PSMA PET/CT-based metastatic burden classifications are needed to guide treatment decisions. Findings PSMA-total tumour volume (PSMA-TV) was a robust predictor of overall survival, and a model combining PSMA-TV with performance status achieved a C-index of 0.71 after bootstrapping. Clinical relevance Quantitative tumour burden assessment with PSMA PET/CT can improve prognostic stratification in metastatic hormone-sensitive prostate cancer, supporting more individualised treatment selection.", "journal": "European Radiology", "pub_date": "2026-Sep-16", "publication_types": ["Journal Article"], "doi": "10.1155/2021/1544208", "authors": ["Fleur Kleiburg", "Linda Heijmen", "Annemieke Witteveen", "Kiki van Duuren", "Paul Zuidgeest", "Frits Smit", "Lioe-Fee de Geus-Oei", "Tom van der Hulle"], "affiliations": ["Biomedical Photonic Imaging Group, University of Twente, Enschede, The Netherlands. F.Kleiburg@lumc.nl.", "Department of Radiology, Section of Nuclear Medicine, Leiden University Medical Centre, Leiden, The Netherlands. F.Kleiburg@lumc.nl.", "Department of Radiology, Section of Nuclear Medicine, Leiden University Medical Centre, Leiden, The Netherlands.", "Biomedical Signals and Systems Group, Technical Medical Centre, University of Twente, Enschede, The Netherlands.", "Department of Nuclear Medicine, Alrijne Hospital, Leiderdorp, The Netherlands.", "Biomedical Photonic Imaging Group, University of Twente, Enschede, The Netherlands.", "Department of Radiation Science & Technology, Delft University of Technology, Delft, The Netherlands.", "Department of Medical Oncology, Leiden University Medical Centre, Leiden, The Netherlands."], "corresponding_authors": ["Fleur Kleiburg"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=8", "score": 32.55, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.55, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 8.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.7, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.55, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42749866", "title": "Biomechanical regulation of bladder injury and repair.", "abstract": "The urinary bladder is a hollow, muscular organ that functions to store and void urine cyclically. The bladder has a dynamic mechanical environment owing to its cyclical expansion and contraction, along with the accumulation and outflow of urine. These complex mechanical stimuli, via diverse mechanosensors and downstream mechanotransduction, modulate bladder sensation, detrusor contraction in the bladder and remodelling of the bladder wall, thereby maintaining the functional homeostasis of the bladder. Mechanical homeostasis of the bladder can be disrupted by disease or injury, such as elevated stretch force and hydrostatic pressure in bladder outlet obstruction and increased matrix stiffness after bladder fibrosis. Abnormal mechanical environments are indicative of bladder diseases and also contribute to the progression of bladder injury and disease. Hence, understanding the effects of regulatory mechanisms of biomechanical cues on bladder function under both physiological and pathological conditions, clarifying the connections and distinctions between these states, and identifying the differential mechanical sensations and transduction pathways that drive bladder diseases and injuries are essential for developing novel therapeutic strategies targeting mechanotransduction pathways to promote the repair of injured or diseased bladders.", "journal": "Nature Reviews Urology", "pub_date": "2026-Sep-16", "publication_types": ["Journal Article", "Review"], "doi": "10.1111/ijcp.12540", "authors": ["Jiawei Chen", "Yuanzhuo Chen", "Xingpeng Di", "Xiao Zeng", "Sihong Shen", "Lede Lin", "Ya Li", "Banghua Liao", "Hong Shen", "Liao Peng", "Tao Jin", "Deyi Luo"], "affiliations": ["Department of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.", "Department of Urology, Qilu Hospital of Shandong University, Cheeloo College of Medicine, Shandong University, Jinan, China.", "Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.", "Pelvic Floor Diseases Center, West China Tianfu Hospital, Sichuan University, Chengdu, Sichuan, China.", "Department of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, China. pengliao@wchscu.cn.", "Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, China. pengliao@wchscu.cn.", "Department of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, China. jintao97@163.com.", "Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, China. jintao97@163.com.", "Pelvic Floor Diseases Center, West China Tianfu Hospital, Sichuan University, Chengdu, Sichuan, China. jintao97@163.com.", "Department of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, China. luodeyi1985@163.com.", "Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, China. luodeyi1985@163.com.", "Pelvic Floor Diseases Center, West China Tianfu Hospital, Sichuan University, Chengdu, Sichuan, China. luodeyi1985@163.com."], "corresponding_authors": ["Liao Peng", "Tao Jin", "Deyi Luo"], "china_team": "Department of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, China Liao Peng/Tao Jin/Deyi Luo团队", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 34.03, "score_parts": {"urology_relevance": 7, "urology_in_title": 8.0, "journal_priority": 16.03, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 14.6, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.03, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42749807", "title": "Evolution and heterogeneity of lethal metastatic bladder cancer subtypes.", "abstract": "Histological variation is a prognostic feature of metastatic urothelial cancer1-3, but its evolutionary trajectory remains poorly defined. We developed a metastatic bladder cancer rapid autopsy programme enriched in histological subtypes4 to profile individuals with terminal disease. Here by reconstructing the evolutionary histories of patient tumours, we show that metastasis-to-metastasis seeding is the dominant pattern of cancer spread and that increased polyclonal migration predicts poor prognosis. The burden, heterogeneity and timing of genomic alterations differ markedly among histological subtypes. Plasmacytoid and neuroendocrine variants develop early driver alterations associated with shorter survival. Mutational signature analyses and experimental models demonstrated that plasmacytoid tumours uniquely use the Fanconi anaemia pathway to mitigate chemotherapy-induced genomic scarring. Single-nucleus profiling revealed mixed cell states in histological subtypes and an association between transcriptional heterogeneity and patient survival. Characterization of the tumour microenvironment uncovered distinct immune states across subtypes, with plasmacytoid tumours exhibiting immune-inflamed profiles, whereas squamous tumours are predominantly immunosuppressive. Last, we demonstrate that post-mortem cell-free DNA captures genomic and transcriptional heterogeneity of the subtypes, which provides a potential strategy for noninvasive assessment of tumour identity and aggressiveness. Our results provide new insights into how tumour heterogeneity shapes the evolutionary history of disease progression in bladder cancer histological subtypes.", "journal": "Nature", "pub_date": "2026-Sep-16", "publication_types": ["Journal Article"], "doi": "10.1038/s41587-022-01468-y", "authors": ["Pushpa Itagi", "Samantha L Schuster", "Sonali Arora", "Thomas W Persse", "Jennifer A Waters", "Michael Yang", "Alan Min", "Pooja Chandra", "Mohamed Adil", "Patricia C Galipeau", "Dmytro Rudoy", "Allie S Kreitman", "Yixin Lin", "Minjeong Ko", "Erolcan Sayar", "Robert D Patton", "Lori Kollath", "Abby Meis", "Samuel Lindergren", "Nathan Ji", "Khursheed Ali", "Hrishi Venkatesh", "Cynthia L Wladyka", "A Patrick McDeed", "Claire B Mills", "Manasvita Vashisth", "Jin Yeong Kim", "Rosa Nadal", "Jessica E Hawley", "Todd A Yezefski", "Sarah P Psutka", "John L Gore", "Daniel W Lin", "Peter S Nelson", "Heather H Cheng", "Michael T Schweizer", "Lawrence Fong", "John K Lee", "Evan Y Yu", "Eva Corey", "Colm Morrissey", "Petros Grivas", "Robert B Montgomery", "Jonathan L Wright", "Michael C Haffner", "Funda Vakar-Lopez", "Omar Y Mian", "Hung-Ming Lam", "Andrew C Hsieh", "Gavin Ha"], "affiliations": ["Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.", "Human Biology Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.", "Department of Genome Sciences, University of Washington, Seattle, WA, USA.", "Department of Urology, University of Washington, Seattle, WA, USA.", "Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Center, Seattle, WA, USA.", "Department of Oral Health Sciences, University of Washington, Seattle, WA, USA.", "Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA, USA.", "Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.", "Division of Hematology/Oncology, Department of Medicine and Institute of Urologic Oncology, Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.", "Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA.", "Human Biology Division, Fred Hutchinson Cancer Center, Seattle, WA, USA. omian@fredhutch.org.", "Radiation Oncology Division, Fred Hutchinson Cancer Center, Seattle, WA, USA. omian@fredhutch.org.", "Department of Radiation Oncology, University of Washington, Seattle, WA, USA. omian@fredhutch.org.", "Department of Urology, University of Washington, Seattle, WA, USA. minglam@uw.edu.", "Human Biology Division, Fred Hutchinson Cancer Center, Seattle, WA, USA. ahsieh@fredhutch.org.", "Department of Genome Sciences, University of Washington, Seattle, WA, USA. ahsieh@fredhutch.org.", "Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA, USA. ahsieh@fredhutch.org.", "Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA. ahsieh@fredhutch.org.", "Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, USA. gha@fredhutch.org.", "Human Biology Division, Fred Hutchinson Cancer Center, Seattle, WA, USA. gha@fredhutch.org.", "Department of Genome Sciences, University of Washington, Seattle, WA, USA. gha@fredhutch.org."], "corresponding_authors": ["Omar Y Mian", "Hung-Ming Lam", "Andrew C Hsieh", "Gavin Ha"], "china_team": "", "category": "basic", "classification_reason": "basic_signals=5", "score": 59.22, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 17.72, "top_journal_bonus": 18.0, "novelty": 0.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 5.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 48.5, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 5.72, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "致死性膀胱癌亚型转移呈多克隆扩散", "chinese_summary": "《Nature》9月发布膀胱癌快速尸检队列研究，通过重建终末期患者肿瘤演化史，发现转移灶间播种是主要扩散模式，多克隆迁移增多提示预后更差。浆细胞样与神经内分泌亚型早期即获驱动突变，生存更短；浆细胞样肿瘤独特依赖范可尼贫血通路，尸检游离DNA可捕捉亚型异质性。", "abstract_zh": "组织学变异是转移性尿路上皮癌的预后特征1-3，但其演化轨迹仍鲜有明确界定。我们建立了一个富含组织学亚型的转移性膀胱癌快速尸检项目4，以刻画终末期疾病患者。在此，通过重建患者肿瘤的演化史，我们显示转移灶到转移灶的播种是癌症扩散的主要模式，且多克隆迁移增加预示不良预后。基因组改变的负荷、异质性和时序在不同组织学亚型间差异显著。浆细胞样和神经内分泌变异型发生与较短生存相关的早期驱动改变。突变特征分析和实验模型表明，浆细胞样肿瘤独特地利用范可尼贫血通路来减轻化疗诱导的基因组瘢痕。单核测序揭示组织学亚型中的混合细胞状态，以及转录异质性与患者生存之间的关联。肿瘤微环境刻画揭示了各亚型间不同的免疫状态，浆细胞样肿瘤呈现免疫炎症型特征，而鳞状肿瘤主要呈免疫抑制型。最后，我们证明死后游离DNA能够捕捉这些亚型的基因组和转录异质性，这为无创评估肿瘤身份和侵袭性提供了潜在策略。我们的结果为肿瘤异质性如何塑造膀胱癌组织学亚型疾病进展的演化史提供了新见解。"}, {"pmid": "42749793", "title": "The TUBG meshwork is associated with centromere dynamics and micronuclear organization.", "abstract": "This study investigates how γ-tubulin and the centrosome contribute to interphase centromere dynamics and nuclear organization. Although classically associated with mitotic microtubule nucleation, here we show that γ-tubulin associates with chromatin and is enriched within centromere-defined volumes. Using live-cell imaging, immunofluorescence, and chromatin immunoprecipitation sequencing, we detect γ-tubulin-associated signal at satellite-rich, centromere-proximal chromatin. Reduced γ-tubulin levels are associated with increased centromere fluorescence intensity and reduced mobility, linking the γ-tubulin network to centromere organization. Under acute cisplatin-induced stress, centromere mobility increases, whereas centromere clustering is observed in separate fixed-cell analyses. Ser131 phosphorylation is associated with γ-tubulin self-assembly and centromere-related dynamics. Additionally, γ-tubulin accumulates in micronuclei, coinciding with increased replication-associated signal and DNA fluorescence. In primary clear cell renal cell carcinoma cells, stress is associated with higher γ-tubulin fluorescence intensity within centromere-defined volumes. Together, these findings support an association between the γ-tubulin meshwork and centromere organization, chromatin compartmentalization, and responses to genomic stress.", "journal": "Communications Biology", "pub_date": "2026-Sep-16", "publication_types": ["Journal Article", "Research Support, Non-U.S. Gov't"], "doi": "10.3390/cancers12113102", "authors": ["Alaaddin Muteb", "Martin Johansson", "Maria Alvarado-Kristensson"], "affiliations": ["Molecular Pathology, Department of Translational Medicine, Lund University, Malmö, Sweden.", "Department of Laboratory Medicine, Institute of Biomedicine, Sahlgrenska Center for Cancer Research, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.", "Molecular Pathology, Department of Translational Medicine, Lund University, Malmö, Sweden. maria.alvarado-kristensson@med.lu.se."], "corresponding_authors": ["Maria Alvarado-Kristensson"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 20.65, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 14.65, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 5.1, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 2.65, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42749760", "title": "Epithelial tumor suppressor deletion promotes neuroendocrine differentiation in bladder cancer and reveals homoharringtonine as a candidate vulnerability.", "abstract": "Neuroendocrine bladder carcinoma (NEBC) is a highly aggressive malignancy with unresolved lineage determinants and limited preclinical models, hindering mechanistic investigation and therapeutic development. Here, we sought to assess whether bladder epithelial-derived models are competent to acquire neuroendocrine lineage programs under defined tumor suppressor alterations and to identify candidate therapeutic vulnerabilities in these systems. We integrated genomic and transcriptomic analyses of human NEBC with genetically engineered mouse models, epithelial-derived bladder organoids, and patient-derived NEBC models. Human NEBC exhibited dominant RB1 and TP53 alterations and an epithelial transcriptional continuum consistent with lineage plasticity. In vivo, intravesical Adeno-Cre-mediated tumor suppressor deletion predominantly generated sarcoma-like tumors, whereas epithelial-restricted organoid models recapitulated the molecular and neuroendocrine features of human NEBC, supporting epithelial lineage competence for neuroendocrine differentiation. Patient-derived models and human NEBC specimens further supported epithelial identity in NEBC. Using these complementary platforms, drug screening identified homoharringtonine (HHT) as a candidate therapeutic vulnerability in the tested NEBC systems. HHT suppressed neuroendocrine marker expression, induced apoptosis, and attenuated IL6-JAK-STAT3 signaling. Together, these findings describe complementary epithelial-derived NEBC models and support further investigation of HHT as a candidate therapeutic vulnerability.", "journal": "Oncogene", "pub_date": "2026-Sep-16", "publication_types": ["Journal Article"], "doi": "10.1016/j.isci.2024.109829", "authors": ["Lei Qian", "Bo Liu", "Ruiyun Zhang", "Weiwei Zhang", "Siqi Wang", "Yuchen Wu", "Tianxiang Zhang", "Guanglei Zhuang", "Di Jin", "Qi Wang", "Haige Chen"], "affiliations": ["Department of Urology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.", "Department of Obstetrics and Gynecology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. zhuangguanglei@gmail.com.", "Shanghai Key Laboratory of Gynecologic Oncology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. zhuangguanglei@gmail.com.", "Department of Urology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. jindi@renji.com.", "Department of Urology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. wqi@sjtu.edu.cn.", "Shanghai Key Laboratory for Tumor Microenvironment and Inflammation, Shanghai Jiao Tong University School of Medicine, Shanghai, China. wqi@sjtu.edu.cn.", "Department of Urology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. rjbladder@163.com."], "corresponding_authors": ["Guanglei Zhuang", "Di Jin", "Qi Wang", "Haige Chen"], "china_team": "Department of Urology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China Guanglei Zhuang/Di Jin/Qi Wang/Haige Chen团队", "category": "basic", "classification_reason": "basic_signals=16", "score": 43.1, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 15.1, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 14.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 7.3, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.1, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "上皮抑癌缺失促膀胱癌神经内分泌分化", "chinese_summary": "上海交通大学医学院附属仁济医院庄光磊/金迪/王琦/陈海戈团队9月Oncogene整合人神经内分泌膀胱癌基因组与转录组分析，并构建上皮来源类器官及患者衍生模型，发现RB1与TP53改变主导谱系可塑性；筛选出高三尖杉酯碱为候选治疗弱点，可抑制神经内分泌标志物并诱导凋亡。", "abstract_zh": "神经内分泌膀胱癌（NEBC）是一种高度侵袭性的恶性肿瘤，其谱系决定因素尚未阐明，且临床前模型有限，阻碍了机制研究和治疗开发。在本研究中，我们试图评估膀胱上皮来源模型是否能够在特定的抑癌基因改变下获得神经内分泌谱系程序，并在这些系统中识别候选治疗弱点。我们将人NEBC的基因组和转录组分析与基因工程小鼠模型、上皮来源膀胱类器官及患者来源NEBC模型相结合。人NEBC表现出占主导地位的RB1和TP53改变，以及一个与谱系可塑性一致的上皮转录连续谱。在体内，经膀胱内Ado-Cre介导的抑癌基因缺失主要产生肉瘤样肿瘤，而上皮限制性类器官模型则再现了人NEBC的分子和神经内分泌特征，支持上皮谱系具有向神经内分泌分化的能力。患者来源模型和人NEBC标本进一步支持NEBC的上皮身份。利用这些互补平台，药物筛选鉴定出高三尖杉酯碱（HHT）为所测试NEBC系统中的候选治疗弱点。HHT抑制神经内分泌标志物表达，诱导凋亡，并减弱IL6-JAK-STAT3信号传导。总之，这些发现描述了互补的上皮来源NEBC模型，并支持进一步研究HHT作为候选治疗弱点。"}, {"pmid": "42749606", "title": "Prostate Cancer Screening: The Population Benefit Outweighs the Harm (Pro).", "abstract": "Long-term evidence from randomized trials demonstrates that prostate-specific antigen (PSA)-based screening reduces prostate cancer (PCa)-specific mortality, and modern risk-adapted strategies reduce unnecessary investigations and overdiagnosis. The relevant policy choice is no longer between screening and no screening. PSA testing is already widespread and largely opportunistic. This \"Wild West\" approach has three fundamental shortcomings: it is less effective in reducing PCa mortality, consumes substantial health care resources, and perpetuates socioeconomic disparities. Organized screening offers an opportunity to screen better by focusing screening and diagnostic evaluation workup on men most likely to benefit while reducing unnecessary interventions among those at low risk. Replacing opportunistic testing with organized, risk-adapted screening can therefore maximize population benefit while minimizing harms, inefficient resource use, and inequity. The debate should move beyond whether PCa screening should occur to how screening can be organized to achieve the greatest population benefit.", "journal": "European Urology Focus", "pub_date": "2026-Sep-16", "publication_types": ["Journal Article"], "doi": "10.1016/j.euf.2026.09.001", "authors": ["Sigrid V Carlsson", "Roderick van den Bergh"], "affiliations": ["Division of Clinical Epidemiology of Early Cancer Detection, and German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Translational Medicine, Division of Urological Cancers, Medical Faculty, Lund University, Lund, Sweden. Electronic address: sigrid.carlsson@dkfz-heidelberg.de.", "Department of Urology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands."], "corresponding_authors": ["Sigrid V Carlsson"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=4", "score": 28.77, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.77, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 4.0}, "journal_metrics": {"status": "ok", "impact_factor": 5.6, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.77, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42749562", "title": "Re: Nicolas Demogeot, Paul Sargos, Julia Salleron, et al. Short-term Androgen Deprivation Therapy and High-dose Radiotherapy in Intermediate- and High-risk Localized Prostate Cancer: Results from the GETUG 14 Randomized Phase 3 Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2025.07.019.", "abstract": "", "journal": "European Urology", "pub_date": "2026-Sep-16", "publication_types": ["Letter"], "doi": "10.1016/j.eururo.2025.10.005", "authors": ["Mattia Longoni", "Giorgio Gandaglia", "Francesco Montorsi"], "affiliations": ["Unit of Urology, Division of Oncology, Gianfranco Soldera Prostate Cancer Laboratory, IRCCS San Raffaele Scientific Institute, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy.", "Unit of Urology, Division of Oncology, Gianfranco Soldera Prostate Cancer Laboratory, IRCCS San Raffaele Scientific Institute, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. Electronic address: giorgio.gandaglia@gmail.com."], "corresponding_authors": ["Giorgio Gandaglia"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=4", "score": 39.79, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 16.79, "top_journal_bonus": 10.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 4.0}, "journal_metrics": {"status": "ok", "impact_factor": 25.2, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.79, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "短期雄激素剥夺联合高剂量放疗证据再审视", "chinese_summary": "欧洲泌尿外刊9月就GETUG 14随机3期试验发表读者来信，讨论中危及高危局限前列腺癌患者接受短期雄激素剥夺治疗联合高剂量放疗的疗效证据，提示需结合试验设计与终点解读审慎看待该治疗策略。", "abstract_zh": "Re: Nicolas Demogeot, Paul Sargos, Julia Salleron, et al. Short-term Androgen Deprivation Therapy and High-dose Radiotherapy in Intermediate- and High-risk Localized Prostate Cancer: Results from the GETUG 14 Randomized Phase 3 Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2025.07.019."}, {"pmid": "42749561", "title": "Re: Derya Tilki, Roderick C.N.van den Bergh, Erik Briers, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II-2026 Update: Treatment of Relapsing and Metastatic Prostate Cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.04.014.", "abstract": "", "journal": "European Urology", "pub_date": "2026-Sep-16", "publication_types": ["Letter"], "doi": "10.1016/j.eururo.2026.08.023", "authors": ["Michael Froehner"], "affiliations": ["Department of Urology, Zeisigwaldkliniken Bethanien Chemnitz, Chemnitz, Germany. Electronic address: michael.froehner@agaplesion.de."], "corresponding_authors": ["Michael Froehner"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 35.79, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 16.79, "top_journal_bonus": 10.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 25.2, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.79, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "欧洲指南更新复发转移前列腺癌治疗", "chinese_summary": "欧洲泌尿外科学会联合多学会9月Eur Urol发布2026版前列腺癌指南第二部分，聚焦复发及转移性前列腺癌的治疗更新，为临床决策提供最新循证依据。", "abstract_zh": "Re: Derya Tilki, Roderick C.N. van den Bergh, Erik Briers, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II-2026 Update: Treatment of Relapsing and Metastatic Prostate Cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.04.014."}, {"pmid": "42749558", "title": "Reply to Roberto Mario Scarpa's Letter to the Editor re: Roberto Contieri, Marco Paciotti, Alessandro Uleri, et al. Second Transurethral Resection of Bladder Tumor Can Be Safely Omitted in Selected Patients with T1 Non-muscle-invasive Bladder Cancer: Results from the Prospective HuNIRe Trial. Eur Urol Oncol 2026;9:404-12.", "abstract": "", "journal": "European Urology Oncology", "pub_date": "2026-Sep-16", "publication_types": ["Letter"], "doi": "10.1016/j.euo.2026.08.015", "authors": ["Roberto Contieri", "Rodolfo Hurle"], "affiliations": ["Department of Urology, Istituto Nazionale Tumori di Napoli, IRCCS \"G. Pascale\", Naples, Italy. Electronic address: contieri.ro@gmail.com.", "Department of Urology, IRCCS Humanitas Research Hospital, Milan, Italy."], "corresponding_authors": ["Roberto Contieri"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=4", "score": 32.42, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 15.42, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 4.0}, "journal_metrics": {"status": "ok", "impact_factor": 9.3, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.42, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42749554", "title": "Development and internal validation of machine-learning models to predict adverse pathological features in upper tract urothelial carcinoma.", "abstract": "Accurate preoperative staging and identification of adverse pathological features in upper tract urothelial carcinoma (UTUC) remain contemporary challenges. We aimed to develop and internally validate machine-learning (ML) models to predict muscle-invasive (≥pT2) and lymph node positive (pN+) disease using preoperative variables. We analyzed a large, multi-institutional registry of patients treated surgically for clinically nonmetastatic UTUC (ROBUUST 3.0). We separately identified patients with ≥pT2 stage and pN+ stage at surgery. Predictors were selected a priori based on clinical relevance, and missing data were imputed using Hyperimpute. Five classifiers (elastic net logistic regression, random forest, LightGBM, support vector machine with radial-basis-function kernel and a stacking ensemble) were trained using an 80/20 stratified train-test split. Discrimination (measured by area under the curve (AUC)), calibration and Brier score were assessed in the independent test cohort. We identified 3,179 patients with ≥pT2 stage (636 designated as the test cohort) and 1493 patients with pN+ disease (299 designated as the test cohort). In the test cohort, discrimination was moderate and comparable across models. For ≥pT2 prediction, AUC ranged from 0.73 to 0.74 (best model: stacking, AUC 0.74, 95% confidence interval [CI]: 0.70-0.78, and Brier 0.21). For pN+, AUC ranged from 0.73 to 0.75 (best model: stacking, AUC 0.75, 95% CI 0.69-0.81, and Brier 0.18). Established clinical predictors, particularly biopsy grade and clinical staging parameters dominated risk estimation. Limitations include retrospective design and lack of external validation. ML models using preoperative variables achieved moderate discrimination for predicting adverse pathological features in UTUC. External validation and prospective assessment of clinical utility are necessary before informing preoperative patient selection.", "journal": "Urologic Oncology", "pub_date": "2026-Sep-16", "publication_types": ["Journal Article"], "doi": "10.1016/j.urolonc.2026.08.017", "authors": ["Philipp Korn", "Maximilian Pallauf", "Soum Lokeshwar", "Giacomo Musso", "Zhenje Wu", "Linhui Wang", "Alex Kutikov", "Randall Lee", "Francesco Ditonno", "Alessandro Veccia", "Riccardo Bertolo", "Alessandro Antonelli", "Lin Lin", "Vitaly Margulis", "Alireza Ghoreifi", "Hooman Ebrahimi", "Hooman Djaladat", "Hidefumi Kinoshita", "Takashi Yoshida", "Gabriele Tuderti", "Flavia Proietti", "Giuseppe Simone", "Andrea Mari", "Luca Lambertini", "Andrea Minervini", "Marco Tozzi", "Matteo Ferro", "Roberto Contieri", "Sisto Perdona", "Daniele Amparore", "Gabriele Bignante", "Francesco Porpiglia", "Omri Falik Nativ", "Mark L Gonzalgo", "Alfonso Santangelo", "Carlo Silvani", "Alex Stephens", "Firas Abdollah", "Melinda Fu", "Saum Ghodoussipour", "Alec Zhu", "Reza Mehrazin", "Daniel A Sidhom", "Chandru P Sundaram", "Takashi Matsumoto", "Masaki Shiota", "Alireza Dehghanmanshadi", "Soroush Rais-Bahrami", "Karim Daher", "Ithar H Derweesh", "Riccardo Autorino", "Nirmish Singla"], "affiliations": ["School of Medicine, Johns Hopkins Medicine, Brady Urological Institute, Baltimore, MD; Department of Urology, Faculty of Medicine, University of Augsburg, Augsburg, Germany; Comprehensive Cancer Center Augsburg (CCCA), University Medical Center Augsburg, Augsburg, Germany; Bavarian Cancer Research Center (BZKF), Augsburg, Germany. Electronic address: philipp.korn@med.uni-augsburg.de.", "School of Medicine, Johns Hopkins Medicine, Brady Urological Institute, Baltimore, MD; Department of Urology, University Hospital Salzburg, Paracelsus Medical University, Salzburg, Austria.", "School of Medicine, Johns Hopkins Medicine, Brady Urological Institute, Baltimore, MD.", "Department of Urology, Rush University, Chicago, IL.", "Department of Urology, Changhai Hospital, Naval Medical University, Shanghai, China.", "Fox Chase - Temple Urologic Institute, Philadelphia, PA.", "Department of Urology, University of Verona, Verona, Italy.", "Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX.", "Institute of Urology, Norris Cancer Center, University of Southern California, Los Angeles, CA.", "Department of Urology and Andrology, Kansai Medical University, Hirakata, Osaka, Japan.", "Department of Urology, IRCCS \"Regina Elena\" National Cancer Institute, Rome, Italy.", "Unit of Urology and Andrology, Oncology Department, Department of Experimental and Clinical Medicine, University of Florence, Careggi University Hospital, Florence, Italy.", "Division of Urology, European Institute of Oncology (IEO)-IRCCS, Milan, Italy.", "Department of Oncology, University of Turin, San Luigi Gonzaga Hospital, Orbassano, Italy.", "Division of Urology, San Luigi Gonzaga Hospital, University of Turin, Orbassano, Italy.", "Desai Sethi Urology Institute, University of Miami Miller School of Medicine, Miami, FL.", "VUI Center for Outcomes Research Analytics and Evaluation, Vattikuti Urology Institute, Henry Ford Hospital, Detroit, MI.", "Section of Urologic Oncology, Department of Surgery, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ.", "Department of Urology, Icahn School of Medicine, Mount Sinai Hospital, New York, NY.", "Department of Urology, Indiana University, Indianapolis, IN.", "Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.", "Department of Urology, Birmingham Heersink School of Medicine, University of Alabama, Birmingham, AL.", "Glickman Urological Institute, Cleveland Clinic, Cleveland, OH.", "School of Medicine, Johns Hopkins Medicine, Brady Urological Institute, Baltimore, MD; Department of Urology, Medical University of Vienna, Vienna, Austria. Electronic address: nsingla2@jhmi.edu."], "corresponding_authors": ["Philipp Korn", "Nirmish Singla"], "china_team": "Department of Urology, Changhai Hospital, Naval Medical University, Shanghai, China Linhui Wang团队", "category": "clinical_review", "classification_reason": "clinical_signals=9", "score": 28.75, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 5.75, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 9.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.3, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.75, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42749198", "title": "The Only Urologist to Become a Head of State: Juscelino Kubitschek, President of Brazil.", "abstract": "", "journal": "Urology", "pub_date": "2026-Sep-16", "publication_types": ["Editorial"], "doi": "10.1016/j.urology.2026.09.038", "authors": ["José Hipólito Dantas"], "affiliations": ["Department of Integrated Medicine, Federal University of Rio Grande do Norte (UFRN), Natal, Rio Grande do Norte, Brazil. Electronic address: jose.hipolito@ufrn.br."], "corresponding_authors": ["José Hipólito Dantas"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 14.61, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 5.61, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.0, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.61, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42749197", "title": "Accuracy of Low-Dose and Ultra-Low-Dose Computed Tomography for Nephrolithiasis in Obesity: A Multicenter Review.", "abstract": "To evaluate the diagnostic accuracy of low-dose (LD) and ultra-low-dose (ULD) computed tomography (CT) scan for stone identification in obese patients compared to conventional-dose CT. A review of patients undergoing CT scans for kidney or ureteral stones at two academic institutions was conducted. Patients with body mass index (BMI) >30 kg/m2 and both a conventional and LD CT within 100 days of each other were included. LD was defined as <4 millisieverts (mSv) and ULD as <1.9 mSv. Renal units with interval treatment or documented stone passage were excluded. CTs were reviewed by board-certified radiologists. Fifty-two patients met inclusion criteria with mean BMI of 36.2 kg/m2 (range: 30.5-63.8). The combined average effective dose of LD and ULD CT was significantly lower than conventional CT (2.3 vs 14.9 mSv; P < .001), an 85% reduction. LD and ULD CT detected 92/96 stones >2 mm (96% sensitivity) and 95/115 stones overall (83% sensitivity). All stones missed were ≤4 mm in size. LD CT BMI-stratified analysis demonstrated 100% sensitivity for stones >2 mm for BMI 30-35 and >40 kg/m2, and 90% for BMI 35-40 kg/m2. ULD CT demonstrated 100% sensitivity for stones >2 mm for BMI 30-35 kg/m2. Overall, LD and ULD CT in obese patients accurately identified stones >2 mm with 96% sensitivity, while reducing radiation dose by 85%. This multicenter study supports the accuracy of LD CT for stone identification in noninfected obese patients across BMI subgroups, with ULD CT best reserved for patients with BMI 30-35 kg/m2.", "journal": "Urology", "pub_date": "2026-Sep-16", "publication_types": ["Journal Article"], "doi": "10.1016/j.urology.2026.09.036", "authors": ["Gabriel E Martin", "Kymora Scotland", "Jason Smith", "Ninous Betdashtoo", "Mohammad Kassir", "Ellie Mehrara", "Ruben Crew", "Zhamshid Okhunov", "D Duane Baldwin"], "affiliations": ["Department of Urology, Loma Linda University Health, Loma Linda, CA.", "Department of Urology, University of California Los Angeles Health, Los Angeles, CA.", "Department of Radiology, Division of Interventional Radiology, Loma Linda University Health, Loma Linda, CA.", "Department of Urology, Loma Linda University Health, Loma Linda, CA. Electronic address: dbaldwin@llu.edu."], "corresponding_authors": ["D Duane Baldwin"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=7", "score": 30.61, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 5.61, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 7.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.0, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.61, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42748379", "title": "Early Termination of Phase II-III Genitourinary Oncology Trials: A Two-Decade Analysis of Causes and Trial-Level Risk Factors.", "abstract": "Early termination of clinical trials delays scientific progress and wastes resources, yet factors associated with trial completion in genitourinary (GU) oncology remain incompletely characterized. We investigated trial-level factors associated with premature discontinuation of phase II-III GU oncology clinical trials. We analyzed US phase II-III interventional GU oncology trials registered on ClinicalTrials.gov that were completed or terminated between January 1, 2005, and January 1, 2025. Prespecified operational and trial-level characteristics at initiation included disease site, phase, randomization, masking, sponsor type, number of sites, multinational status, data monitoring committee (DMC) presence, and intervention category. Reasons for early termination were categorized, and associations with premature discontinuation were assessed using multivariable logistic regression. Among 1,597 trials, 445 (27.9%) were terminated early and 1,152 (72.1%) were completed. Poor accrual accounted for 41.8% of terminations, followed by sponsor or business decisions (14.6%) and interim futility or efficacy findings (10.3%). In multivariable analysis, prostate cancer trials were more likely to complete than bladder cancer trials (odds ratio [OR], 1.77, 95% CI, 1.25 to 2.50), as were multinational (OR, 1.96, 95% CI, 1.27 to 3.02) and multisite studies (OR, 1.72, 95% CI, 1.28 to 2.30). Trials enrolling metastatic-only (OR, 0.45, 95% CI, 0.29 to 0.72) or mixed-stage populations (OR, 0.55, 95% CI, 0.36 to 0.86), as well as those with DMC oversight (OR, 0.62, 95% CI, 0.47 to 0.81), were less likely to complete. More than one quarter of GU oncology trials terminate prematurely, most often due to accrual failure. Early termination is associated with identifiable disease-specific, structural, and operational trial characteristics. Recognition of these patterns may help inform feasibility assessment, trial planning, and resource allocation, with the goal of reducing preventable trial failure in GU oncology research.", "journal": "Jco Oncology Practice", "pub_date": "2026-Sep-16", "publication_types": ["Journal Article"], "doi": "10.1200/OP-26-00162", "authors": ["Kamil Malshy", "Jiacheng Wang", "Yusheng Jia", "Matthew Steidle", "Trevor C Hunt", "Denzel Zhu", "Suiyue Cui", "Zijing Cheng", "Jathin Bandari"], "affiliations": ["Department of Urology, University of Rochester Medical Center, Rochester, NY.", "Department of Computer Science, Vanderbilt University, Nashville, TN.", "Department of Environmental Medicine and Public Health Sciences, University of Rochester Medical Center, Rochester, NY."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=7", "score": 38.53, "score_parts": {"urology_relevance": 11, "urology_in_title": 8.0, "journal_priority": 10.53, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 7.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.6, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.53, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42747946", "title": "Bladder Cancer Incidence in Patients with Microhematuria at the Veterans Health Administration.", "abstract": "Microhematuria may be a sign of underlying genitourinary pathology, but diagnoses of bladder cancer are rare among those who complete evaluations. This study determines the incidence of bladder cancer in a large cohort of patients with microhematuria, assesses the diagnostic potential of current guideline recommendations, and characterizes the relative risks of clinicodemographic factors to inform the need for microhematuria evaluation. This retrospective cohort study used Veterans Health Administration and Medicare-linked data from 2015-2024 and included patients ≥18 years old diagnosed with de novo microhematuria. The main outcome was a new bladder cancer diagnosis within 2 years of index urinalysis with microhematuria. Patients were stratified by American Urologic Association risk categories to compare guideline-based risk classification with model-based estimation. The Fine-Gray method was used to estimate adjusted associations between clinicodemographic characteristics and incident bladder cancer, accounting for the competing risk of death. Among 267,133 patients with microhematuria, the two-year cumulative incidences of cystoscopy completion and a new bladder cancer diagnosis were 11.9% (95% CI 11.7, 12.0) and 1.5% (95% CI 1.4, 1.5), respectively. Older age, male sex, smoking history, and ≥25 RBC/hpf were associated with a new bladder cancer diagnosis when adjusted for competing risk of death. Performance of our bladder cancer prediction model was better (ROC AUC=0.63) than that of the current AUA guidelines (AUC=0.52, p<0.001) and allowed for further risk-estimation of patients designated \"high risk\" by AUA criteria. Estimation of patient-level microhematuria-related bladder cancer risk is possible with readily available clinicodemographic factors. Current approaches lack nuance, particularly among \"high risk\" patients. Precision approaches that use relative risk-factor weights and/or novel diagnostic tools may improve individualized decision-making for evaluation.", "journal": "Journal of Urology", "pub_date": "2026-Sep-16", "publication_types": ["Journal Article"], "doi": "10.1097/JU.0000000000005312", "authors": ["Richard S Matulewicz", "Samuel A Gold", "Andrew Nicholson", "Danielle Candelieri-Surette", "Vincent D D'Andrea", "Patrick R Alba", "Fady Baky", "Amy L Voorhees", "Ekaterina Y Shishova", "Scott E Sherman", "Bernard H Bochner", "Julie A Lynch", "Danil V Makarov"], "affiliations": ["Memorial Sloan Kettering Cancer Center Department of Surgery, Urology Service.", "VA New York Harbor Healthcare System.", "New York University Langone Medical Center.", "VA Informatics and Computing Infrastructure (VINCI), VA Salt Lake City Health Care System.", "Division of Epidemiology, Department of Internal Medicine, University of Utah School of Medicine."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=6", "score": 39.51, "score_parts": {"urology_relevance": 11, "urology_in_title": 8.0, "journal_priority": 11.01, "top_journal_bonus": 0.0, "novelty": 1.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 6.0}, "journal_metrics": {"status": "ok", "impact_factor": 6.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 3.01, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42747670", "title": "Augmented reality in robotic urology: from 3D printed models to cognitive surgical systems. A systematic literature review.", "abstract": "Robotic urological surgery has evolved to become the foundation of contemporary, minimally invasive surgical care. However, current robotic platforms lack imaging systems with contextual interpretation and predictive capabilities, although they provide high resolution imaging. Augmented reality combining contemporary imaging technology and guidance from artificial intelligence and machine learning systems-have the potential to immensely improve robotic surgical training, intraoperative navigation and surgical decision making, in order to ultimately make robotic urological surgery safer with better outcomes. With this review article we systematically investigated recent advances in augmented reality (AR) technology, artificial intelligence guided AR, and their applications into robotic urological procedures. A systematic search of the available literature was conducted following the PRISMA guidelines from Pubmed and Cochrane databases, for studies published between 2015 and 2026. After title and abstract screening, 67 full-text articles were assessed, and 38 studies met inclusion criteria for final qualitative synthesis. A systematic literature review was conducted because of the low quality of data available and relatively high risk of bias. Studies analyzing applications of augmented reality navigation in intraoperative tissue characterization, and predictive surgical guidance, in the context of robotically assisted urological surgery, have been included in our review. The use of AR in robotic-assisted radical prostatectomy (RARP) has shown the potential to reduce the rate of positive surgical margins, while also improving continence and erectile function recovery. In robotic-assisted partial nephrectomy (RAPN), AR displays capabilities in reducing warm ischemia time and increasing healthy parenchyma preservation. Challenges related to clinical validation, data standardization, and ethical considerations are also discussed. Augmented reality is poised to redefine robotic urology by enabling real-time, context-aware surgical perception with predictive capabilities, although further research with prospective randomized controlled trials is essential to translate these technologies into clinical practice.", "journal": "Journal of Robotic Surgery", "pub_date": "2026-Sep-16", "publication_types": ["Systematic Review", "Journal Article"], "doi": "10.1007/s11701-026-03952-y", "authors": ["Nikolaos Kostakopoulos", "Stamatios Katsimperis", "Themistoklis Bellos", "Grigorios Athanasiadis", "Lazaros Tzelves", "Ioannis Varkarakis", "Andreas Skolarikos"], "affiliations": ["Department of Urology, Metropolitan General Hospital, Athens, Greece. nikostakop@gmail.com.", "Department of Urology, Medical School of National, Kapodistrian University of Athens, Sismanoglio General Hospital, Athens, Greece.", "Department of Urology, Karolinska University Hospital, Stockholm, Sweden.", "Department of Urology, Aberdeen Royal Infirmary, NHS Grampian, Aberdeen, UK."], "corresponding_authors": ["Nikolaos Kostakopoulos"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 40.03, "score_parts": {"urology_relevance": 15, "urology_in_title": 8.0, "journal_priority": 6.03, "top_journal_bonus": 0.0, "novelty": 2, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 7.0}, "journal_metrics": {"status": "ok", "impact_factor": 3.0, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 2.03, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42747550", "title": "The safety and efficacy of drug-coated balloon dilation system (Keeway) for benign prostate hyperplasia: a preclinical study.", "abstract": "In recent years, minimally invasive procedures for benign prostatic hyperplasia (BPH) and urethral strictures have attracted great attention. There is an urgent need for studies investigating the safety and efficacy of the drug-coated balloon (DCB) dilation system (Keeway) for BPH. The balloon was coated with paclitaxel (PTX). 21 male Labrador dogs were lastly randomized into the single-dose group (n = 12), double-dose group (n = 3), sham procedure group (n = 3), and blank control group (n = 3). The study period was 90 days. Blood and urine samples were collected before the procedure, and blood, urine, target tissues (prostate and bladder neck), and major organs (heart, liver, spleen, lung, kidney, and brain) were harvested at follow-up time points for subsequent processing and analysis. No significant PTX accumulation was observed in any specimen, and no pathological changes were detected in major organs, suggesting the safety of this approach. At 90 days, dilatation of the prostatic urethra was evident in both treatment and sham groups. This study suggested the safety and efficacy of the DCB dilation system (Keeway), encouraging further clinical investigation as a potential minimally invasive therapy for BPH, especially in Chinese population.", "journal": "World Journal of Urology", "pub_date": "2026-Sep-16", "publication_types": ["Journal Article"], "doi": "10.1007/s00345-026-06781-8", "authors": ["Jinfu Wang", "Tong Li", "Yi Mao", "Ming Liu"], "affiliations": ["Department of Urology, Beijing Hospital, National Center for Gerontology, National Clinical Research Center for Gerontology, The Key Laboratory of Geriatrics of NHC, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.", "Department of Cardiology, Fuwai Hospital, Peking Union Medical College, Chinese Academy of Medical Science, National Center for Cardiovascular Disease, Beijing, China.", "Department of Urology, Beijing Hospital, National Center for Gerontology, National Clinical Research Center for Gerontology, The Key Laboratory of Geriatrics of NHC, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. liumingbjh@126.com."], "corresponding_authors": ["Ming Liu"], "china_team": "Department of Urology, Beijing Hospital, National Center for Gerontology, National Clinical Research Center for Gerontology, The Key Laboratory of Geriatrics of NHC, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China Ming Liu团队", "category": "clinical_review", "classification_reason": "clinical_signals=6", "score": 42.0, "score_parts": {"urology_relevance": 16, "urology_in_title": 8.0, "journal_priority": 10.0, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 6.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.9, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.0, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42747234", "title": "Immunohistochemical stratification of bladder small cell carcinoma reveals two major phenotypes with distinct therapeutic biomarker profiles.", "abstract": "Small cell carcinoma of the bladder (SmCCB) is a rare and aggressive malignancy that remains poorly defined. Using the transcriptional taxonomy established for small cell lung carcinoma (SCLC), we aimed to stratify SmCCB by dominant transcription factors and assess associations between IHC-defined phenotype, neuroendocrine differentiation and therapeutic biomarker expression. A retrospective multi-institutional cohort of 88 SmCCBs was assembled. Of these, 79 cases underwent immunohistochemical characterization for ASCL1, NEUROD1, POU2F3, YAP1 and HNF4α, along with classical neuroendocrine markers, therapeutic biomarkers and antibody-drug conjugate targets. NECTIN4 amplification was also assessed by fluorescence in situ hybridization (FISH). Six IHC-defined subgroups were identified: ASCL1-driven (41.8%), NEUROD1-driven (25.3%), POU2F3-driven (20.3%), YAP1-driven (6.3%), mixed (5.1%) and full-negative (1.3%). ASCL1-driven, NEUROD1-driven and mixed tumours were classified as High-NE, with diffuse NE marker expression, whereas POU2F3-driven, YAP1-driven and full-negative tumours were classified as Low-NE, with weak or absent expression. Overall membranous Nectin-4 expression was low or absent but significantly higher in Low-NE tumours (P < 0.001). NECTIN4 amplification occurred in 21.9% (16/73), comparable to that reported in non-neuroendocrine urothelial carcinoma. Conversely, DLL3 and SLFN11 were significantly overexpressed in High-NE tumours, while expression of the remaining targets was almost entirely absent. SmCCB may be stratified into two IHC-defined phenotypic groups with distinctive neuroendocrine differentiation and therapeutic biomarker profiles. Taken together, low membranous Nectin-4 expression and preferential DLL3 and SLFN11 expression in High-NE tumours support further investigation of alternative therapeutic strategies.", "journal": "Histopathology", "pub_date": "2026-Sep-16", "publication_types": ["Journal Article"], "doi": "10.1111/his.70284", "authors": ["Nazario P Tenace", "Maurizio Colecchia", "Arndt Hartmann", "Maurilio Ponzoni", "Claudio Doglioni", "Sebastian Rauch", "Marco Moschini", "Andrea Necchi", "Alberto Briganti", "Francesco Montorsi", "Markus Eckstein"], "affiliations": ["Pathology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.", "Vita-Salute San Raffaele University, Milan, Italy.", "Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.", "Department of Urology and Division of Experimental Oncology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy.", "Department of Medical Oncology, IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=4", "score": 32.89, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 10.39, "top_journal_bonus": 0.0, "novelty": 0.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 4.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.1, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.39, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42746799", "title": "Lower Urinary Tract Dysfunction in Renal Transplant Candidates: A Scoping Review of Assessment Methods and Post-Transplant Urological Outcomes.", "abstract": "We performed a scoping review to map the available evidence regarding pre-transplant lower urinary tract dysfunction (LUTD) assessment in adult renal transplant candidates and to summarise reported associations between pre-transplant LUTD and post-transplant urological outcomes. Electronic databases were searched up to 30th September 2025. Studies were included if they assessed lower urinary tract function prior to kidney transplantation using clinical history, questionnaires or investigations and reported post-transplant urological complications and/or graft outcomes. Risk of bias was assessed using ROBINS-I V2 for comparative studies and QUIPS for prognostic studies. Owing to substantial clinical and methodological heterogeneity, findings were synthesised narratively. A total of 11 studies comprising 4471 patients met the inclusion criteria. Assessment strategies varied considerably across studies, ranging from clinical history alone to validated symptom questionnaires, uroflowmetry and urodynamic testing. Six studies reported urinary tract infection (UTI) outcomes, with most suggesting an increased risk in patients with pre-transplant LUTD. Evidence for acute urinary retention and urosepsis was limited but directionally consistent with higher complication rates. Data on graft survival outcomes were sparse and heterogeneous, with some studies suggesting an association between pre-transplant LUTD and poorer graft survival. Pre-transplant LUTD appears to be associated with an increased risk of post-transplant urological complications, particularly UTIs. However, the evidence is heterogeneous and largely observational, predominantly derived from retrospective studies, with limited data on graft outcomes. This scoping review highlights marked heterogeneity in pre-transplant LUTD assessment and supports the development of a standardised assessment framework to guide future research and clinical practice.", "journal": "Neurourology and Urodynamics", "pub_date": "2026-Sep-16", "publication_types": ["Journal Article", "Review"], "doi": "10.1002/nau.70442", "authors": ["Dhruv S Sahni", "David B Kingsmore", "Imran Ahmad", "Mehwash Nadeem", "Emma Aitken"], "affiliations": ["Department of Renal Surgery, Queen Elizabeth University Hospital, Glasgow, UK.", "School of Cardiovascular and Metabolic health, University of Glasgow, Glasgow, UK.", "Department of Urology, Queen Elizabeth University Hospital, Glasgow, UK.", "School of Cancer Sciences, University of Glasgow, Glasgow, UK.", "Cancer Research UK Scotland Institute, Glasgow, UK.", "Department of Urology, South Tees Hospital NHS Foundation trust, Middlesbrough, UK."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 35.56, "score_parts": {"urology_relevance": 15, "urology_in_title": 8.0, "journal_priority": 5.56, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 5.0}, "journal_metrics": {"status": "ok", "impact_factor": 1.9, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.56, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42812523", "title": "Clinical improvement of pemphigus-like mucocutaneous disease in a patient with CLL following initiation of zanubrutinib: a case report.", "abstract": "Pemphigus is an autoimmune bullous disease. PNP/PAMS represents a rare subtype of autoimmune bullous disease, and typically associated with an underlying neoplasm, particularly lymphoproliferative disorders. Current management of PNP primarily involves glucocorticoids, immunosuppressants, and rituximab. This article reports a 67-year-old male who presented with generalized erythema, blisters, and oral erosions with pain for one month. Initially diagnosed with pemphigus, he received methylprednisolone treatment, which led to slight improvement in skin lesions but minimal resolution of oral ulcers. Based on the available clinical, histopathological, immunofluorescence, and serological findings, the patient was initially diagnosed with pemphigus vulgaris in the setting of CLL. However, the refractory oral mucositis, dual positivity for Dsg1 and Dsg3, and the underlying B-cell malignancy raised the concern for paraneoplastic pemphigus (PNP). Given that PNP-specific tests-including anti-plakin antibodies, indirect immunofluorescence on rat bladder, and immunoblotting-were not performed, a definitive diagnosis of PNP could not be established. Therefore, the condition was managed as \"suspected CLL-associated PNP\" Following the initiation of zanubrutinib in combination with ongoing corticosteroid therapy and CLL treatment, significant improvement of oral erosions was observed. In this case, the clinical improvement may be potentially related to zanubrutinib, but the concurrent corticosteroid therapy and the control of CLL likely contributed as well. If zanubrutinib did play a role, the mechanism might involve enhanced disease control or immune modulation. However, the current evidence is insufficient to draw a firm conclusion, and its true efficacy needs to be evaluated in further studies.", "journal": "Frontiers in Immunology", "pub_date": "2026", "publication_types": ["Case Reports", "Journal Article"], "doi": "10.1111/cup.14004", "authors": ["Tianyu Li", "Chengbin Lu", "Tong Kang", "Ying Tu", "Dongjie Sun"], "affiliations": ["Department of Dermatology, The First Affiliated Hospital of Kunming Medical University, Yunnan, Kunming, China.", "The Second Xiangya Hospital, Central South University, Changsha, Hunan, China."], "corresponding_authors": [], "china_team": "Department of Dermatology, The First Affiliated Hospital of Kunming Medical University, Yunnan, Kunming, China Dongjie Sun团队", "category": "clinical_review", "classification_reason": "publication_type_clinical", "score": 17.83, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 10.83, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 1.0}, "journal_metrics": {"status": "ok", "impact_factor": 5.9, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.83, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42812299", "title": "Gout, hyperuricemia, and male reproductive health: a systematic review and meta-analysis.", "abstract": "Gout is an inflammatory arthritis characterized by hyperuricemia in humans. Male patients with gout or hyperuricemia have a wide range of reproductive health challenges. However, research on the sexual and reproductive health of male patients with gout or hyperuricemia remains limited. This systematic review and meta-analysis investigated the impact of gout and/or hyperuricemia and its associated factors on male sexual and reproductive health. The PubMed, Cochrane, Embase, Web of Science, Wanfang Data, and China National Knowledge Infrastructure (CNKI) databases were searched for relevant articles from January 2000 to October 2025. Two reviewers extracted the data and completed quality assessment using the Newcastle-Ottawa Scale and the Agency for Healthcare Research and Quality checklist. Meta-analysis was conducted using Review Manager 5.4 and Stata 18.0. The protocol was registered on PROSPERO (CRD 420261302205). The outcomes such as sexual function, reproductive hormones, and fertility were evaluated. In the literature search, 1,527 articles were retrieved. Among these, 11 studies met the inclusion criteria. This meta-analysis included 104,277 patients with gout or hyperuricemia and 342,621 control subjects. The meta-analysis results showed that the risk of erectile dysfunction was higher in patients with gout (RR = 1.37; 95% CI = 1.14 to 1.65, P < 0.001). Compared with the control group, patients with gout or hyperuricemia showed lower levels of testosterone and estradiol (testosterone: MD = -1.00, 95% CI = -1.39 to -0.62, P < 0.001; estradiol: MD = -4.67, 95% CI = -9.31 to -0.02, P = 0.05). A single study showed that semen volume and total sperm counts were lower among infertile men in the hyperuricemia group. Male patients with gout or hyperuricemia are more prone to erectile dysfunction and lower levels of reproductive hormones. Patients with gout showed significantly lower testosterone levels in the subgroup analyses. These findings emphasize the clinical need for increased awareness of male reproductive health problems in men with gout and implementation of effective intervention measures. https://www.crd.york.ac.uk/PROSPERO/, identifier CRD420261302205.", "journal": "Frontiers in Immunology", "pub_date": "2026", "publication_types": ["Journal Article", "Systematic Review", "Meta-Analysis"], "doi": "10.1136/bmj.d4002", "authors": ["Jiping Mao", "Mangmang Xu", "Yanfang Tang", "Jiaqi Chen", "Jia Zhou", "Dehong Wu"], "affiliations": ["The Second Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, China.", "Department of Rheumatology, The Second Affiliated Hospital of Zhejiang Chinese Medical University (Xinhua Hospital of Zhejiang Province), Hangzhou, China.", "School of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou, China."], "corresponding_authors": [], "china_team": "The Second Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, China Dehong Wu团队", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 18.33, "score_parts": {"urology_relevance": 3, "urology_in_title": 0.0, "journal_priority": 10.83, "top_journal_bonus": 0.0, "novelty": 0.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 2.0}, "journal_metrics": {"status": "ok", "impact_factor": 5.9, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.83, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42745507", "title": "Long-term patient-reported outcomes and toxicity following salvage radiotherapy for biochemical recurrence after radical prostatectomy.", "abstract": "Salvage radiotherapy (RT) after prostatectomy is common, but studies reporting long-term follow-up on patient-reported outcomes (PROs) and toxicity are limited. The authors report the largest cohort of patients treated with intensity modulated radiotherapy (IMRT) to date assessing patient-reported quality of life (QOL) and physician-rated toxicity with long-term follow-up. PROs were prospectively collected for men undergoing post-prostatectomy salvage IMRT. Declines in quality of life were defined using established minimum clinically important difference (MCID) thresholds for bowel function (BF), sexual function (SF), urinary incontinence (UI), and urinary obstruction/irritation (UO) domains. Physician-reported genitourinary (GU) and gastrointestinal (GI) toxicities were recorded with Common Terminology Criteria for Adverse Events v3.0. Between 2007 and 2019, 317 men were treated to a median dose of 68.4 Gy to the prostate bed with 72% receiving pelvic nodal treatment and 72% receiving androgen deprivation therapy. Median follow-up was 63 months. The median scores for UI, UO, BF, and SF did not decline more than the MCID at any time point except for the 6-week bowel score. At 5 years, the percentage of men with QOL decline exceeding MCID for BF, SF, UI, and UO domains were 23%, 25%, 29%, and 31%, respectively. The cumulative incidences of grade 3+ GU and GI toxicity at 5 years were 5.1% and 1.6%, respectively. Median patient-reported QOL scores remained largely stable following salvage RT after radical prostatectomy, although clinically meaningful declines occurred in a subset of patients. QOL decline and physician-rated toxicity were transient in approximately one-third of affected patients.", "journal": "Cancer", "pub_date": "2026-Sep-15", "publication_types": ["Journal Article"], "doi": "10.1016/j.eururo.2008.03.026", "authors": ["Connor Lynch", "Muzamil Arshad", "Greeshma Rajeev-Kumar", "Yan Che", "Ted A Skolarus", "Parth K Modi", "Stanley L Liauw"], "affiliations": ["Department of Radiation Oncology, University of Chicago, Chicago, Illinois, USA.", "Department of Statistics, University of Chicago, Chicago, Illinois, USA.", "Department of Urology, University of Chicago, Chicago, Illinois, USA."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=8", "score": 43.65, "score_parts": {"urology_relevance": 11, "urology_in_title": 8.0, "journal_priority": 14.65, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 8.0}, "journal_metrics": {"status": "ok", "impact_factor": 5.1, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 2.65, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "挽救放疗后生活质量总体稳定", "chinese_summary": "Cancer 9月发表迄今最大规模队列，317例前列腺癌根治术后行挽救性调强放疗患者中位随访63个月，5年肠功能、性功能、尿失禁及尿路梗阻症状超过临床最小重要差异的比例分别为23%、25%、29%和31%，3级以上泌尿及消化道毒性累积发生率仅5.1%和1.6%，提示患者报告生活质量总体稳定，部分下降多为一过性。", "abstract_zh": "前列腺切除术后的挽救性放疗（RT）较为常见，但报告患者报告结局（PROs）和毒性长期随访的研究有限。作者报告了迄今为止接受调强放疗（IMRT）治疗的最大队列，评估了长期随访下的患者报告生活质量（QOL）和医生评定的毒性。前瞻性收集了接受前列腺切除术后挽救性IMRT的男性的PROs。使用既定的肠功能（BF）、性功能（SF）、尿失禁（UI）和尿路梗阻/刺激（UO）领域的最小临床重要差异（MCID）阈值来定义生活质量的下降。根据不良事件通用术语标准v3.0记录医生报告的泌尿生殖系统（GU）和胃肠道（GI）毒性。2007年至2019年间，317名男性接受治疗，前列腺床中位剂量为68.4 Gy，72%接受盆腔淋巴结治疗，72%接受雄激素剥夺治疗。中位随访时间为63个月。UI、UO、BF和SF的中位评分在任何时间点均未下降超过MCID，但6周时肠功能评分除外。在5年时，BF、SF、UI和UO领域生活质量下降超过MCID的男性比例分别为23%、25%、29%和31%。5年时3级及以上GU和GI毒性的累积发生率分别为5.1%和1.6%。根治性前列腺切除术后挽救性放疗后，患者报告的生活质量中位评分基本保持稳定，尽管一部分患者出现了具有临床意义的下降。在约三分之一受影响的患者中，生活质量下降和医生评定的毒性是短暂的。"}, {"pmid": "42745263", "title": "Multimodal AI and single-cell transcriptomics integrate to construct a histopathological prognostic model for bladder cancer, revealing the RTN3-glycolysis axis in chemoresistance.", "abstract": "Bladder cancer is a common malignant tumor of the urinary system, and gemcitabine-based chemotherapy often fails because of drug resistance. Tumor heterogeneity, particularly copy number variations (CNVs) heterogeneity at the genomic level, is a core factor that drives disease progression and drug resistance. However, the relationship between CNV heterogeneity at the single-cell level and the histomorphological features that are relied upon in a routine pathological diagnosis remains unclear, limiting its application in clinical prognostic assessments and precision therapy. This study integrated six public single-cell RNA sequencing (scRNA-seq) datasets as discovery cohorts to systematically analyze the cellular landscape of bladder cancer. The inferCNV algorithm was used to infer CNVs at the single-cell level and identify subpopulations with high CNV (HCNV). A multimodal artificial intelligence (AI) strategy combining deep learning and image analysis was employed to construct a prognostic model based on routine H&E-stained pathological sections, with HCNV activity serving as a biological anchor for pathology feature selection. Hub genes were screened using multiomics data, and in vitro and in vivo functional experiments using bladder cancer cell lines were conducted to validate the functions and mechanisms of these hub genes. The single-cell analysis revealed that HCNV cells constitute a malignant subpopulation with a unique molecular phenotype characterized by widespread activation of oncogenic pathways (such as TGF-β, JAK-STAT and PI3K), active communication with the tumor microenvironment (e.g., cancer-associated fibroblasts and M2 macrophages), and a poor prognosis for patients. The multimodal AI-based pathological imaging model effectively predicted patient survival. The model-derived risk score showed a significant but modest correlation with transcriptomic HCNV activity. Through multi-algorithm feature selection, we identified RTN3 as the core gene driving the HCNV phenotype. Our study confirms that RTN3 not only orchestrates an immunosuppressive microenvironment but also directly mediates resistance to gemcitabine. Mechanistically, RTN3 activates the JAK2/STAT3 signaling pathway, which transcriptionally upregulates key glycolytic enzymes (PKM2, GLUT1, and LDHA), thereby driving glycolytic metabolic reprogramming and ultimately conferring gemcitabine resistance in bladder tumors. This study reveals a malignant cell subtype defined by HCNV in bladder cancer at the single-cell level and elucidates the molecular and microenvironmental basis of the poor prognosis of bladder cancer. A clinically translatable multimodal AI pathological prediction model was successfully developed. Furthermore, our findings establish the RTN3/JAK2/STAT3/glycolysis axis as a critical mechanism of gemcitabine resistance, highlighting RTN3 as a promising therapeutic target for overcoming chemoresistance in bladder cancer.", "journal": "Experimental Hematology & Oncology", "pub_date": "2026-Sep-15", "publication_types": ["Journal Article"], "doi": "10.1158/2159-8290.CD-18-0044", "authors": ["Shunli Yu", "Yingjian Wang", "Dapeng Feng", "Xinglai Dai", "Yongbo Luo", "Jianing Wang", "Zihe Wang", "Fuxiang Chen", "Haoran Wang", "Fengyan Tian", "Xuejia Zhai", "Chaohui Gu"], "affiliations": ["Department of Urology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.", "Department of Endocrinology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.", "Department of Pediatrics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China. fccguzh@zzu.edu.cn.", "Department of Immunotherapy, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, Henan, China. 15670557696@163.com.", "Department of Urology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China. zgwhgch@hotmail.com."], "corresponding_authors": ["Fengyan Tian", "Xuejia Zhai", "Chaohui Gu"], "china_team": "Department of Urology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China Fengyan Tian/Xuejia Zhai/Chaohui Gu团队", "category": "basic", "classification_reason": "basic_signals=22", "score": 44.92, "score_parts": {"urology_relevance": 7, "urology_in_title": 8.0, "journal_priority": 11.92, "top_journal_bonus": 0.0, "novelty": 2, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 14.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 13.5, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 3.92, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "膀胱癌高拷贝数亚群驱动化疗耐药", "chinese_summary": "郑州大学第一附属医院田凤艳/翟雪佳/顾朝辉团队9月Exp Hematol Oncol整合6套单细胞数据与多模态AI，构建基于常规H&E切片的膀胱癌预后模型：高拷贝数细胞呈TGF-β、JAK-STAT通路激活并与CAF、M2巨噬细胞活跃通讯，RTN3经JAK2/STAT3上调PKM2、GLUT1、LDHA，驱动吉西他滨耐药。", "abstract_zh": "膀胱癌是泌尿系统常见的恶性肿瘤，以吉西他滨为基础的化疗常因耐药而失败。肿瘤异质性，尤其是基因组水平的拷贝数变异（CNV）异质性，是驱动疾病进展和耐药的核心因素。然而，单细胞水平的CNV异质性与常规病理诊断所依赖的组织形态学特征之间的关系尚不清楚，限制了其在临床预后评估和精准治疗中的应用。本研究整合了六个公开的单细胞RNA测序（scRNA-seq）数据集作为发现队列，系统分析膀胱癌的细胞图谱。采用inferCNV算法在单细胞水平推断CNV，并鉴定高CNV（HCNV）亚群。采用结合深度学习和图像分析的多模态人工智能（AI）策略，以HCNV活性作为病理特征选择的生物学锚点，构建基于常规H&E染色病理切片的预后模型。利用多组学数据筛选枢纽基因，并使用膀胱癌细胞系开展体外和体内功能实验，以验证这些枢纽基因的功能与机制。单细胞分析显示，HCNV细胞构成一个具有独特分子表型的恶性亚群，其特征为致癌通路（如TGF-β、JAK-STAT和PI3K）广泛激活、与肿瘤微环境（如癌相关成纤维细胞和M2巨噬细胞）活跃通讯，且患者预后不良。基于多模态AI的病理影像模型可有效预测患者生存。模型衍生的风险评分与转录组HCNV活性呈显著但中等程度的相关性。通过多算法特征选择，我们确定RTN3是驱动HCNV表型的核心基因。我们的研究证实，RTN3不仅协调免疫抑制微环境，还直接介导对吉西他滨的耐药。在机制上，RTN3激活JAK2/STAT3信号通路，后者转录上调关键糖酵解酶（PKM2、GLUT1和LDHA），从而驱动糖酵解代谢重编程，最终赋予膀胱肿瘤吉西他滨耐药性。本研究在单细胞水平揭示了膀胱癌中以HCNV为特征的恶性细胞亚型，并阐明了膀胱癌预后不良的分子与微环境基础。成功开发了一个具有临床转化潜力的多模态AI病理预测模型。此外，我们的发现确立了RTN3/JAK2/STAT3/糖酵解轴作为吉西他滨耐药的关键机制，凸显RTN3是克服膀胱癌化疗耐药的有前景的治疗靶点。"}, {"pmid": "42744974", "title": "CircLAMA5 traps Sam68 in the cytoplasm to regulate alternative splicing and drive sunitinib resistance in ccRCC.", "abstract": "Tyrosine kinase inhibitor (TKI) resistance remains a major challenge in the treatment of clear cell renal cell carcinoma (ccRCC), yet the underlying molecular mechanisms are not fully understood. Here, we identify circular RNA circLAMA5 (hsa_circ_0061093) as a critical driver of sunitinib resistance in ccRCC. CircLAMA5 is significantly upregulated in sunitinib‑resistant cell lines and cell‑derived xenografts (CDX-R). Functional studies demonstrate that circLAMA5 enhances ccRCC cell survival, colony formation, and apoptosis evasion under sunitinib treatment both in vitro and in vivo. Mechanistically, circLAMA5 binds to the C-terminal region of Sam68 and promotes its cytoplasmic retention, at least in part by impairing the interaction between Sam68 and the nuclear import receptor TNPO1. This reduces nuclear Sam68 availability and suppresses its regulatory role in the alternative splicing of Bcl-x pre-mRNA, leading to a decreased pro‑apoptotic Bcl‑x(s)/anti‑apoptotic Bcl‑x(L) ratio and ultimately conferring sunitinib resistance. Importantly, we developed a biomimetic nanoparticle system coated with ccRCC cell membranes (RCCM@NPs) for targeted delivery of sh‑circLAMA5, effectively restoring sunitinib sensitivity in resistant tumors in vivo. Our findings reveal circLAMA5 as a key regulator of sunitinib resistance via the Sam68‑Bcl‑x splicing axis and propose a promising targeted nanotherapeutic strategy for overcoming resistance in advanced ccRCC.", "journal": "Oncogene", "pub_date": "2026-Sep-15", "publication_types": ["Journal Article"], "doi": "10.3390/cancers11121855", "authors": ["Zhehao Xu", "Haohua Lu", "Zeyi Lu", "Ruyue Wang", "Ziwei Zhu", "Yiming Ding", "Yang Li", "Yi Lu", "Fan Li", "Wenqin Luo", "Yudong Lin", "Xudong Mao", "Chenshuo Xu", "Yi Chen", "Zhen Yan", "Guanghua Huo", "Zhenwei Zhou", "Min Xu", "Lifeng Ding", "Gonghui Li", "Liqun Xia"], "affiliations": ["Department of Urology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.", "Department of Urology, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, China.", "Department of Urology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China. dinglf@zju.edu.cn.", "Department of Urology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China. 3193119@zju.edu.cn.", "Department of Urology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China. xialiqun@zju.edu.cn."], "corresponding_authors": ["Lifeng Ding", "Gonghui Li", "Liqun Xia"], "china_team": "Department of Urology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China Lifeng Ding/Gonghui Li/Liqun Xia团队", "category": "basic", "classification_reason": "basic_signals=16", "score": 35.1, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 15.1, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 14.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 7.3, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.1, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "环状RNA驱动肾癌舒尼替尼耐药", "chinese_summary": "浙江大学医学院附属邵逸夫医院丁立峰/李功辉/夏立群团队9月Oncogene报道，circLAMA5在舒尼替尼耐药ccRCC细胞及CDX模型中显著上调，其结合Sam68 C端促使其滞留胞质，减少核内Sam68对Bcl-x前体mRNA可变剪接的调控，降低Bcl-x(s)/Bcl-x(L)比值，从而介导耐药。", "abstract_zh": "酪氨酸激酶抑制剂（TKI）耐药仍是透明细胞肾细胞癌（ccRCC）治疗中的主要挑战，但其潜在分子机制尚未完全阐明。本研究中，我们鉴定环状RNA circLAMA5（hsa_circ_0061093）为ccRCC舒尼替尼耐药的关键驱动因子。CircLAMA5在舒尼替尼耐药细胞系及细胞衍生异种移植瘤（CDX-R）中显著上调。功能研究显示，circLAMA5在体外和体内均增强ccRCC细胞在舒尼替尼处理下的存活、集落形成及凋亡逃逸。机制上，circLAMA5结合Sam68的C端区域并促进其胞质滞留，至少部分通过破坏Sam68与核输入受体TNPO1之间的相互作用实现。这减少核内Sam68可用性，并抑制其对Bcl-x前体mRNA可变剪接的调控作用，导致促凋亡Bcl-x(s)/抗凋亡Bcl-x(L)比值下降，最终赋予舒尼替尼耐药。重要的是，我们开发了一种涂覆ccRCC细胞膜的仿生纳米颗粒系统（RCCM@NPs），用于靶向递送sh-circLAMA5，在体内有效恢复耐药肿瘤对舒尼替尼的敏感性。我们的发现揭示circLAMA5通过Sam68-Bcl-x剪接轴作为舒尼替尼耐药的关键调控因子，并提出一种有前景的靶向纳米治疗策略以克服晚期ccRCC耐药。"}, {"pmid": "42744862", "title": "Healthy lifestyle and cancer risk: a pan-cancer analysis in the UK Biobank prospective cohort.", "abstract": "Research on healthy lifestyles across various cancers is limited. We conducted a pan-cancer analysis to evaluate the associations of healthy lifestyle with cancer risk. Data from 287,745 UK Biobank participants were analysed. A healthy lifestyle score (HLS) was calculated based on smoking, alcohol, diet, physical activity and BMI. Cox models were used to estimate 27 cancer risks, and population attributable fractions (PAFs) were calculated based on incomplete adherence to a healthy lifestyle. During a median 11.5-year follow-up, 12,947 participants developed cancer. Adhering to 4-5 vs 0-1 healthy lifestyle behaviours was associated with decreased risks of 13 of the 27 cancer types: oral, pharyngeal, laryngeal, oesophageal, stomach, colorectal, liver, pancreatic, lung, soft tissue sarcoma, kidney, bladder and postmenopausal breast cancer (HRs from 0.12 to 0.79). Significant PAFs were observed for 14 cancer types in relation to lower HLS. Smoking and overweight were associated with the largest number of cancer types. These findings extend evidence on associations between a healthy lifestyle and lower risks of both common and less-common cancers. Smoking and overweight were associated with more cancer types than the other components, suggesting that smoking cessation and weight control may be cancer prevention strategies to be prioritised.", "journal": "British Journal of Cancer", "pub_date": "2026-Sep-15", "publication_types": ["Journal Article"], "doi": "10.1186/s12889-025-21537-6", "authors": ["Jie Ding", "Ben Schöttker", "Hermann Brenner", "Michael Hoffmeister"], "affiliations": ["Clinical Epidemiology of Early Cancer Detection, German Cancer Research Center (DKFZ), Heidelberg, Germany.", "Medical Faculty Heidelberg, Heidelberg University, Heidelberg, Germany.", "Cancer Prevention Graduate School, German Cancer Research Center (DKFZ), Heidelberg, Germany.", "Clinical Epidemiology of Early Cancer Detection, German Cancer Research Center (DKFZ), Heidelberg, Germany. m.hoffmeister@dkfz.de."], "corresponding_authors": ["Michael Hoffmeister"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=7", "score": 24.01, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 11.01, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 7.0}, "journal_metrics": {"status": "ok", "impact_factor": 6.8, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 3.01, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42744717", "title": "Risk-dependent Benefit of Adjuvant Pembrolizumab in High-risk Clear Cell Renal Cell Carcinoma: A Multi-institutional Study.", "abstract": "Adjuvant pembrolizumab improves outcomes in high-risk clear cell renal cell carcinoma (ccRCC), but baseline recurrence risk varies substantially. To evaluate treatment selection, outcomes, toxicity, and risk-stratified benefit. A retrospective cohort of consecutive patients with KEYNOTE-564-eligible ccRCC treated surgically at five U.S. tertiary centers (2021-2025). Adjuvant pembrolizumab or surveillance, selected through routine care. Disease-free survival (DFS) was evaluated using a 90-day postoperative landmark, multivariable Cox regression, and inverse probability of treatment weighting (IPTW), stratified by ASSURE risk category. Immune-related adverse events were assessed. Among 739 patients, 288 received pembrolizumab and 451 underwent surveillance; median follow-up was 18.4 months. Treated patients had more adverse pathologic features; 16% experienced grade ≥3 immune-related adverse events. The landmark cohort included 686 patients with median follow-up of 19.8 months, including 212 who initiated pembrolizumab by 90 days. Initiation by 90 days was not significantly associated with DFS in unadjusted (hazard ratio 1.02), multivariable-adjusted (0.91), or IPTW analyses (0.90). At 18 months after the landmark, absolute risk differences favoring pembrolizumab were -9.4%, 3.6%, and 5.7% across low-, intermediate-, and high-risk groups, respectively (interaction p = 0.8). Limitations include nonrandomized treatment allocation and limited follow-up. Baseline recurrence risk varied markedly among eligible patients. Potential absolute benefit appeared greater with higher baseline risk, although the interaction was nonsignificant. Individualized counseling and improved prognostic and predictive tools remain important. After kidney cancer surgery, treatment decisions should consider individual recurrence risk and potential side effects. Serious toxicity affected 16% of recipients.", "journal": "European Urology Oncology", "pub_date": "2026-Sep-15", "publication_types": ["Journal Article"], "doi": "10.1016/j.euo.2026.08.004", "authors": ["Daniel D Shapiro", "Daniel F Roadman", "Viraj A Master", "Charles C Peyton", "Andrew G McIntosh", "Brandon J Manley", "Philippe E Spiess", "Paz Lotan", "Dattatraya Patil", "Alireza Dehghanmanshadi", "Reagan Amason", "Max J Bouvette", "Benjamin Blittschau", "Kendrick H Yim", "Nicholas Abreu", "Vaishnavi Jayakumar", "Glenn O Allen", "Wade J Sexton", "Edwin Jason Abel"], "affiliations": ["Department of Urology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA. Electronic address: ddshapiro@wisc.edu.", "Department of Urology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.", "Department of Urology, Emory University School of Medicine, Atlanta, GA, USA.", "Department of Urology, University of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL, USA.", "Department of Urological Surgery, University of Oklahoma College of Medicine, Oklahoma City, OK, USA.", "Department of Genitourinary Oncology, Moffitt Cancer Center, Tampa, FL, USA."], "corresponding_authors": ["Daniel D Shapiro"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=14", "score": 45.42, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 15.42, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 12.0}, "journal_metrics": {"status": "ok", "impact_factor": 9.3, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.42, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "辅助帕博利珠单抗获益随基线风险升高", "chinese_summary": "欧洲泌尿肿瘤学9月发表一项多中心回顾性研究，纳入符合KEYNOTE-564标准的透明细胞肾癌术后患者739例，帕博利珠单抗组288例、监测组451例，中位随访18.4个月。尽管治疗组不良病理特征更多、16%发生≥3级免疫相关不良事件，但按ASSURE风险分层后，低、中、高危组18个月绝对风险差分别为-9.4%、3.6%和5.7%，交互作用不显著，提。", "abstract_zh": "辅助帕博利珠单抗改善高危透明细胞肾细胞癌（ccRCC）的结局，但基线复发风险差异很大。为了评估治疗选择、结局、毒性及风险分层获益。一项回顾性队列纳入2021至2025年在美国五家三级中心接受手术、符合KEYNOTE-564标准的连续ccRCC患者。辅助帕博利珠单抗或监测，通过常规诊疗选择。采用术后90天landmark、多变量Cox回归和逆概率治疗加权（IPTW）评估无病生存期（DFS），并按ASSURE风险类别分层。评估免疫相关不良事件。在739例患者中，288例接受帕博利珠单抗，451例接受监测；中位随访18.4个月。接受治疗的患者有更多不良病理特征；16%发生≥3级免疫相关不良事件。Landmark队列包括686例患者，中位随访19.8个月，其中212例在90天内开始帕博利珠单抗。90天内开始治疗与DFS在未调整（风险比1.02）、多变量调整（0.91）或IPTW分析（0.90）中均无显著相关。在landmark后18个月，支持帕博利珠单抗的绝对风险差在低、中、高危组分别为-9.4%、3.6%和5.7%（交互作用p=0.8）。局限性包括非随机治疗分配和随访有限。符合条件患者的基线复发风险差异显著。尽管交互作用不显著，基线风险越高，潜在绝对获益似乎越大。个体化咨询以及改进的预后和预测工具仍然重要。肾癌手术后，治疗决策应考虑个体复发风险和潜在副作用。16%的接受者发生严重毒性。"}, {"pmid": "42744708", "title": "Performance of the EORTC and CUETO risk prediction models in contemporary patients undergoing transurethral resection of bladder tumor with blue light cystoscopy.", "abstract": "The European Organization for Research and Treatment of Cancer (EORTC) and the Club Urológico Español de Tratamiento Oncológico (CUETO) risk prediction models are established tools for predicting recurrence and progression in non-muscle invasive bladder cancer. However, their performance in patients undergoing TURBT with blue light cystoscopy (BLC-TURBT), which reduces disease recurrence, has not been examined. We, therefore, evaluated the performance of these models in a contemporary cohort of patients undergoing BLC-TURBT. We identified patients aged 18 to 89 years in the multi-institutional Blue Light Cystoscopy with Cysview Registry who underwent BLC-TURBT between 2014 and 2023. We predicted disease recurrence- and progression-free survival estimates using the EORTC and CUETO models, and estimated observed recurrence-free (RFS) and progression-free (PFS) survival using the Kaplan-Meier method. A total of 899 patients were included. Tumor stage was Ta in 658 (73%) and T1 in 241 (27%) patients. EORTC risk score groups were associated with a statistically significant difference in RFS, whereas CUETO risk score groups were not. Observed RFS and PFS estimates were generally higher than that predicted by the EORTC risk score, while observed RFS and PFS were inconsistently related to that predicted by the CUETO risk score. The c-statistics for RFS and PFS by risk score group were 0.59 and 0.67 for EORTC, and 0.53 and 0.72 for CUETO, respectively. In a contemporary cohort of patients undergoing BLC-TURBT, the EORTC and CUETO models demonstrated poor performance in predicting RFS and PFS. These results underscore the need for development of more accurate predictive models to guide the risk-adapted management of patients undergoing BLC-TURBT.", "journal": "Urologic Oncology", "pub_date": "2026-Sep-15", "publication_types": ["Journal Article"], "doi": "10.1016/j.urolonc.2026.08.005", "authors": ["Agustin Perez-Londoño", "Sumedh Kaul", "Aaron Fleishman", "Badrinath Konety", "Kamal Pohar", "Jeffrey M Holzbeierlein", "John Taylor", "Max Kates", "Brian Willard", "Jennifer M Taylor", "Joseph C Liao", "Hristos Z Kaimakliotis", "Sima P Porten", "Gary D Steinberg", "Mark D Tyson", "Yair Lotan", "Siamak Daneshmand", "Boris Gershman"], "affiliations": ["Division of Urologic Surgery, Beth Israel Deaconess Medical Center, Boston, MA.", "Department of Surgery, Beth Israel Deaconess Medical Center, Boston, MA.", "Allina Health Cancer Institute, Minneapolis, MN.", "Department of Urology, Ohio State University, Columbus, OH.", "Department of Urology, University of Kansas, Kansas City, KS.", "The James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, MD.", "Lexington Medical Center, Lexington, SC.", "Michael E. DeBakey VA Medical Center, Baylor College of Medicine, Houston, TX.", "VA Palo Alto Health Care System, Palo Alto, CA.", "Department of Urology, Indiana University School of Medicine, Indianapolis, IN.", "Department of Urology, University of California San Francisco, San Francisco, CA.", "Department of Urology, Rush University, Chicago, IL.", "Department of Urology, Mayo Clinic Hospital, Phoenix, AZ.", "Department of Urology, UT Southwestern Medical Center, Dallas, TX.", "Department of Urology, USC Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA.", "Division of Urologic Surgery, Beth Israel Deaconess Medical Center, Boston, MA. Electronic address: bgershma@bidmc.harvard.edu."], "corresponding_authors": ["Boris Gershman"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=6", "score": 29.75, "score_parts": {"urology_relevance": 8, "urology_in_title": 8.0, "journal_priority": 5.75, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 6.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.3, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.75, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42744693", "title": "Challenges of Using Circulating Tumour DNA: Insights from Advanced Prostate Cancer.", "abstract": "Precision oncology relies on integrating tumour fraction, variant allele frequency, clonal haematopoiesis of indeterminate potential assessment, pathogenicity, and clinical context into next-generation sequencing interpretation, enabling biologically informed and clinically meaningful treatment decisions while reducing the risk of overinterpreting nontumour or nonactionable genomic alterations.", "journal": "European Urology", "pub_date": "2026-Sep-15", "publication_types": ["Editorial"], "doi": "10.1016/j.eururo.2026.07.025", "authors": ["Tarek Taha", "Ossian Longoria", "Johann de Bono"], "affiliations": ["The Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, London, UK.", "The Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, London, UK. Electronic address: johann.de-bono@icr.ac.uk."], "corresponding_authors": ["Johann de Bono"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 41.79, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 16.79, "top_journal_bonus": 10.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 1.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 25.2, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 4.79, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "循环肿瘤DNA应用面临多重挑战", "chinese_summary": "欧洲泌尿外科杂志9月发表社论指出，晚期前列腺癌液体活检需将肿瘤分数、变异等位基因频率、不确定潜能克隆性造血、致病性及临床背景共同纳入二代测序解读，方能做出具有生物学依据的诊疗决策，避免过度解读非肿瘤或非可干预的基因组改变。", "abstract_zh": "精准肿瘤学依赖于将肿瘤分数、变异等位基因频率、不确定潜能克隆性造血评估、致病性以及临床背景整合到二代测序解读中，从而在降低过度解读非肿瘤或非可干预基因组改变风险的同时，实现具有生物学依据且具有临床意义的治疗决策。"}, {"pmid": "42744245", "title": "Resident immune cell neighborhoods associate with protein kinase pRIPK3 and fatty acid ligase FACL4 expression during cell injury in ANCA associated vasculitis and lupus nephritis.", "abstract": "Tubulointerstitial injury is a key determinant of kidney prognosis and progression to chronic kidney disease in both antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) and lupus nephritis (LN). Identification of immune cell-induced injury of cells outside the glomerulus in vasculitic kidney diseases may inform potential targets for therapeutic interventions. To identify these cells, kidney biopsy samples from 15 patients (5 AAV, 5 class III and IV LN, 5 reference) were analyzed at single cell resolution using Imaging Mass Cytometry. Unbiased clustering of all 106,455 cells identified the expected resident tubule, endothelial, vascular and stromal cells, along with a marked increase in interstitial immune cells. Quantification of cell marker expression in resident cell clusters revealed downregulation of cell differentiation markers and upregulation of phosphorylated protein kinase RIPK3 and fatty acid ligase FACL4 in multiple tubule segments and endothelial cells in both AAV and LN compared to reference samples (non-tumor regions of nephrectomy samples). Spatially, these injury markers were increased in resident cells that were immediately adjacent to immune cells and in particular T cells. Our hypothesis-generating study shows that distinct immune cells are spatially associated with specific cell injury responses in the tubulointerstitium and identify pRIPK3 and FACL4 expression as potential integral components of that injury and cell death response.", "journal": "Kidney International", "pub_date": "2026-Sep-15", "publication_types": ["Journal Article"], "doi": "10.1016/j.kint.2026.07.031", "authors": ["Marlene Weiß", "Megan L Baker", "Tifanny Budiman", "Gabriel Lerner", "Ashish Shelar", "Dennis G Moledina", "Vijayakumar R Kakade", "Lloyd G Cantley"], "affiliations": ["Charité Universitätsmedizin Berlin, Berlin, Germany; Yale University School of Medicine, New Haven, Connecticut, USA. Electronic address: marlene.weiss@charite.de.", "Yale University School of Medicine, New Haven, Connecticut, USA.", "Yale University, New Haven, Connecticut, USA."], "corresponding_authors": ["Marlene Weiß"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 24.83, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 15.83, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 3.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 12.6, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.83, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "肾小管间质损伤与免疫细胞空间相关", "chinese_summary": "9月Kidney Int发表单细胞成像质谱研究，分析15例ANCA相关血管炎及狼疮肾炎肾活检的106455个细胞，发现肾小管及内皮细胞中pRIPK3和FACL4表达上调，且与邻近免疫细胞（尤其T细胞）空间相关，提示这些分子可能参与损伤及细胞死亡反应。", "abstract_zh": "肾小管间质损伤是抗中性粒细胞胞浆抗体（ANCA）相关性血管炎（AAV）和狼疮肾炎（LN）中肾脏预后及进展至慢性肾脏病的关键决定因素。识别血管炎性肾脏疾病中肾小球外细胞由免疫细胞诱导的损伤，可能为治疗干预提供潜在靶点。为识别这些细胞，采用成像质谱流式技术对15例患者（5例AAV、5例III和IV型LN、5例对照）的肾活检样本进行单细胞分辨率分析。对全部106,455个细胞进行无偏聚类，识别出预期的常驻肾小管、内皮、血管和基质细胞，同时间质免疫细胞显著增加。对常驻细胞簇中细胞标志物表达的定量分析显示，与对照样本（肾切除样本的非肿瘤区域）相比，AAV和LN中多个肾小管节段和内皮细胞的细胞分化标志物下调，而磷酸化蛋白激酶RIPK3和脂肪酸连接酶FACL4上调。在空间上，这些损伤标志物在紧邻免疫细胞、尤其是T细胞的常驻细胞中增加。我们的假设生成性研究表明，不同的免疫细胞与肾小管间质中特定的细胞损伤反应在空间上相关，并确定pRIPK3和FACL4表达是该损伤和细胞死亡反应的可能组成部分。"}, {"pmid": "42744022", "title": "Continence Durability for Male Sling Surgery and Subsequent Pelvic Radiation: A Multicenter Analysis.", "abstract": "To evaluate urinary continence outcomes in males who underwent pelvic radiation therapy (RT) before vs after urethral sling placement. We performed a retrospective study of males undergoing urethral sling placement for stress urinary incontinence at three tertiary centers from 2010 to 2025. Patients with history of pelvic radiation were stratified into two cohorts: sling placement before radiation (pre-RT) and sling placement after radiation (post-RT). The primary outcome was continence durability, assessed by pad use. Social continence was defined as the use of ≤1 pads per day (ppd). Secondary outcomes included International Prostate Symptom Score (IPSS), complications, and salvage surgery. Of 666 males undergoing sling placement, 28 (4.2%) had history of pelvic radiation: 15 (2.3%) pre-RT and 13 (2.0%) post-RT. In the pre-RT cohort, 100% experienced social continence post-sling; however, subsequent radiation resulted in marked deterioration, with social continence declining to 11% and median pad use increasing from 0 to 3 ppd. In the post-RT cohort, 50% of men achieved social continence post-sling. No mesh erosions were observed. Salvage artificial urinary sphincter (AUS) placement was performed in 21% (6/28) of the entire cohort, with no significant difference between the pre-RT and post-RT groups (13% vs 31%; P = .37). In this retrospective cohort, pelvic radiation after sling placement was temporally associated with declining continence in some patients. Both a history of pelvic radiation and the potential future need for radiation should be considered during counseling and selection of surgical treatment for stress urinary incontinence.", "journal": "Urology", "pub_date": "2026-Sep-15", "publication_types": ["Journal Article"], "doi": "10.1016/j.urology.2026.09.010", "authors": ["Chung Yon Lin", "Susana Martinez-Diaz", "Jonathan Nicholas Warner", "Elizabeth N Bearrick", "Katherine T Anderson", "Boyd R Viers", "Steven P Petrou", "Christopher E Wolter", "Bridget L Findlay"], "affiliations": ["Department of Urology, Mayo Clinic, Phoenix, AZ.", "Department of Urology, Mayo Clinic, Rochester, MN.", "Department of Urology, Mayo Clinic, Jacksonville, FL.", "Department of Urology, Mayo Clinic, Phoenix, AZ. Electronic address: findlay.bridget@mayo.edu."], "corresponding_authors": ["Bridget L Findlay"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=10", "score": 32.61, "score_parts": {"urology_relevance": 15, "urology_in_title": 0.0, "journal_priority": 5.61, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 10.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.0, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.61, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42744021", "title": "Reply to Editorial Comment on \"Patient-reported Bowel-Related Quality of Life After Urinary Diversion for Radiation Injury: A Single Center Prospective Study\".", "abstract": "", "journal": "Urology", "pub_date": "2026-Sep-15", "publication_types": ["Letter"], "doi": "10.1016/j.urology.2026.09.012", "authors": ["Charles H Schlaepfer", "Jane T Kurtzman", "Joemy Ramsay", "Jeremy B Myers"], "affiliations": ["University of Utah, Division of Urology, Department of Surgery, Salt Lake City, UT. Electronic address: Charles.schlaepfer@utah.edu.", "University of Utah, Division of Urology, Department of Surgery, Salt Lake City, UT."], "corresponding_authors": ["Charles H Schlaepfer"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 13.61, "score_parts": {"urology_relevance": 3, "urology_in_title": 8.0, "journal_priority": 5.61, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.0, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 1.61, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42743317", "title": "Effect of demographic characteristics on the outcome of prostate cancer salvage radiotherapy: Analysis from a randomized controlled trial.", "abstract": "This study investigated the impact of advanced molecular imaging, race, socioeconomic status, and metabolic dysregulation on the outcome of salvage radiotherapy (sRT) for prostate cancer recurrence in a clinical trial setting. The authors randomized post-prostatectomy men with detectable prostate-specific antigen to sRT guided by conventional imaging (arm A) or 18F-fluciclovine-positron emission tomography/computed tomography (arm B) and followed them up for up to 48 months to determine failure-free survival (FFS). The authors computed socioeconomic status (SES) and allostatic load (AL) scores to quantify socioeconomic status and level of metabolic dysregulation. They stratified patients by race as African American men (AAM) versus men of other races (MOR) and compared FFS between them using the z-test. Eighty-one (AAM = 29, MOR = 52) and 76 (AAM = 26, MOR = 50) men completed per-protocol sRT in arms A and B, respectively. Across study arms, AAM showed a higher FFS rate than MOR (72.8% [95% CI, 53.8%-85.0%] vs. 58.7% [95% CI, 46.6%-68.9%]; p = .002). In arm A, FFS rate was better for AAM than MOR, (64.0% [95% CI, 34.4%-82.9%] vs. 45.3% [95% CI, 28.8%-60.4%]; p = .008). In arm B, FFS improved for both groups but less so for AAM, (81.5% [95% CI, 57.2%-92.7%] vs. 73.0% [95% CI, 56.3%-84.1%]; p = .131). The authors found lower SES scores and higher AL scores for AAM in both study arms than MOR. Despite lower socioeconomic status and higher burden of metabolic dysregulation, in a clinical trial setting that controls for disparities in health care access, AAM have a more favorable sRT outcome than MOR.", "journal": "Cancer", "pub_date": "2026-Sep-15", "publication_types": ["Journal Article", "Randomized Controlled Trial"], "doi": "10.1038/s41585-023-00849-5", "authors": ["Ismaheel O Lawal", "Ashesh B Jani", "Subir Goyal", "Olayinka Abiodun-Ojo", "Vishal Dhere", "Sarah Bell", "Pretesh Patel", "Bruce Hershatter", "Krishna Chaudhary", "Aliza Mushtaq", "Joseph Shelton", "Sheela Hanasoge", "Nikhil Sebastian", "Sagar A Patel", "Raghuveer Halkar", "Viraj A Master", "Ruth C Carlos", "David M Schuster"], "affiliations": ["Department of Radiology and Imaging Sciences, Emory University, Atlanta, Georgia, USA.", "Department of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA.", "Biostatistics Shared Resource, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA.", "Department of Obstetrics and Gynecology, University of Michigan Medical School, Ann Arbor, Michigan, USA.", "Department of Urology, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA.", "Department of Radiology, Columbia University Vagelos College of Physicians and Surgeons, New York, New York, USA."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_interventional_trial", "score": 39.65, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 14.65, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 11.0}, "journal_metrics": {"status": "ok", "impact_factor": 5.1, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 2.65, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42743101", "title": "Short-term TRT improved sexual function after radical prostatectomy in men with low-grade prostate cancer.", "abstract": "", "journal": "Cancer", "pub_date": "2026-Sep-15", "publication_types": ["News"], "doi": "10.1002/cncr.70552", "authors": ["Leah Lawrence"], "affiliations": [], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 23.65, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 14.65, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 5.1, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 2.65, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "短期睾酮替代改善术后性功能", "chinese_summary": "《Cancer》9月报道，针对低级别前列腺癌根治术后患者，短期睾酮替代治疗可改善性功能。研究聚焦术后性功能恢复这一临床难题，提示在低危人群中短期雄激素补充具有潜在应用价值，但需注意肿瘤安全性监测。", "abstract_zh": "短期睾酮替代治疗改善了低级别前列腺癌患者根治性前列腺切除术后的性功能。"}, {"pmid": "42742868", "title": "Comparison of YouTube videos on single-port and multi-port robot-assisted radical prostatectomy using the PACE score.", "abstract": "This study aimed to compare the PACE-based procedural demonstration quality of YouTube videos demonstrating single-port robot-assisted radical prostatectomy (SP-RARP) and multi-port robot-assisted radical prostatectomy (MP-RARP). A cross-sectional analysis of publicly available YouTube videos was performed between January 1 and January 15, 2026. Videos containing real operative footage of SP-RARP or MP-RARP were included only if all seven PACE domains could be assessed. Selected procedural-segment videos were defined as edited operative videos that still included all PACE steps; videos with missing or non-assessable PACE domains were excluded. Video characteristics, source, procedure type, narration, and on-screen annotations were recorded. Comparisons between groups and correlations with total PACE score were analyzed. A total of 141 videos were included: 43 SP-RARP and 98 MP-RARP videos. MP-RARP videos were significantly longer (60 vs. 28 min, p < 0.001), older (2096 vs. 1095 days, p < 0.001), and received more likes (p = 0.029). Academic or official sources were more common among SP-RARP videos (69.8% vs. 51.0%, p = 0.044). Total PACE scores were similar between groups (25.86 ± 5.48 vs. 26.50 ± 4.37, p = 0.501). SP-RARP videos had higher scores for apical dissection and urethro-vesical anastomosis. In MP-RARP videos, video length correlated positively with total PACE score. SP-RARP and MP-RARP videos showed comparable overall PACE-based demonstration quality, although SP-RARP better demonstrated apical dissection and urethro-vesical anastomosis. Step-based assessment appears more useful than engagement metrics when selecting RARP videos.", "journal": "Journal of Robotic Surgery", "pub_date": "2026-Sep-15", "publication_types": ["Journal Article", "Comparative Study"], "doi": "10.1007/s11701-026-03961-x", "authors": ["Yunus Colakoglu", "Arda Meric", "Nazim Furkan Gunay"], "affiliations": ["Department of Urology, İstanbul Medipol University, Bahcelievler Medipol University Hospital, Çobançeşme Mahallesi, Fatih Caddesi, No:1/8, Bahçelievler, Istanbul, Turkey. dr.yunusc@gmail.com.", "Department of Urology, Dogubayazit Dr. Yasar Eryilmaz State Hospital, Agri, Turkey.", "Department of Urology, İskilip State Hospital, Corum, Turkey."], "corresponding_authors": ["Yunus Colakoglu"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_clinical", "score": 20.03, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 6.03, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 3.0, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 2.03, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42742845", "title": "Robot-assisted bladder diverticulectomy in adults: a systematic review and pooled analysis of perioperative and functional outcomes.", "abstract": "Robot-assisted bladder diverticulectomy (RABD) is used for symptomatic acquired bladder diverticula, but evidence is dispersed across small single-centre series and the only dedicated systematic review dates from 2010. We reviewed contemporary perioperative and functional outcomes of RABD. Following a protocol registered on the Open Science Framework ( https://doi.org/10.17605/OSF.IO/54CFT ), PubMed, Embase, the Cochrane Library, Scopus and Web of Science were searched from inception to 30 August 2026 (initial search June 2026, re-run and broadened for this version), following PRISMA 2020. Eligible studies were original series of five or more adults undergoing robot-assisted bladder diverticulectomy reporting extractable outcomes. Two reviewers independently screened, extracted data and appraised risk of bias with the Joanna Briggs Institute checklist for case series, with third-reviewer adjudication. Binary outcomes were pooled as proportions with Wilson 95% confidence intervals (CI); continuous outcomes were summarised as patient-number-weighted descriptive values, because mixed median/mean reporting and clinical heterogeneity precluded a formal pooled-effect meta-analysis. Twelve studies (146 patients) were included and all outcomes were extracted from the full-text reports. A transperitoneal route was used throughout. There were no conversions to open surgery (0/129; 95% CI 0-2.9%). Major complications (Clavien-Dindo ≥ III) occurred in 3.0% (4/135; 95% CI 1.2-7.4%). Patient-number-weighted descriptive values (combining study-level medians and means, and therefore not a pooled mean) were: operative time 163 min, blood loss 99 mL, length of stay 3.6 days and catheter duration 7.7 days. Symptom scores and post-void residual improved in every reporting series, significantly in five. The single non-randomised comparison with open surgery reported fewer major complications after RABD (5% [1/20] vs. 50% [3/6], p = 0.007), but the open arm comprised only six patients and this finding should not be regarded as comparative evidence. Across these series, RABD was feasible with low reported short-term morbidity in selected patients: no conversions to open surgery were recorded in the studies reporting conversion status, the major-complication rate was low, and symptom scores and post-void residual improved in every series that measured them. A minority of patients had an incidentally detected intradiverticular tumour; oncological outcomes were not an endpoint of this review. Evidence remains limited by small, heterogeneous, mostly retrospective series, so these findings should be read as descriptive; prospective comparative data are warranted.", "journal": "Journal of Robotic Surgery", "pub_date": "2026-Sep-15", "publication_types": ["Journal Article", "Systematic Review"], "doi": "10.1111/bju.13535", "authors": ["Christos Costa", "Foteini Moniati", "Christoforos Demosthenous"], "affiliations": ["Department of Urology, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.", "Department of Medicine, University Hospitals Birmingham NHS Trust, Birmingham, UK.", "Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK. c.demosthenous@smd22.qmul.ac.uk."], "corresponding_authors": ["Christoforos Demosthenous"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 27.03, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 6.03, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 7.0}, "journal_metrics": {"status": "ok", "impact_factor": 3.0, "cas_zone": 3, "cas_zone_points": 4.0, "impact_factor_points": 2.03, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42742789", "title": "PNE success after new lead introduction: ten years of data from a single institution experience.", "abstract": "Peripheral nerve evaluation (PNE) allows for a trial period for sacral neuromodulation to determine if the treatment is beneficial for a given patient. A new PNE wire was introduced in 2020; however, there is limited data assessing success rates after this change. We aimed to evaluate 10 years of data to assess PNE trial success rates at a single institution before and after the lead change. A retrospective review of PNE patients at a large academic center from 2015 to 2025 was performed. We assessed rates of PNE trial success, which was defined as ≥ 50% improvement in symptoms by patient diary. We carried out 3:1 propensity score matching between patients who received the old lead and the new lead to adjust for baseline differences between the two groups. Outcomes were compared using the Rao-Scott adjusted chi-square tests and weighted logistic regression models with robust standard errors. After propensity score matching there were 388 patients, and demographics were similar between groups. Overall, 82.6% (320/388) of patients had a successful PNE trial. From 2015 to 2019, the success rate was 77.6% (68/88). From 2020 to 2025, the success rate was 84.0% (252/300, p = 0.228), which was not statistically significantly different. PNE is an effective option for sacral neuromodulation trial. We did not find a statistically significant increase in PNE trial success after the introduction of the new lead. While success rates remained high over time, there was a slightly higher percentage of success in the latter group.", "journal": "World Journal of Urology", "pub_date": "2026-Sep-15", "publication_types": ["Journal Article"], "doi": "10.1007/s00345-026-06739-w", "authors": ["Maria J D'Amico", "Mohammad El Hussein", "Emily A Slopnick", "Sandip P Vasavada", "Howard B Goldman"], "affiliations": ["Glickman Urologic Institute and Lerner College of Medicine, Cleveland Clinic, Cleveland, OH, 44195, USA. madamico103@gmail.com.", "Glickman Urologic Institute and Lerner College of Medicine, Cleveland Clinic, Cleveland, OH, 44195, USA."], "corresponding_authors": ["Maria J D'Amico"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=5", "score": 17.5, "score_parts": {"urology_relevance": 0, "urology_in_title": 0.0, "journal_priority": 10.0, "top_journal_bonus": 0.0, "novelty": 0.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 5.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.9, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.0, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42742780", "title": "Efficacy and safety of thulium fiber laser versus conventional holmium:YAG laser in anatomical endoscopic enucleation of the prostate: a systematic review and pairwise meta-analysis.", "abstract": "Anatomical endoscopic enucleation is an established treatment for benign prostatic obstruction. Whether thulium fiber laser enucleation (ThuFLEP) improves outcomes over conventional holmium:YAG laser enucleation (HoLEP) remains uncertain. We compared the efficacy and safety of ThuFLEP versus non-MOSES-modulated HoLEP. We performed a PRISMA-compliant systematic review and pairwise meta-analysis of randomised and comparative cohort studies comparing ThuFLEP and conventional HoLEP in adult men. Six databases were searched. Outcomes included International Prostate Symptom Score (IPSS), IPSS quality-of-life score, maximum urinary flow rate (Qmax), post-void residual volume, hospital stay, and complications. Risk of bias and certainty of evidence were assessed with RoB 2/ROBINS-I and GRADE. Seven non-overlapping comparative populations in eight publications included 3,509 patients. ThuFLEP was associated with a small statistically significant reduction in IPSS at 3 months (mean difference [MD] -1.04 points, 95% confidence interval [CI] -1.81 to -0.28) of uncertain clinical relevance. Qmax differences were small and directionally inconsistent across follow-up (favouring HoLEP at 3 months and ThuFLEP at 6 and 12 months) and derived mainly from retrospective cohorts, with neutral randomised subgroups. Stress and urge urinary incontinence were less frequent overall (RR 0.75, 95% CI 0.58 to 0.96, and RR 0.39, 95% CI 0.22 to 0.68), but both estimates depended on one large registry cohort and were not robust to its exclusion. Most other complications and hospital stay showed no clear between-group difference. Limitations include few studies per outcome, heterogeneity, sparse safety events, inconsistent prostate-specific antigen reporting, and mostly low/very low certainty evidence. ThuFLEP and conventional HoLEP are clinically comparable with no definitive superiority of either laser. Platform selection should be individualised according to surgeon expertise, institutional resources, and patient characteristics. Future trials should standardise cost-effectiveness outcomes and investigate whether the distinct laser-tissue interactions impact adenoma clearance, PSA reduction, enucleation completeness, and long-term durability.", "journal": "World Journal of Urology", "pub_date": "2026-Sep-15", "publication_types": ["Journal Article", "Systematic Review", "Meta-Analysis", "Comparative Study"], "doi": "10.1007/s00345-026-06743-0", "authors": ["Oscar Emilio Valdez-Gil", "Elvira Espinoza-Gonzalez", "Laura Alejandra Zoller-Coronado", "Jorge A Zazueta-Estrada", "Jorge Iván Corrales-O", "Julián Santa Cruz-Venegas", "Jorge L Rivera-Gastelum"], "affiliations": ["Faculty of Medicine, Universidad del Valle de México, Hermosillo Campus, Hermosillo, Sonora, Mexico. oscaremiliovaldezgil7@gmail.com.", "Faculty of Medicine, Universidad del Valle de México, Hermosillo Campus, Hermosillo, Sonora, Mexico.", "Biomedical Engineering Program, Tecnológico Nacional de Mexico, Instituto Tecnológico de Hermosillo, Hermosillo, Sonora, Mexico.", "Faculty of Medicine, Universidad Durango Santander, Hermosillo Campus, Hermosillo, Sonora, Mexico.", "Clinical Neuropsychology, Universidad Tecnológica de Las Islas Canarias, San Cristóbal de La Laguna, Santa Cruz de Tenerife, Spain.", "Department of Surgery, Faculty of Medicine, Universidad Autónoma de Sinaloa (UAS), Campus II \"Dr Carlos Alfredo Zambada Sentíes\", Culiacán, Sinaloa, Mexico."], "corresponding_authors": ["Oscar Emilio Valdez-Gil"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 43.0, "score_parts": {"urology_relevance": 15, "urology_in_title": 8.0, "journal_priority": 10.0, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 8.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.9, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.0, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "铥激光与钬激光前列腺剜除疗效相当", "chinese_summary": "9月World J Urol发表系统评价与配对荟萃分析，纳入8篇文献7个比较人群共3509例患者，比较铥光纤激光剜除（ThuFLEP）与非摩西技术钬激光剜除（HoLEP）。ThuFLEP在3个月IPSS仅降低1.04分，临床意义不确定；最大尿流率差异小且方向不一致；压力性与急迫性尿失禁总体较少，但依赖单一注册队列、剔除后不稳健。", "abstract_zh": "解剖性内镜剜除术是治疗良性前列腺梗阻的成熟方法。铥光纤激光剜除术（ThuFLEP）是否较传统钬：YAG激光剜除术（HoLEP）改善结局仍不确定。我们比较了ThuFLEP与非摩西技术调控HoLEP的有效性和安全性。我们按照PRISMA规范，对比较成人男性ThuFLEP与传统HoLEP的随机和比较队列研究进行了系统评价和配对荟萃分析。检索了六个数据库。结局包括国际前列腺症状评分（IPSS）、IPSS生活质量评分、最大尿流率（Qmax）、排尿后残余尿量、住院时间和并发症。采用RoB 2/ROBINS-I和GRADE评估偏倚风险和证据确定性。八篇文献中的七个非重叠比较人群共纳入3509例患者。ThuFLEP与3个月时IPSS小幅但具有统计学意义的降低相关（平均差[MD] -1.04分，95%置信区间[CI] -1.81至-0.28），其临床相关性不确定。Qmax差异较小，且在各随访时间点方向不一致（3个月时 favoring HoLEP，6个月和12个月时 favoring ThuFLEP），主要来自回顾性队列，随机亚组为中性。压力性和急迫性尿失禁总体较少（RR 0.75，95% CI 0.58至0.96；RR 0.39，95% CI 0.22至0.68），但这两项估计均依赖一个大型注册队列，剔除该队列后不稳健。大多数其他并发症和住院时间未见明显组间差异。局限性包括每个结局研究较少、异质性、安全性事件稀疏、前列腺特异性抗原报告不一致，以及证据确定性多为低或极低。ThuFLEP与传统HoLEP在临床上具有可比性，两种激光均无明确优越性。平台选择应根据术者经验、机构资源和患者特征个体化进行。未来试验应标准化成本效益结局，并研究两种激光与组织相互作用的差异是否影响腺体清除、PSA下降、剜除完整性和长期耐久性。"}, {"pmid": "42742766", "title": "Commentary on \"PSA density for clinically significant prostate cancer detection: a retrospective cohort study on the influence of age and prostate volume\".", "abstract": "", "journal": "World Journal of Urology", "pub_date": "2026-Sep-15", "publication_types": ["Letter"], "doi": "10.1007/s00345-026-06784-5", "authors": ["Tasbehullah Khan", "Rizwan Ahmad", "Rashid Anwar"], "affiliations": ["Ayub Medical College, Abbottabad, Pakistan. tasbehullahkhan55@gmail.com.", "Saidu Medical College, Swat, Pakistan.", "Ayub Medical College, Abbottabad, Pakistan."], "corresponding_authors": ["Tasbehullah Khan"], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=4", "score": 23.0, "score_parts": {"urology_relevance": 4, "urology_in_title": 8.0, "journal_priority": 10.0, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": -3.0, "basic_research_strength": 0.0, "clinical_evidence": 4.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.9, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.0, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42742659", "title": "Transabdominal lumbar approach (TALA) versus retroperitoneal approach for robot-assisted renal surgery: a prospective randomised controlled trial.", "abstract": "Common robotic nephrectomy approaches access the kidney via transperitoneal (TP) or retroperitoneal (RP) routes, each with distinct trade-offs. We developed the transabdominal lumbar approach (TALA), combining advantages of both accesses with improved visualisation and strategic trocar placement, and compared it with conventional RP in a prospective randomised controlled trial using technique-oriented intraoperative endpoints. In this single-centre, prospective, open-label RCT, 40 patients were randomised to TALA (n = 18) or conventional RP (n = 22). Eligible patients were ≥ 18 years with a renal tumour or non-functional kidney requiring robot-assisted total or partial nephrectomy. Exclusions included prior surgery on the affected kidney, renal vein tumour thrombus, and pregnancy. Both groups were followed for 30 days. The primary endpoint was time from first skin incision to renal artery identification. TALA achieved a median time saving of 16 min compared to conventional RP (38 vs. 54 min, p = 0.001). Perioperative safety was comparable between groups, with three patients (7.5%) experiencing Clavien-Dindo grade III-IV complications. TALA met its primary endpoint with a significantly shorter time to renal artery identification than conventional RP access, and improving perceived surgical exposure and instrument handling.", "journal": "World Journal of Urology", "pub_date": "2026-Sep-15", "publication_types": ["Journal Article", "Randomized Controlled Trial", "Comparative Study"], "doi": "10.1007/s00345-026-06757-8", "authors": ["Uwe Bieri", "Franziska Heining", "Aydin Javadov", "Marie Lork", "Philipp Maletzki", "Jean-Pascal Adank", "Lukas Hefermehl"], "affiliations": ["Department of Surgery, Division of Urology, Kantonsspital Baden, 5400, Baden, Switzerland.", "Department Management, Technology, and Economics, Mobiliar Lab for Analytics, ETH Zürich, 8006, Zürich, Switzerland.", "Department of Surgery, Division of Urology, Kantonsspital Baden, 5400, Baden, Switzerland. lukas.hefermehl@ksb.ch."], "corresponding_authors": ["Lukas Hefermehl"], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_interventional_trial", "score": 26.0, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 10.0, "top_journal_bonus": 0.0, "novelty": 1, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 9.0}, "journal_metrics": {"status": "ok", "impact_factor": 2.9, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.0, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42685702", "title": "Enfortumab vedotin induces immunogenic cell death and shows enhanced preclinical antitumor activity when combined with a PD-1 inhibitor.", "abstract": "Enfortumab vedotin is a Nectin-4-directed antibody-drug conjugate designed to deliver the microtubule-disrupting agent monomethyl auristatin E (MMAE) to tumor cells. Using preclinical models of urothelial cancer (UC), we expand the understanding of the multifaceted mechanism of action for enfortumab vedotin that includes direct cytotoxicity on Nectin-4-positive tumor cells, indirect bystander effect on neighboring Nectin-4-negative tumor cells, and MMAE-mediated induction of immunogenic cell death (ICD) and associated increase in activated immune cells in the tumor microenvironment. Importantly, vaccination with enfortumab vedotin-treated tumor cells results in protection against tumor rechallenge in mice, consistent with antitumor immunity. MMAE-mediated ICD induction modulates the tumor microenvironment in a complementary manner to immune checkpoint inhibition. Accordingly, enfortumab vedotin plus PD-1 inhibitor shows enhanced antitumor activity in vivo. These preclinical findings provide mechanistic hypotheses that may be relevant to the improved clinical outcomes observed for enfortumab vedotin plus pembrolizumab relative to chemotherapy.", "journal": "Cell Reports Medicine", "pub_date": "2026-Sep-15", "publication_types": ["Journal Article"], "doi": "10.1007/978-1-4939-8885-3_21", "authors": ["Devra J Olson", "Bernard A Liu", "Patrick Younan", "Gabriele Blahnik-Fagan", "R Greg Stacey", "John Gosink", "Katie Snead", "Elena Tenn", "Kelly Hensley", "Disha Sahetya", "Albina Nesterova", "Margo Zaval", "Anthony Cao", "Christine O'Day", "Ryan A Heiser", "Timothy S Lewis", "Shyra J Gardai", "Taisuke Nakazawa", "Masashi Shimazaki", "Christopher Carosino", "Gregory L Szeto", "Sharsti Sandall"], "affiliations": ["Pfizer, Inc., Bothell, WA 98021, USA.", "Seagen, Inc., Bothell, WA 98021, USA.", "Astellas Pharma Inc., Tsukuba, Ibaraki, Japan.", "Astellas Research Institute of America LLC, Northbrook, IL 60062, USA.", "Pfizer, Inc., Bothell, WA 98021, USA. Electronic address: sharsti.sandall@pfizer.com."], "corresponding_authors": ["Sharsti Sandall"], "china_team": "", "category": "basic", "classification_reason": "basic_signals=10", "score": 31.6, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 15.6, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 10.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 10.6, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.6, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "恩沃利单抗诱导免疫原性细胞死亡增强抗肿瘤活性", "chinese_summary": "2026年9月Cell Rep Med发表临床前研究，显示恩沃利单抗（enfortumab vedotin）通过MMAE介导免疫原性细胞死亡，激活肿瘤微环境免疫细胞，与PD-1抑制剂联用可增强体内抗肿瘤活性，为联合治疗提供机制依据。", "abstract_zh": "恩沃利单抗是一种靶向Nectin-4的抗体偶联药物，设计用于将微管破坏剂单甲基澳瑞他汀E（MMAE）递送至肿瘤细胞。利用尿路上皮癌（UC）临床前模型，我们扩展了对恩沃利单抗多层面作用机制的理解，包括对Nectin-4阳性肿瘤细胞的直接细胞毒性、对邻近Nectin-4阴性肿瘤细胞的间接旁观者效应，以及MMAE介导的免疫原性细胞死亡（ICD）诱导和肿瘤微环境中活化免疫细胞的相应增加。重要的是，用恩沃利单抗处理的肿瘤细胞进行疫苗接种，可使小鼠免于肿瘤再攻击，与抗肿瘤免疫一致。MMAE介导的ICD诱导以互补方式调节肿瘤微环境，与免疫检查点抑制协同。因此，恩沃利单抗联合PD-1抑制剂在体内显示出增强的抗肿瘤活性。这些临床前发现提供了机制假说，可能与恩沃利单抗联合帕博利珠单抗相对于化疗所观察到的改善临床结局相关。"}, {"pmid": "42632240", "title": "Organophosphate flame retardants and incident type 2 diabetes: Integrating population evidence, mechanistic insights, and effect modification by healthy lifestyle.", "abstract": "Higher exposure to organophosphate flame retardants (OPFRs) may contribute to type 2 diabetes mellitus (T2DM), but prospective evidence, lifestyle modification, and biological plausibility remain insufficiently characterized. We conducted a nested case-control study within the Henan Rural Cohort to evaluate associations between OPFRs exposure and incident T2DM. Cox models, WQS, QGC, BKMR, and an adaptive elastic-net-based environmental risk score were used to assess single and mixed OPFRs exposure. Baseline and trajectory-based healthy lifestyle scores were applied to evaluate joint effects, and signed Wald χ² decomposition quantified contributions of OPFRs and lifestyle domains. Mechanistic evidence was integrated from in vitro experiments and toxicogenomic analyses, including RNA-sequencing, network toxicology, molecular docking, and GEO re-analysis, to evaluate EGFR-related signaling and build an integrative adverse outcome pathway. Higher urinary OPFRs, particularly TPHP, were associated with increased T2DM risk, and OPFRs mixtures showed a linear dose-response relationship with T2DM risk. High OPFRs exposure combined with unhealthy or deteriorating lifestyle trajectories conferred the greatest risk, with OPFRs plus lifestyle explaining 55.36% of total model χ². In HepG2 cells, TPHP impaired glucose consumption and downregulated EGFR, whereas EGFR overexpression alleviated the TPHP-associated abnormal glucose consumption. EGFR overexpression was confirmed at both mRNA and protein levels. The p-AKT/total AKT results provided supportive evidence of AKT-related signaling changes, whereas total GLUT2 protein abundance was not significantly altered. Molecular docking supported potential TPHP-EGFR binding affinity of -8.5 kcal/mol, and GEO analyses provided external supportive evidence that EGFR expression tended to be higher in healthier lifestyle-related conditions. These findings suggest that mixed OPFRs exposure, dominated by TPHP, was associated with higher incident T2DM risk, partly attenuated by healthier lifestyle trajectories, supporting combined exposure-reduction and lifestyle-based prevention strategies.", "journal": "Journal of Hazardous Materials", "pub_date": "2026-Sep-15", "publication_types": ["Journal Article"], "doi": "10.1016/j.jhazmat.2026.143347", "authors": ["Xueyan Wu", "Yilin Zhou", "Yue Nie", "Haoran Xu", "Hengrui Liu", "Mengke Cheng", "Yao Guo", "Fangyuan Lin", "Xin Tang", "Peihan Chen", "Dandan Wei", "Jian Hou", "Wenqian Huo", "Xiaotian Liu", "Linlin Li", "Chongjian Wang", "Caini Fan", "Haiying Chen", "Tian Chen", "Zhenxing Mao"], "affiliations": ["Department of Epidemiology and Biostatistics, College of Public Health, Zhengzhou University, Zhengzhou, Henan, PR China.", "Department of Occupational and Environmental Health Sciences, College of Public Health, Zhengzhou University, Zhengzhou, Henan, PR China.", "Department of Hypertension, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Zhengzhou, Henan, PR China.", "Department of Ultrasound, Third Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, PR China.", "Department of Environmental Health, Shanghai Municipal Center for Disease Control and Prevention, Shanghai 200336, PR China.", "Department of Epidemiology and Biostatistics, College of Public Health, Zhengzhou University, Zhengzhou, Henan, PR China. Electronic address: mzx@zzu.edu.cn."], "corresponding_authors": ["Zhenxing Mao"], "china_team": "Department of Epidemiology and Biostatistics, College of Public Health, Zhengzhou University, Zhengzhou, Henan, PR China Zhenxing Mao团队", "category": "basic", "classification_reason": "basic_signals=11", "score": 31.68, "score_parts": {"urology_relevance": 3, "urology_in_title": 0.0, "journal_priority": 15.68, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 11.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 11.3, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.68, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "有机磷阻燃剂升高糖尿病风险", "chinese_summary": "郑州大学毛振兴团队9月J Hazard Mater基于河南农村队列巢式病例对照研究，发现尿中有机磷阻燃剂（尤其TPHP）暴露与2型糖尿病发病风险升高相关，混合暴露呈线性剂量反应，不健康生活方式轨迹进一步放大风险，两者合计解释模型55.36%的卡方贡献；体外实验提示TPHP经EGFR/AKT通路损害葡萄糖消耗。", "abstract_zh": "较高的有机磷阻燃剂（OPFRs）暴露可能促进2型糖尿病（T2DM），但前瞻性证据、生活方式修饰作用及生物学合理性仍不充分。我们在河南农村队列中开展巢式病例对照研究，评估OPFRs暴露与2型糖尿病发病的关联。采用Cox模型、WQS、QGC、BKMR以及基于自适应弹性网的环境风险评分评估单一和混合OPFRs暴露。应用基线及轨迹健康生活方式评分评估联合效应，并用有符号Wald χ²分解量化OPFRs和生活方式各领域的贡献。整合体外实验和毒理基因组学分析的机制证据，包括RNA测序、网络毒理学、分子对接和GEO再分析，以评估EGFR相关信号并构建整合性不良结局路径。较高的尿OPFRs，尤其是TPHP，与T2DM风险升高相关，OPFRs混合物与T2DM风险呈线性剂量反应关系。高OPFRs暴露合并不健康或恶化的生活方式轨迹风险最高，OPFRs加生活方式解释了总模型χ²的55.36%。在HepG2细胞中，TPHP损害葡萄糖消耗并下调EGFR，而EGFR过表达可缓解TPHP相关的葡萄糖消耗异常。EGFR过表达在mRNA和蛋白水平均得到证实。p-AKT/总AKT结果提供了AKT相关信号变化的支持性证据，而总GLUT2蛋白丰度未显著改变。分子对接支持TPHP-EGFR潜在结合亲和力为-8.5 kcal/mol，GEO分析提供外部支持性证据，表明EGFR表达在更健康生活方式相关条件下倾向于更高。这些发现提示，以TPHP为主的混合OPFRs暴露与更高的T2DM发病风险相关，更健康的生活方式轨迹可部分减弱该风险，支持减少暴露与生活方式相结合的预防策略。"}, {"pmid": "42574031", "title": "Liquid Biopsies for Cancer: A Translational Science Review.", "abstract": "Circulating tumor DNA (ctDNA) evaluation, in which fragments of tumor DNA circulating in a patient's bloodstream are extracted and analyzed, can be used to monitor cancer progression, detect residual cancer after treatment, and identify genetic changes within cancer cells that could affect treatment response. ctDNA sequencing identifies cancer cell gene variants that inform the selection of molecularly directed therapies in several types of cancer, including non-small cell lung cancer, colorectal cancer, and breast cancer. Increases or decreases in ctDNA levels can indicate treatment response (ctDNA decrease) or cancer cell resistance and recurrence (ctDNA increase). Detecting ctDNA after curative intent therapy correlates strongly with cancer recurrence and poorer survival. In a meta-analysis of 1725 patients undergoing treatment for urothelial carcinoma, higher ctDNA levels were associated with poorer survival outcomes (hazard ratio for disease-free survival, 20.69 [95% CI, 9.63-44.43]; P < .001). This association was also observed in adjuvant settings (hazard ratio for disease-free survival, 4.51 [95% CI, 3.04-6.69]; P < .001) and in patients undergoing systemic therapy for metastatic disease (hazard ratio for overall survival, 2.0 [95% CI, 1.25-3.38]; P = .004; absolute rates not available). ctDNA detection may indicate minimal residual disease, defined as cancer cells detectable only by highly sensitive testing (eg, detection of 1 cancer cell in a population of 1 million normal cells) before disease progression is identified with imaging. Detecting an early increase in ctDNA and/or a novel sequence variation that may confer resistance to standard treatment can guide therapeutic decisions, such as changing to a new treatment, before tumor progression is detectable with conventional imaging. In a prospective cohort study of 130 patients with colorectal cancer, molecular relapse of disease was detected approximately 8.7 months earlier compared with standard-of-care imaging surveillance (5.5 months vs 14.2 months; P < .001). Similarly, patients with undetectable ctDNA levels may be able to discontinue therapy and be monitored, preventing potentially unnecessary exposure to chemotherapy that may have substantial adverse effects. However, the optimal timing of ctDNA testing, management of positive results in the absence of radiographic disease, and the cost-effectiveness of serial monitoring remain unclear. ctDNA, consisting of small DNA fragments from cancer cells that can be analyzed in human blood, can help clinicians monitor cancer progression, detect minimal residual cancer, and identify genetic variants that may help guide treatment decisions. Use of ctDNA may help select best treatment and timing of therapy for a patient with cancer, but optimal clinical applications remain unclear.", "journal": "Jama", "pub_date": "2026-Sep-15", "publication_types": ["Journal Article", "Review"], "doi": "10.1056/NEJMoa2304714", "authors": ["Jessica Mezzanotte-Sharpe", "Katrina Piemonte", "Ben H Park"], "affiliations": ["Vanderbilt-Ingram Cancer Center, Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.", "Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 43.41, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 17.91, "top_journal_bonus": 10.0, "novelty": 1.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 8.0}, "journal_metrics": {"status": "ok", "impact_factor": 55.0, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 5.91, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "ctDNA监测可提前预警癌症复发", "chinese_summary": "9月Jama发表转化科学综述：循环肿瘤DNA检测可评估疗效、识别耐药突变并发现微小残留病灶，用于指导分子靶向治疗。1725例尿路上皮癌荟萃分析显示，ctDNA水平升高与无病生存期及总生存期显著恶化相关；130例结直肠癌前瞻队列中，分子复发较常规影像学提前约8.7个月被发现。", "abstract_zh": "循环肿瘤DNA（ctDNA）评估通过提取并分析患者血流中循环的肿瘤DNA片段，可用于监测癌症进展、检测治疗后残留癌症以及识别可能影响治疗反应的癌细胞基因改变。ctDNA测序可识别癌细胞基因变异，为多种癌症（包括非小细胞肺癌、结直肠癌和乳腺癌）的分子靶向治疗选择提供依据。ctDNA水平的升高或降低可提示治疗反应（ctDNA降低）或癌细胞耐药与复发（ctDNA升高）。在根治性治疗后检出ctDNA与癌症复发和更差的生存密切相关。一项纳入1725例接受治疗的尿路上皮癌患者的荟萃分析显示，较高的ctDNA水平与更差的生存结局相关（无病生存风险比20.69[95%CI，9.63-44.43]；P<.001）。在辅助治疗背景下（无病生存风险比4.51[95%CI，3.04-6.69]；P<.001）以及接受全身治疗的转移性疾病患者中（总生存风险比2.0[95%CI，1.25-3.38]；P=.004；绝对率不可获得）也观察到这种关联。ctDNA检测可提示微小残留病灶，其定义为在影像学发现疾病进展之前，仅通过高灵敏度检测即可发现的癌细胞（例如在100万个正常细胞群体中检出1个癌细胞）。在影像学可检出肿瘤进展之前，检测到ctDNA早期升高和/或可能赋予标准治疗耐药的新序列变异，可指导治疗决策，例如更换新的治疗方案。在一项纳入130例结直肠癌患者的前瞻性队列研究中，与标准影像学监测相比，分子学复发约提前8.7个月被检测到（5.5个月 vs 14.2个月；P<.001）。同样，ctDNA水平不可测得的患者可能能够停止治疗并接受监测，从而避免可能产生显著不良反应的不必要化疗暴露。然而，ctDNA检测的最佳时机、无影像学疾病时阳性结果的管理以及连续监测的成本效益仍不明确。ctDNA由来自癌细胞的小DNA片段组成，可在人血液中进行分析，能帮助临床医生监测癌症进展、检测微小残留癌症并识别可能有助于指导治疗决策的基因变异。使用ctDNA可能有助于为癌症患者选择最佳治疗及治疗时机，但最佳临床应用仍不明确。"}, {"pmid": "42490143", "title": "PAX5 modulates vascularization and contributes to neuroendocrine lineage transition during carcinoma progression.", "abstract": "Human carcinomas often gain aggressive characteristics and escape cell type-specific treatment regimens through cryptic shifts in lineage states. However, the underlying mechanisms that govern lineage plasticity in carcinomas are undefined. Here in this study, we found that PAX5, a neural/lymphatic transcription factor, contributed to neuroendocrine (NE) lineage transition. PAX5 was highly expressed in aggressive human NE carcinoma cells and tissues but not in non-NE cancer cells and tissues. Deletion of Pax5 in Rb1fl/fl Trp53fl/fl mice caused a reduction of tumor vessels, loss of NE morphologic features, and decreased expression of ASCL1, NCAM, and SYP, whereas ectopic expression of PAX5 in CC10-rtTA TetO-hEGFRex19del/T790M mouse adenocarcinomas and in LNCAP prostate cancer xenografts induced an angiogenic microenvironment and NE morphology. Importantly, antiangiogenic drugs reduced NE features of Rb1fl/fl Trp53fl/fl tumors and blocked PAX5-induced NE transformation. These studies demonstrate an essential role of an angiogenic microenvironment in transition/maintenance of NE lineage, suggesting that targeting PAX5 and its downstream signaling may modulate lineage transitions responsible for treatment failure in both small cell neuroendocrine carcinoma and adenocarcinomas.", "journal": "Journal of Clinical Investigation", "pub_date": "2026-Sep-15", "publication_types": ["Journal Article", "Research Support, U.S. Gov't, P.H.S.", "Research Support, N.I.H., Extramural", "Research Support, Non-U.S. Gov't"], "doi": "10.1016/j.ccr.2014.03.020", "authors": ["Ailing Wu", "Yujie Hao", "Xuemiao Yan", "Junrong Liu", "Lin Wang", "Yan Jin", "Wenxu Liu", "Xiyue Chen", "Yuan Jiang", "Luc Girard", "Zhiqun Shang", "Jun Yan", "Zhenfa Zhang", "Wenchen Gong", "Yuanjie Niu", "Benjamin J Drapkin", "John D Minna", "Lance S Terada", "Zhenyi Ma", "Zhe Liu"], "affiliations": ["Zhejiang Key Laboratory of Medical Epigenetics, Jiande Hospital, Department of Cell Biology, School of Basic Medical Sciences, Hangzhou Normal University, Hangzhou, China.", "Department of Pathology, Tianjin First Center Hospital, Tianjin, China.", "Department of Lung Cancer Center, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.", "Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, Texas, USA.", "Tianjin Institute of Urology, the 2nd Hospital of Tianjin Medical University, Tianjin, China.", "Department of Pathology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.", "Department of Internal Medicine and Simmons Comprehensive Cancer Center and.", "Department of Internal Medicine, Division of Pulmonary and Critical Care, University of Texas Southwestern Medical Center, Dallas, Texas, USA.", "Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, China."], "corresponding_authors": [], "china_team": "Zhejiang Key Laboratory of Medical Epigenetics, Jiande Hospital, Department of Cell Biology, School of Basic Medical Sciences, Hangzhou Normal University, Hangzhou, China Zhe Liu团队", "category": "basic", "classification_reason": "basic_signals=17", "score": 35.93, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 15.93, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 14.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 13.6, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.93, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "PAX5驱动神经内分泌谱系转化", "chinese_summary": "杭州师范大学医学院刘哲团队9月J Clin Invest发现，神经/淋巴转录因子PAX5在侵袭性人神经内分泌癌中高表达。小鼠模型中敲除Pax5可减少肿瘤血管、丧失神经内分泌形态并下调ASCL1、NCAM、SYP；而异位表达PAX5则诱导血管生成微环境及神经内分泌形态。", "abstract_zh": "人类癌常通过谱系状态的隐蔽转变获得侵袭性特征并逃避细胞类型特异性治疗方案。然而，调控癌中谱系可塑性的潜在机制尚不明确。在本研究中，我们发现神经/淋巴转录因子PAX5促进神经内分泌（NE）谱系转化。PAX5在侵袭性人NE癌细胞和组织中高表达，但在非NE癌细胞和组织中不表达。在Rb1fl/fl Trp53fl/fl小鼠中敲除Pax5导致肿瘤血管减少、NE形态特征丧失以及ASCL1、NCAM和SYP表达下降，而在CC10-rtTA TetO-hEGFRex19del/T790M小鼠腺癌和LNCAP前列腺癌异种移植瘤中异位表达PAX5则诱导血管生成微环境和NE形态。重要的是，抗血管生成药物减少了Rb1fl/fl Trp53fl/fl肿瘤的NE特征并阻断了PAX5诱导的NE转化。这些研究证明血管生成微环境在NE谱系转变/维持中起关键作用，提示靶向PAX5及其下游信号可能调控导致小细胞神经内分泌癌和腺癌治疗失败的谱系转变。"}, {"pmid": "42378035", "title": "Cilia-to-basement membrane signaling is a biomechanical driver in models of autosomal dominant polycystic kidney disease.", "abstract": "Autosomal dominant polycystic kidney disease (ADPKD), the leading genetic cause of kidney failure, results from loss-of-function mutations in PKD1, encoding polycystin-1 (PC1). PC1 localizes to the primary cilium. In the absence of PC1, adverse signaling from the primary cilium orchestrates cyst formation, but the biomechanical underpinnings of this cilia-dependent cyst activation (CDCA) remain unclear. Combining tubule-specific orthologous mouse models with a tubule-on-chip platform, we show that PC1 and cilia govern the composition, mechanical properties, and shape of the tubular basement membrane (TBM), the principal rigid determinant of tubule geometry. PC1 loss triggered TBM thinning, heparan sulfate enrichment, and deformation, leading to distension, preferentially of the distal nephron. These changes were driven by a cilia-dependent transcriptional program, with GLIS2 - a key CDCA effector - participating as a downstream mediator. Reduction of TBM stiffness amplified Pkd1-/- tubule-on-chip dilation and increased cyst formation in vivo. Conversely, increasing luminal pressure through ureteral obstruction induced disproportionate distension of Pkd1-deficient tubules and triggered an irreversible cystogenic program. Together, these findings establish a TBM-centered biomechanical model of ADPKD in which tubule deformation is governed by both basolateral and luminal mechanical factors and identify the cilium/TBM axis, operating in part through GLIS2, as a central driver of cystogenesis.", "journal": "Journal of Clinical Investigation", "pub_date": "2026-Sep-15", "publication_types": ["Journal Article"], "doi": "10.1038/s41467-019-10239-4", "authors": ["Manal Mazloum", "Brice Lapin", "Rushdi Alghamdi", "Jessica Vandensteen", "Martine Burtin", "Pascal Houillier", "Lydie Cheval", "Gilles Crambert", "Vicky Scata", "Camille Cohen", "Christoph Schell", "Michael Rehman", "Amandine Aka", "Karim Ourahmoun", "Rui Benedito", "E Wolfgang Kuehn", "Stéphanie Descroix", "Tilman Busch", "Michael Köttgen", "Serge Garbay", "Marie-Christine Verpont", "Ellie Tang", "Brigitte Lelongt", "Nicolas Cagnard", "Stefan Somlo", "Sylvie Coscoy", "Fabiola Terzi", "Amandine Viau", "Frank Bienaimé"], "affiliations": ["Université Paris Cité, INSERM U1151, CNRS UMR 8235, Institut Necker Enfants Malades, Département Croissance et Signalisation, Paris, France.", "Assistance Publique-Hôpitaux de Paris, Hôpital Necker Enfants Malades, Service de Physiologie, Paris, France.", "Institut Curie, Université PSL, Sorbonne Université, CNRS UMR 168, Physics of Cells and Cancer, Paris, France.", "Department of Clinical Physiology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.", "Sorbonne Université et Université Paris Cité, Centre de Recherche des Cordeliers, INSERM, CNRS, Paris, France.", "Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Service de Physiologie, Paris, France.", "Université Paris Cité, Centre de Recherche sur l'Inflammation, INSERM U1149, EMR 8252, Paris, France.", "Service de Néphrologie, Hôpital Bichat, Assistance Publique Hôpitaux de Paris, Paris, France.", "Institute of Surgical Pathology, Faculty of Medicine, Medical Center, University of Freiburg, Freiburg, Germany.", "Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA.", "Institut du Cerveau et de la Moelle Épinière, INSERM U975, CNRS UMR 7225, Hôpital Pitié-Salpêtrière, Sorbonne Université, Paris, France.", "Molecular Genetics of Angiogenesis Group, Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain.", "Renal Division, Faculty of Medicine, Department of Medicine, Medical Center, University of Freiburg, Freiburg, Germany.", "Centre for Integrative Biological Signaling Studies, Freiburg, Germany.", "Sorbonne Université, CoRaKiD, INSERM UMRS 1155, Hôpital Tenon, Paris, France.", "Bioinformatic Platform, INSERM UMR 1163, Imagine Institute, Université Paris Cité, Paris, France.", "Department of Genetics, Yale School of Medicine, New Haven, Connecticut, USA.", "Université Paris Cité, Imagine Institute, Laboratory of Hereditary Kidney Diseases, INSERM UMR 1163, Paris, France."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "basic_signals=8", "score": 29.93, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 15.93, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 8.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 13.6, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.93, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "纤毛-基底膜信号驱动多囊肾病", "chinese_summary": "9月J Clin Invest结合小鼠模型与肾小管芯片发现，PC1缺失经纤毛依赖转录程序重塑肾小管基底膜，使其变薄、硫酸乙酰肝素富集并变形，远端肾单位优先扩张；降低基底膜硬度或升高管腔压力均加重囊肿，提示机械力学是ADPKD囊肿发生的关键驱动。", "abstract_zh": "常染色体显性多囊肾病（ADPKD）是导致肾衰竭的首要遗传性病因，由PKD1基因功能丧失突变引起，该基因编码多囊蛋白-1（PC1）。PC1定位于初级纤毛。在缺乏PC1的情况下，初级纤毛发出的不良信号协调囊肿形成，但这种纤毛依赖性囊肿激活（CDCA）的生物力学基础仍不清楚。我们结合小管特异性直系同源小鼠模型与肾小管芯片平台，证明PC1和纤毛决定肾小管基底膜（TBM）的组成、力学性质和形状，而TBM是小管几何形状的主要刚性决定因素。PC1缺失引发TBM变薄、硫酸乙酰肝素富集和变形，导致小管膨胀，且优先累及远端肾单位。这些变化由纤毛依赖性转录程序驱动，其中GLIS2这一关键CDCA效应因子作为下游介质参与其中。降低TBM硬度放大了Pkd1-/-肾小管芯片的扩张，并增加了体内囊肿形成。相反，通过输尿管梗阻增加管腔压力可诱导Pkd1缺陷小管不成比例的扩张，并触发不可逆的囊肿生成程序。总之，这些发现建立了以TBM为中心的ADPKD生物力学模型，其中小管变形受基底外侧和管腔机械因素共同调控，并确定纤毛/TBM轴部分通过GLIS2发挥作用，是囊肿发生的核心驱动因素。"}, {"pmid": "42143896", "title": "Sensors for urinary system applications: Current developments and future perspectives.", "abstract": "The urinary system regulates waste filtration and fluid homeostasis, yet disorders such as chronic kidney disease, urinary tract infections, prostate cancer, and urinary stones remain major global health challenges. Current diagnostic and therapies are limited by low sensitivity, poor temporal resolution, and lack of real-time physiological feedback, hindering early intervention and precision treatment. Recent advancements in sensor technology offer innovative solutions, enhancing early diagnosis, disease monitoring, and treatment precision. This review highlights physical sensors, biomarker detection sensors and imaging-assisted sensors for urinary applications. These sensors enable early screening, continuous monitoring and precise treatment of urinary diseases, enhanced surgical navigation and personalized medication. Despite rapid progress, challenges remain in long-term biocompatibility, clinical translation, and multimodal data integration. Addressing these barriers through materials innovation and AI-driven sensor fusion will be critical for next-generation intelligent urological systems, ultimately advancing precision medicine and improving patient outcomes. This review underscores the transformative impact of sensors in urology and the need for continued innovation.", "journal": "Biosensors & Bioelectronics", "pub_date": "2026-Sep-15", "publication_types": ["Journal Article", "Review"], "doi": "10.1016/j.bios.2026.118806", "authors": ["Huacui Xiang", "Kun Hu", "Elizabeth Wei", "Eric Jung", "Jiujiang Ji", "Mingrui Wu", "Yen Wei"], "affiliations": ["Department of Chemistry and the Tsinghua Center for Frontier Polymer Research, Tsinghua University, Beijing, 100084, PR China.", "School of Printing and Packaging Engineering, Beijing Institute of Graphic Communication, Beijing, 102600, PR China. Electronic address: kunhu@139.com.", "University of Texas at Austin Dell Medical School, Department of Pediatrics, 4900 Mueller Blvd, Austin, TX, 78723, USA.", "Independent Practice Urologist, 5350 Wilshire Blvd #361111, Los Angeles, CA, 90036, USA.", "Department of Chemistry and the Tsinghua Center for Frontier Polymer Research, Tsinghua University, Beijing, 100084, PR China. Electronic address: weiyen@tsinghua.edu.cn."], "corresponding_authors": ["Kun Hu", "Yen Wei"], "china_team": "Department of Chemistry and the Tsinghua Center for Frontier Polymer Research, Tsinghua University, Beijing, 100084, PR China Kun Hu/Yen Wei团队", "category": "clinical_review", "classification_reason": "publication_type_review_or_guideline", "score": 42.08, "score_parts": {"urology_relevance": 15, "urology_in_title": 8.0, "journal_priority": 15.58, "top_journal_bonus": 0.0, "novelty": 0.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 1.0}, "journal_metrics": {"status": "ok", "impact_factor": 10.5, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.58, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42140065", "title": "Smartphone-based preeclampsia diagnosis through detection of dual biomarkers - nephrin and podocalyxin.", "abstract": "Preeclampsia (PE) causes approximately 15% of maternal deaths globally, with disproportionately high mortality in low- and middle-income countries. Current diagnostic protocols require laboratory infrastructure and trained personnel, excluding women in resource-limited settings. We developed a smartphone-integrated dual-biomarker lateral flow assay (LFA) platform for simultaneous quantification of nephrin (NPHS1) and podocalyxin (PODXL), two podocyturia-associated biomarkers with established clinical cut-off values of >304.6 ng/mL and >59.5 ng/mL, respectively. Six monoclonal antibodies were generated via hybridoma technology and screened to identify optimal capture-detection pairs. Selected antibody-functionalized gold nanoparticles (Ab@AuNPs) were assembled into sandwich immunoassay strips on nitrocellulose membranes. The assay detected both biomarkers across 0-1,000 ng/mL, with LODs of 2.41 (NPHS1) and 2.27 ng/mL (PODXL) and sigmoidal fits (R2 = 0.97 and 0.98). Both biomarkers showed strong correlation with ELISA (R2 > 0.96) and high specificity against urinary interfering proteins. Spiked human urine samples yielded a high correlation (R2 > 0.99) between the added and found concentrations. A reference card-smartphone reader compensates for ambient lighting without specialized instruments. Both targets are resolved on one strip within 15 min, enabling early PE screening without laboratory equipment.", "journal": "Biosensors & Bioelectronics", "pub_date": "2026-Sep-15", "publication_types": ["Journal Article"], "doi": "10.1016/j.bios.2026.118792", "authors": ["Jin-Ho Park", "Dong-Hoon Lee", "Kwang-Myeon Chung", "Eung-Kyu Park", "Young Kwan Cho", "Hakho Lee", "Ik-Soo Shin"], "affiliations": ["Center for Systems Biology, Massachusetts General Hospital, Boston, MA, 02114, USA; Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02114, USA.", "QSTAG Inc., 46 Gongdan-ro 140beon-gil, Gunpo-si, Gyeonggi-do, 15847, Republic of Korea.", "GMNBIO Inc., 6-3 Chiljeondong 2-gil, Chuncheon-si, Gangwon-do, 24456, Republic of Korea.", "Center for Systems Biology, Massachusetts General Hospital, Boston, MA, 02114, USA; Department of Chemistry, Soongsil University, 369 Sangdo-ro, Dongjak-gu, Seoul, 06987, Republic of Korea.", "Center for Systems Biology, Massachusetts General Hospital, Boston, MA, 02114, USA; Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02114, USA. Electronic address: hlee@mgh.harvard.edu.", "Department of Chemistry, Soongsil University, 369 Sangdo-ro, Dongjak-gu, Seoul, 06987, Republic of Korea. Electronic address: extant@ssu.ac.kr."], "corresponding_authors": ["Hakho Lee", "Ik-Soo Shin"], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 24.08, "score_parts": {"urology_relevance": 3, "urology_in_title": 0.0, "journal_priority": 15.58, "top_journal_bonus": 0.0, "novelty": 0.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 3.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 10.5, "cas_zone": 1, "cas_zone_points": 12.0, "impact_factor_points": 3.58, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "手机双标志物试纸早筛子痫前期", "chinese_summary": "Biosens Bioelectron 9月报道一种智能手机集成双标志物侧向层析平台，可同时定量尿中nephrin与podocalyxin，检测限分别为2.41和2.27 ng/mL，与ELISA高度相关，15分钟内完成，无需实验室设备，为资源有限地区子痫前期早期筛查提供思路。", "abstract_zh": "子痫前期（PE）导致全球约15%的孕产妇死亡，在低收入和中等收入国家死亡率尤为高。当前诊断方案需要实验室基础设施和训练有素的人员，将资源有限环境中的女性排除在外。我们开发了一种智能手机集成的双生物标志物侧向层析检测（LFA）平台，用于同时定量nephrin（NPHS1）和podocalyxin（PODXL），这两种与足细胞尿相关的生物标志物已确立的临床截断值分别为>304.6 ng/mL和>59.5 ng/mL。通过杂交瘤技术生成六种单克隆抗体，并筛选以确定最佳的捕获-检测配对。选定的抗体功能化金纳米颗粒（Ab@AuNPs）被组装到硝酸纤维素膜上的夹心免疫测定条中。该检测在0-1,000 ng/mL范围内检测两种生物标志物，LOD分别为2.41（NPHS1）和2.27 ng/mL（PODXL），并呈S形拟合（R2 = 0.97和0.98）。两种生物标志物均与ELISA显示出强相关性（R2 > 0.96），并对尿液干扰蛋白具有高特异性。加标人尿液样本在添加浓度与检出浓度之间显示出高相关性（R2 > 0.99）。参考卡-智能手机读取器可补偿环境光照，无需专用仪器。两个目标物在一条试纸条上15分钟内即可分辨，使得无需实验室设备即可进行早期PE筛查。"}, {"pmid": "42107751", "title": "Pholidota chinensis Lindl alleviates diabetic kidney disease by restoring mitochondrial dynamics and promoting mitophagy.", "abstract": "Pholidota chinensis Lindl. (P. chinensis), a traditional medicinal plant, exhibits notable antioxidant, anti-inflammatory, and antidiabetic properties. In Traditional Chinese Medicine, its pseudobulbs are applied for treating cough, bronchitis, diabetes, and diabetic kidney disease (DKD). The potential mechanism through which P. chinensis alleviates DKD requires further investigation. This investigation was designed to evaluate the potential of P. chinensis to optimize mitochondrial function via the dual regulation of dynamic remodeling and mitophagic flux within DKD models. A DKD animal model was induced through unilateral nephrectomy and streptozotocin administration. Various parameters were evaluated, such as renal function, histopathology, inflammatory and fibrotic markers, and proteins related to mitochondrial fission-fusion balance and mitophagy. In vitro, AGEs-treated HK-2 cell model was employed to assess autophagic flux and mitochondrial function via adenoviral mCherry-GFP-LC3B transduction, JC-1 assay, together with measurements of ROS and ATP production. P. chinensis showed clear renoprotective effects in DKD rats, mainly by alleviating renal inflammation and fibrotic changes. Treatment was associated with improved mitochondrial dynamics, characterized by increased expression of mitochondrial fusion-related proteins (Mfn1, Opa1) and reduced levels of fission-related proteins (Drp1, Fis1). Meanwhile, a pronounced activation of mitophagy was observed, evidenced by increased levels of core regulators involved in the PINK1/Parkin pathway and autophagosome formation, along with reduced p62 accumulation. In vitro, P. chinensis exerted antioxidative effects by enhancing SOD activity while reducing MDA levels. It also facilitated autophagy activation and autophagosome-lysosome fusion, leading to improved mitochondrial membrane potential, reduced ROS production, and increased ATP generation. Overall, P. chinensis improves mitochondrial quality control by promoting fusion, reactivating mitophagy, and enhancing autophagic flux, thereby facilitating mitochondrial clearance and contributing to the attenuation of kidney injury and the slowing of DKD progression.", "journal": "Journal of Ethnopharmacology", "pub_date": "2026-Sep-15", "publication_types": ["Journal Article"], "doi": "10.1016/j.jep.2026.121847", "authors": ["Chenhui Xia", "Huixi Chen", "Jiale Zhang", "Weimin Jiang", "Shunxuan Xue", "Cong Zhao", "Qianhe Zhou", "Yaoxian Wang", "Weiwei Sun"], "affiliations": ["Department of Nephrology and Endocrinology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, 100700, China; Department of Traditional Chinese Medicine, Traditional Chinese and Western Medicine Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430033, China.", "Department of Nephrology and Endocrinology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, 100700, China.", "Department of Nephrology and Endocrinology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, 100700, China; Department of Endocrinology, Fangshan Hospital of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 102400, China.", "Department of Nephrology and Endocrinology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, 100700, China. Electronic address: wyxtcm@163.com.", "Department of Nephrology and Endocrinology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, 100700, China. Electronic address: sunweitcm@163.com."], "corresponding_authors": ["Yaoxian Wang", "Weiwei Sun"], "china_team": "Department of Nephrology and Endocrinology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, 100700, China; Department of Traditional Chinese Medicine, Traditional Chinese and Western Medicine Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430033, China Yaoxian Wang/Weiwei Sun团队", "category": "basic", "classification_reason": "basic_signals=13", "score": 29.72, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 10.72, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 13.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 5.4, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.72, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "中药石仙桃改善糖尿病肾病线粒体", "chinese_summary": "北京中医药大学东直门医院王耀献/孙卫卫团队9月J Ethnopharmacol报道，石仙桃假鳞茎可减轻糖尿病肾病大鼠肾脏炎症与纤维化，机制与促进线粒体融合、激活PINK1/Parkin介导的线粒体自噬并改善自噬流有关，为中药干预DKD提供依据。", "abstract_zh": "石仙桃（Pholidota chinensis Lindl.，P. chinensis）是一种传统药用植物，具有显著的抗氧化、抗炎和抗糖尿病特性。在中医中，其假鳞茎被用于治疗咳嗽、支气管炎、糖尿病及糖尿病肾病（DKD）。石仙桃缓解DKD的潜在机制仍需进一步研究。本研究旨在评估石仙桃通过双重调控DKD模型中的动态重塑和线粒体自噬流来优化线粒体功能的潜力。通过单侧肾切除联合链脲佐菌素给药诱导DKD动物模型。评估了多种参数，如肾功能、组织病理学、炎症和纤维化标志物，以及与线粒体分裂-融合平衡和线粒体自噬相关的蛋白。在体外，采用AGEs处理的HK-2细胞模型，通过腺病毒mCherry-GFP-LC3B转导、JC-1测定以及ROS和ATP生成测量来评估自噬流和线粒体功能。石仙桃对DKD大鼠表现出明显的肾脏保护作用，主要通过减轻肾脏炎症和纤维化改变。治疗与线粒体动力学改善相关，其特征是线粒体融合相关蛋白（Mfn1、Opa1）表达增加，分裂相关蛋白（Drp1、Fis1）水平降低。同时，观察到线粒体自噬明显激活，表现为PINK1/Parkin通路核心调节因子水平升高、自噬体形成增加，以及p62积累减少。在体外，石仙桃通过增强SOD活性同时降低MDA水平发挥抗氧化作用。它还促进自噬激活和自噬体-溶酶体融合，从而改善线粒体膜电位、减少ROS产生并增加ATP生成。总体而言，石仙桃通过促进融合、重新激活线粒体自噬和增强自噬流来改善线粒体质量控制，从而促进线粒体清除，有助于减轻肾损伤并延缓DKD进展。"}, {"pmid": "42050794", "title": "Mental Health Conditions and Incident Cancer: A Prospective Cohort Study of 402,255 UK Biobank Participants.", "abstract": "Mental health conditions (MHCs) affect both psychological health and biological systems and have also been linked to cancer risk. However, evidence from epidemiological studies regarding this link remains inconsistent. We conducted a population-based prospective cohort study involving 402,255 UK Biobank participants to investigate the associations of five MHCs (depressive disorders [DD], anxiety disorders [AD], bipolar disorder [BD], schizophrenia [SZ] and post-traumatic stress disorder [PTSD]) with overall and site-specific cancer risk. Cox proportional hazard models were used, adjusting for sociodemographic, health-related and lifestyle confounders. Over a median follow-up of 13.4 years, 68,065 (17%) incident cancer cases were recorded. DD (HR 1.18; 95% CI 1.13-1.23), AD (HR: 1.17, 95% CI: 1.11-1.24) and BD (HR: 1.29, 95% CI: 1.11-1.51) were associated with increased overall cancer risk. No significant association was found for SZ and PTSD. The associations of DD (HR: 1.27, 95% CI: 1.18-1.35) and BD (HR: 1.54, 95% CI: 1.26-1.88) were only significant in men. AD and DD were positively associated with lung, blood and liver cancers, while AD was also associated with prostate cancer. A dose-response relationship was observed between depressive symptom severity and cancer risk. While we cannot assume causality, our finding suggests that diagnoses of MHCs could be useful for cancer risk stratification and prevention.", "journal": "International Journal of Cancer", "pub_date": "2026-Sep-15", "publication_types": ["Journal Article"], "doi": "10.1002/ijc.70527", "authors": ["Mohammed Sherif Amin", "Solange Parra-Soto", "Ziyi Zhou", "Shinya Nakada", "Ike Dhiah Rochmawati", "Carlos Celis-Morales", "Nancy Meligy", "Jill P Pell", "Frederick K Ho"], "affiliations": ["Department of Clinical Infection, Microbiology, and Immunology, The University of Liverpool, Liverpool, UK.", "School of Health and Wellbeing, University of Glasgow, Glasgow, UK.", "Department of Nutrition and Public Health, Faculty of Health Science and Food, Universidad del Bío-Bío, Chillán, Chile.", "School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK.", "Faculty of Pharmacy, University of Surabaya, Surabaya, Indonesia.", "Human Performance Lab, Education, Physical Activity and Health Research Unit, University Católica del Maule, Talca, Chile.", "Centro de Investigación en Medicina de Altura (CEIMA), Universidad Arturo Prat, Iquique, Chile.", "Faculty of Medicine, Health and Life Sciences, Swansea University, Swansea, UK."], "corresponding_authors": [], "china_team": "", "category": "clinical_review", "classification_reason": "clinical_signals=7", "score": 23.55, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 10.55, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 0.0, "clinical_evidence": 7.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.7, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.55, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}, {"pmid": "42044775", "title": "Scoparone enhances the stability of TAT protein by inhibiting the Ubiquitin-Proteasome pathway, regulates mitochondrial damage against chronic alcoholic liver disease.", "abstract": "Artemisia capillarisThunb. is a traditional Chinese medicinal herb commonly used in clinical practice for chronic alcoholic liver disease (CALD).Scoparone, one of the major active components of Artemisia capillarisThunb., has emerged as a promising candidate for CALD intervention, yet its mechanism remains unclear. This study aimed to systematically elucidate the pharmacological effects of scoparone and its molecular mechanisms in CALD via multi-omics combined with targeted validation. The National Institute on Alcohol Abuse and Alcoholism (NIAAA) animal model was established. The NIAAA-established CALD mouse model (chronic ethanol feeding + acute binge, mimicking acute-on-chronic liver injury) was diagnosed via classic clinical methods (liver function biomarkers + histopathology). After validation, scoparone exhibited significant efficacy across different doses. Metabolomics and transcriptomics analyzed urine/tissue samples, with integrated analysis identifying core hubs. Meanwhile, primary hepatocytes were cultured and treated with scoparone. Potential targets were validated via gene knockdown, CETSA, CHX chase, and ubiquitination assays. We used the Seahorse XF Mito Stress Test to evaluate CALD-associated mitochondrial damage and elucidate the key interrelationships. Scoparone normalized serum biochemical indices and liver pathology to near-healthy levels. Urinary metabolomics identified 9 biomarkers, and liver transcriptomics detected 3665 differentially expressed genes.Integrated omics pinpointed the phenylalanine pathway, with TAT/AST co-regulation identified as key. In vitro, primary hepatocytes were cultured with 100 mmol/L ethanol ±25 μmol/L scoparone; CETSA and CHX chase assays confirmed scoparone enhances TAT stability via inhibiting the Ubiquitin-Proteasome pathway. Seahorse analysis showed TAT knockdown-induced hepatocyte apoptosis, oxidative stress, lipid accumulation, and mitochondrial damage were reversed by scoparone or TAT level restoration. This study first reveals scoparone's novel mechanism in treating CALD: it directly binds tyrosine aminotransferase (TAT), stabilizes its level by inhibiting Ubiquitin-Proteasome-mediated degradation, restores TAT's regulation of phenylalanine to prevent tyrosinemia and associated liver injury or jaundice, and normalizes tyrosine regulation to recover mitochondrial tricarboxylic acid cycle-related pyruvate, reversing oxidative stress and mitochondrial dysfunction.This study validates scoparone as a potential CALD therapeutic and provides robust preclinical data for TAT-targeted therapy.", "journal": "Journal of Ethnopharmacology", "pub_date": "2026-Sep-15", "publication_types": ["Journal Article"], "doi": "10.1016/j.jep.2026.121746", "authors": ["Chaozhong Wang", "Yuran Sun", "Le Yang", "Junling Ren", "Heng Fang", "Ye Sun", "Guangli Yan", "Ling Kong", "Ying Han", "Xijun Wang", "Hui Sun"], "affiliations": ["State Key Laboratory of Integration and Innovation of Classic Formula and Modern Chinese Medicine, National Chinmedomics Research Center, National TCM Key Laboratory of Serum Pharmacochemistry, Metabolomics Laboratory, Department of Pharmaceutical Analysis, Heilongjiang University of Chinese Medicine, Heping Road 24, Harbin, 150040, China.", "State Key Laboratory of Dampness Syndrome, The Second Affiliated Hospital Guangzhou University of Chinese Medicine, Dade Road 111, Guangzhou, China.", "State Key Laboratory of Integration and Innovation of Classic Formula and Modern Chinese Medicine, National Chinmedomics Research Center, National TCM Key Laboratory of Serum Pharmacochemistry, Metabolomics Laboratory, Department of Pharmaceutical Analysis, Heilongjiang University of Chinese Medicine, Heping Road 24, Harbin, 150040, China; State Key Laboratory of Dampness Syndrome, The Second Affiliated Hospital Guangzhou University of Chinese Medicine, Dade Road 111, Guangzhou, China. Electronic address: fh19870215@163.com.", "State Key Laboratory of Integration and Innovation of Classic Formula and Modern Chinese Medicine, National Chinmedomics Research Center, National TCM Key Laboratory of Serum Pharmacochemistry, Metabolomics Laboratory, Department of Pharmaceutical Analysis, Heilongjiang University of Chinese Medicine, Heping Road 24, Harbin, 150040, China; State Key Laboratory of Dampness Syndrome, The Second Affiliated Hospital Guangzhou University of Chinese Medicine, Dade Road 111, Guangzhou, China.", "State Key Laboratory of Integration and Innovation of Classic Formula and Modern Chinese Medicine, National Chinmedomics Research Center, National TCM Key Laboratory of Serum Pharmacochemistry, Metabolomics Laboratory, Department of Pharmaceutical Analysis, Heilongjiang University of Chinese Medicine, Heping Road 24, Harbin, 150040, China. Electronic address: Sunhui7045@163.com."], "corresponding_authors": ["Heng Fang", "Hui Sun"], "china_team": "State Key Laboratory of Integration and Innovation of Classic Formula and Modern Chinese Medicine, National Chinmedomics Research Center, National TCM Key Laboratory of Serum Pharmacochemistry, Metabolomics Laboratory, Department of Pharmaceutical Analysis, Heilongjiang University of Chinese Medicine, Heping Road 24, Harbin, 150040, China Heng Fang/Hui Sun团队", "category": "basic", "classification_reason": "basic_signals=23", "score": 32.22, "score_parts": {"urology_relevance": 3, "urology_in_title": 0.0, "journal_priority": 10.72, "top_journal_bonus": 0.0, "novelty": 2.5, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 14.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 5.4, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.72, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "滨蒿内酯稳定TAT蛋白护肝", "chinese_summary": "黑龙江中医药大学方衡、孙晖团队9月J Ethnopharmacol基于NIAAA慢性酒精性肝病小鼠模型发现，滨蒿内酯可恢复血清生化及肝脏病理至近健康水平，并直接结合酪氨酸转氨酶TAT抑制泛素-蛋白酶体降解，恢复线粒体三羧酸循环，逆转氧化应激与线粒体损伤，为靶向TAT治疗提供临床前依据。", "abstract_zh": "茵陈（Artemisia capillaris Thunb.）是一种临床常用于慢性酒精性肝病（CALD）的传统中草药。滨蒿内酯是茵陈的主要活性成分之一，已成为干预CALD的有前景候选药物，但其作用机制尚不清楚。本研究旨在通过多组学结合靶向验证，系统阐明滨蒿内酯在CALD中的药理作用及其分子机制。建立了美国国家酒精滥用与酒精中毒研究所（NIAAA）动物模型。通过经典临床方法（肝功能生物标志物＋组织病理学）对NIAAA建立的CALD小鼠模型（慢性乙醇喂养＋急性暴饮，模拟慢加急性肝损伤）进行诊断。验证后，滨蒿内酯在不同剂量下均表现出显著疗效。代谢组学和转录组学分析尿液/组织样本，通过整合分析确定核心枢纽。同时，培养原代肝细胞并用滨蒿内酯处理。通过基因敲低、CETSA、CHX chase和泛素化实验验证潜在靶点。我们使用Seahorse XF线粒体应激测试评估CALD相关线粒体损伤并阐明关键相互关系。滨蒿内酯使血清生化指标和肝脏病理恢复正常至接近健康水平。尿液代谢组学鉴定出9种生物标志物，肝脏转录组学检测到3665个差异表达基因。整合组学确定苯丙氨酸通路，其中TAT/AST共调控被确定为关键。体外培养原代肝细胞，给予100 mmol/L乙醇±25 μmol/L滨蒿内酯；CETSA和CHX chase实验证实滨蒿内酯通过抑制泛素-蛋白酶体途径增强TAT稳定性。Seahorse分析显示，TAT敲低诱导的肝细胞凋亡、氧化应激、脂质积累和线粒体损伤可被滨蒿内酯或TAT水平恢复所逆转。本研究首次揭示滨蒿内酯治疗CALD的新机制：它直接结合酪氨酸转氨酶（TAT），通过抑制泛素-蛋白酶体介导的降解稳定其水平，恢复TAT对苯丙氨酸的调节以防止酪氨酸血症及相关肝损伤或黄疸，并正常化酪氨酸调节以恢复线粒体三羧酸循环相关的丙酮酸，从而逆转氧化应激和线粒体功能障碍。本研究验证了滨蒿内酯作为潜在CALD治疗药物，并为靶向TAT治疗提供了有力的临床前数据。"}, {"pmid": "41992467", "title": "Availability of Cancer Screening Across HIV Treatment Sites in the IeDEA Consortium.", "abstract": "Cancer remains a leading cause of morbidity and mortality in people with HIV, and the importance of cancer screening increases as this population ages. In 2017, 2020, and 2023, cross-sectional surveys were conducted at HIV care sites across 5 continents within the International epidemiology Databases to Evaluate AIDS (IeDEA) consortium. We described cancer screening availability in 2023 and over time for cervical and anal cancer screening using generalized estimating equations with a logit link function to account for site clustering, rurality, and country income. Of the 220 sites in the 2023 survey, 61% (134/220) reported cervical cancer screening by cytology or human papillomavirus (HPV) testing on-site, and 88% (194/220) reported cervical cancer screening by any method, including visual inspection. At sites serving predominantly rural populations, 62% (29/47) exclusively performed screening by visual inspection. Overall, 23% (50/220) of sites performed cytology-based anal cancer screening on-site, and 16% (35/220) had availability of high-resolution anoscopy, either on-site or by referral. Screening for cancer of the liver, colon, lung, prostate, or breast (by imaging) were each available at less than 43% of sites. The odds of cervical cancer screening availability increased by 16% annually from 2017 through 2023 (aOR = 1.16, 95% CI: 1.07-1.27, p = 0.001), while the relative odds of anal cancer screening availability decreased by 9% annually (aOR = 0.91, 95% CI: 0.84-0.99, p = 0.023). Lack of trained staff was the most frequently reported barrier, followed by lack of equipment. Understanding current practices and capacity is essential for the continued integration of cancer prevention in HIV care.", "journal": "International Journal of Cancer", "pub_date": "2026-Sep-15", "publication_types": ["Journal Article"], "doi": "10.1371/journal.pgph.0004440", "authors": ["Rachael A Pellegrino", "Bryan E Shepherd", "Sanjay Pujari", "Valeria Fink", "Gad Murenzi", "Miriam Nakalembe", "Sally B Coburn", "Eliane Rohner", "Antoine Jaquet", "Caroline Lade", "Brenda Crabtree Ramirez", "Kathryn Anastos", "Aggrey Semeere", "Lesley S Park", "Limpho Mokone", "Simon Boni", "I Ketut Agus Somia", "Emilia M Jalil", "Adebola Adedimeji", "Omenge Orang'o", "Michael J Silverberg", "Kumbirai Pise Quarter", "Eugène Messou", "Jeremy Ross", "Eduardo Gotuzzo", "Patricia Lelo", "Helen Byakwaga", "Oliver Ezechi", "Jonathan Euvrard", "Fernanda Maruri", "Chad J Achenbach", "Jessica L Castilho", "International epidemiology Databases to Evaluate AIDS (IeDEA)"], "affiliations": ["Division of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.", "Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.", "Institute of Infectious Diseases, Pune, India.", "Research Department, Fundacion Huesped, Buenos Aires, Argentina.", "Goodlife Access, Kigali, Rwanda.", "University of Rwanda, Kigali, Rwanda.", "Department Obstetrics and Gynecology, Makerere University, Kampala, Uganda.", "Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda.", "Johns Hopkins University, Baltimore, Maryland, USA.", "Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.", "University of Bordeaux, National Institute for Health and Medical Research (INSERM) UMR 1219, Research Institute for Sustainable Development (IRD) EMR 271, Bordeaux Population Health Centre, Bordeaux, France.", "Gold Coast Sexual Health Service, Gold Coast Hospital and Health Service, Southport, Queensland, Australia.", "Departamento de Infectología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.", "Department of Medicine, Albert Einstein College of Medicine, Bronx, New York, USA.", "Department of Epidemiology & Population Health, Albert Einstein College of Medicine, Bronx, New York, USA.", "Stanford University School of Medicine, Stanford, California, USA.", "SolidarMed, Mokhotlong, Lesotho.", "PAC-CI Research Program, Abidjan, Côte d'Ivoire.", "Faculty of Medicine, Udayana University-Ngoerah Hospital, Denpasar, Bali, Indonesia.", "Instituto Nacional de Infectologia Evandro Chagas, FIOCRUZ, Rio de Janeiro, Brazil.", "Department of Social Sciences and Health Policy, Wake Forest University School of Medicine, Winson Salem, North Carolina, USA.", "Department of Implementation Science, Wake Forest University School of Medicine, Winson Salem, North Carolina, USA.", "Department of Obstetrics and Gynaecology, Aga Khan University Medical College, Nairobi, Kenya.", "Kaiser Permanente Northern California, Pleasanton, California, USA.", "SolidarMed, Masvingo, Zimbabwe.", "CePReF-Aconda-VS, Abidjan, Côte d'Ivoire.", "TREAT Asia, amfAR-The Foundation for AIDS Research, Bangkok, Thailand.", "Universidad Peruana Cayetano Heredia, Instituto de Medicina Tropical Alexander von Humboldt, Lima, Peru.", "Kalembelembe Pediatric Hospital, Kinshasa, Democratic Republic of Congo.", "Mbarara University of Science and Technology, Mbarara, Uganda.", "Nigerian Institute of Medical Research, Lagos, Nigeria.", "Centre for Integrated Data and Epidemiological Research, School of Public Health, University of Cape Town, Cape Town, South Africa.", "Department of Medicine and Robert J. Havey, MD Institute for Global Health, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.", "Department of Health Policy, Vanderbilt University Medical Center, Nashville, Tennessee, USA."], "corresponding_authors": [], "china_team": "", "category": "basic", "classification_reason": "default_nonclinical_research", "score": 17.55, "score_parts": {"urology_relevance": 4, "urology_in_title": 0.0, "journal_priority": 10.55, "top_journal_bonus": 0.0, "novelty": 0, "gut_microbiome_bonus": 0.0, "abstract_completeness": 2.0, "basic_research_strength": 1.0, "clinical_evidence": 0.0}, "journal_metrics": {"status": "ok", "impact_factor": 4.7, "cas_zone": 2, "cas_zone_points": 8.0, "impact_factor_points": 2.55, "jcr_year": 2024, "cas_year": 2025, "source": "2024JCR完整版（2025.6.18发布）.xlsx + 2025中科院分区表.xlsx"}, "chinese_title": "", "chinese_summary": "", "abstract_zh": ""}], "states": {"40542273": "selected", "40764815": "selected", "40960159": "chosen", "41454188": "selected", "41501560": "selected", "41813580": "selected", "41864432": "selected", "41933100": "selected", "41967136": "selected", "41967740": "selected", "41997105": "eliminated", "42019303": "chosen", "42020257": "selected", "42055905": "selected", "42067413": "selected", "42091407": "selected", "42091408": "selected", "42101252": "selected", "42106277": "selected", "42128751": "chosen", "42135176": "chosen", "42135177": "selected", "42140859": "selected", "42150056": "selected", "42161692": "selected", "42161693": "selected", "42161695": "selected", "42167395": "selected", "42172631": "selected", "42176793": "eliminated", "42176796": "selected", "42231026": "selected", "42233452": "selected", "42236150": "selected", "42236390": "selected", "42242922": "selected", "42246654": "selected", "42258526": "eliminated", "42262115": "selected", "42262878": "chosen", "42265042": "selected", "42267579": "selected", "42276907": "chosen", "42290280": "chosen", "42297102": "chosen", "42299801": "selected", "42308695": "selected", "42315017": "selected", "42315910": "selected", "42320108": "selected", "42320109": "selected", "42321391": "selected", "42341949": "selected", "42350655": "eliminated", "42361796": "eliminated", "42397032": "selected", "42411285": "chosen", "42420069": "selected", "42425882": "selected", "42431158": "eliminated", "42432330": "eliminated", "42437825": "eliminated", "42440313": "selected", "42448545": "selected", "42457452": "selected", "42457453": "selected", "42457454": "selected", "42457456": "selected", "42469053": "selected", "42470727": "eliminated", "42477459": "eliminated", "42477460": "eliminated", "42478522": "selected", "42480737": "chosen", "42483798": "chosen", "42493547": "eliminated", "42498731": "eliminated", "42504409": "chosen", "42508515": "chosen", "42509374": "chosen", "42509414": "eliminated", "42509416": "selected", "42518286": "eliminated", "42521833": "selected", "42521834": "selected", "42527507": "eliminated", "42533112": "chosen", "42538409": "eliminated", "42546910": "selected", "42554478": "eliminated", "42558038": "selected", "42562882": "eliminated", "42564931": "selected", "42581140": "eliminated", "42593769": "chosen", "42593770": "chosen", "42598215": "selected", "42599300": "selected", "42599325": "selected", "42601173": "selected", "42601237": "chosen", "42604152": "chosen", "42604853": "selected", "42605754": "selected", "42605942": "selected", "42606131": "selected", "42606749": "selected", "42607497": "chosen", "42607565": "selected", "42610757": "selected", "42610891": "selected", "42611560": "selected", "42612871": "chosen", "42613225": "selected", "42615373": "selected", "42615562": "chosen", "42616040": "selected", "42616118": "selected", "42616202": "selected", "42616342": "selected", "42616841": "chosen", "42617313": "selected", "42617511": "selected", "42624109": "selected", "42624542": "selected", "42624696": "chosen", "42624713": "selected", "42625061": "selected", "42625361": "chosen", "42627381": "selected", "42627862": "selected", "42628358": "selected", "42628836": "chosen", "42631750": "chosen", "42632240": "selected", "42632292": "chosen", "42632413": "chosen", "42632498": "selected", "42632837": "chosen", "42634016": "chosen", "42634468": "chosen", "42635656": "selected", "42635833": "selected", "42636791": "selected", "42636827": "chosen", "42636837": "selected", "42637598": "chosen", "42637825": "chosen", "42638137": "chosen", "42640591": "selected", "42645707": "selected", "42647038": "selected", "42647600": "chosen", "42647819": "selected", "42648265": "selected", "42648579": "selected", "42648940": "selected", "42659930": "selected", "42665508": "selected", "42665512": "selected", "42665513": "selected", "42665723": "selected", "42667367": "selected", "42667526": "selected", "42667894": "selected", "42668291": "selected", "42668326": "eliminated", "42668497": "chosen", "42669035": "selected", "42670595": "selected", "42670720": "selected", "42671623": "selected", "42671925": "chosen", "42674699": "selected", "42675222": "chosen", "42675224": "chosen", "42676100": "chosen", "42677133": "chosen", "42677575": "chosen", "42678562": "selected", "42678928": "chosen", "42680595": "selected", "42680649": "selected", "42680650": "selected", "42680651": "selected", "42680652": "selected", "42680821": "selected", "42681559": "selected", "42681619": "selected", "42681671": "eliminated", "42682736": "selected", "42685428": "selected", "42685600": "chosen", "42685608": "selected", "42685702": "selected", "42686076": "selected", "42686225": "selected", "42686473": "selected", "42686474": "chosen", "42689555": "selected", "42689576": "selected", "42689585": "selected", "42690463": "selected", "42692375": "eliminated", "42694488": "chosen", "42696293": "chosen", "42697217": "selected", "42697763": "selected", "42697898": "chosen", "42697914": "selected", "42698027": "selected", "42698032": "selected", "42700243": "selected", "42700848": "selected", "42701051": "selected", "42701052": "selected", "42701967": "selected", "42701997": "selected", "42702152": "eliminated", "42702711": "selected", "42702821": "eliminated", "42704986": "chosen", "42706004": "selected", "42707293": "selected", "42707719": "selected", "42707765": "selected", "42707980": "selected", "42708180": "selected", "42708361": "selected", "42708362": "selected", "42708952": "selected", "42710493": "chosen", "42711192": "selected", "42711240": "chosen", "42714024": "selected", "42714908": "selected", "42716079": "selected", "42716822": "selected", "42716948": "chosen", "42716968": "chosen", "42717097": "chosen", "42718489": "chosen", "42720349": "chosen", "42721405": "selected", "42722609": "selected", "42726306": "selected", "42726512": "selected", "42727419": "selected", "42728152": "selected", "42728346": "chosen", "41741676": "selected", "41792501": "selected", "41934820": "selected", "41951848": "selected", "41956861": "selected", "42001218": "selected", "42014098": "selected", "42020578": "selected", "42025513": "selected", "42044775": "selected", "42056552": "selected", "42097289": "selected", "42107751": "selected", "42112793": "selected", "42126225": "selected", "42161694": "selected", "42165001": "selected", "42168001": "selected", "42172622": "selected", "42176776": "selected", "42184675": "selected", "42190231": "selected", "42276908": "selected", "42285214": "selected", "42303525": "selected", "42303526": "selected", "42350166": "selected", "42362411": "selected", "42373845": "selected", "42378035": "selected", "42386399": "selected", "42392907": "selected", "42392908": "selected", "42399196": "selected", "42414479": "selected", "42425857": "selected", "42431754": "selected", "42435930": "selected", "42436321": "selected", "42442599": "selected", "42443559": "selected", "42448494": "selected", "42457063": "selected", "42457459": "selected", "42464684": "selected", "42469054": "selected", "42476284": "selected", "42476286": "selected", "42476886": "selected", "42477998": "selected", "42481326": "selected", "42486192": "selected", "42490143": "selected", "42493341": "selected", "42493599": "selected", "42498607": "selected", "42508612": "selected", "42509104": "selected", "42521073": "selected", "42537900": "selected", "42547555": "selected", "42552153": "selected", "42560765": "selected", "42560769": "selected", "42567227": "selected", "42567750": "selected", "42567751": "selected", "42574031": "selected", "42579369": "selected", "42581823": "selected", "42593773": "selected", "42593775": "selected", "42593810": "selected", "42621345": "selected", "42730040": "selected", "42733517": "selected", "42733656": "selected", "42743938": "selected", "42744693": "selected", "42744974": "selected", "42745263": "selected", "42749561": "selected", "42749562": "selected", "42749760": "selected", "42749807": "selected", "42751148": "selected", "42752508": "selected", "42752749": "selected", "42752828": "selected", "42754663": "selected", "42754720": "selected", "42754954": "selected", "42755408": "selected", "42757133": "selected", "42757823": "selected", "42757853": "selected", "42758829": "selected", "42760039": "selected", "42760245": "selected", "42760390": "selected", "42760428": "selected", "42760560": "selected", "42761474": "selected", "42762460": "selected", "42762645": "selected", "42763990": "selected", "42766295": "selected", "42766303": "selected", "42766312": "selected", "42766432": "selected", "42767223": "selected", "42767280": "selected", "42767871": "selected", "42768826": "selected", "42770303": "selected", "42772066": "selected", "42772167": "selected", "42772447": "selected", "42772449": "selected", "42772619": "selected", "42776240": "selected", "42776523": "selected", "42777663": "selected", "42777936": "selected", "42778538": "selected", "42781259": "selected", "42781429": "selected", "42781772": "selected", "42785539": "selected", "42785920": "selected", "42786066": "selected", "42786067": "selected", "42786421": "selected", "42791106": "selected", "42800733": "selected", "42800742": "selected", "42802299": "selected", "42802799": "selected", "42803139": "selected", "42804174": "selected", "42805200": "selected", "42805201": "selected", "42805210": "selected", "42805335": "selected", "42805527": "selected", "42805760": "selected", "42807169": "selected", "42810248": "selected", "42810571": "selected", "42815467": "selected", "42816307": "selected", "42816308": "selected", "42816309": "selected", "42816310": "selected", "42816311": "selected", "42816312": "selected", "42817820": "selected", "42820299": "selected", "42820819": "selected", "42821636": "selected", "42822280": "selected", "42823146": "selected", "42823170": "selected", "42823216": "selected", "42823217": "selected", "42823218": "selected", "42823219": "selected", "42823220": "selected", "42823600": "selected", "42826192": "selected", "42827132": "selected", "42829264": "selected", "42829266": "selected", "42829267": "selected", "42829268": "selected", "42829270": "selected", "42830000": "selected", "42830190": "selected", "42832819": "selected", "42833915": "selected", "42833933": "selected", "42834174": "selected", "42834176": "selected", "42835125": "selected", "42836583": "selected", "42837154": "selected", "42837186": "selected", "42837196": "selected", "42838066": "selected", "42838165": "selected", "42838799": "selected", "42838800": "selected", "42838801": "selected", "42838802": "selected", "42838867": "selected", "42839290": "selected", "42842364": "selected", "42843106": "selected", "42843390": "selected", "42844112": "selected", "42844113": "selected", "42844465": "selected", "42844644": "selected", "42846147": "selected", "42848391": "selected", "42849042": "selected", "42849062": "selected", "42849919": "selected", "42850571": "selected", "42851436": "selected", "42852005": "selected", "42852385": "selected", "42852388": "selected", "42853849": "selected", "42853943": "selected", "42854704": "selected", "42854902": "selected", "42855348": "selected", "42855349": "selected", "42855516": "selected", "42858301": "selected", "42858533": "selected", "42860231": "selected", "42860576": "selected", "42863464": "selected", "42863477": "selected", "42864228": "selected", "42864412": "selected", "42865221": "selected", "42865436": "selected", "42865476": "selected", "42866843": "selected", "42866857": "selected", "42867371": "selected", "42867550": "selected", "42868004": "selected", "42869123": "selected"}, "published": [{"pmid": "42697898", "doi": "10.1093/bioinformatics/btw413", "title": "Effect of human urinary microenvironment and fluid flow on antibiotic and phage therapy efficacy against uropathogenic Escherichia coli.", "published_date": "2026-09-13", "owner": "YuYao"}, {"pmid": "42717097", "doi": "10.1038/s41586-023-06054-z", "title": "Integrated signatures define mutational processes in prostate cancer.", "published_date": "2026-09-13", "owner": "YuYao"}, {"pmid": "42710493", "doi": "10.1016/j.chom.2026.08.009", "title": "Hippuric acid metabolism by Corynebacteriumglucuronolyticum-like bacteria promotes calcium oxalate crystallization.", "published_date": "2026-09-13", "owner": "YuYao"}, {"pmid": "42290280", "doi": "10.1158/0008-5472.CAN-25-4954", "title": "Reprogramming of TLR-Ferroptosis Signaling and Immunometabolic Pathways Overcomes Myeloid Suppression to Improve Checkpoint Blockade in Prostate Cancer.", "published_date": "2026-09-13", "owner": "YuYao"}, {"pmid": "42716948", "doi": "10.1093/biomet/73.3.751", "title": "Recurrent mechanisms of biallelic epigenetic inactivation reveal new putative tumour suppressor genes in prostate cancer.", "published_date": "2026-09-13", "owner": "YuYao"}, {"pmid": "42411285", "doi": "10.1161/CIRCRESAHA.126.327339", "title": "WTAP Deficiency Promotes Podocyte PANoptosis and FSGS via SPP1 Signaling.", "published_date": "2026-09-13", "owner": "YuYao"}, {"pmid": "42716968", "doi": "10.1158/0008-5472.CAN-03-0946", "title": "Commensal Nakaseomyces glabratus migrates into prostate tumors to accelerate cancer progression.", "published_date": "2026-09-13", "owner": "YuYao"}, {"pmid": "42276907", "doi": "10.1016/j.eururo.2026.05.026", "title": "Regulating Innovation: Why the European Union Artificial Intelligence Act Matters for Urologists-Recommendations from the EAU AI Working Group.", "published_date": "2026-09-13", "owner": "YuYao"}, {"pmid": "42668497", "doi": "10.1016/j.bioactmat.2026.07.037", "title": "Reversing zinc dyshomeostasis and oxidative stress: A metallothionein 1-activating MXene/Zn2+ triple-action nanotherapeutic strategy for chronic non-bacterial prostatitis.", "published_date": "2026-09-13", "owner": "YuYao"}, {"pmid": "42696293", "doi": "10.1001/jama.2026.17683", "title": "Is Phage Therapy the Next Big Hope for Urinary Tract Infections?", "published_date": "2026-09-13", "owner": "YuYao"}, {"pmid": "42128751", "doi": "10.1016/j.eururo.2026.03.037", "title": "Re: Kitamura et al. Active Surveillance Versus Intravesical Bacillus Calmette-Guérin for High-grade T1 Bladder Cancer with Negative Second Transurethral Resection (JCOG1019). Eur Urol 2026. 2026;89:437-445.", "published_date": "2026-09-13", "owner": "YuYao"}, {"pmid": "42601237", "doi": "10.1016/j.eururo.2026.07.034", "title": "Re: Siva S, Ali M, Hardcastle N, et al. Ultra-hypofractionated Stereotactic Ablative Body Radiotherapy for Primary Renal Cell Carcinoma: 5-Year Outcomes from a Pooled Analysis of the FASTRACK Trials. Lancet Oncol. In press. https://doi.org/10.1016/S1470-2045(26)00170-1 and re: Siva S, Pryor D, Martin J, et al. Long-term Outcomes of Stereotactic Ablative Body Radiotherapy for Primary Kidney Cancer (TROG 15.03 FASTRACK II): A Multicentre, Non-randomised, Phase 2 Study. Lancet Oncol. In press. https://doi.org/10.1016/S1470-2045(26)00091-4.", "published_date": "2026-09-13", "owner": "YuYao"}, {"pmid": "42509374", "doi": "10.1016/S0140-6736(26)00718-X", "title": "The first-in-human combined bladder and kidney transplant.", "published_date": "2026-09-13", "owner": "YuYao"}, {"pmid": "42615562", "doi": "10.1158/0008-5472.CAN-26-1480", "title": "The Multimodal Pretraining Framework CarHE Predicts Spatial Transcriptomics in Tumors from Routine Pathology Images.", "published_date": "2026-09-13", "owner": "YuYao"}, {"pmid": "42677575", "doi": "10.1021/jacs.6c06623", "title": "A Direct-to-Biology Amine-Acid Amination for Rapid Phenotypic Profiling of Lysosomotropic Natural Products.", "published_date": "2026-09-13", "owner": "YuYao"}, {"pmid": "42624696", "doi": "10.1016/j.eururo.2026.07.032", "title": "Re: Wenxin Xu, Brian I. Rini, Laurence Albiges, et al. Comprehensive Genomic and Transcriptomic Characterization of Matched Primary and Recurrent Tumors in High-risk Localized Renal Cell Carcinoma. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.03.023.", "published_date": "2026-09-13", "owner": "YuYao"}, {"pmid": "42637598", "doi": "10.1016/j.eururo.2026.05.014", "title": "Re: Prophylactic Ureteral Stenting in Kidney Transplantation: A Multivariable and Propensity Score-matched Analysis of 3407 Recipients from NSQIP Transplant.", "published_date": "2026-09-13", "owner": "YuYao"}, {"pmid": "42593769", "doi": "10.1093/jnci/djab073", "title": "Active Surveillance Use for Favorable-Risk Prostate Cancer in a Veterans Affairs Population.", "published_date": "2026-09-13", "owner": "YuYao"}, {"pmid": "42593770", "doi": "10.1001/jamasurg.2021.0528", "title": "Focal Therapy for Prostate Cancer.", "published_date": "2026-09-13", "owner": "YuYao"}, {"pmid": "42634016", "doi": "10.1038/s41698-025-00876-y", "title": "Beyond prostate-specific antigen: ctDNA as an early compass for treatment adaptation in metastatic prostate cancer.", "published_date": "2026-09-13", "owner": "YuYao"}, {"pmid": "42636827", "doi": "10.1016/S1470-2045(26)00346-3", "title": "Radiotherapy dose intensification for high-risk prostate cancer-what is gained?", "published_date": "2026-09-13", "owner": "YuYao"}, {"pmid": "42676100", "doi": "10.1158/2159-8290.CD-26-1266", "title": "Malignant Transition in Three Dimensions.", "published_date": "2026-09-13", "owner": "YuYao"}, {"pmid": "42135176", "doi": "10.1016/j.eururo.2026.04.028", "title": "Letter to the Editor: Advanced and Metastatic Prostate Cancer: ESMO Clinical Practice Guideline for Diagnosis, Treatment, and Follow-up.", "published_date": "2026-09-13", "owner": "YuYao"}, {"pmid": "42686474", "doi": "10.1016/j.eururo.2026.08.011", "title": "Re: Patient-reported Outcomes After Prostate Stereotactic Body Radiotherapy at 5 yr: Results from the PACE-B Trial.", "published_date": "2026-09-13", "owner": "YuYao"}, {"pmid": "42483798", "doi": "10.1161/CIRCRESAHA.126.328246", "title": "Distinct Urinary Protein Signatures in Adolescent Blood Pressure Phenotypes.", "published_date": "2026-09-13", "owner": "YuYao"}, {"pmid": "42504409", "doi": "10.1158/2159-8290.CD-NW2026-0080", "title": "Oncolytic Virotherapy, Long Stalled, Nears Second Approval.", "published_date": "2026-09-13", "owner": "YuYao"}, {"pmid": "42678928", "doi": "10.1158/2159-8290.CD-26-0839", "title": "Long-Read Haplotype Phasing Resolves Allelic Configuration as a Missing Layer of Precision Oncology.", "published_date": "2026-09-13", "owner": "YuYao"}, {"pmid": "42677133", "doi": "10.1016/j.mtbio.2026.103572", "title": "Advanced nanocatalytic medicine for genitourinary diseases: Reactive oxygen modulation, precision therapeutics, and clinical translation.", "published_date": "2026-09-13", "owner": "YuYao"}, {"pmid": "42711240", "doi": "10.1016/j.euo.2026.08.003", "title": "Gemcitabine-Cisplatin Chemotherapy Induces Nectin-4 Downregulation and Enfortumab Vedotin Resistance in Bladder Cancer.", "published_date": "2026-09-13", "owner": "YuYao"}, {"pmid": "42647600", "doi": "10.1126/scitranslmed.aea1228", "title": "Urogenital immune signatures are associated with birth outcomes after maternal urinary tract infection.", "published_date": "2026-09-13", "owner": "YuYao"}, {"pmid": "42612871", "doi": "10.1016/j.kint.2026.06.050", "title": "Generation of a novel Slc7a9G105R mutant mouse identifies new biomarkers for cystinuria.", "published_date": "2026-09-13", "owner": "YuYao"}, {"pmid": "42675222", "doi": "10.1038/s41586-024-08290-3", "title": "Neuromedin U 'innervation' reprograms myeloid immunosuppression in neuroendocrine prostate cancer.", "published_date": "2026-09-13", "owner": "YuYao"}, {"pmid": "42675224", "doi": "10.1200/JCO.23.01684", "title": "POC1A promotes the proliferation, metastasis and stemness of bladder cancer by stabilizing BMI1 via USP7.", "published_date": "2026-09-13", "owner": "YuYao"}, {"pmid": "42728346", "doi": "10.1016/0304-419x(96)00003-0", "title": "Tumor-derived CTHRC1 mediates ITGB3-dependent osteoclast differentiation to promote prostate cancer bone metastasis.", "published_date": "2026-09-13", "owner": "YuYao"}, {"pmid": "42297102", "doi": "10.1016/j.kint.2026.04.035", "title": "Strategic timing of contralateral nephrectomy after ischemic acute kidney injury prevents chronic kidney disease by enhancing progenitor proliferation, attenuating polyploidization and reshaping the immune response.", "published_date": "2026-09-13", "owner": "YuYao"}, {"pmid": "42607497", "doi": "10.1016/j.gendis.2024.101254", "title": "P4HA3-mediated hydroxylation of SLC7A11 drives tyrosine kinase inhibitor resistance by suppressing ferroptosis in clear cell renal cell carcinoma.", "published_date": "2026-09-13", "owner": "YuYao"}, {"pmid": "40960159", "doi": "10.1097/CM9.0000000000003744", "title": "m6A-modified circCD2AP suppressed ferroptosis in bladder cancer by upregulating FOXC1 to promote PARK7 transcriptional activity.", "published_date": "2026-09-13", "owner": "YuYao"}, {"pmid": "42694488", "doi": "10.1002/cncr.29344", "title": "Identification of interleukin-11 as a comorbid risk factor for prostate cancer and Alzheimer's disease using integrated bioinformatics and machine learning.", "published_date": "2026-09-13", "owner": "YuYao"}, {"pmid": "42631750", "doi": "10.1016/j.taap.2024.117104", "title": "Targeting GLS and LPIN2 in renal fibroblasts: potential therapeutic targets for kidney stone disease identified by integrated multi-omics analysis.", "published_date": "2026-09-13", "owner": "YuYao"}, {"pmid": "42685600", "doi": "10.1016/j.jhazmat.2026.143462", "title": "Urinary biomarkers of emerging contaminants in relation to prevalent Parkinson's disease: An exploratory mixture and network toxicology study.", "published_date": "2026-09-13", "owner": "YuYao"}, {"pmid": "42262878", "doi": "10.1093/bib/bbs017", "title": "Epigenetic and oncogenic inhibitors converge to drive a metabolic catastrophe in castration-resistant prostate cancer.", "published_date": "2026-09-13", "owner": "YuYao"}, {"pmid": "42638137", "doi": "10.18632/oncotarget.27988", "title": "HIRA loss is frequent but not universal in human fumarate hydratase-deficient renal cell carcinoma and defines divergent oncogenic programs.", "published_date": "2026-09-13", "owner": "YuYao"}, {"pmid": "42671925", "doi": "10.1158/2326-6066.CIR-26-0104", "title": "A High Density of Impaired Tertiary Lymphoid Structures Is Associated with Higher Tumor Stage and Recurrence in Non-Muscle-Invasive Bladder Cancer.", "published_date": "2026-09-13", "owner": "YuYao"}, {"pmid": "42480737", "doi": "10.1016/j.phrs.2026.108349", "title": "Celastrol's covalent strike on HK2: Breaking a metabolic-epigenetic circuit to impede bladder cancer.", "published_date": "2026-09-13", "owner": "YuYao"}, {"pmid": "42634468", "doi": "10.1002/ijc.70719", "title": "Assessing the Consistency of Genitourinary Cancer Estimates: A Comparison of Data From the Global Cancer Observatory and the Global Burden of Disease Study.", "published_date": "2026-09-13", "owner": "YuYao"}, {"pmid": "42637825", "doi": "10.1016/j.euf.2022.06.007", "title": "Prostate size and its effect on sexual function following convective water vapor thermal therapy.", "published_date": "2026-09-13", "owner": "YuYao"}, {"pmid": "42628836", "doi": "10.1016/j.kint.2026.07.019", "title": "A self-sustaining hypoxia inducible factor-1α-creatine kinase B feedforward circuit drives macrophage-mediated kidney fibrosis.", "published_date": "2026-09-13", "owner": "YuYao"}, {"pmid": "42720349", "doi": "10.1111/jpi.70183", "title": "Melatonin Inhibits Metastasis of Sunitinib-Resistant Renal Cell Carcinoma Cells Via the GRP78/p38/CTSD Expression.", "published_date": "2026-09-13", "owner": "YuYao"}, {"pmid": "42632413", "doi": "10.1016/j.jare.2026.08.041", "title": "Integrated single-cell and spatial transcriptomic analyses identify a unique subset of pro-fibrotic macrophages in kidney fibrosis.", "published_date": "2026-09-13", "owner": "YuYao"}, {"pmid": "42019303", "doi": "10.1016/j.bios.2026.118710", "title": "Bifunctional DNA multivalent structure integrating stable capture of urothelial carcinoma cells with CRISPR/Cas12a signal amplification for bladder cancer detection.", "published_date": "2026-09-13", "owner": "YuYao"}, {"pmid": "42604152", "doi": "10.1016/j.euros.2026.07.006", "title": "Impact of Photodynamic Diagnosis on Immune Cell Infiltration in BCG-treated Non-muscle-invasive Bladder Cancer.", "published_date": "2026-09-13", "owner": "YuYao"}, {"pmid": "42632837", "doi": "10.1158/1541-7786.MCR-23-0045", "title": "IRE1 activity is prognostic in localised and metastatic prostate cancer and affects epithelial lineage states.", "published_date": "2026-09-13", "owner": "YuYao"}, {"pmid": "42632292", "doi": "10.1016/j.urolonc.2026.07.032", "title": "miR-638 Upregulation in Serum and Tissues Functions as a Diagnostic and Prognostic Biomarker and Facilitates Prostate Cancer Progression.", "published_date": "2026-09-13", "owner": "YuYao"}, {"pmid": "42616841", "doi": "10.1126/scitranslmed.aed4678", "title": "Urea transporter B-mediated urea uptake-induced protein carbamylation in platelets underlies bleeding in chronic kidney disease.", "published_date": "2026-09-13", "owner": "YuYao"}, {"pmid": "42533112", "doi": "10.1002/path.5813", "title": "LncRMRP drives bladder cancer invasion via a lactylation-driven positive feedback circuit.", "published_date": "2026-09-13", "owner": "YuYao"}, {"pmid": "42704986", "doi": "10.1016/j.redox.2026.104374", "title": "A novel Keap1-Nrf2 inhibitor 6K delays the progression of AKI-to-CKD by mitigating maladaptive repair.", "published_date": "2026-09-13", "owner": "YuYao"}, {"pmid": "42718489", "doi": "10.1200/PO-24-00753", "title": "A generalizable covalent car-t platform for solid tumors enabled by oncolytic adenovirus-delivered artificial antigens.", "published_date": "2026-09-13", "owner": "YuYao"}, {"pmid": "42625361", "doi": "10.1002/adhm.71639", "title": "Self-Propelling WO3 Nanomotors Restore the Gut-Kidney Axis by Modulating Intestinal Homeostasis in Inflammatory Bowel Disease.", "published_date": "2026-09-13", "owner": "YuYao"}, {"pmid": "42508515", "doi": "10.1016/j.phrs.2026.108361", "title": "A multi-component intervention enhances intestinal urate excretion and improves metabolic and immune homeostasis in diet-induced hyperuricemia.", "published_date": "2026-09-13", "owner": "YuYao"}]}